PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zhao, DZ; Zhan, YN; Koon, HW; Zeng, HY; Keates, S; Moyer, MP; Pothoulakis, C				Zhao, DZ; Zhan, YN; Koon, HW; Zeng, HY; Keates, S; Moyer, MP; Pothoulakis, C			Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; HELICOBACTER-PYLORI; INDUCE TRANSACTIVATION; CALCIUM MOBILIZATION; TYROSINE KINASE; SMALL-INTESTINE; NERVOUS-SYSTEM; SECRETION	Expression of the neuropeptide neurotensin (NT) and its high affinity receptor (NTR1) is increased during the course of Clostridium difficile toxin A-induced acute colitis, and NTR1 antagonism attenuates the severity of toxin A-induced inflammation. We recently demonstrated in non-transformed human colonic epithelial NCM460 cells that NT treatment caused activation of a Ras-mediated MAP kinase pathway that significantly contributes to NT-induced interleukin-8 (IL-8) secretion. Here we used NCM460 cells, which normally express low levels of NTR1, and NCM460 cells stably transfected with NTR1 to identify the upstream signaling molecules involved in NT-NTR1-mediated MAP kinase activation. We found that inhibition of the epidermal growth factor receptor ( EGFR) by either an EGFR neutralizing antibody or by its specific inhibitor AG1478 (0.2 muM) blocked NT-induced MAP kinase activation. Moreover, NT stimulated tyrosine phosphorylation of the EGFR, and pretreatment with a broad spectrum metalloproteinase inhibitor batimastat reduced NT-induced MAP kinase activation. Using neutralizing antibodies against the EGFR ligands EGF, heparin-binding-EGF, transforming growth factor-alpha (TGFalpha), or amphiregulin we have shown that only the anti-TGFalpha antibody significantly decreases NT-induced phosphorylation of EGFR and MAP kinases. Furthermore, inhibition of the EGF receptor by AG1478 significantly reduced NT-induced IL-8 promoter activity and IL-8 secretion. This is the first report demonstrating that NT binding to NTR1 transactivates the EGFR and that this response is linked to NT-mediated proinflammatory signaling. Our findings indicate that matrix metalloproteinase-mediated release of TGFalpha and subsequent EGFR transactivation triggers a NT-mediated MAP kinase pathway that leads to IL-8 gene expression in human colonic epithelial cells.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02468 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02468 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	cpothoul@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [K01CA098581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060729, K01DK064920] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA098581] Funding Source: Medline; NIDDK NIH HHS [DK060729, KO1 DK064920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adomeit A, 1999, MOL CELL BIOL, V19, P5289; AMAR S, 1986, FEBS LETT, V201, P31, DOI 10.1016/0014-5793(86)80565-8; BACA I, 1982, DIGESTION, V23, P174, DOI 10.1159/000198725; Bertelsen LS, 2004, J BIOL CHEM, V279, P6271, DOI 10.1074/jbc.M311612200; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; BUENO L, 1985, AM J PHYSIOL, V248, pG15, DOI 10.1152/ajpgi.1985.248.1.G15; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; Carraway RE, 1998, MOL CELL ENDOCRINOL, V144, P47, DOI 10.1016/S0303-7207(98)00154-3; Castagliuolo I, 1996, P NATL ACAD SCI USA, V93, P12611, DOI 10.1073/pnas.93.22.12611; Castagliuolo I, 1999, J CLIN INVEST, V103, P843, DOI 10.1172/JCI4217; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Ehlers RA, 1998, SURGERY, V124, P239, DOI 10.1067/msy.1998.90370; Ehlers RA, 2000, BIOCHEM BIOPH RES CO, V269, P704, DOI 10.1006/bbrc.2000.2335; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Guha S, 2003, CANCER RES, V63, P2379; Gui XY, 2000, COMP BIOCHEM PHYS C, V127, P61, DOI 10.1016/S0742-8413(00)00126-2; IZUKURA M, 1992, ANN SURG, V215, P520, DOI 10.1097/00000658-199205000-00015; JONES MK, 1999, FRONT BIOSCI, V4, P303, DOI DOI 10.2741/A428; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; POLAK JM, 1977, NATURE, V270, P183, DOI 10.1038/270183a0; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; REASBECK PG, 1984, GASTROENTEROLOGY, V86, P1552; REINECKE M, 1985, PROG HISTOCHEM CYTOC, V16, P1; Riegler M, 2000, GASTROENTEROLOGY, V119, P348, DOI 10.1053/gast.2000.9310; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Roger T, 1998, BIOCHEM J, V330, P429, DOI 10.1042/bj3300429; SCHAFER B, 2003, ONCOGENE; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; WIKLUND B, 1984, REGUL PEPTIDES, V8, P33, DOI 10.1016/0167-0115(84)90026-0; WOOD JG, 1988, AM J PHYSIOL, V255, P813; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yoshinaga K, 1992, Surg Oncol, V1, P127, DOI 10.1016/0960-7404(92)90025-G; Zhao DZ, 2001, J BIOL CHEM, V276, P30579, DOI 10.1074/jbc.M103761200; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	58	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43547	43554		10.1074/jbc.M401453200	http://dx.doi.org/10.1074/jbc.M401453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15247267	hybrid			2022-12-25	WOS:000224383100025
J	Kerner, J; Distler, AM; Minkler, P; Parland, W; Peterman, SM; Hoppel, CL				Kerner, J; Distler, AM; Minkler, P; Parland, W; Peterman, SM; Hoppel, CL			Phosphorylation of rat liver mitochondrial carnitine palmitoyltransferase-I - Effect on the kinetic properties of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION/IONIZATION MASS-SPECTROMETRY; MALONYL-COA SENSITIVITY; ACID CHANGE SUBSTITUTION; OUTER MEMBRANES; CHIMERIC PROTEINS; CONTACT SITES; INHIBITION; HEPATOCYTES; INVOLVEMENT; OXIDATION	Hepatic carnitine palmitoyltransferase-I (CPT-I-L) isolated from mitochondrial outer membranes obtained in the presence of protein phosphatase inhibitors is readily recognized by phosphoamino acid antibodies. Mass spectrometric analysis of CPT-I-L tryptic digests revealed the presence of three phosphopeptides including one with a protein kinase CKII ( CKII) consensus site. Incubation of dephosphorylated outer membranes with protein kinases and [gamma-P-32]ATP resulted in radiolabeling of CPT-I only by CKII. Using mass spectrometry, only one region of phosphorylation was detected in CPT-I isolated from CKII-treated mitochondria. The sequence of the peptide and position of phosphorylated amino acids have been determined unequivocally as FpSSPETDpSHRFGK (residues 740-752). Furthermore, incubation of dephosphorylated outer membranes with CKII and unlabeled ATP led to increased catalytic activity and rendered malonyl-CoA inhibition of CPT-I from competitive to uncompetitive. These observations identify a new mechanism for regulation of hepatic CPT-I by phosphorylation.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Louis Stokes Dept Vet Affairs Med Ctr, Med Res Serv, Cleveland, OH 44106 USA; Thermo Electron, Somerset, NJ 08873 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Hoppel, CL (corresponding author), Louis Stokes VA Med Ctr, Med Res Serv, 10701 E Blvd, Cleveland, OH 44106 USA.	charles.hoppel@case.edu			NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG15885] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnidge DR, 1999, ANAL BIOCHEM, V269, P1, DOI 10.1006/abio.1999.4012; Bodnar WM, 2003, J AM SOC MASS SPECTR, V14, P971, DOI 10.1016/S1044-0305(03)00209-5; BRADY LJ, 1985, BIOCHEM J, V232, P445, DOI 10.1042/bj2320445; Breaux GA, 2000, ANAL CHEM, V72, P1169, DOI 10.1021/ac9907282; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; Ghaim JB, 1997, BBA-BIOMEMBRANES, V1330, P113, DOI 10.1016/S0005-2736(97)00127-2; Green-Church KB, 1998, ANAL CHEM, V70, P5322, DOI 10.1021/ac980667s; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; GUZMAN M, 1994, BIOCHEM J, V300, P693, DOI 10.1042/bj3000693; Hoppel C, 2004, FASEB J, V18, pA862; Hoppel C, 2002, ANAL BIOCHEM, V302, P60, DOI 10.1006/abio.2001.5531; Hoppel C, 2002, FASEB J, V16, pA158; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; Hoppel CL, 1998, J BIOL CHEM, V273, P23495, DOI 10.1074/jbc.273.36.23495; INGALLS ST, 1982, J LABELLED COMP RADI, V9, P365; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Marx MK, 1998, ANAL BIOCHEM, V256, P192, DOI 10.1006/abio.1997.2492; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Morillas M, 2003, J BIOL CHEM, V278, P9058, DOI 10.1074/jbc.M209999200; MYNATT RL, 1994, BIOCHEM J, V299, P761, DOI 10.1042/bj2990761; Napal L, 2003, J BIOL CHEM, V278, P34084, DOI 10.1074/jbc.M305826200; PEGORIER JP, 1989, BIOCHEM J, V264, P93, DOI 10.1042/bj2640093; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; ROBINSON N, 1982, BIOCHEM J, V266, P177; SAGGERSON ED, 1981, FEBS LETT, V129, P225, DOI 10.1016/0014-5793(81)80170-6; Schey K L, 1996, Methods Mol Biol, V61, P227; SCHINDLER PA, 1993, ANAL BIOCHEM, V213, P256, DOI 10.1006/abio.1993.1418; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3; Sleboda J, 1999, BBA-MOL CELL BIOL L, V1436, P541, DOI 10.1016/S0005-2760(98)00164-7; STAKKESTAD JA, 1983, BIOCHIM BIOPHYS ACTA, V750, P244, DOI 10.1016/0005-2760(83)90025-5; Sugden MC, 1999, HORM METAB RES, V31, P300, DOI 10.1055/s-2007-978741; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Velasco G, 1999, ADV EXP MED BIOL, V466, P43; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5	42	50	52	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41104	41113		10.1074/jbc.M406570200	http://dx.doi.org/10.1074/jbc.M406570200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247243	hybrid			2022-12-25	WOS:000223916800109
J	Penin, F; Brass, V; Appel, N; Ramboarina, S; Montserret, R; Ficheux, D; Blum, HE; Bartenschlager, R; Moradpour, D				Penin, F; Brass, V; Appel, N; Ramboarina, S; Montserret, R; Ficheux, D; Blum, HE; Bartenschlager, R; Moradpour, D			Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS 2C PROTEIN; RNA REPLICATION; AMPHIPATHIC HELIX; BINDING; PEPTIDE; TRYPTOPHAN; HYPERPHOSPHORYLATION; IDENTIFICATION; DETERMINANTS; LOCALIZATION	Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a membrane-associated, essential component of the viral replication complex. Here, we report the three-dimensional structure of the membrane anchor domain of NS5A as determined by NMR spectroscopy. An alpha-helix extending from amino acid residue 5 to 25 was observed in the presence of different membrane mimetic media. This helix exhibited a hydrophobic, Trp-rich side embedded in detergent micelles, while the polar, charged side was exposed to the solvent. Thus, the NS5A membrane anchor domain forms an in-plane amphipathic alpha-helix embedded in the cytosolic leaflet of the membrane bilayer. Interestingly, mutations affecting the positioning of fully conserved residues located at the cytosolic surface of the helix impaired HCV RNA replication without interfering with the membrane association of NS5A. In conclusion, the NS5A membrane anchor domain constitutes a unique platform that is likely involved in specific interactions essential for the assembly of the HCV replication complex and that may represent a novel target for antiviral intervention.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; CNRS, Inst Biol & Chim Proteines, UMR 5086, IFR128 Biosci, F-69367 Lyon 07, France; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ruprecht Karls University Heidelberg	Moradpour, D (corresponding author), Univ Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	Darius.Moradpour@uni-freiburg.de	PENIN, Francois/A-7315-2008; Bartenschlager, Ralf/L-2582-2015; Moradpour, Darius/G-7918-2017	Bartenschlager, Ralf/0000-0001-5601-9307; Moradpour, Darius/0000-0003-1977-6792				Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Dubuisson J, 2002, TRENDS CELL BIOL, V12, P517, DOI 10.1016/S0962-8924(02)02383-8; Echeverri A, 1998, VIRUS RES, V54, P217, DOI 10.1016/S0168-1702(98)00016-1; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Elazar M, 2003, J VIROL, V77, P6055, DOI 10.1128/JVI.77.10.6055-6061.2003; Favier A, 2002, J MOL BIOL, V317, P131, DOI 10.1006/jmbi.2002.5397; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Koch JO, 1999, J VIROL, V73, P7138; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Kusov YY, 1998, ARCH VIROL, V143, P931, DOI 10.1007/s007050050343; Lampio A, 2000, J BIOL CHEM, V275, P37853, DOI 10.1074/jbc.M004865200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Miller DJ, 2002, J VIROL, V76, P9856, DOI 10.1128/JVI.76.19.9856-9867.2002; Miyanari Y, 2003, J BIOL CHEM, V278, P50301, DOI 10.1074/jbc.M305684200; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Moradpour D, 2002, TRENDS MOL MED, V8, P476, DOI 10.1016/S1471-4914(02)02395-X; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; *NIH, 2002, HEPATOLOGY S1, V36, pS2; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; Nina M, 2000, EUR BIOPHYS J BIOPHY, V29, P439, DOI 10.1007/PL00006649; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; Penin F, 1997, J MOL BIOL, V270, P496, DOI 10.1006/jmbi.1997.1123; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; SCHWEIZER A, 1993, J CELL SCI, V104, P671; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; Teterina NL, 1997, J VIROL, V71, P8962, DOI 10.1128/JVI.71.12.8962-8972.1997; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	51	233	243	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40835	40843		10.1074/jbc.M404761200	http://dx.doi.org/10.1074/jbc.M404761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247283	hybrid			2022-12-25	WOS:000223916800078
J	Koh, HJ; Lee, SM; Son, BG; Lee, SH; Ryoo, ZY; Chang, KT; Park, JW; Park, DC; Song, BJ; Veech, RL; Song, HB; Huh, TL				Koh, HJ; Lee, SM; Son, BG; Lee, SH; Ryoo, ZY; Chang, KT; Park, JW; Park, DC; Song, BJ; Veech, RL; Song, HB; Huh, TL			Cytosolic NADP(+)-dependent isocitrate dehydrogenase plays a key role in lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PPAR-GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; OXIDATIVE DAMAGE; TRANSGENIC MICE; ANIMAL TISSUES; ADIPOSE-TISSUE; C/EBP-ALPHA; ADIPOGENESIS; PATHWAY	NADPH is an essential cofactor for many enzymatic reactions including glutathione metabolism and fat and cholesterol biosynthesis. We have reported recently an important role for mitochondrial NADP(+)-dependent isocitrate dehydrogenase in cellular defense against oxidative damage by providing NADPH needed for the regeneration of reduced glutathione. However, the role of cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDPc) is still unclear. We report here for the first time that IDPc plays a critical role in fat and cholesterol biosynthesis. During differentiation of 3T3-L1 adipocytes, both IDPc enzyme activity and its protein content were increased in parallel in a time-dependent manner. Increased expression of IDPc by stable transfection of IDPc cDNA positively correlated with adipogenesis of 3T3-L1 cells, whereas decreased IDPc expression by an antisense IDPc vector retarded adipogenesis. Furthermore, transgenic mice with overexpressed IDPc exhibited fatty liver, hyperlipidemia, and obesity. In the epididymal fat pads of the transgenic mice, the expressions of adipocyte-specific genes including peroxisome proliferator-activated receptor gamma were markedly elevated. The hepatic and epididymal fat pad contents of acetylCoA and malonyl-CoA in the transgenic mice were significantly lower, whereas the total triglyceride and cholesterol contents were markedly higher in the liver and serum of transgenic mice compared with those measured in wild type mice, suggesting that the consumption rate of those lipogenic precursors needed for fat biosynthesis must be increased by elevated IDPc activity. Taken together, our findings strongly indicate that IDPc would be a major NADPH producer required for fat and cholesterol synthesis.	Kyungpook Natl Univ, Dept Genet Engn, Taegu 702701, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 702701, South Korea; Catholic Univ Korea, Catholic Res Inst Med Sci, Res Inst Expt Anim, Seoul 133701, South Korea; Korea Res Inst Biosci & Biotechnol, Genet Resources Ctr, Taejon 305333, South Korea; Kyungpook Natl Univ, TG Biotech Co Ltd, Taegu, South Korea; NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	Kyungpook National University; Kyungpook National University; Catholic University of Korea; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kyungpook National University; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Huh, TL (corresponding author), Kyungpook Natl Univ, Dept Genet Engn, Taegu 702701, South Korea.	tlhuh@knu.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000110, Z01AA000036, ZIAAA000036, ZIAAA000110] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; Chagnon YC, 1996, TRENDS GENET, V12, P441, DOI 10.1016/0168-9525(96)30103-0; CUPP JR, 1991, J BIOL CHEM, V266, P22199; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GLOCK GE, 1955, BIOCHEM J, V61, P388, DOI 10.1042/bj0610388; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUMAA KA, 1973, EUR J BIOCHEM, V34, P188, DOI 10.1111/j.1432-1033.1973.tb02745.x; GUMAA KA, 1969, BIOCHEM J, V114, P253, DOI 10.1042/bj1140253; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; KING MT, 1988, METHOD ENZYMOL, V166, P70; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; MARTIN BR, 1970, BIOCHEM J, V117, P861, DOI 10.1042/bj1170861; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCLEAN P, 1968, CARBOHYD METABOL, P397; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; NOLTMANN EA, 1963, ENZYMES, V7, P223; Pankiewicz A, 2003, INT J BIOCHEM CELL B, V35, P235, DOI 10.1016/S1357-2725(02)00084-5; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PLAUT GWE, 1983, BIOCH METABOLIC PROC, P285; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SHANTZ LM, 1989, P NATL ACAD SCI USA, V86, P3852, DOI 10.1073/pnas.86.10.3852; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; YOUNG JW, 1964, BIOCHEMISTRY-US, V3, P1687, DOI 10.1021/bi00899a015	32	159	163	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39968	39974		10.1074/jbc.M402260200	http://dx.doi.org/10.1074/jbc.M402260200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254034	hybrid			2022-12-25	WOS:000223791500093
J	Takada, Y; Fang, XJ; Jamaluddin, MS; Boyd, DD; Aggarwal, BB				Takada, Y; Fang, XJ; Jamaluddin, MS; Boyd, DD; Aggarwal, BB			Genetic deletion of glycogen synthase kinase-3 beta abrogates activation of I kappa B alpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURVIVAL; BETA-CATENIN; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; P65 PHOSPHORYLATION; TNF-ALPHA; C-JUN; CONSTITUTIVE ACTIVATION; DEPENDENT INDUCTION; DOWN-REGULATION	Glycogen synthase kinase (GSK)-3beta is a constitutively active, proline-directed serine/threonine kinase that controls growth modulation and tumorigenesis through multiple intracellular signaling pathways. How GSK-3beta regulates signaling pathways induced by cytokines such as tumor necrosis factor (TNF) is poorly understood. In this study, we used fibroblasts derived from GSK-3beta gene-deleted mice to understand the role of this kinase in TNF signaling. TNF induced NF-kappaB activation as measured by DNA binding in wild-type mouse embryonic fibroblasts, but deletion of GSK-3beta abolished this activation. This inhibition was due to suppression of IkappaBalpha kinase activation and IkappaBalpha phosphorylation, ubiquitination, and degradation. TNF-induced NF-kappaB reporter gene transcription was also suppressed in GSK-3beta gene-deleted cells. NF-kappaB activation induced by lipopolysaccharide, interleukin-1beta, or cigarette smoke condensate was completely suppressed in GSK-3beta(-/-) cells. Deletion of GSK-3beta also abolished TNF-induced c-Jun N-terminal kinase and p44/p42 mitogen-activated kinase activation. Most surprisingly, TNF-induced Akt activation also required the presence of GSK-3beta. TNF induced expression of the NF-kappaB-regulated gene products cyclin D1, COX-2, MMP-9, survivin, IAP 1, IAP 2, Bcl-x(L), Bfl-1/A1, TRAF1, and FLIP in wild-type mouse embryonic fibroblasts but not in GSK-3beta(-/-) cells, and this correlated with potentiation of TNF-induced apoptosis as indicated by cell viability, annexin V staining, and caspase activation. Overall, our results indicate that GSK-3beta plays a critical role in TNF signaling and in the signaling of other inflammatory stimuli and that its suppression can be exploited as a potential target to inhibit angiogenesis, proliferation, and survival of tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Cytokine Res Lab, Houston, TX 77030 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Virginia Commonwealth University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA97007, P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashikawa K, 2004, BIOCHEM PHARMACOL, V67, P353, DOI 10.1016/j.bcp.2003.08.039; Barbin G, 2001, NEUROCHEM RES, V26, P107, DOI 10.1023/A:1011086426652; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gallagher ED, 2002, J BIOL CHEM, V277, P45785, DOI 10.1074/jbc.M207702200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liao XB, 2003, MOL CANCER THER, V2, P1215; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Tong N, 2001, EUR J NEUROSCI, V13, P1913, DOI 10.1046/j.0953-816x.2001.01572.x; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	87	175	182	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39541	39554		10.1074/jbc.M403449200	http://dx.doi.org/10.1074/jbc.M403449200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252041	hybrid			2022-12-25	WOS:000223791500044
J	Ishimizu, T; Sasaki, A; Okutani, S; Maeda, M; Yamagishi, M; Hase, S				Ishimizu, T; Sasaki, A; Okutani, S; Maeda, M; Yamagishi, M; Hase, S			Endo-beta-mannosidase, a plant enzyme acting on N-glycan - Purification, molecular cloning, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; GAMETOPHYTIC SELF-INCOMPATIBILITY; GLYCOSYL HYDROLASES; SUGAR CHAINS; CELLULOMONAS-FIMI; CDNA; GENE; IDENTIFICATION; EXPRESSION; PROTEINS	Endo-beta-mannosidase is a novel endoglycosidase that hydrolyzes the Manbeta1-4GlcNAc linkage in the trimannosyl core structure of N-glycans. This enzyme was partially purified and characterized in a previous report (Sasaki, A., Yamagishi, M., Mega, T., Norioka, S., Natsuka, S., and Hase, S. ( 1999) J. Biochem. 125, 363 - 367). Here we report the purification and molecular cloning of endo-beta-mannosidase. The enzyme purified from lily flowers gave a single band on native-PAGE and three bands on SDS-PAGE with molecular masses of 42, 31, and 28 kDa. Amino acid sequence information from these three polypeptides allowed the cloning of a homologous gene, AtEBM, from Arabidopsis thaliana. AtEBM was engineered for expression in Escherichia coli, and the recombinant protein comprised a single polypeptide chain with a molecular mass of 112 kDa corresponding to the sum of molecular masses of three polypeptides of the lily enzyme. The recombinant protein hydrolyzed pyridylamino derivatives (PA) of Manalpha1-6Manbeta1-4Glc-NAcbeta1-4GlcNAc into Manalpha1-6Man and GlcNAcbeta1-4Glc-NAc-PA, showing that AtEBM is an endo-beta-mannosidase. AtEBM hydrolyzed Man(n)Manalpha1-6Manbeta1- 4GlcNAcbeta1-4GlcNAc-PA (n = 0 - 2) but not PA-sugar chains containing Manalpha1- 3Manbeta or Xylosebeta1-2Manbeta as for the lily endo-beta-mannosidase. AtEBM belonged to the clan GH-A of glycosyl hydrolases. Site-directed mutagenesis experiments revealed that two glutamic acid residues (Glu-464 and Glu-549) conserved in this clan were critical for enzyme activity. The amino acid sequence of AtEBM has distinct differences from those of the bacterial, fungal, and animal exo-type beta-mannosidases. Indeed, AtEBM-like genes are only found in plants, indicating that endo-beta-mannosidase is a plant-specific enzyme. The role of this enzyme in the processing and/or degradation of N-glycan will be discussed.	Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan	Osaka University	Hase, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan.	suhase@chem.sci.osaka-u.ac.jp	Ishimizu, Takeshi/K-9139-2017	Ishimizu, Takeshi/0000-0003-4910-6810; Yamagishi, Mai/0000-0002-4449-5899				Ademark P, 2001, EUR J BIOCHEM, V268, P2982, DOI 10.1046/j.1432-1327.2001.02188.x; Alkhayat AH, 1998, HUM MOL GENET, V7, P75, DOI 10.1093/hmg/7.1.75; Araki T, 2000, APPL ENVIRON MICROB, V66, P1741, DOI 10.1128/AEM.66.4.1741-1743.2000; Beccari T, 2001, BIOSCIENCE REP, V21, P315, DOI 10.1023/A:1013286216030; Beki E, 2003, APPL ENVIRON MICROB, V69, P1944, DOI 10.1128/AEM.69.4.1944-1952.2003; BERMAN E, 1981, J BIOL CHEM, V256, P6657; Bewley JD, 1997, PLANTA, V203, P454, DOI 10.1007/s004250050214; CHEN H, 1995, J BIOL CHEM, V270, P3841, DOI 10.1074/jbc.270.8.4088; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; Dhanawansa R, 2002, GLYCOBIOLOGY, V12, P229, DOI 10.1093/glycob/12.3.229; Durand P, 1997, GLYCOBIOLOGY, V7, P277, DOI 10.1093/glycob/7.2.277; Hamagashira N, 1996, J BIOCHEM-TOKYO, V119, P998; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; Ishimizu T, 1999, EUR J BIOCHEM, V263, P624, DOI 10.1046/j.1432-1327.1999.00499.x; Ishimizu T, 1996, EUR J BIOCHEM, V242, P627, DOI 10.1111/j.1432-1033.1996.0627r.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leipprandt JR, 1996, GENOMICS, V37, P51, DOI 10.1006/geno.1996.0519; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MALEY F, 1981, J BIOL CHEM, V256, P1088; OKU H, 1990, ANAL BIOCHEM, V185, P331, DOI 10.1016/0003-2697(90)90303-Q; Parker KN, 2001, BIOTECHNOL BIOENG, V75, P322, DOI 10.1002/bit.10020; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sasaki A, 1999, J BIOCHEM-TOKYO, V125, P363, DOI 10.1093/oxfordjournals.jbchem.a022295; Stoll D, 1999, APPL ENVIRON MICROB, V65, P2598; Stoll D, 2000, BIOCHEM J, V351, P833, DOI 10.1042/0264-6021:3510833; SUGAHARA K, 1972, BIOCHIM BIOPHYS ACTA, V268, P488, DOI 10.1016/0005-2744(72)90344-0; Takada G, 1999, BIOSCI BIOTECH BIOCH, V63, P206, DOI 10.1271/bbb.63.206; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VILLARROYA H, 1976, BIOCHIM BIOPHYS ACTA, V438, P200, DOI 10.1016/0005-2744(76)90236-9; Yanagida K, 1998, J CHROMATOGR A, V800, P187, DOI 10.1016/S0021-9673(97)01109-6	34	22	24	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38555	38562		10.1074/jbc.M406886200	http://dx.doi.org/10.1074/jbc.M406886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247239	hybrid			2022-12-25	WOS:000223684100061
J	McNally, LM; Yee, L; McNally, MT				McNally, LM; Yee, L; McNally, MT			Two regions promote U11 small nuclear ribonucleoprotein particle binding to a retroviral splicing inhibitor element (negative regulator of splicing)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; AT-AC; SR PROTEIN; SITE; INTRON; SEQUENCES; REQUIRES; RECOGNITION; SPLICEOSOME	The Rous sarcoma virus (RSV) negative regulator of splicing (NRS) is an RNA element that represses splicing and promotes polyadenylation of viral RNA. The NRS acts as a pseudo 5' splice site ( ss), and serine-arginine (SR) proteins, U1snRNP, and U6 small nuclear ribonucleoproteins (snRNPs) are implicated in its function. The NRS also efficiently binds U11 snRNP of the U12-dependent splicing pathway, which is interesting, because U11 binds only poorly to authentic substrates that lack a U12-type 3' splice site. It is of considerable interest to understand how the low abundance U11 snRNP binds the NRS so well. Here we show that U11 can bind the NRS as a mono-snRNP in vitro and that a G-rich element located downstream of the U11 site is required for efficient binding. Mutational analyses indicated that two of four G tracts in this region were important for optimal U11 binding and that the G-rich region did not function indirectly by promoting U1 snRNP binding to an overlapping site. Surprisingly, inactivation of U2 snRNP also decreased U11 binding to the NRS. The NRS harbors a branch point-like/pyrimidine tract sequence (BP/Py) just upstream of the U1/U11 site that is characteristic of 3' splice sites. Deletion of this region decreased U2 and U11 binding, and deletion of the G-rich region also reduced U2 binding. The G element, but not the BP/Py sequence, was also required for U11 binding to the NRS in vivo as assessed by minor class splicing from the NRS to a minor class 3' ss from the P120 gene. These results indicate that efficient U11 binding to the isolated NRS involves at least two elements in addition to the U11 consensus sequence and may have implications for U11 binding to authentic splicing substrates.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	McNally, MT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mtm@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA078709] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078709, R01 CA078709-07, R01-CA78709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO S, 1988, MOL CELL BIOL, V8, P4858, DOI 10.1128/MCB.8.11.4858; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; Burge CB, 1999, RNA WORLD, P525; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; COFFIN JM, 1997, RETROVIRUSES, P205; Cook CR, 1998, VIROLOGY, V242, P211, DOI 10.1006/viro.1997.8983; Cook CR, 1999, J VIROL, V73, P2394, DOI 10.1128/JVI.73.3.2394-2400.1999; Dietrich RC, 2001, MOL CELL BIOL, V21, P1942, DOI 10.1128/MCB.21.6.1942-1952.2001; Dietrich RC, 2001, RNA, V7, P1378; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; Flint S.J., 2000, PRINCIPLES VIROLOGY; Fogel BL, 2002, NUCLEIC ACIDS RES, V30, P810, DOI 10.1093/nar/30.3.810; Frilander MJ, 1999, GENE DEV, V13, P851, DOI 10.1101/gad.13.7.851; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hibbert CS, 1999, RNA, V5, P333, DOI 10.1017/S1355838299981347; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; McNally LM, 1998, MOL CELL BIOL, V18, P3103, DOI 10.1128/MCB.18.6.3103; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MERIC C, 1986, J VIROL, V60, P450; MILLER JT, 1992, J VIROL, V66, P4242, DOI 10.1128/JVI.66.7.4242-4251.1992; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; O'Sullivan CT, 2002, VIROLOGY, V302, P405, DOI 10.1006/viro.2002.1616; Paca RE, 2001, J VIROL, V75, P7763, DOI 10.1128/JVI.75.16.7763-7768.2001; Polony TS, 2003, J VIROL, V77, P9378, DOI 10.1128/JVI.77.17.9378-9387.2003; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SERAPHIN B, 1991, EMBO J, V10, P1209, DOI 10.1002/j.1460-2075.1991.tb08062.x; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STOLTZFUS CM, 1989, J VIROL, V63, P1669, DOI 10.1128/JVI.63.4.1669-1676.1989; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; Wu Q, 1996, SCIENCE, V274, P1005, DOI 10.1126/science.274.5289.1005; Xu YZ, 2004, EMBO J, V23, P376, DOI 10.1038/sj.emboj.7600050	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38201	38208		10.1074/jbc.M407073200	http://dx.doi.org/10.1074/jbc.M407073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252020	hybrid			2022-12-25	WOS:000223684100019
J	Shin, NY; Dise, RS; Schneider-Mergener, J; Ritchie, MD; Kilkenny, DM; Hanks, SK				Shin, NY; Dise, RS; Schneider-Mergener, J; Ritchie, MD; Kilkenny, DM; Hanks, SK			Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC FAMILY KINASES; SIGNALING COMPLEX-FORMATION; P130(CAS); INTEGRIN; DOMAIN; NCK; LOCALIZATION; INDUCTION; PROTEINS	Crk-associated substrate (p130(CAS) or CAS) is a major integrin-associated Src substrate that undergoes tyrosine phosphorylation at multiple YXXP motifs in its substrate domain (SD) to create docking sites for SH2-containing signaling effectors. Notably, recruitment of Crk adaptor proteins to the CAS SD sites is implicated in promoting cell migration. However, it is unclear which or how many of the 15 CAS SD YXXP tyrosines are critically involved. To gain a better understanding of CAS SD function, we assessed the signaling capacity of individual YXXP motifs. Using site-directed mutagenesis combined with tryptic phosphopeptide mapping, we determined that the ten tyrosines in YXXP motifs 6-15 are the major sites of CAS SD phosphorylation by Src. Phosphopeptide binding assays showed that all of these sites are capable of binding the Crk SH2 domain. To evaluate the requirement for CAS YXXP sites in stimulating cell migration, a series of phenylalanine substitution variants were expressed in CAS -/- mouse embryo fibroblasts. CAS expression enhanced the rate of cell migration into a monolayer wound in a manner dependent on the major sites of Src phosphorylation. Effective wound healing was achieved by CAS variants containing as few as four of the major sites, indicating sufficiency of partial SD signaling function in this cell migration response.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell Imaging Shared Resource, Nashville, TN 37232 USA; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10117 Berlin, Germany	Vanderbilt University; Vanderbilt University; Vanderbilt University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hanks, SK (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Cell & Dev Biol, U-4206 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	steve.hanks@vanderbilt.edu	Ritchie, Marylyn/C-1114-2012		NIGMS NIH HHS [GM49882] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL F, 1995, SHORT PROTOCOLS MOL, P8; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sieg DJ, 1999, J CELL SCI, V112, P2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38331	38337		10.1074/jbc.M404675200	http://dx.doi.org/10.1074/jbc.M404675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247284	hybrid			2022-12-25	WOS:000223684100033
J	Tan, YV; Couvineau, A; Laburthe, M				Tan, YV; Couvineau, A; Laburthe, M			Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa(6)]-VIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXTRACELLULAR DOMAIN; CRUCIAL ROLE; AMINO-ACIDS; BINDING; IDENTIFICATION; SELECTIVITY; MUTAGENESIS; RESIDUES; ACTIVATION	The widespread 28-amino acid neuropeptide vasoactive intestinal peptide (VIP) exerts its many biological effects through interaction with serpentine class II G protein-coupled receptors named VPAC receptors. We previously provided evidence for a physical contact between the side chain at position 22 of VIP and the N-terminal ectodomain of the hVPAC1 receptor (Tan, Y.V., Couvineau, A., Van Rampelbergh, J., and Laburthe, M. (2003) J. Biol. Chem. 278, 36531-36536). We explored here the contact site between hVPAC1 receptor and the side chain at position 6 of VIP by photoaffinity labeling. The photoreactive para-benzoyl-L-Phe (Bpa) was substituted for Phe(6) in VIP resulting in [Bpa(6)]-VIP, which was shown to be a hVPAC1 receptor agonist in Chinese hamster ovary cells stably expressing the recombinant receptor. After obtaining the covalent I-125-[Bpa(6)-VIP].hVPAC1 receptor complex, it was sequentially cleaved by cyanogen bromide, peptide N-glycosidase F, endopeptidase Glu-C, and trypsin, and the cleavage products were analyzed by electrophoresis. The data demonstrated that I-125-[ Bpa(6)-VIP] were covalently attached to the short 104-108 fragment within the N-terminal ectodomain of the receptor. The data were confirmed by creation of a receptor mutant with new CNBr cleavage site. In a three-dimensional model of the receptor N-terminal ectodomain, this fragment was located on one edge of the putative VIP-binding groove and was adjacent to the fragment covalently attached to the side chain at position 22 of VIP. Altogether these data showed that the central part of VIP, at least between Phe(6) and Tyr(22), interacts with the N-terminal ectodomain of the hVPAC1 receptor.	Univ Paris 07, INSERM, U410, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Univ Paris 07, INSERM, U410, F-75018 Paris, France.	laburthe@bichat.inserm.fr	LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Du K, 2002, J BIOL CHEM, V277, P37016, DOI 10.1074/jbc.M203049200; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Gaylinn BD, 2002, RECEPTOR CHANNEL, V8, P155, DOI 10.1080/10606820213679; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Nicole P, 2000, BIOCHEM BIOPH RES CO, V276, P654, DOI 10.1006/bbrc.2000.3375; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200	25	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38889	38894		10.1074/jbc.M404460200	http://dx.doi.org/10.1074/jbc.M404460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247290	hybrid			2022-12-25	WOS:000223684100102
J	Yano, JK; Wester, MR; Schoch, GA; Griffin, KJ; Stout, CD; Johnson, EF				Yano, JK; Wester, MR; Schoch, GA; Griffin, KJ; Stout, CD; Johnson, EF			The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION SITE; ACTIVE-SITE; SCANNING MUTAGENESIS; ANGSTROM RESOLUTION; MEMBRANE-BINDING; CYP3A4; P4502C5; COOPERATIVITY; SPECIFICITY; ACTIVATION	The structure of P450 3A4 was determined by x-ray crystallography to 2.05-Angstrom resolution. P450 3A4 catalyzes the metabolic clearance of a large number of clinically used drugs, and a number of adverse drug-drug interactions reflect the inhibition or induction of the enzyme. P450 3A4 exhibits a relatively large substrate-binding cavity that is consistent with its capacity to oxidize bulky substrates such as cyclosporin, statins, taxanes, and macrolide antibiotics. Family 3A P450s also exhibit unusual kinetic characteristics that suggest simultaneous occupancy by smaller substrates. Although the active site volume is similar to that of P450 2C8 (PDB code: 1PQ2), the shape of the active site cavity differs considerably due to differences in the folding and packing of portions of the protein that form the cavity. Compared with P450 2C8, the active site cavity of 3A4 is much larger near the heme iron. The lower constraints on the motions of small substrates near the site of oxygen activation may diminish the efficiency of substrate oxidation, which may, in turn, be improved by space restrictions imposed by the presence of a second substrate molecule. The structure of P450 3A4 should facilitate a better understanding of the substrate selectivity of the enzyme.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dave@scripps.edu; johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM031001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CORREIA MA, 1995, ARCH BIOCHEM BIOPHYS, V317, P471, DOI 10.1006/abbi.1995.1190; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585; Domanski TL, 2001, BIOCHEMISTRY-US, V40, P10150, DOI 10.1021/bi010758a; Fowler SM, 2000, BIOCHEMISTRY-US, V39, P4406, DOI 10.1021/bi992372u; Fowler SM, 2002, DRUG METAB DISPOS, V30, P452, DOI 10.1124/dmd.30.4.452; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Harlow GR, 1997, J BIOL CHEM, V272, P5396, DOI 10.1074/jbc.272.9.5396; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; He YA, 2003, ARCH BIOCHEM BIOPHYS, V409, P92, DOI 10.1016/S0003-9861(02)00484-8; Jefcoate C R, 1978, Methods Enzymol, V52, P258; JOHNSON EF, 1988, J BIOL CHEM, V263, P17672; Jung F, 1998, BIOCHEMISTRY-US, V37, P16270, DOI 10.1021/bi981704c; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Lee DS, 2002, ACTA CRYSTALLOGR D, V58, P687, DOI 10.1107/S0907444902001762; Li AP, 1995, TOXICOLOGY, V104, P1, DOI 10.1016/0300-483X(95)03155-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Newcomb M, 2003, J AM CHEM SOC, V125, P6064, DOI 10.1021/ja0343858; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; Roussel F, 2000, ARCH BIOCHEM BIOPHYS, V374, P269, DOI 10.1006/abbi.1999.1599; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Tanaka E, 1998, J CLIN PHARM THER, V23, P403, DOI 10.1046/j.1365-2710.1998.00086.x; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Wilkinson GR, 1996, J PHARMACOKINET BIOP, V24, P475, DOI 10.1007/BF02353475; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Zhang ZP, 2002, BIOCHEMISTRY-US, V41, P2712, DOI 10.1021/bi0119971	37	601	620	6	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38091	38094		10.1074/jbc.C400293200	http://dx.doi.org/10.1074/jbc.C400293200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15258162	hybrid			2022-12-25	WOS:000223684100004
J	Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG				Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG			Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells	ONCOGENE			English	Article						15-lipoxygenase 2; gene expression; Sp1; Sp3; prostate cancer; gene regulation	TRANSCRIPTION FACTORS; HISTONE DEACETYLASE; CANCER CELLS; PROMOTER; ACTIVATION; FAMILY; IDENTIFICATION	In this project, we studied the gene regulation of 15-lipoxygenase 2 (15-LOX2), the most abundant arachidonate-metabolizing LOX in adult human prostate and a negative cell-cycle regulator in normal human prostate (NHP) epithelial cells. Through detailed in silico promoter examination and promoter deletion and activity analysis, we found that several Sp1 sites (i.e., three GC boxes and one CACCC box) in the proximal promoter region play a critical role in regulating 15-LOX2 expression in NHP cells. Several pieces of evidence further suggest that the Sp1 and Sp3 proteins play a physiologically important role in positively and negatively regulating the 15-LOX2 gene expression, respectively. First, mutations in the GC boxes affected the 15-LOX2 promoter activity. Second, both Sp1 and Sp3 proteins were detected in the protein complexes that bound the GC boxes revealed by electrophoretic mobility shift assay. Third, importantly, inhibition of Sp1 activity or overexpression of Sp3 both inhibited the endogenous 15-LOX2 mRNA expression. Since 15-LOX2 is normally expressed in the prostate luminal epithelial cells, we subsequently explored whether androgen/androgen receptor may directly regulate its gene expression. The results indicate that androgen does not directly regulate 15-LOX2 gene expression. Together, these observations provide insight on how 15-LOX2 gene expression may be regulated in NHP cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk R 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NATIONAL CANCER INSTITUTE [R01CA090297, T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90297, T32 CA09480-16] Funding Source: Medline; NIDDK NIH HHS [R01 DK 37340] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chopra DP, 1996, J CELL PHYSIOL, V169, P269, DOI 10.1002/(SICI)1097-4652(199611)169:2<269::AID-JCP6>3.0.CO;2-M; Frith MC, 2001, BIOINFORMATICS, V17, P878, DOI 10.1093/bioinformatics/17.10.878; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaluz S, 2003, CANCER RES, V63, P917; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Sambrook J., 2001, MOL CLONING LAB MANU; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; STRACHAN T, 2000, HUM MOL GENET, P169; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	34	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6942	6953		10.1038/sj.onc.1207913	http://dx.doi.org/10.1038/sj.onc.1207913			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15247906				2022-12-25	WOS:000223750700011
J	Hintner, JP; Remtsma, T; Stolz, A				Hintner, JP; Remtsma, T; Stolz, A			Biochemical and molecular characterization of a ring fission dioxygenase with the ability to oxidize (substituted) salicylate(s) from Pseudaminobacter salicylatoxidans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PSEUDOALCALIGENES JS45; META-CLEAVAGE PATHWAY; GENTISATE 1,2-DIOXYGENASE; 2-AMINOPHENOL 1,6-DIOXYGENASE; ENZYMES; PURIFICATION; 1-HYDROXY-2-NAPHTHOATE; PHENANTHRENE; CATABOLISM; METABOLISM	The gene coding for a dioxygenase with the ability to cleave salicylate by a direct ring fission mechanism to 2-oxohepta-3,5-dienedioic acid was cloned from Pseudaminobacter salicylatoxidans strain BN12. The deduced amino acid sequence encoded a protein with a molecular mass of 41,176 Da, which showed 28 and 31% sequence identity, respectively, to a gentisate 1,2-dioxygenase from Pseudomonas alcaligenes NCIMB 9867 and a 1-hydroxy-2- naphthoate 1,2-dioxygenase from Nocardioides sp. KP7. The highest degree of sequence identity (58%) was found to a presumed gentisate 1,2-dioxygenase from Corynebacterium glutamicum. The enzyme from P. salicylatoxidans BN12 was heterologously expressed in Escherichia coli and purified as a His-tagged enzyme variant. The purified enzyme oxidized in addition to salicylate, gentisate, 5-aminosalicylate, and 1-hydroxy-2- naphthoate also 3-amino- and 3- and 4-hydroxysalicylate, 5-fluorosalicylate, 3-, 4-, and 5-chlorosalicylate, 3-, 4-, and 5-bromosalicylate, 3-, 4-, and 5-methylsalicylate, and 3,5-dichlorosalicylate. The reactions were analyzed by high pressure liquid chromatography/ mass spectrometry, and the reaction products were tentatively identified. For comparison, the putative gentisate 1,2-dioxygenase from C. glutamicum was functionally expressed in E. coli and shown to convert gentisate but not salicylate or 1-hydroxy-2- naphthoate.	Univ Stuttgart, Inst Microbiol, D-70569 Stuttgart, Germany; Tech Univ Berlin, Dept Water Qual Control, Secretariat KF4, D-10623 Berlin, Germany	University of Stuttgart; Technical University of Berlin	Stolz, A (corresponding author), Univ Stuttgart, Inst Microbiol, Allmandring 31, D-70569 Stuttgart, Germany.	Andreas.Stolz@PO.UNi-Stuttgart.DE						Adachi K, 1999, J BACTERIOL, V181, P757, DOI 10.1128/JB.181.3.757-763.1999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugg TDH, 2001, CHEM COMMUN, P941, DOI 10.1039/b100484k; Chua CH, 2001, FEMS MICROBIOL LETT, V204, P141, DOI 10.1016/S0378-1097(01)00393-7; CRAWFORD RL, 1975, J BACTERIOL, V121, P794, DOI 10.1128/JB.121.3.794-799.1975; CRAWFORD RL, 1979, APPL ENVIRON MICROB, V38, P379, DOI 10.1128/AEM.38.3.379-384.1979; Davis JK, 1999, ARCH MICROBIOL, V172, P330, DOI 10.1007/s002030050787; DORN E, 1974, ARCH MICROBIOL, V99, P61, DOI 10.1007/BF00696222; Feng YM, 1999, APPL ENVIRON MICROB, V65, P946; Fu WJ, 1998, EXTREMOPHILES, V2, P439, DOI 10.1007/s007920050090; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HARPEL MR, 1990, J BIOL CHEM, V265, P22187; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Hintner JP, 2001, J BACTERIOL, V183, P6936, DOI 10.1128/JB.183.23.6936-6942.2001; Iwabuchi T, 1998, J BIOL CHEM, V273, P8332, DOI 10.1074/jbc.273.14.8332; Kampfer P, 1999, INT J SYST BACTERIOL, V49, P887, DOI 10.1099/00207713-49-2-887; KIYOHARA H, 1977, AGR BIOL CHEM TOKYO, V41, P705, DOI 10.1080/00021369.1977.10862566; Kucharczyk R, 1998, FEBS LETT, V424, P127, DOI 10.1016/S0014-5793(98)00153-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lendenmann U, 1996, J BACTERIOL, V178, P6227, DOI 10.1128/jb.178.21.6227-6232.1996; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Mishra V, 2001, CRIT REV MICROBIOL, V27, P133, DOI 10.1080/20014091096729; NORTEMANN B, 1987, THESIS U STUTTGART G; Pang KM, 1997, BIOTECHNIQUES, V22, P1046, DOI 10.2144/97226bm07; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; RUBIO MA, 1986, ARCH MICROBIOL, V145, P116, DOI 10.1007/BF00446767; Scott A., 1964, INTERPRETATION ULTRA, P45; STOLZ A, 1992, BIOCHEM J, V282, P675, DOI 10.1042/bj2820675; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Stumpp T., 2000, BIOSPEKTRUM, V6, P33; Suarez M, 1996, FEMS MICROBIOL LETT, V143, P89, DOI 10.1016/0378-1097(96)00299-6; Takenaka S, 1998, ARCH MICROBIOL, V170, P132, DOI 10.1007/s002030050624; Takenaka S, 1997, J BIOL CHEM, V272, P14727, DOI 10.1074/jbc.272.23.14727; Titus GP, 2000, NAT STRUCT BIOL, V7, P542; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x; Werwath J, 1998, J BACTERIOL, V180, P4171, DOI 10.1128/JB.180.16.4171-4176.1998; Zhou NY, 2001, J BACTERIOL, V183, P700, DOI 10.1128/JB.183.2.700-708.2001	38	38	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37250	37260		10.1074/jbc.M313500200	http://dx.doi.org/10.1074/jbc.M313500200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220336	hybrid			2022-12-25	WOS:000223554600009
J	Majumdar, M; Tarui, T; Shi, BA; Akakura, N; Ruf, W; Takada, Y				Majumdar, M; Tarui, T; Shi, BA; Akakura, N; Ruf, W; Takada, Y			Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL THROMBIN RECEPTOR; ENDOTHELIAL-CELL MIGRATION; HUMAN PERIPHERAL MONOCYTES; ANGIOGENESIS INHIBITOR; NEUTROPHIL MIGRATION; PLATELET ACTIVATION; KRINGLE DOMAINS; ANGIOSTATIN; SITE; COAGULATION	Plasmin is a major extracellular protease that elicits intracellular signals to mediate platelet aggregation, chemotaxis of peripheral blood monocytes, and release of arachidonate and leukotriene from several cell types in a G protein-dependent manner. Angiostatin, a fragment of plasmin( ogen), is a ligand and an antagonist for integrin alpha(9)beta(1). Here we report that plasmin specifically interacts with alpha(9)beta(1) and that plasmin induces migration of cells expressing recombinant alpha(9)beta(1) (alpha(9)-Chinese hamster ovary (CHO) cells). Migration was dependent on an interaction of the kringle domains of plasmin with alpha(9)beta(1) as well as the catalytic activity of plasmin. Angiostatin, representing the kringle domains of plasmin, alone did not induce the migration of alpha(9)-CHO cells, but simultaneous activation of the G protein-coupled protease-activated receptor (PAR)-1 with an agonist peptide induced the migration on angiostatin, whereas PAR-2 or PAR-4 agonist peptides were without effect. Furthermore, a small chemical inhibitor of PAR-1 (RWJ 58259) and a palmitoylated PAR-1-blocking peptide inhibited plasmin-induced migration of alpha(9)-CHO cells. These results suggest that plasmin induces migration by kringle-mediated binding to alpha(9)beta(1) and simultaneous proteolytic activation of PAR-1.	Univ Calif Davis, Med Ctr, Dept Dermatol, Sacramento, CA 95817 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California Davis; Scripps Research Institute; Scripps Research Institute	Takada, Y (corresponding author), Univ Calif Davis, Med Ctr, Dept Dermatol, Suite 3300,4645 2nd Ave, Sacramento, CA 95817 USA.	ytakada@ucdavis.edu	Tarui, Takehiko/L-4778-2019	Tarui, Takehiko/0000-0002-2519-7052; takada, yoshikazu/0000-0001-5481-9589	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL060742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16411, HL60742, T32HL07196] Funding Source: Medline; NIGMS NIH HHS [GM47157] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altrogge LM, 2000, ANAL BIOCHEM, V277, P33, DOI 10.1006/abio.1999.4356; Cao Y, 1998, Prog Mol Subcell Biol, V20, P161; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Castellino FJ, 1997, CIBA F SYMP, V212, P46; CHANG WC, 1993, AM J PHYSIOL, V264, pC271, DOI 10.1152/ajpcell.1993.264.2.C271; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; Kimura M, 1996, AM J PHYSIOL-CELL PH, V271, pC54, DOI 10.1152/ajpcell.1996.271.1.C54; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Okamoto H, 2000, EUR SURG RES, V32, P374, DOI 10.1159/000052220; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pendurthi UR, 2002, ARTERIOSCL THROM VAS, V22, P1421, DOI 10.1161/01.ATV.0000030200.59331.3F; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; SCHAFER AI, 1985, J CLIN INVEST, V75, P456, DOI 10.1172/JCI111720; Shang T, 1999, J LEUKOCYTE BIOL, V66, P809, DOI 10.1002/jlb.66.5.809; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Weide I, 1996, THROMB HAEMOSTASIS, V76, P561; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; Yokasaki Y, 2000, TRENDS CARDIOVAS MED, V10, P155, DOI 10.1016/S1050-1738(00)00055-4; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Young BA, 2001, MOL BIOL CELL, V12, P3214, DOI 10.1091/mbc.12.10.3214; Zhang HC, 2001, J MED CHEM, V44, P1021, DOI 10.1021/jm000506s; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	49	65	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37528	37534		10.1074/jbc.M401372200	http://dx.doi.org/10.1074/jbc.M401372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247268	hybrid			2022-12-25	WOS:000223554600043
J	Yokochi, N; Yoshikane, Y; Trongpanich, Y; Ohnishi, K; Yagi, T				Yokochi, N; Yoshikane, Y; Trongpanich, Y; Ohnishi, K; Yagi, T			Molecular cloning, expression, and properties of an unusual aldo-keto reductase family enzyme, pyridoxal 4-dehydrogenase, that catalyzes irreversible oxidation of pyridoxal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-FUCOSE DEHYDROGENASE; XYLOSE REDUCTASE; RAT-LIVER; PURIFICATION; VITAMIN-B6; DEFINES; GENE	Microbacterium luteolum YK-1 has pyridoxine degradation pathway I. We have cloned the structural gene for the second step enzyme, pyridoxal 4-dehydrogenase. The gene consists of 1,026-bp nucleotides and encodes 342 amino acids. The enzyme was overexpressed under cold shock conditions with a coexpression system and chaperonin GroEL/ES. The recombinant enzyme showed the same properties as the M. luteolum enzyme. The primary sequence of the enzyme was 54% identical with that of D-threo- aldose 1-dehydrogenase from Agrobacterium tumefaciens, a probable aldo-keto reductase (AKR). Upon multiple alignment with enzymes belonging to the 14 AKR families so far reported, pyridoxal 4-dehydrogenase was found to form a new AKR superfamily (AKR15) together with A. tumefaciens D-threo- aldose 1-dehydrogenase and Pseudomonas sp. L-fucose dehydrogenase. These enzymes belong to a distinct branch from the two main ones found in the phylogenic tree of AKR proteins. The enzymes on the new branch are characterized by their inability to reduce the corresponding lactones, which are produced from pyridoxal or sugars. Furthermore, pyridoxal 4-dehydrogenase prefers NAD(+) to NADP(+) as a cofactor, although AKRs generally show higher affinities for the latter.	Kochi Univ, Fac Agr, Dept Bioresource Sci, Nanko Ku, Kochi 7838502, Japan; Kochi Univ, Res Inst Mol Genet, Nanko Ku, Kochi 7838502, Japan	Kochi University; Kochi University	Yagi, T (corresponding author), Kochi Univ, Fac Agr, Dept Bioresource Sci, Nanko Ku, Monobe Otsu 200, Kochi 7838502, Japan.	yagito@cc.kochi-u.ac.jp	Ohnishi, Kouhei/AAN-9527-2020					Achterholt S, 1998, J BACTERIOL, V180, P4387, DOI 10.1128/JB.180.17.4387-4391.1998; BERKOWITZ DB, 1987, BIOCHEMISTRY-US, V26, P2606, DOI 10.1021/bi00383a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG RW, 1969, J BIOL CHEM, V244, P2585; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; ENDO M, 1979, J BIOCHEM-TOKYO, V86, P1559, DOI 10.1093/oxfordjournals.jbchem.a132673; Hacker B, 1999, BIOL CHEM, V380, P1395, DOI 10.1515/BC.1999.179; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; JOSEPH MJ, 2001, CHEM-BIOL INTERACT, V130, P499; Kaneda Y, 2002, BIOSCI BIOTECH BIOCH, V66, P1022, DOI 10.1271/bbb.66.1022; Kavanagh KL, 2002, BIOCHEMISTRY-US, V41, P8785, DOI 10.1021/bi025786n; KORYTNYK W, 1963, J AM CHEM SOC, V85, P2813, DOI 10.1021/ja00901a032; Kozma E, 2002, J BIOL CHEM, V277, P16285, DOI 10.1074/jbc.M110808200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JK, 2003, APPL ENVIRON MICROB, V69, P6179, DOI 10.1128/AEM.69.10.6179-6188.2003; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; Morita T, 2002, J BIOCHEM, V132, P635, DOI 10.1093/oxfordjournals.jbchem.a003267; Nakano M, 1999, J BIOL CHEM, V274, P23185, DOI 10.1074/jbc.274.33.23185; NELSON MJK, 1986, J BIOL CHEM, V261, P5115; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Trongpanich Y, 2002, BIOSCI BIOTECH BIOCH, V66, P543, DOI 10.1271/bbb.66.543; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; YAMAMOTOOTAKE H, 1994, BIOSCI BIOTECH BIOCH, V58, P2281, DOI 10.1271/bbb.58.2281; Yoshikane Y, 2004, PROTEIN EXPRES PURIF, V34, P243, DOI 10.1016/j.pep.2003.11.013	24	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37377	37384		10.1074/jbc.M405344200	http://dx.doi.org/10.1074/jbc.M405344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226311	hybrid, Green Published			2022-12-25	WOS:000223554600024
J	Cabelof, DC; Raffoul, JJ; Nakamura, J; Kapoor, D; Abdalla, H; Heydari, AR				Cabelof, DC; Raffoul, JJ; Nakamura, J; Kapoor, D; Abdalla, H; Heydari, AR			Imbalanced base excision repair in response to folate deficiency is accelerated by polymerase beta haploinsufficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MONOFUNCTIONAL ALKYLATING-AGENTS; URACIL-DNA GLYCOSYLASE; DIETARY-FOLATE; IN-VITRO; COLONIC NEOPLASIA; HUMAN-LYMPHOCYTES; PURINE SYNTHESIS; STRAND BREAKS; UP-REGULATION	The mechanism by which folate deficiency influences carcinogenesis is not well established, but a phenotype of DNA strand breaks, mutations, and chromosomal instability suggests an inability to repair DNA damage. To elucidate the mechanism by which folate deficiency influences carcinogenicity, we have analyzed the effect of folate deficiency on base excision repair (BER), the pathway responsible for repairing uracil in DNA. We observe an up-regulation in initiation of BER in liver of the folate-deficient mice, as evidenced by an increase in uracil DNA glycosylase protein (30%, p < 0.01) and activity (31%, p < 0.05). However, no up-regulation in either BER or its rate-determining enzyme, DNA polymerase beta (beta-pol) is observed in response to folate deficiency. Accordingly, an accumulation of repair intermediates in the form of DNA single strand breaks (37% increase, p < 0.03) is observed. These data indicate that folate deficiency alters the balance and coordination of BER by stimulating initiation without subsequently stimulating the completion of repair, resulting in a functional BER deficiency. In directly establishing that the inability to induce beta-pol and mount a BER response when folate is deficient is causative in the accumulation of toxic repair intermediates, beta-pol-haploinsufficient mice subjected to folate deficiency displayed additional increases in DNA single strand breaks (52% increase, p < 0.05) as well as accumulation in aldehydic DNA lesions (38% increase, p < 0.01). Since young beta-polhaploinsufficient mice do not spontaneously exhibit increased levels of these repair intermediates, these data demonstrate that folate deficiency and beta-pol haploinsufficiency interact to increase the accumulation of DNA damage. In addition to establishing a direct role for beta-pol in the phenotype expressed by folate deficiency, these data are also consistent with the concept that repair of uracil and abasic sites is more efficient than repair of oxidized bases.	Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48202 USA; Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA	Wayne State University; University of North Carolina; University of North Carolina Chapel Hill	Heydari, AR (corresponding author), Wayne State Univ, Dept Nutr & Food Sci, 3009 Sci Hall, Detroit, MI 48202 USA.	ahmad.heydari@wayne.edu		Nakamura, Jun/0000-0002-1756-7199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062256] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R21 DK 62256] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basnakian AG, 1996, DNA CELL BIOL, V15, P255, DOI 10.1089/dna.1996.15.255; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Branda RF, 1999, MUTAT RES-FUND MOL M, V427, P79, DOI 10.1016/S0027-5107(99)00095-0; Branda RF, 1997, CANCER RES, V57, P2586; Branda RF, 1998, ENVIRON MOL MUTAGEN, V32, P33, DOI 10.1002/(SICI)1098-2280(1998)32:1&lt;33::AID-EM4&gt;3.0.CO;2-C; Bronder JL, 2003, J BIOL CHEM, V278, P48861, DOI 10.1074/jbc.M304844200; Cabelof DC, 2003, CANCER RES, V63, P5799; Cabelof DC, 2002, CARCINOGENESIS, V23, P1419, DOI 10.1093/carcin/23.9.1419; CABELOF DC, 2003, MUTAT RES, V500, P135; Cappelli E, 2001, CARCINOGENESIS, V22, P387, DOI 10.1093/carcin/22.3.387; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; Choi SW, 1998, GUT, V43, P93, DOI 10.1136/gut.43.1.93; Courtemanche C, 2004, FASEB J, V18, P209, DOI 10.1096/fj.03-0382fje; CRAVO ML, 1992, CANCER RES, V52, P5002; Crott JW, 2004, CARCINOGENESIS, V25, P69, DOI 10.1093/carcin/bgg150; Duthie SJ, 2000, BRIT J CANCER, V83, P1532, DOI 10.1054/bjoc.2000.1481; Duthie SJ, 2000, NUTR CANCER, V37, P245, DOI 10.1207/S15327914NC372_18; Duthie SJ, 1998, FASEB J, V12, P1491, DOI 10.1096/fasebj.12.14.1491; EVERSON RB, 1988, JNCI-J NATL CANCER I, V80, P525, DOI 10.1093/jnci/80.7.525; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Guillet M, 2003, MOL CELL BIOL, V23, P8386, DOI 10.1128/MCB.23.22.8386-8394.2003; Hofer T, 1998, CHEM RES TOXICOL, V11, P882, DOI 10.1021/tx980041x; HOOVER KL, 1984, J NATL CANCER I, V73, P1327; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; James SJ, 1997, CARCINOGENESIS, V18, P287, DOI 10.1093/carcin/18.2.287; Kim YI, 1996, GUT, V39, P732, DOI 10.1136/gut.39.5.732; Kim YI, 2000, GASTROENTEROLOGY, V119, P151, DOI 10.1053/gast.2000.8518; Koury MJ, 2000, BLOOD, V96, P3249; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Lin LH, 2000, J NEUROCHEM, V74, P1098; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MACGREGOR JT, 1990, P NATL ACAD SCI USA, V87, P9962, DOI 10.1073/pnas.87.24.9962; Melnyk S, 1999, CANCER LETT, V146, P35, DOI 10.1016/S0304-3835(99)00213-X; Nakamura J, 1998, CANCER RES, V58, P222; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; SIROVER MA, 1979, CANCER RES, V39, P2090; SOKAL RR, 1981, BIOMETRY, P169; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; WALZEM RL, 1983, J NUTR, V113, P1032, DOI 10.1093/jn/113.5.1032; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; WILLIAMS MV, 1987, MOL PHARMACOL, V31, P200; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	50	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36504	36513		10.1074/jbc.M405185200	http://dx.doi.org/10.1074/jbc.M405185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218023	hybrid, Green Published			2022-12-25	WOS:000223453600044
J	Gotte, G; Libonati, M				Gotte, G; Libonati, M			Oligomerization of ribonuclease A - Two novel three-dimensional domain-swapped tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN AGGREGATION; CRYSTAL-STRUCTURE; CYSTATIN-C; DIMER; MECHANISM; DISEASES; TRIMERS; FORMS	By lyophilization from 40% acetic acid solutions, bovine ribonuclease A forms several types of three-dimensional domain-swapped oligomers: dimers, trimers, tetramers, and higher order multimers. Each oligomeric species comprehends at least two conformers: one less basic and one more basic. The structures of the two dimers and one trimer have been solved. Plausible models have been proposed for the other oligomers. Among them, all chromatographic patterns show the constant presence of minority species, and we focused our attention on two of them. The first oligomer (named X) elutes between the two trimeric conformers; the second (named Y) elutes as a shoulder in the ascending limb of the more basic trimer. After purification with cation-exchange chromatography, on the basis of (a) gel filtration analyses, (b) gel electrophoreses under nondenaturing conditions, (c) SDS-PAGE, (d) cross-linking experiments with divinylsulfone and 1,5-difluoro2,4-dinitrobenzene, (e) enzymatic activity assays, (f) identification of the products of their spontaneous dissociation, and (g) controlled proteolysis with subtilisin, we propose that the X and Y oligomeric species contain two novel three-dimensional domain-swapped tetrameric conformers of RNase A, differing from each other as well as from the two tetramers already identified. For the two novel tetramers we showed tentative structural models. X-TT could be a circular NCNC-tetramer; Y-TT could be a propeller-like C-trimer with an attached N-swapping monomer (NCCCTT), identical to a model proposed by Liu and Eisenberg (Liu, Y., and Eisenberg, D. (2002) Protein Sci. 11, 1285-1299).	Univ Verona, Fac Med & Chirurg, Dipartimento Sci Neurol & Vis, Sez Chim Biol, I-37134 Verona, Italy	University of Verona	Libonati, M (corresponding author), Univ Verona, Fac Med & Chirurg, Dipartimento Sci Neurol & Vis, Sez Chim Biol, Strada Grazie 8, I-37134 Verona, Italy.	massimo.libonati@univr.it		Gotte, Giovanni/0000-0003-3179-7158				BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; Doscher M. S., 1967, METHOD ENZYMOL, VXI, P640; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRUCHTER RG, 1965, J BIOL CHEM, V240, P3868; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gotte G, 1998, BBA-PROTEIN STRUCT M, V1386, P106, DOI 10.1016/S0167-4838(98)00087-9; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; KLAFKI HW, 1993, BIOL CHEM H-S, V374, P1117, DOI 10.1515/bchm3.1993.374.7-12.1117; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KUNITZ M, 1946, J BIOL CHEM, V164, P563; Libonati M, 2004, BIOCHEM J, V380, P311, DOI 10.1042/BJ20031922; Libonati M, 2001, METHOD ENZYMOL, V341, P234, DOI 10.1016/S0076-6879(01)41155-4; Libonati M, 1996, BIOCHEM J, V318, P287, DOI 10.1042/bj3180287; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; Merlino A, 2004, BIOPHYS J, V86, P2383, DOI 10.1016/S0006-3495(04)74295-2; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; Nenci A, 2001, BBA-PROTEIN STRUCT M, V1545, P255, DOI 10.1016/S0167-4838(00)00287-9; Nilsson M, 2004, J BIOL CHEM, V279, P24236, DOI 10.1074/jbc.M402621200; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5	31	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36670	36679		10.1074/jbc.M404780200	http://dx.doi.org/10.1074/jbc.M404780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218036	hybrid			2022-12-25	WOS:000223453600066
J	Hrabchak, C; Varmuza, S				Hrabchak, C; Varmuza, S			Identification of the spermatogenic zip protein Spz1 as a putative protein phosphatase-1 (PP1) regulatory protein that specifically binds the PP1c gamma 2 splice variant in mouse testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CATALYTIC SUBUNIT; EXPRESSION; SERINE; GENES; CELLS; PP1-GAMMA-2; HOMOLOG; STAUFEN; YEAST	The spermatogenic zip protein (Spz1) was originally isolated from a mouse testis library and identified as a novel member of the basic helix-loop-helix family of transcription factors. Here we identify Spz1 as a specific binding partner of the gamma2 catalytic subunit of protein phosphatase-1. Male mice homozygous for a null mutation in the protein phosphatase-1cgamma (PP1cgamma) gene are infertile and display a distinct impairment in spermiogenesis despite the continued presence of closely related PP1c isoforms. Yeast two-hybrid screening using the PP1cgamma2 splice variant has identified Spz1 as an interacting protein and possible mediator of the sterile PP1cgamma mutant phenotype. Spz1 was shown to interact specifically with PP1cgamma2 but did not show an interaction with PP1calpha or with a truncated version of PP1cgamma2 lacking 18 amino acids from the C terminus. Interaction between full-length Spz1 and PP1cgamma2 was verified by co-immunoprecipitation and co-localization experiments in COS-1 cells as well as gel-shift and sedimentation assays using whole testis lysates. Immunohistochemistry on wild type testis sections reveals a stage-specific expression pattern for Spz1 during spermatogenesis that appeared grossly abnormal in the testes of PP1cgamma mutant mice. Phosphatase assays using recombinant PP1c indicate that increasing concentrations of Spz1 are able to inhibit PP1cgamma2 activity while having little effect on the activity of PP1calpha. Furthermore, an interaction between PP1cgamma2 and Spz1 was shown to prevent binding of the latter to the consensus E-box promoter sequence. We propose that the interaction between Spz1 and PP1cgamma2 may be required for proper regulation of spermatogenesis and fertility in males.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada	University of Toronto	Varmuza, S (corresponding author), Univ Toronto, Dept Zool, 25 Harbord St, Toronto, ON M5S 3G5, Canada.	svarmuza@zoo.utoronto.ca						Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; CHUN YS, 1994, P NATL ACAD SCI USA, V91, P3319, DOI 10.1073/pnas.91.8.3319; Chun YS, 2000, BIOCHEM BIOPH RES CO, V273, P972, DOI 10.1006/bbrc.2000.3045; Cohen PTW, 2002, J CELL SCI, V115, P241; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Enz R, 2002, J NEUROCHEM, V81, P1130, DOI 10.1046/j.1471-4159.2002.00922.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HOWARD GC, 2001, ANTIBODY PRODUCTION; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Huang ZH, 2002, BIOL REPROD, V67, P1936, DOI 10.1095/biolreprod.102.004093; IWAMURA M, 1994, J HISTOCHEM CYTOCHEM, V42, P783, DOI 10.1177/42.6.8189040; Jurisicova A, 1999, MOL HUM REPROD, V5, P323, DOI 10.1093/molehr/5.4.323; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; LUDLOW JW, 1998, PROTEIN PHOSPHATASE, P91; MANN M, 1995, DEV GENET, V17, P223, DOI 10.1002/dvg.1020170307; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Monshausen M, 2002, J NEUROCHEM, V81, P557, DOI 10.1046/j.1471-4159.2002.00887.x; NICKOLOFF JA, 1995, ELECTROPORATION PROT, P55; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Okano K, 1997, GENOMICS, V45, P211, DOI 10.1006/geno.1997.4907; Oppedisano L, 2002, HUM REPROD, V17, P710, DOI 10.1093/humrep/17.3.710; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saunders PTK, 2000, MOL HUM REPROD, V6, P983, DOI 10.1093/molehr/6.11.983; Sharma RC, 1996, BIOTECHNIQUES, V20, P42; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Varmuza S, 1999, DEV BIOL, V205, P98, DOI 10.1006/dbio.1998.9100; Varmuza S, 2003, MOL REPROD DEV, V64, P499, DOI 10.1002/mrd.10253; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	39	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37079	37086		10.1074/jbc.M403710200	http://dx.doi.org/10.1074/jbc.M403710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15226296	hybrid			2022-12-25	WOS:000223453600111
J	Kang, SK; Yi, KS; Kwon, NS; Park, KH; Kim, UH; Baek, KJ; Im, MJ				Kang, SK; Yi, KS; Kwon, NS; Park, KH; Kim, UH; Baek, KJ; Im, MJ			alpha(1B)-Adrenoceptor signaling and cell motility - GTPase function of G(h)/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; G-ALPHA(H) TRANSGLUTAMINASE-II; CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; ALPHA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE C-DELTA-1; PROTEIN; G(H); IDENTIFICATION; CALRETICULIN	A multifunctional enzyme, G(h), is a GTP-binding protein that couples to the alpha(1B)-adrenoreceptor and stimulates phospholipase C-delta1 but also displays transglutaminase 2 (TG2) activity. G(h)/TG2 has been implicated to play a role in cell motility. In this study we have examined which function of G(h)/TG2 is involved in this cellular response and the molecular basis. Treatment of human aortic smooth muscle cell with epinephrine inhibits migration to fibronectin and vitronectin, and the inhibition is blocked by the alpha(1)-adrenoreceptor antagonist prazosin or chloroethylclonidine. Up-regulation or overexpression of G(h)/TG2 in human aortic smooth muscle cells, DDT1-MF2, or human embryonic kidney cells, HEK 293 cells, results in inhibition of the migratory activity, and stimulation of the alpha(1B)-adrenoreceptor with the alpha(1) agonist further augments the inhibition of migration of human aortic smooth muscle cells and DDT1-MF2. G(h)/TG2 is coimmunoprecipitated by an integrin alpha(5) antibody and binds to the cytoplasmic tail peptide of integrins alpha(5), alpha(v), and alpha(IIb) subunits in the presence of guanosine 5'-3-O-(thio)triphosphate (GTPgammaS). Mutation of Lys-Arg residues in the GFFKR motif, present in the alpha(5)-tail, significantly reduces the binding of GTPgammaS-G(h)/TG2. Moreover, the motif-containing integrin alpha(5)-tail peptides block G(h)/TG2 coimmunoprecipitation and reverse the inhibition of the migratory activity of HEK 293 cells caused by overexpression G(h)/TG2. These results provide evidence that G(h) function initiates the modulation of cell motility via association of GTP-bound G(h)/TG2 with the GFFKR motif located in integrin alpha subunits.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea; Dongkuk Univ, Oriental Herbal Res Inst, Pohang, South Korea; Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea	Jeonbuk National University; Dongguk University; Chung Ang University; Chung Ang University Hospital	Im, MJ (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Keumam Dong, Jeonju 561182, South Korea.	imm@chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190				Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Baek KJ, 1996, BIOCHEM J, V315, P739; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1999, BIOCHEMISTRY-US, V38, P10743, DOI 10.1021/bi9905009; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Hwang KC, 1996, CIRCULATION, V94, P718, DOI 10.1161/01.CIR.94.4.718; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IWAI N, 1995, BIOCHEM BIOPH RES CO, V209, P527, DOI 10.1006/bbrc.1995.1533; Jones RA, 1997, J CELL SCI, V110, P2461; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; Klekotka PA, 2001, J BIOL CHEM, V276, P32353, DOI 10.1074/jbc.M101921200; Lee KH, 2003, J STEROID BIOCHEM, V84, P101, DOI 10.1016/S0960-0760(03)00006-2; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; Lee MY, 1997, PFLUG ARCH EUR J PHY, V433, P671, DOI 10.1007/s004240050330; Lee ZW, 2003, BIOCHEM BIOPH RES CO, V305, P633, DOI 10.1016/S0006-291X(03)00835-0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Orru S, 2003, J BIOL CHEM, V278, P31766, DOI 10.1074/jbc.M305080200; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Small K, 1999, J BIOL CHEM, V274, P21291, DOI 10.1074/jbc.274.30.21291; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Wu J, 2000, J BIOL CHEM, V275, P22213, DOI 10.1074/jbc.M000091200; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45	49	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36593	36600		10.1074/jbc.M402084200	http://dx.doi.org/10.1074/jbc.M402084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220331	hybrid			2022-12-25	WOS:000223453600056
J	Pan, GJ; Qin, BM; Liu, N; Scholer, HR; Pei, DQ				Pan, GJ; Qin, BM; Liu, N; Scholer, HR; Pei, DQ			Identification of a nuclear localization signal in OCT4 and generation of a dominant negative mutant by its ablation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR OCT4; EMBRYONIC STEM-CELLS; PLURIPOTENCY	OCT4 plays a critical role in maintaining stem cell pluripotency in a dose-dependent manner by activating and repressing multiple downstream genes. The precise mechanism by which OCT4 achieves these diverse biological functions remains unknown. In this report, we identify and characterize (RKRKR)-R-195 as a nuclear localization signal responsible for its localization in the nuclei and required for the transactivation of its target genes. Point mutations within this motif yielded a mutant that localizes randomly throughout the cells and is defective in transactivating target genes. However, restoration of nuclear localization with a heterologous nuclear localization signal failed to rescue its transactivation function, suggesting that this (RKRKR)-R-195 motif has additional function in mediating transactivation function. We further demonstrate that this mutant is competent in dimerization with not only itself but also wild type OCT4 and can interfere with the activity of wild type OCT4, thus acting as a dominant negative mutant. Indeed, this mutant can induce the differentiation of P19 cells into trophoblast-like giant cells. These data suggest that this dominant negative form of OCT4 may be a useful tool for modulating the activity of OCT4 in pluripotent cells such as embryonic stem cells to achieve the desired cell types for therapeutic applications.	Tsing Hua Univ, Inst Pharmacol, Beijing 100084, Peoples R China; Tsing Hua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsing Hua Univ, Dept Biol & Biotechnol, Beijing 100084, Peoples R China; Univ Penn, Sch Vet Med, Dept Anim Biol, Ctr Anim Transgenesis & Germ Cell Res, Kennett Sq, PA 19348 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Tsinghua University; Tsinghua University; Tsinghua University; University of Pennsylvania; University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Tsing Hua Univ, Inst Pharmacol, Beijing 100084, Peoples R China.	duanqing@aol.com	, HS/AAB-4434-2019; Liu, Nan/D-8913-2011; zhou, xingru/G-4442-2012	, HS/0000-0003-2643-5136; Pan, Guangjin/0000-0002-2378-7198				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Buehr M, 2003, BIOL REPROD, V68, P222, DOI 10.1095/biolreprod.102.006197; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Daley GQ, 2002, CURR OPIN GENET DEV, V12, P607, DOI 10.1016/S0959-437X(02)00346-5; Donovan PJ, 2001, NAT GENET, V29, P246, DOI 10.1038/ng1101-246; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Goh ELK, 2003, J HEMATOTH STEM CELL, V12, P671, DOI 10.1089/15258160360732696; Mitalipov SM, 2003, BIOL REPROD, V69, P1785, DOI 10.1095/biolreprod.103.019455; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nie J, 2003, CANCER RES, V63, P6758; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rippon HJ, 2004, CELL PROLIFERAT, V37, P23, DOI 10.1111/j.1365-2184.2004.00298.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A	21	67	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37013	37020		10.1074/jbc.M405117200	http://dx.doi.org/10.1074/jbc.M405117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218026	hybrid			2022-12-25	WOS:000223453600104
J	Vogler, O; Casas, J; Capo, D; Nagy, T; Borchert, G; Martorell, G; Escriba, PV				Vogler, O; Casas, J; Capo, D; Nagy, T; Borchert, G; Martorell, G; Escriba, PV			The G beta gamma dimer drives the interaction of Heterotrimeric G(i) proteins with nonlamellar membrane structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID POLYMORPHISM; BINDING; PHOSPHOLIPIDS; CAVEOLAE; MODEL; RAFTS; LOCALIZATION	Heterotrimeric G proteins are peripheral membrane proteins that propagate signals from membrane receptors to regulatory proteins localized in distinct cellular compartments. To facilitate signal amplification, G proteins are in molar excess with respect to G protein-coupled receptors. Because G proteins are capable of translocating from membrane to cytosol, protein-lipid interactions play a crucial role in signal transduction. Here, we studied the binding of heterotrimeric G proteins (Galphabetagamma) to model membranes (liposomes) and that of the entities formed upon receptor-mediated activation (Galpha and Gbetagamma). The model membranes used were composed of defined membrane lipids capable of organizing into either lamellar or nonlamellar (hexagonal H-II) membrane structures. We demonstrated that although heterotrimeric G(i) proteins and Gbetagamma dimers can bind to lipid bilayers of phosphatidylcholine, their binding to membranes was markedly and significantly enhanced by the presence of nonlamellar phases of phosphatidylethanolamine. Conversely, activated G protein alpha subunits showed an opposite membrane binding behavior with a marked preference for lamellar membranes. These results have important consequences in cell signaling. First, the binding characteristics of the Gbetagamma dimer account for the lipid binding behavior and the cellular localization of heterotrimeric G proteins. Second, the distinct protein-lipid interactions of heterotrimeric G proteins, Gbetagamma dimers, and Galpha subunits with membrane lipids explain, in part, their different cellular mobilizations during signaling upon receptor activation. Finally, their differential interactions with lipids suggest an active role of the membrane lipid secondary structure in the propagation of signals through G protein-coupled receptors.	Univ Balearic Isl, Dept Biol, Inst Grasa,CSIC,Associated Unit, Inst Univ Invest Ciencies Salut,Lab Mol & Cellula, E-07122 Palma de Mallorca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); Universitat de les Illes Balears	Escriba, PV (corresponding author), Univ Balearic Isl, Dept Biol, Inst Grasa,CSIC,Associated Unit, Inst Univ Invest Ciencies Salut,Lab Mol & Cellula, Carretera Valldemossa Kilometro 7-5, E-07122 Palma de Mallorca, Spain.	pablo.escriba@uib.es	Borchert, Gudrun/AAN-6306-2020; Martorell, Gabriel/K-6711-2014; Vögler, Oliver/D-7658-2011	Borchert, Gudrun/0000-0002-0634-4352; Escriba, Pablo/0000-0001-9795-182X; Martorell, Gabriel/0000-0002-8384-0755				BASNEZ G, 1996, BIOCHEMISTRY-US, V35, P15183; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; BUDA C, 1994, P NATL ACAD SCI USA, V91, P8234, DOI 10.1073/pnas.91.17.8234; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CULLIS PR, 1991, BIOCH LIPIDS LIPOPRO, P1; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; ESCRIBA PV, 1995, P NATL ACAD SCI USA, V92, P7595, DOI 10.1073/pnas.92.16.7595; Escriba PV, 1997, P NATL ACAD SCI USA, V94, P11375, DOI 10.1073/pnas.94.21.11375; ESCRIBA PV, 1994, ARCH GEN PSYCHIAT, V51, P494; Escriba PV, 2003, HYPERTENSION, V41, P176, DOI 10.1161/01.HYP.0000047647.72162.A8; Escriba PV, 2002, DNA CELL BIOL, V21, P355, DOI 10.1089/104454902753759762; Franco R, 1996, BIOCHEMISTRY-US, V35, P3007, DOI 10.1021/bi952415g; Funari SS, 2003, J LIPID RES, V44, P567, DOI 10.1194/jlr.M200356-JLR200; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GIORGIONE J, 1995, P NATL ACAD SCI USA, V92, P9767, DOI 10.1073/pnas.92.21.9767; ISENBERG WM, 1989, AM J ANAT, V185, P142, DOI 10.1002/aja.1001850207; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Perkins WR, 1996, SCIENCE, V273, P330, DOI 10.1126/science.273.5273.330; ROTHMAN JE, 1977, SCIENCE, V195, P743, DOI 10.1126/science.402030; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; van der Wel PCA, 2000, BIOCHEMISTRY-US, V39, P3124, DOI 10.1021/bi9922594; Vereb G, 2003, P NATL ACAD SCI USA, V100, P8053, DOI 10.1073/pnas.1332550100; Yang SY, 2001, FEBS LETT, V498, P76, DOI 10.1016/S0014-5793(01)02493-0	30	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36540	36545		10.1074/jbc.M402061200	http://dx.doi.org/10.1074/jbc.M402061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15231827	hybrid			2022-12-25	WOS:000223453600049
J	Delgado, M; Gonzalez-Rey, E; Ganea, D				Delgado, M; Gonzalez-Rey, E; Ganea, D			VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells	FASEB JOURNAL			English	Article						neuroimmunology; Th1/Th2 cells; cell migration; CXCL10; CCL22	VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; GAMMA-INDUCIBLE PROTEIN-10; T-CELLS; MULTIPLE-SCLEROSIS; INTERFERON-GAMMA; IN-VITRO; EXPRESSION; VIP; RECEPTOR	The neuropeptides vasoactive intestinal peptide ( VIP) and the structurally related pituitary adenylate cyclase-activating polypeptide ( PACAP) are potent immunomodulatory agents, acting as general anti-inflammatory factors. VIP, produced and secreted by Th2 cells following antigen stimulation, participates in a Th2 autoregulatory loop, promoting Th2-type responses through several nonexcluding mechanisms. VIP and PACAP affect the differentiation of CD4(+) T cells directly and indirectly through antigen-presenting cells and promote the proliferation and/or survival of the Th2 effectors. Th1 and Th2 effectors express different chemokine receptors that control migration in response to various chemokines. In this study, we investigated the effects of VIP/PACAP on the production of CXCL10 ( a Th1 chemokine) and of CCL22 ( a Th2 chemokine) by bone marrow-derived dendritic cells. We found that VIP and PACAP inhibit CXCL10, while promoting CCL22 production, and that the effects are mediated through the VPAC1 receptor and involve cAMP/PKA as intracellular messengers. The induction of CCL22 and the suppression of CXCL10 in VIP/PACAP-treated dendritic cells results in the preferential chemoattraction of Th2 effectors both in vivo and in vitro. This is in agreement with the general Th2 bias induced by the two neuropeptides and adds an important parameter to their immunomodulatory function. By promoting Th2 migration, and preventing or reducing Th1 infiltration in inflammatory foci and sites of antigen presentation, VIP and PACAP help in resolving acute inflammatory processes and contribute to the prevention of chronic inflammation.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu	Delgado, Mario/P-1524-2016; GONZALEZ-REY, ELENA/L-3296-2014	Delgado, Mario/0000-0003-1893-5982; GONZALEZ-REY, ELENA/0000-0003-3917-9020	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041786, R21AI041786, R01AI052306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52306-01, AI 041786-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrew DP, 1998, J IMMUNOL, V161, P5027; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonecchi R, 1998, BLOOD, V92, P2668, DOI 10.1182/blood.V92.8.2668.420k39_2668_2671; Boorsma DM, 1999, CYTOKINE, V11, P469, DOI 10.1006/cyto.1998.0463; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2004, J LEUKOCYTE BIOL, V75, P1122, DOI 10.1189/jlb.1203626; Delgado M, 2003, J BIOL CHEM, V278, P27620, DOI 10.1074/jbc.M303199200; Delgado M, 2002, FASEB J, V16, P1844, DOI 10.1096/fj.02-0248fje; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 2003, TRENDS IMMUNOL, V24, P221, DOI 10.1016/S1471-4906(03)00069-3; Delgado M, 1999, J IMMUNOL, V163, P3629; DELGADO M, 2004, IN PRESS PHARM REV; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Ganea D, 2003, CELL MOL BIOL, V49, P127; Ganea D, 2003, CURR PHARM DESIGN, V9, P997, DOI 10.2174/1381612033455116; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Jiang XJ, 2002, J NEUROIMMUNOL, V133, P81, DOI 10.1016/S0165-5728(02)00365-X; Kuroda E, 2001, J IMMUNOL, V166, P1650, DOI 10.4049/jimmunol.166.3.1650; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Martinez C, 1999, J NEUROIMMUNOL, V93, P126, DOI 10.1016/S0165-5728(98)00216-1; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Patel DD, 2001, CLIN IMMUNOL, V98, P39, DOI 10.1006/clim.2000.4957; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Singh UP, 2003, J IMMUNOL, V171, P1401, DOI 10.4049/jimmunol.171.3.1401; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Sozzani S, 1999, J LEUKOCYTE BIOL, V66, P1, DOI 10.1002/jlb.66.1.1; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; VANGURI P, 1990, J BIOL CHEM, V265, P15049; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Yoneyama H, 2000, SPRINGER SEMIN IMMUN, V22, P329, DOI 10.1007/s002810000050; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	58	81	90	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1453	+		10.1096/fj.04-1548fje	http://dx.doi.org/10.1096/fj.04-1548fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231725				2022-12-25	WOS:000222979200021
J	Kim, HP; Wang, X; Galbiati, F; Ryter, SW; Choi, AMK				Kim, HP; Wang, X; Galbiati, F; Ryter, SW; Choi, AMK			Caveolae compartmentalization of heme oxygenase-1 in endothelial cells	FASEB JOURNAL			English	Article						HO-1; biliverdin reductase; HO activity	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; CARBON-MONOXIDE; BILIVERDIN REDUCTASE; SKELETAL-MUSCLE; EXPRESSION; RECEPTOR; STRESS; ALPHA; PALMITOYLATION	The heme oxygenase (HO) and nitric oxide synthase ( NOS) enzymes generate the gaseous signaling molecules carbon monoxide ( CO) and nitric oxide, respectively. Constitutive NOSs localize to caveolae, and their activities are modulated by caveolin-1. Nothing is known of the localization of the inducible heme oxygenase-1 (HO-1) in plasma membrane caveolae. Thus, we examined the distribution and subcellular localization of HO-1, biliverdin reductase (BVR), and NADPH: cytochrome P450 reductase (NPR) in pulmonary artery endothelial cells. Each of these proteins localized in part to plasma membrane caveolae in endothelial cells. Inducers of HO-1 or overexpression of HO-1 increased the content of this protein in a detergent-resistant fraction containing caveolin-1. Inducible HO activity appeared in plasma membrane, cytosol, and isolated caveolae. In addition, caveolae contained endogenous BVR activity, supporting the same compartmentalization of both enzymes. Caveolin-1 physically interacted with HO-1, as shown by coimmunoprecipitation studies. HO activity dramatically increased in cells expressing caveolin-1 antisense transcripts, suggesting a negative regulatory role for caveolin-1. Conversely, caveolin-1 expression attenuated LPS-inducible HO activity. Since their initial characterization in 1969, HO enzymes have been described as endoplasmic reticulum-associated proteins. We demonstrate for the first time the localization of heme degradation enzymes to plasma membrane caveolae, and present novel evidence that caveolin-1 interacts with and modulates HO activity.	Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Dept Med, Div Pulm Allergy & Crit Care Med, MUH 628NW,3459 5th Ave, Pittsburgh, PA 15213 USA.	Choiam@msx.upmc.edu	Galbiati, Ferruccio/AAF-3527-2020		NHLBI NIH HHS [R01-HL60234, R01-HL55330] Funding Source: Medline; NIAID NIH HHS [R01-AI42365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Baum O, 2000, ACTA HISTOCHEM, V102, P281, DOI 10.1078/S0065-1281(04)70036-7; Bogdan CT, 2000, IMMUNOL REV, V173, P17, DOI 10.1034/j.1600-065X.2000.917307.x; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Hartsfield C, 1999, AM J PHYSIOL-LUNG C, V277, pL1133, DOI 10.1152/ajplung.1999.277.6.L1133; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Ko YG, 1999, J IMMUNOL, V162, P7217; Kyokane T, 2001, GASTROENTEROLOGY, V120, P1227, DOI 10.1053/gast.2001.23249; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lei MG, 2000, INFECT IMMUN, V68, P5084, DOI 10.1128/IAI.68.9.5084-5089.2000; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maines MD, 2001, ADV EXP MED BIOL, V502, P249; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Osada M, 2002, J BIOL CHEM, V277, P23367, DOI 10.1074/jbc.M112413200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Parat MO, 2002, BIOCHEM J, V361, P681, DOI 10.1042/0264-6021:3610681; Parfenova H, 2003, J CEREBR BLOOD F MET, V23, P190, DOI 10.1097/01.WCB.000004823561824.C4; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Ryter SW, 2000, METH MOL B, V99, P369; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang JL, 2003, J BIOL CHEM, V278, P20069, DOI 10.1074/jbc.M300989200; Weaver LK, 1999, CRIT CARE CLIN, V15, P297, DOI 10.1016/S0749-0704(05)70056-7; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7786; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	51	150	154	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1080	1089		10.1096/fj.03-1391com	http://dx.doi.org/10.1096/fj.03-1391com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226268				2022-12-25	WOS:000222979200035
J	Ryten, M; Yang, SY; Dunn, PM; Goldspink, G; Burnstock, G				Ryten, M; Yang, SY; Dunn, PM; Goldspink, G; Burnstock, G			Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures	FASEB JOURNAL			English	Article						ATP; P2 receptor; myotube	LEUKEMIA INHIBITORY FACTOR; ACETYLCHOLINE-RECEPTOR; C2C12 MYOTUBES; MYOBLAST PROLIFERATION; NUCLEOTIDE RECEPTORS; GLYCOPROTEIN COMPLEX; SYMPATHETIC NEURONS; EXTRACELLULAR ATP; P2X(5) RECEPTOR; P2Y RECEPTORS	ATP is an important extracellular signaling molecule mediating its effects by activation of P2X and P2Y receptors. P2 receptors are expressed during muscle development, and recent findings demonstrate that ATP can regulate myoblast proliferation and differentiation in vitro. However, the role of purinergic signaling during regeneration of injured skeletal muscle has not been investigated. To examine this process in a clinically relevant system, we used the mouse model of muscular dystrophy (mdx), in which muscle degeneration is rapidly followed by regeneration. The latter process, in vivo muscle regeneration, was the focus of this study, and to study the cellular mechanisms involved in it, a parallel study on normal rat skeletal myoblast cultures was conducted. Using immunohistochemistry, RT-PCR, and electrophysiology, we investigated the expression of the P2X(1-7) receptor subtypes and the P2Y(1,2,4,6) receptors. Experiments in vitro and in vivo demonstrated the sequential expression of the P2X(5), P2Y(1), and P2X(2) receptors during the process of muscle regeneration. The P2X(5) and P2Y(1) receptors were expressed first on activated satellite cells, and the P2Y(1) receptor was also expressed on infiltrating immune cells. Subsequent P2X(2) receptor expression on newly formed myotubes showed significant colocalization with AChRs, suggesting a role in regulation of muscle innervation. Thus, this study provides the first evidence for a role for purinergic signaling in muscle regeneration and raises the possibility of new therapeutic strategies in the treatment of muscle disease.	UCL Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, London NW3 2PF, England; Univ Coll, Royal Free & Univ Coll Med Sch, Dept Surg, Mol Tissue Repair Unit, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London	Burnstock, G (corresponding author), UCL Royal Free & Univ Coll Med Sch, Auton Neurosci Inst, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	g.burnstock@ucl.ac.uk						AUSTIN L, 1991, J NEUROL SCI, V101, P193, DOI 10.1016/0022-510X(91)90045-9; Bailey MA, 2001, J AM SOC NEPHROL, V12, P1640, DOI 10.1681/ASN.V1281640; Bailey MA, 2000, KIDNEY INT, V58, P1893, DOI 10.1111/j.1523-1755.2000.00361.x; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; BRAJASLOPEZ C, 1998, J PHYSL, V513, P671; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Carlson CG, 1999, PFLUG ARCH EUR J PHY, V437, P371, DOI 10.1007/s004240050791; Ceruti S, 2000, NEUROMUSCULAR DISORD, V10, P436, DOI 10.1016/S0960-8966(00)00118-8; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; CUNHA RA, 1993, PFLUG ARCH EUR J PHY, V424, P503, DOI 10.1007/BF00374914; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dunn PM, 1996, BRIT J PHARMACOL, V117, P35, DOI 10.1111/j.1476-5381.1996.tb15151.x; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Hellsten Y, 1998, CIRCULATION, V98, P6, DOI 10.1161/01.CIR.98.1.6; HENNING RH, 1992, BRIT J PHARMACOL, V106, P853, DOI 10.1111/j.1476-5381.1992.tb14424.x; HENNING RH, 1993, BRIT J PHARMACOL, V110, P747, DOI 10.1111/j.1476-5381.1993.tb13875.x; HENNING RH, 1993, BRIT J PHARMACOL, V110, P133, DOI 10.1111/j.1476-5381.1993.tb13782.x; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUME RI, 1988, J PHYSIOL-LONDON, V406, P503, DOI 10.1113/jphysiol.1988.sp017393; HUME RI, 1986, J NEUROSCI, V6, P681; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Jin Y, 2000, ACTA NEUROPATHOL, V99, P619, DOI 10.1007/s004010051172; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; KOLB HA, 1983, NATURE, V303, P621, DOI 10.1038/303621a0; Kong JM, 1999, BRAIN RES, V839, P298, DOI 10.1016/S0006-8993(99)01737-0; Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097-4598(199610)19:10<1291::AID-MUS6>3.0.CO;2-9; Meyer MP, 1999, DEV DYNAM, V216, P442, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<442::AID-DVDY12>3.0.CO;2-Z; Meyer MP, 1999, DEV DYNAM, V214, P152, DOI 10.1002/(SICI)1097-0177(199902)214:2<152::AID-AJA5>3.0.CO;2-L; NAKAZAWA K, 1994, J NEUROSCI, V14, P740; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Ralevic V, 1998, PHARMACOL REV, V50, P413; REDMAN RS, 1994, J PHYSIOL-LONDON, V477, P117, DOI 10.1113/jphysiol.1994.sp020176; Ruppelt A, 2001, J NEUROCHEM, V77, P1256, DOI 10.1046/j.1471-4159.2001.00348.x; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Shibuya I, 1999, J PHYSIOL-LONDON, V514, P351, DOI 10.1111/j.1469-7793.1999.351ae.x; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Silinsky EM, 1996, J PHYSIOL-LONDON, V492, P815, DOI 10.1113/jphysiol.1996.sp021348; SMITH DO, 1991, J PHYSIOL-LONDON, V432, P343, DOI 10.1113/jphysiol.1991.sp018388; Straub RH, 2002, J NEUROIMMUNOL, V125, P73, DOI 10.1016/S0165-5728(02)00035-8; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	60	41	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1404	+		10.1096/fj.03-1175fje	http://dx.doi.org/10.1096/fj.03-1175fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231720				2022-12-25	WOS:000222979200024
J	Pilkington, KR; Clark-Lewis, I; McColl, SR				Pilkington, KR; Clark-Lewis, I; McColl, SR			Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3 beta antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; B-CELLS; EBI1-LIGAND CHEMOKINE; ECTOPIC EXPRESSION; CUTTING EDGE; MICE; CHEMOATTRACTANT; RESPONSES; CCR7; ARTHRITIS	Chemokines constitute a group of over 40 secreted peptides that are important for the control of leukocyte migration both during homeostasis and inflammation. Recent studies have implicated the ligands CCL19 and CCL21 and their receptor, CCR7, in the specific migration of naive lymphocytes and mature dendritic cells to secondary lymphoid organs during immune homeostasis. However, the role that these molecules play during immune priming is not well understood. In this study, using CCL19((8-83)), a novel N-terminal truncation mutant, we have investigated the role of CCL19 in a primary allogeneic immune response, a response of particular relevance to transplant rejection. This antagonist specifically inhibited wild type CCL19-induced chemotaxis and intracellular calcium mobilization without affecting that of CCL21. The treatment of mice with CCL19((8-83)) did not globally inhibit the recruitment of cells into lymph nodes; however, it inhibited the generation of cytotoxic T lymphocytes toward allogeneic dendritic cells. This is the first evidence that CCL19 plays a role in immune priming.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide	McColl, SR (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	shaun.mccoll@adelaide.edu.au	Pilkington, Kate/AFZ-2883-2022	Pilkington, Kate/0000-0002-1848-1645				ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chen SC, 2002, J IMMUNOL, V168, P1001, DOI 10.4049/jimmunol.168.3.1001; Cyster JG, 2000, CURR BIOL, V10, pR30, DOI 10.1016/S0960-9822(99)00253-5; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Engeman TM, 2000, J IMMUNOL, V164, P5207, DOI 10.4049/jimmunol.164.10.5207; Fan L, 2000, J IMMUNOL, V164, P3955, DOI 10.4049/jimmunol.164.8.3955; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Junt T, 2002, J IMMUNOL, V168, P6032, DOI 10.4049/jimmunol.168.12.6032; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6, DOI 10.1002/jlb.65.1.6; Kim CH, 1998, J IMMUNOL, V160, P2418; Kohler RE, 2003, J IMMUNOL, V170, P6298, DOI 10.4049/jimmunol.170.12.6298; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; McColl SR, 1999, J IMMUNOL, V163, P2829; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sasaki M, 2003, J IMMUNOL, V170, P588, DOI 10.4049/jimmunol.170.1.588; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Volkmann A, 1996, EUR J IMMUNOL, V26, P2565, DOI 10.1002/eji.1830261105; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	32	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40276	40282		10.1074/jbc.M405808200	http://dx.doi.org/10.1074/jbc.M405808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15231820	hybrid			2022-12-25	WOS:000223916800007
J	Chaturvedi, R; Cheng, YL; Asim, M; Bussiere, FI; Xu, HX; Gobert, AP; Hacker, A; Casero, RA; Wilson, KT				Chaturvedi, R; Cheng, YL; Asim, M; Bussiere, FI; Xu, HX; Gobert, AP; Hacker, A; Casero, RA; Wilson, KT			Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ORNITHINE-DECARBOXYLASE; LEUKEMIC-CELLS; LUNG-CARCINOMA; ANALOG; IDENTIFICATION; CATABOLISM; EXPRESSION; INFECTION; DEATH	Helicobacter pylori infects the human stomach by escaping the host immune response. One mechanism of bacterial survival and mucosal damage is induction of macrophage apoptosis, which we have reported to be dependent on polyamine synthesis by arginase and ornithine decarboxylase. During metabolic back-conversion, polyamines are oxidized and release H2O2, which can cause apoptosis by mitochondrial membrane depolarization. We hypothesized that this mechanism is induced by H. pylori in macrophages. Polyamine oxidation can occur by acetylation of spermine or spermidine by spermidine/spermine N-1-acetyltransferase prior to back-conversion by acetylpolyamine oxidase, but recently direct conversion of spermine to spermidine by the human polyamine oxidase h1, also called spermine oxidase, has been demonstrated. H. pylori induced expression and activity of the mouse homologue of this enzyme ( polyamine oxidase 1 (PAO1)) by 6 h in parallel with ornithine decarboxylase, consistent with the onset of apoptosis, while spermidine/spermine N-1-acetyltransferase activity was delayed until 18 h when late stage apoptosis had already peaked. Inhibition of PAO1 by MDL 72527 or by PAO1 small interfering RNA significantly attenuated H. pylori-induced apoptosis. Inhibition of PAO1 also significantly reduced H2O2 generation, mitochondrial membrane depolarization, cytochrome c release, and caspase-3 activation. Overexpression of PAO1 by transient transfection induced macrophage apoptosis. The importance of H2O2 was confirmed by inhibition of apoptosis with catalase. These studies demonstrate a new mechanism for pathogen-induced oxidative stress in macrophages in which activation of PAO1 leads to H2O2 release and apoptosis by a mitochondrial-dependent cell death pathway, contributing to deficiencies in host defense in diseases such as H. pylori infection.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Wilson, KT (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Rm N3W62, Baltimore, MD 21201 USA.	kwilson@umaryland.edu	Gobert, Alain P/AHB-1368-2022	Bussiere, Francoise I/0000-0001-9365-6831; Wilson, Keith/0000-0003-4421-1830; Casero, Robert/0000-0001-5653-3306	NCI NIH HHS [CA51085, CA98454] Funding Source: Medline; NIDDK NIH HHS [DK53620, DK63626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051085, R01CA098454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, R21DK063626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhtar M, 2001, CANCER RES, V61, P2399; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; Casero RA, 2003, BIOCHEM SOC T, V31, P361, DOI 10.1042/BST0310361; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153; Chen Y, 2001, CANCER RES, V61, P6437; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Devereux W, 2003, CANCER CHEMOTH PHARM, V52, P383, DOI 10.1007/s00280-003-0662-4; Fraser AV, 2002, BIOCHEM J, V367, P307, DOI 10.1042/BJ20020156; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gobert AP, 2002, J IMMUNOL, V168, P6002, DOI 10.4049/jimmunol.168.12.6002; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; Li L, 2001, AM J PHYSIOL-GASTR L, V280, pG992, DOI 10.1152/ajpgi.2001.280.5.G992; Lindsay GS, 1999, BIOCHEM J, V337, P83, DOI 10.1042/0264-6021:3370083; LUK GD, 1982, SCIENCE, V216, P75, DOI 10.1126/science.6950518; Maccarrone M, 2001, FEBS LETT, V507, P30, DOI 10.1016/S0014-5793(01)02949-0; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Meyer F, 2000, INFECT IMMUN, V68, P6265, DOI 10.1128/IAI.68.11.6265-6272.2000; Murray-Stewart T, 2002, BIOCHEM J, V368, P673, DOI 10.1042/BJ20021587; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Panchal PC, 2003, CURR OPIN GASTROEN, V19, P4, DOI 10.1097/00001574-200301000-00002; Pavlov V, 2002, LIFE SCI, V71, P1161, DOI 10.1016/S0024-3205(02)01832-5; Rao JN, 1999, AM J PHYSIOL-GASTR L, V277, pG1149, DOI 10.1152/ajpgi.1999.277.6.G1149; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Salh B, 2002, J LEUKOCYTE BIOL, V72, P790; Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wallace Heather M., 1998, V79, P59; Wang J, 2001, J IMMUNOL, V167, P926, DOI 10.4049/jimmunol.167.2.926; Wang YL, 2001, CANCER RES, V61, P5370; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wilson KT, 1996, GASTROENTEROLOGY, V111, P1524, DOI 10.1016/S0016-5085(96)70014-8; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P; Zahedi K, 2003, AM J PHYSIOL-RENAL, V284, pF1046, DOI 10.1152/ajprenal.00318.2002; Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	53	130	133	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40161	40173		10.1074/jbc.M401370200	http://dx.doi.org/10.1074/jbc.M401370200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247269	hybrid			2022-12-25	WOS:000223791500115
J	Das, D; Shah, RB; Imperiale, MJ				Das, D; Shah, RB; Imperiale, MJ			Detection and expression of human BK virus sequences in neoplastic prostate tissues	ONCOGENE			English	Review						polyomavirus BK; large T antigen; p53; postatrophic hyperplasia; proliferative inflammatory atrophy; in situ hybridization; immunohistochemistry; immunofluorescence; high-grade prostate intraepithelial neoplasia	LARGE-T-ANTIGEN; PROLIFERATIVE INFLAMMATORY ATROPHY; POLYMERASE-CHAIN-REACTION; P53 PROTEIN; HUMAN-PAPILLOMAVIRUS; HUMAN POLYOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; MONOCLONAL-ANTIBODIES; JC-VIRUS; CYTOPLASMIC SEQUESTRATION	BK virus (BKV) is ubiquitous in the human population and establishes a lifelong, subclinical persistent infection in the urinary tract. When the immune system is compromised, it can cause severe disease in the kidney and bladder. Detection of BKV sequences in urinary tract neoplasms has led to the postulate that this virus may induce human oncogenesis through the function of its large tumor antigen (TAg). In this study, examination of prostate tumor tissue sections using in situ hybridization shows the presence of BKV sequences in atrophic epithelium. Solution polymerase chain reaction on DNA extracted from the tissues and sequence analysis of the products reveal the presence of BKV regulatory and early region sequences. In addition, immunohistochemical analysis using monoclonal antibodies specific to TAg or p53 shows the expression of TAg in some of the samples and p53 staining that can be correlated to TAg expression. Although the normal cellular localization of TAg and p53 is nuclear, double immunofluorescence labeling with anti-p53 and TAg antibodies indicates colocalization of p53 and TAg to the cytoplasm in the glandular epithelial cells of the sections. Although BKV DNA was found in benign and atrophic lesions, TAg and p53 coexpression was observed only in atrophic lesions.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	imperial@umich.edu						Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BERGER CN, 1986, EMBO J, V5, P85, DOI 10.1002/j.1460-2075.1986.tb04181.x; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOSARI S, 1995, AM J PATHOL, V147, P790; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO;2-7; Brewster SF, 1999, J UROLOGY, V161, P1238, DOI 10.1016/S0022-5347(01)61646-X; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; CUZICK J, 1995, CANCER SURV, V23, P91; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Flaegstad T, 1999, CANCER RES, V59, P1160; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P617, DOI 10.1002/path.1700680234; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GARDNER SD, 1973, BMJ-BRIT MED J, V1, P77, DOI 10.1136/bmj.1.5845.77; GARDNER SD, 1971, LANCET, V1, P1253; GARDNER WA, 1987, J UROLOGY, V137, P53, DOI 10.1016/S0022-5347(17)43869-9; GARDNER WA, 1992, PATHOLOGY PATHOBIOLO, P129; Geetha D, 2002, TRANSPLANTATION, V73, P1933, DOI 10.1097/00007890-200206270-00015; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; HIRAOKA A, 1991, BONE MARROW TRANSPL, V7, P107; Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9; IBRAHIM GK, 1992, J UROLOGY, V148, P1822, DOI 10.1016/S0022-5347(17)37040-4; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Imperiale MJ, 2001, ONCOGENE, V20, P7917, DOI 10.1038/sj.onc.1204916; IWASAKA T, 1993, GYNECOL ONCOL, V48, P104, DOI 10.1006/gyno.1993.1016; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Jorgensen GEK, 2000, MED PEDIATR ONCOL, V35, P593, DOI 10.1002/1096-911X(20001201)35:6<593::AID-MPO22>3.0.CO;2-I; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; Knippschild U, 1996, ONCOGENE, V12, P1755; Kuefer R, 2002, AM J PATHOL, V161, P841, DOI 10.1016/S0002-9440(10)64244-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li RM, 2002, TRANSPLANTATION, V74, P1497, DOI 10.1097/00007890-200212150-00004; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P619, DOI 10.1097/00000478-198808000-00003; MCNICOL PJ, 1991, J UROLOGY, V145, P850, DOI 10.1016/S0022-5347(17)38476-8; Melamed J, 1997, CLIN CANCER RES, V3, P1867; MOENS U, 2001, HUMAN POLYOMAVIRUSES, P215; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NAKASHATRI H, 1988, J VIROL, V62, P4613; NEGRINI M, 1991, J VIROL, V65, P5092, DOI 10.1128/JVI.65.9.5092-5095.1991; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Noda T, 1998, UROL RES, V26, P165, DOI 10.1007/s002400050041; Nuovo G. J., 1996, PCR IN SITU HYBRIDIZ; Nupponen N, 1999, EUR UROL, V35, P351, DOI 10.1159/000019907; Osman I, 1999, CLIN CANCER RES, V5, P2082; PADGETT B, 1981, HUMAN PAPOVAVIRUSES, P339; Pappo O, 1996, MODERN PATHOL, V9, P105; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PORTOLANI M, 1975, J VIROL, V15, P420, DOI 10.1128/JVI.15.2.420-422.1975; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Randhawa PS, 1999, TRANSPLANTATION, V67, P103, DOI 10.1097/00007890-199901150-00018; Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813; ROTOLA A, 1992, INT J CANCER, V52, P359, DOI 10.1002/ijc.2910520306; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; RUBINSTEIN R, 1987, J VIROL, V61, P1747, DOI 10.1128/JVI.61.5.1747-1750.1987; Ruska KM, 1998, AM J SURG PATHOL, V22, P1073, DOI 10.1097/00000478-199809000-00005; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIF I, 1979, CELL, V18, P963, DOI 10.1016/0092-8674(79)90209-5; Shah KV, 1996, FIELDS VIROLOGY, P2027; Shah R, 2001, AM J PATHOL, V158, P1767, DOI 10.1016/S0002-9440(10)64132-6; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1995, ONCOGENIC MECH, P27; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; SUNDSFJORD A, 1990, J VIROL, V64, P3864, DOI 10.1128/JVI.64.8.3864-3871.1990; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vilchez RA, 2002, AIDS RES HUM RETROV, V18, P237, DOI 10.1089/088922202753472793; Vivaldi A, 2003, J CLIN ENDOCR METAB, V88, P892, DOI 10.1210/jc.2002-020436; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Volter C, 1997, VIROLOGY, V237, P389, DOI 10.1006/viro.1997.8772; WATANABE S, 1989, VIROLOGY, V169, P204, DOI 10.1016/0042-6822(89)90056-1; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Wiedorn KH, 1999, HISTOCHEM CELL BIOL, V111, P89, DOI 10.1007/s004180050338; YANG RCA, 1979, SCIENCE, V206, P456, DOI 10.1126/science.228391; Yang XMJ, 2002, AM J SURG PATHOL, V26, P921, DOI 10.1097/00000478-200207000-00011; Zambrano A, 2002, ONCOGENE, V21, P5725, DOI 10.1038/sj.onc.1205692; Zambrano A, 2002, PROSTATE, V53, P263, DOI 10.1002/pros.10157	113	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7031	7046		10.1038/sj.onc.1207920	http://dx.doi.org/10.1038/sj.onc.1207920			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258563				2022-12-25	WOS:000223885100004
J	Dantsker, D; Samuni, U; Ouellet, Y; Wittenberg, BA; Wittenberg, JB; Milani, M; Bolognesi, M; Guertin, M; Friedman, JM				Dantsker, D; Samuni, U; Ouellet, Y; Wittenberg, BA; Wittenberg, JB; Milani, M; Bolognesi, M; Guertin, M; Friedman, JM			Viscosity-dependent relaxation significantly modulates the kinetics of CO recombination in the truncated hemoglobin TrHbN from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL HEME POCKET; GEL ENCAPSULATED HEMOGLOBIN; HYDROGEN-BOND NETWORK; SPERM-WHALE MYOGLOBIN; LIGAND-BINDING; STRUCTURAL DYNAMICS; NITRIC-OXIDE; CARBONMONOXY DERIVATIVES; FERRIC HEME; X-RAY	Kinetic traces were generated for the nanosecond and slower rebinding of photodissociated CO to trHbN in solution and in porous sol-gel matrices as a function of viscosity, conformation, and mutation. TrHbN is one of the two truncated hemoglobins from Mycobacterium tuberculosis. The kinetic traces were analyzed in terms of three distinct phases. These three phases are ascribed to rebinding: (i) from the distal heme pocket, (ii) from the adjacent apolar tunnel prior to conformational relaxation, and (iii) from the apolar tunnel subsequent to conformational relaxation. The fractional content of each of these phases was shown to be a function of the viscosity and, in the case of the sol-gel-encapsulated samples, sample preparation history. The observed kinetic patterns support a model consisting of the following elements: (i) the viscosity and conformation-sensitive dynamics of the Tyr(B10) side chain facilitate diffusion of the dissociated ligand from the distal heme pocket into the adjacent tunnel; (ii) the distal heme pocket architecture determines ligand access from the tunnel back to the heme iron; (iii) the distal heme pocket architecture is governed by a ligand-dependent hydrogen bonding network that limits the range of accessible side chain positions; and (iv) the apolar tunnel linking the heme site to the solvent biases the competition between water and ligand for occupancy of the vacated polar distal heme pocket greatly toward the nonpolar ligand. Implications of these finding with respect to biological function are discussed.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Laval, Fac Sci & Engn, Dept Biochem & Microbiol, Quebec City, PQ G1K 7P4, Canada; Univ Genoa, Dept Phys, INFM, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; G Gaslini Inst Children, I-16147 Genoa, Italy	Yeshiva University; Albert Einstein College of Medicine; Laval University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu	Milani, Mario/B-6446-2015; Bolognesi, Martino/B-7924-2017	Milani, Mario/0000-0001-6098-3991; Bolognesi, Martino/0000-0002-9253-5170	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01 EB00296] Funding Source: Medline; NIGMS NIH HHS [P01 GM58890] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2001, EMBO REP, V2, P674, DOI 10.1093/embo-reports/kve159; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Cao WX, 2001, BIOCHEMISTRY-US, V40, P5728, DOI 10.1021/bi010067e; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; Das TK, 2000, J PHYS CHEM B, V104, P10750, DOI 10.1021/jp000452y; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; FRAUENFELDER H, 1995, NAT STRUCT BIOL, V2, P821, DOI 10.1038/nsb1095-821; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Juszczak LJ, 1999, J BIOL CHEM, V274, P30357, DOI 10.1074/jbc.274.43.30357; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; Lecomte JTJ, 2001, BIOCHEMISTRY-US, V40, P6541, DOI 10.1021/bi010226u; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Navati MS, 2003, P NATL ACAD SCI USA, V100, P3832, DOI 10.1073/pnas.262526399; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Pesce A, 2002, STRUCTURE, V10, P725, DOI 10.1016/S0969-2126(02)00763-3; Samuni U, 2004, J AM CHEM SOC, V126, P2682, DOI 10.1021/ja038093i; Samuni U, 2003, J BIOL CHEM, V278, P27241, DOI 10.1074/jbc.M212634200; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 2003, J AM CHEM SOC, V125, P3780, DOI 10.1021/ja029237g; SHULMAN RG, 1969, J MOL BIOL, V48, P517; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Sugimoto T, 1998, BIOPHYS J, V75, P2188, DOI 10.1016/S0006-3495(98)77662-3; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679	56	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38844	38853		10.1074/jbc.M401513200	http://dx.doi.org/10.1074/jbc.M401513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234986	hybrid			2022-12-25	WOS:000223684100097
J	Fan, YX; Wong, L; Deb, TB; Johnson, GR				Fan, YX; Wong, L; Deb, TB; Johnson, GR			Ligand regulates epidermal growth factor receptor kinase specificity - Activation increases preference for GAB1 and SHC versus autophosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; PROTEIN-KINASE; EGF-RECEPTOR; CONFORMATIONAL-CHANGE; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; DOMAIN; IDENTIFICATION; SUBSTRATE	The epidermal growth factor receptor (EGFR) kinase catalyzes phosphorylation of tyrosines in its C terminus and in other cellular targets upon epidermal growth factor (EGF) stimulation. Here, by using peptides derived from EGFR autophosphorylation sites and cellular substrates, we tested the hypothesis that ligand may function to regulate EGFR kinase specificity by modulating the binding affinity of peptide sequences to the active site. Measurement of the steady-state kinetic parameters, K-m and k(cat), revealed that EGF did not affect the binding of EGFR peptides but increased the binding affinity for peptides corresponding to the major EGFR-mediated phosphorylation sites of the adaptor proteins Gab1 (Tyr-627) and Shc (Tyr-317), and for peptides containing the previously identified optimal EGFR kinase substrate sequence EEEEYFELV (3-7-fold). Conversely, EGF stimulation increased k(cat) similar to5-fold for all peptides. Thus, ligand changed the relative preference of the EGFR kinase for substrates as evidenced by EGF increases of similar to5-fold in the specificity constants (k(cat)/K-m) for EGFR peptides, whereas similar to 15 - 40-fold increases were observed for other peptides, such as Gab1 Tyr-627. Furthermore, we demonstrate that EGF (i) increased the binding affinity of EGFR to Gab1 Tyr-627 and Shc Tyr-317 sites in purified GST fusion proteins similar to 4-6-fold, and (ii) EGF significantly enhanced the phosphorylation of these sites, relative to EGFR autophosphorylation, in cell lysates containing the full-length Gab1 and Shc proteins. Analysis of peptides containing amino acid substitutions indicated that residues C-terminal to the target tyrosine were critical for EGF-stimulated increases in substrate binding and regulation of kinase specificity. To our knowledge, this represents the first demonstration that ligand can alter specificity of a receptor kinase toward physiologically relevant targets.	US FDA, Div Therapeut Prot, Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Fan, YX (corresponding author), US FDA, Div Therapeut Prot, Ctr Drug Evaluat & Res, Bldg 29A,Rm 3B-20,8800 Rockville Pike, Bethesda, MD 20892 USA.	fany@cber.fda.gov; johnsong@cber.fda.gov						Ablooglu AJ, 2001, BIOCHEMISTRY-US, V40, P504, DOI 10.1021/bi002292m; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Fan YX, 1996, BIOCHEM J, V315, P97, DOI 10.1042/bj3150097; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; KIM JW, 1990, J BIOL CHEM, V265, P3940; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIEMEISTER G, 1995, J BIOL CHEM, V270, P4870, DOI 10.1074/jbc.270.9.4870; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Yarden Y, 2001, EUR J CANCER, V37, pS3	53	42	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38143	38150		10.1074/jbc.M405760200	http://dx.doi.org/10.1074/jbc.M405760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231819	hybrid			2022-12-25	WOS:000223684100012
J	Jeong, JY; Kim, YJ; Cho, NW; Shin, DW; Nam, TW; Ryu, S; Seok, YJ				Jeong, JY; Kim, YJ; Cho, NW; Shin, DW; Nam, TW; Ryu, S; Seok, YJ			Expression of ptsG encoding the major glucose transporter is regulated by ArcA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL REPRESSOR MLC; PHOSPHOTRANSFERASE SYSTEM; GENE-EXPRESSION; ALLOSTERIC REGULATION; 2-COMPONENT SYSTEM; PROTEIN; OPERON; TRANSCRIPTION; INDUCTION; BACTERIA	Because the phosphoenolpyruvate: sugar phosphotransferase system plays multiple regulatory roles in addition to the phosphorylation-coupled transport of many sugars in bacteria, synthesis of its protein components is regulated in a highly sophisticated way. Thus far, the cAMP receptor protein (CRP) complex and Mlc are known to be the major regulators of ptsHIcrr and ptsG expression in response to the availability of carbon sources. In this report, we performed ligand fishing experiments by using the promoters of ptsHIcrr and ptsG as bait to find out new factors involved in the transcriptional regulation of the phosphoenolpyruvate: sugar phosphotransferase system in Escherichia coli, and we found that the anaerobic regulator ArcA specifically binds to the promoters. Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA significantly decreased glucose consumption. In vitro transcription assays showed that phospho-ArcA (ArcA-P) represses ptsG P1 transcription. DNase I footprinting experiments revealed that ArcA-P binds to three sites upstream of the ptsG P1 promoter, two of which overlap the CRP-binding sites, and the ArcA-P binding decreases the CRP binding that is essential for the ptsG P1 transcription. These results suggest that the response regulator ArcA regulates expression of enzyme IICBGlc mediating the first step of glucose metabolism in response to the redox conditions of growth in E. coli.	Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; Seoul Natl Univ, Dept Food Sci & Technol, Sch Agr Biotechnol, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Seok, YJ (corresponding author), Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea.	yjseok@plaza.snu.ac.kr		Seok, Yeong-Jae/0000-0003-0379-3619				Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; DRAPAL N, 1995, J BACTERIOL, V177, P5338, DOI 10.1128/jb.177.18.5338-5341.1995; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; IUCHI S, 1993, MOL MICROBIOL, V9, P9, DOI 10.1111/j.1365-2958.1993.tb01664.x; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; Koo BM, 2004, J BIOL CHEM, V279, P31613, DOI 10.1074/jbc.M405048200; Koo BM, 2001, J MICROBIOL, V39, P24; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Liu XQ, 2004, J BIOL CHEM, V279, P12588, DOI 10.1074/jbc.M313454200; LUX R, 1995, P NATL ACAD SCI USA, V92, P11583, DOI 10.1073/pnas.92.25.11583; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Peterkofsky A, 2001, J MOL MICROB BIOTECH, V3, P347; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; RYU S, 1994, J BIOL CHEM, V269, P4767; RYU S, 1995, J BIOL CHEM, V270, P2489, DOI 10.1074/jbc.270.6.2489; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Seok YJ, 1997, P NATL ACAD SCI USA, V94, P13515, DOI 10.1073/pnas.94.25.13515; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; Shin D, 2003, J BIOL CHEM, V278, P14776, DOI 10.1074/jbc.M213248200; Shin D, 2001, J BIOL CHEM, V276, P25871, DOI 10.1074/jbc.M101757200; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stulke J, 1999, CURR OPIN MICROBIOL, V2, P195, DOI 10.1016/S1369-5274(99)80034-4; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	40	46	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38513	38518		10.1074/jbc.M406667200	http://dx.doi.org/10.1074/jbc.M406667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252051	hybrid			2022-12-25	WOS:000223684100056
J	Pagliarini, DJ; Worby, CA; Dixon, JE				Pagliarini, DJ; Worby, CA; Dixon, JE			A PTEN-like phosphatase with a novel substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 5-PHOSPHATE; PHOSPHOINOSITIDE 3-PHOSPHATASE; LIPID 2ND-MESSENGER; MYOTUBULARIN; DEPHOSPHORYLATES; PTDINS(4,5)P-2	We show that a novel PTEN-like phosphatase ( PLIP) exhibits a unique preference for phosphatidylinositol 5-phosphate (PI(5) P) as a substrate in vitro. PI(5) P is the least characterized member of the phosphoinositide ( PI) family of lipid signaling molecules. Recent studies suggest a role for PI( 5) P in a variety of cellular events, such as tumor suppression, and in response to bacterial invasion. Determining the means by which PI( 5) P levels are regulated is therefore key to understanding these cellular processes. PLIP is highly enriched in testis tissue and, similar to other PI phosphatases, exhibits poor activity against several proteinaceous substrates. Despite a recent report suggesting a role for PI( 5) P in the regulation of Akt, the overexpression of wild-type or catalytically inactive PLIP in Chinese hamster ovary-insulin receptor cells or a dsRNA-mediated knockdown of PLIP mRNA levels in Drosophila S2 cells does not alter Akt activity or phosphorylation. The unique in vitro catalytic activity and detailed biochemical and kinetic analyses reported here will be of great value in our continued efforts to identify in vivo substrate(s) for this highly conserved phosphatase.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dixon, JE (corresponding author), Univ Calif San Diego, Dept Pharmacol, MC 0721,9500 Gilman Dr,Leichtag Biomed Res Bldg,R, La Jolla, CA 92093 USA.	jedixon@ucsd.edu		Pagliarini, David J./0000-0002-0001-0087	NIGMS NIH HHS [2 T32 GM07752-25] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; Carricaburu V, 2003, P NATL ACAD SCI USA, V100, P9867, DOI 10.1073/pnas.1734038100; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Lindsay MR, 2001, ARCH MICROBIOL, V175, P413, DOI 10.1007/s002030100280; Lizcano JM, 2003, BIOCHEM J, V374, P297, DOI 10.1042/BJ20030577; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Merlot S, 2003, J BIOL CHEM, V278, P39866, DOI 10.1074/jbc.M306318200; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tronchere H, 2004, J BIOL CHEM, V279, P7304, DOI 10.1074/jbc.M311071200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; WORBY CA, 2001, SCI STKE; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; ZHAO ZZ, 1992, ANAL BIOCHEM, V202, P361, DOI 10.1016/0003-2697(92)90119-R; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	43	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38590	38596		10.1074/jbc.M404959200	http://dx.doi.org/10.1074/jbc.M404959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247229	hybrid			2022-12-25	WOS:000223684100065
J	ten Dam, GB; van de Westerlo, EMA; Smetsers, TFCM; Willemse, M; van Muijen, GNP; Merry, CLR; Gallagher, JT; Kim, YS; van Kuppevelt, TH				ten Dam, GB; van de Westerlo, EMA; Smetsers, TFCM; Willemse, M; van Muijen, GNP; Merry, CLR; Gallagher, JT; Kim, YS; van Kuppevelt, TH			Detection of 2-O-sulfated iduronate and N-acetylglucosamine units in heparan sulfate by an antibody selected against acharan sulfate (IdoA2S-GlcNAc)(n)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K5 CAPSULAR POLYSACCHARIDE; SINGLE-CHAIN ANTIBODIES; SNAIL ACHATINA-FULICA; DIFFERENTIAL EXPRESSION; SUBSTRATE-SPECIFICITY; DOMAIN-STRUCTURE; LIGAND-BINDING; HUMAN KIDNEY; BIOSYNTHESIS; GLYCOSAMINOGLYCANS	The snail glycosaminoglycan acharan sulfate (AS) is structurally related to heparan sulfates (HS) and has a repeating disaccharide structure of alpha-D-N-acetylglucosaminyl-2-O-sulfo-alpha-L-iduronic acid (GlcNAc-IdoA2S) residues. Using the phage display technology, a unique antibody (MW3G3) was selected against AS with a V(H)3, DP 47, and a CDR3 amino acid sequence of QKKRPRF. Antibody MW3G3 did not react with desulfated, N-deacetylated or N-sulfated AS, indicating that reactivity depends on N-acetyl and 2-O-sulfate groups. Antibody MW3G3 also had a high preference for (modified) heparin oligosaccharides containing N-acetylated glucosamine and 2-O-sulfated iduronic acid residues. In tissues, antibody MW3G3 identified a HS oligosaccharide epitope containing N-acetylated glucosamine and 2-O-sulfated iduronic acid residues as enzymatic N-deacetylation of HS in situ prevented staining, and 2-O-sulfotransferase-deficient Chinese hamster ovary cells were not reactive. An immunohistochemical survey using various rat organs revealed a distinct distribution of the MW3G3 epitope, which was primarily present in the basal laminae of most (but not all) blood vessels and of some epithelia, including human skin. No staining was observed in the glycosaminoglycan-rich tumor matrix of metastatic melanoma. In conclusion, we have selected an antibody that identifies HS oligosaccharides containing N-acetylated glucosamine and 2-O-sulfated iduronic acid residues. This antibody may be instrumental in identifying structural alterations in HS in health and disease.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Manchester, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Seoul Natl Univ, Inst Nat Prod Res, Seoul 110460, South Korea	Radboud University Nijmegen; Radboud University Nijmegen; University of Manchester; Seoul National University (SNU)	van Kuppevelt, TH (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem 194, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.vankuppevelt@ncmls.kun.nl	van Kuppevelt, A.H.M.S.M./L-4463-2015	merry, catherine/0000-0002-3490-2809				Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bianchini P, 1997, SEMIN THROMB HEMOST, V23, P3, DOI 10.1055/s-2007-996063; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Ghosh AK, 2002, BRIT J PHARMACOL, V137, P441, DOI 10.1038/sj.bjp.0704886; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Hagner-McWhirter A, 2000, GLYCOBIOLOGY, V10, P159, DOI 10.1093/glycob/10.2.159; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Jeong J, 2001, COMP BIOCHEM PHYS B, V130, P513, DOI 10.1016/S1096-4959(01)00468-7; KATO M, 1994, J BIOL CHEM, V269, P18881; Kim YS, 1996, J BIOL CHEM, V271, P11750, DOI 10.1074/jbc.271.20.11750; Lee YS, 2003, EUR J PHARMACOL, V465, P191, DOI 10.1016/S0014-2999(03)01458-4; LINDAHL U, 1976, BIOCHEM BIOPH RES CO, V70, P492, DOI 10.1016/0006-291X(76)91073-1; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Smetsers TFCM, 2004, J INVEST DERMATOL, V122, P707, DOI 10.1111/j.0022-202X.2004.22316.x; Smetsers TFCM, 2003, CANCER RES, V63, P2965; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; van de Westerlo EMA, 2002, BLOOD, V99, P2427, DOI 10.1182/blood.V99.7.2427; van den Born J, 2003, GLYCOBIOLOGY, V13, P1, DOI 10.1093/glycob/cwg011; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VANDELEST CHA, 1994, ANAL BIOCHEM, V221, P356, DOI 10.1006/abio.1994.1425; vandenBorn J, 1996, J BIOL CHEM, V271, P22802, DOI 10.1074/jbc.271.37.22802; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; Wu SJ, 1998, THROMB RES, V92, P273, DOI 10.1016/S0049-3848(98)00146-7	42	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38346	38352		10.1074/jbc.M404166200	http://dx.doi.org/10.1074/jbc.M404166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247295	hybrid, Green Published			2022-12-25	WOS:000223684100035
J	Wilcox, A; Katsanakis, KD; Bheda, F; Pillay, TS				Wilcox, A; Katsanakis, KD; Bheda, F; Pillay, TS			Asb6, an adipocyte-specific ankyrin and SOCS box protein, interacts with APS to enable recruitment of elongins B and C to the insulin receptor signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; STIMULATED GLUCOSE-TRANSPORT; GLUT4 TRANSLOCATION; ADAPTER PROTEIN; MEDIATED DEGRADATION; 3T3-L1 ADIPOCYTES; CBL; PHOSPHORYLATION; ELONGATION; CLONING	The APS adapter protein plays a pivotal role in coupling the insulin receptor to CAP and c-Cbl in the phosphatidylinositol 3-kinase-independent pathway of insulin-stimulated glucose transport. Yeast two-hybrid screening of a 3T3-L1 adipocyte library using APS as a bait identified a 418-amino acid ankyrin and SOCS (suppressor of cytokine signaling) box protein Asb6 as an interactor. Asb6 is an orphan member of a larger family of Asb proteins that are ubiquitously expressed. However, Asb6 expression appears to be restricted to adipose tissue. Asb6 was specifically expressed in 3T3-L1 adipocytes as a 50-kDa protein but not in fibroblasts. In Chinese hamster ovary-insulin receptor (CHO-IR) cells Myc epitope-tagged APS interacted constitutively with FLAG-tagged Asb6 in the presence or absence of insulin stimulation and insulin stimulation did not alter the interaction. In 3T3-L1 adipocytes, insulin receptor activation was accompanied by the APS-dependent recruitment of Asb6. Asb6 did not appear to undergo tyrosine phosphorylation. Immunofluorescence and confocal microscopy studies revealed that Asb6 colocalized with APS in CHO cells and in 3T3-L1 adipocytes. In immunoprecipitation studies in CHO cells or 3T3-L1 adipocytes, the Elongin BC complex was found to be bound to Asb6, and activation of the insulin receptor was required to facilitate Asb6 recruitment along with Elongins B/C. Prolonged insulin stimulation resulted in the degradation of APS when Asb6 was co-expressed but not in the absence of Asb6. We conclude that Asb6 functions to regulate components of the insulin signaling pathway in adipocytes by facilitating degradation by the APS-dependent recruitment of Asb6 and Elongins BC.	Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signaling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Pillay, TS (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signaling, Nottingham NG7 2UH, England.	tpillay@nottingham.ac.uk		pillay, tahir/0000-0002-9982-9710				Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kile BT, 2000, GENE, V258, P31, DOI 10.1016/S0378-1119(00)00402-9; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; KREBS DL, 2003, SCI STKE; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki T, 2001, J BIOL CHEM, V276, P27511, DOI 10.1074/jbc.M011726200; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	34	47	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38881	38888		10.1074/jbc.M406101200	http://dx.doi.org/10.1074/jbc.M406101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231829	hybrid			2022-12-25	WOS:000223684100101
J	Kelley, EE; Trostschansky, A; Rubbo, H; Freeman, BA; Radi, R; Tarpey, MM				Kelley, EE; Trostschansky, A; Rubbo, H; Freeman, BA; Radi, R; Tarpey, MM			Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC HEART-FAILURE; SUPEROXIDE-DISMUTASE; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; CELL-SURFACE; URIC-ACID; ALLOPURINOL; DISEASE; PLASMA; HYPOXANTHINE	Although the binding of xanthine oxidase (XO) to glycosaminoglycans (GAGs) results in significant alterations in its catalytic properties, the consequence of XO/GAG immobilization on interactions with clinically relevant inhibitors is unknown. Thus, the inhibition kinetics of oxypurinol for XO was determined using saturating concentrations of xanthine. When XO was bound to a prototypical GAG, heparin-Sepharose 6B (HS6B-XO), the rate of inactivation for uric acid formation from xanthine was less than that for XO in solution (k(inact) = 0.24 versus 0.39 min(-1)). Additionally, the overall inhibition constant (K-i) of oxypurinol for HS6B-XO was 2-5-fold greater than for free XO ( 451 versus 85 nM). Univalent electron flux (O-2(radical anion) formation) was diminished by the binding of XO to heparin from 28.5% for free XO to 18.7% for GAG-immobilized XO. Similar to the results obtained with HS6B- XO, the binding of XO to bovine aortic endothelial cells rendered the enzyme resistant to inhibition by oxypurinol, achieving similar to 50% inhibition. These results reveal that GAG immobilization of XO in both HS6B and cell models substantially limits oxypurinol inhibition of XO, an event that has important relevance for the use of pyrazolo inhibitors of XO in clinical situations where XO and its products may play a pathogenic role.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Free Rad Biomed Res, Birmingham, AL 35294 USA; Univ Republica, Fac Med, Ctr Free Rad & Biomed Res, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay	Kelley, EE (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, BMRII 19th St S, Birmingham, AL 35294 USA.	ekelley@uab.edu	Freeman, Bruce A/H-9342-2012; Trostchansky, Andres/I-5624-2019	Trostchansky, Andres/0000-0002-9721-7577; Rubbo, Homero/0000-0002-7897-6551	FIC NIH HHS [R03 TW001493, R01 TW05682] Funding Source: Medline; NHLBI NIH HHS [R01-HL06611] Funding Source: Medline; NIGMS NIH HHS [1T32 GM6349003] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063490] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI T, 1993, BIOCHEM J, V289, P523, DOI 10.1042/bj2890523; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Camejo G, 2002, ATHEROSCLEROSIS SUPP, V3, P3, DOI 10.1016/S1567-5688(01)00005-8; Desco MC, 2002, DIABETES, V51, P1118, DOI 10.2337/diabetes.51.4.1118; Ellis A, 1998, EUR J PHARMACOL, V356, P41, DOI 10.1016/S0014-2999(98)00510-X; Farquharson CA, 2002, CIRCULATION, V106, P221, DOI 10.1161/01.CIR.0000022140.61460.1D; FREEMAN BA, 1982, LAB INVEST, V47, P412; FUKUSHIMA T, 1995, BIOL PHARM BULL, V18, P156; Granell S, 2003, CRIT CARE MED, V31, P525, DOI 10.1097/01.CCM.0000049948.64660.06; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; HANDE K, 1978, CLIN PHARMACOL THER, V23, P598; Hare JM, 2003, CIRCULATION, V107, P1951, DOI 10.1161/01.CIR.0000066420.36123.35; HIMMEL HM, 1991, J CHROMATOGR-BIOMED, V568, P105, DOI 10.1016/0378-4347(91)80344-C; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; LARTIGUEMATTEI C, 1990, J CHROMATOGR-BIOMED, V529, P93, DOI 10.1016/S0378-4347(00)83810-4; Leyva F, 1998, EUR HEART J, V19, P1814, DOI 10.1053/euhj.1998.1188; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; McCord JM, 2002, METHOD ENZYMOL, V349, P331, DOI 10.1016/S0076-6879(02)49348-2; MIESEL R, 1993, INFLAMMATION, V17, P551, DOI 10.1007/BF00914193; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; PARKS D, 1988, J APPL PHYSIOL, V254, P768; Pesonen EJ, 1998, GASTROENTEROLOGY, V114, P1009, DOI 10.1016/S0016-5085(98)70321-X; Poss WB, 1996, AM J PHYSIOL-LUNG C, V270, pL941, DOI 10.1152/ajplung.1996.270.6.L941; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; Radi R, 1997, ARCH BIOCHEM BIOPHYS, V339, P125, DOI 10.1006/abbi.1996.9844; SPECTOR T, 1986, BIOCHEM PHARMACOL, V35, P3109, DOI 10.1016/0006-2952(86)90394-1; SPECTOR T, 1970, J BIOL CHEM, V245, P5079; SPECTOR T, 1977, BIOCHEM PHARMACOL, V26, P355, DOI 10.1016/0006-2952(77)90191-5; Turnheim K, 1999, BRIT J CLIN PHARMACO, V48, P501; Ukai T, 2001, CIRCULATION, V103, P750; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; Wolko K, 1974, Mater Med Pol, V6, P95; Yamamoto T, 1996, J CHROMATOGR B, V681, P395, DOI 10.1016/0378-4347(96)00071-0	39	58	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37231	37234		10.1074/jbc.M402077200	http://dx.doi.org/10.1074/jbc.M402077200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231841	hybrid			2022-12-25	WOS:000223554600006
J	Mitra, P; Zheng, XX; Czech, MP				Mitra, P; Zheng, XX; Czech, MP			RNAi-based analysis of CAP, Cbl, and CrkII function in the regulation of GLUT4 by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; C-CBL; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; RECEPTOR; PROTEIN	Stimulation of glucose transport by insulin in cultured adipocytes through translocation of intracellular GLUT4 glucose transporters to the plasma membrane has been suggested to require phosphatidylinositol ( PI) 3-kinase-dependent and independent mechanisms. To test the involvement of a PI 3-kinase-independent pathway leading to activation of the TC10 GTPase, the putative intermediates CAP, c-Cbl, Cbl-b, and CrkII were selectively depleted in 3T3-L1 adipocytes using highly efficient small interfering ( si) RNAs. Simultaneous depletion of the ubiquitination factors c-Cbl plus Cbl-b in cultured adipocytes had the expected effect of delaying dephosphorylation of EGF receptors upon removal of EGF. However, siRNA-mediated gene silencing of both Cbl isoforms or CAP or CrkII in these cells failed to attenuate insulin-stimulated deoxyglucose transport or Myc-tagged GLUT4-GFP translocation at either submaximal or maximal concentrations of insulin. The dose-response relationship for insulin stimulation of deoxyglucose transport in primary adipocytes derived from c-Cbl knock-out mice was also identical to insulin action on adipocytes from wild type mice. These data are consistent with the hypothesis that CAP, Cbl isoforms, and CrkII are not required components of insulin signaling to GLUT4 transporters.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	michael.czech@umassmed.edu		MITRA, PRASENJIT/0000-0001-6494-4623	NIDDK NIH HHS [DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn MY, 2004, J BIOL CHEM, V279, P21526, DOI 10.1074/jbc.M307740200; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; OKADA T, 1994, J BIOL CHEM, V269, P3568; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Sakurai K, 2004, BRIT J PHARMACOL, V141, P209, DOI 10.1038/sj.bjp.0705520; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Thirone ACP, 2004, ENDOCRINOLOGY, V145, P281, DOI 10.1210/en.2003-0575; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078	49	80	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37431	37435		10.1074/jbc.C400180200	http://dx.doi.org/10.1074/jbc.C400180200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15258163	hybrid			2022-12-25	WOS:000223554600030
J	Sancho, R; Marquez, N; Gomez-Gonzalo, M; Calzado, MA; Bettoni, G; Coiras, MT; Alcami, J; Lopez-Cabrera, M; Appendino, G; Munoz, E				Sancho, R; Marquez, N; Gomez-Gonzalo, M; Calzado, MA; Bettoni, G; Coiras, MT; Alcami, J; Lopez-Cabrera, M; Appendino, G; Munoz, E			Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; SP1 TRANSCRIPTION FACTOR; NF-KAPPA-B; TAT-ACTIVATED TRANSCRIPTION; DEPENDENT KINASE INHIBITORS; T-CELL ACTIVATION; IN-VITRO; TYPE-1 TRANSCRIPTION; ANGELICA-DAHURICA	Coumarins and structurally related compounds have been recently shown to present anti-human immunodeficiency virus, type 1 (HIV-1) activity. Among them, the dietary furanocoumarin imperatorin is present in citrus fruits, in culinary herbs, and in some medicinal plants. In this study we report that imperatorin inhibits either vesicular stomatitis virus-pseudotyped or gp160-enveloped recombinant HIV-1 infection in several T cell lines and in HeLa cells. These recombinant viruses express luciferase as a marker of viral replication. Imperatorin did not inhibit the reverse transcription nor the integration steps in the viral cell cycle. Using several 5' long terminal repeat-HIV-1 constructs where critical response elements were either deleted or mutated, we found that the transcription factor Sp1 is critical for the inhibitory activity of imperatorin induced by both phorbol 12-myristate 13-acetate and HIV-1 Tat. Moreover in transient transfections imperatorin specifically inhibited phorbol 12-myristate 13-acetate-induced transcriptional activity of the Gal4-Sp1 fusion protein. Since Sp1 is also implicated in cell cycle progression we further studied the effect of imperatorin on cyclin D1 gene transcription and protein expression and in HeLa cell cycle progression. We found that imperatorin strongly inhibited cyclin D1 expression and arrested the cells at the G1 phase of the cell cycle. These results highlight the potential of Sp1 transcription factor as a target for natural anti-HIV-1 compounds such as furanocoumarins that might have a potential therapeutic role in the management of AIDS.	Univ Cordoba, Fac Med, Dept Biol Celular Fisiol & Inmunol, E-14004 Cordoba, Spain; Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; Univ Studi Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, I-28100 Novara, Italy; Inst Salud Carlos III, Ctr Biol Fundamental, Madrid 28220, Spain	Universidad de Cordoba; Hospital de La Princesa; University of Eastern Piedmont Amedeo Avogadro; Instituto de Salud Carlos III	Munoz, E (corresponding author), Univ Cordoba, Fac Med, Dept Biol Celular Fisiol & Inmunol, Avda Menendez Pidal S-N, E-14004 Cordoba, Spain.	fi1muble@uco.es	Alcami, Pepe/T-2242-2018; Calzado, Marco/E-9046-2016; Coiras, Mayte/R-9530-2019; Cabrera, Manuel López/AAA-5463-2019; Munoz, Eduardo/I-5225-2012; Appendino, Giovanni/O-4832-2015; Calzado, Marco A./S-2295-2019	Alcami, Pepe/0000-0003-0023-7377; Calzado, Marco/0000-0002-5338-535X; Munoz, Eduardo/0000-0001-8478-5842; Appendino, Giovanni/0000-0002-4170-9919; Calzado, Marco A./0000-0002-5338-535X; Sancho, Rocio/0000-0002-4894-5391; Lopez Cabrera, Manuel/0000-0002-0976-9719; Coiras, Mayte/0000-0001-6464-5770				Appendino G, 2004, J NAT PROD, V67, P532, DOI 10.1021/np0340652; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baek NI, 2000, ARCH PHARM RES, V23, P467, DOI 10.1007/BF02976574; Ban HS, 2003, PLANTA MED, V69, P408, DOI 10.1055/s-2003-39702; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CESKA O, 1987, PHYTOCHEMISTRY, V26, P165, DOI 10.1016/S0031-9422(00)81503-4; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Clapham PR, 1999, MOL MEMBR BIOL, V16, P49, DOI 10.1080/096876899294751; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Garcia-Argaez AN, 2000, PLANTA MED, V66, P279, DOI 10.1055/s-2000-14894; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; GNABRE JN, 1995, P NATL ACAD SCI USA, V92, P11239, DOI 10.1073/pnas.92.24.11239; Gomez-Gonzalo M, 2001, J BIOL CHEM, V276, P35435, DOI 10.1074/jbc.M103020200; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAMINE J, 1993, J VIROL, V67, P6828, DOI 10.1128/JVI.67.11.6828-6834.1993; Kawaii S, 2001, ANTICANCER RES, V21, P1905; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Loregian A, 2003, FEBS LETT, V543, P61, DOI 10.1016/S0014-5793(03)00399-5; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Murray R. D. H., 1982, NATURAL COUMARINS OC; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Ptak RG, 2002, EXPERT OPIN INV DRUG, V11, P1099, DOI 10.1517/13543784.11.8.1099; Pumfery A, 2003, CURR HIV RES, V1, P343, DOI 10.2174/1570162033485186; Sadaie AR, 2004, ANTIVIR RES, V61, P1, DOI 10.1016/j.antiviral.2003.09.004; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; SUNE C, 1995, J VIROL, V69, P6572; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; Van Maele B, 2003, J VIROL, V77, P4685, DOI 10.1128/JVI.77.8.4685-4694.2003; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wu TS, 2001, BIOORGAN MED CHEM, V9, P77, DOI 10.1016/S0968-0896(00)00225-X; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yu DL, 2003, MED RES REV, V23, P322, DOI 10.1002/med.10034; Zhou C, 2002, J MOL BIOL, V320, P925, DOI 10.1016/S0022-2836(02)00556-9; Zhou MS, 2001, J BIOL CHEM, V276, P44633, DOI 10.1074/jbc.M107466200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	70	96	109	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37349	37359		10.1074/jbc.M401993200	http://dx.doi.org/10.1074/jbc.M401993200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15218031	hybrid			2022-12-25	WOS:000223554600021
J	Silva, AM; Whitmore, M; Xu, Z; Jiang, ZF; Li, XX; Williams, BRG				Silva, AM; Whitmore, M; Xu, Z; Jiang, ZF; Li, XX; Williams, BRG			Protein kinase R (PKR) interacts with and activates mitogen-activated protein kinase kinase 6 (MKK6) in response to double-stranded RNA stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MAP KINASE; SIGNALING PATHWAYS; DEPENDENT KINASE; GENE-EXPRESSION; HUMAN-CELLS; ENCEPHALOMYOCARDITIS VIRUS; INTERFERON ACTION; ADAPTER MOLECULE; MAJOR ACTIVATOR	The double-stranded RNA (dsRNA)-activated protein kinase R (PKR) has been invoked in different signaling pathways. In cells pre-exposed to the PKR inhibitor 2-aminopurine or in PKR-null cells, the activation of p38 mitogen-activated protein kinase ( MAPK) following dsRNA stimulation is attenuated. We found that the p38 MAPK activator MKK6, but not its close relatives MKK3 or MKK4, exhibited an increased affinity for PKR following the exposure of cells to poly(rI: rC), a dsRNA analog. In vitro kinase assays revealed that MKK6 was efficiently phosphorylated by PKR, and this could be inhibited by 2-aminopurine. Expression of kinase-inactive PKR (K296R) in cells inhibited the poly(IC)-induced phosphorylation of MKK3/6 detected by phosphospecific antiserum but did not affect the poly(IC)-induced gel migration retardation of MKK3. This suggests that poly(IC)-mediated in vivo activation of MKK6, but not MKK3, is through PKR. Consistent with this observation, PKR was capable of activating MKK6 as assessed in a coupled kinase assay containing the components of the p38 MAPK pathway. Our results indicate that the interaction of MKK6 and PKR provides a mechanism for regulating p38 MAPK activation in response to dsRNA stimulation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, 9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Silva, Aristobolo AMS/F-7326-2016; Silva, Aristobolo/CAF-4874-2022; Williams, Bryan R. G./A-5021-2009; Silva, Aristóbolo/AAA-2239-2021	Williams, Bryan R. G./0000-0002-4969-1151; Silva, Aristóbolo/0000-0001-7473-7433	NCI NIH HHS [P01-CA62220] Funding Source: Medline; NIAID NIH HHS [R01-AI34039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; GUSELLA GL, 1995, J IMMUNOL, V154, P345; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; KRUST B, 1984, J BIOL CHEM, V259, P8494; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SEGER R, 1994, J BIOL CHEM, V269, P25699; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Takizawa T, 2002, EUR J BIOCHEM, V269, P6126, DOI 10.1046/j.1432-1033.2002.03325.x; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	61	79	88	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37670	37676		10.1074/jbc.M406554200	http://dx.doi.org/10.1074/jbc.M406554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15229216	hybrid			2022-12-25	WOS:000223554600058
J	Cheng, SH; Shakespeare, T; Mui, R; White, TW; Valdimarsson, G				Cheng, SH; Shakespeare, T; Mui, R; White, TW; Valdimarsson, G			Connexin 48.5 is required for normal cardiovascular function and lens development in zebrafish embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; MOLECULAR-CLONING; SELECTIVE INTERACTIONS; EXPRESSION; HEART; XENOPUS; MUTATIONS; MICROPHTHALMIA; DISRUPTION; CHANNELS	Gap junctions are composed of connexin (Cx) proteins and mediate intercellular communication required for many developmental and physiological processes. Here we describe the isolation and characterization of Cx48.5, a zebrafish connexin with the highest sequence identity to mammalian Cx46. Expression analysis showed that Cx48.5 is expressed in the adult and embryonic lens and heart, adult testis, and transiently in the embryonic otic vesicles. Injection of Cx48.5 cRNA into Xenopus oocytes elicited intercellular electrical coupling with voltage sensitivity similar to mammalian Cx46. In single oocytes, Cx48.5 also induced large outward currents on depolarization, consistent with gap-junctional hemichannels. Disruption of Cx48.5 expression in embryos with antisense morpholino oligos (morpholinos) revealed that Cx48.5 has an essential role in the maintenance of lens homeostasis. The morpholino-treated embryos also developed small lenses and eyes as well as severe cardiovascular abnormalities.	Univ Manitoba, Dept Zool, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3T 2N2, Canada; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	University of Manitoba; University of Manitoba; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Valdimarsson, G (corresponding author), Univ Manitoba, Dept Zool, Winnipeg, MB R3T 2N2, Canada.	valdimar@cc.umanitoba.ca	White, Thomas W./R-3605-2019; White, Thomas/GPG-4026-2022	White, Thomas/0000-0002-3285-7434	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006652] Funding Source: NIH RePORTER; NEI NIH HHS [EY 13163] Funding Source: Medline; NICHD NIH HHS [N01 HD 73263] Funding Source: Medline; NIDCD NIH HHS [DC 06652] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085; Alexander J, 1998, DEV GENET, V22, P288, DOI 10.1002/(SICI)1520-6408(1998)22:3<288::AID-DVG10>3.3.CO;2-T; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Cason N, 2001, DEV DYNAM, V221, P238, DOI 10.1002/dvdy.1133; Chandross KJ, 1996, MOL CELL NEUROSCI, V7, P501, DOI 10.1006/mcne.1996.0036; Chen JN, 2000, TRENDS GENET, V16, P383, DOI 10.1016/S0168-9525(00)02075-8; Chen JN, 1996, DEVELOPMENT, V123, P293; Cheng SH, 2003, DEV DYNAM, V228, P709, DOI 10.1002/dvdy.10436; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DAHL G, 1987, SCIENCE, V236, P1290, DOI 10.1126/science.3035715; DAVIS LM, 1995, J CARDIOVASC ELECTR, V6, P813, DOI 10.1111/j.1540-8167.1995.tb00357.x; Easter SS, 1996, DEV BIOL, V180, P646; Ebihara L, 2003, NEWS PHYSIOL SCI, V18, P100, DOI 10.1152/nips.01431.2002; EBIHARA L, 1995, BIOPHYS J, V68, P1796, DOI 10.1016/S0006-3495(95)80356-5; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; Ekker SC, 2000, YEAST, V17, P302, DOI 10.1002/1097-0061(200012)17:4<302::AID-YEA53>3.0.CO;2-#; Ekker SC, 2001, GENESIS, V30, P89, DOI 10.1002/gene.1038; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; GOURDIE RG, 1992, ANAT EMBRYOL, V185, P363; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Guldenagel M, 2000, J COMP NEUROL, V425, P193; GUPTA VK, 1994, INVEST OPHTH VIS SCI, V35, P3747; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; Hopperstad MG, 2000, BIOPHYS J, V79, P1954, DOI 10.1016/S0006-3495(00)76444-7; Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282; Hu N, 2000, ANAT REC, V260, P148, DOI 10.1002/1097-0185(20001001)260:2<148::AID-AR50>3.0.CO;2-X; Hu N, 2001, ANAT REC, V264, P1, DOI 10.1002/ar.1111; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; Kruger O, 2000, DEVELOPMENT, V127, P4179; Kumai M, 2000, DEVELOPMENT, V127, P3501; Lohr JL, 2000, AM J MED GENET, V97, P248, DOI 10.1002/1096-8628(200024)97:4<248::AID-AJMG1275>3.0.CO;2-C; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Martinez-Wittinghan FJ, 2003, J CELL BIOL, V161, P969, DOI 10.1083/jcb.200303068; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Pelster B, 1996, CIRC RES, V79, P358, DOI 10.1161/01.RES.79.2.358; POSTLETHWAIT J, 2000, ZEABRAFISH MONITOR, V7, P3; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Rees MI, 2000, HUM GENET, V106, P206, DOI 10.1007/s004390051029; Rong P, 2002, DEVELOPMENT, V129, P167; Schutte M, 1998, EXP EYE RES, V66, P605, DOI 10.1006/exer.1997.0460; Sedmera D, 2003, AM J PHYSIOL-HEART C, V284, pH1152, DOI 10.1152/ajpheart.00870.2002; Severs NJ, 2001, MICROSC RES TECHNIQ, V52, P301, DOI 10.1002/1097-0029(20010201)52:3<301::AID-JEMT1015>3.0.CO;2-Q; Silverstein DM, 2003, PEDIATR NEPHROL, V18, P216, DOI 10.1007/s00467-002-1065-1; Simon AM, 1997, NATURE, V385, P525, DOI 10.1038/385525a0; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Verheule S, 2001, AM J PHYSIOL-HEART C, V280, pH2103, DOI 10.1152/ajpheart.2001.280.5.H2103; Warren KS, 1998, AM J PHYSIOL-HEART C, V275, pH1, DOI 10.1152/ajpheart.1998.275.1.H1; WESTERFIELD M, 1995, ZEBRAFISH BOOK; White TW, 2000, CURR BIOL, V10, pR685, DOI 10.1016/S0960-9822(00)00689-8; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; WHITE TW, 1994, J CELL BIOL, V125, P879, DOI 10.1083/jcb.125.4.879; White TW, 2002, SCIENCE, V295, P319, DOI 10.1126/science.1067582; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yamamoto Y, 2002, METHODS, V28, P420, DOI 10.1016/S1046-2023(02)00261-X; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Yelon D, 1999, DEV BIOL, V214, P23, DOI 10.1006/dbio.1999.9406; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	74	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36993	37003		10.1074/jbc.M401355200	http://dx.doi.org/10.1074/jbc.M401355200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213236	hybrid			2022-12-25	WOS:000223453600102
J	Jono, H; Lim, JH; Chen, LF; Xu, HD; Trompouki, E; Pan, ZXK; Mosialos, G; Li, JD				Jono, H; Lim, JH; Chen, LF; Xu, HD; Trompouki, E; Pan, ZXK; Mosialos, G; Li, JD			NF-kappa B is essential for induction of CYLD, the negative regulator of NF-kappa B - Evidence for a novel inducible autoregulatory feedback pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTYPABLE HAEMOPHILUS-INFLUENZAE; TUMOR-NECROSIS-FACTOR; ACTIVATION; ALPHA; APOPTOSIS; IKK; PHOSPHORYLATION; SUBUNIT; CANCER; MICE	The transcription factor NF-kappaB regulates genes involved in inflammatory and immune responses, tumorigenesis, and apoptosis. In contrast to the pleiotropic stimuli that lead to its positive regulation, the known signaling mechanisms that underlie the negative regulation of NF-kappaB are very few. Recent studies have identified the tumor suppressor CYLD, loss of which causes a benign human syndrome called cylindromatosis, as a key negative regulator for NF-kappaB signaling by deubiquitinating tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2, TRAF6, and NEMO (NF-kappaB essential modulator, also known as IkappaB kinase gamma). However, how CYLD is regulated remains unknown. The present study revealed a novel autoregulatory feedback pathway through which activation of NF-kappaB by TNF-alpha and bacterium nontypeable Haemophilus influenzae (NTHi) induces CYLD that in turn leads to the negative regulation of NF-kappaB signaling. In addition, TRAF2 and TRAF6 appear to be differentially involved in NF-kappaB-dependent induction of CYLD by TNF-alpha and NTHi. These findings provide novel insights into the autoregulation of NF-kappaB activation.	House Ear Res Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, Dept Otolaryngol, San Francisco, CA 94141 USA; Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Vari 16672, Greece; Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA	House Research Institute; University of Southern California; University of California System; University of California San Francisco; The J David Gladstone Institutes; Alexander Fleming Biomedical Sciences Research Center	Li, JD (corresponding author), House Ear Res Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org	Trompouki, Eirini/AAX-9539-2020	Trompouki, Eirini/0000-0002-7242-8810; Li, Jian-Dong/0000-0002-5593-050X; Lim, Jae Hyang/0000-0003-0972-9271	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562, R01DC005843] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 070293] Funding Source: Medline; NIDCD NIH HHS [DC 004562, DC 005843] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Watanabe T, 2004, P NATL ACAD SCI USA, V101, P3563, DOI 10.1073/pnas.0400557101; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630	21	151	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36171	36174		10.1074/jbc.M406638200	http://dx.doi.org/10.1074/jbc.M406638200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15226292	hybrid, Green Published			2022-12-25	WOS:000223453600002
J	Madrid, M; Soto, T; Franco, A; Paredes, V; Vicente, J; Hidalgo, E; Gacto, M; Cansado, J				Madrid, M; Soto, T; Franco, A; Paredes, V; Vicente, J; Hidalgo, E; Gacto, M; Cansado, J			A cooperative role for Atf1 and Pap1 in the detoxification of the oxidative stress induced by glucose deprivation in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR PAP1; FISSION YEAST; MAP KINASE; HYDROGEN-PEROXIDE; CELL-CYCLE; SEXUAL DEVELOPMENT; ADAPTIVE RESPONSE; STATIONARY-PHASE	In Schizosaccharomyces pombe, glucose concentrations below a certain threshold trigger the stress-activated protein kinase ( SAPK) signal transduction pathway and promote increased transcription of Atf1-dependent genes coding for the general stress response. Removal of glucose specifically induces the nuclear accumulation of green fluorescent protein-labeled Pap1 (GFP-Pap1) and the expression of genes dependent on this transcription factor. In contrast, depletion of the nitrogen source triggers the SAPK pathway but does not activate Pap1-dependent gene transcription, indicating that carbon stress rather than growth arrest leads to an endogenous oxidative condition that favors nuclear accumulation of Pap1. The reductant agents glutathione or N-acetylcysteine suppress the nuclear accumulation of GFP-Pap1 induced by glucose deprivation without inhibiting the activation of the MAPK Sty1. In addition, cells expressing a mutant GFP-Pap1 unable to accumulate into the nucleus upon hydrogen peroxide-mediated oxidative stress failed to show this protein into the nucleus in the absence of glucose. These results support the concept of a concerted action between the SAPK pathway and the Pap1 transcription factor during glucose exhaustion by which glucose limitation induces activation of the SAPK pathway prior to the oxidative stress caused by glucose deprivation. The ensuing induction of Atf1-dependent genes ( catalase) decreases the level of hydroperoxides allowing Pap1 nuclear accumulation and function. Congruent with this interpretation, glucose-depleted cells show higher adaptive response to exogenous oxidative stress than those maintained in the presence of glucose.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, Barcelona 08003, Spain	University of Murcia; Pompeu Fabra University	Gacto, M (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, Campus Univ Espinardo, E-30071 Murcia, Spain.	maga@um.es	Hidalgo, Elena/K-2919-2014; Pino, Teresa Soto/AAC-6096-2020; Madrid, Marisa/K-7755-2014; Vicente-Soler, Jerónima/ABF-6293-2020; Cansado, Jose/ABC-6872-2020; Madrid, Marisa/AAV-2154-2020; Franco, Alejandro/ABG-6823-2020; Cansado, Jose/K-5212-2014	Hidalgo, Elena/0000-0002-3768-6785; Pino, Teresa Soto/0000-0003-2965-318X; Madrid, Marisa/0000-0002-7970-2587; Vicente-Soler, Jerónima/0000-0001-8759-6545; Cansado, Jose/0000-0002-2342-8152; Madrid, Marisa/0000-0002-7970-2587; Franco, Alejandro/0000-0001-7461-3414; 				Aguilaniu H, 2001, J BIOL CHEM, V276, P35396, DOI 10.1074/jbc.M101796200; Benko Z, 1997, CURR GENET, V31, P481, DOI 10.1007/s002940050233; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; BURNETT JA, 1986, YEASTS CHARACTERISTI, P484; CARRILLO D, 1994, MICROBIOL-SGM, V140, P1467, DOI 10.1099/00221287-140-6-1467; Castillo EA, 2002, MOL MICROBIOL, V45, P243, DOI 10.1046/j.1365-2958.2002.03020.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; DEWINDE JH, 1997, YEAST STRESS RESPONS, P7; Flores CL, 2000, FEMS MICROBIOL REV, V24, P507, DOI 10.1111/j.1574-6976.2000.tb00553.x; Franco A, 2000, J BACTERIOL, V182, P5880, DOI 10.1128/JB.182.20.5880-5884.2000; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Higuchi T, 2002, MOL CELL BIOL, V22, P1, DOI 10.1128/MCB.22.1.1-11.2002; HOFFMAN CS, 1990, GENETICS, V124, P807; Izawa S, 1998, BIOCHEM J, V330, P811, DOI 10.1042/bj3300811; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Minard KL, 2001, FREE RADICAL BIO MED, V31, P832, DOI 10.1016/S0891-5849(01)00666-9; Mutoh N, 2002, CURR GENET, V41, P82, DOI 10.1007/s00294-002-0288-9; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SHIOZAKI K, 1997, METHOD ENZYMOL, V283, P503; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Soto T, 1998, BBA-GENE STRUCT EXPR, V1443, P225, DOI 10.1016/S0167-4781(98)00214-0; Soto T, 2002, EUR J BIOCHEM, V269, P1; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Stettler S, 1996, J CELL SCI, V109, P1927; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDIJKEN JP, 1993, ANTON LEEUW INT J G, V63, P343, DOI 10.1007/BF00871229; VIVANCOS AP, 2004, IN PRESS MOL MICROBI; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Welton RM, 2000, GENETICS, V156, P513; Wiatrowski HA, 2003, EUKARYOT CELL, V2, P19, DOI 10.1128/EC.2.1.19-26.2003; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Yamada K, 1999, YEAST, V15, P1125, DOI 10.1002/(SICI)1097-0061(199908)15:11<1125::AID-YEA442>3.0.CO;2-Z	57	56	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41594	41602		10.1074/jbc.M405509200	http://dx.doi.org/10.1074/jbc.M405509200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247218	hybrid			2022-12-25	WOS:000224075500044
J	Hu, HY; Horton, JK; Gryk, MR; Prasad, R; Naron, JM; Sun, DA; Hecht, SM; Wilson, SH; Mullen, GP				Hu, HY; Horton, JK; Gryk, MR; Prasad, R; Naron, JM; Sun, DA; Hecht, SM; Wilson, SH; Mullen, GP			Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL 8-KDA DOMAIN; BASE EXCISION-REPAIR; BINDING; SITE; ACID; PROTEIN; ALPHA; CELLS; TRITERPENOIDS; CYTOTOXICITY	DNA polymerase beta (beta-pol) plays a central role in repair of damaged DNA bases by base excision repair (BER) pathways. A predominant phenotype of beta-pol null mouse fibroblasts is hypersensitivity to the DNA-methylating agent methyl methanesulfonate. Residues in the 8-kDa domain of beta-pol that seem to interact with a known natural product beta-pol inhibitor, koetjapic acid, were identified by NMR chemical shift mapping. The data implicate the binding pocket as the hydrophobic cleft between helix-2 and helix-4, which provides the DNA binding and deoxyribose phosphate lyase activities of the enzyme. Nine structurally related synthetic compounds, containing aromatic or other hydrophobic groups in combination with two carboxylate groups, were then tested. They were found to bind to the same or a very similar region on the surface of the enzyme. The ability of these compounds to potentiate methyl methanesulfonate cytotoxicity, an indicator of cellular BER capacity, in wild-type and beta-pol null mouse fibroblasts, was next ascertained. The most active and beta-pol-specific of these agents, pamoic acid, was further characterized and found to be an inhibitor of the deoxyribose phosphate lyase and DNA polymerase activities of purified beta-pol on a BER substrate. Our results illustrate that NMR-based mapping techniques can be used in the design of small molecule enzyme inhibitors including those with potential use in a clinical setting.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Structr Biol, Farmington, CT 06032 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22901 USA	University of Connecticut; University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Virginia; University of Virginia	Wilson, SH (corresponding author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA50771] Funding Source: Medline; NIEHS NIH HHS [ES09847] Funding Source: Medline; NIGMS NIH HHS [GM52738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA050771, U19CA050771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Chen J, 1998, CHEM COMMUN, P2769, DOI 10.1039/a807053i; Deng JZ, 2000, BIOORGAN MED CHEM, V8, P247, DOI 10.1016/S0968-0896(99)00276-X; Deng JZ, 2000, J NAT PROD, V63, P1356, DOI 10.1021/np000129m; Deng JZ, 1999, J NAT PROD, V62, P477, DOI 10.1021/np980522g; Deng JZ, 1999, J CHEM SOC PERK T 1, P1147, DOI 10.1039/a901123d; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Kasai N, 2002, J BIOCHEM, V132, P819, DOI 10.1093/oxfordjournals.jbchem.a003292; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; Ma J, 1999, J NAT PROD, V62, P1660, DOI 10.1021/np990326p; Maciejewski MW, 2000, J MOL BIOL, V296, P229, DOI 10.1006/jmbi.1999.3455; MILLER MR, 1982, J BIOL CHEM, V257, P204; Mizushina Y, 2000, BIOCHEM J, V350, P757, DOI 10.1042/0264-6021:3500757; Mizushina Y, 2000, BIOCHEMISTRY-US, V39, P12606, DOI 10.1021/bi001276m; Mizushina Y, 1999, J BIOCHEM, V126, P430, DOI 10.1093/oxfordjournals.jbchem.a022468; Mizushina Y, 1999, J BIOL CHEM, V274, P25599, DOI 10.1074/jbc.274.36.25599; Mizushina Y, 2002, J BIOL CHEM, V277, P630, DOI 10.1074/jbc.M105144200; Mizushina Y, 1998, BIOCHEM PHARMACOL, V55, P537, DOI 10.1016/S0006-2952(97)00536-4; Mullen GP, 1997, BIOCHEMISTRY-US, V36, P4713, DOI 10.1021/bi962363a; Ogawa A, 1998, INT J CANCER, V76, P512, DOI 10.1002/(SICI)1097-0215(19980518)76:4<512::AID-IJC12>3.3.CO;2-3; Perpelescu M, 2002, BIOCHEMISTRY-US, V41, P7610, DOI 10.1021/bi020115a; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Raaphorst GP, 2002, INT J HYPERTHER, V18, P33, DOI 10.1080/02656730110072352; Saraswat V, 2002, BIOCHEMISTRY-US, V41, P15566, DOI 10.1021/bi020552p; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Sun DA, 1999, J NAT PROD, V62, P1110, DOI 10.1021/np990104r; Tanaka N, 1998, J NAT PROD, V61, P193, DOI 10.1021/np970127a; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837	39	79	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39736	39744		10.1074/jbc.M402842200	http://dx.doi.org/10.1074/jbc.M402842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258144	hybrid			2022-12-25	WOS:000223791500066
J	Ho, DL; Byrnes, WM; Ma, WP; Shi, Y; Callaway, DJE; Bu, ZM				Ho, DL; Byrnes, WM; Ma, WP; Shi, Y; Callaway, DJE; Bu, ZM			Structure-specific DNA-induced conformational changes in Taq polymerase revealed by small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; ESCHERICHIA-COLI; THERMUS-AQUATICUS; GENETIC ALGORITHM; CRYSTAL-STRUCTURE; NUCLEASE DOMAIN; ENDONUCLEASE; REPLICATION; DYNAMICS; PROTEIN	The DNA polymerase I from Thermus aquaticus (Taq polymerase) performs lagging-strand DNA synthesis and DNA repair. Taq polymerase contains a polymerase domain for synthesizing a new DNA strand and a 5'-nuclease domain for cleaving RNA primers or damaged DNA strands. The extended crystal structure of Taq polymerase poses a puzzle on how this enzyme coordinates its polymerase and the nuclease activities to generate only a nick. Using contrast variation solution small angle neutron scattering, we have examined the conformational changes that occur in Taq polymerase upon binding "overlap flap" DNA, a structure-specific DNA substrate that mimics the substrate in strand replacement reactions. In solution, apoTaq polymerase has an overall expanded equilibrium conformation similar to that in the crystal structure. Upon binding to the DNA substrate, both the polymerase and the nuclease domains adopt more compact overall conformations, but these changes are not enough to bring the two active sites close enough to generate a nick. Reconstruction of the three-dimensional molecular envelope from small angle neutron scattering data shows that in the DNA-bound form, the nuclease domain is lifted up relative to its position in the non-DNA-bound form so as to be in closer contact with the thumb and palm subdomains of the polymerase domain. The results suggest that a form of structure sensing is responsible for the coordination of the polymerase and nuclease activities in nick generation. However, interactions between the polymerase and the nuclease domains can assist in the transfer of the DNA substrate from one active site to the other.	NYU, Sch Med, N Shore LIJ Res Inst, Manhasset, NY 11030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Natl Inst Stand & Technol, Gaithersburg, MD 20898 USA; Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA; Third Wave Technol Inc, Madison, WI 53719 USA	New York University; Northwell Health; Fox Chase Cancer Center; National Institute of Standards & Technology (NIST) - USA; Howard University	Callaway, DJE (corresponding author), NYU, Sch Med, N Shore LIJ Res Inst, 350 Community Dr, Manhasset, NY 11030 USA.	dcallawa@nshs.edu; Zimei.Bu@fccc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003048] Funding Source: NIH RePORTER; NCRR NIH HHS [2 G12 RR003048] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bu ZM, 1999, BIOPHYS J, V77, P1064, DOI 10.1016/S0006-3495(99)76956-0; Bu ZM, 2001, J MOL BIOL, V312, P865, DOI 10.1006/jmbi.2001.5006; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Ceska TA, 1998, TRENDS BIOCHEM SCI, V23, P331, DOI 10.1016/S0968-0004(98)01259-6; Chacon P, 2000, J MOL BIOL, V299, P1289, DOI 10.1006/jmbi.2000.3784; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Feigen L.A., 1987, STRUCTURE ANAL SMALL; Garforth SJ, 1997, NUCLEIC ACIDS RES, V25, P3801, DOI 10.1093/nar/25.19.3801; Glatter O., 1982, SMALL ANGLE XRAY SCA, P119; Glinka CJ, 1998, J APPL CRYSTALLOGR, V31, P430, DOI 10.1107/S0021889897017020; Halford SE, 2002, EUR BIOPHYS J BIOPHY, V31, P257, DOI 10.1007/s00249-002-0224-4; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Joubert AM, 2003, J BIOL CHEM, V278, P25341, DOI 10.1074/jbc.M302118200; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kim CY, 1999, J BIOL CHEM, V274, P1233, DOI 10.1074/jbc.274.3.1233; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Ma WP, 2000, J BIOL CHEM, V275, P24693, DOI 10.1074/jbc.M002268200; May RP, 2002, N-HOLLAND D, P463; Murali R, 1998, P NATL ACAD SCI USA, V95, P12562, DOI 10.1073/pnas.95.21.12562; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Tehei M, 2004, EMBO REP, V5, P66, DOI 10.1038/sj.embor.7400049; Urs UK, 1999, ACTA CRYSTALLOGR D, V55, P1971; VANHOLDE KE, 1998, PRINCIPLES PHYS BIOC, P325; Walther D, 2000, J APPL CRYSTALLOGR, V33, P350, DOI 10.1107/S0021889899015976; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Wriggers W, 2001, J APPL CRYSTALLOGR, V34, P773, DOI 10.1107/S0021889801012869; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199; Zaccai G, 2000, SCIENCE, V288, P1604, DOI 10.1126/science.288.5471.1604	43	27	28	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39146	39154		10.1074/jbc.M404565200	http://dx.doi.org/10.1074/jbc.M404565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247286	hybrid			2022-12-25	WOS:000223684100131
J	Schwarz-Linek, U; Pilka, ES; Pickford, AR; Kim, JH; Hook, M; Campbell, ID; Potts, JR				Schwarz-Linek, U; Pilka, ES; Pickford, AR; Kim, JH; Hook, M; Campbell, ID; Potts, JR			High affinity streptococcal binding to human fibronectin requires specific recognition of sequential F1 modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; INTRINSICALLY UNSTRUCTURED PROTEINS; RESPIRATORY EPITHELIAL-CELLS; STAPHYLOCOCCUS-AUREUS; BACTERIAL ADHERENCE; NMR-SPECTROSCOPY; LIGAND-BINDING; SFB PROTEIN; PYOGENES; ADHESIN	Fibronectin (Fn) binding by the Streptococcus pyogenes protein SfbI has been shown to trigger integrin-dependent internalization of this pathogen by human epithelial and endothelial cells. Here, using nuclear magnetic resonance spectroscopy and isothermal titration calorimetry in a dissection approach, the basis for the specificity and high affinity of the interaction between the N-terminal domain of Fn and SfbI is revealed. Each of the five Fn type 1 modules is directly involved in the interaction and is recognized by short consecutive motifs within the repeat region of SfbI. Crucially, these motifs must be combined in the correct order to form a high affinity ligand for the N-terminal domain of Fn.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Texas A&M Univ Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	University of Oxford; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Potts, JR (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	jennifer.potts@bioch.ox.ac.uk	Pickford, Andy/AGB-6901-2022	Pickford, Andy/0000-0002-7237-0030; Schwarz-Linek, Ulrich/0000-0003-0526-223X				BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Ensenberger MG, 2001, J BIOL CHEM, V276, P35606, DOI 10.1074/jbc.M105417200; GRECO R, 1995, RES MICROBIOL, V146, P551, DOI 10.1016/0923-2508(96)80561-4; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Gunasekaran K, 2003, TRENDS BIOCHEM SCI, V28, P81, DOI 10.1016/S0968-0004(03)00003-3; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; LINDGREN PE, 1993, EUR J BIOCHEM, V214, P819, DOI 10.1111/j.1432-1033.1993.tb17985.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; Osterlund A, 1997, ACTA OTO-LARYNGOL, V117, P883, DOI 10.3109/00016489709114219; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2001, FEBS LETT, V497, P137, DOI 10.1016/S0014-5793(01)02418-8; Schwarz-Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365-2958.2004.04027.x; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; Sela S, 1999, ANN MED, V31, P303, DOI 10.3109/07853899908995895; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SOFFE N, 1995, J MAGN RESON SER A, V116, P117, DOI 10.1006/jmra.1995.1197; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; VALENTINWEIGAND P, 1994, MICROB PATHOGENESIS, V17, P111, DOI 10.1006/mpat.1994.1057; WEMMER DE, 1994, METHOD ENZYMOL, V239, P739; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	46	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39017	39025		10.1074/jbc.M405083200	http://dx.doi.org/10.1074/jbc.M405083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247227	hybrid			2022-12-25	WOS:000223684100116
J	Shibata, H; Kashiwayama, Y; Imanaka, T; Kato, H				Shibata, H; Kashiwayama, Y; Imanaka, T; Kato, H			Domain architecture and activity of human Pex19p, a chaperone-like protein for intracellular trafficking of peroxisomal membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYLATED PROTEIN; BIOGENESIS DISORDERS; TARGETING SIGNALS; SYNTHESIS SYSTEM; DISTINCT; RECEPTOR; IMPORT; PEX3	Pex19p is a peroxin involved in peroxisomal membrane biogenesis and probably functions as a chaperone and/or soluble receptor specific for cargo peroxisomal membrane proteins (PMPs). To elucidate the functional constituents of Pex19p in terms of the protein structure, we investigated its domain architecture and binding affinity toward various PMPs and peroxins. The human Pex19p cDNA was overexpressed in Escherichia coli, and a highly purified sample of the Pex19p protein was prepared. When PMP22 was synthesized by cell-free translation in the presence of Pex19p, the PMP22 bound to Pex19p was soluble, whereas PMP22 alone was insoluble. This observation shows that Pex19p plays a role in capturing PMP and maintaining its solubility. In a similar manner, Pex19p was bound to PMP70 and Pex16p as well as the Pex3p soluble fragment. Limited proteolysis analyses revealed that Pex19p consists of the C-terminal core domain flanking the flexible N-terminal region. Separation of Pex19p into its N- and C-terminal halves abolished interactions with PMP22, PMP70, and Pex16p. In contrast, the flexible N-terminal half of Pex19p was bound to the Pex3p soluble fragment, suggesting that the binding mode of Pex3p toward Pex19p differs from that of other PMPs. This idea is supported by our detection of the Pex19p-Pex3p-PMP22 ternary complex.	RIKEN, Harima Inst SPring 8, Membrane Dynam Res Grp, Kinet Crystallog Res Team, Mikazuki, Hyogo 6795148, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sakyo Ku, Kyoto 6068501, Japan	RIKEN; University of Toyama; Kyoto University	Kato, H (corresponding author), RIKEN, Harima Inst SPring 8, Membrane Dynam Res Grp, Kinet Crystallog Res Team, 1-1-1 Kouto, Mikazuki, Hyogo 6795148, Japan.	katohiro@pharm.kyoto-u.ac.jp		Imanaka, Tsuneo/0000-0003-4677-1356; Kato, Hiroaki/0000-0002-5993-4532				Arnold U, 1999, ANAL BIOCHEM, V271, P197, DOI 10.1006/abio.1999.4149; BARELA TD, 1974, BIOCHEMISTRY-US, V13, P1694, DOI 10.1021/bi00705a022; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mayerhofer PU, 2002, BIOCHEM BIOPH RES CO, V291, P1180, DOI 10.1006/bbrc.2002.6568; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Pause B, 1997, FEBS LETT, V414, P95, DOI 10.1016/S0014-5793(97)00975-7; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sawasaki T, 2002, FEBS LETT, V514, P102, DOI 10.1016/S0014-5793(02)02329-3; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Voos W, 2003, MOL CELL, V11, P1, DOI 10.1016/S1097-2765(03)00002-9; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040	31	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38486	38494		10.1074/jbc.M402204200	http://dx.doi.org/10.1074/jbc.M402204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252024	hybrid			2022-12-25	WOS:000223684100053
J	Cunninghan, R; Steplock, D; Wang, FY; Huang, HJ; E, XF; Shenolikar, S; Weinman, EJ				Cunninghan, R; Steplock, D; Wang, FY; Huang, HJ; E, XF; Shenolikar, S; Weinman, EJ			Defective parathyroid hormone regulation of NHE3 activity and phosphate adaptation in cultured NHERF-1(-/-) renal proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; PROTEIN-KINASE-A; NA+/H+ EXCHANGER; PDZ DOMAINS; TRANSPORT; ISOFORMS; REQUIRES; EZRIN; IIA; PHOSPHORYLATION	The present experiments using primary cultures of renal proximal tubule cells derived from wild-type and NHERF-1 knockout animals examines the regulation of NHE3 by phenylthiohydantoin (PTH) and the regulation of phosphate transport in response to alterations in the media content of phosphate. Forskolin (34.8 +/- 6.2%) and PTH (29.7 +/- 1.8%) inhibited NHE3 activity in wild-type proximal tubule cells but neither forskolin ( - 3.2 +/- 3.3%) nor PTH ( - 16.6 +/- 8.1%) inhibited NHE3 activity in NHERF-1(-/-) cells. Using adenovirus-mediated gene transfer, expression of NHERF-1 in NHERF-1(-/-) proximal tubule cells restored the inhibitory response to forskolin (28.2 +/- 3.0%) and PTH (33.2 +/- 3.9%). Compared with high phosphate media, incubation of wild-type cells in low phosphate media resulted in a 36.0 +/- 6.3% higher rate of sodium-dependent phosphate transport and a significant increase in the abundance of Npt2a and PDZK1. NHERF-1(-/-) cells, on the other hand, had lower rates of sodium-dependent phosphate uptake and low phosphate media did not stimulate phosphate transport. Npt2a expression was not affected by the phosphate content of the media in NHERF-1 null cells although low phosphate media up-regulated PDZK1 abundance. Primary cultures of mice proximal tubule cells retain selected regulatory pathways observed in intact kidneys. NHERF-1(-/-) proximal tubule cells demonstrate defective regulation of NHE3 by PTH and indicate that reintroduction of NHERF-1 repairs this defect. NHERF-1(-/-) cells also do not adapt to alterations in the phosphate content of the media indicating that the defect resides within the cells of the proximal tubule and is not dependent on systemic factors.	Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Med Serv, Baltimore, MD 21201 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Duke University	Weinman, EJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.	eweinman@medicine.umaryland.edu			NIDDK NIH HHS [DK55881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; CAVERZASIO J, 1985, AM J PHYSIOL, V248, pF122, DOI 10.1152/ajprenal.1985.248.1.F122; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; DOLSON GM, 1985, AM J PHYSIOL, V249, pF409, DOI 10.1152/ajprenal.1985.249.3.F409; Dunbar LA, 2000, EUR J CELL BIOL, V79, P557, DOI 10.1078/0171-9335-00079; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Gisler SM, 2003, KIDNEY INT, V64, P1733, DOI 10.1046/j.1523-1755.2003.00266.x; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Lederer ED, 2003, J AM SOC NEPHROL, V14, P1711, DOI 10.1097/01.ASN.0000072744.67971.21; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahon MJ, 2003, MOL ENDOCRINOL, V17, P2355, DOI 10.1210/me.2003-0043; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Murer H, 2003, ANNU REV PHYSIOL, V65, P531, DOI 10.1146/annurev.physiol.65.042902.092424; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; Pfister MF, 1998, PFLUG ARCH EUR J PHY, V435, P713, DOI 10.1007/s004240050573; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; SOLTOFF SP, 1984, J GEN PHYSIOL, V84, P643, DOI 10.1085/jgp.84.4.643; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2003, AM J PHYSIOL-RENAL, V285, pF1225, DOI 10.1152/ajprenal.00215.2003; Weinman EJ, 2002, PATHOBIOLOGY, V70, P314, DOI 10.1159/000071271; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1988, J MEMBRANE BIOL, V103, P237, DOI 10.1007/BF01993983; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	43	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37815	37821		10.1074/jbc.M405893200	http://dx.doi.org/10.1074/jbc.M405893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15218020	hybrid			2022-12-25	WOS:000223554600074
J	Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E				Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E			Jak kinase activity is required for lymphoma invasion and metastasis	ONCOGENE			English	Article						integrin; adhesion; G-protein; CXCR4 migration	ZAP-70 TYROSINE KINASE; JAK/STAT PATHWAY; ACTIVATION; PHOSPHORYLATION; MIGRATION; CXCR4; LFA-1; CELLS; DISSEMINATION; INVASIVENESS	Jak tyrosine kinases are activated by interleukins and other growth factors, and promote survival and proliferation of cells in multiple tissues. These kinases are constitutively active in many hematopoietic malignancies and certain carcinomas. We have investigated whether Jak kinases play a role in lymphoma invasion and metastasis. Proliferation and survival of a highly metastatic T-lymphoma was made independent of its constitutively active Jak by expression of active forms of both STAT3 and PI3-kinase. Jak activity was then blocked by the isolated JH2 'pseudokinase' domain of Jak2. In vitro invasion was blocked by the JH2 domain, and the metastatic capacity of the JH2-expressing cells was much reduced. The Jak inhibitor AG490 inhibited invasion as well. Invasion and metastasis of these cells requires activation of the integrin LFA-1 by the CXCR4 chemokine receptor. We show that Jak kinases act downstream of LFA-1. We conclude that Jak kinase activity is essential for lymphoma invasion and metastasis, independent of its role in survival and proliferation, and independent of STAT and PI3K signaling. This indicates that Jak kinases contribute in multiple ways to the induction of malignant behavior.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Roos, E (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	E.ROOS@NKI.NL						Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Carron C, 2000, BLOOD, V95, P3891; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; LARIVIERE G, 1988, CANCER RES, V48, P3405; LARIVIERE G, 1993, J LEUKOCYTE BIOL, V53, P381, DOI 10.1002/jlb.53.4.381; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371; Soede RDM, 2001, J IMMUNOL, V166, P4293, DOI 10.4049/jimmunol.166.7.4293; Soede RDM, 1999, J IMMUNOL, V163, P4253; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	33	16	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6647	6653		10.1038/sj.onc.1207887	http://dx.doi.org/10.1038/sj.onc.1207887			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235585				2022-12-25	WOS:000223530800012
J	Yang, KT; Pan, SF; Chien, CL; Hsu, SM; Tseng, YZ; Wang, SM; Wu, ML				Yang, KT; Pan, SF; Chien, CL; Hsu, SM; Tseng, YZ; Wang, SM; Wu, ML			Mitochondrial Na+ overload is caused by oxidative stress and leads to activation of the caspase 3-dependent apoptotic machinery	FASEB JOURNAL			English	Article						Ca2+; mitochondria; apoptosis; cardiomyocyte	DEPENDENT ANION CHANNEL; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; SIGNAL PROPAGATION; CALCIUM OVERLOAD; CA2+ UPTAKE; RADICALS; SODIUM; MECHANISMS; GENERATION	Oxidative stress is one of the major causes of cell death. Using time-lapse confocal recording of live cardiomyocytes, we showed that H2O2 (OH.) caused a marked increase in Na+ and Ca2+ levels in both the cytosol ([Na](cyt), [Ca](cyt)) and mitochondria ([Na](m), [Ca](m)). The H2O2-induced intracellular Na+ ([Na](i)) overload contributed to the H2O2-induced [Ca](cyt)/[Ca](m) overload via activation of the reverse mode of the Na-Ca exchanger. When myocytes were treated for 40 min with 100 muM H2O2 in normal medium, then returned to H2O2-free medium, the percentage of apoptotic cells increased from 4% at 0 h to 55 and 85% at 4.5 and 16 h, respectively. H2O2-induced apoptosis was completely prevented by using Na-free, but not Ca-free, medium. When a Na+ ionophore cocktail in Ca-free medium was used instead of H2O2 to increase the [Na](i) by more than 30 mM without any change in the [Ca](i), cytochrome c release and caspase 3-dependent apoptosis occurred, showing that [Na](i) overload per se induced apoptosis. We also showed that the increase in the mitochondrial, but not the cytosolic, Na+ levels resulted in the opening of the permeation transition pore, followed by cytochrome c release. Our findings therefore suggest that H2O2-induced [Na](m) overload is an important upstream signal for the apoptotic machinery, and the prevention of [Na](m) overload thus represents a particularly attractive target for strategies aimed at preventing oxidative stress-induced cell death.	Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Physiol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Anat & Cell Biol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10764, Taiwan; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10764, Taiwan; Ming Chuan Univ, Dept Biotechnol, Taoyuan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Ming Chuan University	Wu, ML (corresponding author), Natl Taiwan Univ 1, Coll Med, Dept Physiol, Sec 1,Jen Ai Rd, Taipei, Taiwan.	mlw@ha.mc.ntu.edu.tw		CHIEN, CHUNG-LIANG/0000-0001-9806-486X				Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; BLAUSTEIN MP, 1991, ELECTROGENIC TRANSPO, P129; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; Chen WH, 2001, J PHYSIOL-LONDON, V537, P497, DOI 10.1111/j.1469-7793.2001.00497.x; Chen WH, 1999, J PHYSIOL-LONDON, V515, P133, DOI 10.1111/j.1469-7793.1999.133ad.x; Chen ZH, 2002, J BIOL CHEM, V277, P24653, DOI 10.1074/jbc.M111862200; CLAGUE JR, 1994, J MOL CELL CARDIOL, V26, P11, DOI 10.1006/jmcc.1994.1003; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; CORRETTI MC, 1991, J CLIN INVEST, V88, P1014, DOI 10.1172/JCI115361; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hool LC, 2002, CIRC RES, V91, P601, DOI 10.1161/01.RES.0000035528.00678.D5; Huang CS, 2002, CANCER RES, V62, P5689; Ide T, 2000, CIRC RES, V86, P152, DOI 10.1161/01.RES.86.2.152; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kimura J, 1999, BRIT J PHARMACOL, V128, P969, DOI 10.1038/sj.bjp.0702869; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Park CO, 1999, AM J PHYSIOL-HEART C, V276, pH1581, DOI 10.1152/ajpheart.1999.276.5.H1581; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; POWIS DA, 1994, CELL CALCIUM, V16, P377, DOI 10.1016/0143-4160(94)90031-0; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Saraste A, 1997, CIRCULATION, V95, P320; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wang SM, 1998, J CELL BIOCHEM, V71, P82, DOI 10.1002/(SICI)1097-4644(19981001)71:1<82::AID-JCB9>3.0.CO;2-Y; WENDTGALLITELLI MF, 1985, PFLUG ARCH EUR J PHY, V405, P310, DOI 10.1007/BF00595683; Wu ML, 2000, CIRC RES, V86, pE55	44	20	20	2	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1442	+		10.1096/fj.03-1038fje	http://dx.doi.org/10.1096/fj.03-1038fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231730	Green Submitted			2022-12-25	WOS:000222979200029
J	Vergote, D; Sautiere, PE; Vandenbulcke, F; Vieau, D; Mitta, G; Macagno, ER; Salzet, M				Vergote, D; Sautiere, PE; Vandenbulcke, F; Vieau, D; Mitta, G; Macagno, ER; Salzet, M			Up-regulation of neurohemerythrin expression in the central nervous system of the medicinal leech, Hirudo medicinalis, following septic injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MP-II; ANTIMICROBIAL PEPTIDES; PARAVENTRICULAR NUCLEUS; ANTIBACTERIAL ACTIVITY; DENDROSTOMUM-PYROIDES; POLYACRYLAMIDE-GELS; GLIAL-CELLS; TRANSFERRIN; HEMOGLOBIN; DEFENSE	We report here some results of a proteomic analysis of changes in protein expression in the leech Hirudo medicinalis in response to septic injury. Comparison of two-dimensional protein gels revealed several significant differences between normal and experimental tissues. One protein found to be up-regulated after septic shock was identified, through a combination of Edman degradation, mass spectrometry, and molecular cloning, as a novel member of the hemerythrin family, a group of non-heme-iron oxygen transport proteins found in four invertebrate phyla: sipunculids, priapulids, brachiopods, and annelids. We found by in situ hybridization and immunocytochemistry that the new leech protein, which we have called neurohemerythrin, is indeed expressed in the leech central nervous system. Both message and protein were detected in the pair of large glia within the ganglionic neuropile, in the six packet glia that surround neuronal somata in each central ganglion, and in the bilateral pair of glia that separate axonal fascicles in the interganglionic connective nerves. No expression was detected in central neurons or in central nervous system microglia. Expression was also observed in many other, non-neuronal tissues in the body wall. Real-time PCR experiments suggest that neurohemerythrin is up-regulated posttranscriptionaly. We consider potential roles of neurohemerythrin, associated with its ability to bind oxygen and iron, in the innate immune response of the leech nervous system to bacterial invasion.	Univ Sci & Technol Lille, INSERM, CNRS,UMR 8017, Lab Neuroimmunol Annelides, F-59655 Villeneuve Dascq, France; Univ Perpignan, CNRS, UMR 5555, Ctr Biol & Ecol Trop & Mediterraneenne Parasitol, F-66860 Perpignan, France; Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; University of California System; University of California San Diego	Salzet, M (corresponding author), Univ Sci & Technol Lille, INSERM, CNRS,UMR 8017, Lab Neuroimmunol Annelides, IFR 17, F-59655 Villeneuve Dascq, France.	michel.salzet@univ-lille1.fr	Salzet, Michel/A-7675-2011; MITTA, Guillaume/A-6489-2010	Salzet, Michel/0000-0003-4318-0817; Vergote, David/0000-0002-1298-3783; mitta, guillaume/0000-0003-1188-1467; SAUTIERE, Pierre-Eric/0000-0003-4974-7116; vieau, didier/0000-0002-3254-3662; Vandenbulcke, Franck/0000-0002-9735-1784				Anderson RS, 2001, ADV EXP MED BIOL, V484, P131; [Anonymous], EXP BIOL ONLINE; BATES G, 1968, BIOCHEMISTRY-US, V7, P3016, DOI 10.1021/bi00848a044; Bilej M, 2001, J BIOL CHEM, V276, P45840, DOI 10.1074/jbc.M107220200; Blackshaw SE, 2004, J ANAT, V204, P13, DOI 10.1111/j.1469-7580.2004.00260.x; Cameron GR, 1932, J PATHOL BACTERIOL, V35, P933, DOI 10.1002/path.1700350613; Cantera R, 1999, J NEUROBIOL, V38, P16, DOI 10.1002/(SICI)1097-4695(199901)38:1<16::AID-NEU2>3.0.CO;2-0; COGGESHALL RE, 1964, J NEUROPHYSIOL, V27, P229, DOI 10.1152/jn.1964.27.2.229; COGGESHALL RE, 1974, J NEUROBIOL, V5, P463, DOI 10.1002/neu.480050507; Coutte L, 2001, BBA-GENE STRUCT EXPR, V1518, P282, DOI 10.1016/S0167-4781(00)00312-2; DAMERVAL C, 1986, ELECTROPHORESIS, V7, P52, DOI 10.1002/elps.1150070108; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; Deitmer JW, 2001, RESP PHYSIOL, V129, P71, DOI 10.1016/S0034-5687(01)00283-3; Deloffre L, 2003, NEUROENDOCRINOL LETT, V24, P39; DEMUYNCK S, 1991, CR ACAD SCI III-VIE, V312, P317; DEMUYNCK S, 1993, EUR J BIOCHEM, V217, P151, DOI 10.1111/j.1432-1033.1993.tb18230.x; Destoumieux-Garzon D, 2001, J BIOL CHEM, V276, P47070, DOI 10.1074/jbc.M103817200; EHRENBERG CG, 1836, BEOBACHTUNGEN AUFFAL; Farr M, 1999, LEARN MEMORY, V6, P331; FENG MH, 1994, J MED CHEM, V37, P924, DOI 10.1021/jm00033a009; FERRELL RE, 1970, BIOCHEMISTRY-US, V9, P3053, DOI 10.1021/bi00817a018; Fogaca AC, 1999, J BIOL CHEM, V274, P25330, DOI 10.1074/jbc.274.36.25330; Hall M, 1999, P NATL ACAD SCI USA, V96, P1965, DOI 10.1073/pnas.96.5.1965; HENDRICKSON WA, 1975, P NATL ACAD SCI USA, V72, P2160, DOI 10.1073/pnas.72.6.2160; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; HUNT TK, 1988, ANN EMERG MED, V17, P1265, DOI 10.1016/S0196-0644(88)80351-2; ILAN E, 1993, BIOCHIM BIOPHYS ACTA, V1162, P77, DOI 10.1016/0167-4838(93)90130-J; Ivanov VT, 1997, BIOPOLYMERS, V43, P171; Iwanaga S, 1998, J BIOCHEM, V123, P1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kakizaki Y, 1999, ENDOCR J, V46, P487, DOI 10.1507/endocrj.46.487; Khush RS, 2000, TRENDS GENET, V16, P442, DOI 10.1016/S0168-9525(00)02095-3; KLIPPENSTEIN GL, 1972, J BIOL CHEM, V247, P5959; Korneev Sergei, 1997, Invertebrate Neuroscience, V3, P185, DOI 10.1007/BF02480373; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KRAUS DW, 1988, BIOL BULL, V174, P346, DOI 10.2307/1541960; Lassegues M, 1997, EUR J BIOCHEM, V246, P756, DOI 10.1111/j.1432-1033.1997.00756.x; Laurent V, 2000, EUR J BIOCHEM, V267, P2354, DOI 10.1046/j.1432-1327.2000.01239.x; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; MACAGNO ER, 1986, P NATL ACAD SCI USA, V83, P2746, DOI 10.1073/pnas.83.8.2746; MACAGNO ER, 1980, J COMP NEUROL, V190, P283, DOI 10.1002/cne.901900206; Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200; MANGUM CP, 1975, COMP BIOCHEM PHYS A, V50, P777, DOI 10.1016/0300-9629(75)90145-0; MANWELL C, 1988, COMP BIOCHEM PHYS B, V89, P453, DOI 10.1016/0305-0491(88)90159-9; MILLER JS, 1994, P NATL ACAD SCI USA, V91, P12418, DOI 10.1073/pnas.91.26.12418; Mitta G, 2000, J CELL SCI, V113, P2759; Mitta G, 2000, FEBS LETT, V486, P185, DOI 10.1016/S0014-5793(00)02192-X; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Munoz M, 2002, EUR J BIOCHEM, V269, P2678, DOI 10.1046/j.1432-1033.2002.02934.x; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OKA K, 1987, BIOL RES PREG PERIN, V8, P1; OKAMOTO R, 1990, DRUG EXP CLIN RES, V16, P157; Pace KE, 2002, J BIOL CHEM, V277, P13091, DOI 10.1074/jbc.M112105200; Pech LL, 1996, J CELL SCI, V109, P2053; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFAFFL MW, 2001, NUCLEIC ACIDS RES, V29, pE425; Preiss A, 2001, MECH DEVELOP, V100, P109, DOI 10.1016/S0925-4773(00)00506-2; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; RETZIUS G, 1891, BIOL UNTERSUCH, V2, P1; Rivest S, 2000, P SOC EXP BIOL MED, V223, P22, DOI 10.1046/j.1525-1373.2000.22304.x; ROGERS HJ, 1976, IMMUNOLOGY, V30, P425; SALZET M, 1993, COMP BIOCHEM PHYS A, V104, P75, DOI 10.1016/0300-9629(93)90011-R; Salzet M, 1996, J BIOL CHEM, V271, P7237, DOI 10.1074/jbc.271.12.7237; Salzet M., 2000, CURRENT TRENDS IMMUN, V3, P151; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seitz V, 2003, DEV COMP IMMUNOL, V27, P207, DOI 10.1016/S0145-305X(02)00097-6; SHAW C, 1987, J NEUROCHEM, V49, P1348, DOI 10.1111/j.1471-4159.1987.tb00998.x; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; STENKAMP RE, 1985, P NATL ACAD SCI USA, V82, P713, DOI 10.1073/pnas.82.3.713; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Thompson GJ, 2003, INSECT MOL BIOL, V12, P1, DOI 10.1046/j.1365-2583.2003.00381.x; VALENTI P, 1983, INT J TISSUE REACT, V5, P97; VILLARO AC, 1985, J MORPHOL, V186, P307, DOI 10.1002/jmor.1051860307; WARD CG, 1986, INFECT IMMUN, V51, P723, DOI 10.1128/IAI.51.3.723-730.1986; Wu XQ, 2000, J NEUROBIOL, V44, P320, DOI 10.1002/1097-4695(20000905)44:3<320::AID-NEU3>3.0.CO;2-4; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Yoshiga T, 1999, EUR J BIOCHEM, V260, P414, DOI 10.1046/j.1432-1327.1999.00173.x; Yoshiga T, 1997, P NATL ACAD SCI USA, V94, P12337, DOI 10.1073/pnas.94.23.12337; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	81	26	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43828	43837		10.1074/jbc.M403073200	http://dx.doi.org/10.1074/jbc.M403073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15258158	hybrid			2022-12-25	WOS:000224383100059
J	Sapetschnig, A; Koch, F; Rischitor, G; Mennenga, T; Suske, G				Sapetschnig, A; Koch, F; Rischitor, G; Mennenga, T; Suske, G			Complexity of translationally controlled transcription factor Sp3 isoform expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; INITIATING TRANSLATION; FAMILY; EUKARYOTES; ACTIVATION; CLONING; DOMAIN; GENES	Sp3 is a ubiquitous transcription factor closely related to Sp1. Both proteins contain a highly conserved DNA-binding domain close to the C terminus and two glutamine-rich domains in the N-terminal moiety. Immunoblot analyses of Sp3 reveal a striking complex protein pattern of up to eight distinct species. This pattern is not observed in Sp3-deficient cell lines showing that all signals reflect Sp3 antigen. In this study, we have unraveled the complexity of Sp3 expression. We show that four isoforms of Sp3 that retain different parts of the N terminus are expressed in vivo. The four isoforms derive from alternative translational start sites at positions 1, 37, 856, and 907. An upstream open reading frame located at position - 47 to - 18 regulates expression of the two long isoforms. Unlike Sp1, none of the Sp3 isoforms is glycosylated. However, all four isoforms become SUMO-modified in vivo and in vitro specifically and exclusively at lysine residue 551. The transcriptional activity of the two long isoforms strongly depends on the promoter settings, whereas the small isoforms appear to be inactive. The transcriptional activity of all the Sp3 isoforms is regulated by SUMO modification. Our results demonstrate that Sp3 has many unique features and is not simply a functional equivalent of Sp1.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	Philipps University Marburg	Suske, G (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	Suske@imt.uni-marburg.de		Suske, Guntram/0000-0002-4807-0513				Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; BRASIER AR, 1997, CURRENT PROTOCOL S29, V1; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Calkhoven CF, 2000, GENE DEV, V14, P1920; Calkhoven CF, 2003, GENE DEV, V17, P959, DOI 10.1101/gad.251903; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kolell KJ, 2002, MOL BIOL EVOL, V19, P216, DOI 10.1093/oxfordjournals.molbev.a004074; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Oleksiak MF, 2002, MOL BIOL EVOL, V19, P2026, DOI 10.1093/oxfordjournals.molbev.a004026; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Suske G, 2000, Methods Mol Biol, V130, P175; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	90	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42095	42105		10.1074/jbc.M404989200	http://dx.doi.org/10.1074/jbc.M404989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247228	hybrid			2022-12-25	WOS:000224075500102
J	Brozinick, JT; Hawkins, ED; Strawbridge, AB; Elmendorf, JS				Brozinick, JT; Hawkins, ED; Strawbridge, AB; Elmendorf, JS			Disruption of cortical actin in skeletal muscle demonstrates an essential role of the cytoskeleton in glucose transporter 4 translocation in insulin-sensitive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; ISOLATED RAT ADIPOCYTES; CELL-SURFACE GLUT4; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GLYCOPROTEIN-COMPLEX; PLASMA-MEMBRANE; L6 MYOTUBES; C-CBL; TYROSINE PHOSPHORYLATION	Cell culture work suggests that signaling to polymerize cortical filamentous actin (F-actin) represents a required pathway for the optimal redistribution of the insulin-responsive glucose transporter, GLUT4, to the plasma membrane. Recent in vitro study further suggests that the actin-regulatory neural Wiskott-Aldrich syndrome protein (N-WASP) mediates the effect of insulin on the actin filament network. Here we tested whether similar cytoskeletal mechanics are essential for insulin-regulated glucose transport in isolated rat epitrochlearis skeletal muscle. Microscopic analysis revealed that cortical F-actin is markedly diminished in muscle exposed to latrunculin B. Depolymerization of cortical F-actin with latrunculin B caused a time- and concentration-dependent decline in 2-deoxyglucose transport. The loss of cortical F-actin and glucose transport was paralleled by a decline in insulin-stimulated GLUT4 translocation, as assessed by photolabeling of cell surface GLUT4 with Bio-LC-ATB-BMPA. Although latrunculin B impaired insulin-stimulated GLUT4 translocation and glucose transport, activation of phosphatidylinositol 3-kinase and Akt by insulin was not rendered ineffective. In contrast, the ability of insulin to elicit the cortical F-actin localization of N-WASP was abrogated. These data provide the first evidence that actin cytoskeletal mechanics are an essential feature of the glucose transport process in intact skeletal muscle. Furthermore, these findings support a distal actin-based role for N-WASP in insulin action in vivo.	Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Brozinick, JT (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Drop Code 0545, Indianapolis, IN 46285 USA.	brozinick_joseph_t@lilly.com			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001846] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT001846-01A1, R01 AT001846] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Asahi Yoshihiko, 1999, Journal of Medical Investigation, V46, P192; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; Brozinick JT, 1999, BIOCHEM J, V339, P533, DOI 10.1042/0264-6021:3390533; Brozinick JT, 2001, DIABETES, V50, P593, DOI 10.2337/diabetes.50.3.593; Brozinick JT, 1997, BIOCHEM J, V321, P75, DOI 10.1042/bj3210075; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Fenteany G, 2003, CURR TOP MED CHEM, V3, P593, DOI 10.2174/1568026033452348; FERRANNINI E, 1985, J CLIN INVEST, V76, P357, DOI 10.1172/JCI111969; GABELLA G, 1978, J ULTRA MOL STRUCT R, V65, P135, DOI 10.1016/S0022-5320(78)90051-5; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; HENRIKSEN EJ, 1991, ACTA PHYSIOL SCAND, V143, P381, DOI 10.1111/j.1748-1716.1991.tb09249.x; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; KAYANO T, 1990, J BIOL CHEM, V265, P13276; Khayat ZA, 2000, J CELL SCI, V113, P279; KLIP A, 2001, CSBMCB SCBBMC B, P39; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Peterson JR, 2001, P NATL ACAD SCI USA, V98, P10624, DOI 10.1073/pnas.201393198; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Ruan H, 2003, J BIOL CHEM, V278, P47585, DOI 10.1074/jbc.M305257200; Ryder JW, 2000, DIABETES, V49, P647, DOI 10.2337/diabetes.49.4.647; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Takenawa T, 2001, J CELL SCI, V114, P1801; Thirone ACP, 2004, ENDOCRINOLOGY, V145, P281, DOI 10.1210/en.2003-0575; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; Tsakiridis T, 1997, SOC GEN PHY, V52, P257; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; Yang J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1299, DOI 10.1152/ajpendo.00341.2002; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	71	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40699	40706		10.1074/jbc.M402697200	http://dx.doi.org/10.1074/jbc.M402697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247264	Green Accepted, hybrid			2022-12-25	WOS:000223916800061
J	Chong, PA; Ozdamar, B; Wrana, JL; Forman-Kay, JD				Chong, PA; Ozdamar, B; Wrana, JL; Forman-Kay, JD			Disorder in a target for the Smad2 mad Homology 2 domain and its implications for binding and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSCRIPTIONAL COREPRESSOR; RESONANCE SPECTROSCOPY; SIGNALING PATHWAYS; UNFOLDED STATE; NMR EXPERIMENT; AMIDE-PROTON; SH3 DOMAIN; PROTEIN; RECEPTOR	The Smad2 Mad homology 2 (MH2) domain binds to a diverse group of proteins which do not share a common sequence motif. We have used NMR to investigate the structure of one of these interacting proteins, the Smad binding domain (SBD) of Smad anchor for receptor activation ( SARA). Our results indicate that the unbound SBD is highly disordered and forms no stable secondary or tertiary structures. Additionally we have used fluorescence binding studies to study the interaction between the MH2 domain and SBD and find that no region of the SBD dominates the interaction between the MH2 and the SBD. Our results are consistent with a series of hydrophobic patches on the MH2 that are able to recognize disordered regions of proteins. These findings elucidate a mechanism by which a single domain (MH2) can specifically recognize a diverse set of proteins which are unrelated by sequence, lead to a clearer picture of how MH2 domains function in the transforming growth factor-beta-signaling pathway and suggest possible mechanisms for controlling interactions with MH2 domains.	Hosp Sick Children, Dept Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Forman-Kay, JD (corresponding author), Hosp Sick Children, Dept Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	forman@sickkids.ca	Wrana, Jeffrey/F-8857-2013	Forman-Kay, Julie/0000-0001-8265-972X				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Crowhurst KA, 2003, BIOCHEMISTRY-US, V42, P8687, DOI 10.1021/bi034601p; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DORMAN DE, 1973, J ORG CHEM, V38, P2379, DOI 10.1021/jo00953a021; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Germain S, 2000, GENE DEV, V14, P435; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1987, J BIOL CHEM, V262, P17467; Leopold M. F., 1994, Molecular Biotechnology, V2, P61, DOI 10.1007/BF02789290; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; LOVE JJ, 1999, THESIS U CALIFORNIA; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; Mok YK, 1999, J MOL BIOL, V289, P619, DOI 10.1006/jmbi.1999.2769; Myers JK, 1996, J MOL BIOL, V263, P390, DOI 10.1006/jmbi.1996.0583; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; ROMERO P, 1997, P IEEE INT C NEUR NE, V1, P90; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Zhang OW, 1997, J MOL BIOL, V272, P9, DOI 10.1006/jmbi.1997.1219; Zhang OW, 1997, J BIOMOL NMR, V9, P181, DOI 10.1023/A:1018658305040	61	16	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40707	40714		10.1074/jbc.M404375200	http://dx.doi.org/10.1074/jbc.M404375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15231848	hybrid			2022-12-25	WOS:000223916800062
J	Perez, R; Melero, R; Balboa, MA; Balsinde, J				Perez, R; Melero, R; Balboa, MA; Balsinde, J			Role of group VIA calcium-independent phospholipase A(2) in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; BROMOENOL LACTONE; DISTINCT ROLES; INHIBITION; ENZYMES; ACTIVATION; MACROPHAGES; INVOLVEMENT; METABOLISM; MECHANISM	Group VIA calcium-independent phospholipase A(2) (iPLA(2)) has been shown to play a major role in regulating basal phospholipid deacylation reactions in certain cell types. More recently, roles for this enzyme have also been suggested in the destruction of membrane phospholipid during apoptosis and after oxidant injury. Proposed iPLA(2) roles have rested heavily on the use of bromoenol lactone as an iPLA(2)-specific inhibitor, but this compound actually inhibits other enzymes and lipid pathways unrelated to PLA(2), which makes it difficult to define the contribution of iPLA(2) to specific functions. In previous work, we pioneered the use of antisense technology to decrease cellular iPLA(2) activity as an alternative approach to study iPLA(2) functions. In the present study, we followed the opposite strategy and prepared U937 cells that exhibited enhanced iPLA(2) activity by stably expressing a plasmid containing iPLA(2) cDNA. Compared with control cells, the iPLA(2)-overexpressing U937 cells showed elevated responses to hydrogen peroxide with regard to both arachidonic acid mobilization and incorporation of the fatty acid into phospholipids, thus providing additional evidence for the key role that iPLA(2) plays in these events. Long-term exposure of the cells to hydrogen peroxide resulted in cell death by apoptosis, and this process was accelerated in the iPLA(2)-overexpressing cells. Increased phospholipid hydrolysis and fatty acid release also occurred in these cells. Unexpectedly, however, abrogation of U937 cell iPLA(2) activity by either methyl arachidonyl fluorophosphonate or an antisense oligonucleotide did not delay or decrease the extent of apoptosis induced by hydrogen peroxide. These results indicate that, although iPLA(2)-mediated phospholipid hydrolysis occurs during apoptosis, iPLA(2) may actually be dispensable for the apoptotic process to occur. Thus, beyond a mere destructive role, iPLA(2) may play other roles during apoptosis.	Univ Valladolid, Sch Med, Fac Med, CSIC,IBGM,Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Balsinde, J (corresponding author), Univ Valladolid, Sch Med, Fac Med, CSIC,IBGM,Inst Mol Biol & Genet, Ave Ramon & Cajal 7, E-47005 Valladolid, Spain.	jbalsinde@ibgm.uva.es	Balsinde, Jesús/C-7833-2018; Pérez, Rebeca/M-5235-2015; Melero, Roberto/J-8780-2014; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Pérez, Rebeca/0000-0002-0445-868X; Melero, Roberto/0000-0001-9467-9381; Balboa, María A./0000-0002-2130-5298				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bailleux A, 2004, BIOCHEM J, V378, P307, DOI 10.1042/BJ20031014; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 2002, J BIOL CHEM, V277, P40384, DOI 10.1074/jbc.M206155200; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Balsinde Jesus, 2004, P61; Barbour Suzanne E., 2004, P13; Birbes H, 2000, BIOCHEM BIOPH RES CO, V276, P613, DOI 10.1006/bbrc.2000.3479; Birbes H, 2000, EUR J BIOCHEM, V267, P7118, DOI 10.1046/j.1432-1327.2000.01814.x; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Chiu CH, 2001, BIOCHEM BIOPH RES CO, V287, P600, DOI 10.1006/bbrc.2001.5632; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; Daniele JJ, 1999, PROSTAG OTH LIPID M, V57, P341, DOI 10.1016/S0090-6980(98)00084-7; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Dessen A, 2000, BBA-MOL CELL BIOL L, V1488, P40, DOI 10.1016/S1388-1981(00)00108-6; Diaz BL, 2003, PROSTAG LEUKOTR ESS, V69, P87, DOI 10.1016/S0952-3278(03)00069-3; Fadok VA, 2003, NAT CELL BIOL, V5, P697, DOI 10.1038/ncb0803-697; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; Horrobin DF, 1999, PROSTAG LEUKOTR ESS, V60, P141, DOI 10.1054/plef.1999.0027; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; KAEVER V, 1988, PROSTAGLANDINS, V35, P885, DOI 10.1016/0090-6980(88)90114-1; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Panini SR, 2001, J LIPID RES, V42, P1678; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Ravichandran KS, 2003, CELL, V113, P817, DOI 10.1016/S0092-8674(03)00471-9; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tommasini I, 2004, MOL PHARMACOL, V65, P964, DOI 10.1124/mol.65.4.964; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4	51	77	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40385	40391		10.1074/jbc.M402562200	http://dx.doi.org/10.1074/jbc.M402562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15252038	hybrid, Green Submitted			2022-12-25	WOS:000223916800022
J	MacPherson, MR; Lohmann, SM; Davies, SA				MacPherson, MR; Lohmann, SM; Davies, SA			Analysis of Drosophila cGMP-dependent protein kinases and assessment of their in vivo roles by targeted expression in a renal transporting epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MALPIGHIAN TUBULES; SIGNALING PATHWAY; FLUID SECRETION; GENE-EXPRESSION; MELANOGASTER; LOCALIZATION; CHANNELS; PHOSPHODIESTERASE; STIMULATION	cGMP-dependent protein kinase (cGK) forms encoded by the dg2 (for) gene are implicated in behavior and epithelial transport in Drosophila melanogaster. Here, we provide the first biochemical characterization and cellular localization of cGKs encoded by the major transcripts of dg2: dg2P1 and dg2P2. cGMP stimulates kinase activity of DG2P1 (EC50: 0.13 +/- 0.039 muM) and DG2P2 (EC50: 0.32 +/- 0.14 muM) in Malpighian tubule and S2 cell extracts. DG2P1 and DG2P2 are magnesium-requiring enzymes and were inhibited by 10 and 100 muM of a cGK inhibitor, 8-(4-chlorophenylthio) guanosine-3', 5'-cyclic monophosphorothioate, Rp isomer; whereas DG1, the cGK encoded by the D. melanogaster dg1 gene, was unaffected. DG2P1 and DG2P2 were localized in the plasma membrane in S2 cells, whereas DG1 was localized in the cytosol. The D. melanogaster fluid-transporting Malpighian tubule was used as an organotypic model to analyze cGK localization and function in vivo. Targeted expression of DG2P2, DG2P1, and DG1 in tubule cells via the UAS/GAL4 system in transgenic flies revealed differential localization of all three cGKs in vivo: DG2P2 expression at the apical membrane; DG2P1 expression at both the apical and basolateral membranes; and DG1 expression at the basolateral membrane and in the cytosol. Transgenic tubules for all three cGKs displayed enhanced cGK activity compared with wild-type tubules. The physiological impact of targeted expression of individual cGKs in tubule principal cells was assessed by measuring basal and stimulated rates of fluid transport. DG1 expression greatly enhanced fluid transport by the tubule in response to exogenous cGMP, whereas DG2P2 expression significantly increased fluid transport in response to the nitridergic neuropeptide, capa-1. Thus, dg2-encoded proteins are bona fide cGKs, which have differential roles in epithelial fluid transport, as assessed by in vivo studies. Furthermore, a novel epithelial role is suggested for DG1, which is considerably more responsive to cGMP than to capa-1 stimulation.	Univ Glasgow, Anderson Coll, Inst Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of Glasgow; University of Wurzburg	Davies, SA (corresponding author), Univ Glasgow, Anderson Coll, Inst Biomed & Life Sci, Div Mol Genet, Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	s.a.davies@bio.gla.ac.uk						Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Ben-Shahar Y, 2003, J EXP BIOL, V206, P2507, DOI 10.1242/jeb.00442; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Biel M, 1998, N-S ARCH PHARMACOL, V358, P140, DOI 10.1007/PL00005235; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broderick KE, 2004, J BIOL CHEM, V279, P8159, DOI 10.1074/jbc.M304679200; Broderick KE, 2003, AM J PHYSIOL-CELL PH, V285, pC1207, DOI 10.1152/ajpcell.00123.2003; Casteel DE, 2002, J BIOL CHEM, V277, P32003, DOI 10.1074/jbc.M112332200; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Davies SA, 1997, AM J PHYSIOL-REG I, V273, pR823, DOI 10.1152/ajpregu.1997.273.2.R823; De Vente J, 2001, NEUROSCIENCE, V108, P27, DOI 10.1016/S0306-4522(01)00401-8; Dow JAT, 2003, PHYSIOL REV, V83, P687, DOI 10.1152/physrev.00035.2002; Dow JAT, 1999, J BIOENERG BIOMEMBR, V31, P75, DOI 10.1023/A:1005400731289; Dow JAT, 2001, ADV INSECT PHYSIOL, V28, P1, DOI 10.1016/S0065-2806(01)28008-4; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; DOW JAT, 1994, J EXP BIOL, V197, P421; Eisenhaber F, 2003, NUCLEIC ACIDS RES, V31, P3631, DOI 10.1093/nar/gkg537; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Foster JL, 1996, J BIOL CHEM, V271, P23322, DOI 10.1074/jbc.271.38.23322; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MacPherson MR, 2004, J EXP BIOL, V207, P2769, DOI 10.1242/jeb.01086; MacPherson MR, 2001, AM J PHYSIOL-CELL PH, V280, pC394, DOI 10.1152/ajpcell.2001.280.2.C394; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Oster H, 2003, CURR BIOL, V13, P725, DOI 10.1016/S0960-9822(03)00252-5; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Riegel JA, 1998, J EXP BIOL, V201, P3411; Rosay P, 1997, J CELL SCI, V110, P1683; Schmidt H, 2002, J CELL BIOL, V159, P489, DOI 10.1083/jcb.200207058; SOZEN HA, 1997, P NATL ACAD SCI USA, V94, P5207; Stansberry J, 2001, J NEUROCHEM, V76, P1177, DOI 10.1046/j.1471-4159.2001.00131.x; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1997, J BIOL CHEM, V272, P4195, DOI 10.1074/jbc.272.7.4195; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; WANG J, 2004, IN PRESS GENOME BIOL; WOLFE L, 1989, J BIOL CHEM, V264, P4157	52	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40026	40034		10.1074/jbc.M405619200	http://dx.doi.org/10.1074/jbc.M405619200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15218025	hybrid			2022-12-25	WOS:000223791500100
J	Puce, S; Basile, G; Bavestrello, G; Bruzzone, S; Cerrano, C; Giovine, M; Arillo, A; Zocchi, E				Puce, S; Basile, G; Bavestrello, G; Bruzzone, S; Cerrano, C; Giovine, M; Arillo, A; Zocchi, E			Abscisic acid signaling through cyclic ADP-ribose in hydroid regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE ACTIVITY; CELLS; 3T3-CELLS; RELEASE; CD38	Cyclic ADP-ribose ( cADPR) is an intracellular calcium (Ca-i(2+)) mobilizer involved in fundamental cell functions from protists to higher plants and mammals. Biochemical similarities between the drought-signaling cascade in plants and the temperature-sensing pathway in marine sponges suggest an ancient evolutionary origin of a signaling cascade involving the phytohormone abscisic acid (ABA), cADPR, and Ca-i(2+). In Eudendrium racemosum ( Hydrozoa, Cnidaria), exogenously added ABA stimulated ADP-ribosyl cyclase activity via a protein kinase A (PKA)-mediated phosphorylation and increased regeneration in the dark to levels observed under light conditions. Light stimulated endogenous ABA synthesis, which was conversely inhibited by the inhibitor of plant ABA synthesis Fluridone. The signal cascade of light-induced regeneration uncovered in E. racemosum: light -->up arrowABA-->PKA-->cyclase activation -->up arrow[cADPR](i) -->up arrow [Ca2+](i) --> regeneration is the first report of a complete signaling pathway in Eumetazoa involving a phytohormone.	Univ Genoa, Dipartimento Med Sperimentale, Sez Biochim, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Genoa, Dipartimineto Studio Terr & Risorse, I-16132 Genoa, Italy; CNR, Direz Progetto Finalizzato Biotecnol, I-16132 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR)	Zocchi, E (corresponding author), Univ Genoa, Dipartimento Med Sperimentale, Sez Biochim, Viale Benedetto XV 1, I-16132 Genoa, Italy.	ezocchi@unige.it	Bruzzone, Santina/A-4264-2015; Cerrano, Carlo/AAF-3557-2019	Bruzzone, Santina/0000-0003-2034-3716; Cerrano, Carlo/0000-0001-9580-5546; GIOVINE, Marco/0000-0001-8085-0619				Azzini F., 2003, Biologia Marina Mediterranea, V10, P146; BOYER RF, 1993, MODERN EXPT BIOCH, P379; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; Bruzzone S, 2003, BIOCHEM J, V375, P395, DOI 10.1042/BJ20030556; Burnette RN, 2003, PLANT PHYSIOL, V132, P1011, DOI 10.1104/pp.019000; Cutler AJ, 1999, TRENDS PLANT SCI, V4, P472, DOI 10.1016/S1360-1385(99)01497-1; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Frank U, 2001, BIOESSAYS, V23, P963, DOI 10.1002/bies.1137; Galliot B, 2002, INT J DEV BIOL, V46, P39; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Himmelbach A, 2003, CURR OPIN PLANT BIOL, V6, P470, DOI 10.1016/S1369-5266(03)00090-6; Hsu YT, 2003, PLANT CELL ENVIRON, V26, P867, DOI 10.1046/j.1365-3040.2003.01018.x; KOWALCZYKSCHRODER S, 1992, PESTIC BIOCHEM PHYS, V42, P7, DOI 10.1016/0048-3575(92)90068-B; Leckie CP, 1998, P NATL ACAD SCI USA, V95, P15837, DOI 10.1073/pnas.95.26.15837; Lee HC, 1996, BIOL SIGNAL, V5, P101; LEE HC, 2002, CYCLIC ADP RIBOSE NA; LEPAGEDEGIVRY MT, 1986, P NATL ACAD SCI USA, V83, P1155; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; Podesta M, 2002, FASEB J, V16, P310, DOI 10.1096/fj.02-0520fje; Spollen WG, 2000, PLANT PHYSIOL, V122, P967, DOI 10.1104/pp.122.3.967; Sternfeld L, 2003, J BIOL CHEM, V278, P33629, DOI 10.1074/jbc.M301043200; Sulaeman A, 2001, J AGR FOOD CHEM, V49, P3253, DOI 10.1021/jf010142s; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TERAGAWA CK, 1995, DEV BIOL, V171, P286, DOI 10.1006/dbio.1995.1281; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Xiong LM, 2003, PLANT PHYSIOL, V133, P29, DOI 10.1104/pp.103.025395; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2003, J CELL SCI, V116, P629, DOI 10.1242/jcs.00277; Zocchi E, 2001, P NATL ACAD SCI USA, V98, P14859, DOI 10.1073/pnas.261448698	33	52	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39783	39788		10.1074/jbc.M405348200	http://dx.doi.org/10.1074/jbc.M405348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252012	hybrid			2022-12-25	WOS:000223791500072
J	Reddy, YVR; Ding, Q; Lees-Miller, SP; Meek, K; Ramsden, DA				Reddy, YVR; Ding, Q; Lees-Miller, SP; Meek, K; Ramsden, DA			Non-homologous end joining requires that the DNA-PK complex undergo an autophosphorylation-dependent rearrangement at DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; PROTEIN-KINASE; CATALYTIC SUBUNIT; LIGASE-IV; V(D)J RECOMBINATION; MAMMALIAN-CELLS; POLYMERASE-MU; KU; PHOSPHORYLATION; MICE	Repair of chromosome breaks by non-homologous end joining requires the XRCC4-ligase IV complex, Ku, and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PKcs must also retain kinase activity and undergo autophosphorylation at six closely linked sites (ABCDE sites). We describe here an end-joining assay using only purified components that reflects cellular requirements for both Ku and kinase-active DNA-PKcs and investigate the mechanistic basis for these requirements. A need for DNA-PKcs autophosphorylation is sufficient to explain the requirement for kinase activity, in part because autophosphorylation is generally required for end-joining factors to access DNA ends. However, DNA-PKcs with all six ABCDE autophosphorylation sites mutated to alanine allows access to ends through autophosphorylation of other sites, yet our in vitro end-joining assay still reflects the defectiveness of this mutant in cellular end joining. In contrast, mutation of ABCDE sites to aspartate, a phosphorylation mimic, supports high levels of end joining that is now independent of kinase activity. This is likely because DNA-PKcs with aspartate substitutions at ABCDE sites allow access to DNA ends while retaining affinity for Ku-bound ends and stabilizing recruitment of the XRCC4-ligase IV complex. Autophosphorylation at ABCDE sites thus apparently directs a rearrangement of the DNA-PK complex that ensures access to broken ends and joining steps are coupled together within a synaptic complex, making repair more accurate.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Michigan State Univ, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA; Univ Calgary, Dept Biochem, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Mol Biol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Michigan State University; University of Calgary; University of Calgary; University of Calgary	Ramsden, DA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB-7295, Chapel Hill, NC 27599 USA.	dale_ramsden@med.unc.edu		Lees-Miller, Susan/0000-0001-5809-2516; Ramsden, Dale/0000-0003-1575-4748	NATIONAL CANCER INSTITUTE [R01CA084442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032600] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084442, CA-84442] Funding Source: Medline; NIAID NIH HHS [AI32600, AI42938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen C, 2003, MOL CANCER RES, V1, P913; Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6; Bogue MA, 1998, P NATL ACAD SCI USA, V95, P15559, DOI 10.1073/pnas.95.26.15559; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; Calsou P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Soubeyrand S, 2003, CANCER RES, V63, P1198; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Udayakumar D, 2003, J BIOL CHEM, V278, P41631, DOI 10.1074/jbc.M306470200; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	30	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39408	39413		10.1074/jbc.M406432200	http://dx.doi.org/10.1074/jbc.M406432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258142	Green Published, hybrid			2022-12-25	WOS:000223791500028
J	Baker, HM; Proft, T; Webb, PD; Arcus, VL; Fraser, JD; Baker, EN				Baker, HM; Proft, T; Webb, PD; Arcus, VL; Fraser, JD; Baker, EN			Crystallographic and mutational data show that the streptococcal pyrogenic exotoxin J can use a common binding surface for T-cell receptor binding and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MHC; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL ENTEROTOXINS; SYNDROME TOXIN-1; BETA-CHAIN; SUPERANTIGENS; SITES; IDENTIFICATION; MODE	The protein toxins known as superantigens (SAgs), which are expressed primarily by the pathogenic bacteria Staphylococcus aureus and Streptococcus pyogenes, are highly potent immunotoxins with the ability to cause serious human disease. These SAgs share a conserved fold but quite varied activities. In addition to their common role of cross-linking T-cell receptors (TCRs) and major histocompatibility complex class II (MHC-II) molecules, some SAgs can cross-link MHC-II, using diverse mechanisms. The crystal structure of the streptococcal superantigen streptococcal pyrogenic exotoxin J (SPE-J) has been solved at 1.75 Angstrom resolution ( R = 0.209, R-free = 0.240), both with and without bound Zn2+. The structure displays the canonical two-domain SAg fold and a zinc-binding site that is shared by a subset of other SAgs. Most importantly, in concentrated solution and in the crystal, SPE-J forms dimers. These dimers, which are present in two different crystal environments, form via the same face that is used for TCR binding in other SAgs. Site-directed mutagenesis shows that this face is also used for TCR binding SPE-J. We infer that SPE-J cross-links TCR and MHC-II as a monomer but that dimers may form on the antigen-presenting cell surface, cross-linking MHC-II and eliciting intracellular signaling.	Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1, New Zealand; Univ Auckland, Dept Mol Med, Auckland 1, New Zealand	University of Auckland; University of Auckland; University of Auckland	Baker, EN (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland 1, New Zealand.	ted.baker@auckland.ac.nz	Proft, Thomas/H-4686-2019	Proft, Thomas/0000-0002-9275-5042; Baker, Edward/0000-0003-2456-7661				Arcus VL, 2000, J MOL BIOL, V299, P157, DOI 10.1006/jmbi.2000.3725; Arcus VL, 2002, J BIOL CHEM, V277, P32274, DOI 10.1074/jbc.M203914200; ARCUS VL, 2004, CURR OPIN STRUC BIOL, V12, P794; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Bernal A, 1999, J CLIN IMMUNOL, V19, P149, DOI 10.1023/A:1020547509410; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Fraser J, 2000, MOL MED TODAY, V6, P125, DOI 10.1016/S1357-4310(99)01657-3; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; HURLEY JM, 1995, J EXP MED, V181, P2229, DOI 10.1084/jem.181.6.2229; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; Keskin O, 2004, PROTEIN SCI, V13, P1043, DOI 10.1110/ps.03484604; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li PL, 1997, J EXP MED, V186, P375, DOI 10.1084/jem.186.3.375; Lina G, 2004, J INFECT DIS, V189, P2334, DOI 10.1086/420852; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Papageorgiou AC, 1997, STRUCTURE, V5, P991, DOI 10.1016/S0969-2126(97)00252-9; Papageorgiou AC, 1996, J MOL BIOL, V260, P553, DOI 10.1006/jmbi.1996.0421; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POSTINGL H, 2000, PROTEIN-STRUCT FUNCT, V41, P47; Proft T, 1999, J EXP MED, V189, P89, DOI 10.1084/jem.189.1.89; Proft T, 2001, J IMMUNOL, V166, P6711, DOI 10.4049/jimmunol.166.11.6711; Roussel A, 1997, NAT STRUCT BIOL, V4, P635, DOI 10.1038/nsb0897-635; ROUSSEL A, 1998, SILICON GRAPHICS GEO, P77; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Sundberg EJ, 2002, STRUCTURE, V10, P687, DOI 10.1016/S0969-2126(02)00759-1; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0	44	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38571	38576		10.1074/jbc.M406695200	http://dx.doi.org/10.1074/jbc.M406695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247241	hybrid			2022-12-25	WOS:000223684100063
J	Chen, HW; North, SH; Nakai, H				Chen, HW; North, SH; Nakai, H			Properties of the PriA helicase domain and its role in binding PriA to specific DNA structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN PRIA; DEPENDENT ATPASE ACTIVITY; PHI X174-TYPE PRIMOSOME; ESCHERICHIA-COLI; FACTOR-Y; BACTERIOPHAGE-MU; FORK BINDING; RECOMBINATION; IDENTIFICATION; MUTANTS	Primosome assembly protein PriA functions in the assembly of the replisome at forked DNA structures. Whereas its N-terminal DNA binding domain (DBD) binds independently to DNA, the affinity of DBD protein for forked structures is relatively weak. Although the PriA helicase domain (HD) is required for high affinity fork binding, HD protein had very low affinity for DNA. It had only low levels of ATPase activity, and it hydrolyzed ATP when DNA was absent whereas PriA did not. HD catalyzed unwinding of a minimal substrate composed of a duplex with a 3' single-stranded tail. Single-strand binding protein (SSB) bound to the tail of this substrate inhibited this reaction by full-length PriA but enhanced the reaction by HD. SSB stabilized binding of PriA but not of DBD or HD to duplexes with a 5' or 3' single-stranded tail. On forked substrates SSB enhanced helicase action on the lagging-strand arm by PriA but not by HD. The results indicate that synergy of the DBD and HD allows stable binding at the interface between duplex and single-stranded DNA bound by SSB. This mode of binding may be analogous to fork binding, which orients the helicase to act on the lagging-strand side of the fork.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20057 USA	Georgetown University	Nakai, H (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Box 571455, Washington, DC 20057 USA.	nakai@bc.georgetown.edu	Chen, Hua-Wei/A-8018-2011		NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049649] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA51008] Funding Source: Medline; NIGMS NIH HHS [GM49649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Jaktaji RP, 2003, MOL MICROBIOL, V47, P1091, DOI 10.1046/j.1365-2958.2003.03357.x; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Mizukoshi T, 2003, J BIOL CHEM, V278, P42234, DOI 10.1074/jbc.C300285200; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 2001, MOL MICROBIOL, V41, P697, DOI 10.1046/j.1365-2958.2001.02547.x; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	38	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38503	38512		10.1074/jbc.M404769200	http://dx.doi.org/10.1074/jbc.M404769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252043	hybrid			2022-12-25	WOS:000223684100055
J	Reimers, MJ; Hahn, ME; Tanguay, RL				Reimers, MJ; Hahn, ME; Tanguay, RL			Two zebrafish alcohol dehydrogenases share common ancestry with mammalian class I, II, IV, and V alcohol dehydrogenase genes but have distinct functional characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; ETHANOL; RAT; EXPRESSION; BINDING; MOUSE; 4-METHYLPYRAZOLE; ISOZYME; SYSTEM; FAMILY	Ethanol is teratogenic to many vertebrates. We are utilizing zebrafish as a model system to determine whether there is an association between ethanol metabolism and ethanol-mediated developmental toxicity. Here we report the isolation and characterization of two cDNAs encoding zebrafish alcohol dehydrogenases (ADHs). Phylogenetic analysis of these zebrafish ADHs indicates that they share a common ancestor with mammalian class I, II, IV, and V ADHs. The genes encoding these zebrafish ADHs have been named Adh8a and Adh8b by the nomenclature committee. Both genes were genetically mapped to chromosome 13. The 1450-bp Adh8a is 82, 73, 72, and 72% similar at the amino acid level to the Baltic cod ADH8 (previously named ADH1), the human ADH1B2, the mouse ADH1, and the rat ADH1, respectively. Also, the 1484-bp Adh8b is 77, 68, 67, and 66% similar at the amino acid level to the Baltic cod ADH8, the human ADH1B2, the mouse ADH1, and the rat ADH1, respectively. ADH8A and ADH8B share 86% amino acid similarity. To characterize the functional properties of ADH8A and ADH8B, recombinant proteins were purified from SF-9 insect cells. Kinetic studies demonstrate that ADH8A metabolizes ethanol, with a V-max of 13.4 nmol/min/mg protein, whereas ADH8B does not metabolize ethanol. The ADH8A K-m for ethanol as a substrate is 0.7 mM. 4-Methyl pyrazole, a classical competitive inhibitor of class I ADH, failed to inhibit ADH8A. ADH8B has the capacity to efficiently biotransform longer chain primary alcohols(greater than or equal to5 carbons) and S-hydroxymethlyglutathione, whereas ADH8A does not efficiently metabolize these substrates. Finally, mRNA expression studies indicate that both ADH8A and ADH8B mRNA are expressed during early development and in the adult brain, fin, gill, heart, kidney, muscle, and liver. Together these results indicate that class I-like ADH is conserved in zebrafish, albeit with mixed functional properties.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Oregon State University; Woods Hole Oceanographic Institution	Tanguay, RL (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, 1007 Agr & Life Sci, Corvallis, OR 97331 USA.	Robert.Tanguay@oregonstate.edu	Hahn, Mark/AAV-7516-2020	Hahn, Mark/0000-0003-4358-2082	NIAAA NIH HHS [R21 AA012783-04, R21 AA012783, AA12783] Funding Source: Medline; NIEHS NIH HHS [ES03850, R01ES06272, P30 ES000210-38, R01 ES006272-13, P30 ES000210, P30 ES003850, ES00210, R01 ES006272] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003850, R01ES006272, P50ES003850, P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA012783] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Agarwal DP, 2001, PATHOL BIOL, V49, P703, DOI 10.1016/S0369-8114(01)00242-5; AGARWAL DP, 1990, PHARMACOL THERAPEUT, V45, P69, DOI 10.1016/0163-7258(90)90008-P; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Becker HC, 1996, PHARMACOL BIOCHEM BE, V55, P501, DOI 10.1016/S0091-3057(96)00255-9; Becker SRB, 1998, ALCOHOL ALCOHOLISM, V33, P457, DOI 10.1093/alcalc/33.5.457; Bilotta J, 2002, NEUROTOXICOL TERATOL, V24, P759, DOI 10.1016/S0892-0362(02)00319-7; Blader P, 1998, DEV BIOL, V201, P185, DOI 10.1006/dbio.1998.8995; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Bottoms CA, 2002, PROTEIN SCI, V11, P2125, DOI 10.1110/ps.0213502; Canestro C, 2002, J MOL EVOL, V54, P81, DOI 10.1007/s00239-001-0020-2; CRABB DW, 1987, PHARMACOL THERAPEUT, V34, P59, DOI 10.1016/0163-7258(87)90092-1; DANIELSSON O, 1992, BIOCHEMISTRY-US, V31, P3751, DOI 10.1021/bi00130a004; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; DANIELSSON O, 1992, P NATL ACAD SCI USA, V89, P9247, DOI 10.1073/pnas.89.19.9247; Dasmahapatra AK, 2001, BIOCHEM BIOPH RES CO, V286, P1082, DOI 10.1006/bbrc.2001.5511; Dlugos CA, 2003, PHARMACOL BIOCHEM BE, V74, P471, DOI 10.1016/S0091-3057(02)01026-2; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; ENGELAND K, 1993, P NATL ACAD SCI USA, V90, P2491, DOI 10.1073/pnas.90.6.2491; ESTONIUS M, 1994, BIOCHEMISTRY-US, V33, P15080, DOI 10.1021/bi00254a017; Estonius M, 1996, FEBS LETT, V397, P338, DOI 10.1016/S0014-5793(96)01204-5; Granato M, 1996, CURR OPIN GENET DEV, V6, P461, DOI 10.1016/S0959-437X(96)80068-2; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Hedberg JJ, 1998, FEBS LETT, V436, P67, DOI 10.1016/S0014-5793(98)01100-4; Henderson GI, 1999, FRONT BIOSCI, V4, pD541, DOI [DOI 10.2741/HENDERSON, 10. 2741/Henderson]; HJELMQVIST L, 1995, P NATL ACAD SCI USA, V92, P10904, DOI 10.1073/pnas.92.24.10904; HOLMQUIST B, 1993, BIOCHEMISTRY-US, V32, P5139, DOI 10.1021/bi00070a024; HOOG JO, 1993, EUR J BIOCHEM, V213, P31, DOI 10.1111/j.1432-1033.1993.tb17731.x; Hoog JO, 2001, CHEM-BIOL INTERACT, V130, P395, DOI 10.1016/S0009-2797(00)00264-7; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; JONES KL, 1973, LANCET, V2, P999; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LAALE HW, 1971, J EXP ZOOL, V177, P51, DOI 10.1002/jez.1401770107; MCMARTIN KE, 1988, J TOXICOL-CLIN TOXIC, V26, P451, DOI 10.3109/15563658809038561; PARES X, 1981, BIOCHEM BIOPH RES CO, V98, P122, DOI 10.1016/0006-291X(81)91878-7; PIERCE DR, 1989, TERATOLOGY, V40, P113, DOI 10.1002/tera.1420400205; RAMASWAMY S, 1994, FEBS LETT, V350, P122, DOI 10.1016/0014-5793(94)00746-2; RANGANATHAN S, 1987, TERATOLOGY, V36, P45, DOI 10.1002/tera.1420360107; REIMERS MJ, IN PRESS NEUROTOXICO; Reynolds JD, 1995, CAN J PHYSIOL PHARM, V73, P1209, DOI 10.1139/y95-173; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; SYTKOWSKI AJ, 1979, BIOCH PHARM ETHANOL, V1, P43; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; Tanguay RL, 2000, BBA-GENE STRUCT EXPR, V1494, P117, DOI 10.1016/S0167-4781(00)00225-6; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; Xie PGT, 1999, PROTEIN SCI, V8, P2639; Yin SJ, 1999, ADV EXP MED BIOL, V463, P265; ZORZANO A, 1990, GEN PHARMACOL, V21, P697, DOI 10.1016/0306-3623(90)91020-R	56	68	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38303	38312		10.1074/jbc.M401165200	http://dx.doi.org/10.1074/jbc.M401165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231826	Green Accepted, hybrid			2022-12-25	WOS:000223684100030
J	Wang, YL; Wei, ZY; Bian, Q; Cheng, ZJ; Wan, M; Liu, L; Gong, WM				Wang, YL; Wei, ZY; Bian, Q; Cheng, ZJ; Wan, M; Liu, L; Gong, WM			Crystal structure of human bisphosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHOSPHOGLYCERATE MUTASE; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; BACILLUS-STEAROTHERMOPHILUS; ACID-PHOSPHATASE; TERMINAL REGION; PURIFICATION; MUTAGENESIS; EXPRESSION; HOMOLOGY	Bisphosphoglycerate mutase is a trifunctional enzyme of which the main function is to synthesize 2,3-bisphosphoglycerate, the allosteric effector of hemoglobin. The gene coding for bisphosphoglycerate mutase from the human cDNA library was cloned and expressed in Escherichia coli. The protein crystals were obtained and diffract to 2.5 and produced the first crystal structure of bisphosphoglycerate mutase. The model was refined to a crystallographic R-factor of 0.200 and R-free of 0.266 with excellent stereochemistry. The enzyme remains a dimer in the crystal. The overall structure of the enzyme resembles that of the cofactor-dependent phosphoglycerate mutase except the regions of 13-21, 98-117, 127-151, and the C-terminal tail. The conformational changes in the backbone and the side chains of some residues reveal the structural basis for the different activities between phosphoglycerate mutase and bisphosphoglycerate mutase. The bisphosphoglycerate mutase-specific residue Gly-14 may cause the most important conformational changes, which makes the side chain of Glu-13 orient toward the active site. The positions of Glu-13 and Phe-22 prevent 2,3-bisphosphoglycerate from binding in the way proposed previously. In addition, the side chain of Glu-13 would affect the Glu-89 protonation ability responsible for the low mutase activity. Other structural variations, which could be connected with functional differences, are also discussed.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gong, WM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd,Chaoyang Dist, Beijing 100101, Peoples R China.	wgong@sun5.ibp.ac.cn	Wei, Zhiyi/C-4315-2014; wang, yanli/G-3306-2010; Cheng, zhongjun/D-6929-2011; Wei, Zhiyi/B-5001-2010; Wei, Zhiyi/N-9995-2019	Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Bian, Qian/0000-0001-7022-2213; Wang, Yanli/0000-0002-5969-1745				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bond CS, 2001, J BIOL CHEM, V276, P3247, DOI 10.1074/jbc.M007318200; Bond CS, 2002, J MOL BIOL, V316, P1071, DOI 10.1006/jmbi.2002.5418; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL JW, 1974, NATURE, V250, P301, DOI 10.1038/250301a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHERFILS J, 1991, J MOL BIOL, V218, P269, DOI 10.1016/0022-2836(91)90710-N; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; GAREL MC, 1994, P NATL ACAD SCI USA, V91, P3593, DOI 10.1073/pnas.91.9.3593; GAREL MC, 1989, J BIOL CHEM, V264, P18966; GLINA SC, 1999, ACTA CRYSTALLOGR D, V55, P1822; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HASS LF, 1978, J BIOL CHEM, V253, P77; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; LaCount MW, 1998, J BIOL CHEM, V273, P30406, DOI 10.1074/jbc.273.46.30406; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ortlund E, 2003, BIOCHEMISTRY-US, V42, P383, DOI 10.1021/bi0265067; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ravel P, 1997, J BIOL CHEM, V272, P14045, DOI 10.1074/jbc.272.22.14045; Rigden DJ, 2001, PROTEIN SCI, V10, P1835, DOI 10.1110/ps.15701; Rigden DJ, 2002, J MOL BIOL, V315, P1129, DOI 10.1006/jmbi.2001.5290; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; Rigden DJ, 1999, J MOL BIOL, V286, P1507, DOI 10.1006/jmbi.1999.2566; ROSA R, 1973, BIOCHEM BIOPH RES CO, V51, P536, DOI 10.1016/0006-291X(73)91347-8; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; ROSE ZB, 1970, J BIOL CHEM, V245, P3232; ROSE ZB, 1968, J BIOL CHEM, V243, P4810; ROSE ZB, 1973, J BIOL CHEM, V248, P1513; ROSE ZB, 1976, J BIOL CHEM, V251, P4817; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Uhrinova S, 2001, J MOL BIOL, V306, P275, DOI 10.1006/jmbi.2000.4390; Walter RA, 1999, BIOCHEM J, V337, P89, DOI 10.1042/0264-6021:3370089; WHITE MF, 1992, EUR J BIOCHEM, V207, P709, DOI 10.1111/j.1432-1033.1992.tb17099.x; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066	37	25	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39132	39138		10.1074/jbc.M405982200	http://dx.doi.org/10.1074/jbc.M405982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15258155	hybrid			2022-12-25	WOS:000223684100129
J	Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR				Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR			Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis	ONCOGENE			English	Article						lung cancer; orthotopic model; prognostic marker; expression profiling; metastatic model	BREAST-CANCER; ADENOCARCINOMA; EXPRESSION; ESTABLISHMENT; CARCINOMAS; RECEPTOR; NCI-H460-LNM35; ACTIVATION; SURVIVAL; PROFILES	Endobronchial implantation of NCI-H460 cells into the nude rat generates a primary lung tumor with mediastinal lymph node spread, but rarely systemic metastases. We isolated tumor cells from mediastinal nodes, orthotopically reimplanted the cells into nude rats and repeated this four times to derive a cell line, designated H460SM, that spontaneously metastasizes to bone, kidney, brain, soft tissue and contralateral lung. H460SM cells demonstrated higher invasive activity in vitro than parental NCI-H460 cells. Spectral karyotyping revealed a new inversion within 17q and loss of an extra normal copy of chromosome 14 present in parental NCI-H460 cells. Expression pro. ling of orthotopic primary tumors revealed differential expression of 360 genes. Of these, 173 were represented in the probe set of a 19.2K OCI cDNA microarray previously used to pro. le the gene expression of surgically resected lung cancer specimens. We have computationally validated clinical importance of these genes by using in silico analysis of 18 cases of pulmonary adenocarcinoma, which were split into two patient groups with markedly different clinical outcome. The model identifies additional novel candidate genes for the progression of lung cancer to systemic metastases and poor prognosis.	Princess Margaret Hosp, Univ Hlth Network, Div Thorac Surg, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Cellular Mol Biol, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Johnston, MR (corresponding author), Toronto Gen Hosp, Div Thorac Surg, Suite EN10-230,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	michael.johnston@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Navab, Roya/AGD-7380-2022; Blackhall, Fiona H/N-2186-2015	Tsao, Ming Sound/0000-0002-9160-5405; Blackhall, Fiona H/0000-0001-8716-3395; Hu, Jim/0000-0001-9134-7103; Sultan, Mujahid/0000-0001-6721-4044				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CARNEY DN, 1985, CANCER RES, V45, P2913; Fontao L, 2003, MOL BIOL CELL, V14, P1978, DOI 10.1091/mbc.e02-08-0548; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Gorogh T, 1999, INT J CANCER, V83, P750, DOI 10.1002/(SICI)1097-0215(19991210)83:6<750::AID-IJC9>3.0.CO;2-V; Howard RB, 1999, CLIN EXP METASTAS, V17, P157, DOI 10.1023/A:1006637712294; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liu J, 2002, SURG ONCOL, V11, P217, DOI 10.1016/S0960-7404(02)00053-1; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MERCER KE, 2003, BIOCHIM BIOPHYS ACTA, V1653, P23; Miura K, 2002, CANCER RES, V62, P3244; Nakamura H, 2003, CANCER-AM CANCER SOC, V97, P2798, DOI 10.1002/cncr.11406; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; SAIGA T, 1987, IN VITRO CELL DEV B, V23, P850; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shindo-Okada N, 2002, JPN J CANCER RES, V93, P50, DOI 10.1111/j.1349-7006.2002.tb01200.x; Shindo-Okada N, 2001, JPN J CANCER RES, V92, P174, DOI 10.1111/j.1349-7006.2001.tb01080.x; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Wigle DA, 2002, CANCER RES, V62, P3005; Wigle Dennis A, 2004, Genome Biol, V5, P309, DOI 10.1186/gb-2004-5-2-309	31	24	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6316	6324		10.1038/sj.onc.1207795	http://dx.doi.org/10.1038/sj.onc.1207795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247903				2022-12-25	WOS:000223399000016
J	Dohi, T; Okada, K; Xia, F; Wilford, CE; Samuel, T; Welsh, K; Marusawa, H; Zou, H; Armstrong, R; Matsuzawa, S; Salvesen, GS; Reed, JC; Altieri, DC				Dohi, T; Okada, K; Xia, F; Wilford, CE; Samuel, T; Welsh, K; Marusawa, H; Zou, H; Armstrong, R; Matsuzawa, S; Salvesen, GS; Reed, JC; Altieri, DC			An IAP-IAP complex inhibits apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVIN; XIAP; CANCER	Regulators of apoptosis are thought to work in concert, but the molecular interactions of this process are not understood. Here, we show that in response to cell death stimulation, survivin, a member of the inhibitor of apoptosis (IAP) gene family, associates with another IAP protein, XIAP, via conserved baculovirus IAP repeats. Formation of a survivin-XIAP complex promotes increased XIAP stability against ubiquitination/proteasomal destruction and synergistic inhibition of apoptosis, which is abolished in XIAP(-/-) cells. Therefore, orchestration of an IAP-IAP complex regulates apoptosis.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Burnham Inst, La Jolla, CA 92037 USA; IDUN Pharmaceut, San Diego, CA 92121 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Sanford Burnham Prebys Medical Discovery Institute	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	高, 雨莉/HGU-8187-2022	Marusawa, Hiroyuki/0000-0002-4286-2712	NCI NIH HHS [CA 90917, CA 78810] Funding Source: Medline; NHLBI NIH HHS [HL 54131] Funding Source: Medline; NIA NIH HHS [AG 15393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Fortugno P, 2002, J CELL SCI, V115, P575; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Giodini A, 2002, CANCER RES, V62, P2462; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Lens SMA, 2003, CELL CYCLE, V2, P507, DOI 10.4161/cc.2.6.559; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Wang XD, 2001, GENE DEV, V15, P2922; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	21	319	337	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34087	34090		10.1074/jbc.C400236200	http://dx.doi.org/10.1074/jbc.C400236200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15218035	hybrid			2022-12-25	WOS:000223134800003
J	Lai, R; Takeuchi, H; Lomas, LO; Jonczy, J; Rigden, DJ; Rees, HH; Turner, PC				Lai, R; Takeuchi, H; Lomas, LO; Jonczy, J; Rigden, DJ; Rees, HH; Turner, PC			A new type of antimicrobial protein with multiple histidines from the hard tick, Amblyomma hebraeum	FASEB JOURNAL			English	Article						hebraein; innate immunity; pH-dependent; hemolymph; SELDI-TOF	TOAD BOMBINA-MAXIMA; SALIVARY HISTATIN-5; CANDIDA-ALBICANS; PEPTIDES; ANTIBACTERIAL	A novel 11 kDa antimicrobial protein, named as hebraein, and having a unique amino acid sequence, was purified from the hemolymph of fed female Amblyomma hebraeum ticks. A full-length cDNA clone encoding hebraein was isolated from a cDNA library made from tick synganglia. Hebraein consists of 102 amino acids, including 6 cysteine residues; has 9 histidines in its C-terminal domain that are mainly present as HX repeats; and has no significant similarity to any known protein. The secondary structure prediction is very clearly all alpha-helical ( 4 - 6 helices) except for a very short extension at the C terminus. Such high alpha-helical content is quite different from known antimicrobial proteins. Recombinant hebraein and a mutant lacking the histidine residues in the C-terminal domain were constructed and expressed. Assayed at the slightly acidic pH equivalent of fed female tick hemolymph, the wild-type and the histidine-rich recombinant hebraein had stronger antimicrobial activities than the histidine-deficient mutant. The pH-dependent properties of histidine-rich antimicrobial proteins may allow the design of agents that would function selectively in specific pH environments. The results from protein profiling of hemolymph, analyzed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry combined with ProteinChip technology and RT-PCR analysis suggested that this antimicrobial protein was up-regulated by blood feeding. Our findings describe a new type of antimicrobial protein with multiple cysteine and histidine residues, and with unique secondary structure.	Univ Liverpool, Sch Biol Sci, Huw H Rees Cellular Regulat & Signaling Div, Liverpool L69 7ZB, Merseyside, England; Ciphergen Biosyst Inc, Fremont, CA USA; Novartis Anim Hlth Ctr Rech Sante Anim, Basel, Switzerland	University of Liverpool; Novartis	Rees, HH (corresponding author), Univ Liverpool, Sch Biol Sci, Huw H Rees Cellular Regulat & Signaling Div, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	reeshh@liv.ac.uk		Rigden, Daniel/0000-0002-7565-8937				Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Edgerton M, 2000, ANTIMICROB AGENTS CH, V44, P3310, DOI 10.1128/AAC.44.12.3310-3316.2000; Fogaca AC, 2004, DEV COMP IMMUNOL, V28, P191, DOI 10.1016/j.dci.2003.08.001; Gusman H, 2001, INFECT IMMUN, V69, P1402, DOI 10.1128/IAI.69.3.1402-1408.2001; JOHNS R, 2001, INSECT BIOCHEM MOLEC, V31, P957; KAUFMAN WR, 1973, J EXP BIOL, V58, P523; Kobayashi S, 2001, BIOCHEMISTRY-US, V40, P14330, DOI 10.1021/bi015626w; Lai R, 2002, BIOCHEM BIOPH RES CO, V295, P796, DOI 10.1016/S0006-291X(02)00762-3; Lai R, 2002, PEPTIDES, V23, P427, DOI 10.1016/S0196-9781(01)00641-6; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; Lee IH, 2001, J PEPT RES, V58, P445; Lehane MJ, 1997, P NATL ACAD SCI USA, V94, P11502, DOI 10.1073/pnas.94.21.11502; Lomas LO, 1997, P ROY SOC B-BIOL SCI, V264, P589, DOI 10.1098/rspb.1997.0084; Nakajima Y, 2002, INSECT MOL BIOL, V11, P611, DOI 10.1046/j.1365-2583.2002.00372.x; RICHARD ME, 1999, BIOCHIM BIOPHYS ACTA, V1462, P11; Schibli DJ, 2002, BIOCHEM CELL BIOL, V80, P667, DOI 10.1139/O02-147; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; TASIEMSKI A, 2004, IN PRESS J BIOL CHEM; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yuan J, 2000, INSECT BIOCHEM MOLEC, V30, P1099, DOI 10.1016/S0965-1748(00)00087-4	21	60	65	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1447	+		10.1096/fj.03-1154fje	http://dx.doi.org/10.1096/fj.03-1154fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247144				2022-12-25	WOS:000222979200008
J	Iwatsubo, K; Minamisawa, S; Tsunematsu, T; Nakagome, M; Toya, Y; Tomlinson, JE; Umemura, S; Scarborough, RM; Levy, DE; Ishikawa, Y				Iwatsubo, K; Minamisawa, S; Tsunematsu, T; Nakagome, M; Toya, Y; Tomlinson, JE; Umemura, S; Scarborough, RM; Levy, DE; Ishikawa, Y			Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; SITE-MEDIATED INHIBITION; CONGESTIVE-HEART-FAILURE; MOUSE CARDIAC MYOCYTES; TRANSGENIC MICE; ACTIVATION; NOREPINEPHRINE; PROTEINS; CARDIOMYOCYTES; STIMULATION	Adenylyl cyclase, a major target enzyme of beta-adrenergic receptor signals, is potently and directly inhibited by P-site inhibitors, classic inhibitors of this enzyme, when the enzyme catalytic activity is high. Unlike beta-adrenergic receptor antagonists, this is a non- or uncompetitive inhibition with respect to ATP. We have examined whether we can utilize this enzymatic property to regulate the effects of beta-adrenergic receptor stimulation differentially. After screening multiple new and classic compounds, we found that some compounds, including 1R, 4R-3-(6-aminopurin-9-yl)-cyclopentanecarboxylic acid hydroxyamide, potently inhibited type 5 adenylyl cyclase, the major cardiac isoform, but not other isoforms. In normal mouse cardiac myocytes, contraction induced by low beta-adrenergic receptor stimulation was poorly inhibited with this compound, but the induction of cardiac myocyte apoptosis by high beta-adrenergic receptor stimulation was effectively prevented by type 5 adenylyl cyclase inhibitors. In contrast, when cardiac myocytes from type 5 adenylyl cyclase knock-out mice were examined, beta-adrenergic stimulation poorly induced apoptosis. Our data suggest that the inhibition of beta-adrenergic signaling at the level of the type 5 adenylyl cyclase isoform by P-site inhibitors may serve as an effective method to prevent cardiac myocyte apoptosis induced by excessive beta-adrenergic stimulation without deleterious effect on cardiac myocyte contraction.	Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Med Cardiol, Newark, NJ 07103 USA; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Med, Yokohama, Kanagawa 2360004, Japan; Portola Pharmaceut Inc, San Francisco, CA 94080 USA; Scios Inc, Fremont, CA 94555 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yokohama City University; Yokohama City University; Scios	Ishikawa, Y (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, 185 S Orange Ave, Newark, NJ 07103 USA.	ishikayo@umdnj.edu		Minamisawa, Susumu/0000-0003-4728-2116				BABICH M, 1985, J MOL CELL CARDIOL, V17, P565, DOI 10.1016/S0022-2828(85)80025-0; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; Boolell M, 1996, Int J Impot Res, V8, P47; BUCKNER CK, 1978, EUR J PHARMACOL, V47, P259, DOI 10.1016/0014-2999(78)90233-9; Calaghan S, 1998, BIOCHEM BIOPH RES CO, V248, P701, DOI 10.1006/bbrc.1998.9036; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; Geng YJ, 1999, CIRC RES, V84, P34; GUPTA RC, 1993, CIRC RES, V72, P65, DOI 10.1161/01.RES.72.1.65; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HOSONO M, 1992, J CARDIOVASC PHARM, V19, P625, DOI 10.1097/00005344-199204000-00021; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Iwatsubo K, 2003, EXPERT OPIN THER TAR, V7, P441, DOI 10.1517/eott.7.3.441.22433; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Levy DE, 2003, J MED CHEM, V46, P2177, DOI 10.1021/jm0205604; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Nyui N, 1997, BIOCHEM BIOPH RES CO, V235, P36, DOI 10.1006/bbrc.1997.6706; Okumura S, 2003, P NATL ACAD SCI USA, V100, P9986, DOI 10.1073/pnas.1733772100; Okumura S, 2003, CIRC RES, V93, P364, DOI 10.1161/01.RES.0000086986.35568.63; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; OPIE LH, 2001, HEART DIS TXB CARDIO, P443; POLSON JB, 1977, J PHARMACOL EXP THER, V200, P630; Prichard BNC, 2001, BLOOD PRESSURE, V10, P366, DOI 10.1080/080370501753400665; Rybin VO, 2003, MOL PHARMACOL, V63, P1338, DOI 10.1124/mol.63.6.1338; Sabbah HN, 2000, J AM COLL CARDIOL, V36, P1698, DOI 10.1016/S0735-1097(00)00913-X; Sambrano GR, 2002, NATURE, V420, P712, DOI 10.1038/nature01306; SHAFIQ J, 1992, CIRC RES, V71, P70, DOI 10.1161/01.RES.71.1.70; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Toya Y, 1998, J MOL CELL CARDIOL, V30, P97, DOI 10.1006/jmcc.1997.0575; Vantrimpont P, 1998, EUR HEART J, V19, P1552, DOI 10.1053/euhj.1998.1093; Yamamoto S, 2001, J MOL CELL CARDIOL, V33, P1829, DOI 10.1006/jmcc.2001.1446; Zaugg M, 2000, CIRCULATION, V102, P344; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	48	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40938	40945		10.1074/jbc.M314238200	http://dx.doi.org/10.1074/jbc.M314238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262973	hybrid			2022-12-25	WOS:000223916800090
J	Wang, CZ; Misra, I; Miziorko, HM				Wang, CZ; Misra, I; Miziorko, HM			Utility of acetyldithio-CoA in detecting the influence of active site residues on substrate enolization by 3-hydroxyl-3-methylglutaryl-CoA synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; S-ENZYME; CITRATE SYNTHASE; ALKALINE-HYDROLYSIS; IDENTIFICATION; PARTICIPATION; SULFHYDRYL; KINETICS; LIVER	Hydroxymethylglutaryl-CoA synthase-catalyzed condensation of acetyl-CoA with acetoacetyl-CoA requires enolization/carbanion formation from the acetyl C-2 methyl group prior to formation of a new carbon-carbon bond. Acetyldithio-CoA, a readily enolizable analog of acetyl-CoA, was an effective competitive inhibitor of avian hydroxymethylglutaryl-CoA synthase (K-i = 28 muM). In the absence of cosubstrate, enzyme catalyzed the enolization/ proton exchange from the C-2 methyl group of acetyldithio-CoA. Mutant enzymes that exhibited impaired formation of the covalent acetyl-S-enzyme reaction intermediate exhibited diminished (D159A and D203A) or undetectable (C129S) rates of enolization of acetyldithio-CoA. The results suggest that covalent thioacetylation of protein, which has not been detected previously for other enzymes that enolize this analog, occurs with hydroxymethylglutaryl-CoA synthase. Enzyme catalyzed the transfer of the thioacetyl group of this analog to 3'-dephospho-CoA suggesting the intermediacy of a covalent thioacetyl-S-enzyme species, which appears to be important for proton abstraction from C-2 of the thioacetyl group. Avian enzyme glutamate 95 is crucial to substrate condensation to form a new carbon-carbon bond. Mutations of this invariant residue ( avian enzyme E95A and E95Q; Staphylococcus aureus enzyme E79Q) correlated with diminished ability to catalyze enolization of acetyldithio-CoA. Enolization by E95Q was not stimulated in the presence of acetoacetyl-CoA. These observations suggest either a direct ( proton abstraction) or indirect ( solvent polarization) role for this active site glutamate.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Miziorko, HM (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21491] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON VE, 1990, J BIOL CHEM, V265, P6255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chun KY, 2000, BIOCHEMISTRY-US, V39, P14670, DOI 10.1021/bi001805m; Chun KY, 2000, J BIOL CHEM, V275, P17946, DOI 10.1074/jbc.M909725199; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; EGGERER H, 1967, EUR J BIOCHEM, V1, P447, DOI 10.1111/j.1432-1033.1967.tb00094.x; EGGERER H, 1965, BIOCHEM Z, V343, P111; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; Kurz LC, 1997, BIOCHEMISTRY-US, V36, P3981, DOI 10.1021/bi963058s; MISRA I, 1993, J BIOL CHEM, V268, P12129; Misra I, 2003, J BIOL CHEM, V278, P26443, DOI 10.1074/jbc.M300244200; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; MIZIORKO HM, 1975, J BIOL CHEM, V250, P5768; REED WD, 1975, J BIOL CHEM, V250, P3117; SMITH SG, 1968, J ORG CHEM, V33, P1022, DOI 10.1021/jo01267a018; SMITH SG, 1963, J ORG CHEM, V28, P2825, DOI 10.1021/jo01045a081; STORER AC, 1985, BIOCHEMISTRY-US, V24, P6808, DOI 10.1021/bi00345a012; TAGAKI W, 1968, BIOCHEMISTRY-US, V7, P905, DOI 10.1021/bi00843a004; Tuinstra RL, 2004, BIOCHEMISTRY-US, V43, P5287, DOI 10.1021/bi0499765; VOLLMER SH, 1988, BIOCHEMISTRY-US, V27, P4288, DOI 10.1021/bi00412a014; WLASSICS ID, 1989, BIOCHEMISTRY-US, V28, P1627, DOI 10.1021/bi00430a030; WLASSICS ID, 1988, BIOCHIM BIOPHYS ACTA, V952, P269, DOI 10.1016/0167-4838(88)90126-4; WRENSFORD LV, 1991, BIOCHEM MED METAB B, V45, P204, DOI 10.1016/0885-4505(91)90022-D	23	4	5	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40283	40288		10.1074/jbc.M406566200	http://dx.doi.org/10.1074/jbc.M406566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247244	hybrid			2022-12-25	WOS:000223916800008
J	Cybulski, LE; del Solar, G; Craig, PO; Espinosa, M; de Mendoza, D				Cybulski, LE; del Solar, G; Craig, PO; Espinosa, M; de Mendoza, D			Bacillus subtilis DesR functions as a phosphorylation-activated switch to control membrane lipid fluidity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; RESPONSE REGULATOR; TRANSCRIPTION ACTIVATION; DELTA-5 DESATURASE; ESCHERICHIA-COLI; PROMOTER; PROTEIN; BINDING; GENE; DIMERIZATION	The Des pathway of Bacillus subtilis regulates the synthesis of the cold-shock induced membrane-bound enzyme Delta5-fatty acid desaturase (Delta5-Des). A central component of the Des pathway is the response regulator, DesR, which is activated by a membrane-associated kinase, DesK, in response to a decrease in membrane lipid fluidity. Despite genetic and biochemical studies, specific details of the interaction between DesR and the DNA remain unknown. In this study we show that only the phosphorylated form of protein DesR is able to bind to a regulatory region immediately upstream of the promoter of the Delta5-Des gene (Pdes). Phosphorylation of the regulatory domain of dimeric DesR promotes, in a cooperative fashion, the hierarchical occupation of two adjacent, non-identical, DesR-P DNA binding sites, so that there is a shift in the equilibrium toward the tetrameric active form of the response regulator. Subsequently, this phosphorylation signal propagation leads to the activation of the des gene through recruitment of RNA polymerase to Pdes. This is the first dissected example of a transcription factor functioning as a phosphorylation-activated switch for a cold-shock gene, allowing the cell to optimize the fluidity of membrane phospholipids.	Univ Nacl Rosario, Consejo Nacl Invest Cient & Tecn, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Santa Fe, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Santa Fe, Argentina; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Inst Leloir, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; National University of Rosario; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Leloir Institute	de Mendoza, D (corresponding author), Univ Nacl Rosario, Consejo Nacl Invest Cient & Tecn, Inst Biol Mol & Celular Rosario, Suipacha 531,2002LRK, RA-2000 Rosario, Santa Fe, Argentina.	diegonet@citynet.net.ar	del Solar, Gloria/K-2485-2014; Espinosa, Manuel/M-5282-2019; del Solar, Gloria/ABD-2668-2020	del Solar, Gloria/0000-0002-7356-9164; del Solar, Gloria/0000-0002-7356-9164				Aguilar PS, 1999, J BACTERIOL, V181, P7028, DOI 10.1128/JB.181.22.7028-7033.1999; Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; Albanesi D, 2004, J BACTERIOL, V186, P2655, DOI 10.1128/JB.186.9.2655-2663.2004; Altabe SG, 2003, J BACTERIOL, V185, P3228, DOI 10.1128/JB.185.10.3228-3231.2003; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Browning DF, 2004, NAT REV MICROBIOL, V2, P57, DOI 10.1038/nrmicro787; Cybulski LE, 2002, MOL MICROBIOL, V45, P1379, DOI 10.1046/j.1365-2958.2002.03103.x; Da Re S, 1999, MOL MICROBIOL, V34, P504, DOI 10.1046/j.1365-2958.1999.01614.x; Dartois V, 1998, J BACTERIOL, V180, P1855, DOI 10.1128/JB.180.7.1855-1861.1998; DELSOLAR GH, 1990, J BIOL CHEM, V265, P12569; Diaz AR, 2002, J BIOL CHEM, V277, P48099, DOI 10.1074/jbc.M208960200; Fabret C, 1999, J BACTERIOL, V181, P1975, DOI 10.1128/JB.181.7.1975-1983.1999; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; Gualerzi CO, 2003, J MOL BIOL, V331, P527, DOI 10.1016/S0022-2836(03)00732-0; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jeon Y, 2001, J BIOL CHEM, V276, P40873, DOI 10.1074/jbc.M104855200; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P1907; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lewis RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/jmbi.2001.5331; Liu W, 1997, J BACTERIOL, V179, P6302, DOI 10.1128/jb.179.20.6302-6310.1997; MANSILLA C, 1997, J BACTERIOL, V179, P76; Maris AE, 2002, NAT STRUCT BIOL, V9, P771, DOI 10.1038/nsb845; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Monsalve M, 1997, MOL CELL, V1, P99, DOI 10.1016/S1097-2765(00)80011-8; Nechaev S, 2000, J BIOL CHEM, V275, P25516, DOI 10.1074/jbc.M002511200; Phadtare S, 2000, BACTERIAL STRESS RESPONSES, P33; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Repoila F, 2003, J BACTERIOL, V185, P6609, DOI 10.1128/JB.185.22.6609-6614.2003; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	37	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39340	39347		10.1074/jbc.M405150200	http://dx.doi.org/10.1074/jbc.M405150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247225	hybrid, Green Published			2022-12-25	WOS:000223791500019
J	Flannery, AR; Graham, LA; Stevens, TH				Flannery, AR; Graham, LA; Stevens, TH			Topological characterization of the c, c ', and c '' subunits of the vacuolar ATPase from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; V-ATPASE; CROSS-LINKING; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; COATED VESICLE; ROTARY MOTOR; BINDING-SITE; SECTOR	The vacuolar ATPase (V-ATPase) is a multisubunit enzyme that acidifies intracellular organelles in eukaryotes. Similar to the F-type ATP synthase (F-ATPase), the V-ATPase is composed of two subcomplexes, V-1 and V-0. Hydrolysis of ATP in the V-1 subcomplex is tightly coupled to proton translocation accomplished by the V-0 subcomplex, which is composed of five unique subunits (a, d, c, c', and c"). Three of the subunits, subunit c (Vma3p), c' (Vma11p), and c" (Vma16p), are small highly hydrophobic integral membrane proteins called "proteolipids" that share sequence similarity to the F-ATPase subunit c. Whereas subunit c from the F-ATPase spans the membrane bilayer twice, the V-ATPase proteolipids have been modeled to have at least four transmembrane-spanning helices. Limited proteolysis experiments with epitope-tagged copies of the proteolipids have revealed that the N and the C termini of c (Vma3p) and c' (Vma11p) were in the lumen of the vacuole. Limited proteolysis of epitope-tagged c" ( Vma16p) indicated that the N terminus is located on the cytoplasmic face of the vacuole, whereas the C terminus is located within the vacuole. Furthermore, a chimeric fusion between Vma16p and Vma3p, Vma16-Vma3p, was found to assemble into a fully functional V-ATPase complex, further supporting the conclusion that the C terminus of Vma16p resides within the lumen of the vacuole. These results indicate that subunits c and c' have four transmembrane segments with their N and C termini in the lumen and that c" has five transmembrane segments, with the N terminus exposed to the cytosol and the C terminus lumenal.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Stevens, TH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	stevens@molbio.uoregon.edu		Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J EXP BIOL, V172, P67; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BBA-BIOENERGETICS, V1555, P71, DOI 10.1016/S0005-2728(02)00257-8; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Aviezer-Hagai K, 2003, J EXP BIOL, V206, P3227, DOI 10.1242/jeb.00543; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Conibear E, 2002, METHOD ENZYMOL, V351, P408; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Findlay JBC, 1997, BIOCHEM SOC T, V25, P1107, DOI 10.1042/bst0251107; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P18286; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200	53	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39856	39862		10.1074/jbc.M406767200	http://dx.doi.org/10.1074/jbc.M406767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252052	hybrid			2022-12-25	WOS:000223791500081
J	Galijasevic, S; Saed, GM; Diamond, MP; Abu-Soud, HM				Galijasevic, S; Saed, GM; Diamond, MP; Abu-Soud, HM			High dissociation rate constant of ferrous-dioxy complex linked to the catalase-like activity in lactoperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; RESONANCE RAMAN; GLUTATHIONE-PEROXIDASE; ANTIBACTERIAL ACTIVITY; ELECTRON-TRANSFER; COMPOUND-II; IN-VIVO; MYELOPEROXIDASE; MECHANISM	Heme reduction of ferric lactoperoxidase (LPO) into its ferrous form initially leads to the accumulation of the unstable form of LPO-Fe(II), which spontaneously converts to a more stable species, the two of which can be identified by Soret peaks at 440 and 434 nm, respectively. Our data demonstrate that both LPO-Fe(II) species are capable of binding O-2 at a similar rate to generate the ferrous-dioxy complex. Its formation with respect to O-2 was first order and monophasic and with rate constants of k(on)=3.8x10(4) M-1 s(-1) and k(off)=11.2 s(-1). The dissociation rate constant for the formation of LPO-Fe(II)-O-2 is relatively high, in contrast to hemoprotein model compounds. This high dissociation rate can be attributed to a combination of effects that include the positive trans effect of the proximal ligand, the heme pocket environment, and the geometry of the Fe-O-2 linkage. Our results have also shown that the decay of the LPO-Fe(II)-O-2 complex occurs by two sequential O-2-independent steps. The first step involves formation of a short-lived intermediate that can be characterized by its Soret absorption peak at 416 nm and may be attributed to the weakening of the Fe(II)-O-2 linkage with a rate constant of 0.5 s(-1). The second step is spontaneous conversion of this intermediate to generate the native enzyme and presumably superoxide as end products with a rate constant of 0.03 s(-1). A comprehensive kinetic model that links LPO-Fe(II)-O-2 complex formation to the LPO catalase-like activity, combined with the classic catalytic cycle, is presented here.	Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Abu-Soud, HM (corresponding author), Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, 275 E Hancock, Detroit, MI 48201 USA.	habusoud@med.wayne.edu		Galijasevic, Semira/0000-0001-5799-4219; Diamond, Michael/0000-0001-6353-4489	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066367] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL066367] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P10747, DOI 10.1021/bi010478v; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; [Anonymous], 1985, HURRIYET 0627, P15; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHANCE B, 1984, ARCH BIOCHEM BIOPHYS, V235, P596, DOI 10.1016/0003-9861(84)90234-0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Conner GE, 2002, AM J RESP CRIT CARE, V166, pS57, DOI 10.1164/rccm.2206018; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813, DOI 10.1164/ajrccm.154.3.8810624; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DESBOIS A, 1989, INORG CHEM, V28, P825, DOI 10.1021/ic00304a007; Dunforb HB, 1999, HEME PEROXIDASES, P349; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; El-Chemaly S, 2003, AM J RESP CRIT CARE, V167, P425, DOI 10.1164/rccm.200206-531OC; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256, DOI 10.1152/jappl.1993.75.3.1256; ESWORTHY RS, 1993, ARCH BIOCHEM BIOPHYS, V307, P29, DOI 10.1006/abbi.1993.1555; Furtmuller PG, 2000, BIOCHEMISTRY-US, V39, P15578, DOI 10.1021/bi0020271; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; Ghibaudi E, 2003, EUR J BIOCHEM, V270, P4403, DOI 10.1046/j.1432-1033.2003.03849.x; Halliwell B., 1989, FREE RADICAL BIO MED, P1; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; HUWILER M, 1986, EUR J BIOCHEM, V158, P609, DOI 10.1111/j.1432-1033.1986.tb09798.x; JENZER H, 1986, J BIOL CHEM, V261, P5550; Jobsis Q, 1997, EUR RESPIR J, V10, P519; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KOHLER H, 1989, FREE RADICAL BIO MED, V6, P323, DOI 10.1016/0891-5849(89)90059-2; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; LANGE R, 1994, BIOPHYS J, V66, P89, DOI 10.1016/S0006-3495(94)80772-6; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V272, P245, DOI 10.1016/0003-9861(89)90216-6; NAKAMURA S, 1969, BIOCHIM BIOPHYS ACTA, V189, P29, DOI 10.1016/0005-2728(69)90221-7; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Reiter B., 1991, PEROXIDASES CHEM BIO, P143; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Salathe M, 1997, AM J RESP CELL MOL, V17, P97, DOI 10.1165/ajrcmb.17.1.2719; Schallreuter KU, 1999, J INVEST DERM SYMP P, V4, P91, DOI 10.1038/sj.jidsp.5640189; Sharonov YA, 1995, FEBS LETT, V377, P512, DOI 10.1016/0014-5793(95)01409-8; THOMAS EL, 1981, BIOCHEMISTRY-US, V20, P3273, DOI 10.1021/bi00514a045; THOMAS EL, 1994, INFECT IMMUN, V62, P529, DOI 10.1128/IAI.62.2.529-535.1994; TRUESDALE GA, 1954, NATURE, V173, P1236, DOI 10.1038/1731236a0; VANWART HE, 1985, J BIOL CHEM, V260, P8372; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WOLFSON LM, 1993, J FOOD PROTECT, V56, P887, DOI 10.4315/0362-028X-56.10.887; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458	66	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39465	39470		10.1074/jbc.M406003200	http://dx.doi.org/10.1074/jbc.M406003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258136	hybrid			2022-12-25	WOS:000223791500035
J	Gunther, CV; Riddle, DL				Gunther, CV; Riddle, DL			Alternative polyadenylation results in a truncated daf-4 BMP receptor that antagonizes DAF-7-mediated development in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; DAUER LARVA DEVELOPMENT; EARLY XENOPUS EMBRYO; TGF-BETA RECEPTOR; C-ELEGANS; I RECEPTORS; GENE ENCODES; TRANSCRIPTION; COMPLEX; KINASE	The DAF-4 receptor kinase, which promotes larval development, is encoded by a 2.9 kb mRNA transcribed from the only type II TGF-beta/BMP receptor gene in Caenorhabditis elegans. Here we report that alternative polyadenylation in intron 5 of daf-4 results in a 2.0 kb mRNA that encodes an open reading frame including only the N-terminal secretion signal and ligand-binding domains, and not the transmembrane or kinase domains, of DAF-4. Northern blots and real-time RT-PCR amplifications using RNA samples from developmentally staged animals show that expression levels of both the 2.9 kb and 2.0 kb transcripts are relatively constant, and their abundances similar, except for the transition between non-dauer and dauer stages. In dauer larvae, the steady-state level of the 2.0 kb mRNA increases more than 10-fold and exceeds the 2.9 kb transcript, coincident with an absence of signaling from DAF-4. Transgenic expression of a recombinant daf-4 transgene that encodes only the 2.0 kb mRNA enhances the Daf-c phenotype of a daf-4 hypomorph, whereas the same transgene with a nonsense mutation does not. These data suggest that a polypeptide encoded by the 2.0 kb transcript can function as an antagonist of full-length DAF-4 signaling. Alternative processing of type II receptor transcripts to generate an antagonist is a novel mechanism for negative regulation of a TGF-beta signaling pathway.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Riddle, DL (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	riddled@missouri.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17491, GM60151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antebi A, 2000, GENE DEV, V14, P1512; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Birnby DA, 2000, GENETICS, V155, P85; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; Coghlan A, 2002, GENOME RES, V12, P857, DOI 10.1101/gr.172702; CUSHLEY W, 1982, NATURE, V298, P77, DOI 10.1038/298077a0; deWinter JP, 1996, EXP CELL RES, V224, P323, DOI 10.1006/excr.1996.0142; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; ESTEVEZ AO, 1997, THESIS U MISSOURI CO; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Gunther CV, 2000, DEVELOPMENT, V127, P3337; Hodgkin J, 1997, GENETICS, V146, P149; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Inoue T, 2000, DEV BIOL, V217, P192, DOI 10.1006/dbio.1999.9545; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Jovelin R, 2003, MOL ECOL, V12, P1325, DOI 10.1046/j.1365-294X.2003.01805.x; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kiontke K, 2004, P NATL ACAD SCI USA, V101, P9003, DOI 10.1073/pnas.0403094101; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; Krishna S, 1999, DEVELOPMENT, V126, P251; LIU F, 1995, MOL CELL BIOL, V15, P3479; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle DL, 1997, C ELEGANS, P739; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Stanley E, 1998, MECH DEVELOP, V77, P173, DOI 10.1016/S0925-4773(98)00139-7; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	49	3	8	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39555	39564		10.1074/jbc.M407602200	http://dx.doi.org/10.1074/jbc.M407602200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254038	hybrid			2022-12-25	WOS:000223791500045
J	Necela, BM; Cidlowski, JA				Necela, BM; Cidlowski, JA			A single amino acid change in the first zinc finger of the DNA binding domain of the glucocorticoid receptor regulates differential promoter selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; STRUCTURAL DETERMINANTS; ALLOSTERIC REGULATION; FUNCTIONAL DOMAINS; HORMONE RECEPTORS; ANDROGEN RECEPTOR; GENE; MUTATIONS	Mammalian species are well known to differ in their sensitivity to glucocorticoids, but the molecular basis for this difference remains largely uncharacterized. To address this issue, the transcriptional activity of the mouse and human glucocorticoid receptor (GR) was analyzed on two model glucocorticoid-responsive promoters. Mouse GR (mGR) displayed unique promoter discrimination in response to a range of glucocorticoids, with enhanced activity on a simple glucocorticoid response element (GRE)-based promoter and diminished activity on the complex mouse mammary tumor virus promoter compared with human GR (hGR). Promoter discrimination between mGR and hGR was mapped to a single amino acid change at residue 437 ( glycine to valine) of mGR and to sequence differences within individual GREs of the different promoters. Mouse GR displayed higher activation on GREs with a guanine rather than a thymine at the -6 position. Binding studies indicated mGR (mGR437V) displayed a weaker affinity for GREs containing a thymine at the - 6 position than a mGR mutant containing a glycine at residue 437 (mGR437G). Despite distinct transcriptional activities, both receptors had similar affinities for response elements that contain a guanine at the - 6 position. Our findings support a model by which the presence of a valine residue at position 437 of mGR induces a conformational change that leads to alterations in affinity and/or transcriptional activation in a promoter-dependent context.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 Alexander Dr,Bldg 101,MD F3-07, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090057, ZIAES090057] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; ALLERA A, 1995, J CLIN ENDOCR METAB, V80, P2697, DOI 10.1210/jc.80.9.2697; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BECK CA, 1993, ENDOCRINOLOGY, V133, P728, DOI 10.1210/en.133.2.728; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen FH, 1999, J CELL BIOCHEM, V74, P418, DOI 10.1002/(SICI)1097-4644(19990901)74:3<418::AID-JCB10>3.0.CO;2-6; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; GIANNOPOULOS G, 1981, ENDOCRINOLOGY, V108, P1414, DOI 10.1210/endo-108-4-1414; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; HOSCHUTZKY H, 1985, BIOCHEMISTRY-US, V24, P7348, DOI 10.1021/bi00346a049; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KASAI Y, 1990, FEBS LETT, V274, P99, DOI 10.1016/0014-5793(90)81339-P; Keightley MC, 1998, ENDOCRINOLOGY, V139, P2479, DOI 10.1210/en.139.5.2479; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Kumar R, 2003, MOL ENDOCRINOL, V17, P1, DOI 10.1210/me.2002-0258; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Malkoski SP, 1997, MOL CELL ENDOCRINOL, V127, P189, DOI 10.1016/S0303-7207(96)04004-X; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Otto C, 1997, J BIOL CHEM, V272, P26665, DOI 10.1074/jbc.272.42.26665; Pandit S, 2002, J BIOL CHEM, V277, P1538, DOI 10.1074/jbc.M105438200; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RAY A, 1994, P NATL ACAD SCI USA, V91, P401; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shen Z, 2002, BIOTECHNIQUES, V32, P1168, DOI 10.2144/02325dd07; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; van Tilborg MAA, 2000, J MOL BIOL, V301, P947, DOI 10.1006/jmbi.2000.4001; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Webster JC, 1997, J BIOL CHEM, V272, P9287; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; ZANDI E, 1993, J MOL BIOL, V230, P124, DOI 10.1006/jmbi.1993.1130	62	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39279	39288		10.1074/jbc.M405489200	http://dx.doi.org/10.1074/jbc.M405489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15220338	hybrid			2022-12-25	WOS:000223791500012
J	Prince, T; Matts, RL				Prince, T; Matts, RL			Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; REGULATED EIF2-ALPHA KINASE; 7-AMINO ACID SEQUENCE; C-TERMINAL DOMAIN; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; CATALYTIC DOMAIN; AMINO-TERMINUS	Hsp90 cooperates with its co-chaperone Cdc37 to provide obligatory support to numerous protein kinases involved in the regulation of cellular signal transduction pathways. In this report, the crystal structure of the Src family tyrosine kinase Lck was used to guide the creation of kinase constructs to determine features recognized by Hsp90 and its "kinase-specific" co-chaperone Cdc37. Two parameters were assayed: the ability and extent to which the constructs bound to Hsp90 and Cdc37, and the ability of the constructs to trigger salt-resistant high affinity complexes with Hsp90 and Cdc37 independent of the presence of molybdate. Although Hsp90 interacted with both the N-terminal and C-terminal lobes (NL and CL, respectively) of the catalytic domains of the kinases, the lobes themselves were not sufficient to trigger the high affinity binding of Hsp90. Only constructs containing a complete N- or C-terminal lobe and part of the adjacent lobe bound to Hsp90 and Cdc37 in salt-stable complexes independent of molybdate. The two minimum constructs that bound Hsp90 and Cdc37 contained the alpha-C-helix and the beta4- and beta5-strands of the NL through to end of the CL and the NL through to the alpha-E-helix and the amino acids that cap the helix. Cdc37 interacted with only the NL and minimally required the alpha-C-helix and beta4- and beta5-strands of this lobe of Lck. The results indicate that the high affinity binding activity of Hsp90 is triggered through its interaction with adjacent subdomain structures of kinase catalytic domains. Furthermore, the alpha-C-helix and part of its adjoining loop connection to the beta4-strand appear to be the primary determinants recognized by Cdc37.	Oklahoma State Univ, Dept Biochem & Mol Biol, NRC 246, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, NRC 246, Stillwater, OK 74078 USA.	rmatts@biochem.okstate.edu						Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Caamano CA, 1998, J BIOL CHEM, V273, P20473, DOI 10.1074/jbc.273.32.20473; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Couette B, 1998, MOL ENDOCRINOL, V12, P855, DOI 10.1210/me.12.6.855; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; MacLean M, 2003, CELL STRESS CHAPERON, V8, P114, DOI 10.1379/1466-1268(2003)008<0114:CGBHAK>2.0.CO;2; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Mort-Bontemps-Soret M, 2002, MOL GENET GENOMICS, V267, P447, DOI 10.1007/s00438-002-0676-3; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Scholz GM, 2001, J BIOL CHEM, V276, P30971, DOI 10.1074/jbc.M103889200; Scroggins BT, 2003, BIOCHEMISTRY-US, V42, P12550, DOI 10.1021/bi035001t; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Shao JY, 2003, BIOCHEMISTRY-US, V42, P12577, DOI 10.1021/bi035138j; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Uma S, 1997, J BIOL CHEM, V272, P11648; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998; Zhao Q, 2004, J BIOL CHEM, V279, P12560, DOI 10.1074/jbc.M308242200	55	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39975	39981		10.1074/jbc.M406882200	http://dx.doi.org/10.1074/jbc.M406882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258137	hybrid			2022-12-25	WOS:000223791500094
J	Ritter, LM; Boesze-Battaglia, K; Tam, BM; Moritz, OL; Khattree, N; Chen, SC; Goldberg, AFX				Ritter, LM; Boesze-Battaglia, K; Tam, BM; Moritz, OL; Khattree, N; Chen, SC; Goldberg, AFX			Uncoupling of photoreceptor peripherin/rds fusogenic activity from biosynthesis, subunit assembly, and targeting - A potential mechanism for pathogenic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; RDS MUTANT MICE; HEMAGGLUTININ FUSION PEPTIDE; TRANSGENIC XENOPUS-LAEVIS; PROMOTES MEMBRANE-FUSION; OUTER SEGMENT MEMBRANES; DEGENERATION SLOW RDS; RETINAL DEGENERATION; INFLUENZA HEMAGGLUTININ; ROD PHOTORECEPTORS	Inherited defects in the RDS gene cause a multiplicity of progressive retinal diseases in humans. The gene product, peripherin/rds (P/rds), is a member of the tetraspanin protein family required for normal vertebrate photoreceptor outer segment (OS) architecture. Although its molecular function remains uncertain, P/rds has been suggested to catalyze membrane fusion events required for the OS renewal process. This study investigates the importance of two charged residues within a predicted C-terminal helical region for protein biosynthesis, localization, and interaction with model membranes. Targeted mutagenesis was utilized to neutralize charges at Glu(321) and Lys(324) individually and in combination to generate three mutant variants. Studies were conducted on variants expressed as 1) full-length P/rds in COS-1 cells, 2) glutathione S-transferase fusion proteins in Escherichia coli, and 3) membrane-associated green fluorescent protein fusion proteins in transgenic Xenopus laevis. None of the mutations affected biosynthesis of full-length P/rds in COS-1 cells as assessed by Western blotting, sedimentation velocity, and immunofluorescence microscopy. Although all mutations reside within a recently identified localization signal, none altered the ability of this region to direct OS targeting in transgenic X. laevis retinas. In contrast, individual or simultaneous neutralization of the charged amino acids Glu(321) and Lys(324) abolished the ability of the C-terminal domain to promote model membrane fusion as assayed by lipid mixing. These results demonstrate that, although overlapping, C-terminal determinants responsible for OS targeting and fusogenicity are separable and that fusogenic activity has been uncoupled from other protein properties. The observation that subunit assembly and OS targeting can both proceed normally in the absence of fusogenic activity suggests that properly assembled and targeted yet functionally altered proteins could potentially generate pathogenic effects within the vertebrate photoreceptor.	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA; Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada	Oakland University; University of Pennsylvania; University of British Columbia	Goldberg, AFX (corresponding author), Oakland Univ, Eye Res Inst, Dodge Hall,Rm 417, Rochester, MI 48309 USA.	goldberg@oakland.edu		Moritz, Orson L/0000-0002-6183-6499	NCRR NIH HHS [S10 RR026365-01, S10 RR026365] Funding Source: Medline; NEI NIH HHS [R01 EY013246-01, EY13246, R01 EY010420, R01 EY010420-08, R01 EY013246-03S1, R01 EY010420-13A2, R21 EY018705, R01 EY010420-10A2, R24 EY014803, R01 EY010420-16, R01 EY013246-03, R01 EY010420-09, R21 EY018705-02, R01 EY010420-07, R01 EY013246, R01 EY013246-02, R29 EY010420-03, R01 EY010420-06, R01 EY010420-14, EY014803, R01 EY010420-12, R01 EY010420-15, R21 EY018705-01A1, EY10420, R29 EY010420, R01 EY010420-11] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026365] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY010420, R01EY013246, R01EY010420, R21EY018705] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; Boesze-Battaglia K, 2003, INVEST OPHTH VIS SCI, V44, pU481; Boesze-Battaglia K, 2003, EXP EYE RES, V77, P505, DOI 10.1016/S0014-4835(03)00151-9; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; Boesze-Battaglia K, 2002, EXP EYE RES, V75, P227, DOI 10.1006/exer.2002.2004; Boesze-Battaglia K, 2002, INT REV CYTOL, V217, P183; Boesze-Battaglia K, 2000, METHOD ENZYMOL, V316, P65; Boesze-Battaglia K, 2000, BBA-BIOMEMBRANES, V1463, P343, DOI 10.1016/S0005-2736(99)00226-6; BoeszeBattaglia K, 1997, BIOCHEMISTRY-US, V36, P6835, DOI 10.1021/bi9627370; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DEMANT P, 1979, TISSUE ANTIGENS, V13, P53, DOI 10.1111/j.1399-0039.1979.tb01136.x; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; Felbor U, 1997, HUM MUTAT, V10, P301, DOI 10.1002/(SICI)1098-1004(1997)10:4<301::AID-HUMU6>3.3.CO;2-Y; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; Goldberg AFX, 2001, J BIOL CHEM, V276, P42700, DOI 10.1074/jbc.M107511200; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 2000, METHOD ENZYMOL, V316, P671; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; Grover S, 2002, OPHTHALMOLOGY, V109, P1110, DOI 10.1016/S0161-6420(02)01029-1; GRUNING G, 1994, HUM MUTAT, V3, P321, DOI 10.1002/humu.1380030326; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; Trujillo MJ, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<80::AID-HUMU27>3.0.CO;2-G; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Kedzierski W, 1999, J NEUROCHEM, V72, P430, DOI 10.1046/j.1471-4159.1999.0720430.x; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kedzierski W, 2001, P NATL ACAD SCI USA, V98, P7718, DOI 10.1073/pnas.141124198; Kedzierski W, 1996, J CELL SCI, V109, P2551; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kohl S, 1998, ACTA ANAT, V162, P75; Kohl S, 1997, J MED GENET, V34, P620, DOI 10.1136/jmg.34.8.620; Korte T, 2001, VIROLOGY, V289, P353, DOI 10.1006/viro.2001.1108; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lau WL, 2004, BIOPHYS J, V86, P272, DOI 10.1016/S0006-3495(04)74103-X; Loewen CJR, 2003, MOL BIOL CELL, V14, P3400, DOI 10.1091/mbc.e03-02-0077; Loewen CJR, 2001, J BIOL CHEM, V276, P22388, DOI 10.1074/jbc.M011710200; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McNally N, 2002, HUM MOL GENET, V11, P1005, DOI 10.1093/hmg/11.9.1005; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Moritz OL, 2002, GENE, V298, P173, DOI 10.1016/S0378-1119(02)00923-X; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Souied EH, 1998, EUR J OPHTHALMOL, V8, P98, DOI 10.1177/112067219800800208; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tam BM, 2004, MOL BIOL CELL, V15, P2027, DOI 10.1091/mbc.e03-09-0650; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Wrigley JDJ, 2000, J BIOL CHEM, V275, P13191, DOI 10.1074/jbc.C900853199; WU M, 1991, METHOD CELL BIOL, V36, P3; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700; Zhang K, 2002, ARCH OPHTHALMOL-CHIC, V120, P485	70	22	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39958	39967		10.1074/jbc.M403943200	http://dx.doi.org/10.1074/jbc.M403943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252042	Green Accepted, hybrid			2022-12-25	WOS:000223791500092
J	Santhamma, KR; Sadhukhan, R; Kinter, M; Chattopadhyay, S; McCue, B; Sen, I				Santhamma, KR; Sadhukhan, R; Kinter, M; Chattopadhyay, S; McCue, B; Sen, I			Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; DEFICIENT MICE; BLOOD-PRESSURE; CELL-SURFACE; RECEPTOR; GLYCOSYLATION; ECTODOMAIN; EXPRESSION; KINASE	Both germinal (gACE) and somatic (sACE) isozymes of angiotensin-converting enzyme (ACE) are type I ectoproteins whose enzymatically active ectodomains are cleaved and shed by a membrane-bound protease. Here, we report a role of protein tyrosine phosphorylation in regulating this process. Strong enhancements of ACE cleavage secretion was observed upon enhancing protein Tyr phosphorylation by treating gACE- or sACE-expressing cells with pervanadate, an inhibitor of protein Tyr phosphatases. Secreted gACE, cell-bound mature gACE and its precursors were all Tyr-phosphorylated, as was the endoplasmic reticulum protein, immunoglobulin heavy chain-binding protein, that co-immunoprecipitated with ACE. The enhancement of cleavage secretion by pervanadate did not require the presence of the cytoplasmic domain of ACE, and it was not accomplished by enhancing the rate of intracellular processing of the protein. The observed enhancement of cleavage secretion of ACE in pervanadate-treated cells was specifically blocked by an inhibitor of the p38 mitogen-activated protein (MAP) kinase but not by inhibitors of many other Ser/Thr and Tyr protein kinases, including a specific inhibitor of protein kinase C that, however, could block the enhancement of cleavage secretion elicited by phorbol ester. These results indicate that ACE Tyr phosphorylation, probably in the endoplasmic reticulum, enhances the rate of its cleavage secretion at the plasma membrane using a regulatory pathway that may involve p38 MAP kinase.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, I (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	seni@ccf.org	Chattopadhyay, Saurabh/I-4091-2019	Chattopadhyay, Saurabh/0000-0002-2930-1523; Kinter, Michael/0000-0001-7409-8918	NHLBI NIH HHS [HL54297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hwang JB, 2000, BBA-MOL CELL RES, V1499, P74, DOI 10.1016/S0167-4889(00)00109-9; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; Kessler SP, 2003, J BIOL CHEM, V278, P21105, DOI 10.1074/jbc.M3023472000; KINTNER M, 2000, PROTEIN SEQUENCING I; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Ramchandran R, 1996, AM J PHYSIOL-HEART C, V271, pH744, DOI 10.1152/ajpheart.1996.271.2.H744; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Sadhukhan R, 1996, J BIOL CHEM, V271, P6429, DOI 10.1074/jbc.271.11.6429; Safer R. L., 1981, BIOCH REGULATION BLO, P123; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; SEN GC, 1990, J CARDIOVASC PHARM, V16, pS14, DOI 10.1097/00005344-199016004-00005; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; STRITTMATTER SM, 1987, NEUROSCIENCE, V21, P407, DOI 10.1016/0306-4522(87)90131-X; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; WEI L, 1991, J BIOL CHEM, V266, P5540; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Williams TA, 1996, BIOCHEM J, V318, P125, DOI 10.1042/bj3180125	45	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40227	40236		10.1074/jbc.M407176200	http://dx.doi.org/10.1074/jbc.M407176200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252021	hybrid			2022-12-25	WOS:000223791500122
J	Varadi, B; Kolev, K; Tenekedjiev, K; Meszaros, G; Kovalszky, I; Longstaff, C; Machovich, R				Varadi, B; Kolev, K; Tenekedjiev, K; Meszaros, G; Kovalszky, I; Longstaff, C; Machovich, R			Phospholipid barrier to fibrinolysis - Role for the anionic polar head charge and the gel phase crystalline structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ACTIVATOR INHIBITOR PAI-1; PLASMINOGEN-ACTIVATOR; LIGAND INTERACTIONS; LEUKOCYTE ELASTASE; BINDING CONSTANTS; ARTERIAL THROMBI; SURFACE-ACTIVITY; HUMAN-PLATELETS; HUMAN-PLASMA	The massive presence of phospholipids is demonstrated in frozen sections of human arterial thrombi. Purified platelet phospholipids and synthetic phospholipids retard in vitro tissue-type plasminogen activator (tPA)-induced fibrinolysis through effects on plasminogen activation and plasmin function. The inhibition of plasminogen activation on the surface of fibrin correlates with the fraction of anionic phospholipid. The phospholipids decrease the amount of tPA penetrating into the clot by 75% and the depth of the reactive surface layer occupied by the activator by up to 30%, whereas for plasmin both of these parameters decrease by similar to 50%. The phospholipids are not only a diffusion barrier, they also bind the components of the fibrinolytic system. Isothermal titration calorimetry shows binding characterized with dissociation constants in the range 0.35 - 7.64 muM for plasmin and tPA ( lower values with more negative phospholipids). The interactions are endothermic and thermodynamically driven by an increase in entropy, probably caused by the rearrangements in the ordered gel structure of the phospholipids ( in line with the stronger inhibition at gel phase temperatures compared with liquid crystalline phase temperatures). These findings show a phospholipid barrier, which should be overcome during lysis of arterial thrombi.	Semmelweis Univ, Dept Med Biochem, H-1088 Budapest, Hungary; Semmelweis Univ, Dept Pathol 1, H-1088 Budapest, Hungary; Natl Inst Biol Stand & Controls, Div Haematol, Potters Bar EN6 3QG, Herts, England	Semmelweis University; Semmelweis University; National Institute for Biological Standards & Control	Kolev, K (corresponding author), Semmelweis Univ, Dept Med Biochem, Puskin 9, H-1088 Budapest, Hungary.	kale@puskin.sote.hu	Longstaff, Colin/D-2413-2013; Tenekedjiev, Kiril/D-8141-2012; Kovalszky, Ilona/ABH-2832-2020; Kolev, Krasimir/A-3517-2008; Kolev, Krasimir/J-7648-2019	Longstaff, Colin/0000-0001-7608-208X; Tenekedjiev, Kiril/0000-0003-3549-0671; Kovalszky, Ilona/0000-0002-0179-3378; Kolev, Krasimir/0000-0002-5612-004X; Kolev, Krasimir/0000-0002-5612-004X				Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; COOK BC, 1994, J COLLOID INTERF SCI, V162, P171, DOI 10.1006/jcis.1994.1022; Crowe JH, 1999, CRYOBIOLOGY, V38, P180, DOI 10.1006/cryo.1998.2137; Cunningham MT, 1999, THROMB RES, V95, P325, DOI 10.1016/S0049-3848(99)00058-4; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EPAND RM, 1990, J BIOL CHEM, V265, P20829; FAY WP, 1994, BLOOD, V83, P351; Fisher HF, 1995, METHOD ENZYMOL, V259, P194; GUNTHER A, 1993, AM J PHYSIOL, V265, pL186, DOI 10.1152/ajplung.1993.265.2.L186; GUNTHER A, 1994, AM J PHYSIOL-LUNG C, V267, pL618, DOI 10.1152/ajplung.1994.267.5.L618; Gunther A, 1999, AM J RESP CELL MOL, V21, P738; HARMON JT, 1992, METHOD ENZYMOL, V215, P32; HAZEL JR, 1995, ANNU REV PHYSIOL, V57, P19, DOI 10.1146/annurev.ph.57.030195.000315; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; Indyk L, 1998, METHOD ENZYMOL, V295, P350; Inglese J, 1998, BIOCHEMISTRY-US, V37, P2372, DOI 10.1021/bi972161u; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; JOUANEL P, 1980, CLIN CHIM ACTA, V105, P173, DOI 10.1016/0009-8981(80)90459-3; Kolev K, 2003, THROMB HAEMOSTASIS, V89, P610, DOI 10.1055/s-0037-1613567; KOLEV K, 1994, J BIOL CHEM, V269, P17030; KOLEV K, 1995, BBA-PROTEIN STRUCT M, V1247, P239, DOI 10.1016/0167-4838(94)00220-B; Kolev K, 1996, THROMB HAEMOSTASIS, V75, P140; LAMBERS JWJ, 1987, J BIOL CHEM, V262, P17492; LEE AG, 1977, BIOCHIM BIOPHYS ACTA, V472, P237, DOI 10.1016/0304-4157(77)90018-1; Lentz BR, 2003, PROG LIPID RES, V42, P423, DOI 10.1016/S0163-7827(03)00025-0; Longstaff C, 2004, J THROMB HAEMOST, V2, P1416, DOI 10.1111/j.1538-7836.2004.00816.x; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; LUNA EJ, 1977, BIOCHIM BIOPHYS ACTA, V470, P303, DOI 10.1016/0005-2736(77)90108-0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAHADEVAPPA VG, 1982, BIOCHIM BIOPHYS ACTA, V713, P73, DOI 10.1016/0005-2760(82)90168-0; McBane RD, 2000, THROMB HAEMOSTASIS, V84, P83, DOI 10.1055/s-0037-1613972; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; NATHAN I, 1979, J BIOL CHEM, V254, P9822; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Politis DN, 1998, IEEE SIGNAL PROC MAG, V15, P39, DOI 10.1109/79.647042; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; PRENNER E, 1993, ARCH BIOCHEM BIOPHYS, V305, P473, DOI 10.1006/abbi.1993.1449; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RETZINGER GS, 1994, J COLLOID INTERF SCI, V168, P514, DOI 10.1006/jcis.1994.1449; RETZINGER GS, 1995, ARTERIOSCL THROM VAS, V15, P786, DOI 10.1161/01.ATV.15.6.786; RETZINGER GS, 1985, ANAL BIOCHEM, V150, P131, DOI 10.1016/0003-2697(85)90451-8; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; Robbie LA, 1996, THROMB HAEMOSTASIS, V75, P127; RODGERS W, 1991, P NATL ACAD SCI USA, V88, P1364, DOI 10.1073/pnas.88.4.1364; SCHICK PK, 1994, HEMOSTASIS THROMBOSI, P574; SKARLATOS SI, 1993, VIRCHOWS ARCH B, V64, P241, DOI 10.1007/BF02915118; Smith JL, 1908, J PATHOL BACTERIOL, V12, P1, DOI 10.1002/path.1700120103; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; VANLOON BJP, 1992, THROMB HAEMOSTASIS, V67, P101; VERSTRAETE M, 2003, NEW THERAPEUTIC AGEN, P477; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	54	10	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39863	39871		10.1074/jbc.M405172200	http://dx.doi.org/10.1074/jbc.M405172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254044	hybrid			2022-12-25	WOS:000223791500082
J	Wong, CK; Luo, W; Deng, Y; Zou, HY; Ye, ZY; Lin, SC				Wong, CK; Luo, W; Deng, Y; Zou, HY; Ye, ZY; Lin, SC			The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by axin and dishevelled through distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT-SIGNALING PATHWAY; BETA-CATENIN; NEGATIVE REGULATOR; JNK ACTIVATION; COMPLEX; POLARITY; DVL; GSK3-BETA; ABILITY; ENCODES	Axin, Ccd1 (coiled-coil-DIX1), and dishevelled (Dvl or Dsh) are three known DIX domain proteins that play important roles in Wnt signaling. In addition, Dvl and Axin can activate the mitogen-activated protein kinase JNK via distinct mechanisms, through interaction with MEKK1/4 and Rac GTPase, respectively. Axin utilizes two distinct domains for interaction with MEKK1 and MEKK4. JNK activation by Axin is regulated by several factors in the Wnt pathway, whereas little is known about cross-regulation of Dvl-mediated JNK activation. In the present study, we have investigated whether Ccd1 could play a regulatory role in Axin- and Dvl-mediated JNK activation. Here we show that Ccd1 drastically inhibited JNK activation both by Axin and by Dvl. Although DIX domains are sufficient for dimer formation between Dvl and Ccd1, Ccd1 also required its coiled-coil domain for inhibition of JNK activation by Dvl. Interestingly, Rac remained associated with Dvl heterodimerized with Ccd1. How Ccd1 blocks Rac/Dvl signaling to JNK is unclear. In contrast, Axin, when complexed with Ccd1, did not bind to MEKK1. Furthermore, Ccd1 physically interacted with MEKK4 in their physiological concentrations and prevented MEKK4 from binding to Axin. Reduction of Ccd1 protein by small interfering RNA could elevate JNK signaling as assayed with an AP1-dependent transcriptional reporter. We have therefore demonstrated that Ccd1 inhibits Axin- mediated JNK activation by simultaneously adopting two distinct mechanisms, one through conformational changes that disallow MEKK1 binding and the other via direct sequestration of MEKK4.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Xiamen Univ, Sch Life Sci, State Key Lab Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China	Hong Kong University of Science & Technology; Xiamen University	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	linsc@ust.hk	Lin, SC/G-4666-2010					Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LIN SC, 1991, J BIOL CHEM, V266, P23347; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Polakis P, 2000, GENE DEV, V14, P1837; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Shiomi K, 2003, CURR BIOL, V13, P73, DOI 10.1016/S0960-9822(02)01398-2; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	30	35	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39366	39373		10.1074/jbc.M404598200	http://dx.doi.org/10.1074/jbc.M404598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262978	Green Published, hybrid			2022-12-25	WOS:000223791500022
J	Avramopoulou, V; Mamalaki, A; Tzartos, SJ				Avramopoulou, V; Mamalaki, A; Tzartos, SJ			Soluble, oligomeric, and ligand-binding extracellular domain of the human alpha 7 acetylcholine receptor expressed in yeast - Replacement of the hydrophobic cysteine loop by the hydrophilic loop of the ACh-binding protein enhances protein solubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPIC EVIDENCE; NICOTINIC RECEPTORS; SUBUNIT; BUNGAROTOXIN; GLYCOSYLATION; DIVERSITY; SITES	The N-terminal extracellular domain (ECD; amino acids 1-208) of the neuronal nicotinic acetylcholine receptor (AChR) alpha7 subunit, the only human AChR subunit known to assemble as a homopentamer, was expressed as a glycosylated form in the yeast Pichia pastoris in order to obtain a native-like model of the extracellular part of an intact pentameric nicotinic AChR. This molecule, alpha7-ECD, although able to bind the specific ligand alpha-bungarotoxin, existed mainly in the form of microaggregates. Substitution of Cys-116 in the alpha7-ECD with serine led to a decrease in microaggregate size. A second mutant form, alpha7-ECD(C116S, Cys-loop), was generated in which, in addition to the C116S mutation, the hydrophobic Cys-loop (Cys(128)-Cys(142)) was replaced by the corresponding hydrophilic Cys-loop from the snail glial cell acetylcholine-binding protein. This second mutant protein was water-soluble, expressed at a moderate level (0.5+/-0.1 mg/liter), and had a size corresponding approximately to a pentamer as judged by gel filtration and electron microscopy studies. It also bound I-125-alpha-bungarotoxin with relatively high affinity (K-d=57 nM), the binding being inhibited by unlabeled alpha-bungarotoxin, d-tubocurarine, or nicotine (K-i=0.8x10(-7) M, K-i=1x10(-5) M, and K-i=0.9x10(-2) M, respectively). All three constructs were expressed as glycosylated forms, but in vitro deglycosylation reduced the heterogeneity without affecting their ligand binding properties. These results show that alpha7-ECD(C116S, Cys-loop) was expressed in P. pastoris as an oligomer (probably a pentamer) with a near native conformation and that its deglycosylated form seems to be suitable starting material for structural studies on the ligand-binding domain of a neurotransmitter receptor.	Hellenic Pasteur Inst, Dept Biochem, GR-11521 Athens, Greece; Univ Patras, Dept Pharm, GR-26500 Patras, Greece	University of Patras	Tzartos, SJ (corresponding author), Hellenic Pasteur Inst, Dept Biochem, 127 Vassilissis Sofias Ave, GR-11521 Athens, Greece.	tzartos@mail.pasteur.gr						ANAND R, 1993, MOL PHARMACOL, V44, P1046; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; Clementi F, 2000, EUR J PHARMACOL, V393, P3, DOI 10.1016/S0014-2999(00)00066-2; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Dunckley T, 2003, BIOCHEMISTRY-US, V42, P870, DOI 10.1021/bi020586x; EISELE JL, 1993, NATURE, V227, P680; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; HERTLINGJAWEED S, 1988, FEBS LETT, V241, P29, DOI 10.1016/0014-5793(88)81024-X; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Marinou M, 2003, BIOCHEM J, V372, P543, DOI 10.1042/BJ20021537; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Paas Y, 2003, P NATL ACAD SCI USA, V100, P11309, DOI 10.1073/pnas.1834451100; Psaridi-Linardaki L, 2002, J BIOL CHEM, V277, P26980, DOI 10.1074/jbc.M110731200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Tierney ML, 2000, J MOL BIOL, V303, P185, DOI 10.1006/jmbi.2000.4137; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; Tsetlin VI, 2002, EUR J BIOCHEM, V269, P2801, DOI 10.1046/j.1432-1033.2002.02961.x; Tsouloufis T, 2000, INT IMMUNOL, V12, P1255, DOI 10.1093/intimm/12.9.1255; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Utkin YN, 2001, J BIOL CHEM, V276, P15810, DOI 10.1074/jbc.M100788200; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4	38	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38287	38293		10.1074/jbc.M402533200	http://dx.doi.org/10.1074/jbc.M402533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226316	hybrid			2022-12-25	WOS:000223684100028
J	Burk, O; Koch, I; Raucy, J; Hustert, E; Eichelbaum, M; Brockmoller, J; Zanger, UM; Wojnowski, L				Burk, O; Koch, I; Raucy, J; Hustert, E; Eichelbaum, M; Brockmoller, J; Zanger, UM; Wojnowski, L			The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; HUMAN HEPATOCYTES; INTERINDIVIDUAL VARIABILITY; RESPONSIVE ENHANCER; DRUG-INTERACTIONS; EXPRESSION; MIDAZOLAM; GENE; IDENTIFICATION; METABOLISM	Induction of cytochrome P450 3A (CYP3A) by xenobiotics may lead to clinically relevant drug interactions. In contrast with other CYP3A family members, studies on the inducibility of CYP3A5 indicate conflicting results. We report the induction of CYP3A5 mRNA in 13 of 16 hepatocyte preparations exposed to rifampin. Furthermore, induction of CYP3A5 mRNA was observed in intestinal biopsies in three of eight probands following exposure to the antibiotic. The highest absolute levels of CYP3A5 transcripts were found following rifampin treatment in hepatocytes and intestines from carriers of CYP3A5*1 alleles. Elucidation of the mechanism involved in CYP3A5 induction revealed that constitutively activated receptor (CAR) and pregnane X receptor (PXR) transactivated the CYP3A5 promoter (-688 to +49) and that the transactivation was dependent on an everted repeat separated by 6 bp (ER6-dependent). Treatment with the prototypical PXR ligand rifampin led to a 2-fold induction of the CYP3A5 promoter activity. In agreement with these observations, PXR and CAR bound specifically to the ER6 motif. Hepatic expression of PXR correlated with that of CYP3A5 mRNA levels in a bank of liver samples. Taken together, studies here revealed the presence of a functional ER6 motif in the CYP3A5 promoter located -100 bp upstream from the transcription start site, suggesting that CYP3A5 is inducible by mechanisms similar to those involved in CYP3A4 induction. Enhanced expression of CYP3A5 caused by exposure to inducers may phenocopy the effects of the high expression allele CYP3A5*1. In this manner, induction of CYP3A5 may contribute to the overall importance of this P450 in drug metabolism and drug interactions.	Univ Gottingen, Dept Clin Pharmacol, D-37085 Gottingen, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Epidauros Biotechnol AG, D-82347 Bernried, Germany; Calif Toxicol Res Inst, Carlsbad, CA 92009 USA; Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	University of Gottingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Johannes Gutenberg University of Mainz	Wojnowski, L (corresponding author), Univ Gottingen, Dept Clin Pharmacol, Robert Koch Str 40, D-37085 Gottingen, Germany.	wojnowski@uni-mainz.de	Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002				Backman JT, 1998, EUR J CLIN PHARMACOL, V54, P53, DOI 10.1007/s002280050420; Barwick JL, 1996, MOL PHARMACOL, V50, P10; Bertilsson G, 2001, BIOCHEM BIOPH RES CO, V280, P139, DOI 10.1006/bbrc.2000.4066; Burk O, 2004, N-S ARCH PHARMACOL, V369, P105, DOI 10.1007/s00210-003-0815-3; Burk O, 2002, J BIOL CHEM, V277, P24280, DOI 10.1074/jbc.M202345200; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Gellner K, 2001, PHARMACOGENETICS, V11, P111, DOI 10.1097/00008571-200103000-00002; Gibson GG, 2002, XENOBIOTICA, V32, P165, DOI 10.1080/00498250110102674; GILLUM JG, 1993, CLIN PHARMACOKINET, V25, P450, DOI 10.2165/00003088-199325060-00005; Goh BC, 2002, J CLIN ONCOL, V20, P3683, DOI 10.1200/JCO.2002.01.025; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643; GRANGE JM, 1994, DRUG SAFETY, V11, P242, DOI 10.2165/00002018-199411040-00003; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Hukkanen J, 2003, J PHARMACOL EXP THER, V304, P745, DOI 10.1124/jpet.102.038208; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Hustert E, 2001, DRUG METAB DISPOS, V29, P1454; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; Koch I, 2002, DRUG METAB DISPOS, V30, P1108, DOI 10.1124/dmd.30.10.1108; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Li AP, 1995, TOXICOLOGY, V104, P1, DOI 10.1016/0300-483X(95)03155-9; Lin YS, 2002, MOL PHARMACOL, V62, P162, DOI 10.1124/mol.62.1.162; LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T; Rae JM, 2001, J PHARMACOL EXP THER, V299, P849; Raucy JL, 2003, DRUG METAB DISPOS, V31, P533, DOI 10.1124/dmd.31.5.533; Rodriguez-Antona C, 2000, ARCH BIOCHEM BIOPHYS, V376, P109, DOI 10.1006/abbi.2000.1697; SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Shih PS, 2002, DRUG METAB DISPOS, V30, P1491, DOI 10.1124/dmd.30.12.1491; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; WESTLINDJOHNSSO.A, 2003, DRUG METAB DISPOS, V31, P1; Wilkinson GR, 1996, J PHARMACOKINET BIOP, V24, P475, DOI 10.1007/BF02353475; Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393; WRIGHTON SA, 1989, MOL PHARMACOL, V36, P97; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	38	146	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38379	38385		10.1074/jbc.M404949200	http://dx.doi.org/10.1074/jbc.M404949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252010	hybrid			2022-12-25	WOS:000223684100039
J	Doolman, R; Leichner, GS; Avner, R; Roitelman, J				Doolman, R; Leichner, GS; Avner, R; Roitelman, J			Ubiquitin is conjugated by membrane ubiquitin ligase to three sites, including the N terminus, in transmembrane region of mammalian 3-hydroxy-3-methylglutaryl coenzyme A reductase - Implications for sterol-regulated enzyme degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; RETICULUM-ASSOCIATED DEGRADATION; ELEMENT-BINDING PROTEINS; CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; SENSING DOMAIN; NUCLEOTIDE-SEQUENCE; ER; PROTEASOME	The stability of the endoplasmic reticulum ( ER) glycoprotein 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), the key enzyme in cholesterol biosynthesis, is negatively regulated by sterols. HMGR is anchored in the ER via its N-terminal region, which spans the membrane eight times and contains a sterol-sensing domain. We have previously established that degradation of mammalian HMGR is mediated by the ubiquitin-proteasome system (Ravid, T., Doolman, R., Avner, R., Harats, D., and Roitelman, J. ( 2000) J. Biol. Chem. 275, 35840 - 35847). Here we expressed in HEK-293 cells an HA-tagged-truncated version of HMGR that encompasses all eight transmembrane spans ( 350 N-terminal residues). Similar to endogenous HMGR, degradation of this HMG(350)-3HA protein was accelerated by sterols, validating it as a model to study HMGR turnover. The degradation of HMG(240)-3HA, which lacks the last two transmembrane spans yet retains an intact sterol-sensing domain, was no longer accelerated by sterols. Using HMG(350)-3HA, we demonstrate that transmembrane region of HMGR is ubiquitinated in a sterol-regulated fashion. Through site-directed Lys --> Arg mutagenesis, we pinpoint Lys(248) and Lys(89) as the internal lysines for ubiquitin attachment, with Lys(248) serving as the major acceptor site for polyubiquitination. Moreover, the data indicate that the N terminus is also ubiquitinated. The degradation rates of the Lys --> Arg mutants correlates with their level of ubiquitination. Notably, lysine-less HMG(350)-3HA is degraded faster than wild-type protein, suggesting that lysines other than Lys(89) and Lys(248) attenuate ubiquitination at the latter residues. The ATP-dependent ubiquitination of HMGR in isolated microsomes requires E1 as the sole cytosolic protein, indicating that ER-bound E2 and E3 enzymes catalyze this modification. Polyubiquitination of HMGR is correlated with its extraction from the ER membrane, a process likely to be assisted by cytosolic p97/VCP/Cdc48p-Ufd1-Npl4 complex, as only ubiquitinated HMGR pulls down p97.	Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Ramat Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Roitelman, J (corresponding author), Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel.	roitelma@post.tau.ac.il						Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; Cheng HH, 1999, J BIOL CHEM, V274, P17171, DOI 10.1074/jbc.274.24.17171; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUA X, 1996, J BIOL CHEM, V271, P10979; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Kikkert M, 2001, BIOCHEM J, V358, P369, DOI 10.1042/0264-6021:3580369; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; Song BL, 2004, J BIOL CHEM, V279, P28798, DOI 10.1074/jbc.M402442200; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Xu LW, 2003, ARCH BIOCHEM BIOPHYS, V414, P232, DOI 10.1016/S0003-9861(03)00168-1; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	60	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38184	38193		10.1074/jbc.M405935200	http://dx.doi.org/10.1074/jbc.M405935200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247208	hybrid			2022-12-25	WOS:000223684100017
J	Jones, AL; Hulett, MD; Altin, JG; Hogg, P; Parish, CR				Jones, AL; Hulett, MD; Altin, JG; Hogg, P; Parish, CR			Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDE UNIT; HEPARIN BINDING; FIBRINOLYTIC SYSTEM; IMMUNE-COMPLEXES; ANNEXIN-II; HUMAN-IGG; ACTIVATION; INHIBITOR; PROLINE; SERUM	Plasminogen has been implicated in extracellular matrix degradation by invading cells, but few high affinity cell surface receptors for the molecule have been identified. Previous studies have reported that the plasma protein, histidine-rich glycoprotein (HRG), interacts with plasminogen and cell surfaces, raising the possibility that HRG may immobilize plasminogen/plasmin to cell surfaces. Here we show, based on optical biosensor analyses, that immobilized HRG interacts with soluble plasminogen with high affinity and with an extremely slow dissociation rate. Furthermore, the HRG-plasminogen interaction is lysine-dissociable and involves predominately the amino-terminal domain of HRG, and the fifth kringle domain of plasminogen, but not the carboxyl-terminal lysine of HRG. HRG was also shown to tether plasminogen to cell surfaces, with this interaction being potentiated by elevated Zn2+ levels and low pH, conditions that prevail at sites of tissue injury, tumor growth, and angiogenesis. Based on these data we propose that HRG acts as a soluble adaptor molecule that binds to cells at sites of tissue injury, tumor growth, and angiogenesis, providing a high affinity receptor for tethering plasminogen to the cell surface and thereby enhancing the migratory potential of cells.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 2601, Australia; Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW 2033, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; University of New South Wales Sydney	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 2601, Australia.	christopher.parish@anu.edu.au	Hulett, Mark D/C-4160-2012; Altin, Joseph G/C-9935-2009	Hulett, Mark/0000-0003-2072-5968; Parish, Christopher/0000-0001-7740-0430; Hogg, Philip/0000-0001-6486-2863				AKTULGA A, 1974, RECENT ADV BASIC RES, P185; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Brown KH, 1998, AM J CLIN NUTR, V68, p425S, DOI 10.1093/ajcn/68.2.425S; Brownstein C, 2001, ANN NY ACAD SCI, V947, P143; Brunner G, 1998, EXP CELL RES, V239, P301, DOI 10.1006/excr.1997.3877; BURCH MK, 1987, BIOCHEMISTRY-US, V26, P7477, DOI 10.1021/bi00397a042; CHANG NS, 1992, BLOOD, V79, P2973; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 2002, J IMMUNOL, V169, P4745, DOI 10.4049/jimmunol.169.9.4745; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GUTHANS SL, 1982, ARCH BIOCHEM BIOPHYS, V218, P320, DOI 10.1016/0003-9861(82)90350-2; HAYES ML, 1979, J BIOL CHEM, V254, P8768; HAYES ML, 1979, J BIOL CHEM, V254, P8772; HAYES ML, 1979, J BIOL CHEM, V254, P8777; ICHINOSE A, 1984, THROMB RES, V33, P401, DOI 10.1016/0049-3848(84)90079-3; Jones AL, 2004, J BIOL CHEM, V279, P30114, DOI 10.1074/jbc.M401996200; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; Lahteenmaki K, 2000, METHODS, V21, P125, DOI 10.1006/meth.2000.0983; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MIYASHITA C, 1988, Haemostasis, V18, P7; MORGAN WT, 1978, BIOCHIM BIOPHYS ACTA, V535, P319, DOI 10.1016/0005-2795(78)90098-3; MORGAN WT, 1981, BIOCHEMISTRY-US, V20, P1054, DOI 10.1021/bi00508a002; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MOROI M, 1976, J BIOL CHEM, V251, P5956; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; Ploplis VA, 2000, METHODS, V21, P103, DOI 10.1006/meth.2000.0981; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; REICH E, 1978, BIOL MARKERS NEOPLAS, P491; RICKLI EE, 1975, EUR J BIOCHEM, V59, P441, DOI 10.1111/j.1432-1033.1975.tb02472.x; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SAIGO K, 1989, J BIOL CHEM, V264, P8249; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; Scherrer A, 1999, BRIT J HAEMATOL, V105, P920, DOI 10.1046/j.1365-2141.1999.01432.x; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTHER PJ, 1975, J BIOL CHEM, V250, P5926; WALZ DA, 1987, SEMIN THROMB HEMOST, V13, P317, DOI 10.1055/s-2007-1003507; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	56	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38267	38276		10.1074/jbc.M406027200	http://dx.doi.org/10.1074/jbc.M406027200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15220341	hybrid			2022-12-25	WOS:000223684100026
J	Kissova, I; Deffieu, M; Manon, S; Camougrand, N				Kissova, I; Deffieu, M; Manon, S; Camougrand, N			Uth1p is involved in the autophagic degradation of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CYTOCHROME-C; SUN FAMILY; SYMPATHETIC NEURONS; OXIDATIVE-STRESS; PICHIA-PASTORIS; CELL-DEATH; BIOGENESIS; APOPTOSIS; PROTEINS	The absence of the outer mitochondrial membrane protein Uth1p was found to induce resistance to rapamycin treatment and starvation, two conditions that induce the autophagic process. Biochemical studies showed the onset of a fully active autophagic activity both in wild-type and Deltauth1 strains. On the other hand, the disorganization of the mitochondrial network induced by rapamycin treatment or 15 h of nitrogen starvation was followed in cells expressing mitochondria-targeted green fluorescent protein; a rapid colocalization of green fluorescent protein fluorescence with vacuole-selective FM4-64 labeling was observed in the wild-type but not in the Deltauth1 strain. Degradation of mitochondrial proteins, followed by Western blot analysis, did not occur in mutant strains carrying null mutations of the vacuolar protease Pep4p, the autophagy-specific protein Atg5p, and Uth1p. These data show that, although the autophagic machinery was fully functional in the absence of Uth1p, this protein is involved in the autophagic degradation of mitochondria.	Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, Unite Mixte Rech 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Camougrand, N (corresponding author), Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, CNRS, Unite Mixte Rech 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	n.camougrand@ibgc.u-bordeaux2.fr	Bhatia, Ingrid/H-7016-2016; Manon, Stéphen/C-7088-2017	Manon, Stephen/0000-0002-5792-1084				Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Austriaco NR, 1996, YEAST, V12, P623, DOI 10.1002/(SICI)1097-0061(19960615)12:7<623::AID-YEA968>3.0.CO;2-G; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bandara PDS, 1998, CURR GENET, V34, P259, DOI 10.1007/s002940050395; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Camougrand N, 2003, MOL MICROBIOL, V47, P495, DOI 10.1046/j.1365-2958.2003.03311.x; Camougrand N, 2001, RESP PHYSIOL, V128, P393, DOI 10.1016/S0034-5687(01)00314-0; Camougrand NM, 2000, ARCH BIOCHEM BIOPHYS, V375, P154, DOI 10.1006/abbi.1999.1655; Campbell CL, 1998, J CELL SCI, V111, P2455; DAMSKY CH, 1976, J CELL BIOL, V71, P123, DOI 10.1083/jcb.71.1.123; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Guo L, 2004, AM J PHYSIOL-CELL PH, V286, pC1109, DOI 10.1152/ajpcell.00183.2003; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Mouassite M, 2000, YEAST, V16, P905, DOI 10.1002/1097-0061(200007)16:10<905::AID-YEA584>3.0.CO;2-1; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Roberts ML, 2000, MOL CELL NEUROSCI, V16, P97, DOI 10.1006/mcne.2000.0867; Roberts P, 2003, MOL BIOL CELL, V14, P129, DOI 10.1091/mbc.E02-08-0483; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Shafer KS, 1999, CURR GENET, V36, P183, DOI 10.1007/s002940050489; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THORSNESS PE, 1992, MUTAT RES, V275, P237, DOI 10.1016/0921-8734(92)90027-M; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tuleva B, 1998, FEMS MICROBIOL LETT, V161, P139; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; Velours G, 2002, FEMS MICROBIOL LETT, V207, P165, DOI 10.1111/j.1574-6968.2002.tb11046.x; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yuan WP, 1997, J CELL SCI, V110, P1935	48	338	357	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39068	39074		10.1074/jbc.M406960200	http://dx.doi.org/10.1074/jbc.M406960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247238	hybrid			2022-12-25	WOS:000223684100122
J	Trevino, MA; Garcia-Mayoral, MF; Barral, P; Villalba, M; Santoro, J; Rico, M; Rodriguez, R; Bruix, M				Trevino, MA; Garcia-Mayoral, MF; Barral, P; Villalba, M; Santoro, J; Rico, M; Rodriguez, R; Bruix, M			NMR solution structure of Ole e 6, a major allergen from olive tree pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR-MAGNETIC-RESONANCE; OLE-E-I; CROSS-REACTIVITY; CRYSTAL-STRUCTURE; IMMUNOLOGICAL CHARACTERIZATION; PROTEIN STRUCTURES; BINDING EPITOPES; PICHIA-PASTORIS; GRASS-POLLEN	Ole e 6 is a pollen protein from the olive tree ( Olea europaea) that exhibits allergenic activity with a high prevalence among olive-allergic individuals. The three-dimensional structure of Ole e 6 has been determined in solution by NMR methods. This is the first experimentally determined structure of an olive tree pollen allergen. The structure of this 50-residue protein is based on 486 upper limit distance constraints derived from nuclear Overhauser effects and 24 phi torsion angle restraints. The global fold of Ole e 6 consists of two nearly antiparallel alpha-helices, spanning residues 3 - 19 and 23 - 33, that are connected by a short loop and followed by a long, unstructured C-terminal tail. Viewed edge-on, the structured N terminus has a dumbbell-like shape with the two helices on the outside and with the hydrophobic core, mainly composed of 3 aromatic and 6 cysteine residues, on the inside. All the aromatic rings lie on top of and pack against the three disulfide bonds. The lack of thermal unfolding, even at 85 degreesC, indicates a high conformational stability. Based on the analysis of the molecular surface, we propose five plausible epitopes for IgE recognition. The results presented here provide the structural foundation for future experiments to verify the antigenicity of the proposed epitopes, as well as to design novel hypoallergenic forms of the protein suitable for diagnosis and treatment of type-I allergies. In addition, three-dimensional structure features of Ole e 6 are discussed to provide a basis for future functional studies.	CSIC, Inst Quim Fis Rocasolano, Dept Espectroscopia & Estructura Mol, E-28006 Madrid, Spain; Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Complutense University of Madrid	Bruix, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Dept Espectroscopia & Estructura Mol, Serrano 119, E-28006 Madrid, Spain.	mbruix@iqfr.csic.es	Villalba, Mayte/K-5365-2014; Villalba, María Teresa/AAW-1067-2020; RODRIGUEZ, ROSALIA/K-4993-2014; Bruix, Marta/H-4161-2011; Trevino, Miguel Angel/C-5877-2009	Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Bruix, Marta/0000-0002-0096-3558; Trevino, Miguel Angel/0000-0002-0738-5973; Barral, Patricia/0000-0003-4324-8973				Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Barral P, 2004, J IMMUNOL, V172, P3644, DOI 10.4049/jimmunol.172.6.3644; BARRAL P, 2004, IN PRESS PROTEIN EXP; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, ANN ALLERGY, V69, P439; Breiteneder H, 2001, CURR OPIN ALLERGY CL, V1, P261, DOI 10.1097/01.all.0000011024.76416.01; Budde IK, 2003, CLIN EXP ALLERGY, V33, P1175, DOI 10.1046/j.1365-2222.2003.01767.x; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Case D. A., 2002, AMBER 7; Cheung AY, 2000, ANN BOT-LONDON, V85, P29, DOI 10.1006/anbo.1999.1016; Crowley P, 2000, J AM CHEM SOC, V122, P2968, DOI 10.1021/ja9942787; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Furmonaviciene R, 2000, CLIN EXP ALLERGY, V30, P1307, DOI 10.1046/j.1365-2222.2000.00897.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gonzalez E, 2001, CLIN EXP ALLERGY, V31, P313, DOI 10.1046/j.1365-2222.2001.00980.x; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Helgstrand M, 2000, J BIOMOL NMR, V18, P329, DOI 10.1023/A:1026729404698; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; Huecas S, 2001, J BIOL CHEM, V276, P27959, DOI 10.1074/jbc.M103041200; Ipsen H, 1997, CLIN REV ALLERG IMMU, V15, P389, DOI 10.1007/BF02737734; Ivanciuc O, 2002, BIOINFORMATICS, V18, P1358, DOI 10.1093/bioinformatics/18.10.1358; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; Midoro-Horiuti T, 2000, J IMMUNOL, V164, P2188, DOI 10.4049/jimmunol.164.4.2188; Miescher SM, 2002, MOL ASPECTS MED, V23, P413, DOI 10.1016/S0098-2997(02)00009-2; Mine Y, 2002, BIOCHEM BIOPH RES CO, V292, P1070, DOI 10.1006/bbrc.2002.6725; MOMMA T, 1985, EUR J BIOCHEM, V149, P491, DOI 10.1111/j.1432-1033.1985.tb08951.x; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; Pajaron MJ, 1997, ALLERGY, V52, P829, DOI 10.1111/j.1398-9995.1997.tb02154.x; PALMER AG, 1992, J MAGN RESON, V96, P416, DOI 10.1016/0022-2364(92)90097-Q; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Reyda S, 2003, J MOL BIOL, V325, P963, DOI 10.1016/S0022-2836(02)01337-2; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; Rodriguez R, 2002, ALLERGY, V57, P6, DOI 10.1034/j.1398-9995.2002.057s71006.x; Roy D, 2003, BIOCHEM BIOPH RES CO, V307, P422, DOI 10.1016/S0006-291X(03)01193-8; SEAVEY B R, 1991, Journal of Biomolecular NMR, V1, P217, DOI 10.1007/BF01875516; Soman KV, 2000, BIOPHYS J, V79, P1601, DOI 10.1016/S0006-3495(00)76410-1; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Venarske D, 2003, SOUTH MED J, V96, P1049, DOI 10.1097/01.SMJ.0000097887.04639.39; Wahl R, 1996, J ALLERGY CLIN IMMUN, V98, P99, DOI 10.1016/S0091-6749(96)70231-2; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOTHRICH K, 1986, NMR PROTEINS NUCL AC	67	19	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39035	39041		10.1074/jbc.M406045200	http://dx.doi.org/10.1074/jbc.M406045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247256	Green Published, hybrid			2022-12-25	WOS:000223684100118
J	Perez-Villamil, B; Mirasierra, M; Vallejo, M				Perez-Villamil, B; Mirasierra, M; Vallejo, M			The homeoprotein Alx3 contains discrete functional domains and exhibits cell-specific and selective monomeric binding and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOSTATIN GENE-TRANSCRIPTION; HOMEOBOX GENE; HOMEODOMAIN; EXPRESSION; PROTEIN; PROLINE; MUTANT; CART1; PRX2; DNA	Alx3 is a paired class aristaless-like homeoprotein expressed during embryonic development. Transcriptional transactivation by aristaless-like proteins has been associated with cooperative dimerization upon binding to artificially generated DNA consensus sequences known as P3 sites, but natural target sites in genes regulated by Alx3 are unknown. We report the cloning of a cDNA encoding the rat homolog of Alx3, and we characterize the protein domains that are important for transactivation, dimerization, and binding to DNA. Two proline-rich domains located amino-terminal to the homeodomain (Pro1 and Pro2) are necessary for Alx3-dependent transactivation, whereas another one (Pro3) located in the carboxyl terminus is dispensable but contributes to enhance the magnitude of the response. We confirmed that transcriptional activity of Alx3 from a P3 site correlates with cooperative dimerization upon binding to DNA. However, Alx3 was found to bind selectively to non-P3-related TAAT-containing sites present in the promoter of the somatostatin gene in a specific manner that depends on the nuclear protein environment. Cell-specific transactivation elicited by Alx3 from these sites could not be predicted from in vitro DNA-binding experiments by using recombinant Alx3. In addition, transactivation did not depend on cooperative dimerization upon binding to cognate somatostatin DNA sites. Our data indicate that the paradigm according to which Alx3 must act homodimerically via cooperative binding to P3-like sites is insufficient to explain the mechanism of action of this homeoprotein to regulate transcription of natural target genes. Instead, Alx3 undergoes restrictive or permissive interactions with nuclear proteins that determine its binding to and transactivation from TAAT target sites selected in a cell-specific manner.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Harvard University; Massachusetts General Hospital	Vallejo, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Calle Arturo Duperier 4, Madrid 28029, Spain.	mvallejo@iib.uam.es	Perez-Villamil, Beatriz/AAB-3572-2019; Mirasierra, Mercedes/ABG-6999-2020; Vallejo, Mario/ABG-4610-2020	Perez-Villamil, Beatriz/0000-0002-6881-7442; Mirasierra, Mercedes/0000-0002-0023-8903; Vallejo, Mario/0000-0002-6422-0323	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049670] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49670] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Beverdam A, 2001, MECH DEVELOP, V107, P163, DOI 10.1016/S0925-4773(01)00450-6; Beverdam A, 2001, DEVELOPMENT, V128, P3975; Boras K, 2002, J BIOL CHEM, V277, P1120, DOI 10.1074/jbc.M109912200; BRENNER M, 1994, BRAIN PATHOL, V4, P245, DOI 10.1111/j.1750-3639.1994.tb00840.x; Brouwer A, 2003, MECH DEVELOP, V120, P241, DOI 10.1016/S0925-4773(02)00416-1; CONDORELLI DF, 1994, J NEUROSCI RES, V39, P694, DOI 10.1002/jnr.490390610; Edwards SJ, 2003, ONCOGENE, V22, P4517, DOI 10.1038/sj.onc.1206726; Furukawa K, 2002, GENES CELLS, V7, P1135, DOI 10.1046/j.1365-2443.2002.00587.x; Galliot B, 1999, DEV GENES EVOL, V209, P186, DOI 10.1007/s004270050243; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Green PD, 2001, GENE EXPRESSION, V9, P265, DOI 10.3727/000000001783992515; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; Hudson R, 1998, DEV DYNAM, V213, P159, DOI 10.1002/(SICI)1097-0177(199810)213:2<159::AID-AJA1>3.0.CO;2-F; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; McManus MF, 1999, J NEUROSCI, V19, P9004, DOI 10.1523/JNEUROSCI.19-20-09004.1999; Meijlink F, 1999, INT J DEV BIOL, V43, P651; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Norris RA, 2001, DNA CELL BIOL, V20, P89, DOI 10.1089/104454901750070292; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; Papatsenko D, 2001, MECH DEVELOP, V101, P143, DOI 10.1016/S0925-4773(00)00581-5; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Qu SM, 1997, DEVELOPMENT, V124, P3999; Qu SM, 1999, DEVELOPMENT, V126, P359; Qu SM, 1997, GENE, V203, P217, DOI 10.1016/S0378-1119(97)00497-6; Qu SM, 1998, DEVELOPMENT, V125, P2711; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz PT, 1998, MOL ENDOCRINOL, V12, P1280, DOI 10.1210/me.12.9.1280; Schwartz PT, 2000, J BIOL CHEM, V275, P19106, DOI 10.1074/jbc.M000655200; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Takahashi M, 1998, DEVELOPMENT, V125, P4417; ten Berge D, 1998, DEVELOPMENT, V125, P3831; ten Berge D, 1998, DEV BIOL, V199, P11, DOI 10.1006/dbio.1998.8921; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; Tucker SC, 1999, J BIOL CHEM, V274, P32325, DOI 10.1074/jbc.274.45.32325; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wilson DS, 1999, NAT STRUCT BIOL, V6, P297, DOI 10.1038/7524; Wimmer K, 2002, GENE CHROMOSOME CANC, V33, P285, DOI 10.1002/gcc.10030; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275; ZIEMER MA, 1982, J BIOL CHEM, V257, P1176	52	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38062	38071		10.1074/jbc.M400800200	http://dx.doi.org/10.1074/jbc.M400800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226305	hybrid, Green Submitted			2022-12-25	WOS:000223554600101
J	Baudin-Creuza, V; Vasseur-Godbillon, C; Pato, C; Prehu, C; Wajcman, H; Marden, MC				Baudin-Creuza, V; Vasseur-Godbillon, C; Pato, C; Prehu, C; Wajcman, H; Marden, MC			Transfer of human alpha- to beta-hemoglobin via its chaperone protein - Evidence for a new state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABILIZING PROTEIN; TUBULIN; RBL2P	The alpha-hemoglobin-stabilizing protein (AHSP), a small protein of 102 amino acids, is synthesized in red blood cell precursors. It binds specifically to alpha-hemoglobin (alpha-Hb) subunits acting as a chaperone protein, preventing the formation of alpha-hemoglobin-cytotoxic precipitates. We have engineered recombinant AHSP in a pGEX vector to study the functional consequence of interaction between AHSP and alpha-Hb. By in vitro binding assays, we have isolated the complexes glutathione S-transferase-AHSP.alpha-Hb and AHSP.alpha-Hb. The latter assembles as a heterodimer based on size-exclusion chromatography. These complexes exhibited monophasic CO binding kinetics, as observed for isolated alpha- and beta-subunits of hemoglobin. However, the rate of CO (or oxygen) binding to alpha-hemoglobin bound to its chaperone is three times slower than that observed for isolated alpha-hemoglobin, demonstrating a form that is intermediate to the R- and T-hemoglobin states. The physiologically relevant replacement of the chaperone by beta-hemoglobin chains could be detected by both ligand binding kinetics and tryptophan fluorescence quenching.	INSERM, U473, F-94276 Le Kremlin Bicetre, France; Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Marden, MC (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	marden@kb.inserm.fr	Vasseur, Corinne/AAV-1384-2021; Marden, Michael/AAA-5923-2020; BAUDIN-CREUZA, Véronique/K-7309-2017; Marden, Michael C/G-3139-2012	Vasseur, Corinne/0000-0002-4422-7069; BAUDIN-CREUZA, Véronique/0000-0003-1032-3236; Marden, Michael C/0000-0002-5254-6385				Abruzzi KC, 2002, MOL CELL BIOL, V22, P138, DOI 10.1128/MCB.22.1.138-147.2002; ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; Baudin-Creuza V, 2002, PROTEIN SCI, V11, P129, DOI 10.1110/ps.ps.35702; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; Bucci E, 1981, Methods Enzymol, V76, P97; dos Santos CO, 2004, EXP HEMATOL, V32, P157, DOI 10.1016/j.exphem.2003.11.002; FORSTER T, 1959, DISCUSS FARADAY SOC, P7; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GERACI G, 1969, J BIOL CHEM, V244, P4664; Guasch A, 2002, J MOL BIOL, V318, P1139, DOI 10.1016/S0022-2836(02)00185-7; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Manning LR, 1996, PROTEIN SCI, V5, P775; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; Mueser TC, 2000, BIOCHEMISTRY-US, V39, P15353, DOI 10.1021/bi0012944; Shikama K, 2003, EUR J BIOCHEM, V270, P4041, DOI 10.1046/j.1432-1033.2003.03791.x; Thein SL, 2000, DISORDERS HEMOGLOBIN, P342; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5	18	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36530	36533		10.1074/jbc.M405389200	http://dx.doi.org/10.1074/jbc.M405389200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220346	hybrid			2022-12-25	WOS:000223453600047
J	Boxrud, PD; Bock, PE				Boxrud, PD; Bock, PE			Coupling of conformational and proteolytic activation in the kinetic mechanism of plasminogen activation by streptokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE-CATALYZED ACTIVATION; EQUIMOLAR COMPLEXES; ACID; DOMAIN; SITE; EFFECTORS; ZYMOGEN; BINDING	Binding of streptokinase (SK) to plasminogen (Pg) induces conformational activation of the zymogen and initiates its proteolytic conversion to plasmin (Pm). The mechanism of coupling between conformational activation and Pm formation was investigated in kinetic studies. Parabolic time courses of Pg activation by SK monitored by chromogenic substrate hydrolysis had initial rates (upsilon(1)) representing conformational activation and subsequent rates of activity increase (upsilon(2)) corresponding to the rate of Pm generation determined by a specific discontinuous assay. The upsilon(2) dependence on SK concentration for [Lys]Pg showed a maximum rate at a Pg to SK ratio of similar to2:1, with inhibition at high SK concentrations. [Glu]Pg and [Lys]Pg activation showed similar kinetic behavior but much slower activation of [Glu]Pg, due to an similar to12-fold lower affinity for SK and an similar to20-fold lower k(cat)/K-m. Blocking lysine-binding sites on Pg inhibited SK.Pg* cleavage of [Lys]Pg to a rate comparable with that of [Glu]Pg, whereas [Glu]Pg activation was not significantly affected. The results support a kinetic mechanism in which SK activates Pg conformationally by rapid equilibrium formation of the SK.Pg* complex, followed by intermolecular cleavage of Pg to Pm by SK.Pg* and subsequent cleavage of Pg by SK.Pm. A unified model of SK-induced Pg activation suggests that generation of initial Pm by SK.Pg* acts as a self-limiting triggering mechanism to initiate production of one SK equivalent of SK.Pm, which then converts the remaining free Pg to Pm.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010082, R01HL056181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 10082, HL 56181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; CHIBBER BAK, 1986, J BIOL CHEM, V261, P5289; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HORREVOETS AJG, 1995, J BIOL CHEM, V270, P15770, DOI 10.1074/jbc.270.26.15770; KOSOW DP, 1975, BIOCHEMISTRY-US, V14, P4459, DOI 10.1021/bi00691a018; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; URANO T, 1987, J BIOL CHEM, V262, P15959; URANO T, 1987, P NATL ACAD SCI USA, V84, P4031, DOI 10.1073/pnas.84.12.4031; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WOHL RC, 1978, J BIOL CHEM, V253, P1402; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	32	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36642	36649		10.1074/jbc.M405265200	http://dx.doi.org/10.1074/jbc.M405265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215239	hybrid			2022-12-25	WOS:000223453600063
J	Cervantes, S; Saura, CA; Pomares, E; Gonzalez-Duarte, R; Marfany, G				Cervantes, S; Saura, CA; Pomares, E; Gonzalez-Duarte, R; Marfany, G			Functional implications of the presenilin dimerization - Reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-PROTEIN; INTRAMEMBRANE CLEAVAGE; TERMINAL FRAGMENTS; COMPLEX-FORMATION; SPLIT-UBIQUITIN; IN-VIVO; APP; NOTCH	Presenilins are the catalytic components of gamma-secretase, an intramembrane-cleaving protease whose substrates include beta-amyloid precursor protein (betaAPP) and the Notch receptors. These type I transmembrane proteins undergo two distinct presenilin-dependent cleavages within the transmembrane region, which result in the production of Abeta and APP intracellular domain (from betaAPP) and the Notch intracellular domain signaling peptide. Most cases of familial Alzheimer's disease are caused by presenilin mutations, which are scattered throughout the coding sequence. Although the underlying molecular mechanism is not yet known, the familial Alzheimer's disease mutations produce a shift in the ratio of the long and short forms of the Abeta peptide generated by the gamma-secretase. We and others have previously shown that presenilin homodimerizes and suggested that a presenilin dimer is at the catalytic core of gamma-secretase. Here, we demonstrate that presenilin transmembrane domains contribute to the formation of the dimer. In-frame substitution of the hydrophilic loop 1, located between transmembranes I and II, which modulates the interactions within the N-terminal fragment/N-terminal fragment dimer, abolishes both presenilinase and gamma-secretase activities. In addition, by reconstituting gamma-secretase activity from two catalytically inactive presenilin aspartic mutants, we provide evidence of an active diaspartyl group assembled at the interface between two presenilin monomers. Under our conditions, this catalytic group mediates the generation of APP intracellular domain and Abeta but not Notch intracellular domain, therefore suggesting that specific diaspartyl groups within the presenilin catalytic core of gamma-secretase mediate the cleavage of different substrates.	Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	University of Barcelona; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Marfany, G (corresponding author), Univ Barcelona, Fac Biol, Dept Genet, Avda Diagonal 645, E-08028 Barcelona, Spain.	gmarfany@ub.edu	Saura, Carlos A/AFM-9239-2022; Marfany, Gemma/I-5668-2015; Saura, Carlos A/D-2727-2011	Marfany, Gemma/0000-0001-7941-983X; Saura, Carlos A/0000-0003-3692-5657; Pomares, Esther/0000-0002-3818-3303				Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COLS N, 1993, FEBS LETT, V319, P90, DOI 10.1016/0014-5793(93)80043-T; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goo JH, 2004, DNA CELL BIOL, V23, P59, DOI 10.1089/104454904322745934; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hebert SS, 2003, FEBS LETT, V550, P30, DOI 10.1016/S0014-5793(03)00813-5; Hebert SS, 2003, BIOCHEM BIOPH RES CO, V301, P119, DOI 10.1016/S0006-291X(02)02984-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Knappenberger KS, 2004, BIOCHEMISTRY-US, V43, P6208, DOI 10.1021/bi036072v; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ramdya P, 2003, J NEUROCHEM, V87, P843, DOI 10.1046/j.1471-4159.2003.02030.x; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	71	52	52	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36519	36529		10.1074/jbc.M404832200	http://dx.doi.org/10.1074/jbc.M404832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220354	hybrid			2022-12-25	WOS:000223453600046
J	Li, YK; Ge, MT; Ciani, L; Kuriakose, G; Westover, EJ; Dura, M; Covey, DF; Freed, JH; Maxfield, FR; Lytton, J; Tabas, I				Li, YK; Ge, MT; Ciani, L; Kuriakose, G; Westover, EJ; Dura, M; Covey, DF; Freed, JH; Maxfield, FR; Lytton, J; Tabas, I			Enrichment of endoplasmic reticulum with cholesterol inhibits sarcoplasmic-endoplasmic reticulum calcium ATPase-2b activity in parallel with increased order of membrane lipids - Implications for depletion of endoplasmic reticulum calcium stores and apoptosis in cholesterol-loaded macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; HUMAN ATHEROSCLEROTIC PLAQUES; ELECTRON-SPIN-RESONANCE; CA-ATPASE; MICROSOMAL MEMBRANE; PROTEIN; FLUIDITY; STRESS; PHOSPHATIDYLCHOLINE; ACYLTRANSFERASE	Macrophages in advanced atherosclerotic lesions accumulate large amounts of unesterified, or "free," cholesterol (FC). FC accumulation induces macrophage apoptosis, which likely contributes to plaque destabilization. Apoptosis is triggered by the enrichment of the endoplasmic reticulum (ER) with FC, resulting in depletion of ER calcium stores, and induction of the unfolded protein response. To explain the mechanism of ER calcium depletion, we hypothesized that FC enrichment of the normally cholesterol-poor ER membrane inhibits the macrophage ER calcium pump, sarcoplasmic-endoplasmic reticulum calcium ATPase-2b (SERCA2b). FC enrichment of ER membranes to a level similar to that occuring in vivo inhibited both the ATPase activity and calcium sequestration function of SERCA2b. Enrichment of ER with ent-cholesterol or 14:0-18:0 phosphatidylcholine, which possess the membrane-ordering properties of cholesterol, also inhibited SERCA2b. Moreover, at various levels of FC enrichment of ER membranes, there was a very close correlation between increasing membrane lipid order, as monitored by 16-doxyl-phosphatidycholine electron spin resonance, and SERCA2b inhibition. In view of these data, we speculate that SERCA2b, a conformationally active protein with 11 membrane-spanning regions, loses function due to decreased conformational freedom in FC-ordered membranes. This biophysical model may underlie the critical connection between excess cholesterol, unfolded protein response induction, macrophage death, and plaque destabilization in advanced atherosclerosis.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ, Ctr Mol Cardiol, New York, NY 10032 USA; Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14853 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Columbia University; Columbia University; Columbia University; Columbia University; Cornell University; Washington University (WUSTL); Cornell University; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; Lytton, Jonathan/0000-0003-4770-2512	NCRR NIH HHS [RR 016292] Funding Source: Medline; NHLBI NIH HHS [HL 75662, HL 57560, HL 54591] Funding Source: Medline; NIGMS NIH HHS [GM 47969, GM 25862] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR016292] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, R01HL057560, R01HL075662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025862, P01GM047969] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113; BURK SE, 1989, J BIOL CHEM, V264, P18561; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; CASTUMA CE, 1991, BIOCHEMISTRY-US, V30, P9492, DOI 10.1021/bi00103a015; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHAUTAN M, 1990, CHEM PHYS LIPIDS, V54, P25, DOI 10.1016/0009-3084(90)90056-W; CHENG KH, 1986, J BIOL CHEM, V261, P5081; DAVIS PJ, 1987, P NATL ACAD SCI USA, V84, P118, DOI 10.1073/pnas.84.1.118; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Dolis D, 1996, J BIOL CHEM, V271, P11879, DOI 10.1074/jbc.271.20.11879; East JM, 2000, MOL MEMBR BIOL, V17, P189, DOI 10.1080/09687680010009646; FAJER P, 1992, BIOPHYS J, V61, P879, DOI 10.1016/S0006-3495(92)81895-7; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hunter GW, 1999, BIOCHEMISTRY-US, V38, P1356, DOI 10.1021/bi9822224; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JOHANNSSON A, 1981, BIOCHEM J, V196, P505, DOI 10.1042/bj1960505; KIMELBERG HK, 1978, CRYOBIOLOGY, V15, P222, DOI 10.1016/0011-2240(78)90028-7; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MADDEN TD, 1979, NATURE, V279, P538, DOI 10.1038/279538a0; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nilsson IM, 2001, J BIOL CHEM, V276, P41748, DOI 10.1074/jbc.M105823200; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; RAPP JH, 1983, J LIPID RES, V24, P1329; Rodriguez A, 1999, ARTERIOSCL THROM VAS, V19, P2199, DOI 10.1161/01.ATV.19.9.2199; Rog T, 2003, BIOPHYS J, V84, P1818, DOI 10.1016/S0006-3495(03)74989-3; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHNEIDER DJ, 1989, SPIN LABEL THEORY AP; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SQUIER TC, 1988, J BIOL CHEM, V263, P9178; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Westover EJ, 2003, J BIOL CHEM, V278, P51125, DOI 10.1074/jbc.M304332200; Whiting KP, 2000, LIFE SCI, V67, P743, DOI 10.1016/S0024-3205(00)00669-X; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Zhang Y, 2003, J BIOL CHEM, V278, P11642, DOI 10.1074/jbc.M211559200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	63	222	230	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37030	37039		10.1074/jbc.M405195200	http://dx.doi.org/10.1074/jbc.M405195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215242	hybrid			2022-12-25	WOS:000223453600106
J	Muhlenhoff, U; Balk, J; Richhardt, N; Kaiser, JT; Sipos, K; Kispal, G; Lill, R				Muhlenhoff, U; Balk, J; Richhardt, N; Kaiser, JT; Sipos, K; Kispal, G; Lill, R			Functional characterization of the eukaryotic cysteine desulfurase Nfs1p from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ENTERICA SEROVAR TYPHIMURIUM; CYTOSOLIC FE/S PROTEINS; THIOLATED NUCLEOSIDES PRESENT; NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; TRANSFER-RNA; AZOTOBACTER-VINELANDII; MOLYBDENUM-COFACTOR; CRYSTAL-STRUCTURE	Previous studies have indicated that the essential protein Nfs1 performs a crucial role in cellular iron-sulfur (Fe/S) protein maturation. The protein is located predominantly in mitochondria, yet low amounts are present in cytosol and nucleus. Here we examined several aspects concerning the molecular function of yeast Nfs1p as a model protein. First, we demonstrated that purified Nfs1p facilitates the in vitro assembly of Fe/S proteins by using cysteine as its specific substrate. Thus, eukaryotic Nfs1 is a functional orthologue of the bacterial cysteine desulfurase IscS. Second, we showed that only the mitochondrial version but not the extramitochondrial version of Nfs1p is functional in generating cytosolic and nuclear Fe/S proteins. Mutation of the nuclear targeting signal of Nfs1p did not affect the maturation of cytosolic and nuclear Fe/S proteins, despite a severe growth defect under this condition. Nfs1p could not assemble an Fe/S cluster on the Isu scaffold proteins when they were located in the yeast cytosol. The lack of function of these central Fe/S cluster assembly components suggests that the maturation of extramitochondrial Fe/S protein does not involve functional copies of the mitochondrial Fe/S cluster assembly machinery in the yeast cytosol. Third, the extramitochondrial version of Nfs1p was shown to play a direct role in the thio-modification of tRNAs. Finally, we identified a highly conserved N-terminal beta-sheet of Nfs1p as a functionally essential part of the protein. The implication of these findings for the structural stability of Nfs1p and for its targeting mechanism to mitochondria and cytosol/nucleus will be discussed.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; CALTECH, Pasadena, CA 91125 USA; Univ Pecs, Fac Med, Inst Biochem, H-7624 Pecs, Hungary	Philipps University Marburg; California Institute of Technology; University of Pecs	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de	Sipos, Katalin/B-5242-2015	Sipos, Katalin/0000-0002-6706-2682; Lill, Roland/0000-0002-8345-6518				Balk J, 2004, EMBO J, V23, P2105, DOI 10.1038/sj.emboj.7600216; BALK J, 2004, IN PRESS CHEMBIOCHEM, V5; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Floss B, 1997, PHOTOSYNTH RES, V54, P63, DOI 10.1023/A:1005823620291; Frazzon J, 2002, MET IONS BIOL SYST, V39, P163; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARLOW E, 1998, USING ANTIBODIES LAB; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1999, AM J HUM GENET, V64, P365, DOI 10.1086/302270; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leibrecht I, 1997, J BIOL CHEM, V272, P10442; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Matthies A, 2004, P NATL ACAD SCI USA, V101, P5946, DOI 10.1073/pnas.0308191101; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V871, P243, DOI 10.1016/0167-4838(86)90205-0; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Nett JH, 2001, EUR J BIOCHEM, V268, P5209, DOI 10.1046/j.0014-2956.2001.02454.x; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Roy A, 2003, EMBO J, V22, P4826, DOI 10.1093/emboj/cdg455; Sambrook J, 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wang T, 2004, J BACTERIOL, V186, P956, DOI 10.1128/JB.186.4.956-967.2004; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	67	106	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36906	36915		10.1074/jbc.M406516200	http://dx.doi.org/10.1074/jbc.M406516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220327	Green Accepted, hybrid			2022-12-25	WOS:000223453600093
J	Saffran, WA; Ahmed, S; Bellevue, S; Pereira, G; Patrick, T; Sanchez, W; Thomas, S; Alberti, M; Hearst, JE				Saffran, WA; Ahmed, S; Bellevue, S; Pereira, G; Patrick, T; Sanchez, W; Thomas, S; Alberti, M; Hearst, JE			DNA repair defects channel interstrand DNA cross-links into alternate recombinational and error-prone repair pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; 8-METHOXYPSORALEN PLUS; YEAST DNA; POSTREPLICATION REPAIR; PSORALEN; GENE; MUTATIONS; REMOVAL	The repair of psoralen interstrand cross-links in the yeast Saccharomyces cerevisiae involves the DNA repair groups nucleotide excision repair (NER), homologous recombination (HR), and post-replication repair (PRR). In repair-proficient yeast cells cross-links induce double-strand breaks, in an NER-dependent process; the double-strand breaks are then repaired by HR. An alternate error-prone repair pathway generates mutations at cross-link sites. We have characterized the repair of plasmid molecules carrying a single psoralen cross-link, psoralen monoadduct, or double-strand break in yeast cells with deficiencies in NER, HR, or PRR genes, measuring the repair efficiencies and the levels of gene conversions, crossing over, and mutations. Strains with deficiencies in the NER genes RAD1, RAD3, RAD4, and RAD10 had low levels of cross-link-induced recombination but higher mutation frequencies than repair-proficient cells. Deletion of the HR genes RAD51, RAD52, RAD54, RAD55, and RAD57 also decreased induced recombination and increased mutation frequencies above those of NER-deficient yeast. Strains lacking the PRR genes RAD5, RAD6, and RAD18 did not have any cross-link-induced mutations but showed increased levels of recombination; rad5 and rad6 cells also had altered patterns of cross-link-induced gene conversion in comparison with repair-proficient yeast. Our observations suggest that psoralen cross-links can be repaired by three pathways: an error-free recombinational pathway requiring NER and HR and two PRR-dependent error-prone pathways, one NER-dependent and one NER-independent.	CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Berkeley, CA 94720 USA	City University of New York (CUNY) System; Queens College NY (CUNY); University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Saffran, WA (corresponding author), CUNY Queens Coll, Dept Chem & Biochem, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	Wilma_Saffran@qc.edu						Ahne F, 1997, NUCLEIC ACIDS RES, V25, P743, DOI 10.1093/nar/25.4.743; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; AVERBECK D, 1992, J PHOTOCH PHOTOBIO B, V14, P47, DOI 10.1016/1011-1344(92)85082-6; AVERBECK D, 1975, BIOCHIM BIOPHYS ACTA, V395, P393, DOI 10.1016/0005-2787(75)90063-5; Averbeck D, 1998, PHOTOCHEM PHOTOBIOL, V68, P289, DOI 10.1111/j.1751-1097.1998.tb09683.x; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Barbour L, 2003, MUTAT RES-FUND MOL M, V532, P137, DOI 10.1016/j.mrfmmm.2003.08.014; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Barre FX, 1999, NUCLEIC ACIDS RES, V27, P743, DOI 10.1093/nar/27.3.743; Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; Bessho T, 2003, J BIOL CHEM, V278, P5250, DOI 10.1074/jbc.M212323200; CASSIER C, 1985, PHOTOCHEM PHOTOBIOL, V41, P289, DOI 10.1111/j.1751-1097.1985.tb03487.x; CASSIER C, 1984, PHOTOCHEM PHOTOBIOL, V39, P799, DOI 10.1111/j.1751-1097.1984.tb08862.x; CHIOU CC, 1995, CARCINOGENESIS, V16, P1357, DOI 10.1093/carcin/16.6.1357; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; Dardalhon M, 1998, CURR GENET, V34, P30; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Fan HY, 1996, GENETICS, V142, P749; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HENRIQUES JAP, 1980, PHOTOCHEM PHOTOBIOL, V31, P557, DOI 10.1111/j.1751-1097.1980.tb03746.x; HENRIQUES JAP, 1981, J BACTERIOL, V148, P248, DOI 10.1128/JB.148.1.248-256.1981; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; HOY CA, 1985, CANCER RES, V45, P1737; ISLAS AL, 1994, BIOCHEMISTRY-US, V33, P10794, DOI 10.1021/bi00201a029; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Kiakos K, 2002, J BIOL CHEM, V277, P44576, DOI 10.1074/jbc.M208169200; LUI N, 1998, MOL CELL, V1, P783; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MENIEL V, 1995, MUTAGENESIS, V10, P543, DOI 10.1093/mutage/10.6.543; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; PAPADOPOULO D, 1993, MUTAT RES, V294, P167, DOI 10.1016/0921-8777(93)90025-C; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; SAGE E, 1993, EMBO J, V12, P397, DOI 10.1002/j.1460-2075.1993.tb05671.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; TESSMAN JW, 1985, BIOCHEMISTRY-US, V24, P1669, DOI 10.1021/bi00328a015; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Xiao W, 2000, GENETICS, V155, P1633; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	58	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36462	36469		10.1074/jbc.M402323200	http://dx.doi.org/10.1074/jbc.M402323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15213235	hybrid, Green Submitted			2022-12-25	WOS:000223453600039
J	Spencer, ML; Theodosiou, M; Noonan, DJ				Spencer, ML; Theodosiou, M; Noonan, DJ			NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; RETINOIC ACID; CELL-CYCLE; FAMILY PROTEINS; UBIQUITIN; EXPRESSION; E2F; DIFFERENTIATION; PHOSPHORYLATION; PROTEOLYSIS	Neural proliferation and differentiation control protein-1 (NPDC-1) is a protein expressed primarily in brain and lung and whose expression can be correlated with the regulation of cellular proliferation and differentiation. Embryonic differentiation in brain and lung has classically been linked to retinoid signaling, and we have recently characterized NPDC-1 as a regulator of retinoic acid-mediated events. Regulators of differentiation and development are themselves highly regulated and usually through multiple mechanisms. One such mechanism, protein degradation via the ubiquitin/proteasome degradation pathway, has been linked to the expression of a number of proteins involved in control of proliferation or differentiation, including cyclin D1 and E2F-1. The data presented here demonstrate that NPDC-1 is likewise degraded by the ubiquitin/proteasome system. MG-132, a proteasome inhibitor, stabilized the expression of NPDC-1 and allowed detection of ubiquitinated NPDC-1 in vivo. A PEST motif (rich in proline, glutamine, serine, and threonine) located in the carboxyl terminus of NPDC-1 was shown to target the protein for degradation. Deletion of the PEST motif increased NPDC-1 protein stability and NPDC-1 inhibitory effect on retinoic acid-mediated transcription. NPDC-1 was phosphorylated by several kinases, including extracellular signal-regulated kinase. Phosphorylation of NPDC-1 increased the in vitro rate of NPDC-1 ubiquitination. The MEK inhibitor, PD-98059, an inhibitor of extracellular signal-regulated activation, also inhibited the formation of ubiquitinated NPDC-1 in vivo. Together these results suggest that retinoic acid signaling can be modulated by the presence of NPDC-1 and that the protein level and activity of NPDC-1 can be regulated by phosphorylation-mediated proteasomal degradation.	Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Noonan, DJ (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dnoonan@uky.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067321] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67321] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Belz T, 2002, METHODS, V26, P233, DOI 10.1016/S1046-2023(02)00027-0; BRASIER AR, 1992, METHOD ENZYMOL, V216, P386; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Clarke DJ, 2002, CELL CYCLE, V1, P231, DOI 10.4161/cc.1.4.129; Cosgaya JM, 2001, J NEUROCHEM, V76, P661, DOI 10.1046/j.1471-4159.2001.00078.x; DALESSIO J, 1992, J CLIN MICROBIOL, V30, P1005, DOI 10.1128/JCM.30.4.1005-1007.1992; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Dupont E, 1998, J NEUROSCI RES, V51, P257, DOI 10.1002/(SICI)1097-4547(19980115)51:2<257::AID-JNR14>3.0.CO;2-5; GALIANA E, 1995, P NATL ACAD SCI USA, V92, P1560, DOI 10.1073/pnas.92.5.1560; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HENRY IK, 2003, NUCL RECEPT, V1, P1; HENRY K, 2000, THESIS U KENTUCKY LE, P235; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Imai N, 2003, J VIROL, V77, P923, DOI 10.1128/JVI.77.2.923-930.2003; Kaelin WG, 2003, CANCER BIOL THER, V2, pS48; KISTLER A, 1981, TERATOLOGY, V23, P25, DOI 10.1002/tera.1420230106; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LEE YM, 1995, DEVELOPMENT, V121, P825; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Malpel S, 2000, DEVELOPMENT, V127, P3057; Mercado-Pimentel ME, 2002, PROTEIN EXPRES PURIF, V26, P260, DOI 10.1016/S1046-5928(02)00524-7; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Qu XH, 2001, GENE, V264, P37, DOI 10.1016/S0378-1119(01)00324-9; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Sansal I, 2000, ONCOGENE, V19, P5000, DOI 10.1038/sj.onc.1203843; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Suzui M, 2002, CANCER RES, V62, P3997; Tanaka K, 1998, MOL CELLS, V8, P503; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670; Yen A, 2000, IN VITRO CELL DEV-AN, V36, P249	49	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37069	37078		10.1074/jbc.M402507200	http://dx.doi.org/10.1074/jbc.M402507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15229225	hybrid			2022-12-25	WOS:000223453600110
J	Botta, R; Gao, E; Stassi, G; Bonci, D; Pelosi, E; Zwas, D; Patti, M; Colonna, L; Baiocchi, M; Coppola, S; Ma, X; Condorelli, G; Peschle, C				Botta, R; Gao, E; Stassi, G; Bonci, D; Pelosi, E; Zwas, D; Patti, M; Colonna, L; Baiocchi, M; Coppola, S; Ma, X; Condorelli, G; Peschle, C			Heart infarct in NOD-SCID mice: Therapeutic vasculogenesis by transplantation of human CD34(+) cells and low dose CD34(+)KDR(+) cells	FASEB JOURNAL			English	Article						neoangiogenesis; endothelial precursors; hematopoietic stem cells	ENDOTHELIAL PROGENITOR CELLS; MYOCARDIAL-ISCHEMIA; CARDIAC-MUSCLE; STEM-CELLS; NEOVASCULARIZATION; CARDIOMYOCYTES; VIVO; ANGIOGENESIS; REGENERATION; ANGIOBLASTS	Hematopoietic ( Hem) and endothelial ( End) lineages derive from a common progenitor cell, the hemangioblast: specifically, the human cord blood (CB) CD34(+)KDR(+) cell fraction comprises primitive Hem and End cells, as well as hemangioblasts. In humans, the potential therapeutic role of Hem and End progenitors in ischemic heart disease is subject to intense investigation. Particularly, the contribution of these cells to angiogenesis and cardiomyogenesis in myocardial ischemia is not well established. In our studies, we induced myocardial infarct (MI) in the immunocompromised NOD-SCID mouse model, and monitored the effects of myocardial transplantation of human CB CD34(+) cells on cardiac function. Specifically, we compared the therapeutic effect of unseparated CD34(+) cells vs. PBS and mononuclear cells (MNCs); moreover, we compared the action of the CD34(+) KDR+ cell subfraction vs. the CD34(+) KDR- subset. CD34(+) cells significantly improve cardiac function after MI, as compared with PBS/MNCs. Similar beneficial actions were obtained using a 2-log lower number of CD34(+)KDR(+) cells, while the same number of CD34(+)KDR(-) cells did not have any effects. The beneficial effect of CD34(+)KDR(+) cells may mostly be ascribed to their notable resistance to apoptosis and to their angiogenic action, since cardiomyogenesis was limited. Altogether, our results indicate that, within the CD34(+) cell population, the CD34(+)KDR(+) fraction is responsible for the improvement in cardiac hemodynamics and hence represents the candidate active CD34(+) cell subset.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Thomas Jefferson Univ, Dept Med, Ctr Translat Med, Philadelphia, PA 19107 USA; Univ Palermo, Dept Surg & Oncol Sci, I-90133 Palermo, Italy; Thomas Jefferson Univ, Dept Med, Div Cardiol, Philadelphia, PA 19107 USA; Mol Cardiol Lab, I-00128 Rome, Italy; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA	Jefferson University; Istituto Superiore di Sanita (ISS); Jefferson University; University of Palermo; Jefferson University; University of California System; University of California San Diego	Peschle, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,Room 609-233,S 10th St, Philadelphia, PA 19107 USA.	cesare.peschle@mail.jci.tju.edu	Bonci, Desiree/K-6488-2016; Condorelli, Gerolama/AAC-3472-2022; pelosi, elvira/J-7298-2016; Stassi, Giorgio/AAC-1175-2022; Coppola, Simona/A-6638-2015; Condorelli, Gianluigi/Q-6736-2017	Bonci, Desiree/0000-0002-2472-5140; Condorelli, Gerolama/0000-0003-0177-8829; pelosi, elvira/0000-0002-3043-6249; Coppola, Simona/0000-0001-7851-9409; Baiocchi, Marta/0000-0003-0976-0690; Condorelli, Gianluigi/0000-0003-0481-6843	NHLBI NIH HHS [1R01HL6368] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P9977, DOI 10.1073/pnas.161120198; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; ONDORELLI GL, 1999, CIRCULATION, V23, P3071; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pelosi E, 2002, BLOOD, V100, P3203, DOI 10.1182/blood-2002-05-1511; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tsuda T, 2003, CARDIOVASC RES, V59, P926, DOI 10.1016/S0008-6363(03)00519-4; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	26	83	89	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1392	+		10.1096/fj.03-0879fje	http://dx.doi.org/10.1096/fj.03-0879fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231728				2022-12-25	WOS:000222979200030
J	Jurgensen, JS; Rosenberger, C; Wiesener, MS; Warnecke, C; Horstrup, JH; Grafe, M; Philipp, S; Griethe, W; Maxwell, PH; Frei, U; Bachmann, S; Willenbrock, R; Eckardt, KU				Jurgensen, JS; Rosenberger, C; Wiesener, MS; Warnecke, C; Horstrup, JH; Grafe, M; Philipp, S; Griethe, W; Maxwell, PH; Frei, U; Bachmann, S; Willenbrock, R; Eckardt, KU			Persistent induction of HIF-1 alpha and -2 alpha in cardiomyocytes and stromal cells of ischemic myocardium	FASEB JOURNAL			English	Article						hypoxia; ischemia; infarction; endothelium; macrophages	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; HEME OXYGENASE-1 PROTECTS; NITRIC-OXIDE SYNTHASE; PAS DOMAIN PROTEIN-1; INFARCTION MODEL; EARLY EXPRESSION; FACTOR 1-ALPHA; HEART-FAILURE; FACTOR-ALPHA; HIF-ALPHA	Hypoxia-inducible factor (HIF)-1alpha and -2alpha are key regulators of the transcriptional response to hypoxia and pivotal in mediating the consequences of many disease states. In the present work, we define their temporo-spatial accumulation after myocardial infarction and systemic hypoxia. Rats were exposed to hypoxia or underwent coronary artery ligation. Immunohistochemistry was used for detection of HIF-1alpha and - 2alpha proteins and target genes, and mRNA levels were determined by RNase protection. Marked nuclear accumulation of HIF-1alpha and - 2alpha occurred after both systemic hypoxia and coronary ligation in cardiomyocytes as well as interstitial and endothelial cells (EC) without pronounced changes in HIF mRNA levels. While systemic hypoxia led to widespread induction of HIF, expression after coronary occlusion occurred primarily at the border of infarcted tissue. This expression persisted for 4 wk, included infiltrating macrophages, and colocalized with target gene expression. Subsets of cells simultaneously expressed both HIF-alpha subunits, but EC more frequently induced HIF-2alpha. A progressive increase of HIF-2alpha but not HIF-1alpha occurred in areas remote from the infarct, including the interventricular septum. Cardiomyocytes and cardiac stromal cells exhibit a marked potential for a prolonged transcriptional response to ischemia mediated by HIF. The induction of HIF-1alpha and - 2alpha appears to be complementary rather than solely redundant.	Humboldt Univ, Charite, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany; Humboldt Univ, Charite, Dept Cardiol, D-13353 Berlin, Germany; Humboldt Univ, Charite, Inst Anat, D-13353 Berlin, Germany; German Heart Ctr, Berlin, Germany; Univ London Imperial Coll Sci Technol & Med, Renal Sect, London, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; Imperial College London	Eckardt, KU (corresponding author), Humboldt Univ, Charite, Dept Nephrol & Med Intens Care, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	kai-uwe.eckardt@charite.de	Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679				Bing RJ, 2001, CARDIOVASC RES, V51, P13, DOI 10.1016/S0008-6363(01)00250-4; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burke B, 2002, J PATHOL, V196, P204, DOI 10.1002/path.1029; Choi AMK, 2001, CIRC RES, V89, P105, DOI 10.1161/res.89.2.105; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GRAFE M, 1994, AM J PHYSIOL-HEART C, V267, pH2138, DOI 10.1152/ajpheart.1994.267.6.H2138; Heba G, 2001, J VASC RES, V38, P288, DOI 10.1159/000051057; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kakinuma Y, 2001, CIRCULATION, V103, P2387; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee RJ, 2000, CIRCULATION, V102, P898; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Moldovan NI, 2000, CIRC RES, V87, P378; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; Semenza GL, 2000, GENE DEV, V14, P1983; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Takeuchi K, 1998, CIRCULATION, V98, pII234; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Vargas SO, 1999, MODERN PATHOL, V12, P635; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Willam C, 2000, CIRC RES, V87, P370; Williams RS, 2000, J CLIN INVEST, V106, P813, DOI 10.1172/JCI11205; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yue P, 1998, J MOL CELL CARDIOL, V30, P1615, DOI 10.1006/jmcc.1998.0727; Zhong H, 2000, CANCER RES, V60, P1541; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	48	99	102	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1415	+		10.1096/fj.04-1605fje	http://dx.doi.org/10.1096/fj.04-1605fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247145				2022-12-25	WOS:000222979200007
J	Ursitti, JA; Lee, PC; Resneck, WG; McNally, MM; Bowman, AL; O'Neill, A; Stone, MR; Bloch, RJ				Ursitti, JA; Lee, PC; Resneck, WG; McNally, MM; Bowman, AL; O'Neill, A; Stone, MR; Bloch, RJ			Cloning and characterization of cytokeratins 8 and 19 in adult rat striated muscle - Interaction with the dystrophin glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEIN; SKELETAL-MUSCLE; MEMBRANE SKELETON; BETA-SPECTRIN; MOLECULAR CHARACTERISTICS; ALPHA-DYSTROBREVIN; LACKING DESMIN; SARCOLEMMA; EXPRESSION; VINCULIN	We used degenerate primers for the amino- and carboxyl-terminal ends of the rod domains of intermediate filament proteins in reverse transcriptase-PCR experiments to identify and clone cytokeratins 8 and 19 (K8 and K19) from cardiac muscle of the adult rat. Northern blots showed that K8 has a 2.2-kb transcript and K19 has a 1.9-kb transcript in both adult cardiac and skeletal muscles. Immunolocalization of the cytokeratins in adult cardiac muscle with isoform-specific antibodies for K8 and K19 showed labeling at Z-lines within the muscle fibers and at Z-line and M-line domains at costameres at the sarcolemmal membrane. Dystrophin and K19 could be co-immunoprecipitated and co-purified from extracts of cardiac muscle, suggesting a link between the cytokeratins and the dystrophin-based cytoskeleton at the sarcolemma. Furthermore, transfection experiments indicate that K8 and K19 may associate with dystrophin through a specific interaction with its actin-binding domain. Consistent with this observation, the cytokeratins are disrupted at the sarcolemmal membrane of skeletal muscle of the mdx mouse that lacks dystrophin. Together these results indicate that at least two cytokeratins are expressed in adult striated muscle, where they may contribute to the organization of both the myoplasm and sarcolemma.	Univ Maryland, Sch Med, Maryland Biotechnol Inst, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Ursitti, JA (corresponding author), Univ Maryland, Sch Med, Maryland Biotechnol Inst, Baltimore, MD 21201 USA.	jursitti@umaryland.edu						Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bloch RJ, 2002, CLIN ORTHOP RELAT R, pS203, DOI 10.1097/01.blo.0000031982.92980.da; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; Dubell WH, 2002, AM J PHYSIOL-HEART C, V282, pH38, DOI 10.1152/ajpheart.00536.2001; Ehmer S, 1997, ACTA NEUROPATHOL, V94, P240, DOI 10.1007/s004010050699; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; Hijikata T, 2003, HISTOCHEM CELL BIOL, V119, P109, DOI 10.1007/s00418-003-0496-5; ISHIKAWA H, 1968, J CELL BIOL, V38, P538, DOI 10.1083/jcb.38.3.538; KACHINSKY AM, 1994, DEV BIOL, V165, P216, DOI 10.1006/dbio.1994.1248; Kirfel J, 2003, CELL MOL LIFE SCI, V60, P56, DOI 10.1007/s000180300004; KOSMEHL H, 1990, ANAT ANZEIGER, V171, P39; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGBEIN L, 1989, EXP PATHOL-JENA, V36, P23, DOI 10.1016/S0232-1513(89)80107-0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; Macioce P, 1999, EXP CELL RES, V250, P142, DOI 10.1006/excr.1999.4479; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; NELSON WJ, 1983, P NATL ACAD SCI-BIOL, V80, P363, DOI 10.1073/pnas.80.2.363; NELSON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3292, DOI 10.1073/pnas.81.11.3292; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; O'Neill A, 2002, MOL BIOL CELL, V13, P2347, DOI 10.1091/mbc.01-12-0576; Orlova A, 2001, BIOPHYS J, V80, P1926, DOI 10.1016/S0006-3495(01)76162-0; OSBORN M, 1980, EXP CELL RES, V125, P37, DOI 10.1016/0014-4827(80)90186-X; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; PIEROBONBORMIOLI S, 1981, J MUSCLE RES CELL M, V2, P401, DOI 10.1007/BF00711967; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; SAM S, 2002, AM J PHYSIOL-CELL PH, V279, pC1116; SHEAR CR, 1985, J CELL BIOL, V101, P240, DOI 10.1083/jcb.101.1.240; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; Sutherland-Smith AJ, 2003, J MOL BIOL, V329, P15, DOI 10.1016/S0022-2836(03)00422-4; Ursitti JA, 2001, MOL BIOL CELL, V12, p40A; Williams MW, 1999, J CELL BIOL, V144, P1259, DOI 10.1083/jcb.144.6.1259; Williams MW, 2001, J CELL SCI, V114, P751; Williams MW, 2000, MUSCLE NERVE, V23, P590, DOI 10.1002/(SICI)1097-4598(200004)23:4<590::AID-MUS19>3.3.CO;2-Q; Zhou DX, 1998, MOL BIOL CELL, V9, P47, DOI 10.1091/mbc.9.1.47	46	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41830	41838		10.1074/jbc.M400128200	http://dx.doi.org/10.1074/jbc.M400128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247274	hybrid			2022-12-25	WOS:000224075500073
J	Schwanbeck, R; Xiao, H; Wu, C				Schwanbeck, R; Xiao, H; Wu, C			Spatial contacts and nucleosome step movements induced by the NURF chromatin remodeling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; TRANSCRIPTION FACTOR; ANGSTROM RESOLUTION; DNA TRANSLOCATION; GENE-EXPRESSION; CORE PARTICLE; IN-VIVO; ISWI; PROTEIN; DROSOPHILA	The nucleosome remodeling factor NURF is a four-subunit, ISWI-containing chromatin remodeling complex that catalyzes nucleosome sliding in an ATP-dependent fashion, thereby modulating the accessibility of the DNA. To elucidate the mechanism of nucleosome sliding, we have investigated by hydroxyl radical footprinting how NURF makes initial contact with a nucleosome positioned at one end of a DNA fragment. NURF binds to two separate locations on the nucleosome: a continuous stretch of linker DNA up to the nucleosome entry site and a region asymmetrically surrounding the nucleosome dyad within the minor grooves, close to residues of the histone H4 tail that have been implicated in the activation of ISWI activity. Kinetic analysis reveals that nucleosome sliding occurs in apparent increments or steps of 10 bp. Furthermore, single nucleoside gaps as well as nicks about two helical turns before the dyad interfere with sliding, indicating that structural stress at this region assists the relative movement of DNA. These findings support a sliding model in which the position-specific tethering of NURF forces a translocating ISWI ATPase to pump a DNA distortion over the histone octamer, thereby changing the translational position of the nucleosome.	NCI, Mol Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 6068, Bethesda, MD 20892 USA.	carlwu@helix.nih.gov	Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X	NATIONAL CANCER INSTITUTE [ZIABC005263, Z01BC005263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badenhorst P, 2002, GENE DEV, V16, P3186, DOI 10.1101/gad.1032202; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Borrmann L, 2003, NUCLEIC ACIDS RES, V31, P6841, DOI 10.1093/nar/gkg884; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Clapier CR, 2002, NUCLEIC ACIDS RES, V30, P649, DOI 10.1093/nar/30.3.649; Corona DFV, 2004, BBA-GENE STRUCT EXPR, V1677, P113, DOI 10.1016/j.bbaexp.2003.09.018; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flaus A, 2003, BIOPOLYMERS, V68, P563, DOI 10.1002/bip.10323; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Fyodorov DV, 2004, GENE DEV, V18, P170, DOI 10.1101/gad.1139604; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Kukimoto I, 2004, MOL CELL, V13, P265, DOI 10.1016/S1097-2765(03)00523-9; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Langst G, 2004, BBA-GENE STRUCT EXPR, V1677, P58, DOI 10.1016/j.bbaexp.2003.10.011; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Langst G, 2001, J CELL SCI, V114, P2561; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mellor J, 2004, BBA-GENE STRUCT EXPR, V1677, P100, DOI 10.1016/j.bbaexp.2003.10.014; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Whitehouse I, 2003, MOL CELL BIOL, V23, P1935, DOI 10.1128/MCB.23.6.1935-1945.2003; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8	56	109	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39933	39941		10.1074/jbc.M406060200	http://dx.doi.org/10.1074/jbc.M406060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262970	hybrid			2022-12-25	WOS:000223791500090
J	Tian, G; Wilcockson, D; Perry, VH; Rudd, PM; Dwek, RA; Platt, FM; Platt, N				Tian, G; Wilcockson, D; Perry, VH; Rudd, PM; Dwek, RA; Platt, FM; Platt, N			Inhibition of alpha-glucosidases I and II increases the cell surface expression of functional class A macrophage scavenger receptor (SR-A) by extending its half-life	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS ENTRY; LOW-DENSITY-LIPOPROTEIN; N-BUTYLDEOXYNOJIRIMYCIN; INTERFERON-GAMMA; MANNOSE RECEPTOR; QUALITY-CONTROL; LIGAND-BINDING; IFN-GAMMA; TYROSINASE; DOMAIN	The class A scavenger receptor (SR-A) is a multifunctional trimeric membrane glycoprotein involved in atherogenesis. The mature receptor can mediate the binding and internalization of a number of specific ligands, including modified low-density lipoprotein. We have investigated the effects of inhibiting N-glycan processing on SR-A expression, distribution, and activity in the murine macrophage cell line RAW264.7. We have found that SR-A normally interacts with calnexin in the endoplasmic reticulum and in its mature form carries complex N-glycans. The imino sugar, N-butyldeoxynojirimycin (NB-DNJ) is an inhibitor of the N-glycan processing enzymes alpha-glucosidases I and II. Following NB-DNJ treatment SR-A became Endo H-sensitive, consistent with inhibition of N-glycan processing. A dose-dependent increase in cell surface expression of SR-A was observed in response to NB-DNJ treatment. The receptor on inhibitor-treated cells was still functional because the increased surface expression resulted in a proportional enhancement in the endocytosis of the ligand, acetylated low-density lipoprotein. The expression of SR-A on NB-DNJ cultured cells was further enhanced by co-treatment with interferon-gamma. Quantitative reverse transcriptase-PCR analysis did not show a significant difference in the amount of SR-A mRNA in NB-DNJ- treated RAW264.7 cells. However, the half-life of SR-A protein was significantly increased. These data indicate the retention of glucosylated N-glycans does not result in gross misfolding and degradation of this receptor or prevent its transport to the cell surface. SR-A interacts with calnexin and when the association is prevented changes in the recycling kinetics and rate of turnover of the receptor result, leading to enhanced cell surface expression.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Xian Jiaotong Univ, Hosp 1, Dept Cardiol, Xian 710061, Peoples R China; Univ Southampton, Sch Biol Sci, Southampton Neurosci Grp, CNS Inflammat Grp, Southampton SO16 7PX, Hants, England; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford; Xi'an Jiaotong University; University of Southampton; University of Oxford	Platt, N (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.	nick.platt@anat.ox.ac.uk	Platt, Frances/G-1004-2010; Perry, V. Hugh/Y-2935-2019	Wilcockson, David/0000-0002-5923-4472; Platt, Frances/0000-0001-7614-0403				Alvarez-Dominguez C, 1998, J BIOL CHEM, V273, P33901, DOI 10.1074/jbc.273.51.33901; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; ASHKENAS J, 1993, J LIPID RES, V34, P983; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Daugherty A, 2000, J LIPID RES, V41, P1568; DOI T, 1994, J BIOL CHEM, V269, P25598; DOI T, 1993, J BIOL CHEM, V268, P2126; EMI M, 1993, J BIOL CHEM, V268, P2120; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; Fischer PB, 1996, J VIROL, V70, P7143, DOI 10.1128/JVI.70.10.7143-7152.1996; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Montaner LJ, 1999, J IMMUNOL, V162, P4606; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MORI T, 1994, LAB INVEST, V71, P409; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Platt N, 2002, INT REV CYTOL, V212, P1; SCHREIBER S, 1993, J IMMUNOL, V151, P4973; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Tsang AW, 2000, J LEUKOCYTE BIOL, V68, P487; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; Yamamoto K, 1997, FEBS LETT, V414, P182, DOI 10.1016/S0014-5793(97)01006-5	34	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39303	39309		10.1074/jbc.M405219200	http://dx.doi.org/10.1074/jbc.M405219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15234963	hybrid			2022-12-25	WOS:000223791500015
J	Wyllie, S; Cunningham, ML; Fairlamb, AH				Wyllie, S; Cunningham, ML; Fairlamb, AH			Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENITE-RESISTANT LEISHMANIA; NONSELECTIVE CATION CHANNELS; TRANSPORTER GENE PGPA; TRYPANOTHIONE REDUCTASE; VISCERAL LEISHMANIASIS; PENTAVALENT ANTIMONY; OXIDATIVE STRESS; SODIUM STIBOGLUCONATE; CRITHIDIA-FASCICULATA; GAMMA-INTERFERON	Despite extensive use of antimonial compounds in the treatment of leishmaniasis, their mode of action remains uncertain. Here we show that trivalent antimony (Sb-III) interferes with trypanothione metabolism in drug-sensitive Leishmania parasites by two inherently distinct mechanisms. First, SbIII decreases thiol buffering capacity by inducing rapid efflux of intracellular trypanothione and glutathione in approximately equimolar amounts. Second, SbIII inhibits trypanothione reductase in intact cells resulting in accumulation of the disulfide forms of trypanothione and glutathione. These two mechanisms combine to profoundly compromise the thiol redox potential in both amastigote and promastigote stages of the life cycle. Furthermore, we demonstrate that sodium stibogluconate, a pentavalent antimonial used clinically for the treatment for leishmaniasis, induces similar effects on thiol redox metabolism in axenically cultured amastigotes. These observations suggest ways in which current antimony therapies could be improved, overcoming the growing problem of antimony resistance.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Biol, Dundee DD1 5EH, Scotland; Univ London London Sch Hyg & Trop Med, Dept Med Parasitol, London WC1E 7HT, England	University of Dundee; University of London; London School of Hygiene & Tropical Medicine	Fairlamb, AH (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Biol, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Wyllie, Susan/AAI-4430-2021; Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329; Wyllie, Susan/0000-0001-8810-5605	Wellcome Trust [059056] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; BERGER BJ, 1993, PARASITOLOGY, V107, pS71; BERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916; BERMAN JD, 1987, BIOCHEM PHARMACOL, V36, P197, DOI 10.1016/0006-2952(87)90689-7; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460, DOI 10.1111/j.1432-1033.1995.tb20583.x; Denton H, 2004, BIOCHEM J, V381, P405, DOI 10.1042/BJ20040283; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; Fairlamb A.H., 1987, NATO ASI Series Series H Cell Biology, V11, P29; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Frezard F, 2001, ANTIMICROB AGENTS CH, V45, P913, DOI 10.1128/AAC.45.3.913-916.2001; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; GLASER TA, 1990, EXP PARASITOL, V71, P343, DOI 10.1016/0014-4894(90)90039-F; Goodwin LG, 1943, BIOCHEM J, V37, P198, DOI 10.1042/bj0370198; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Haimeur A, 1999, MOL MICROBIOL, V34, P726, DOI 10.1046/j.1365-2958.1999.01634.x; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; Kaye PM, 1995, ANN TROP MED PARASIT, V89, P75, DOI 10.1080/00034983.1995.11813016; KELLY JM, 1993, EUR J BIOCHEM, V218, P29, DOI 10.1111/j.1432-1033.1993.tb18348.x; Laguna F, 2003, ANN TROP MED PARASIT, V97, P135, DOI 10.1179/000349803225002606; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; Mehta A, 2004, J BIOL CHEM, V279, P11798, DOI 10.1074/jbc.M309341200; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383; Murray HW, 2000, INFECT IMMUN, V68, P288, DOI 10.1128/IAI.68.1.288-293.2000; Murray HW, 2001, ANTIMICROB AGENTS CH, V45, P2185, DOI 10.1128/AAC.45.8.2185-2197.2001; MURRAY HW, 1988, J INFECT DIS, V157, P973, DOI 10.1093/infdis/157.5.973; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001; Shaked-Mishan P, 2001, J BIOL CHEM, V276, P3971, DOI 10.1074/jbc.M005423200; SHIM H, 1988, J GEN MICROBIOL, V134, P807; Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200; Sun HZ, 2000, EUR J BIOCHEM, V267, P5450, DOI 10.1046/j.1432-1327.2000.01605.x; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; Vickers TJ, 2004, J BIOL CHEM, V279, P27246, DOI 10.1074/jbc.M311039200; VICKERS TJ, 2004, IN PRESS P NATL ACAD; Yan SC, 2003, J BIOL INORG CHEM, V8, P689, DOI 10.1007/s00775-003-0468-1; Yan SC, 2000, ANGEW CHEM INT EDIT, V39, P4260, DOI 10.1002/1521-3773(20001201)39:23<4260::AID-ANIE4260>3.0.CO;2-9	52	220	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39925	39932		10.1074/jbc.M405635200	http://dx.doi.org/10.1074/jbc.M405635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252045	hybrid			2022-12-25	WOS:000223791500089
J	Canning, M; Boutell, C; Parkinson, J; Everett, RD				Canning, M; Boutell, C; Parkinson, J; Everett, RD			A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; IMMEDIATE-EARLY PROTEIN; REGULATORY PROTEIN; DEUBIQUITINATING ENZYME; GENE-EXPRESSION; FACTOR-RECEPTOR; ICP0 INTERACTS; CELL; PML; VMW110	Herpes simplex virus type 1 immediate-early regulatory protein ICP0 stimulates lytic infection and reactivation from latency, processes that require the ubiquitin E3 ligase activity mediated by the RING finger domain in the N-terminal portion of the protein. ICP0 stimulates the production of polyubiquitin chains by the ubiquitin-conjugating enzymes UbcH5a and UbcH6 in vitro, and in infected and transfected cells it induces the proteasome-dependent degradation of a number of cellular proteins including PML, the major constituent protein of PML nuclear bodies. However, ICP0 binds strongly to the cellular ubiquitin-specific protease USP7, a member of a family of proteins that cleave polyubiquitin chains and/or ubiquitin precursors. The region of ICP0 that is required for its interaction with USP7 has been mapped, and mutations in this domain reduce the functionality of ICP0. These findings pose the question: why does ICP0 include domains that are associated with the potentially antagonistic functions of ubiquitin conjugation and deconjugation? Here we report that although neither protein affected the intrinsic activities of the other in vitro, USP7 protected ICP0 from autoubiquitination in vitro, and their interaction can greatly increase the stability of ICP0 in vivo. These results demonstrate that RING finger-mediated autoubiquitination of ICP0 is biologically relevant and can be regulated by interaction with USP7. This principle may extend to a number of cellular RING finger E3 ubiquitin ligase proteins that have analogous interactions with ubiquitin-specific cleavage enzymes.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland		Everett, RD (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	r.everett@vir.gla.ac.uk		Boutell, Chris/0000-0002-2970-7785				Boutell C, 2004, J VIROL, V78, P8068, DOI 10.1128/JVI.78.15.8068-8077.2004; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2003, J VIROL, V77, P8686, DOI 10.1128/JVI.77.16.8686-8694.2003; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; EVERETT R, 1993, J GEN VIROL, V74, P1955, DOI 10.1099/0022-1317-74-9-1955; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 2004, J VIROL, V78, P1763, DOI 10.1128/JVI.78.4.1763-1774.2004; EVERETT RD, 1993, VIROLOGY, V197, P751, DOI 10.1006/viro.1993.1651; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; EVERETT RD, 1987, EMBO J, V6, P2069, DOI 10.1002/j.1460-2075.1987.tb02472.x; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; EVERETT RD, 1991, J GEN VIROL, V72, P651, DOI 10.1099/0022-1317-72-3-651; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; Hagglund R, 2003, J VIROL, V77, P13194, DOI 10.1128/JVI.77.24.13194-13202.2003; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P631, DOI 10.1073/pnas.022531599; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jones JM, 2003, P NATL ACAD SCI USA, V100, P15446, DOI 10.1073/pnas.2637012100; Kawaguchi Y, 1997, J VIROL, V71, P1019, DOI 10.1128/JVI.71.2.1019-1024.1997; Kawaguchi Y, 1997, J VIROL, V71, P7328, DOI 10.1128/JVI.71.10.7328-7336.1997; Kawaguchi Y, 2001, P NATL ACAD SCI USA, V98, P1877, DOI 10.1073/pnas.041592598; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Muller S, 1999, J VIROL, V73, P5137; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Preston CM, 2000, J GEN VIROL, V81, P1; Roizman B, 2001, FIELDS VIROL, P2381; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; Rothenberger S, 2003, ONCOGENE, V22, P5614, DOI 10.1038/sj.onc.1206497; Samaniego LA, 1998, J VIROL, V72, P3307, DOI 10.1128/JVI.72.4.3307-3320.1998; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YAO F, 1995, J VIROL, V69, P6249, DOI 10.1128/JVI.69.10.6249-6258.1995; YAO F, 1994, J VIROL, V68, P8158, DOI 10.1128/JVI.68.12.8158-8168.1994; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	58	109	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38160	38168		10.1074/jbc.M402885200	http://dx.doi.org/10.1074/jbc.M402885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247261	hybrid			2022-12-25	WOS:000223684100014
J	Nagawa, F; Hirose, S; Nishizumi, H; Nishihara, T; Sakano, H				Nagawa, F; Hirose, S; Nishizumi, H; Nishihara, T; Sakano, H			Joining mutants of RAG1 and RAG2 that demonstrate impaired interactions with the coding-end DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; RECOMBINATION SIGNAL SEQUENCES; FREE V(D)J RECOMBINATION; LEAKY SCID PHENOTYPE; IN-VITRO; SYNAPTIC COMPLEX; KU86-DEFICIENT MICE; FOOTPRINT ANALYSIS; 12/23 RULE; CLEAVAGE	In V(D)J joining of antigen receptor genes, two recombination signal sequences (RSSs), 12- and 23-RSSs, form a complex with the protein products of recombination activating genes, RAG1 and RAG2. DNaseI footprinting demonstrates that the interaction of RAG proteins with substrate RSS DNA is not just limited to the signal region but involves the coding sequence as well. Joining mutants of RAG1 and RAG2 demonstrate impaired interactions with the coding region in both pre- and post-cleavage type complexes. A possible role of this RAG coding region interaction is discussed in the context of V(D)J recombination.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol Program, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Sakano, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130032, Japan.	sakano@mail.ecc.u-tokyo.ac.jp	Hirose, Satoshi/CAF-1500-2022	Hirose, Satoshi/0000-0001-7825-501X				Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; Bailin T, 1999, MOL CELL BIOL, V19, P4664; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Brandt VL, 2002, CURR OPIN IMMUNOL, V14, P224, DOI 10.1016/S0952-7915(02)00325-4; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1997, NUCLEIC ACIDS RES, V25, P4370, DOI 10.1093/nar/25.21.4370; Eastman QM, 1999, MOL CELL BIOL, V19, P3788; Evans CJ, 2003, GENE, V322, P1, DOI 10.1016/j.gene.2003.08.022; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fugmann SD, 2001, MOL CELL, V8, P899, DOI 10.1016/S1097-2765(01)00352-5; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; Jones JM, 2002, EMBO J, V21, P4162, DOI 10.1093/emboj/cdf394; Jung D, 2003, IMMUNITY, V18, P65, DOI 10.1016/S1074-7613(02)00507-1; Kim DR, 1998, MOL CELL BIOL, V18, P4679, DOI 10.1128/MCB.18.8.4679; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; Mo XM, 2000, NUCLEIC ACIDS RES, V28, P1228, DOI 10.1093/nar/28.5.1228; Mo XM, 2001, MOL CELL BIOL, V21, P2038, DOI 10.1128/MCB.21.6.2038-2047.2001; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; Nagawa F, 2002, MOL CELL BIOL, V22, P7217, DOI 10.1128/MCB.22.20.7217-7225.2002; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nishihara T, 2004, MOL CELL BIOL, V24, P3692, DOI 10.1128/MCB.24.9.3692-3702.2004; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; Schultz HY, 2001, MOL CELL, V7, P65, DOI 10.1016/S1097-2765(01)00155-1; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tsai CL, 2002, GENE DEV, V16, P1934, DOI 10.1101/gad.984502; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; West RB, 1998, MOL CELL BIOL, V18, P6408, DOI 10.1128/MCB.18.11.6408; Yoshida T, 2000, INT IMMUNOL, V12, P721, DOI 10.1093/intimm/12.5.721; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	53	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38360	38368		10.1074/jbc.M405485200	http://dx.doi.org/10.1074/jbc.M405485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15249552	hybrid			2022-12-25	WOS:000223684100037
J	Robblee, JP; Olivares, AO; De la Cruz, EM				Robblee, JP; Olivares, AO; De la Cruz, EM			Mechanism of nucleotide binding to actomyosin VI - Evidence for allosteric head-head communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-I ATPASE; KINETIC CHARACTERIZATION; ADENOSINE 5'-DIPHOSPHATE; DICTYOSTELIUM-DISCOIDEUM; SMOOTH-MUSCLE; ACTIN; MOTOR; TRIPHOSPHATASE; COOPERATIVITY; ISOMERIZATION	We have examined the kinetics of nucleotide binding to actomyosin VI by monitoring the fluorescence of pyrene-labeled actin filaments. ATP binds single-headed myosin VI following a two-step reaction mechanism with formation of a low affinity collision complex (1/K-1' = 5.6 mM) followed by isomerization (k(+2)' = 176 s(-1)) to a state with weak actin affinity. The rates and affinity for ADP binding were measured by kinetic competition with ATP. This approach allows a broader range of ADP concentrations to be examined than with fluorescent nucleotide analogs, permitting the identification and characterization of transiently populated intermediates in the pathway. ADP binding to actomyosin VI, as with ATP binding, occurs via a two-step mechanism. The association rate constant for ADP binding is similar to five times greater than for ATP binding because of a higher affinity in the collision complex (1/K-5b' = 2.2 mM) and faster isomerization rate constant (k(+5a)' = 366 s(-1)). By equilibrium titration, both heads of a myosin VI dimer bind actin strongly in rigor and with bound ADP. In the presence of ATP, conditions that favor processive stepping, myosin VI does not dwell with both heads strongly bound to actin, indicating that the second head inhibits strong binding of the lead head to actin. With both heads bound strongly, ATP binding is accelerated 2.5-fold, and ADP binding is accelerated > 10-fold without affecting the rate of ADP release. We conclude that the heads of myosin VI communicate allosterically and accelerate nucleotide binding, but not dissociation, when both are bound strongly to actin.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	De la Cruz, EM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 260 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	enrique.delacruz@yale.edu	Olivares, Adrian/D-7717-2012	Olivares, Adrian/0000-0002-0895-7988	NIGMS NIH HHS [5T32GM07223, 5T32GM08283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223, T32GM008283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Batters C, 2004, EMBO J, V23, P1433, DOI 10.1038/sj.emboj.7600169; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; HIGHSMITH S, 1978, BIOCHEMISTRY-US, V17, P22, DOI 10.1021/bi00594a004; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P61; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Mehta A, 2001, J CELL SCI, V114, P1981; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Xiao M, 2003, NAT STRUCT BIOL, V10, P402, DOI 10.1038/nsb916; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	40	42	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38608	38617		10.1074/jbc.M403504200	http://dx.doi.org/10.1074/jbc.M403504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247304	hybrid			2022-12-25	WOS:000223684100068
J	Rosenberg, MF; Kamis, AB; Aleksandrov, LA; Ford, RC; Riordan, JR				Rosenberg, MF; Kamis, AB; Aleksandrov, LA; Ford, RC; Riordan, JR			Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; RESISTANCE P-GLYCOPROTEIN; CHINESE-HAMSTER OVARY; ABC TRANSPORTER; PLASMA-MEMBRANE; CHLORIDE CHANNEL; ATPASE ACTIVITY; ION-CHANNEL; SACCHAROMYCES-CEREVISIAE; ELECTRON CRYSTALLOGRAPHY	The cystic fibrosis transmembrane conductance regulator ( CFTR) is a membrane protein that is mutated in patients suffering from cystic fibrosis. Here we report the purification and first crystallization of wild-type human CFTR. Functional characterization of the material showed it to be highly active. Electron crystallography of negatively stained two-dimensional crystals of CFTR has revealed the overall architecture of this channel for two different conformational states. These show a strong structural homology to two conformational states of another eukaryotic ATP-binding cassette transporter, P-glycoprotein. In contrast to P-glycoprotein, however, both conformational states can be observed in the presence of a nucleotide, which may be related to the role of CFTR as an ion channel rather than a transporter. The hypothesis that the two conformations could represent the "open" and "closed" states of the channel is considered.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Mayo Fdn & Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	University of Manchester; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.	r.ford@umist.ac.uk		Ford, Robert/0000-0002-0958-1505	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051619] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51619] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov AA, 1998, FEBS LETT, V431, P97, DOI 10.1016/S0014-5793(98)00713-3; Aleksandrov AA, 2002, FEBS LETT, V518, P183, DOI 10.1016/S0014-5793(02)02698-4; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Auer M, 1999, J MOL BIOL, V287, P961, DOI 10.1006/jmbi.1999.2652; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chami M, 2002, J MOL BIOL, V315, P1075, DOI 10.1006/jmbi.2001.5309; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Ferreira-Pereira A, 2003, J BIOL CHEM, V278, P11995, DOI 10.1074/jbc.M212198200; FRIZZELL RA, 1999, PHYSIOL REV, V79, P1; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gelman MS, 2002, J CLIN INVEST, V110, P1591, DOI 10.1172/JCI200216786; GLAESER RM, 1992, ULTRAMICROSCOPY, V47, P256, DOI 10.1016/0304-3991(92)90201-T; HANRAHAN JW, 2002, ABC PROTEINS BACTERI, P589; HARRIS JR, 1995, J STRUCT BIOL, V115, P102, DOI 10.1006/jsbi.1995.1034; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Kiser GL, 2001, ARCH BIOCHEM BIOPHYS, V390, P195, DOI 10.1006/abbi.2001.2385; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li CY, 2004, J BIOL CHEM, V279, P24673, DOI 10.1074/jbc.M400688200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Ruffle SV, 2002, J BIOL CHEM, V277, P25692, DOI 10.1074/jbc.M202670200; SCARBOROUGH GA, 1994, ACTA CRYSTALLOGR D, V50, P643, DOI 10.1107/S0907444993014283; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Velarde G, 2001, J BIOL CHEM, V276, P46054, DOI 10.1074/jbc.M108435200; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Yue HW, 2000, J BIOL CHEM, V275, P10030, DOI 10.1074/jbc.275.14.10030	56	116	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39051	39057		10.1074/jbc.M407434200	http://dx.doi.org/10.1074/jbc.M407434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247233	hybrid			2022-12-25	WOS:000223684100120
J	Weisshart, K; Friedl, S; Taneja, P; Nasheuer, HP; Schlott, B; Grosse, F; Fanning, E				Weisshart, K; Friedl, S; Taneja, P; Nasheuer, HP; Schlott, B; Grosse, F; Fanning, E			Partial proteolysis of Simian virus 40 T antigen reveals intramolecular contacts between domains and conformation changes upon hexamer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SIMIAN VIRUS-40 LARGE; SV40 DNA-REPLICATION; LARGE TUMOR-ANTIGEN; VIRAL ORIGIN; POLYMERASE-ALPHA; IN-VITRO; BINDING; PHOSPHORYLATION; TRANSFORMATION	Simian virus 40 large tumor antigen ( Tag) is a multifunctional viral protein that binds specifically to SV40 origin DNA, serves as the replicative DNA helicase, and orchestrates the assembly and operation of the viral replisome. Tag associated with Mg-ATP forms hexamers and, in the presence of SV40 origin DNA, double hexamers. Limited tryptic digestion of monomeric Tag revealed three major stable structural domains. The N-terminal domain spans amino acids 1 - 130, the central domain comprises amino acids 131 - 476, and the C-terminal domain extends from amino acid 513 to amino acid 698. Co-immunoprecipitation of digestion products of monomeric Tag suggests that the N-terminal domain associates stably with sequences located in the central region of the same Tag molecule. Hexamer formation protected the tryptic cleavage sites in the exposed region between the central and C-terminal domains. Upon hexamerization, this exposed region also became less accessible to a monoclonal antibody whose epitope maps in that region. The tryptic digestion products of the soluble hexamer and the DNA-bound double hexamer were indistinguishable. A low-resolution model of the intramolecular and intermolecular interactions among Tag domains in the double hexamer is proposed.	Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Inst Mol Biotechnol, D-07745 Jena, Germany	Vanderbilt University	Fanning, E (corresponding author), Vanderbilt Univ, Dept Biol Sci, VU Stn B 351634, Nashville, TN 37235 USA.	fanning@vanderbilt.edu	Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Barbaro BA, 2000, J VIROL, V74, P8601, DOI 10.1128/JVI.74.18.8601-8613.2000; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fanning Ellen, 1994, Trends in Cell Biology, V4, P250, DOI 10.1016/0962-8924(94)90123-6; Gai DH, 2004, J BIOL CHEM, V279, P38952, DOI 10.1074/jbc.M406160200; Gomez-Lorenzo MG, 2003, EMBO J, V22, P6205, DOI 10.1093/emboj/cdg612; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Luo XL, 1996, NAT STRUCT BIOL, V3, P1034, DOI 10.1038/nsb1296-1034; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MASTRANGELO IA, 1994, BIOPHYS J, V66, P293, DOI 10.1016/S0006-3495(94)80800-8; Reese DK, 2004, J VIROL, V78, P2921, DOI 10.1128/JVI.78.6.2921-2934.2004; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SIMMONS DT, 1988, P NATL ACAD SCI USA, V85, P2086, DOI 10.1073/pnas.85.7.2086; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; SMITH AE, 1978, J VIROL, V28, P140, DOI 10.1128/JVI.28.1.140-153.1978; Stenlund A, 2003, NAT REV MOL CELL BIO, V4, P777, DOI 10.1038/nrm1226; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; TEGTMEYER P, 1977, J VIROL, V21, P647, DOI 10.1128/JVI.21.2.647-657.1977; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; Weisshart K, 1996, J VIROL, V70, P3509, DOI 10.1128/JVI.70.6.3509-3516.1996; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	36	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38943	38951		10.1074/jbc.M406159200	http://dx.doi.org/10.1074/jbc.M406159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247253	hybrid			2022-12-25	WOS:000223684100108
J	Stratford, S; Hoehn, KL; Liu, F; Summers, SA				Stratford, S; Hoehn, KL; Liu, F; Summers, SA			Regulation of insulin action by ceramide - Dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN PHOSPHATASE 2A; SKELETAL-MUSCLE CELLS; SATURATED FATTY-ACIDS; SIGNAL-TRANSDUCTION; INTRACELLULAR SIGNAL; 3T3-L1 ADIPOCYTES; SER/THR KINASE; GROWTH ARREST; AKT KINASE	The sphingolipid ceramide negatively regulates insulin action by inhibiting Akt/protein kinase B (PKB), a serine/threonine kinase that is a central regulator of glucose uptake and anabolic metabolism. Despite considerable attention, the molecular mechanism accounting for this action of ceramide has remained both elusive and controversial. Herein we utilized deletion constructs encoding two different functional domains of Akt/PKB to identify which region of the enzyme conferred responsiveness to ceramide. Surprisingly the findings obtained with these separate domains reveal that ceramide blocks insulin stimulation of Akt/PKB by two independent mechanisms. First, using the isolated pleckstrin homology domain, we found that ceramide specifically blocks the translocation of Akt/PKB, but not its upstream activator phosphoinositide-dependent kinase-1, to the plasma membrane. Second, using a construct lacking this pleckstrin homology domain, which does not require translocation for activation, we found that ceramide stimulates the dephosphorylation of Akt/PKB by protein phosphatase 2A. Collectively these findings identify at least two independent mechanisms by which excessive ceramide accumulation in peripheral tissues could contribute to the development of insulin resistance. Moreover the results obtained provide a unifying theory to account for the numerous dissenting reports investigating the actions of ceramide toward Akt/PKB.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Colorado State University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Summers, SA (corresponding author), Univ Utah, Dept Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA.	scott.summers@hsc.utah.edu	/AAE-5384-2020	Hoehn, Kyle/0000-0002-0214-3238	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058784, R01DK056166, R01DK058784] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 56166, R012 DK 58784] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hresko RC, 2003, J BIOL CHEM, V278, P21615, DOI 10.1074/jbc.M302937200; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johannessen M, 2003, BIOCHEM PHARMACOL, V65, P1317, DOI 10.1016/S0006-2952(03)00071-6; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; SHIMA H, 1994, P NATL ACAD SCI USA, V91, P9267, DOI 10.1073/pnas.91.20.9267; Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215; Stratford S, 2001, BIOCHEM J, V354, P359, DOI 10.1042/0264-6021:3540359; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 2000, INT J OBESITY, V24, pS67, DOI 10.1038/sj.ijo.0801509; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang Li-Ping, 2003, Methods Mol Med, V83, P127; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whiteman EL, 2003, ENDOCRINOLOGY, V144, P3811, DOI 10.1210/en.2003-0480; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	62	299	308	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36608	36615		10.1074/jbc.M406499200	http://dx.doi.org/10.1074/jbc.M406499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220355	hybrid			2022-12-25	WOS:000223453600058
J	Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma	ONCOGENE			English	Article						thymosin beta-4; colorectal carcinoma; beta-catenin; MMP-7; Fas; metastasis	BETA-CATENIN; FAS LIGAND; E-CADHERIN; MATRIX METALLOPROTEINASE-7; CANCER CELLS; MATRILYSIN EXPRESSION; TUMOR PROGRESSION; LIVER METASTASES; IMMUNE PRIVILEGE; BREAST-CANCER	Cell-matrix and cell-cell adhesive interactions play important roles in the normal organization and stabilization of the cell layer in epithelial tissue. Alterations in the expression and function of these adhesion systems that cause a switch to a migratory phenotype in tumor invasion and metastasis are critical for the malignant conversion of epithelial cells. Thymosin beta-4 (Tbeta-4) is the major actin-sequestering protein that has been shown to be upregulated in a wide variety of human carcinomas and has been implicated to be involved in altering the motility of certain tumors. We have recently demonstrated that the growth rate, colony formation in soft agar, and motility, all good indicators for malignant progression, of SW480 colon carcinoma cells are dramatically increased by enforced Tbeta-4 expression. To test the hypothesis that overexpression of this G- actin sequestering peptide also promotes tumor invasion, we examined not only the invasion capability of Tbeta-4-overexpressing SW480 cells, but also the expression levels of Tbeta-4 as well as several proteins that participate in different stages of tumor progression in matched samples of human primary colorectal adenocarcinoma and liver metastases from several patients. A marked increase on the invasiveness in Tbeta-4-overexpressing SW480 cells with increased levels and activity of matrix metalloproteinase-7 (MMP-7) was observed. Furthermore, the levels of Fas as well as the susceptibility to Fas ligand-mediated apoptosis in Tbeta-4-overexpressing cells were significantly decreased. Interestingly, the levels of Tbeta-4 mRNA, beta-catenin, c-Myc, and MMP-7 in metastatic liver lesions were relatively higher, whereas the levels of E-cadherin and Fas were significantly lower than those in the matched primary colorectal tumors. These results suggest that upregulation of Tbeta-4, by promoting the disruption of cell-cell adhesion and a consequential activation of the beta-catenin signaling, could be a key event in the acquisition of growth advantages as well as invasive phenotypes in human colorectal carcinomas.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Div Med Oncol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Califano D, 1998, CANCER RES, V58, P823; Cardi G, 1998, CANCER RES, V58, P2078; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Chopin D, 2003, AM J PATHOL, V162, P1139, DOI 10.1016/S0002-9440(10)63910-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; MORI M, 1995, CANCER, V75, P1516, DOI 10.1002/1097-0142(19950315)75:6+<1516::AID-CNCR2820751522>3.0.CO;2-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; Noe V, 2001, J CELL SCI, V114, P111; O'Connell J, 1998, J PATHOL, V186, P240; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; O'Connell J, 2000, ANN NY ACAD SCI, V910, P178; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xie D, 2002, INT J ONCOL, V21, P499; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	41	98	105	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6666	6671		10.1038/sj.onc.1207888	http://dx.doi.org/10.1038/sj.onc.1207888			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235586				2022-12-25	WOS:000223530800014
J	Wang, Y; Wimmer, U; Lichtlen, P; Inderbitzin, D; Stieger, B; Meier, PJ; Hunziker, L; Stallmach, T; Forrer, R; Rulicke, T; Georgiev, O; Schaffner, W				Wang, Y; Wimmer, U; Lichtlen, P; Inderbitzin, D; Stieger, B; Meier, PJ; Hunziker, L; Stallmach, T; Forrer, R; Rulicke, T; Georgiev, O; Schaffner, W			Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liver	FASEB JOURNAL			English	Article						heavy metal stress; cadmium toxicity; hematopoiesis; conditional knockout	PLACENTA GROWTH-FACTOR; METALLOTHIONEIN GENE-EXPRESSION; NF-KAPPA-B; MICE LACKING; C-JUN; MOUSE; CELLS; ZINC; DIFFERENTIATION; DEFICIENT	Metal-responsive transcription factor-1 (MTF-1) activates the transcription of metallothionein genes and other target genes in response to heavy metal load and other stresses such as hypoxia and oxidative stress. It also has an essential function during embryogenesis: targeted disruption of Mtf1 in the mouse results in lethal liver degeneration on day 14 of gestation. Here we studied Mtf1 knockout mice at embryonic and adult stages, the latter by means of conditional knockout. Hepatocytes from Mtf1 null mutant and wild-type embryos were taken into culture on day 12.5 of gestation. Both initially appeared normal, but mutant cells were lost within a few days. Furthermore, Mtf1 null hepatocytes were poorly, if at all, rescued by cocultivation with wild-type rat embryo hepatocytes, indicating a cell-autonomous defect. When the Mtf1 gene was excised by Cre recombinase after birth in liver and bone marrow and to a lesser extent in other organs, mice were viable under non-stress conditions but highly susceptible to cadmium toxicity, in support of a role of MTF-1 in coping with heavy metal stress. An additional MTF-1 function was revealed upon analysis of the hematopoietic system in conditional knockout mice where leukocytes, especially lymphocytes, were found to be severely underrepresented. Together, these findings point to a critical role of MTF-1 in embryonic liver formation, heavy metal toxicity, and hematopoiesis.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Dept Internal Med, Div Clin Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Klin Pathol, CH-8091 Zurich, Switzerland; Univ Zurich, Vet Med Labor, CH-8091 Zurich, Switzerland; Univ Zurich, Biol Zent Labor, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich; University of Zurich; University of Zurich; University of Zurich	Schaffner, W (corresponding author), Univ Zurich, Inst Mol Biol, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	walter.schaffner@molbio.unizh.ch	Stieger, Bruno/U-6323-2017	Stieger, Bruno/0000-0002-7190-5785; Hunziker, Lukas/0000-0003-0081-8518				Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Erickson JC, 1997, J NEUROSCI, V17, P1271; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Giroux S, 1998, DEV BIOL, V195, P16, DOI 10.1006/dbio.1997.8823; Green CJ, 2001, CANCER RES, V61, P2696; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Kelly EJ, 1996, J NUTR, V126, P1782; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 1999, BIOL CHEM, V380, P711, DOI 10.1515/BC.1999.089; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nordberg M, 2000, CELL MOL BIOL, V46, P451; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Reimold AM, 2000, GENE DEV, V14, P152; Ren XY, 2003, WORLD J GASTROENTERO, V9, P1554, DOI 10.3748/wjg.v9.i7.1554; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schofield JP, 1999, HEPATOLOGY, V29, P181, DOI 10.1002/hep.510290112; SCHULZ WA, 1988, EXP CELL RES, V174, P433, DOI 10.1016/0014-4827(88)90313-8; Shiojiri N, 1997, TOHOKU J EXP MED, V181, P1, DOI 10.1620/tjem.181.1; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	42	78	79	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1071	1079		10.1096/fj.03-1282com	http://dx.doi.org/10.1096/fj.03-1282com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226267				2022-12-25	WOS:000222979200034
J	Coste, F; Ober, M; Carell, T; Boiteux, S; Zelwer, C; Castaing, B				Coste, F; Ober, M; Carell, T; Boiteux, S; Zelwer, C; Castaing, B			Structural basis for the recognition of the FapydG lesion (2,6-diamino-4-hydroxy-5-formamidopyrimidine) by formamidopyrimidine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FPG PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; REPAIR ENZYME; CENTER-DOT; SUBSTRATE-SPECIFICITY; PURINE NUCLEOSIDES; CRYSTAL-STRUCTURE; EXCISION-REPAIR; OGG1 PROTEIN	Formamidopyrimidine-DNA glycosylase (Fpg) is a DNA repair enzyme that excises oxidized purines such as 7,8-dihydro-8-oxoguanine (8-oxoG) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) from damaged DNA. Here, we report the crystal structure of the Fpg protein from Lactococcus lactis (LlFpg) bound to a carbocyclic FapydG (cFapydG)-containing DNA. The structure reveals that Fpg stabilizes the cFapydG nucleoside into an extrahelical conformation inside its substrate binding pocket. In contrast to the recognition of the 8-oxodG lesion, which is bound with the glycosidic bond in a syn conformation, the cFapydG lesion displays in the complex an anti conformation. Furthermore, Fpg establishes interactions with all the functional groups of the FapyG base lesion, which can be classified in two categories: (i) those specifying a purine-derived lesion (here a guanine) involved in the Watson-Crick face recognition of the lesion and probably contributing to an optimal orientation of the pyrimidine ring moiety in the binding pocket and (ii) those specifying the imidazole ring-opened moiety of FapyG and probably participating also in the rotameric selection of the FapydG nucleobase. These interactions involve strictly conserved Fpg residues and structural water molecules mediated interactions. The significant differences between the Fpg recognition modes of 8-oxodG and FapydG provide new insights into the Fpg substrate specificity.	Univ Munich, Dept Chem, D-81377 Munich, Germany; Ctr Biophys Mol, CNRS, UPR4301, F-45071 Orleans 02, France; Commissariat Energie Atom, CNRS, UMR217, F-92265 Fontenay Aux Roses, France	University of Munich; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Carell, T (corresponding author), Univ Munich, Dept Chem, 5-13, D-81377 Munich, Germany.	thomas.carell@cup.uni-muenchen.de; castaing@cnrs-orleans.fr	Carell, Thomas/G-4799-2012; coste, franck/F-6832-2015; coste, franck/ABC-1407-2020	Carell, Thomas/0000-0001-7898-2831; coste, franck/0000-0002-7409-0470; coste, franck/0000-0002-7409-0470; Castaing, Bertrand/0000-0001-5077-8978				Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Alseth I, 1999, MOL CELL BIOL, V19, P3779; Amara P, 2004, PROTEIN SCI, V13, P2009, DOI 10.1110/ps.04772404; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P5429, DOI 10.1093/nar/12.13.5429; BOITEUX S, 1989, CARCINOGENESIS, V10, P1905, DOI 10.1093/carcin/10.10.1905; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGDORF LT, 2000, CHEMISTRY, V8, P293; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Castaing B, 1999, NUCLEIC ACIDS RES, V27, P608, DOI 10.1093/nar/27.2.608; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CHETSANGA CJ, 1982, CANCER RES, V42, P2616; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; Connor EE, 2002, CHEM BIOL, V9, P1033, DOI 10.1016/S1074-5521(02)00215-6; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; de Jesus KP, 2002, ACTA CRYSTALLOGR D, V58, P679, DOI 10.1107/S0907444902001397; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Guibourt N, 2000, BIOCHEMISTRY-US, V39, P1716, DOI 10.1021/bi992262n; Haraguchi K, 2001, J AM CHEM SOC, V123, P8636, DOI 10.1021/ja0160952; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; Kamiya H, 2003, NUCLEIC ACIDS RES, V31, P517, DOI 10.1093/nar/gkg137; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Koval VV, 2004, NUCLEIC ACIDS RES, V32, P926, DOI 10.1093/nar/gkh237; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAGRAVERE C, 1984, NATURE, V310, P798, DOI 10.1038/310798a0; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; LESLIE AG, 1996, CCP4 NEWSLETT, V18, P33; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1987, BRIT J CANCER, V56, P91, DOI 10.1038/bjc.1987.163; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Mao H, 1998, BIOCHEMISTRY-US, V37, P4374, DOI 10.1021/bi9718292; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ober M, 2003, ANGEW CHEM INT EDIT, V42, P4947, DOI 10.1002/anie.200351287; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V86, P81; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tudek B, 2003, J BIOCHEM MOL BIOL, V36, P12; TUDEK B, 1992, NUCLEIC ACIDS RES, V20, P3079, DOI 10.1093/nar/20.12.3079; UESUGI S, 1977, J AM CHEM SOC, V99, P3250, DOI 10.1021/ja00452a008; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Wiederholt CJ, 2002, BIOCHEMISTRY-US, V41, P15838, DOI 10.1021/bi025903e; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	66	106	106	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44074	44083		10.1074/jbc.M405928200	http://dx.doi.org/10.1074/jbc.M405928200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15249553	hybrid			2022-12-25	WOS:000224383100087
J	Yang, CS; Sineshchekov, O; Spudich, EN; Spudich, JL				Yang, CS; Sineshchekov, O; Spudich, EN; Spudich, JL			The cytoplasmic membrane-proximal domain of the HtrII transducer interacts with the E-F loop of photoactivated Natronomonas pharaonis sensory rhodopsin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; MOLECULAR-MECHANISM; COGNATE TRANSDUCER; INTERHELICAL LOOP; SIGNAL TRANSFER; BACTERIORHODOPSIN; INSIGHTS; RECEPTOR; COMPLEX	The structures of the cytoplasmic loops of the phototaxis receptor sensory rhodopsin II (SRII) and the membrane-proximal cytoplasmic domain of its bound transducer HtrII were examined in the dark and in the light-activated state by fluorescent probes and cysteine cross-linking. Light decreased the accessibility of E-F loop position 154 in the SRII-HtrII complex, but not in free SRII, consistent with HtrII proximity, which was confirmed by tryptophans placed within a 5-residue region identified in the HtrII membrane-proximal domain that exhibited Forster resonance energy transfer to a fluorescent probe at position 154 in SRII. The Forster resonance energy transfer was eliminated in the signaling deficient HtrII mutant G83F without loss of affinity for SRII. Finally, the presence of SRII and HtrII reciprocally inhibit homodimer disulfide cross-linking reactions in their membrane-proximal domains, showing that each interferes with the others self-interaction in this region. The results demonstrate close proximity between SRII-HtrII in the membrane-proximal domain, and in addition, light stimulation of the SRII inhibition of HtrII cross-linking was observed, indicating that the contact is enhanced in the photoactivated complex. A mechanism is proposed in which photoactivation alters the SRII-HtrII interaction in the membrane-proximal region during the signal relay process.	Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Spudich, JL (corresponding author), Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu	Hsiao, Wei-Hung/B-9931-2013	YANG, CHII-SHEN/0000-0002-2792-6247	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM27750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiev U, 2003, J MOL BIOL, V328, P705, DOI 10.1016/S0022-2836(03)00326-7; Brown LS, 2002, J MOL BIOL, V317, P471, DOI 10.1006/jmbi.2002.5428; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chen XP, 2004, J BIOL CHEM, V279, P42964, DOI 10.1074/jbc.M406503200; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Hippler-Mreyen S, 2003, J MOL BIOL, V330, P1203, DOI 10.1016/S0022-2836(03)00656-9; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Jung KH, 1998, J BACTERIOL, V180, P2033, DOI 10.1128/JB.180.8.2033-2042.1998; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kunji ERS, 2001, J MOL BIOL, V308, P279, DOI 10.1006/jmbi.2001.4565; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; Rink T, 2000, BIOPHYS J, V78, P1519, DOI 10.1016/S0006-3495(00)76704-X; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; SPUDICH JL, 2004, MICROBIAL RHODOPSINS; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Sudo Y, 2002, J PHOTOCH PHOTOBIO B, V67, P171, DOI 10.1016/S1011-1344(02)00322-6; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; Xiao WZ, 2000, J MOL BIOL, V304, P715, DOI 10.1006/jmbi.2000.4255; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379; Yang CS, 2001, BIOCHEMISTRY-US, V40, P14207, DOI 10.1021/bi010985c; Zhang XN, 1999, P NATL ACAD SCI USA, V96, P857, DOI 10.1073/pnas.96.3.857; Zhang XN, 1998, J BIOL CHEM, V273, P19722, DOI 10.1074/jbc.273.31.19722	32	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42970	42976		10.1074/jbc.M406504200	http://dx.doi.org/10.1074/jbc.M406504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15262967	hybrid			2022-12-25	WOS:000224226400077
J	Zheng, ZF; Butler, KD; Tweten, RK; Mensa-Wilmot, K				Zheng, ZF; Butler, KD; Tweten, RK; Mensa-Wilmot, K			Endosomes, glycosomes, and glycosylphosphatidylinositol catabolism in Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL ANCHOR; INTRACELLULAR TRAFFICKING; CLOSTRIDIUM-SEPTICUM; PARASITIC PROTOZOA; SIGNAL SEQUENCES; MAMMALIAN-CELLS	Glycosylphosphatidylinositols (GPIs) serve as membrane anchors of polysaccharides and proteins in the protozoan parasite Leishmania major. Free GPIs that are not attached to macromolecules are present in L. major as intermediates of protein-GPI and polysaccharide-GPI synthesis or as terminal glycolipids. The importance of the intracellular location of GPIs in vivo for functions of the glycolipids is not appreciated. To examine the roles of intracellular free GPI pools for attachment to polypeptide, a GPI-specific phospholipase C (GPI-PLCp) from Trypanosoma brucei was used to probe trafficking of GPI pools inside L. major. The locations of GPIs were determined, and their catabolism by GPI-PLCp was analyzed with respect to the intracellular location of the enzyme. GPIs accumulated on the endo-lysosomal system, where GPI-PLCp was also detected. A peptide motif [CS][CS]-x(0,2)-G-x(1)-C-x(2,3)-S-x( 3)-L formed part of an endosome targeting signal for GPI-PLCp. Mutations of the endosome targeting motif caused GPI-PLCp to associate with glycosomes (peroxisomes). Endosomal GPI-PLCp caused a deficiency of protein-GPI in L. major, whereas glycosomal GPI-PLCp failed to produce the GPI deficiency. We surmise that (i) endo-lysosomal GPIs are important for biogenesis of GPI-anchored proteins in L. major; (ii) sequestration of GPI-PLCp to glycosomes protects free protein-GPIs from cleavage by the phospholipase. In T. brucei, protein-GPIs are concentrated at the endoplasmic reticulum, separated from GPI-PLCp. These observations support a model in which glycosome sequestration of a catabolic GPI-PLCp preserves free protein-GPIs in vivo.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA	University System of Georgia; University of Georgia; University of Oklahoma System; University of Oklahoma Health Sciences Center	Mensa-Wilmot, K (corresponding author), Univ Georgia, Dept Cellular Biol, 724 Biol Sci Bldg, Athens, GA 30602 USA.	mensawil@cb.uga.edu			NIAID NIH HHS [AI53086, R01 AI032097] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032097, R03AI053086] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlQahtani A, 1996, NUCLEIC ACIDS RES, V24, P1173, DOI 10.1093/nar/24.6.1173; Armah DA, 1999, J BIOL CHEM, V274, P5931, DOI 10.1074/jbc.274.9.5931; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; BANGS JD, 1993, J CELL SCI, V105, P1101; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BLACK SJ, 1982, PARASITE IMMUNOL, V4, P233, DOI 10.1111/j.1365-3024.1982.tb00435.x; Blattner J, 1998, P NATL ACAD SCI USA, V95, P11596, DOI 10.1073/pnas.95.20.11596; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Carnall N, 1997, MOL BIOCHEM PARASIT, V90, P423, DOI 10.1016/S0166-6851(97)00177-1; Carrington M, 1998, MOL BIOCHEM PARASIT, V91, P153, DOI 10.1016/S0166-6851(97)00190-4; CARRINGTON M, 1989, MOL BIOCHEM PARASIT, V33, P289, DOI 10.1016/0166-6851(89)90091-1; CLAYTON CE, 1987, J CELL BIOL, V105, P2649, DOI 10.1083/jcb.105.6.2649; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FOX JA, 1986, J BIOL CHEM, V261, P5767; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Garg N, 1997, J BIOL CHEM, V272, P12482, DOI 10.1074/jbc.272.19.12482; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Guerra-Giraidez C, 2002, J CELL SCI, V115, P2651; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; Guther MLS, 2003, BIOCHEMISTRY-US, V42, P14532, DOI 10.1021/bi034869g; HERELD D, 1988, P NATL ACAD SCI USA, V85, P8914, DOI 10.1073/pnas.85.23.8914; HERELD D, 1986, J BIOL CHEM, V261, P3813; Ilgoutz SC, 1999, EMBO J, V18, P3643, DOI 10.1093/emboj/18.13.3643; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Lutjens R, 2000, EUR J NEUROSCI, V12, P2224, DOI 10.1046/j.1460-9568.2000.00112.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MCGWIRE B, 1994, MOL BIOCHEM PARASIT, V66, P345, DOI 10.1016/0166-6851(94)90160-0; Mensa-Wilmot K, 1999, MOL BIOCHEM PARASIT, V99, P103, DOI 10.1016/S0166-6851(99)00003-1; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1990, MOL CELL BIOL, V10, P720, DOI 10.1128/MCB.10.2.720; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Naderer T, 2002, MOL BIOCHEM PARASIT, V125, P147, DOI 10.1016/S0166-6851(02)00236-0; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Parsons M, 2001, MOL BIOCHEM PARASIT, V115, P19, DOI 10.1016/S0166-6851(01)00261-4; Philippe H, 2000, CURR OPIN GENET DEV, V10, P596, DOI 10.1016/S0959-437X(00)00137-4; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; Rashid MB, 2000, BIOTECHNIQUES, V28, P90, DOI 10.2144/00281st03; Rashid MB, 1999, EUR J BIOCHEM, V264, P914, DOI 10.1046/j.1432-1327.1999.00690.x; Shaw JD, 2001, EXP CELL RES, V271, P1, DOI 10.1006/excr.2001.5373; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Stockli J, 2004, MOL BIOL CELL, V15, P2617, DOI 10.1091/mbc.E03-11-0808; SUETTERLIN C, 1997, J CELL SCI, V110, P2703; Teilhet M, 1998, GENE, V222, P91, DOI 10.1016/S0378-1119(98)00470-3; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Waller RF, 2002, INT J PARASITOL, V32, P1435, DOI 10.1016/S0020-7519(02)00140-6; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wiederkehr A, 2001, YEAST, V18, P759, DOI 10.1002/yea.726	64	8	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42106	42113		10.1074/jbc.M403780200	http://dx.doi.org/10.1074/jbc.M403780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15254033	hybrid			2022-12-25	WOS:000224075500103
J	Chan, MWC; El Sayegh, TY; Arora, PD; Laschinger, CA; Overall, CM; Morrison, C; McCulloch, CAG				Chan, MWC; El Sayegh, TY; Arora, PD; Laschinger, CA; Overall, CM; Morrison, C; McCulloch, CAG			Regulation of intercellular adhesion strength in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; UVOMORULIN-CATENIN COMPLEX; FILAMENT BARBED ENDS; N-CADHERIN; ALPHA-CATENIN; MUSCLE DIFFERENTIATION; ADHERENS JUNCTIONS; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; DOWN-REGULATION	The regulation of adherens junction formation in cells of mesenchymal lineage is of critical importance in tumorigenesis but is poorly characterized. As actin filaments are crucial components of adherens junction assembly, we studied the role of gelsolin, a calcium-dependent, actin severing protein, in the formation of N-cadherin-mediated intercellular adhesions. With a homotypic, donor-acceptor cell model and plates or beads coated with recombinant N-cadherin-Fc chimeric protein, we found that gelsolin spatially co-localizes to, and is transiently associated with, cadherin adhesion complexes. Fibroblasts from gelsolin-null mice exhibited marked reductions in kinetics and strengthening of N-cadherin-dependent junctions when compared with wild-type cells. Experiments with lanthanum chloride ( 250 muM) showed that adhesion strength was dependent on entry of calcium ions subsequent to N-cadherin ligation. Cadherin-associated gelsolin severing activity was required for localized actin assembly as determined by rhodamine actin monomer incorporation onto actin barbed ends at intercellular adhesion sites. Scanning electron microscopy showed that gelsolin was an important determinant of actin filament architecture of adherens junctions at nascent N-cadherin-mediated contacts. These data indicate that increased actin barbed end generation by the severing activity of gelsolin associated with N-cadherin regulates intercellular adhesion strength.	Univ Toronto, Canadian Inst Hlth Res, Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E2, Canada; Univ British Columbia, Canadian Inst Hlth Res, Grp Matrix Dynam, Dept Oral Biol & Med Sci,Fac Dent, Vancouver, BC V6T 1Z3, Canada	Institute for Work & Health; University of Toronto; Institute for Work & Health; University of British Columbia	El Sayegh, TY (corresponding author), Univ Toronto, Canadian Inst Hlth Res, Grp Matrix Dynam, Fac Dent, Rm 243,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	t.elsayegh@utoronto.ca						ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Allen PG, 2003, NAT CELL BIOL, V5, P972, DOI 10.1038/ncb1059; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; Asch HL, 1999, BREAST CANCER RES TR, V55, P179; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chou DHI, 1996, J IMMUNOL, V156, P4354; CIVITELLI R, 1995, CALCIFIED TISSUE INT, V56, pS29, DOI 10.1007/BF03354649; De Corte V, 2002, EMBO J, V21, P6781, DOI 10.1093/emboj/cdf680; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; ERICKSON CA, 1993, DEV BIOL, V159, P60, DOI 10.1006/dbio.1993.1221; Falet H, 2002, P NATL ACAD SCI USA, V99, P16782, DOI 10.1073/pnas.222652499; Garcia-Castro MI, 2000, SCIENCE, V288, P1047, DOI 10.1126/science.288.5468.1047; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Gloushankova NA, 1997, P NATL ACAD SCI USA, V94, P879, DOI 10.1073/pnas.94.3.879; Gloushankova NA, 1998, P NATL ACAD SCI USA, V95, P4362, DOI 10.1073/pnas.95.8.4362; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gremm D, 2000, EUR J BIOCHEM, V267, P4339, DOI 10.1046/j.1432-1327.2000.01463.x; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Ko KS, 2001, J CELL SCI, V114, P1155; Ko KS, 2001, J BIOL CHEM, V276, P35967, DOI 10.1074/jbc.M104106200; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Larue L, 1996, DEVELOPMENT, V122, P3185; Lin KM, 2000, J BIOL CHEM, V275, P27746; Lueck A, 2000, BIOCHEMISTRY-US, V39, P5274, DOI 10.1021/bi992871v; Marie PJ, 2002, J CELL PHYSIOL, V190, P297, DOI 10.1002/jcp.10073; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; Roe S, 1998, CELL ADHES COMMUN, V5, P283, DOI 10.3109/15419069809040298; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Woodward WA, 1999, DEV GENET, V24, P178, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<178::AID-DVG16>3.0.CO;2-M; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	63	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41047	41057		10.1074/jbc.M406631200	http://dx.doi.org/10.1074/jbc.M406631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247242	hybrid			2022-12-25	WOS:000223916800103
J	Pye, VE; Tingey, AP; Robson, RL; Moody, PCE				Pye, VE; Tingey, AP; Robson, RL; Moody, PCE			The structure and mechanism of serine acetyltransferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CYSTEINE; 3-DIMENSIONAL STRUCTURE; FEEDBACK-CONTROL; ACTIVE-SITE; PURIFICATION; RESOLUTION; COMPLEX; EXPRESSION; PROGRAM; PLANTS	Serine acetyltransferase (SAT) catalyzes the first step of cysteine synthesis in microorganisms and higher plants. Here we present the 2.2 Angstrom crystal structure of SAT from Escherichia coli, which is a dimer of trimers, in complex with cysteine. The SAT monomer consists of an amino-terminal alpha-helical domain and a carboxyl- terminal left-handed beta-helix. We identify His(158) and Asp(143) as essential residues that form a catalytic triad with the substrate for acetyl transfer. This structure shows the mechanism by which cysteine inhibits SAT activity and thus controls its own synthesis. Cysteine is found to bind at the serine substrate site and not the acetyl-CoA site that had been reported previously. On the basis of the geometry around the cysteine binding site, we are able to suggest a mechanism for the O-acetylation of serine by SAT. We also compare the structure of SAT with other left-handed beta-helical structures.	Univ Leicester, Dept Biochem, Leicester LE1 7HX, Leics, England; Univ Reading, Sch Anim & Microbial Sci, Div Microbiol, Reading RG6 6AJ, Berks, England	University of Leicester; University of Reading	Moody, PCE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7HX, Leics, England.	pcem1@leicester.ac.uk	Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238; Pye, Valerie E/0000-0001-9616-2992				Aguilar CF, 1997, J MOL BIOL, V267, P899, DOI 10.1006/jmbi.1996.0880; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P10363, DOI 10.1021/bi980759b; BLUNDELL TL, 1990, J MOL BIOL, V211, P919, DOI 10.1016/0022-2836(90)90084-Y; Bogdanova N, 1997, PLANT J, V11, P251, DOI 10.1046/j.1365-313X.1997.11020251.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; DENK D, 1987, J GEN MICROBIOL, V133, P515; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Hindson VJ, 2003, BIOCHEM J, V375, P745, DOI 10.1042/BJ20030429; Hindson VJ, 2003, BIOCHEMISTRY-US, V42, P3113, DOI 10.1021/bi0267893; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; Lee BI, 2003, PROTEINS, V53, P772, DOI 10.1002/prot.10436; Leslie AGW, 1994, MOSFLM USERS GUIDE; LEU LS, 1994, BIOCHEMISTRY-US, V33, P2667, DOI 10.1021/bi00175a040; Maier THP, 2003, NAT BIOTECHNOL, V21, P422, DOI 10.1038/nbt807; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOODY PCE, 1990, PROTEIN ENG FOCUS, P50; Murray IA, 1997, ANTIMICROB AGENTS CH, V41, P1; Nakamori S, 1998, APPL ENVIRON MICROB, V64, P1607; Olsen LR, 2004, BIOCHEMISTRY-US, V43, P6013, DOI 10.1021/bi0358521; Otwinowski Z., 2000, INT TABLES CRYSTALLO, VF; Parker G, 2001, MICROBIOL-SGM, V147, P2553, DOI 10.1099/00221287-147-9-2553; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Saito K, 1999, BOOK SOIL P, P267; SMITH IK, 1969, BIOCHEM BIOPH RES CO, V35, P939, DOI 10.1016/0006-291X(69)90715-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; WIEBERS JL, 1967, J BIOL CHEM, V242, P12; WIGLEY DB, 1990, FEBS LETT, V277, P267, DOI 10.1016/0014-5793(90)80862-D; Wirtz M, 2001, EUR J BIOCHEM, V268, P686, DOI 10.1046/j.1432-1327.2001.01920.x	40	80	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40729	40736		10.1074/jbc.M403751200	http://dx.doi.org/10.1074/jbc.M403751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15231846	hybrid			2022-12-25	WOS:000223916800065
J	Triantafilou, M; Manukyan, M; Mackie, A; Morath, S; Hartung, T; Heine, H; Triantafilou, K				Triantafilou, M; Manukyan, M; Mackie, A; Morath, S; Hartung, T; Heine, H; Triantafilou, K			Lipoteichoic acid and Toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDE; STAPHYLOCOCCUS-AUREUS; FLUORESCENCE RECOVERY; MYD88-DEFICIENT MICE; CD14; LPS; RECOGNITION; DOMAINS	Lipoteichoic acid (LTA), a key cell wall component of Gram-positive bacteria, seems to function as an immune activator with characteristics very similar to lipopolysaccharide from Gram-negative bacteria. It has been shown that LTA binds CD14 and triggers activation via Toll-like receptor 2, but whether the activation occurs at the cell surface or internalization is required to trigger signaling has yet to be demonstrated. In this work we have investigated LTA binding and internalization and found that LTA and its receptor molecules accumulate in lipid rafts and are subsequently targeted rapidly to the Golgi apparatus. This internalization seems to be lipid raft-dependent because raft-disrupting drugs inhibited LTA/Toll-like receptor 2 colocalization in the Golgi. Similarly to lipopolysaccharide, LTA activation occurs at the cell surface, and the observed trafficking is independent of signaling.	Univ Sussex, Sch Life Sci, Infect & Immun Grp, Brighton BN1 9QG, E Sussex, England; Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany; Inst Food Res, Inst Food Res, Dept Food Mat Sci, Norwich NR4 7UA, Norfolk, England; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany	University of Sussex; Forschungszentrum Borstel; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Konstanz	Triantafilou, K (corresponding author), Univ Sussex, Sch Life Sci, Infect & Immun Grp, JMS Bldg, Brighton BN1 9QG, E Sussex, England.	K.Triantafilou@sussex.ac.uk	Heine, Holger/H-4552-2012; Mackie, Alan/N-7780-2018	Heine, Holger/0000-0001-8128-5068; Mackie, Alan/0000-0002-5681-0593				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cohen J, 2001, J CHEMOTHERAPY, V13, P153, DOI 10.1179/joc.2001.13.Supplement-2.153; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hermann C, 2002, EUR J IMMUNOL, V32, P541, DOI 10.1002/1521-4141(200202)32:2<541::AID-IMMU541>3.0.CO;2-P; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; JONES BW, 2001, ANN RHEUM DIS     S3, V60, P6; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; KENWORTHY AK, 1998, METHOD MOL BIOL, P37; Ladha S, 1996, BIOPHYS J, V71, P1364, DOI 10.1016/S0006-3495(96)79339-6; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Morath S, 2002, INFECT IMMUN, V70, P938, DOI 10.1128/IAI.70.2.938-944.2002; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Toshchakov V, 2003, J ENDOTOXIN RES, V9, P169, DOI 10.1179/096805103125001577; Triantafilou K, 2001, J CELL SCI, V114, P2535; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, J CELL SCI, V115, P2603; VISHWAJEET P, 2001, J CELL BIOL, V154, P535; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; von Aulock S, 2003, IMMUNOBIOLOGY, V208, P413, DOI 10.1078/0171-2985-00285; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang PY, 1996, J INFLAMM, V47, P126; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; WINQVIST L, 1979, J CELL SCI, V39, P101; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yipp BG, 2002, J IMMUNOL, V168, P4650, DOI 10.4049/jimmunol.168.9.4650; Yoshimura A, 1999, J IMMUNOL, V163, P1	57	109	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40882	40889		10.1074/jbc.M400466200	http://dx.doi.org/10.1074/jbc.M400466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247273	hybrid			2022-12-25	WOS:000223916800084
J	Balbis, A; Baquiran, G; Mounier, C; Posner, BI				Balbis, A; Baquiran, G; Mounier, C; Posner, BI			Effect of insulin on caveolin-enriched membrane domains in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; HEPATOCYTE PLASMA-MEMBRANES; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR KINASE; CAVEOLIN-1-DEFICIENT MICE; GOLGI-APPARATUS; CELL-SURFACE; CHOLESTEROL; PROTEIN; ACTIVATION	Compartmentalization of signaling molecules may explain, at least in part, how insulin or growth factors achieve specificity. Caveolae/rafts are specialized lipid compartments that have been implicated in insulin signaling. In the present study, we investigated the role of caveolin-enriched membrane domains (CMD) in mediating insulin signaling in rat liver. We report the existence of at least two different populations of CMD in rat liver plasma membranes ( PM). One population is soluble in Triton X-100 and seems to be constitutively associated with cytoskeletal elements. The other population of CMD is located in a membrane compartment insoluble in Triton X-100 with light buoyant density and is hence designated CMD/rafts. We found evidence of rapid actin reorganization in rat liver PM in response to insulin, along with the association of CMD/rafts and insulin signaling molecules with a cell fraction enriched in cytoskeletal elements. The presence of CMD in liver parenchyma cells was confirmed by the presence of caveolin-1 in primary rat hepatocyte cultures. Cholesterol depletion, effected by incubating hepatocytes with 2 mM methyl-beta-cyclodextrin, did not permeabilize the cells or interfere with clathrin-dependent internalization. However, at this concentration, methyl-beta-cyclodextrin perturbed CMD of hepatocyte PM and inhibited insulin-induced Akt activation and glycogen synthesis but did not affect insulin-induced insulin receptor kinase tyrosine phosphorylation. These events, together with the presence of a functional insulin receptor in CMD of rat liver PM, suggest that insulin signaling is influenced by the interaction of caveolae with cytoskeletal elements in liver.	McGill Univ, Fac Med, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Fac Med, Polypeptide Hormone Lab, 3640 Univ St,Suite W315, Montreal, PQ H3A 2B2, Canada.	barry.posner@staff.mcgill.ca	Mounier, Catherine/D-3690-2011; Posner, Barry/B-6733-2008	Mounier, Catherine/0000-0003-3608-4229				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balbis A, 2000, ENDOCRINOLOGY, V141, P4041, DOI 10.1210/en.141.11.4041; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, BIOESSAYS, V23, P215, DOI 10.1002/1521-1878(200103)23:3<215::AID-BIES1031>3.0.CO;2-S; BERGERON JJM, 1982, J CELL BIOL, V94, P36, DOI 10.1083/jcb.94.1.36; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUCKEL PE, 2002, AM J PHYSIOL, V282, pE1; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; Calvo M, 2001, HEPATOLOGY, V33, P1259, DOI 10.1053/jhep.2001.23937; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Khayat ZA, 2000, J CELL SCI, V113, P279; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lange K, 1998, EXP CELL RES, V239, P139, DOI 10.1006/excr.1997.3894; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; Li WP, 2001, J CELL SCI, V114, P1397; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Malerod L, 2002, CELL TISSUE RES, V307, P173, DOI 10.1007/s00441-001-0476-9; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PIGNATARO OP, 1990, MOL ENDOCRINOL, V4, P758, DOI 10.1210/mend-4-5-758; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Runnegar M, 1997, HEPATOLOGY, V26, P176; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 2002, METHOD ENZYMOL, V353, P131; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Souto RP, 2003, J BIOL CHEM, V278, P18321, DOI 10.1074/jbc.M211541200; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	54	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39348	39357		10.1074/jbc.M404280200	http://dx.doi.org/10.1074/jbc.M404280200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252027	hybrid			2022-12-25	WOS:000223791500020
J	Medina, R; Perdomo, D; Bubis, J				Medina, R; Perdomo, D; Bubis, J			The hydrodynamic properties of dark- and light-activated states of n-dodecyl beta-D-maltoside-solubilized bovine rhodopsin support the dimeric structure of both conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR OLIGOMERIZATION; PHOTORECEPTOR DISK MEMBRANES; CHEMICAL CROSS-LINKING; G-PROTEIN ACTIVATION; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; TRANSMEMBRANE HELICES; 2 SITES; TRANSDUCIN	Rhodopsin (Rho) has been extracted in n-dodecyl beta-D-maltoside (DM) from bovine retinal rod outer segments and purified to homogeneity by affinity chromatography on concanavalin A-Sepharose. Because chemical cross-linking of Rho and photoactivated Rho (Rho*) provided initial evidence for the oligomeric nature of the photoreceptor protein, we carried out a hydrodynamic characterization of the native and activated conformations of detergent-solubilized Rho. The molecular weights of the complexes between dark and photoexcited states of Rho and DM were determined by gel filtration chromatography on Sephacryl S-300, in the presence of 0.1% DM. Subtracting the size of the corresponding detergent micelles resulted in molecular masses of 78 kDa for native Rho and 76 kDa for Rho*. The measured content of 0.97 g of detergent/g of protein resulted in a calculated partial specific volume of 0.765 cm(3)/g for the protein-detergent complex and a molar mass of 64-65 kDa for the protein moiety. The sizes of Rho.DM and Rho*.DM complexes were also evaluated by sedimentation on 10-30% sucrose gradients, in the presence of 0.1% DM, and molecular masses of about 60 kDa were estimated for both the dark- and light-activated states of the photoreceptor protein. The size of Rho was determined to be 65,300 and 69,800 Da, respectively, when the purified Rho.DM complex was either chromatographed on Sephacryl S-300 or ultracentrifuged on sucrose gradients in the absence of DM. All these results were consistent with a dimeric quaternary structure for both conformations of Rho. Additionally, the functional integrity of the purified photoreceptor protein following gel filtration chromatography and ultracentrifugation was demonstrated by three criteria as follows: (i) its characteristic UV-visible absorption spectra, (ii) its capability to photoactivate transducin, and (iii) its ability to serve as a substrate for rhodopsin kinase.	Univ Simon Bolivar, Dept Biol Celular, Caracas 1081A, Venezuela	Simon Bolivar University	Bubis, J (corresponding author), Univ Simon Bolivar, Dept Biol Celular, Apartado 89-000,Valle Sartenejas, Caracas 1081A, Venezuela.	jbubis@usb.ve		Bubis, Jose/0000-0002-8839-6745				Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Arimoto R, 2001, BIOPHYS J, V81, P3285, DOI 10.1016/S0006-3495(01)75962-0; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BLASIE JK, 1969, J MOL BIOL, V39, P417, DOI 10.1016/0022-2836(69)90136-3; BLASIE JK, 1969, J MOL BIOL, V39, P407, DOI 10.1016/0022-2836(69)90135-1; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; BRETT M, 1979, BIOCHEM J, V177, P215, DOI 10.1042/bj1770215; BUBIS J, 1990, J BIOL CHEM, V265, P12995; Bubis J, 2001, ARCH BIOCHEM BIOPHYS, V395, P146, DOI 10.1006/abbi.2001.2550; Bubis J, 1998, BIOL RES, V31, P59; Bubis J, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P227; Bubis Jose, 1995, Biological Research, V28, P291; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P539; Chabre M, 2003, NATURE, V426, P30, DOI 10.1038/426030b; CHABRE M, 1975, BIOCHIM BIOPHYS ACTA, V382, P322, DOI 10.1016/0005-2736(75)90274-6; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; DOWNER NW, 1985, BIOPHYS J, V47, P285, DOI 10.1016/S0006-3495(85)83918-7; DOWNER NW, 1985, BIOPHYS J, V47, P277, DOI 10.1016/S0006-3495(85)83917-5; Elliott MH, 2003, BIOCHEMISTRY-US, V42, P7892, DOI 10.1021/bi027162n; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fotiadis D, 2003, NATURE, V426, P31, DOI 10.1038/426031a; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P4396, DOI 10.1021/bi00614a007; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; HARGRAVE PA, 1977, BIOCHIM BIOPHYS ACTA, V492, P83, DOI 10.1016/0005-2795(77)90216-1; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; Kajimura N, 2000, J ELECTRON MICROSC, V49, P691, DOI 10.1093/oxfordjournals.jmicro.a023860; KNIGHT P, 1979, BIOCHEM J, V179, P191, DOI 10.1042/bj1790191; Kosoy A, 2003, BIOL RES, V36, P389, DOI 10.4067/S0716-97602003000300010; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; LEMAIRE M, 1981, BIOCHIMIE, V63, P863; LIANG CJ, 1979, J BIOL CHEM, V254, P6414; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Marshall GR, 2001, BIOPOLYMERS, V60, P246, DOI 10.1002/1097-0282(2001)60:3<246::AID-BIP10044>3.0.CO;2-V; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Millan EJ, 2002, J PROTEIN CHEM, V21, P1, DOI 10.1023/A:1014174630063; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Ortiz JO, 2001, ARCH BIOCHEM BIOPHYS, V387, P233, DOI 10.1006/abbi.2000.2219; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Papermaster DS, 2002, INVEST OPHTH VIS SCI, V43, P1300; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PLUMMER DT, 1978, INTRO PRACTICAL BIOC, P183; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; Schertler GFX, 2000, METHOD ENZYMOL, V315, P91; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; TANFORD C, 1961, PHYSICAL CHEM MACROM, P1; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uzcanga GL, 2004, BIOCHEMISTRY-US, V43, P595, DOI 10.1021/bi0301946; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WESSLINGRESNICK M, 1989, BIOCHEM BIOPH RES CO, V159, P651, DOI 10.1016/0006-291X(89)90044-2; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	87	32	33	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39565	39573		10.1074/jbc.M402446200	http://dx.doi.org/10.1074/jbc.M402446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258159	hybrid			2022-12-25	WOS:000223791500046
J	Barnes, BR; Marklund, S; Steiler, TL; Walter, M; Hjalm, G; Amarger, V; Mahlapuu, M; Leng, Y; Johansson, C; Galuska, D; Lindgren, K; Abrink, M; Stapleton, D; Zierath, JR; Andersson, L				Barnes, BR; Marklund, S; Steiler, TL; Walter, M; Hjalm, G; Amarger, V; Mahlapuu, M; Leng, Y; Johansson, C; Galuska, D; Lindgren, K; Abrink, M; Stapleton, D; Zierath, JR; Andersson, L			The 5 '-AMP-activated protein kinase gamma 3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; GLUCOSE-TRANSPORT; GLYCOGEN-SYNTHASE; ENZYME-ACTIVITIES; SUBUNIT ISOFORMS; EUKARYOTIC CELL; CARRIER PIGS; AMP KINASE; CONTRACTION; EXPRESSION	5'-AMP-activated protein kinase (AMPK) is a metabolic stress sensor present in all eukaryotes. A dominant missense mutation (R225Q) in pig PRKAG3, encoding the muscle-specific gamma3 isoform, causes a marked increase in glycogen content. To determine the functional role of the AMPK gamma3 isoform, we generated transgenic mice with skeletal muscle-specific expression of wild type or mutant (225Q) mouse gamma3 as well as Prkag3 knockout mice. Glycogen resynthesis after exercise was impaired in AMPK gamma3 knock-out mice and markedly enhanced in transgenic mutant mice. An AMPK activator failed to increase skeletal muscle glucose uptake in AMPK gamma3 knock-out mice, whereas contraction effects were preserved. When placed on a high fat diet, transgenic mutant mice but not knock-out mice were protected against excessive triglyceride accumulation and insulin resistance in skeletal muscle. Transfection experiments reveal the R225Q mutation is associated with higher basal AMPK activity and diminished AMP dependence. Our results validate the muscle-specific AMPK gamma3 isoform as a therapeutic target for prevention and treatment of insulin resistance.	Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Anim Breeding & Genet, Uppsala Biomed Ctr, SE-75124 Uppsala, Sweden; St Vincents Inst, Fitzroy, Vic 3065, Australia; Swedish Univ Agr Sci, Dept Mol Biosci, SE-75123 Uppsala, Sweden; Arexis AB, Arvid Wallgrens Backe, SE-41346 Gothenburg, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Dept Med Biochem & Microbiol, SE-75124 Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish University of Agricultural Sciences; St. Vincent's Institute of Medical Research; Swedish University of Agricultural Sciences; Uppsala University	Zierath, JR (corresponding author), Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, von Eulers Vag 4,II, SE-17177 Stockholm, Sweden.	Juleen.Zierath@fyfa.ki.se; Leif.Andersson@imbim.uu.se	Åbrink, Magnus/AAK-8346-2020	Amarger, Valerie/0000-0001-9258-6675; Zierath, Juleen/0000-0001-6891-7497; Mahlapuu, Margit/0000-0001-8740-8874; Abrink, Magnus/0000-0002-1335-3927				Adams J, 2004, PROTEIN SCI, V13, P155, DOI 10.1110/ps.03340004; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; Ciobanu D, 2001, GENETICS, V159, P1151; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; ESTRADE M, 1994, COMP BIOCHEM PHYS B, V108, P295, DOI 10.1016/0305-0491(94)90080-9; ESTRADE M, 1993, COMP BIOCHEM PHYS B, V104, P321, DOI 10.1016/0305-0491(93)90375-F; Gros L, 1999, HUM GENE THER, V10, P1207, DOI 10.1089/10430349950018193; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; HUNDAL HS, 1993, FEBS LETT, V328, P253, DOI 10.1016/0014-5793(93)80938-Q; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Koistinen HA, 2003, DIABETES, V52, P1066, DOI 10.2337/diabetes.52.5.1066; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Lebret B, 1999, J ANIM SCI, V77, P1482; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MONIN G, 1992, 38 INT C MEAT SCI TE, V3, P391; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Ryder JW, 1999, FASEB J, V13, P2246, DOI 10.1096/fasebj.13.15.2246; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; YOUNG DA, 1990, DIABETES, V39, P1408, DOI 10.2337/diabetes.39.11.1408; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	38	250	267	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38441	38447		10.1074/jbc.M405533200	http://dx.doi.org/10.1074/jbc.M405533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247217	hybrid			2022-12-25	WOS:000223684100047
J	Jiang, X; Norman, M; Roth, L; Li, XQ				Jiang, X; Norman, M; Roth, L; Li, XQ			Protein-DNA array-based identification of transcription factor activities regulated by interaction with the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; STEROID-HORMONE RECEPTORS; FUNCTIONAL ANTAGONISM; GENE-TRANSCRIPTION; HUMAN-CELLS; ACTIVATION; BINDING; EXPRESSION; STAT5; ALPHA	The glucocorticoid receptor (GR) regulates gene expression by binding specific sequence elements within the promoters of target genes or by cross-talk with other transcription factors (TFs). For some TFs, interaction with the GR results in alteration of DNA binding and transcriptional regulation. We used a protein-DNA array, a system that facilitates simultaneous profiling of the activities of multiple transcription factors, to systematically examine the potential cross-talk of GRalpha with 149 TFs. Using this array, we identified several TFs, including IRF, E47, and COUP-TF, whose DNA binding activities were modulated by GRalpha. We then confirmed these results with in vitro electrophoretic mobility shift assays and in vivo reporter assays. In this study, IRF and E47 were identified as participants in GRalpha cross-talk for the first time. This new finding expands our understanding of the functional role of GRalpha in the context of gene expression regulation.	Panomics Inc, Redwood City, CA 94063 USA; Univ Bristol, LINE, Bristol BS1 3NY, Avon, England	University of Bristol	Jiang, X (corresponding author), Panomics Inc, E Bayshore Rd, Redwood City, CA 94063 USA.	xjiang@panomics.com						Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Coccia EM, 2001, BIOCHEM J, V360, P285, DOI 10.1042/0264-6021:3600285; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Jiang X, 2003, BBA-MOL CELL RES, V1642, P1, DOI 10.1016/S0167-4889(03)00080-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Lam Robert, 2002, American Biotechnology Laboratory, V20, P26; Lechner J, 1997, IMMUNOBIOLOGY, V198, P112, DOI 10.1016/S0171-2985(97)80032-0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASSIMO U, 2004, MOL ENDOCRINOL, V18, P820; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Rudiger JJ, 2002, FASEB J, V16, P177, DOI 10.1096/fj.01-0226com; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schimmere BP., 1996, GOODMAN GILMANS PHAR, V9th ed., P1459; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Suh DS, 1997, MOL ENDOCRINOL, V11, P1822, DOI 10.1210/me.11.12.1822; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; YEN PM, 1995, ENDOCRINOLOGY, V136, P440, DOI 10.1210/en.136.2.440	36	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38480	38485		10.1074/jbc.M403948200	http://dx.doi.org/10.1074/jbc.M403948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247296	hybrid			2022-12-25	WOS:000223684100052
J	Hirai, M; Ono, K; Morimoto, T; Kawamura, T; Wada, H; Kita, T; Hasegawa, K				Hirai, M; Ono, K; Morimoto, T; Kawamura, T; Wada, H; Kita, T; Hasegawa, K			FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; GENE-EXPRESSION; CARDIOMYOCYTE HYPERTROPHY; HEART MORPHOGENESIS; DNA-SYNTHESIS; PROTEIN; COFACTOR; BINDING; PHOSPHORYLATION; ACETYLATION	A multizinc finger protein, FOG-2, associates with a cardiac transcription factor, GATA-4, and represses GATA-4-dependent transcription. GATA-4 is required not only for normal heart development but is also involved in hypertrophic responses in cardiac myocytes; however, the effects of FOG-2 on these responses are unknown. The interaction of GATA-4 with a transcriptional coactivator p300 is required for its full transcriptional activity and the activation of the embryonic program during myocardial cell hypertrophy. We show here that exogenous FOG-2 represses phenylephrine-induced hypertrophic responses such as myofibrillar organization, increases in cell size, and hypertrophy-associated gene transcription. Using immunoprecipitation Western blotting, we demonstrate that FOG-2 physically interacted with p300 and reduced the binding of GATA-4 to p300. In addition, in COS7 cells, in which the function of endogenous p300 is disrupted, FOG-2 is unable to repress the GATA-4-dependent transcriptional activities; however, FOG-2 markedly repressed the p300-mediated increase in the DNA-binding and transcriptional activities of GATA-4 in these cells. Similarly, FOG-2 inhibited a phenylephrine-induced increase in the p300/GATA-4 interaction, the GATA-4/DNA-binding, and transcriptional activities of GATA-4-dependent promoters in cardiac myocytes as well. These findings demonstrate that FOG-2 represses hypertrophic responses in cardiac myocytes and that p300 is involved in these repressive effects.	Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, Kyoto 6128555, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, Mukaihata Cho, Kyoto 6128555, Japan.	koj@kuhp.kyoto-u.ac.jp		Wada, Hiromichi/0000-0002-8980-224X				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, J CELL SCI, V114, P2363; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	36	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37640	37650		10.1074/jbc.M401737200	http://dx.doi.org/10.1074/jbc.M401737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220332	hybrid			2022-12-25	WOS:000223554600055
J	Monticelli, S; Solymar, DC; Rao, A				Monticelli, S; Solymar, DC; Rao, A			Role of NFAT proteins in IL13 gene transcription in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; EMBRYONIC STEM-CELLS; T-CELLS; FACTOR GATA-1; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC-CELLS; CYTOKINE PRODUCTION; IN-VIVO; EXPRESSION; IL-4	Th2 and mast cells are participants in the asthmatic response to allergens, and both cell types produce the cytokines interleukin (IL)-4 and IL-13. IL-13 in particular is both necessary and sufficient for experimental models of asthma. The transcription factor NFAT plays a central role in cytokine transcriptional regulation in both cell types. Here, we analyze the molecular basis of IL13 gene transcription in Th2 and mast cells. We show that NFAT1 is the major NFAT protein involved in regulating IL13 transcription in mast cells. Although NFAT2 is correctly expressed and regulated in mast cells, it does not contribute to IL13 gene transcription as shown by analysis of cells lacking NFAT2 and cells expressing a constitutively active version of NFAT2. The difference between NFAT1 and NFAT2 appears to be due to a preferential synergistic interaction of NFAT1 with GATA proteins at the IL13 promoter. We suggest that mast cells lack a co-activator protein that stabilizes the binding of NFAT2 to the IL13 promoter by interacting either with NFAT2 itself or with a DNA-bound complex of NFAT2 and GATA proteins.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; CBR Inst Biomed Res, Boston, MA 02115 USA; Univ Milan, Div Biotechnol Appl Med Sci, I-20133 Milan, Italy; Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); University of Milan; Harvard University; Harvard Medical School	Rao, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Warren Alpert Bldg,Rm 152,200 Longwood Ave, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu	Monticelli, Silvia/ABE-7054-2020	Monticelli, Silvia/0000-0002-5909-8802	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044432] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hanks MC, 1998, DEVELOPMENT, V125, P4521; Hock MB, 2003, J BIOL CHEM, V278, P26695, DOI 10.1074/jbc.M301007200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hural JA, 2000, J IMMUNOL, V165, P3239, DOI 10.4049/jimmunol.165.6.3239; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; LEONARD M, 1993, BLOOD, V82, P1071; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Malynn BA, 2000, GENE DEV, V14, P1390; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Morimoto T, 2001, J BIOL CHEM, V276, P34983, DOI 10.1074/jbc.M005498200; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nemer G, 2002, DEVELOPMENT, V129, P4045; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Pai SY, 2003, IMMUNITY, V19, P863, DOI 10.1016/S1074-7613(03)00328-5; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; Stroud JC, 2003, J MOL BIOL, V334, P1009, DOI 10.1016/j.jmb.2003.09.065; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsai M, 2000, P NATL ACAD SCI USA, V97, P9186, DOI 10.1073/pnas.160254997; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wang YK, 1997, DEVELOPMENT, V124, P2507; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; Weiss DL, 2001, IMMUNOL REV, V179, P35, DOI 10.1034/j.1600-065X.2001.790104.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamaguchi Y, 1998, BLOOD, V91, P3447, DOI 10.1182/blood.V91.9.3447.3447_3447_3458; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	61	74	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36210	36218		10.1074/jbc.M406354200	http://dx.doi.org/10.1074/jbc.M406354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15229217	hybrid			2022-12-25	WOS:000223453600008
J	Petyuk, V; McDermott, J; Cook, M; Sauer, B				Petyuk, V; McDermott, J; Cook, M; Sauer, B			Functional mapping of Cre recombinase by pentapeptide insertional mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; HOLLIDAY JUNCTION COMPLEX; CRYSTAL-STRUCTURE; LOXP SITE; IN-VITRO; DNA TRANSPOSITION; TOPOISOMERASE-I; INTEGRASE; CLEAVAGE; SYNAPSE	Cre is a site-specific recombinase from bacteriophage P1. It is a member of the tyrosine integrase family and catalyzes reciprocal recombination between specific 34-bp sites called loxP. To analyze the structure-function relationships of this enzyme, we performed large scale pentapeptide insertional mutagenesis to generate insertions of five amino acids at random positions in the protein. The high density of insertion mutations into Cre allowed us to identify an unexpected degree of functional tolerance to insertions into the 4-5 beta-hairpin and into the loop between helices J and K (both of which contact the DNA in the minor groove) and also into helix A. The phenotypes of the majority of inserts allowed us to confirm a variety of predictions made on the basis of sequence conservation, known three-dimensional structure, and proposed catalytic mechanism. In particular, most insertions into conserved regions or secondary structure elements inactivated Cre, and most insertions located in non-conserved, unstructured regions preserved Cre activity. Less expectedly, the non-conserved and poorly structured loops and linkers between helices A-B, E-F, and M-N did not tolerate insertions, thus identifying these as critical regions for recombinase activity. We purified and characterized in vitro several representatives of these "unexpected" Cre insertion mutants. The role of those regions in the recombination process is discussed.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Sauer, B (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	BLS@stowers-institute.org		Cook, Malcolm/0000-0002-2825-9183; Petyuk, Vladislav/0000-0003-4076-151X				Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biery MC, 2000, NUCLEIC ACIDS RES, V28, P1067, DOI 10.1093/nar/28.5.1067; Cao YH, 1997, J MOL BIOL, V274, P39, DOI 10.1006/jmbi.1997.1380; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haapa S, 1999, NUCLEIC ACIDS RES, V27, P2777, DOI 10.1093/nar/27.13.2777; Haapa-Paananen S, 2002, J BIOL CHEM, V277, P2843, DOI 10.1074/jbc.M108044200; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Lee L, 2003, J BIOL CHEM, V278, P36905, DOI 10.1074/jbc.M305464200; Lee L, 2003, J BIOL CHEM, V278, P23118, DOI 10.1074/jbc.M302272200; MACK A, 1992, NUCLEIC ACIDS RES, V20, P4451, DOI 10.1093/nar/20.17.4451; Martin SS, 2003, BIOCHEMISTRY-US, V42, P6814, DOI 10.1021/bi0272306; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Poussu E, 2004, PROTEINS, V54, P681, DOI 10.1002/prot.10467; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; Rufer A, 2002, ANAL BIOCHEM, V308, P90, DOI 10.1016/S0003-2697(02)00247-6; Rufer AW, 2002, NUCLEIC ACIDS RES, V30, P2764, DOI 10.1093/nar/gkf399; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shaikh AC, 2000, J BIOL CHEM, V275, P30186, DOI 10.1074/jbc.M005256200; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Woods KC, 2001, J MOL BIOL, V313, P49, DOI 10.1006/jmbi.2001.5012	34	14	15	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37040	37048		10.1074/jbc.M406042200	http://dx.doi.org/10.1074/jbc.M406042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218019	hybrid			2022-12-25	WOS:000223453600107
J	Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK				Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK			Independent component analysis of microarray data in the study of endometrial cancer	ONCOGENE			English	Article						endometrial cancer; lipid metabolism; principal components analysis; independent component analysis; gene microarrays	GENE-EXPRESSION PROFILES; ENDOGENOUS HORMONES; CLASSIFICATION; HETEROZYGOSITY	Gene microarray technology is highly effective in screening for differential gene expression and has hence become a popular tool in the molecular investigation of cancer. When applied to tumours, molecular characteristics may be correlated with clinical features such as response to chemotherapy. Exploitation of the huge amount of data generated by microarrays is difficult, however, and constitutes a major challenge in the advancement of this methodology. Independent component analysis (ICA), a modern statistical method, allows us to better understand data in such complex and noisy measurement environments. The technique has the potential to significantly increase the quality of the resulting data and improve the biological validity of subsequent analysis. We performed microarray experiments on 31 postmenopausal endometrial biopsies, comprising 11 benign and 20 malignant samples. We compared ICA to the established methods of principal component analysis (PCA), Cyber-T, and SAM. We show that ICA generated patterns that clearly characterized the malignant samples studied, in contrast to PCA. Moreover, ICA improved the biological validity of the genes identified as differentially expressed in endometrial carcinoma, compared to those found by Cyber-T and SAM. In particular, several genes involved in lipid metabolism that are differentially expressed in endometrial carcinoma were only found using this method. This report highlights the potential of ICA in the analysis of microarray data.	Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England; Univ Cambridge, Dept Pathol, Cambridge CB1 1QP, England; Univ Cambridge, Cavendish Lab, Dept Phys, Inference Grp, Cambridge CB3 0HE, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Saidi, SA (corresponding author), Rosie Hosp, Dept Obstet & Gynaecol, Box 223,Robinson Way, Cambridge CB2 2SW, England.	samsaidi@obgyn.cam.ac.uk	Charnock-Jones, D. Stephen/AAE-3391-2020; Kreil, D/O-1783-2013; Charnock-Jones, D. Stephen/B-3743-2009; Smith, Stephen K/F-6938-2012	Charnock-Jones, D. Stephen/0000-0002-2936-4890; Kreil, D/0000-0001-7538-2056; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Saidi, Samir/0000-0001-5165-2461; Print, Cristin/0000-0001-8345-7812; Smith, Stephen/0000-0003-1912-3935				Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Badawi AF, 2002, INT J ONCOL, V20, P1109; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Borthwick JM, 2003, MOL HUM REPROD, V9, P19, DOI 10.1093/molehr/gag004; Burgess JK, 2001, CLIN EXP PHARMACOL P, V28, P321, DOI 10.1046/j.1440-1681.2001.03448.x; Draghici S, 2001, Curr Opin Drug Discov Devel, V4, P332; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans Amanda L., 2003, Angiogenesis, V6, P93, DOI 10.1023/B:AGEN.0000011732.83724.e5; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kreil DP, 2003, COMP FUNCT GENOM, V4, P300, DOI 10.1002/cfg.298; Liebermeister W, 2002, BIOINFORMATICS, V18, P51, DOI 10.1093/bioinformatics/18.1.51; Martoglio AM, 2002, BIOINFORMATICS, V18, P1617, DOI 10.1093/bioinformatics/18.12.1617; Miskin J. W., 2000, THESIS U CAMBRIDGE; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Niederacher D, 1998, EUR J CANCER, V34, P1770, DOI 10.1016/S0959-8049(98)00270-6; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Risinger JI, 2003, CANCER RES, V63, P6; Sirchia SM, 2000, CANCER GENET CYTOGEN, V121, P156, DOI 10.1016/S0165-4608(00)00240-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wernisch L, 2003, BIOINFORMATICS, V19, P53, DOI 10.1093/bioinformatics/19.1.53; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Wildsmith SE, 2001, BIOTECHNIQUES, V30, P202, DOI 10.2144/01301dd04	29	71	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6677	6683		10.1038/sj.onc.1207562	http://dx.doi.org/10.1038/sj.onc.1207562			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247901				2022-12-25	WOS:000223530800016
J	Xu, XZ; Lee, J; Stern, DF				Xu, XZ; Lee, J; Stern, DF			Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; IONIZING IRRADIATION; SIGNALING PATHWAYS; CHECKPOINT; PHOSPHORYLATION; 53BP1; MEDIATOR; MDC1; ATM; ACTIVATION	Microcephalin (MCPH1) is the first gene identified among at least six loci that contribute to the autosomal recessive disease, primary microcephaly. MCPH1, like NFBD1/MDC1, 53BP1, and BRCA1, encodes a protein with twin carboxyl-terminal BRCT domains (PTCB). Here, we report that Mcph1 forms ionizing radiation-induced foci. Down-regulation of Mcph1, like other PTCBs, by siRNA, impairs ionizing radiation-induced intra-S-phase and G(2)/M checkpoints. Inhibition of the expression of Mcph1 decreases both protein and transcript levels of endogenous Brca1 but not exogenous Brca1. Mcph1 inhibition also decreases both endogenous and heterologous Chk1 transcripts and protein. We conclude that Mcph1 is involved in DNA damage-induced cellular responses, and we propose that regulation of Brca1 and/or Chk1 by Mcph1 may contribute to these cellular responses.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Xu, XZ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, L-G 133,1500 E Duarte Rd, Duarte, CA 91010 USA.	xaxu@coh.org; df.stern@yale.edu	xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Mochan TA, 2003, CANCER RES, V63, P8586; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Suri M, 2003, EUR J PAEDIATR NEURO, V7, P389, DOI 10.1016/j.ejpn.2003.09.002; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	26	141	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34091	34094		10.1074/jbc.C400139200	http://dx.doi.org/10.1074/jbc.C400139200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15220350	hybrid			2022-12-25	WOS:000223134800004
J	Sever, N; Lee, PCW; Song, BL; Rawson, RB; DeBose-Boyd, RA				Sever, N; Lee, PCW; Song, BL; Rawson, RB; DeBose-Boyd, RA			Isolation of mutant cells lacking Insig-1 through selection with SR-12813, an agent that stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; HMG COA REDUCTASE; ELEMENT-BINDING PROTEINS; LOW-DENSITY-LIPOPROTEIN; STEROL-SENSING DOMAIN; HAMSTER OVARY CELLS; MESSENGER-RNA; ACCELERATES DEGRADATION; REGULATED DEGRADATION	Insig-1 and Insig-2 are membrane proteins of the endoplasmic reticulum that regulate lipid metabolism by the following two actions: 1) sterol-induced binding to 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an action that leads to ubiquitination and degradation of the enzyme; and 2) sterol-induced binding to SREBP cleavage-activating protein, an action that blocks the proteolytic processing of sterol regulatory element-binding proteins (SREBPs), membrane-bound transcription factors that enhance the synthesis of cholesterol and fatty acids. Here we report the isolation of a new mutant line of Chinese hamster ovary cells, designated SRD-14, in which Insig-1 mRNA and protein are not produced due to a partial deletion of the INSIG-1 gene. The SRD-14 cells were produced by gamma-irradiation, followed by selection with the 1,1-bisphosphonate ester SR-12813, which mimics sterols in accelerating reductase degradation but does not block SREBP processing. SRD-14 cells fail to respond to sterols by promoting reductase ubiquitination and degradation. The rate at which sterols suppress SREBP processing is significantly slower in SRD-14 cells than wild type CHO-7 cells. Sterol regulation of reductase degradation and SREBP processing is restored when SRD-14 cells are transfected with expression plasmids encoding either Insig-1 or Insig-2. These results provide formal genetic proof for the essential role of Insig-1 in feedback control of lipid synthesis in cultured cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu	Sever, Navdar/AAB-7906-2022	Sever, Navdar/0000-0001-9462-7979; Song, Bao-Liang/0000-0002-6397-5935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, HL70441] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Berkhout TA, 1996, J BIOL CHEM, V271, P14376, DOI 10.1074/jbc.271.24.14376; Berkhout TA, 1997, ATHEROSCLEROSIS, V133, P203, DOI 10.1016/S0021-9150(97)00131-7; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 1998, CURR OPIN LIPIDOL, V9, P93, DOI 10.1097/00041433-199804000-00003; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1983, J BIOL CHEM, V258, P8450; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Roitelman J, 2004, J BIOL CHEM, V279, P6465, DOI 10.1074/jbc.M308094200; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ylitalo R, 2000, GEN PHARMACOL-VASC S, V35, P287, DOI 10.1016/S0306-3623(01)00121-5	49	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43136	43147		10.1074/jbc.M406406200	http://dx.doi.org/10.1074/jbc.M406406200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15247248	hybrid			2022-12-25	WOS:000224226400098
J	Koshkin, V; Bikopoulos, G; Chan, CB; Wheeler, MB				Koshkin, V; Bikopoulos, G; Chan, CB; Wheeler, MB			The characterization of mitochondrial permeability transition in clonal pancreatic beta-cells - Multiple modes and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; HYDROGEN-PEROXIDE PRODUCTION; RAT-LIVER MITOCHONDRIA; ENZYME GENE-EXPRESSION; CYTOCHROME-C RELEASE; CYCLOSPORINE-A; PHOSPHATE DEHYDROGENASE; INORGANIC-PHOSPHATE; BRAIN MITOCHONDRIA; OXIDATIVE STRESS	Mitochondrial permeability transition (MPT), which contributes substantially to the regulation of normal mitochondrial metabolism, also plays a crucial role in the initiation of cell death. It is known that MPT is regulated in a tissue-specific manner. The importance of MPT in the pancreatic beta-cell is heightened by the fact that mitochondrial bioenergetics serve as the main glucose-sensing regulator and energy source for insulin secretion. In the present study, using MIN6 and INS-1 beta-cells, we revealed that both Ca2+-phosphate- and oxidant-induced MPT is remarkably different from other tissues. Ca2+-phosphate-induced transition is accompanied by a decline in mitochondrial reactive oxygen species production related to a significant potential dependence of reactive oxygen species formation in beta-cell mitochondria. Hydroperoxides, which are indirect MPT co-inducers active in liver and heart mitochondria, are inefficient in beta-cell mitochondria, due to the low mitochondrial ability to metabolize them. Direct cross-linking of mitochondrial thiols in pancreatic beta-cells induces the opening of a low conductance ion permeability of the mitochondrial membrane instead of the full scale MPT opening typical for liver mitochondria. Low conductance MPT is independent of both endogenous and exogenous Ca2+, suggesting a novel type of nonclassical MPT in beta-cells. It results in the conversion of electrical transmembrane potential into DeltapH instead of a decrease in total protonmotive force, thus mitochondrial respiration remains in a controlled state. Both Ca2+- and oxidant-induced MPTs are phosphate-dependent and, through the "phosphate flush" (associated with stimulation of insulin secretion), are expected to participate in the regulation in beta-cell glucose-sensing and secretory activity.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Prince Edward Isl, Dept Anat & Physiol, Charlottetown, PE C1A 7P3, Canada	University of Toronto; University of Toronto; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Wheeler, Michael B./0000-0002-7480-7267				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; BELEZNAI Z, 1988, EUR J BIOCHEM, V170, P631, DOI 10.1111/j.1432-1033.1988.tb13744.x; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; BUKOWIECKI L, 1979, BIOCHIM BIOPHYS ACTA, V583, P370, DOI 10.1016/0304-4165(79)90461-6; CHANCE B, 1961, J BIOL CHEM, V236, P1534; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Contreras JL, 2002, TRANSPLANTATION, V74, P1252, DOI 10.1097/00007890-200211150-00010; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; Drahota Z, 2002, J BIOENERG BIOMEMBR, V34, P105, DOI 10.1023/A:1015123908918; Dubuisson MLN, 2000, BIOCHEM PHARMACOL, V60, P471, DOI 10.1016/S0006-2952(00)00359-2; Dufer M, 2001, MOL PHARMACOL, V60, P873; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FERGUSON SJ, 1982, ANNU REV BIOCHEM, V51, P185, DOI 10.1146/annurev.bi.51.070182.001153; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; GIROIX MH, 1993, BIOCHEM MED METAB B, V50, P301, DOI 10.1006/bmmb.1993.1072; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Herson PS, 1997, J PHYSIOL-LONDON, V501, P59, DOI 10.1111/j.1469-7793.1997.059bo.x; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Ishihara H, 1996, DIABETES, V45, P1238, DOI 10.2337/diabetes.45.9.1238; JOHNSON RC, 1985, BIOCHEM BIOPH RES CO, V129, P862, DOI 10.1016/0006-291X(85)91971-0; Kicinska A, 2000, ACTA BIOCHIM POL, V47, P541; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2000, AM J PHYSIOL-CELL PH, V279, pC852, DOI 10.1152/ajpcell.2000.279.3.C852; Kowaltowski AJ, 2002, J BIOL CHEM, V277, P42802, DOI 10.1074/jbc.M207765200; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; Kwong LK, 2002, METHOD ENZYMOL, V349, P341, DOI 10.1016/S0076-6879(02)49349-4; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; LECABEC V, 1995, J BIOL CHEM, V270, P2067; Lemasters JJ, 1997, BIOSCIENCE REP, V17, P281, DOI 10.1023/A:1027332611839; Lemeshko VV, 2002, BIOCHEM BIOPH RES CO, V291, P170, DOI 10.1006/bbrc.2002.6417; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; Mander AP, 2001, STATA J, V1, P58, DOI 10.1177/1536867X0100100104; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Nethery D, 2000, J APPL PHYSIOL, V89, P72, DOI 10.1152/jappl.2000.89.1.72; Nicholls D., 2002, BIOENERGETICS; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; OHTA M, 1992, BIOCHEM PHARMACOL, V43, P1859, DOI 10.1016/0006-2952(92)90722-U; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; Panov AV, 2004, ARCH BIOCHEM BIOPHYS, V424, P44, DOI 10.1016/j.abb.2004.01.013; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Poitout V, 1996, DIABETES METAB, V22, P7; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Schild L, 2001, FASEB J, V15, P565; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wu DF, 2002, HEPATOLOGY, V35, P1420, DOI 10.1053/jhep.2002.33639; YAGI T, 1984, BIOCHEMISTRY-US, V23, P2449, DOI 10.1021/bi00306a020; Zoccarato F, 2004, J BIOL CHEM, V279, P4166, DOI 10.1074/jbc.M308143200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	79	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41368	41376		10.1074/jbc.M406914200	http://dx.doi.org/10.1074/jbc.M406914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15231823	hybrid			2022-12-25	WOS:000224075500017
J	Fuda, C; Suvorov, M; Vakulenko, SB; Mobashery, S				Fuda, C; Suvorov, M; Vakulenko, SB; Mobashery, S			The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; PBP 2A; CEPHALOSPORIN; KINETICS; INVOLVEMENT; ACYLATION; STRAIN	Penicillin-binding protein 2a (PBP2a) of Staphylococcus aureus is refractory to inhibition by available beta-lactam antibiotics, resulting in resistance to these antibiotics. The strains of S. aureus that have acquired the mecA gene for PBP2a are designated as methicillin-resistant S. aureus (MRSA). The mecA gene was cloned and expressed in Escherichia coli, and PBP2a was purified to homogeneity. The kinetic parameters for interactions of several beta-lactam antibiotics (penicillins, cephalosporins, and a carbapenem) and PBP2a were evaluated. The enzyme manifests resistance to covalent modification by beta-lactam antibiotics at the active site serine residue in two ways. First, the microscopic rate constant for acylation (k(2)) is attenuated by 3 to 4 orders of magnitude over the corresponding determinations for penicillin-sensitive penicillin-binding proteins. Second, the enzyme shows elevated dissociation constants (K-d) for the non-covalent pre-acylation complexes with the antibiotics, the formation of which ultimately would lead to enzyme acylation. The two factors working in concert effectively prevent enzyme acylation by the antibiotics in vivo, giving rise to drug resistance. Given the opportunity to form the acyl enzyme species in in vitro experiments, circular dichroism measurements revealed that the enzyme undergoes substantial conformational changes in the course of the process that would lead to enzyme acylation. The observed conformational changes are likely to be a hallmark for how this enzyme carries out its catalytic function in cross-linking the bacterial cell wall.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu			NIGMS NIH HHS [GM61629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartley Judene, 2002, Infect Control Hosp Epidemiol, V23, P480; Bush K, 1998, ADV EXP MED BIOL, V456, P71; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P931; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P322; Crisostomo MI, 2001, P NATL ACAD SCI USA, V98, P9865, DOI 10.1073/pnas.161272898; Dailey CF, 2001, ANTIMICROB AGENTS CH, V45, P2304, DOI 10.1128/AAC.45.8.2304-2308.2001; Drew RH, 2000, J ANTIMICROB CHEMOTH, V46, P775, DOI 10.1093/jac/46.5.775; Enright MC, 2002, P NATL ACAD SCI USA, V99, P7687, DOI 10.1073/pnas.122108599; Entenza JM, 2002, ANTIMICROB AGENTS CH, V46, P171, DOI 10.1128/AAC.46.1.171-177.2002; GEORGOPAPADAKOU NH, 1986, ANTIMICROB AGENTS CH, V29, P333, DOI 10.1128/AAC.29.2.333; Goffin C, 2002, MICROBIOL MOL BIOL R, V66, P702, DOI 10.1128/MMBR.66.4.702-738.2002; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Graves-Woodward K, 1998, BIOCHEM J, V332, P755, DOI 10.1042/bj3320755; HACKBARTH CJ, 1994, ANTIMICROB AGENTS CH, V38, P2568, DOI 10.1128/AAC.38.11.2568; Ishikawa T, 2003, BIOORGAN MED CHEM, V11, P2427, DOI 10.1016/S0968-0896(03)00126-3; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; Katayama Y, 2004, ANTIMICROB AGENTS CH, V48, P453, DOI 10.1128/AAC.48.2.453-459.2004; Katayama Y, 2003, J BACTERIOL, V185, P5465, DOI 10.1128/JB.185.18.5465-5472.2003; Lee W, 2001, P NATL ACAD SCI USA, V98, P1427, DOI 10.1073/pnas.98.4.1427; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; Lu WP, 1999, BIOCHEMISTRY-US, V38, P6537, DOI 10.1021/bi990025e; Malouin F, 2003, ANTIMICROB AGENTS CH, V47, P658, DOI 10.1128/AAC.47.2.658-664.2003; Pinho MG, 2001, P NATL ACAD SCI USA, V98, P10886, DOI 10.1073/pnas.191260798; Pinho MG, 1997, MICROB DRUG RESIST, V3, P409, DOI 10.1089/mdr.1997.3.409; Richter SS, 2003, J ANTIMICROB CHEMOTH, V52, P123, DOI 10.1093/jac/dkg288; ROYCHOUDHURY S, 1994, J BIOL CHEM, V269, P12067; Sun YP, 1998, J MASS SPECTROM, V33, P1009, DOI 10.1002/(SICI)1096-9888(1998100)33:10<1009::AID-JMS717>3.0.CO;2-4; Tsiodras S, 2001, LANCET, V358, P207, DOI 10.1016/S0140-6736(01)05410-1; Walsh TR, 2001, J CLIN MICROBIOL, V39, P2439, DOI 10.1128/JCM.39.7.2439-2444.2001; WU CYE, 1994, J BACTERIOL, V176, P443, DOI 10.1128/JB.176.2.443-449.1994; Zhao GS, 1999, ANTIMICROB AGENTS CH, V43, P1124, DOI 10.1128/AAC.43.5.1124	33	166	177	0	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40802	40806		10.1074/jbc.M403589200	http://dx.doi.org/10.1074/jbc.M403589200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15226303	hybrid			2022-12-25	WOS:000223916800074
J	Muntener, K; Zwicky, R; Csucs, G; Rohrer, J; Baici, A				Muntener, K; Zwicky, R; Csucs, G; Rohrer, J; Baici, A			Exon skipping of cathepsin B - Mitochondrial targeting of a lysosomal peptidase provokes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED HEPATOCYTE APOPTOSIS; FEMORAL-HEAD CARTILAGE; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; GOLGI-APPARATUS; QUALITY-CONTROL; ENZYME FORMS; PROTEASE; GENE; OSTEOARTHRITIS	The alternatively spliced messenger RNA of the human cysteine peptidase cathepsin B missing exons 2 and 3 encodes a truncated form of the enzyme lacking the signal peptide and part of the inhibitory propeptide. This deletion results in a new N-terminal leader sequence characteristic of proteins predestined for transport into mitochondria. We determined enzyme targeting to intracellular organelles by transfecting HeLa cells with constructs containing segments of variable length of the N terminus of truncated cathepsin B fused to green fluorescent protein. Co-localization of the constructs with mitochondria and the endoplasmic reticulum was probed with specific markers. None of the chimeric products were found in the endoplasmic reticulum, showing that truncated cathepsin B is misrouted from its regular biosynthetic pathway and forced to enter the mitochondria instead of lysosomes as its final destination. The first 20 amino acids of the new N terminus were necessary and sufficient for mitochondrial targeting, but only cells expressing the complete truncated cathepsin B sequence died by nuclear fragmentation. This new and unexpected behavior draws attention to an additional extralysosomal role for a cysteine peptidase with several recognized important pathophysiological functions. Mitochondrial targeting of cathepsin B may have significant consequences on cell life in pathological or physiological situations characterized by excessive transcription of the cathepsin B message lacking exons 2 and 3, as observed for instance in osteoarthritic cartilage.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Light Microscopy Ctr, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Zurich, Dept Physiol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Baici, A (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	abaici@bioc.unizh.ch		Baici, Antonio/0000-0002-2980-0541; Rohrer, Jack/0000-0002-2058-490X				BAICI A, 1995, ANN RHEUM DIS, V54, P289, DOI 10.1136/ard.54.4.289; BAICI A, 1995, ANN RHEUM DIS, V54, P281, DOI 10.1136/ard.54.4.281; Berardi S, 2001, ARTHRITIS RHEUM, V44, P1819, DOI 10.1002/1529-0131(200108)44:8<1819::AID-ART319>3.0.CO;2-4; BERQUIN IM, 1995, GENE, V159, P143, DOI 10.1016/0378-1119(95)00072-E; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Muntener K, 2003, HISTOCHEM CELL BIOL, V119, P93, DOI 10.1007/s00418-002-0487-y; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; Yan SQ, 1998, BIOL CHEM, V379, P113; Zwicky R, 2003, BIOL CHEM, V384, P1007, DOI 10.1515/BC.2003.113	25	47	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41012	41017		10.1074/jbc.M405333200	http://dx.doi.org/10.1074/jbc.M405333200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262981	hybrid			2022-12-25	WOS:000223916800099
J	Arrisi-Mercado, P; Romano, M; Muro, AF; Baralle, FE				Arrisi-Mercado, P; Romano, M; Muro, AF; Baralle, FE			An exonic splicing enhancer offsets the atypical GU-rich 3 ' splice site of human apolipoprotein A-II exon 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYPYRIMIDINE TRACT; FUNCTIONAL-ANALYSIS; SR-PROTEINS; SEQUENCES; SITE; SELECTION; GENE; ELEMENT; IDENTIFICATION	Human apolipoprotein A-II (apoA-II) intron 2/exon 3 junction shows a peculiar tract of alternating pyrimidines and purines (GU tract) that makes the acceptor site deviate significantly from the consensus. However, apoA-II exon 3 is constitutively included in mRNA. We have studied this unusual exon definition by creating a construct with the genomic fragment encompassing the whole gene from apoA-II and its regulatory regions. Transient transfections in Hep3B cells have shown that deletion or replacement of the GU repeats at the 3' splice site resulted in a decrease of apoA-II exon 3 inclusion, indicating a possible role of the GU tract in splicing. However, a 3' splice site composed of the GU tract in heterologous context, such as the extra domain A of human fibronectin or cystic fibrosis transmembrane conductance regulator exon 9, resulted in total skipping of the exons. Next, we identified the exonic cis-acting elements that may affect the splicing efficiency of apoA-II exon 3 and found that the region spanning from nucleotide 87 to 113 of human apoA-II exon 3 is essential for its inclusion in the mRNA. Overlapping deletions and point mutations ( between nucleotides 91 and 102) precisely defined an exonic splicing enhancer (ESEwt). UV cross-linking assays followed by immunoprecipitation with anti-SR protein monoclonal antibodies showed that ESEwt, but not mutated ESE RNA, was able to bind both alternative splicing factor/splicing factor 2 and SC35. Furthermore, overexpression of both splicing factors enhanced exon 3 inclusion. These results show that this protein-ESE interaction is able to promote the incorporation of exon 3 in mRNA and suggest that they can rescue the splicing despite the noncanonical 3' splice site.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	baralle@icgeb.org	Muro, Andrés F/K-3156-2016; Romano, Maurizio/G-9431-2012	Muro, Andrés F/0000-0002-9628-0494; Romano, Maurizio/0000-0002-4820-2897	Telethon [GGP02453] Funding Source: Medline	Telethon(Fondazione Telethon)		Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DORK T, 1994, HUM GENET, V93, P67; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Kwok JBJ, 2003, J BIOL CHEM, V278, P6748, DOI 10.1074/jbc.M211827200; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Muro AF, 1998, FEBS LETT, V437, P137, DOI 10.1016/S0014-5793(98)01201-0; Niksic M, 1999, HUM MOL GENET, V8, P2339, DOI 10.1093/hmg/8.13.2339; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schaal TD, 1999, MOL CELL BIOL, V19, P261; SHELLEY CS, 1985, J MOL BIOL, V186, P43, DOI 10.1016/0022-2836(85)90255-4; SHELLEY CS, 1987, NUCLEIC ACIDS RES, V15, P3787, DOI 10.1093/nar/15.9.3787; Shin D, 2003, BIOCHEM J, V374, P175, DOI 10.1042/BJ20030132; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Webb KE, 2003, EXP HEMATOL, V31, P488, DOI 10.1016/S0301-472X(03)00065-1; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	34	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39331	39339		10.1074/jbc.M405566200	http://dx.doi.org/10.1074/jbc.M405566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247216	hybrid			2022-12-25	WOS:000223791500018
J	da-Silva, WS; Gomez-Puyou, A; de Gomez-Puyou, MT; Moreno-Sanchez, R; De Felice, FG; de Meis, L; Oliveira, MF; Galina, A				da-Silva, WS; Gomez-Puyou, A; de Gomez-Puyou, MT; Moreno-Sanchez, R; De Felice, FG; de Meis, L; Oliveira, MF; Galina, A			Mitochondrial bound hexokinase activity as a preventive antioxidant Defense - Steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; RAT-BRAIN HEXOKINASE; APOPTOTIC CELL-DEATH; CYTOCHROME-C; HYDROGEN-PEROXIDE; OXIDATIVE-PHOSPHORYLATION; ENERGY-METABOLISM; INTRAMITOCHONDRIAL COMPARTMENTS; INTRACELLULAR-LOCALIZATION; MAMMALIAN HEXOKINASE	Brain hexokinase is associated with the outer membrane of mitochondria, and its activity has been implicated in the regulation of ATP synthesis and apoptosis. Reactive oxygen species (ROS) are by-products of the electron transport chain in mitochondria. Here we show that the ADP produced by hexokinase activity in rat brain mitochondria (mt-hexokinase) controls both membrane potential (DeltaPsi(m)) and ROS generation. Exposing control mitochondria to glucose increased the rate of oxygen consumption and reduced the rate of hydrogen peroxide generation. Mitochondrial associated hexokinase activity also regulated DeltaPsi(m), because glucose stabilized low DeltaPsi(m) values in state 3. Interestingly, the addition of glucose 6-phosphate significantly reduced the time of state 3 persistence, leading to an increase in the DeltaPsi(m) and in H2O2 generation. The glucose analogue 2-deoxyglucose completely impaired H2O2 formation in state 3-state 4 transition. In sharp contrast, the mt-hexokinase-depleted mitochondria were, in all the above mentioned experiments, insensitive to glucose addition, indicating that the mt-hexokinase activity is pivotal in the homeostasis of the physiological functions of mitochondria. When mt-hexokinase-depleted mitochondria were incubated with exogenous yeast hexokinase, which is not able to bind to mitochondria, the rate of H2O2 generation reached levels similar to those exhibited by control mitochondria only when an excess of 10-fold more enzyme activity was supplemented. Hyperglycemia induced in embryonic rat brain cortical neurons increased ROS production due to a rise in the intracellular glucose 6-phosphate levels, which were decreased by the inclusion of 2-deoxyglucose, N-acetyl cysteine, or carbonyl cyanide p-trifluoromethoxyphenylhydrazone. Taken together, the results presented here indicate for the first time that mt-hexokinase activity performed a key role as a preventive antioxidant against oxidative stress, reducing mitochondrial ROS generation through an ADP-recycling mechanism.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico	Universidade Federal do Rio de Janeiro; Universidad Nacional Autonoma de Mexico; National Institute of Cardiology - Mexico	Oliveira, MF (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Av Brigadeiro Trompowsky S-N,CCS,Bloco E,Sala E-0, BR-21941590 Rio De Janeiro, Brazil.	maroli@bioqmed.ufrj; galina@bioqmed.ufrj.br	De Felice, Fernanda G/M-1074-2017; Oliveira, Marcus/G-3158-2011; da Silva, Wagner S/A-7835-2008; Moreno-Sanchez, Rafael/A-3158-2011; Galina, Antonio/A-9292-2008	Oliveira, Marcus/0000-0002-9890-8425; da Silva, Wagner S/0000-0002-0001-0386; Moreno-Sanchez, Rafael/0000-0002-9587-7184; 				Ahmad A, 2002, AM J PHYSIOL-LUNG C, V283, pL573, DOI 10.1152/ajplung.00410.2001; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BELTRANDELRIO H, 1991, ARCH BIOCHEM BIOPHYS, V286, P183, DOI 10.1016/0003-9861(91)90026-F; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1980, BIOCHEMISTRY-US, V19, P4972, DOI 10.1021/bi00563a006; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cesar MD, 2004, ARCH BIOCHEM BIOPHYS, V422, P191, DOI 10.1016/j.abb.2003.12.030; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; CHEN W, 1992, BIOCHIMIE, V74, P867, DOI 10.1016/0300-9084(92)90070-U; CRANE RK, 1954, J BIOL CHEM, V210, P597; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3; FISKUM G, 1985, ANN EMERG MED, V14, P810, DOI 10.1016/S0196-0644(85)80063-9; Fujimura M, 1999, J NEUROSCI, V19, P3414; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KABIR F, 1993, ARCH BIOCHEM BIOPHYS, V300, P641, DOI 10.1006/abbi.1993.1089; KAJI A, 1965, J BIOL CHEM, V240, P4454; KEENOY BMY, 1992, BIOCHEM J, V288, P433, DOI 10.1042/bj2880433; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Low PA, 1997, DIABETES, V46, pS38, DOI 10.2337/diab.46.2.S38; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MOORE CL, 1970, ARCH BIOCHEM BIOPHYS, V138, P295, DOI 10.1016/0003-9861(70)90310-3; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; PARRY DM, 1984, J BIOL CHEM, V259, P8917; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VIITANEN PV, 1984, J BIOL CHEM, V259, P9679; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893; Wilson JE, 1997, J BIOENERG BIOMEMBR, V29, P97, DOI 10.1023/A:1022472124746; WILSON JE, 1973, ARCH BIOCHEM BIOPHYS, V154, P332, DOI 10.1016/0003-9861(73)90065-9; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	71	212	214	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39846	39855		10.1074/jbc.M403835200	http://dx.doi.org/10.1074/jbc.M403835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247300	hybrid			2022-12-25	WOS:000223791500080
J	Aiello, DP; Fu, LW; Miseta, A; Sipos, K; Bedwell, DM				Aiello, DP; Fu, LW; Miseta, A; Sipos, K; Bedwell, DM			The Ca2+ Homeostasis defects in a pgm2 Delta strain of Saccharomyces cerevisiae are caused by excessive vacuolar Ca2+ uptake mediated by the Ca2+-ATPase Pmc1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN-RESPONSE; YEAST SECRETORY PATHWAY; TRANSCRIPTION FACTOR; QUALITY-CONTROL; LACKING PMR1; CALCIUM; HOMOLOG; GOLGI; CHANNEL	Loss of the major isoform of phosphoglucomutase (PGM) causes an accumulation of glucose 1-phosphate when yeast cells are grown with galactose as the carbon and energy source. Remarkably, the pgm2Delta strain also exhibits a severe imbalance in intracellular Ca2+ homeostasis when grown under these conditions. In the present study, we examined how the pgm2Delta mutation alters yeast Ca2+ homeostasis in greater detail. We found that a shift from glucose to galactose as the carbon source resulted in a 2-fold increase in the rate of cellular Ca2+ uptake in wild-type cells, whereas Ca2+ uptake increased 8-fold in the pgm2Delta mutant. Disruption of the PMC1 gene, which encodes the vacuolar Ca2+-ATPase Pmc1p, suppressed the Ca2+-related phenotypes observed in the pgm2Delta strain. This suggests that excessive vacuolar Ca2+ uptake is tightly coupled to these defects in Ca2+ homeostasis. An in vitro assay designed to measure Ca2+ sequestration into intracellular compartments confirmed that the pgm2Delta mutant contained a higher level of Pmc1p-dependent Ca2+ transport activity than the wild-type strain. We found that this increased rate of vacuolar Ca2+ uptake also coincided with a large induction of the unfolded protein response in the pgm2Delta mutant, suggesting that Ca2+ uptake into the endoplasmic reticulum compartment was reduced. These results indicate that the excessive Ca2+ uptake and accumulation previously shown to be associated with the pgm2Delta mutation are due to a severe imbalance in the distribution of cellular Ca2+ into different intracellular compartments.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Med Sch, Dept Clin Chem, H-7624 Pecs, Hungary; Univ Med Sch, Dept Biochem, H-7624 Pecs, Hungary	University of Alabama System; University of Alabama Birmingham; University of Pecs; University of Pecs	Bedwell, DM (corresponding author), Univ Alabama, Dept Microbiol, BBRB 432,Box 8,1530 3rd Ave S, Birmingham, AL 35294 USA.	dbedwell@uab.edu	Sipos, Katalin/B-5242-2015	Sipos, Katalin/0000-0002-6706-2682; Bedwell, David/0000-0002-6605-818X; Miseta, Attila/0000-0002-7984-3347; Fu, Karl/0000-0001-5386-9429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams A, 1997, METHODS YEAST GENETI; Aiello DP, 2002, J BIOL CHEM, V277, P45751, DOI 10.1074/jbc.M208748200; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BEULLENS M, 1988, EUR J BIOCHEM, V172, P227, DOI 10.1111/j.1432-1033.1988.tb13877.x; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; Cronin SR, 2002, J CELL BIOL, V157, P1017, DOI 10.1083/jcb.200203052; Cronin SR, 2000, J CELL BIOL, V148, P915, DOI 10.1083/jcb.148.5.915; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Dlugai S, 2001, FEBS LETT, V505, P389, DOI 10.1016/S0014-5793(01)02854-X; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; IIDA H, 1990, J BIOL CHEM, V265, P13391; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Koh JY, 2001, MOL CELL BIOL, V21, P7576, DOI 10.1128/MCB.21.22.7576-7586.2001; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; LOUKIN S, 1995, J CELL BIOL, V131, P1025, DOI 10.1083/jcb.131.4.1025; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Schneider S, 1996, BIOTECHNIQUES, V20, P960; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorin A, 1997, J BIOL CHEM, V272, P9895; Suzuki C, 1999, MOL MICROBIOL, V32, P813, DOI 10.1046/j.1365-2958.1999.01400.x; Tokes-Fuzesi M, 2002, MOL MICROBIOL, V44, P1299, DOI 10.1046/j.1365-2958.2002.02956.x; Vashist S, 2002, MOL BIOL CELL, V13, P3955, DOI 10.1091/mbc.02-06-0090; Zhou XL, 2003, P NATL ACAD SCI USA, V100, P7105, DOI 10.1073/pnas.1230540100	47	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38495	38502		10.1074/jbc.M400833200	http://dx.doi.org/10.1074/jbc.M400833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252028	hybrid			2022-12-25	WOS:000223684100054
J	Cerosaletti, K; Concannon, P				Cerosaletti, K; Concannon, P			Independent roles for nibrin and Mre11-Rad50 in the activation and function of Atm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; SYNDROME PROTEIN; CHK2 ACTIVATION; FOCUS FORMATION; DNA; NBS1; COMPLEX	The Atm protein kinase and Mre11-Rad50-nibrin (MRN) complex play an integral role in the cellular response to DNA double-strand breaks. Mutations in Mre11 and nibrin result in the radiosensitivity disorders ataxia-telangiectasia-like disorder (ATLD) and Nijmegen breakage syndrome (NBS), respectively. Cells from ATLD and NBS patients are deficient in activation of the Atm protein kinase and phosphorylation of downstream Atm targets following irradiation. However, the roles of individual MRN complex proteins in Atm function are not clear, because the mutations in NBS and ATLD cells result in global effects on the MRN complex. Previously we showed that the C-terminal 100 amino acids of nibrin were necessary and sufficient to translocate the MRN complex to the nucleus. Here we have taken advantage of this feature of nibrin to create isogenic cell lines lacking either nibrin or Mre11-Rad50 in the nucleus. We found that nuclear expression of Mre11-Rad50, but not nibrin, stimulated Atm activation at early times after low doses of radiation. At later times or higher doses of irradiation, Atm activation was independent of Mre11-Rad50 or nibrin. The requirement of MRN complex proteins for downstream Atm phosphorylation events following irradiation was more complex. Phosphorylation of nibrin and Chk2 by Atm required Mre11-Rad50 expression in the nucleus at early times after irradiation, reflecting the stimulation of Atm activation by Mre11-Rad50. By contrast, autophosphorylation of Chk2 and phosphorylation of Smc1 at Ser-957 was dependent on the MRN complex 60 min after irradiation, even though Atm was activated at that time point. These results indicate an independent role for Mre11-Rad50 in the activation of Atm and suggest nibrin and/or Mre11-Rad50 also act as adaptors for some downstream Atm phosphorylation events.	Virginia Mason, Benaroya Res Inst, Mol Genet Program, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98101 USA	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Concannon, P (corresponding author), Virginia Mason, Benaroya Res Inst, Mol Genet Program, 1201 9th Ave, Seattle, WA 98101 USA.	patcon@benaroyaresearch.org		Concannon, Patrick/0000-0002-5801-1859	NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER; NCI NIH HHS [CA57569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2000, MUTAGENESIS, V15, P281, DOI 10.1093/mutage/15.3.281; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Perlman Susan, 2003, Semin Pediatr Neurol, V10, P173, DOI 10.1016/S1071-9091(03)00026-3; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	40	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38813	38819		10.1074/jbc.M404294200	http://dx.doi.org/10.1074/jbc.M404294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234984	hybrid			2022-12-25	WOS:000223684100093
J	del Rio, B; Pedrero, JMG; Martinez-Campa, C; Zuazua, P; Lazo, PS; Ramos, S				del Rio, B; Pedrero, JMG; Martinez-Campa, C; Zuazua, P; Lazo, PS; Ramos, S			Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; PINEAL HORMONE MELATONIN; ER-BETA; NURSES HEALTH; DNA-BINDING; ACTIVATION; MCF-7; MODULATION; EXPRESSION; ESTRADIOL	Melatonin is an indole hormone produced mainly by the pineal gland. We have previously demonstrated that melatonin interferes with estrogen (E-2) signaling in MCF7 cells by impairing estrogen receptor (ER) pathways. Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E-2-induced ERalpha-mediated transcription in both estrogen response element- and AP1-containing promoters, whereas ERbeta-mediated transactivation is not inhibited or even activated at certain promoters. We show that the sensitivity of MCF-7 cells to melatonin depends on the ERalpha/ERbeta ratio, and ectopic expression of ERbeta results in MCF-7 cells becoming insensitive to this hormone. Melatonin acts as a calmodulin antagonist inducing conformational changes in the ERalpha-calmodulin (CaM) complex, thus impairing the binding of E-2.ERalpha.CaM complex to DNA and, therefore, preventing ERalpha-dependent transcription. Moreover the mutant ERalpha (K302G, K303G), unable to bind calmodulin, becomes insensitive to melatonin. The effect of melatonin is specific since other related indoles neither interact with CaM nor inhibit ERalpha-mediated transactivation. Interestingly, melatonin does not affect the binding of coactivators to ERalpha, indicating that melatonin action is different from that of current therapeutic anti-estrogens used in breast cancer therapy. Thus, they target ERalpha at different levels, representing two independent ways to control ERalpha activity. It is, therefore, conceivably a synergistic pharmacological effect of melatonin and current anti-estrogen drugs.	Univ Oviedo, Dept Bioquim & Biol Mol, E-33071 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol Del Principado Asturias, E-33071 Oviedo, Spain	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Ramos, S (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, E-33071 Oviedo, Spain.	sramos@uniovi.es	del Rio, beatriz/L-3082-2014; Lazo, Pranvera/I-5299-2019; Pedrero, Juana María García/AAP-4251-2021; Lazo, Pedro/C-4087-2008	del Rio, beatriz/0000-0001-8107-1975; Lazo, Pranvera/0000-0002-7202-4058; Pedrero, Juana María García/0000-0002-5891-9488; Lazo, Pedro/0000-0002-1278-6878; martinez-campa, carlos manuel/0000-0001-8926-5977				Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; Blask D.E., 1984, P253; BLASK DE, 1988, MELATONIN CLIN PERSP, P128; BLASK DE, 1989, ADV PINEAL RES, V3, P259; Bollig A, 2000, MOL ENDOCRINOL, V14, P634, DOI 10.1210/me.14.5.634; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Campbell-Thompson M, 2001, CANCER RES, V61, P632; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; COLEMAN MP, 1992, EUR J CANCER, V28A, P501, DOI 10.1016/S0959-8049(05)80087-5; Cos S, 1998, CANCER RES, V58, P4383; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; Foley EF, 2000, CANCER RES, V60, P245; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304-3835(95)03970-8; Hall JM, 2000, MOL ENDOCRINOL, V14, P2010, DOI 10.1210/me.14.12.2010; Hardcastle IR, 1996, J MED CHEM, V39, P999, DOI 10.1021/jm9505472; HILL SM, 1988, CANCER RES, V48, P6121; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; LEYGUE E, 1999, BREAST CANCER RES, V58, P64; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; LISSONI P, 1995, BRIT J CANCER, V71, P854, DOI 10.1038/bjc.1995.164; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; Matsushima N, 2000, BIOCHEM J, V347, P211, DOI 10.1042/0264-6021:3470211; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MOLIS TM, 1995, J PINEAL RES, V18, P93, DOI 10.1111/j.1600-079X.1995.tb00146.x; MOLIS TM, 1994, MOL ENDOCRINOL, V8, P1681, DOI 10.1210/me.8.12.1681; MORREY KM, 1994, J IMMUNOL, V153, P2671; Newton CJ, 2000, J STEROID BIOCHEM, V73, P29, DOI 10.1016/S0960-0760(00)00047-9; Ogawa S, 1998, FEBS LETT, V423, P129, DOI 10.1016/S0014-5793(98)00079-9; Osawa M, 1999, FEBS LETT, V442, P173, DOI 10.1016/S0014-5793(98)01637-8; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pedrero JMG, 2003, ENDOCRINOLOGY, V144, P2967, DOI 10.1210/en.2002-0027; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Pujol P, 1998, CANCER RES, V58, P5367; Rato AG, 1999, FASEB J, V13, P857, DOI 10.1096/fasebj.13.8.857; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Romero MP, 1998, FASEB J, V12, P1401, DOI 10.1096/fasebj.12.13.1401; Sanchez-Barcelo EJ, 1997, PINEAL UPDATE, P361; Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563; Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; WILSON ST, 1992, J CLIN ENDOCR METAB, V75, P669, DOI 10.1210/jc.75.2.669; [No title captured]	50	114	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38294	38302		10.1074/jbc.M403140200	http://dx.doi.org/10.1074/jbc.M403140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15229223	hybrid			2022-12-25	WOS:000223684100029
J	Kaneko, M; Kato, Y; Kunita, A; Fujita, N; Tsuruo, T; Osawa, M				Kaneko, M; Kato, Y; Kunita, A; Fujita, N; Tsuruo, T; Osawa, M			Functional sialylated O-glycan to platelet aggregation on Aggrus (T1 alpha/podoplanin) molecules expressed in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI VESICLE MEMBRANES; MUCIN-TYPE GLYCOPROTEIN; BREAST-CANCER; COLON ADENOCARCINOMA-26; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; MUTANT DEFICIENT; PLASMA-MEMBRANE; GLYCOSYLATION; IDENTIFICATION	Aggrus, also called T1alpha and podoplanin, is a novel platelet aggregation-inducing factor that is expressed in various carcinoma cells. Aggrus/T1alpha/podoplanin is known to be expressed in lung type I alveolar cells or lymphatic endothelial cells. However, its physiological role has not been clarified. To assess the attribution of glycosylation to Aggrus platelet aggregation activity, recombinant molecules were stably expressed in a series of Chinese hamster ovary (CHO) cell mutants, N-glycan-deficient Lec1, CMP-sialic acid transporter-deficient Lec2, and UDP-galactose transporter-deficient Lec8. A new anti-human Aggrus monoclonal antibody, YM-1, was established to detect the expression of human Aggrus on these CHO cell mutants. Aggrus on Lec1 cells induced platelet aggregation, but those on Lec2 and Lec8 cells did not. Further, the glycans on Aggrus were analyzed by lectin blotting. Aggrus expressed in CHO and Lec1 cells showed Wheat-germ agglutinin, Jacalin, and Vicia villosa lectin bindings. Lectin blotting results indicated that sialylated core 1 structures, sialic acid plus Galbeta1,3GalNAc-Ser/Thr, were critical for the platelet aggregation activity. This oligosaccharide structure is known as tumor-associated antigen, which is potentially related to the metastasis process of cancer cells.	Yamagata Univ, Sch Med, Dept Expt & Forens Pathol, Yamagata 9909585, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	Yamagata University; University of Tokyo; Japanese Foundation for Cancer Research	Osawa, M (corresponding author), Yamagata Univ, Sch Med, Dept Expt & Forens Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.	mosawa@med.id.yamagata-u.ac.jp		Fujita, Naoya/0000-0002-9631-9264; K. Kaneko, Mika/0000-0002-4158-9208; Kato, Yukinari/0000-0001-5385-8201				Backstrom M, 2003, BIOCHEM J, V376, P677, DOI 10.1042/BJ20031130; BASTIDA E, 1988, HAEMOSTASIS, V18, P29; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bugert P, 2003, THROMB HAEMOSTASIS, V90, P738; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Dabelsteen E, 1996, J PATHOL, V179, P358; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; Gandarillas A, 1997, MOL CARCINOGEN, V20, P10, DOI 10.1002/(SICI)1098-2744(199709)20:1<10::AID-MC3>3.0.CO;2-M; HANISCH FG, 1989, J BIOL CHEM, V264, P872; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Kaneko M, 2003, IMMUNOL LETT, V86, P45, DOI 10.1016/S0165-2478(02)00294-8; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; KATO Y, 2004, IN PRESS ONCOGENE; Kotani M, 2003, J NEUROSCI RES, V73, P603, DOI 10.1002/jnr.10696; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Scholl FG, 1999, J CELL SCI, V112, P4601; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Tian W, 2004, CANCER SCI, V95, P491, DOI 10.1111/j.1349-7006.2004.tb03238.x; TOYOSHIMA M, 1995, CANCER RES, V55, P767; WATANABE M, 1990, CANCER RES, V50, P6657; WATANABE M, 1988, CANCER RES, V48, P6411; ZIMMER G, 1995, J BIOL CHEM, V270, P17815, DOI 10.1074/jbc.270.30.17815; Zimmer G, 1997, BIOCHEM J, V326, P99, DOI 10.1042/bj3260099	40	68	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38838	38843		10.1074/jbc.M407210200	http://dx.doi.org/10.1074/jbc.M407210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231832	hybrid			2022-12-25	WOS:000223684100096
J	Munshi, HG; Wu, YI; Mukhopadhyay, S; Ottaviano, AJ; Sassano, A; Koblinski, JE; Platanias, LC; Stack, MS				Munshi, HG; Wu, YI; Mukhopadhyay, S; Ottaviano, AJ; Sassano, A; Koblinski, JE; Platanias, LC; Stack, MS			Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK1/2-and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta 1-induced pericellular collagenolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; SQUAMOUS-CELL CARCINOMA; HUMAN GINGIVAL FIBROBLASTS; IV COLLAGENASE EXPRESSION; MATRIX-METALLOPROTEINASE; TGF-BETA; GELATINASE-A; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION	Acquisition of matrix metalloproteinase-2 (MMP-2) activity is temporally associated with increased migration and invasiveness of cancer cells. ProMMP-2 activation requires multimolecular complex assembly involving proMMP-2, membrane type 1-MMP (MT1-MMP, MMP-14), and tissue inhibitor of metalloproteinases-2 (TIMP-2). Because transforming growth factor-beta1 (TGF-beta1) promotes tumor invasion in advanced squamous cell carcinomas, the role of TGF-beta1 in the regulation of MMP activity in a cellular model of invasive oral squamous cell carcinoma was examined. Treatment of oral squamous cell carcinoma cells with TGF-beta1 promoted MMP-dependent cell scattering and collagen invasion, increased expression of MMP-2 and MT1-MMP, and enhanced MMP-2 activation. TGF-beta1 induced concomitant activation of ERK1/2 and p38 MAPK, and kinase inhibition studies revealed a negative regulatory role for ERK1/2 in modulating acquisition of MMP-2 activity. Thus, a reciprocal effect on proMMP-2 activation was observed whereupon blocking ERK1/2 phosphorylation promoted proMMP-2 activation and MT1-MMP activity, whereas inhibiting p38 MAPK activity decreased proteolytic potential. The cellular mechanism for the control of MT1-MMP catalytic activity involved concurrent reciprocal modulation of TIMP-2 expression by ERK1/2 and p38 MAPKs, such that inhibition of ERK1/2 phosphorylation decreased TIMP-2 production, and downregulation of p38 MAPK activity enhanced TIMP-2 synthesis. Further, p38 MAPK inhibition promoted ERK1/2 phosphorylation, providing additional evidence for cross-talk between MAPK pathways. These observations demonstrate the complex reciprocal effects of ERK1/2 and p38 MAPK in the regulation of MMP activity, which could complicate the use of MAPK-specific inhibitors as therapeutic agents to down-regulate the biologic effects of TGF-beta1 on pericellular collagen degradation and tumor invasion.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu	yi, wu/GLR-2824-2022		NCI NIH HHS [R01CA94079, K08CA94877, T32 CA70085, R01CA85870, R01CA77816] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085870, R01CA094079, R01CA077816, T32CA070085, K08CA094877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000482, P01DE012328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bakin AV, 2002, J CELL SCI, V115, P3193; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kurahara S, 1999, HEAD NECK-J SCI SPEC, V21, P627, DOI 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.3.CO;2-U; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Li SP, 2003, CANCER RES, V63, P3473; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077; Ohashi R, 2004, AM J PATHOL, V164, P477, DOI 10.1016/S0002-9440(10)63138-0; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SALO T, 1991, J BIOL CHEM, V266, P11436; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Stanton H, 1998, J CELL SCI, V111, P2789; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sutinen M, 1998, BRIT J CANCER, V77, P2239, DOI 10.1038/bjc.1998.372; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Weeks BH, 2001, CANCER RES, V61, P7435; Yamada KM, 2003, NATURE, V424, P889, DOI 10.1038/424889a; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhong ZD, 2000, J BIOL CHEM, V275, P18602, DOI 10.1074/jbc.M001389200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	75	123	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39042	39050		10.1074/jbc.M404958200	http://dx.doi.org/10.1074/jbc.M404958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247230	hybrid			2022-12-25	WOS:000223684100119
J	Sauer, B; Vogler, R; von Wenckstern, H; Fujii, M; Anzano, MB; Glick, AB; Schafer-Korting, M; Roberts, AB; Kleuser, B				Sauer, B; Vogler, R; von Wenckstern, H; Fujii, M; Anzano, MB; Glick, AB; Schafer-Korting, M; Roberts, AB; Kleuser, B			Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE-CELLS; FACTOR-BINDING PROTEIN-3; FOCAL ADHESION KINASE; BREAST-CANCER CELLS; TGF-BETA; SPHINGOSINE-1-PHOSPHATE RECEPTORS; EGF RECEPTOR; ENDOTHELIAL-CELLS	The lysophospholipid sphingosine 1-phosphate and the cytokine-transforming growth factor beta are both released from degranulating platelets at wound sites, suggesting a broad spectrum of effects involved in wound healing. Interestingly, both of these molecules have been previously shown to induce chemotaxis but to strongly inhibit the growth of keratinocytes, while stimulating the proliferation of fibroblasts. In contrast to sphingosine 1-phosphate, the signaling cascade of the growth factor has been extensively examined. Specifically, Smad3 has been shown to be an essential mediator of transforming growth factor beta-dependent chemotaxis of keratinocytes and mediates, in part, its growth-inhibitory effect. Here we show that sphingosine 1-phosphate, independently of transforming growth factor beta secretion, induces a rapid phosphorylation of Smad3 on its C-terminal serine motif and induces its partnering with Smad4 and the translocation of the complex into the nucleus. Moreover, sphingosine 1-phosphate fails to induce chemotaxis or inhibit the growth of Smad3-deficient keratinocytes, suggesting that Smad3 plays an unexpected functional role as a new target in sphingosine 1-phosphate signaling. Both sphingosine 1-phosphate receptors and the transforming growth factor beta-type I receptor serine/threonine kinase are essential for activation of Smad3 by this lysophospholipid and the dependent biological responses, indicating a novel crosstalk between serine/threonine kinase receptors and G-protein coupled receptors.	Free Univ Berlin, Inst Pharm Pharmacol & Toxicol, D-14195 Berlin, Germany; NCI, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Free University of Berlin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kleuser, B (corresponding author), Free Univ Berlin, Inst Pharm Pharmacol & Toxicol, Konigin Luise Str 2&4, D-14195 Berlin, Germany.	kleuser@zedat.fu-berlin.de		Kleuser, Burkhard/0000-0002-1888-9595	DIVISION OF BASIC SCIENCES - NCI [Z01BC005051] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P3928; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; FUJIMOTO A, 1976, CLIN CHIM ACTA, V68, P177, DOI 10.1016/0009-8981(76)90417-4; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee OH, 2000, BIOCHEM BIOPH RES CO, V268, P47, DOI 10.1006/bbrc.2000.2087; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; SATO M, 2003, J BIOL CHEM; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; Vogler R, 2003, J INVEST DERMATOL, V120, P693, DOI 10.1046/j.1523-1747.2003.12096.x; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yatomi Y, 1997, J BIOCHEM, V121, P969	65	59	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38471	38479		10.1074/jbc.M313557200	http://dx.doi.org/10.1074/jbc.M313557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247277	hybrid			2022-12-25	WOS:000223684100051
J	Wang, LZ; Kenyon, GL; Johnson, KA				Wang, LZ; Kenyon, GL; Johnson, KA			Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MITOCHONDRIAL-DNA POLYMERASE; NUCLEOSIDE ANALOGS; RESISTANCE; MUTATIONS; LOPINAVIR/RITONAVIR; TOXICITY; FIDELITY; DRUGS; AIDS	2-Naphthalenesulfonic acid (4-hydroxy-7-[[[[5-hydroxy-6-[(4 cinnamylphenyl) azo]-7-sulfo-2-naphthalenyl] amino]carbonyl] amino]-3-[(4-cinnamylphenyl)]azo (KM-1)) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that was designed to bind at an unconventional site on human immunodeficiency virus type 1 reverse transcriptase (RT) (Skillman, A.G., Maurer, K.W., Roe, D.C., Stauber, M.J., Eargle, D., Ewing, T.J., Muscate, A., Davioud-Charvet, E., Medaglia, M.V., Fisher, R.J., Arnold, E., Gao, H.Q., Buckheit, R., Boyer, P.L., Hughes, S.H., Kuntz, I.D., and Kenyon, G.L. (2002) Bioorg. Chem. 30, 443-458). We have investigated the mechanism by which KM-1 inhibits wild-type human immunodeficiency virus type 1 RT by using pre-steady state kinetic methods to examine the effect of KM-1 on the parameters governing the single nucleotide incorporation catalyzed by RT. Analysis of the pre-steady-state burst phase of dATP incorporation showed that KM-1 decreased the amplitude of the reaction as previously shown for other NNRTIs, because of the slow equilibration of the inhibitor with RT. In the ternary enzyme-DNA-KM-1 complex (E-DNA-I), incorporation of the next nucleotide onto the primer is blocked. However, unlike conventional NNRTIs, the inhibitory effect was caused primarily by weakening the DNA binding affinity and displacing DNA from the enzyme. Wild-type RT binds a 25/45-mer DNA duplex with an apparent K-d of 3 nM, which was increased to 400 nM upon saturation with KM-1. Likewise, the apparent K-d for KM-1 binding to RT increased at higher DNA concentrations. We therefore conclude that KM-1 represents a new class of inhibitor distinct from nevirapine and related NNRTIs. KM-1 can bind to RT in both the absence and presence of DNA but weakens the affinity for DNA 140-fold so that it favors DNA dissociation. The data suggest that KM-1 distorts RT conformation and misaligns DNA at the active site.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan	Johnson, KA (corresponding author), Univ Texas, Inst Mol & Cellular Biol, 2500 Speedway,A4800,MBB 3-122, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [GM44613, GM39552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, P01GM039552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Gao HQ, 1998, J MOL BIOL, V277, P559, DOI 10.1006/jmbi.1998.1624; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; Hasson H, 2004, AIDS, V18, P123, DOI [10.1097/01.aids.0000104382.21567.34, 10.1097/00002030-200401020-00016]; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Johnson K. A, 1992, TRANSIENT STATE KINE, P1; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Lu J, 2004, J VIROL, V78, P4628, DOI 10.1128/JVI.78.9.4628-4637.2004; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 2003, VIROLOGY, V307, P116, DOI 10.1016/S0042-6822(02)00069-7; Mansky LM, 2002, J VIROL, V76, P9253, DOI 10.1128/JVI.76.18.9253-9259.2002; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Motakis D, 2002, ANTIMICROB AGENTS CH, V46, P1851, DOI 10.1128/AAC.46.6.1851-1856.2002; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perach M, 1997, J MOL BIOL, V268, P648, DOI 10.1006/jmbi.1997.0927; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Sebastian J, 2004, MED RES REV, V24, P115, DOI 10.1002/med.10057; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Shulman Nancy, 2003, Current Drug Targets - Infectious Disorders, V3, P273, DOI 10.2174/1568005033481024; Skillman AG, 2002, BIOORG CHEM, V30, P443, DOI 10.1016/S0045-2068(02)00502-3; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STAHLHUT M, 1994, PROTEIN EXPRES PURIF, V5, P614, DOI 10.1006/prep.1994.1084; Sturmer M, 2003, ANTIVIR THER, V8, P239; Tramontano E, 1998, BIOCHEM PHARMACOL, V56, P1583, DOI 10.1016/S0006-2952(98)00206-8; Voigt E, 2004, INFECTION, V32, P82, DOI 10.1007/s15010-004-3059-3; White KL, 2004, ANTIMICROB AGENTS CH, V48, P992, DOI 10.1128/AAC.48.3.992-1003.2004	38	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38424	38432		10.1074/jbc.M406241200	http://dx.doi.org/10.1074/jbc.M406241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231830	hybrid			2022-12-25	WOS:000223684100045
J	Arolas, JL; Bronsoms, S; Lorenzo, J; Aviles, FX; Chang, JY; Ventura, S				Arolas, JL; Bronsoms, S; Lorenzo, J; Aviles, FX; Chang, JY; Ventura, S			Role of kinetic intermediates in the folding of leech carboxypeptidase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; DISULFIDE-BOND FORMATION; PANCREATIC TRYPSIN-INHIBITOR; BOVINE ALPHA-LACTALBUMIN; EPIDERMAL-GROWTH-FACTOR; RIBONUCLEASE-A; MASS-SPECTROMETRY; FIBRINOLYSIS INHIBITOR; HYDROGEN-EXCHANGE; UNFOLDING PATHWAY	The oxidative folding and reductive unfolding pathways of leech carboxypeptidase inhibitor (LCI; four disulfides) have been characterized in this work by structural and kinetic analysis of the acid-trapped folding intermediates. The oxidative folding of reduced and denatured LCI proceeds rapidly through a sequential flow of 1-, 2-, 3-, and 4-disulfide ( scrambled) species to reach the native form. Folding intermediates of LCI comprise two predominant 3- disulfide species ( designated as III-A and III-B) and a heterogeneous population of scrambled isomers that consecutively accumulate along the folding reaction. Our study reveals that forms III-A and III-B exclusively contain native disulfide bonds and correspond to stable and partially structured species that interconvert, reaching an equilibrium prior to the formation of the scrambled isomers. Given that these intermediates act as kinetic traps during the oxidative folding, their accumulation is prevented when they are destabilized, thus leading to a significant acceleration of the folding kinetics. III-A and III-B forms appear to have both native disulfides bonds and free thiols similarly protected from the solvent; major structural rearrangements through the formation of scrambled isomers are required to render native LCI. The reductive unfolding pathway of LCI undergoes an apparent all-or-none mechanism, although low amounts of intermediates III-A and III-B can be detected, suggesting differences in protection against reduction among the disulfide bonds. The characterization of III-A and III-B forms shows that the former intermediate structurally and functionally resembles native LCI, whereas the III-B form bears more resemblance to scrambled isomers.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Inst Mol Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Texas System; University of Texas System	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.	fxaviles@einstein.uab.es; salvador.ventura@uab.es	Ventura, Salvador/C-7021-2008; Aviles, Francesc Xavier/F-3482-2019; Avilés, Francesc Xavier/A-2664-2015; Ventura, Salvador/AAY-3170-2021; Lorenzo, Julia/E-9015-2011	Ventura, Salvador/0000-0002-9652-6351; Aviles, Francesc Xavier/0000-0002-1399-6789; Avilés, Francesc Xavier/0000-0002-1399-6789; Ventura, Salvador/0000-0002-9652-6351; Lorenzo, Julia/0000-0001-5659-6008; Lopez Arolas, Joan/0000-0002-4198-5016; Bronsoms, Silvia/0000-0001-9763-762X				ADAMS MWW, 1992, BIOCATALYSIS EXTREME; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Bouma BN, 2003, J THROMB HAEMOST, V1, P1566, DOI 10.1046/j.1538-7836.2003.00329.x; Chang JY, 2000, J PROTEIN CHEM, V19, P299, DOI 10.1023/A:1007099430211; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; Chang JY, 2002, BIOCHEMISTRY-US, V41, P8405, DOI 10.1021/bi020169k; Chang JY, 1999, PROTEIN SCI, V8, P1463, DOI 10.1110/ps.8.7.1463; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1997, J BIOL CHEM, V272, P69; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; Chang JY, 2002, J BIOL CHEM, V277, P120, DOI 10.1074/jbc.M108057200; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Creighton T E, 1986, Methods Enzymol, V131, P83; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Demetrius L, 2002, J THEOR BIOL, V217, P397, DOI 10.1006/jtbi.2002.3006; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; Honig B, 1999, J MOL BIOL, V293, P283, DOI 10.1006/jmbi.1999.3006; Ikeguchi M, 1998, PROTEIN SCI, V7, P1564, DOI 10.1002/pro.5560070710; Kim DE, 1998, P NATL ACAD SCI USA, V95, P4982, DOI 10.1073/pnas.95.9.4982; LI YJ, 1995, NAT STRUCT BIOL, V2, P489, DOI 10.1038/nsb0695-489; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Narayan M, 2000, ACCOUNTS CHEM RES, V33, P805, DOI 10.1021/ar000063m; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; Reverter D, 1998, J BIOL CHEM, V273, P32927, DOI 10.1074/jbc.273.49.32927; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Rothwarf DM, 1998, BIOCHEMISTRY-US, V37, P3760, DOI 10.1021/bi972822n; Salamanca S, 2003, BIOCHEMISTRY-US, V42, P6754, DOI 10.1021/bi034308p; Salamanca S, 2002, J BIOL CHEM, V277, P17538, DOI 10.1074/jbc.M200040200; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; Scheraga HA, 2001, METHOD ENZYMOL, V341, P189, DOI 10.1016/S0076-6879(01)41153-0; Venhudova G, 2001, J BIOL CHEM, V276, P11683, DOI 10.1074/jbc.M007927200; Villanueva J, 2000, FEBS LETT, V472, P27, DOI 10.1016/S0014-5793(00)01418-6; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 1999, FEBS LETT, V460, P477, DOI 10.1016/S0014-5793(99)01391-5; Welker E, 2001, P NATL ACAD SCI USA, V98, P2312, DOI 10.1073/pnas.041615798; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; Wu J, 1998, PROTEIN SCI, V7, P1017; Xu XB, 1996, BIOCHEMISTRY-US, V35, P6406, DOI 10.1021/bi960090d; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598; Zhang JX, 1997, PROTEIN SCI, V6, P1563, DOI 10.1002/pro.5560060720; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	59	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37261	37270		10.1074/jbc.M405565200	http://dx.doi.org/10.1074/jbc.M405565200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226306	hybrid			2022-12-25	WOS:000223554600010
J	Deepa, SS; Yamada, S; Zako, M; Goldberger, O; Sugahara, K				Deepa, SS; Yamada, S; Zako, M; Goldberger, O; Sugahara, K			Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors - A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE ZETA/RPTP-BETA; AMYLOID PRECURSOR PROTEIN; MOLECULAR-CLONING; SURFACE PROTEOGLYCAN; CORE PROTEIN; SEQUENCE-ANALYSIS; HUMAN RYUDOCAN; FINE-STRUCTURE; HB-GAM; RECEPTOR	A comparative analysis was carried out of heparan sulfate (HS) and chondroitin sulfate ( CS) chains of the ectodomains of hybrid type transmembrane proteoglycans, syndecan-1 and -4, synthesized simultaneously by normal murine mammary gland epithelial cells. Although the HS chains were structurally indistinguishable, intriguingly the CS chains were structurally and functionally distinct, probably reflecting the differential regulation of sulfotransferases involved in the synthesis of HS and CS. The CS chains of the two syndecans comprised nonsulfated, 4-O-, 6-O-, and 4,6-O- disulfated N-acetylgalactosamine- containing disaccharide units and were significantly different, with a higher degree of sulfation for syndecan-4. Functional analysis using a BIAcore system showed that basic fibroblast growth factor ( bFGF) specifically bound only to the HS chains of both syndecans, whereas midkine (MK) and pleiotrophin (PTN) bound not only to the HS but also to the CS chains. Stronger binding of MK and PTN to the CS chains of syndecan- 4 than those of syndecan- 1 was revealed, supporting the structural and functional differences. Intriguingly, removal of the CS chains decreased the association and dissociation rate constants of MK, PTN, and bFGF for both syndecans, suggesting the simultaneous binding of these growth factors to both types of chains, producing a ternary complex that transfers the growth factors to the corresponding cell surface receptors more efficiently compared with the HS chains alone. The involvement of the core protein was also shown in the binding of MK and PTN to syndecan-1, suggesting the possibility of cooperation with the HS and/or CS chains in the binding of these growth factors and their delivery to the cell surface receptors.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med,Dept Med, Boston, MA 02115 USA	Kobe Pharmaceutical University; Aichi Medical University; Harvard University; Boston Children's Hospital; Harvard Medical School	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyama Kita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp		Deepa, Sathyaseelan/0000-0002-3669-4820				BACIU PC, 1994, J BIOL CHEM, V269, P696; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANN REV CELL BIOL, V12, P107; Carey DJ, 1997, BIOCHEM J, V327, P1; Chen Y, 1996, MOL CARCINOGEN, V17, P112, DOI 10.1002/(SICI)1098-2744(199611)17:3<112::AID-MC2>3.0.CO;2-H; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Fitzgerald M. L., 1999, SYNDECANS GUIDEBOOK, P306; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1994, J BIOL CHEM, V269, P18881; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; KODA JE, 1985, J BIOL CHEM, V260, P8157; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOJIMA T, 1993, BIOCHEM BIOPH RES CO, V190, P814, DOI 10.1006/bbrc.1993.1122; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kurtz A, 1998, BIOCHEM SOC SYMP, P51; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lavandero S, 1998, FEBS LETT, V439, P351, DOI 10.1016/S0014-5793(98)01370-2; Ledoux D, 1997, J HISTOCHEM CYTOCHEM, V45, P1239, DOI 10.1177/002215549704500907; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; Rosfjord EC, 1999, J MAMMARY GLAND BIOL, V4, P229, DOI 10.1023/A:1018789527533; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Simian M, 2001, DEVELOPMENT, V128, P3117; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUN XJ, 1989, J BIOL CHEM, V264, P11288; Takagaki K, 2002, J BIOL CHEM, V277, P8882, DOI 10.1074/jbc.M106479200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Umehara Y, 2004, FEBS LETT, V557, P233, DOI 10.1016/S0014-5793(03)01506-0; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yamashita Y, 1999, J IMMUNOL, V162, P5940; Zako M, 2003, J BIOL CHEM, V278, P13561, DOI 10.1074/jbc.M209658200; Zimmermann P, 1999, FASEB J, V13, pS91; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	69	145	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37368	37376		10.1074/jbc.M403031200	http://dx.doi.org/10.1074/jbc.M403031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226297	hybrid			2022-12-25	WOS:000223554600023
J	Hayashi, I; Urano, Y; Fukuda, R; Isoo, N; Kodama, T; Hamakubo, T; Tomita, T; Iwatsubo, T				Hayashi, I; Urano, Y; Fukuda, R; Isoo, N; Kodama, T; Hamakubo, T; Tomita, T; Iwatsubo, T			Selective reconstitution and recovery of functional gamma-secretase complex on budded baculovirus particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; COUPLED RECEPTOR; BETA-PROTEIN; PRESENILIN 2; C-TERMINUS; NICASTRIN; ENDOPROTEOLYSIS; OVERPRODUCTION; STABILIZATION; A-BETA-42	In vitro reconstitution of functions of membrane proteins is often hampered by aggregation, misfolding, or lack of post-translational modifications of the proteins attributable to overexpression. To overcome this technical obstacle, we have developed a method to express multimeric integral membrane proteins in extracellular ( budded) baculovirus particles that are released from Sf9 cells co-infected with multiple transmembrane proteins. We applied this method to the reconstitution of gamma-secretase, a membrane protease complex that catalyzes the intramembrane cleavage of beta-amyloid precursor protein to release Abeta peptides, the major component of amyloid deposits in Alzheimer brains as well as of Notch. When we co-infected Sf9 cells with human presenilin 1 (PS1), nicastrin, APH-1a, and PEN-2, a high-molecular-weight membrane protein complex that contained PS1 exclusively in its fragment form associated with three other cofactor proteins was reconstituted and recovered in a highly gamma-secretase-active state in budded virus particles, whereas nonfunctional PS1 holoproteins massively contaminated the parental Sf9 cell membranes. The relative gamma-secretase activity ( per molar PS1 fragments) was concentrated by similar to2.5 fold in budded virus particles compared with that in Sf9 membranes. The budded baculovirus system will facilitate structural and functional analyses of gamma-secretase, as well as screening of its binding molecules or inhibitors, and will also provide a versatile methodology for the characterization of a variety of membrane protein complexes.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol, Tokyo 1538904, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Med, Tokyo 1538904, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Urano, Yasuomi/0000-0002-4901-1937				Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; Braunagel SC, 2003, P NATL ACAD SCI USA, V100, P9797, DOI 10.1073/pnas.1733972100; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Iwatsubo T, 2004, MOL PSYCHIATR, V9, P8, DOI 10.1038/sj.mp.4001438; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kan T, 2003, CHEM COMMUN, P2244, DOI 10.1039/b306970b; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Loisel TP, 1997, NAT BIOTECHNOL, V15, P1300, DOI 10.1038/nbt1197-1300; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Marheineke K, 1998, FEBS LETT, V441, P49, DOI 10.1016/S0014-5793(98)01523-3; Massotte D, 2003, BBA-BIOMEMBRANES, V1610, P77, DOI 10.1016/S0005-2736(02)00720-4; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Octave JN, 2000, J BIOL CHEM, V275, P1525, DOI 10.1074/jbc.275.3.1525; Pitsi D, 2002, J NEUROCHEM, V83, P390, DOI 10.1046/j.1471-4159.2002.01138.x; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Urano Y, 2003, BIOCHEM BIOPH RES CO, V308, P191, DOI 10.1016/S0006-291X(03)01355-X; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yeh LHP, 1997, LIPIDS, V32, P481, DOI 10.1007/s11745-997-0062-8; Zhang SXX, 2003, J VIROL, V77, P6265, DOI 10.1128/JVI.77.11.6265-6273.2003	40	75	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38040	38046		10.1074/jbc.M405597200	http://dx.doi.org/10.1074/jbc.M405597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15215237	hybrid			2022-12-25	WOS:000223554600098
J	Nikolaev, VO; Bunemann, M; Hein, L; Hannawacker, A; Lohse, MJ				Nikolaev, VO; Bunemann, M; Hein, L; Hannawacker, A; Lohse, MJ			Novel single chain cAMP sensors for receptor-induced signal propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLIC-AMP; DIFFUSION-COEFFICIENT; EPAC; FAMILY; TARGET; CELLS	cAMP is a universal second messenger of many G-protein-coupled receptors and regulates a wide variety of cellular events. cAMP exerts its effects via cAMP-dependent protein kinase (PKA), cAMP-gated ion channels, and two isoforms of exchange protein directly activated by cAMP ( Epac). Here we report the development of novel fluorescent indicators for cAMP based on the cAMP-binding domains of Epac and PKA. Fluorescence resonance energy transfer between variants of green fluorescent protein ( enhanced cyan fluorescent protein and enhanced yellow fluorescent protein) fused directly to the cAMP-binding domains was used to analyze spatial and temporal aspects of cAMP-signaling in different cells. In contrast to previously developed PKA-based indicators, these probes are comprised of only a single binding site lacking cooperativity, catalytic properties, and interactions with other proteins and thereby allow us to easily image free intracellular cAMP and rapid signaling events. Rapid beta-adrenergic receptor-induced cAMP signals were observed to travel with high speed (approximate to 40 mum/s) throughout the entire cell body of hippocampal neurons and peritoneal macrophages. The developed indicators could be ubiquitously applied to studying cAMP, its physiological role and spatiotemporal regulation.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacherstr 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Nikolaev, Vyacheslav/AAT-7746-2020; Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510; Nikolaev, Viacheslav/0000-0002-7529-5179				Arslan G, 1999, N-S ARCH PHARMACOL, V359, P28, DOI 10.1007/PL00005319; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Chen CH, 1999, BIOPHYS J, V76, P2861, DOI 10.1016/S0006-3495(99)77440-0; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Dityatev A, 2000, NEURON, V26, P207, DOI 10.1016/S0896-6273(00)81151-4; Dremier S, 2003, FEBS LETT, V546, P103, DOI 10.1016/S0014-5793(03)00561-1; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Odaka C, 2003, J IMMUNOL, V171, P1507, DOI 10.4049/jimmunol.171.3.1507; OLSON A, 1993, BIOPHYS J, V65, P1335, DOI 10.1016/S0006-3495(93)81177-9; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Prasad KN, 2003, APOPTOSIS, V8, P579, DOI 10.1023/A:1026179324295; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; TASKEN K, 2004, PHYSIOL REV, V84, P751; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922	27	556	577	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37215	37218		10.1074/jbc.C400302200	http://dx.doi.org/10.1074/jbc.C400302200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231839	hybrid			2022-12-25	WOS:000223554600002
J	Torgler, R; Jakob, S; Ontsouka, E; Nachbur, U; Mueller, C; Green, DR; Brunner, T				Torgler, R; Jakob, S; Ontsouka, E; Nachbur, U; Mueller, C; Green, DR; Brunner, T			Regulation of activation-induced fas (CD95/Apo-1) ligand expression in T cells by the cyclin B1/Cdk1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERSUS-HOST-DISEASE; INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; C-MYC; CYCLOSPORINE-A; IMMUNE-SYSTEM; DEATH OCCURS; KAPPA-B; APOPTOSIS; CD95; TRANSCRIPTION	Fas (CD95/Apo-1) ligand-mediated apoptosis has been recognized as an important mechanism of cell-mediated cytotoxicity and maintenance of immune homeostasis. Chronically activated T cells undergo activation-induced cell death ( AICD), which depends on simultaneous Fas and Fas ligand expression. Previous reports have suggested that AICD might be linked to cell cycle progression of T cells and therefore to the expression of cell cycle-related molecules. In particular, cyclin B1 has been implicated in the induction of AICD in T cells. In this study, we have investigated the role of cyclin B1 in AICD and the expression of effector molecules involved in this form of cell death. Our results show that inhibition of cyclin B1 blocks AICD in T cells through specific inhibition of Fas ligand expression but not Fas-induced apoptosis. This effect of cyclin B1 appears to be mediated through the cyclin B1/cyclin-dependent kinase 1 (Cdk1/Cdc2) complex because overexpression of cyclin B1 enhances FasL promoter activity, whereas a dominant-negative version of Cdk1 blocks Fas ligand promoter induction. We provide further evidence that cyclin B1/Cdk1 regulates FasL transcription through the regulation of NFkappaB activation because dominant-negative Cdk1 inhibits activation-induced NFkappaB reporter and Rel A-induced FasL promoter activity. In conclusion, our data support a link between cell cycle progression, activation-induced Fas ligand expression, and apoptosis in T cells.	Univ Bern, Inst Pathol, Div Immunopathol, CH-3010 Bern, Switzerland; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	University of Bern; La Jolla Institute for Immunology	Brunner, T (corresponding author), Univ Bern, Inst Pathol, Div Immunopathol, Murtenstr 31,POB 62, CH-3010 Bern, Switzerland.	tbrunner@pathology.unibe.ch	Green, Douglas R/N-8083-2018; Mueller, Christoph/F-2233-2014	Green, Douglas R/0000-0002-7332-1417; Mueller, Christoph/0000-0002-3921-8678; Nachbur, Ueli/0000-0001-5968-2235				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Badley AD, 2000, BLOOD, V96, P2951, DOI 10.1182/blood.V96.9.2951.h8002951_2951_2964; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1999, NAT MED, V5, P19, DOI 10.1038/4695; Brunner T, 2003, SEMIN IMMUNOL, V15, P167, DOI 10.1016/S1044-5323(03)00035-6; Brunner T, 2001, CELL DEATH DIFFER, V8, P706, DOI 10.1038/sj.cdd.4400854; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Brunner T, 1996, Behring Inst Mitt, P161; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; DE LA, 1997, J CELL BIOCHEM, V64, P579; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fromm L, 1996, ONCOGENE, V12, P69; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; GONG JP, 1994, CANCER RES, V54, P4285; HWANG A, 1995, J BIOL CHEM, V270, P28419; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kao GD, 1997, CANCER RES, V57, P753; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Piedimonte G, 1999, AIDS, V13, P1159, DOI 10.1097/00002030-199907090-00003; Pinkoski MJ, 2002, J BIOL CHEM, V277, P42380, DOI 10.1074/jbc.M208167200; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Rieux-Laucat F, 2003, CURR OPIN IMMUNOL, V15, P325, DOI 10.1016/S0952-7915(03)00042-6; Sabelko-Downes KA, 1999, J EXP MED, V189, P1195, DOI 10.1084/jem.189.8.1195; Van Parijs L, 1998, SCIENCE, V280, P243; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Via CS, 1996, J IMMUNOL, V157, P5387; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Waring P, 2001, IMMUNOL CELL BIOL, V79, P264, DOI 10.1046/j.1440-1711.2001.01008.x; Wasem C, 2001, J IMMUNOL, V167, P2936, DOI 10.4049/jimmunol.167.5.2936; Wersto RP, 1998, J VIROL, V72, P9491, DOI 10.1128/JVI.72.12.9491-9502.1998; Yang YL, 2002, J BIOL CHEM, V277, P19482, DOI 10.1074/jbc.M201687200; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; ZHU LQ, 1995, J IMMUNOL, V154, P192	60	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37334	37342		10.1074/jbc.M406913200	http://dx.doi.org/10.1074/jbc.M406913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15215233	hybrid, Green Published			2022-12-25	WOS:000223554600019
J	Watanabe, H; Yokozeki, T; Yamazaki, M; Miyazaki, H; Sasaki, T; Maehama, T; Itoh, K; Frohman, MA; Kanaho, Y				Watanabe, H; Yokozeki, T; Yamazaki, M; Miyazaki, H; Sasaki, T; Maehama, T; Itoh, K; Frohman, MA; Kanaho, Y			Essential role for phospholipase D2 activation downstream of ERK MAP kinase in nerve growth factor-stimulated neurite outgrowth from PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; RHO-FAMILY GTPASES; PHOSPHATIDIC-ACID; ACTIN CYTOSKELETON; MAMMALIAN-CELLS; PLASMA-MEMBRANE; P35/CDK5 KINASE; AXON GUIDANCE	The signaling pathway that triggers morphological differentiation of PC12 cells is mediated by extracellular signal-regulated kinase (ERK), the classic mitogen-activated protein ( MAP) kinase. However, mediators of the pathway downstream of ERK have not been identified. We show here that phospholipase D2 (PLD2), which generates the pleiotropic signaling lipid phosphatidic acid (PA), links ERK activation to neurite outgrowth in nerve growth factor (NGF)-stimulated PC12 cells. Increased expression of wild type PLD2 (WT-PLD2) dramatically elongated neurites induced by NGF stimulation or transient expression of the active form of MAP kinase-ERK kinase (MEK-CA). The response was activity-dependent, because it was inhibited by pharmacological suppression of the PLD-mediated PA production and by expression of a lipase-deficient PLD2 mutant. Furthermore, PLD2 was activated by MEK-CA, whereas NGF-stimulated PLD2 activation and hypertrophic neurite extension were blocked by an MEK-specific inhibitor. Taken together, these results provide evidence that PLD2 functions as a downstream signaling effector of ERK in the NGF signaling pathway, which leads to neurite outgrowth by PC12 cells.	Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; RIKEN Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Akita Univ, Sch Med, 21st Century Ctr Excellence Program, Akita 0108543, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Pharmaceut Technol, Sanuki City, Kagawa 7692193, Japan; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA	Tokyo Metropolitan Institute of Medical Science; RIKEN; Tokyo Institute of Technology; Akita University; Japan Science & Technology Agency (JST); Tokushima Bunri University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	ykanaho@rinshoken.or.jp	Maehama, Tomohiko/HGB-4896-2022; Maehama, Tomohiko/AAX-8926-2020; Watanabe, Hiroshi/GOP-0177-2022	Maehama, Tomohiko/0000-0002-9685-2317; Watanabe, Hiroshi/0000-0001-8887-5407; Sasaki, Takehiko/0000-0003-1837-3748	NIDDK NIH HHS [DK64166] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Banno Y, 2001, NEUROREPORT, V12, P2271, DOI 10.1097/00001756-200107200-00045; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; FUKUDA M, 1995, ONCOGENE, V11, P239; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Jacobson M., 1991, DEV NEUROBIOLOGY; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; McDermott M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/o03-079; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parmentier JH, 2001, J BIOL CHEM, V276, P15704, DOI 10.1074/jbc.M011473200; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Saito S, 2000, DEV BRAIN RES, V120, P41, DOI 10.1016/S0165-3806(99)00189-3; Sechi AS, 2000, J CELL SCI, V113, P3685; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; van Horck FPG, 2002, CURR BIOL, V12, P241, DOI 10.1016/S0960-9822(01)00660-1; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Watanabe H, 2004, J NEUROCHEM, V89, P142, DOI 10.1111/j.1471-4159.2004.02308.x; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200	52	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37870	37877		10.1074/jbc.M402610200	http://dx.doi.org/10.1074/jbc.M402610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226317	hybrid			2022-12-25	WOS:000223554600080
J	Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O				Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O			Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice	ONCOGENE			English	Article						influenza A virus; lung tumor; C-Raf; MEK; ERK; in vivo; mouse	PSEUDORABIES VIRUS; TRANSGENIC MICE; GENE-EXPRESSION; CANCER; PROTEIN; VACCINATION; PROPAGATION; ACTIVATION; TUMORS	Alterations in signalling via the Raf/MEK/ERK pathway interfere with influenza A virus replication in cell culture. While virus yields are reduced in cells expressing dominant-negative Raf or ERK, virus propagation is enhanced upon expression of constitutively active Raf or MEK. To study the impact of active Raf on influenza virus propagation in vivo, we investigated transgenic mice expressing an activated mutant of c-Raf (Raf-BxB) in the main target tissue of influenza virus, the lung. Raf-BxB expression results in multicentric alveolar adenomas. Influenza virus A infection of Raf-BxB mice results in increased disease symptoms and higher mortality rates. The immune response against viral pathogens in transgenic animals did not differ from wild-type mice as determined by the use of a Pseudorabies virus (PRV) as a model for a viral infection not affecting the lung. No significant differences of influenza virus titers in the lung of Raf-BxB and wild-type mice were observed. However, immunohistology revealed increased numbers of influenza NP-positive cells in the alveolar linings of Raf-BxB mice, demonstrating the strong tropism of influenza virus for cells expressing active Raf. These findings disclose the possibility to use modified influenza virus for the therapy of tumors with an activated Ras/Raf signalling pathway.	Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Tubingen, Germany; Univ Giessen, Inst Med Virol, D-35390 Giessen, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Justus Liebig University Giessen; University of Wurzburg; Heinrich Heine University Dusseldorf	Planz, O (corresponding author), Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Paul Ehrlich Str 28, Tubingen, Germany.	oliver.planz@tue.bfav.de	Pleschka, Stephan/HGU-9354-2022	Pleschka, Stephan/0000-0002-7372-7089; Ludwig, Stephan/0000-0003-4490-3052				Anderson H, 1999, BRIT J CANCER, V80, P219, DOI 10.1038/sj.bjc.6690342; Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219; Bergmann M, 2001, CANCER RES, V61, P8188; BOS JL, 1989, CANCER RES, V49, P4682; Brydak LB, 2000, DRUGS, V60, P35, DOI 10.2165/00003495-200060010-00004; CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137; Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X; Fischer T, 2003, J VIROL, V77, P9312, DOI 10.1128/JVI.77.17.9312-9323.2003; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LITTLE JW, 1976, ANN INTERN MED, V85, P177, DOI 10.7326/0003-4819-85-2-177; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Ober BT, 1998, J VIROL, V72, P4866, DOI 10.1128/JVI.72.6.4866-4873.1998; Olshaker JS, 2003, EMERG MED CLIN N AM, V21, P353, DOI 10.1016/S0733-8627(03)00018-X; Palese P, 1996, P NATL ACAD SCI USA, V93, P11354, DOI 10.1073/pnas.93.21.11354; PESCHKE T, 1993, IMMUNOBIOLOGY, V189, P340, DOI 10.1016/S0171-2985(11)80365-7; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Porter DD, 1999, CLIN INFECT DIS, V29, P437, DOI 10.1086/520230; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; SCHOLTISSEK C, 1997, ARCH VIROL         S, V13, P99; Steinhauer DA, 2002, ANNU REV GENET, V36, P305, DOI 10.1146/annurev.genet.36.052402.152757; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279	29	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6639	6646		10.1038/sj.onc.1207883	http://dx.doi.org/10.1038/sj.onc.1207883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235583				2022-12-25	WOS:000223530800011
J	Leite, RS; Brown, AG; Strauss, JF				Leite, RS; Brown, AG; Strauss, JF			Tumor necrosis factor-alpha suppresses the expression of steroid receptor coactivator-1 and-2: A possible mechanism contributing to changes in steroid hormone responsiveness	FASEB JOURNAL			English	Article						progesterone receptor; uterine smooth muscle cells; parturition; cofactors; inflammation	HUMAN PROGESTERONE-RECEPTOR; FACTOR-KAPPA-B; FETAL MEMBRANES; HUMAN LABOR; BINDING; PARTURITION; TERM; COREPRESSORS; CYTOKINES; PRETERM	Inflammation is associated in some tissues with diminished responsiveness to steroid hormone action. We hypothesized that proinflammatory cytokines alter steroid hormone sensitivity, in part, by reducing levels of key nuclear receptor coactivators. Treatment of cultured human uterine smooth muscle cells (UtSMC) with TNF-alpha significantly reduced mRNA for the coactivators, SRC-1 (42%, P< 0.01) and 2 (47%, P< 0.03), and diminished the respective protein levels, but did not significantly alter the mRNAs encoding SRC-3, CBP and the corepressors, NCoR and SMRT; or progesterone receptor protein levels. To assess TNF-alpha effects on steroid hormone-mediated transcriptional activity, UtSMC were transfected with progesterone receptor B (PR-B) and a model PRE(2)-luciferase reporter construct. Transfected UtSMC were treated with progesterone alone or in the presence of TNF-alpha, and assayed for luciferase activity. TNF-alpha (10 ng/ml) diminished progesterone-stimulated PR-B-mediated transactivation by similar to60% (P< 0.02). The TNF-alpha-dependent decrease in PRE-luciferase activity was fully prevented by cotransfection with SRC-2, and partially prevented with exogenous SRC-1. In conclusion, TNF-alpha impairs progesterone-stimulated PR-B-mediated transactivation, and these effects appear to be due, in part, to reduced expression of SRC-1 and -2, which is a novel mechanism by which inflammation can functionally block steroid hormone action.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Strauss, JF (corresponding author), 1354 Biomed Res Bldg,II-III 421 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu			FIC NIH HHS [D43-TW00671] Funding Source: Medline; NICHD NIH HHS [T32-HD07305, R01 HD34612] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034612, T32HD007305] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; ANDERSON ABM, 1975, J ENDOCRINOL, V66, P61, DOI 10.1677/joe.0.0660061; Arechavaleta-Velasco F, 2002, BIOL REPROD, V67, P1952, DOI 10.1095/biolreprod.102.004721; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; CSAPO AI, 1965, P NATL ACAD SCI USA, V54, P1069, DOI 10.1073/pnas.54.4.1069; Fukuda H, 2002, INT J GYNECOL OBSTET, V77, P123, DOI 10.1016/S0020-7292(02)00016-4; Garland SM, 2002, J REPROD IMMUNOL, V57, P169, DOI 10.1016/S0165-0378(02)00018-9; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Henderson D, 2001, AM J OBSTET GYNECOL, V185, P579, DOI 10.1067/mob.2001.116753; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948; Keelan JA, 1997, CLIN OBSTET GYNECOL, V40, P460, DOI 10.1097/00003081-199709000-00004; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MCDONNELL DP, 1995, TRENDS ENDOCRIN MET, V6, P133, DOI 10.1016/1043-2760(95)00065-P; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; ONATE SA, 1995, SCIENCE, V270, P1354; Osman I, 2003, MOL HUM REPROD, V9, P41, DOI 10.1093/molehr/gag001; Peltier M, 2003, REPROD BIOL ENDOCRIN, V1, P122, DOI [10.1186/1477-7827-1-122, DOI 10.1186/1477-7827-1-122]; Rowan BG, 2000, STEROIDS, V65, P545, DOI 10.1016/S0039-128X(00)00112-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIITERI PK, 1982, BIOL REPROD, V26, P1, DOI 10.1095/biolreprod26.1.1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steinborn A, 1995, PROSTAGLANDINS, V50, P237, DOI 10.1016/0090-6980(95)00138-7; Steinborn A, 1996, J PERINAT MED, V24, P381, DOI 10.1515/jpme.1996.24.4.381; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Xu JJ, 1998, ELECTROCHEM SOLID ST, V1, P1, DOI 10.1149/1.1390615; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Young A, 2002, BIOL REPROD, V66, P445, DOI 10.1095/biolreprod66.2.445	38	29	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1418	+		10.1096/fj.04-1684fje	http://dx.doi.org/10.1096/fj.04-1684fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231721				2022-12-25	WOS:000222979200016
J	Maupas-Schwalm, F; Auge, N; Robinet, C; Cambus, JP; Parsons, SJ; Salvayre, R; Negre-Salvayre, A				Maupas-Schwalm, F; Auge, N; Robinet, C; Cambus, JP; Parsons, SJ; Salvayre, R; Negre-Salvayre, A			The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator	FASEB JOURNAL			English	Article						tPA; sphingosine kinase; Src	SMOOTH-MUSCLE-CELLS; SPHINGOSINE KINASE TYPE-2; LOW-DENSITY-LIPOPROTEIN; UROKINASE RECEPTOR; SIGNALING PATHWAY; CYTOSKELETON REORGANIZATION; EPITHELIAL-CELLS; PROTEIN-KINASE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE	Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV-304 carcinoma cells, tPA and ATF (the N-terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine-1-phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D-erythro-2-(N-myristoylamino)-1-phenyl-propanol (D-MAPP) and N-N'-dimethyl sphingosine (DMS), two classical inhibitors of sphingosine-1-phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase-1 that was mediated by a common pertussis toxin (PTX)-sensitive mechanism. The tPA-induced sphingosine kinase-1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK-cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 ( early phase peaking at 15 min). Sphingosine kinase-1 activation was followed by a second phase of ERK1/2 phosphorylation ( peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D-MAPP and DMS, by anti-EGD-1 antibodies and in SrcK-cells ( in which the mitogenic signaling was rescued by sphingosine-1-phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA-induced mitogenic signaling.	CHU Rangueil, INSERM, U466, F-31043 Toulouse 4, France; CHU Rangueil, Hematol Lab, F-31054 Toulouse, France; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; University of Virginia; University of Virginia	Salvayre, R (corresponding author), CHU Rangueil, INSERM, U466, IFR 31,1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	salvayre@rangueil.inserm.fr; anesalv@rangueil.inserm.fr		Maupas-Schwalm, Francoise/0000-0002-7355-7091; Negre-Salvayre, Anne/0000-0003-2136-5706; Auge, Nathalie/0000-0003-2088-7211				Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Binder BR, 2002, NEWS PHYSIOL SCI, V17, P56, DOI 10.1152/nips.01369.2001; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Irigoyen JP, 1999, BIOCHEM BIOPH RES CO, V262, P666, DOI 10.1006/bbrc.1999.1202; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu GL, 2002, J BIOL CHEM, V277, P48427, DOI 10.1074/jbc.M202130200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Montuori N, 2001, FEBS LETT, V508, P379, DOI 10.1016/S0014-5793(01)03104-0; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4	53	35	37	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1398	+		10.1096/fj.03-1123fje	http://dx.doi.org/10.1096/fj.03-1123fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231724				2022-12-25	WOS:000222979200026
J	Norberg, A; Hoa, NK; Liepinsh, E; Van Phan, D; Thuan, ND; Jornvall, H; Sillard, R; Ostenson, CG				Norberg, A; Hoa, NK; Liepinsh, E; Van Phan, D; Thuan, ND; Jornvall, H; Sillard, R; Ostenson, CG			A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; RAT PANCREAS; GYPENOSIDES; CELLS; SAPONINS; MAKINO	Extracts from Gynostemma pentaphyllum Makino (Cucurbitaceae), a Southeast Asian herb, has been reported to affect numerous activities resulting in antitumor, cholesterol-lowering, immunopotentiating, antioxidant, and hypoglycemic effects. We have isolated one active compound by ethanol extraction, distribution in n-butyl alcohol/water, solid phase extraction/separation, and several rounds of reverse phase high pressure liquid chromatography. We have shown by NMR and mass spectrometry that this active compound is a novel saponin, a gypenoside, which we have named phanoside (21-, 23-epoxy-,3beta-,20-,21-trihydroxydammar-24-ene-3-O-([alpha-D-rhamnopyranosyl(1-->2)]-[beta-D-glycopyranosyl(1-->3)]-beta-D-lyxopyranoside)), with a molecular mass of 914.5 Da. Phanoside is a dammarane-type saponin, and four stereoisomers differing in configurations at positions 21 and 23 were identified, each of which were found to stimulate insulin release from isolated rat pancreatic islets. We have also found that the stereoisomers are interconvertible. Dose-dependent insulin-releasing activities at 3.3 and 16.7 mM glucose levels were determined for the racemic mixture containing all four stereoisomers. Phanoside at 500 muM stimulates insulin release in vitro 10-fold at 3.3 mM glucose and potentiates the release almost 4-fold at 16.7 mM glucose. At these glucose levels, 2 muM glibenclamide stimulates insulin release only 2-fold. Interestingly, beta-cell sensitivity to phanoside is higher at 16.7 mM than at 3.3 mM glucose, although insulin responses were significantly increased by phanoside below 125 muM only at high glucose levels. Also when given orally to rats, phanoside (40 and 80 mg/ml) improved glucose tolerance and enhanced plasma insulin levels at hyperglycemia.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Hanoi Med Univ, Dept Pharmacol, Hanoi, Vietnam; Inst Mat Med, Hanoi, Vietnam	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Hanoi Medical University	Sillard, R (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	rannar@ki.se						Aktan F, 2003, NITRIC OXIDE-BIOL CH, V8, P235, DOI 10.1016/S1089-8603(03)00032-6; Anhauser M, 2003, DRUG DISCOV TODAY, V8, P868, DOI 10.1016/S1359-6446(03)02856-3; Attele AS, 2002, DIABETES, V51, P1851, DOI 10.2337/diabetes.51.6.1851; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; Hu LH, 1996, J NAT PROD, V59, P1143, DOI 10.1021/np960445u; Izzo AA, 2001, DRUGS, V61, P2163, DOI 10.2165/00003495-200161150-00002; JANG YJ, 2001, YAKHAK HOECHI, V45, P545; KUWAHARA M, 1989, CHEM PHARM BULL, V37, P135; LACOUR B, 1995, J ETHNOPHARMACOL, V46, P125, DOI 10.1016/0378-8741(95)01234-5; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lamba SS, 2000, STUD NAT PROD CHEM, V21, P457; LI L, 1993, CANCER BIOTHERAPY, V8, P263, DOI 10.1089/cbr.1993.8.263; LIN JM, 1993, AM J CHINESE MED, V21, P59, DOI 10.1142/S0192415X9300008X; MALAISSE WJ, 1990, DIABETES CARE, V13, P9, DOI 10.2337/diacare.13.3.9; Nakata M, 2003, PANCREAS, V27, P209, DOI 10.1097/00006676-200310000-00001; OSTENSON CG, 1983, DIABETES METAB, V9, P58; PANAGIOTIDIS G, 1992, EUR J PHARMACOL, V229, P277, DOI 10.1016/0014-2999(92)90568-O; SHEN Z, 1993, LINCHAN HUAXUE YU GO, V13, P265; TAKEMOTO T, 1983, YAKUGAKU ZASSHI, V103, P173, DOI 10.1248/yakushi1947.103.2_173; Tanner MA, 1999, NITRIC OXIDE-BIOL CH, V3, P359, DOI 10.1006/niox.1999.0245; UR RA, 1989, J ETHNOPHARMACOL, V26, P1; Vuksan V, 2001, J AM COLL NUTR, V20, p370S, DOI 10.1080/07315724.2001.10719170; Wang QF, 2002, CANCER LETT, V183, P169, DOI 10.1016/S0304-3835(01)00828-X; Xie JT, 2002, PHYTOMEDICINE, V9, P254, DOI 10.1078/0944-7113-00106; Zhou ZT, 1998, CHINESE MED J-PEKING, V111, P847	25	85	98	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41361	41367		10.1074/jbc.M403435200	http://dx.doi.org/10.1074/jbc.M403435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15220351	hybrid			2022-12-25	WOS:000224075500016
J	Kirchhofer, D; Yao, XY; Peek, M; Eigenbrot, C; Lipari, MT; Billeci, KL; Maun, HR; Moran, P; Santell, L; Wiesmann, C; Lazarus, RA				Kirchhofer, D; Yao, XY; Peek, M; Eigenbrot, C; Lipari, MT; Billeci, KL; Maun, HR; Moran, P; Santell, L; Wiesmann, C; Lazarus, RA			Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; C-MET; FACTOR RECEPTOR; SEMA DOMAIN; PLASMINOGEN-ACTIVATOR; PROTEOLYTIC CLEAVAGE; MOLECULAR-CLONING; SURFACE RESIDUES; SCATTER-FACTOR; SITE	Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the ligand for Met, a receptor tyrosine kinase implicated in development, tissue regeneration, and invasive tumor growth. HGF acquires signaling activity only upon proteolytic cleavage of single-chain HGF into its alpha/beta heterodimer, similar to zymogen activation of structurally related serine proteases. Although both chains are required for activation, only the alpha-chain binds Met with high affinity. Recently, we reported that the protease-like HGF beta-chain binds to Met with low affinity (Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D., and Wiesmann, C. ( 2004) EMBO J. 23, 2325 - 2335). Here we demonstrate that the zymogen-like form of HGF beta also binds Met, albeit with 14-fold lower affinity than the protease-like form, suggesting optimal interactions result from conformational changes upon cleavage of the single-chain form. Extensive mutagenesis of the HGF beta region corresponding to the active site and activation domain of serine proteases showed that 17 of the 38 purified two-chain HGF mutants resulted in impaired cell migration or Met phosphorylation but no loss in Met binding. However, reduced biological activities were well correlated with reduced Met binding of corresponding mutants of HGF beta itself in assays eliminating dominant alpha-chain binding contributions. Moreover, the crystal structure of HGF beta determined at 2.53 Angstrom resolution provides a structural context for the mutagenesis data. The functional Met binding site is centered on the "active site region" including "triad" residues Gln(534) [c57], Asp(578) [c102], and Tyr(673) [c195] and neighboring "activation domain" residues Val(692), Pro(693), Gly(694), Arg(695), and Gly(696) [c214-c219]. Together they define a region that bears remarkable resemblance to substrate processing regions of serine proteases. Models of HGF-dependent Met receptor activation are discussed.	Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay & Automat Technol, San Francisco, CA 94080 USA; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Freiburg	Kirchhofer, D (corresponding author), Genentech Inc, Dept Physiol, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com; laz@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Broze GJ, 2001, THROMB HAEMOSTASIS, V86, P8; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Danilkovitch A, 1999, J BIOL CHEM, V274, P29937, DOI 10.1074/jbc.274.42.29937; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; Drain J, 2001, J BIOL CHEM, V276, P30254, DOI 10.1074/jbc.M010198200; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; Matsumoto K, 1998, J BIOL CHEM, V273, P22913, DOI 10.1074/jbc.273.36.22913; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miller M, 1998, FEBS LETT, V429, P1, DOI 10.1016/S0014-5793(98)00533-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Peek M, 2002, J BIOL CHEM, V277, P47804, DOI 10.1074/jbc.M209778200; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999	50	77	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39915	39924		10.1074/jbc.M404795200	http://dx.doi.org/10.1074/jbc.M404795200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15218027	hybrid			2022-12-25	WOS:000223791500088
J	Mazhari, SM; Selser, CT; Cremo, CR				Mazhari, SM; Selser, CT; Cremo, CR			Novel sensors of the regulatory switch on the regulatory light chain of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; SCALLOP HEAVY-MEROMYOSIN; STRUCTURAL-CHANGES; 2-HEADED STRUCTURE; ATPASE ACTIVITY; MOTOR DOMAIN; LOOP REGION; ACTIN; CONFORMATION; CYSTEINE	Smooth muscle myosin can be switched on by phosphorylation of Ser-19 of the regulatory light chain. Our previous photocross-linking results suggested that an element of the structural mechanism for the regulatory switch was a phosphorylation-induced motion of the regulatory light chain N terminus (Wahlstrom, J. L., Randall, M. A., Jr., Lawson, J. D., Lyons, D. E., Siems, W. F., Crouch, G. J., Barr, R., Facemyer, K. C., and Cremo, C. R. ( 2003) J. Biol. Chem. 278, 5123 - 5131). Here we used three different approaches to test this notion, which are reactivity of cysteine thiols, pyrene and acrylodan spectral analysis, and pyrene fluorescence quenching. All methods detected significant differences between the unphosphorylated and phosphorylated regulatory light chain N termini in heavy meromyosin, a double-headed subfragment with an intact regulatory switch. These differences were not observed for subfragment-1, a single-headed, unregulated subfragment. In the presence of either ATP or ADP, phosphorylation increased the solvent exposure and decreased the polarity of the environment about position 23 of the regulatory light chain of heavy meromyosin. These phosphorylation-induced structural changes were not as evident in the absence of nucleotides. Nucleotide binding to unphosphorylated heavy meromyosin caused a decrease in exposure and an increase in polarity of the N terminus, whereas the effects of nucleotide on phosphorylated heavy meromyosin were the opposite. We showed a direct correlation between the kinetics of nucleotide binding/ turnover and the conformational change reported by acrylodan at position 23 of the regulatory light chain. Acrylodan-A23C also reports the heads up ( extended) to flexed ( folded) transition in unphosphorylated heavy meromyosin. This is the first demonstration of direct coupling of nucleotide binding to conformational changes in the N terminus of the regulatory light chain.	Univ Nevada, Dept Biochem 330, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Cremo, CR (corresponding author), Univ Nevada, Dept Biochem 330, 1664 N Virginia St, Reno, NV 89557 USA.	cremo@unr.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040917, R29AR040917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Bartegi A, 1999, EUR J BIOCHEM, V262, P335, DOI 10.1046/j.1432-1327.1999.00390.x; Bass RB, 1998, J BIOL CHEM, V273, P25006, DOI 10.1074/jbc.273.39.25006; Britto PJ, 2002, J BIOL CHEM, V277, P29018, DOI 10.1074/jbc.M204263200; CHANTLER PD, 1981, BIOCHEMISTRY-US, V20, P210, DOI 10.1021/bi00504a035; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; Espenson JH, 1995, CHEM KINETICS REACTI; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FRADO LLY, 1992, J MUSCLE RES CELL M, V13, P436; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, V4; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P88; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEHARA M, 1968, BIOCHIM BIOPHYS ACTA, V155, P82, DOI 10.1016/0005-2787(68)90337-7; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; Kojima S, 1999, BIOCHEMISTRY-US, V38, P11670, DOI 10.1021/bi990081f; Konishi K, 1998, J BIOCHEM-TOKYO, V124, P163, DOI 10.1093/oxfordjournals.jbchem.a022075; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Nyitrai M, 2002, BIOCHEM J, V365, P19, DOI 10.1042/BJ20020099; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; ONISHI H, 1995, P NATL ACAD SCI USA, V92, P704, DOI 10.1073/pnas.92.3.704; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers J. R., 1999, MYOSINS; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; Shi JX, 2002, J BIOL CHEM, V277, P43301, DOI 10.1074/jbc.M204391200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stafford WF, 2001, J MOL BIOL, V307, P137, DOI 10.1006/jmbi.2000.4490; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1994, J MUSCLE RES CELL M, V15, P587, DOI 10.1007/BF00121066; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TRYBUS KM, 1991, J CELL SCI, P87; Wahlstrom JL, 2003, J BIOL CHEM, V278, P5123, DOI 10.1074/jbc.M206963200; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; Yamaguchi Y, 2002, J CONTROL RELEASE, V81, P235, DOI 10.1016/S0168-3659(02)00060-3; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; ZHI G, 1994, J BIOL CHEM, V269, P24723	64	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39905	39914		10.1074/jbc.M407062200	http://dx.doi.org/10.1074/jbc.M407062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262959	hybrid			2022-12-25	WOS:000223791500087
J	Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK				Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK			Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro	ONCOGENE			English	Article						FLIP; caspases; chemoresistance; cisplatin; ovarian cancer	X-LINKED INHIBITOR; APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; DOWN-REGULATION; CELLULAR FLIP; UP-REGULATION; C-FLIP; CISPLATIN; EXPRESSION; RESISTANCE	Chemoresistance is a major therapeutic problem and the current knowledge on cellular mechanisms involved is incomplete. In the present study, we have investigated the possible involvement of Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein ( FLIP) in ovarian cancer resistance by comparing chemosensitive (OV2008) and chemoresistant (C13*) ovarian cancer cells treated with cisplatin in vitro, and/ or transfected with FLIP sense cDNA or FLIP small interfering RNA ( siRNA) and determining FLIP protein content, cleavage of caspase-8 and caspase-3 and apoptosis. Cisplatin significantly decreased FLIP protein level, induced cleavage of caspase-8 and caspase-3 and apoptosis in a concentration-dependent manner in cisplatin-sensitive but not - resistant cells. While overexpression of FLIP-attenuated cisplatin-induced cleavage of caspase-8 and caspase-3 and apoptosis in chemosensitive cells, downregulation of FLIP in chemoresistant cells by siRNA increased apoptosis induced by cisplatin. These results suggest that FLIP plays a significant role in the regulation of apoptosis in human ovarian cancer cells and their sensitivity to cisplatin. This cell survival factor may be an important determinant in chemoresistance in ovarian cancer and may serve as a molecular target for the development of novel therapy for chemoresistant ovarian cancer.	Univ Ottawa, Dept Obstet, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Gynaecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular Med, Ottawa, ON, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Tsang, BK (corresponding author), 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Arts HJG, 2000, INT J GYNECOL CANCER, V10, P47, DOI 10.1046/j.1525-1438.2000.99511.x; Asselin E, 2001, CANCER RES, V61, P1862; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fraser M, 2003, CANCER RES, V63, P7081; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Hu LM, 2002, CANCER RES, V62, P1087; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kim JH, 2003, CLIN CANCER RES, V9, P3134; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Sasaki H, 2000, CANCER RES, V60, P5659; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Song JH, 2003, CLIN CANCER RES, V9, P4255; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant Harald, 2003, Mol Interv, V3, P124, DOI 10.1124/mi.3.3.124; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yoshikawa H, 2000, J IMMUNOL, V165, P6262, DOI 10.4049/jimmunol.165.11.6262; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	31	103	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					6997	7004		10.1038/sj.onc.1207925	http://dx.doi.org/10.1038/sj.onc.1207925			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258564				2022-12-25	WOS:000223885100001
J	Diakov, A; Korbmacher, C				Diakov, A; Korbmacher, C			A novel pathway of epithelial sodium channel activation involves a serum- and glucocorticoid-inducible kinase consensus motif in the C terminus of the channel's alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; COLLECTING DUCT CELLS; NA+ CHANNEL; LIDDLES-SYNDROME; A6 CELLS; MINERALOCORTICOID REGULATION; XENOPUS-OOCYTES; PROTEIN-KINASE; IN-VIVO; ENAC	Aldosterone-induced serum- and glucocorticoid-inducible kinase isoform 1 (SGK1) contributes to the regulation of the epithelial sodium channel (ENaC), the activity of which is critical for long term blood pressure control. Aldosterone-induced SGK1 is thought to enhance ENaC surface expression by phosphorylating Nedd4-2 and thereby preventing ENaC retrieval and degradation. In outside-out membrane patches of Xenopus laevis oocytes heterologously expressing ENaC, amiloride-sensitive ENaC currents were enhanced by phosphatase inhibitors and were dependent on cytosolic Mg2+. This indicates that a kinase is involved in channel regulation. Indeed, recombinant constitutively active SGK1, included in the pipette solution, caused a sustained 2- to 3-fold increase of ENaC currents. Deletion of the C terminus of alphaENaC largely reduced the stimulatory effect of SGK1, whereas stimulation by SGK1 did not require the presence of the C termini of the beta- or gamma-subunits. Replacing the serine residue Ser(621) of the SGK1 consensus motif in the C terminus of the alpha-subunit by an alanine specifically abolished the stimulatory effect of SGK. Our findings indicate that SGK1 can stimulate ENaC activity independently of an inhibition of Nedd4-2-mediated channel retrieval. This defines a novel regulatory pathway likely to be relevant for aldosterone-induced stimulation of ENaC in vivo.	Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Korbmacher, C (corresponding author), Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Waldstr 6, D-91054 Erlangen, Germany.	christoph.korbmacher@physiologie2.med.uni-erlangen.de						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Becchetti A, 2002, AM J PHYSIOL-RENAL, V283, pF1030, DOI 10.1152/ajprenal.00011.2002; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Brennan FE, 2000, MOL CELL ENDOCRINOL, V166, P129, DOI 10.1016/S0303-7207(00)00274-4; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Dahlmann A, 2003, AM J PHYSIOL-RENAL, V285, pF310, DOI 10.1152/ajprenal.00016.2003; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2002, J BIOL CHEM, V277, P21346, DOI 10.1074/jbc.M202005200; KORBMACHER C, 1995, J MEMBRANE BIOL, V146, P29; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce D, 2003, CELL PHYSIOL BIOCHEM, V13, P13, DOI 10.1159/000070245; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shi HK, 2002, EUR J BIOCHEM, V269, P4551, DOI 10.1046/j.1432-1033.2002.03154.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696; Yue G, 2000, AM J PHYSIOL-CELL PH, V279, pC81, DOI 10.1152/ajpcell.2000.279.1.C81	51	140	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38134	38142		10.1074/jbc.M403260200	http://dx.doi.org/10.1074/jbc.M403260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234985	hybrid			2022-12-25	WOS:000223684100011
J	Joo, NS; Lee, DJ; Winges, KM; Rustagi, A; Wine, JJ				Joo, NS; Lee, DJ; Winges, KM; Rustagi, A; Wine, JJ			Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; EPITHELIAL-CELLS; MUCUS SECRETION; CL-SECRETION; LINE CALU-3; CFTR; STIMULATION; EXOCYTOSIS; MECHANISM; LYSOZYME	Airway submucosal gland serous cells express the cystic fibrosis transmembrane conductance regulator (CFTR) and secrete antimicrobial, anti-inflammatory, and antioxidant molecules. In cystic fibrosis, diminished gland secretion may impair innate airway host defenses. We used Calu-3 cells as a serous cell model to study the types of proteins released, the pathways that release them, and the possible involvement of CFTR activity in protein release. Many proteins were secreted constitutively into the apical fluid and showed increased release to agonists. We identified some of them by high pressure liquid chromatography-mass spectrometry and reverse transcriptase PCR, including lysozyme, siderocalin (the protein NGAL), which inhibits bacterial growth by binding iron-containing siderophores, HSC-71, which is thought to have anti-inflammatory properties, and the serine protease inhibitors alpha-1-antitrypsin and alpha-1-antichymotrypsin, which may function as antimicrobials as well as play a potential role in diminishing the activation of epithelial Na+ channels by serine proteases. We used an enzyme-linked immunosorbent assay to quantify lysozyme secretion by Calu-3 cells in response to various agonists and inhibitors. Forskolin increased the lysozyme secretion rate (J(lyz)) from 32 to 77 ng/hr/cm(2) (n=36, p<0.005). Thapsigargin increased J(lyz) from 40 to 63 ng/h/cm(2) (n=16, p<0.005), and forskolin plus thapsigargin further increased the forskolin-stimulated J(lyz) by 48% (n=9, p<0.05). 1-Ethyl-benzimidazolinone and carbachol were less effective. Glibenclamide inhibited basal and stimulated J(lyz), but clotrimazole was without effect. CFTR(inh)172 caused a small (15%) but significant inhibition of forskolin-stimulated J(lyz) without affecting basal J(lyz). Thus, Calu-3 cells secrete diverse proteins that in aggregate would be expected to suppress microbial growth, protect the airways from damage, and limit the activation of epithelial Na+ channels via serine proteases.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA	Stanford University	Joo, NS (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Rm 516,Bldg 420,Main Quad, Stanford, CA 94305 USA.	nsjoo@psych.stanford.edu		Rustagi, Arjun/0000-0002-6921-1012; Winges, Kimberly/0000-0001-9271-1640	NIDDK NIH HHS [DK-51817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; BABU PBR, 2003, PEDIATR PULM, V25, P281; Clarke LL, 2004, AM J PHYSIOL-GASTR L, V286, pG1050, DOI 10.1152/ajpgi.00393.2003; Cowley EA, 2002, J PHYSIOL-LONDON, V538, P747, DOI 10.1113/jphysiol.2001.013300; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Dubin RF, 2004, AM J PHYSIOL-LUNG C, V286, pL750, DOI 10.1152/ajplung.00326.2003; Duszyk M, 2001, PFLUG ARCH EUR J PHY, V443, pS45; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Hille B, 1999, J PHYSIOL-LONDON, V520, P23, DOI 10.1111/j.1469-7793.1999.00023.x; IROKAWA T, 2004, IN PRESS AM J PHYSL, V287; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Lehtihet M, 2003, AM J PHYSIOL-ENDOC M, V285, pE438, DOI 10.1152/ajpendo.00057.2003; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; McPherson MA, 2001, PFLUG ARCH EUR J PHY, V443, pS121; Moon S, 1997, AM J PHYSIOL-LUNG C, V273, pL1208, DOI 10.1152/ajplung.1997.273.6.L1208; Parfrey H, 2003, INT J BIOCHEM CELL B, V35, P1009, DOI 10.1016/S1357-2725(02)00250-9; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Sallenave JM, 2002, BIOCHEM SOC T, V30, P111, DOI 10.1042/BST0300111; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Trout L, 2001, AM J PHYSIOL-LUNG C, V281, pL639, DOI 10.1152/ajplung.2001.281.3.L639; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Zhang Y, 2001, AM J RESP CELL MOL, V25, P196, DOI 10.1165/ajrcmb.25.2.4211	30	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38854	38860		10.1074/jbc.M407077200	http://dx.doi.org/10.1074/jbc.M407077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234967	hybrid			2022-12-25	WOS:000223684100098
J	Karagiannis, ED; Popel, AS				Karagiannis, ED; Popel, AS			A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; EXTRACELLULAR-MATRIX; CATALYTIC DOMAIN; KINETIC-ANALYSIS; GROWTH-FACTOR; ACTIVATION; BINDING; PROGELATINASE; MECHANISM; TIMP-2	One well documented family of enzymes responsible for the proteolytic processes that occur in the extracellular matrix is the soluble and membrane-associated matrix metalloproteinases. Here we present the first theoretical model of the biochemical network describing the proteolysis of collagen I by matrix metalloproteinases 2 (MMP2) and membrane type 1 matrix metalloproteinases (MT1-MMP) in the presence of the tissue inhibitor of metalloproteinases 2 (TIMP2) in a bulk, cell-free, well stirred environment. The model can serve as a tool for describing quantitatively the activation of the MMP2 proenzyme (pro-MMP2), the ectodomain shedding of MT1-MMP, and the collagenolysis arising from both of the enzymes. We show that pro-MMP2 activation, a process that involves a trimer formation of the proenzyme with TIMP2 and MT1-MMP, is suppressed at high inhibitor levels and paradoxically attains maximum only at intermediate TIMP2 concentrations. We also calculate the conditions for which pro-MMP2 activation is maximal. Furthermore we demonstrate that the ectodomain shedding of MT1-MMP can serve as a mechanism controlling the MT1-MMP availability and therefore the pro-MMP2 activation. Finally the proteolytic synergism of MMP2 and MT1-MMP is introduced and described quantitatively. The model provides us a tool to determine the conditions under which the synergism is optimized. Our approach is the first step toward a more complete description of the proteolytic processes that occur in the extracellular matrix and include a wider spectrum of enzymes and substrates as well as naturally occurring or artificial inhibitors.	Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University	Karagiannis, ED (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.	ekaragia@bme.jhu.edu	Popel, Aleksander S/A-6724-2009	Popel, Aleksander/0000-0002-6706-9235; Karagiannis, Emmanouil/0000-0003-0131-6552				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Filion RJ, 2004, ANN BIOMED ENG, V32, P645, DOI 10.1023/B:ABME.0000030231.88326.78; Haas TL, 2002, CAN J APPL PHYSIOL, V27, P491, DOI 10.1139/h02-027; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hornebeck W, 2002, SEMIN CANCER BIOL, V12, P231, DOI 10.1016/S1044-579X(02)00026-3; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; Mac Gabhann F, 2004, AM J PHYSIOL-HEART C, V286, pH153, DOI 10.1152/ajpheart.00254.2003; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	27	70	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39105	39114		10.1074/jbc.M403627200	http://dx.doi.org/10.1074/jbc.M403627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252025	hybrid			2022-12-25	WOS:000223684100126
J	Legler, PM; Cai, ML; Peterkofsky, A; Clore, GM				Legler, PM; Cai, ML; Peterkofsky, A; Clore, GM			Three-dimensional solution structure of the cytoplasmic B domain of the mannitol transporter IIMannitol of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PHOSPHORYL TRANSFER COMPLEX; C-TERMINAL DOMAIN; NMR STRUCTURE REFINEMENT; CRYSTAL-STRUCTURE; ENZYME-II; BACILLUS-SUBTILIS; PHOSPHOTYROSYL PHOSPHATASE; RESOLUTION STRUCTURE; MOLECULAR-DYNAMICS	The solution structure of the cytoplasmic B domain of the mannitol (Mtl) transporter (IIMtl) from the mannitol branch of the Escherichia coli phosphotransferase system has been solved by multidimensional NMR spectroscopy with extensive use of residual dipolar couplings. The ordered IIBMtl domain (residues 375-471 of IIMtl) consists of a four-stranded parallel beta-sheet flanked by two helices (alpha(1) and alpha(3)) on one face and helix alpha(2) on the opposite face with a characteristic Rossmann fold comprising two right-handed beta(1)alpha(1)beta(2) and beta(3)alpha(2)beta(4) motifs. The active site loop is structurally very similar to that of the eukaryotic protein tyrosine phosphatases, with the active site cysteine (Cys-384) primed in the thiolate state (pK(a)less than or equal to5.6) for nucleophilic attack at the phosphorylated histidine (His-554) of the IIA(Mtl) domain through stabilization by hydrogen bonding interactions with neighboring backbone amide groups at positions i+2/3/4 from Cys-384 and with the hydroxyl group of Ser-391 at position i+7. Modeling of the phosphorylated state of IIBMtl suggests that the phosphoryl group can be readily stabilized by hydrogen bonding interactions with backbone amides in the i+2/4/5/6/7 positions as well as with the hydroxyl group of Ser390 at position i+6. Despite the absence of any significant sequence identity, the structure of IIBMtl is remarkably similar to the structures of bovine protein tyrosine phosphatase (which contains two long insertions relative to IIBMtl) and the cytoplasmic B component of enzyme IIChb, which fulfills an analogous role to IIBMtl in the N,N'-diacetylchitobiose branch of the phosphotransferase system. All three proteins utilize a cysteine residue in the nucleophilic attack of a phosphoryl group covalently bound to another protein.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029023, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AB E, 1997, PROTEIN SCI, V6, P304; AB E, 2001, J MOL BIOL, V308, P993, DOI 10.1006/jmbi.2001.4623; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P1008; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KALBITZER HR, 1993, EUR J BIOCHEM, V216, P205, DOI 10.1111/j.1432-1033.1993.tb18134.x; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9538; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; ORNISS GL, 2003, J MOL BIOL, V327, P1111; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Sliz P, 1997, STRUCTURE, V5, P775, DOI 10.1016/S0969-2126(97)00232-3; STEPHAN MM, 1989, BIOCHEMISTRY-US, V28, P7941, DOI 10.1021/bi00445a058; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tchieu JH, 2001, J MOL MICROB BIOTECH, V3, P329; van Montfort RLM, 1998, STRUCTURE, V6, P377, DOI 10.1016/S0969-2126(98)00039-2; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; VANNULAND NAJ, 1994, J MOL BIOL, V237, P544, DOI 10.1006/jmbi.1994.1254; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10383; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947	78	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39115	39121		10.1074/jbc.M406764200	http://dx.doi.org/10.1074/jbc.M406764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15258141	hybrid			2022-12-25	WOS:000223684100127
J	Yang, LK; Prasad, S; Di Cera, E; Rezaie, AR				Yang, LK; Prasad, S; Di Cera, E; Rezaie, AR			The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; MONO-VALENT CATIONS; CRYSTAL-STRUCTURE; ACTIVE-SITE; CALCIUM; SPECIFICITY; MUTAGENESIS; PROTEASES; DOMAIN; GENE	Previous studies have suggested that the conformation of the activation peptide of protein C is influenced by the binding of Ca2+. To provide direct evidence for the linkage between Ca2+ binding and the conformation of the activation peptide, we have constructed a protein C mutant in the gamma-carboxyglutamic acid-domainless form in which the P1 Arg(169) of the activation peptide is replaced with the fluorescence reporter Trp. Upon binding of Ca2+, the intrinsic fluorescence of the mutant decreases similar to 30%, as opposed to only 5% for the wild-type, indicating that Trp(169) is directly influenced by the divalent cation. The K-d of Ca2+ binding for the mutant protein C was impaired similar to4-fold compared with wild-type. Interestingly, the conformation of the activation peptide was also found to be sensitive to the binding of Na+, and the affinity for Na+ binding increased similar to5-fold in the presence of Ca2+. These findings suggest that Ca2+ changes the conformation of the activation peptide of protein C and that protein C is also capable of binding Na+, although with a weaker affinity compared with the mature protease. The mutant protein C can no longer be activated by thrombin but remarkably it can be activated efficiently by chymotrypsin and by the thrombin mutant D189S. Activation of the mutant protein C by chymotrypsin proceeds at a rate comparable to the activation of wild-type protein C by the thrombin-thrombomodulin complex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NHLBI NIH HHS [HL49413, HL58141, HL73813, HL62565, HL68571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R29HL049413, R01HL058141, R01HL049413, R01HL062565, R01HL073813] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; ESMON NL, 1983, J BIOL CHEM, V258, P5548; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1987, J BIOL CHEM, V262, P140; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Perera L, 2000, BIOPHYS J, V79, P2925, DOI 10.1016/S0006-3495(00)76530-1; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; REZAIE AR, 1994, BLOOD, V83, P2526, DOI 10.1182/blood.V83.9.2526.bloodjournal8392526; REZAIE AR, 1995, BIOCHEMISTRY-US, V34, P12221, DOI 10.1021/bi00038a016; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STEINER SA, 1982, BIOCHEMISTRY-US, V21, P4609, DOI 10.1021/bi00262a015; STENFLO J, 1991, BLOOD, V78, P1637; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200	32	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38519	38524		10.1074/jbc.M407304200	http://dx.doi.org/10.1074/jbc.M407304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15254039	hybrid			2022-12-25	WOS:000223684100057
J	Das, J; Addona, GH; Sandberg, WS; Husain, SS; Stehle, T; Miller, KW				Das, J; Addona, GH; Sandberg, WS; Husain, SS; Stehle, T; Miller, KW			Identification of a general anesthetic binding site in the diacylglycerol-binding domain of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM-ALBUMIN; PHORBOL ESTER; INHALED ANESTHETICS; ADENYLATE KINASE; ALPHA; INHIBITION; HALOTHANE; NONEQUIVALENT; ACTIVATION; MEMBRANES	Protein kinase C (PKC) is an important signal transduction protein that has been proposed to interact with general anesthetics at its cysteine-rich diacylglycerol/ phorbol ester-binding domain C1, a tandem repeat of C1A and C1B subdomains. To test this hypothesis, we expressed, purified, and characterized the high affinity phorbol-binding subdomain, C1B, of mouse protein kinase Cdelta, and studied its interaction with general anesthetic alcohols. When the fluorescent phorbol ester, sapintoxin-D, bound to PKCdelta C1B in buffer at a molar ratio of 1: 2, its fluorescence emission maximum, lambda(max), shifted from 437 to 425 nm. The general anesthetic alcohols, butanol and octanol, further shifted lambda(max) of the PKCdelta C1B-bound sapintoxin-D in a concentration-dependent, saturable manner to similar to415 nm, suggesting that alcohols interact at a discrete allosteric binding site. To identify this site, PKCdeltaC1B was photolabeled with three photoactivable diazirine alcohol analogs, 3-azioctanol, 7-azioctanol, and 3-azibutanol. Mass spectrometry showed photoincorporation of all three alcohols in PKCdeltaC1B at a stoichiometry of 1: 1 in the labeled fraction. The photolabeled PKCdeltaC1B was subjected to tryptic digest, the fragments were separated by online chromatography and sequenced by mass spectrometry. Each azialcohol photoincorporated at Tyr-236. Inspection of the known structure of PKCdeltaC1B shows that this residue is situated adjacent to the phorbol ester binding pocket, and within similar to10 Angstrom of the bound phorbol ester. The present results provide direct evidence for an allosteric anesthetic site on protein kinase C.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Miller, KW (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA.	k_miller@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069726, P01GM058448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58448, GM 07592, GM 069726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addona GH, 2002, J BIOL CHEM, V277, P25685, DOI 10.1074/jbc.M201303200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; CHURCH RFR, 1970, J ORG CHEM, V35, P2465, DOI 10.1021/jo00833a001; DODSON BA, 1987, MOL PHARMACOL, V32, P119; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; HEMMINGS HC, 1994, ANESTHESIOLOGY, V81, P147, DOI 10.1097/00000542-199407000-00021; Hunn M, 1997, FEBS LETT, V400, P226, DOI 10.1016/S0014-5793(96)01395-6; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; LAKOWICZ JR, 1999, PRINCIPLES FLUORESEN; Liu RY, 2003, BIOPHYS J, V84, p169A; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; QUEST AFG, 1995, METHOD ENZYMOL, V252, P153; Rebecchi MJ, 2002, BRIT J ANAESTH, V89, P62, DOI 10.1093/bja/aef160; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Slater SJ, 1997, J BIOL CHEM, V272, P6167, DOI 10.1074/jbc.272.10.6167; Slater SJ, 2004, BIOCHEMISTRY-US, V43, P7601, DOI 10.1021/bi049755z; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; VANDUUREN BL, 1976, CHEM-BIOL INTERACT, V15, P233, DOI 10.1016/0009-2797(76)90149-6; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	38	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37964	37972		10.1074/jbc.M405137200	http://dx.doi.org/10.1074/jbc.M405137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234976	hybrid			2022-12-25	WOS:000223554600090
J	Yoneyama, T; Shiozawa, M; Nakamura, M; Suzuki, T; Sagane, Y; Katoh, Y; Watanabe, T; Ohyama, T				Yoneyama, T; Shiozawa, M; Nakamura, M; Suzuki, T; Sagane, Y; Katoh, Y; Watanabe, T; Ohyama, T			Characterization of a novel acid phosphatase from embryonic axes of kidney bean exhibiting vanadate-dependent chloroperoxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS CURVULARIA-INAEQUALIS; ESCULENTUM CELL-CULTURES; ARABIDOPSIS-THALIANA; ASCOPHYLLUM-NODOSUM; PURPLE PHOSPHATASE; HYDROGEN-PEROXIDE; VANADIUM ENZYME; PURIFICATION; SEEDS; SITE	A novel colorless acid phosphatase (KeACP), which was distinct from the kidney bean purple acid phosphatase, was purified to apparent homogeneity and cloned from embryonic axes of kidney bean ( Phaseolus vulgaris L. Ohfuku) during germination. When orthovanadate (VO4-3) is added to the apo form of the enzyme, KeACP uniquely exhibits the chloroperoxidase activity with loss of phosphatase activity. This is the first demonstration that KeACP is a vanadate-dependent chloroperoxidase in plants to be characterized and suggests that KeACP may play a role in modifying a wide variety of chlorinated compounds that are present in higher plants. The enzyme is a dimer that presents three forms made up of the combination of the dominant 56-kDa and the minor 45-kDa subunits, and both subunits contain carbohydrate. The full-length cDNA of the KeACP gene is 1641 nucleotides, and this sequence is predicted to encode a protein having 457 amino acid residues ( 52,865 Da), including a signal peptide. The complete nucleotide sequence of the genomic DNA ( 3228 bp) of KeACP consists of seven exons and six introns. Northern blot analysis demonstrated that the KeACP gene was expressed specifically in embryonic axes of the kidney bean, and its expression coincided with elongation of the embryonic axis during germination.	Tokyo Univ Agr, Fac Bioind, Dept Food Sci & Technol, Abashiri 0992493, Japan; Asahikawa Med Coll, Dept Chem, Asahikawa, Hokkaido 0788510, Japan; Sars Int Ctr Marine Mol Biol, N-5008 Bergen, Norway; Hokkaido Inst Publ Hlth, Kita Ku, Sapporo, Hokkaido 0600819, Japan	Tokyo University of Agriculture; Asahikawa Medical College	Ohyama, T (corresponding author), Tokyo Univ Agr, Fac Bioind, Dept Food Sci & Technol, 196 Yasaka, Abashiri 0992493, Japan.	t-oyama@bioindustry.nodai.ac.jp	Sagane, Yoshimasa/C-7635-2013; Sagane, Yoshimasa/AAG-5543-2019; Yoneyama, Tohru/ABG-2670-2020; Yoneyama, Tohru/P-7820-2016	Sagane, Yoshimasa/0000-0002-7815-3141; Yoneyama, Tohru/0000-0002-1098-407X				BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BHARGAVA R, 1987, Phytochemistry (Oxford), V26, P1293, DOI 10.1016/S0031-9422(00)81797-5; Bozzo GG, 2004, BIOCHEM J, V377, P419, DOI 10.1042/BJ20030947; Bozzo GG, 2002, EUR J BIOCHEM, V269, P6278, DOI 10.1046/j.1432-1033.2002.03347.x; Carswell M. C., 1999, PLANT RESPONSES ENV, P349, DOI 10.1017/CBO9781107415324.004; CRASNIER M, 1980, PLANT CELL ENVIRON, V3, P217; del Pozo JC, 1999, PLANT J, V19, P579, DOI 10.1046/j.1365-313X.1999.00562.x; DUFF SMG, 1994, PHYSIOL PLANTARUM, V90, P791, DOI 10.1111/j.1399-3054.1994.tb02539.x; Durmus A, 1999, EUR J BIOCHEM, V260, P709, DOI 10.1046/j.1432-1327.1999.00230.x; GABER BP, 1979, J BIOL CHEM, V254, P8340; GIDROL X, 1994, EUR J BIOCHEM, V224, P21, DOI 10.1111/j.1432-1033.1994.tb19990.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; Jakobek JL, 2002, J EXP BOT, V53, P387, DOI 10.1093/jexbot/53.367.387; JAKOBEK JL, 1993, PLANT CELL, V5, P49, DOI 10.1105/tpc.5.1.49; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; LEBANSKY BR, 1992, PLANT PHYSIOL, V99, P391, DOI 10.1104/pp.99.2.391; Li DP, 2002, J BIOL CHEM, V277, P27772, DOI 10.1074/jbc.M204183200; Liao H, 2003, GENE, V318, P103, DOI 10.1016/S0378-1119(03)00764-9; Littlechild J, 2002, J MOL RECOGNIT, V15, P291, DOI 10.1002/jmr.590; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; LOFTFIELD RB, 1969, SCIENCE, V164, P305, DOI 10.1126/science.164.3877.305; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Nakatsuka Momoe, 2000, Japanese Journal of Electrophoresis, V44, P139; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Ogawa K, 2001, PLANT CELL PHYSIOL, V42, P286, DOI 10.1093/pcp/pce032; Olczak M, 1997, BBA-PROTEIN STRUCT M, V1341, P14, DOI 10.1016/S0167-4838(97)00055-1; Olmos E, 1997, J EXP BOT, V48, P1529, DOI 10.1093/jexbot/48.313.1529; PARK HSC, 1986, PHYTOCHEMISTRY, V25, P351, DOI 10.1016/S0031-9422(00)85479-5; PLAT H, 1987, BIOCHEM J, V248, P277, DOI 10.1042/bj2480277; PUNTARULO S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P277, DOI 10.1016/0304-4165(91)90164-C; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; SAINI MS, 1978, BIOCHIM BIOPHYS ACTA, V526, P468, DOI 10.1016/0005-2744(78)90138-9; Schenk G, 1999, ARCH BIOCHEM BIOPHYS, V370, P183, DOI 10.1006/abbi.1999.1407; Schenk G, 2000, GENE, V250, P117, DOI 10.1016/S0378-1119(00)00186-4; TROMP MGM, 1990, BIOCHIM BIOPHYS ACTA, V1040, P192, DOI 10.1016/0167-4838(90)90075-Q; VANSCHIJNDEL JWPM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P249, DOI 10.1016/0167-4838(93)90221-C; VILTER H, 1984, PHYTOCHEMISTRY, V23, P1387, DOI 10.1016/S0031-9422(00)80471-9; VOLLENBROEK EGM, 1995, BIOCHEM SOC T, V23, P267, DOI 10.1042/bst0230267; Wasaki J, 1999, SOIL SCI PLANT NUTR, V45, P439, DOI 10.1080/00380768.1999.10409358; Wever R, 1990, ADV INORG CHEM RA<D>, V35, P81, DOI 10.1016/S0898-8838(08)60161-0; Yildiz M, 2002, NATURWISSENSCHAFTEN, V89, P259, DOI 10.1007/s00114-002-0310-6	43	26	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37477	37484		10.1074/jbc.M405305200	http://dx.doi.org/10.1074/jbc.M405305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247223	hybrid			2022-12-25	WOS:000223554600036
J	Zhou, Y; Messier, N; Ouellette, M; Rosen, BP; Mukhopadhyay, R				Zhou, Y; Messier, N; Ouellette, M; Rosen, BP; Mukhopadhyay, R			Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug Pentostam	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENATE REDUCTASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ARSENITE TRANSPORT; MEMBRANE-VESICLES; PROTEIN; TRYPANOTHIONE; PHOSPHATASE; AMASTIGOTES; RESISTANCE	Arsenicals and antimonials are first line drugs for the treatment of trypanosomal and leishmanial diseases. To create the active form of the drug, Sb(V) must be reduced to Sb(III). Because arsenic and antimony are related metalloids, and arsenical resistant Leishmania strains are frequently cross-resistant to antimonials, we considered the possibility that Sb( V) is reduced by a leishmanial As( V) reductase. The sequence for the arsenate reductase of Saccharomyces cerevisiae, ScAcr2p, was used to clone the gene for a homologue, LmACR2, from Leishmania major. LmACR2 was able to complement the arsenate-sensitive phenotype of an arsC deletion strain of Escherichia coli or an ScACR2 deletion strain of Saccharomyces cerevisiae. Transfection of Leishmania infantum with LmACR2 augmented Pentostam sensitivity in intracellular amastigotes. LmACR2 was purified and shown to reduce both As( V) and Sb( V). This is the first report of an enzyme that confers Pentostam sensitivity in intracellular amastigotes of Leishmania. We propose that LmACR2 is responsible for reduction of the pentavalent antimony in Pentostam to the active trivalent form of the drug in Leishmania.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Laval, Fac Med, Dept Microbiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada	Wayne State University; Laval University; Laval University	Mukhopadhyay, R (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rmukhopa@med.wayne.edu	Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM2216-08] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Denton H, 2004, BIOCHEM J, V381, P405, DOI 10.1042/BJ20040283; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, J BIOL CHEM, V269, P25442; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Ephros M, 1999, ANTIMICROB AGENTS CH, V43, P278, DOI 10.1128/AAC.43.2.278; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Gourbal B, 2004, J BIOL CHEM, V279, P31010, DOI 10.1074/jbc.M403959200; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Liu ZJ, 2004, BIOCHEM BIOPH RES CO, V316, P1178, DOI 10.1016/j.bbrc.2004.03.003; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; Lockwood D, 2004, NAT MED, V10, P110, DOI 10.1038/nm0204-110b; Meng YL, 2004, J BIOL CHEM, V279, P18334, DOI 10.1074/jbc.M400037200; Miekeley N, 2002, ANAL BIOANAL CHEM, V372, P495, DOI 10.1007/s00216-001-1213-7; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; Mukhopadhyay R, 2003, J BIOL CHEM, V278, P24476, DOI 10.1074/jbc.M302610200; Mukhopadhyay R, 2002, ENVIRON HEALTH PERSP, V110, P745, DOI 10.1289/ehp.02110s5745; Mukhopadhyay R, 1998, FEMS MICROBIOL LETT, V168, P127, DOI 10.1016/S0378-1097(98)00430-3; Mukhopadhyay R, 2001, J BIOL CHEM, V276, P34738, DOI 10.1074/jbc.M103354200; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001; Shaked-Mishan P, 2001, J BIOL CHEM, V276, P3971, DOI 10.1074/jbc.M005423200; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; WHITE TC, 1988, J BIOL CHEM, V263, P16977	35	115	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37445	37451		10.1074/jbc.M404383200	http://dx.doi.org/10.1074/jbc.M404383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220340	hybrid			2022-12-25	WOS:000223554600032
J	DiPerna, G; Stack, J; Bowie, AG; Boyd, A; Kotwal, G; Zhang, ZN; Arvikar, S; Latz, E; Fitzgerald, KA; Marshall, WL				DiPerna, G; Stack, J; Bowie, AG; Boyd, A; Kotwal, G; Zhang, ZN; Arvikar, S; Latz, E; Fitzgerald, KA; Marshall, WL			Poxvirus protein N1L targets the I-kappa B kinase complex, inhibits signaling to NF-kappa B by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappa B and IRF3 signaling by Toll-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING ADAPTER; VACCINIA VIRUS; CUTTING EDGE; IKK-EPSILON; ACTIVATION; BETA; INNATE; MOLECULE; ALPHA; DISTINCT	Poxviruses encode proteins that suppress host immune responses, including secreted decoy receptors for pro-inflammatory cytokines such as interleukin-1 (IL-1) and the vaccinia virus proteins A46R and A52R that inhibit intracellular signaling by members of the IL-1 receptor (IL-1R) and Toll-like receptor (TLR) family. In vivo, the TLRs mediate the innate immune response by serving as pathogen recognition receptors, whose oligomerized intracellular Toll/IL-1 receptor (TIR) domains can initiate innate immune signaling. A family of TIR domain-containing adapter molecules transduces signals from engaged receptors that ultimately activate NF-kappaB and/or interferon regulatory factor 3 (IRF3) to induce proinflammatory cytokines. Data base searches detected a significant similarity between the N1L protein of vaccinia virus and A52R, a poxvirus inhibitor of TIR signaling. Compared with other poxvirus virulence factors, the poxvirus N1L protein strongly affects virulence in vivo; however, the precise target of N1L was previously unknown. Here we show that N1L suppresses NF-kappaB activation following engagement of Toll/IL-1 receptors, tumor necrosis factor receptors, and lymphotoxin receptors. N1L inhibited receptor-, adapter-, TRAF-, and IKK-alpha and IKK-beta-dependent signaling to NF-kappaB. N1L associated with several components of the multisubunit I-kappaB kinase complex, most strongly associating with the kinase, TANK-binding kinase 1 (TBK1). Together these findings are consistent with the hypothesis that N1L disrupts signaling to NF-kappaB by Toll/IL-1Rs and TNF superfamily receptors by targeting the IKK complex for inhibition. Furthermore, N1L inhibited IRF3 signaling, which is also regulated by TBK1. These studies define a role for N1L as an immunomodulator of innate immunity by targeting components of NF-kappaB and IRF3 signaling pathways.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Dublin Trinity Coll, Dept Biochem, Viral Immune Evas Grp, Dublin 2, Ireland; Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Cape Town, Sch Med, Inst Infect Dis & Mol Med, Div Med Virol,Observ, ZA-7925 Cape Town, South Africa	University of Massachusetts System; University of Massachusetts Worcester; Trinity College Dublin; University of Louisville; University of Cape Town	Marshall, WL (corresponding author), Univ Massachusetts, Sch Med, Dept Med, 364 Plantat St, Worcester, MA 01605 USA.	william.marshall@umassmed.edu	Latz, Eicke/H-3951-2014; Fitzgerald, Katherine/ABE-6317-2020	Latz, Eicke/0000-0003-1488-5666; Fitzgerald, Kate/0000-0003-3175-609X; Bowie, Andrew/0000-0001-5316-4373	NIAID NIH HHS [U19 AI 57319] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057319] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afonso CL, 2002, J VIROL, V76, P783, DOI 10.1128/JVI.76.2.783-790.2002; Akira S, 2000, J ENDOTOXIN RES, V6, P383, DOI 10.1177/09680519000060050901; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bartlett N, 2002, J GEN VIROL, V83, P1965, DOI 10.1099/0022-1317-83-8-1965; Benedict CA, 2003, CURR OPIN IMMUNOL, V15, P59, DOI 10.1016/S0952-7915(02)00018-3; Benedict CA, 2001, VIROLOGY, V289, P1, DOI 10.1006/viro.2001.1109; Berger DP, 1999, VIROLOGY, V260, P136, DOI 10.1006/viro.1999.9811; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bowie AG, 2004, J CELL BIOCHEM, V91, P1099, DOI 10.1002/jcb.20026; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Dreyfus DH, 1999, J IMMUNOL, V163, P6261; DUNNE A, 2003, SCI STKE; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Granger SW, 2001, J IMMUNOL, V167, P5122, DOI 10.4049/jimmunol.167.9.5122; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOTWAL GJ, 1989, VIROLOGY, V171, P579, DOI 10.1016/0042-6822(89)90627-2; Kumaraguru U, 2001, J IMMUNOL, V166, P1066, DOI 10.4049/jimmunol.166.2.1066; Kurt-Jones EA, 2002, BLOOD, V100, P1860, DOI 10.1182/blood.V100.5.1860.h81702001860_1860_1868; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Moss B, 2001, FIELDS VIROLOGY, P2849; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Reading PC, 2002, VIROLOGY, V292, P285, DOI 10.1006/viro.2001.1236; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2002, MICROBES INFECT, V4, P887, DOI 10.1016/S1286-4579(02)01615-5; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	60	193	200	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36570	36578		10.1074/jbc.M400567200	http://dx.doi.org/10.1074/jbc.M400567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215253	Green Published, hybrid			2022-12-25	WOS:000223453600053
J	Fernando, H; Chin, C; Rosgen, J; Rajarathnam, K				Fernando, H; Chin, C; Rosgen, J; Rajarathnam, K			Dimer dissociation is essential for interleukin-8 (IL-8) binding to CXCR1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS; OLIGOMERIZATION; IDENTIFICATION; MONOMER; SURFACE	Chemokines play a fundamental role in trafficking of immune cells and in host defense against infection. The role of chemokines in the recruitment process is highly regulated spatially and temporally and involves interactions with G protein-coupled receptors and cell surface glycosaminoglycans. The dynamic equilibrium between chemokine monomers and dimers, both free in solution and in cell surface-bound forms, regulates different components of recruitment such as chemotaxis and receptor signaling. The binding and activity of the chemokine interleukin-8 (IL-8) for its receptors, previously studied using "trapped" non-associating monomers and non-dissociating dimers, show that the monomer has a native-like function but support conflicting roles for the dimer. We have measured the binding of native IL-8 to the CXCR1 N-domain, using isothermal titration calorimetry and sedimentation equilibrium techniques. The N-domain constitutes a critical binding site, and IL-8 binding affinity to the receptor N-domain is in the same concentration range as the IL-8 monomer-dimer equilibrium. We observed that only the IL-8 monomer, and not the dimer, is competent in binding the receptor N-domain. Based on our results, we propose that IL-8 dimerization functions as a negative regulator for the receptor function and as a positive regulator for binding to glycosaminoglycans and that both play a role in the neutrophil recruitment process.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rajarathnam, K (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	krrajara@utmb.edu	Pillay, Nischalan/F-9536-2012	Rosgen, Jorg/0000-0001-8820-2202				Attwood MR, 1996, BIOORG MED CHEM LETT, V6, P1869, DOI 10.1016/0960-894X(96)00331-9; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Frevert CW, 2002, J IMMUNOL, V168, P3550, DOI 10.4049/jimmunol.168.7.3550; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Leong SR, 1997, PROTEIN SCI, V6, P609; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lowman HB, 1997, PROTEIN SCI, V6, P598; Murphy PM, 2000, PHARMACOL REV, V52, P145; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200; Rajarathnam K, 1997, J BIOL CHEM, V272, P1725, DOI 10.1074/jbc.272.3.1725; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579	25	62	62	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36175	36178		10.1074/jbc.C400283200	http://dx.doi.org/10.1074/jbc.C400283200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15252057	hybrid			2022-12-25	WOS:000223453600003
J	Offterdinger, M; Georget, V; Girod, A; Bastiaens, PIH				Offterdinger, M; Georget, V; Girod, A; Bastiaens, PIH			Imaging phosphorylation dynamics of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; ENERGY-TRANSFER MEASUREMENTS; FLUORESCENT INDICATORS; SIGNAL PROPAGATION; LIVING CELLS; PROTEIN; BINDING; SITES; AUTOPHOSPHORYLATION; STIMULATION	Epidermal growth factor receptor (EGFR) signaling is initiated by ligand binding followed by homodimerization and rapid receptor autophosphorylation. Monitoring EGFR phosphorylation was achieved by measuring translocation and binding of an enhanced yellow fluorescent protein (EYFP)-labeled phosphotyrosine-binding domain (PTB) to enhanced cyan fluorescent protein (ECFP)-tagged EGFR using fluorescence lifetime imaging microscopy or sensitized emission measurements. To simplify dynamic phosphorylation pattern measurements in cells, FLAME, a ratiometric sensor containing both EGFR-ECFP and PTB-EYFP in one molecule, was designed and examined in COS7 cells. Epidermal growth factor (EGF) treatment demonstrated rapid and reversible changes in the EYFP/ECFP fluorescence emission ratios, due to binding of the PTB domain to its consensus binding sites upon phosphorylation at the cell periphery, whereas perinuclear regions failed to respond to EGF but were responsive to tyrosine kinase inhibition. Long-term EGF treatment resulted in accumulation of dephosphorylated receptor in the perinuclear region due to active dephosphorylation occurring at intracellular sites. This indicates that the sensor closely approaches the true dynamics of tyrosine kinase autophosphorylation and dephosphorylation. Phosphatase inhibition by pervanadate resulted in an irreversible response in all cellular compartments. These data show that EGFR is under tonic phosphatase suppression maintaining the receptor in an unphosphorylated (silent) state and is dephosphorylated at endomembranes after ligand-mediated endocytosis.	European Mol Biol Lab, Cell Biol & Cell Biophys Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Bastiaens, PIH (corresponding author), European Mol Biol Lab, Cell Biol & Cell Biophys Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bastiaens@embl-heidelberg.de	Georget, Virginie/AAQ-1843-2020					BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; HSU CYJ, 1991, J BIOL CHEM, V266, P603; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Klein P, 2004, P NATL ACAD SCI USA, V101, P929, DOI 10.1073/pnas.0307285101; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nagy P, 1998, EUR BIOPHYS J BIOPHY, V27, P377, DOI 10.1007/s002490050145; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Sawano A, 2002, DEV CELL, V3, P245, DOI 10.1016/S1534-5807(02)00224-1; SOLER C, 1994, J BIOL CHEM, V269, P12320; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	28	72	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36972	36981		10.1074/jbc.M405830200	http://dx.doi.org/10.1074/jbc.M405830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215236	hybrid			2022-12-25	WOS:000223453600100
J	Donnes, P; Hoglund, A; Sturm, M; Comtesse, N; Backes, C; Meese, E; Kohlbacher, O; Lenhof, HP				Donnes, P; Hoglund, A; Sturm, M; Comtesse, N; Backes, C; Meese, E; Kohlbacher, O; Lenhof, HP			Integrative analysis of cancer-related data using CAP	FASEB JOURNAL			English	Article						cancer-associated protein database; overexpression	HUMAN PROTEIN FUNCTION; HIGH EXPRESSION; TUMOR-ANTIGENS; GENE; PREDICTION; MENINGIOMA; RESPONSES	The development of human cancer is a highly complex process and can be considered the result of several combined events, such as genetic alterations, disturbance of signal transduction, or failure of immunological surveillance. Cancer-related databases usually focus on specific fields of research, e. g., cancer genetics or cancer immunology, whereas the complexity of cancer genesis requires an integrated analysis of heterogeneous data from several sources. Here we present the cancer-associated protein database (CAP), a novel analysis system for cancer-related data. CAP integrates data from multiple external databases, augments these data with functional annotations, and offers tools for statistical analysis of these data. We have employed CAP to analyze genes that have been found to cause an autoimmune response in cancer. In particular, we explored the connection between the autoimmune response, mutations, and overexpression of these genes. Our preliminary results suggest that mutations are not significant contributors to raising an antibody response against tumor antigens, whereas overexpression seems to play a more important role. We hereby demonstrate how different types of data can be integrated and analyzed successfully, providing interesting results. As the amount of available data is growing rapidly, a combined analysis will play an important role in exploring the genetic and immunological basis of cancer. CAP is freely available at the following web site: http://www.bioinf.uni-sb.de/CAP/.	Univ Tubingen, Dept Simulat Biol Syst, D-72076 Tubingen, Germany; Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Inst Human Genet, D-66421 Homburg, Germany; Univ Tubingen, Dept Simulat Biol Syst, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Saarland University; Saarland University; Eberhard Karls University of Tubingen	Kohlbacher, O (corresponding author), Univ Tubingen, Dept Simulat Biol Syst, Sand 14, D-72076 Tubingen, Germany.	oliver.kohlbacher@uni-tuebingen.de	Kohlbacher, Oliver/B-7310-2008; Meese, Eckart Ulrich/ABD-1983-2021; Kohlbacher, Oliver/AAF-3297-2021	Kohlbacher, Oliver/0000-0003-1739-4598; Kohlbacher, Oliver/0000-0003-1739-4598; Sturm, Marc/0000-0002-6552-8362; Donnes, Pierre/0000-0002-4613-2952				Angelopoulou K, 2000, CLIN BIOCHEM, V33, P53, DOI 10.1016/S0009-9120(99)00084-3; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bayani J, 2002, CANCER RES, V62, P3466; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brass N, 1999, BLOOD, V93, P2158, DOI 10.1182/blood.V93.7.2158.407a34_2158_2166; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Buckingham S, 2004, NATURE, V428, P774, DOI 10.1038/428774a; Cheng L, 1999, INT J CANCER, V84, P220, DOI 10.1002/(SICI)1097-0215(19990621)84:3<220::AID-IJC4>3.0.CO;2-S; Cheung KH, 1998, BIOINFORMATICS, V14, P486, DOI 10.1093/bioinformatics/14.6.486; Comtesse N, 2002, ONCOGENE, V21, P239, DOI 10.1038/sj/onc/1205005; Comtesse N, 1999, CLIN CANCER RES, V5, P3560; Diesinger I, 2002, INT J CANCER, V102, P372, DOI 10.1002/ijc.10714; Donnes P, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-25; Fischer U, 2001, CLIN EXP IMMUNOL, V126, P206, DOI 10.1046/j.1365-2249.2001.01635.x; Hazan C, 2002, CANCER, V95, P634, DOI 10.1002/cncr.10685; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Henrique R, 2000, J AM ACAD DERMATOL, V43, P991, DOI 10.1067/mjd.2000.109282; Hua SJ, 2001, BIOINFORMATICS, V17, P721, DOI 10.1093/bioinformatics/17.8.721; Jensen LJ, 2003, BIOINFORMATICS, V19, P635, DOI 10.1093/bioinformatics/btg036; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; Meese E, 2002, GENE CHROMOSOME CANC, V33, P107, DOI 10.1002/gcc.1224; Mitrunen K, 2003, MUTAT RES-REV MUTAT, V544, P9, DOI 10.1016/S1383-5742(03)00016-4; Monz D, 2001, CLIN CANCER RES, V7, P113; Nair R, 2002, PROTEIN SCI, V11, P2836, DOI 10.1110/ps.0207402; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nishie A, 2001, CLIN CANCER RES, V7, P2145; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rumbaugh J, 1999, UNIFIED MODELLING LA; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Soussi T, 2000, CANCER RES, V60, P1777; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; Zhou Y, 2003, CANCER RES, V63, P5781	35	7	7	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1465	+		10.1096/fj.04-1797fje	http://dx.doi.org/10.1096/fj.04-1797fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231723				2022-12-25	WOS:000222979200015
J	Graf, SA; Haigh, SE; Corson, ED; Shirihai, OS				Graf, SA; Haigh, SE; Corson, ED; Shirihai, OS			Targeting, import, and dimerization of a mammalian mitochondrial ATP binding cassette (ABC) transporter, ABCB10 (ABC-me)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEIN; TRANSLOCATION; RECOGNITION; MECHANISMS; PEPTIDE; DOMAIN; IDENTIFICATION; BIOGENESIS; COOPERATE; PATHWAY	ATP binding cassette (ABC) transporters are a diverse superfamily of energy-dependent membrane translocases. Although responsible for the majority of transmembrane transport in bacteria, they are relatively uncommon in eukaryotic mitochondria. Organellar trafficking and import, in addition to quaternary structure assembly, of mitochondrial ABC transporters is poorly understood and may offer explanations for the paucity of their diversity. Here we examine these processes in ABCB10 (ABC-me), a mitochondrial inner membrane erythroid transporter involved in heme biosynthesis. We report that ABCB10 possesses an unusually long 105-amino acid mitochondrial targeting presequence (mTP). The central subdomain of the mTP ( amino acids (aa) 36 - 70) is sufficient for mitochondrial import of enhanced green fluorescent protein. The N-terminal subdomain ( aa 1 - 35) of the mTP, although not necessary for the trafficking of ABCB10 to mitochondria, participates in the proper import of the molecule into the inner membrane. We performed a series of amino acid mutations aimed at changing specific properties of the mTP. The mTP requires neither arginine residues nor predictable alpha-helices for efficient mitochondrial targeting. Disruption of its hydrophobic character by the mutation L46Q/ I47Q, however, greatly diminishes its efficacy. This mutation can be rescued by cryptic downstream ( aa 106 715) mitochondrial targeting signals, highlighting the redundancy of this protein's targeting qualities. Mass spectrometry analysis of chemically cross-linked, immunoprecipitated ABCB10 indicates that ABCB10 embedded in the mitochondrial inner membrane homodimerizes and homo-oligomerizes. A deletion mutant of ABCB10 that lacks its mTP efficiently targets to the endoplasmic reticulum. Quaternary structure assembly of ABCB10 in the ER appears to be similar to that in the mitochondria.	Tufts Univ, Dept Pharmacol, Boston, MA 02111 USA; BioCurrents Res Ctr, Marine Biol Lab, Woods Hole, MA 02543 USA	Tufts University; Marine Biological Laboratory - Woods Hole	Shirihai, OS (corresponding author), Tufts Univ, Dept Pharmacol, Boston, MA 02111 USA.	orian.shirihai@tufts.edu		Shirihai, Orian/0000-0002-9502-2661	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001395] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, R01HL071629] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR001395] Funding Source: Medline; NHLBI NIH HHS [P01HL032262, R01HL071629] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; Duby G, 2001, PLANT J, V27, P539, DOI 10.1046/j.1365-313X.2001.01098.x; Emanuelsson O, 2001, METHOD CELL BIOL, V65, P175, DOI 10.1016/S0091-679X(01)65011-8; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; GALANIS M, 1991, FEBS LETT, V282, P425, DOI 10.1016/0014-5793(91)80529-C; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Holland B., 2003, ABC PROTEINS BACTERI; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; KRUPENKO SA, 1995, BBA-BIOMEMBRANES, V1235, P387, DOI 10.1016/0005-2736(95)80028-E; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Lill R, 2001, RES MICROBIOL, V152, P331, DOI 10.1016/S0923-2508(01)01204-9; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Ma YL, 2002, J BIOL CHEM, V277, P27328, DOI 10.1074/jbc.M201421200; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; Obita T, 2003, J MOL BIOL, V328, P495, DOI 10.1016/S0022-2836(03)00288-2; Ramjeesingh M, 2003, BIOCHEM J, V375, P633, DOI 10.1042/BJ20030774; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Stan T, 2003, MOL CELL BIOL, V23, P2239, DOI 10.1128/MCB.23.7.2239-2250.2003; Taketani S, 2003, BLOOD, V101, P3274, DOI 10.1182/blood-2002-04-1212; van Leeuwen HC, 2001, J CELL SCI, V114, P2115; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Wilcox SK, 2001, ANTIMICROB AGENTS CH, V45, P3046, DOI 10.1128/AAC.45.11.3046-3055.2001; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang F, 2000, FEBS LETT, V478, P89, DOI 10.1016/S0014-5793(00)01823-8	44	56	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42954	42963		10.1074/jbc.M405040200	http://dx.doi.org/10.1074/jbc.M405040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15215243	hybrid, Green Published			2022-12-25	WOS:000224226400075
J	Dev, KK; Nakanishi, S; Henley, JM				Dev, KK; Nakanishi, S; Henley, JM			The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and GluR2 as interacting ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTOR TRAFFICKING; BINDING-PROTEIN; PHOSPHORYLATION; SYNAPSES; TERMINUS; POTENTIATION; EXPRESSION; REQUIRES; NSF	The C terminus (ct) of protein kinase C-alpha(PKCalpha) has a type I PDZ binding motif, whereas GluR2 has a type II PDZ binding motif. Both motifs are recognized by the PDZ domain of protein interacting with protein kinase C (PICK1), and PICK1-PKCalpha-controlled phosphorylation regulates the synaptic expression and function of GluR2. Here, we show that a specific mutation within the carboxylate-binding loop of the PDZ domain of PICK1 (K27E; PICK1-KE) results in a loss of interaction with GluR2 but not with PKCalpha. In GST pull-down studies, PICK1-WT (wild type) but not PICK1-KE was retained by GST-ct-GluR2. Furthermore, PICK1-WT co-immunoprecipitated both PKCalpha and GluR2, whereas PICK1-KE only co-immunoprecipitated PKCalpha. In heterologous cells, PICK1-WT, but not PICK1-KE, clustered GluR2 and also clustered GluR1 in a GluR2-dependent manner. However, neither PICK1-WT nor PICK1-KE altered the distribution of PKCalpha, even after phorbol ester-induced redistribution of PKCalpha to the membrane. Finally, PICK1-KE showed no mislocalization when compared with PICK1-WT in neurons. Taken together, it appears that the PDZ domain of PICK1 is less sensitive to mutations for PKCalpha when compared with GluR2 binding. These results suggest that the PDZ domain of PICK1 has distinct PKCalpha and GluR2 binding subsite(s).	Univ Bristol, MRC, Ctr Synapt Plastic, Dept Anat, Bristol BS8 1TD, Avon, England; Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan	University of Bristol; Kyoto University	Dev, KK (corresponding author), Novartis Pharma AG, Neurosci Res, Novartis Inst Biomed Res, WSJ 386-7-43, CH-4002 Basel, Switzerland.	kumlesh_k.dev@pharma.novartis.com	Henley, Jeremy M/A-2776-2009	Henley, Jeremy/0000-0003-3589-8335; Dev, Kumlesh/0000-0003-4274-9119	Medical Research Council [G9629038(61600), G9629038] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9629038] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Chung HJ, 2000, J NEUROSCI, V20, P7258; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; El Far O, 2000, EUR J NEUROSCI, V12, P16; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Henley JM, 2003, NEUROSCI RES, V45, P243, DOI 10.1016/S0168-0102(02)00229-8; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Takeya R, 2000, BIOCHEM BIOPH RES CO, V267, P149, DOI 10.1006/bbrc.1999.1932; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	36	32	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41393	41397		10.1074/jbc.M404499200	http://dx.doi.org/10.1074/jbc.M404499200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247289	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000224075500020
J	Yucel, R; Kosan, C; Heyd, F; Moroy, T				Yucel, R; Kosan, C; Heyd, F; Moroy, T			Gfi1 : Green fluorescent protein knock-in mutant reveals differential expression and autoregulation of the growth factor independence 1 (Gfi1) gene during lymphocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; THYMIC SELECTION; CELL DEVELOPMENT; PIM-1; MYC; REARRANGEMENT; PROGRESSION; ACTIVATION	The Gfi1 gene encodes a 55-kDa transcriptional repressor protein with important functions in T-cell development, in granulopoiesis, and in the regulation of the innate immune response. To follow expression of the Gfi1 gene during the differentiation of specific immune cells, we have generated a mouse mutant in which the Gfi1 coding region is replaced by the gene for the green fluorescent protein (GFP). We found that Gfi1 gene expression is highest in early B-cell subpopulation and differentially expressed during T-cell development with peak levels at stages where pre-TCR or positive/negative selection takes place. Gfi1 is absent in mature B-cells, whereas in peripheral T-cells Gfi1 gene expression is low but rises significantly upon T-cell receptor triggering and decreases again in T-memory cells. Constitutive expression of an lck promoter-driven Gfi1 transgene led to transcriptional silencing of the Gfi1:GFP allele in T-cells. Because Gfi1 was found to occupy genomic sites of its own promoter in thymocytes and was able to repress its own transcription in vitro we propose that transcription of the Gfi1 gene is regulated through an autoregulatory feedback loop.	Univ Klinikum Essen, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Kosan, Christian/C-1213-2017; Moroy, Tarik/D-9923-2011	Kosan, Christian/0000-0002-8387-3653; 				Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2; Barthlott T, 1997, J EXP MED, V185, P357, DOI 10.1084/jem.185.2.357; Bosselut R, 2001, IMMUNITY, V14, P483, DOI 10.1016/S1074-7613(01)00128-5; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; Doan LL, 2004, NUCLEIC ACIDS RES, V32, P2508, DOI 10.1093/nar/gkh570; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Guidos CJ, 1996, CURR OPIN IMMUNOL, V8, P225, DOI 10.1016/S0952-7915(96)80061-6; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; MURRAY R, 1998, INT IMMUNOL, V1, P526; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Saito T, 1998, CRIT REV IMMUNOL, V18, P359, DOI 10.1615/CritRevImmunol.v18.i4.40; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Shimizu C, 2001, INT IMMUNOL, V13, P105, DOI 10.1093/intimm/13.1.105; Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	31	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40906	40917		10.1074/jbc.M400808200	http://dx.doi.org/10.1074/jbc.M400808200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15252036	hybrid			2022-12-25	WOS:000223916800087
J	Guilherme, A; Soriano, NA; Furcinitti, PS; Czech, MP				Guilherme, A; Soriano, NA; Furcinitti, PS; Czech, MP			Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; PLASMA-MEMBRANE; GOLGI NETWORK; TRANSLOCATION; COMPARTMENT; CELLS; VESICLES; TRAFFICKING; ENDOSOMES; MUSCLE	Insulin stimulates glucose transport in muscle and adipose tissues by recruiting intracellular membrane vesicles containing the glucose transporter GLUT4 to the plasma membrane. The mechanisms involved in the biogenesis of these vesicles and their translocation to the cell surface are poorly understood. Here, we report that an Eps15 homology (EH) domain-containing protein, EHD1, controls the normal perinuclear localization of GLUT4-containing membranes and is required for insulin-stimulated recycling of these membranes in cultured adipocytes. EHD1 is a member of a family of four closely related proteins (EHD1, EHD2, EHD3, and EHD4), which also contain a P-loop near the N terminus and a central coiled-coil domain. Analysis of cultured adipocytes stained with anti-GLUT4, anti-EHD1, and anti-EHD2 antibodies revealed that EHD1, but not EHD2, partially co-localizes with perinuclear GLUT4. Expression of a dominant-negative construct of EHD1 missing the EH domain (DeltaEH-EHD1) markedly enlarged endosomes, dispersed perinuclear GLUT4-containing membranes throughout the cytoplasm, and inhibited GLUT4 translocation to the plasma membranes of 3T3-L1 adipocytes stimulated with insulin. Similarly, small interfering RNA-mediated depletion of endogenous EHD1 protein also markedly dispersed perinuclear GLUT4 in cultured adipocytes. Moreover, EHD1 is shown to interact through its EH domain with the protein EHBP1, which is also required for insulin-stimulated GLUT4 movements and hexose transport. In contrast, disruption of EHD2 function was without effect on GLUT4 localization or translocation to the plasma membrane. Taken together, these results show that EHD1 and EHBP1, but not EHD2, are required for perinuclear localization of GLUT4 and reveal that loss of EHBP1 disrupts insulin-regulated GLUT4 recycling in cultured adipocytes.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087; Benmerah A, 1999, J CELL SCI, V112, P1303; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; Galperin E, 2002, TRAFFIC, V3, P575, DOI 10.1034/j.1600-0854.2002.30807.x; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Holloszy JO, 2003, AM J PHYSIOL-ENDOC M, V284, pE453, DOI 10.1152/ajpendo.00463.2002; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; POLO S, 2003, SCI STKE; Ramm G, 2000, MOL BIOL CELL, V11, P4079, DOI 10.1091/mbc.11.12.4079; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	47	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40062	40075		10.1074/jbc.M401918200	http://dx.doi.org/10.1074/jbc.M401918200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247266	hybrid			2022-12-25	WOS:000223791500104
J	Leveille, F; Blom, E; Medhurst, AL; Bier, P; Laghmani, EH; Johnson, M; Rooimans, MA; Sobeck, A; Waisfisz, Q; Arwert, F; Patel, KJ; Hoatlin, ME; Joenje, H; de Winter, JP				Leveille, F; Blom, E; Medhurst, AL; Bier, P; Laghmani, EH; Johnson, M; Rooimans, MA; Sobeck, A; Waisfisz, Q; Arwert, F; Patel, KJ; Hoatlin, ME; Joenje, H; de Winter, JP			The Fanconi anemia gene product FANCF is a flexible adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX; PATHWAY; BRCA2; SUSCEPTIBILITY; INACTIVATION; FANCG/XRCC9; LINK	The Fanconi anemia (FA) protein FANCF is an essential component of a nuclear core complex that protects the genome against chromosomal instability, but the specific function of FANCF is still poorly understood. Based upon the homology between human and Xenopus laevis FANCF, we carried out an extensive mutagenesis study to examine which domains are functionally important and to gain more insight into the function of FANCF. In contrast to previous suggestions, we show that FANCF does not have a ROM-like function. We found that the C terminus of FANCF interacts directly with FANCG and allows the assembly of other FA proteins into a stable complex. The N terminus appears to stabilize the interaction with FANCA and FANCG and is essential for the binding of the FANCC/FANCE subcomplex. We identified several important amino acids in this N-terminal region but, surprisingly, many amino acid changes failed to affect the function of the FANCF protein. Our data demonstrate that FANCF acts as a flexible adaptor protein that plays a key role in the proper assembly of the FA core complex.	Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; Guys Kings & St Thomas Sch Med, Div Genet & Dev, London SE1 9RT, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97239 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of London; King's College London; MRC Laboratory Molecular Biology; Oregon Health & Science University	de Winter, JP (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Clin Genet & Human Genet, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	j.dewinter@vumc.nl	Blom, Eric/B-4485-2010	Blom, Eric/0000-0002-6226-0903; Waisfisz, Quinten/0000-0002-7384-9182				Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 2002, GENETIC BASIS HUMAN, P317; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; ISHIDA R, 1982, CANCER RES, V42, P4000; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kuang Y, 2000, BLOOD, V96, P1625, DOI 10.1182/blood.V96.5.1625.h8001625a_1625_1632; Kupfer G, 1999, EXP HEMATOL, V27, P587, DOI 10.1016/S0301-472X(99)00022-3; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Nakanishi K, 2001, EXP HEMATOL, V29, P842, DOI 10.1016/S0301-472X(01)00663-4; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2001, BLOOD, V98, P1392, DOI 10.1182/blood.V98.5.1392; Pichierri P, 2002, HUM MOL GENET, V11, P2531, DOI 10.1093/hmg/11.21.2531; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	38	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39421	39430		10.1074/jbc.M407034200	http://dx.doi.org/10.1074/jbc.M407034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262960	Green Published, hybrid			2022-12-25	WOS:000223791500030
J	Nessler, S; Friedrich, O; Bakouh, N; Fink, RHA; Sanchez, CP; Planelles, G; Lanzer, M				Nessler, S; Friedrich, O; Bakouh, N; Fink, RHA; Sanchez, CP; Planelles, G; Lanzer, M			Evidence for activation of endogenous transporters in Xenopus laevis oocytes expressing the Plasmodium falciparum chloroquine resistance transporter, PfCRT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEIN PFCRT; NONSELECTIVE CATION CHANNEL; FERRIPROTOPORPHYRIN-IX; DRUG-RESISTANCE; FUNCTIONAL-CHARACTERIZATION; MALARIA PARASITES; ION CHANNELS; INHIBITION; MEMBRANE; MECHANISM	A large body of genetic, reverse genetic, and epidemiological data has linked chloroquine-resistant malaria to polymorphisms within a gene termed pfcrt in the human malarial parasite Plasmodium falciparum. To investigate the biological function of the chloroquine resistance transporter, PfCRT, as well as its role in chloroquine resistance, we functionally expressed this protein in Xenopus laevis oocytes. Our data show that PfCRT-expressing oocytes exhibit a depolarized resting membrane potential and a higher intracellular pH compared with control oocytes. Pharmacological and electrophysiological studies link the higher intracellular pH to an enhanced amiloride-sensitive H+ extrusion and the low membrane potential to an activated nonselective cation conductance. The finding that both properties are independent of each other, together with the fact that they are endogenously present in X. laevis oocytes, supports a model in which PfCRT activates transport systems. Our data suggest that PfCRT plays a role as a direct or indirect activator or modulator of other transporters.	Univ Klinikum Heidelberg, Inst Hyg, Abt Parasitol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Univ Paris 05, Fac Med Necker Enfants Malad, INSERM, U467, F-75730 Paris 15, France	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lanzer, M (corresponding author), Univ Klinikum Heidelberg, Inst Hyg, Abt Parasitol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	michael_lanzer@med.uniheidelberg.de	Lanzer, Michael/E-9752-2013; Planelles, Gabrielle/F-9603-2013	Lanzer, Michael/0000-0002-0220-6526; Planelles, Gabrielle/0000-0002-7314-8837; Friedrich, Oliver/0000-0003-2238-2049				ANAGNOSTOPOULOS T, 1987, J PHYSIOL-LONDON, V393, P73, DOI 10.1113/jphysiol.1987.sp016811; ARELLANO RO, 1995, J PHYSIOL-LONDON, V484, P593, DOI 10.1113/jphysiol.1995.sp020689; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Bennett TN, 2004, MOL BIOCHEM PARASIT, V133, P99, DOI 10.1016/j.molbiopara.2003.09.008; Bray Patrick G., 1999, Novartis Foundation Symposium, V226, P252; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P78, DOI 10.1007/BF00378644; Burckhardt G, 2002, J NEPHROL, V15, pS3; Busch S, 1998, PFLUG ARCH EUR J PHY, V436, P828, DOI 10.1007/s004240050711; Chaudhry FA, 2001, EMBO J, V20, P7041, DOI 10.1093/emboj/20.24.7041; CHOU AC, 1980, J CLIN INVEST, V66, P856, DOI 10.1172/JCI109925; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; Cougnon M, 1999, AM J PHYSIOL-CELL PH, V277, pC280, DOI 10.1152/ajpcell.1999.277.2.C280; Cougnon M, 2002, AM J PHYSIOL-CELL PH, V282, pC1445, DOI 10.1152/ajpcell.00410.2001; Cougnon M, 1996, PFLUG ARCH EUR J PHY, V431, P658, DOI 10.1007/BF02191917; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; Crider BP, 2003, J BIOL CHEM, V278, P44281, DOI 10.1074/jbc.M307372200; de Dios AC, 2003, J PHYS CHEM A, V107, P5821, DOI 10.1021/jp0342982; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P727, DOI 10.1016/S0006-2952(97)00510-8; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Fairman WA, 1998, NAT NEUROSCI, V1, P105, DOI 10.1038/355; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1983, BLOOD, V62, P1165; Friedrich O, 1999, J PHYSIOL-LONDON, V517, P757, DOI 10.1111/j.1469-7793.1999.0757s.x; Friedrich O, 2001, BIOPHYS J, V80, P2046, DOI 10.1016/S0006-3495(01)76178-4; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Ginsburg H, 1999, PARASITOL TODAY, V15, P357, DOI 10.1016/S0169-4758(99)01502-1; GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; Guizouarn H, 2004, J BIOL CHEM, V279, P11513, DOI 10.1074/jbc.M311920200; Kathofer S, 2000, J BIOL CHEM, V275, P26743; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; LAFAIRE AV, 1986, J MEMBRANE BIOL, V91, P43, DOI 10.1007/BF01870213; Leed A, 2002, BIOCHEMISTRY-US, V41, P10245, DOI 10.1021/bi020195i; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Sanchez CP, 2003, BIOCHEMISTRY-US, V42, P9383, DOI 10.1021/bi034269h; Sha Q, 2001, J PHYSIOL-LONDON, V535, P407, DOI 10.1111/j.1469-7793.2001.t01-1-00407.x; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; SILVA AM, 1994, J BIOL CHEM, V269, P17095; Tran CV, 2004, MICROBIOL-SGM, V150, P1, DOI 10.1099/mic.0.26818-0; Ursos LMB, 2002, MED RES REV, V22, P465, DOI 10.1002/med.10016; Ursos LMB, 2001, MOL BIOCHEM PARASIT, V112, P11, DOI 10.1016/S0166-6851(00)00342-X; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wagner CA, 2000, J PHYSIOL-LONDON, V526, P35, DOI 10.1111/j.1469-7793.2000.00035.x; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Warhurst DC, 2002, LANCET, V360, P1527, DOI 10.1016/S0140-6736(02)11577-7; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784; Zhang HB, 2002, J BIOL CHEM, V277, P49767, DOI 10.1074/jbc.M204005200; ZHANG Y, 1987, BIOCHEM PHARMACOL, V36, P1267, DOI 10.1016/0006-2952(87)90080-3	67	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39438	39446		10.1074/jbc.M404671200	http://dx.doi.org/10.1074/jbc.M404671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258157	hybrid			2022-12-25	WOS:000223791500032
J	Sheng, Z; Lewis, JA; Chirico, WJ				Sheng, Z; Lewis, JA; Chirico, WJ			Nuclear and nucleolar localization of 18-kDa fibroblast growth factor-2 is controlled by C-terminal signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOTHELIAL-CELLS; SUBCELLULAR-LOCALIZATION; TARGETING SIGNAL; PROTEIN; TRANSLOCATION; FGF-2; BFGF; PROLIFERATION; TRANSCRIPTION	Members of high (22-, 22.5-, 24-, and 34-kDa) and low (18-kDa) molecular mass forms of fibroblast growth factor-2 (FGF-2) regulate cell proliferation, differentiation, and migration. FGF-2s have been previously shown to accumulate in the nucleus and nucleolus. Although high molecular weight forms of FGF-2 contain at least one nuclear localization signal (NLS) in their N-terminal extension, the 18-kDa FGF-2 does not contain a standard NLS. To determine signals controlling the nuclear and subnuclear localization of the 18-kDa FGF-2, its full-length cDNA was fused to that of green fluorescent protein (GFP). The fusion protein was primarily localized to the nucleus of COS-7 and HeLa cells and accumulated in the nucleolus. The subcellular distribution was confirmed using wild type FGF-2 and FGF-2 tagged with a FLAG epitope. A 17-amino acid sequence containing two groups of basic amino acid residues separated by eight amino acid residues directed GFP and a GFP dimer into the nucleus. We systematically mutated the basic amino acid residues in this nonclassical NLS and determined the effect on nuclear and nucleolar accumulation of 18-kDa FGF-2. Lys(119) and Arg(129) are the key amino acid residues in both nuclear and nucleolar localization, whereas Lys(128) regulates only nucleolar localization of 18-kDa FGF-2. Together, these results demonstrate that the 18-kDa FGF-2 harbors a C-terminal nonclassical bipartite NLS, a portion of which also regulates its nucleolar localization.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Mol & Cellular Biol Program, Sch Grad Studies, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Chirico, WJ (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, Box 5,450 Clarkson Ave, Brooklyn, NY 11203 USA.	william.chirico@downstate.edu	Sheng, Zhi/F-8433-2010					Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Chang SN, 2000, FEBS LETT, V484, P22, DOI 10.1016/S0014-5793(00)02118-9; Choi JK, 2000, MOL VIS, V6, P222; Claus P, 2003, J BIOL CHEM, V278, P479, DOI 10.1074/jbc.M206056200; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; DELLERA P, 1991, EXP CELL RES, V192, P505, DOI 10.1016/0014-4827(91)90070-B; Dono R, 1998, ONCOGENE, V16, P2151, DOI 10.1038/sj.onc.1201746; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; Foletti A, 2003, CELL MOL LIFE SCI, V60, P2254, DOI 10.1007/s00018-003-3258-6; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Hsia E, 2003, J CELL BIOCHEM, V88, P1214, DOI 10.1002/jcb.10470; Hu GF, 2000, BIOCHEM BIOPH RES CO, V273, P551, DOI 10.1006/bbrc.2000.2978; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; MOY FJ, 1995, J BIOMOL NMR, V6, P245; Ojakian GK, 1997, J CELL SCI, V110, P2781; Ornitz DM, 2001, GENOME BIOL, V2; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Piston DW, 1999, METHOD CELL BIOL, V58, P31; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; PRESTA M, 1992, BIOCHEM BIOPH RES CO, V185, P1098, DOI 10.1016/0006-291X(92)91739-D; PRESTA M, 1993, GROWTH FACTORS, V9, P269, DOI 10.3109/08977199308991587; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Sheng Z, 2003, PROTEIN EXPRES PURIF, V27, P267, DOI 10.1016/S1046-5928(02)00601-0; Sohn YD, 2001, BIOCHEM BIOPH RES CO, V284, P931, DOI 10.1006/bbrc.2001.5076; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; THOMPSON SA, 1991, METHOD ENZYMOL, V198, P96; Timmers ACJ, 1999, FEBS LETT, V452, P335, DOI 10.1016/S0014-5793(99)00669-9; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	48	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40153	40160		10.1074/jbc.M400123200	http://dx.doi.org/10.1074/jbc.M400123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247275	hybrid			2022-12-25	WOS:000223791500114
J	Cochran, JC; Sontag, CA; Maliga, Z; Kapoor, TM; Correia, JJ; Gilbert, SP				Cochran, JC; Sontag, CA; Maliga, Z; Kapoor, TM; Correia, JJ; Gilbert, SP			Mechanistic analysis of the mitotic kinesin Eg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY DATA; CROSS-LINKS MICROTUBULES; SMALL-MOLECULE INHIBITOR; KAR3 MOTOR DOMAIN; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; KINETIC MECHANISM; SPINDLE; PROTEIN; ORGANIZATION	Eg5 is a slow, plus-end-directed microtubule-based motor of the BimC kinesin family that is essential for bipolar spindle formation during eukaryotic cell division. We have analyzed two human Eg5/KSP motors, Eg5-367 and Eg5-437, and both are monomeric based on results from sedimentation velocity and sedimentation equilibrium centrifugation as well as analytical gel filtration. The steady-state parameters were: for Eg5-367: k(cat)=5.5 s(-1), K-1/2,K-Mt=0.7 muM, and K-m,K-ATP=25 muM; and for Eg5-437: k(cat)=2.9 s(-1), K-1/2,K-Mt=4.5 muM, and K-m,K-ATP=19 muM. 2'(3')-O-(N-Methylanthraniloyl)-ATP (mantATP) binding was rapid at 2-3 muM(-1) s(-1), followed immediately by ATP hydrolysis at 15 s(-1). ATP-dependent Mt.Eg5 dissociation was relatively slow and rate-limiting at 8 s(-1) with mantADP release at 40 s(-1). Surprisingly, Eg5-367 binds microtubules more effectively (11 muM(-1) s(-1)) than Eg5-437 (0.7 muM(-1) s(-1)), consistent with the steady-state K-1/2,K-Mt and the mantADP release K-1/2,K-Mt. These results indicate that the ATPase pathway for monomeric Eg5 is more similar to conventional kinesin than the spindle motors Ncd and Kar3, where ADP product release is rate-limiting for steady-state turnover.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Mississippi; University of Mississippi Medical Center; Harvard University; Harvard Medical School; Rockefeller University	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	spg1@pitt.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054141, R37GM054141] Funding Source: NIH RePORTER; NIAMS NIH HHS [K02-AR47841, K02 AR047841] Funding Source: Medline; NIGMS NIH HHS [R37 GM054141, R01 GM054141, GM54141] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Chakravarty A, 2004, MOL BIOL CELL, V15, P2116, DOI 10.1091/mbc.E03-08-0579; COLE DG, 1994, J BIOL CHEM, V269, P22913; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel IMTC, 2004, EMBO J, V23, P23, DOI 10.1038/sj.emboj.7600042; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; Cytrynbaum EN, 2003, BIOPHYS J, V84, P757, DOI 10.1016/S0006-3495(03)74895-4; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2001, J BIOL CHEM, V276, P19259, DOI 10.1074/jbc.M008347200; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Inoue S, 1997, J STRUCT BIOL, V118, P87, DOI 10.1006/jsbi.1996.3839; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kaseda K, 2003, NAT CELL BIOL, V5, P1079, DOI 10.1038/ncb1067; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Klumpp LM, 2004, P NATL ACAD SCI USA, V101, P3444, DOI 10.1073/pnas.0307691101; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Kwon M, 2004, TRENDS CELL BIOL, V14, P194, DOI 10.1016/j.tcb.2004.03.003; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; Mackey AT, 2003, J BIOL CHEM, V278, P3527, DOI 10.1074/jbc.M206219200; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; MOYER ML, 1998, THESIS PENNSYLVANIA; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; Pechatnikova E, 1997, J BIOL CHEM, V272, P30735, DOI 10.1074/jbc.272.49.30735; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schief WR, 2004, P NATL ACAD SCI USA, V101, P1183, DOI 10.1073/pnas.0304369101; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Skiniotis G, 2004, EMBO J, V23, P989, DOI 10.1038/sj.emboj.7600118; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Uemura S, 2003, NAT STRUCT BIOL, V10, P308, DOI 10.1038/nsb911; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	87	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38861	38870		10.1074/jbc.M404203200	http://dx.doi.org/10.1074/jbc.M404203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247293	Green Accepted, hybrid			2022-12-25	WOS:000223684100099
J	Mak, SK; Kultz, D				Mak, SK; Kultz, D			Gadd45 proteins induce G(2)/M arrest and modulate apoptosis in kidney cells exposed to hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MAP KINASE PATHWAYS; DNA-REPAIR; MOLECULAR-CLONING; HYPERTONIC STRESS; UV-IRRADIATION; CYCLE ARREST; GENE FAMILY; ION CONTENT; EXPRESSION	Gadd45 proteins are induced by hyperosmolality in renal inner medullary (IM) cells, but their role for cell adaptation to osmotic stress is not known. We show that a cell line derived from murine renal IM cells responds to moderate hyperosmotic stress (540 mosmol/kg) by activation of G(2)/M arrest without significant apoptosis. If the severity of hyperosmotic stress exceeds the tolerance limit of this cell line (620 mosmol/kg) apoptosis is strongly induced. Using transient overexpression of ectopic Gadd45 proteins and simultaneous analysis of transfected versus non-transfected cells by laser-scanning cytometry, we were able to measure the effects of Gadd45 super-induction during hyperosmolality on G(2)/M arrest and apoptosis. Our results demonstrate that induction of all three Gadd45 isoforms inhibits mitosis and promotes G(2)/M arrest during moderate hyperosmotic stress but not in isosmotic controls. Furthermore, all three Gadd45 proteins are also involved in control of apoptosis during severe hyperosmotic stress. Under these conditions Gadd45gamma induction strongly potentiates apoptosis. In contrast, Gadd45alpha/beta induction transiently increases caspase 3/7 and annexin V binding before 12 h but inhibits later stages of apoptosis during severe hyperosmolality. These results show that Gadd45 isoforms function in common but also in distinct pathways during hyperosmolality and that their increased abundance contributes to the low mitotic index and protection of genomic integrity in cells of the mammalian renal inner medulla.	Univ Calif Davis, Dept Anim Sci, Physiol Genom Grp, Davis, CA 95616 USA	University of California System; University of California Davis	Kultz, D (corresponding author), Univ Calif Davis, Dept Anim Sci, Physiol Genom Grp, 1 Shields Ave,Meyer Hall, Davis, CA 95616 USA.	dkueltz@ucdavis.edu	, DK/AAU-3163-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059470] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59470] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Bortner CD, 2004, PFLUG ARCH EUR J PHY, V448, P313, DOI 10.1007/s00424-004-1266-5; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Chakravarty D, 2002, AM J PHYSIOL-RENAL, V283, pF1020, DOI 10.1152/ajprenal.00118.2002; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Chi HB, 2004, EMBO J, V23, P1576, DOI 10.1038/sj.emboj.7600173; Chou TT, 2001, J BIOL CHEM, V276, P41120, DOI 10.1074/jbc.M102832200; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; Dmitrieva NI, 2004, P NATL ACAD SCI USA, V101, P2317, DOI 10.1073/pnas.0308463100; Dmitrieva NI, 2002, P NATL ACAD SCI USA, V99, P184, DOI 10.1073/pnas.231623498; FLAMION B, 1990, AM J PHYSIOL, V259, pF986, DOI 10.1152/ajprenal.1990.259.6.F986; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GRUNEWALD JM, 1994, AM J PHYSIOL, V267, pF13, DOI 10.1152/ajprenal.1994.267.1.F13; GRUNEWALD JM, 1993, KIDNEY INT, V44, P509, DOI 10.1038/ki.1993.275; Hildesheim J, 2002, CANCER RES, V62, P7305; Hoffmeyer A, 2001, MOL CELL BIOL, V21, P3137, DOI 10.1128/MCB.21.9.3137-3143.2001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kiiltz D, 2000, CE MO RE ST, V1, P157; Kojima S, 1999, FEBS LETT, V446, P313, DOI 10.1016/S0014-5793(99)00234-3; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kultz D, 2001, P NATL ACAD SCI USA, V98, P1999, DOI 10.1073/pnas.98.4.1999; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; McLaughlin B, 2004, APOPTOSIS, V9, P111, DOI 10.1023/B:APPT.0000018793.10779.dc; Michea L, 2002, AM J PHYSIOL-RENAL, V282, pF981, DOI 10.1152/ajprenal.00301.2001; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; O'Prey J, 2003, BIOCHEM PHARMACOL, V66, P2075, DOI 10.1016/j.bcp.2003.07.007; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Santos BC, 1998, AM J PHYSIOL, V274, P1167; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Sutter AP, 2003, BRIT J CANCER, V89, P564, DOI 10.1038/sj.bjc.6601125; Suzuki M, 1999, J HUM GENET, V44, P300, DOI 10.1007/s100380050164; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang Z, 2004, P NATL ACAD SCI USA, V101, P9491, DOI 10.1073/pnas.0402961101	55	75	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39075	39084		10.1074/jbc.M406643200	http://dx.doi.org/10.1074/jbc.M406643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262964				2022-12-25	WOS:000223684100123
J	Montalvetti, A; Rohloff, P; Docampo, R				Montalvetti, A; Rohloff, P; Docampo, R			A functional aquaporin co-localizes with the vacuolar proton pyrophosphatase to acidocalcisomes and the contractile vacuole complex of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER; EXPRESSION; CLONING; PLANT; PHOSPHATIDYLINOSITOL; IDENTIFICATION; ORGANELLES; EVOLUTION; MEMBRANE; VESICLES	We cloned an aquaporin gene from Trypanosoma cruzi (TcAQP) that encodes a protein of 231 amino acids, which is highly hydrophobic. The protein has six putative transmembrane domains and the two signature motifs asparagine-proline-alanine (NPA) which have been shown, in other aquaporins, to be involved in the formation of an aqueous channel spanning the bilayer. TcAQP was sensitive to endo H treatment, suggesting that the protein is N-glycosylated. Oocytes of Xenopus laevis expressing TcAQP swelled under hyposmotic conditions indicating water permeability, which was abolished after preincubating oocytes with very low concentrations of the AQP inhibitors HgCl2 and AgNO3. No glycerol transport was detected. Immunofluorescence microscopy of T. cruzi expressing GFP-TcAQP showed co-localization of TcAQP with the vacuolar proton pyrophosphatase (V-H+-PPase), a marker of acidocalcisomes. This localization was confirmed by Western blotting and immunofluorescence staining using polyclonal antibodies against a C-terminal peptide of TcAQP. In addition, there was a strong anterior labeling in a vacuole, close to the flagellar pocket, that was distinct from the acidocalcisomes and that was identified by immunogold electron microscopy as the contractile vacuole complex. Taking together, the presence of an aquaporin in acidocalcisomes and the contractile vacuole complex of T. cruzi, provides support for the role of these organelles in osmotic adaptations of these parasites.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Rohloff, Peter/P-8722-2017	Rohloff, Peter/0000-0001-7274-8315	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKBARIEH M, 1988, J PROTOZOOL, V35, P99, DOI 10.1111/j.1550-7408.1988.tb04085.x; Allen RD, 2002, INT REV CYTOL, V215, P351; Attias M, 1996, CELL STRUCT FUNCT, V21, P297, DOI 10.1247/csf.21.297; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Bertello LE, 2000, BIOCHEM J, V345, P77, DOI 10.1042/0264-6021:3450077; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; BOWERS B, 1973, J CELL BIOL, V59, P784, DOI 10.1083/jcb.59.3.784; Burleigh BA, 2002, CELL MICROBIOL, V4, P701, DOI 10.1046/j.1462-5822.2002.00226.x; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; CLARK TB, 1959, J PROTOZOOL, V6, P227, DOI 10.1111/j.1550-7408.1959.tb04362.x; CRONKITE DL, 1991, J PROTOZOOL, V38, P565, DOI 10.1111/j.1550-7408.1991.tb06081.x; De Souza W, 2000, AN ACAD BRAS CIENC, V72, P421, DOI 10.1590/S0001-37652000000300016; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Finkelstein A., 1987, WATER MOVEMENT LIPID; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Hansen M, 2002, J BIOL CHEM, V277, P4874, DOI 10.1074/jbc.M110683200; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V244, P268, DOI 10.1006/bbrc.1998.8252; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Johansson I, 2000, BBA-BIOMEMBRANES, V1465, P324, DOI 10.1016/S0005-2736(00)00147-4; Kollien AH, 2000, PARASITOL TODAY, V16, P381, DOI 10.1016/S0169-4758(00)01724-5; Kollien AH, 2001, J INSECT PHYSIOL, V47, P739, DOI 10.1016/S0022-1910(00)00170-0; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; Pavlovic-Djuranovic S, 2003, FEBS LETT, V555, P500, DOI 10.1016/S0014-5793(03)01313-9; PIMENTA PFP, 1989, EUR J CELL BIOL, V50, P263; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sarkar M, 2003, J BIOL CHEM, V278, P22703, DOI 10.1074/jbc.M302419200; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Seufferheld M, 2003, J BIOL CHEM, V278, P29971, DOI 10.1074/jbc.M304548200; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SOARES MJ, 1991, PARASITOL RES, V77, P461, DOI 10.1007/BF00928410; Steck TL, 1997, J EUKARYOT MICROBIOL, V44, P503, DOI 10.1111/j.1550-7408.1997.tb05731.x; Temesvari LA, 1996, J CELL SCI, V109, P1479; VANROSSUM GDV, 1987, CURR TOP MEMBR TRANS, V30, P45; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4	49	92	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38673	38682		10.1074/jbc.M406304200	http://dx.doi.org/10.1074/jbc.M406304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252016	hybrid			2022-12-25	WOS:000223684100076
J	Svetlov, V; Vassylyev, DG; Artsimovitch, I				Svetlov, V; Vassylyev, DG; Artsimovitch, I			Discrimination against deoxyribonucleotide substrates by bacterial RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3.3 ANGSTROM RESOLUTION; STRUCTURAL BASIS; DNA-POLYMERASE; REVERSE-TRANSCRIPTASE; ELONGATION COMPLEX; CRYSTAL-STRUCTURE; TRANSLOCATION; SELECTION; MECHANISM; BINDING	Nucleic acid polymerases have evolved elaborate mechanisms that prevent incorporation of the non-cognate substrates, which are distinguished by both the base and the sugar moieties. While the mechanisms of substrate selection have been studied in single-subunit DNA and RNA polymerases (DNAPs and RNAPs, respectively), the determinants of substrate binding in the multisubunit RNAPs are not yet known. Molecular modeling of Thermus thermophilus RNAP-substrate NTP complex identified a conserved beta' subunit Asn(737) residue in the active site that could play an essential role in selection of the substrate ribose. We utilized the Escherichia coli RNAP model system to assess this prediction. Functional in vitro analysis demonstrates that the substitutions of the corresponding beta' Asn(458) residue lead to the loss of discrimination between ribo- and deoxyribonucleotide substrates as well as to defects in RNA chain extension. Thus, in contrast to the mechanism utilized by the single-subunit T7 RNAP where substrate selection commences in the inactive pre-insertion site prior to its delivery to the catalytic center, the bacterial RNAPs likely recognize the sugar moiety in the active insertion) site.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; SPring 8, RIKEN Harima Inst, Struct & Mol Biol Lab, Mikazuki, Hyogo 6795148, Japan; SPring 8, RIKEN Harima Inst, Structurome Res Grp, Mikazuki, Hyogo 6795148, Japan	University System of Ohio; Ohio State University; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Artsimovitch, I (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	artsimovitch.1@osu.edu	Vassylyev, Dmitry/A-9005-2008; Artsimovitch, Irina/L-3467-2019		NIGMS NIH HHS [R01 GM067153, R01 GM067153-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Schwartz A, 2003, EMBO J, V22, P3385, DOI 10.1093/emboj/cdg310; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	25	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38087	38090		10.1074/jbc.C400316200	http://dx.doi.org/10.1074/jbc.C400316200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262972	hybrid, Green Accepted			2022-12-25	WOS:000223684100003
J	Entingh-Pearsall, A; Kahn, CR				Entingh-Pearsall, A; Kahn, CR			Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HYBRID RECEPTORS; TYROSINE KINASE; TRANSGENIC MICE; GLUCOSE-UPTAKE; BROWN FAT; SUBSTRATE; PROTEIN; STIMULATION; CELLS	Insulin and insulin-like growth factor-I (IGF-I) receptors are highly homologous tyrosine kinase receptors that share many common steps in their signaling pathways and have ligands that can bind to either receptor with differing affinities. To define precisely the signaling specific to the insulin receptor (IR) or the IGF-I receptor, we have generated brown preadipocyte cell lines that lack either receptor ( insulin receptor knockout (IRKO) or insulin-like growth factor receptor knockout (IGFRKO)). Control preadipocytes expressed fewer insulin receptors than IGF-I receptors ( 20,000 versus 60,000), but during differentiation, insulin receptor levels increased so that mature adipocytesexpressed slightly more insulin receptors than IGF-I receptors ( 120,000 versus 100,000). In these cells, insulin stimulated IR homodimer phosphorylation, whereas IGF-I activated both IGF-I receptor homodimers and hybrid receptors. Insulin-stimulated IRS-1 phosphorylation was significantly impaired in IRKO cells but was surprisingly elevated in IGFRKO cells. IRS-2 phosphorylation was unchanged in either cell line upon insulin stimulation. IGF-I-dependent phosphorylation of IRS-1 and IRS-2 was ablated in IGFRKO cells but not in IRKO cells. In control cells, both insulin and IGF-I produced a dose-dependent increase in phosphorylated Akt and MAPK, although IGF-I elicited a stronger response at an equivalent dose. In IRKO cells, the insulin-dependent increase in phospho-Akt was completely abolished at the lowest dose and reached only 20% of the control stimulation at 10 nM. Most interestingly, the response to IGF-I was also impaired at low doses, suggesting that IR is required for both insulin-and IGF-I-dependent phosphorylation of Akt. Most surprisingly, insulin-or IGF-I-dependent phosphorylation of MAPK was unaltered in either receptor-deficient cell line. Taken together, these results indicate that the insulin and IGF-I receptors contribute distinct signals to common downstream components in response to both insulin and IGF-I.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Cellular & Mol Physiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Kahn, CR (corresponding author), 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301, T32DK007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33301, DK07260] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BEGUINOT F, 1988, BIOCHEMISTRY-US, V27, P3222, DOI 10.1021/bi00409a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Entingh AJ, 2003, J BIOL CHEM, V278, P33377, DOI 10.1074/jbc.M303056200; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Guerra C, 2001, J CLIN INVEST, V108, P1205, DOI 10.1172/JCI200113103; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; Holzenberger M, 2000, ENDOCRINOLOGY, V141, P2557, DOI 10.1210/en.141.7.2557; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KallooHosein HE, 1997, J BIOL CHEM, V272, P24325, DOI 10.1074/jbc.272.39.24325; KATO H, 1993, J CELL PHYSIOL, V156, P145, DOI 10.1002/jcp.1041560120; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Klein J, 2002, BIOESSAYS, V24, P382, DOI 10.1002/bies.10058; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Lamothe B, 1998, FEBS LETT, V426, P381, DOI 10.1016/S0014-5793(98)00377-9; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Mur C, 2003, ENDOCRINOLOGY, V144, P581, DOI 10.1210/en.2002-220828; Mur C, 2002, DIABETES, V51, P743, DOI 10.2337/diabetes.51.3.743; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; WERNER H, 1991, INSULIN LIKE GROWTH, P17; Wertheimer E, 2000, J INVEST DERMATOL, V115, P24, DOI 10.1046/j.1523-1747.2000.00008.x; Wertheimer E, 2001, ENDOCRINOLOGY, V142, P1234, DOI 10.1210/en.142.3.1234; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631	43	99	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38016	38024		10.1074/jbc.M313201200	http://dx.doi.org/10.1074/jbc.M313201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247278	hybrid			2022-12-25	WOS:000223554600095
J	Alce, TM; Popik, W				Alce, TM; Popik, W			APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRION INFECTIVITY FACTOR; VIF PROTEIN; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; TYPE-1; DEGRADATION; PROTEASOME; RNA; DNA; REPLICATION	APOBEC3G belongs to the family of cellular cytidine deaminase-editing enzymes with a potent antiretroviral activity, which is counteracted by the Vif protein expressed by lentiviruses. Antiretroviral activity of APOBEC3G requires its packaging into assembling virions, presumably to ensure its close association with nascent retroviral cDNA. Here, we demonstrate that APOBEC3G is encapsidated through a direct interaction with the HIV-1 Gag polyprotein which likely takes place on the membranes of the multivesicular bodies (MVB)/ late endosomal compartments. This interaction is mediated by the Gag nucleocapsid protein NC, and the N-terminal part of NC is most critical for this interaction. Binding to the NC domain would ensure that APOBEC3G will be concentrated in the viral core of mature HIV-1, in close proximity to the reverse transcription complex.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Popik, W (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.	wpopik@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050461, R21AI050461] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 50461] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Nydegger S, 2003, TRAFFIC, V4, P902, DOI 10.1046/j.1600-0854.2003.00145.x; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	33	196	204	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34083	34086		10.1074/jbc.C400235200	http://dx.doi.org/10.1074/jbc.C400235200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15215254	hybrid			2022-12-25	WOS:000223134800002
J	Chen, XP; Spudich, JL				Chen, XP; Spudich, JL			Five residues in the HtrI transducer membrane-proximal domain close the cytoplasmic proton-conducting channel of sensory rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTING CHEMOTAXIS PROTEINS; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; MUTATIONAL ANALYSIS; LINKER REGION; BACTERIAL CHEMORECEPTORS; MOLECULAR-MECHANISM; NITRATE SENSOR; I-TRANSDUCER; RECEPTOR	Transducer-free sensory rhodopsins carry out light-driven proton transport in Halobacterium salinarum membranes. Transducer binding converts the proton pumps to signal-relay devices in which the transport is inhibited. In sensory rhodopsin I (SRI) binding of its cognate transducer HtrI inhibits transport by closing a cytoplasmic proton-conducting channel necessary for proton uptake during the SRI photochemical reaction cycle. To investigate the channel closure, a series of HtrI mutants truncated in the membrane-proximal cytoplasmic portion of an SRI-HtrI fusion were constructed and expressed in H. salinarum membranes. We found that binding of the membrane-embedded portion of HtrI is insufficient for channel closure, whereas cytoplasmic extension of the second HtrI transmembrane helix by 13 residues blocks proton conduction through the channel as well as full-length HtrI. Specifically the closure activity is localized in this 13-residue membrane-proximal cytoplasmic domain to the 5 final residues, each of which incrementally contributes to reduction of proton conductivity. Moreover, these same residues in the dark incrementally and proportionally increase the pK(a) of the Asp-76 counterion to the protonated Schiff base chromophore in the membrane-embedded photoactive site. We conclude that this critical region of HtrI alters the dark conformation of SRI as well as light-induced channel opening. The 5 residues in HtrI correspond in position to 5 residues demonstrated on the homologous NpHtrII to interact with the E-F loop of its cognate receptor NpSRII in the accompanying article ( Yang, C.-S., Sineshchekov, O., Spudich, E. N., and Spudich, J. L. (2004) J. Biol. Chem. 279, 42970 - 42976). These results strongly suggest that the membrane-proximal region of Htr proteins interact with their cognate sensory rhodopsin cytoplasmic domains as part of the signal-relay coupling between the proteins.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas System	Spudich, JL (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu			NIGMS NIH HHS [R37GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Appleman JA, 2003, J BACTERIOL, V185, P89, DOI 10.1128/JB.185.1.89-97.2003; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bogomolni R. A., 1995, P63; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chen XP, 2002, BIOCHEMISTRY-US, V41, P3891, DOI 10.1021/bi015966h; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; Essen LO, 2002, CURR OPIN STRUC BIOL, V12, P516, DOI 10.1016/S0959-440X(02)00356-1; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; HAUPTS U, 1995, P NATL ACAD SCI USA, V92, P3834, DOI 10.1073/pnas.92.9.3834; Hippler-Mreyen S, 2003, J MOL BIOL, V330, P1203, DOI 10.1016/S0022-2836(03)00656-9; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jung KH, 1998, J BACTERIOL, V180, P2033, DOI 10.1128/JB.180.8.2033-2042.1998; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; Kolbe M, 2000, SCIENCE, V288, P1390, DOI 10.1126/science.288.5470.1390; Luecke H, 2003, ADV PROTEIN CHEM, V63, P111; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; OLSON KD, 1993, BIOPHYS J, V65, P2578, DOI 10.1016/S0006-3495(93)81295-5; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Schmies G, 2000, BIOPHYS J, V78, P967, DOI 10.1016/S0006-3495(00)76654-9; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; Spudich JL, 1995, ISR J CHEM, V35, P495; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; SPUDICH JL, 2004, IN PRESS HDB PHOTOSE; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Sudo Y, 2001, BIOPHYS J, V80, P916, DOI 10.1016/S0006-3495(01)76070-5; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200; YAO VJ, 1994, J BACTERIOL, V176, P6931, DOI 10.1128/JB.176.22.6931-6935.1994; Zhang XN, 1999, P NATL ACAD SCI USA, V96, P857, DOI 10.1073/pnas.96.3.857; Zhang XN, 1998, J BIOL CHEM, V273, P19722, DOI 10.1074/jbc.273.31.19722	42	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42964	42969		10.1074/jbc.M406503200	http://dx.doi.org/10.1074/jbc.M406503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15252049	hybrid			2022-12-25	WOS:000224226400076
J	Abrink, M; Grujic, M; Pejler, G				Abrink, M; Grujic, M; Pejler, G			Serglycin is essential for maturation of mast cell secretory granule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; GROWTH-FACTOR; EXPRESSION; PROTEASES; BIOSYNTHESIS; DISRUPTION; CARTILAGE; GLYCOSAMINOGLYCANS; INTERLEUKIN-3	To address the biological function of the scarcely studied intracellular proteoglycans, we targeted the gene for serglycin (SG), the only known committed intracellular proteoglycan. SG(-/-) mice developed normally and were fertile, but their mast cells (MCs) were severely affected. In peritoneum there was a complete absence of normal granulated MCs. Furthermore, peritoneal cells and ear tissue from SG(-/-) animals were devoid of the various MC-specific proteases. However, mRNA for the proteases was present in SG(+/+), SG(+/+), and SG(-/-) tissues, indicating that SG is essential for the storage, but not expression, of the MC proteases. Experiments, in which the differentiation of bone marrow stem cells into mature MCs was followed, showed that secretory granule maturation was compromised in SG(-/-) cells. Moreover, SG(+/+) and SG(+/-) cells, but not SG(-/-) cells, synthesized proteoglycans of high anionic charge density. Taken together, we demonstrate a key role for SG proteoglycan in MC function.	Swedish Univ Agr Sci, Dept Mol Biosci, Ctr Biomed, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Abrink, M (corresponding author), Swedish Univ Agr Sci, Dept Mol Biosci, Ctr Biomed, Box 575, S-75123 Uppsala, Sweden.	magnus.abrink@bmc.uu.se	Åbrink, Magnus/AAK-8346-2020	Abrink, Magnus/0000-0002-1335-3927				Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Biederbick A, 2003, EUR J CELL BIOL, V82, P19, DOI 10.1078/0171-9335-00287; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; DAYTON ET, 1988, P NATL ACAD SCI USA, V85, P569, DOI 10.1073/pnas.85.2.569; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; Henningsson F, 2002, BIOL CHEM, V383, P793, DOI 10.1515/BC.2002.083; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LIDHOLT K, 1995, BIOCHEM J, V311, P233, DOI 10.1042/bj3110233; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schick BP, 2003, BBA-MOL CELL RES, V1593, P259, DOI 10.1016/S0167-4889(02)00396-8; Schick BP, 2001, J BIOL CHEM, V276, P24726, DOI 10.1074/jbc.M102958200; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831	48	148	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40897	40905		10.1074/jbc.M405856200	http://dx.doi.org/10.1074/jbc.M405856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15231821	hybrid			2022-12-25	WOS:000223916800086
J	Wang, H; Luo, WJ; Zhang, YW; Li, YM; Thinakaran, G; Greengard, P; Xu, HX				Wang, H; Luo, WJ; Zhang, YW; Li, YM; Thinakaran, G; Greengard, P; Xu, HX			Presenilins and gamma-secretase inhibitors affect intracellular trafficking and cell surface localization of the gamma-secretase complex components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TRANS-GOLGI NETWORK; BETA-PEPTIDE PRODUCTION; ALZHEIMERS-DISEASE; INTRAMEMBRANE PROTEOLYSIS; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; APH-1 INTERACTS; NICASTRIN; PEN-2	The intramembranous cleavage of Alzheimer beta-amyloid precursor protein and the signaling receptor Notch is mediated by the presenilin (PS, PS1/PS2)-gamma-secretase complex, the components of which also include nicastrin, APH-1, and PEN-2. In addition to its essential role in gamma-secretase activity, we and others have reported that PS1 plays a role in intracellular trafficking of select membrane proteins including nicastrin. Here we examined the fate of PEN-2 in the absence of PS expression or gamma-secretase activity. We found that PEN-2 is retained in the endoplasmic reticulum and has a much shorter half-life in PS-deficient cells than in wild type cells, suggesting that PSs are required for maintaining the stability and proper subcellular trafficking of PEN-2. However, the function of PS in PEN-2 trafficking is distinct from its contribution to gamma-secretase activity because inhibition of gamma-secretase activity by gamma-secretase inhibitors did not affect the PEN-2 level or its egress from the endoplasmic reticulum. Instead, membrane-permeable gamma-secretase inhibitors, but not a membrane-impermeable derivative, markedly increased the cell surface levels of PS1 and PEN-2 without affecting that of nicastrin. In support of its role in PEN-2 trafficking, PS1 was also required for the gamma-secretase inhibitor-induced plasma membrane accumulation of PEN-2. We further showed that gamma-secretase inhibitors specifically accelerated the Golgi to the cell surface transport of PS1 and PEN-2. Taken together, we demonstrate an essential role for PSs in intracellular trafficking of the gamma-secretase components, and that selective gamma-secretase inhibitors differentially affect the trafficking of the gamma-secretase components, which may contribute to an inactivation of gamma-secretase.	Rockefeller Univ, Fisher Ctr Alzheimers Dis Res, New York, NY 10021 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	Rockefeller University; Rockefeller University; Sanford Burnham Prebys Medical Discovery Institute; Memorial Sloan Kettering Cancer Center; University of Chicago	Xu, HX (corresponding author), Rockefeller Univ, Fisher Ctr Alzheimers Dis Res, 1230 York Ave, New York, NY 10021 USA.	xuh@burnham.org	Xu, Huaxi/AAV-7177-2021; Luo, Wenjie/ABF-8451-2020	Zhang, Yun-wu/0000-0002-7152-7630	NIA NIH HHS [P01 AG009464, F32 AG023432-01, AG09464] Funding Source: Medline; NINDS NIH HHS [NS046673] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464, F32AG023432] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CHEN F, 2003, J BIOL CHEM, V18, P18; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; GU Y, 2004, J BIOL CHEM; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 2001, J MOL NEUROSCI, V17, P183, DOI 10.1385/JMN:17:2:183; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wolfe MS, 2001, J NEUROCHEM, V76, P1615, DOI 10.1046/j.1471-4159.2001.00245.x; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	75	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40560	40566		10.1074/jbc.M404345200	http://dx.doi.org/10.1074/jbc.M404345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247291	hybrid			2022-12-25	WOS:000223916800043
J	Boshoff, HIM; Myers, TG; Copp, BR; McNeil, MR; Wilson, MA; Barry, CE				Boshoff, HIM; Myers, TG; Copp, BR; McNeil, MR; Wilson, MA; Barry, CE			The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism - Novel insights into drug mechanisms of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ARABINAN BIOSYNTHESIS; ETHAMBUTOL; OXIDASE; TARGET; GROWTH; POLYPHOSPHATE; RESISTANCE; ADAPTATION; SMEGMATIS	The differential transcriptional response of Mycobacterium tuberculosis to drugs and growth-inhibitory conditions was monitored to generate a data set of 430 microarray profiles. Unbiased grouping of these profiles independently clustered agents of known mechanism of action accurately and was successful at predicting the mechanism of action of several unknown agents. These predictions were validated biochemically for two agents of previously uncategorized mechanism, pyridoacridones and phenothiazines. Analysis of this data set further revealed 150 underlying clusters of coordinately regulated genes offering the first glimpse at the full metabolic potential of this organism. A signature subset of these gene clusters was sufficient to classify all known agents as to mechanism of action. Transcriptional profiling of both crude and purified natural products can provide critical information on both mechanism and detoxification prior to purification that can be used to guide the drug discovery process. Thus, the transcriptional profile generated by a crude marine natural product recapitulated the mechanistic prediction from the pure active component. The underlying gene clusters further provide fundamental insights into the metabolic response of bacteria to drug-induced stress and provide a rational basis for the selection of critical metabolic targets for screening for new agents with improved activity against this important human pathogen.	NIAID, TB Res Sect, NIH, Rockville, MD 20852 USA; NIAID, Res Technol Branch, NIH, Bethesda, MD 20892 USA; Univ Auckland, Dept Chem, Auckland 1020, New Zealand; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Auckland; Colorado State University	Boshoff, HIM (corresponding author), Twinbrook 2,Rm 239,12441 Parklawn Dr, Rockville, MD 20852 USA.	HBOSHOFF@niaid.nih.gov	McNeil, Michael/G-3325-2019; Barry, III, Clifton/H-3839-2012; Copp, B/D-3706-2009; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Copp, B/0000-0001-5492-5269; Barry, Clifton E/0000-0002-2927-270X; Myers, Timothy Gene/0000-0002-7059-5906	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000734, Z01AI000783] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Alland D, 2000, J BACTERIOL, V182, P1802, DOI 10.1128/JB.182.7.1802-1811.2000; Amaral L, 2001, J ANTIMICROB CHEMOTH, V47, P505, DOI 10.1093/jac/47.5.505; Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Betts JC, 2003, ANTIMICROB AGENTS CH, V47, P2903, DOI 10.1128/AAC.47.9.2903-2913.2003; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; Boshoff HIM, 2000, J BACTERIOL, V182, P5479, DOI 10.1128/JB.182.19.5479-5485.2000; Brekasis D, 2003, EMBO J, V22, P4856, DOI 10.1093/emboj/cdg453; Copp BR, 2003, PLANTA MED, V69, P527, DOI 10.1055/s-2003-40640; Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100; Davis EO, 2002, J BACTERIOL, V184, P3287, DOI 10.1128/JB.184.12.3287-3295.2002; Dawes SS, 2003, INFECT IMMUN, V71, P6124, DOI 10.1128/IAI.71.11.6124-6131.2003; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; Drlica K, 1999, CURR OPIN MICROBIOL, V2, P504, DOI 10.1016/S1369-5274(99)00008-9; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FILPULA D, 1977, J BACTERIOL, V130, P107, DOI 10.1128/JB.130.1.107-113.1977; Gormley NA, 1996, BIOCHEMISTRY-US, V35, P5083, DOI 10.1021/bi952888n; Grabbe R, 2003, EUR J BIOCHEM, V270, P1555, DOI 10.1046/j.1432-1033.2003.03520.x; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Kana BD, 2001, J BACTERIOL, V183, P7076, DOI 10.1128/JB.183.24.7076-7086.2001; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; Krivankova L, 1980, Methods Enzymol, V67, P111; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; Lee RE, 2003, J COMB CHEM, V5, P172, DOI 10.1021/cc020071p; LEUNG D, 1994, FEMS MICROBIOL LETT, V119, P351, DOI 10.1111/j.1574-6968.1994.tb06912.x; Matsumoto SS, 2003, CHEM RES TOXICOL, V16, P113, DOI 10.1021/tx025618w; McLean KJ, 2002, MICROBIOL-SGM, V148, P2937, DOI 10.1099/00221287-148-10-2937; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; Munro AW, 2003, BIOCHEM SOC T, V31, P625, DOI 10.1042/BST0310625; Ng TB, 2003, BIOL CHEM, V384, P289, DOI 10.1515/BC.2003.032; Normark BH, 2002, J INTERN MED, V252, P91, DOI 10.1046/j.1365-2796.2002.01026.x; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000; Rand L, 2003, MOL MICROBIOL, V50, P1031, DOI 10.1046/j.1365-2958.2003.03765.x; Rousseeuw P.J., 1990, FINDING GROUPS DATA; San KY, 2002, METAB ENG, V4, P182, DOI 10.1006/mben.2001.0220; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Savoie CJ, 2003, DNA RES, V10, P19, DOI 10.1093/dnares/10.1.19; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; YASSIN AF, 1988, ZBL BAKT-INT J MED M, V267, P339; Zhang HY, 2002, P NATL ACAD SCI USA, V99, P16678, DOI 10.1073/pnas.262655199	54	461	483	3	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40174	40184		10.1074/jbc.M406796200	http://dx.doi.org/10.1074/jbc.M406796200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247240	hybrid			2022-12-25	WOS:000223791500116
J	de Graffenried, CL; Bertozzi, CR				de Graffenried, CL; Bertozzi, CR			The stem region of the sulfotransferase GlcNAc6ST-1 is a determinant of substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGAND; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GOLGI MEMBRANE-PROTEIN; CARBOHYDRATE SULFOTRANSFERASES; CHONDROITIN 6-SULFOTRANSFERASE; MOLECULAR-CLONING; KIN RECOGNITION; SIGNAL ANCHOR; O-GLYCANS; CORE 2	The GlcNAc-6-sulfotransferases are a family of Golgi-resident enzymes that modulate glycan function. Two members of this family, GlcNAc6ST-1 and -2, collaborate in the biosynthesis of ligands for the leukocyte adhesion molecule L-selectin. Although their biochemical properties are similar in vitro, the enzymes have distinct glycoprotein substrate preferences in vivo. The sulfotransferases share similar overall architecture with the exception of an extended stem region in GlcNAc6ST-1 that is absent in GlcNAc6ST-2. In this study we probed the importance of the stem region with respect to substrate preference, localization, and oligomerization. Analysis of truncation mutants demonstrated that perturbation of the stem region of GlcNAc6ST-1 affects the cellular substrate preference of the enzyme without altering its retention within the Golgi. A chimeric enzyme comprising the stem region of GlcNAc6ST-1 inserted between the catalytic and transmembrane domains of GlcNAc6ST-2 had the same substrate preference as native GlcNAc6ST-1. In cells, GlcNAc6ST-1 exists as a dimer; two cysteine residues within the stem and transmembrane domain were found to be critical for dimerization. However, disruption of the dimer by mutagenesis did not affect either localization or substrate preference. Collectively, these results indicate that the stem region of GlcNAc6ST-1 influences substrate specificity, independent of its role in dimerization or Golgi retention.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	crb@berkeley.edu	de Graffenried, Christopher/I-6172-2019	de Graffenried, Christopher/0000-0003-3386-6487	NIGMS NIH HHS [GM59907] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Bhakta S, 2000, J BIOL CHEM, V275, P40226, DOI 10.1074/jbc.M006414200; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; de Graffenried CL, 2003, J BIOL CHEM, V278, P40282, DOI 10.1074/jbc.M304928200; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; El-Battari A, 2003, GLYCOBIOLOGY, V13, P941, DOI 10.1093/glycob/cwg117; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Gillingham AK, 2002, MOL BIOL CELL, V13, P3761, DOI 10.1091/mbc.E02-06-0349; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P15590, DOI 10.1021/bi0269557; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hiraoka N, 2004, J BIOL CHEM, V279, P3058, DOI 10.1074/jbc.M311150200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 2002, MED RES REV, V22, P637, DOI 10.1002/med.10020; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Kitazume-Kawaguchi S, 1999, GLYCOBIOLOGY, V9, P1397; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; Renkonen J, 2002, AM J PATHOL, V161, P543, DOI 10.1016/S0002-9440(10)64210-1; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Seko A, 2002, GLYCOBIOLOGY, V12, P379, DOI 10.1093/glycob/12.6.379; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; van Zante A, 2003, BIOCHEM SOC T, V31, P313, DOI 10.1042/BST0310313; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	53	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40035	40043		10.1074/jbc.M405709200	http://dx.doi.org/10.1074/jbc.M405709200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15220337	hybrid			2022-12-25	WOS:000223791500101
J	Fessler, MB; Arndt, PG; Frasch, SC; Lieber, JG; Johnson, CA; Murphy, RC; NickO, JA; Bratton, DL; Malcolm, KC; Worthen, GS				Fessler, MB; Arndt, PG; Frasch, SC; Lieber, JG; Johnson, CA; Murphy, RC; NickO, JA; Bratton, DL; Malcolm, KC; Worthen, GS			Lipid rafts regulate lipopolysaccharide-induced activation of Cdc42 and inflammatory functions of the human neutrophil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; CHOLESTEROL DEPLETION; PLASMA-MEMBRANE; PROTEIN-KINASE; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDE; TYROSINE PHOSPHORYLATION; STIMULATED NEUTROPHILS; INDEPENDENT ACTIVATION; RHO PROTEINS	Lipid rafts are cholesterol-rich membrane microdomains that are thought to act as coordinated signaling platforms by regulating dynamic, agonist-induced translocation of signaling proteins. They have been described to play a role in multiple prototypical cascades, among them the lipopolysaccharide pathway, and to host multiple signaling proteins, including kinases and low molecular weight G-proteins. Here we report lipopolysaccharide-induced activation of the Rho family GTPase Cdc42, and we show its activation in the human neutrophil to be mediated by a p38 mitogen-activated protein kinase-dependent mechanism. Subcellular fractionation reveals that lipopolysaccharide induces translocation of Cdc42 to lipid rafts, where it and p38 are both found to be activated. By contrast, lipopolysaccharide causes translocation of Rac from the polymorphonuclear leukocyte (PMN) rafts and does not induce its activation. With the use of methyl-beta-cyclodextrin, a cholesterol-depleting agent that reversibly disrupts rafts, we confirm an important regulatory role for rafts in the activation state of p38 and Cdc42 and in the Rho GTPase-dependent functions superoxide anion production and actin polymerization. Methyl-beta-cyclodextrin induces activation of p38 and Cdc42, but not Rac, in the nonstimulated PMN, yet inhibits subsequent lipopolysaccharide-induced activation of p38 and Cdc42. In parallel, methyl-beta-cyclodextrin primes the human PMN for subsequent superoxide release triggered by the formylated bacterial tripeptide formyl-Met-Leu-Phe, and induces actin polymerization in a subcellular distribution distinct from that induced by lipopolysaccharide. In sum, these findings provide evidence for an important regulatory role of cholesterol in both transmission of the lipopolysaccharide signal and the inflammatory phenotype of the human neutrophil.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Fessler, MB (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,D403, Denver, CO 80206 USA.	Michael.fessler@uchsc.edu	Fessler, Michael B/C-6323-2019	Fessler, Michael B/0000-0002-8262-8613	NHLBI NIH HHS [HL061407-05, HL67179, HL68743, HL34303] Funding Source: Medline; NIAID NIH HHS [AI58228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061407, P01HL068743, K08HL067179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058228] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Amar S, 2001, J ENDOTOXIN RES, V7, P281, DOI 10.1179/096805101101532855; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Cheng PC, 2001, SEMIN IMMUNOL, V13, P107, DOI 10.1006/smim.2000.0302; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chernow B, 1999, CHEST, V115, p71S, DOI 10.1378/chest.115.suppl_2.71S; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Eggesbo JB, 1996, SCAND J CLIN LAB INV, V56, P199, DOI 10.3109/00365519609088609; ERZURUM SC, 1992, J IMMUNOL, V149, P154; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; GERLACH E, 1963, BIOCHEM Z, V337, P477; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hippenstiel S, 2000, BLOOD, V95, P3044; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Keresztes M, 1998, BIOCHEM BIOPH RES CO, V252, P723, DOI 10.1006/bbrc.1998.9730; Kindzelskii AL, 2004, J IMMUNOL, V172, P4681, DOI 10.4049/jimmunol.172.8.4681; MADDOX PH, 1987, J CLIN PATHOL, V40, P1256, DOI 10.1136/jcp.40.10.1256; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Nakamura M, 2003, EXP CELL RES, V290, P381, DOI 10.1016/S0014-4827(03)00343-4; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; OKAMURA N, 1980, J BIOCHEM-TOKYO, V88, P139; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; Schade AE, 2002, J IMMUNOL, V168, P2233, DOI 10.4049/jimmunol.168.5.2233; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sitrin RG, 2004, AM J RESP CELL MOL, V30, P233, DOI 10.1165/rcmb.2003-0079OC; Stokes KY, 2001, CIRC RES, V88, P499, DOI 10.1161/01.RES.88.5.499; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Triantafilou M, 2002, J CELL SCI, V115, P2603; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang Ping-Yuan, 1995, Journal of Inflammation, V47, P126; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Woo CH, 2002, MOL CELLS, V13, P470; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001	66	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39989	39998		10.1074/jbc.M401080200	http://dx.doi.org/10.1074/jbc.M401080200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262974	hybrid			2022-12-25	WOS:000223791500096
J	Sar, F; Lindsey-Boltz, LA; Subramanian, D; Croteau, DL; Hutsell, SQ; Griffith, JD; Sancar, A				Sar, F; Lindsey-Boltz, LA; Subramanian, D; Croteau, DL; Hutsell, SQ; Griffith, JD; Sancar, A			Human claspin is a ring-shaped DNA-binding protein with high affinity to branched DNA structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; DAMAGE CHECKPOINT; CLAMP LOADER; REPLICATION; COMPLEXES; ATR; KINASE; BRCA1; RAD17; CHK1	Claspin is an essential protein for the ATR-dependent activation of the DNA replication checkpoint response in Xenopus and human cells. Here we describe the purification and characterization of human Claspin. The protein has a ring-like structure and binds with high affinity to branched DNA molecules. These findings suggest that Claspin may be a component of the replication ensemble and plays a role in the replication checkpoint by directly associating with replication forks and with the various branched DNA structures likely to form at stalled replication forks because of DNA damage.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.	Aziz_Sancar@med.unc.edu	Croteau, Deb/AAP-5933-2020; Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019014, R01GM032833, R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833, GM31819, GM19014] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	29	61	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39289	39295		10.1074/jbc.M405793200	http://dx.doi.org/10.1074/jbc.M405793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15226314	Green Published, hybrid			2022-12-25	WOS:000223791500013
J	Dosil, M; Bustelo, XR				Dosil, M; Bustelo, XR			Functional characterization of pwp2, a WD family protein essential for the assembly of the 90 S pre-ribosomal particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; U3 SNORNA; BOX-C; RNA; YEAST; BIOGENESIS; COMPLEXES; GENE; MOTIF	Here we report the functional characterization of Pwp2, an evolutionary conserved component of the 90 S pre-ribosome. Conditional depletion of the Pwp2 protein in yeast specifically impairs pre-rRNA proccessing at sites A(0), A(1), and A(2), leading to a strong decrease in 18 S rRNA and 40 S ribosomal subunit levels. Pre-ribosomal particle sedimentation analysis indicated that these defects are caused by a block in the formation of 90 S pre-ribosomes. We demonstrate that in Pwp2-depleted cells the U3 small nucleolar ribonucleoprotein is not able to interact with the 35 S pre-rRNA and accumulates as a free complex. Similarly, other 90 S particle components such as Imp3 and Imp4 do not associate with the pre-rRNA precursor in the absence of Pwp2. In addition, we have found that after blocking U3 ribonucleoprotein assembly, Pwp2 predominantly accumulates as a complex in association with five proteins: Dip2, Utp6, Utp13, Utp18, and Utp21. Immunoprecipitation and gradient sedimentation analysis revealed that this Pwp2 small subcomplex is capable of interacting directly with the 35 S pre-rRNA 5' end. Taken together, these results indicate that Pwp2 forms part of a stable particle subunit independent of the U3 small nucleolar ribonucleoprotein that is essential for the initial assembly steps of the 90 S pre-ribosome.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Dosil, M (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	mdosil@usal.es	Dosil, Mercedes/A-9536-2016; Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Dosil, Mercedes/0000-0001-8119-8263; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Buscemi G, 2000, J CELL SCI, V113, P1199; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Decatur WA, 2003, J BIOL CHEM, V278, P695, DOI 10.1074/jbc.R200023200; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kressler D, 1997, MOL CELL BIOL, V17, P7283, DOI 10.1128/MCB.17.12.7283; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lalioti MD, 1996, GENOMICS, V35, P321, DOI 10.1006/geno.1996.0363; Leary DJ, 2004, MOL BIOL CELL, V15, P281, DOI 10.1091/mbc.e03-06-0363; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lukowiak AA, 2000, NUCLEIC ACIDS RES, V28, P3462, DOI 10.1093/nar/28.18.3462; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Oeffinger M, 2003, EMBO J, V22, P6573, DOI 10.1093/emboj/cdg616; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Pluk H, 1998, MOL CELL BIOL, V18, P488, DOI 10.1128/MCB.18.1.488; Preker PJ, 1998, TRENDS BIOCHEM SCI, V23, P15, DOI 10.1016/S0968-0004(97)01156-0; Shafaatian R, 1996, MOL GEN GENET, V252, P101, DOI 10.1007/BF02173210; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Wehner KA, 2002, MOL CELL BIOL, V22, P7258, DOI 10.1128/MCB.22.20.7258-7267.2002; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Yamakawa K, 1996, CYTOGENET CELL GENET, V74, P140, DOI 10.1159/000134402; Zhang YX, 2002, CELL, V109, P849, DOI 10.1016/S0092-8674(02)00805-X; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	47	72	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37385	37397		10.1074/jbc.M404909200	http://dx.doi.org/10.1074/jbc.M404909200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231838	hybrid			2022-12-25	WOS:000223554600025
J	Huh, JW; Yoon, HY; Lee, HJ; Choi, WB; Yang, SJ; Cho, SW				Huh, JW; Yoon, HY; Lee, HJ; Choi, WB; Yang, SJ; Cho, SW			Importance of Gly-13 for the coenzyme binding of human UDP-glucose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; HUMAN GLUTAMATE-DEHYDROGENASE; HEPARAN-SULFATE PROTEOGLYCANS; GROUP-A STREPTOCOCCI; ADP REGULATORY SITE; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; CASSETTE MUTAGENESIS; SARCOSINE OXIDASE; CDNA CLONING	UDP-glucose dehydrogenase (UGDH) is the unique pathway enzyme furnishing in vertebrates UDP-glucuronate for numerous transferases. In this report, we have identified an NAD(+)-binding site within human UGDH by photoaffinity labeling with a specific probe, [P-32] nicotinamide 2-azidoadenosine dinucleotide (2N(3)NAD(+)), and cassette mutagenesis. For this work, we have chemically synthesized a 1509-base pair gene encoding human UGDH and expressed it in Escherichia coli as a soluble protein. Photolabel-containing peptides were generated by photolysis followed by tryptic digestion and isolated using the phosphopeptide isolation kit. Photolabeling of these peptides was effectively prevented by the presence of NAD(+) during photolysis, demonstrating a selectivity of the photoprobe for the NAD(+)-binding site. Amino acid sequencing and compositional analysis identified the NAD(+)-binding site of UGDH as the region containing the sequence ICCIGAXYVGGPT, corresponding to Ile-7 through Thr-19 of the amino acid sequence of human UGDH. The unidentified residue, X, can be designated as a photolabeled Gly-13 because the sequences including the glycine residue in question have a complete identity with those of other UGDH species known. The importance of Gly-13 residue in the binding of NAD(+) was further examined with a G13E mutant by cassette mutagenesis. The mutagenesis at Gly-13 had no effects on the expression or stability of the mutant. Enzyme activity of the G13E point mutant was not measurable under normal assay conditions, suggesting an important role for the Gly-13 residue. No incorporation of [P-32] 2N(3)NAD(+) was observed for the G13E mutant. These results indicate that Gly-13 plays an important role for efficient binding of NAD(+) to human UGDH.	Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea	University of Ulsan	Cho, SW (corresponding author), Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, 388-1 Poongnap Dong, Seoul 138736, South Korea.	swcho@amc.seoul.kr						AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; Benevolenskaya EV, 1998, MOL GEN GENET, V260, P131, DOI 10.1007/s004380050879; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bontemps Y, 2000, BIOCHEM BIOPH RES CO, V275, P981, DOI 10.1006/bbrc.2000.3389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell RE, 1997, J BIOL CHEM, V272, P3416, DOI 10.1074/jbc.272.6.3416; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Eschenbrenner M, 2001, BIOCHEMISTRY-US, V40, P5352, DOI 10.1021/bi010101p; FEINGOLD DS, 1981, TRENDS BIOCHEM SCI, V6, P103, DOI 10.1016/0968-0004(81)90038-4; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Figueroa JE, 1999, ATHEROSCLEROSIS, V143, P135, DOI 10.1016/S0021-9150(98)00292-5; FRANZEN JS, 1973, BIOCHEM BIOPH RES CO, V50, P517, DOI 10.1016/0006-291X(73)90870-X; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; GUNNERSEN D, 1992, P NATL ACAD SCI USA, V89, P11949, DOI 10.1073/pnas.89.24.11949; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Johansson H, 2002, BBA-GENE STRUCT EXPR, V1576, P53, DOI 10.1016/S0167-4781(02)00292-0; KARLINSKY JB, 1992, CIRC RES, V71, P782, DOI 10.1161/01.RES.71.4.782; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; Kleiger G, 2002, J MOL BIOL, V323, P69, DOI 10.1016/S0022-2836(02)00885-9; Lapointe J, 1999, ENDOCRINOLOGY, V140, P4486, DOI 10.1210/en.140.10.4486; Lee EY, 2001, J BIOL CHEM, V276, P47930, DOI 10.1074/jbc.M108918200; Lind T, 1999, GLYCOBIOLOGY, V9, P595, DOI 10.1093/glycob/9.6.595; MAK AS, 1978, ANAL BIOCHEM, V84, P432, DOI 10.1016/0003-2697(78)90061-1; Marcu O, 1999, CYTOGENET CELL GENET, V86, P244, DOI 10.1159/000015350; Nishiya Y, 1996, APPL ENVIRON MICROB, V62, P2405, DOI 10.1128/AEM.62.7.2405-2410.1996; OLCOTT M, 1994, BIOCHEMISTRY-US, V33, P11835; ORDMAN AB, 1977, J BIOL CHEM, V252, P1320; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RESCIGNO M, 1994, BIOCHEMISTRY-US, V33, P5721, DOI 10.1021/bi00185a008; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSSMANN MG, 1976, J MOL BIOL, V105, P75, DOI 10.1016/0022-2836(76)90195-9; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Shoemaker MT, 1996, BIOCONJUGATE CHEM, V7, P302, DOI 10.1021/bc960014n; Sommer BJ, 2004, J BIOL CHEM, V279, P23590, DOI 10.1074/jbc.M401928200; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Stewart DC, 1998, PLANT PHYSIOL, V116, P349, DOI 10.1104/pp.116.1.349; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tenhaken R, 1996, PLANT PHYSIOL, V112, P1127, DOI 10.1104/pp.112.3.1127; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Turner W, 2002, ARCH BIOCHEM BIOPHYS, V407, P209, DOI 10.1016/S0003-9861(02)00500-3; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Wegrowski Y, 1998, BIOCHEM BIOPH RES CO, V250, P206, DOI 10.1006/bbrc.1998.9262; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Yoon HY, 2002, BIOCHEMISTRY-US, V41, P6817, DOI 10.1021/bi0121757; Yoon HY, 2002, J BIOL CHEM, V277, P41448, DOI 10.1074/jbc.M208208200	60	13	13	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37491	37498		10.1074/jbc.M404234200	http://dx.doi.org/10.1074/jbc.M404234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247292	hybrid			2022-12-25	WOS:000223554600038
J	Nishinaka, Y; Masutani, H; Oka, S; Matsuo, Y; Yamaguchi, Y; Nishio, K; Ishii, Y; Yodoi, J				Nishinaka, Y; Masutani, H; Oka, S; Matsuo, Y; Yamaguchi, Y; Nishio, K; Ishii, Y; Yodoi, J			Importin alpha(1) (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D-3-up-regulated protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATED PROTEIN-1; OXIDATIVE STRESS; CELL-GROWTH; EXPRESSION; VDUP1; GENE; D-3; CANCER; IMPORT; SIGNAL	Thioredoxin-binding protein-2 (TBP-2)/vitamin D-3 upregulated protein 1 is an endogenous molecule interacting with thioredoxin (TRX), negatively regulating TRX function, and being implicated in the suppression of tumor development and metastasis. We found that TBP-2 ectopically expressed in the breast cancer cell line MCF-7 was localized predominantly in the nucleus exhibiting growth suppressive activity. The nuclear accumulation of endogenous TBP-2 protein was also demonstrated when the cells were treated with an anticancer drug, suberoylanilide hydroxamic acid. To investigate the mechanism underlying the nuclear localization, we performed a yeast two-hybrid screening and identified importin alpha(1) (Rch1) as a protein interacting with TBP-2. The physical interaction between TBP-2 and Rch1 was confirmed with a glutathione S-transferase pull-down assay. The interaction of TBP-2 was specific to Rch1 among other importin alpha subfamilies (Qip1 and NPI-1), and amino acids 1 - 227 of TBP-2 were sufficient for both the interaction with Rch1 and the nuclear localization, although there is no typical nuclear localization signal in this sequence. The expression of short interfering RNA of Rch1 suppressed suberoylanilide hydroxamic acid-induced nuclear accumulation of TBP-2. Collectively, our results strongly suggest that an interaction with importin system is required for TBP-2 nuclear translocation and growth control tightly associated with TRX-dependent redox regulation of transcription factors.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol AIST, Human Stress Signal Res Ctr, Biomed Special Res Unit, Osaka 5638577, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Yodoi, J (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Kawaharacho, Kyoto 6068507, Japan.	yodoi@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Matsuo, Yoshiyuki/0000-0002-3183-4871; Masutani, Hiroshi/0000-0001-7633-2827				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Goldberg SF, 2003, CANCER RES, V63, P432; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kogaki H, 1996, J CLIN LAB ANAL, V10, P257, DOI 10.1002/(SICI)1098-2825(1996)10:5<257::AID-JCLA5>3.3.CO;2-#; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Marelli M, 2001, BIOCHEM CELL BIOL, V79, P603; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Yamanaka H, 2000, BIOCHEM BIOPH RES CO, V271, P796, DOI 10.1006/bbrc.2000.2699; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	24	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37559	37565		10.1074/jbc.M405473200	http://dx.doi.org/10.1074/jbc.M405473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234975	hybrid			2022-12-25	WOS:000223554600047
J	Thompson, TB; Katayama, K; Watanabe, K; Hutchinson, CR; Rayment, I				Thompson, TB; Katayama, K; Watanabe, K; Hutchinson, CR; Rayment, I			Structural and functional analysis of tetracenomycin F2 cyclase from Streptomyces glaucescens - A type II polyketide cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; BETA-SHEET BARRELS; PROTEINS; BIOSYNTHESIS; EFFICIENT; MOLSCRIPT; SEQUENCE; SYNTHASE; SURFACE; SYSTEM	Tetracenomycin F2 cyclase ( tcmI gene product), catalyzes an aromatic rearrangement in the biosynthetic pathway for tetracenomycin C in Streptomyces glaucescens. The x-ray structure of this small enzyme has been determined to 1.9-Angstrom resolution together with an analysis of site-directed mutants of potential catalytic residues. The protein exhibits a dimeric betaalphabeta ferredoxin-like fold that utilizes strand swapping between subunits in its assembly. The fold is dominated by four strands of antiparallel sheet and a layer of alpha-helices, which creates a cavity that is proposed to be the active site. This type of secondary structural arrangement has been previously observed in polyketide monooxygenases and suggests an evolutionary relationship between enzymes that catalyze adjacent steps in these biosynthetic pathways. Mutational analysis of all of the obvious catalytic bases within the active site suggests that the enzyme functions to steer the chemical outcome of the cyclization rather than providing a specific catalytic group. Together, the structure and functional analysis provide insight into the structural framework necessary to perform the complex rearrangements catalyzed by this class of polyketide cyclases.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Sapporo, Hokkaido 0608589, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hokkaido University	Hutchinson, CR (corresponding author), Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA.	hutchinson@kosan.com; Ivan_Rayment@biochem.wisc.edu	rayment, ivan/A-2720-2008; Watanabe, Kenji/N-2012-2015	rayment, ivan/0000-0001-9279-7835; Watanabe, Kenji/0000-0002-0463-4831; Thompson, Thomas/0000-0002-7041-5047	NIAMS NIH HHS [AR35186] Funding Source: Medline; NIGMS NIH HHS [GM08293] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; OHagan D., 1991, POLYKETIDE METABOLIT; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan H, 2002, STRUCTURE, V10, P1559, DOI 10.1016/S0969-2126(02)00889-4; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rayment I, 2002, STRUCTURE, V10, P147, DOI 10.1016/S0969-2126(02)00711-6; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; SHEN B, 1993, J NAT PROD, V56, P1288, DOI 10.1021/np50098a013; SHEN B, 1993, BIOCHEMISTRY-US, V32, P11149, DOI 10.1021/bi00092a026; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Studts JM, 1999, PROTEIN EXPRES PURIF, V16, P109, DOI 10.1006/prep.1999.1067; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4	33	46	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37956	37963		10.1074/jbc.M406144200	http://dx.doi.org/10.1074/jbc.M406144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231835	hybrid			2022-12-25	WOS:000223554600089
J	Imai, K; Nishiwaki, T; Kondo, T; Iwasaki, H				Imai, K; Nishiwaki, T; Kondo, T; Iwasaki, H			Circadian rhythms in the synthesis and degradation of a master clock protein KaiC in cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-ELONGATUS; EXPRESSION; PHOSPHORYLATION; MECHANISM; SYSTEM	A circadian rhythm in the accumulation of the core clock protein KaiC has been proposed to be important for proper circadian timing in the cyanobacterium Synechococcus elongatus PCC 7942 under continuous light conditions. Cycling in the abundance of the KaiC protein is delayed to the rhythm of its mRNA by similar to8 h, consistent with the proposed function of KaiC as a negative feedback regulator of kaiBC transcription. Here, we present temporal profiles of the synthesis and degradation of KaiC protein that determine the rhythm of its accumulation. The rate of KaiC synthesis shows a robust circadian oscillation, which is delayed to the mRNA rhythm slightly and advances the rhythm of KaiC accumulation by similar to6 h. The stability of KaiC protein also shows circadian fluctuations, such that KaiC degradation is suppressed during the mid-subjective night. These results suggest that transcriptional, translational, and posttranslational processes are important for the proper circadian changes in KaiC accumulation. Moreover, the turnovers of the phosphorylated and non-phosphorylated forms of KaiC show robust circadian rhythms with an anti-phase relationship to each other. Interestingly, when translation was inhibited, KaiC degradation and phosphorylation proceeded within at least 4 h in a circadian phase-dependent manner. Thus, the circadian timing seems flexible even when any perturbation in protein synthesis occurs.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; JST, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Iwasaki, H (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	iwasaki@bio.nagoya-u.ac.jp		Iwasaki, Hideo/0000-0002-3754-4955				CHEN TH, 1991, PLANT PHYSIOL, V97, P55, DOI 10.1104/pp.97.1.55; Ditty JL, 2003, ANNU REV GENET, V37, P513, DOI 10.1146/annurev.genet.37.110801.142716; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2000, PLANT CELL PHYSIOL, V41, P1013, DOI 10.1093/pcp/pcd024; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Nakahira Y, 2004, P NATL ACAD SCI USA, V101, P881, DOI 10.1073/pnas.0307411100; Nishimura H, 2002, MICROBIOL-SGM, V148, P2903, DOI 10.1099/00221287-148-9-2903; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2000, EMBO J, V19, P3349, DOI 10.1093/emboj/19.13.3349; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	23	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36534	36539		10.1074/jbc.M405861200	http://dx.doi.org/10.1074/jbc.M405861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15229218	hybrid			2022-12-25	WOS:000223453600048
J	Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A				Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A			Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas	ONCOGENE			English	Article						hepatoblastoma; expression profile; oligocapping cDNA library; PLK1; prognostic factor	POLO-LIKE-KINASE; ALPHA-FETOPROTEIN LEVELS; BETA-CATENIN GENE; HEPATOCELLULAR-CARCINOMA; APC GENE; METASTATIC HEPATOBLASTOMA; CHILDHOOD HEPATOBLASTOMA; CANCER; MUTATIONS; TUMOR	Hepatoblastoma is one of the most common malignant liver tumors in young children. Recent evidences have suggested that the abnormalities in Wnt signaling pathway, as seen in frequent mutation of the beta-catenin gene, may play a role in the genesis of hepatoblastoma. However, the precise mechanism to cause the tumor has been elusive. To identify novel hepatoblastoma-related genes for unveiling the molecular mechanism of the tumorigenesis, a large-scale cloning of cDNAs and differential screening of their expression between hepatoblastomas and the corresponding normal livers were performed. We constructed four full-length-enriched cDNA libraries using an oligo-capping method from the primary tissues which included two hepatoblastomas with high levels of alpha-fetoprotein (AFP), a hepatoblastoma without production of AFP, and a normal liver tissue corresponded to the tumor. Among the 10431 cDNAs randomly picked up and successfully sequenced, 847 (8.1%) were the genes with unknown function. Of interest, the expression profile among the two subsets of hepatoblastoma and a normal liver was extremely different. A semiquantitative RT-PCR analysis showed that 86 out of 1188 genes tested were differentially expressed between hepatoblastomas and the corresponding normal livers, but that only 11 of those were expressed at high levels in the tumors. Notably, PLK1 oncogene was expressed at very high levels in hepatoblastomas as compared to the normal infant's livers. Quantitative real-time RT-PCR analysis for the PLK1 mRNA levels in 74 primary hepatoblastomas and 29 corresponding nontumorous livers indicated that the patients with hepatoblastoma with high expression of PLK1 represented significantly poorer outcome than those with its low expression (5-year survival rate: 55.9 vs 87.0%, respectively, p = 0.042), suggesting that the level of PLK1 expression is a novel marker to predict the prognosis of hepatoblastoma. Thus, the differentially expressed genes we have identified may become a useful tool to develop new diagnostic as well as therapeutic strategies of hepatoblastoma.	Chiba Cancer Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo 1006221, Japan	Chiba Cancer Center; University of Tokyo; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Cancer Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp	Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALBRECHT S, 1994, CANCER RES, V54, P5041; BRADY RO, 1989, NEUROL CLIN, V7, P75, DOI 10.1016/S0733-8619(18)30829-6; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gray SG, 2000, BRIT J CANCER, V82, P1561, DOI 10.1054/bjoc.1999.1179; HAAS JE, 1989, CANCER-AM CANCER SOC, V64, P1082, DOI 10.1002/1097-0142(19890901)64:5<1082::AID-CNCR2820640520>3.0.CO;2-G; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HATA Y, 1990, JPN J SURG, V20, P498, DOI 10.1007/BF02471004; HATA Y, 1991, CANCER, V68, P2566, DOI 10.1002/1097-0142(19911215)68:12<2566::AID-CNCR2820681206>3.0.CO;2-Z; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; Kinoshita M, 2002, HEPATOLOGY, V36, P433, DOI 10.1053/jhep.2002.34851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knecht R, 1999, CANCER RES, V59, P2794; Koch A, 1999, CANCER RES, V59, P269; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P2475, DOI 10.1001/jama.257.18.2475; LI XR, 1995, ONCOGENE, V11, P221; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MANN JR, 1978, ARCH DIS CHILD, V53, P366, DOI 10.1136/adc.53.5.366; Miao JY, 2003, HEPATOL RES, V25, P174, DOI 10.1016/S1386-6346(02)00264-4; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagata T, 2003, CANCER GENET CYTOGEN, V145, P152, DOI 10.1016/S0165-4608(03)00065-7; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; ODA H, 1995, INT J CANCER, V60, P786, DOI 10.1002/ijc.2910600610; Oda H, 1996, CANCER RES, V56, P3320; Okabe H, 2001, CANCER RES, V61, P2129; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; ORTEGA JA, 1991, J CLIN ONCOL, V9, P2167, DOI 10.1200/JCO.1991.9.12.2167; Park WS, 2001, J PATHOL, V193, P483; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; RAINIER S, 1995, CANCER RES, V55, P1836; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Sasaki F, 2002, J PEDIATR SURG, V37, P851, DOI 10.1053/jpsu.2002.32886; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thomas D, 2003, EUR J CANCER, V39, P2200, DOI 10.1016/S0959-8049(03)00618-X; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uotani H, 1998, J PEDIATR SURG, V33, P639, DOI 10.1016/S0022-3468(98)90333-5; VanTornout J, 1997, J CLIN ONCOL, V15, P1190, DOI 10.1200/JCO.1997.15.3.1190; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; von Horn H, 2001, CANCER LETT, V162, P253, DOI 10.1016/S0304-3835(00)00668-6; VONSCHWEINITZ D, 1995, J PEDIATR SURG, V30, P845, DOI 10.1016/0022-3468(95)90762-9; VONSCHWEINITZ D, 1994, EUR J CANCER, V30, P152; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yun K, 1998, J PATHOL, V185, P91, DOI 10.1002/(SICI)1096-9896(199805)185:1<91::AID-PATH44>3.0.CO;2-K	72	102	136	4	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5901	5911		10.1038/sj.onc.1207782	http://dx.doi.org/10.1038/sj.onc.1207782			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15221005				2022-12-25	WOS:000222941100004
J	Weinreb, O; Bar-Am, O; Amit, T; Chillag-Talmor, O; Youdim, MBH				Weinreb, O; Bar-Am, O; Amit, T; Chillag-Talmor, O; Youdim, MBH			Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members	FASEB JOURNAL			English	Article						survival genes and proteins; neurotrophic factors; rasagiline; propargylamine; Parkinson's disease	ANTI-PARKINSON DRUG; NEUROTROPHIC FACTOR; CELL-DEATH; DOPAMINERGIC-NEURONS; OXIDATIVE STRESS; GENE-EXPRESSION; MAP KINASE; RASAGILINE; APOPTOSIS; INHIBITOR	This study provides new insights into neuroprotection involving interaction of protein kinase C (PKC) pathway with Bcl-2 family proteins. Using a model of serum deprivation, we investigated the mechanism by which the anti-Parkinson/monoamine oxidase (MAO)-B inhibitor drug, rasagiline, exerts its neuroprotective effect in rat pheochromocytoma PC12 cells. Here, we report that rasagiline (0.1 - 10 muM) decreased apoptosis via multiple protection mechanisms, including the stimulation of PKC phosphorylation; up-regulation of PKCalpha and PKCepsilon mRNAs, induction of Bcl-xL, Bcl-w, and brain-derived neurotrophic factor (BDNF) mRNAs; and down-regulation of Bad and Bax mRNAs. Moreover, rasagiline inhibited the cleavage and activation of procaspase-3 and poly (ADP-ribose) polymerase (PARP), whereas the PKC inhibitor, GF109203X, reversed these actions. Similarly, rasagiline decreased serum-free-induced levels of the important regulator of cell death, Bad, which was also blocked by GF109203X, indicating the involvement of PKC in rasagiline-induced cell survival. Furthermore, these studies have established that PKC- and Bcl-2-dependent neuroprotective activity of rasagiline is dependent on its propargyl moiety, because propargylamine had similar effects with the same potency.	Technion Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Fac Med, Rappaport Family Res Inst, IL-31096 Haifa, Israel; Technion Fac Med, Eve Topf & USA Natl PArkinson Fdn Ctr Excellence, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Durkin JP, 1997, J NEUROCHEM, V68, P1400; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finberg JPM, 1998, NEUROREPORT, V9, P703; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; Hsieh YC, 2003, SHOCK, V19, P582, DOI 10.1097/01.shk.0000065705.84144.ed; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Katsura K, 2003, NEUROL RES, V25, P522, DOI 10.1179/016164103101201760; Kochman A, 2003, POL J PHARMACOL, V55, P389; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Maroto R, 1997, J NEUROCHEM, V69, P514; Maruyama W, 2004, NEUROCHEM INT, V44, P393, DOI 10.1016/j.neuint.2003.08.005; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Middleton G, 2001, DEVELOPMENT, V128, P447; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sagi Y., 2003, Neural Plasticity, V10, P227; SAGI Y, 2001, NEURAL PLAST, V8, P197; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Selvatici R, 2003, J NEUROSCI RES, V71, P64, DOI 10.1002/jnr.10464; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Weinreb O, 2003, FASEB J, V17, P935, DOI 10.1096/fj.02-0712fje; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; Youdim Moussa Bh, 2003, Expert Rev Neurother, V3, P737, DOI 10.1586/14737175.3.6.737; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	51	157	168	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1471	+		10.1096/fj.04-1916fje	http://dx.doi.org/10.1096/fj.04-1916fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247150				2022-12-25	WOS:000222979200002
J	Nyborg, AC; Jansen, K; Ladd, TB; Fauq, A; Golde, TE				Nyborg, AC; Jansen, K; Ladd, TB; Fauq, A; Golde, TE			A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE INHIBITOR; YOUNG PLAQUE-FREE; A-BETA LEVELS; INTRAMEMBRANE PROTEOLYSIS; CEREBROSPINAL-FLUID; IN-VIVO; NICASTRIN; COMPLEX; APP; IDENTIFICATION	Signal peptide peptidase (SPP) is an intramembrane-cleaving protease identified by its cleavage of several type II membrane signal peptides after signal peptidase cleavage. Here we describe a novel, quantitative, cell-based SPP reporter assay. This assay utilizes a substrate consisting of the NH2 terminus of the ATF6 transcription factor fused to a transmembrane domain susceptible to SPP cleavage in vitro. In cells, cleavage of the substrate releases ATF6 from the membrane. This cleavage can be monitored by detection of an epitope that is unmasked in the cleaved substrate or by luciferase activity induced by the cleaved ATF6 substrate binding to and activating an ATF6 luciferase reporter construct. Using this assay we show that (i) SPP is the first aspartyl intramembrane-cleaving protease whose activity increases proportionally to its overexpression and (ii) selectivity of various SPP and gamma-secretase inhibitors can be rapidly evaluated. Because this assay was designed based on data suggesting that SPP has an orientation distinct from presenilin and cleaves type II membrane proteins, we determined whether the segment of SPP located between the two presumptive catalytic aspartates was in the lumen or cytoplasm. Using site-directed mutagenesis to insert an N-linked glycosylation site we show that a portion of this region is present in the lumen. These data provide strong evidence that although the SPP and presenilin active sites have some similarities, their presumptive catalytic domains are inverted. This assay should prove useful for additional functional studies of SPP as well as evaluation of SPP and gamma-secretase inhibitors.	Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic	Golde, TE (corresponding author), Mayo Clin, Coll Med, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039072, F32NS044734] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39072, NS44734] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; DOVEY H, 2000, J NEUROCHEM, V76, P1; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GELLER AI, 1991, J NEUROSCI METH, V36, P91, DOI 10.1016/0165-0270(91)90142-M; Golde TE, 2001, TRENDS MOL MED, V7, P264, DOI 10.1016/S1471-4914(01)02064-0; GOLDE TE, 2003, SCI STKE; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Hebert SS, 2003, BIOCHEM BIOPH RES CO, V301, P119, DOI 10.1016/S0006-291X(02)02984-4; KARRE K, 1991, IMMUNOL TODAY, V12, P343, DOI 10.1016/0167-5699(91)90062-X; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Marlow L, 2003, BIOCHEM BIOPH RES CO, V305, P502, DOI 10.1016/S0006-291X(03)00797-6; Martoglio B, 2003, BIOCHEM SOC T, V31, P1243; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Murphy MP, 2003, FASEB J, V17, P1138, DOI 10.1096/fj.02-1050fje; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Urny J, 2003, GENE EXPR PATTERNS, V3, P685, DOI 10.1016/S1567-133X(03)00094-2; Wang Y, 2000, J BIOL CHEM, V275, P27013; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	36	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43148	43156		10.1074/jbc.M405879200	http://dx.doi.org/10.1074/jbc.M405879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15252014	hybrid			2022-12-25	WOS:000224226400099
J	Park, EI; Baenziger, JU				Park, EI; Baenziger, JU			Closely related mammals have distinct asialoglycoprotein receptor carbohydrate specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; STRUCTURAL-ANALYSIS; RECOGNITION DOMAINS; MICE LACKING; SUBUNIT; LIVER; OLIGOSACCHARIDE; GLYCOPROTEINS; CIRCULATION; CLEARANCE	We recently reported that the rat asialoglycoprotein receptor binds oligosaccharides terminating with sialic acid (Sia) alpha2,6GalNAc. Despite a high percentage of identical amino acids in their sequences, orthologues of the asialoglycoprotein receptor (ASGP-R) in different mammals differ in their specificity for terminal Siaalpha2,6GalNAc. The recombinant subunit 1 of the ASGP-R from the rat (RHL-1 or rat hepatic lectin) and the mouse (MHL-1 or mouse hepatic lectin), which differ at only 12 positions in the amino acid sequence of their carbohydrate recognition domains, binds Siaalpha2,6GalNAcbeta1,4GlcNAcbeta1,2Man-bovine serum albumin and GalNAcbeta1,4GlcNAcbeta1,2Man-bovine serum albumin in ratios of 16:1.0 and 1.0:1.0, respectively. Mutagenesis was used to show that amino acids both in the immediate vicinity of the proposed binding site for terminal GalNAc and on the alpha2 helix that is distant from the binding site contribute to the specificity for terminal Siaalpha2,6GalNAc. Thus, multiple amino acid sequence alterations in two key locations contribute to the difference in specificity observed for the rat and mouse ASGP-Rs. We hypothesize that the altered specificity of ASPG-R orthologues in such evolutionarily closely related species reflects rapidly changing requirements for recognition of endogenous or exogenous oligosaccharides in vivo.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	Baenziger@pathology.wustl.edu	Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA21923] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Braun JR, 1996, J BIOL CHEM, V271, P21160, DOI 10.1074/jbc.271.35.21160; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; Manzella SM, 1997, J BIOL CHEM, V272, P4775, DOI 10.1074/jbc.272.8.4775; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; MORELL AG, 1971, J BIOL CHEM, V246, P1461; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Park EI, 2003, J BIOL CHEM, V278, P4597, DOI 10.1074/jbc.M210612200; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; VANDENHA.CJ, 1970, J BIOL CHEM, V245, P4397; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597	23	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40954	40959		10.1074/jbc.M406647200	http://dx.doi.org/10.1074/jbc.M406647200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262963	hybrid			2022-12-25	WOS:000223916800092
J	Miyadai, H; Tanaka-Masuda, K; Matsuayama, S; Tokuda, H				Miyadai, H; Tanaka-Masuda, K; Matsuayama, S; Tokuda, H			Effects of lipoprotein overproduction on the induction of DegP (HtrA) involved in quality control in the Escherichia coli periplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; SIGNAL-TRANSDUCTION PATHWAY; ENVELOPE STRESS-RESPONSE; INNER MEMBRANE; CYTOPLASMIC MEMBRANE; 2-COMPONENT SYSTEM; SORTING SIGNALS; CELL-ENVELOPE; LOCALIZATION; PROTEIN	Recent biochemical examination has revealed the presence of at least 90 different lipoproteins in Escherichia coli. Among previously identified lipoproteins, only an outer membrane lipoprotein, NlpE, is known to induce expression of the degP gene upon its overproduction. The degP gene encodes a periplasmic protease, which is thought to be involved in the digestion of unfolded proteins, and is essential for growth at high temperatures. However, it is not completely clear why NlpE overproduction causes degP expression. Moreover, among newly confirmed lipoproteins, there may be others that also induce degP expression. Therefore, we overproduced each of the 90 lipoproteins and examined the level of degP expression as beta-galactosidase activity by using a degP promoter-lacZ fusion. The extent of degP expression caused by NlpE overproduction was dependent on the mode of degP-lacZ fusion. On the other hand, new inner membrane lipoprotein YafY strongly induced degP expression irrespective of the mode of fusion even though the level of overproduced YafY was lower than that of NlpE. The induction of degP expression by YafY overproduction was dependent on the Cpx two-component system. Alteration of the lipoprotein-sorting signals of NlpE and YafY did not abolish the degP induction. However, a YafY derivative possessing the outer membrane signal remained on inner membranes. The non-lipidated derivative of NlpE did not induce degP expression, indicating that membrane anchoring is essential for degP induction. The amino acid sequences of YafY and YfjS, another inner membrane lipoprotein, are highly identical, but overproduction of the latter did not induce degP expression. Construction of various YafY-YfjS chimeric lipoproteins revealed that only a few residues located in the N- and C-terminal regions were important for the induction of DegP.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp						Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; DiGiuseppe PA, 2003, J BACTERIOL, V185, P2432, DOI 10.1128/JB.185.8.2432-2440.2003; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miller JH., 1972, EXPT MOL GENETICS; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Otto K, 2002, P NATL ACAD SCI USA, V99, P2287, DOI 10.1073/pnas.042521699; Pan KL, 2003, J BACTERIOL, V185, P3020, DOI 10.1128/JB.185.10.3020-3030.2003; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; Robichon C, 2003, MOL MICROBIOL, V49, P1145, DOI 10.1046/j.1365-2958.2003.03654.x; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SCHNEIDER K, 1986, GENE, V42, P37, DOI 10.1016/0378-1119(86)90148-4; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	32	52	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39807	39813		10.1074/jbc.M406390200	http://dx.doi.org/10.1074/jbc.M406390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252048	hybrid			2022-12-25	WOS:000223791500075
J	Greenwood, IA; Ledoux, J; Sanguinetti, A; Perrino, BA; Leblanc, N				Greenwood, IA; Ledoux, J; Sanguinetti, A; Perrino, BA; Leblanc, N			Calcineurin A alpha but not A beta augments I-Cl(Ca) in rabbit pulmonary artery smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CURRENT; PORTAL-VEIN; PHOSPHATASE-ACTIVITY; PROTEIN PHOSPHATASE; CATALYTIC SUBUNIT; DEFICIENT MICE; CL-CURRENTS; CHANNELS; CALMODULIN; MYOCYTES	Activation of Ca2+-dependent Cl- currents (I-Cl(Ca)) increases membrane excitability in vascular smooth muscle cells. Previous studies showed that Ca2+-dependent phosphorylation suppresses I-Cl(Ca) in pulmonary artery myocytes, and the aim of the present study was to determine the role of the Ca2+-dependent phosphatase calcineurin on chloride channel activity. Immunocytochemical and Western blot studies with isoform-specific antibodies revealed that the alpha and beta forms of the CaN catalytic subunit are expressed in PA cells but that only the alpha variant translocated to the cell periphery upon a rise in intracellular [Ca2+]. I-Cl(Ca) evoked by pipette solutions containing a [Ca2+] set at 500 nM was considerably larger when the pipette solution included constitutively active CaN containing the alpha catalytic isoform. This stimulatory effect was lost by boiling the enzyme or by the inclusion of a specific CaN inhibitory peptide and was not shared by the inclusion of the beta form of the catalytic subunit. In the absence of constitutively active CaN, cyclosporin A, an inhibitor of CaN, suppressed I-Cl(Ca) evoked by 500 nM Ca2+ when the current amplitude was relatively large but was ineffective in cells with smaller currents. In perforated patch recordings, cyclosporin A consistently inhibited I-Cl(Ca) evoked as a consequence of Ca2+ influx through voltage-dependent calcium channels. These novel data show that in PA myocytes activation of I-Cl(Ca) is enhanced by Ca2+-dependent dephosphorylation and that the regulation of this conductance is highly isoform-specific.	Univ Nevada, Sch Med, Dept Pharmacol, COBRE, Reno, NV 89557 USA; Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA; St George Hosp, Sch Med, Dept Basic Med Sci Pharmacol & Clin Pharmacol, London SW17 0RE, England	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; St Georges University London	Leblanc, N (corresponding author), Univ Nevada, Sch Med, Dept Pharmacol, COBRE, Mail Stop 318, Reno, NV 89557 USA.	NLeblanc@med.unr.edu	Ledoux, Jonathan/D-2945-2012	Ledoux, Jonathan/0000-0001-8540-7763; Greenwood, Iain/0000-0002-0603-0492; Leblanc, Normand/0000-0002-1090-9432	NCRR NIH HHS [5 P20 RR15581] Funding Source: Medline; NIDDK NIH HHS [DK-57168] Funding Source: Medline; NINDS NIH HHS [NS-36318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036318] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham ST, 1996, J BIOL CHEM, V271, P2506, DOI 10.1074/jbc.271.5.2506; AKBARALI HI, 1993, J PHYSIOL-LONDON, V460, P117, DOI 10.1113/jphysiol.1993.sp019462; Amberg GC, 2001, AM J PHYSIOL-CELL PH, V281, pC2020, DOI 10.1152/ajpcell.2001.281.6.C2020; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; Britton FC, 2002, J PHYSIOL-LONDON, V539, P107, DOI 10.1113/jphysiol.2001.013170; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chipperfield AR, 2000, PROG BIOPHYS MOL BIO, V74, P175, DOI 10.1016/S0079-6107(00)00024-9; Greenwood IA, 1996, PFLUG ARCH EUR J PHY, V432, P970, DOI 10.1007/s004240050224; Greenwood IA, 2001, J PHYSIOL-LONDON, V534, P395, DOI 10.1111/j.1469-7793.2001.00395.x; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; LAMB FS, 1994, CIRC RES, V75, P742, DOI 10.1161/01.RES.75.4.742; Large WA, 2002, CURR TOP MEMBR, V53, P99, DOI 10.1016/S1063-5823(02)53030-1; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Ledoux J, 2003, J PHYSIOL-LONDON, V552, P701, DOI 10.1113/jphysiol.2003.043836; PACAUD P, 1992, PFLUG ARCH EUR J PHY, V421, P125, DOI 10.1007/BF00374818; Perrino BA, 2002, EUR J BIOCHEM, V269, P3540, DOI 10.1046/j.1432-1033.2002.03040.x; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; Piper AS, 2003, BRIT J PHARMACOL, V138, P31, DOI 10.1038/sj.bjp.0705000; PIPER AS, 2002, J PHYSL, V593, P117; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Wilson AJ, 2000, CIRC RES, V87, P1019, DOI 10.1161/01.RES.87.11.1019; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	29	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38830	38837		10.1074/jbc.M406234200	http://dx.doi.org/10.1074/jbc.M406234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247251	hybrid			2022-12-25	WOS:000223684100095
J	Le Boeuf, F; Houle, F; Huot, J				Le Boeuf, F; Houle, F; Huot, J			Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGF-INDUCED ACTIVATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; AKT KINASE; INTEGRIN; CELLS; HSP90; GELDANAMYCIN	Exposure of endothelial cells to vascular endothelial growth factor (VEGF) induced tyrosine phosphorylation of focal adhesion kinase (FAK) on site Tyr(407), an effect that required the association of VEGF receptor 2 (VEGFR2) with HSP90. The association of VEGFR2 with HSP90 involved the last 130 amino acids of VEGFR2 and was blocked by geldanamycin, a specific inhibitor of HSP90. Moreover, geldanamycin inhibited the VEGF-induced activation of the small GTPase RhoA, which resulted in an inhibition of phosphorylation of FAK on site Tyr(407). In this context, the inhibition of RhoA kinase (ROCK) with Y27632 or by expression of dominant negative forms of RhoA or ROCK impaired the VEGF-induced phosphorylation of Tyr(407) within FAK. In contrast to phosphorylation of Tyr(861), the phosphorylation of site Tyr(407) was insensitive to Src kinase inhibition by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine (PP2). We also found that the recruitment of paxillin to FAK was inhibited by geldanamycin but not by PP2, whereas both geldanamycin and PP2 inhibited the recruitment of vinculin to FAK. In accordance, the recruitment of paxillin and vinculin to FAK was inhibited in cells that express the mutant FAK-Y407F, whereas the expression of the mutant Y861F inhibited the recruitment of paxillin but not of vinculin. Importantly, cell migration was abolished in cells in which the signal from the VEGFR2-HSP90 pathway was blocked by the expression of Delta130VEGFR2, a deletant of VEGFR2 that does not associate with HSP90. Our findings underscore for the first time the key role played by the VEGFR2-HSP90-RhoA-ROCK-FAK/Tyr(407) pathway in transducing the VEGF signal that leads to the assembly of focal adhesions and endothelial cell migration.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Huot, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bohnsack BL, 2003, CIRC RES, V92, P255, DOI 10.1161/01.RES.0000059260.91342.6E; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chaudhary A, 2002, BIOCHEM BIOPH RES CO, V294, P293, DOI 10.1016/S0006-291X(02)00475-8; Chavany C, 1996, J BIOL CHEM, V271, P4974; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Cornillon J, 2003, M S-MED SCI, V19, P743, DOI 10.1051/medsci/20031967743; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; LeCouter J, 2002, NAT MED, V8, P913, DOI 10.1038/nm0902-913; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; MATSUMOTO T, 2001, SCI STKE; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Morano KA, 1999, EMBO J, V18, P5953, DOI 10.1093/emboj/18.21.5953; Nollen EAA, 2002, J CELL SCI, V115, P2809; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; Pai KS, 2002, J NEUROCHEM, V80, P715, DOI 10.1046/j.0022-3042.2001.00761.x; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Petitclerc E, 1999, CANCER RES, V59, P2724; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Qi JH, 2001, EXP CELL RES, V263, P173, DOI 10.1006/excr.2000.5102; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shi Q, 2003, MOL BIOL CELL, V14, P4306, DOI 10.1091/mbc.E03-01-0046; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Solit DB, 2003, CANCER RES, V63, P2139; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Turner CE, 2000, J CELL SCI, V113, P4139; Xu WP, 2002, CELL STRESS CHAPERON, V7, P91, DOI 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	55	109	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39175	39185		10.1074/jbc.M405493200	http://dx.doi.org/10.1074/jbc.M405493200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247219	hybrid			2022-12-25	WOS:000223684100134
J	Orton, KC; Ling, J; Waskiewicz, AJ; Cooper, JA; Merrick, WC; Korneeva, NL; Rhoads, RE; Sonenberg, N; Traugh, JA				Orton, KC; Ling, J; Waskiewicz, AJ; Cooper, JA; Merrick, WC; Korneeva, NL; Rhoads, RE; Sonenberg, N; Traugh, JA			Phosphorylation of Mnk1 by caspase-activated pak2/gamma-PAK inhibits phosphorylation and interaction of eIF4G with Mnk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MULTIPOTENTIAL S6 KINASE; ELONGATION-FACTOR 1; PROTEIN-KINASE; TRANSLATION INITIATION; INSULIN STIMULATION; PHORBOL ESTERS; GAMMA-PAK; CLEAVAGE; EIF-4F	The mitogen-activated protein kinase-interacting kinase 1 (Mnk1) is phosphorylated by caspase-cleaved protein kinase Pak2/gamma-PAK but not by Cdc42-activated Pak2. Phosphorylation of Mnk1 is rapid, reaching 1 mol/ mol within 15 min of incubation with Pak2. A kinetic analysis of the phosphorylation of Mnk1 by Pak2 yields a K-m of 0.6 muM and a V-max of 14.9 pmol of P-32/min/mug of Pak2. Two-dimensional tryptic phosphopeptide mapping of Mnk1 phosphorylated by Pak2 yields two distinct phosphopeptides. Analysis of the phosphopeptides by automated microsequencing and manual Edman degradation identified the sites in Mnk1 as Thr(22) and Ser(27). Mnk1, activated by phosphorylation with Erk2, phosphorylates the eukaryotic initiation factor (eIF) 4E and the eIF4G components of eIF4F. Phosphorylation of Mnk1 by Pak2 does not activate Mnk1, as measured with either eIF4E or eIF4F as substrate. Phosphorylation of Erk2-activated Mnk1 by Pak2 has no effect on phosphorylation of eIF4E but reduces phosphorylation of eIF4G by Mnk1 by up to 50%. Phosphorylation of Mnk1 by Pak2 inhibits binding of eIF4G peptides containing the Mnk1 binding site by up to 80%. When 293T cells are subjected to apoptotic induction by hydrogen peroxide, Mnk1 is phosphorylated at both Thr(22) and Ser(27). These results indicate a role for Pak2 in the down-regulation of translation initiation in apoptosis by phosphorylation of Mnk1.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	University of California System; University of California Riverside; Fred Hutchinson Cancer Center; Case Western Reserve University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; McGill University	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu	Waskiewicz, Andrew/A-3769-2014		NCI NIH HHS [CA73879] Funding Source: Medline; NIGMS NIH HHS [GM20818, GM26738, GM26796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738, R01GM026796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Chang YWE, 1998, EUR J BIOCHEM, V251, P201, DOI 10.1046/j.1432-1327.1998.2510201.x; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; Huang ZD, 2003, J BIOL CHEM, V278, P13101, DOI 10.1074/jbc.M212557200; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MORLEY SJ, 2001, PROG MOL SUBCELL BIO, V127, P599; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1998, J IMMUNOL, V160, P7; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	53	26	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38649	38657		10.1074/jbc.M407337200	http://dx.doi.org/10.1074/jbc.M407337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234964	hybrid, Green Published			2022-12-25	WOS:000223684100073
J	Poirot, O; Vukicevic, M; Boesch, A; Kellenberger, S				Poirot, O; Vukicevic, M; Boesch, A; Kellenberger, S			Selective regulation of acid-sensing ion channel 1 by serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; EPITHELIAL SODIUM-CHANNELS; NA+ CHANNEL; HIPPOCAMPAL-NEURONS; SENSORY NEURONS; XENOPUS-OOCYTES; NERVOUS-SYSTEM; BRAIN NEURONS; H+; MODULATION	Acid-sensing ion channels (ASICs) are neuronal Na+ channels that belong to the epithelial Na+ channel/degenerin family. ASICs are transiently activated by a rapid drop in extracellular pH. Conditions of low extracellular pH, such as ischemia and inflammation in which ASICs are thought to be active, are accompanied by increased protease activity. We show here that serine proteases modulate the function of ASIC1a and ASIC1b but not of ASIC2a and ASIC3. We show that protease exposure shifts the pH dependence of ASIC1a activation and steady-state inactivation to more acidic pH. As a consequence, protease exposure leads to a decrease in current response if ASIC1a is activated by a pH drop from pH 7.4. If, however, acidification occurs from a basal pH of similar to7, protease-exposed ASIC1a shows higher activity than untreated ASIC1a. We provide evidence that this bi-directional regulation of ASIC1a function also occurs in neurons. Thus, we have identified a mechanism that modulates ASIC function and may allow ASIC1a to adapt its gating to situations of persistent extracellular acidification.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Kellenberger, S (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Stephan.Kellenberger@ipharm.unil.ch		Kellenberger, Stephan/0000-0003-1755-6198; Boesch, Anne/0000-0003-3376-3111				Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Bolshakov KV, 2002, NEUROSCIENCE, V110, P723, DOI 10.1016/S0306-4522(01)00582-6; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; DICKENSON AH, 1987, BRAIN RES, V408, P185, DOI 10.1016/0006-8993(87)90370-2; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Holt JC, 2001, HEARING RES, V152, P25, DOI 10.1016/S0378-5955(00)00225-2; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; LEWIS SA, 1991, J MEMBRANE BIOL, V122, P77, DOI 10.1007/BF01872741; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109; Shubayev VI, 2002, J PERIPHER NERV SYST, V7, P28, DOI 10.1046/j.1529-8027.2002.02003.x; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; VUKICEVIC M, 2004, AM J PHYSIOL-CELL PH, P2004; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xie JH, 2003, J NEUROPHYSIOL, V89, P2459, DOI 10.1152/jn.00707.2002; Yamanaka H, 2004, EUR J NEUROSCI, V19, P93, DOI 10.1046/j.1460-9568.2003.03080.x; Yousef GM, 2003, CLIN CHIM ACTA, V329, P1, DOI 10.1016/S0009-8981(03)00004-4	52	49	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38448	38457		10.1074/jbc.M407381200	http://dx.doi.org/10.1074/jbc.M407381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247234	hybrid			2022-12-25	WOS:000223684100048
J	Li, YF; Dudek, J; Guiard, B; Pfanner, N; Rehling, P; Voos, W				Li, YF; Dudek, J; Guiard, B; Pfanner, N; Rehling, P; Voos, W			The presequence translocase-associated protein import motor of mitochondria - Pam16 functions in an antagonistic manner to Pam18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE; J-DOMAIN; MOLECULAR CHAPERONES; HSP70; COCHAPERONE; TIM23; COOPERATION; MECHANISMS; SEPARATION; CYCLE	Transport of preproteins into the mitochondrial matrix requires the presequence translocase of the inner membrane (TIM23 complex) and the presequence translocase-associated motor (PAM). The motor consists of five essential subunits, the mitochondrial heat shock protein 70 (mtHsp70) and four cochaperones, the nucleotide exchange-factor Mge1, the translocase-associated fulcrum Tim44, the J-protein Pam18, and Pam16. Pam16 forms a complex with Pam18 and displays similarity to J-proteins but lacks the canonical tripeptide motif His-Pro-Asp (HPD). We report that Pam16 does not function as a typical J-domain protein but, rather, antagonizes the function of Pam18. Pam16 specifically inhibits the Pam18-mediated stimulation of the ATPase activity of mtHsp70. The inclusion of the HPD motif in Pam16 does not confer the ability to stimulate mtHsp70 activity. Pam16-HPD fully substitutes for wild-type Pam16 in vitro and in vivo but is not able to replace Pam18. Pam16 represents a new type of cochaperone that controls the stimulatory effect of the J-protein Pam18 and regulates the interaction of mtHsp70 with precursor proteins during import into mitochondria.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, Lab Propre, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de; Peter.Rehling@biochemie.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021					Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Cyr DM, 1995, METHOD ENZYMOL, V260, P241, DOI 10.1016/0076-6879(95)60142-2; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Geissler A, 2001, MOL CELL BIOL, V21, P7097, DOI 10.1128/MCB.21.20.7097-7104.2001; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Herrmann JM, 2000, BBA-BIOENERGETICS, V1459, P331, DOI 10.1016/S0005-2728(00)00169-9; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Mayer MP, 2004, NAT STRUCT MOL BIOL, V11, P6, DOI 10.1038/nsmb0104-6; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Scheffler IE, 2001, MITOCHONDRION, V1, P3, DOI 10.1016/S1567-7249(00)00002-7; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Strub A, 2000, BIOL CHEM, V381, P943, DOI 10.1515/BC.2000.115; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Westermann B, 1997, J MOL BIOL, V272, P477, DOI 10.1006/jmbi.1997.1267; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200	44	85	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38047	38054		10.1074/jbc.M404319200	http://dx.doi.org/10.1074/jbc.M404319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15218029	hybrid			2022-12-25	WOS:000223554600099
J	Vicogne, J; Cailliau, K; Tulasne, D; Browaeys, E; Yan, YT; Fafeur, V; Vilain, JP; Legrand, D; Trolet, J; Dissous, C				Vicogne, J; Cailliau, K; Tulasne, D; Browaeys, E; Yan, YT; Fafeur, V; Vilain, JP; Legrand, D; Trolet, J; Dissous, C			Conservation of epidermal growth factor receptor function in the human parasitic helminth Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; XENOPUS OOCYTES; GENE; HOMOLOG; EXPRESSION; SPOROCYSTS; INDUCTION; ENCODES; BINDING	The epidermal growth factor receptor (EGF-R) plays an important role in development and cell differentiation, and homologues of EGF-R have been identified in a broad range of vertebrate and invertebrate organisms. This work concerns the functional characterization of SER, the EGF-R-like molecule previously identified in the helminth parasite Schistosoma mansoni ( Shoemaker, C. B., Ramachandran, H., Landa, A., dos Reis, M. G., and Stein, L. D. ( 1992) Mol. Biochem. Parasitol. 53, 17 - 32). Transactivation assays performed in epithelial Madin-Darby canine kidney cells co-transfected with SER and a Ras-responsive reporter vector indicated that SER was able to trigger a Ras/ERK pathway in response to human epidermal growth factor (EGF). These results were confirmed in Xenopus oocytes showing that human EGF induced meiosis reinitiation characterized by germinal vesicle breakdown in SER-expressing oocytes. Germinal vesicle breakdown induced by EGF was dependent on receptor kinase activity and shown to be associated with phosphorylation of SER and of downstream ERK proteins. I-125-EGF binding experiments performed on SER-expressing oocytes revealed high affinity (2.9 x 10(-9) M) of the schistosome receptor for human EGF. Phosphorylation of the native SER protein present in S. mansoni membranes was also shown to occur upon binding of human EGF. These data demonstrate the ability of the SER schistosome receptor to be activated by vertebrate EGF ligands as well as to activate the classical ERK pathway downstream, indicating the conservation of EGF-R function in S. mansoni. Moreover, human EGF was shown to increase protein and DNA synthesis as well as protein phosphorylation in parasites, supporting the hypothesis that host EGF could regulate schistosome development. The possible role of SER as a receptor for host EGF peptides and its implication in host-parasite signaling and parasite development are discussed.	Inst Pasteur, INSERM, U547, F-59019 Lille, France; Univ Sci & Technol Lille, UPRES EA 1033, IFR 118, F-59655 Villeneuve Dascq, France; Inst Biol Lille, CNRS, UMR 8117, F-59019 Lille, France; Univ Sci & Technol Lille, UMR 8576, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Dissous, C (corresponding author), Inst Pasteur, INSERM, U547, F-59019 Lille, France.	colette.dissous@pasteur-lille.fr	Fafeur, Veronique/L-9072-2018; Tulasne, David/AAR-5287-2020; Legrand, Dominique/AAT-5715-2021; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; cailliau, katia/0000-0003-1772-1034; Cailliau, Katia/0000-0001-7993-8437; Vicogne, Jerome/0000-0001-8360-7497; Dissous, Colette/0000-0002-5003-8205; LEGRAND, Dominique/0000-0002-0814-221X				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beall MJ, 2000, MOL BIOCHEM PARASIT, V111, P131, DOI 10.1016/S0166-6851(00)00307-8; Browaeys-Poly E, 2000, EUR J BIOCHEM, V267, P6256, DOI 10.1046/j.1432-1327.2000.01710.x; Cailliau K, 2003, FEBS LETT, V548, P43, DOI 10.1016/S0014-5793(03)00726-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coppin JF, 2003, PARASITOL RES, V89, P113, DOI 10.1007/s00436-002-0643-2; Davies SJ, 1998, J BIOL CHEM, V273, P11234, DOI 10.1074/jbc.273.18.11234; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PIERCE RJ, 1985, MOL BIOCHEM PARASIT, V15, P171, DOI 10.1016/0166-6851(85)90118-5; Ramachandran H, 1996, MOL BIOCHEM PARASIT, V83, P1, DOI 10.1016/S0166-6851(96)02731-4; SCHALLIG HDFH, 1990, PARASITOL RES, V76, P278, DOI 10.1007/BF00930825; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SHOEMAKER CB, 1992, MOL BIOCHEM PARASIT, V53, P17, DOI 10.1016/0166-6851(92)90003-3; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vicogne J, 2003, MOL BIOCHEM PARASIT, V126, P51, DOI 10.1016/S0166-6851(02)00249-9; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WILEY HS, 1989, J BIOL CHEM, V264, P18912; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	31	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37407	37414		10.1074/jbc.M313738200	http://dx.doi.org/10.1074/jbc.M313738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231836	hybrid			2022-12-25	WOS:000223554600027
J	Huang, SL; Shu, LL; Easton, J; Harwood, FC; Germain, GS; Ichijo, H; Houghton, PJ				Huang, SL; Shu, LL; Easton, J; Harwood, FC; Germain, GS; Ichijo, H; Houghton, PJ			Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; PROTEIN PHOSPHATASE 5; TOP MESSENGER-RNAS; SERINE/THREONINE PHOSPHATASE; CATALYTIC SUBUNIT; DIRECT BINDING; CELL-GROWTH; 2A; ASK1; INTERACTS	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53. Here we have investigated how mTOR regulates ASK1 signaling using p53-mutant rhabdomyosarcoma cells. In Rh30 cells, ASK1 was found to physically interact with protein phosphatase 5 (PP5), previously identified as a negative regulator of ASK1. Rapamycin did not affect either protein level of PP5 or association of PP5 with ASK1. Instead, rapamycin caused rapid dissociation of the PP2A-B" regulatory subunit (PR72) from the PP5-ASK1 complex, which was associated with reduced phosphatase activity of PP5. This effect was dependent on expression of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Down-regulation of PP5 activity by rapamycin coordinately activated ASK1, leading to elevated phosphorylation of c-Jun. Amino acid deprivation, which like rapamycin inhibits mTOR signaling, also inhibited PP5 activity, caused rapid dissociation of PR72, and activated ASK1 signaling. Overexpression of PP5, but not the PP2A catalytic subunit, blocked rapamycin-induced phosphorylation of c-Jun, and protected cells from rapamycin-induced apoptosis. The results suggest that PP5 is downstream of mTOR, and positively regulated by the mTOR pathway. The findings suggest that in the absence of serum factors, mTOR signaling suppresses apoptosis through positive regulation of PP5 activity and suppression of cellular stress.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Bunkyo Ku, Tokyo 1130033, Japan	St Jude Children's Research Hospital; University of Tokyo	Huang, SL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Huang, Shile/I-1632-2019; Houghton, Peter/E-3265-2011	Huang, Shile/0000-0002-3239-1072; Ichijo, Hidenori/0000-0002-5005-6438; Easton, John/0000-0003-4503-6608	NCI NIH HHS [CA 23099, CA 96696, CA 28765, CA 77776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077776, R01CA096696, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER W, 1994, J BIOL CHEM, V269, P22586; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DILLING MB, 1994, CANCER RES, V54, P903; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Huang SL, 2001, CANCER RES, V61, P3373; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Kono Y, 2002, GENES CELLS, V7, P821, DOI 10.1046/j.1365-2443.2002.00562.x; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Tamura S, 2002, EUR J BIOCHEM, V269, P1060, DOI 10.1046/j.0014-2956.2002.02754.x; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x	61	98	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36490	36496		10.1074/jbc.M401208200	http://dx.doi.org/10.1074/jbc.M401208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218033	hybrid			2022-12-25	WOS:000223453600042
J	Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S				Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S			Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer	ONCOGENE			English	Article						prostate cancer; Gleason score; intronic transcripts; antisense RNA; microarray	GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; SEQUENCE; HUMAN-CHROMOSOME-21; SITES	A large fraction of transcripts are expressed antisense to introns of known genes in the human genome. Here we show the construction and use of a cDNA microarray platform enriched in intronic transcripts to assess their biological relevance in pathological conditions. To validate the approach, prostate cancer was used as a model, and 27 patient tumor samples with Gleason scores ranging from 5 to 10 were analyzed. We find that a considerably higher fraction (6.6%,[23/346]) of intronic transcripts are significantly correlated (Pless than or equal to0.001) to the degree of prostate tumor differentiation ( Gleason score) when compared to transcripts from unannotated genomic regions (1%,[6/539]) or from exons of known genes (2%,[27/1369]). Among the top twelve transcripts most correlated to tumor differentiation, six are antisense intronic messages as shown by orientation-specific RTPCR or Northern blot analysis with strand-specific riboprobe. Orientation-specific real-time RT-PCR with six tumor samples, confirmed the correlation ( P = 0.024) between the low/high degrees of tumor differentiation and antisense intronic RASSF1 transcript levels. The need to use intron arrays to reveal the transcriptome profile of antisense intronic RNA in cancer has clearly emerged.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Lab Bioinformat, BR-05508900 Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Div Oncol, BR-05651901 Sao Paulo, Brazil; Hosp Sirio Libanes, Lab Patol Cirurg & Mol, BR-01308050 Sao Paulo, Brazil; Inst Nacl Canc MS, BR-20230130 Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Hospital Sirio Libanes	Verjovski-Almeida, S (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.	verjo@iq.usp.br	Reis, Eduardo M/H-2008-2011; LEITE, KATIA RM/C-2055-2008; Gimba, Etel/B-4473-2016; Brito, Glauber/C-4415-2013; Tesaarin e Almeida, Giulliana/F-5936-2013; Sogayar, Mari C/B-3980-2017; Nakaya, Helder/AAF-1738-2020; Gimba, Etel/H-7195-2012; moreira-filho, carlos alberto/J-2551-2014; da Silva, Aline Maria/C-3649-2012; Reis, Eduardo Moraes Rego/AAF-3553-2020; Nakaya, Helder I/A-1397-2010; Verjovski-Almeida, Sergio/E-4082-2012	Reis, Eduardo M/0000-0002-9556-3070; LEITE, KATIA RM/0000-0002-2615-7730; Brito, Glauber/0000-0002-9887-3939; Sogayar, Mari C/0000-0003-4805-4609; Nakaya, Helder/0000-0001-5297-9108; moreira-filho, carlos alberto/0000-0003-3433-4714; da Silva, Aline Maria/0000-0001-9249-4922; Nakaya, Helder I/0000-0001-5297-9108; Verjovski-Almeida, Sergio/0000-0002-6356-2401; Festa, Fernanda/0000-0002-2822-823X				Best CJM, 2003, DIAGN MOL PATHOL, V12, P63, DOI 10.1097/00019606-200306000-00001; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Brunschwig EB, 2003, CANCER RES, V63, P1568; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Camargo AA, 2001, P NATL ACAD SCI USA, V98, P12103, DOI 10.1073/pnas.201182798; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Iseli C, 1999, Proc Int Conf Intell Syst Mol Biol, P138; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Neto ED, 2000, P NATL ACAD SCI USA, V97, P3491; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Shendure J, 2002, GENOME BIOL, V3; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	37	115	141	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6684	6692		10.1038/sj.onc.1207880	http://dx.doi.org/10.1038/sj.onc.1207880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221013				2022-12-25	WOS:000223530800017
J	Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK				Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK			SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion	ONCOGENE			English	Article						Ets; transcription; invasion; SP100; MMP; UPA	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; MATRIX METALLOPROTEINASE-1; PROTEIN INTERACTIONS; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; ANDROGEN RECEPTOR	The ETS1 transcription factor is a member of the Ets family of conserved sequence-specific DNA-binding proteins. ETS1 has been shown to play important roles in various cellular processes such as proliferation, differentiation, lymphoid development, motility, invasion and angiogenesis. These diverse roles of ETS1 are likely to be dependent on specific protein interactions. To identify proteins that interact with ETS1, a yeast two-hybrid screen was conducted. Here, we describe the functional interaction between SP100 and ETS1. SP100 protein interacts with ETS1 both in vitro and in vivo. SP100 is localized to nuclear bodies and ETS1 expression alters the nuclear body morphology in living cells. SP100 negatively modulates ETS1 transcriptional activation of the MMP1 and uPA promoters in a dose-dependent manner, decreases the expression of these endogenous genes, and reduces ETS1 DNA binding. Expression of SP100 inhibits the invasion of breast cancer cells and is induced by Interferon-alpha, which has been shown to inhibit the invasion of cancer cells. These data demonstrate that SP100 modulates ETS1-dependent biological processes.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu			NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGERON D, 1995, CELL MOL BIOL RES, V41, P155; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Chen ZQ, 1997, CANCER RES, V57, P2013; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FISHER RJ, 1991, ONCOGENE, V6, P2249; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GULDNER HH, 1992, J IMMUNOL, V149, P4067; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kita D, 2001, CANCER RES, V61, P7985; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Negorev D, 2001, J CELL SCI, V114, P59; Obika S, 2003, J MOL BIOL, V331, P345, DOI 10.1016/S0022-2836(03)00726-5; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pei HP, 2003, ONCOGENE, V22, P2699, DOI 10.1038/sj.onc.1206374; Quaranta V, 2003, TUMORI J, V89, P343, DOI 10.1177/030089160308900401; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Rutter JL, 1998, CANCER RES, V58, P5321; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	67	34	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6654	6665		10.1038/sj.onc.1207891	http://dx.doi.org/10.1038/sj.onc.1207891			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247905				2022-12-25	WOS:000223530800013
J	Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J				Sgarbanti, M; Arguello, M; tenOever, BR; Battistini, A; Lin, RT; Hiscott, J			A requirement for NF-kappa B induction in the production of replication-competent HHV-8 virions	ONCOGENE			English	Article						HHV8; NF-kappa B; herpesvirus; lytic infection	SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY EFFUSION LYMPHOMA; PROTEIN-COUPLED RECEPTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; HUMAN-HERPESVIRUS-8 INFECTION; DNA-SEQUENCES; IKK-GAMMA; KINASE; ALPHA	The gammaherpesvirus human herpesvirus 8 (HHV-8) infects endothelial and B-lymphoid cells and is responsible for the development of Kaposi's sarcoma and primary effusion lymphoma (PEL). In the present study, we demonstrate that the activation of the NF-kappaB pathway during HHV-8 lytic replication is required for the generation of replication-competent virions capable of initiating a de novo infection of endothelial cells. In the HHV-8-positive PEL cell line BCBL-1, tetradecanoyl phorbol acetate (TPA) induction of the lytic cycle activates the NF-kappaB pathway, and this activation requires the induction of the IKKbeta component of the classical IkappaB kinase (IKK) complex. To further investigate the role of NF-kappaB activation in HHV-8 lytic replication, the NF-kappaB super-repressor IkappaBalpha-2NDelta4 was introduced into BCBL-1 cells by retroviral transduction. Expression of IkappaBalpha-2NDelta4 completely abolished NF-kappaB activity, as demonstrated by the loss of NF-kappaB DNA-binding activity and the absence of expression of the endogenous, NF-kappaB-regulated IkappaBalpha gene. NF-kappaB blockade dramatically impaired the ability of HHV-8 to produce infectious particles capable of initiating an effective de novo infection of endothelial EA.hy926 cells, as demonstrated by the lack of viral protein production in the target cells. Diminished infectivity did not appear to be caused by a reduction in virus titer, as demonstrated by equivalent viral DNA content in the supernatant of TPA-stimulated BCBL-1 and BCBL-1/2N4 cells. Although the viral and/or cellular products affected by NF-kappaB inactivation remain to be fully characterized, these data demonstrate an unexpected role for NF-kappaB induction during lytic reactivation in the production of replication-competent HHV-8 virions.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Istituto Superiore di Sanita (ISS)	Lin, RT (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008; BATTISTINI, ANGELA/C-2944-2016	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503; 				ANTOINE N, 1994, CANCER RES, V54, P2073; Arguello M, 2003, ONCOGENE, V22, P964, DOI 10.1038/sj.onc.1206270; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Curreli F, 2002, J VIROL, V76, P5208, DOI 10.1128/JVI.76.10.5208-5219.2002; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Gaidano G, 1997, BLOOD, V89, P3755; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jones KD, 1999, BLOOD, V94, P2871; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keller SA, 2000, BLOOD, V96, P2537; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Means RE, 2002, EMBO J, V21, P1638, DOI 10.1093/emboj/21.7.1638; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2001, CANCER RES, V61, P2641; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurada S, 2001, J VIROL, V75, P7717, DOI 10.1128/JVI.75.16.7717-7722.2001; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Webb JH, 1999, FEBS LETT, V444, P136, DOI 10.1016/S0014-5793(99)00025-3; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu YM, 1999, J GEN VIROL, V80, P83, DOI 10.1099/0022-1317-80-1-83; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	64	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5770	5780		10.1038/sj.onc.1207707	http://dx.doi.org/10.1038/sj.onc.1207707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15235582				2022-12-25	WOS:000222629800006
J	Guenther, E; Schmid, S; Wheeler-Schilling, T; Albach, G; Grunder, T; Fauser, S; Kohler, K				Guenther, E; Schmid, S; Wheeler-Schilling, T; Albach, G; Grunder, T; Fauser, S; Kohler, K			Developmental plasticity of NMDA receptor function in the retina and the influence of light	FASEB JOURNAL			English	Article						retinal ganglion cells; light modulation; neurotransmitter receptor; development; glutamate receptor	OCULAR DOMINANCE PLASTICITY; NR2A SUBUNIT EXPRESSION; GANGLION-CELLS; NEUROTRANSMITTER REGULATION; SYNAPTIC CURRENTS; VISUAL EXPERIENCE; GLUTAMATE; RAT; BRAIN; STRATIFICATION	Despite the early expression of NMDA receptors (NMDARs) in the retina, not much is known about their regulation and involvement in plasticity processes during retinal development and synapse formation. Here we report that NMDAR function in the inner retina is developmentally regulated and controlled by ambient light condition. A prominent down-regulation after eye opening of NMDAR function was observed in rat retinal ganglion cells (RGCs), which was prevented by dark rearing the animals for 1 month but was again induced by subsequent light exposure. As shown by molecular analysis of single RGCs, alterations in the subunit composition of NMDAR did not account for the light-dependent regulation of NMDAR function. Immunocytochemistry showed no differences in the NMDAR protein expression pattern between normal and dark-reared animals. In conclusion, our data clearly demonstrate that NMDAR function is modulated during periods of retinal plasticity independent of structural alterations in its subunit composition and thus different from mechanisms observed in higher visual centers.	Univ Tubingen, Hosp Eye, Dept Pathophysiol Vis & Neuroophthalmol, Div Expt Ophthalmol,Lab Cell Physiol & Mol Biol, D-72076 Tubingen, Germany; Univ Tubingen, Nat Med Sci Inst NMI, D-72770 Reutlingen, Germany; Univ Tubingen, Inst Zool, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Guenther, E (corresponding author), NMI Reutlingen, Markwiesenstr 55, D-72770 Reutlingen, Germany.	guenther@nmi.de	Schmid, Susanne/J-3201-2012	Schmid, Susanne/0000-0001-5366-8061; Dr. Guenther, Elke/0000-0002-8758-1607; Wheeler-Schilling, Thomas H./0000-0003-3754-0193				Barnstable C J, 1993, Curr Opin Neurobiol, V3, P520, DOI 10.1016/0959-4388(93)90050-9; Bear MF, 1996, PROG BRAIN RES, V108, P205, DOI 10.1016/S0079-6123(08)62541-8; Bisti S, 1998, J NEUROSCI, V18, P5019; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; BODNARENKO SR, 1995, J NEUROSCI, V15, P7037; Brandstatter JH, 1998, VISION RES, V38, P1385, DOI 10.1016/S0042-6989(97)00176-4; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; COHEN ED, 1994, VISUAL NEUROSCI, V11, P317, DOI 10.1017/S0952523800001668; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DUVOISIN RM, 1995, NEUROSCI LETT, V183, P83, DOI 10.1016/0304-3940(94)11120-8; Flint AC, 1997, J NEUROSCI, V17, P2469; Fox K, 1999, NAT NEUROSCI, V2, P297, DOI 10.1038/7203; Fox Kevin, 1994, Current Opinion in Neurobiology, V4, P112, DOI 10.1016/0959-4388(94)90040-X; Grunder T, 2000, INVEST OPHTH VIS SCI, V41, P3600; Grunder T, 2000, J NEUROBIOL, V44, P333; Grzywacz NM, 1998, VISUAL NEUROSCI, V15, P1119, DOI 10.1017/S0952523898156109; GUENTHER E, 1994, J NEUROSCI METH, V51, P177, DOI 10.1016/0165-0270(94)90008-6; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; HERMES B, 1992, INT J DEV NEUROSCI, V10, P215, DOI 10.1016/0736-5748(92)90061-4; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Izumi Y, 1995, NEUROBIOL DIS, V2, P139, DOI 10.1006/nbdi.1995.0015; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; Kroger RHH, 1996, VISION RES, V36, P3879, DOI 10.1016/S0042-6989(96)00132-0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Liets LC, 2001, PROG BRAIN RES, V134, P1; MASSEY SC, 1990, J NEUROPHYSIOL, V63, P16, DOI 10.1152/jn.1990.63.1.16; MULLER F, 1992, NEUROSCI LETT, V138, P179, DOI 10.1016/0304-3940(92)90500-7; PENG YW, 1995, NEUROSCIENCE, V66, P483, DOI 10.1016/0306-4522(94)00569-Q; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587, DOI 10.1152/jn.1999.81.5.2587; Roberts EB, 1998, J NEUROPHYSIOL, V80, P1021, DOI 10.1152/jn.1998.80.3.1021; Schmid S, 1998, NEUROSCIENCE, V85, P249, DOI 10.1016/S0306-4522(97)00644-1; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Taylor WR, 1996, VISUAL NEUROSCI, V13, P979, DOI 10.1017/S0952523800009202; Tehrani A, 2000, INVEST OPHTH VIS SCI, V41, P314; Tian N, 2003, NEURON, V39, P85, DOI 10.1016/S0896-6273(03)00389-1; Tian N, 2001, NEURON, V32, P439, DOI 10.1016/S0896-6273(01)00470-6; Velte TJ, 1996, J NEUROPHYSIOL, V75, P2129, DOI 10.1152/jn.1996.75.5.2129; WEIDMAN TA, 1969, INVEST OPHTH VISUAL, V8, P60; WINGATE RJT, 1994, J NEUROSCI, V14, P6621; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987; Wong WT, 2000, J NEUROSCI, V20, P351, DOI 10.1523/JNEUROSCI.20-01-00351.2000; Wu SM, 1998, VISION RES, V38, P1371, DOI 10.1016/S0042-6989(97)00296-4; Xue J, 2002, DEV BRAIN RES, V138, P61, DOI 10.1016/S0165-3806(02)00460-1; Xue J, 2001, MOL BRAIN RES, V91, P196, DOI 10.1016/S0169-328X(01)00141-3	47	24	24	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1433	+		10.1096/fj.03-0618fje	http://dx.doi.org/10.1096/fj.03-0618fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247153				2022-12-25	WOS:000222979200011
J	Sun, XC; Zemel, MB				Sun, XC; Zemel, MB			Role of uncoupling protein 2 (UCP2) expression and 1 alpha,25-dihydroxyvitamin D-3 in modulating adipocyte apoptosis	FASEB JOURNAL			English	Article						calcitriol; calcium; mitochondrial potential; obesity	CELL-DEATH; ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; INTRACELLULAR CALCIUM; ENERGY RESTRICTION; DIETARY CALCIUM; CA2+; MITOCHONDRIA; INHIBITION; INDUCTION	We previously found that 1alpha, 25-dihydroxyvitamin D-3 [1alpha, 25-(OH)(2)-D-3] modulates adipocyte lipid metabolism via a Ca2+-dependent mechanism and inhibits adipocyte UCP2 expression, indicating that the anti-obesity effects of dietary calcium are mediated by suppression of 1a, 25-(OH)(2)-D-3 levels. However, because UCP2 reduces mitochondrial potential, we have evaluated the roles of UCP2, mitochondrial uncoupling, and 1alpha, 25-(OH)(2)-D-3 in adipocyte apoptosis. Overexpressing UCP2 in 3T3-L1 cells induced marked reductions in mitochondrial potential (Deltapsi) and ATP production (P< 0.01), increases in the expression of caspases (P< 0.05), and a decrease in Bcl-2/Bax expression ratio (P< 0.01). Physiological doses of 1 alpha, 25-(OH)(2)-D-3 (0.1 - 10 nM) restored mitochondrial Delta psi in LI-UCP2 cells and protected against UCP2 overexpression-induced apoptosis ( P< 0.01), whereas a high dose ( 100 nM) stimulated apoptosis in 3T3-L1 and L1-UCP2 cells (P< 0.05). 1 alpha, 25-(OH)(2)-D-3 stimulated cytosolic Ca2+ dose-dependently in both 3T3-L1 and L1-UCP2 cells. However, physiological doses suppressed mitochondrial Ca2+ levels by similar to 50% whereas the high dose increased mitochondrial Ca2+ by 25% (P< 0.05); this explains stimulation of apoptosis by the high dose of 1alpha, 25-(OH)(2)-D-3. Using high-calcium diets to suppress 1alpha, 25-(OH)(2)-D-3 stimulated adipose tissue apoptosis in aP2 transgenic mice ( P< 0.01), suggesting that increasing dietary calcium stimulates adipose apoptosis and thereby further contributes to an anti-obesity effect of dietary calcium.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.	mzemel@utk.edu		sun, xiaocun/0000-0003-3053-1518; Zemel, Michael/0000-0003-4104-5750				Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Elias J, 2003, RECENT RESULTS CANC, V164, P319; Ferrara C, 2002, PEDIATR RADIOL, V32, P413, DOI 10.1007/s00247-001-0617-z; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kato T, 2002, LIFE SCI, V71, P581, DOI 10.1016/S0024-3205(02)01725-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Ma TS, 1998, ANN NY ACAD SCI, V853, P325, DOI 10.1111/j.1749-6632.1998.tb08291.x; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; McCarty MF, 2000, MED HYPOTHESES, V55, P187, DOI 10.1054/mehy.1999.1010; McConkey David J., 1996, Scanning Microscopy, V10, P777; Narvaez CJ, 2003, J STEROID BIOCHEM, V84, P199, DOI 10.1016/S0960-0760(03)00029-3; Niesler CU, 1998, DIABETES, V47, P1365, DOI 10.2337/diabetes.47.8.1365; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sergeev IN, 2003, ENDOCRINE, V22, P169, DOI 10.1385/ENDO:22:2:169; Shi H, 2002, FASEB J, V16, P1808, DOI 10.1096/fj.02-0255fje; Shi H, 2001, FASEB J, V15, P2751, DOI 10.1096/fj.01-0584fje; Shi H, 2001, FASEB J, V15, P291; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Sun XC, 2003, FASEB J, V17, pA746; Swamy N, 2003, J CELL BIOCHEM, V89, P909, DOI 10.1002/jcb.10585; Takadera T, 1998, BBA-MOL CELL RES, V1401, P63, DOI 10.1016/S0167-4889(97)00116-X; Tang YZ, 2004, GASTROENTEROLOGY, V126, P220, DOI 10.1053/j.gastro.2003.10.077; Tantral L, 2004, CELL BIOCHEM FUNCT, V22, P35, DOI 10.1002/cbf.1050; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wagner N, 2003, EXP EYE RES, V77, P1, DOI 10.1016/s0014-4835(03)00108-8; Weedon D, 1979, Am J Dermatopathol, V1, P133; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; Xue BZ, 2001, FASEB J, V15, P2527, DOI 10.1096/fj.01-0278fje; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698; Zemel MB, 2003, LIPIDS, V38, P139, DOI 10.1007/s11745-003-1044-6; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132; Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67	51	74	97	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1430	+		10.1096/fj.04-1971fje	http://dx.doi.org/10.1096/fj.04-1971fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231722				2022-12-25	WOS:000222979200012
J	Whiteman, M; Armstrong, JS; Cheung, NS; Siau, JL; Rose, P; Schantz, JT; Jones, DP; Halliwell, B				Whiteman, M; Armstrong, JS; Cheung, NS; Siau, JL; Rose, P; Schantz, JT; Jones, DP; Halliwell, B			Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains	FASEB JOURNAL			English	Article						mitochondria; nitrosative stress; apoptosis; SIN-1; reactive nitrogen species	PERMEABILITY TRANSITION PORE; NITRIC-OXIDE; REACTIVE OXYGEN; TYROSINE-NITRATION; HYPOCHLOROUS ACID; OXIDATIVE DAMAGE; CYTOCHROME-C; APOPTOSIS; CARTILAGE; NECROSIS	Chondrocyte cell death is a hallmark of inflammatory and degenerative joint diseases such as rheumatoid arthritis ( RA) and osteoarthritis (OA), but the molecular and cellular mechanisms involved have yet to be elucidated. Because 3-nitrotyrosine, a marker for reactive nitrogen species such as peroxynitrite, has been observed in OA and RA cartilage and has been associated with chondrocyte cell death, we investigated the mechanisms by which peroxynitrite induces cell death in human articular chondrocytes. The earliest biochemical event observed, subsequent to treatment with either peroxynitrite or the peroxynitrite generator SIN-1, was a rapid rise in intracellular calcium that lead to mitochondrial dysfunction and cell death. Although, chondrocyte death exhibited several classical hallmarks of apoptosis, including annexin V labeling, increased fraction of cells with subG1 DNA content and DNA condensation, we did not find evidence for caspase involvement either by Western blotting, fluorimetric assays, or caspase inhibition. Additionally, peroxynitrite did not inhibit cellular caspase activity. Furthermore, using other established assays of cell viability, including the MTT assay and release of lactate dehydrogenase, we found that the predominant mode of cell death involved calcium-dependent cysteine proteases, otherwise known as calpains. Our data show, for the first time, that peroxynitrite induces mitochondrial dysfunction in cells via a calcium-dependent process that leads to caspase-independent apoptosis mediated by calpains.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Plast Surg, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Bioengn, Singapore 117597, Singapore; Emory Univ, Sch Med, Ctr Clin & Mol Nutr, Clin Biomarkers Lab, Atlanta, GA USA	National University of Singapore; National University of Singapore; National University of Singapore; Emory University	Whiteman, M (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore.	bchwml@nus.edu.sg		Halliwell, Barry/0000-0002-3560-7123				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Bauerova K, 1999, GEN PHYSIOL BIOPHYS, V18, P15; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Brookes PS, 2004, AM J PHYSIOL-HEART C, V286, pH39, DOI 10.1152/ajpheart.00742.2003; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cuzzocrea S, 2002, CRIT CARE MED, V30, P2284, DOI 10.1097/00003246-200210000-00017; Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6; Darzynkiewicz Z, 2000, METHOD ENZYMOL, V322, P18; Del Carlo M, 2002, ARTHRITIS RHEUM, V46, P394, DOI 10.1002/art.10056; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Georget M, 2002, FASEB J, V16, P1636, DOI 10.1096/fj.02-0292fje; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GREENACRE SAB, 2001, FREE RADICAL RES, V34, P514; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; Hadjigogos K, 2003, PANMINERVA MED, V45, P7; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; He LH, 2003, J BIOL CHEM, V278, P16755, DOI 10.1074/jbc.M300153200; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Holm P, 1998, EUR J PHARMACOL, V346, P97, DOI 10.1016/S0014-2999(98)00009-0; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jang D, 1998, FREE RADICAL BIO MED, V24, P1511, DOI 10.1016/S0891-5849(97)00459-0; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kim HA, 2000, J RHEUMATOL, V27, P455; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7; Loeser RF, 2002, ARTHRITIS RHEUM, V46, P2349, DOI 10.1002/art.10496; Mapp PI, 2001, ARTHRITIS RHEUM, V44, P1534, DOI 10.1002/1529-0131(200107)44:7<1534::AID-ART276>3.0.CO;2-#; Matsuo M, 2001, ACTA MED OKAYAMA, V55, P333; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; Mykles DL, 2001, METHOD CELL BIOL, V66, P247; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Rose P, 2003, BIOCHEM BIOPH RES CO, V302, P397, DOI 10.1016/S0006-291X(03)00193-1; Sandhu JK, 2003, J RHEUMATOL, V30, P1173; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; Simpson PB, 1998, J PHYSIOL-LONDON, V508, P413, DOI 10.1111/j.1469-7793.1998.413bq.x; Spencer JPE, 1996, CHEM RES TOXICOL, V9, P1152, DOI 10.1021/tx960084i; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Studer R, 1999, OSTEOARTHR CARTILAGE, V7, P377, DOI 10.1053/joca.1998.0216; SUZUKI K, 1990, ARTHRITIS RHEUM, V33, P728, DOI 10.1002/art.1780330516; SZOMOR Z, 1995, ANN RHEUM DIS, V54, P477, DOI 10.1136/ard.54.6.477; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Trakranrungsie N, 2001, LIFE SCI, V69, P2349, DOI 10.1016/S0024-3205(01)01320-0; Ueta E, 2003, INT J CANCER, V103, P717, DOI 10.1002/ijc.10832; VANDERVLIET A, 1994, BIOCHEM J, V303, P295, DOI 10.1042/bj3030295; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Whiteman M, 2003, ARTHRITIS RHEUM-US, V48, P3140, DOI 10.1002/art.11284; Whiteman M, 2003, J BIOL CHEM, V278, P8380, DOI 10.1074/jbc.M211086200; YAMAMOTO S, 1992, ARTHRITIS RHEUM-US, V35, P1309, DOI 10.1002/art.1780351111; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	77	84	94	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1395	+		10.1096/fj.03-1096fje	http://dx.doi.org/10.1096/fj.03-1096fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240564				2022-12-25	WOS:000222979200027
J	Hess, JF; Budamagunta, MS; Voss, JC; FitzGerald, PG				Hess, JF; Budamagunta, MS; Voss, JC; FitzGerald, PG			Structural characterization of human vimentin Rod 1 and the sequencing of assembly steps in intermediate filament formation in vitro using site-directed spin labeling and electron paramagnetic resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-STRUCTURE; CROSS-LINKING; DIMER; PROTEINS; DOMAINS; DIVERSITY; ALIGNMENT; MECHANISM; MOLECULES; DYNAMICS	We have previously established the utility of site-directed spin labeling and electron paramagnetic resonance to determine structural relationships among proteins in intact intermediate filaments. Using this same approach we have introduced spin labels at 21 residues between amino acids 169 and 193 in rod domain 1 of human vimentin. The electron paramagnetic resonance spectra provide direct evidence for the coiled coil nature of the vimentin dimer in this region. This finding is consistent with predictions but has never been demonstrated previously. In a previous study we identified residue 348 in the rod domain 2 as one point of overlap between adjacent dimers in intact filaments. In the present study we defined residue 191 in the rod domain 1 as a second point of overlap and established that the dimers are arranged in an anti-parallel and staggered orientation at this site. Finally, by isolating spin-labeled samples at successive stages during the dialysis that lead to filament assembly in vitro, we have been able to establish a sequence of interactions that occurs during in vitro assembly, starting with the alpha helix and loose coiled coil dimer formation, then the formation of tetrameric species centered on residue 191, followed by interactions centered on residue 348 suggestive of octamer or higher order multimer formation. A continuation of this strategy revealed that both 191-191 and 348-348 interactions are present in low ionic strength Tris buffers when vimentin is maintained at the "protofilament" stage of assembly.	Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	FitzGerald, PG (corresponding author), Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.	pgfitzgerald@ucdavis.edu	Budamagunta, Madhu S/C-4628-2011	Voss, John/0000-0001-9279-209X	NATIONAL EYE INSTITUTE [R01EY015560] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY015560, R01 EY015560-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1983, CELL, V34, P332, DOI 10.1016/0092-8674(83)90367-7; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Herrmann H, 1998, Subcell Biochem, V31, P319; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; Hess JF, 2002, J BIOL CHEM, V277, P35516, DOI 10.1074/jbc.M206500200; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; KOKORIN AI, 1972, BIOFIZIKA+, V17, P34; Mehrani T, 2001, J BIOL CHEM, V276, P2088, DOI 10.1074/jbc.M007260200; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; RENNER W, 1981, J MOL BIOL, V149, P285, DOI 10.1016/0022-2836(81)90303-X; Rogers KR, 1996, J STRUCT BIOL, V117, P55, DOI 10.1006/jsbi.1996.0069; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; Strelkov SV, 2002, EMBO J, V21, P1255, DOI 10.1093/emboj/21.6.1255; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442	25	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44841	44846		10.1074/jbc.M406257200	http://dx.doi.org/10.1074/jbc.M406257200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15231822	Green Accepted, hybrid			2022-12-25	WOS:000224505600074
J	Arselin, G; Vaillier, J; Salin, B; Schaeffer, J; Giraud, MF; Dautant, A; Brethes, D; Velours, J				Arselin, G; Vaillier, J; Salin, B; Schaeffer, J; Giraud, MF; Dautant, A; Brethes, D; Velours, J			The modulation in subunits e and g amounts of yeast ATP synthase modifies mitochondrial cristae morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; OUTER-MEMBRANE; MGM1P; PURIFICATION; DISRUPTION; F-1-ATPASE	Subunits e and g of Saccharomyces cerevisiae ATP synthase are required to maintain ATP synthase dimeric forms. Mutants devoid of these subunits display anomalous mitochondrial morphologies. An expression system regulated by doxycycline was used to modulate the expression of the genes encoding the subunits e and g. A decrease in the amount of subunit e induces a decrease in the amount of subunit g, but a decrease in the amount of subunit g does not affect subunit e. The loss of subunit e or g leads to the loss of supramolecular structures of ATP synthase, which is fully reversible upon removal of doxycycline. In the absence of doxycycline, mitochondria present poorly defined cristae. In the presence of doxycycline, onion-like structures are formed after five generations. When doxycycline is removed after five generations, cristae are mainly observed. The data demonstrate that the inner structure of mitochondria depends upon the ability of ATP synthase to make supramolecular structures.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Velours, J (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jean.velours@ibgc.u-bordeaux2.fr						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Guerin B, 1979, Methods Enzymol, V55, P149; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Pelloquin L, 1999, J CELL SCI, V112, P4151; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	48	117	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40392	40399		10.1074/jbc.M404316200	http://dx.doi.org/10.1074/jbc.M404316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262977	hybrid			2022-12-25	WOS:000223916800023
J	Qin, YP; Luo, ZQ; Farrand, SK				Qin, YP; Luo, ZQ; Farrand, SK			Domains formed within the N-terminal region of the quorum-sensing activator TraR are required for transcriptional activation and direct interaction with RpoA from Agrobacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID CONJUGAL TRANSFER; TI-PLASMID; RNA-POLYMERASE; ALPHA-SUBUNIT; ESCHERICHIA-COLI; GENE-EXPRESSION; LUX OPERON; BINDING; DNA; AUTOINDUCTION	TraR, a quorum-sensing activator, induces transcription from its binding site, the tra-box, located upstream of Ti plasmid target promoters. TraR activated expression of a lacZ reporter in Escherichia coli only when RpoA(At) from Agrobacterium tumefaciens was co-expressed. As assessed by gel retardation assays RpoAAt, but not RpoA(Ec), formed a ternary complex with TraR and a tra-box probe in vitro. TraR formed similar ternary complexes with alphaCTD(At) but not with alphaNTD(At), the C- and N-terminal segments of RpoA(At). As measured by surface plasmon resonance refractometry, TraR interacted directly with RpoAAt with an affinity about five times greater than that observed for its interaction with RpoAEc. The activator interacted with alphaCTD(At) with kinetics and affinities similar to those of the full-sized alpha-subunit. Positive control ( PC) mutations at Asp-10 and Gly-123 of TraR did not affect DNA binding but greatly decreased the TraR-RpoA(At) interaction. These two residues combine to form two patches on the activator, one of which may be involved in interaction with RpoA. When co-expressed, mutants of TraR with substitutions at Asp-10 complementing mutants with substitutions at Gly-123 for gene activation in an allele-specific manner. Co-expression studies with TraR and its PC mutants, and also with complementary PC alleles of TraR, coupled with three-dimensional structure are consistent with a hypothesis that both Asp-10/Gly-123 patches are required for activator function.	Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Farrand, SK (corresponding author), Univ Illinois, Dept Crop Sci, 240 ERML,1201 W Gregory Dr, Urbana, IL 61801 USA.	stephenf@uiuc.edu		Luo, Zhao-Qing/0000-0001-8890-6621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052465] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Cangelosi GA, 1991, METHOD ENZYMOL, V145, P177; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; Egland KA, 2000, J BACTERIOL, V182, P805, DOI 10.1128/JB.182.3.805-811.2000; Farrand SK, 1996, J BACTERIOL, V178, P4233, DOI 10.1128/jb.178.14.4233-4247.1996; Farrand SK, 2002, METHOD ENZYMOL, V358, P452; Finney AH, 2002, J BACTERIOL, V184, P4520, DOI 10.1128/JB.184.16.4520-4528.2002; Fuqua C, 1996, J BACTERIOL, V178, P435, DOI 10.1128/jb.178.2.435-440.1996; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; HWANG IY, 1994, P NATL ACAD SCI USA, V91, P4639, DOI 10.1073/pnas.91.11.4639; HWANG IY, 1995, J BACTERIOL, V177, P449, DOI 10.1128/jb.177.2.449-458.1995; Johnson DC, 2003, FEMS MICROBIOL LETT, V228, P193, DOI 10.1016/S0378-1097(03)00750-X; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; Li PL, 2000, J BACTERIOL, V182, P179, DOI 10.1128/JB.182.1.179-188.2000; Li PL, 1998, J BACTERIOL, V180, P6164; Lohrke SM, 1999, J BACTERIOL, V181, P4533, DOI 10.1128/JB.181.15.4533-4539.1999; Lohrke SM, 2001, J BACTERIOL, V183, P3704, DOI 10.1128/JB.183.12.3704-3711.2001; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 2003, J BIOL CHEM, V278, P13173, DOI 10.1074/jbc.M210035200; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; Luo ZQ, 2001, MOL PLANT MICROBE IN, V14, P98, DOI 10.1094/MPMI.2001.14.1.98; Minogue TD, 2002, MOL MICROBIOL, V44, P1625, DOI 10.1046/j.1365-2958.2002.02987.x; Oger P, 1998, MOL MICROBIOL, V27, P277, DOI 10.1046/j.1365-2958.1998.00671.x; Piper KR, 2000, J BACTERIOL, V182, P1080, DOI 10.1128/JB.182.4.1080-1088.2000; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; STEVENS AM, 1994, P NATL ACAD SCI USA, V91, P12619, DOI 10.1073/pnas.91.26.12619; Stevens AM, 1999, J BACTERIOL, V181, P4704, DOI 10.1128/JB.181.15.4704-4707.1999; STEVENS AM, 2000, P NAT AC SCI USA, V182, P179; Urbanowski AL, 2004, J BACTERIOL, V186, P631, DOI 10.1128/JB.186.3.631-637.2004; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	38	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40844	40851		10.1074/jbc.M405299200	http://dx.doi.org/10.1074/jbc.M405299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15237104	hybrid			2022-12-25	WOS:000223916800079
J	Banchio, C; Schang, LM; Vance, DE				Banchio, C; Schang, LM; Vance, DE			Phosphorylation of Sp1 by cyclin-dependent kinase 2 modulates the role of Sp1 in CTP : phosphocholine cytidylyltransferase alpha regulation during the S phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; PROTEIN-KINASE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE-2; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; RAT-LIVER; ACTIVATION; IDENTIFICATION; EXPRESSION; CDC2	Phosphatidylcholine is the major lipid component in mammalian membranes. Phosphatidylcholine synthesis increases in C3H10T1/2 fibroblasts during the G(1) and S phases of the cell cycle. Previous studies demonstrated that the mRNA encoding CTP:phosphocholine cytidylyltransferase alpha (CTalpha) increases during S phase (Golfman, L. S., Bakovic, M., and Vance, D. E. (2001) J. Biol. Chem. 276, 43688-43692) and that this activation is driven by increased binding of Sp1 to the CTalpha promoter (Banchio, C., Schang, L. M., and Vance, D. E. (2003) J. Biol. Chem. 278, 32457-32464). We now demonstrate that cyclin-dependent kinase 2 (CDK2) phosphorylation of Sp1 activates CTalpha transcription during S phase. Sp1 binds in a phosphorylated state to the CTalpha promoter. Sp1 binding is enhanced by association with cyclin A/E and CDK2, both in vivo and in vitro. In cells that overexpress Sp1, co-expression of cyclin A and CDK2 induces a high and constant level of CTalpha expression, whereas reduction in the expression of cyclin A, cyclin E, and CDK2 eliminates the induction of CTalpha expression in S phase. Furthermore, CTalpha expression is decreased in cells overexpressing a dominant-negative form of CDK2 and in cells treated with the CDK2 kinase inhibitors roscovitine and olomoucine. These results enhance our understanding of the regulatory mechanisms involved in the expression of CTalpha in preparation for cell division.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Schang, Luis Maria/0000-0002-5789-8590				Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FOJAS DB, 2001, EMBO J, V20, P5737; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40220	40226		10.1074/jbc.M406468200	http://dx.doi.org/10.1074/jbc.M406468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247247	hybrid			2022-12-25	WOS:000223791500121
J	Barnewitz, K; Guo, CS; Sevvana, M; Ma, GJ; Sheldrick, GM; Soling, HD; Ferrari, DM				Barnewitz, K; Guo, CS; Sevvana, M; Ma, GJ; Sheldrick, GM; Soling, HD; Ferrari, DM			Mapping of a substrate binding site in the protein disulfide isomerase-related chaperone wind based on protein function and crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING; DOMAIN; SPECIFICITY; LOCALIZATION; DIMERIZATION; MECHANISM; RESIDUES; DSBA; PDIP	The protein disulfide isomerase (PDI)-related protein Wind is essential in Drosophila melanogaster, and is required for correct targeting of Pipe, an essential Golgi transmembrane 2-O-sulfotransferase. Apart from a thioredoxin fold domain present in all PDI proteins, Wind also has a unique C-terminal D-domain found only in PDI-D proteins. Here, we show that Pipe processing requires dimeric Wind, which interacts directly with the soluble domain of Pipe in vitro, and we map an essential substrate binding site in Wind to the vicinity of an exposed cluster of tyrosines within the thioredoxin fold domain. In vitro, binding occurs to multiple sites within the Pipe polypeptide and shows specificity for two consecutive aromatic residues. A second site in Wind, formed by a cluster of residues within the D-domain, is likewise required for substrate processing. This domain, expressed separately, impairs Pipe processing by the full-length Wind protein, indicating competitive binding to substrate. Our data represent the most accurate map of a peptide binding site in a PDI-related protein available to date and directly show peptide specificity for a naturally occurring substrate.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Gottingen, Dept Struct Chem, D-37077 Gottingen, Germany	Max Planck Society; University of Gottingen	Ferrari, DM (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dferrar@gwdg.de	Sevvana, Madhumati/S-3297-2019	Sevvana, Madhumati/0000-0003-4992-6296				EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoshijima K, 2002, GENE DEV, V16, P2518, DOI 10.1101/gad.1001302; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Monnat J, 2000, MOL BIOL CELL, V11, P3469, DOI 10.1091/mbc.11.10.3469; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Ruddock LW, 2000, PROTEIN SCI, V9, P758; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sen J, 2000, DEVELOPMENT, V127, P5541; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	22	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39829	39837		10.1074/jbc.M406839200	http://dx.doi.org/10.1074/jbc.M406839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252019	hybrid, Green Published			2022-12-25	WOS:000223791500078
J	Kamioka, Y; Fukuhara, S; Sawa, H; Nagashima, J; Masuda, M; Matsuda, M; Mochizuki, N				Kamioka, Y; Fukuhara, S; Sawa, H; Nagashima, J; Masuda, M; Matsuda, M; Mochizuki, N			A novel dynamin-associating molecule, formin-binding protein 17, induces tubular membrane invaginations and participates in endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; RHO-FAMILY; ENDOTHELIAL-CELLS; INTERACTS; ISOFORMS; MICROTUBULES; ORGANIZATION; AMPHIPHYSIN; EXPRESSION; CAVEOLAE	Dynamin associates with a variety of SH3 domain-containing molecules via a C-terminal proline-rich motif and takes part, with them, in endocytic processes. Here, we have investigated a new dynamin-associating molecule, formin-binding protein 17 (FBP17), involved in deforming the plasma membrane and in endocytosis. FBP17 formed tubular invaginations originating from the plasma membrane. Its N-terminal Fer/CIP4 homology domain, a coiled-coil domain, and a proline-rich motif were required for tubular invagination and self-assembly, by which tubular invagination might be induced. Using anti-FBP17 antibody, we detected positive immunoreactions in the testis that were restricted to the germ cells. We also detected FBP17 in the brain by immunoblotting and in situ hybridization. When COS cells expressing enhanced green fluorescent protein-tagged FBP17 were incubated with fluorescently labeled transferrin, epidermal growth factor, and cholera toxin, these molecules co-localized with FBP17-induced tubular invaginations, suggesting that FBP17 is involved in dynamin-mediated endocytosis in both a clathrin-dependent and -independent manner. These observations therefore indicate that FBP17 interacts with dynamin and regulates endocytosis by forming vesicotubular structures.	Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Osaka 5658565, Japan; Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan	National Cerebral & Cardiovascular Center - Japan; Hokkaido University; Osaka University	Mochizuki, N (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, 5-7-1 Fujishirodai, Osaka 5658565, Japan.	nmochizu@ri.ncvc.go.jp	Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; Matsuda, Michiyuki/0000-0002-5876-9969				Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Kamitani A, 2002, BIOCHEM BIOPH RES CO, V294, P261, DOI 10.1016/S0006-291X(02)00470-9; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; Modregger J, 2000, J CELL SCI, V113, P4511; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Naud N, 2003, BIOCHEM J, V372, P105, DOI 10.1042/BJ20021652; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohnishi J, 2001, MOL ENDOCRINOL, V15, P747, DOI 10.1210/me.15.5.747; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Ramjaun AR, 1999, J BIOL CHEM, V274, P19785, DOI 10.1074/jbc.274.28.19785; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	34	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40091	40099		10.1074/jbc.M404899200	http://dx.doi.org/10.1074/jbc.M404899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252009	hybrid			2022-12-25	WOS:000223791500107
J	Nienhaus, K; Maes, EM; Weichsel, A; Montfort, WR; Nienhaus, GU				Nienhaus, K; Maes, EM; Weichsel, A; Montfort, WR; Nienhaus, GU			Structural dynamics controls nitric oxide affinity nitrophorin 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CRYSTAL-STRUCTURES; HEME-PROTEINS; INFRARED-SPECTROSCOPY; BLOODSUCKING INSECT; TRANSPORT PROTEIN; MYOGLOBIN; RESOLUTION; MIGRATION; CAVITIES	Nitrophorin 4 (NP4) is one of seven nitric oxide (NO) transporting proteins in the blood-sucking insect Rhodnius prolixus. In its physiological function, NO binds to a ferric iron centered in a highly ruffled heme plane. Carbon monoxide (CO) also binds after reduction of the heme iron. Here we have used Fourier transform infrared spectroscopy at cryogenic temperatures to study CO and NO binding and migration in NP4, complemented by x-ray cryo-crystallography on xenon-containing NP4 crystals to identify cavities that may serve as ligand docking sites. Multiple infrared stretching bands of the heme-bound ligands indicate different active site conformations with varying degrees of hydrophobicity. Narrow infrared stretching bands are observed for photodissociated CO and NO; temperature-derivative spectroscopy shows that these bands are associated with ligand docking sites close to the extremely reactive heme iron. No rebinding from distinct secondary sites was detected, although two xenon binding cavities were observed in the x-ray structure. Photolysis studies at similar to200 K show efficient NO photoproduct formation in the more hydrophilic, open NP4 conformation. This result suggests that ligand escape is facilitated in this conformation, and blockage of the active site by water hinders immediate reassociation of NO to the ferric iron. In the closed, low-pH conformation, ligand escape from the active site of NP4 is prevented by an extremely reactive heme iron and the absence of secondary ligand docking sites.	Univ Ulm, Dept Biophys, D-89081 Ulm, Germany; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; University of Arizona; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, GU (corresponding author), Univ Ulm, Dept Biophys, Albert Einstein Allee 11, D-89081 Ulm, Germany.	uli@uiuc.edu	Nienhaus, Gerd Ulrich/G-8698-2012	Nienhaus, Gerd Ulrich/0000-0002-5027-3192	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062969] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62969] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; Andersen JF, 1998, STRUCTURE, V6, P1315, DOI 10.1016/S0969-2126(98)00131-2; Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Berry RE, 2004, J BIOL INORG CHEM, V9, P135, DOI 10.1007/s00775-003-0505-0; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; BRAUNSTEIN DP, 1993, BIOPHYS J, V65, P2447, DOI 10.1016/S0006-3495(93)81310-9; CHAMPAGNE DE, 1995, J BIOL CHEM, V270, P8691, DOI 10.1074/jbc.270.15.8691; COTTON FA, 1980, ADV INORG CHEM, P370; Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b; Ding XD, 1999, J AM CHEM SOC, V121, P128, DOI 10.1021/ja982979i; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EWING GE, 1962, J CHEM PHYS, V37, P2250, DOI 10.1063/1.1732994; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kriegl JM, 2003, P NATL ACAD SCI USA, V100, P7069, DOI 10.1073/pnas.1231856100; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Maes EM, 2004, BIOCHEMISTRY-US, V43, P6679, DOI 10.1021/bi049748a; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller LM, 1997, BIOCHEMISTRY-US, V36, P12199, DOI 10.1021/bi962744o; Montfort WR, 2000, BBA-PROTEIN STRUCT M, V1482, P110, DOI 10.1016/S0167-4838(00)00165-5; Moreira MF, 2003, INSECT BIOCHEM MOLEC, V33, P23, DOI 10.1016/S0965-1748(02)00163-7; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Parak FG, 2002, CHEMPHYSCHEM, V3, P249, DOI 10.1002/1439-7641(20020315)3:3<249::AID-CPHC249>3.0.CO;2-A; Park ES, 2002, J PHYS CHEM B, V106, P5800, DOI 10.1021/jp0203043; Park ES, 2000, J AM CHEM SOC, V122, P12297, DOI 10.1021/ja0014741; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; Roberts SA, 2001, BIOCHEMISTRY-US, V40, P11327, DOI 10.1021/bi0109257; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; Weichsel A, 2000, NAT STRUCT BIOL, V7, P551, DOI 10.1038/76769; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	50	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39401	39407		10.1074/jbc.M406178200	http://dx.doi.org/10.1074/jbc.M406178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258143	hybrid			2022-12-25	WOS:000223791500027
J	Rosenfeld, SS; Sweeney, HL				Rosenfeld, SS; Sweeney, HL			A model of myosin V processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CONTRACTION; KINETIC MECHANISM; MOLECULAR MOTOR; ACTIN; NUCLEOTIDE; BINDING; SUBFRAGMENT-1; PROTEINS; WALK	Cytoplasmic transport is mediated by a group of molecular motors that typically work in isolation, under conditions where they must move their cargos long distances without dissociating from their tracks. This processive behavior requires specific adaptations of motor enzymology to meet these unique physiologic demands. One of these involves the ability of the two heads of a processive motor to communicate their structural states to each other. In this study, we examine a processive motor from the myosin superfamily myosin V. We have measured the kinetics of nucleotide release, of phosphate release, and of the weak-to-strong transition, as this motor interacts with actin, and we have used these studies to develop a model of how myosin V functions as a transport motor. Surprisingly, both heads release phosphate rapidly upon the initial encounter with an actin filament, suggesting that there is little or no intramolecular strain associated with this step. However, ADP release can be affected by both forward and rearward strain, and under steady-state conditions it is essentially prevented in the lead head until the rear head detaches. Many of these features are remarkably like those underlying the processive movement of kinesin on microtubules, supporting our hypothesis that different molecular motors satisfy the requirement for processive movement in similar ways, regardless of their particular family of origin.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Pennsylvania	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, FOT 1020,1530 3rd Ave S, Birmingham, AL 35294 USA.	stevensr@uab.edu	Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR048565, AR35661] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048565, R01AR035661] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Holmes KC, 2000, PHILOS T R SOC B, V355, P419, DOI 10.1098/rstb.2000.0583; Marcussen M, 1996, CELL MOTIL CYTOSKEL, V35, P94, DOI 10.1002/(SICI)1097-0169(1996)35:2<94::AID-CM2>3.0.CO;2-I; MARCUSSEN M, 1994, BBA-BIOMEMBRANES, V1194, P197, DOI 10.1016/0005-2736(94)90220-8; Mehta A, 2001, J CELL SCI, V114, P1981; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nagamatsu S, 1996, BIOCHEM J, V319, P477, DOI 10.1042/bj3190477; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	137	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40100	40111		10.1074/jbc.M402583200	http://dx.doi.org/10.1074/jbc.M402583200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254035	hybrid			2022-12-25	WOS:000223791500108
J	Yung, TMC; Sato, S; Satoh, MS				Yung, TMC; Sato, S; Satoh, MS			Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; STRAND BREAK REPAIR; HELA-CELL NUCLEI; NF-KAPPA-B; TOPOISOMERASE-I; ADP-RIBOSE; LIVING CELLS; POLYMERASE-ALPHA; EXCISION-REPAIR; LIGASE-III	Poly(ADP-ribosyl) ation is a post-translational modification that occurs immediately after exposure of cells to DNA damaging agents. In vivo, 90% of ADP-ribose polymers are attached to the automodification domain of poly( ADP-ribose) polymerase-1 (PARP-1), the main enzyme catalyzing this modification reaction. This enzyme forms complexes with transcription initiation, DNA replication, and DNA repair factors. In most known cases, the interactions occur through the automodification domain. However, functional implications of the automodification reaction on these interactions have not yet been elucidated. In the present study, we created fluorescent protein-tagged PARP-1 to study this enzyme in live cells and focused on the interaction between PARP-1 and topoisomerase I ( Topo I), one of the enzymes that interacts with PARP-1 in vitro. Here, we demonstrate that PARP-1 co-localizes with Topo I throughout the cell cycle. Results from bioluminescence resonance energy transfer assays suggest that the co-localization is because of a direct protein-protein interaction. In response to DNA damage, PARP-1 de-localization and a reduction in bioluminescence resonance energy transfer signal because of the automodification reaction are observed, suggesting that the automodification reaction results in the disruption of the interaction between PARP-1 and Topo I. Because Topo I activity has been reported to be promoted by PARP-1, we then investigated the effect of the disruption of this interaction on Topo I activity, and we found that this disruption results in the reduction of Topo I activity. These results suggest that a function for the automodification reaction is to regulate the interaction between PARP-1 and Topo I, and consequently, the Topo I activity, in response to DNA damage.	Univ Laval, Fac Med, CHUQ, Med Ctr,Lab DNA Rapair,Hlth & Environm Unit, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, CHUQ, Med Ctr,Glycobiol Lab,Res Ctr Infect Dis, Ste Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Satoh, MS (corresponding author), Univ Laval, Fac Med, CHUQ, Med Ctr,Lab DNA Rapair,Hlth & Environm Unit, Ste Foy, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bauer PI, 2000, INT J MOL MED, V5, P533; Bauer PI, 2001, FEBS LETT, V506, P239, DOI 10.1016/S0014-5793(01)02919-2; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; Ho ELY, 2003, NUCLEIC ACIDS RES, V31, P7032, DOI 10.1093/nar/gkg892; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JONGSTRABILEN J, 1983, EUR J BIOCHEM, V136, P391, DOI 10.1111/j.1432-1033.1983.tb07754.x; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Malone JP, 2001, ELECTROPHORESIS, V22, P919, DOI 10.1002/1522-2683()22:5<919::AID-ELPS919>3.0.CO;2-U; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MIWA M, 1984, METHOD ENZYMOL, V106, P441; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OGATA N, 1981, J BIOL CHEM, V256, P4135; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Somanathan S, 2001, J CELL BIOCHEM, V81, P56, DOI 10.1002/1097-4644(20010401)81:1<56::AID-JCB1023>3.0.CO;2-#; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Vispe S, 2003, J BIOL CHEM, V278, P35279, DOI 10.1074/jbc.M303448200; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wesierska-Gadek J, 2003, J CELL BIOCHEM, V89, P220, DOI 10.1002/jcb.10521; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; YOSHIDA S, 1994, MOL CELL BIOCHEM, V138, P39, DOI 10.1007/BF00928441; Yung TMC, 2004, J BIOL CHEM, V279, P11992, DOI 10.1074/jbc.M312459200; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	69	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39686	39696		10.1074/jbc.M402729200	http://dx.doi.org/10.1074/jbc.M402729200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247263	hybrid			2022-12-25	WOS:000223791500060
J	Cao, C; Mu, Y; Hallahan, DE; Lu, B				Cao, C; Mu, Y; Hallahan, DE; Lu, B			XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer	ONCOGENE			English	Article						XIAP; survivin; lung cancer; radio therapy	X-LINKED INHIBITOR; ENDOTHELIAL-CELLS; IAP PROTEINS; APOPTOSIS; EXPRESSION; MARKER; GENE; ANGIOPOIETIN-1; ANGIOGENESIS; SUPPRESSION	Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs ( P = 0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI NIH HHS [R01-CA89674, R01-CA88076, R01-CA58508, P50-CA90949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090949, R01CA058508, R01CA088076, R01CA089674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Bao RD, 2002, J NATL CANCER I, V94, P522; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Edwards E, 2002, CANCER RES, V62, P4671; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Geng L, 2001, CANCER RES, V61, P2413; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ikehara M, 2002, ONCOL REP, V9, P835; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7	28	147	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7047	7052		10.1038/sj.onc.1207929	http://dx.doi.org/10.1038/sj.onc.1207929			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258565				2022-12-25	WOS:000223885100005
J	Zhou, Y; Gu, GY; Goodlett, DR; Zhang, T; Pan, C; Montine, TJ; Montine, KS; Aebersold, RH; Zhang, J				Zhou, Y; Gu, GY; Goodlett, DR; Zhang, T; Pan, C; Montine, TJ; Montine, KS; Aebersold, RH; Zhang, J			Analysis of alpha-synuclein-associated proteins by quantitative proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL LEWY BODIES; PARKINSONS-DISEASE; TYROSINE-HYDROXYLASE; HUMAN BRAIN; UBIQUITIN; MUTATION; BINDING; PROTEASOME; COMPONENT; DEMENTIA	To identify the proteins associated with soluble alpha-synuclein (AS) that might promote AS aggregation, a key event leading to neurodegeneration, we quantitatively compared protein profiles of AS-associated protein complexes in MES cells exposed to rotenone, a pesticide that produces parkinsonism in animals and induces Lewy body (LB)-like inclusions in the remaining dopaminergic neurons, and to vehicle. We identified more than 250 proteins associated with Nonidet P-40 soluble AS, and demonstrated that at least 51 of these proteins displayed significant differences in their relative abundance in AS complexes under conditions where rotenone was cytotoxic and induced formation of cytoplasmic inclusions immunoreactive to anti-AS. Overexpressing one of these proteins, heat shock protein (hsp) 70, not only protected cells from rotenonemediated cytotoxicity but also decreased soluble AS aggregation. Furthermore, the protection afforded by hsp70 transfection appeared to be related to suppression of rotenone-induced oxidative stress as well as mitochondrial and proteasomal dysfunction.	Univ Washington, Sch Med, Dept Pathol,Div Neuropathol, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Med Chem, Seattle, WA 98104 USA; Inst Syst Biol, Seattle, WA 98103 USA; Thermo Electron Corp, San Jose, CA 95134 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB)	Zhang, J (corresponding author), Univ Washington, Sch Med, Dept Pathol,Div Neuropathol, Harborview Med Ctr, Box 359635, Seattle, WA 98104 USA.	zhangj@u.washington.edu		Montine, Kathleen/0000-0003-2110-8363; Zhang, Jing/0000-0002-9224-6299	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010196, R01ES012703] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05842, ES10196, ES12703] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; ARAI H, 1992, BRAIN RES, V585, P386, DOI 10.1016/0006-8993(92)91242-7; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BRION JP, 1995, AM J PATHOL, V147, P1465; D'Andrea MR, 2001, NEUROSCI LETT, V306, P137, DOI 10.1016/S0304-3940(01)01811-0; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Elkon H, 2002, J MOL NEUROSCI, V18, P229, DOI 10.1385/JMN:18:3:229; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Gai WP, 1996, ACTA NEUROPATHOL, V91, P78; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Goodlett David R, 2002, Funct Integr Genomics, V2, P138; Goodlett DR, 2001, RAPID COMMUN MASS SP, V15, P1214, DOI 10.1002/rcm.362; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Ihara M, 2003, J BIOL CHEM, V278, P24095, DOI 10.1074/jbc.M301352200; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; IWATSUBO T, 1991, ACTA NEUROPATHOL, V82, P159, DOI 10.1007/BF00294440; Jansen R P, 2000, Hum Reprod, V15 Suppl 2, P1; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; KINTER M, 2002, WILEY INTERSCIENCE S, P152; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Lansbury PT, 2002, CURR OPIN GENET DEV, V12, P299, DOI 10.1016/S0959-437X(02)00302-7; Lee D, 2002, J NEUROCHEM, V82, P1007, DOI 10.1046/j.1471-4159.2002.01024.x; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Li XJ, 2003, ANAL CHEM, V75, P6648, DOI 10.1021/ac034633i; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; LOWE JS, 2002, GREENFIELDS NEUROPAT, V2, P325; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; Murray IVJ, 2003, ACTA NEUROPATHOL, V105, P177, DOI 10.1007/s00401-002-0629-2; NAKASHIMA S, 1984, J NEUROL SCI, V66, P91, DOI 10.1016/0022-510X(84)90144-8; NISHIYAMA K, 1995, ACTA NEUROPATHOL, V89, P471; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2004, J NEUROCHEM, V89, P1318, DOI 10.1111/j.1471-4159.2004.02423.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Power JHT, 2002, AM J PATHOL, V161, P885, DOI 10.1016/S0002-9440(10)64249-6; Rao P, 2003, J NEUROCHEM, V85, P13; Sasaki K, 2002, ACTA NEUROPATHOL, V104, P225, DOI 10.1007/s00401-002-0546-4; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Takao M, 2002, ACTA NEUROPATHOL, V104, P155, DOI 10.1007/s00401-002-0536-6; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x; Trojanowski JQ, 2002, NEUROTOXICOLOGY, V23, P457, DOI 10.1016/S0161-813X(02)00065-7; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Yi EC, 2002, ELECTROPHORESIS, V23, P3205, DOI 10.1002/1522-2683(200209)23:18<3205::AID-ELPS3205>3.0.CO;2-Y; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang J, 2000, J NEUROCHEM, V74, P970, DOI 10.1046/j.1471-4159.2000.0740970.x; ZHANG J, 2004, IN PRESS NEUROBIOL A	77	144	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39155	39164		10.1074/jbc.M405456200	http://dx.doi.org/10.1074/jbc.M405456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234983	hybrid			2022-12-25	WOS:000223684100132
J	Bennett, MK; Toth, JI; Osborne, TF				Bennett, MK; Toth, JI; Osborne, TF			Selective association of sterol regulatory element-binding protein isoforms with target promoters in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; GENE-EXPRESSION; SYNTHASE GENE; CHOLESTEROL; SREBPS; LIVER; RECRUITMENT	The mRNAs for all three members of the sterol regulatory element-binding protein ( SREBP) family are widely expressed, and the proteins are highly similar. They have potential to both hetero- and homodimerize through their bHLHLZ domains, so it has been difficult to definitively study the role of each one apart from the other two. In the current study, we have utilized cell lines that express only one functional SREBP and the chromatin immunoprecipitation technique to analyze individual SREBP binding to three specific target genes: hydroxymethylglutaryl-CoA reductase ( Red), fatty acid synthase (FAS), and squalene synthase (SQS). Our studies show that SREBP-2 binds to promoters for all three genes, and in agreement with the original report using these cells, all three mRNAs are also induced. In the line expressing only SREBP-1a, mRNAs for Red and FAS are induced, but SQS is not. Chromatin immunoprecipitation also shows that SREBP-1a is recruited efficiently to Red and FAS promoters but not to SQS. This observation indicates SREBP-2 selectively binds the SQS promoter and is sufficient to explain the lack of SQS mRNA induction in the SREBP-1a-expressing cells. SREBP-1c protein was not stably recruited to any SREBP target promoter despite being fully active in DNA binding when purified from extracts of the corresponding cells. This is also sufficient to explain the lack of SREBP target gene induction by the singular expression of SREBP-1c. We also show that whereas SREBP-1a and -2 proteins interact efficiently with transcriptional co-activators that modify cellular chromatin, SREBP-1c does not. Taken together, our data support a model suggesting that chromatin modification is required during the initial stage of specific site recognition by SREBPs in native chromatin in vivo.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Goodman RH, 2000, GENE DEV, V14, P1553; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Osborne TF, 2001, GENE DEV, V15, P1873, DOI 10.1101/gad.916601; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; SATO R, 1994, J BIOL CHEM, V269, P17267; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247	26	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37360	37367		10.1074/jbc.M404693200	http://dx.doi.org/10.1074/jbc.M404693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220339	hybrid			2022-12-25	WOS:000223554600022
J	Crespo, JL; Helliwell, SB; Wiederkehr, C; Demougin, P; Fowler, B; Primig, M; Hall, MN				Crespo, JL; Helliwell, SB; Wiederkehr, C; Demougin, P; Fowler, B; Primig, M; Hall, MN			NPR1 kinase and RSP5-BUL1/2 ubiquitin ligase control GLN3-dependent transcription in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; TOR SIGNALING PATHWAY; INTRACELLULAR TRAFFICKING; TRYPTOPHAN PERMEASE; SECRETORY PATHWAY; GENE-EXPRESSION; GATA FACTORS; CELL-GROWTH; NITROGEN; YEAST	The GATA transcription factors GLN3 and GAT1 activate nitrogen-regulated genes in Saccharomyces cerevisiae. NPR1 is a protein kinase that controls post-Golgi sorting of amino acid permeases. In the presence of a good nitrogen source, TOR ( target of rapamycin) maintains GLN3 and NPR1 phosphorylated and inactive by inhibiting the type 2A-related phosphatase SIT4. We identified NPR1 as a regulator of GLN3. Specifically, loss of NPR1 causes nuclear translocation and activation of GLN3, but not GAT1, in nitrogen-rich conditions. NPR1-mediated inhibition of GLN3 is independent of the phosphatase SIT4. We also demonstrate that the E3/E4 ubiquitin-protein ligase proteins RSP5 and BUL1/2 are required for GLN3 activation under poor nitrogen conditions. Thus, NPR1 and BUL1/2 antagonistically control GLN3-dependent transcription, suggesting a role for regulated ubiquitination in the control of nutrient-responsive transcription.	Univ Basel, Div Biochem, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Swiss Inst Bioinformat, CH-4056 Basel, Switzerland; Univ Childrens Hosp, CH-4005 Basel, Switzerland	University of Basel; Swiss Institute of Bioinformatics; University of Basel	Hall, MN (corresponding author), Univ Basel, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch	Crespo, Jose L/L-3977-2014; Primig, Michael/G-3175-2013	Crespo, Jose L/0000-0003-3514-1025; Primig, Michael/0000-0002-2061-0119; Hall, Michael N/0000-0002-2998-0757				Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Coffman JA, 1997, J BACTERIOL, V179, P5609, DOI 10.1128/jb.179.17.5609-5613.1997; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COOPER TG, 1990, J BACTERIOL, V172, P1014, DOI 10.1128/jb.172.2.1014-1018.1990; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; ELBERRY HM, 1993, J BACTERIOL, V175, P4688, DOI 10.1128/JB.175.15.4688-4698.1993; GILMAN M, 1998, CURRENT PROTOCOLS MO; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Roberg KJ, 1997, GENETICS, V147, P1569; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Saxena D, 2003, EUKARYOT CELL, V2, P552, DOI 10.1128/EC.2.3.552-559.2003; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845	32	44	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37512	37517		10.1074/jbc.M407372200	http://dx.doi.org/10.1074/jbc.M407372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247235	hybrid, Green Accepted			2022-12-25	WOS:000223554600041
J	Hashimoto, S; Hashimoto, A; Yamada, A; Kojima, C; Yamamoto, H; Tsutsumi, T; Higashi, M; Mizoguchi, A; Yagi, R; Sabe, H				Hashimoto, S; Hashimoto, A; Yamada, A; Kojima, C; Yamamoto, H; Tsutsumi, T; Higashi, M; Mizoguchi, A; Yagi, R; Sabe, H			A novel mode of action of an ArfGAP, AMAP2/PAG3/Pap alpha, in Arf6 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RECEPTOR-MEDIATED PHAGOCYTOSIS; ADP-RIBOSYLATION; PLASMA-MEMBRANE; CRYSTAL-STRUCTURE; BINDING PROTEIN; DOMAIN; COATOMER; GAP; PAG3/PAP-ALPHA/KIAA0400	Previously we reported that AMAP2/PAG3/Papalpha/ KIAA0400, a GTPase-activating protein ( GAP), acts to antagonize Arf6 function when overexpressed, whereas it was shown to exhibit efficient GAP activities for other Arf isoforms in vitro. Here, we found that AMAP2, through its ArfGAP domain, binds to GTP-Arf6 but not to GDP-Arf6 or other Arfs irrespective of nucleotide status. The majority of AMAP2 was localized to intracellular tubulovesicular structures and redistributed to Arf6-enriched membrane areas upon Arf6 activation. In HeLa cells, Arf6 has been shown to be involved in the clathrin-independent endocytosis of Tac, but not the clathrin-dependent endocytosis of transferrin. We found that Arf6 silencing inhibited the internalization of Tac, but not transferrin, in HeLa cells. Internalization of Tac, but not transferrin, was also significantly inhibited by AMAP2 silencing and overexpression. AMAP2 was moreover found to bind to amphiphysin IIm, a component of the endocytic machinery, via its proline-rich domain. We propose that AMAP2 has dual mechanisms for its function; it exhibits efficient catalytic GAP activity for the class I and II Arfs and yet is involved in the cellular function of the class III Arf without immediate GAP activity. These dual mechanisms of AMAP2 may be important for the cellular function of GTP-Arf6.	Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan; Mie Univ, Fac Med, Dept Neural Regenerat & Cell Commun, Tsu, Mie 5148507, Japan	Kyoto University; Mie University	Sabe, H (corresponding author), Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan.	sabe@obi.or.jp	Hashimoto, Ari/D-7125-2012; Kojima, Chie/GOV-5380-2022; Sabe, Hisataka/GPF-4385-2022; Hashimoto, Shigeru/D-7138-2012					Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; De Camilli P, 2001, SYNAPSES, P217; Donaldson JG, 2001, METHOD ENZYMOL, V329, P247; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; Gold ES, 2000, IMMUNITY, V12, P285, DOI 10.1016/S1074-7613(00)80181-8; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HART MJ, 1994, J BIOL CHEM, V269, P62; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Perry DG, 1999, J IMMUNOL, V162, P380; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Roth MG, 2000, FR MOLEC B, V24, P176; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Sabe H, 2003, PROTEINS CELL REG, V1, P185; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Uchida H, 2001, J EXP MED, V193, P955, DOI 10.1084/jem.193.8.955; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	53	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37677	37684		10.1074/jbc.M404196200	http://dx.doi.org/10.1074/jbc.M404196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231847	hybrid			2022-12-25	WOS:000223554600059
J	Niimi, T; Hayashi, Y; Futaki, S; Sekiguchi, K				Niimi, T; Hayashi, Y; Futaki, S; Sekiguchi, K			SOX7 and SOX17 regulate the parietal endoderm-specific enhancer activity of mouse laminin alpha 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-Y; RETINOIC ACID; DIFFERENTIAL EXPRESSION; RESTRICTED DISTRIBUTION; TRANSCRIPTION FACTORS; CARTILAGE FORMATION; MESSENGER-RNA; B-CHAINS; A-CHAIN; CELLS	Laminin-1 is the major component of embryonic basement membrane and consists of alpha1, beta1, and gamma1 chains. The expression of laminin-1 is induced in mouse F9 embryonal carcinoma cells upon differentiation into parietal endoderm cells. We recently identified a parietal endoderm-specific enhancer in the mouse laminin alpha1 (Lama1) gene and showed that Sp1/Sp3 and YY1 transcription factors were involved in the enhancer activity. Although here we identified that NF-Y binds to the enhancer sequence between Sp1/Sp3- and YY1-binding sites, all these transcription factors are ubiquitously expressed and thus are not sufficient to explain parietal endoderm-specific enhancer activity. In the present study, we further showed that SOX7 and SOX17 are involved in the regulation of parietal endoderm-specific enhancer activity of the mouse Lama1 gene. Northern blot analysis revealed that the steady-state levels of mouse Sox7 and Sox17 mRNAs increased in parallel with that of Lama1 mRNA during the differentiation of F9 cells. Both SOX7 and SOX17 markedly trans-activated the transcription of the Lama1 enhancer-reporter construct in undifferentiated F9 cells in a manner dependent on high mobility group box-mediated DNA binding. Electrophoretic mobility shift assays and mutational analyses revealed that SOX7 and SOX17 bound specifically to two SOX-binding sites within the Lama1 enhancer, and that these SOX-binding sites functioned synergistically to confer the trans-activation by SOX7 and SOX17. Furthermore, this trans-activation was dependent on the integrity of the binding sites for Sp1/Sp3 and NF-Y located at upstream of the two SOX-binding sites. These results indicate that the transcription of the mouse Lama1 gene during the differentiation of F9 cells is controlled by a combination of the actions of the ubiquitous factors, Sp1/Sp3 and NF-Y, and the parietal endoderm-specific factors, SOX7 and SOX17.	Aichi Med Univ, JApan Sci & Technol Agcy, Sekiguchi Biomatrix Signaling Project, ERATO, Aichi 4801195, Japan; Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan	Aichi Medical University; Japan Science & Technology Agency (JST); Osaka University	Hayashi, Y (corresponding author), Aichi Med Univ, JApan Sci & Technol Agcy, Sekiguchi Biomatrix Signaling Project, ERATO, 21 KArimata, Aichi 4801195, Japan.	hayashiy@aichi-med-u.ac.jp	Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Clements D, 2001, INT REV CYTOL, V203, P383; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Falk M, 1999, MATRIX BIOL, V18, P557, DOI 10.1016/S0945-053X(99)00047-5; Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; Hosking BM, 2004, J BIOL CHEM, V279, P5314, DOI 10.1074/jbc.M308512200; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; KLEIN G, 1990, DEVELOPMENT, V110, P823; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Magan N, 2003, BIOCHEM J, V374, P723, DOI 10.1042/BJ20030032; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Niimi T, 2003, J BIOL CHEM, V278, P9332, DOI 10.1074/jbc.M212578200; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; RODER KH, 1997, BIOCHEM SOC T, V25, P72; SASAKI M, 1988, J BIOL CHEM, V263, P16536; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Taniguchi K, 1999, BBA-GENE STRUCT EXPR, V1445, P225, DOI 10.1016/S0167-4781(99)00047-0; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wells JM, 2000, DEVELOPMENT, V127, P1563; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200	45	63	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38055	38061		10.1074/jbc.M403724200	http://dx.doi.org/10.1074/jbc.M403724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220343	hybrid, Green Published			2022-12-25	WOS:000223554600100
J	Wu, DL; Dou, XW; Hashmi, SB; Osmani, SA				Wu, DL; Dou, XW; Hashmi, SB; Osmani, SA			The Pho80-like cyclin of Aspergillus nidulans regulates development independently of its role in phosphate acquisition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL-CYCLE; ACID-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATORS; MOLECULAR ANALYSIS; TRANSCRIPTIONAL REGULATION; SUBSTRATE-SPECIFICITY; ASEXUAL SPORULATION; NEUROSPORA-CRASSA	In Saccharomyces cerevisiae, phosphate acquisition enzymes are regulated by a cyclin-dependent kinase (Pho85), a cyclin (Pho80), the cyclin-dependent kinase inhibitor Pho81, and the helix-loop-helix transcription factor Pho4 ( the PHO system). Previous studies in Aspergillus nidulans indicate that a Pho85-like kinase, PHOA, does not regulate the classic PHO system but regulates development in a phosphate-dependent manner. A Pho80-like cyclin has now been isolated through its interaction with PHOA. Surprisingly, unlike PHOA, An-PHO80 does play a negative role in the PHO system. Similarly, an ortholog of Pho4 previously identified genetically as palcA also regulates the PHO system. However, An-PHO81, a putative cyclin- dependent kinase inhibitor, does not regulate the PHO system. Therefore, there are significant differences between the classic PHO system conserved between S. cerevisiae and Neurospora crassa compared with that which has evolved in A. nidulans. Most interestingly, under low phosphate conditions, the An-PHO80 cyclin also promotes sexual development while having a negative effect on asexual development. These effects are independent of the role An-PHO80 has in the classic PHO system. However, in high phosphate medium, An-PHO80 affects development because of deregulation of the PHO system as loss of palcA(Pho4) function negates the developmental defects caused by lack of An-pho80. Therefore, under low phosphate conditions the An-PHO80 cyclin regulates development independently of the PHO system, whereas in high phosphate it affects development through the PHO system. The data indicate that a single cyclin can control various aspects of growth and development in a multicellular organism.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Osmani, SA (corresponding author), Ohio State Univ, Dept Mol Genet, 802 Riffe Bldg,496 W 12th Ave, Columbus, OH 43210 USA.	osmani.2@osu.edu	Osmani, Stephen A./AAS-3904-2021		NIGMS NIH HHS [GM42564] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Aerne BL, 1998, MOL BIOL CELL, V9, P945, DOI 10.1091/mbc.9.4.945; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BERGMAN LW, 1986, MOL CELL BIOL, V6, P2298, DOI 10.1128/MCB.6.7.2298; BERGMAN LW, 1986, MOL CELL BIOL, V6, P38, DOI 10.1128/MCB.6.1.38; BERGMAN LW, 1986, P NATL ACAD SCI USA, V83, P6070, DOI 10.1073/pnas.83.16.6070; Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133; BOSTIAN KA, 1980, P NATL ACAD SCI-BIOL, V77, P4504, DOI 10.1073/pnas.77.8.4504; Bussink HJ, 1998, EMBO J, V17, P3990, DOI 10.1093/emboj/17.14.3990; BUTNICK NZ, 1984, J BACTERIOL, V160, P533, DOI 10.1128/JB.160.2.533-540.1984; CADDICK MX, 1986, GENET RES, V47, P83, DOI 10.1017/S0016672300022904; CADDICK MX, 1986, GENET RES, V47, P93, DOI 10.1017/S0016672300022916; Calvo AM, 2001, J BIOL CHEM, V276, P25766, DOI 10.1074/jbc.M100732200; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMPE SP, 1987, J GEN MICROBIOL, V133, P1383; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Colwill K, 1999, GENETICS, V152, P881; DORN G, 1965, GENET RES, V6, P13, DOI 10.1017/S0016672300003943; DORN G, 1965, SCIENCE, V150, P1183, DOI 10.1126/science.150.3700.1183; Dou XW, 2003, GENETICS, V165, P1105; Friesen H, 2003, MOL BIOL CELL, V14, P3027, DOI 10.1091/mbc.E02-09-0613; GILLIQUET V, 1993, FEMS MICROBIOL LETT, V108, P333, DOI 10.1016/0378-1097(93)90564-I; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KANG S, 1993, GENETICS, V133, P193; Kuwayama H, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e2; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; MADDEN SL, 1990, MOL CELL BIOL, V10, P5950, DOI 10.1128/MCB.10.11.5950; MADDEN SL, 1988, NUCLEIC ACIDS RES, V16, P2625, DOI 10.1093/nar/16.6.2625; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1980, GENETICS, V96, P627; OAKLEY BR, 1987, GENE, V61, P385, DOI 10.1016/0378-1119(87)90201-0; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Osmani AH, 2003, MOL BIOL CELL, V14, P3169, DOI 10.1091/mbc.E02-11-0715; OSMANI AH, 1994, J CELL SCI, V107, P1519; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; Peleg Y, 1996, FUNGAL GENET BIOL, V20, P185, DOI 10.1006/fgbi.1996.0034; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Schier N, 2002, FEBS LETT, V523, P143, DOI 10.1016/S0014-5793(02)02964-2; Schier N, 2001, MOL CELL BIOL, V21, P4075, DOI 10.1128/MCB.21.12.4075-4088.2001; Tennyson CN, 1998, MOL MICROBIOL, V28, P69, DOI 10.1046/j.1365-2958.1998.00773.x; Timblin BK, 1996, GENETICS, V143, P57; Toh EA, 2001, J GEN APPL MICROBIOL, V47, P107; Tsitsigiannis DI, 2004, J BIOL CHEM, V279, P11344, DOI 10.1074/jbc.M310840200; UESONO Y, 1992, MOL GEN GENET, V231, P426, DOI 10.1007/BF00292712; Wang Z, 2001, FEBS LETT, V506, P277, DOI 10.1016/S0014-5793(01)02914-3; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	63	29	37	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37693	37703		10.1074/jbc.M403853200	http://dx.doi.org/10.1074/jbc.M403853200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247298	hybrid			2022-12-25	WOS:000223554600061
J	Dash, C; Yi-Brunozzi, HY; Le Grice, SFJ				Dash, C; Yi-Brunozzi, HY; Le Grice, SFJ			Two modes of HIV-1 polypurine tract cleavage are affected by introducing locked nucleic acid analogs into the (-) DNA template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 REVERSE-TRANSCRIPTASE; MURINE LEUKEMIA-VIRUS; PRIMER GRIP REGION; SEQUENCE FEATURES IMPORTANT; GROOVE BINDING TRACK; ALPHA-L-LNA; IMMUNODEFICIENCY-VIRUS; RNASE-H; THUMB SUBDOMAIN; SCANNING MUTAGENESIS	Unusual base-pairing in a co-crystal of reverse transcriptase (RT) and a human immunodeficiency virus type 1 (HIV-1) polypurine tract (PPT)-containing RNA/DNA hybrid suggests local nucleic acid flexibility mediates selection of the plus-strand primer. Structural elements of HIV-1 RT potentially participating in recognition of this duplex include the thumb subdomain and the ribonuclease H (RNase H) primer grip, the latter comprising elements of the connection subdomain and RNase H domain. To investigate how stabilizing HIV-1 PPT structure influences its recognition, we modified the (-) DNA template by inserting overlapping locked nucleic acid (LNA) doublets and triplets. Modified RNA/DNA hybrids were evaluated for cleavage at the PPT/U3 junction. Altered specificity was observed when the homopolymeric dA.rU tract immediately 5' of the PPT was modified, whereas PPT/U3 cleavage was lost after substitutions in the adjacent dT.rA tract. In contrast, the "unzipped" portion of the PPT was moderately insensitive to LNA insertions. Although a portion of the dC.rG and neighboring dT.rA tract were minimally affected by LNA insertion, RNase H activity was highly sensitive to altering the junction between these structural elements. Using 3'-end-labeled PPT RNA primers, we also identified novel cleavage sites ahead (+5/+6) of the PPT/U3 junction. Differential cleavage at the PPT/U3 junction and U3 +5/+6 site in response to LNA-induced template modification suggests two binding modes for HIV-1 RT, both of which may be controlled by the interaction of its thumb subdomain (potentially via the minor groove binding track) at either site of the unzipped region.	NCI, Reverse Transcriptase Biochem Sect, HIV Drug Resistance Program, Resistance Mech Lab,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, HIV Drug Resistance Program, Resistance Mech Lab,NIH, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov		Dash, Chandravanu/0000-0003-4466-8355	DIVISION OF BASIC SCIENCES - NCI [Z01BC010492] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacharach E, 2000, J VIROL, V74, P4755, DOI 10.1128/JVI.74.10.4755-4764.2000; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Dash C, 2004, NUCLEIC ACIDS RES, V32, P1539, DOI 10.1093/nar/gkh307; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; Han GW, 1997, J MOL BIOL, V269, P811, DOI 10.1006/jmbi.1997.1085; Horton NC, 1996, J MOL BIOL, V264, P521, DOI 10.1006/jmbi.1996.0658; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNG SH, 1994, NUCLEIC ACIDS RES, V22, P4326, DOI 10.1093/nar/22.20.4326; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; Julias JG, 2003, J VIROL, V77, P8548, DOI 10.1128/JVI.77.15.8548-8554.2003; Kanagawa M, 1998, NUCLEOS NUCLEOT NUCL, V17, P831, DOI 10.1080/07328319808004678; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; Lim D, 2002, J VIROL, V76, P8360, DOI 10.1128/JVI.76.16.8360-8373.2002; McWilliams MJ, 2003, J VIROL, V77, P11150, DOI 10.1128/JVI.77.20.11150-11157.2003; Nielsen KME, 2002, CHEM-EUR J, V8, P3001, DOI 10.1002/1521-3765(20020703)8:13<3001::AID-CHEM3001>3.0.CO;2-1; Orum H, 2001, CURR OPIN MOL THER, V3, P239; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d; Petersen M, 2003, TRENDS BIOTECHNOL, V21, P74, DOI 10.1016/S0167-7799(02)00038-0; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Rausch JW, 2002, BIOCHEMISTRY-US, V41, P4856, DOI 10.1021/bi015970t; SALAZAR M, 1994, J MOL BIOL, V241, P440, DOI 10.1006/jmbi.1994.1519; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 2003, J VIROL, V77, P5275, DOI 10.1128/JVI.77.9.5275-5285.2003; Szyperski T, 1999, J BIOMOL NMR, V13, P343, DOI 10.1023/A:1008350604637; Telesnitsky A., 1997, P121; Wengel J, 2003, NUCLEOS NUCLEOT NUCL, V22, P601, DOI 10.1081/NCN-120021963; Wisniewski M, 1999, J BIOL CHEM, V274, P28175, DOI 10.1074/jbc.274.40.28175; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; Yu Q, 1998, J VIROL, V72, P7676, DOI 10.1128/JVI.72.9.7676-7680.1998; ZHU LM, 1995, BIOCHEMISTRY-US, V34, P2372, DOI 10.1021/bi00007a033	59	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37095	37102		10.1074/jbc.M403306200	http://dx.doi.org/10.1074/jbc.M403306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220330	hybrid			2022-12-25	WOS:000223453600113
J	Lia, LJ; Cheng, DM; Wang, J; Duong, DM; Losik, TG; Gearing, M; Rees, HD; Lah, JJ; Levey, AI; Peng, JM				Lia, LJ; Cheng, DM; Wang, J; Duong, DM; Losik, TG; Gearing, M; Rees, HD; Lah, JJ; Levey, AI; Peng, JM			Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ALZHEIMER-DISEASE PATIENTS; MASS-SPECTROMETRY; NEUROFIBRILLARY TANGLES; CYSTATIN-C; PROTEIN IDENTIFICATION; YEAST PROTEOME; TAU-PROTEIN; BRAIN; BETA	The presence of amyloid plaques in the brain is one of the pathological hallmarks of Alzheimer's disease (AD). We report here a comprehensive proteomic analysis of senile plaques from postmortem AD brain tissues. Senile plaques labeled with thioflavin-S were procured by laser capture microdissection, and their protein components were analyzed by liquid chromatography coupled with tandem mass spectrometry. We identified a total of 488 proteins coisolated with the plaques, and we found multiple phosphorylation sites on the neurofilament intermediate chain, implicating the complexity and diversity of cellular processes involved in the plaque formation. More significantly, we identified 26 proteins enriched in the plaques of two AD cases by quantitative comparison with surrounding non-plaque tissues. The localization of several proteins in the plaques was further confirmed by the approach of immunohistochemistry. In addition to previously identified plaque constituents, we discovered novel association of dynein heavy chain with the plaques in human postmortem brain and in a double transgenic AD mouse model, suggesting that neuronal transport may play a role in neuritic degeneration. Overall, our results revealed for the first time the sub-proteome of amyloid plaques that is important for further studies on disease biomarker identification and molecular mechanisms of AD pathogenesis.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Peng, JM (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.	jpeng@genetics.emory.edu	Liao, Lujian/G-5976-2010; Peng, Junmin/N-2614-2018; Levey, Allan/F-2104-2011	Peng, Junmin/0000-0003-0472-7648; Levey, Allan/0000-0002-3153-502X; Duong, Duc/0000-0001-5880-1888				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Chelius D, 2003, ANAL CHEM, V75, P6658, DOI 10.1021/ac034607k; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Crawford FC, 2000, NEUROLOGY, V55, P763, DOI 10.1212/WNL.55.6.763; Deng A, 2001, AM J PATHOL, V159, P1061, DOI 10.1016/S0002-9440(10)61781-6; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Forloni G, 2002, NEUROBIOL AGING, V23, P957, DOI 10.1016/S0197-4580(02)00076-3; FURUTA A, 1995, AM J PATHOL, V146, P357; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; KALARIA RN, 1992, NEUROSCIENCE, V51, P177, DOI 10.1016/0306-4522(92)90482-H; Kinoshita A, 1998, AM J PATHOL, V153, P1551, DOI 10.1016/S0002-9440(10)65743-4; Kopec K, 1997, P SOC EXP BIOL MED, V216, P429; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levy E, 2001, J NEUROPATH EXP NEUR, V60, P94, DOI 10.1093/jnen/60.1.94; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MANDYBUR TI, 1990, NEUROLOGY, V40, P635, DOI 10.1212/WNL.40.4.635; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Masliah E, 1996, AM J PATHOL, V148, P201; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; Meda L, 2001, NEUROBIOL AGING, V22, P885, DOI 10.1016/S0197-4580(01)00307-4; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Narita M, 1997, J NEUROCHEM, V69, P1904; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rappsilber J, 2002, TRENDS BIOCHEM SCI, V27, P74, DOI 10.1016/S0968-0004(01)02021-7; RENKAWEK K, 1993, NEUROREPORT, V5, P14, DOI 10.1097/00001756-199310000-00003; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; SMITH MA, 1994, AM J PATHOL, V145, P42; SNOW AD, 1988, AM J PATHOL, V133, P456; TERRY RD, 1964, AM J PATHOL, V44, P269; Terry RD, 1998, J NEURAL TRANSM-SUPP, P141; Trinczek B, 1999, J CELL SCI, V112, P2355; Tsuji T, 2002, NEUROCHEM RES, V27, P1245, DOI 10.1023/A:1020941929414; VINTERS HV, 1990, AM J PATHOL, V137, P233; Wang WX, 2003, ANAL CHEM, V75, P4818, DOI 10.1021/ac026468x; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Zhou G, 2002, MOL CELL PROTEOMICS, V1, P117, DOI 10.1074/mcp.M100015-MCP200	72	218	228	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37061	37068		10.1074/jbc.M403672200	http://dx.doi.org/10.1074/jbc.M403672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220353	hybrid			2022-12-25	WOS:000223453600109
J	Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T				Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T			Nuclear localization of Tob is important for regulation of its antiproliferative activity	ONCOGENE			English	Article						Tob; NLS; NES; antiproliferative activity; subcellular localization	EXPORT SIGNALS; NUCLEOCYTOPLASMIC TRANSPORT; PC3/BTG/TOB FAMILY; TOB/BTG1 FAMILY; PROTEIN BTG1; MICE LACKING; REV PROTEIN; IDENTIFICATION; MEMBER; GENE	tob is a member of an antiproliferative gene family that includes btg1, pc3/tis21/btg2, pc3b, ana/btg3, and tob2. Exogenous overexpression of the family proteins suppresses cell proliferation. These proteins participate in transcriptional regulation of several genes. Here, we show that Tob is a nuclear protein that is imported into the nucleus through a nuclear localization signal (NLS)mediated mechanism. Mutation in the NLS sequence of Tob affects its nuclear localization and impairs antiproliferative activity. Additionally, Tob contains a nuclear export signal (NES). In oncogenic ErbB2-transformed cells, nuclear export of Tob is facilitated by NES-mediated mechanism, resulting in decrease of its antiproliferative activity. These results indicate that regulation of nuclear localization of Tob is important for its antiproliferative activity.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp						ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Matsuda S, 1996, ONCOGENE, V12, P705; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakamura T, 2004, NAT GENET, V36, P528, DOI 10.1038/ng1344; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	45	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6630	6638		10.1038/sj.onc.1207890	http://dx.doi.org/10.1038/sj.onc.1207890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235587				2022-12-25	WOS:000223530800010
J	Granata, R; Trovato, L; Garbarino, G; Taliano, M; Ponti, R; Sala, G; Ghidoni, R; Ghigo, E				Granata, R; Trovato, L; Garbarino, G; Taliano, M; Ponti, R; Sala, G; Ghidoni, R; Ghigo, E			Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways	FASEB JOURNAL			English	Article						doxorubicin; ceramide; sphingosine kinase	FACTOR-BINDING PROTEIN-3; GROWTH-FACTOR-I; CERAMIDE SYNTHASE; EPITHELIAL-CELLS; GENE-EXPRESSION; CANCER CELLS; MECHANISM; DEATH; ANGIOGENESIS; ACTIVATION	Insulin-like growth factor binding protein (IGFBP)-3 has both growth-inhibiting and growth-promoting effects at the cellular level. The cytotoxic action of several anticancer drugs is linked to increased ceramide generation through sphingomyelin hydrolysis or de novo biosynthesis. Herein, we investigated the role of IGFBP-3 on apoptosis of human umbilical vein endothelial cells ( HUVEC) and its relationship with ceramide levels. We report that IGFBP-3 exerts dual effects on HUVEC, potentiating doxorubicin-induced apoptosis but enhancing survival in serum-starved conditions. Ceramide was increased by IGFBP-3 in the presence of doxorubicin and decreased when IGFBP-3 was added alone to cells cultured in serum-free medium. The protection exerted by the ceramide synthase inhibitor fumonisin B1 over doxorubicin-induced apoptosis was enhanced by IGFBP-3 with concomitant reduction of ceramide levels. IGFBP-3 alone activated sphingosine kinase (SK) and increased SK1 mRNA; the SK inhibitor N,N-dimethylsphingosine (DMS) blocked IGFBP-3 antiapoptotic effect. Moreover, IGFBP-3 increased IGF-I mRNA and dramatically enhanced IGF-I release. IGF-I receptor (IGF-IR) and its downstream signaling pathways Akt and ERK were phosphorylated by IGFBP-3, whereas inhibition of IGF-IR phosphorylation with tyrphostin AG1024 suppressed the antiapopoptic effect of IGFBP-3. Finally, IGFBP-3 increased endothelial cell motility in all experimental conditions. These findings provide evidence that IGFBP-3 differentially regulates endothelial cell apoptosis by involvement of the sphingolipid signaling pathways. Moreover, the survival effect of IGFBP-3 seems to be mediated by the IGF-IR.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; Univ Turin, Sect Clin & Oncol Dermatol, I-10126 Turin, Italy; Univ Milan, Milan, Italy; San Paolo Univ Hosp, Biochem & Mol Biol Lab, Milan, Italy	University of Turin; University of Turin; University of Milan	Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Corso Dogliotti 14, I-10126 Turin, Italy.	ezio.ghigo@unito.it	Granata, Riccarda/K-7775-2016	Granata, Riccarda/0000-0003-4164-7313; Trovato, Letizia/0000-0001-6004-795X; GHIDONI, RICCARDO/0000-0002-6300-5867				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bjarnason R, 1998, J CLIN ENDOCR METAB, V83, P1566, DOI 10.1210/jc.83.5.1566; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Buckley J. S., 1995, SPE ADV TECH SER, V3, P53; Cohen P, 2000, AM J PHYSIOL-LUNG C, V278, pL545, DOI 10.1152/ajplung.2000.278.3.L545; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Desai K, 2002, BBA-MOL CELL BIOL L, V1585, P188, DOI 10.1016/S1388-1981(02)00340-2; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Granata R, 2003, J ENDOCRINOL INVEST, V26, P1231, DOI 10.1007/BF03349163; HAN DKM, 1995, AM J PATHOL, V147, P267; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lee DY, 2002, BIOCHEM BIOPH RES CO, V294, P480, DOI 10.1016/S0006-291X(02)00491-6; Liu LQ, 2003, ONCOL RES, V13, P359; LIU YY, 2004, IN PRESS J LIPID RES; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Martin JL, 2003, J BIOL CHEM, V278, P2969, DOI 10.1074/jbc.M210739200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McCaig C, 2002, BRIT J CANCER, V86, P1963, DOI 10.1038/sj.bjc.6600355; Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Schmid MC, 2003, INT J CANCER, V103, P577, DOI 10.1002/ijc.10874; Shigematsu S, 1999, ENDOCR J, V46, pS59; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; TANIMOTO T, 2004, IN PRESS CIRC RES; Tedgui A, 2001, CIRC RES, V88, P877, DOI 10.1161/hh0901.090440; Turner HE, 2003, ENDOCR REV, V24, P600, DOI 10.1210/er.2002-0008; Veldman RJ, 2004, BRIT J CANCER, V90, P917, DOI 10.1038/sj.bjc.6601581; Yamada M, 1999, CATAL SURV JPN, V3, P3, DOI 10.1023/A:1019063416425	52	99	101	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1456	+		10.1096/fj.04-1618fje	http://dx.doi.org/10.1096/fj.04-1618fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247143				2022-12-25	WOS:000222979200006
J	Joussen, AM; Poulaki, V; Le, ML; Koizumi, K; Esser, C; Janicki, H; Schraermeyer, U; Kociok, N; Fauser, S; Kirchhof, B; Kern, TS; Adamis, AP				Joussen, AM; Poulaki, V; Le, ML; Koizumi, K; Esser, C; Janicki, H; Schraermeyer, U; Kociok, N; Fauser, S; Kirchhof, B; Kern, TS; Adamis, AP			A central role for inflammation in the pathogenesis of diabetic retinopathy	FASEB JOURNAL			English	Article						adhesion molecules; retina; vascular lesions	INTERCELLULAR-ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; SELECTIN; RETINA; MODEL; ANGIOPOIETIN-1; LEUKOSTASIS; MOUSE; DEATH; RATS	Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much of the retinal damage that characterizes the disease results from retinal vascular leakage and nonperfusion. Diabetic retinal vascular leakage, capillary nonperfusion, and endothelial cell damage are temporary and spatially associated with retinal leukocyte stasis in early experimental diabetes. Retinal leukostasis increases within days of developing diabetes and correlates with the increased expression of retinal intercellular adhesion molecule-1 (ICAM-1) and CD18. Mice deficient in the genes encoding for the leukocyte adhesion molecules CD18 and ICAM-1 were studied in two models of diabetic retinopathy with respect to the long-term development of retinal vascular lesions. CD18(-/-) and ICAM-1(-/-) mice demonstrate significantly fewer adherent leukocytes in the retinal vasculature at 11 and 15 months after induction of diabetes with STZ. This condition is associated with fewer damaged endothelial cells and lesser vascular leakage. Galactosemia of up to 24 months causes pericyte and endothelial cell loss and formation of acellular capillaries. These changes are significantly reduced in CD18(-/-) and ICAM(-/-) deficient mice. Basement membrane thickening of the retinal vessels is increased in long-term galactosemic animals independent of the genetic strain. Here we show that chronic, low-grade subclinical inflammation is responsible for many of the signature vascular lesions of diabetic retinopathy. These data highlight the central and causal role of adherent leukocytes in the pathogenesis of diabetic retinopathy. They also underscore the potential utility of anti-inflammatory treatment in diabetic retinopathy.	Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany; Univ Cologne, Ctr Ophthalmol, Angiogenesis Lab, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, Cologne, Germany; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA USA; Harvard Univ, Sch Med, Childrens Hosp, Surg Res Lab, Boston, MA USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Diabet Res, Cleveland, OH 44106 USA; Eyetech Res Ctr, Woburn, MA USA	University of Cologne; University of Cologne; University of Cologne; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Boston Children's Hospital; Harvard Medical School; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Joussen, AM (corresponding author), Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	JoussenA@aol.com; tony.adamis@eyetk.com	Joussen, Antonia/AAA-6901-2022		NEI NIH HHS [EY12611, EY11627] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011627, R01EY012611] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; BULLARD SR, 1994, EXP EYE RES, V58, P641, DOI 10.1006/exer.1994.1061; CHIECO P, 1993, TOXICOL PATHOL, V21, P402, DOI 10.1177/019262339302100409; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CUTLER LS, 1979, VIRCHOWS ARCH A, V382, P301, DOI 10.1007/BF00430406; FREEDMAN SF, 1992, EXP EYE RES, V55, P767, DOI 10.1016/0014-4835(92)90181-Q; Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Karadayi K, 2003, OCUL IMMUNOL INFLAMM, V11, P123, DOI 10.1076/ocii.11.2.123.15920; Kern TS, 1996, ARCH OPHTHALMOL-CHIC, V114, P986, DOI 10.1001/archopht.1996.01100140194013; KERN TS, 1995, EXP EYE RES, V60, P545, DOI 10.1016/S0014-4835(05)80069-7; KERN TS, 1995, INVEST OPHTH VIS SCI, V36, P490; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Knudsen ST, 2003, AM J PHYSIOL-ENDOC M, V284, pE1, DOI 10.1152/ajpendo.00198.2002; KOHNER EM, 1970, AM J OPHTHALMOL, V69, P778, DOI 10.1016/0002-9394(70)93420-3; Limb GA, 1999, INVEST OPHTH VIS SCI, V40, P2453; MCLEOD DS, 1995, AM J PATHOL, V147, P642; MILLER JW, 1994, AM J PATHOL, V145, P574; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; SCHRODER S, 1991, AM J PATHOL, V139, P81; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; WILSON RW, 1993, J IMMUNOL, V151, P1571; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789	26	880	955	1	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1450	+		10.1096/fj.03-1476fje	http://dx.doi.org/10.1096/fj.03-1476fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231732				2022-12-25	WOS:000222979200022
J	Carrere-Kremer, S; Montpellier, C; Lorenzo, L; Brulin, B; Cocquerel, L; Belouzard, S; Penin, F; Dubuisson, J				Carrere-Kremer, S; Montpellier, C; Lorenzo, L; Brulin, B; Cocquerel, L; Belouzard, S; Penin, F; Dubuisson, J			Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; RECOMBINANT VACCINIA; ION-CHANNEL; TRANSMEMBRANE DOMAINS; NS2B-3 PROTEINASE; E2-NS2 REGION; IN-VITRO; GLYCOPROTEIN; CLEAVAGE; EXPRESSION	The hepatitis C virus genome encodes a polyprotein precursor that is co- and post-translationally processed by cellular and viral proteases to yield 10 mature protein products (C, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). Although most cleavages in hepatitis C virus polyprotein precursor proceed to completion during or immediately after translation, the cleavages mediated by a host cell signal peptidase are partial at the E2/p7 and p7/NS2 sites, leading to the production of an E2p7NS2 precursor. The sequences located immediately N-terminally of E2/p7 and p7/NS2 cleavage sites can function as signal peptides. When fused to a reporter protein, the signal peptides of p7 and NS2 were efficiently cleaved. However, when full-length p7 was fused to the reporter protein, partial cleavage was observed, indicating that a sequence located N-terminally of the signal peptide reduces the efficiency of p7/NS2 cleavage. Sequence analyses and mutagenesis studies have also identified structural determinants responsible for the partial cleavage at both the E2/p7 and p7/NS2 sites. Finally, the short distance between the cleavage site of E2/p7 or p7/NS2 and the predicted transmembrane alpha-helix within the P' region might impose additional structural constraints to the cleavage sites. The insertion of a linker polypeptide sequence between P-3' and P-4' of the cleavage site released these constraints and led to improved cleavage efficiency. Such constraints in the processing of a polyprotein precursor are likely essential for hepatitis C virus to post-translationally regulate the kinetics and/or the level of expression of p7 as well as NS2 and E2 mature proteins.	Inst Biol Lille, CNRS, UPR 2511, F-59021 Lille, France; Inst Biol & Chim Prot, CNRS, UMR5086, IFR128, F-69367 Lyon, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UPR 2511, 1 Rue Calmette,BP 447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Belouzard, Sandrine/AAX-1584-2021; Belouzard, Sandrine/O-8527-2016; Cocquerel, Laurence/P-1951-2016; Lorenzo, Lazaro/H-7902-2017; PENIN, Francois/A-7315-2008; Dubuisson, Jean/E-6813-2016	Belouzard, Sandrine/0000-0002-9972-4054; Belouzard, Sandrine/0000-0002-9972-4054; Cocquerel, Laurence/0000-0002-2136-5178; Lorenzo, Lazaro/0000-0001-6648-8684; Dubuisson, Jean/0000-0003-1626-7693; MONTPELLIER, Claire/0000-0002-3112-8491				AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Carrere-Kremer S, 2002, J VIROL, V76, P3720, DOI 10.1128/JVI.76.8.3720-3730.2002; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COMBET C, 2004, IN PRESS APPL BIOINF; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; DRILLIEN R, 1982, VIROLOGY, V119, P372, DOI 10.1016/0042-6822(82)90096-4; Dubuisson J, 2000, J BIOL CHEM, V275, P30605, DOI 10.1074/jbc.M004326200; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; Dubuisson J, 2002, TRENDS CELL BIOL, V12, P517, DOI 10.1016/S0962-8924(02)02383-8; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Griffin SDC, 2004, J GEN VIROL, V85, P451, DOI 10.1099/vir.0.19634-0; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Konan KV, 2003, J VIROL, V77, P7843, DOI 10.1128/JVI.77.14.7843-7855.2003; Lee E, 2000, J VIROL, V74, P24, DOI 10.1128/JVI.74.1.24-32.2000; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P6218, DOI 10.1073/pnas.90.13.6218; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAJOR ME, 2001, FIELDS VIROLOGY, P1127; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Premkumar A, 2004, FEBS LETT, V557, P99, DOI 10.1016/S0014-5793(03)01453-4; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Sakai A, 2003, P NATL ACAD SCI USA, V100, P11646, DOI 10.1073/pnas.1834545100; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; Stocks CE, 1998, J VIROL, V72, P2141, DOI 10.1128/JVI.72.3.2141-2149.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Yamaga AK, 2002, J BIOL CHEM, V277, P33228, DOI 10.1074/jbc.M202304200; YAMSHCHIKOV VF, 1993, VIROLOGY, V192, P38, DOI 10.1006/viro.1993.1006	52	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41384	41392		10.1074/jbc.M406315200	http://dx.doi.org/10.1074/jbc.M406315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247249	hybrid			2022-12-25	WOS:000224075500019
J	Soni, KG; Lehner, R; Metalnikov, P; O'Donnell, P; Semache, M; Gao, WH; Ashman, K; Pshezhetsky, AV; Mitchell, GA				Soni, KG; Lehner, R; Metalnikov, P; O'Donnell, P; Semache, M; Gao, WH; Ashman, K; Pshezhetsky, AV; Mitchell, GA			Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; CHOLESTEROL ESTER HYDROLASE; RAT ADIPOSE-TISSUE; PURIFICATION; PERILIPIN; CLEAVAGE; SURFACE; ENZYME	Hydrolysis of triglycerides is central to energy homeostasis in white adipose tissue (WAT). Hormone-sensitive lipase (HSL) was previously felt to mediate all lipolysis in WAT. Surprisingly, HSL-deficient mice show active HSL-independent lipolysis, suggesting that other lipase(s) also mediate triglyceride hydrolysis. To clarify this, we used functional proteomics to detect non-HSL lipase(s) in mouse WAT. After cell fractionation of intra-abdominal WAT, most non-HSL neutral lipase activity is localized in the 100,000 x g infranatant and fat cake fractions. By oleic acid-linked agarose chromatography of infranatant followed by elution in a 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid gradient, we identified two peaks of esterase activity using p-nitrophenyl butyrate as a substrate. One of the peaks contained most of the lipase activity. In the corresponding fractions, gel permeation chromatography and SDS-PAGE, followed by tandem mass spectrometric analysis of excised Coomassie Blue-stained peptides, revealed carboxylesterase 3 (triacylglycerol hydrolase (TGH); EC 3.1.1.1). TGH is also the principle lipase of WAT fat cake extracts. Partially purified WAT TGH had lipase activity as well as lesser but detectable neutral cholesteryl ester hydrolase activity. Western blotting of subcellular fractions of WAT and confocal microscopy of fibroblasts following in vitro adipocytic differentiation are consistent with a distribution of TGH to endoplasmic reticulum, cytosol, and the lipid droplet. TGH is responsible for a major part of non-HSL lipase activity in WAT in vitro and may mediate some or all HSL-independent lipolysis in adipocytes.	Hop St Justine, Div Med Genet, Montreal, PQ H3T 1C5, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; MDS Sciex, Concord, ON L4K 4V8, Canada	Universite de Montreal; University of Alberta; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; SCIEX	Mitchell, GA (corresponding author), Hop St Justine, Div Med Genet, 3175 Cote Ste Catherine Rd, Montreal, PQ H3T 1C5, Canada.	grant.mitchell@recherche-ste-justine.qc.ca	Ashman, Keith/G-2328-2011	A, Pshezhetsky/0000-0002-6612-1062; Metalnikov, Pavel/0000-0003-3261-4421; Lehner, Richard/0000-0002-6008-1805				Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Caldas H, 2003, HUM MOL GENET, V12, P2981, DOI 10.1093/hmg/ddg321; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; HAAS MJ, 1992, LIPIDS, V27, P571, DOI 10.1007/BF02536112; Holm C, 1999, METH MOL B, V109, P109; HOUTHAEVE T, 1995, FEBS LETT, V376, P91, DOI 10.1016/0014-5793(95)01242-7; KHOO JC, 1993, J LIPID RES, V34, P1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; MEER GV, 2001, J CELL BIOL, V152, pF29; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Natarajan R, 1996, BIOCHEM BIOPH RES CO, V225, P413, DOI 10.1006/bbrc.1996.1188; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; Prattes S, 2000, J CELL SCI, V113, P2977; RICKWOOD D, 1984, CENTRIFUGATION, P161; SANDO GN, 1985, J BIOL CHEM, V260, P5186; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SMALL CA, 1989, FEBS LETT, V247, P205, DOI 10.1016/0014-5793(89)81335-3; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wu GS, 2003, J BIOL CHEM, V278, P11925, DOI 10.1074/jbc.M212736200	27	124	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40683	40689		10.1074/jbc.M400541200	http://dx.doi.org/10.1074/jbc.M400541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15220344	hybrid			2022-12-25	WOS:000223916800059
J	Dumitru, RV; Ragsdale, SW				Dumitru, RV; Ragsdale, SW			Mechanism of 4-(beta-D-ribofuranosyl) aminobenzene 5 '-phosphate synthase, a key enzyme in the methanopterin biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; CRYSTAL-STRUCTURE; COMPLEX; BINDING; XMP	The first committed step in methanopterin biosynthesis is catalyzed by 4-(beta-D-ribofuranosyl) aminobenzene 5'-phosphate (RFA-P) synthase. Unlike all known phosphoribosyltransferases, beta-RFA-P synthase catalyzes the unique formation of a C-riboside instead of an N-riboside in the condensation of p-aminobenzoic acid (pABA) and 5-phospho-alpha-D-ribosyl-1-pyrophosphate ( PRPP) to produce 4-(beta-D-ribofuranosyl) aminobenzene 5'-phosphate (beta-RFA-P), CO2, and inorganic pyrophosphate (PPi). Here we report the successful cloning, active overexpression in Escherichia coli, and purification of this homodimeric enzyme containing two 36.2-kDa subunits from the methanogen Methanococcus jannaschii. Steady-state initial velocity and product inhibition kinetic studies indicate an ordered Bi-Ter mechanism involving binding of PRPP, then pABA, followed by release of the products CO2, then beta-RFA-P, and finally PPi. The Michaelis parameters are as follows: K(m)pABA, 0.15 mM; KmPRPP, 1.50 mM; V-max, 375 nmol/min/mg; k(cat), 0.23 s(-1). CO2 showed uncompetitive inhibition, K-i = 0.990 mM, under varied PRPP and saturated pABA, and a mixed type of inhibition, K-1 = 1.40 mM and K-2 = 3.800 mM, under varied pABA and saturated PRPP. RFA-P showed uncompetitive inhibition, K-i = 0.210 mM, under varied PRPP and saturated pABA, and again uncompetitive, K-i = 0.300 mM, under saturated PRPP and varied pABA. PPi exhibits competitive inhibition, K-i = 0.320 mM, under varied PRPP and saturated pABA, and a mixed type of inhibition, K-1 = 0.60 mM and K-2 = 1.900 mM, under saturated PRPP and varied pABA. Synthase lacks any chromogenic cofactor, and the presence of pyridoxal phosphate and the mechanistically related pyruvoyl cofactors has been strictly excluded.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.	sragsdale1@unl.edu			NCRR NIH HHS [1P20RR17675] Funding Source: Medline; NIGMS NIH HHS [R41 GM67952-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R41GM067952] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Craig SP, 2000, J BIOL CHEM, V275, P20231, DOI 10.1074/jbc.R000002200; DAVIS L, 1964, BIOCHEM BIOPH RES CO, V14, P482, DOI 10.1016/0006-291X(64)90091-9; Dumitru R, 2003, APPL ENVIRON MICROB, V69, P7236, DOI 10.1128/AEM.69.12.7236-7241.2003; GOLDERER G, 1995, J BACTERIOL, V177, P5994, DOI 10.1128/jb.177.20.5994-5996.1995; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Maden BEH, 2000, BIOCHEM J, V350, P609, DOI 10.1042/0264-6021:3500609; Rasche ME, 1998, BIOCHEMISTRY-US, V37, P11343, DOI 10.1021/bi973086q; RILEY AW, 1953, J GEN MICROBIOL, V8, P233; Scott JW, 2002, J BACTERIOL, V184, P4442, DOI 10.1128/JB.184.16.4442-4448.2002; SEGEL IH, 1975, ENZYME KINETICS BEHA, P653; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; White RH, 1996, BIOCHEMISTRY-US, V35, P3447, DOI 10.1021/bi952308m; White Robert H., 1993, P409	19	13	16	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39389	39395		10.1074/jbc.M406442200	http://dx.doi.org/10.1074/jbc.M406442200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262968	hybrid			2022-12-25	WOS:000223791500025
J	Humphries, JE; Kimber, MJ; Barton, YW; Hsu, W; Marks, NJ; Greer, B; Harriott, P; Maule, AG; Day, TA				Humphries, JE; Kimber, MJ; Barton, YW; Hsu, W; Marks, NJ; Greer, B; Harriott, P; Maule, AG; Day, TA			Structure and bioactivity of neuropeptide F from the human parasites Schistosoma mansoni and Schistosoma japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ADENYLATE-CYCLASE; HUMAN BLOOD FLUKE; PANCREATIC-POLYPEPTIDE; PEPTIDE YY; FASCIOLA-HEPATICA; MONIEZIA-EXPANSA; NERVOUS-SYSTEM; PRAZIQUANTEL; RECEPTORS; RESISTANCE	The blood flukes Schistosoma mansoni and Schistosoma japonicum inflict immense suffering as agents of human schistosomiasis. Previous investigations have found the nervous systems of these worms contain abundant immunoreactivity to antisera targeting invertebrate neuropeptide Fs (NPFs) as well as structurally similar neuropeptides of the mammalian neuropeptide Y (NPY) family. Here, cDNAs encoding NPF in these worms were identified, and the mature neuropeptides from the two species differed by only a single amino acid. Both neuropeptides feature the characteristics common among NPFs; they are 36 amino acids long with a carboxyl-terminal Gly-Arg-X-Arg-Phe-amide and Tyr residues at positions 10 and 17 from the carboxyl terminus. Synthetic S. mansoni NPF potently inhibits the forskolin-stimulated accumulation of cAMP in worm homogenates, with significant effects at 10(-11) M. This is the first demonstration of an endogenous inhibition of cAMP by an NPF, and because this is the predominant pathway associated with vertebrate NPY family peptides, it demonstrates a conservation of downstream signaling pathways used by NPFs and NPY peptides.	Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; Iowa State Univ, Neurosci Program, Ames, IA 50011 USA; Queens Univ Belfast, Sch Biol & Biochem, Parasitol Res Grp, Belfast BT9 7BL, Antrim, North Ireland	Iowa State University; Iowa State University; Queens University Belfast	Day, TA (corresponding author), Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA.	day@iastate.edu		Maule, Aaron/0000-0003-0862-2667; Day, Tim/0000-0002-9037-6540	NIAID NIH HHS [R01-AI49162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; ANDREWS P, 1983, MED RES REV, V3, P147, DOI 10.1002/med.2610030204; Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196-9781(96)00347-6; Bennett JL, 1997, EXP PARASITOL, V87, P260, DOI 10.1006/expr.1997.4229; Cioli D, 2003, PARASITOL RES, V90, pS3, DOI 10.1007/s00436-002-0751-z; Day TA, 1999, PEPTIDES, V20, P999, DOI 10.1016/S0196-9781(99)00093-5; DAY TA, 1992, PARASITOL TODAY, V8, P342, DOI 10.1016/0169-4758(92)90070-I; Dougan PM, 2002, J COMP NEUROL, V454, P58, DOI 10.1002/cne.10440; ESTEY SJ, 1987, MOL BIOCHEM PARASIT, V26, P47, DOI 10.1016/0166-6851(87)90129-0; Fairweather I, 1995, ACTA BIOL HUNG, V46, P211; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FREDHOLM BB, 1985, ACTA PHYSIOL SCAND, V124, P467, DOI 10.1111/j.1748-1716.1985.tb07683.x; Garczynski SF, 2002, PEPTIDES, V23, P773, DOI 10.1016/S0196-9781(01)00647-7; Gryseels B, 2001, TROP MED INT HEALTH, V6, P864, DOI 10.1046/j.1365-3156.2001.00811.x; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Ismail Magdi M., 1994, Journal of the Egyptian Society of Parasitology, V24, P685; JOHNSTON RN, 1995, J COMP NEUROL, V357, P76, DOI 10.1002/cne.903570108; Larhammar D, 1996, REGUL PEPTIDES, V65, P165, DOI 10.1016/0167-0115(96)00110-3; Larhammar D, 1996, REGUL PEPTIDES, V62, P1, DOI 10.1016/0167-0115(95)00169-7; LEUNG PS, 1992, REGUL PEPTIDES, V41, P71, DOI 10.1016/0167-0115(92)90515-V; Mair GR, 2000, PARASITOLOGY, V120, P71, DOI 10.1017/S0031182099005296; MANSOUR JM, 1986, MOL BIOCHEM PARASIT, V21, P139, DOI 10.1016/0166-6851(86)90017-4; MARKS NJ, 1995, PARASITOLOGY, V110, P371, DOI 10.1017/S0031182000064714; Matz Mikhail V, 2002, Methods Mol Biol, V183, P3; MAULE AG, 1991, PARASITOLOGY, V102, P309, DOI 10.1017/S0031182000062648; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; Michel MC, 1998, PHARMACOL REV, V50, P143; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; Olson PD, 2003, INT J PARASITOL, V33, P733, DOI 10.1016/S0020-7519(03)00049-3; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; RICHARDS JS, 1979, ENDOCRINOLOGY, V104, P765, DOI 10.1210/endo-104-3-765; SKUCE PJ, 1990, CELL TISSUE RES, V261, P573, DOI 10.1007/BF00313537; SKUCE PJ, 1990, PARASITOLOGY, V101, P227, DOI 10.1017/S0031182000063277; Tensen CP, 1998, EUR J NEUROSCI, V10, P3409, DOI 10.1046/j.1460-9568.1998.00350.x; William S, 2001, PARASITOLOGY, V122, P63, DOI 10.1017/S0031182000007137; William S, 2001, INT J PARASITOL, V31, P1093, DOI 10.1016/S0020-7519(01)00215-6	37	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39880	39885		10.1074/jbc.M405624200	http://dx.doi.org/10.1074/jbc.M405624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15229227	hybrid, Green Published			2022-12-25	WOS:000223791500084
J	Conigrave, AD; Mun, HC; Delbridge, L; Quinn, SJ; Wilkinson, M; Brown, EM				Conigrave, AD; Mun, HC; Delbridge, L; Quinn, SJ; Wilkinson, M; Brown, EM			L-amino acids regulate parathyroid hormone secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CA2+-SENSING RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; CALCIUM-SENSING RECEPTOR; DIETARY-PROTEIN INTAKE; PLASMA-CONCENTRATIONS; CIRCADIAN-RHYTHM; DIURNAL-VARIATIONS; OSTEOPOROSIS; TRYPTOPHAN	Parathyroid hormone (PTH) secretion is acutely regulated by the extracellular Ca2+-sensing receptor (CaR). Thus, Ca2+ ions, and to a lesser extent Mg2+ ions, have been viewed as the principal physiological regulators of PTH secretion. Herein we show that in physiological concentrations, L-amino acids acutely and reversibly activated the extracellular Ca2+-sensing receptor in normal human parathyroid cells and inhibited parathyroid hormone secretion. Individual L-amino acids, especially of the aromatic and aliphatic classes, as well as plasma-like amino acid mixtures, stereoselectively mobilized Ca2+ ions in normal human parathyroid cells in the presence but not the absence of the CaR agonists, extracellular Ca2+ (Ca-o(2+)), or spermine. The order of potency was L-Trp = L-Phe > L-His > L-Ala > L-Glu > L-Arg = L-Leu. CaR-active amino acids also acutely and reversibly suppressed PTH secretion at physiological ionized Ca2+ concentrations. At a Ca-o(2+) of 1.1 mM and an amino acid concentration of 1 mM, CaR-active amino acids (L-Phe = L-Trp > L-His = L-Ala), but not CaR-inactive amino acids (L-Leu and L-Arg), stereoselectively suppressed PTH secretion by up to 40%, similar to the effect of raising Ca-o(2+) to 1.2 mM. A physiologically relevant increase in the -fold concentration of the plasma-like amino acid mixture ( from 1 x to 2 x) also reversibly suppressed PTH secretion in the Ca-o(2+) concentration range 1.05 - 1.25 mM. In conclusion, L-amino acids acutely and reversibly activate endogenous CaRs and suppress PTH secretion at physiological concentrations. The results indicate that L-amino acids are physiological regulators of PTH secretion and thus whole body calcium metabolism.	Univ Sydney, Sch Mol & Microbial Biosci G08, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia; Royal N Shore Hosp, Dept Endocrinol, St Leonards, NSW 2065, Australia; Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Sydney; Royal North Shore Hospital; Royal North Shore Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Conigrave, AD (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci G08, Sydney, NSW 2006, Australia.	a.conigrave@mmb.usyd.edu.au	Centeno, Patricia Pacios/O-8368-2016	Conigrave, Arthur/0000-0002-7232-3891; Delbridge, leigh/0000-0001-8281-8831	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048330, R01DK041415, R01DK052005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41415, DK48330, DK52005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; ALLEN LH, 1979, AM J CLIN NUTR, V32, P741, DOI 10.1093/ajcn/32.4.741; BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; Bradbury RA, 1996, J ENDOCRINOL, V149, P135, DOI 10.1677/joe.0.1490135; Brand HS, 1997, CLIN CHIM ACTA, V264, P37, DOI 10.1016/S0009-8981(97)00070-3; Brown EM, 1996, KIDNEY INT, V49, P1042, DOI 10.1038/ki.1996.152; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem-72-1-69; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Conigrave AD, 2000, TRENDS PHARMACOL SCI, V21, P401, DOI 10.1016/S0165-6147(00)01546-7; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Dockray GJ, 2001, GASTROENTEROLOGY, V120, P1279, DOI 10.1053/gast.2001.23440; FERNSTROM JD, 1979, AM J CLIN NUTR, V32, P1912, DOI 10.1093/ajcn/32.9.1912; FRASER WD, 1994, CLIN ENDOCRINOL, V40, P523, DOI 10.1111/j.1365-2265.1994.tb02493.x; Fraser WD, 1998, OSTEOPOROSIS INT, V8, P121, DOI 10.1007/BF02672507; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; JOHNSON NE, 1970, J NUTR, V100, P1425, DOI 10.1093/jn/100.12.1425; JUBIZ W, 1972, J CLIN INVEST, V51, P2040, DOI 10.1172/JCI107010; Kerstetter JE, 1997, AM J CLIN NUTR, V66, P1188, DOI 10.1093/ajcn/66.5.1188; LENTNER C, 1984, GEIGY SCI TABLES, V3, P89; MAHER TJ, 1984, AM J CLIN NUTR, V39, P722, DOI 10.1093/ajcn/39.5.722; MARKOWITZ ME, 1988, J CLIN ENDOCR METAB, V67, P1068, DOI 10.1210/jcem-67-5-1068; MCARTHUR KE, 1983, J CLIN INVEST, V71, P1254, DOI 10.1172/JCI110875; MEDDINGS JB, 1989, AM J PHYSIOL, V257, pG982, DOI 10.1152/ajpgi.1989.257.6.G982; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; Ray JM, 1997, J CLIN INVEST, V99, P2328, DOI 10.1172/JCI119413; WURTMAN RJ, 1968, NEW ENGL J MED, V279, P171, DOI 10.1056/NEJM196807252790401	31	87	91	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38151	38159		10.1074/jbc.M406373200	http://dx.doi.org/10.1074/jbc.M406373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234970	hybrid			2022-12-25	WOS:000223684100013
J	Zamora, M; Merono, C; Vinas, O; Mampel, T				Zamora, M; Merono, C; Vinas, O; Mampel, T			Recruitment of NF-kappa B into mitochondria is involved in adenine nucleotide translocase 1 (ANT1)-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; PERMEABILITY TRANSITION-PORE; ALPHA-INDUCED APOPTOSIS; ADP/ATP CARRIERS; GENE-EXPRESSION; INNER MEMBRANE; CELL-DEATH; INHIBITION; BCL-2; BAX	Overexpression of adenine nucleotide translocase-1 (ANT1) is known to induce apoptosis (Bauer, M. K., Schubert, A., Rocks, O., and Grimm, S. (1999) J. Cell Biol. 147, 1493-1501), but the mechanisms involved remain unclear. In this study we show that ANT1 overexpression results in a recruitment of the IkappaBalpha-NF-kappaB complex into mitochondria, with a coincident decrease in nuclear NF-kappaB DNA binding activity. In this situation, NF-kappaB transcriptionally regulated genes with antiapoptotic activity, such as Bcl-XL, MnSOD2, and c-IAP2, are down-regulated, and consequently, cells are sensitized to apoptosis. Accordingly, co-expression of p65 partially interferes with the proapoptotic effect of ANT1 overexpression. Despite the high identity of the two isoforms, overexpression of ANT2 does not exert an apoptotic effect; this lack of apoptotic activity is correlated with the absence of mitochondrial IkappaBalpha-NF-kappaB recruitment or changes in NF-kappaB activity. Thus, we propose that the mitochondrial recruitment of NF-kappaB observed following ANT1 overexpression has an important role in ANT1 proapoptotic activity.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of Barcelona	Mampel, T (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Diagonal 645, E-08028 Barcelona, Spain.	tmampel@ub.edu	Mampel, Teresa/C-5571-2017					Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2003, CANCER RES, V63, P541; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Cogswell PC, 2003, J BIOL CHEM, V278, P2963, DOI 10.1074/jbc.M209995200; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Sharer JD, 2002, MOL BIOL CELL, V13, P71, DOI 10.1091/mbc.01-05-0245; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yamazaki N, 2002, MITOCHONDRION, V1, P371, DOI 10.1016/S1567-7249(01)00041-1; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	38	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38415	38423		10.1074/jbc.M404928200	http://dx.doi.org/10.1074/jbc.M404928200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231833	hybrid			2022-12-25	WOS:000223684100044
J	Bacia, K; Schuette, CG; Kahya, N; Jahn, R; Schwille, P				Bacia, K; Schuette, CG; Kahya, N; Jahn, R; Schwille, P			SNAREs prefer liquid-disordered over "raft" (liquid-ordered) domains when reconstituted into giant unilamellar vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CORRELATION SPECTROSCOPY; GPI-ANCHORED PROTEINS; LIPID RAFTS; MEMBRANE-FUSION; BIOLOGICAL-MEMBRANES; MODEL MEMBRANES; CELL-MEMBRANES; CHOLESTEROL; EXOCYTOSIS; RESISTANCE	Membrane domains ("rafts") have received great attention as potential platforms for proteins in signaling and trafficking. Because rafts are believed to form by cooperative lipid interactions but are not directly accessible in vivo, artificial phase-separating lipid bilayers are useful model systems. Giant unilamellar vesicles (GUVs) offer large free-standing bilayers, but suitable methods for incorporating proteins are still scarce. Here we report the reconstitution of two water-insoluble SNARE proteins into GUVs without fusogenic additives. Following reconstitution, protein functionality was assayed by confocal imaging and fluorescence auto- and cross-correlation spectroscopy. Incorporation into GUVs containing phase-separating lipids revealed that, in the absence of other cellular factors, both proteins exhibit an intrinsic preference for the liquid-disordered phase. Although the picture from detergent resistance assays on whole cells is ambiguous, reconstitutions of components of the exocytic machinery into GUVs by this new approach should yield insight into the dynamics of protein complex associations with hypothesized liquid-ordered phase microdomains, the correspondence between detergent-resistant membranes and liquid-ordered phase, and the mechanism of SNARE-mediated membrane fusion.	Dresden Univ Technol, Inst Biophys, D-01307 Dresden, Germany; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Technische Universitat Dresden; Max Planck Society	Schwille, P (corresponding author), Dresden Univ Technol, Inst Biophys, Tatzberg 47-51, D-01307 Dresden, Germany.	pschwil@gwdg.de	Schwille, Petra/A-4983-2010	Jahn, Reinhard/0000-0003-1542-3498				ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; Bacia K, 2003, METHODS, V29, P74, DOI 10.1016/S1046-2023(02)00291-8; Bacia K, 2002, BIOPHYS J, V83, P1184, DOI 10.1016/S0006-3495(02)75242-9; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; Kahya N, 2001, BIOPHYS J, V81, P1464, DOI 10.1016/S0006-3495(01)75801-8; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; Saslowsky DE, 2003, J MEMBRANE BIOL, V194, P153, DOI 10.1007/s00232-003-2035-7; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schuette CG, 2004, P NATL ACAD SCI USA, V101, P2858, DOI 10.1073/pnas.0400044101; Schwille P, 1997, BIOPHYS J, V72, P1878, DOI 10.1016/S0006-3495(97)78833-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Wagner ML, 2000, BIOPHYS J, V79, P1400, DOI 10.1016/S0006-3495(00)76392-2; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	37	129	133	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37951	37955		10.1074/jbc.M407020200	http://dx.doi.org/10.1074/jbc.M407020200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226320	hybrid, Green Published			2022-12-25	WOS:000223554600088
J	Mehta, A; Rebsch, CM; Kinzy, SA; Fletcher, JE; Copeland, PR				Mehta, A; Rebsch, CM; Kinzy, SA; Fletcher, JE; Copeland, PR			Efficiency of mammalian selenocysteine incorporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GLUTATHIONE-PEROXIDASE; BINDING PROTEIN; MEDIATED DECAY; SECIS RNA; MECHANISM; UGA; INSERTION; ABUNDANCE; SEQUENCE	Five components have thus far been identified that are necessary for the incorporation of selenocysteine ( Sec) into similar to25 mammalian proteins. Two of these are cis sequences, a SECIS element in the 3'-untranslated region and a Sec codon (UGA) in the coding region. The three known trans-acting factors are a Sec-specific translation elongation factor (eEFSec), the Sec-tRNA(Sec), and a SECIS-binding protein, SBP2. Here we describe a system in which the efficiency of Sec incorporation was determined quantitatively both in vitro and in transfected cells, and in which the contribution of each of the known factors is examined. The efficiency of Sec incorporation into a luciferase reporter system in vitro is maximally 5 - 8%, which is 6 - 10 times higher than that in transfected rat hepatoma cells, McArdle 7777. In contrast, the efficiency of Sec incorporation into selenoprotein P in vitro is similar to40%, suggesting that as yet unidentified cis-elements may regulate differential selenoprotein expression. In addition, we have found that SBP2 is the only limiting factor in rabbit reticulocyte lysate but not in transfected rat hepatoma cells where SBP2 is found to be mostly if not entirely cytoplasmic despite having a strong putative nuclear localization signal. The significance of these findings with regard to the function of known Sec incorporation factors is discussed.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Cleveland Clinic Foundation	Copeland, PR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Lane,Rm 728, Piscataway, NJ 08854 USA.	paul.copeland@umdnj.edu		Copeland, Paul/0000-0003-3343-0587	NIGMS NIH HHS [R01 GM068077, GM068077, R01 GM068077-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068077] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allmang C, 2002, RNA, V8, P1308, DOI 10.1017/S1355838202020034; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2001, MOL CELL BIOL, V21, P1491, DOI 10.1128/MCB.21.5.1491-1498.2001; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Fletcher JE, 2001, RNA, V7, P1442; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Judd PA, 1997, BRIT MED J, V314, P1834, DOI 10.1136/bmj.314.7097.1834a; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; LEE BJ, 1989, J BIOL CHEM, V264, P9696; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; MA S, 2002, J BIOL CHEM, V30, P30; Martin GW, 1996, RNA, V2, P171; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Nasim MT, 2000, J BIOL CHEM, V275, P14846, DOI 10.1074/jbc.275.20.14846; Sachdev SW, 2001, BIOCHEM J, V357, P851; Sun XL, 2001, MOL BIOL CELL, V12, P1009, DOI 10.1091/mbc.12.4.1009; Sunde RA, 2001, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, P81; Suppmann S, 1999, EMBO J, V18, P2284, DOI 10.1093/emboj/18.8.2284; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9	26	73	74	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37852	37859		10.1074/jbc.M404639200	http://dx.doi.org/10.1074/jbc.M404639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15229221	hybrid, Green Accepted			2022-12-25	WOS:000223554600078
J	Liu, YH; Li, RX; Ladisch, S				Liu, YH; Li, RX; Ladisch, S			Exogenous ganglioside G(D1a) enhances epidermal growth factor receptor binding and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; EXTRACELLULAR DOMAIN; CELL-PROLIFERATION; TYROSINE PHOSPHORYLATION; MEDIATED MODULATION; KINASE ACTIVATION; SIGNALING PATHWAY; LIPID RAFTS; CROSS-TALK; MEMBRANE	Gangliosides are shed by tumor cells and can bind to normal cells in the tumor microenvironment and affect their function. Exposure of fibroblasts to exogenous gangliosides increases epidermal growth factor (EGF)-induced fibroblast proliferation and enhances EGF receptor (EGFR)-mediated activation of the mitogen-activated protein kinase signaling pathway (Li, R., Liu, Y., and Ladisch, S. (2001) J. Biol. Chem. 276, 42782-42792). Here we report that the EGFR itself is the target of this ganglioside effect: Preincubation of normal human dermal fibroblasts with G(D1a) ganglioside enhanced both EGF-induced EGFR autophosphorylation and receptor-tyrosine kinase activity. The enhancement was rapid (within 30 min), not due to alteration of time kinetics of the EGFR response to EGF, and reproduced in purified G(D1a)-enriched cell membranes isolated from ganglioside-preincubated fibroblasts. Evaluating the initial steps underlying activation, EGF binding, and EGFR dimerization, we found that G(D1a) enrichment of the cell membrane increased EGFR dimerization and the effective number of high affinity EGFR without increasing total receptor protein. Unexpectedly, G(D1a) enrichment also triggered increased EGFR dimerization in the absence of growth factor. This resulted in enhanced activation of the EGFR signal transduction cascade when EGF was added. We conclude that membrane ganglioside enrichment of normal fibroblasts (such as by tumor cell ganglioside shedding) facilitates receptor-receptor interactions (possibly by altering membrane topology), causing ligand-independent EGFR dimerization and, in turn, enhanced EGF signaling.	Childrens Natl Med Ctr, Childrens Res Inst, Ctr Canc & Immunol Res, Glycobiol Program, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Biochem Mol Biol, Washington, DC 20010 USA	Children's National Health System; George Washington University; George Washington University	Ladisch, S (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, Ctr Canc & Immunol Res, Glycobiol Program, 111 Michigan Ave NW, Washington, DC 20010 USA.	Sladisch@cnmc.org			NATIONAL CANCER INSTITUTE [R01CA061010] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 61010] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSANDRI G, 1987, CANCER RES, V47, P4243; BERGELSON LD, 1989, EUR J IMMUNOL, V19, P1979, DOI 10.1002/eji.1830191102; Blanchetot C, 2000, FEBS LETT, V484, P235, DOI 10.1016/S0014-5793(00)02165-7; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burke PM, 1999, J CELL PHYSIOL, V180, P448, DOI 10.1002/(SICI)1097-4652(199909)180:3<448::AID-JCP16>3.0.CO;2-8; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chang FM, 1997, EXP CELL RES, V234, P341, DOI 10.1006/excr.1997.3619; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Duchemin AM, 2002, J NEUROCHEM, V81, P696, DOI 10.1046/j.1471-4159.2002.00831.x; Duchemin AM, 1998, ANN NY ACAD SCI, V845, P406, DOI 10.1111/j.1749-6632.1998.tb09696.x; Farooqui T, 1999, ANTICANCER RES, V19, P5007; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; GRAYSON G, 1992, CELL IMMUNOL, V139, P18, DOI 10.1016/0008-8749(92)90096-8; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANAI N, 1987, BIOCHEM BIOPH RES CO, V147, P127, DOI 10.1016/S0006-291X(87)80096-7; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HILBUSH BS, 1992, J BIOL CHEM, V267, P24789; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; LADISCH S, 1983, CANCER RES, V43, P3808; LADISCH S, 1987, INT J CANCER, V39, P73; Lang ZH, 2001, BIOCHEM BIOPH RES CO, V282, P1031, DOI 10.1006/bbrc.2001.4630; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu P, 1996, CELL IMMUNOL, V173, P22, DOI 10.1006/cimm.1996.0248; Manfredi MG, 1999, CANCER RES, V59, P5392; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Mirkin BL, 2002, CELL PROLIFERAT, V35, P105, DOI 10.1046/j.1365-2184.2002.00228.x; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RABIN SJ, 1995, J NEUROCHEM, V65, P347; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schaefer EM, 1998, ANAL BIOCHEM, V261, P100, DOI 10.1006/abio.1998.2716; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Tagami S, 2002, J BIOL CHEM, V277, P3085, DOI 10.1074/jbc.M103705200; Wang XQ, 2002, J BIOL CHEM, V277, P47028, DOI 10.1074/jbc.M208257200; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zeng GC, 2000, CANCER RES, V60, P6670; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	68	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36481	36489		10.1074/jbc.M402880200	http://dx.doi.org/10.1074/jbc.M402880200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215248	hybrid			2022-12-25	WOS:000223453600041
J	Mancini, A; Koch, A; Whetton, AD; Tamura, T				Mancini, A; Koch, A; Whetton, AD; Tamura, T			The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation	ONCOGENE			English	Article						Fms tyrosine kinase; serine phosphorylation; nuclear localization signal; macrophage differentiation; M-CSF-mediated signaling	STIMULATING FACTOR-RECEPTOR; BINDING-SITE; ACTIVATION; MUTATION; MURINE; OSTEOPETROSIS; GRANULOCYTE; SIGNAL; ALPHA; CELLS	Macrophage colony-stimulating factor (M-CSF or CSF-1) and its cognate receptor, the tyrosine kinase c-fms, are essential for monocyte and macrophage development. We have recently identified an Fms-interacting protein (FMIP) that binds transiently to the cytoplasmic domain of activated Fms molecules and is phosphorylated on tyrosine by Fms tyrosine kinase. FMIP is a substrate not only for Fms but also for protein kinase C (PKC). Mutagenesis reveals that this occurs on serines 5 and 6. Adjacent to these sites is a nuclear localization signal (NLS). We show that this NLS is essential for the predominantly nuclear localization of FMIP. Generation of phosphomimetic substitutions on serine residues 5 and 6 confirms that PKC-mediated phosphorylation on this site leads to translocation of FMIP to the cytosol. Furthermore, the mutant FMIP (FMIPSS5,6AA) was detected abundantly in the nucleus even in the presence of activated PKCalpha. Wild-type FMIP and FMIPSS5,6AA inhibited M-CSF-mediated survival signaling, while FMIPSS5,6EE-expressing cells survived and differentiated into macrophages more efficiently than wild-type cells in the presence of M-CSF or TPA. We conclude M-CSF-mediated activation of PKCalpha can potentiate FMIP action to initiate survival/differentiation signaling.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Christie Hosp, Fac Med, Manchester M20 9BX, Lancs, England	Hannover Medical School; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de		WHETTON, ANTHONY D/0000-0002-1098-3878				Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DATTA R, 1992, BLOOD, V79, P904; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HEYWORTH CM, 1992, BLOOD, V80, P2230; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Novak U, 1996, ONCOGENE, V13, P2607; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wagner S, 2000, EXP CELL RES, V258, P204, DOI 10.1006/excr.2000.4925; WAYS DK, 1991, BLOOD, V78, P2633; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	28	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6581	6589		10.1038/sj.onc.1207841	http://dx.doi.org/10.1038/sj.onc.1207841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221008				2022-12-25	WOS:000223530800005
J	Kerkis, A; Kerkis, I; Radis-Baptista, G; Oliveira, EB; Vianna-Morgante, AM; Pereira, LV; Yamane, T				Kerkis, A; Kerkis, I; Radis-Baptista, G; Oliveira, EB; Vianna-Morgante, AM; Pereira, LV; Yamane, T			Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus	FASEB JOURNAL			English	Article						chromosomes; centrosomes; cell penetrating peptide	EMBRYONIC STEM-CELLS; IN-VITRO DIFFERENTIATION; ARGININE-RICH PEPTIDES; TAT-MEDIATED DELIVERY; AMINO-ACID SEQUENCE; INTRACELLULAR DELIVERY; INTERCELLULAR TRAFFICKING; ANTIMICROBIAL PEPTIDES; TRANSDUCTION; DOMAINS	Herein we report that crotamine, a small lysine- and cysteine-rich protein from the venom of the South American rattlesnake, can rapidly penetrate into different cell types and mouse blastocysts in vitro. In vivo, crotamine strongly labels cells from mouse bone marrow and spleen and from peritoneal liquid, as shown by fluorescent confocal laser-scanning microscopy. Nuclear localization of crotamine was observed in both fixed and unfixed cells. In the cytoplasm, crotamine specifically associates with centrosomes and thus allows us to follow the process of centriole duplication and separation. In the nucleus, it binds to the chromosomes at S/G2 phase, when centrioles start dividing. Moreover, crotamine appears as a marker of actively proliferating cells, as shown by 5-BrdU cell-proliferation assay. Crotamine in the micromolar range proved nontoxic to any of the cell cultures tested and did not affect the pluripotency of ES cells or the development of mouse embryos.	Univ Sao Paulo, Inst Biociencias, Dept Biol, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Mol Toxicol Lab, Sao Paulo, Brazil; Univ Sao Paulo, Dept Bioquim & Imunol, BR-14049 Ribeirao Preto, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade de Sao Paulo	Kerkis, A (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Biol, Rua Matao 277, BR-05508900 Sao Paulo, Brazil.	akerkis@usp.br	Pereira, Lygia V/C-1049-2012; RADIS-BAPTISTA, GANDHI/H-9574-2016; Kerkis, Irina/AAD-1006-2019; RADIS-BAPTISTA, GANDHI/J-4991-2019	Pereira, Lygia V/0000-0002-0002-725X; RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X; RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bautch VL, 1996, DEV DYNAM, V205, P1; Bieber AL, 1997, J TOXICOL-TOXIN REV, V16, P33, DOI 10.3109/15569549709064092; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Cashman SM, 2002, MOL THER, V6, P813, DOI 10.1006/mthe.2002.0806; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRIN G, 2003, J BIOL CHEM; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Ford KG, 2000, MECH AGEING DEV, V121, P113; FOX JW, 1979, BIOCHEMISTRY-US, V18, P678, DOI 10.1021/bi00571a020; FRAICHARD A, 1995, J CELL SCI, V108, P3181; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LAURE CJ, 1975, H-S Z PHYSIOL CHEM, V356, P213; Leahy A, 1999, J EXP ZOOL, V284, P67, DOI 10.1002/(SICI)1097-010X(19990615)284:1&lt;67::AID-JEZ10&gt;3.0.CO;2-O; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; Martin A, 2002, J VIROL, V76, P4961, DOI 10.1128/JVI.76.10.4961-4970.2002; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; OWNBY CL, 1976, AM J PATHOL, V85, P149; Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Radis-Baptista G, 1999, TOXICON, V37, P973, DOI 10.1016/S0041-0101(98)00226-8; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Scholz G, 1999, CELLS TISSUES ORGANS, V165, P203, DOI 10.1159/000016700; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sukoyan MA, 2002, BRAZ J MED BIOL RES, V35, P535, DOI 10.1590/S0100-879X2002000500004; TALBOT NC, 1993, MOL REPROD DEV, V36, P139, DOI 10.1002/mrd.1080360204; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WILSON AP, 1986, ANIMAL CELL CULTURE, P182; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Yoon HY, 2002, NEUROCHEM INT, V41, P37, DOI 10.1016/S0197-0186(01)00138-3; Yuan JP, 2002, CANCER RES, V62, P4186	54	91	96	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1407	+		10.1096/fj.03-1459fje	http://dx.doi.org/10.1096/fj.03-1459fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231729				2022-12-25	WOS:000222979200023
J	Gonzalez, D; Drapier, JC; Bouton, C				Gonzalez, D; Drapier, JC; Bouton, C			Endogenous nitration of iron regulatory protein-1 (IRP-1) in nitric oxide-producing murine macrophages - Further insight into the mechanism of nitration in vivo and its impact on IRP-1 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE NITRATION; RNA-BINDING; DEPENDENT TOXICITY; HYDROGEN-PEROXIDE; SULFUR CLUSTER; PEROXYNITRITE; MYELOPEROXIDASE; CELLS; MODULATION; OXIDATION	Iron regulatory protein-1 (IRP-1) is a bifunctional [4Fe-4S] protein that functions as a cytosolic aconitase or as a trans-regulatory factor controlling iron homeostasis at a post-transcriptional level. Because IRP-1 is a sensitive target protein for nitric oxide ( NO), we investigated whether this protein is nitrated in inflammatory macrophages and whether this post-transcriptional modification changes its activities. RAW 264.7 macrophages were first stimulated with interferon-gamma and lipopolysaccharide (IFN-gamma/LPS) and then triggered by phorbol 12-myristate 13-acetate (PMA) in order to promote co-generation of NO. and O-2.(.(center dot) over bar). IRP-1 was isolated by immunoprecipitation and analyzed for protein-bound nitrotyrosine by Western blotting. We show that nitration of endogenous IRP-1 in NO-producing macrophages boosted to produce O2. was accompanied by aconitase inhibition and impairment of its capacity to bind the iron-responsive element ( IRE) of ferritin mRNA. Lost IRE-binding activity was not recovered by exposure of IRP-1 to 2% 2-mercaptoethanol and was not due to protein degradation. Inclusion of cis-aconitate with cell extract to stabilize the [4Fe-4S] cluster of holo-IRP-1 rendered protein insensitive to nitration by peroxynitrite, suggesting that loss of [Fe-S] cluster and subsequent change of conformation are prerequisites for tyrosine nitration. IRP-1 nitration was strongly reduced when IFN-gamma/LPS/PMA-stimulated cells were incubated with myeloperoxidase inhibitors, which points to the contribution of the nitrite/H2O2/peroxidase pathway to IRP-1 nitration in vivo. Interestingly, under these conditions, IRP-1 recovered full IRE binding as assessed by treatment with 2% 2-mercaptoethanol. Peroxidase-mediated nitration of critical tyrosine residues, by holding IRP-1 in an inactive state, may constitute, in activated macrophages, a self-protecting mechanism against iron-induced toxicity.	CNRS, Inst Chim Subst Nat, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouton, C (corresponding author), CNRS, Inst Chim Subst Nat, Ave Terrasse, F-91190 Gif Sur Yvette, France.	Cecile.Bouton@icsn.cnrs-gif.fr	Bouton, Cecile/J-8663-2013	Gonzalez, Deyarina/0000-0002-1838-6752				Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bian K, 2003, P NATL ACAD SCI USA, V100, P5712, DOI 10.1073/pnas.0931291100; Bouton C, 1999, CELL MOL LIFE SCI, V55, P1043, DOI 10.1007/s000180050355; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; BOUTON C, 2003, SCI STKE, pPE17; Brazzolotto X, 2002, J BIOL CHEM, V277, P11995, DOI 10.1074/jbc.M110938200; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Cairo G, 2002, BIOCHEMISTRY-US, V41, P7435, DOI 10.1021/bi025756k; Casella L, 2002, ENVIRON HEALTH PERSP, V110, P709, DOI 10.1289/ehp.02110s5709; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DAVIES B, 1989, BIOCHEM J, V258, P801, DOI 10.1042/bj2580801; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schroeder P, 2003, BIOCHEM BIOPH RES CO, V307, P69, DOI 10.1016/S0006-291X(03)01132-X; Shibuya A, 2002, FEBS LETT, V525, P43, DOI 10.1016/S0014-5793(02)03059-4; Soum E, 2003, BIOCHEMISTRY-US, V42, P7648, DOI 10.1021/bi030041i; Soum E, 2003, J BIOL INORG CHEM, V8, P226, DOI 10.1007/s00775-002-0412-9; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILLETTE JR, 1993, BIOTECHNOL APPL BIOC, V17, P205; Wippel R, 2004, BIOCHEM PHARMACOL, V67, P1285, DOI 10.1016/j.bcp.2003.11.017	47	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43345	43351		10.1074/jbc.M401889200	http://dx.doi.org/10.1074/jbc.M401889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15258160	hybrid			2022-12-25	WOS:000224226400119
J	Kim, YW; Lee, SS; Warren, RAJ; Withers, SG				Kim, YW; Lee, SS; Warren, RAJ; Withers, SG			Directed evolution of a glycosynthase from Agrobacterium sp increases its catalytic activity dramatically and expands its substrate repertoire	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDASE; OLIGOSACCHARIDE SYNTHESIS; CRYSTAL-STRUCTURE; CELLULOMONAS-FIMI; SULFOLOBUS-SOLFATARICUS; MUTANT GLYCOSIDASES; ALPHA-GLUCOSIDASE; ESCHERICHIA-COLI; SWISS-MODEL; PROTEIN	The Agrobacterium sp. beta-glucosidase (Abg) is a retaining beta-glycosidase and its nucleophile mutants, termed Abg glycosynthases, catalyze the formation of glycosidic bonds using alpha-glycosyl fluorides as donor sugars and various aryl glycosides as acceptor sugars. Two rounds of random mutagenesis were performed on the best glycosynthase to date (AbgE358G), and transformants were screened using an on-plate endocellulase coupled assay. Two highly active mutants were obtained, 1D12 (A19T, E358G) and 2F6 ( A19T, E358G, Q248R, M407V) in the first and second rounds, respectively. Relative catalytic efficiencies (k(cat)/K-m) of 1: 7: 27 were determined for AbgE358G, 1D12, and 2F6, respectively, using alpha-D-galactopyranosyl fluoride and 4-nitrophenyl beta-D-glucopyranoside as substrates. The 2F6 mutant is not only more efficient but also has an expanded repertoire of acceptable substrates. Analysis of a homology model structure of 2F6 indicated that the A19T and M407V mutations do not interact directly with substrates but exert their effects by changing the conformation of the active site. Much of the improvement associated with the A19T mutation seems to be caused by favorable interactions with the equatorial C2-hydroxyl group of the substrate. The alteration of torsional angles of Glu-411, Trp-412, and Trp-404, which are components of the aglycone ( +1) subsite, is an expected consequence of the A19T and M407V mutations based on the homology model structure of 2F6.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Ctr Excellence Canada, Prot Engn Network, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Withers, Stephen G/I-7229-2019; Lee, Seung S/K-8669-2018	Withers, Stephen G/0000-0002-6722-5701; Lee, Seung S/0000-0002-8598-3303				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brun E, 2001, J BIOMOL NMR, V21, P67, DOI 10.1023/A:1011927400439; Chi YI, 1999, FEBS LETT, V445, P375, DOI 10.1016/S0014-5793(99)00090-3; Corbett K, 2001, FEBS LETT, V509, P355, DOI 10.1016/S0014-5793(01)03154-4; Crout DHG, 1998, CURR OPIN CHEM BIOL, V2, P98, DOI 10.1016/S1367-5931(98)80041-0; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Eneyskaya EV, 2003, CARBOHYD RES, V338, P313, DOI 10.1016/S0008-6215(02)00467-6; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakulinen N, 2000, J STRUCT BIOL, V129, P69, DOI 10.1006/jsbi.1999.4206; Howard S, 1998, BIOCHEMISTRY-US, V37, P3858, DOI 10.1021/bi9727085; JACOB GS, 1995, CURR OPIN STRUC BIOL, V5, P605, DOI 10.1016/0959-440X(95)80051-4; Jaeger KE, 2001, APPL MICROBIOL BIOT, V55, P519, DOI 10.1007/s002530100643; Jakeman DL, 2002, TRENDS GLYCOSCI GLYC, V14, P13, DOI 10.4052/tigg.14.13; Johnson PE, 1999, J MOL BIOL, V287, P609, DOI 10.1006/jmbi.1999.2627; Kaper T, 2000, BIOCHEMISTRY-US, V39, P4963, DOI 10.1021/bi992463r; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KIM IC, 1992, J BIOL CHEM, V267, P22108; Koeller KM, 2000, CHEM REV, V100, P4465, DOI 10.1021/cr990297n; KOHLRAUSCH U, 1991, J BACTERIOL, V173, P3425, DOI 10.1128/jb.173.11.3425-3431.1991; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEATHERBARROW R, 1990, GRAFIT 4 0; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; Marana SR, 2002, EUR J BIOCHEM, V269, P3705, DOI 10.1046/j.1432-1033.2002.03061.x; Mayer C, 2000, FEBS LETT, V466, P40, DOI 10.1016/S0014-5793(99)01751-2; Mayer C, 2001, CHEM BIOL, V8, P437, DOI 10.1016/S1074-5521(01)00022-9; MCCARTER JD, 1992, BIOCHEM J, V286, P721, DOI 10.1042/bj2860721; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minshull J, 1999, CURR OPIN CHEM BIOL, V3, P284, DOI 10.1016/S1367-5931(99)80044-1; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; MOSER B, 1989, APPL ENVIRON MICROB, V55, P2480, DOI 10.1128/AEM.55.10.2480-2487.1989; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Okuyama M, 2002, BIOSCI BIOTECH BIOCH, V66, P928, DOI 10.1271/bbb.66.928; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Perugino G, 2004, TRENDS BIOTECHNOL, V22, P31, DOI 10.1016/j.tibtech.2003.10.008; Perugino G, 2003, BIOCHEMISTRY-US, V42, P8484, DOI 10.1021/bi0345384; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; Tolborg JF, 2002, J ORG CHEM, V67, P4143, DOI 10.1021/jo0163445; Trincone A, 2003, BIOORG MED CHEM LETT, V13, P4039, DOI 10.1016/j.bmcl.2003.08.037; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Williams SJ, 2002, AUST J CHEM, V55, P3, DOI 10.1071/CH02005; Withers SG, 2001, CARBOHYD POLYM, V44, P325, DOI 10.1016/S0144-8617(00)00249-6; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zechel DL, 2003, J AM CHEM SOC, V125, P14313, DOI 10.1021/ja036833h	52	115	123	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42787	42793		10.1074/jbc.M406890200	http://dx.doi.org/10.1074/jbc.M406890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15252054	hybrid			2022-12-25	WOS:000224226400054
J	Kee, K; Foster, BA; Merali, S; Kramer, DL; Hensen, ML; Diegelman, P; Kisiel, N; Vujcic, S; Mazurchuk, RV; Porter, CW				Kee, K; Foster, BA; Merali, S; Kramer, DL; Hensen, ML; Diegelman, P; Kisiel, N; Vujcic, S; Mazurchuk, RV; Porter, CW			Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; FATTY-ACID SYNTHASE; ANALOG-INDUCED INCREASES; HUMAN-MELANOMA CELLS; HAMSTER OVARY CELLS; TRANSGENIC MOUSE; BIS(ETHYL)POLYAMINE ANALOGS; CANCER PROGRESSION; GENE-EXPRESSION; ORNITHINE DECARBOXYLASE	The enzyme spermidine/spermine N-1-acetyltransferase (SSAT) regulates the catabolism and export of intracellular polyamines. We have previously shown that activation of polyamine catabolism by conditional overexpression of SSAT has antiproliferative consequences in LNCaP prostate carcinoma cells. Growth inhibition was causally linked to high metabolic flux arising from a compensatory increase in polyamine biosynthesis. Here we examined the in vivo consequences of SSAT overexpression in a mouse model genetically predisposed to develop prostate cancer. TRAMP(transgenic adenocarcinoma of mouse prostate) female C57BL/6 mice carrying the SV40 early genes (T/t antigens) under an androgen-driven probasin promoter were cross-bred with male C57BL/6 transgenic mice that systemically overexpress SSAT. At 30 weeks of age, the average genitourinary tract weights of TRAMP mice were similar to4 times greater than those of TRAMP/SSAT bigenic mice, and by 36 weeks, they were similar to12 times greater indicating sustained suppression of tumor outgrowth. Tumor progression was also affected as indicated by a reduction in the prostate histopathological scores. By immunohistochemistry, SV40 large T antigen expression in the prostate epithelium was the same in TRAMP and TRAMP/SSAT mice. Consistent with the 18-fold increase in SSAT activity in the TRAMP/SSAT bigenic mice, prostatic N-1-acetylspermidine and putrescine pools were remarkably increased relative to TRAMP mice, while spermidine and spermine pools were minimally decreased due to a compensatory 5-7-fold increase in biosynthetic enzymes activities. The latter led to heightened metabolic flux through the polyamine pathway and an associated similar to70% reduction in the SSAT cofactor acetylCoA and a similar to40% reduction in the polyamine aminopropyl donor S-adenosylmethionine in TRAMP/SSAT compared with TRAMP prostatic tissue. In addition to elucidating the antiproliferative and metabolic consequences of SSAT overexpression in a prostate cancer model, these findings provide genetic support for the discovery and development of specific small molecule inducers of SSAT as a novel therapeutic strategy targeting prostate cancer.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; New York University	Porter, CW (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org	Deeb, Kristin K/H-5619-2016		NATIONAL CANCER INSTITUTE [P30CA016056, R01CA076428] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA-76428, CA10972] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; Bettuzzi S, 2000, CANCER RES, V60, P1472; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153; Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coleman CS, 2002, CARCINOGENESIS, V23, P359, DOI 10.1093/carcin/23.2.359; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gingrich JR, 1996, TOXICOL PATHOL, V24, P502, DOI 10.1177/019262339602400414; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gupta S, 2000, CANCER RES, V60, P5125; Hector S, 2004, MOL CANCER THER, V3, P813; HESTON WDW, 1987, BIOCHEM PHARMACOL, V36, P1849, DOI 10.1016/0006-2952(87)90250-4; HESTON WDW, 1991, CANCER SURV, V11, P217; Hsu CX, 1998, J UROLOGY, V160, P1500, DOI 10.1016/S0022-5347(01)62603-X; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kee K, 2004, J BIOL CHEM, V279, P27050, DOI 10.1074/jbc.M403323200; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; Liu GS, 2003, ANAL CHEM, V75, P78, DOI 10.1021/ac0261505; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Mi Z, 1998, PROSTATE, V34, P51, DOI 10.1002/(SICI)1097-0045(19980101)34:1<51::AID-PROS7>3.0.CO;2-N; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Pietila M, 2001, J INVEST DERMATOL, V116, P801, DOI 10.1046/j.1523-1747.2001.01330.x; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1993, CANCER RES, V53, P581; Rhodes DR, 2002, CANCER RES, V62, P4427; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1997, CANCER RES, V57, P1086; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200	50	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40076	40083		10.1074/jbc.M406002200	http://dx.doi.org/10.1074/jbc.M406002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252047	hybrid			2022-12-25	WOS:000223791500105
J	Vagin, O; Turdikulova, S; Sachs, G				Vagin, O; Turdikulova, S; Sachs, G			The H,K-ATPase beta subunit as a model to study the role of N-glycosylation in membrane trafficking and apical sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; TRANS-GOLGI NETWORK; DARBY CANINE KIDNEY; EPITHELIAL-CELLS; PLASMA-MEMBRANE; GASTRIC H+,K+-ATPASE; ENDOPLASMIC-RETICULUM; TRANSPORTING ATPASE; EXPRESSION; SIGNALS	The role of N-glycosylation in trafficking of an apical membrane protein, the gastric H, K-ATPase beta subunit linked to yellow fluorescent protein, was analyzed in polarized LLC-PK1 cells by confocal microscopy and surface-specific biotinylation. Deletion of the N-glycosylation sites at N1, N3, N5, and N7 but not at N2, N4, and N6 significantly slowed endoplasmic reticulum-to-Golgi trafficking, impaired apical sorting, and enhanced endocytosis from the apical membrane, resulting in decreased apical expression. Golgi mannosidase inhibition to prevent carbohydrate chain branching and elongation resulted in faster internalization and degradation of the beta subunit, indicating that terminal glycosylation is important for stabilization of the protein in the apical membrane and protection of internalized protein from targeting to the degradation pathway. The decrease in the apical content of the beta subunit was less with mannosidase inhibition compared with that found in the N1, N3, N5, and N7 site mutants, suggesting that the core region sugars are more important than the terminal sugars for apical sorting.	Vet Affairs Greater Los Angeles Hlth Care Syst W, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vagin, O (corresponding author), Vet Affairs Greater Los Angeles Hlth Care Syst W, Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	olgav@uvla.edu	Turdikulova, Shahlo/R-7669-2016	Turdikulova, Shahlo/0000-0003-0764-2332	NIDDK NIH HHS [DK41301, DK46917, DK53462, DK17294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046917, R37DK017294, R01DK017294, P30DK041301, R21DK053462] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano S, 2000, J BIOL CHEM, V275, P8324, DOI 10.1074/jbc.275.12.8324; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1997, J CELL SCI, V110, P3001; Kimura T, 2002, J BIOL CHEM, V277, P20671, DOI 10.1074/jbc.M200523200; Klaassen CHW, 1997, BIOCHEM J, V321, P419, DOI 10.1042/bj3210419; Kroepfl JF, 2001, J NEUROCHEM, V77, P1301, DOI 10.1046/j.1471-4159.2001.00343.x; Lambrecht N, 2000, J BIOL CHEM, V275, P4041, DOI 10.1074/jbc.275.6.4041; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mobasheri A, 2001, HISTOL HISTOPATHOL, V16, P141, DOI 10.14670/HH-16.141; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nelson WJ, 2004, NAT CELL BIOL, V6, P282, DOI 10.1038/ncb0404-282; Potter BA, 2004, MOL BIOL CELL, V15, P1407, DOI 10.1091/mbc.E03-08-0550; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Vagin O, 2003, AM J PHYSIOL-CELL PH, V285, pC968, DOI 10.1152/ajpcell.00068.2003; Wilson PD, 2000, AM J PATHOL, V156, P253, DOI 10.1016/S0002-9440(10)64726-8; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	32	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39026	39034		10.1074/jbc.M405453200	http://dx.doi.org/10.1074/jbc.M405453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247221	hybrid			2022-12-25	WOS:000223684100117
J	De Marchi, U; Campello, S; Szabo, I; Tombola, F; Martinou, JC; Zoratti, M				De Marchi, U; Campello, S; Szabo, I; Tombola, F; Martinou, JC; Zoratti, M			Bax does not directly participate in the Ca2+-induced permeability transition of isolated mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ADENINE-NUCLEOTIDE TRANSLOCATOR; DEPENDENT ANION CHANNEL; RAT-BRAIN MITOCHONDRIA; CELL-DEATH; INDUCED APOPTOSIS; OXIDATIVE-PHOSPHORYLATION; CONTROL POINT; PORE COMPLEX; CONTACT SITE	The mitochondrial permeability transition pore and Bax have both been proposed to be involved in the release of pro-apoptotic factors from mitochondria in the "intrinsic" pathway of apoptosis. The permeability transition pore is widely thought to be a supramolecular complex including or interacting with Bax. Given the relevance of the permeability transition in vivo, we have verified whether Bax influences the formation and/or the properties of the Ca2+/P-i-induced permeability transition by using mitochondria isolated from isogenic human colon cancer bax(+/-) and bax(-/-) HCT116 cell lines. We used mitochondria isolated from both types of cells and from Bax(+) cells exposed to apoptotic stimuli, as well as Bax-less mitochondria into which exogenous Bax had been incorporated. All exhibited the same behavior and pharmacological profile in swelling and Ca2+-retention experiments. Mitochondria from a bax(-)/bak(-) cell line also underwent an analogous Ca2+/P-i-inducible swelling. This similarity indicates that Bax has no major role in regulating the Ca2+-induced mitochondrial permeability transition.	Univ Padua, CNR, Inst Neurosci, Biomembranes Sect,Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Biol, I-35121 Padua, Italy; Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Geneva	Zoratti, M (corresponding author), Univ Padua, CNR, Inst Neurosci, Biomembranes Sect,Dept Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	zoratti@civ.bio.unipd.it	Padova, Ildiko/K-5344-2016; Tombola, Francesco/ABA-6002-2020; Campello, Silvia/AAB-3399-2019; Szabo, Ildiko/AAW-5972-2021; Tombola, Francesco/C-7311-2011	Tombola, Francesco/0000-0002-9315-0352; Szabo, Ildiko/0000-0002-3637-3947; martinou, Jean-claude/0000-0002-9847-2051; De Marchi, Umberto/0000-0002-6011-5446; campello, silvia/0000-0003-0536-2484				Appaix F, 2002, BBA-BIOENERGETICS, V1556, P155, DOI 10.1016/S0005-2728(02)00358-4; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; CIMAN M, 1992, NEUROSCI RES COMMUN, V11, P87; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; D'Herde K, 2000, CELL DEATH DIFFER, V7, P331, DOI 10.1038/sj.cdd.4400655; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Evtodienko YV, 1999, MOL CELL BIOCHEM, V194, P251, DOI 10.1023/A:1006913526643; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; He LH, 2003, P NATL ACAD SCI USA, V100, P1022, DOI 10.1073/pnas.0333594100; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; KORZENIEWSKI B, 1992, BIOCHIM BIOPHYS ACTA, V1102, P67, DOI 10.1016/0005-2728(92)90066-B; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Krysko DV, 2001, J HISTOCHEM CYTOCHEM, V49, P1277, DOI 10.1177/002215540104901010; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Polster BM, 2003, J NEUROSCI, V23, P2735; Polster BM, 2001, J BIOL CHEM, V276, P37887; Priault M, 2002, EUR J BIOCHEM, V269, P5440, DOI 10.1046/j.1432-1033.2002.03234.x; Saris NEL, 1998, MAGNESIUM RES, V11, P155; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; SZABO I, 1992, J BIOL CHEM, V267, P2940; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Theodorakis P, 2002, CANCER RES, V62, P3373; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wu CH, 2001, ONCOGENE, V20, P7006, DOI 10.1038/sj.onc.1204893; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	77	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37415	37422		10.1074/jbc.M314093200	http://dx.doi.org/10.1074/jbc.M314093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15229226	hybrid			2022-12-25	WOS:000223554600028
J	Roosbeek, S; Peelman, F; Verhee, A; Labeur, C; Caster, H; Lensink, MF; Cirulli, C; Grooten, J; Cochet, C; Vandekerckhove, JL; Amoresano, A; Chimini, G; Tavernier, J; Rosseneu, M				Roosbeek, S; Peelman, F; Verhee, A; Labeur, C; Caster, H; Lensink, MF; Cirulli, C; Grooten, J; Cochet, C; Vandekerckhove, JL; Amoresano, A; Chimini, G; Tavernier, J; Rosseneu, M			Phosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABC TRANSPORTERS; TANGIER-DISEASE; IDENTIFICATION; DEGRADATION; EXPRESSION; MUTATIONS; SECRETION; SITES	In a previous characterization of the ABCA subfamily of the ATP-binding cassette (ABC) transporters, we identified potential protein kinase 2 (CK2) phosphorylation sites, which are conserved in eukaryotic and prokaryotic members of the ABCA transporters (Peelman, F., Labeur, C., Vanloo, B., Roosbeek, S., Devaud, C., Duverger, N., Denefle, P., Rosier, M., Vandekerckhove, J., and Rosseneu, M. ( 2003) J. Mol. Biol. 325, 259 - 274). These phosphorylation residues are located in the conserved cytoplamic R1 and R2 domains, downstream of the nucleotide binding domains NBD1 and NBD2. To study the possible regulation of the ABCA1 transporter by CK2, we expressed the recombinant cytoplasmic domains of ABCA1, NBD1 + R1 and NBD2 + R2. We demonstrated that in vitro ABCA1 NBD1 + R1, and not NBD2 + R2, is phosphorylated by CK2, and we identified Thr-1242, Thr-1243, and Ser-1255 as the phosphorylated residues in the R1 domain by mass spectrometry. We further investigated the functional significance of the threonine and serine phosphorylation sites in NBD1 by site-directed mutagenesis of the entire ABCA1 followed by transfection into Hek-293 Tet-Off cells. The ABCA1 flippase activity, apolipoprotein AI and AII binding, and cellular phospholipid and cholesterol efflux were enhanced by mutations preventing CK2 phosphorylation of the threonine and serine residues. This was confirmed by the effect of specific protein kinase CK2 inhibitors upon the activity of wild type and mutant ABCA1 in transfected Hek-293 Tet-Off cells. The activities of the mutants mimicking threonine phosphorylation were close to that of wild type ABCA1. Our data, therefore, suggest that besides protein kinase A and C, protein kinase CK2 might play an important role in vivo in regulating the function and transport activity of ABCA1 and possibly of other members of the ABCA subfamily.	Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; Ctr Immunol, F-13288 Marseille, France; Commissariat Energie Atom Saclay, F-38054 Grenoble, France; Univ Naples Federico II, I-80126 Naples, Italy; Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Ghent University; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Naples Federico II; Ghent University	Roosbeek, S (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Hosp Str 13, B-9000 Ghent, Belgium.	stein.roosbeek@UGent.be	Lensink, Marc F/A-1678-2008; Tavernier, Jan/AAG-3636-2019	Lensink, Marc F/0000-0003-3957-9470; AMORESANO, Angela/0000-0002-8386-655X; Cochet, Claude/0000-0002-1772-4270				Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100; Amoresano A, 2004, EUR J MASS SPECTROM, V10, P401, DOI 10.1255/ejms.599; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cheng HH, 1999, J BIOL CHEM, V274, P17171, DOI 10.1074/jbc.274.24.17171; Dean M, 2001, J LIPID RES, V42, P1007; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOPEZ J, 1994, EUR J BIOCHEM, V225, P1141, DOI 10.1111/j.1432-1033.1994.1141b.x; Maizel A, 2002, DEVELOPMENT, V129, P3545; Martel V, 2002, ANN NY ACAD SCI, V973, P272, DOI 10.1111/j.1749-6632.2002.tb04648.x; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Peelman F, 2003, J MOL BIOL, V325, P259, DOI 10.1016/S0022-2836(02)01105-1; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Roosbeek S, 2004, PROTEIN EXPRES PURIF, V35, P102, DOI 10.1016/j.pep.2003.12.015; Roosbeek S, 2001, J LIPID RES, V42, P31; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schmitz Gerd, 2002, Curr Atheroscler Rep, V4, P243, DOI 10.1007/s11883-002-0026-2; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; van Veen HW, 2001, J MOL MICROB BIOTECH, V3, P185; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	37	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37779	37788		10.1074/jbc.M401821200	http://dx.doi.org/10.1074/jbc.M401821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15218032	hybrid			2022-12-25	WOS:000223554600070
J	Wang, CB; Hu, HZ; Colton, CK; Wood, JD; Zhu, MX				Wang, CB; Hu, HZ; Colton, CK; Wood, JD; Zhu, MX			An alternative splicing product of the murine trpv1 gene dominant negatively modulates the activity of TRPV1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; CAPSAICIN RECEPTOR; VANILLOID RECEPTOR; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; ION-CHANNEL; DESENSITIZATION; AGONIST; ACTIVATION; VR1	Transient receptor potential vanilloid 1 (TRPV1), or vanilloid receptor 1, is the founding member of the vanilloid type of TRP superfamily of nonselective cation channels. TRPV1 is activated by noxious heat, acid, and alkaloid irritants as well as several endogenous ligands and is sensitized by inflammatory factors, thereby serving important functions in detecting noxious stimuli in the sensory system and pathological states in different parts of the body. Whereas numerous studies have been carried out using the rat and human TRPV1 cDNA, the mouse TRPV1 cDNA has not been characterized. Here, we report molecular cloning of two TRPV1 cDNA variants from dorsal root ganglia of C57BL/6 mice. The deduced proteins are designated TRPV1alpha and TRPV1beta and contain 839 and 829 amino acids, respectively. TRPV1beta arises from an alternative intron recognition signal within exon 7 of the trpv1 gene. We found a predominant expression of TRPV1alpha in many tissues and significant expression of TRPV1beta in dorsal root ganglia, skin, stomach, and tongue. When expressed in HEK 293 cells or Xenopus oocytes, TRPV1alpha formed a Ca2+-permeable channel activated by ligands known to stimulate TRPV1. TRPV1beta was not functional by itself but its coexpression inhibited the function of TRPV1alpha. Furthermore, although both isoforms were synthesized at a similar rate, less TRPV1beta than TRPV1alpha protein was found in cells and on the cell surface, indicating that the beta isoform is highly unstable. Our data suggest that TRPV1beta is a naturally occurring dominant-negative regulator of the responses of sensory neurons to noxious stimuli.	Ohio State Univ, Ctr Mol Biol, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zhu, MX (corresponding author), Ohio State Univ, Ctr Mol Biol, 168 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	zhu.55@osu.edu		Hu, Hongzhen/0000-0002-8967-7522	NIDDK NIH HHS [DK057075] Funding Source: Medline; NINDS NIH HHS [NS42183] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Cortright DN, 2001, BIOCHEM BIOPH RES CO, V281, P1183, DOI 10.1006/bbrc.2001.4482; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Hail N, 2003, APOPTOSIS, V8, P251, DOI 10.1023/A:1023620821878; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959-4388(03)00101-6; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; McIntyre P, 2001, BRIT J PHARMACOL, V132, P1084, DOI 10.1038/sj.bjp.0703918; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Salzberg SL, 1997, COMPUT APPL BIOSCI, V13, P365; Sanchez JF, 2001, NEUROSCIENCE, V107, P373, DOI 10.1016/S0306-4522(01)00373-6; SANFORD J, 1991, J BIOL CHEM, V266, P9570; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Shin JS, 2001, NEUROSCI LETT, V299, P135, DOI 10.1016/S0304-3940(00)01777-8; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; SZALLASI A, 1992, NEUROSCI LETT, V140, P51, DOI 10.1016/0304-3940(92)90679-2; SZOLCSANYI J, 1988, BRAIN RES, V446, P262, DOI 10.1016/0006-8993(88)90885-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; Turner H, 2003, BIOCHEM J, V371, P341, DOI 10.1042/BJ20021381; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Xue Q, 2001, GENOMICS, V76, P14, DOI 10.1006/geno.2001.6582; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	46	82	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37423	37430		10.1074/jbc.M407205200	http://dx.doi.org/10.1074/jbc.M407205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234965	hybrid			2022-12-25	WOS:000223554600029
J	Guo, RJ; Huang, E; Ezaki, T; Patel, N; Sinclair, K; Wu, JL; Klein, P; Suh, ER; Lynch, JP				Guo, RJ; Huang, E; Ezaki, T; Patel, N; Sinclair, K; Wu, JL; Klein, P; Suh, ER; Lynch, JP			Cdx1 inhibits human colon cancer cell proliferation by reducing beta-catenin/T-cell factor transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE CDX1; CYCLIN D1 GENE; COLORECTAL-CANCER; E-CADHERIN; DOWN-REGULATION; EXPRESSION; PROTEIN; TARGET; ACTIVATION; GROWTH	The cessation of proliferation and the induction of differentiation are highly coordinated processes that occur continuously in the intestinal crypts. The homeodomain transcription factors Cdx1 and Cdx2 regulate intestine-specific gene expression and enterocyte differentiation. Their roles in regulating proliferation are recognized but remain poorly understood. Previously, we demonstrated that Cdx1 expression diminished the proliferation of human colon cancer cells in part by reducing cyclin D1 gene expression. In order to elucidate further the molecular mechanisms underlying this phenomenon, we first hypothesized that Cdx1 or Cdx2 expression reduces colon cancer cell proliferation by inhibiting beta-catenin/T-cell factor (TCF) transcriptional activity. We report that Cdx1 or Cdx2 expression does inhibit beta-catenin/TCF transcriptional activity in colon cancer cells. This inhibitory effect is dose-dependent and is observed in different colon cancer cell lines, and the degree of inhibition correlates with the ability of Cdx1 to reduce cell proliferation. Cdx1 expression does not alter beta-catenin protein levels or intracellular distribution nor does it induce an inhibitory TCF isoform. We also find that Cdx1 expression is lost in Min mouse polyps with increased nuclear localization of beta-catenin, suggesting that Cdx1 does not support beta-catenin-mediated transformation. Finally, we show that colon cancer cells effectively reduce Cdx2-mediated inhibition of Wnt/beta-catenin/TCF transcriptional activity when compared with other model systems. This suggests that colon cancer and possibly crypt epithelial cells can modulate the effects of Cdx2 on beta-catenin signaling and proliferation. We conclude that Cdx1 and Cdx2 inhibit colon cancer cell proliferation by blocking beta-catenin/TCF transcriptional activity.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lynch, JP (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 660 CRB,415 Curie Bldg, Philadelphia, PA 19104 USA.	lynchj@mail.med.upenn.edu			NIDDK NIH HHS [DK 02695-02, DK 047437-09, DK 062819-01, P30 DK 50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK062819, P30DK050306, K08DK002695, R01DK047437] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Barker N, 2000, BIOESSAYS, V22, P961; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Epstein M, 1997, DEVELOPMENT, V124, P3805; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; GUO RJ, 2004, IN PRESS CANC BIOL T; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Howe LR, 1999, CANCER RES, V59, P1572; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Levy V, 2002, DEV BIOL, V248, P40, DOI 10.1006/dbio.2002.0705; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2002, HEMATOL ONCOL CLIN N, V16, P775, DOI 10.1016/S0889-8588(02)00029-1; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Oh EJ, 2002, INT J ONCOL, V20, P23; Orsulic S, 1999, J CELL SCI, V112, P1237; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Pillemer G, 1998, MECH DEVELOP, V74, P133, DOI 10.1016/S0925-4773(98)00075-6; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rankin EB, 2004, AM J PHYSIOL-GASTR L, V286, pG872, DOI 10.1152/ajpgi.00326.2003; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Roel G, 2002, CURR BIOL, V12, P1941, DOI 10.1016/S0960-9822(02)01280-0; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SILBERG DG, 2003, GASTROINTESTINAL CAN, P105; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Sparks AB, 1998, CANCER RES, V58, P1130; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uesaka T, 2004, J MOL BIOL, V337, P647, DOI 10.1016/j.jmb.2004.01.061; Uesaka T, 2002, AM J PHYSIOL-GASTR L, V283, pG840, DOI 10.1152/ajpgi.00075.2002; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wu R, 2001, CANCER RES, V61, P8247; Xu FH, 1999, J BIOL CHEM, V274, P34310, DOI 10.1074/jbc.274.48.34310; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Yang J, 2002, DEVELOPMENT, V129, P5743, DOI 10.1242/dev.00150; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	85	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36865	36875		10.1074/jbc.M405213200	http://dx.doi.org/10.1074/jbc.M405213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215241	hybrid			2022-12-25	WOS:000223453600088
J	Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H				Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H			Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents	ONCOGENE			English	Article						mitotic catastrophe; spindle checkpoint; DNA damage; p53; time lapse; BubR1	HUMAN LUNG CANCERS; ASSEMBLY CHECKPOINT; MAMMALIAN-CELLS; FREQUENT IMPAIRMENT; LYMPHOMA-CELLS; P53 MUTATION; TUMOR-CELLS; SENSITIVITY; ARREST; LINES	Mitotic catastrophe is an important mechanism for the induction of cell death in cancer cells by antineoplastic agents that damage DNA. This process is facilitated by defects in the G(1) and G(2) checkpoints of the cell cycle that are apparent in most cancer cells and which allow the cells to enter mitosis with DNA damage. We have now characterized the dynamics of mitotic catastrophe induced by DNA-damaging agents in p53-deficient cancer cells. Cells that entered mitosis with DNA damage transiently arrested at metaphase for more than 10 h without segregation of chromosomes and subsequently died directly from metaphase. In those metaphase arrested precatastrophic cells, anaphase-promoting complex appeared to be inactivated and BubR1 was persistently localized at kinetochores, suggesting that spindle checkpoint is activated after the DNA damage. Furthermore, suppression of spindle checkpoint function by BubR1 or Mad2 RNA interference in the DNA damaged cells led to escape from catastrophic death and to subsequent abnormal mitosis. Dysfunction of the spindle checkpoint in p53-deficient cancer cells is thus likely a critical factor in resistance to DNA-damaging therapeutic agents.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013					Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Borel F, 2002, J CELL SCI, V115, P2829; BRACHMAN DG, 1993, CANCER RES, V53, P3667; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erenpreisa JE, 2000, CELL BIOL INT, V24, P61, DOI 10.1006/cbir.1999.0466; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FINGERT HJ, 1986, CANCER RES, V46, P2463; Garber PM, 2002, GENETICS, V161, P521; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Vogt U, 2002, J CANCER RES CLIN, V128, P141, DOI 10.1007/s00432-001-0305-2; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang XH, 2002, CANCER RES, V62, P1662	41	132	143	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6548	6558		10.1038/sj.onc.1207873	http://dx.doi.org/10.1038/sj.onc.1207873			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221012				2022-12-25	WOS:000223530800002
J	Sweeney, C; Morrow, D; Birney, YA; Coyle, S; Hennessy, C; Scheller, A; Cummins, PM; Walls, D; Redmond, EM; Cahill, PA				Sweeney, C; Morrow, D; Birney, YA; Coyle, S; Hennessy, C; Scheller, A; Cummins, PM; Walls, D; Redmond, EM; Cahill, PA			Notch 1 and 3 receptors modulate vascular smooth muscle cell growth, apoptosis and migration via a CBF-1/RBP-Jk dependent pathway	FASEB JOURNAL			English	Article						vascular disease; cell fate; developmental; phenotype; signaling	3 INTRACELLULAR DOMAIN; ENDOTHELIAL-CELLS; PULSE PRESSURE; RBP-J; NOTCH; DIFFERENTIATION; EXPRESSION; PROLIFERATION; ACTIVATION; RECEPTOR	Vascular smooth muscle cell (SMC) fate decisions ( cell growth, migration, and apoptosis) are fundamental features in the pathogenesis of vascular disease. We investigated the role of Notch 1 and 3 receptor signaling in controlling adult SMC fate in vitro by establishing that hairy enhancer of split (hes-1 and -5) and related hrt's (hrt-1, -2, and -3) are direct downstream target genes of Notch 1 and 3 receptors in SMC and identified an essential role for nuclear protein CBF-1/RBP-Jk in their regulation. Constitutive expression of active Notch 1 and 3 receptors (Notch IC) resulted in a significant up-regulation of CBF-1/RBP-Jk-dependent promoter activity and Notch target gene expression concomitant with significant increases in SMC growth while concurrently inhibiting SMC apoptosis and migration. Moreover, inhibition of endogenous Notch mediated CBF-1/RBP-Jk regulated gene expression with a non-DNA binding mutant of CBF-1, a Notch IC deleted of its delta RAM domain and the Epstein-Barr virus encoded RPMS-1, in conjunction with pharmacological inhibitors of Notch IC receptor trafficking ( brefeldin A and monensin), resulted in a significant decrease in cell growth while concomitantly increasing SMC apoptosis and migration. These findings suggest that endogenous Notch receptors and downstream target genes control vascular cell fate in vitro. Notch signaling, therefore, represents a novel therapeutic target for disease states in which changes in vascular cell fate occur in vivo.	Dublin City Univ, Fac Sci & Hlth, Vasc Hlth Res Ctr, Dublin 9, Ireland; Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; Dublin City Univ, Natl Ctr Sensor Res, Dublin 9, Ireland; Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA	Dublin City University; Dublin City University; Dublin City University; University of Rochester	Cahill, PA (corresponding author), Dublin City Univ, Fac Sci & Hlth, Vasc Hlth Res Ctr, Dublin 9, Ireland.	paul.cahill@dcu.ie	Cahill, Paul A/E-8061-2011	Cahill, Paul A/0000-0002-5385-6502; Redmond, Eileen M/0000-0001-8642-4418; Walls, Dermot/0000-0002-2244-2294	NHLBI NIH HHS [HL59696] Funding Source: Medline; NIAAA NIH HHS [AA-12610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059696, R29HL059696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bongarzone ER, 2000, J NEUROSCI RES, V62, P319, DOI 10.1002/1097-4547(20001101)62:3<319::AID-JNR1>3.0.CO;2-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Cappadona C, 1999, EXP CELL RES, V250, P174, DOI 10.1006/excr.1999.4502; D'Amore PA, 2002, CELL, V110, P289, DOI 10.1016/S0092-8674(02)00869-3; DELALUNA S, 1988, GENE, V62, P121; DICORLETO PE, 1993, AM J HYPERTENS, V6, pS314; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Ferguson JE, 2003, CELL CYCLE, V2, P211, DOI 10.4161/cc.2.3.366; Iso T, 2003, ARTERIOSCL THROM VAS, V23, P543, DOI 10.1161/01.ATV.0000060892.81529.8F; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kalaria RN, 2002, J NEURAL TRANSM-SUPP, P75; Kato H, 1997, DEVELOPMENT, V124, P4133; Kleinstreuer C, 2001, CRIT REV BIOMED ENG, V29, P1, DOI 10.1615/CritRevBiomedEng.v29.i1.10; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Majesky Mark W, 2003, Curr Atheroscler Rep, V5, P208, DOI 10.1007/s11883-003-0026-x; Manabe Ichiro, 2003, Curr Atheroscler Rep, V5, P214, DOI 10.1007/s11883-003-0027-9; Marchenko GN, 2003, BIOCHEM J, V372, P503, DOI 10.1042/BJ20030174; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Redmond EM, 2001, CIRCULATION, V103, P597, DOI 10.1161/01.CIR.103.4.597; Redmond EM, 1999, THROMB HAEMOSTASIS, V81, P293; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwartz Robert S, 2002, Rev Cardiovasc Med, V3 Suppl 5, pS4; Shawber C, 1996, DEVELOPMENT, V122, P3765; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Smith P, 2001, SEMIN CANCER BIOL, V11, P469, DOI 10.1006/scbi.2001.0414; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; Sullivan DD, 2003, BRIT J CANCER, V89, P228, DOI 10.1038/sj.bjc.6601107; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wang WL, 2003, BIOCHEM BIOPH RES CO, V308, P596, DOI 10.1016/S0006-291X(03)01453-0; Wang WL, 2002, J BIOL CHEM, V277, P23165, DOI 10.1074/jbc.M201409200; Weinstein BM, 2002, COLD SPRING HARB SYM, V67, P155, DOI 10.1101/sqb.2002.67.155; Zhang JX, 2001, J VIROL, V75, P2946, DOI 10.1128/JVI.75.6.2946-2956.2001; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	57	116	123	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1421	+		10.1096/fj.04-1700fje	http://dx.doi.org/10.1096/fj.04-1700fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247148				2022-12-25	WOS:000222979200005
J	Xu, Y; Wang, L; Buttice, G; Sengupta, PK; Smith, BD				Xu, Y; Wang, L; Buttice, G; Sengupta, PK; Smith, BD			Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RNA-POLYMERASE-II; BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; LEUCINE-RICH REPEATS; IDIOPATHIC PULMONARY-FIBROSIS; CARBOXYL-TERMINAL DOMAIN; GENE-EXPRESSION; GTP-BINDING; NUCLEAR ACCUMULATION	Interferon gamma (IFN-gamma) plays an important role during inflammation by repressing collagen and activating major histocompatibility class II (MHC-II) expression. Activation of MHC-II by IFN-gamma requires regulatory factor for X-box 5 (RFX5) complex as well as class II transactivator (CIITA). We have shown that the RFX family binds to the COL1A2 transcription start site (Sengupta, P. K., Fargo, J., and Smith, B. D. (2002) J. Biol. Chem. 277, 24926-24937), and the RFX5 complex represses COL1A2 gene expression during IFN-gamma response (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2003) J. Biol. Chem. 278, 49134-49144). In this report, we demonstrate that CIITA is a key mediator of COL1A2 repression by IFN-gamma. IFN-gamma up-regulates the expression of CIITA in a time-dependent manner in lung fibroblasts and promotes CIITA protein occupancy on COL1A2 transcription start site in vivo as judged by chromatin immunoprecipitation (ChIP) assays. There are coordinate decreases in the occupancy of RNA polymerase II on the collagen transcription start site with increasing CIITA occupancy during IFN-gamma treatment. In addition, we are able to specifically knockdown the IFN-gamma-stimulated expression of CIITA utilizing short hairpin interference RNA (shRNA) against CIITA. This leads to the alleviation of COL1A2 repression and MHC-II activation by IFN-gamma. RFX5 recruits CIITA to the collagen site as evidenced by DNA affinity chromatography. The presence of RFX5 complex proteins enhances the collagen repression by CIITA reaching levels occurring during IFN-gamma treatment. Co-expression of CIITA with deletion mutations and collagen promoter constructs demonstrates that CIITA represses collagen promoter mainly through its N-terminal region including the acidic domain and the proline/serine/threonine domain. Our data suggest that CIITA is a crucial member of a repressor complex responsible for mediating COL1A2 transcription repression by IFN-gamma.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Vet Adm Boston Healthcare Syst, Boston, MA 02118 USA	Boston University	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Buttice', Giovanna/0000-0001-6550-5585; Smith, Barbara/0000-0002-5375-7627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068094, P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01--HL68094, P01-HL013262-31] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Bontron S, 1997, HUM GENET, V99, P541, DOI 10.1007/s004390050403; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Camacho-Carvajal MM, 2004, INT IMMUNOL, V16, P65, DOI 10.1093/intimm/dxh010; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; CZUWARALADYKOWS.J, 2001, J BIOL CHEM, V16, P16; Fontes JD, 1997, J MOL BIOL, V270, P336, DOI 10.1006/jmbi.1997.1121; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2002, J IMMUNOL, V168, P4414, DOI 10.4049/jimmunol.168.9.4414; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2002, HUM IMMUNOL, V63, P588, DOI 10.1016/S0198-8859(02)00400-7; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Higashi K, 2003, J BIOL CHEM, V278, P5156, DOI 10.1074/jbc.M208724200; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Jabrane-Ferrat N, 2003, INT IMMUNOL, V15, P467, DOI 10.1093/intimm/dxg048; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Majello B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1358, DOI 10.2741/Majello; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; Masternak K, 2002, EMBO J, V21, P1379, DOI 10.1093/emboj/21.6.1379; McDevitt H, 2002, IMMUNOL REV, V185, P78, DOI 10.1034/j.1600-065X.2002.18509.x; McDevitt HO, 2000, ANNU REV IMMUNOL, V18, P1, DOI 10.1146/annurev.immunol.18.1.1; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; OKADA T, 1993, LYMPHOKINE CYTOK RES, V12, P87; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; Raval A, 2003, J IMMUNOL, V170, P922, DOI 10.4049/jimmunol.170.2.922; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; ROSENBLOOM J, 1984, BIOCHEM BIOPH RES CO, V123, P365, DOI 10.1016/0006-291X(84)90422-4; Santos AN, 1997, IMMUNOL LETT, V58, P53, DOI 10.1016/S0165-2478(97)02712-0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; Westerheide SD, 1997, J IMMUNOL, V158, P4812; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; Yee CSK, 2004, J IMMUNOL, V172, P5528, DOI 10.4049/jimmunol.172.9.5528; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001; Ziesche R, 2000, WIEN KLIN WOCHENSCHR, V112, P785; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	91	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41319	41332		10.1074/jbc.M404174200	http://dx.doi.org/10.1074/jbc.M404174200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247294	hybrid			2022-12-25	WOS:000224075500011
J	Pradeep, L; Udgaonkar, JB				Pradeep, L; Udgaonkar, JB			Osmolytes induce structure in an early intermediate on the folding pathway of barstar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIAL HYDROPHOBIC COLLAPSE; CIRCULAR-DICHROISM; RIBONUCLEASE-A; MOLTEN GLOBULE; ELASMOBRANCH FISHES; ORGANIC OSMOLYTES; PROTEIN STABILITY; MULTIPLE PATHWAYS; ENERGY LANDSCAPE; AMINO-ACIDS	Osmolytes stabilize proteins against denaturation, but little is known about how their stabilizing effect might affect a protein folding pathway. Here, we report the effects of the osmolytes, trimethylamine-N-oxide, and sarcosine on the stability of the native state of barstar as well as on the structural heterogeneity of an early intermediate ensemble, I-E, on its folding pathway. Both osmolytes increase the stability of the native protein to a similar extent, with stability increasing linearly with osmolyte concentration. Both osmolytes also increase the stability of I-E but to different extents. Such stabilization leads to an acceleration in the folding rate. Both osmolytes also alter the structure of I-E but do so differentially; the fluorescence and circular dichroism properties of I-E differ in the presence of the different osmolytes. Because these properties also differ from those of the unfolded form in refolding conditions, different burst phase changes in the optical signals are seen for folding in the presence of the different osmolytes. An analysis of the urea dependence of the burst phase changes in fluorescence and circular dichroism demonstrates that the formation of I-E is itself a multistep process during folding and that the two osmolytes act by stabilizing, differentially, different structural components present in the I-E ensemble. Thus, osmolytes can alter the basic nature of a protein folding pathway by discriminating, through differential stabilization, between different members of an early intermediate ensemble, and in doing so, they thereby appear to channel folding along one route when many routes are available.	Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Udgaonkar, JB (corresponding author), Tata Inst Fundamental Res, Natl Ctr Biol Sci, Gandhi Krishi Vigyan Kendra Campus, Bangalore 560065, Karnataka, India.	jayant@ncbs.res.in						AGASHE VR, 1995, BIOCHEMISTRY-US, V34, P3286, DOI 10.1021/bi00010a019; AGASHE VR, 1995, NATURE, V377, P754, DOI 10.1038/377754a0; Akiyama S, 2000, NAT STRUCT BIOL, V7, P514; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Bhuyan AK, 1999, BIOCHEMISTRY-US, V38, P9158, DOI 10.1021/bi990285w; BOYD TA, 1977, J EXP ZOOL, V199, P435, DOI 10.1002/jez.1401990318; BROWN AD, 1972, J GEN MICROBIOL, V72, P589, DOI 10.1099/00221287-72-3-589; DEGENNES PG, 1985, J PHYS LETT-PARIS, V46, pL639, DOI 10.1051/jphyslet:019850046014063900; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; FORSTER RP, 1976, AM J PHYSIOL, V230, P925, DOI 10.1152/ajplegacy.1976.230.4.925; Garcia-Mira MM, 2004, J MOL BIOL, V339, P555, DOI 10.1016/j.jmb.2004.04.011; GARCIAPEREZ A, 1990, HYPERTENSION, V16, P595, DOI 10.1161/01.HYP.16.6.595; Georgescu RE, 1998, BIOCHEMISTRY-US, V37, P10286, DOI 10.1021/bi9805083; Goldbeck RA, 1999, P NATL ACAD SCI USA, V96, P2782, DOI 10.1073/pnas.96.6.2782; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; HOCHACHKA PW, 1984, WATER SOLUTE ADAPTAT, P304; Houry WA, 1996, BIOCHEMISTRY-US, V35, P11734, DOI 10.1021/bi961085c; Houry WA, 1996, BIOCHEMISTRY-US, V35, P10125, DOI 10.1021/bi960617m; Juneja J, 2002, BIOCHEMISTRY-US, V41, P2641, DOI 10.1021/bi011480p; KHURANA R, 1994, BIOCHEMISTRY-US, V33, P106, DOI 10.1021/bi00167a014; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; Mello CC, 2003, PROTEIN SCI, V12, P1522, DOI 10.1110/ps.0372903; Melo EP, 2003, BIOCHEMISTRY-US, V42, P7611, DOI 10.1021/bi034267x; Morgan CJ, 1998, BIOCHEMISTRY-US, V37, P8473, DOI 10.1021/bi9731504; NAKANISHI T, 1993, AM J PHYSIOL, V264, pF472, DOI 10.1152/ajprenal.1993.264.3.F472; Nishimura C, 2002, J MOL BIOL, V322, P483, DOI 10.1016/S0022-2836(02)00810-0; Nolting B, 1997, BIOCHEMISTRY-US, V36, P9899, DOI 10.1021/bi962879u; Noppert A, 1998, FOLD DES, V3, P213, DOI 10.1016/S1359-0278(98)00029-7; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; Pradeep L, 2002, J MOL BIOL, V324, P331, DOI 10.1016/S0022-2836(02)01068-9; Rami BR, 2003, BIOCHEMISTRY-US, V42, P7986, DOI 10.1021/bi030006b; Rami BR, 2002, BIOCHEMISTRY-US, V41, P1710, DOI 10.1021/bi0120300; Russo AT, 2003, J MOL BIOL, V330, P851, DOI 10.1016/S0022-2836(03)00626-0; Sadqi M, 2003, P NATL ACAD SCI USA, V100, P12117, DOI 10.1073/pnas.2033863100; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHELLMAN JA, 1990, BIOPHYS CHEM, V37, P121, DOI 10.1016/0301-4622(90)88013-I; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P11195, DOI 10.1021/bi00092a032; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; SHASTRY MCR, 1994, PROTEIN SCI, V3, P1409, DOI 10.1002/pro.5560030907; Sridevi K, 2004, J MOL BIOL, V337, P699, DOI 10.1016/j.jmb.2003.12.083; Sridevi K, 2002, BIOCHEMISTRY-US, V41, P1568, DOI 10.1021/bi011494v; Timasheff S. N., 1992, WATER LIFE, P70; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Wang AJ, 1996, BIOPHYS J, V71, P2117, DOI 10.1016/S0006-3495(96)79410-9; Wright CF, 2003, NAT STRUCT BIOL, V10, P658, DOI 10.1038/nsb947; Yamasaki K, 1995, BIOCHEMISTRY-US, V34, P16552, DOI 10.1021/bi00051a003; Yancey P.H., 1985, P424; YANCEY PH, 1980, J EXP ZOOL, V212, P205, DOI 10.1002/jez.1402120207; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zaidi FN, 1997, NAT STRUCT BIOL, V4, P1016, DOI 10.1038/nsb1297-1016	61	54	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40303	40313		10.1074/jbc.M406323200	http://dx.doi.org/10.1074/jbc.M406323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15258135	hybrid			2022-12-25	WOS:000223916800011
J	Liang, HB; Luo, WT; Green, N; Fang, H				Liang, HB; Luo, WT; Green, N; Fang, H			Cargo sequences are important for Som1p-dependent signal peptide cleavage in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE PEPTIDASE; SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; CATALYTIC SUBUNITS; PROTEIN; COMPLEX; SUBSTRATE; REVEALS; SITES	The inner membrane protease (IMP) has two catalytic subunits, Imp1p and Imp2p, that exhibit nonoverlapping substrate specificity in mitochondria of the yeast Saccharomyces cerevisiae. The IMP also has at least one noncatalytic subunit, Som1p, which is required to cleave signal peptides from a subset of Imp1p substrates. To understand how Som1p mediates Imp1p substrate specificity, we addressed the possibility that Som1p functions as a molecular chaperone, which binds to specific substrates and directs them to the catalytic site. Our results show that cargo sequences attached to the signal peptide are important for Som1p-dependent presequence cleavage; however, no specific cargo sequence is required. Indeed, we show that a substrate normally destined for Imp2p is cleaved in a Som1p-dependent manner when the substrate is directed to Imp1p. These results argue against the notion that Som1p is a molecular chaperone. Instead, we propose that the cargo of some Imp1p substrates can assume a conformation incompatible with presequence cleavage. Som1p could thus act through Imp1p to improve cleavage efficiency early during substrate maturation.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Fang, H (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.	hong.fang@vanderbilt.edu						BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; Chen XM, 1999, J BIOL CHEM, V274, P37750, DOI 10.1074/jbc.274.53.37750; Esser K, 1996, MOL GEN GENET, V252, P437, DOI 10.1007/s004380050248; Esser K, 2004, MOL GENET GENOMICS, V271, P616, DOI 10.1007/s00438-004-1011-y; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Jan PS, 2000, MOL GEN GENET, V263, P483, DOI 10.1007/s004380051192; Liang HB, 2003, J BIOL CHEM, V278, P50932, DOI 10.1074/jbc.M307542200; Luo WT, 2003, J BIOL CHEM, V278, P4943, DOI 10.1074/jbc.M210916200; MORGANHUGHES JA, 1994, MYOLOGY BASIC CLIN, V2, P1610; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PRATJE E, 1983, EMBO J, V2, P1049, DOI 10.1002/j.1460-2075.1983.tb01544.x; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	20	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39396	39400		10.1074/jbc.M406915200	http://dx.doi.org/10.1074/jbc.M406915200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254042	hybrid			2022-12-25	WOS:000223791500026
J	Lofstedt, T; Jogi, A; Sigvardsson, M; Gradin, K; Poellinger, L; Pahlman, S; Axelson, H				Lofstedt, T; Jogi, A; Sigvardsson, M; Gradin, K; Poellinger, L; Pahlman, S; Axelson, H			Induction of ID2 expression by hypoxia-inducible factor-1 - A role in dedifferentiation of hypoxic neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING ACTIVITY; CELLULAR SENESCENCE; ANGIOGENESIS; GROWTH; TRANSCRIPTION; GENE; PHENOTYPE; CANCER; FAMILY	ID ( inhibitor of differentiation/DNA binding) proteins, frequently deregulated in advanced human malignancies, can participate in multiple fundamental traits of cancer, such as block of differentiation, increased proliferation, tissue invasiveness, and angiogenesis. We have previously demonstrated that hypoxia decreases expression of neuronal marker genes in neuroblastoma, but induces genes expressed in the neural crest, such as ID2. Because of its involvement in normal neural crest development and its ability to inhibit proneuronal bHLH proteins, the hypoxic induction of ID2 was of particular interest. Here we report fast induction kinetics of ID2 expression in hypoxic neuroblastoma cells. The up-regulation of ID2 was abolished by addition of actinomycin D, implicating a hypoxia-driven transcriptional mechanism. Analyzing the ID2 promoter revealed several potential binding sites for hypoxia-inducible factors. Subsequent electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrated two functional HIF-1 binding sites within ID2 gene regulatory sequences located at -725 and -1893 relative to the transcriptional initiation point. In transfection assays, DNA constructs of the ID2 promoter, including the functional HIF-1 binding sites, induced luciferase reporter activity in a HIF-1-specific manner. These observations demonstrate that ID2 is actively engaged by hypoxia and represents a novel HIF-1 target. Hypoxia-induced ID2 expression could play a significant role in the previously observed dedifferentiation of hypoxic neuroblastoma cells, which in a clinical setting could lead to less mature and more aggressive tumors.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden; Lund Univ, BMC, Dept Med, Hematopoiet Stem Cell Lab, S-22184 Lund, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Lund University; Skane University Hospital; Lund University; Karolinska Institutet	Axelson, H (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, Entrance 78, S-20502 Malmo, Sweden.	hakan.axelson@molmed.mas.lu.se		Sigvardsson, Mikael/0000-0001-8527-7276; Jogi, Annika/0000-0003-1697-8030				BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brizel DM, 1996, CANCER RES, V56, P941; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; De Preter K, 2002, MODERN PATHOL, V15, P159, DOI 10.1038/modpathol.3880508; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gestblom C, 1999, LAB INVEST, V79, P67; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HEDBORG F, 1995, EUR J CANCER, V31A, P435, DOI 10.1016/0959-8049(95)00025-E; Helczynska K, 2003, CANCER RES, V63, P1441; Hockel M, 1996, CANCER RES, V56, P4509; Hoehner JC, 1996, LAB INVEST, V75, P659; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lin CQ, 2000, CANCER RES, V60, P1332; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; O'Toole PJ, 2003, J BIOL CHEM, V278, P45770, DOI 10.1074/jbc.M306056200; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Pahlman S, 2000, NEUROBLASTOMA, P9; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	53	119	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39223	39231		10.1074/jbc.M402904200	http://dx.doi.org/10.1074/jbc.M402904200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252039	Green Published, hybrid			2022-12-25	WOS:000223791500006
J	Wei, YN; Li, HL; Fu, D				Wei, YN; Li, HL; Fu, D			Oligomeric state of the Escherichia coli metal transporter YiiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC TRANSPORTER; LIGHT-SCATTERING; MULTIDRUG-RESISTANCE; ELECTRON-MICROSCOPY; DETERGENT BINDING; MEMBRANE-PROTEINS; ABC TRANSPORTERS; MECHANISM; ZITB; SELECTIVITY	YiiP is a 32.9-kDa metal transporter found in the plasma membrane of Escherichia coli (Chao, Y., and Fu, D. (2004) J. Biol. Chem. 279, 17173 - 17180). Here we report the determination of the YiiP oligomeric state in detergent-lipid micelles and in membranes. Molecular masses of YiiP solubilized with dodecyl-, undecyl-, decyl-, or nonyl-beta-D-maltoside were measured directly using size-exclusion chromatography coupled with laser light-scattering photometry, yielding a mass distribution of YiiP homo-oligomers within a narrow range (68.0 - 68.8 kDa) that equals the predicted mass of a YiiP dimer within experimental error. The detergent-lipid masses associated with YiiP in the mixed micelles were found to increase from 135.5 to 232.6 kDa, with an apparent correlation with the alkyl chain length of the maltoside detergents. Cross-linking the detergent-solubilized YiiP with 1-ethyl-3- [3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) resulted in a dimeric cross-linked product in an EDC concentration-dependent manner. The oligomeric state of the purified YiiP in reconstituted membranes was determined by electron microscopic analysis of two-dimensional YiiP crystals in negative stain. A projection structure calculated from measurable optical diffractions to 25 Angstrom revealed a pseudo-2-fold symmetry within a molecular boundary of similar to 75 x 40 Angstrom, indicative of the presence of YiiP dimers in membranes. These data provide direct structural evidence for a dimeric association of YiiP both in detergent-lipid micelles and in the reconstituted lipid bilayer. The functional relevance of the dimeric association in YiiP is discussed.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Li, Huilin/0000-0001-8085-8928; Fu, Dax/0000-0002-2663-1316	NIGMS NIH HHS [R01 GM65137] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BEAVIS R, 1996, METHOD ENZYMOL, V70, P519; Borgnia MJ, 2001, P NATL ACAD SCI USA, V98, P2888, DOI 10.1073/pnas.051628098; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Chao Y, 2004, J BIOL CHEM, V279, P17173, DOI 10.1074/jbc.M400208200; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Grass G, 2001, J BACTERIOL, V183, P4664, DOI 10.1128/JB.183.15.4664-4667.2001; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; HAYASHI Y, 1989, METHOD ENZYMOL, V172, P514; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y; KUHLBRANDT W, 1988, Q REV BIOPHYS, V21, P429, DOI 10.1017/S0033583500004625; Lee SM, 2002, FEMS MICROBIOL LETT, V215, P273, DOI 10.1016/S0378-1097(02)00961-8; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; TAKAGI T, 1990, J CHROMATOGR, V506, P409, DOI 10.1016/S0021-9673(01)91596-1; Tomii K, 1998, GENOME RES, V8, P1048, DOI 10.1101/gr.8.10.1048; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Werten PJL, 2002, FEBS LETT, V529, P65, DOI 10.1016/S0014-5793(02)03290-8; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	30	49	50	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39251	39259		10.1074/jbc.M407044200	http://dx.doi.org/10.1074/jbc.M407044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258151	hybrid			2022-12-25	WOS:000223791500009
J	Bai, J; Nakamura, H; Ueda, S; Kwon, YW; Tanaka, T; Ban, S; Yodoi, J				Bai, J; Nakamura, H; Ueda, S; Kwon, YW; Tanaka, T; Ban, S; Yodoi, J			Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA; DOPAMINE NEURONS; TRANSGENIC MICE; BETA-CATENIN; PC12 CELLS; INHIBITION; MPTP; PATHWAY; P21; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	1-Methyl-4-phenylpyridinium ion (MPP+), an active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, induces cell death and inhibition of cell proliferation in various cells. However, the mechanism whereby MPP+ inhibits cell proliferation is still unclear. In this study, we found that MPP+ suppressed the proliferation with accumulation in G(1) phase without inducing cell death in p53-deficient MG63 osteosarcoma cells. MPP+ induced hypophosphorylation of retinoblastoma protein and rapidly down-regulated the protein but not mRNA levels of cyclin D1 in MG63 cells. The down-regulation of cyclin D1 protein was suppressed by a proteasome inhibitor, MG132. The cyclin D1 down-regulation by MPP+ was also observed in p53-positive PC12, HeLa S3, and HeLa rho(0) cells, which are a subclone of HeLa S3 lacking mitochondrial DNA. Moreover, MPP+ dephosphorylated Akt in PC12 cells, which was rescued by the pretreatment with nerve growth factor. In addition, the pretreatment with nerve growth factor or lithium chloride, a glycogen synthase kinase-3beta inhibitor, suppressed the cyclin D1 down-regulation caused by MPP+. Our results demonstrate that MPP+ induces cell cycle arrest independently of its mitochondrial toxicity or the p53 status of the target cells, but rather through the proteasome- and phosphatidylinositol 3-Akt-glycogen synthase kinase-3beta-dependent cyclin D1 degradation.	Kyoto Univ, Translat Res Ctr, Dept Expt Therapeut, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Kyoto 6068507, Japan; Natl Inst Radiol Sci, Frontier Res Ctr, Inage Ku, Chiba 2638555, Japan	Kyoto University; Kyoto University; National Institutes for Quantum Science & Technology	Nakamura, H (corresponding author), Kyoto Univ, Translat Res Ctr, Dept Expt Therapeut, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hnakamur@kuhp.kyoto-u.ac.jp	Yodoi, Junji/F-6189-2011	Yodoi, Junji/0000-0001-6849-4914				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bai J, 2002, NEUROSCI LETT, V321, P81, DOI 10.1016/S0304-3940(02)00058-7; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIMONTE D, 1986, BIOCHEM BIOPH RES CO, V137, P310, DOI 10.1016/0006-291X(86)91211-8; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; FILMUS J, 1994, ONCOGENE, V9, P3627; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LANGSTON JW, 1986, CLIN NEUROPHARMACOL, V9, P485, DOI 10.1097/00002826-198612000-00001; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Maruyama T, 1997, MOL HUM REPROD, V3, P989, DOI 10.1093/molehr/3.11.989; MICHIELI P, 1994, CANCER RES, V54, P3391; Miyako K, 1997, J BIOL CHEM, V272, P9605; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V135, P269, DOI 10.1016/0006-291X(86)90972-1; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soldner F, 1999, EXP CELL RES, V250, P75, DOI 10.1006/excr.1999.4504; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TALLINI G, 1994, CYTOGENET CELL GENET, V66, P253, DOI 10.1159/000133706; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZANG LY, 1993, J BIOL CHEM, V268, P16504; ZANG LY, 1992, J BIOL CHEM, V267, P17547	38	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38710	38714		10.1074/jbc.M403329200	http://dx.doi.org/10.1074/jbc.M403329200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247282	hybrid			2022-12-25	WOS:000223684100080
J	Lou, XH; Liu, Q; Tu, XY; Wang, J; Teng, M; Niu, LW; Schuller, DJ; Huang, QQ; Hao, Q				Lou, XH; Liu, Q; Tu, XY; Wang, J; Teng, M; Niu, LW; Schuller, DJ; Huang, QQ; Hao, Q			The atomic resolution crystal structure of atratoxin determined by single wavelength anomalous diffraction phasing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SITE-DIRECTED MUTAGENESIS; CHAIN ALPHA-NEUROTOXIN; X-RAY-STRUCTURE; NAJA-NAJA-ATRA; ERABUTOXIN-B; TERTIARY STRUCTURE; SNAKE TOXINS; COBRA VENOM; PROTEIN	By using single wavelength anomalous diffraction phasing based on the anomalous signal from copper atoms, the crystal structure of atratoxin was determined at the resolution of 1.5 Angstrom and was refined to an ultrahigh resolution of 0.87 Angstrom. The ultrahigh resolution electron density maps allowed the modeling of 38 amino acid residues in alternate conformations and the location of 322 of 870 possible hydrogen atoms. To get accurate information at the atomic level, atratoxin-b (an analog of atratoxin with reduced toxicity) was also refined to an atomic resolution of 0.92 Angstrom. By the sequence and structural comparison of these two atratoxins, Arg(33) and Arg(36) were identified to be critical to their varied toxicity. The effect of copper ions on the distribution of hydrogen atoms in atratoxin was discussed, and the interactions between copper ions and protein residues were analyzed based on a statistical method, revealing a novel pentahedral copper-binding motif.	Univ Sci & Technol China, Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Cornell University	Niu, LW (corresponding author), Univ Sci & Technol China, Chinese Acad Sci, Key Lab Struct Biol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	lwniu@ustc.edu.cn; qh22@cornell.edu	Hao, Quan/C-4304-2009; Liu, Qun/A-8757-2011; Tu, Xiongying/H-7983-2012	Liu, Qun/0000-0002-1179-290X; Lou, Xiaohua/0000-0002-8864-0912; Hao, Quan/0000-0002-9642-0514	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AIRD SD, 1985, TOXICON, V23, P361, DOI 10.1016/0041-0101(85)90020-0; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang LS, 1997, J BIOCHEM, V122, P1252, DOI 10.1093/oxfordjournals.jbchem.a021889; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; Cheng Y, 2002, BBA-PROTEIN STRUCT M, V1594, P353, DOI 10.1016/S0167-4838(01)00326-0; *COMM COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; FAN HF, 1984, ACTA CRYSTALLOGR A, V40, P495, DOI 10.1107/S0108767384001057; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Hao Q, 2000, J APPL CRYSTALLOGR, V33, P980, DOI 10.1107/S0021889800001424; Hao Q, 2004, J APPL CRYSTALLOGR, V37, P498, DOI 10.1107/S0021889804008696; Hao Q, 2003, J APPL CRYSTALLOGR, V36, P1274, DOI 10.1107/S0021889803014031; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMBALL MR, 1979, BIOCHEM BIOPH RES CO, V88, P950, DOI 10.1016/0006-291X(79)91500-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Le Du MH, 2000, J MOL BIOL, V296, P1017; Lou XH, 2003, ACTA CRYSTALLOGR D, V59, P1038, DOI 10.1107/S0907444903005687; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; Meng QX, 2002, COMP BIOCHEM PHYS C, V132, P113, DOI 10.1016/S1532-0456(02)00049-2; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nastopoulos V, 1998, ACTA CRYSTALLOGR D, V54, P964, DOI 10.1107/S0907444998005125; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PILLET L, 1993, J BIOL CHEM, V268, P909; SALUDJIAN P, 1992, ACTA CRYSTALLOGR B, V48, P520, DOI 10.1107/S010876819200096X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1978, MOL PHARMACOL, V14, P710; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; Tu XY, 2002, ACTA CRYSTALLOGR D, V58, P839, DOI 10.1107/S0907444902002639; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WOOLFSON MM, 1994, ACTA CRYSTALLOGR D, V50, P7, DOI 10.1107/S0907444993008091; YU C, 1993, BIOCHEMISTRY-US, V32, P2131, DOI 10.1021/bi00060a002	43	10	13	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39094	39104		10.1074/jbc.M403863200	http://dx.doi.org/10.1074/jbc.M403863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252034	hybrid			2022-12-25	WOS:000223684100125
J	Rangaswami, H; Bulbule, A; Kundu, GC				Rangaswami, H; Bulbule, A; Kundu, GC			Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/I kappa B alpha kinase-dependent nuclear factor kappa B-mediated promatrix metalloproteinase-9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR; BREAST-CANCER; MATRIX-METALLOPROTEINASE; DIFFERENTIAL REGULATION; SIGNALING PATHWAYS; DOWN-REGULATION; CELL MOTILITY; GELATINASE-B; TUMOR	We have recently demonstrated that osteopontin (OPN) induces nuclear factor kappaB (NFkappaB)-mediated promatrix metalloproteinase-2 activation through IkappaBalpha/ IkappaBalpha kinase (IKK) signaling pathways. However, the molecular mechanism(s) by which OPN regulates promatrix metalloproteinase-9 (pro-MMP-9) activation, MMP-9-dependent cell motility, and tumor growth and the involvement of upstream kinases in regulation of these processes in murine melanoma cells are not well defined. Here we report that OPN induced alpha(v)beta(3) integrin-mediated phosphorylation and activation of nuclear factor-inducing kinase (NIK) and enhanced the interaction between phosphorylated NIK and IKKalpha/beta in B16F10 cells. Moreover, NIK was involved in OPN-induced phosphorylations of MEK-1 and ERK1/2 in these cells. OPN induced NIK-dependent NFB activation through ERK/ IKKalpha/beta-mediated pathways. Furthermore OPN enhanced NIK-regulated urokinase-type plasminogen activator (uPA) secretion, uPA-dependent pro-MMP-9 activation, cell motility, and tumor growth. Wild type NIK, IKKalpha/beta, and ERK1/2 enhanced and kinase-negative NIK (mut NIK), dominant negative IKKalpha/beta (dn IKKalpha/beta), and dn ERK1/2 suppressed the OPN-induced NFkappaB activation, uPA secretion, pro-MMP-9 activation, cell motility, and chemoinvasion. Pretreatment of cells with anti-MMP-2 antibody along with anti-MMP-9 antibody drastically inhibited the OPN-induced cell migration and chemoinvasion, whereas cells pretreated with anti-MMP-2 antibody had no effect on OPN-induced pro-MMP-9 activation suggesting that OPN induces pro-MMP-2 and pro-MMP-9 activations through two distinct pathways. The level of active MMP-9 in the OPN-induced tumor was higher compared with control. To our knowledge, this is the first report that NIK plays a crucial role in OPN-induced NFkappaB activation, uPA secretion, and pro-MMP-9 activation through MAPK/IKKalpha/beta-mediated pathways, and all of these ultimately control the cell motility, invasiveness, and tumor growth.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN Y, 1992, J BIOL CHEM, V267, P24871; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DAVIES B, 1993, CANCER RES, V53, P5365; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Devalaraja MN, 1999, CANCER RES, V59, P1372; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Fini ME, 1998, BIOL EXTRAC, P299; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; HOUDE M, 1993, INT J CANCER, V53, P395, DOI 10.1002/ijc.2910530309; Hrabec E, 2001, RESP MED, V95, P1, DOI 10.1053/rmed.2000.0923; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Liaw L, 1998, J CLIN INVEST, V101, P1468; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RITTER NM, 1992, J BONE MINER RES, V7, P877; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Sehgal G, 1998, AM J PATHOL, V152, P591; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shen KH, 2000, ANTICANCER RES, V20, P1307; SINGH K, 1990, J BIOL CHEM, V265, P18696; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takaori-Kondo A, 2000, BIOCHEM BIOPH RES CO, V272, P856, DOI 10.1006/bbrc.2000.2860; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamashita K, 2004, INT J CANCER, V110, P201, DOI 10.1002/ijc.20067	52	162	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38921	38935		10.1074/jbc.M404674200	http://dx.doi.org/10.1074/jbc.M404674200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247285	hybrid			2022-12-25	WOS:000223684100106
J	Du, GG; Avila, G; Sharma, P; Khanna, VK; Dirksen, RT; MacLennan, DH				Du, GG; Avila, G; Sharma, P; Khanna, VK; Dirksen, RT; MacLennan, DH			Role of the sequence surrounding predicted transmembrane helix M4 in membrane association and function of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor isoform 1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNEL; MOLECULAR-CLONING; P-GLYCOPROTEIN; MUTATIONS; PROTEINS; TOPOLOGY; CONSEQUENCES; SENSITIVITY; CAFFEINE; SEGMENTS	The role of the sequence surrounding M4 in ryanodine receptors (RyR) in membrane association and function was investigated. This sequence contains a basic, 19-amino acid M3/M4 loop, a hydrophobic 44 - 49 amino acid sequence designated M4 ( or M4a/M4b), and a hydrophilic M4/M5 loop. Enhanced green fluorescent protein (EGFP) was inserted into RyR1 and truncated just after the basic sequence, just after M4, within the M4/M5 loop, just before M5 and just after M5. The A52 epitope was inserted into RyR2 and truncated just after M4a. Analysis of these constructs ruled out a M3/M4 transmembrane hairpin and narrowed the region of membrane association to M4a/M4b. EGFP inserted between M4a and M4b in full-length RyR2 was altered conformationally, losing fluorescence and gaining trypsin sensitivity. Although it was accessible to an antibody from the cytosolic side, tryptic fragments were membrane-bound. The expressed protein containing EGFP retained caffeine-induced Ca2+ release channel function. These results suggest that M4a/M4b either forms a transmembrane hairpin or associates in an unorthodox fashion with the cytosolic leaflet of the membrane, possibly involving the basic M3/M4 loop. The expression of a mutant RyR1, Delta4274-4535, deleted in the sequence surrounding both M3 and M4, restored robust, voltage-gated L-type Ca2+ currents and Ca2+ transients in dyspedic myotubes, demonstrating that this sequence is not required for either orthograde ( DHPR activation of sarcoplasmic reticulum Ca2+ release) or retrograde ( RyR1 increase in DHPR Ca2+ channel activity) signals of excitation-contraction coupling. Maximal amplitudes of L-currents and Ca2+ transients with Delta4274-4535 were larger than with wild-type RyR1, and voltage-gated sarcoplasmic reticulum Ca2+ release was more sensitive to activation by sarcolemmal voltage sensors. Thus, this region may act as a negative regulatory module that increases the energy barrier for Ca2+ release channel opening.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Inst Politecn Nacl, CINVESTAV, Dept Biochem, Mexico City 07000, DF, Mexico; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Toronto; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of Rochester	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca	Avila, Guillermo/B-5782-2013	Avila, Guillermo/0000-0001-7615-8945	NIAMS NIH HHS [AR44657] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044657, R29AR044657] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARGOS P, 1986, METHOD ENZYMOL, V130, P185; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee EH, 2004, AM J PHYSIOL-CELL PH, V286, pC179, DOI 10.1152/ajpcell.00176.2003; LOO TW, 1993, J BIOL CHEM, V268, P3143; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; OTSU K, 1990, J BIOL CHEM, V265, P13472; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37566	37574		10.1074/jbc.M406637200	http://dx.doi.org/10.1074/jbc.M406637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226293	hybrid			2022-12-25	WOS:000223554600048
J	Khan, AH; Capilla, E; Hou, JC; Watson, RT; Smith, JR; Pessin, JE				Khan, AH; Capilla, E; Hou, JC; Watson, RT; Smith, JR; Pessin, JE			Entry of newly synthesized GLUT4 into the insulin-responsive storage compartment is dependent upon both the amino terminus and the large cytoplasmic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; TARGETING MOTIF; INTRACELLULAR SEQUESTRATION; SUBCELLULAR TRAFFICKING; NH2 TERMINUS; SIGNAL; ENDOCYTOSIS; FIBROBLASTS	We have recently reported that following initial biosynthesis, the GLUT4 protein exits the Golgi apparatus and directly enters the insulin-responsive compartment(s) without transiting the plasma membrane ( Watson, R. T., Khan, A. H., Furukawa, M., Hou, J. C., Li, L., Kanzaki, M., Okada, S., Kandror, K. V., and Pessin, J. E. ( 2004) EMBO J. 23, 2059 - 2070). To investigate the structural motifs involved in these initial sorting events, we have generated a variety of loss-of-function and gain-of-function GLUT4/ GLUT1 chimera proteins. Substitution of the GLUT4 carboxyl-terminal domain with GLUT1 had no significant effect on the acquisition of insulin responsiveness. In contrast, substitution of either the GLUT4 amino-terminal domain or the large cytoplasmic loop between transmembrane domains 6 and 7 resulted in the rapid default of GLUT4 to the plasma membrane with blunted insulin response. Consistent with these findings, substitution of the amino-terminal, cytoplasmic loop, or carboxyl-terminal domains individually into GLUT1 backbone did not recapitulate normal GLUT4 trafficking. Similarly, dual substitutions of the GLUT1 amino and carboxyl termini with GLUT4 domains or the combination of the cytoplasmic loop plus the carboxyl terminus failed to display normal GLUT4 trafficking. However, the dual replacement of the amino terminus plus the cytoplasmic loop of GLUT4 in the GLUT1 backbone resulted in a complete restoration of normal GLUT4 trafficking. Alanine-scanning mutagenesis of the GLUT4 amino terminus demonstrated that Phe(5) and Ile(8) within the FQQI motif and, to a lesser extent, Asp(12)/Gly(13) were necessary for the appropriate initial trafficking following biosynthesis. In addition, amino acids 229 - 271 in the large intracellular loop between transmembrane domains 6 and 7 functionally cooperated with the amino-terminal domain. These data demonstrate that initial trafficking of GLUT4 from the Golgi to the insulin-responsive GLUT4 compartment requires the functional interaction of two distinct domains.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Iowa	Pessin, JE (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, BST-8 Rm 140, Stony Brook, NY 11794 USA.	pessin@pharm.sunysb.edu	Capilla, Encarnación/L-6143-2014	Capilla, Encarnación/0000-0002-0863-9728	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823, R01DK055811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK55811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 2002, J CELL SCI, V115, P131; ASANO T, 1992, J BIOL CHEM, V267, P19636; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Ducluzeau PH, 2002, DIABETES METAB, V28, P85; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; KARYLAWSKI O, 2004, BIOL CELL, V15, P870; Lalioti V, 2001, MOL MEMBR BIOL, V18, P257, DOI 10.1080/09687680110090780; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763; YANG J, 1993, J BIOL CHEM, V268, P4600	37	30	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37505	37511		10.1074/jbc.M405694200	http://dx.doi.org/10.1074/jbc.M405694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247212	hybrid			2022-12-25	WOS:000223554600040
J	Lopez-Hernandez, GY; Sanchez-Padilla, J; Ortiz-Acevedo, A; Lizardi-Ortiz, J; Salas-Vincenty, J; Rojas, LV; Lasalde-Dominicci, JA				Lopez-Hernandez, GY; Sanchez-Padilla, J; Ortiz-Acevedo, A; Lizardi-Ortiz, J; Salas-Vincenty, J; Rojas, LV; Lasalde-Dominicci, JA			Nicotine-induced up-regulation and desensitization of alpha 4 beta 2 neuronal nicotinic receptors depend on subunit ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; ACETYLCHOLINE-RECEPTORS; CHRONIC EXPOSURE; BINDING-SITES; BRAIN; EXPRESSION; MECHANISMS; DIVERSITY; INFUSION; SUBTYPES	Desensitization induced by chronic nicotine exposure has been hypothesized to trigger the up-regulation of the alpha4beta2 neuronal nicotinic acetylcholine receptor ( nAChR) in the central nervous system. We studied the effect of acute and chronic nicotine exposure on the desensitization and up-regulation of different alpha4beta2 subunit ratios (1alpha: 4beta, 2alpha: 3beta, and 4alpha: 1beta) expressed in Xenopus oocytes. The presence of alpha4 subunit in the oocyte plasmatic membrane increased linearly with the amount of alpha4 mRNA injected. nAChR function and expression were assessed during acute and after chronic nicotine exposure using a two-electrode voltage clamp and whole-mount immunofluorescence assay along with confocal imaging for the detection of the alpha4 subunit. The 2alpha4: 3beta2 subunit ratio displayed the highest ACh sensitivity. Nicotine dose-response curves for the 1alpha4: 4beta2 and 2alpha4: 3beta2 subunit ratios displayed a biphasic behavior at concentrations ranging from 0.1 to 300 muM. A biphasic curve for 4alpha4: 1beta2 was obtained at nicotine concentrations higher than 300 muM. The 1alpha4: 4beta2 subunit ratio exhibited the lowest ACh- and nicotine-induced macroscopic current, whereas 4alpha4: 1beta2 presented the largest currents at all agonist concentrations tested. Desensitization by acute nicotine exposure was more evident as the ratio of beta2:alpha4 subunits increased. All three alpha4beta2 subunit ratios displayed a reduced state of activation after chronic nicotine exposure. Chronic nicotine-induced up-regulation was obvious only for the 2alpha4: 3beta2 subunit ratio. Our data suggest that the subunit ratio of alpha4beta2 determines the functional state of activation, desensitization, and up-regulation of this neuronal nAChR. We propose that independent structural sites regulate alpha4beta2 receptor activation and desensitization.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Univ Cent Caribe, Dept Physiol, Bayamon, PR 00916 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Baylor College of Medicine	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, POB 23360,JGD-114, San Juan, PR 00931 USA.	joseal@coqui.net		Lizardi-Ortiz, Jose E/0000-0001-7634-078X	NIGMS NIH HHS [P20 GM103642, GM08102-27, 2R01 GM56371-05, R01 GM056371, 5R25 GM61151] Funding Source: Medline; PHS HHS [S13705-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM061151, R01GM056371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND R, 1991, J BIOL CHEM, V266, P11192; BALFOUR DJK, 1994, ADDICTION, V89, P1419, DOI 10.1111/j.1360-0443.1994.tb03738.x; BENCHERIF M, 1995, J PHARMACOL EXP THER, V275, P987; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; Bohler S, 2001, BIOCHEMISTRY-US, V40, P2066, DOI 10.1021/bi0020022; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Eilers H, 1997, MOL PHARMACOL, V52, P1105, DOI 10.1124/mol.52.6.1105; Fenster CP, 1999, J NEUROSCI, V19, P4804; Fenster CP, 1997, J NEUROSCI, V17, P5747; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Harkness PC, 2002, J NEUROSCI, V22, P10172; Hsu YN, 1996, J NEUROCHEM, V66, P667; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; LAPCHAK PA, 1989, J NEUROCHEM, V52, P483, DOI 10.1111/j.1471-4159.1989.tb09146.x; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LUKAS RJ, 1991, J NEUROCHEM, V56, P1134, DOI 10.1111/j.1471-4159.1991.tb11403.x; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; MARKS MJ, 1993, J PHARMACOL EXP THER, V266, P1268; Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332; OHLSSON RI, 1981, EUR J BIOCHEM, V115, P367, DOI 10.1111/j.1432-1033.1981.tb05247.x; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PENG X, 1994, MOL PHARMACOL, V46, P523; Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109; Role L W, 1992, Curr Opin Neurobiol, V2, P254, DOI 10.1016/0959-4388(92)90112-X; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; SHARP BM, 1986, J PHARMACOL EXP THER, V238, P486; Sharples Christopher G.V., 2001, NEURONAL NICOTINIC R, P1; VIBAT CRT, 1995, CELL MOL NEUROBIOL, V15, P411, DOI 10.1007/BF02071877; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Zwart R, 1998, MOL PHARMACOL, V54, P1124, DOI 10.1124/mol.54.6.1124	37	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38007	38015		10.1074/jbc.M403537200	http://dx.doi.org/10.1074/jbc.M403537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247303	hybrid			2022-12-25	WOS:000223554600094
J	Cereghetti, GM; Negro, A; Vinck, E; Massimino, ML; Sorgato, MC; Van Doorslaer, S				Cereghetti, GM; Negro, A; Vinck, E; Massimino, ML; Sorgato, MC; Van Doorslaer, S			Copper(II) binding to the human doppel protein may mark its functional diversity from the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP-LIKE PROTEIN; C-TERMINAL DOMAIN; FULL-LENGTH; STRUCTURAL IMPLICATIONS; SITES; RESONANCE; CELLS; CU2+; MICE; COORDINATION	Doppel (Dpl) is the first described homologue of the prion protein, the main constituent of the agent responsible for prion diseases. The cellular prion protein (PrPC) is predominantly present in the central nervous system. Although its role is not yet completely clarified, PrPC seems to be involved in Cu2+ recycling from synaptic clefts and in preventing neuronal oxidative damage. Conversely, Dpl is expressed in heart and testis and has been shown to regulate male fertility by intervening in gametogenesis and sperm-egg interactions. Therefore, despite a high sequence homology and a similar three-dimensional fold, the functions of PrPC and Dpl appear unrelated. Here we show by electron paramagnetic resonance and fluorescence spectroscopy that the in vitro binding of copper(II) to human recombinant Dpl occurs with a different pattern from that observed for recombinant PrP. At physiological pH values, two copper(II)-binding sites with different affinities were found in Dpl. At lower pH values, two additional copper( II)binding sites can be identified as follows: one complex is present only at pH 4, and the other is observed in the pH range 5-6. As derived from the electron paramagnetic resonance characteristics, all Dpl-copper(II) complexes have a different coordination sphere from those present in PrP. Furthermore, in contrast to the effect shown previously for PrPC, addition of Cu2+ to Dpl-expressing cells does not cause Dpl internalization. These results suggest that binding of the ion to PrPC and Dpl may contribute to the different functional roles ascribed to these highly homologous proteins.	Univ Antwerp, Dept Phys, B-2610 Antwerp, Belgium; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, CRIBI, I-35121 Padua, Italy; Univ Padua, CNR, Ist Neurosci, I-35121 Padua, Italy	University of Antwerp; University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Van Doorslaer, S (corresponding author), Univ Antwerp, Dept Phys, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.	Sabine.VanDoorslaer@ua.ac.be	Massimino, Maria Lina/AAX-8773-2020; Van Doorslaer, Sabine/E-5050-2017	Van Doorslaer, Sabine/0000-0002-1685-9202; NEGRO, ALESSANDRO/0000-0003-3142-7632; massimino, maria lina/0000-0002-1839-1404; Vinck, Evi/0000-0001-6167-1068	Telethon [E.0945] Funding Source: Medline	Telethon(Fondazione Telethon)		Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Behrens A, 2002, EMBO J, V21, P3652, DOI 10.1093/emboj/cdf386; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Cereghetti GM, 2003, BIOPHYS J, V84, P1985, DOI 10.1016/S0006-3495(03)75007-3; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Hachiya NS, 2004, BIOCHEM BIOPH RES CO, V315, P802, DOI 10.1016/j.bbrc.2004.01.126; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Lee KS, 2001, J NEUROCHEM, V79, P79, DOI 10.1046/j.1471-4159.2001.00529.x; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Luhrs T, 2003, J MOL BIOL, V326, P1549, DOI 10.1016/S0022-2836(02)01471-7; Massimino ML, 2004, INT J BIOCHEM CELL B, V36, P2016, DOI 10.1016/j.biocel.2004.03.002; Messerschmidt A, 1998, STRUCT BOND, V90, P37; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Peoc'h K, 2002, J BIOL CHEM, V277, P43071, DOI 10.1074/jbc.M206357200; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; Qin KF, 2003, J BIOL CHEM, V278, P8888, DOI 10.1074/jbc.M210875200; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SZABOPLANKA T, 1989, J CHEM SOC DALTON, P1925, DOI 10.1039/dt9890001925; Van Doorslaer S, 2001, J PHYS CHEM B, V105, P1631, DOI 10.1021/jp003115y; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042	37	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36497	36503		10.1074/jbc.M404341200	http://dx.doi.org/10.1074/jbc.M404341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218028	hybrid			2022-12-25	WOS:000223453600043
J	Grant, M; Collier, B; Kumar, U				Grant, M; Collier, B; Kumar, U			Agonist-dependent dissociation of human somatostatin receptor 2 dimers - A role in receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CELL-SURFACE; HETEROMERIC COMPLEXES; FUNCTIONAL-RESPONSES; HORMONE RECEPTORS; DIMERIZATION; HETERODIMERIZATION; OLIGOMERIZATION; INTERNALIZATION; SUBTYPES	G-protein-coupled receptors (GPCRs) represent the largest and most diverse family of cell surface receptors. Several GPCRs have been documented to dimerize with resulting changes in pharmacology and signaling. We have previously reported, by means of photobleaching fluorescence resonance energy transfer (pbFRET) microscopy and fluorescence correlation spectroscopic analysis in live cells, that human somatostatin receptor (hSSTR) 5 could both homodimerize and heterodimerize with hSSTR1 in the presence of the agonist SST-14. By contrast, hSSTR1 remained monomeric when expressed alone regardless of agonist exposure in live cells. However, the effect of the agonist on other hSSTR members remains unknown. Using pbFRET microscopy and Western blot, we provide evidence for agonist-dependent dissociation of self-associated hSSTR2 stably expressed in CHO-K1 and HEK-293 cells. Furthermore, the dissociation of the hSSTR2 dimer occurred in a concentration-dependent manner. Moreover, blocking receptor dissociation using a cross-linker agent perturbed receptor trafficking. Taking these data together, we suggest that the process of GPCR dimerization may operate differently, even among members of the same family, and that receptor dissociation as well as dimerization may be important steps for receptor dynamics.	Royal Victoria Hosp, Dept Med, Fraser Labs Diabet Res, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University; Royal Victoria Hospital; McGill University	Kumar, U (corresponding author), Royal Victoria Hosp, Dept Med, Fraser Labs Diabet Res, Rm M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	ujendra.kumar@muhc.mcgill.ca		Grant, Michael/0000-0003-3758-5009				AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bai M, 2004, CELL SIGNAL, V16, P175, DOI 10.1016/S0898-6568(03)00128-1; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Berglund MM, 2003, J PHARMACOL EXP THER, V307, P1120, DOI 10.1124/jpet.103.055673; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Latif R, 2002, J BIOL CHEM, V277, P45059, DOI 10.1074/jbc.M206693200; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Perron A, 2003, J BIOL CHEM, V278, P27956, DOI 10.1074/jbc.M212302200; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Tao YX, 2004, J BIOL CHEM, V279, P5904, DOI 10.1074/jbc.M311162200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6	38	76	81	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36179	36183		10.1074/jbc.M407310200	http://dx.doi.org/10.1074/jbc.M407310200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15231824	hybrid			2022-12-25	WOS:000223453600004
J	Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX				Sin, WC; Zhang, YP; Zhong, W; Adhikarakunnathu, S; Powers, S; Hoey, T; An, SZ; Yang, JX			G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers	ONCOGENE			English	Article						human cancers; G protein-coupled receptors; GPR4; TDAG8; overexpression; tumorigenesis	CELL-PROLIFERATION; IDENTIFICATION; CLONING; TARGET; TRANSFORMATION; EXPRESSION; ACTIVATION; MECHANISMS; PATHWAYS; LIGANDS	The GPR4 subfamily consists of four G protein-coupled receptors that share significant sequence homology. In addition to GPR4, this subfamily includes OGR1, TDAG8 and G2A. G2A has previously been shown to be a potent transforming oncogene for murine 3T3 cells. Here we show that GPR4 also malignantly transforms NIH3T3 cells and that TDAG8 malignantly transforms the normal mammary epithelial cell line NMuMG. Overexpression of GPR4 or TDAG8 in HEK293 cells led to transcriptional activation from SRE- and CRE-driven promoters, independent of exogenously added ligand. TDAG8 and GPR4 are also overexpressed in a range of human cancer tissues. Our results suggest that GPR4 and TDAG8 overexpression in human tumors plays a role in driving or maintaining tumor formation.	Tularik Inc, Genom Div, Greenlawn, NY 11740 USA; Tularik Inc, Dept Biol, San Francisco, CA 94080 USA		Yang, JX (corresponding author), Tularik Inc, Genom Div, 266 E Pulaski Rd, Greenlawn, NY 11740 USA.	jyang@tularik.com		Powers, Scott/0000-0003-2769-1932				ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; MAHADEVAN MS, 1995, GENOMICS, V30, P84, DOI 10.1006/geno.1995.0013; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; RUSSO D, 1995, ONCOGENE, V11, P1907; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	32	74	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6299	6303		10.1038/sj.onc.1207838	http://dx.doi.org/10.1038/sj.onc.1207838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221007				2022-12-25	WOS:000223399000014
J	Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG				Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG			The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR	ONCOGENE			English	Article						epidermal growth factor receptor; phosphatidylinositol-3 kinase; cell survial; dimerization	CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; CELLULAR-RESPONSE; LUNG CARCINOMAS; CANCER-THERAPY	Mutations of the epidermal growth factor receptor (EGFR) gene are found at a relatively high frequency in glioma, with the most common being the de2-7 EGFR (or EGFRvIII). This mutation arises from an in-frame deletion of exons 2-7, which removes 267 amino acids from the extracellular domain of the receptor. Despite being unable to bind ligand, the de2-7 EGFR is constitutively active and imparts a significant in vivo growth advantage to glioma cells. In order to examine the signalling pathways activated by the de2-7 EGFR and its biological effects in an in vitro system, the de2-7 EGFR gene was transfected into the murine IL-3-dependent pro-B-cell line BaF/3. Expression of the de2-7 EGFR enhanced the survival of BaF/3 cells in the absence of IL-3 by reducing apoptosis in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. Interestingly, while de2-7 EGFR also enhanced proliferation of BaF/3 cells in low levels of IL-3, this effect was independent of PI3-K. Survival and proliferation were further enhanced when BaF/3 cells were cotransfected with the de2-7 and wt EGFR. This was due to heterodimerization between the de2-7 and wt EGFR leading to trans-phosphorylation of the wt EGFR. This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia; Royal Melbourne Hosp, Epithelial Biochem Lab, Parkville, Vic 3050, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia.	Terry.Johns@ludwig.edu.au	Johns, Terrance/C-2441-2008	Johns, Terrance/0000-0002-8874-4543; Luwor, Rodney/0000-0002-3020-4245; Zhu, Hong-Jian/0000-0002-1478-995X; Scott, Andrew/0000-0002-6656-295X				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; Korshunov A, 1999, J CLIN PATHOL, V52, P574, DOI 10.1136/jcp.52.8.574; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Luwor RB, 2001, CANCER RES, V61, P5355; MASUI H, 1984, CANCER RES, V44, P1002; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CK, 2000, CANCER RES, V60, P3081; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Weinmann P, 1999, BLOOD, V93, P3106; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	45	63	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6095	6104		10.1038/sj.onc.1207870	http://dx.doi.org/10.1038/sj.onc.1207870			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15221011				2022-12-25	WOS:000223261000009
J	del Monte, F; Dalal, R; Tabchy, A; Couget, J; Bloch, KD; Peterson, R; Hajjar, RJ				del Monte, F; Dalal, R; Tabchy, A; Couget, J; Bloch, KD; Peterson, R; Hajjar, RJ			Transcriptional changes following restoration of SERCA2a levels in failing rat hearts	FASEB JOURNAL			English	Article						heart failure; calcium ATPase; transcript profile	SARCOPLASMIC-RETICULUM CA2+-ATPASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; ADENOVIRAL GENE-TRANSFER; IN-VIVO; VENTRICULAR-FUNCTION; SIGNAL-TRANSDUCTION; AKT ACTIVATION; FAILURE; TENSIN; EXPRESSION	Heart failure is characterized at the cellular level by impaired contractility and abnormal Ca2+ homeostasis. We have previously shown that restoration of a key enzyme that controls intracellular Ca2+ handling, the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), induces functional improvement in heart failure. We used high-density oligonucleotide arrays to explore the effects of gene transfer of SERCA2a on genetic reprogramming in a model of heart failure. A total of 1,300 transcripts were identified to be unmodified by the effect of virus alone. Of those, 251 transcripts were found to be up- or down-regulated upon failure. A total of 51 transcripts which were either up- ( 27) or down- ( 24) regulated in heart failure were normalized to the nonfailing levels by the restoration of SERCA2a by gene transfer. The microarray analysis identified new genes following SERCA2a restoration in heart failure, which will give us insights into their role in the normalization of multiple pathways within the failing cell.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Harvard Univ, Bauer Ctr Genom Res, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University	del Monte, F (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, E 149 13th St, Charlestown, MA 02129 USA.	fdelmonte@partners.org	del Monte, Federica/AAF-3961-2020; del Monte, Federica/AAB-3982-2019	del Monte, Federica/0000-0001-9506-9665				Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Blaxall BC, 2003, PHYSIOL GENOMICS, V15, P105, DOI 10.1152/physiolgenomics.00087.2003; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bristow MR, 2003, J AM COLL CARDIOL, V41, P1107, DOI 10.1016/S0735-1097(03)00051-2; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cook SA, 2002, CIRC RES, V91, P559, DOI 10.1161/01.RES.0000036019.55901.62; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; Del Monte F, 2002, PHYSIOL GENOMICS, V9, P49, DOI 10.1152/physiolgenomics.00035.2001; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hajjar RJ, 1997, CIRCULATION, V95, P423; Hajjar RJ, 1998, P NATL ACAD SCI USA, V95, P5251, DOI 10.1073/pnas.95.9.5251; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Haq S, 2001, CIRCULATION, V103, P670; HASENFUSS G, 1994, CIRC RES, V75, P434, DOI 10.1161/01.RES.75.3.434; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JANKOWSKI SA, 1995, MAMM GENOME, V6, P744, DOI 10.1007/BF00354299; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Matsui T, 2001, CIRCULATION, V104, P330; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Nielsen TH, 2000, J APPL MICROBIOL, V89, P992, DOI 10.1046/j.1365-2672.2000.01201.x; PATCH LA, 1995, J CELL SCI, V108, P1371; Ueno S, 2003, BIOCHEM BIOPH RES CO, V307, P771, DOI 10.1016/S0006-291X(03)01252-X; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; Yang JC, 2000, CIRCULATION, V102, P3046	28	11	11	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1474	+		10.1096/fj.04-1714fje	http://dx.doi.org/10.1096/fj.04-1714fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247151				2022-12-25	WOS:000222979200004
J	Fuentealba, J; Olivares, R; Ales, E; Tapia, L; Rojo, J; Arroyo, G; Aldea, M; Criado, M; Gandia, L; Garcia, AG				Fuentealba, J; Olivares, R; Ales, E; Tapia, L; Rojo, J; Arroyo, G; Aldea, M; Criado, M; Gandia, L; Garcia, AG			A choline-evoked [Ca2+](C) signal causes catecholamine release and hyperpolarization of chromaffin cells	FASEB JOURNAL			English	Article						choline; alpha7 nicotinic receptor; calcium signal; neurotransmitter release	NICOTINIC ACETYLCHOLINE-RECEPTOR; HIGH-CALCIUM PERMEABILITY; ALPHA-BUNGAROTOXIN; ADRENAL-MEDULLA; MOLECULAR-CLONING; CHANNELS; SUBUNIT; NEURONS; AGONIST; ACTIVATION	In bovine chromaffin cells fast-superfused with Krebs-HEPES solution containing 1 - 2 mM Ca2+, 5 s pulses of choline ( 1 - 10 mM), elicited catecholamine secretory responses that were only similar to10% of those evoked by ACh (0.01 - 0.1 mM). However, in high-Ca2+ solutions (10 - 20 mM) the size of the choline secretory responses approached those of ACh. The choline responses ( 10 mM choline in 20 mM Ca2+, 10Cho/20Ca(2+)) tended to decline upon repetitive pulsing, whereas those of ACh were well maintained. The confocal [Ca2+](c) increases evoked by 10Cho/20Ca(2+) were similar to those of ACh. Whereas 10Cho/20Ca(2+) caused mostly hyperpolarization of chromaffin cells, 0.1 ACh/20 Ca2+ caused first depolarization and then hyperpolarization; in regular solutions (2 mM Ca2+), the hyperpolarizing responses did not show up. In Xenopus oocytes injected with mRNA for bovine alpha7 nicotinic receptors (nAChRs), 10Cho/20 Ca2+ fully activated an inward current; in oocytes expressing alpha3beta4, however, the inward current elicited by choline amounted to only 4% of the size of alpha7 current. Our results suggest that choline activates the entry of Ca2+ through a7 nAChRs; this leads to a cytosolic concentration of calcium ([Ca2+](c)) rise that causes the activation of nearby Ca2+-dependent K+ channels and the hyperpolarization of the chromaffin cell. This response, which could be unmasked provided that cells were stimulated with high-Ca2+ solutions, may be the underlying mechanism through which choline exerts a modulatory effect on the electrical activity of the chromaffin cell and on neurotransmitter release at cholinergic synapses.	Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Hosp Princesa, Inst Invest Gerontol & Metab, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Serv Farmacol Clin, E-28029 Madrid, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Garcia, AG (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Inst Teofilo Hernando, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.	agg@uam.es	Criado, Manuel/K-5109-2014; Rojo, Jonathan/K-5942-2014; Ales, Eva/E-6315-2010; GANDIA, LUIS/L-2889-2013; Del Moral, Gonzalo/H-3996-2015; Aldea, Marcos/H-8154-2015; GARCIA, ANTONIO G/E-9961-2018	Criado, Manuel/0000-0002-3953-0346; Rojo, Jonathan/0000-0003-1155-2858; Ales, Eva/0000-0002-5536-4616; GANDIA, LUIS/0000-0001-9597-8519; Del Moral, Gonzalo/0000-0001-5581-0471; Aldea, Marcos/0000-0003-2146-2733; GARCIA, ANTONIO G/0000-0002-6517-3565				Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARTALEJO AR, 1993, PFLUG ARCH EUR J PHY, V423, P97, DOI 10.1007/BF00374966; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BORGES R, 1986, J NEUROSCI METH, V16, P289, DOI 10.1016/0165-0270(86)90054-3; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Cuchillo-Ibanez I, 2002, PFLUG ARCH EUR J PHY, V444, P133, DOI 10.1007/s00424-002-0810-4; Cuevas J, 1998, J NEUROSCI, V18, P10335; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; DOUGLAS WW, 1965, NATURE, V208, P1102, DOI 10.1038/2081102a0; Fabian-Fine R, 2001, J NEUROSCI, V21, P7993, DOI 10.1523/JNEUROSCI.21-20-07993.2001; FELDBERG W, 1934, J PHYSL, V137, P218; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GARCIA AG, 2000, SEAFOOD FRESHWATER T, P91; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; HERRERO CJ, 1999, BRIT J PHARMACOL, V6, P1375; HOLZ RW, 1981, SCIENCE, V214, P466, DOI 10.1126/science.7291988; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KAGEYAMA H, 1984, J NEUROSCI METH, V10, P9, DOI 10.1016/0165-0270(84)90074-8; KILPATRICK DL, 1981, J NEUROCHEM, V37, P125, DOI 10.1111/j.1471-4159.1981.tb05299.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRNJEVIC K, 1979, SCIENCE, V206, P1321, DOI 10.1126/science.515735; KUMAKURA K, 1980, NATURE, V283, P489, DOI 10.1038/283489a0; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; Lopez MG, 1998, P NATL ACAD SCI USA, V95, P14184, DOI 10.1073/pnas.95.24.14184; MANDELZYS A, 1995, J NEUROPHYSIOL, V74, P1212, DOI 10.1152/jn.1995.74.3.1212; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; MONTIEL C, 1995, J PHYSIOL-LONDON, V486, P427, DOI 10.1113/jphysiol.1995.sp020823; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; PAPKE RL, 1991, J PHYSIOL-LONDON, V440, P95, DOI 10.1113/jphysiol.1991.sp018698; Papke RL, 1996, NEUROSCI LETT, V213, P201; Seddik R, 2003, EUR J PHARMACOL, V471, P165, DOI 10.1016/S0014-2999(03)01860-0; SEGUELA P, 1993, J NEUROSCI, V13, P596; STAUDERMAN KA, 1991, J BIOL CHEM, V266, P19150; Taylor Palmer, 1999, P213; TRIFARO JM, 1980, NEUROSCIENCE, V5, P1533, DOI 10.1016/0306-4522(80)90018-4; TROUSLARD J, 1993, J PHYSIOL-LONDON, V468, P53, DOI 10.1113/jphysiol.1993.sp019759; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x; ZHOU Z, 1993, PFLUG ARCH EUR J PHY, V425, P511, DOI 10.1007/BF00374879	49	21	22	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1468	+		10.1096/fj.04-1828fje	http://dx.doi.org/10.1096/fj.04-1828fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231719				2022-12-25	WOS:000222979200014
J	Maita, N; Anzai, T; Aoyagi, H; Mizuno, H; Fujiwara, H				Maita, N; Anzai, T; Aoyagi, H; Mizuno, H; Fujiwara, H			Crystal structure of the endonuclease domain encoded by the telomere-specific long interspersed nuclear element, TRAS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; TARGET SITE; RNA GENES; RETROTRANSPOSONS; IDENTIFICATION; RECOGNITION; INTEGRATION; SILKWORM; TRANSCRIPTION; MECHANISM	The telomere-specific long interspersed nuclear element, TRAS1, encodes an endonuclease domain, TRAS1-EN, which specifically cleaves the telomeric repeat targets (TTAGG)(n) of insects and (TTAGGG)(n) of vertebrates. To elucidate the sequence-specific recognition properties of TRAS1-EN, we determined the crystal structure at 2.4-Angstrom resolution. TRAS1-EN has a four-layered alpha/beta sandwich structure; its topology is similar to apurinic/ apyrimidinic endonucleases, but the beta-hairpin (beta(10)-beta(11)) at the edge of the DNA-binding surface makes an extra loop that distinguishes TRAS1-EN from cellular apurinic/ apyrimidinic endonucleases. A protein-DNA complex model suggests that the beta(10)-beta(11) hairpin fits into the minor groove, enabling interaction with the telomeric repeats. Mutational studies of TRAS1-EN also indicated that the Asp-130 and beta(10)-beta(11) hairpin structure are involved in specific recognition of telomeric repeats.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan	University of Tokyo; National Institute of Agrobiological Sciences - Japan	Fujiwara, H (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Biosci Bldg 501, Kashiwa, Chiba 2778562, Japan.	haruh@k.u-tokyo.ac.jp	Maita, Nobuo/J-1443-2012	Maita, Nobuo/0000-0003-2260-5783				Anzai T, 2001, MOL CELL BIOL, V21, P100, DOI 10.1128/MCB.21.1.100-108.2001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Eickbush T.H., 2002, MOBILE DNA, P813; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Feng QH, 1998, P NATL ACAD SCI USA, V95, P2083, DOI 10.1073/pnas.95.5.2083; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kojima KK, 2004, MOL BIOL EVOL, V21, P207, DOI 10.1093/molbev/msg235; Kojima KK, 2003, MOL BIOL EVOL, V20, P351, DOI 10.1093/molbev/msg031; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubo Y, 2001, MOL BIOL EVOL, V18, P848, DOI 10.1093/oxfordjournals.molbev.a003866; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; OKAZAKI S, 1995, MOL CELL BIOL, V15, P4545; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Rothwell DG, 1996, NUCLEIC ACIDS RES, V24, P4217, DOI 10.1093/nar/24.21.4217; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Takahashi H, 1999, NUCLEIC ACIDS RES, V27, P2015, DOI 10.1093/nar/27.9.2015; Takahashi H, 1997, NUCLEIC ACIDS RES, V25, P1578, DOI 10.1093/nar/25.8.1578; Takahashi H, 2002, EMBO J, V21, P408, DOI 10.1093/emboj/21.3.408; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Weichenrieder O, 2004, STRUCTURE, V12, P975, DOI 10.1016/j.str.2004.04.011; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; XIONG Y, 1988, MOL CELL BIOL, V8, P114, DOI 10.1128/MCB.8.1.114; Yang J, 1999, P NATL ACAD SCI USA, V96, P7847, DOI 10.1073/pnas.96.14.7847; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	46	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41067	41076		10.1074/jbc.M406556200	http://dx.doi.org/10.1074/jbc.M406556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247245	hybrid			2022-12-25	WOS:000223916800105
J	Roldan, A; Russell, RS; Marchand, B; Gotte, M; Liang, C; Wainberg, MA				Roldan, A; Russell, RS; Marchand, B; Gotte, M; Liang, C; Wainberg, MA			In vitro identification and characterization of an early complex linking HIV-1 genomic RNA recognition and Pr55Gag multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ROUS-SARCOMA-VIRUS; NUCLEOCAPSID PROTEIN; CAPSID PROTEIN; GAG POLYPROTEIN; MATRIX PROTEIN; PARTICLE-PRODUCTION; DIMERIZATION DOMAIN; PACKAGING SIGNAL; BINDING-SITE	The minimal protein requirements that drive virus-like particle formation of human immunodeficiency virus type 1 (HIV-1) have been established. The C-terminal domain of capsid (CTD-CA) and nucleocapsid (NC) are the most important domains in a so-called minimal Gag protein (mGag). The CTD is essential for Gag oligomerization. NC is known to bind and encapsidate HIV-1 genomic RNA. The spacer peptide, SP1, located between CA and NC is important for the multimerization process, viral maturation and recognition of HIV-1 genomic RNA by NC. In this study, we show that NC in the context of an mGag protein binds HIV-1 genomic RNA with almost 10-fold higher affinity. The protein region encompassing the 11th alpha-helix of CA and the proposed alpha-helix in the CA/SP1 boundary region play important roles in this increased binding capacity. Furthermore, sequences downstream from stem loop 4 of the HIV-1 genomic RNA are also important for this RNA-protein interaction. In gel shift assays using purified mGag and a model RNA spanning the region from + 223 to + 506 of HIV-1 genomic RNA, we have identified an early complex (EC) formation between 2 proteins and 1 RNA molecule. This EC was not present in experiments performed with a mutant mGag protein, which contains a CTD dimerization mutation (M318A). These data suggest that the dimerization interface of the CTD plays an important role in EC formation, and, as a consequence, in RNA-protein association and multimerization. We propose a model for the RNA-protein interaction, based on previous results and those presented in this study.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst, AIDS Ctr, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	mark.wainberg@mcgill.ca	Russell, Rod/AAU-3109-2021	Roldan, Ariel/0000-0002-8159-5450				Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Accola MA, 1998, J VIROL, V72, P2072, DOI 10.1128/JVI.72.3.2072-2078.1998; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2000.5182; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BENNETT RP, 1993, J VIROL, V67, P6487, DOI 10.1128/JVI.67.11.6487-6498.1993; Berglund JA, 1997, NUCLEIC ACIDS RES, V25, P1042, DOI 10.1093/nar/25.5.1042; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; BERKOWITZ RD, 1993, J VIROL, V67, P7190, DOI 10.1128/JVI.67.12.7190-7200.1993; BERKOWITZ RD, 1994, VIROLOGY, V202, P233, DOI 10.1006/viro.1994.1339; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUCHSCHACHER GL, 1992, J VIROL, V66, P2731, DOI 10.1128/JVI.66.5.2731-2739.1992; Burniston MT, 1999, J VIROL, V73, P8527, DOI 10.1128/JVI.73.10.8527-8540.1999; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698; CHAZAL N, 1994, J VIROL, V68, P111, DOI 10.1128/JVI.68.1.111-122.1994; Cimarelli A, 2000, J VIROL, V74, P3046, DOI 10.1128/JVI.74.7.3046-3057.2000; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; COFFIN JM, 1997, RETROVIRUSES, P263; Craven RC, 1996, CURR TOP MICROBIOL, V214, P65; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; Das AT, 1999, J VIROL, V73, P81, DOI 10.1128/JVI.73.1.81-91.1999; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; Dawson L, 1998, VIROLOGY, V251, P141, DOI 10.1006/viro.1998.9374; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gottlinger HG, 2001, AIDS, V15, pS13; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103; Guo XF, 2004, J VIROL, V78, P551, DOI 10.1128/JVI.78.2.551-560.2004; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; Kaye JF, 1998, J VIROL, V72, P5877, DOI 10.1128/JVI.72.7.5877-5885.1998; KRAUSSLICH HG, 1995, J VIROL, V69, P3407; KRAUSSLICH HG, 1996, CURR TOP MICROBIOL, V214, P65; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; Liang C, 2003, J VIROL, V77, P1772, DOI 10.1128/JVI.77.3.1772-1783.2003; Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004; Maki AH, 2001, BIOCHEMISTRY-US, V40, P1403, DOI 10.1021/bi002010i; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; Mayo K, 2003, J MOL BIOL, V325, P225, DOI 10.1016/S0022-2836(02)01176-2; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McDermott J, 1996, J VIROL, V70, P5106, DOI 10.1128/JVI.70.8.5106-5114.1996; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; Morikawa Y, 1998, J VIROL, V72, P7659, DOI 10.1128/JVI.72.9.7659-7663.1998; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Scarlata S, 2003, BBA-BIOMEMBRANES, V1614, P62, DOI 10.1016/S0005-2736(03)00163-9; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; Wang CT, 1998, J VIROL, V72, P7950, DOI 10.1128/JVI.72.10.7950-7959.1998; Wang SW, 2004, J VIROL, V78, P716, DOI 10.1128/JVI.78.2.716-723.2004; Wiegers K, 1998, J VIROL, V72, P2846, DOI 10.1128/JVI.72.4.2846-2854.1998; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575; Xie B, 2004, J VIROL, V78, P1456, DOI 10.1128/JVI.78.3.1456-1463.2004; Zabransky A, 2002, VIROLOGY, V294, P141, DOI 10.1006/viro.2001.1315	84	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39886	39894		10.1074/jbc.M405632200	http://dx.doi.org/10.1074/jbc.M405632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247214	hybrid			2022-12-25	WOS:000223791500085
J	Simpson, RJY; Lee, SHY; Bartle, N; Sum, EY; Visvader, JE; Matthews, JM; Mackay, JP; Crossley, M				Simpson, RJY; Lee, SHY; Bartle, N; Sum, EY; Visvader, JE; Matthews, JM; Mackay, JP; Crossley, M			A classic zinc finger from friend of GATA mediates an interaction with the coiled-coil of transforming acidic coiled-coil 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMBIGUOUS DISTANCE RESTRAINTS; TRANSCRIPTIONAL COFACTOR FOG; PROTEIN-PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; NMR; FAMILY; PROGRAM; GENE; COMPLEX; TACC3	Classic zinc finger domains (cZFs) consist of a beta-hairpin followed by an alpha-helix. They are among the most abundant of all protein domains and are often found in tandem arrays in DNA-binding proteins, with each finger contributing an alpha-helix to effect sequence-specific DNA recognition. Lone cZFs, not found in tandem arrays, have been postulated to function in protein interactions. We have studied the transcriptional co-regulator Friend of GATA ( FOG), which contains nine zinc fingers. We have discovered that the third cZF of FOG contacts a coiled-coil domain in the centrosomal protein transforming acidic coiled-coil 3 (TACC3). Although FOG-ZF3 exhibited low solubility, we have used a combination of mutational mapping and protein engineering to generate a derivative that was suitable for in vitro and structural analysis. We report that the alpha-helix of FOG-ZF3 recognizes a C-terminal portion of the TACC3 coiled-coil. Remarkably, the alpha-helical surface utilized by FOG-ZF3 is the same surface responsible for the well established sequence-specific DNA-binding properties of many other cZFs. Our data demonstrate the versatility of cZFs and have implications for the analysis of many as yet uncharacterized cZF proteins.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia	University of Sydney; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, G08, Sydney, NSW 2006, Australia.	j.mackay@mmb.usyd.edu.au	Matthews, Jacqueline/A-7322-2013; Crossley, Merlin/D-7888-2011; Mackay, Joel/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Mackay, Joel/0000-0001-7508-8033; Matthews, Jacqueline/0000-0001-8518-3472				ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Fossett N, 2001, DIFFERENTIATION, V69, P83, DOI 10.1046/j.1432-0436.2001.690202.x; Fossett N, 2001, P NATL ACAD SCI USA, V98, P7342, DOI 10.1073/pnas.131215798; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Garriga-Canut M, 2004, J BIOL CHEM, V279, P23597, DOI 10.1074/jbc.M313987200; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hayes D. B., 1995, SEDNTERP; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kwan AHY, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng124; Kwan AHY, 2003, STRUCTURE, V11, P803, DOI 10.1016/S0969-2126(03)00122-9; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Lu D, 2003, NATURE, V426, P96, DOI 10.1038/nature02088; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Worrall JAR, 2003, BIOCHEMISTRY-US, V42, P7068, DOI 10.1021/bi0342968	49	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39789	39797		10.1074/jbc.M404130200	http://dx.doi.org/10.1074/jbc.M404130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15234987	hybrid			2022-12-25	WOS:000223791500073
J	Avalos, AM; Arthur, WT; Schneider, P; Quest, AFG; Burridge, K; Leyton, L				Avalos, AM; Arthur, WT; Schneider, P; Quest, AFG; Burridge, K; Leyton, L			Aggregation of integrins and RhoA activation are required for Thy-1-induced morphological changes in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEIN RHO; FOCAL ADHESIONS; NEURITE OUTGROWTH; MEMBRANE PROTRUSION; NEURONAL THY-1; CELL; INHIBITOR; GTPASES; RAC	Thy-1, a cell adhesion molecule abundantly expressed in mammalian neurons, binds to a beta(3)-containing integrin on astrocytes and thereby stimulates the assembly of focal adhesions and stress fibers. Such events lead to morphological changes in astrocytes that resemble those occurring upon injury in the brain. Extracellular matrix proteins, typical integrin ligands, bind to integrins and promote receptor clustering as well as signal transduction events that involve small G proteins and cytoskeletal changes. Here we investigated the possibility that the cell surface protein Thy-1, when interacting with a beta(3)-containing integrin on astrocytes, could trigger signaling events similar to those generated by extracellular matrix proteins. DI-TNC1 astrocytes were stimulated with Thy-1-Fc immobilized on beads, and increased RhoA activity was confirmed using an affinity precipitation assay. The effect of various inhibitors on the cellular response was also studied. The presence of Y-27632, an inhibitor of Rho kinase (p160ROCK), a key downstream effector of RhoA, significantly reduced focal adhesion and stress fiber formation induced by Thy-1. Similar effects were obtained when astrocytes were treated with C3 transferase, an inhibitor of RhoA. Alternatively, astrocytes were transfected with an expression vector encoding fusion proteins of enhanced green fluorescent protein with either the Rho-binding domain of Rhotekin, which blocks RhoA function, or the dominant-negative N19RhoA mutant. In both cases, Thy-1-induced focal adhesion formation was inhibited. Furthermore, we observed that RhoA activity after stimulation with soluble Thy-1-Fc molecule was augmented upon further cross-linking using protein A-Sepharose beads. The same was shown by crosslinking beta(3)-containing integrin with anti-beta(3) antibodies. Together, these results indicate that Thy-1-mediated astrocyte stimulation depended on beta(3) integrin clustering and the resulting increase in RhoA activity.	Univ Chile, Fac Med, Inst Biomed Sci, FONDAP Ctr Mol Studies Cell,Program Morphol, Santiago, Chile; Univ Chile, Fac Med, Inst Biomed Sci, FONDAP Ctr Mol Studies Cell,Program Cell & Mol Bi, Santiago, Chile; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Universidad de Chile; Universidad de Chile; University of North Carolina; University of North Carolina Chapel Hill; University of Lausanne	Leyton, L (corresponding author), Univ Chile, Fac Med, Inst Biomed Sci, FONDAP Ctr Mol Studies Cell,Program Morphol, Independencia 1027-A, Santiago, Chile.	lleyton@med.uchile.cl		Schneider, Pascal/0000-0003-0677-9409	FOGARTY INTERNATIONAL CENTER [R03TW006024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; FIC NIH HHS [1-R03-TW06024-01] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Avalos AM, 2002, BIOL RES, V35, P231, DOI 10.4067/S0716-97602002000200015; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; DREYER EB, 1995, P NATL ACAD SCI USA, V92, P11195, DOI 10.1073/pnas.92.24.11195; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MAHANTHAPPA NK, 1992, DEV BIOL, V150, P47, DOI 10.1016/0012-1606(92)90006-3; Miao H, 2002, J CELL SCI, V115, P2199; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RAHEMTULLA N, 1994, BRAIN RES, V642, P221, DOI 10.1016/0006-8993(94)90925-3; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Shen YJ, 1998, MOL CELL NEUROSCI, V12, P79, DOI 10.1006/mcne.1998.0700; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048	39	57	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39139	39145		10.1074/jbc.M403439200	http://dx.doi.org/10.1074/jbc.M403439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15220352	hybrid			2022-12-25	WOS:000223684100130
J	Deb, TB; Coticchia, CM; Dickson, RB				Deb, TB; Coticchia, CM; Dickson, RB			Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; CAPACITATIVE CA2+ ENTRY; LUNG-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; BREAST-CANCER; SELECTIVE INHIBITOR; NEURONAL SURVIVAL; SIGNALING PATHWAY	c-Myc-overexpressing mammary epithelial cells are proapoptotic; their survival is strongly promoted by epidermal growth factor (EGF). We now demonstrate that EGF-induced Akt activation and survival in transgenic mouse mammary tumor virus-c-Myc mouse mammary carcinoma cells are both calcium/calmodulin-dependent. Akt activation is abolished by the phospholipase C-gamma inhibitor U-73122, by the intracellular calcium chelator BAPTA-AM, and by the specific calmodulin antagonist W-7. These results implicate calcium/calmodulin in the activation of Akt in these cells. In addition, Akt activation by serum and insulin is also inhibited by W-7. EGF-induced and calcium/calmodulin-mediated Akt activation occurs in both tumorigenic and non-tumorigenic mouse and human mammary epithelial cells, independent of their overexpression of c-Myc. These results imply that calcium/calmodulin may be a common regulator of Akt activation, irrespective of upstream receptor activator, mammalian species, and transformation status in mammary epithelial cells. However, only c-Myc-overexpressing mouse mammary carcinoma cells (but not normal mouse mammary epithelial cells) undergo apoptosis in the presence of the calmodulin antagonist W-7, indicating the vital selective role of calmodulin for survival of these cells. Calcium/calmodulin-regulated Akt activation is mediated directly by neither calmodulin kinases nor phosphatidylinositol 3-kinase (PI-3 kinase). Pharmacological inhibitors of calmodulin kinase kinase and calmodulin kinases II and III do not inhibit EGF-induced Akt activation, and calmodulin antagonist W-7 does not inhibit phosphotyrosine-associated PI-3 kinase activation. Akt is, however, co-immunoprecipitated with calmodulin in an EGF-dependent manner, which is inhibited by calmodulin antagonist W-7. We conclude that calmodulin may serve a vital regulatory function to direct the localization of Akt to the plasma membrane for its activation by PI-3 kinase.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, New Res Bldg,Room W417,3970 Reservoir Rd NW, Washington, DC 20057 USA.	dicksonr@georgetown.edu			NCI NIH HHS [R01-CA72460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aifa S, 2002, CELL SIGNAL, V14, P1005, DOI 10.1016/S0898-6568(02)00034-7; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Benaud CM, 2001, ONCOGENE, V20, P4554, DOI 10.1038/sj.onc.1204609; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; CHENG A, 2003, J BIOL CHEM, V198, P653; Cheng AW, 2003, J BIOL CHEM, V278, P7591, DOI 10.1074/jbc.M207232200; Clark AS, 2003, CANCER RES, V63, P780; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; DIETER P, 1993, BIOL CHEM H-S, V374, P171, DOI 10.1515/bchm3.1993.374.1-6.171; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Earp H Shelton 3rd, 2003, Trans Am Clin Climatol Assoc, V114, P315; Egea J, 2001, J CELL BIOL, V154, P585, DOI 10.1083/jcb.200101023; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fischer R, 1998, FEBS LETT, V425, P175, DOI 10.1016/S0014-5793(98)00225-7; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Gnegy ME, 2000, CRIT REV NEUROBIOL, V14, P91; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; Ichikawa J, 2001, CELL BIOCHEM FUNCT, V19, P213, DOI 10.1002/cbf.914; Ichikawa J, 2000, CELL BIOCHEM FUNCT, V18, P215; ISHII A, 1991, BIOCHEM BIOPH RES CO, V176, P1051, DOI 10.1016/0006-291X(91)90389-O; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KISS Z, 1995, BBA-MOL CELL RES, V1265, P93, DOI 10.1016/0167-4889(94)00242-7; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; MEDINA D, 1986, J NATL CANCER I, V76, P1143; MINAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P241, DOI 10.1006/bbrc.1994.1220; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Perez-Garcia MJ, 2004, J BIOL CHEM, V279, P6132, DOI 10.1074/jbc.M308367200; Ramljak D, 2003, EXP CELL RES, V287, P397, DOI 10.1016/S0014-4827(03)00135-6; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RASMUSSEN CD, 1987, EMBO J, V6, P3961, DOI 10.1002/j.1460-2075.1987.tb02738.x; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schmalzigaug R, 2001, IMMUNOLOGY, V103, P332, DOI 10.1046/j.1365-2567.2001.01259.x; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soler RM, 1998, J NEUROSCI, V18, P1230; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Troyer KL, 2001, J MAMMARY GLAND BIOL, V6, P7, DOI 10.1023/A:1009560330359; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; WENNSTROM S, 1994, ONCOGENE, V9, P651; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003	94	78	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38903	38911		10.1074/jbc.M405314200	http://dx.doi.org/10.1074/jbc.M405314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247222	hybrid			2022-12-25	WOS:000223684100104
J	Gensch, E; Gallup, M; Sucher, A; Li, DZ; Gebremichael, A; Lemjabbar, H; Mengistab, A; Dasari, V; Hotchkiss, J; Harkema, J; Basbaum, C				Gensch, E; Gallup, M; Sucher, A; Li, DZ; Gebremichael, A; Lemjabbar, H; Mengistab, A; Dasari, V; Hotchkiss, J; Harkema, J; Basbaum, C			Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; CIGARETTE-SMOKE; PROTEIN-KINASE; C-JUN; IN-VITRO; ACTIVATION; PHOSPHORYLATION; MUC5AC; SRC; TRANSCRIPTION	In smokers' lungs, excessive mucus clogs small airways, impairing respiration and promoting recurrent infection. A breakthrough in understanding this pathology was the realization that smoke could directly stimulate mucin synthesis in lung epithelial cells and that this phenomenon was dependent on the cell surface receptor for epidermal growth factor, EGFR. Distal steps in the smoke-triggered pathway have not yet been determined. We report here that the predominant airway mucin (MUC5AC) undergoes transcriptional up-regulation in response to tobacco smoke; this is mediated by an AP-1-containing response element, which binds JunD and Fra-2. These transcription factors require phosphorylation by upstream kinases JNK and ERK, respectively. Whereas ERK activation results from the upstream activation of EGFR, JNK activation is chiefly EGFR-independent. Our experiments demonstrated that smoke activates JNK via a Src-dependent, EGFR-independent signaling cascade initiated by smoke-induced reactive oxygen species. Taken together with our earlier results, these data indicate that the induction of mucin by smoke is the combined effect of mutually independent, reactive oxygen species activation of both EGFR and JNK.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anat, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075602, R01HL043762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL75602, R0-1 HL43762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; BHASKAR KR, 1985, EXP LUNG RES, V9, P289, DOI 10.3109/01902148509057529; CHEN BT, 1992, J AEROSOL MED, V5, P19, DOI 10.1089/jam.1992.5.19; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES SJ, 1979, AM J PATHOL, V94, P459; Di Stefano A, 2001, CLIN EXP ALLERGY, V31, P893, DOI 10.1046/j.1365-2222.2001.01098.x; DOHRMAN A, 1994, EXP LUNG RES, V20, P367, DOI 10.3109/01902149409064393; Elliot JG, 2004, AM J RESP CRIT CARE, V169, P712, DOI 10.1164/rccm.200308-1167OC; Gebremichael A, 1996, TOXICOL APPL PHARM, V141, P76; GRUDA MC, 1994, ONCOGENE, V9, P2537; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JEFFERY PK, 1981, J PATHOL, V133, P341, DOI 10.1002/path.1711330406; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kim JO, 2003, FEBS LETT, V541, P163, DOI 10.1016/S0014-5793(03)00326-0; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, pS76, DOI 10.1164/ajrccm.164.supplement_2.2106067; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smirnova MG, 2000, CYTOKINE, V12, P1732, DOI 10.1006/cyto.2000.0763; Smith CJ, 2001, ATHEROSCLEROSIS, V158, P257, DOI 10.1016/S0021-9150(01)00570-6; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; THURLBECK WM, 1994, THORAX, V49, P1276, DOI 10.1136/thx.49.12.1276; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	48	122	133	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39085	39093		10.1074/jbc.M406866200	http://dx.doi.org/10.1074/jbc.M406866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262961	hybrid			2022-12-25	WOS:000223684100124
J	Inouye, S; Izu, H; Takaki, E; Suzuki, H; Shirai, M; Yokota, Y; Ichikawa, H; Fujimoto, M; Nakai, A				Inouye, S; Izu, H; Takaki, E; Suzuki, H; Shirai, M; Yokota, Y; Ichikawa, H; Fujimoto, M; Nakai, A			Impaired IgG production in mice deficient for heat shock transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; GENE-EXPRESSION; MOLECULAR CHAPERONES; CHEMOKINE RANTES; INTERFERON-GAMMA; IMMUNE-RESPONSES; HSF1; SPERMATOGENESIS; PROTECTION; THERMOTOLERANCE	Heat shock factor 1 (HSF1) is a major transactivator of heat shock proteins in response to heat shock, and it is also involved in oogenesis, spermatogenesis, and placental development. However, we do not know the molecular mechanisms controlling developmental processes. In this study, we found that HSF1-null mice exhibited a significant decrease in the T cell-dependent B cell response. When mice were immunized intraperitoneally with sheep red blood cells, the sheep red blood cell-specific IgG production, especially IgG2a production, in HSF1-null mice was about 50% lower than that in wildtype mice at 6 days after the immunization, whereas IgM production was normal. The number of bromodeoxyuridine-incorporated spleen cells in immunized HSF1-null mice was one-third that in immunized wild-type mice, indicating reduced proliferation of the spleen cells. We analyzed levels of cytokines and chemokines in spleen cells and in peritoneal macrophages stimulated with lipopolysaccharide and interferon-gamma and found that expression levels of interleukin-6 and CCL5 were significantly lower in HSF1-null cells than those in wild-type cells. Furthermore, we demonstrated that the IL-6 gene is a direct target gene of HSF1. These results revealed a novel molecular link between HSF1 and a gene related to immune response and inflammation.	Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Microbiol, Ube, Yamaguchi 7558505, Japan; Univ Fukui, Sch Med, Dept Mol Genet, Fukui 9101193, Japan; Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Chuo Ku, Tokyo 1040045, Japan	Yamaguchi University; Yamaguchi University; University of Fukui; National Cancer Center - Japan	Nakai, A (corresponding author), Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Minami Kogushi 1-1-1, Ube, Yamaguchi 7558505, Japan.	anakai@yamaguchi-u.ac.jp	Suzuki, Harumi/L-1271-2013	Suzuki, Harumi/0000-0003-3616-9361				Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; DANOFF TM, 1994, J IMMUNOL, V152, P1182; Febbraio MA, 2002, BIOCHEM BIOPH RES CO, V296, P1264, DOI 10.1016/S0006-291X(02)02079-X; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Inouye S, 2003, MOL CELL BIOL, V23, P5882, DOI 10.1128/MCB.23.16.5882-5895.2003; Izu H, 2004, BIOL REPROD, V70, P18, DOI 10.1095/biolreprod.103.020065; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kopf M, 1995, IMMUNOL REV, V148, P45, DOI 10.1111/j.1600-065X.1995.tb00093.x; Lillard JW, 2001, J IMMUNOL, V166, P162, DOI 10.4049/jimmunol.166.1.162; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Nishiyama Y, 2002, J IMMUNOL, V168, P2626, DOI 10.4049/jimmunol.168.6.2626; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; SAVARD CE, 2002, GASTROENTEROLOGY, V2, P1; Schett G, 1998, J CLIN INVEST, V102, P302, DOI 10.1172/JCI2465; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STELLATO C, 1995, J IMMUNOL, V155, P410; Stephanou A, 1997, BIOCHEM J, V321, P103, DOI 10.1042/bj3210103; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; TANABE O, 1988, J IMMUNOL, V141, P3875; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Ulett GC, 2000, INFECT IMMUN, V68, P2034, DOI 10.1128/IAI.68.4.2034-2042.2000; Wang GH, 2004, GENESIS, V38, P66, DOI 10.1002/gene.20005; Wang GH, 2003, GENESIS, V36, P48, DOI 10.1002/gene.10200; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232	35	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38701	38709		10.1074/jbc.M405986200	http://dx.doi.org/10.1074/jbc.M405986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226319	hybrid			2022-12-25	WOS:000223684100079
J	Magnani, F; Tate, CG; Wynne, S; Williams, C; Haase, J				Magnani, F; Tate, CG; Wynne, S; Williams, C; Haase, J			Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; HEPATITIS-B-VIRUS; PLASMA-MEMBRANE; CELL-MEMBRANES; NEUROTRANSMITTER TRANSPORTERS; BLOOD-PLATELETS; RAT-BRAIN; RAFTS; CHOLESTEROL	The serotonin transporter (SERT) is an integral membrane protein responsible for the clearance of serotonin from the synaptic cleft following the release of the neurotransmitter. SERT plays a prominent role in the regulation of serotoninergic neurotransmission and is a molecular target for multiple antidepressants as well as substances of abuse. Here we show that SERT associates with lipid rafts in both heterologous expression systems and rat brain and that the inclusion of the transporter into lipid microdomains is critical for serotonin uptake activity. SERT is present in a subpopulation of lipid rafts, which is soluble in Triton X-100 but insoluble in other non-ionic detergents such as Brij 58. Disaggregation of lipid rafts upon depletion of cellular cholesterol results in a decrease of serotonin transport capacity (V-max), due to the reduction of turnover number of serotonin transport. Our data suggest that the association of SERT with lipid rafts may represent a mechanism for regulating the transporter activity and, consequently, serotoninergic signaling in the central nervous system, through the modulation of the cholesterol content in the cell membrane. Furthermore, SERT-containing rafts are detected in both intracellular and cell surface fractions, suggesting that raft association may be important for trafficking and targeting of SERT.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Conway Inst, Dublin 4, Ireland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Trinity College Dublin; University College Dublin; MRC Laboratory Molecular Biology	Haase, J (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	jana.haase@ucd.ie	Haase, Jana/C-1210-2008; Magnani, Francesca/AAL-9945-2020	Haase, Jana/0000-0002-5949-8355; Magnani, Francesca/0000-0003-0812-9397; Tate, Christopher/0000-0002-2008-9183				ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BAKER CR, 1997, THESIS TRINITY COLL; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Berditchevski F, 2001, J CELL SCI, V114, P4143; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; FOLCH J, 1957, J BIOL CHEM, V226, P497; Haase J, 2001, BIOCHEM SOC T, V29, P722, DOI 10.1042/BST0290722; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; JIKOH Y, 1990, JPN J PHARMACOL, V53, P403, DOI 10.1254/jjp.53.403; KANNER BI, 1994, J EXP BIOL, V196, P237; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Leitinger B, 2002, J CELL SCI, V115, P963; Lusa S, 2001, J CELL SCI, V114, P1893; MARKWELL MA, 1978, METHOD ENZYMOL, V72, P296; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYSER W, 1991, FEBS LETT, V295, P203, DOI 10.1016/0014-5793(91)81418-8; NISHIO H, 1979, BRIT J PHARMACOL, V65, P557, DOI 10.1111/j.1476-5381.1979.tb07864.x; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rudge JS, 1996, MOL CELL NEUROSCI, V7, P204, DOI 10.1006/mcne.1996.0016; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sakai N, 1997, J NEUROCHEM, V68, P2618; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; TALVENHEIMO J, 1980, J BIOL CHEM, V255, P8606; Tao-Cheng JH, 1999, NEUROSCIENCE, V94, P821, DOI 10.1016/S0306-4522(99)00373-5; Tate CG, 2003, BBA-BIOMEMBRANES, V1610, P141, DOI 10.1016/S0005-2736(02)00719-8; Taylor CM, 2002, J NEUROCHEM, V81, P993, DOI 10.1046/j.1471-4159.2002.00884.x; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Ulrich R, 1998, ADV VIRUS RES, V50, P141, DOI 10.1016/S0065-3527(08)60808-8; WALL SC, 1993, MOL PHARMACOL, V43, P264; Wynne SA, 1999, ACTA CRYSTALLOGR D, V55, P557, DOI 10.1107/S0907444998012621; Zhou FC, 1998, BRAIN RES, V805, P241, DOI 10.1016/S0006-8993(98)00691-X	59	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38770	38778		10.1074/jbc.M400831200	http://dx.doi.org/10.1074/jbc.M400831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226315	hybrid			2022-12-25	WOS:000223684100088
J	Mansell, A; Brint, E; Gould, JA; O'Neill, LA; Hertzog, PJ				Mansell, A; Brint, E; Gould, JA; O'Neill, LA; Hertzog, PJ			Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappa B activation by Toll-like receptor (TLR)-2 and TLR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING ADAPTER; SIGNALING PATHWAY; INTERFERON-BETA; CUTTING EDGE; P65 SUBUNIT; MOLECULE; TIRAP; INTERLEUKIN-1; SPECIFICITY; KINASE-1	The Toll-interleukin-1 receptor domain-containing adapter Mal (MyD88 adapter-like protein) is involved in Toll-like receptor (TLR)-2 and TLR4 signal transduction. However, no studies have yet identified a function for Mal distinct from the related adapter MyD88. In this study, we have identified a putative TRAF6 interaction site in Mal but not in MyD88 and we demonstrate that Mal can be co-immunoprecipitated with TRAF6. Overexpression of MalE190A, which contains a mutation within the TRAF6-binding motif, failed to induce the expression of an NF-kappaB-dependent reporter gene, p65-mediated transactivation of gene expression, or activation of Jun N-terminal kinase or p42/p44 MAP kinase, which are induced with wild type Mal. MalE190A inhibited TLR2- and TLR4-mediated activation of NF-kappaB. These results identify a specific role for Mal in TLR-mediated signaling in regulating NF-kappaB-dependent gene transcription via its interaction with TRAF6.	Monash Univ, Monash Inst Reprod & Dev, Ctr Funct Genom & Human Dis, Melbourne, Vic 3168, Australia; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Cooperat Res Ctr Chron Inflammatory Dis, Dublin 2, Ireland	Monash University; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin	Mansell, A (corresponding author), Monash Med Ctr, Monash Inst Reprod & Dev, Ctr Funct Genom & Human Dis, 246 Clayton Rd, Clayton, Vic 3168, Australia.	ashley.mansell@med.monash.edu.au	Mansell, Ashley/B-9553-2008; Hertzog, Paul J/I-7053-2013; Hertzog, Paul J/G-6734-2013	Mansell, Ashley/0000-0002-6540-1281; Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472; O'Neill, Luke/0000-0002-4333-2748; Brint, Elizabeth/0000-0001-9214-149X				Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	22	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37227	37230		10.1074/jbc.C400289200	http://dx.doi.org/10.1074/jbc.C400289200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247281	hybrid, Green Published			2022-12-25	WOS:000223554600005
J	Cleator, JH; Ravenell, R; Kurtz, DT; Hildebrandt, JD				Cleator, JH; Ravenell, R; Kurtz, DT; Hildebrandt, JD			A dominant negative G alpha(s) mutant that prevents thyroid-stimulating hormone receptor activation of cAMP production and inositol 1,4,5-trisphosphate turnover - competition by different G proteins for activation by a common receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN TSH RECEPTOR; 3RD CYTOPLASMIC LOOP; ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; MG-2+-BINDING SITE; SOMATIC MUTATIONS; PHOSPHOLIPASE-C; RAS; ALPHA; GENE	A Ser to Asn mutation at position 54 of the alpha subunit of G(s) (designated N54-alpha(s)) was characterized after transient expression of it with various components of the receptor-adenylyl cyclase pathway in COS-1, COS-7, and HEK 293 cells. Previous studies of the N54-alpha(s) mutant revealed that it has a conditional dominant negative phenotype that prevents hormone-stimulated increases in cAMP without interfering with the regulation of basal cAMP levels (Cleator, J. H., Mehta, N. D., Kurtz, D. K., Hildebrandt, J. D. (1999) FEBS Lett. 243, 205-208). Experiments reported here were conducted to localize the mechanism of the dominant negative effect of the mutant. Competition studies conducted with activated alpha(s)* (Q212L) showed that the N54 mutant did not work downstream by blocking the interaction of endogenous alpha(s) with adenylyl cyclase. The co-expression of wild type or N54-alpha(s) along with the thyroid-stimulating hormone (TSH) receptor and adenylyl cyclase isotypes differing with respect to betagamma stimulation (AC II or AC III) revealed that the phenotype of the mutant is not dependent upon the presence of adenylyl cyclase isoforms regulated by betagamma. These studies ruled out a downstream site of action of the mutant. To investigate an upstream site of action, N54-alpha(s) was co-expressed with either the TSH receptor that activates both alpha(s) and alpha(q) or with the alpha(1B)-adrenergic receptor that activates only alpha(q). N54-alpha(s) failed to inhibit alpha(1B)-adrenergic receptor stimulation of inositol 1,4,5-trisphosphate production but did inhibit TSH stimulation of inositol 1,4,5-trisphosphate. These results show that G(s) and G(q) compete for activation by the TSH receptor. They also indicate that the N54 protein has a dominant negative phenotype by blocking upstream receptor interactions with normal G proteins. This phenotype is different from that seen in analogous mutants of other G protein alpha subunits and suggests that either regulation or protein-protein interactions differ among G protein alpha subunits.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Hildebrandt, JD (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA.	hildebjd@musc.edu			NIDDK NIH HHS [DK 37219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Cleator JH, 1999, FEBS LETT, V443, P205, DOI 10.1016/S0014-5793(98)01704-9; CODINA J, 1984, J BIOL CHEM, V259, P1408; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Grishina G, 2000, MOL PHARMACOL, V57, P1081; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; HILDEBRANDT JD, 1983, J BIOL CHEM, V258, P3141; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1992, J BIOL CHEM, V267, P1212; MCKENZIE FR, 1988, BIOCHEM SOC T, V16, P434, DOI 10.1042/bst0160434; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SPIEGEL AM, 1992, MED RES REV, V12, P55, DOI 10.1002/med.2610120105; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5	62	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36601	36607		10.1074/jbc.M406232200	http://dx.doi.org/10.1074/jbc.M406232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15234971	hybrid			2022-12-25	WOS:000223453600057
J	Kandasamy, P; Vemula, M; Oh, CS; Chellappa, R; Martin, CE				Kandasamy, P; Vemula, M; Oh, CS; Chellappa, R; Martin, CE			Regulation of unsaturated fatty acid biosynthesis in Saccharomyces - The endoplasmic reticulum membrane protein, Mga2p, a transcription activator of the OLE1 gene, regulates the stability of the OLE1 mRNA through exosome-mediated mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIC INDUCTION; DESATURASE GENE; YEAST EXOSOME; RIBOSOMAL-RNA; CEREVISIAE; DEGRADATION; ASSOCIATION; REPRESSION; EUKARYOTES; EXPRESSION	The Saccharomyces cerevisiae OLE1 gene encodes a membrane-bound Delta9 fatty-acid desaturase, whose expression is regulated through transcriptional and mRNA stability controls. In wild type cells grown on fatty acid-free medium, OLE1 mRNA has a half- life of 10 +/- 1.5 min (basal stability) that becomes highly unstable when cells are exposed to unsaturated fatty acids ( regulated stability). Activation of OLE1 transcription is dependent on N-terminal fragments of two membrane proteins, Mga2p and Spt23p, that are proteolytically released from the membrane by a ubiquitin-mediated mechanism. Surprisingly, disruption of the MGA2 gene also reduces the half- life of the OLE1 transcript and abolishes fatty acid regulated instability. Disruption of its cognate, SPT23, has no effect on the half- life of the mRNA. Mga2p appears to have two distinct functions with respect to the OLE1 mRNA stability: a stabilizing effect in cells grown in fatty acid-free medium and a destabilizing function in cells that are exposed to unsaturated fatty acids. These functions are independent of OLE1 transcription and can confer basal and regulated stability on OLE1 mRNAs that are produced under the control of the unrelated GAL1 promoter. Expression of soluble, N-terminal fragments of Mga2p stabilize the transcript but do not confer fatty acid-regulated instability on the mRNA suggesting that the stabilizing functions of Mga2p do not require membrane processing and that modifications to the protein introduced during proteolysis may play a role in the destabilizing effect. An analysis of mutants that are defective in mRNA degradation indicate that the Mga2p-requiring control mechanism that regulates the fatty acid-mediated instability of the OLE1 transcript acts by activating exosomal 3' --> 5'-exonuclease degradation activity.	Rutgers State Univ, Dept Cell Biol & Neurosci, Div Life Sci, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Div Life Sci, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	martin@biology.Rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; Choi JY, 1996, J BIOL CHEM, V271, P3581; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Jiang YD, 2002, EUKARYOT CELL, V1, P481, DOI 10.1128/EC.1.3.481-490.2002; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Nakagawa Y, 2001, J BACTERIOL, V183, P745, DOI 10.1128/JB.183.2.745-751.2001; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; Tharun S, 2001, MOL CELL, V8, P1075, DOI 10.1016/S1097-2765(01)00395-1; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 2000, MOL CELL BIOL, V20, P8230, DOI 10.1128/MCB.20.21.8230-8243.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhang SR, 1999, GENETICS, V151, P473	29	40	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36586	36592		10.1074/jbc.M401557200	http://dx.doi.org/10.1074/jbc.M401557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220333	hybrid			2022-12-25	WOS:000223453600055
J	Lambeth, DO; Tews, KN; Adkins, S; Frohlich, D; Milavetz, BI				Lambeth, DO; Tews, KN; Adkins, S; Frohlich, D; Milavetz, BI			Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; PHOSPHOENOLPYRUVATE CARBOXYKINASE; THIOKINASES; ATP; ENZYME	For nearly 50 years, succinyl-CoA synthetase in animals was thought to be specific for guanine nucleotides. Recently, we purified and characterized both an ADP-forming succinyl-CoA synthetase from pigeon breast muscle and the GDP-forming enzyme from liver (Johnson, J. D., Muhonen, W. W., and Lambeth, D. O. (1998) J. Biol. Chem. 273, 27573-27579). Using the sequences of the pigeon enzymes as queries in BLAST searches, we obtained genetic evidence that both enzymes are expressed in a wide range of animal species (Johnson, J. D., Mehus, J. G., Tews, K., Milavetz, B. I., and Lambeth, D. O. (1998) J. Biol. Chem. 273, 27580-27586). Here we extend those observations by presenting data from Western and Northern blots and enzymatic assays showing that both proteins are widely expressed in mammals with the relative amounts varying from tissue to tissue. We suggest that both succinyl-CoA synthetases catalyze the reverse reaction in the citric acid cycle in which the ADP-forming enzyme augments ATP production, whereas the GDP-forming enzyme supports GTP-dependent anabolic processes. Widely accepted shuttle mechanisms are invoked to explain how transport of P-enolpyruvate across mitochondrial membranes can transfer high energy phosphate between the cytosol and mitochondrial matrix.	Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Lambeth, DO (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, POB 9037, Grand Forks, ND 58202 USA.	dlambeth@medicine.nodak.edu						Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496; Atkinson D. E., 1977, CELLULAR ENERGY META, P32; CHA S, 1964, J BIOL CHEM, V239, P1961; DRAHOTA Z, 1981, FEBS LETT, V157, P347; Furuyama K, 2000, J CLIN INVEST, V105, P757, DOI 10.1172/JCI6816; JENKINS TM, 1988, BIOCHEM BIOPH RES CO, V151, P257, DOI 10.1016/0006-291X(88)90587-6; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; Jones JG, 2001, AM J PHYSIOL-ENDOC M, V281, pE848, DOI 10.1152/ajpendo.2001.281.4.E848; KELLY CJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P208, DOI 10.1016/0003-9861(77)90186-2; KLEINEKE J, 1973, FEBS LETT, V29, P82, DOI 10.1016/0014-5793(73)80531-9; KREBS H. A., 1937, Enzymologia, V4, P148; Lambeth David O, 2002, IUBMB Life, V54, P143; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; Modaressi S, 1998, BIOCHEM J, V333, P359, DOI 10.1042/bj3330359; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; Przybyla-Zawislak B, 1998, EUR J BIOCHEM, V258, P736, DOI 10.1046/j.1432-1327.1998.2580736.x; SANADI DR, 1954, BIOCHIM BIOPHYS ACTA, V14, P434, DOI 10.1016/0006-3002(54)90205-X; WEITZMAN PDJ, 1982, FEBS LETT, V143, P237, DOI 10.1016/0014-5793(82)80107-5; WILSON DF, 1983, J BIOL CHEM, V258, P464	23	89	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36621	36624		10.1074/jbc.M406884200	http://dx.doi.org/10.1074/jbc.M406884200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15234968	hybrid			2022-12-25	WOS:000223453600060
J	Sarcina, M; Mullineaux, CW				Sarcina, M; Mullineaux, CW			Mobility of the IsiA chlorophyll-binding protein in cyanobacterial thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS SP PCC7942; PHOTOSYSTEM-II; PHOTOSYNTHETIC MEMBRANES; SYNECHOCYSTIS PCC-6803; ANGSTROM RESOLUTION; LIPID DIFFUSION; IRON-DEFICIENCY; DYNAMICS; COMPLEX; SPECTROSCOPY	We are using fluorescence recovery after photobleaching (FRAP) to probe the dynamics of thylakoid membranes in vivo in cells of the cyanobacterium Synechococcus sp. PCC7942. We have shown previously that the light-harvesting phycobilisomes diffuse quite rapidly on the thylakoid membrane surface. However, the photosystem II core complexes appear completely immobile. This raises the possibility that all of the membrane integral protein complexes in the thylakoid membrane are locked into a rather rigid array. Alternatively, it is possible that photosystem II is specifically anchored in the membrane, with other membrane proteins able to diffuse around it. We have now resolved this question by studying the diffusion of a second integral membrane protein, the IsiA chlorophyll-binding protein. IsiA is induced under iron starvation and some other stress conditions. In iron-stressed cyanobacterial cells, a high proportion of chlorophyll fluorescence comes from IsiA. This makes it straightforward to examine the diffusion of IsiA by FRAP. We find that the complex is mobile with a mean diffusion coefficient of similar to3 x 10(-11) cm(2) s(-1). Thus it is clear that some thylakoid membrane proteins are mobile and that there must be a specific anchor that prevents photosystem II diffusion. We discuss the implications for the structure and function of the cyanobacterial thylakoid membrane.	UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London	Mullineaux, CW (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	c.mullineaux@ucl.ac.uk						Albertsson PA, 2001, TRENDS PLANT SCI, V6, P349, DOI 10.1016/S1360-1385(01)02021-0; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Andrizhiyevskaya EG, 2002, BBA-BIOENERGETICS, V1556, P265, DOI 10.1016/S0005-2728(02)00371-7; Aspinwall CL, 2004, PHOTOSYNTH RES, V79, P179, DOI 10.1023/B:PRES.0000015399.43503.95; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kirchhoff H, 2002, BIOCHEMISTRY-US, V41, P4872, DOI 10.1021/bi011650y; KUBITSCHECK U, 1994, BIOPHYS J, V67, P948, DOI 10.1016/S0006-3495(94)80596-X; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Michel KP, 2004, PHYSIOL PLANTARUM, V120, P36, DOI 10.1111/j.0031-9317.2004.0229.x; Mullineaux CW, 2004, J EXP BOT, V55, P1207, DOI 10.1093/jxb/erh106; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; Mullineaux CW, 2002, TRENDS PLANT SCI, V7, P237, DOI 10.1016/S1360-1385(02)02283-5; Mullineaux CW, 1999, AUST J PLANT PHYSIOL, V26, P671, DOI 10.1071/PP99027; Olive J, 1997, BBA-BIOENERGETICS, V1319, P275, DOI 10.1016/S0005-2728(96)00168-5; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Sandstrom S, 2002, PHYSIOL PLANTARUM, V116, P255, DOI 10.1034/j.1399-3054.2002.1160216.x; Sandstrom S, 2001, PHOTOCHEM PHOTOBIOL, V74, P431, DOI 10.1562/0031-8655(2001)074<0431:CTIGPF>2.0.CO;2; Sarcina M, 2003, FEBS LETT, V553, P295, DOI 10.1016/S0014-5793(03)01031-7; Sarcina M, 2001, J BIOL CHEM, V276, P46830, DOI 10.1074/jbc.M107111200; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Szalontai B, 2000, BBA-BIOMEMBRANES, V1509, P409, DOI 10.1016/S0005-2736(00)00323-0; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; ZHANG F, 1993, BIOESSAYS, V15, P579, DOI 10.1002/bies.950150903; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	30	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36514	36518		10.1074/jbc.M405881200	http://dx.doi.org/10.1074/jbc.M405881200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218021	hybrid			2022-12-25	WOS:000223453600045
J	Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY				Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY			Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; methyl-CpG-binding protein; non-small-cell lung cancer	HISTONE DEACETYLASE INHIBITOR; BRONCHIAL EPITHELIAL-CELLS; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CPG METHYLATION; RETINOIC ACID; HEPATOCELLULAR-CARCINOMA; CHROMOSOMAL PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION	Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferation of non-small-cell lung cancer (NSCLC) cells by inducing apoptosis, is lost in about half of stage I NSCLC cases. Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in loss of IGFBP-3 expression in NSCLC. We found the IGFBP-3 promoter to be methylated in seven of 13 NSCLC cell lines and in 16 of 23, seven of 9, eight of 11, and six of six tumor specimens from patients with stage I, II, III, and IV NSCLC, respectively. Methylation status correlated with IGFBP-3 mRNA and protein levels in a subset of NSCLC cell lines tested in our study. However, treatment with 5'-aza-2'-deoxycytidine (5'-aza- dC) restored IGFBP-3 expression in four of seven NSCLC cell lines with the methylated promoter, suggesting that multiple mechanisms regulate IGFBP-3 expression in NSCLC. Gel shift and chromatin immunoprecipitation assays showed that methylation of the Sp-1/ Sp-3-binding element in the IGFBP-3 promoter influenced the binding of Sp-1, methyl-CpG-binding protein-2 (MeCP2), and histone deacetylase ( HDAC). A luciferase construct expressing IGFBP-3 promoter in which the Sp1/ Sp-3-binding element was methylated showed significantly reduced transcriptional activity. The reduction in promoter activity was further suppressed by overexpression of MeCP2, which was rescued by 5'-aza- dC. Thus interference with Sp-1 transactivation by MeCP2 may contribute to the transcriptional defect of IGFBP-3 expression in NSCLC cells with methylated promoter.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Texas Childrens Liver Ctr, Houston, TX 77030 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Emory University	Lee, HY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	hlee@mdanderson.org	Mao, Li/C-7570-2011; Khuri, Fadlo R./AAU-4942-2020	Mao, Li/0000-0001-7263-3358; Khuri, Fadlo R./0000-0002-8638-7618; Chang, Yoon Soo/0000-0003-3340-4223; Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [1R01 CA10081-01A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; DEAR C, 2001, J CLIN ENDOCR METAB, V86, P1274; Fowler CA, 2000, INT J CANCER, V88, P448, DOI 10.1002/1097-0215(20001101)88:3<448::AID-IJC18>3.3.CO;2-M; Graessmann M, 1993, EXS, V64, P404; Gray SG, 2000, INT J MOL MED, V5, P33; Gucev ZS, 1996, CANCER RES, V56, P1545; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kim SK, 1997, CANCER RES, V57, P400; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee HY, 2002, CANCER RES, V62, P3530; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nakao M, 2001, BRAIN DEV-JPN, V23, pS174, DOI 10.1016/S0387-7604(01)00348-5; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zi XL, 2000, CANCER RES, V60, P5617	50	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6569	6580		10.1038/sj.onc.1207882	http://dx.doi.org/10.1038/sj.onc.1207882			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247904				2022-12-25	WOS:000223530800004
J	Bando, Y; Tsukamoto, Y; Katayama, T; Ozawa, K; Kitao, Y; Hori, O; Stern, DM; Yamauchi, A; Ogawa, S				Bando, Y; Tsukamoto, Y; Katayama, T; Ozawa, K; Kitao, Y; Hori, O; Stern, DM; Yamauchi, A; Ogawa, S			ORP150/HSP12A protects renal tubular epithelium from ischemia-induced cell death	FASEB JOURNAL			English	Article						stress protein; acute renal failure; apoptosis; ischemic injury	OXYGEN-REGULATED PROTEIN; MOLECULAR CHAPERONE; EXPRESSION; ORP150; HYPOXIA; INDUCTION; APOPTOSIS; TRANSPORT; NEURONS; STRESS	The 150 kDa oxygen-regulated protein (ORP150) is an inducible endoplasmic reticulum ( ER) chaperone with cytoprotective properties in settings of cell stress, such as ischemia/reperfusion (I/R). Renal tissue from patients with acute renal failure displayed strong induction of ORP150 in tubular epithelium. In a rodent model of renal I/R injury, ORP150 was expressed in both the ischemic and contralateral kidney, principally in the thick ascending loop of Henle ( TAL) and distal tubules. Cultured renal epithelial cells exposed to hypoxic or hyperosmotic conditions displayed induction of ORP150. Renal tubular epithelial cells stably transfected with ORP150 sense or antisense cDNA displayed a strong correlation between ORP150 expression and vulnerability to hypoxic/osmotic stress; higher levels of ORP150 were protective, whereas lower levels increased susceptibility to cell death. Compared with nontransgenic controls, transgenic mice overexpressing ORP150 subjected to renal I/R displayed a blunted rise of serum creatinine and blood urea nitrogen, and enhanced survival of TAL, consistent with cytoprotection. In contrast, heterozygous ORP150(+/-) mice, with lower levels of ORP150, showed enhanced renal injury. These data are consistent with the possibility that ORP150 exerts cytoprotective effects in renal tubular epithelia subjected to I/R injury and suggest a key role for ER stress in the renal tubular response to acute renal failure.	Asahikawa Med Coll, Dept Anat 1, Asahikawa, Hokkaido 0788510, Japan; Osaka Med Ctr Canc, Dept Pathol, Higashinari Ku, Osaka 5378511, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka 5650871, Japan; Osaka Rosai Hosp, Dept Med, Div Nephrol, Sakai, Osaka 5918025, Japan; Kanazawa Univ, Sch Med, Dept Neurosci, Kanazawa, Ishikawa 9208640, Japan; Med Coll Georgia, Deans Off, Augusta, GA 30912 USA	Asahikawa Medical College; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Osaka Rosai Hospital; Kanazawa University; University System of Georgia; Augusta University	Bando, Y (corresponding author), Asahikawa Med Coll, Dept Anat 1, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	ybando@asahikawa-med.ac.jp						Akcetin Z, 1999, UROL RES, V27, P306, DOI 10.1007/s002400050155; Aufricht C, 1998, AM J PHYSIOL-RENAL, V274, pF215, DOI 10.1152/ajprenal.1998.274.1.F215; Bando Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1172, DOI 10.1152/ajpcell.2000.278.6.C1172; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; Brady H.R., 1996, KIDNEY, P1200; BREZIS M, 1994, AM J PHYSIOL-RENAL, V267, pF1059, DOI 10.1152/ajprenal.1994.267.6.F1059; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; Cuttle L, 2001, KIDNEY INT, V59, P1779, DOI 10.1046/j.1523-1755.2001.0590051779.x; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Kelly KJ, 2000, SEMIN NEPHROL, V20, P4; Kelly KJ, 2001, J CLIN INVEST, V108, P1291, DOI 10.1172/JCI13018; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI200112978; Kobayashi T, 2003, TRANSGENIC RES, V12, P13, DOI 10.1023/A:1022176004928; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P229, DOI 10.1038/jcbfm.1993.28; Miyazaki M, 2002, J CEREBR BLOOD F MET, V22, P979, DOI 10.1097/00004647-200208000-00009; Neuhofer W, 2001, J AM SOC NEPHROL, V12, P2565, DOI 10.1681/ASN.V12122565; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Ozawa K, 2001, CANCER RES, V61, P4206; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; SCHUMER M, 1992, AM J PATHOL, V140, P831; Shimizu H, 2000, CRIT CARE MED, V28, P809, DOI 10.1097/00003246-200003000-00033; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; Yamauchi A, 1997, KIDNEY INT, V51, P1847, DOI 10.1038/ki.1997.252; Yamauchi A, 1996, J CLIN INVEST, V97, P263, DOI 10.1172/JCI118401; Yamauchi A, 1998, KIDNEY INT, V54, pS183, DOI 10.1046/j.1523-1755.1998.06741.x	32	68	80	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1401	+		10.1096/fj.03-1161fje	http://dx.doi.org/10.1096/fj.03-1161fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240565				2022-12-25	WOS:000222979200025
J	Roman, J; Ritzenthaler, JD; Acosta, AG; Rivera, HN; Roser-Page, S				Roman, J; Ritzenthaler, JD; Acosta, AG; Rivera, HN; Roser-Page, S			Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling	FASEB JOURNAL			English	Article						nicotinic receptors; CREB; protein kinases; signal transduction; gene transcription	BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE-C; ACETYLCHOLINE-RECEPTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL REGULATION; CHEMOTACTIC ACTIVITY; GROWTH-FACTOR; INTEGRINS; BINDING	Tobacco-related lung diseases are associated with alterations in tissue remodeling and are characterized by increased matrix deposition. Among the matrix molecules found to be highly expressed in tobacco-related lung diseases is fibronectin, a cell adhesive glycoprotein implicated in tissue injury and repair. We hypothesize that nicotine, a component of tobacco, stimulates the expression of fibronectin in lung fibroblasts via the activation of intracellular signals that lead to increased fibronectin gene transcription. In support of this, we found that nicotine stimulated the expression of fibronectin in lung fibroblasts and that its stimulatory effect was associated with activation of protein kinase C and mitogen-activated protein kinases, increased levels of intracellular cAMP, and phosphorylation and DNA binding of the transcription factor CREB. Increased transcription of the gene was dependent on cAMP-response elements (CREs) present on the 5' end of its gene promoter. The stimulatory effect of nicotine on fibronectin expression was abolished by alpha-bungarotoxin, an inhibitor of alpha7 nicotinic acetylcholine receptors (alpha7 AChRs). Of note, nicotine increased the expression of alpha7 nAChRs on fibroblasts. Our data suggest that nicotine induces lung fibroblasts to produce fibronectin by stimulating alpha7 nAChR-dependent signals that regulate the transcription of the fibronectin gene.	Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Dept Med, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Roman, J (corresponding author), Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	jroman@emory.edu						Aztiria EM, 2000, NEUROCHEM RES, V25, P171, DOI 10.1023/A:1007512121082; BITTERMAN PB, 1983, J CELL BIOL, V97, P1925, DOI 10.1083/jcb.97.6.1925; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOWERSOX JC, 1982, CANCER RES, V42, P2547; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; Cattaneo MG, 1997, BIOCHEM J, V328, P499; CHANG ZL, 1993, J LEUKOCYTE BIOL, V53, P79, DOI 10.1002/jlb.53.1.79; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DENHOLM EM, 1989, AM J PATHOL, V135, P571; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; END P, 1991, RECEPTORS EXTRACELLU, P79; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graves KL, 1996, AM J PHYSIOL-LUNG C, V271, pL61, DOI 10.1152/ajplung.1996.271.1.L61; GUDEWICZ PW, 1994, J LEUKOCYTE BIOL, V55, P423, DOI 10.1002/jlb.55.4.423; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hiemke C, 1996, NEUROSCI LETT, V214, P171, DOI 10.1016/0304-3940(96)12908-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kirkpatrick CJ, 2001, JPN J PHARMACOL, V85, P24, DOI 10.1254/jjp.85.24; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Lee BH, 1996, BIOCHEM MOL BIOL INT, V39, P895; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LUCEY EC, 1985, AM REV RESPIR DIS, V132, P362; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MCDONAGH J, 1985, PLASMA FIBRONECTIN S, P121; Michaelson JE, 2002, AM J PHYSIOL-LUNG C, V282, pL291, DOI 10.1152/ajplung.00445.2000; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PACIFICI R, 1992, J CLIN INVEST, V89, P61, DOI 10.1172/JCI115586; Perez RL, 2000, J INTERF CYTOK RES, V20, P795, DOI 10.1089/10799900050151067; PEREZ RL, 1995, J IMMUNOL, V154, P1879; Perez RL, 1999, AM J RESP CELL MOL, V20, P1059, DOI 10.1165/ajrcmb.20.5.3281; Petty TL, 2002, CHEST, V121, p116S, DOI 10.1378/chest.121.5_suppl.116S; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; Rivera-Marrero CA, 2000, MICROB PATHOGENESIS, V29, P231, DOI 10.1006/mpat.2000.0383; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; ROMAN J, 1992, AM J RESP CELL MOL, V6, P472, DOI 10.1165/ajrcmb/6.5.472; Roman J, 1996, IMMUNOL RES, V15, P163, DOI 10.1007/BF02918505; ROMAN J, 1991, DEVELOPMENT, V112, P551; Roman J, 1999, IMMUNOLOGY, V98, P228; Roman J, 2000, CYTOKINE, V12, P1581, DOI 10.1006/cyto.2000.0759; ROMAN J, 1997, LUNG SCI FDN; ROMAN J, 1998, INTERSTITIAL LUNG DI, P207; ROWELL PP, 1983, J PHARMACOL METHOD, V9, P249, DOI 10.1016/0160-5402(83)90064-5; ROY F, 1993, J BIOMED MATER RES, V27, P389, DOI 10.1002/jbm.820270312; Ryder MI, 1998, J PERIODONTAL RES, V33, P359, DOI 10.1111/j.1600-0765.1998.tb02211.x; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Shiomi T, 2003, EXP LUNG RES, V29, P1, DOI 10.1080/01902140303761; SONG WD, 1995, RESPIRATION, V62, P125; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; THURLBECK WM, 1990, CLIN CHEST MED, V11, P389; Tipton DA, 1995, J PERIODONTOL, V66, P1056, DOI 10.1902/jop.1995.66.12.1056; URAKAWA N, 1994, INT J LEGAL MED, V106, P232, DOI 10.1007/BF01225411; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; VILLIGER B, 1981, AM REV RESPIR DIS, V124, P652; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZHOU X, 1992, AM J PHYSIOL, V262, pL600, DOI 10.1152/ajplung.1992.262.5.L600; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	67	79	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1436	+		10.1096/fj.03-0826fje	http://dx.doi.org/10.1096/fj.03-0826fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247149				2022-12-25	WOS:000222979200010
J	de la Serna, JB; Perez-Gil, J; Simonsen, AC; Bagatolli, LA				de la Serna, JB; Perez-Gil, J; Simonsen, AC; Bagatolli, LA			Cholesterol rules - Direct observation of the coexistence of two fluid phases in native pulmonary surfactant membranes at physiological temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIR-WATER-INTERFACE; 2-PHOTON FLUORESCENCE MICROSCOPY; MODEL MEMBRANES; SP-C; TERNARY MIXTURES; DOMAIN FORMATION; LIPID RAFTS; SP-B; FILMS; MONOLAYERS	Pulmonary surfactant, the lipid-protein material that stabilizes the respiratory surface of the lungs, contains approximately equimolar amounts of saturated and unsaturated phospholipid species and significant proportions of cholesterol. Such lipid composition suggests that the membranes taking part in the surfactant structures could be organized heterogeneously in the form of in-plane domains, originating from particular distributions of specific proteins and lipids. Here we report novel results concerning the lateral organization of bilayer membranes made of native pulmonary surfactant where the coexistence of two distinct micrometer sized fluid phases (fluid ordered and fluid disordered-like phases) is observed at physiological temperatures by using fluorescence microscopy and atomic force microscopy. Additional experiments using fluorescent-labeled proteins SP-B and SP-C show that at physiological temperatures these hydrophobic proteins are located exclusively in the fluid disordered-like phase. Most interestingly, the microscopic coexistence of fluid phases is maintained up to 37.5 degreesC, where most fluid ordered phases melt. This observation suggests that the particular composition of this material is naturally designed to be at the "edge" of a lateral structure transition under physiological conditions, likely providing particular structural and dynamic properties for its mechanical function. The observed lateral structure in native pulmonary surfactant membranes is dramatically affected by the extraction of cholesterol, an effect not observed upon extraction of the surfactant proteins. Furthermore, the spreading properties of the native surfactant material at the air-liquid interface were also greatly affected by cholesterol extraction, suggesting a connection between the observed lateral structure and a physiologically relevant function of the material. We suggest that the particular lipid composition of surfactant could be finely tuned to provide, under physiological conditions, a structural scaffold for surfactant proteins to act at appropriate local densities and lipid composition.	Univ So Denmark, MEMPHYS Ctr Biomembrane Phys, Dept Biochem & Mol Biol, Odense 5230 M, Denmark; Univ Complutense, Dept Bioquim, Fac Biol, Madrid 28040, Spain; Univ So Denmark, MEMPHYS Ctr Biomembrane Phys, Dept Phys, Odense 5230, Denmark	University of Southern Denmark; Complutense University of Madrid; University of Southern Denmark	Bagatolli, LA (corresponding author), Univ So Denmark, MEMPHYS Ctr Biomembrane Phys, Dept Biochem & Mol Biol, Odense 5230 M, Denmark.	bagatolli@memphys.sdu.dk	Perez-Gil, Jesus/H-3102-2019; de la Serna, Jorge Bernardino/K-9766-2015; de la Serna, Jorge Bernardino/O-6355-2019; Bagatolli, Luis/L-5159-2016	Perez-Gil, Jesus/0000-0003-3587-7147; de la Serna, Jorge Bernardino/0000-0002-1396-3338; de la Serna, Jorge Bernardino/0000-0002-1396-3338; Simonsen, Adam Cohen/0000-0003-1937-8524; Bagatolli, Luis/0000-0002-4727-8611				ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; Bagatolli LA, 2000, BIOPHYS J, V79, P434, DOI 10.1016/S0006-3495(00)76305-3; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; CASALS C, 1989, BIOCHIM BIOPHYS ACTA, V1003, P201, DOI 10.1016/0005-2760(89)90256-7; Casals C, 2003, AM J PHYSIOL-LUNG C, V284, pL466, DOI 10.1152/ajplung.00325.2002; Daniels CB, 2003, NEWS PHYSIOL SCI, V18, P151, DOI 10.1152/nips.01438.2003; DANIELS CB, 1990, EXP LUNG RES, V16, P435, DOI 10.3109/01902149009068819; Diemel RV, 2002, BIOCHEMISTRY-US, V41, P15007, DOI 10.1021/bi0256532; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Discher BM, 1999, BIOPHYS J, V77, P2051, DOI 10.1016/S0006-3495(99)77046-3; Discher BM, 1999, BIOCHEMISTRY-US, V38, P374, DOI 10.1021/bi981386h; Discher BM, 1996, BIOPHYS J, V71, P2583, DOI 10.1016/S0006-3495(96)79450-X; DUZGUNES N, 2003, LIPOSOMES, V2, P105; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; INOUE H, 1982, J APPL PHYSIOL, V53, P567, DOI 10.1152/jappl.1982.53.3.567; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; Langman C, 1996, AM J PHYSIOL-REG I, V271, pR437, DOI 10.1152/ajpregu.1996.271.2.R437; Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434; McConnell HM, 2003, ANNU REV BIOPH BIOM, V32, P469, DOI 10.1146/annurev.biophys.32.110601.141704; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Nag K, 1997, BIOPHYS J, V72, P2638, DOI 10.1016/S0006-3495(97)78907-0; Nag K, 2002, BIOPHYS J, V82, P2041, DOI 10.1016/S0006-3495(02)75552-5; Nag K, 1998, BIOPHYS J, V74, P2983, DOI 10.1016/S0006-3495(98)78005-1; Orgeig S, 2001, COMP BIOCHEM PHYS A, V129, P75, DOI 10.1016/S1095-6433(01)00307-5; Orgeig S, 2003, REPROD FERT DEVELOP, V15, P55, DOI 10.1071/RD02087; Perez-Gil J, 1998, BBA-MOL BASIS DIS, V1408, P203, DOI 10.1016/S0925-4439(98)00068-4; Perez-Gil J, 2002, BIOL NEONATE, V81, P6, DOI 10.1159/000056765; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; Piknova B, 2002, CURR OPIN STRUC BIOL, V12, P487, DOI 10.1016/S0959-440X(02)00352-4; Plasencia I, 2001, ANAL BIOCHEM, V296, P49, DOI 10.1006/abio.2001.5222; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Scherfeld D, 2003, BIOPHYS J, V85, P3758, DOI 10.1016/S0006-3495(03)74791-2; Schief WR, 2003, BIOPHYS J, V84, P3792, DOI 10.1016/S0006-3495(03)75107-8; Schurch S, 1998, BBA-MOL BASIS DIS, V1408, P180, DOI 10.1016/S0925-4439(98)00067-2; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Taneva S, 1997, BIOCHEMISTRY-US, V36, P912, DOI 10.1021/bi9623542; TRAUBLE H, 1974, NATURWISSENSCHAFTEN, V61, P344; Veatch SL, 2003, BIOPHYS J, V85, P3074, DOI 10.1016/S0006-3495(03)74726-2; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650; Yu SH, 2003, J LIPID RES, V44, P621, DOI 10.1194/jlr.M200380-JLR200; Yu SH, 2001, J LIPID RES, V42, P1421	46	225	227	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40715	40722		10.1074/jbc.M404648200	http://dx.doi.org/10.1074/jbc.M404648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15231828	hybrid			2022-12-25	WOS:000223916800063
J	Midgley, VC; Khachigian, LM				Midgley, VC; Khachigian, LM			Fibroblast growth factor-2 induction of platelet-derived growth factor-C chain transcription in vascular smooth muscle cells is ERK-dependent but not JNK-dependent and mediated by Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED LIGAND; RESPONSE FACTOR-I; PDGF-C; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ALPHA; FAMILY; SP1; PROMOTER; RECEPTOR	Platelet-derived growth factors (PDGFs) play an integral role in normal tissue growth and maintenance as well as many human pathological states including atherosclerosis, fibrosis, and tumorigenesis. The PDGF family of ligands is comprised of A, B, C, and D chains. Here, we provide the first functional characterization of the PDGF-C promoter. We examined 797 bp of the human PDGF-C promoter and identified several putative recognition elements for Sp1, Ets Egr-1, and Smad. The proximal region of the PDGF-C promoter bears a remarkable resemblance to a comparable region of the PDGF-A promoter ( 1). Binding and transient transfection analysis in primary vascular smooth muscle cells revealed that PDGF-C, like PDGF-A, is under the transcriptional control of the zinc finger nuclear protein Egr-1 ( early growth response-1). Electrophoretic mobility shift analysis using both smooth muscle cell nuclear extracts and recombinant protein revealed that Egr-1 and Sp1 bind this region of the PDGF-C promoter ( Oligo C, -35 to -1). Egr-1 competes with Sp1 for overlapping binding sites even when the former is at a stoichiometric disadvantage. Reverse transcriptase PCR and supershift analysis demonstrate that fibroblast growth factor-2 (FGF-2) stimulates both Egr-1 and PDGF-C mRNA expression in a time-dependent and transient manner and that FGF-2- inducible Egr-1 binds the proximal PDGF-C promoter. FGF-2- inducible PDGF-C expression was completely abrogated using catalytic DNA ( DNAzymes) targeting Egr-1 but not by its scrambled counterpart. Moreover, using pharmacological inhibitors we demonstrate the critical role of ERK but not JNK in FGF-2- inducible PDGF-C expression. These findings thus demonstrate that PDGF-C transcription, activated by FGF-2, is mediated by Egr-1 and its upstream kinase ERK.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Aase K, 2002, MECH DEVELOP, V110, P187, DOI 10.1016/S0925-4773(01)00560-3; Andrae J, 2002, BIOCHEM BIOPH RES CO, V296, P604, DOI 10.1016/S0006-291X(02)00917-8; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; Dijkmans J, 2002, INT J BIOCHEM CELL B, V34, P414, DOI 10.1016/S1357-2725(01)00124-8; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Eitner F, 2003, J AM SOC NEPHROL, V14, P1145, DOI 10.1097/01.ASN.0000062964.75006.A8; Fang L, 2004, ARTERIOSCL THROM VAS, V24, P787, DOI 10.1161/01.ATV.0000120785.82268.8b; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hamada T, 2002, MECH DEVELOP, V112, P161, DOI 10.1016/S0925-4773(01)00625-6; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359-6101(02)00090-4; Lowe HC, 2001, THROMB HAEMOSTASIS, V85, P574, DOI 10.1055/s-0037-1615632; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Ornitz DM, 2001, GENOME BIOL, V2; Reigstad LJ, 2003, J BIOL CHEM, V278, P17114, DOI 10.1074/jbc.M301728200; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Uutela M, 2001, CIRCULATION, V103, P2242; Zhuo Y, 2004, AM J PHYSIOL-LUNG C, V286, pL182, DOI 10.1152/ajplung.00083.2003; Zwerner JP, 2002, ONCOGENE, V21, P3847, DOI 10.1038/sj.onc.1205486; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	30	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40289	40295		10.1074/jbc.M406063200	http://dx.doi.org/10.1074/jbc.M406063200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247255	hybrid			2022-12-25	WOS:000223916800009
J	Kim, SH; Kim, K; Kwagh, JG; Dicker, DT; Herlyn, M; Rustgi, AK; Chen, YH; El-Deiry, WS				Kim, SH; Kim, K; Kwagh, JG; Dicker, DT; Herlyn, M; Rustgi, AK; Chen, YH; El-Deiry, WS			Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human Esophageal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; CANCER-CELLS; IN-VIVO; RECEPTOR FAMILY; TUMOR-CELLS; ACTIVATION; CARCINOMA; MEMBER; CD95; IDENTIFICATION	The cytotoxic death ligand TRAIL ( tumor necrosis factor-related apoptosis-inducing ligand) is a tumor-specific agent under development as a novel anticancer therapeutic agent. However, some reports have demonstrated toxicity of certain TRAIL preparations toward human hepatocytes and keratinocytes through a caspase-dependent mechanism that involves activation of the extrinsic death pathway and Type II signaling through the mitochondria. We have isolated and purified both His-tagged protein and three versions of native recombinant human TRAIL protein from Escherichia coli. We found that 5 mM dithiothreitol in the purification process enhanced oligomerization of TRAIL and resulted in the formation of hyper-oligomerized TRAILs, including hexamers and nonomers with an extremely high potency in apoptosis induction. Although death-inducing signaling complex formation was much more efficient in cells treated with hyper-oligomerized TRAILs, this did not convert TRAIL-sensitive Type II HCT116 colon tumor cells to a Type I death pattern as judged by their continued sensitivity to a caspase 9 inhibitor. Moreover, TRAIL-resistant Type II Bax-null colon carcinoma cells were not converted to a TRAIL-sensitive Type I state by hyper-oligomerized TRAIL. Primary human esophageal epithelial 2 cells were found to be sensitive to all TRAIL preparations used, including trimer TRAIL. TRAIL-induced death in esophageal epithelial 2 cells was prevented by caspase 9 inhibition for up to 4 h after TRAIL exposure. This result suggests a possible therapeutic application of caspase 9 inhibition as a strategy to reverse TRAIL toxicity. Hyper-oligomerized TRAIL may be considered as an alternative agent for testing in clinical trials.	Univ Penn, Sch Med, Dept Med Genet & Pharmacol, Howard Hughes Med Inst,Lab Mol Oncol & Cell Cycle, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Dept Endocrinol, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; The Wistar Institute; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), 415 Curie Blvd,CRB 437, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020; Chen, Youhai/AAJ-4031-2021; Kim, Kunhong/C-1304-2008	El-Deiry, Wafik/0000-0002-9577-8266; Kim, Kunhong/0000-0001-5639-6372	NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NCI NIH HHS [CA 098101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 2002, CANCER RES, V62, P3093; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kim K, 2004, CELL DEATH DIFFER, V11, P583, DOI 10.1038/sj.cdd.4401388; Kim K, 2001, INT J ONCOL, V18, P241; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Lacour S, 2001, CANCER RES, V61, P1645; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagane M, 2000, CANCER RES, V60, P847; Nagata S, 2000, NAT MED, V6, P502, DOI 10.1038/74972; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ozoren N, 2000, CANCER RES, V60, P6259; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Qin JZ, 2002, EXP DERMATOL, V11, P573, DOI 10.1034/j.1600-0625.2002.110610.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	74	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40044	40052		10.1074/jbc.M404541200	http://dx.doi.org/10.1074/jbc.M404541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15226295	hybrid			2022-12-25	WOS:000223791500102
J	Schneider, D; Berry, S; Volkmer, T; Seidler, A; Rogner, M				Schneider, D; Berry, S; Volkmer, T; Seidler, A; Rogner, M			PetC1 is the major Rieske iron-sulfur protein in the cytochrome b(6)f complex of Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME STRUCTURE; RESPIRATORY TERMINAL OXIDASES; SP STRAIN PCC-6803; SP PCC 6803; B(6)F COMPLEX; BC(1) COMPLEX; DIRECTED MUTAGENESIS; ELECTRON-TRANSPORT; INHIBITOR BINDING; DOMAIN MOVEMENT	Many of the completely sequenced cyanobacterial genomes contain a gene family that encodes for putative Rieske iron-sulfur proteins. The Rieske protein is one of the large subunits of the cytochrome bc-type complexes involved in respiratory and photosynthetic electron transfer. In contrast to all other subunits of this complex that are encoded by single genes, the genome of the cyanobacterium Synechocystis PCC 6803 contains three petC genes, all encoding potential Rieske subunits. Most interestingly, any of the petC genes can be deleted individually without altering the Synechocystis phenotype dramatically. In contrast, double deletion experiments revealed that petC1 and petC2 cannot be deleted in combination, whereas petC3 can be deleted together with any of the other two petC genes. Further results suggest a different physiological function for each of the Rieske proteins. Whereas PetC2 can partly replace the dominating Rieske isoform PetC1, PetC3 is unable to functionally replace either PetC1 or PetC2 and may have a special function involving a special donor with a lower redox potential than plastoquinone. A predominant role of PetC1, which is ( partly) different from PetC2, is suggested by the mutational analysis and a detailed characterization of the electron transfer reactions in the mutant strains.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Ruhr Univ Bochum, Lehrstuhl Biochem Pflanzen, D-44780 Bochum, Germany	University of Freiburg; Ruhr University Bochum	Schneider, D (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Dirk.Schneider@biochemie.uni-freiburg.de						ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; Berry S, 2002, BIOCHEMISTRY-US, V41, P3422, DOI 10.1021/bi011683d; Breyton C, 2000, J BIOL CHEM, V275, P13195, DOI 10.1074/jbc.275.18.13195; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cooley JW, 2000, J BACTERIOL, V182, P714, DOI 10.1128/JB.182.3.714-722.2000; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; Ehira S, 2003, DNA RES, V10, P97, DOI 10.1093/dnares/10.3.97; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; HAUSKA G, 1997, BIOENERGETICS, P389; Howitt CA, 1998, BIOCHEMISTRY-US, V37, P17944, DOI 10.1021/bi981486n; KALLAS T, 1988, P NATL ACAD SCI USA, V85, P5794, DOI 10.1073/pnas.85.16.5794; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P109; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Lee TX, 2001, BBA-BIOENERGETICS, V1504, P235, DOI 10.1016/S0005-2728(00)00253-X; MOHAMED A, 1993, MOL GEN GENET, V238, P161, DOI 10.1007/BF00279543; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; Nakamura Y, 2002, DNA RES, V9, P123, DOI 10.1093/dnares/9.4.123; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; OSIEWACZ HD, 1992, ARCH MICROBIOL, V157, P336, DOI 10.1007/BF00248678; Pils D, 1997, FEMS MICROBIOL LETT, V152, P83, DOI 10.1111/j.1574-6968.1997.tb10412.x; Pils D, 2001, FEMS MICROBIOL LETT, V203, P217, DOI 10.1111/j.1574-6968.2001.tb10844.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Salih GF, 1997, PLANT CELL, V9, P869, DOI 10.1105/tpc.9.6.869; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; Schneider D, 2002, J BIOL CHEM, V277, P10949, DOI 10.1074/jbc.M104076200; Schneider D, 2001, J BIOL CHEM, V276, P16780, DOI 10.1074/jbc.M009503200; Schneider D, 2000, BBA-GENE STRUCT EXPR, V1491, P364, DOI 10.1016/S0167-4781(00)00048-8; Schneider Dirk, 2003, Methods Mol Biol, V228, P37, DOI 10.1385/1-59259-400-X:37; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Vass I, 2000, EUR J BIOCHEM, V267, P2640, DOI 10.1046/j.1432-1327.2000.01274.x; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	43	38	39	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39383	39388		10.1074/jbc.M406288200	http://dx.doi.org/10.1074/jbc.M406288200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262969	hybrid			2022-12-25	WOS:000223791500024
J	Hitchcock, TM; Dong, L; Connor, EE; Meira, LB; Samson, LD; Wyatt, MD; Cao, WG				Hitchcock, TM; Dong, L; Connor, EE; Meira, LB; Samson, LD; Wyatt, MD; Cao, WG			Oxanine DNA glycosylase activity from mammalian alkyladenine glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NITRIC-OXIDE; NITROUS-ACID; ENDONUCLEASE-VIII; BASE EXCISION; CYTOSINE RESIDUES; MOLECULAR-BASIS; DIMP RESIDUES; N-GLYCOSYLASE; CALF THYMUS	Oxanine (Oxa) is a deaminated base lesion derived from guanine in which the N-1-nitrogen is substituted by oxygen. This work reports the mutagenicity of oxanine as well as oxanine DNA glycosylase (ODG) activities in mammalian systems. Using human DNA polymerase beta, deoxyoxanosine triphosphate is only incorporated opposite cytosine (Cyt). When an oxanine base is in a DNA template, Cyt is efficiently incorporated opposite the template oxanine; however, adenine and thymine are also incorporated opposite Oxa with an efficiency similar to 80% of a Cyt/Oxa (C/O) base pair. Guanine is incorporated opposite Oxa with the least efficiency, 16% compared with cytosine. ODG activity was detected in several mammalian cell extracts. Among the known human DNA glycosylases tested, human alkyladenine glycosylase (AAG) shows ODG activity, whereas hOGG1, hNEIL1, or hNEIL2 did not. ODG activity was detected in spleen cell extracts of wild type age-matched mice, but little activity was observed in that of Aag knock-out mice, confirming that the ODG activity is intrinsic to AAG. Human AAG can excise Oxa from all four Oxa-containing double-stranded base pairs, Cyt/Oxa, Thy/Oxa, Ade/Oxa, and Gua/Oxa, with no preference to base pairing. Surprisingly, AAG can remove Oxa from single-stranded Oxa-containing DNA as well. Indeed, AAG can also remove 1, N-6-ethenoadenine from single-stranded DNA. This study extends the deaminated base glycosylase activities of AAG to oxanine; thus, AAG is a mammalian enzyme that can act on all three purine deamination bases, hypoxanthine, xanthine, and oxanine.	Clemson Univ, S Carolina Expt Stn, Dept Genet Biochem & Life Sci Studies, Clemson, SC 29634 USA; Univ S Carolina, Coll Pharm, Dept Basic Pharmaceut Sci, Columbia, SC 29208 USA; MIT, Biol Engn Div, Cambridge, MA 02142 USA	Clemson University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Massachusetts Institute of Technology (MIT)	Cao, WG (corresponding author), Clemson Univ, S Carolina Expt Stn, Dept Genet Biochem & Life Sci Studies, Rm 219,Biosyst Res Complex,51 New Cherry St, Clemson, SC 29634 USA.	wgc@clemson.edu	Meira, Lisiane/AAA-4326-2020	Wyatt, Michael/0000-0003-1815-9565; Meira, Lisiane/0000-0003-4289-2986	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES000333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM067744] Funding Source: NIH RePORTER; NIEHS NIH HHS [K22 ES000333-01, K22 ES000333-02, K22 ES000333-03] Funding Source: Medline; NIGMS NIH HHS [GM 067744] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aamodt RM, 2004, J BIOL CHEM, V279, P13601, DOI 10.1074/jbc.M314277200; Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; *APPL BIOS INC, 1992, COMPL GUID EV IS SYN; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Connor EE, 2002, CHEM BIOL, V9, P1033, DOI 10.1016/S1074-5521(02)00215-6; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P8135, DOI 10.1093/nar/14.20.8135; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hazra TK, 2000, J BIOL CHEM, V275, P27762; He B, 2000, MUTAT RES-DNA REPAIR, V459, P109, DOI 10.1016/S0921-8777(99)00063-4; Hoops GC, 1997, NUCLEIC ACIDS RES, V25, P4866, DOI 10.1093/nar/25.24.4866; Huang JM, 2001, BIOCHEMISTRY-US, V40, P8738, DOI 10.1021/bi010183h; KAMIYA H, 1992, CHEM PHARM BULL, V40, P2792, DOI 10.1248/cpb.40.2792; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; Katafuchi A, 2004, J BIOL CHEM, V279, P14464, DOI 10.1074/jbc.M400393200; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lucas LT, 1999, J BIOL CHEM, V274, P18319, DOI 10.1074/jbc.274.26.18319; Nakano T, 2003, J BIOL CHEM, V278, P25264, DOI 10.1074/jbc.M212847200; O'Brien PJ, 2004, J BIOL CHEM, V279, P9750, DOI 10.1074/jbc.M312232200; O'Brien PJ, 2003, BIOCHEMISTRY-US, V42, P12418, DOI 10.1021/bi035177v; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Saparbaev M, 2000, NUCLEIC ACIDS RES, V28, P1332, DOI 10.1093/nar/28.6.1332; Schouten KA, 1999, MUTAT RES-DNA REPAIR, V435, P245, DOI 10.1016/S0921-8777(99)00049-X; Shapiro R, 1981, CHROMOSOME DAMAGE RE, P3; Spencer JPE, 2000, FREE RADICAL BIO MED, V28, P1039, DOI 10.1016/S0891-5849(00)00190-8; Suzuki T, 1998, BIOCHEMISTRY-US, V37, P11592, DOI 10.1021/bi980971f; Suzuki T, 2000, NUCLEIC ACIDS RES, V28, P544, DOI 10.1093/nar/28.2.544; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P8013, DOI 10.1021/bi970166l; Suzuki T, 1996, J AM CHEM SOC, V118, P2515, DOI 10.1021/ja952550g; Terato H, 2002, NUCLEIC ACIDS RES, V30, P4975, DOI 10.1093/nar/gkf630; Vallur AC, 2002, J BIOL CHEM, V277, P31673, DOI 10.1074/jbc.M204475200; Vongchampa V, 2003, NUCLEIC ACIDS RES, V31, P1045, DOI 10.1093/nar/gkg177; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wuenschell GE, 2003, BIOCHEMISTRY-US, V42, P3608, DOI 10.1021/bi0205597; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Wyatt MD, 2000, CARCINOGENESIS, V21, P901, DOI 10.1093/carcin/21.5.901	45	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38177	38183		10.1074/jbc.M405882200	http://dx.doi.org/10.1074/jbc.M405882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247209	hybrid			2022-12-25	WOS:000223684100016
J	Huyer, G; Fansler, Z; Kreft, SG; Hochstrasser, M; Brodsky, JL; Michaelis, S				Huyer, G; Fansler, Z; Kreft, SG; Hochstrasser, M; Brodsky, JL; Michaelis, S			Distinct machinery is required in Saccharomyces cerevisiae for the endoplasmic reticulum-associated degradation of a multispanning membrane protein and a soluble luminal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; ER-ASSOCIATED DEGRADATION; QUALITY-CONTROL; MOLECULAR CHAPERONES; RETRO-TRANSLOCATION; UBIQUITIN LIGASE; MISFOLDED PROTEINS; ESCHERICHIA-COLI; PROTEASOME; TRANSPORT	The folding and assembly of proteins in the endoplasmic reticulum (ER) lumen and membrane are monitored by ER quality control. Misfolded or unassembled proteins are retained in the ER and, if they cannot fold or assemble correctly, ultimately undergo ER-associated degradation (ERAD) mediated by the ubiquitin-proteasome system. Whereas luminal and integral membrane ERAD substrates both require the proteasome for their degradation, the ER quality control machinery for these two classes of proteins likely differs because of their distinct topologies. Here we establish the requirements for the ERAD of Ste6p*, a multispanning membrane protein with a cytosolic mutation, and compare them with those for mutant form of carboxypeptidase Y (CPY*), a soluble luminal protein. We show that turnover of Ste6p* is dependent on the ubiquitin-protein isopeptide ligase Doa10p and is largely independent of the ubiquitin-protein isopeptide ligase Hrd1p/Der3p, whereas the opposite is true for CPY*. Furthermore, the cytosolic Hsp70 chaperone Ssa1p and the Hsp40 co-chaperones Ydj1p and Hlj1p are important in ERAD of Ste6p*, whereas the ER luminal chaperone Kar2p is dispensable, again opposite their roles in CPY* turnover. Finally, degradation of Ste6p*, unlike CPY*, does not appear to require the Sec61p translocon pore but, like CPY*, could depend on the Sec61p homologue Ssh1p. The ERAD pathways for Ste6p* and CPY* converge at a post-ubiquitination, pre-proteasome step, as both require the ATPase Cdc48p. Our results demonstrate that ERAD of Ste6p* employs distinct machinery from that of the soluble luminal substrate CPY* and that Ste6p* is a valuable model substrate to dissect the cellular machinery required for the ERAD of multispanning membrane proteins with a cytosolic mutation.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Johns Hopkins University; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Michaelis, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	michaelis@jhmi.edu		Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058029, R21DK060835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046904, R01GM046904, R01GM051508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58029, DK60835] Funding Source: Medline; NIGMS NIH HHS [GM51508, GM46904] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Becker J, 1996, MOL CELL BIOL, V16, P4378; Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; HITZEMAN RA, 1983, NUCLEIC ACIDS RES, V11, P2745, DOI 10.1093/nar/11.9.2745; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoppe T, 2001, CURR OPIN CELL BIOL, V13, P344, DOI 10.1016/S0955-0674(00)00218-0; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Huyer G, 2004, MOL BIOL CELL, V15, P908, DOI 10.1091/mbc.E03-07-0546; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Kaiser C., 1994, METHODS YEAST GENETI; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lee C, 2002, J BIOL CHEM, V277, P34760, DOI 10.1074/jbc.M204750200; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	76	203	204	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38369	38378		10.1074/jbc.M402468200	http://dx.doi.org/10.1074/jbc.M402468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252059	Green Submitted, hybrid			2022-12-25	WOS:000223684100038
J	Kampmann, M				Kampmann, M			Obstacle bypass in protein motion along DNA by two-dimensional rather than one-dimensional sliding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION; DIFFUSION; RNA	Site-specific DNA-binding proteins locate their target sites by facilitated diffusion. Several proteins have been shown to slide along DNA in vitro. However, whereas sliding is often envisaged as one-dimensional tracking of the DNA major groove, such a mechanism would not allow linear diffusion over long distances in vivo, where short stretches of free DNA are delimited by bound proteins. I propose a two-dimensional sliding mechanism, in which the protein diffuses freely on the cylindrical DNA surface, and I present experiments that can distinguish between one- and higher-dimensional diffusion along the DNA contour length. At 100 mM NaCl, translocation of EcoRI restriction endonuclease between sites on two DNA helices connected by a Holliday junction is as efficient as between sites on the same helix, indicating a three-dimensional mechanism. At 25 mM NaCl, translocation between sites on the same DNA helix is more efficient, indicating a role for sliding at low ionic strength. Obstacles attached to the major groove of one face of the DNA helix did not interfere with sliding, regardless of their orientation relative to the cleavage sites. This result is compatible with two-dimensional but not one- dimensional sliding. As illustrated by Monte-Carlo simulation, two-dimensional sliding may not only allow proteins to move around nucleosomes in vivo but also reduce the redundancy of their search for the target site.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Kampmann, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	martin.kampmann@rockefeller.edu		Kampmann, Martin/0000-0002-3819-7019				ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; COOK PR, 2001, PRIN CIPLES NUCL STR; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Eichman BF, 2000, P NATL ACAD SCI USA, V97, P3971, DOI 10.1073/pnas.97.8.3971; Guthold M, 1999, BIOPHYS J, V77, P2284, DOI 10.1016/S0006-3495(99)77067-0; Polya G., 1921, Math. Ann., V84, P149, DOI DOI 10.1007/BF01458701; Sambrook J, 2001, MOL CLONING LAB MANU; SCHURR JM, 1979, BIOPHYS CHEM, V9, P413, DOI 10.1016/0301-4622(75)80057-3; Shimamoto N, 1999, J BIOL CHEM, V274, P15293, DOI 10.1074/jbc.274.22.15293; Stanford NP, 2000, EMBO J, V19, P6546, DOI 10.1093/emboj/19.23.6546; Sun J, 2003, BIOPHYS J, V84, P3317, DOI 10.1016/S0006-3495(03)70056-3; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	16	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38715	38720		10.1074/jbc.M404504200	http://dx.doi.org/10.1074/jbc.M404504200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234977	hybrid			2022-12-25	WOS:000223684100081
J	Schick, N; Oakeley, EJ; Hynes, NE; Badache, A				Schick, N; Oakeley, EJ; Hynes, NE; Badache, A			TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ACTIVATION; GROWTH-INHIBITION; TYROSINE KINASE; CELL-GROWTH; TEL; GENE; PROTEIN; FUSION; DIFFERENTIATION; EXPRESSION	The signal transducer and activator of transcription 3 (Stat3) transcription factor is required for the antiproliferative effects induced by cytokines, such as the interleukin-6 type. In order to investigate the role of Stat3 in inhibition of cell proliferation, we have used an inducible Stat3 construct in A375 melanoma cells. We found that activation of Stat3 to moderate levels was sufficient to repress A375 proliferation, by slowing cell transit through the cell cycle. Enhanced and prolonged Stat3 activity led to cell cycle arrest and apoptosis. Genes whose expression was altered by Stat3 activation were identified by oligonucleotide microarray analysis. We found that TEL (ETV6), a novel Stat3 target identified in this study, is a negative regulator of Stat3 activity. Small interfering RNA-mediated inhibition of TEL expression resulted in increased Stat3-ependent transcriptional activity and stronger Stat3 antiproliferative activity. Confirming these results, overexpression of TEL repressed Stat3 transcriptional activity. Intriguingly, Stat3 repression did not require TEL DNA binding and appeared to proceed via recruitment of TEL to Stat3. Inhibition of Stat3 activity by TEL represents a novel mechanism regulating the Stat3 signaling pathway.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	hynes@fmi.ch	Badache, Ali/Q-6098-2017	Badache, Ali/0000-0001-7710-2505				Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Badache A, 2001, CANCER RES, V61, P383; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Guidez F, 2000, BLOOD, V96, P2557; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003; Kortylewski M, 2001, ADV EXP MED BIOL, V495, P169; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; LOPEZ RG, 2003, J BIOL CHEM; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sherman CT, 2001, MOL ENDOCRINOL, V15, P441, DOI 10.1210/me.15.3.441; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Sriuranpong V, 2003, CANCER RES, V63, P2948; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takeda K, 1998, J IMMUNOL, V161, P4652; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	58	24	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38787	38796		10.1074/jbc.M312581200	http://dx.doi.org/10.1074/jbc.M312581200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15229229	hybrid			2022-12-25	WOS:000223684100090
J	Cheng, JB; Russell, DW				Cheng, JB; Russell, DW			Mammalian wax biosynthesis - II. ERxpression cloning of wax synthase cDNAs encoding a member of the acyltransferase enzyme family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; MEIBOMIAN GLAND; SEBACEOUS GLANDS; LIPIDS; ESTER; MOUSE; GENE	Wax monoesters are synthesized by the esterification of fatty alcohols and fatty acids. A mammalian enzyme that catalyzes this reaction has not been isolated. We used expression cloning to identify cDNAs encoding a wax synthase in the mouse preputial gland. The wax synthase gene is located on the X chromosome and encodes a member of the acyltransferase family of enzymes that synthesize neutral lipids. Expression of wax synthase in cultured cells led to the formation of wax monoesters from straight chain saturated, unsaturated, and polyunsaturated fatty alcohols and acids. Polyisoprenols also were incorporated into wax monoesters by the enzyme. The wax synthase had little or no ability to synthesize cholesteryl esters, diacylglycerols, or triacylglycerols, whereas other acyltransferases, including the acyl-CoA: monoacylglycerol acyltransferase 1 and 2 enzymes and the acyl-CoA: diacylglycerol acyltransferase 1 and 2 enzymes, exhibited modest wax monoester synthesis activities. Confocal light microscopy indicated that the wax synthase was localized in membranes of the endoplasmic reticulum. Wax synthase mRNA was abundant in tissues rich in sebaceous glands such as the preputial gland and eyelid and was present at lower levels in other tissues. Coexpression of cDNAs specifying fatty acyl-CoA reductase 1 and wax synthase led to the synthesis of wax monoesters. The data suggest that wax monoester synthesis in mammals involves a two step biosynthetic pathway catalyzed by fatty acyl-CoA reductase and wax synthase enzymes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.russell@utsouthwestern.edu		Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL20948, P01 HL020948-32, P01 HL020948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown CJ, 2003, TRENDS GENET, V19, P432, DOI 10.1016/S0168-9525(03)00177-X; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; Cheng JB, 2004, J BIOL CHEM, V279, P37789, DOI 10.1074/jbc.M406225200; Driver PJ, 1996, SURV OPHTHALMOL, V40, P343, DOI 10.1016/S0039-6257(96)80064-6; Jenks Matthew A, 2002, Arabidopsis Book, V1, pe0016, DOI 10.1199/tab.0016; Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1074/jbc.M210533200; Kolattukudy P.E., 1976, CHEM BIOCH NATURAL W; Kunst L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; Lardizabal KD, 2000, PLANT PHYSIOL, V122, P645, DOI 10.1104/pp.122.3.645; McCulley JP, 2002, ADV EXP MED BIOL, V506, P373; Miyazaki M, 2002, J LIPID RES, V43, P2146, DOI 10.1194/jlr.M200271-JLR200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; NICOLAIDES N, 1965, J AM OIL CHEM SOC, V42, P691, DOI 10.1007/BF02540042; NICOLAIDES N, 1981, INVEST OPHTH VIS SCI, V20, P522; NIKKARI T, 1974, J INVEST DERMATOL, V62, P257, DOI 10.1111/1523-1747.ep12676800; SANSONE G, 1969, LIPIDS, V4, P435, DOI 10.1007/BF02531019; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SYNDER F, 1969, ARCH BIOCHEM BIOPHYS, V130, P101, DOI 10.1016/0003-9861(69)90015-0; THODY AJ, 1989, PHYSIOL REV, V69, P383, DOI 10.1152/physrev.1989.69.2.383	21	99	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37798	37807		10.1074/jbc.M406226200	http://dx.doi.org/10.1074/jbc.M406226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220349	Green Accepted, hybrid			2022-12-25	WOS:000223554600072
J	Galindo, CL; Fadl, AA; Sha, JA; Gutierrez, C; Popov, VL; Boldogh, I; Aggarwal, BB; Chopra, AK				Galindo, CL; Fadl, AA; Sha, JA; Gutierrez, C; Popov, VL; Boldogh, I; Aggarwal, BB; Chopra, AK			Aeromonas hydrophila cytotoxic enterotoxin activates mitogen-activated protein kinases and induces apoptosis in murine macrophages and human intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERMENTANS MEMBRANE LIPOPROTEINS; ALPHA GENE-EXPRESSION; CYTOCHROME-C RELEASE; RIBOSOMAL S6 KINASE; FACTOR TNF RECEPTOR; N-TERMINAL KINASE; FACTOR-KAPPA-B; MAP KINASE; MITOCHONDRIAL DEPOLARIZATION; POLY(ADP-RIBOSE) POLYMERASE	A cytotoxic enterotoxin ( Act) of Aeromonas hydrophila possesses several biological activities, induces an inflammatory response in the host, and causes apoptosis of murine macrophages. In this study, we utilized five target cell types ( a murine macrophage cell line ( RAW 264.7), bone marrow-derived transformed macrophages, murine peritoneal macrophages, and two human intestinal epithelial cell lines (T84 and HT-29)) to investigate the effect of Act on mitogen-activated protein kinase ( MAPK) pathways and mechanisms leading to apoptosis. As demonstrated by immunoprecipitation/kinase assays or Western blot analysis, Act activated stress-associated p38, c-Jun NH2-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells. Act also induced phosphorylation of upstream MAPK factors ( MAPK kinase 3/6 (MKK3/6), MKK4, and MAP/ERK kinase 1 (MEK1)) and downstream effectors (MAPK-activated protein kinase-2, activating transcription factor-2, and c-Jun). Act evoked cell membrane blebbing, caspase 3-cleavage, and activation of caspases 8 and 9 in these cells. In macrophages that do not express functional tumor necrosis factor receptors, apoptosis and caspase activities were significantly decreased. Immunoblotting of host whole cell lysates revealed Act-induced up-regulation of apoptosis-related proteins, including the mitochondrial proteins cytochrome c and apoptosis-inducing factor. However, mitochondrial membrane depolarization was not detected in response to Act. Taken together, the data demonstrated for the first time Act-induced activation of MAPK signaling and classical caspase-associated apoptosis in macrophages and intestinal epithelial cells. Given the importance of MAPK pathways and apoptosis in inflammation-associated diseases, this study provided new insights into the mechanism of action of Act on host cells.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center	Chopra, AK (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	achopra@utmb.edu	Aggarwal, Bharat B/G-3388-2013		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041611] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41611] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerlund K, 1999, CLIN EXP IMMUNOL, V115, P32; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alavandi SV, 1999, INDIAN J MED RES, V110, P50; Albert MJ, 2000, J CLIN MICROBIOL, V38, P3785, DOI 10.1128/JCM.38.10.3785-3790.2000; ALTWEGG M, 1991, EUR J CLIN MICROBIOL, V10, P44, DOI 10.1007/BF01967100; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; BERRYMAN MA, 1990, J HISTOCHEM CYTOCHEM, V38, P159, DOI 10.1177/38.2.1688894; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; BIANCHI M, 1995, MOL MED, V1, P254, DOI 10.1007/BF03401550; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brandi G, 1999, LETT APPL MICROBIOL, V29, P211, DOI 10.1046/j.1365-2672.1999.00584.x; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chopra AK, 1999, MICROBES INFECT, V1, P1129, DOI 10.1016/S1286-4579(99)00202-6; Chopra AK, 2000, INFECT IMMUN, V68, P2808, DOI 10.1128/IAI.68.5.2808-2818.2000; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; Denham W, 2000, CRIT CARE MED, V28, P2567, DOI 10.1097/00003246-200007000-00064; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Ferguson MR, 1997, INFECT IMMUN, V65, P4299, DOI 10.1128/IAI.65.10.4299-4308.1997; Fleischer F, 2001, WORLD J GASTROENTERO, V7, P259; Galindo CL, 2003, J BIOL CHEM, V278, P40198, DOI 10.1074/jbc.M305788200; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HANNINEN ML, 1995, J MED MICROBIOL, V42, P26, DOI 10.1099/00222615-42-1-26; Hanninen ML, 1997, INT J FOOD MICROBIOL, V34, P17, DOI 10.1016/S0168-1605(96)01163-4; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Hommes DW, 2003, GUT, V52, P144, DOI 10.1136/gut.52.1.144; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Janda JM, 1998, CLIN INFECT DIS, V27, P332, DOI 10.1086/514652; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KALRA N, 2004, J BIOL CHEM; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KIROV SM, 1993, INT J FOOD MICROBIOL, V20, P159, DOI 10.1016/0168-1605(93)90108-S; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MAJEED KN, 1990, J APPL BACTERIOL, V69, P332, DOI 10.1111/j.1365-2672.1990.tb01524.x; Marie C, 1999, INFECT IMMUN, V67, P688, DOI 10.1128/IAI.67.2.688-693.1999; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; PALUMBO SA, 1989, J CLIN MICROBIOL, V27, P854, DOI 10.1128/JCM.27.5.854-859.1989; Pearl-Yafe M, 2004, BIOCHEM PHARMACOL, V67, P539, DOI 10.1016/j.bcp.2003.09.024; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rawadi G, 1998, J IMMUNOL, V160, P1330; Ribardo DA, 2002, MICROB PATHOGENESIS, V32, P149, DOI 10.1006/mpat.2001.0490; ROSE JM, 1989, INFECT IMMUN, V57, P1170, DOI 10.1128/IAI.57.4.1170-1176.1989; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Scherf U, 1996, P NATL ACAD SCI USA, V93, P2670, DOI 10.1073/pnas.93.7.2670; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Slomiany BL, 2001, IUBMB LIFE, V51, P315, DOI 10.1080/152165401317190833; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; ten Hove T, 2002, GUT, V50, P507, DOI 10.1136/gut.50.4.507; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANOSTADE X, 1993, NATURE, V361, P266; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Yamada S, 1997, EPIDEMIOL INFECT, V119, P121, DOI 10.1017/S0950268897007942; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	83	85	88	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37597	37612		10.1074/jbc.M404641200	http://dx.doi.org/10.1074/jbc.M404641200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15215244	hybrid			2022-12-25	WOS:000223554600051
J	Liu, YL; Dong, W; Chen, L; Xiang, R; Xiao, HZ; De, GJ; Wang, ZM; Qi, YP				Liu, YL; Dong, W; Chen, L; Xiang, R; Xiao, HZ; De, GJ; Wang, ZM; Qi, YP			BCL10 mediates lipopolysaccharide/Toll-like receptor-4 signaling through interaction with Pellino2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MARGINAL-ZONE; MALT LYMPHOMA; PROTEIN; ACTIVATION; DOMAIN; FAMILY; INTERLEUKIN-1; SUPPRESSORS; INVOLVEMENT	Toll-like receptor (TLR) pathways signal through microbial components stimulation to induce innate immune responses. Herein, we demonstrate that BCL10, a critical molecule that signals between the T cell receptor and IkappaB kinase complexes, is involved in the innate immune system and is required for appropriate TLR4 pathway and nuclear factor-kappaB (NF-kappaB) activation. In response to lipopolysaccharide (LPS) stimulation, BCL10 was recruited to TLR4 signaling complexes and associated with Pellino2, an essential component downstream of BCL10 in the TLR4 pathway. In a BCL10-deficient macrophage cell line, LPS-induced NF-kappaB activation was consistently defective, whereas activator protein-1 and Elk-1 signaling was intact. In addition, we found that BCL10 was targeted by SOCS3 for negative regulation in LPS signaling. The recruitment of BCL10 to TLR4 signaling complexes was attenuated by induced expression of SOCS3 in a feedback loop. Furthermore, ectopic SOCS3 expression blocked the interaction between BCL10 and Pellino2 together with BCL10-generated NF-kappaB activation and inducible nitric-oxide synthase expression. Together, these data define an important role of BCL10 in the innate immune system.	Wuhan Univ, Coll Life Sci, Dept Biotechnol, Key Lab Minist Educ, Wuhan 430072, Peoples R China	Wuhan University	Qi, YP (corresponding author), Wuhan Univ, Coll Life Sci, Dept Biotechnol, Key Lab Minist Educ, Wuhan 430072, Peoples R China.	mvlwu@whu.edu.cn	Dong, Wei/D-2399-2015					Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Cavalli F, 2001, Hematology Am Soc Hematol Educ Program, P241; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; ICHIKO K, 2002, IMMUNITY, V17, P583; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LOSMAN JA, 1997, NATURE, V387, P917; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Mak TW, 2002, NATURE, V418, P835, DOI 10.1038/418835a; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Stoiber D, 1999, J IMMUNOL, V163, P2640; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wotherspoon AC, 2002, CURR OPIN HEMATOL, V9, P50, DOI 10.1097/00062752-200201000-00009; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	33	41	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37436	37444		10.1074/jbc.M400241200	http://dx.doi.org/10.1074/jbc.M400241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15213237	hybrid			2022-12-25	WOS:000223554600031
J	Kaniuk, NA; Vinogradov, E; Whitfield, C				Kaniuk, NA; Vinogradov, E; Whitfield, C			Investigation of the structural requirements in the lipopolysaccharide core acceptor for ligation of O antigens in the genus Salmonella - WaaL "ligase" is not the sole determinant of acceptor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; OUTER-MEMBRANE; POLYACRYLAMIDE GELS; CHAIN-LENGTH; SHIGELLA-FLEXNERI; TYPHIMURIUM LT2; ASSEMBLY SYSTEM; ENTERICA; REGION; PROTEINS	The ligation of O antigen polysaccharide to lipid A-core oligosaccharide is a late step in the formation of the complex glycolipid known as lipopolysaccharide. Although the process has been localized to the periplasmic face of the inner membrane, details of the ligation mechanism have not been resolved. To date, there is only one gene product (WaaL, often referred to as "ligase") known to be required. There exists a requirement for a specific lipid A-core oligosaccharide acceptor structure for ligation activity, and it has been proposed that the WaaL protein imparts this acceptor specificity. Here the structural requirements in the core oligosaccharide acceptor for O antigen ligation are investigated in prototype serovars of Salmonella enterica. Complementation experiments in mutants with defined core oligosaccharide structure indicate that the specificity of the ligation reaction for a particular core oligosaccharide structure is not dependent on the WaaL protein alone. The data provide the first indication of a more complicated recognition process involving additional cellular components.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				Amer AO, 2000, J BACTERIOL, V182, P498, DOI 10.1128/JB.182.2.498-503.2000; BASTIN DA, 1993, MOL MICROBIOL, V7, P725, DOI 10.1111/j.1365-2958.1993.tb01163.x; BATCHELOR RA, 1991, J BACTERIOL, V173, P5699, DOI 10.1128/jb.173.18.5699-5704.1991; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Boyd EF, 1996, APPL ENVIRON MICROB, V62, P804, DOI 10.1128/AEM.62.3.804-808.1996; Brenner FW, 2000, J CLIN MICROBIOL, V38, P2465, DOI 10.1128/JCM.38.7.2465-2467.2000; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Geremia RA, 1996, BIOCHEM J, V318, P133, DOI 10.1042/bj3180133; Geue L, 2002, VET MICROBIOL, V84, P79, DOI 10.1016/S0378-1135(01)00437-0; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; Joiner K A, 1985, Curr Top Microbiol Immunol, V121, P99; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; KAST P, 1994, GENE, V138, P109, DOI 10.1016/0378-1119(94)90790-0; Kingsley RA, 2000, MOL MICROBIOL, V36, P1006, DOI 10.1046/j.1365-2958.2000.01907.x; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Kostova Z, 2003, EUR J BIOCHEM, V270, P4507, DOI 10.1046/j.1432-1033.2003.03844.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; Olsthoorn MA, 2000, EUR J BIOCHEM, V267, P2014, DOI 10.1046/j.1432-1327.2000.01205.x; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; OSBORN MJ, 1980, J BIOL CHEM, V255, P4246; Popoff MY, 2003, RES MICROBIOL, V154, P173, DOI 10.1016/S0923-2508(03)00025-1; Rabsch W, 2002, INFECT IMMUN, V70, P2249, DOI 10.1128/IAI.70.5.2249-2255.2002; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahn A, 2003, MOL MICROBIOL, V47, P1045, DOI 10.1046/j.1365-2958.2003.03354.x; REEVES P, 1993, TRENDS GENET, V9, P17, DOI 10.1016/0168-9525(93)90067-R; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; SEOL WG, 1993, J BACTERIOL, V175, P565, DOI 10.1128/JB.175.2.565-567.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TSANG RSW, 1987, INFECT IMMUN, V55, P211, DOI 10.1128/IAI.55.1.211-216.1987; TSANG RSW, 1991, RES MICROBIOL, V142, P521, DOI 10.1016/0923-2508(91)90185-D; TSANG RSW, 1992, ZBL BAKT-INT J MED M, V276, P330, DOI 10.1016/S0934-8840(11)80539-6; Vinogradov E, 2002, CARBOHYD RES, V337, P1285, DOI 10.1016/S0008-6215(02)00160-X; VINOGRADOV EV, 1994, CARBOHYD RES, V253, P101, DOI 10.1016/0008-6215(94)80058-8; WANG L, 1994, J BACTERIOL, V176, P4348, DOI 10.1128/jb.176.14.4348-4356.1994; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	55	30	36	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36470	36480		10.1074/jbc.M401366200	http://dx.doi.org/10.1074/jbc.M401366200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215252	hybrid			2022-12-25	WOS:000223453600040
J	Jia, HY; Bagherzadeh, A; Bicknell, R; Duchen, MR; Liu, D; Zachary, I				Jia, HY; Bagherzadeh, A; Bicknell, R; Duchen, MR; Liu, D; Zachary, I			Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; PROSTACYCLIN PRODUCTION; TYROSINE KINASES; TUMOR-CELLS; IN-VIVO; ACTIVATION; RECEPTOR; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF)-D binds to VEGF receptors (VEGFR) VEGFR2/KDR and VEGFR3/Flt4, but the signaling mechanisms mediating its biological activities in endothelial cells are poorly understood. Here we investigated the mechanism of action of VEGF-D, and we compared the signaling pathways and biological responses induced by VEGF-D and VEGF-A in endothelial cells. VEGF-D induced KDR and phospholipase C-gamma tyrosine phosphorylation more slowly and less effectively than VEGF-A at early times but had a more sustained effect and was as effective as VEGF-A after 60 min. VEGF-D activated extracellular signal-regulated protein kinases 1 and 2 with similar efficacy but slower kinetics compared with VEGF-A, and this effect was blocked by inhibitors of protein kinase C and mitogen-activated protein kinase kinase. In contrast to VEGF-A, VEGF-D weakly stimulated prostacyclin production and gene expression, had little effect on cell proliferation, and stimulated a smaller and more transient increase in intracellular [Ca(2+)]. VEGF-D induced strong but more transient phosphatidylinositol 3-kinase (PI3K)-mediated Akt activation and increased PI3K-dependent endothelial nitric-oxide synthase phosphorylation and cell survival more weakly. VEGF-D stimulated chemotaxis via a PI3K/Akt- and endothelial nitric-oxide synthase-dependent pathway, enhanced protein kinase C- and PI3K-dependent endothelial tubulogenesis, and stimulated angiogenesis in a mouse sponge implant model less effectively than VEGF-A. VEGF-D-induced signaling and biological effects were blocked by the KDR inhibitor SU5614. The finding that differential KDR activation by VEGF-A and VEGF-D has distinct consequences for endothelial signaling and function has important implications for understanding how multiple ligands for the same VEGF receptors can generate ligand-specific biological responses.	UCL, Rayne Inst, Dept Med, London WC1E 6JJ, England; Univ Oxford, Inst Mol Med, Canc Res UK, Oxford, England; UCL, Dept Physiol, London WC1E 6BT, England	University of London; King's College London; University College London; Cancer Research UK; University of Oxford; University of London; University College London	Zachary, I (corresponding author), UCL, Rayne Inst, Dept Med, 5 Univ St, London WC1E 6JJ, England.	i.zachary@ucl.ac.uk	duchen, michael/A-2116-2009	duchen, michael/0000-0003-2548-4294; Bicknell, Roy/0000-0002-0941-8919				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P164, DOI 10.1006/bbrc.2001.4761; Joukov V, 1996, EMBO J, V15, P290; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rutanen J, 2004, CIRCULATION, V109, P1029, DOI 10.1161/01.CIR.0000115519.03688.A2; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yang WT, 2002, CANCER, V94, P2855, DOI 10.1002/cncr.10553; Yokoyama Y, 2003, BRIT J CANCER, V88, P237, DOI 10.1038/sj.bjc.6600701; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	36	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36148	36157		10.1074/jbc.M401538200	http://dx.doi.org/10.1074/jbc.M401538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15215251	hybrid			2022-12-25	WOS:000223303400117
J	Kim, EC; Edmonston, CR; Wu, XP; Schaffer, AS; Casali, P				Kim, EC; Edmonston, CR; Wu, XP; Schaffer, AS; Casali, P			The HoxC4 homeodomain protein mediates activation of the immunoglobulin heavy chain 3 ' hs1,2 enhancer in human B cells - Relevance to class switch DNA recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRTUALLY IDENTICAL ENHANCERS; HUMAN-ANTIBODY RESPONSE; IGH REGULATORY REGION; NF-KAPPA-B; SOMATIC HYPERMUTATION; TRANSCRIPTIONAL REGULATION; TARGETED DISRUPTION; CLONAL ANALYSIS; GERMINAL CENTER; RABIES VIRUS	The immunoglobulin heavy chain (IgH) 3' regulatory region modulates IgH locus transcription, upon induction by specific trans-acting factors, and plays a significant role in class switch DNA recombination (CSR) and, perhaps, somatic hypermutation (SHM). CSR and SHM are central to the maturation of the antibody response. In contrast to the single 5'-hs3a-hs1,2-hs3b-hs4-3' mouse IgH 3' regulatory region, the human IgH 3' regulatory region exists as a 5'-hs3-hs1,2-hs4-3' cluster duplicated 3' of Calpha1 and Calpha2. We show here that the human hs1,2 element is the strongest enhancer of transcription, as directed by a V(H)1 or the ECS-Igamma3 promoter, thereby suggesting a dominant role for hs1,2 over hs3 and hs4 in the overall activity of the 3' regulatory region. Within hs1,2, we identified three regions (1, 2, and 3) that are all necessary, but individually not sufficient, for enhancement of transcription. In region 2, a HoxC4 site and a HoxC4/embedded octamer (HoxC4/Oct) site are conserved across human, mouse, rat, and rabbit. These two sites recruit HoxC4 and Oct-1/Oct-2, which act synergistically with the Oca-B coactivator to effect the full hs1,2-enhancing activity. HoxC4, Oct-1/Oct-2, and Oca-B recruitment is negligible in pro-B cells, moderate in pre-B cells, and maximal in germinal center B cells and plasma cells, where HoxC4, Oct-2, and Oca-B expression correlates with hs1,2 activation and ongoing CSR. The hs1,2-mediated enhancement of V-H and C-H promoter-driven transcription as induced by HoxC4 and Oct-1/Oct-2 suggests an important role of these homeodomain proteins in the overall regulation of the IgH locus expression.	Univ Calif Irvine, Ctr Immunol, Coll Med, Sch Biol Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine	Casali, P (corresponding author), Univ Calif Irvine, Ctr Immunol, Coll Med, Sch Biol Sci, 3028 Hewitt Hall, Irvine, CA 92697 USA.	pcasali@uci.edu	Casali, Paolo/F-6579-2010		NIAID NIH HHS [R01 AI045011, AI 45011, R56 AI045011] Funding Source: Medline; NIAMS NIH HHS [AR 40908, R01 AR040908] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045011, R01AI045011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040908] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Birshtein BK, 1997, CURR TOP MICROBIOL, V224, P73; Boulet AM, 1996, DEV BIOL, V177, P232, DOI 10.1006/dbio.1996.0159; Cerutti A, 1998, J IMMUNOL, V160, P2145; Chauveau C, 1999, J IMMUNOL, V163, P4637; Chen CQ, 1997, J IMMUNOL, V159, P1310; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; Denizot Y, 2001, IMMUNOLOGY, V103, P35, DOI 10.1046/j.1365-2567.2001.01217.x; Drexler HG, 2001, BLOOD, V98, P3495, DOI 10.1182/blood.V98.12.3495; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Hombria JCG, 2003, DIFFERENTIATION, V71, P461, DOI 10.1046/j.1432-0436.2003.7108004.x; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Hu YZ, 2000, J IMMUNOL, V164, P6380, DOI 10.4049/jimmunol.164.12.6380; Humbert PO, 1997, J IMMUNOL, V159, P5273; HURWITZ R, 1979, INT J CANCER, V23, P174, DOI 10.1002/ijc.2910230206; IKEMATSU H, 1993, J IMMUNOL, V150, P1325; Johnson K, 2003, CURR OPIN GENET DEV, V13, P522, DOI 10.1016/j.gde.2003.08.004; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Le Morvan C, 2003, BLOOD, V102, P1421, DOI 10.1182/blood-2002-12-3827; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Manis JP, 1998, J EXP MED, V188, P1421, DOI 10.1084/jem.188.8.1421; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; MAX EE, 1999, FUNDAMENTAL IMMUNOLO, P148; MEAZZA R, 1995, BLOOD, V85, P2084, DOI 10.1182/blood.V85.8.2084.bloodjournal8582084; Mills FC, 1997, J EXP MED, V186, P845, DOI 10.1084/jem.186.6.845; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; Ong J, 1998, J IMMUNOL, V160, P4896; Pan Q, 2000, EUR J IMMUNOL, V30, P1019, DOI 10.1002/(SICI)1521-4141(200004)30:4<1019::AID-IMMU1019>3.0.CO;2-W; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Pinaud E, 2001, IMMUNITY, V15, P187, DOI 10.1016/S1074-7613(01)00181-9; PUSTELL JM, 1988, NUCLEIC ACIDS RES, V16, P1813, DOI 10.1093/nar/16.5.1813; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Saegusa H, 1996, DEV BIOL, V174, P55, DOI 10.1006/dbio.1996.0051; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Saleque S, 1997, J IMMUNOL, V158, P4780; Schaffer A, 1999, J IMMUNOL, V162, P5327; Schaffer A, 2003, J BIOL CHEM, V278, P23141, DOI 10.1074/jbc.M212952200; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Seidl KJ, 1999, P NATL ACAD SCI USA, V96, P3000, DOI 10.1073/pnas.96.6.3000; Sepulveda MA, 2004, J IMMUNOL, V172, P1054, DOI 10.4049/jimmunol.172.2.1054; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Tang H, 1999, IMMUNITY, V11, P517, DOI 10.1016/S1074-7613(00)80127-2; Teitell MA, 2003, TRENDS IMMUNOL, V24, P546, DOI 10.1016/j.it.2003.08.002; Terauchi A, 2001, J IMMUNOL, V167, P811, DOI 10.4049/jimmunol.167.2.811; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TumasBrundage KM, 1997, MOL IMMUNOL, V34, P367, DOI 10.1016/S0161-5890(97)00065-5; UEKI Y, 1990, J EXP MED, V171, P19, DOI 10.1084/jem.171.1.19; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Wu XP, 2003, J CLIN IMMUNOL, V23, P235, DOI 10.1023/A:1024571714867; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zan H, 1998, J IMMUNOL, V161, P5217; Zan H, 2003, IMMUNITY, V18, P727, DOI 10.1016/S1074-7613(03)00151-1	64	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42258	42269		10.1074/jbc.M407496200	http://dx.doi.org/10.1074/jbc.M407496200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15252056	Green Accepted, hybrid			2022-12-25	WOS:000224075500118
J	Yu, LG; Packman, LC; Weldon, M; Hamlett, J; Rhodes, JM				Yu, LG; Packman, LC; Weldon, M; Hamlett, J; Rhodes, JM			Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGARICUS-BISPORUS LECTIN; NUCLEAR-PROTEIN; CELL-PROLIFERATION; BINDING LECTINS; PEANUT LECTIN; 2A; CANCER; IDENTIFICATION; EXPRESSION; KINASES	Protein phosphatase 2A (PP2A) is a family of mammalian serine/threonine phosphatases that is involved in the control of many cellular functions including those mediated by extracellular signal-regulated kinase (ERK) signaling. While investigating the reversible antiproliferative effect of the dietary lectin, jacalin, which binds the Thomsen-Friedenreich antigen (galactose beta1-3N-acetylgalactosamine alpha-), we have found that this lectin (30 mug/ml) induces rapid, transient, tyrosine phosphorylation of putative human HLA-DR-associated protein I (PHAPI, also known as the tumor suppressor pp32) in HT29 human colon cancer cells. This is accompanied by the release of PP2A from association with PHAPI, allowing increased phosphatase activity of PP2A (by 42+/-10% at 10 min) and consequent complete dephosphorylation of the ERK kinase, MEK1/2, by 10 min and of ERK1/2 by 60 min. PHAPI knockdown by RNA interference abolished the effects of jacalin on PP2A activation and MEK inhibition. Thus phosphorylation of PHAPI/pp32 is a critical regulatory step in PP2A activation and ERK signaling.	Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Dept Human Anat & Cell Biol, Liverpool L69 3GA, Merseyside, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Liverpool; University of Liverpool; University of Cambridge	Yu, LG (corresponding author), Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England.	lgyu@liv.ac.uk	Rhodes, Jonathan M/C-2496-2009					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Campbell BJ, 2001, GLYCOCONJUGATE J, V18, P851, DOI 10.1023/A:1022240107040; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; Nangia-Makker P, 2002, TRENDS MOL MED, V8, P187, DOI 10.1016/S1471-4914(02)02295-5; Ryder SD, 1998, GASTROENTEROLOGY, V114, P44, DOI 10.1016/S0016-5085(98)70631-6; RYDER SD, 1992, JNCI-J NATL CANCER I, V84, P1410, DOI 10.1093/jnci/84.18.1410; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Ulitzur N, 1997, J BIOL CHEM, V272, P30577, DOI 10.1074/jbc.272.48.30577; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; YU LG, 1993, CANCER RES, V53, P4627; Yu LG, 2002, J BIOL CHEM, V277, P24538, DOI 10.1074/jbc.M203550200; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890; Yu LG, 2001, J CELL PHYSIOL, V186, P282, DOI 10.1002/1097-4652(200102)186:2&lt;282::AID-JCP1028&gt;3.0.CO;2-2	32	55	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41377	41383		10.1074/jbc.M400017200	http://dx.doi.org/10.1074/jbc.M400017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247276	hybrid			2022-12-25	WOS:000224075500018
J	Filipeanu, CM; Zhou, FG; Claycomb, WC; Wu, GY				Filipeanu, CM; Zhou, FG; Claycomb, WC; Wu, GY			Regulation of the cell surface expression and function of angiotensin II type 1 receptor by Rab1-mediated endoplasmic reticulum-to-Golgi transport in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AT(1) RECEPTOR; PLASMA-MEMBRANE; RAB PROTEINS; TRAFFICKING; HYPERTROPHY; INTERNALIZATION; GROWTH; OVEREXPRESSION; CARDIOMYOCYTES	Rab1 GTPase coordinates vesicle-mediated protein transport specifically from the endoplasmic reticulum ( ER) to the Golgi apparatus. We recently demonstrated that Rab1 is involved in the export of angiotensin II (Ang II) type 1 receptor (AT1R) to the cell surface in HEK293 cells and that transgenic mice overexpressing Rab1 in the myocardium develop cardiac hypertrophy. To expand these studies, we determined in this report whether the modification of Rab1-mediated ER-to-Golgi transport can alter the cell surface expression and function of endogenous AT1R and AT1R-mediated hypertrophic growth in primary cultures of neonatal rat ventricular myocytes. Adenovirus-mediated gene transfer of wild-type Rab1 (Rab1WT) significantly increased cell surface expression of endogenous AT1R in neonatal cardiomyocytes, whereas the dominant-negative mutant Rab1N124I had the opposite effect. Brefeldin A treatment blocked the Rab1WT-induced increase in AT1R cell surface expression. Fluorescence analysis of the subcellular localization of AT1R revealed that Rab1 regulated AT1R transport specifically from the ER to the Golgi in HL-1 cardiomyocytes. Consistent with their effects on AT1R export, Rab1WT and Rab1N124I differentially modified the AT1R-mediated activation of ERK1/2 and its upstream kinase MEK1. More importantly, adenovirus-mediated expression of Rab1N124I markedly attenuated the Ang II-stimulated hypertrophic growth as measured by protein synthesis, cell size, and sarcomeric organization in neonatal cardiomyocytes. In contrast, Rab1WT expression augmented the Ang II-mediated hypertrophic response. These data strongly indicate that AT1R function in cardiomyocytes can be modulated through manipulating AT1R traffic from the ER to the Golgi and provide the first evidence implicating the ER-to-Golgi transport as a regulatory site for control of cardiomyocyte growth.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu		Filipeanu, Catalin/0000-0002-7298-9327	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR018766] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14920; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; De Rosa ML, 2002, J HUM HYPERTENS, V16, P133, DOI 10.1038/sj.jhh.1001305; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Filipeanu CM, 2001, J RENIN-ANGIO-ALDO S, V2, P219, DOI 10.3317/jraas.2001.035; Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Hunyady L, 2000, REGUL PEPTIDES, V91, P29, DOI 10.1016/S0167-0115(00)00137-3; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lanctot PM, 1999, BIOCHEMISTRY-US, V38, P8621, DOI 10.1021/bi9830516; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Touyz RM, 2000, PHARMACOL REV, V52, P639; Vanderheyden PML, 1999, BRIT J PHARMACOL, V126, P1057, DOI 10.1038/sj.bjp.0702398; vanKesteren CAM, 1997, J MOL CELL CARDIOL, V29, P2147, DOI 10.1006/jmcc.1997.0448; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Wada H, 1996, AM J PHYSIOL-HEART C, V271, pH29, DOI 10.1152/ajpheart.1996.271.1.H29; White SM, 2004, AM J PHYSIOL-HEART C, V286, pH823, DOI 10.1152/ajpheart.00986.2003; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	51	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41077	41084		10.1074/jbc.M405988200	http://dx.doi.org/10.1074/jbc.M405988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15252015	hybrid			2022-12-25	WOS:000223916800106
J	Kunnimalaiyaan, S; Kruger, R; Ross, W; Rakowski, SA; Filutowicz, M				Kunnimalaiyaan, S; Kruger, R; Ross, W; Rakowski, SA; Filutowicz, M			Binding modes of the initiator and inhibitor forms of the replication protein pi to the gamma ori iteron of plasmid R6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; REPEATS; SEQUENCES; SITES; REPA; DIMERIZATION; ASSEMBLIES; REGION; P1	Discerning the interactions between initiator protein and the origin of replication should provide insights into the mechanism of DNA replication initiation. In the gamma origin of plasmid R6K, the Rep protein, pi, is distinctive in that it can bind the seven 22-bp iterons in two forms; pi monomers activate replication, whereas pi dimers act as inhibitors. In this work, we used wild type and variants of the pi protein with altered monomer/dimer ratios to study iteron/pi interactions. High resolution contact mapping was conducted using multiple techniques ( missing base contact probing, methylation protection, base modification, and hydroxyl radical footprinting), and the electrophoretic separation of nucleoprotein complexes allowed us to discriminate between contact patterns produced by pi monomers and dimers. We also isolated iteron mutants that affected the binding of pi monomers ( only) or both monomers and dimers. The mutational studies and footprinting analyses revealed that, when binding DNA, pi monomers interact with nucleotides spanning the entire length of the iteron. In contrast, pi dimers interact with only the left half of the iteron; however, the retained interactions are strikingly similar to those seen with monomers. These results support a model in which Rep protein dimerization disturbs one of two DNA binding domains important for monomer/ iteron interaction; the dimer/iteron interaction utilizes only one DNA binding domain.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Filutowicz, M (corresponding author), Univ Wisconsin, Dept Bacteriol, 420 Henry Mall, Madison, WI 53706 USA.	msfiluto@facstaff.wisc.edu	Kruger, Ricardo/Y-9595-2019	Kruger, Ricardo/0000-0002-8443-9402	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040314, R01GM037048, R37GM037048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40314, GM37048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abhyankar MM, 2004, J BIOL CHEM, V279, P6711, DOI 10.1074/jbc.M312052200; Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; Chattoraj DK, 1997, PROG NUCLEIC ACID RE, V57, P145, DOI 10.1016/S0079-6603(08)60280-9; Enoru-Eta J, 2002, MOL MICROBIOL, V45, P1541, DOI 10.1046/j.1365-2958.2002.03136.x; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; Filutowicz M, 1998, GENE, V223, P195, DOI 10.1016/S0378-1119(98)00367-9; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; FILUTOWICZ M, 1994, NUCLEIC ACIDS RES, V22, P4211, DOI 10.1093/nar/22.20.4211; Forest KT, 2003, NAT STRUCT BIOL, V10, P496, DOI 10.1038/nsb0703-496; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; Giraldo R, 2003, NAT STRUCT BIOL, V10, P565, DOI 10.1038/nsb937; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; KOLTER R, 1982, J MOL BIOL, V161, P45, DOI 10.1016/0022-2836(82)90277-7; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; Kruger R, 2004, PLASMID BIOLOGY, P25; Kruger R, 2004, BIOCHEM BIOPH RES CO, V313, P834, DOI 10.1016/j.bbrc.2003.12.022; Kruger R, 2000, J BACTERIOL, V182, P2461, DOI 10.1128/JB.182.9.2461-2467.2000; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Leung DW, 1989, TECHNIQUE, V1, P11; Levchenko I, 1996, NUCLEIC ACIDS RES, V24, P1936, DOI 10.1093/nar/24.10.1936; Maxam A M, 1980, Methods Enzymol, V65, P499; MCEACHERN MJ, 1985, P NATL ACAD SCI USA, V82, P1480, DOI 10.1073/pnas.82.5.1480; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MCEACHERN MJ, 1987, THESIS U CALIFORNIA; MIAO DM, 1995, NUCLEIC ACIDS RES, V23, P3295, DOI 10.1093/nar/23.16.3295; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; NOVICK RP, 1987, MICROBIOL REV, V51, P381, DOI 10.1128/MMBR.51.4.381-395.1987; PAPP PP, 1993, J MOL BIOL, V233, P219, DOI 10.1006/jmbi.1993.1501; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider TD, 2001, NUCLEIC ACIDS RES, V29, P4881, DOI 10.1093/nar/29.23.4881; Sharma S, 2004, J BIOL CHEM, V279, P6027, DOI 10.1074/jbc.M310917200; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Urh M, 1998, J MOL BIOL, V283, P619, DOI 10.1006/jmbi.1998.2120; URH M, 1996, THESIS U WISCONSIN M; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Wu F, 1996, J BACTERIOL, V178, P4965, DOI 10.1128/jb.178.16.4965-4974.1996; Wu JW, 1999, ACTA BIOCHIM POL, V46, P591, DOI 10.18388/abp.1999_4131; Wu JZ, 1997, P NATL ACAD SCI USA, V94, P13967, DOI 10.1073/pnas.94.25.13967	43	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41058	41066		10.1074/jbc.M403151200	http://dx.doi.org/10.1074/jbc.M403151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247259	hybrid			2022-12-25	WOS:000223916800104
J	Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Tang, MJ; Chang, WC; Lin, YS				Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Tang, MJ; Chang, WC; Lin, YS			Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide- and etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; STRESS-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; CELL-DEATH; SIGNAL-TRANSDUCTION; FAS; PATHWAY; PROTEIN; CLEAVAGE; RECEPTOR	Recently, caspase-2 was shown to act upstream of mitochondria in stress-induced apoptosis. Activation of caspase-8, a key event in death receptor-mediated apoptosis, also has been demonstrated in death receptor-independent apoptosis. The regulation of these initiator caspases, which trigger the mitochondrial apoptotic pathway, is unclear. Here we report a potential regulatory role of caspase-2 on caspase-8 during ceramide-induced apoptosis. Our results demonstrate the sequential events of initiator caspase-2 and caspase-8 activation, Bid cleavage and translocation, and mitochondrial damage followed by downstream caspase-9 and -3 activation and cell apoptosis after ceramide induction in T cell lines. The expression of truncated Bid (tBid) and the reduction in mitochondrial transmembrane potential were blocked by caspase-2 or caspase-8, but not caspase-3, knockdown using an RNA interference technique. Ceramide-induced caspase-8 activation, mitochondrial damage, and apoptosis were blocked in caspase-2 short interfering RNA-expressing cells. Therefore, caspase-2 acts upstream of caspase-8 during ceramide-induced mitochondrial apoptosis. Similarly, sequential caspase-2 and caspase-8 activation upstream of mitochondria was also observed in etoposide-induced apoptosis. These data suggest sequential initiator caspase-2 and caspase-8 activation in the mitochondrial apoptotic pathway induced by ceramide or etoposide.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung 402, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chung Shan Medical University	Lin, YS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.	yslin1@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011	Tang, Ming-Jer/0000-0002-0883-4363				Adam D, 2002, TRENDS IMMUNOL, V23, P1, DOI 10.1016/S1471-4906(01)02091-9; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Darios F, 2003, J NEUROCHEM, V84, P643, DOI 10.1046/j.1471-4159.2003.01590.x; Dirsch VM, 2004, ONCOGENE, V23, P1586, DOI 10.1038/sj.onc.1207281; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; LAI MZ, 1987, J IMMUNOL, V139, P3973; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Movsesyan VA, 2002, BIOCHEM BIOPH RES CO, V299, P201, DOI 10.1016/S0006-291X(02)02593-7; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Schweizer A, 2003, J BIOL CHEM, V278, P42441, DOI 10.1074/jbc.M304895200; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Watts JD, 1999, TRENDS BIOCHEM SCI, V24, P228, DOI 10.1016/S0968-0004(99)01411-5; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	43	103	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40755	40761		10.1074/jbc.M404726200	http://dx.doi.org/10.1074/jbc.M404726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262979	hybrid			2022-12-25	WOS:000223916800068
J	Swan, MK; Hansen, T; Schonheit, P; Davies, C				Swan, MK; Hansen, T; Schonheit, P; Davies, C			A novel phosphoglucose isomerase (PGI)/phosphomannose isomerase from the crenarchaeon Pyrobaculum aerophilum is a member of the PGI superfamily - Structural evidence at 1.16-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON PYROCOCCUS-FURIOSUS; AUTOCRINE MOTILITY FACTOR; CRYSTAL-STRUCTURE; DIFFRACTION DATA; CONFORMATIONAL-CHANGES; GLYCOLYTIC ENZYME; RABBIT; CATALYSIS; MECHANISM; PROTEIN	The crystal structure of a dual specificity phosphoglucose isomerase (PGI)/phosphomannose isomerase from Pyrobaculum aerophilum (PaPGI/PMI) has been determined in native form at 1.16-Angstrom resolution and in complex with the enzyme inhibitor 5-phosphoarabinonate at 1.45-Angstrom resolution. The similarity of its fold, with the inner core structure of PGIs from eubacterial and eukaryotic sources, confirms this enzyme as a member of the PGI superfamily. The almost total conservation of amino acids in the active site, including the glutamate base catalyst, shows that PaPGI/PMI uses the same catalytic mechanisms for both ring opening and isomerization for the interconversion of glucose 6-phosphate (Glc-6-P) to fructose 6-phosphate (Fru-6-P). The lack of structural differences between native and inhibitor-bound enzymes suggests this activity occurs without any of the conformational changes that are the hallmark of the well characterized PGI family. The lack of a suitable second base in the active site of PaPGI/PMI argues against a PMI mechanism involving a trans-enediol intermediate. Instead, PMI activity may be the result of additional space in the active site imparted by a threonine, in place of a glutamine in other PGI enzymes, which could permit rotation of the C-2-C-3 bond of mannose 6-phosphate.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	Medical University of South Carolina; University of Kiel	Davies, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	davies@musc.edu						Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Arsenieva D, 2002, J MOL BIOL, V323, P77, DOI 10.1016/S0022-2836(02)00892-6; Arsenieva D, 2002, P NATL ACAD SCI USA, V99, P5872, DOI 10.1073/pnas.052131799; Berrisford JM, 2003, J BIOL CHEM, V278, P33290, DOI 10.1074/jbc.M305170200; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P1111, DOI 10.1107/S0907444903007352; Davies C, 2003, ACTA CRYSTALLOGR D, V59, P453, DOI 10.1107/S0907444902023387; Davies C, 2002, PROTEINS, V49, P577, DOI 10.1002/prot.10255; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Hansen T, 2004, J BIOL CHEM, V279, P2262, DOI 10.1074/jbc.M309849200; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; HANSEN T, 2004, IN PRESS EXTREMOPHIL; Jeffery CJ, 2000, BIOCHEMISTRY-US, V39, P955, DOI 10.1021/bi991604m; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; Jeong JJ, 2003, FEBS LETT, V535, P200, DOI 10.1016/S0014-5793(02)03900-5; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISSINEL K, 2003, P 5 INT C MOL STRUCT, P88; Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; ROSE IA, 1973, J BIOL CHEM, V248, P2232; SEEHOLZER SH, 1993, P NATL ACAD SCI USA, V90, P1237, DOI 10.1073/pnas.90.4.1237; SIGLER PB, 1970, BIOCHEMISTRY-US, V9, P3609, DOI 10.1021/bi00820a017; SOLOMONS JT, 2004, IN PRESS J MOL BIOL; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Swan MK, 2004, ACTA CRYSTALLOGR D, V60, P1481, DOI 10.1107/S0907444904014052; Swan MK, 2003, J BIOL CHEM, V278, P47261, DOI 10.1074/jbc.M308603200; SWENSON CA, 1971, BIOCHEMISTRY-US, V10, P3151, DOI 10.1021/bi00792a026; Verhees CH, 2001, J BIOL CHEM, V276, P40926, DOI 10.1074/jbc.M104603200; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918	41	24	26	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39838	39845		10.1074/jbc.M406855200	http://dx.doi.org/10.1074/jbc.M406855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252053	hybrid			2022-12-25	WOS:000223791500079
J	Zhang, Z; Reese, JC				Zhang, Z; Reese, JC			Redundant mechanisms are used by Ssn6-Tup1 in repressing chromosomal gene transcription in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RPD3 HISTONE DEACETYLASE; POLYMERASE-II HOLOENZYME; CELL-SPECIFIC GENE; CHROMATIN-STRUCTURE; DNA-DAMAGE; IN-VIVO; CYC8-TUP1 COREPRESSOR; SAGA COMPLEX; SWI-SNF	The Ssn6-Tup1 corepressor complex regulates many genes in Saccharomyces cerevisiae. Three mechanisms have been proposed to explain its repression functions: 1) nucleosome positioning by binding histone tails; 2) recruitment of histone deacetylases; and 3) direct interference with the general transcription machinery or activators. It is unclear if Ssn6-Tup1 utilizes each of these mechanisms at a single gene in a redundant manner or each individually at different loci. A systematic analysis of the contribution of each mechanism at a native promoter has not been reported. Here we employed a genetic strategy to analyze the contributions of nucleosome positioning, histone deacetylation, and Mediator interference in the repression of chromosomal Tup1 target genes in vivo. We exploited the fact that Ssn6-Tup1 requires the ISW2 chromatin remodeling complex to establish nucleosome positioning in vivo to disrupt chromatin structure without affecting other Tup1 repression functions. Deleting ISW2, the histone deacetylase gene HDA1, or genes encoding Mediator subunits individually caused slight or no derepression of RNR3 and HUG1. However, when Mediator mutations were combined with Deltaisw2 or Deltahda1 mutations, enhanced transcription was observed, and the strongest level of derepression was observed in triple Deltaisw2/Deltahda1/Mediator mutants. The increased transcription in the mutants was not due to the loss of Tup1 at the promoter and correlated with increased TBP cross-linking to promoters. Thus, Tup1 utilizes multiple redundant mechanisms to repress transcription of native genes, which may be important for it to act as a global corepressor at a wide variety of promoters.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 203, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reese, JC (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 203, University Pk, PA 16802 USA.	Jcr8@psu.edu		Zhang, Zhengjian/0000-0002-2840-0837	NIGMS NIH HHS [GM58672, R01 GM058672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; Brachmann CB, 1998, YEAST, V14, P115; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Conlan RS, 2001, J MOL BIOL, V309, P1007, DOI 10.1006/jmbi.2001.4742; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Deckert J, 2002, MOL CELL BIOL, V22, P6458, DOI 10.1128/MCB.22.18.6458-6470.2002; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Gavin IM, 2000, EMBO J, V19, P5875, DOI 10.1093/emboj/19.21.5875; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Han SJ, 2001, J BIOL CHEM, V276, P37020, DOI 10.1074/jbc.M105596200; HARASHIMA S, 1995, MOL GEN GENET, V247, P716, DOI 10.1007/BF00290403; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; Huang L, 1997, MOL CELL BIOL, V17, P6555, DOI 10.1128/MCB.17.11.6555; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee M, 2000, GENETICS, V155, P1535; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; Li B, 2000, EMBO J, V19, P4091, DOI 10.1093/emboj/19.15.4091; Mennella TA, 2003, EUKARYOT CELL, V2, P1288, DOI 10.1128/EC.2.6.1288-1303.2003; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; PATTERSON HG, 1994, MOL CELL BIOL, V14, P4002, DOI 10.1128/MCB.14.6.4002; Redd MJ, 1996, MOL CELL BIOL, V16, P2865; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Ryan MP, 1999, METHOD ENZYMOL, V304, P376; Sabet N, 2003, P NATL ACAD SCI USA, V100, P4084, DOI 10.1073/pnas.0637524100; Sharma VM, 2003, GENE DEV, V17, P502, DOI 10.1101/gad.1039503; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Weiss K, 1997, EMBO J, V16, P4352, DOI 10.1093/emboj/16.14.4352; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Yu YX, 2000, MOL CELL BIOL, V20, P2350, DOI 10.1128/MCB.20.7.2350-2357.2000; Yu YX, 2003, MOL CELL BIOL, V23, P1910, DOI 10.1128/MCB.23.6.1910-1921.2003; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198; Zhang Z, 2004, EMBO J, V23, P2246, DOI 10.1038/sj.emboj.7600227; ZHOU Z, 1992, GENETICS, V131, P851	56	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39240	39250		10.1074/jbc.M407159200	http://dx.doi.org/10.1074/jbc.M407159200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254041	hybrid			2022-12-25	WOS:000223791500008
J	Bertrand, T; Eady, NAJ; Jones, JN; Nagy, JM; Jamart-Gregoire, B; Raven, EL; Brown, KA				Bertrand, T; Eady, NAJ; Jones, JN; Nagy, JM; Jamart-Gregoire, B; Raven, EL; Brown, KA			Crystal structure of Mycobacterium tuberculosis catalase-peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; ISONIAZID-RESISTANT; HORSERADISH-PEROXIDASE; KATG GENE; BURKHOLDERIA-PSEUDOMALLEI; RADICAL FORMATION; ESCHERICHIA-COLI; RAPID FORMATION; S315T MUTANT; WILD-TYPE	The Mycobacterium tuberculosis catalase-peroxidase is a multifunctional heme-dependent enzyme that activates the core anti-tuberculosis drug isoniazid. Numerous studies have been undertaken to elucidate the enzyme-dependent mechanism of isoniazid activation, and it is well documented that mutations that reduce activity or inactivate the catalase-peroxidase lead to increased levels of isoniazid resistance in M. tuberculosis. Interpretation of the catalytic activities and the effects of mutations upon the action of the enzyme to date have been limited due to the lack of a three-dimensional structure for this enzyme. In order to provide a more accurate model of the three-dimensional structure of the M. tuberculosis catalase-peroxidase, we have crystallized the enzyme and now report its crystal structure refined to 2.4-Angstrom resolution. The structure reveals new information about dimer assembly and provides information about the location of residues that may play a role in catalysis including candidates for protein-based radical formation. Modeling and computational studies suggest that the binding site for isoniazid is located near the delta-meso heme edge rather than in a surface loop structure as currently proposed. The availability of a crystal structure for the M. tuberculosis catalase-peroxidase also permits structural and functional effects of mutations implicated in causing elevated levels of isoniazid resistance in clinical isolates to be interpreted with improved confidence.	Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, London SW7 2AZ, England; Ecole Natl Super Ind Chim, Inst Natl Polytech Lorraine, Lab Chim Phys Macromol, CNRS,UMR 7568, F-54001 Nancy, France; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	Imperial College London; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Leicester	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, Flowers Bldg, London SW7 2AZ, England.	k.brown@imperial.ac.uk		Raven, Emma/0000-0002-1643-8694				Bodiguel J, 2001, J AM CHEM SOC, V123, P3832, DOI 10.1021/ja002674f; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2003, J BIOL CHEM, V278, P8154, DOI 10.1074/jbc.M208256200; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEMONTELLANO PRO, 1995, BIOCHEM SOC T, V23, P223, DOI 10.1042/bst0230223; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; Donald LJ, 2003, J BIOL CHEM, V278, P35687, DOI 10.1074/jbc.M304053200; Dunford H.B., 1999, HEME PEROXIDASES, P219; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Erman JE, 2002, BBA-PROTEIN STRUCT M, V1597, P193, DOI 10.1016/S0167-4838(02)00317-5; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Ghiladi RA, 2004, J AM CHEM SOC, V126, P4772, DOI 10.1021/ja031728t; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601, DOI 10.1128/AAC.41.7.1601; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3; Jakopitsch C, 2003, BIOCHEMISTRY-US, V42, P5292, DOI 10.1021/bi026944d; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapetanaki S, 2003, BIOCHEMISTRY-US, V42, P3835, DOI 10.1021/bi026992y; Lackner P, 2000, PROTEIN ENG, V13, P745, DOI 10.1093/protein/13.11.745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lukat-Rodgers GS, 2001, BIOCHEMISTRY-US, V40, P7149, DOI 10.1021/bi010369g; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443, DOI 10.1128/AAC.42.9.2443; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MOSS TH, 1969, BIOCHEMISTRY-US, V8, P4159, DOI 10.1021/bi00838a037; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; Nagy JM, 1997, BIOCHEM SOC T, V25, pS617, DOI 10.1042/bst025s617; OTWINOSKI Z, 1993, DENZO FILM PROCESSIN; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; Raven EL, 2003, NAT PROD REP, V20, P367, DOI 10.1039/b210426c; Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 1999, BIOCHEMISTRY-US, V38, P10480, DOI 10.1021/bi990886n; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; ROUSE DA, 1995, INFECT IMMUN, V63, P1427, DOI 10.1128/IAI.63.4.1427-1433.1995; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753; Sharp KH, 2004, BIOCHEMISTRY-US, V43, P8644, DOI 10.1021/bi049343q; Sharp KH, 2003, DALTON T, P4208, DOI 10.1039/b309648n; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMULEVICH G, 1995, BIOCHEM SOC T, V23, P240, DOI 10.1042/bst0230240; Todorovic S, 1999, J AM CHEM SOC, V121, P10962, DOI 10.1021/ja9918674; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Soolingen D, 2000, J INFECT DIS, V182, P1788, DOI 10.1086/317598; Veitch NC, 2001, ADV INORG CHEM, V51, P107; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; Wengenack NL, 2000, BIOCHEMISTRY-US, V39, P11508, DOI 10.1021/bi001239v; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Wilming M, 2001, FEBS LETT, V509, P272, DOI 10.1016/S0014-5793(01)03179-9; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOUATT J, 1969, AM REV RESPIR DIS, V100, P77; YOUATT J, 1969, AM REV RESPIR DIS, V100, P31; Yu SW, 2003, J BIOL CHEM, V278, P14769, DOI 10.1074/jbc.M300326200; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	90	157	162	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38991	38999		10.1074/jbc.M402382200	http://dx.doi.org/10.1074/jbc.M402382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231843	hybrid			2022-12-25	WOS:000223684100113
J	Dombek, KM; Kacherovsky, N; Young, ET				Dombek, KM; Kacherovsky, N; Young, ET			The Reg1-interacting proteins, Bmh1, Bmh2, Ssb1, and Ssb2, have roles in maintaining glucose repression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; PHOSPHATASE TYPE-1; GENE DISRUPTION; NUCLEAR-LOCALIZATION; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; STRUCTURAL BASIS; ADH2 EXPRESSION; YEAST SNF1; KINASE	In Saccharomyces cerevisiae, a type 1 protein phosphatase complex composed of the Glc7 catalytic subunit and the Reg1 regulatory subunit represses expression of many glucose-regulated genes. Here we show that the Reg1-interacting proteins Bmh1, Bmh2, Ssb1, and Ssb2 have roles in glucose repression. Deleting both BMH genes causes partially constitutive ADH2 expression without significantly increasing the level of Adr1 protein, the major activator of ADH2 expression. Adr1 and Bcy1, the regulatory subunit of cAMP-dependent protein kinase, are both required for this effect indicating that constitutive expression in Deltabmh1Deltabmh2 cells uses the same activation pathway that operates in Deltareg1 cells. Deletion of both BMH genes and REG1 causes a synergistic relief from repression, suggesting that Bmh proteins also act independently of Reg1 during glucose repression. A two-hybrid interaction with the Bmh proteins was mapped to amino acids 187-232, a region of Reg1 that is conserved in different classes of fungi. Deleting this region partially releases SUC2 from glucose repression. This indicates a role for the Reg1-Bmh interaction in glucose repression and also suggests a broad role for Bmh proteins in this process. An in vivo Reg1-Bmh interaction was confirmed by copurification of Bmh proteins with HA(3)-TAP-tagged Reg1. The nonconventional heat shock proteins Ssb1 and Ssb2 are also copurified with HA(3)-TAP-tagged Reg1. Deletion of both SSB genes modestly decreases repression of ADH2 expression in the presence of glucose, suggesting that Ssb proteins, perhaps through their interaction with Reg1, play a minor role in glucose repression.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Dombek, KM (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	kmd@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bisson LF, 2003, RES MICROBIOL, V154, P603, DOI 10.1016/S0923-2508(03)00170-0; Bonner JJ, 2000, MOL BIOL CELL, V11, P1739, DOI 10.1091/mbc.11.5.1739; Brachmann CB, 1998, YEAST, V14, P115; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1984, MOL CELL BIOL, V4, P54, DOI 10.1128/MCB.4.1.54; Cereghino GP, 1996, EMBO J, V15, P363, DOI 10.1002/j.1460-2075.1996.tb00366.x; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Comparot S, 2003, J EXP BOT, V54, P595, DOI 10.1093/jxb/erg057; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ferl RJ, 2002, GENOME BIOL, V3; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Guthrie C, 1991, METHODS ENZYMOL, V194; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Horak J, 2002, J BIOL CHEM, V277, P8248, DOI 10.1074/jbc.M107255200; Huang DQ, 1996, GENETICS, V143, P119; HUBBARD EJA, 1992, GENETICS, V130, P71; KAPLAN KB, 1997, PROTEIN FUNCTION PRA, P245; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; Mayordomo I, 2003, FEBS LETT, V544, P160, DOI 10.1016/S0014-5793(03)00498-8; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MORTIMER RK, 1986, GENETICS, V113, P35; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; NEIGEBORN L, 1987, GENETICS, V115, P247; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIEDERACHER D, 1991, EUR J BIOCHEM, V200, P311, DOI 10.1111/j.1432-1033.1991.tb16187.x; Pfund C, 2001, MOL BIOL CELL, V12, P3773, DOI 10.1091/mbc.12.12.3773; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Sloan JS, 1999, J BIOL CHEM, V274, P37575, DOI 10.1074/jbc.274.53.37575; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; WILLIAMSON VM, 1980, NATURE, V283, P214, DOI 10.1038/283214a0; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Wu X, 2001, MOL GENET GENOMICS, V265, P622, DOI 10.1007/s004380100455; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Young ET, 2003, J BIOL CHEM, V278, P26146, DOI 10.1074/jbc.M301981200; Young ET, 2002, J BIOL CHEM, V277, P38095, DOI 10.1074/jbc.M206158200; Young ET, 2000, GENE, V245, P299, DOI 10.1016/S0378-1119(00)00035-4	70	48	48	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39165	39174		10.1074/jbc.M400433200	http://dx.doi.org/10.1074/jbc.M400433200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15220335	hybrid			2022-12-25	WOS:000223684100133
J	Kelly, WL; Townsend, CA				Kelly, WL; Townsend, CA			Mutational analysis and characterization of nocardicin C-9 ' epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N EPIMERASE; LIQUID-CHROMATOGRAPHIC RESOLUTION; PYRIDOXAL 5'-PHOSPHATE BINDING; UNIFORMIS-SUBSP-TSUYAMANENSIS; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE DEAMINASE; AMINO-ACID; CLAVULANIC ACID; 2,3,4,6-TETRA-O-ACETYL-BETA-D-GLUCOPYRANOSYL ISOTHIOCYANATE; STREPTOMYCES-CLAVULIGERUS; S-ADENOSYLMETHIONINE	The biosynthetic gene cluster for the nocardicin A producer Nocardia uniformis subsp. tsuyamanensis ATCC 21806 was recently identified. Nocardicin A is the most potent of a series of monocyclic beta-lactam antibiotics produced by this organism. Its activity has been attributed to a syn-configured oxime moiety and a D-homoseryl side chain attached through an unusual ether linkage to the core nocardicin framework. Notably present in the nocardicin biosynthetic gene cluster is nocJ, encoding a protein with sequence similarity to the pyridoxal 5'-phosphate (PLP)-dependent1-aminocyclopropane-1- carboxylic acid deaminases. Insertional mutagenesis of nocJ abolished nocardicin A production, while the L-homoseryl isomer, isonocardicin A, was still observed. Expression of the disrupted nocJ gene in trans was sufficient to restore production of nocardicin A in the disruption mutant. Heterologous expression, purification, and in vitro characterization of NocJ by UV spectroscopy, cofactor reduction, chiral HPLC analysis of the products and their exchange behavior in deuterium oxide led to confirmation of its role as the PLP-dependent nocardicin C-9' epimerase responsible for interconversion of the nocardicin homoseryl side chain in both nocardicin A with isonocardicin A, and nocardicin C with isonocardicin C. NocJ is the first member of a new class of beta-lactam aminoacyl side chain epimerases, the first two classes being the evolutionarily distinct prokaryotic PLP-dependent isopenicillin N epimerase and the fungal isopenicillin N epimerase two protein system.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Johns Hopkins University	Townsend, CA (corresponding author), Johns Hopkins Univ, Dept Chem, Charles & 34th St, Baltimore, MD 21218 USA.	ctownsend@jhu.edu			NIAID NIH HHS [AI14937] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014937, R01AI014937] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AOKI H, 1976, J ANTIBIOT, V29, P492, DOI 10.7164/antibiotics.29.492; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; BURROUGHS LF, 1957, NATURE, V179, P360, DOI 10.1038/179360a0; BYCROFT BW, 1988, J ANTIBIOT, V41, P1231, DOI 10.7164/antibiotics.41.1231; Chen DW, 2001, BIOCHEMISTRY-US, V40, P596, DOI 10.1021/bi002265w; ESAKI N, 1986, BIOCHEMISTRY-US, V25, P3261, DOI 10.1021/bi00359a027; Gunsior M, 2004, CHEM BIOL, V11, P927, DOI 10.1016/j.chembiol.2004.04.012; HASHIMOTO M, 1976, J ANTIBIOT, V29, P890, DOI 10.7164/antibiotics.29.890; HASHIMOTO M, 1976, J AM CHEM SOC, V98, P3023, DOI 10.1021/ja00426a063; HONMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1825, DOI 10.1080/00021369.1978.10863261; HOSODA J, 1977, AGR BIOL CHEM TOKYO, V41, P2013, DOI 10.1080/00021369.1977.10862799; HOSODA J, 1977, AGR BIOL CHEM TOKYO, V41, P2007, DOI 10.1080/00021369.1977.10862798; ISENRING HP, 1983, TETRAHEDRON, V39, P2591, DOI 10.1016/S0040-4020(01)92152-0; JENSEN SE, 1983, CAN J MICROBIOL, V29, P1526, DOI 10.1139/m83-234; Jia YJ, 1999, BIOSCI BIOTECH BIOCH, V63, P542, DOI 10.1271/bbb.63.542; Kelly WL, 2002, J AM CHEM SOC, V124, P8186, DOI 10.1021/ja025926g; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; Kim CF, 2003, APPL ENVIRON MICROB, V69, P1308, DOI 10.1128/AEM.69.2.1308-1314.2003; KINOSHITA T, 1981, J CHROMATOGR, V210, P77, DOI 10.1016/S0021-9673(00)91182-8; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; KUMAR CV, 1994, FEMS MICROBIOL LETT, V118, P107; KUMAR CV, 1994, APPL ENVIRON MICROB, V60, P4086, DOI 10.1128/AEM.60.11.4086-4093.1994; Kurokawa Y, 1998, J BIOCHEM-TOKYO, V124, P1163, DOI 10.1093/oxfordjournals.jbchem.a022234; LAIZ L, 1990, J GEN MICROBIOL, V136, P663, DOI 10.1099/00221287-136-4-663; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; Lim YH, 1998, J BIOL CHEM, V273, P4001, DOI 10.1074/jbc.273.7.4001; MATSUO Y, 1959, J BIOL CHEM, V234, P507; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Minami R, 1998, J BIOCHEM, V123, P1112; Murakami T, 1997, BIOSCI BIOTECH BIOCH, V61, P506, DOI 10.1271/bbb.61.506; NEUSS N, 1982, J ANTIBIOT, V35, P580, DOI 10.7164/antibiotics.35.580; NIMURA N, 1980, J CHROMATOGR, V202, P375, DOI 10.1016/S0021-9673(00)91821-1; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; Quiros LM, 1998, MOL MICROBIOL, V28, P1177, DOI 10.1046/j.1365-2958.1998.00880.x; Recktenwald J, 2002, MICROBIOL-SGM, V148, P1105, DOI 10.1099/00221287-148-4-1105; Reeve AM, 1998, J BIOL CHEM, V273, P30695, DOI 10.1074/jbc.273.46.30695; SALITURO GM, 1990, J AM CHEM SOC, V112, P760, DOI 10.1021/ja00158a040; Sambrook J., 1989, MOL CLONING, pA1; Shah S, 1998, CAN J MICROBIOL, V44, P833, DOI 10.1139/cjm-44-9-833; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; Tang KH, 2002, BIOCHEMISTRY-US, V41, P8767, DOI 10.1021/bi020255k; TOWNSEND CA, 1985, J AM CHEM SOC, V107, P1065, DOI 10.1021/ja00290a056; TOWNSEND CA, 1985, J AM CHEM SOC, V107, P1066, DOI 10.1021/ja00290a057; TOWNSEND CA, 1981, J AM CHEM SOC, V103, P2873, DOI 10.1021/ja00400a069; TOWNSEND CA, 1983, J AM CHEM SOC, V105, P913, DOI 10.1021/ja00342a046; Ullan RV, 2002, J BIOL CHEM, V277, P46216, DOI 10.1074/jbc.M207482200; USUI S, 1989, BIOCHIM BIOPHYS ACTA, V999, P78, DOI 10.1016/0167-4838(89)90033-2; VAHATALO ML, 1957, ACTA CHEM SCAND, V11, P741, DOI 10.3891/acta.chem.scand.11-0741; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; WILSON BA, 1988, J AM CHEM SOC, V110, P8238, DOI 10.1021/ja00232a047; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200; YORIFUJI T, 1971, J BIOL CHEM, V246, P5093	56	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38220	38227		10.1074/jbc.M405450200	http://dx.doi.org/10.1074/jbc.M405450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252031	hybrid			2022-12-25	WOS:000223684100021
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CROSS-LINKING ANALYSIS; CYSTIC-FIBROSIS; ATP-BINDING; FUNCTIONAL CONSEQUENCES; DRUG-BINDING; CHLORIDE CHANNEL; TRANSPORTER; DELTA-F508; CFTR	The most common cause of cystic fibrosis is misfolding of the cystic fibrosis transmembrane conductance regulator (CFTR) protein because of deletion of residue Phe508 (DeltaF508). P-glycoprotein (P-gp) is an ideal model protein for studying how mutations disrupt folding of ATP-binding cassette proteins such as CFTR because specific chemical chaperones can be used to correct folding defects. Interactions between the nucleotide binding domains (NBDs) are critical because ATP binds at the interface between the NBDs. Here, we used disulfide cross-linking between cysteines in the Walker A sites and the LSGGQ signature sequences to test whether processing mutations located throughout P-gp disrupted interactions between the NBDs. We found that mutations present in the cytoplasmic loops, transmembrane segments, and linker regions or deletion of Tyr-490 (equivalent to Phe-508 in CFTR) inhibited crosslinking between the NBDs. Deletion of Phe-508 in the P-gp/CFTR chimera also inhibited cross-linking between the NBDs. Cross-linking was restored, however, when the mutants were expressed in the presence of the chemical chaperone cyclosporin A. The "rescued" mutants exhibited drug-stimulated ATPase activity, and cross-linking between the NBDs was inhibited by vanadate trapping of nucleotide. These results together with our previous findings (Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2002) J. Biol. Chem. 277, 27585-27588) indicate that processing mutations disrupt interactions among all four domains. It appears that cross-talk between the cytoplasmic and the transmembrane domains is required for establishment of proper domain-domain interactions that occur during folding of ATP-binding cassette protein transporters.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; HOOF T, 1994, J BIOL CHEM, V269, P20575; HORIO M, 1989, J BIOL CHEM, V264, P14880; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Komar AA, 1997, J BIOL CHEM, V272, P10646; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2004, J BIOL CHEM, V279, P18232, DOI 10.1074/jbc.M400229200; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 1999, FASEB J, V13, P1724, DOI 10.1096/fasebj.13.13.1724; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	50	29	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38395	38401		10.1074/jbc.M405623200	http://dx.doi.org/10.1074/jbc.M405623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247215	hybrid			2022-12-25	WOS:000223684100041
J	Pierattelli, R; Banci, L; Eady, NAJ; Bodiguel, J; Jones, JN; Moody, PCE; Raven, EL; Jamart-Gregoire, B; Brown, KA				Pierattelli, R; Banci, L; Eady, NAJ; Bodiguel, J; Jones, JN; Moody, PCE; Raven, EL; Jamart-Gregoire, B; Brown, KA			Enzyme-catalyzed mechanism of isoniazid activation in class I and class III peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS KATG; ARTHROMYCES-RAMOSUS PEROXIDASE; CATALASE-PEROXIDASE; HORSERADISH-PEROXIDASE; CRYSTAL-STRUCTURE; MOLECULAR-DYNAMICS; SUBSTRATE-BINDING; ASCORBATE PEROXIDASE; BENZHYDROXAMIC ACID	There is an urgent need to understand the mechanism of activation of the frontline anti-tuberculosis drug isoniazid by the Mycobacterium tuberculosis catalase-peroxidase. To address this, a combination of NMR spectroscopic, biochemical, and computational methods have been used to obtain a model of the frontline anti-tuberculosis drug isoniazid bound to the active site of the class III peroxidase, horseradish peroxidase C. This information has been used in combination with the new crystal structure of the M. tuberculosis catalase-peroxidase to predict the mode of INH binding across the class I heme peroxidase family. An enzyme-catalyzed mechanism for INH activation is proposed that brings together structural, functional, and spectroscopic data from a variety of sources. Collectively, the information not only provides a molecular basis for understanding INH activation by the M. tuberculosis catalase-peroxidase but also establishes a new conceptual framework for testing hypotheses regarding the enzyme-catalyzed turnover of this compound in a number of heme peroxidases.	Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, London SW7 2AZ, England; Univ Florence, Dipartimento Chim, Polo Sci, I-50019 Florence, Italy; Univ Florence, Ctr Risonanze Magnet, Polo Sci, I-50019 Florence, Italy; Ecole Natl Super Ind Chim, Inst Natl Polytech Lorraine, Lab Chim Phys Macromol, CNRS,UMR 7568, F-54001 Nancy, France; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	Imperial College London; University of Florence; University of Florence; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Leicester; University of Leicester	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, Flowers Bldg, London SW7 2AZ, England.	k.brown@imperial.ac.uk	Moody, Peter/A-6832-2008; Pierattelli, Roberta/F-9439-2012	Moody, Peter/0000-0003-1762-9238; Pierattelli, Roberta/0000-0001-7755-0885; BANCI, LUCIA/0000-0003-0562-5774; Raven, Emma/0000-0002-1643-8694				AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; Aitken SM, 2001, BIOCHEMISTRY-US, V40, P13980, DOI 10.1021/bi010445f; Banci L, 1996, J BIOL INORG CHEM, V1, P264, DOI 10.1007/s007750050052; BANCI L, 1994, BIOCHEMISTRY-US, V33, P12356, DOI 10.1021/bi00207a002; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BANCI L, 1995, BIOCHEMISTRY-US, V34, P11385, DOI 10.1021/bi00036a011; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P572, DOI 10.1063/1.1743771; Bodiguel J, 2001, J AM CHEM SOC, V123, P3832, DOI 10.1021/ja002674f; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; Brosse N, 1998, J CHEM SOC PERK T 1, P3685, DOI 10.1039/a807230b; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2003, J BIOL CHEM, V278, P8154, DOI 10.1074/jbc.M208256200; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; de Ropp JS, 1999, BIOCHEMISTRY-US, V38, P1077, DOI 10.1021/bi982125a; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dunford H. B., 1991, PEROXIDASES CHEM BIO, P1; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FRITSCH MJ, 1995, GAUSSIAN 94 REVISION; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Jakopitsch C, 2003, BIOCHEMISTRY-US, V42, P5292, DOI 10.1021/bi026944d; Jakopitsch C, 2001, BIOCHEM BIOPH RES CO, V287, P682, DOI 10.1006/bbrc.2001.5616; Jamart-Gregoire B, 1998, SYNTHESIS-STUTTGART, P269; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kapetanaki S, 2003, BIOCHEMISTRY-US, V42, P3835, DOI 10.1021/bi026992y; Lad L, 2002, BIOCHEMISTRY-US, V41, P13774, DOI 10.1021/bi0261591; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; MACURA S, 1982, J MAGN RESON, V47, P351, DOI 10.1016/0022-2364(82)90128-7; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; MAR GNL, 1995, J AM CHEM SOC, V117, P411; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PEARLMAN DA, 1995, AMBER 4 1; Sharp KH, 2004, BIOCHEMISTRY-US, V43, P8644, DOI 10.1021/bi049343q; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; Smith AT, 1998, CURR OPIN CHEM BIOL, V2, P269, DOI 10.1016/S1367-5931(98)80069-0; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VEITCH NC, 1990, EUR J BIOCHEM, V189, P351, DOI 10.1111/j.1432-1033.1990.tb15496.x; Veitch NC, 1997, BIOCHEMISTRY-US, V36, P14751, DOI 10.1021/bi9718402; VEITCH NC, 1995, BIOCHEM SOC T, V23, P232, DOI 10.1042/bst0230232; VEITCH NC, 1991, BIOCH MOL PHYSL ASPE, P99; VOLD RL, 1968, J CHEM PHYS, V48, P3831, DOI 10.1063/1.1669699; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; WINDER F G, 1970, Journal of General Microbiology, V63, P41	64	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39000	39009		10.1074/jbc.M402384200	http://dx.doi.org/10.1074/jbc.M402384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231844	hybrid			2022-12-25	WOS:000223684100114
J	Puustinen, P; Makinen, K				Puustinen, P; Makinen, K			Uridylylation of the potyvirus VPg by viral replicase NIb correlates with the nucleotide binding capacity of VPg	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-LINKED PROTEIN; POLIOVIRUS RNA-POLYMERASE; POTATO-VIRUS-A; COAT PROTEIN; SUBCELLULAR TRANSPORT; TYROSINE RESIDUE; IDENTIFICATION; CELLS; SEQUENCE; SITES	Poty- and picornaviruses share similar genome organizations and polyprotein processing strategies. By analogy to picornaviruses it has been proposed that the genome-linked protein VPg may serve as a primer for genome replication of potyviruses. The multifunctional VPg of potato virus A (PVA; genus Potyvirus) was found to be uridylylated by NIb, the RNA polymerase of PVA. The nucleotidylation activity of NIb is more efficient in the presence of Mn2+ than Mg2+ and does not require an RNA template. Our results suggest that the nucleotidylation reaction exhibits weak preference for UTP over the other NTPs. An NTP-binding experiment with oxidized [alpha-P-32] UTP revealed that PVA VPg contains an NTP-binding site. Deletion of a 7-amino acid-long putative NTP-binding site from VPg reduced nucleotide-binding capacity and debilitated uridylylation reaction. These results provide evidence that VPg may play a similar role in RNA synthesis of potyviruses as it does in the case of picornaviruses.	Univ Helsinki, Dept Appl Biol, FIN-00014 Helsinki, Finland	University of Helsinki	Makinen, K (corresponding author), Univ Helsinki, Dept Appl Biol, POB 27, FIN-00014 Helsinki, Finland.	kristiina.makinen@helsinki.fi	Mäkinen, Kristiina M/C-8650-2012	Mäkinen, Kristiina M/0000-0001-8233-8942				AMBROS V, 1978, J BIOL CHEM, V253, P5263; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CALDENTEY J, 1992, NUCLEIC ACIDS RES, V20, P3971, DOI 10.1093/nar/20.15.3971; CARRINGTON JC, 1993, J VIROL, V67, P6995, DOI 10.1128/JVI.67.12.6995-7000.1993; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; CRAWFORD NM, 1983, P NATL ACAD SCI-BIOL, V80, P7452, DOI 10.1073/pnas.80.24.7452; Crotty S, 2003, J VIROL, V77, P5378, DOI 10.1128/JVI.77.9.5378-5388.2003; Fellers J, 1998, J GEN VIROL, V79, P2043, DOI 10.1099/0022-1317-79-8-2043; Hong YL, 1996, VIROLOGY, V226, P146, DOI 10.1006/viro.1996.0639; HONG YL, 1995, VIROLOGY, V214, P159, DOI 10.1006/viro.1995.9944; Ivanov KI, 2001, J BIOL CHEM, V276, P13530, DOI 10.1074/jbc.M009551200; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; Kekarainen T, 2002, GENOME RES, V12, P584, DOI 10.1101/gr.220702; LI XH, 1995, P NATL ACAD SCI USA, V92, P457, DOI 10.1073/pnas.92.2.457; Li XH, 1997, J VIROL, V71, P1598, DOI 10.1128/JVI.71.2.1598-1607.1997; Machin A, 2001, J BIOL CHEM, V276, P27787, DOI 10.1074/jbc.M100707200; MARTIN MT, 1995, VIRUS RES, V37, P127, DOI 10.1016/0168-1702(95)00028-O; McKnight KL, 1996, J VIROL, V70, P1941, DOI 10.1128/JVI.70.3.1941-1952.1996; Merits A, 1999, VIROLOGY, V263, P15, DOI 10.1006/viro.1999.9926; Merits A, 1998, J GEN VIROL, V79, P3123, DOI 10.1099/0022-1317-79-12-3123; Merits A, 2002, J GEN VIROL, V83, P1211, DOI 10.1099/0022-1317-83-5-1211; MURPHY JF, 1991, J VIROL, V65, P511, DOI 10.1128/JVI.65.1.511-513.1991; Murphy JF, 1996, VIROLOGY, V220, P535, DOI 10.1006/viro.1996.0344; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oruetxebarria I, 2001, VIRUS RES, V73, P103, DOI 10.1016/S0168-1702(00)00216-1; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 2003, J VIROL, V77, P891, DOI 10.1128/JVI.77.2.891-904.2003; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; Puustinen P, 2002, J VIROL, V76, P12703, DOI 10.1128/JVI.76.24.12703-12711.2002; RESTREPOHARTWIG MA, 1994, J VIROL, V68, P2388, DOI 10.1128/JVI.68.4.2388-2397.1994; RICHARDS OC, 1995, BIOCHEMISTRY-US, V34, P6288, DOI 10.1021/bi00019a005; Richards OC, 1997, J BIOL CHEM, V272, P23261, DOI 10.1074/jbc.272.37.23261; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; Sadowy E, 2001, ADV VIRUS RES, V57, P185, DOI 10.1016/S0065-3527(01)57004-9; Schaad MC, 1996, J VIROL, V70, P7039, DOI 10.1128/JVI.70.10.7039-7048.1996; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	40	68	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38103	38110		10.1074/jbc.M402910200	http://dx.doi.org/10.1074/jbc.M402910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15218030	hybrid			2022-12-25	WOS:000223684100007
J	Zhang, F; Chen, Y; Su, ZL; Shin, YK				Zhang, F; Chen, Y; Su, ZL; Shin, YK			SNARE assembly and membrane fusion, a kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; STRUCTURAL INSIGHTS; SYNAPTIC EXOCYTOSIS; CRYSTAL-STRUCTURE; VESICLE FUSION; COILED-COIL; T-SNARE; COMPLEX; PROTEINS; MECHANISM	SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) assembly may promote intracellular membrane fusion, an essential process for vesicular transport in cells. Core complex formation between vesicle-associated SNARE and target membrane SNARE perhaps drives the merging of two membranes into a single bilayer. Using spin-labeling EPR, trans-SNARE complex formation was monitored "locally" at four different core locations of recombinant yeast SNAREs, which are individually reconstituted into phospholipid vesicles. The results indicate that the time scales of core formation are virtually the same at all four locations throughout the core region, indicating the possibility of a single step core assembly, which appears to be somewhat different from what has been postulated by the "zipper" model. The EPR data were then compared with the kinetics of the lipid mixing measured with the fluorescence assay. The analysis suggests that SNARE core assembly occurs on a much faster time scale than the lipid mixing, providing a new insight into the timing of individual events in SNARE-induced membrane fusion.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Shin, YK (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	colishin@iastate.edu	Zhang, Fan/A-3477-2011; Su, Zengliu/E-3156-2010					AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; Chen Y, 2004, EMBO J, V23, P681, DOI 10.1038/sj.emboj.7600083; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v; Kweon DH, 2003, J BIOL CHEM, V278, P12367, DOI 10.1074/jbc.M211123200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Mahal LK, 2002, J CELL BIOL, V158, P273, DOI 10.1083/jcb.200203135; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matos MF, 2003, NEUROPHARMACOLOGY, V45, P777, DOI 10.1016/S0028-3908(03)00318-6; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHNEIDER DJ, 1989, LASERS MOL METHODS, P387; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	46	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38668	38672		10.1074/jbc.M404904200	http://dx.doi.org/10.1074/jbc.M404904200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247231	hybrid			2022-12-25	WOS:000223684100075
J	Wu, XQ; Zimmerman, GA; Prescott, SM; Stafforini, DM				Wu, XQ; Zimmerman, GA; Prescott, SM; Stafforini, DM			The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PHOSPHOLIPASE A(2); PROTEIN-KINASE; SP1 BINDING; PAF-ACETYLHYDROLASE; BACTERIAL-ENDOTOXIN; DENDRITIC CELLS; EXPRESSION; DIFFERENTIATION; INHIBITION	Administration of lipopolysaccharide (LPS) to experimental animals results in the up-regulation of expression of the plasma form of platelet-activating factor acetylhydrolase (PAF AH) in tissue macrophages. To investigate the mechanism underlying induction of PAF AH by LPS we used murine RAW264.7 and human THP-1 macrophages as model systems. We found that the p38 mitogen-activated protein kinase (p38 MAPK) pathway mediates transcriptional activation of the PAF AH gene through the participation of nucleotides -68/-316 relative to the transcriptional initiation site. This promoter region spans two Sp1/Sp3 binding sites (SP-A and SP-B) and is necessary and sufficient for the observed effect. Disruption of these Sp binding sites significantly reduces promoter activity in LPS-stimulated cells. The ability of LPS to induce transcriptional activation of PAF AH is not due to enhanced Sp1/Sp3 binding to the promoter but involves enhanced transactivation function of Sp1 via p38 MAPK activation. These studies characterize the mechanism by which LPS modulates expression of PAF AH at the transcriptional level, and they have important implications for our understanding of responses that occur during the development of LPS-mediated inflammatory diseases.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Suite 5362, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NHLBI NIH HHS [HL35828, HL50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Al-Darmaki S, 2003, J IMMUNOL, V170, P167, DOI 10.4049/jimmunol.170.1.167; Asano K, 1999, BIOCHEM BIOPH RES CO, V261, P511, DOI 10.1006/bbrc.1999.1066; Bethea JR, 1997, J IMMUNOL, V158, P5815; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Bulger EM, 2002, SHOCK, V17, P173, DOI 10.1097/00024382-200203000-00003; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; Carpenter KLH, 2001, FEBS LETT, V505, P357, DOI 10.1016/S0014-5793(01)02840-X; Caslake MJ, 2000, ATHEROSCLEROSIS, V150, P413, DOI 10.1016/S0021-9150(99)00406-2; Chen CC, 1999, MOL PHARMACOL, V55, P481; Cook AD, 2003, J IMMUNOL, V171, P4816, DOI 10.4049/jimmunol.171.9.4816; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; ENDO S, 1994, RES COMMUN CHEM PATH, V83, P289; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; Grissom CK, 2003, CRIT CARE MED, V31, P770, DOI 10.1097/01.CCM.0000053647.82608.29; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hakkinen T, 1999, ARTERIOSCL THROM VAS, V19, P2909, DOI 10.1161/01.ATV.19.12.2909; Howard KM, 2000, J BIOL CHEM, V275, P19891, DOI 10.1074/jbc.M001462200; Howard KM, 1997, J BIOL CHEM, V272, P27543, DOI 10.1074/jbc.272.44.27543; Jarvis BW, 1997, INFECT IMMUN, V65, P1640, DOI 10.1128/IAI.65.5.1640-1643.1997; KIM DK, 1995, AM J PHYSIOL-LUNG C, V269, pL109, DOI 10.1152/ajplung.1995.269.1.L109; Laskin DL, 2001, J LEUKOCYTE BIOL, V70, P163; Leach CA, 2001, FARMACO, V56, P45, DOI 10.1016/S0014-827X(01)01011-4; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lo CJ, 1997, ARCH SURG-CHICAGO, V132, P1342; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; Makoto HA, 2002, PROSTAG OTH LIPID M, V70, P107, DOI 10.1016/S0090-6980(02)00015-1; Marco E, 2003, J MOL BIOL, V328, P9, DOI 10.1016/S0022-2836(03)00243-2; Memon RA, 1999, AM J PHYSIOL-REG I, V277, pR94, DOI 10.1152/ajpregu.1999.277.1.R94; Morgan EN, 1999, CIRCULATION, V100, P365; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NARAHARA H, 1993, AM J OBSTET GYNECOL, V169, P531, DOI 10.1016/0002-9378(93)90614-O; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; Noto H, 2003, ARTERIOSCL THROM VAS, V23, P829, DOI 10.1161/01.ATV.0000067701.09398.18; Packard CJ, 2000, NEW ENGL J MED, V343, P1148, DOI 10.1056/NEJM200010193431603; Palucka KA, 1998, J IMMUNOL, V160, P4587; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Quarck R, 2001, CIRCULATION, V103, P2495; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Svetlov SI, 1999, HEPATOLOGY, V30, P128, DOI 10.1002/hep.510300122; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TAKAKUWA T, 1994, RES COMMUN CHEM PATH, V84, P271; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trimoreau F, 2000, MEDIAT INFLAMM, V9, P197, DOI 10.1080/09629350020002921; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wu XQ, 2003, BIOCHEM J, V375, P351, DOI 10.1042/BJ20030636; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200	56	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36158	36165		10.1074/jbc.M402454200	http://dx.doi.org/10.1074/jbc.M402454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15215249	hybrid			2022-12-25	WOS:000223303400118
J	Marques, C; Pereira, P; Taylor, A; Liang, JN; Reddy, VN; Szweda, LI; Shang, F				Marques, C; Pereira, P; Taylor, A; Liang, JN; Reddy, VN; Szweda, LI; Shang, F			Ubiquitin-dependent lysosomal degradation of the HNE-modified proteins in lens epithelial cells	FASEB JOURNAL			English	Article						lipid peroxidation; hydroxynonenal; proteasome; protein quality control	LIPID-PEROXIDATION; OXIDATIVE STRESS; PROTEOLYTIC SYSTEM; ALDEHYDIC PRODUCT; OXIDIZED PROTEINS; PROTEASOME; CONJUGATION; RECEPTOR; PATHWAY; IDENTIFICATION	4-Hydroxynonenal (HNE), a highly reactive lipid peroxidation product, may adversely modify proteins. Accumulation of HNE-modified proteins may be responsible for pathological lesions associated with oxidative stress. The objective of this work was to determine how HNE-modified proteins are removed from cells. The data showed that alphaB-crystallin modified by HNE was ubiquitinated at a faster rate than that of native alphaB-crystallin in a cell-free system. However, its susceptibility to proteasome-dependent degradation in the cell-free system did not increase. When delivered into cultured lens epithelial cells, HNE-modified alphaB-crystallin was degraded at a faster rate than that of unmodified alphaB-crystallin. Inhibition of the lysosomal activity stabilized HNE-modified alphaB-crystallin, but inhibition of the proteasome activity alone had little effect. To determine if other HNE-modified proteins are also degraded in a ubiquitin-dependent lysosomal pathway, lens epithelial cells were treated with HNE and the removal of HNE-modified proteins in the cells was monitored. The levels of HNE-modified proteins in the cell decreased rapidly upon removal of HNE from the medium. Depletion of ATP or the presence of MG132, a proteasome/lysosome inhibitor, resulted in stabilization of HNE-modified proteins. However, proteasome-specific inhibitors, lactacystin-beta-lactone and epoxomicin, could not stabilize HNE-modified proteins in the cells. In contrast, chloroquine, a lysosome inhibitor, stabilized HNE-modified proteins. The enrichment of HNE-modified proteins in the fraction of ubiquitin conjugates suggests that HNE-modified proteins are preferentially ubiquitinated. Taken together, these findings show that HNE-modified proteins are degraded via a novel ubiquitin and lysosomal-dependent but proteasome-independent pathway.	Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Univ Coimbra, IBILI, Ctr Ophatmol, Coimbra, Portugal; Harvard Univ, Brigham & Womens Hosp, Ophthalm Res Ctr, Boston, MA 02115 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Tufts University; United States Department of Agriculture (USDA); Universidade de Coimbra; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; Case Western Reserve University	Shang, F (corresponding author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	fu.shang@tufts.edu	Pereira, Paulo/AAD-8375-2022; Marques, Carla/AAC-9838-2019	Pereira, Paulo/0000-0002-9908-2290; Marques, Carla/0000-0002-1817-4813	NATIONAL EYE INSTITUTE [R01EY011717, R29EY011717, R01EY013250] Funding Source: NIH RePORTER; NEI NIH HHS [R29 EY011717-04, R01 EY011717, R29 EY011717-03, R01 EY011717-06A1, R01 EY013250, R29 EY011717, R29 EY011717-05, EY11717, EY 13250] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Blanc EM, 1997, J NEUROCHEM, V69, P570; BLONDIN J, 1987, MECH AGEING DEV, V41, P39, DOI 10.1016/0047-6374(87)90052-2; CADENAS E, 1983, BIOCHEM J, V214, P479, DOI 10.1042/bj2140479; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; de Melker AA, 2001, J CELL SCI, V114, P2167; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; Grune T, 2002, FASEB J, V16, P1602, DOI 10.1096/fj.02-0015com; Grune Tilman, 2003, Molecular Aspects of Medicine, V24, P195, DOI 10.1016/S0098-2997(03)00014-1; Haas AL, 1997, FASEB J, V11, P1257; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Mark RJ, 1997, J NEUROCHEM, V68, P255; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PAROLA M, 1990, CHEM-BIOL INTERACT, V73, P103, DOI 10.1016/0009-2797(90)90111-Y; REDDAN JR, 1993, EXP EYE RES, V56, P543, DOI 10.1006/exer.1993.1068; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SCHWARTZ AL, 1988, EMBO J, V7, P2962; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; Sun TX, 1999, J BIOL CHEM, V274, P34067, DOI 10.1074/jbc.274.48.34067; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; WINDSOR DP, 1993, J REPROD FERTIL, V99, P359, DOI 10.1530/jrf.0.0990359; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	48	91	96	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2004	18	10					1424	+		10.1096/fj.04-1743fje	http://dx.doi.org/10.1096/fj.04-1743fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247152	Green Submitted, Green Accepted			2022-12-25	WOS:000222979200003
J	Behr, R; Brestelli, J; Fulmer, JT; Miyawaki, N; Kleyman, TR; Kaestner, KH				Behr, R; Brestelli, J; Fulmer, JT; Miyawaki, N; Kleyman, TR; Kaestner, KH			Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; BARTTERS-SYNDROME; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DEFINITIVE ENDODERM; RECEPTOR GENE; IN-VIVO; MUTATIONS; CHANNEL; HEPATOCYTE	Foxa1 is a member of the winged helix family of transcription factors and is expressed in the collecting ducts of the kidney. We investigated its potential contribution to renal physiology in Foxa1-deficient mice on a defined genetic background. Foxa1(-/-) mice are dehydrated and exhibit electrolyte imbalance as evidenced by elevated hematocrit and plasma urea levels, hypernatremia, and hyperkalemia. This phenotype is the consequence of decreased urine osmolality secondary to renal vasopressin resistance. Mutations of the human genes encoding the vasopressin 2 receptor and aquaporin 2 cause nephrogenic diabetes insipidus; however, expression of these genes is maintained or increased, respectively, in Foxa1(-/-) mice. Likewise, expression of the genes encoding the Na-K-2Cl cotransporter (NKCC2), the potassium channel ROMK, the chloride channel CLCNKB, barttin (BSND), and the calcium-sensing receptor ( CASR), each of which is important in sodium reabsorption in the loop of Henle, is maintained or even increased in Foxa1-deficient mice. Thus, we have shown that Foxa1(-/-) mice represent a new model of nephrogenic diabetes insipidus with unique molecular etiology, and we have identified the first transcription factor whose mutation leads to a defect in renal water homeostasis in vivo.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Winthrop Univ Hosp, Div Nephrol, Mineola, NY 11501 USA; Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Pennsylvania; Winthrop University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kaestner, KH (corresponding author), Univ Penn, Sch Med, Dept Genet, 560 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	kaestner@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051391, R37DK051391, R01DK055342, P01DK049210, T32DK007006] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51391, R01 DK55342, DK 07006, P01 DK49210] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG SL, 1993, DEVELOPMENT, V119, P1301; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Moore K, 2003, CLIN MED, V3, P28, DOI 10.7861/clinmedicine.3-1-28; Nguyen Minhtri K, 2003, Clin Exp Nephrol, V7, P9, DOI 10.1007/s101570300001; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SASAKI H, 1993, DEVELOPMENT, V118, P47; Silver L.M., 1995, MOUSE GENETICS CONCE; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; Watanabe S, 2002, LANCET, V360, P692, DOI 10.1016/S0140-6736(02)09842-2; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	27	24	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41936	41941		10.1074/jbc.M403354200	http://dx.doi.org/10.1074/jbc.M403354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15252040	hybrid			2022-12-25	WOS:000224075500085
J	Buckley, CT; Sekiya, F; Kim, YJ; Rhee, SG; Caldwell, KK				Buckley, CT; Sekiya, F; Kim, YJ; Rhee, SG; Caldwell, KK			Identification of phospholipase C-gamma 1 as a mitogen-activated protein kinase substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; C-GAMMA; GROWTH-FACTOR; DOCKING SITES; MAP KINASE; TRANSCRIPTION FACTORS; SH3 DOMAIN; C-GAMMA-1; PHOSPHORYLATION; EXPRESSION	The discovery of sequence motifs that mediate protein-protein interactions, coupled with the availability of protein amino acid sequence data, allows for the identification of putative protein binding pairs. The present studies were based on our identification of an amino acid sequence in phosphatidylinositol-specific phospholipase C-gamma1 (PLC-gamma1) that fits the consensus sequence for a mitogen-activated protein kinase (MAPK) binding site, termed the D-domain. Extracellular signal-regulated kinase 2 (ERK2), an MAPK, and phospho-ERK2 were bound by an immobilized peptide sequence containing the identified PLC-gamma1 D-domain. Furthermore, a peptide containing the PLC-gamma1 D-domain was able to competitively inhibit the in vitro phosphorylation of recombinant PLC-gamma1 by recombinant phospho-ERK2, whereas a control peptide derived from a distant region of PLC-gamma1 was ineffective. Similarly, the peptide containing the PLC-gamma1 D-domain, but not the control peptide, competitively inhibited the in vitro phosphorylation of Elk-1 and c-Jun catalyzed by recombinant phospho-ERK2 and phospho-c-Jun N-terminal kinase 3 (phospho-JNK3), another type of MAPK, respectively. Incubation of anti-PLC-gamma1 immunocomplexes isolated from rat brain with recombinant phospho-ERK2 opposed the increase in PLC-gamma1-catalyzed hydrolysis of phosphatidylinositol 4,5-P-2 (PtdIns(4,5)P-2), which was produced by a tyrosine kinase associated with the immunocomplexes, whereas in vitro phosphorylation of recombinant PLC-gamma1 by recombinant phospho-ERK2 did not alter PLC-gamma1-catalyzed PtdIns(4,5)P-2 hydrolysis. These studies have uncovered a previously unidentified mechanism for the integration of PLC-gamma1- and ERK2-dependent signaling.	Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	University of New Mexico; University of New Mexico's Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Caldwell, KK (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, MSC08 4740, Albuquerque, NM 87131 USA.	kcaldwell@salud.unm.edu						Ahn SJ, 1998, BIOCHEM BIOPH RES CO, V244, P62, DOI 10.1006/bbrc.1998.8220; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Buckley CT, 2003, ANAL BIOCHEM, V320, P193, DOI 10.1016/S0003-2697(03)00394-4; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Choi DY, 2001, MOL CELL BIOL, V21, P2695, DOI 10.1128/MCB.21.8.2695-2705.2001; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Espanel X, 2003, J BIOL CHEM, V278, P15162, DOI 10.1074/jbc.M211887200; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gurd JW, 1997, J NEUROCHEM, V69, P623; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Hoek JB, 1998, ALCOHOL CLIN EXP RES, V22, p224S, DOI 10.1111/j.1530-0277.1998.tb04007.x; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Husi H, 2001, J NEUROCHEM, V77, P281, DOI 10.1046/j.1471-4159.2001.t01-1-00248.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Liao HJ, 2001, J BIOL CHEM, V276, P8627, DOI 10.1074/jbc.C100030200; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rong R, 2003, J BIOL CHEM, V278, P52497, DOI 10.1074/jbc.M306744200; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Vitale M, 2001, FASEB J, V15, P1789, DOI 10.1096/fj.01-0008fje; Vossmeyer D, 2002, J BIOL CHEM, V277, P4636, DOI 10.1074/jbc.M105415200; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; Weeber EJ, 2001, NEUROBIOL LEARN MEM, V76, P151, DOI 10.1006/nlme.2000.3994; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Yang JM, 2001, MOL PHARMACOL, V60, P674; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	51	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41807	41814		10.1074/jbc.M407851200	http://dx.doi.org/10.1074/jbc.M407851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15258148	hybrid			2022-12-25	WOS:000224075500070
J	Olsten, MEK; Canton, DA; Zhang, CJ; Walton, PA; Litchfield, DW				Olsten, MEK; Canton, DA; Zhang, CJ; Walton, PA; Litchfield, DW			The pleckstrin homology domain of CK2 interacting protein-1 is required for interactions and recruitment of protein kinase CK2 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO PHOSPHORYLATION; II ALPHA-SUBUNIT; PH DOMAINS; CASEIN KINASE-2; FUNCTIONAL SPECIALIZATION; SACCHAROMYCES-CEREVISIAE; PHOSPHOINOSITIDE-BINDING; SIGNALING MOLECULES; INSULIN-RECEPTOR; BETA-SUBUNIT	CKIP-1 is a recently identified interaction partner of protein kinase CK2 with a number of protein-protein interaction motifs, including an N-terminal pleckstrin homology domain. To test the hypothesis that CKIP-1 has a role in targeting CK2 to specific locations, we examined the effects of CKIP-1 on the localization of CK2. These studies demonstrated that CKIP-1 can recruit CK2 to the plasma membrane. Furthermore, the pleckstrin homology domain of CKIP-1 was found to be required for interactions with CK2 and for the recruitment of CK2 to the plasma membrane. In this regard, point mutations in this domain abolish membrane localization and compromise interactions with CK2. In addition, replacement of the pleckstrin homology domain with a myristoylation signal was insufficient to elicit any interaction with CK2. An investigation of the lipid binding of CKIP-1 reveals that it has broad specificity. A comparison with other pleckstrin homology domains revealed that the pleckstrin homology domain of CKIP-1 is distinct from other defined classes of pleckstrin homology domains. Finally, examination of CK2alpha for a region that mediates interactions with CKIP-1 revealed a putative HIKE domain, a complex motif found exclusively in proteins that bind pleckstrin homology domains. However, mutations within this motif were not able to abolish CKIP-1-CK2 interactions suggesting that this motif by itself may not be sufficient to mediate interactions. Overall, these results provide novel insights into how CK2, a predominantly nuclear enzyme, is targeted to the plasma membrane, and perhaps more importantly how it may be regulated.	Univ Western Ontario, Dept Biochem, Siebens Drake Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, Siebens Drake Res Inst, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Litchfield, David/E-4636-2015; Canton, David/N-7463-2015	Litchfield, David/0000-0002-2425-6620; 				Alberti S, 1999, PROTEINS, V35, P360; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; CORVERA S, 1988, J BIOL CHEM, V263, P3116; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Diviani D, 2001, J CELL SCI, V114, P1431; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Georgescu MM, 2000, CANCER RES, V60, P7033; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; GRANDE J, 1988, FEBS LETT, V232, P130, DOI 10.1016/0014-5793(88)80401-0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James P, 1996, GENETICS, V144, P1425; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Ma AD, 1999, THROMB HAEMOSTASIS, V82, P399, DOI 10.1055/s-0037-1615859; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Safi A, 2004, MOL CELL BIOL, V24, P1245, DOI 10.1128/MCB.24.3.1245-1255.2004; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schnapp BJ, 2003, J CELL SCI, V116, P2125, DOI 10.1242/jcs.00488; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; Smith PJ, 2002, SIGHT SOUND, V12, P32; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; WEI TQ, 1993, ARCH BIOCHEM BIOPHYS, V307, P206, DOI 10.1006/abbi.1993.1580; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	76	55	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42114	42127		10.1074/jbc.M407628200	http://dx.doi.org/10.1074/jbc.M407628200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15254037	hybrid			2022-12-25	WOS:000224075500104
J	Ortiz-Acevedo, A; Melendez, M; Asseo, AM; Biaggi, N; Rojas, LV; Lasalde-Dominicci, JA				Ortiz-Acevedo, A; Melendez, M; Asseo, AM; Biaggi, N; Rojas, LV; Lasalde-Dominicci, JA			Tryptophan scanning mutagenesis of the gamma M4 transmembrane domain of the acetylcholine receptor from Torpedo californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE-RESISTANT CORE; M4 DOMAIN; NICOTINIC RECEPTORS; SECONDARY STRUCTURE; MUTATIONS; SUBUNIT; SUBSTITUTIONS; SEGMENT; SPECTROSCOPY; RESIDUES	The periodicity of structural and functional effects induced by tryptophan scanning mutagenesis has been successfully used to define function and secondary structure of various transmembrane domains of the acetylcholine receptor of Torpedo californica. We expand the tryptophan scanning of the AchR of T. californica to the gammaM4 transmembrane domain (gammaTM4) by introducing tryptophan, at residues 451-462, along the gammaTM4. Wild type (WT) and mutant AChR were expressed in Xenopus laevis oocytes. Using [I-125]alpha-bungarotoxin binding assays and voltage clamp, we determined that the nAChR expression, EC50, and Hill coefficient values for WT are 1.8+/-0.4 fmol, 30.3+/-1.1 muM, and 1.8+/-0.3, respectively. Mutations L456W, F459W, and G462W induce a significant increase in nAChR expression (2.8+/-0.5, 3.6+/-0.6, and 3.0+/-0.5 fmol, respectively) when compared with WT. These data suggest that these residues are important for AChR oligomerization. Mutations A455W, L456W, F459W, and G462W result in a significant decrease in EC50 (19.5+/-1.7, 11.4+/-0.7, 16.4+/-3.8, and 19.1+/-2.6 muM, respectively), thus suggesting a gain in function when compared with WT. In contrast, mutation L458W induced an increase in EC50 (42.8+/-6.8 muM) or loss in function when compared with WT. The Hill coefficient values were the same for WT and all of the mutations studied. The periodicity in function (EC50 and macroscopic peak current) and nAChR expression reveals an average of 3.3 and 3.0 amino acids respectively, thus suggesting a helical secondary structure for the gammaTM4.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Univ Cent Caribe, Sch Med, Dept Physiol, Bayamon, PR 00960 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA.	joseal@coqui.net			NIGMS NIH HHS [5T34 GM07821, GM08102-27, GM56371-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056371, T34GM007821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Bouzat C, 1998, MOL PHARMACOL, V54, P146, DOI 10.1124/mol.54.1.146; Bouzat C, 2002, BIOPHYS J, V82, P1920, DOI 10.1016/S0006-3495(02)75541-0; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Cruz-Martin A, 2001, J MEMBRANE BIOL, V183, P61, DOI 10.1007/s00232-001-0051-z; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; Guzman GR, 2003, BIOCHEMISTRY-US, V42, P12243, DOI 10.1021/bi034764d; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Jenkins A, 2002, NEUROPHARMACOLOGY, V43, P669, DOI 10.1016/S0028-3908(02)00175-2; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Lasalde JA, 1996, BIOCHEMISTRY-US, V35, P14139, DOI 10.1021/bi961583l; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; Santiago J, 2004, BIOCHEMISTRY-US, V43, P10064, DOI 10.1021/bi0362368; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SHARP LL, 1995, P NATL ACAD SCI USA, V92, P7946, DOI 10.1073/pnas.92.17.7946; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamamizu S, 1999, J MEMBRANE BIOL, V170, P157, DOI 10.1007/s002329900545; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	36	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42250	42257		10.1074/jbc.M405132200	http://dx.doi.org/10.1074/jbc.M405132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247226	hybrid			2022-12-25	WOS:000224075500117
J	Sinha, S; Perdomo, G; Brown, NF; O'Doherty, RM				Sinha, S; Perdomo, G; Brown, NF; O'Doherty, RM			Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE; METABOLIC SYNDROME; RECEPTOR SUBSTRATE-1; PRACTICAL GUIDE; MECHANISM; SENSITIVITY; CERAMIDE; OMEGA-3-FATTY-ACIDS; DIACYLGLYCEROL	Recent studies have implicated inhibitor of kappaB kinase (IKK) in mediating fatty acid (FA)-induced insulin resistance. How IKK causes these effects is unknown. The present study addressed the role of nuclear factor kappaB (NFkappaB), the distal target of IKK activity, in FA-induced insulin resistance in L6 myotubes, an in vitro skeletal muscle model. A 6-h exposure of myotubes to the saturated FA palmitate reduced insulin-stimulated glucose uptake by similar to30%, phosphatidylinositol-3 kinase and protein kinase B phosphorylation by similar to40%, and stimulated inhibitor of kappaBalpha degradation and the nuclear translocation of NFkappaB. On the other hand, the Omega-3 polyunsaturated FA linolenate neither induced insulin resistance nor promoted nuclear localization of NFkappaB. Supporting the hypothesis that IKK acts through NFkappaB to cause insulin resistance, the IKK inhibitors acetylsalicylate and parthenolide prevented FA-induced reductions in insulin-stimulated glucose uptake and NFkappaB nuclear translocation. Most importantly, NFkappaB SN50, a cell-permeable peptide that inhibits NFkappaB nuclear translocation downstream of IKK, was sufficient to prevent palmitate-induced reductions in insulin-stimulated glucose uptake. Acetylsalicylate, but not NFkappaB SN50, prevented FA effects on phosphatidylinositol-3 kinase activity and protein kinase B phosphorylation. We conclude that FAs induce insulin resistance and activates NFkappaB in L6 cells. Furthermore, inhibition of NFkappaB activation, indirectly by preventing IKK activation or directly by inhibiting NFkappaB nuclear translocation, prevents the detrimental effects of palmitate on the metabolic actions of insulin in L6 myotubes.	Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	O'Doherty, RM (corresponding author), E1112 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	odohertyr@msx.dept-med.pitt.edu	Perdomo, German/K-6703-2014	Perdomo, German/0000-0002-2301-0012	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058855] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK58855-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Boden G, 2001, DIABETES, V50, P1612, DOI 10.2337/diabetes.50.7.1612; Cai DS, 2004, DIABETES, V53, pA19; Chalkley SM, 1998, METABOLISM, V47, P1121, DOI 10.1016/S0026-0495(98)90287-6; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gurnell M, 2003, J CLIN ENDOCR METAB, V88, P2412, DOI 10.1210/jc.2003-030435; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kelley DE, 2002, ANNU REV NUTR, V22, P325, DOI 10.1146/annurev.nutr.22.010402.102912; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; LARDINOIS CK, 1991, J AM COLL NUTR, V10, P340; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lopez-Candales Angel, 2001, Journal of Medicine (Westbury), V32, P283; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Oakes ND, 1997, DIABETES, V46, P2022, DOI 10.2337/diabetes.46.12.2022; Paolisso G, 1998, DIABETIC MED, V15, P360, DOI 10.1002/(SICI)1096-9136(199805)15:5<360::AID-DIA568>3.0.CO;2-W; Pellizzon M, 2002, OBES RES, V10, P947, DOI 10.1038/oby.2002.129; POPPSNIJDERS C, 1987, DIABETES RES CLIN EX, V4, P141; RAMLAL T, 1988, BIOCHEM BIOPH RES CO, V157, P1329, DOI 10.1016/S0006-291X(88)81020-9; RICHIERI GV, 1995, J LIPID RES, V36, P229; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; SPECTOR A A, 1978, P229; SPECTOR AA, 1975, J LIPID RES, V16, P165; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tamura Y, 2004, DIABETES, V53, pA36; Taouis M, 2002, AM J PHYSIOL-ENDOC M, V282, pE664, DOI 10.1152/ajpendo.00320.2001; Tremblay F, 2001, J BIOL CHEM, V276, P38052; VESSBY B, 1989, J INTERN MED, V225, P207, DOI 10.1111/j.1365-2796.1989.tb01458.x; Wilson PWF, 2003, CIRCULATION, V108, P1422, DOI 10.1161/01.CIR.0000089505.34741.E5; Wilson PWF, 2003, CIRCULATION, V108, P1537, DOI 10.1161/01.CIR.0000089506.12223.F1; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2004, DIABETES, V53, pA19; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	48	175	190	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41294	41301		10.1074/jbc.M406514200	http://dx.doi.org/10.1074/jbc.M406514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15252018	hybrid			2022-12-25	WOS:000224075500008
J	Feng, JH; Park, J; Cron, P; Hess, D; Hemmings, BA				Feng, JH; Park, J; Cron, P; Hess, D; Hemmings, BA			Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; GROWTH-FACTOR RECEPTOR; CATALYTIC SUBUNIT; PHOSPHORYLATION SITES; INOSITOL PHOSPHATE; PDK2 ACTIVITY; KU ANTIGEN; BINDING; PK; ACTIVATION	Full activation of protein kinase B (PKB)/Akt requires phosphorylation on Thr-308 and Ser-473 by 3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-473 kinase (S473K), respectively. Although PDK1 has been well characterized, the identification of the S473K remains controversial. A major PKB Ser-473 kinase activity was purified from the membrane fraction of HEK293 cells and found to be DNA-dependent protein kinase (DNA-PK). DNA-PK co-localized and associated with PKB at the plasma membrane. In vitro, DNA-PK phosphorylated PKB on Ser-473, resulting in a similar to10-fold enhancement of PKB activity. Knockdown of DNA-PK by small interfering RNA inhibited Ser-473 phosphorylation induced by insulin and pervanadate. DNA-PK-deficient glioblastoma cells did not respond to insulin at the level of Ser-473 phosphorylation; this effect was restored by complementation with the human PRKDC gene. We conclude that DNA-PK is a long sought after kinase responsible for the Ser-473 phosphorylation step in the activation of PKB.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch	Park, Jongsun/E-7465-2010	Park, Jongsun/0000-0002-4690-1854				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brewerton SC, 2004, J STRUCT BIOL, V145, P295, DOI 10.1016/j.jsb.2003.11.024; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Byrum J, 2004, NUCLEIC ACIDS RES, V32, P2776, DOI 10.1093/nar/gkh592; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Danska JS, 1996, MOL CELL BIOL, V16, P5507; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; DVIR A, 1993, J BIOL CHEM, V268, P10440; Erdemir T, 2002, J CELL SCI, V115, P207; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fujimori A, 2000, IMMUNOGENETICS, V51, P965, DOI 10.1007/s002510000227; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Henkels KM, 1997, CANCER RES, V57, P4488; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Hresko RC, 2003, J BIOL CHEM, V278, P21615, DOI 10.1074/jbc.M302937200; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Jeggo PA, 1996, CURR TOP MICROBIOL, V217, P79; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Lucero H, 2003, J BIOL CHEM, V278, P22136, DOI 10.1074/jbc.M301579200; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; Nilsson A, 1999, CELL PROLIFERAT, V32, P239, DOI 10.1046/j.1365-2184.1999.3240239.x; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Piccolo E, 2004, ONCOGENE, V23, P1754, DOI 10.1038/sj.onc.1207296; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2003, CANCER RES, V63, P1198; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	70	399	425	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41189	41196		10.1074/jbc.M406731200	http://dx.doi.org/10.1074/jbc.M406731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262962	hybrid			2022-12-25	WOS:000223916800118
J	Kittanakom, S; Cordat, E; Akkarapatumwong, V; Yenchitsomanus, P; Reithmeier, RAF				Kittanakom, S; Cordat, E; Akkarapatumwong, V; Yenchitsomanus, P; Reithmeier, RAF			Trafficking defects of a novel autosomal recessive distal renal tubular acidosis mutant (S773P) of the human kidney anion exchanger (kAE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOUTHEAST-ASIAN OVALOCYTOSIS; HUMAN-ERYTHROCYTE-MEMBRANE; TRANSPORT PROTEIN; INTRACELLULAR-TRANSPORT; ANION-EXCHANGER-1 GENE; IMPAIRED TRAFFICKING; BAND-3 MUTATIONS; PLASMA-MEMBRANE; GLYCOPHORIN-A; H+-ATPASE	Autosomal dominant and recessive distal renal tubular acidosis (dRTA) can be caused by mutations in the anion exchanger 1 (AE1 or SLC4A1) gene, which encodes the erythroid chloride/bicarbonate anion exchanger membrane glycoprotein (eAE1) and a truncated kidney isoform (kAE1). The biosynthesis and trafficking of kAE1 containing a novel recessive missense dRTA mutation (kAE1 S773P) was studied in transiently transfected HEK-293 cells, expressing the mutant alone or in combination with wild-type kAE1 or another recessive mutant, kAE1 G701D. The kAE1 S773P mutant was expressed at a three times lower level than wild-type, had a 2-fold decrease in its half-life, and was targeted for degradation by the proteasome. It could not be detected at the plasma membrane in human embryonic kidney cells and showed predominant endoplasmic reticulum immunolocalization in both human embryonic kidney and LLC-PK1 cells. The oligosaccharide on a kAE1 S773P N-glycosylation mutant (N555) was not processed to the complex form indicating impaired exit from the endoplasmic reticulum. The kAE1 S773P mutant showed decreased binding to an inhibitor affinity resin and increased sensitivity to proteases, suggesting that it was not properly folded. The other recessive dRTA mutant, kAE1 G701D, also exhibited defective trafficking to the plasma membrane. The recessive kAE1 mutants formed dimers like wild-type AE1 and could hetero-oligomerize with wild-type kAE1 or with each other. Hetero-oligomers of wild-type kAE1 with recessive kAE1 S773P or G701D, in contrast to the dominant kAE1 R589H mutant, were delivered to the plasma membrane.	Univ Toronto, Dept Biochem, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Mahidol Univ, Inst Mol Biol & Genet, Nakhon Pathom, Thailand; Mahidol Univ, Div Med Mol Biol, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; Natl Sci & Technol Dev Agcy, Med Biotechnol Unit, Natl Ctr Biotechnol & Genet Engn, Bangkok 10700, Thailand	University of Toronto; University of Toronto; Mahidol University; Mahidol University; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC)	Reithmeier, RAF (corresponding author), Univ Toronto, Dept Biochem, Canadian Inst Hlth, Res Grp Membrane Biol, Rm 5216,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	r.reithmeier@utoronto.ca						Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Bajaj G, 1996, AM J KIDNEY DIS, V27, P880, DOI 10.1016/S0272-6386(96)90526-0; BENTUR L, 1989, AM J NEPHROL, V9, P470, DOI 10.1159/000168015; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Bruce LJ, 2000, BIOCHEM J, V350, P41, DOI 10.1042/0264-6021:3500041; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Cheidde L, 2003, PEDIATRICS, V112, P1361, DOI 10.1542/peds.112.6.1361; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cordat E, 2003, TRAFFIC, V4, P642, DOI 10.1034/j.1600-0854.2003.00123.x; Devonald MAJ, 2003, NAT GENET, V33, P125, DOI 10.1038/ng1082; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; JENNINGS ML, 1995, BIOCHEMISTRY-US, V34, P3588, DOI 10.1021/bi00011a013; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUDRYCKI KE, 1993, AM J PHYSIOL, V264, pF540, DOI 10.1152/ajprenal.1993.264.3.F540; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; Marr N, 2001, PFLUG ARCH EUR J PHY, V442, P73, DOI 10.1007/s004240000498; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; Quilty JA, 2002, BIOCHEM J, V368, P895, DOI 10.1042/BJ20020574; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Quilty JA, 2000, TRAFFIC, V1, P987, DOI 10.1034/j.1600-0854.2000.011208.x; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Rungroj N, 2004, J BIOL CHEM, V279, P13833, DOI 10.1074/jbc.M400188200; Rysava R, 1997, NEPHROL DIAL TRANSPL, V12, P1869, DOI 10.1093/ndt/12.9.1869; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; Sritippayawan S, 2004, AM J KIDNEY DIS, V44, P64, DOI 10.1053/j.ajkd.2004.03.033; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; Taylor JP, 2002, J CLIN ENDOCR METAB, V87, P1778, DOI 10.1210/jc.87.4.1778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; Vasuvattakul S, 1999, KIDNEY INT, V56, P1674, DOI 10.1046/j.1523-1755.1999.00756.x; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Wrong O, 2002, KIDNEY INT, V62, P10, DOI 10.1046/j.1523-1755.2002.00417.x; Yenchitsomanus PT, 2002, AM J KIDNEY DIS, V40, P21, DOI 10.1053/ajkd.2002.33909; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Young MT, 2000, BIOCHEM J, V350, P53, DOI 10.1042/0264-6021:3500053; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	54	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40960	40971		10.1074/jbc.M405356200	http://dx.doi.org/10.1074/jbc.M405356200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15252044	hybrid			2022-12-25	WOS:000223916800093
J	Tokumitsu, H; Hatano, N; Inuzuka, H; Yokokura, S; Nozaki, N; Kobayashi, R				Tokumitsu, H; Hatano, N; Inuzuka, H; Yokokura, S; Nozaki, N; Kobayashi, R			Mechanism of the generation of autonomous activity of Ca2+/calmodulin-dependent protein kinase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAM-KINASE; GENE-EXPRESSION; DEFICIENT MICE; T-LYMPHOCYTES; CALMODULIN; ACTIVATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; CALCIUM; CREB	Ca2+/calmodulin-dependent protein kinase IV (CaM-KIV) is phosphorylated at Thr(196) by Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), resulting in induction of both autonomous activity and a high level of Ca2+/CaM-dependent activity. We have shown that the kinetics of Thr(196) phosphorylation of CaM-KIV by CaM-KK is well correlated with the generation of its autonomous activity, although Thr(177) phosphorylation of CaM-KI does not induce its autonomous activity. The activities of CaM-KI chimera mutants fused with C-terminal regions ( residues 296 - 469 and 296 - 350) of CaM-KIV are completely dependent on Ca2+/CaM, which is also the case for CaM-KI. Unlike wild-type CaM-KI, however, phosphorylation of Thr177 in the chimera mutants by CaM-KK resulted in generation of significant autonomous activities, indicating that the phosphorylation of Thr in the activation loop is sufficient to partially release the autoinhibitory region of CaM-KIV from the catalytic core. Indeed, the CaM-KIV peptide ( residues 304 - 325) containing minimum autoinhibitory sequences ( residues 314 - 321) suppressed the activity of non-phosphorylated CaM-KIV with an IC50 of similar to50 muM, and this suppression was competitive with respect to the peptide substrate; however, the CaM-KIV peptide was not capable of inhibiting Thr(196)-phosphorylated CaM-KIV. Taken together, these results indicated that the Thr(196) phosphorylation of CaM-KIV by CaM-KK reduced the interaction of the catalytic core with the autoinhibitory region, resulting in generation of the autonomous activity.	Kagawa Univ, Fac Med, Dept Signal Transduct Sci, Miki, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Cell Physiol, Miki, Kagawa 7610793, Japan; Kanagawa Dent Coll, Dept Biochem & Mol Biol, Yokosuka, Kanagawa 2388580, Japan	Kagawa University; Kagawa University; Kanagawa Dental College	Tokumitsu, H (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	tokumit@med.kagawa-u.ac.jp	Hatano, Naoya/F-6147-2011; Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Anderson KA, 2004, J BIOL CHEM, V279, P31708, DOI 10.1074/jbc.M404523200; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; KIMURA K, 1994, J BIOL CHEM, V269, P24523; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wu JY, 2000, ENDOCRINOLOGY, V141, P4777, DOI 10.1210/en.141.12.4777; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199	48	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40296	40302		10.1074/jbc.M406534200	http://dx.doi.org/10.1074/jbc.M406534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262966	hybrid			2022-12-25	WOS:000223916800010
J	Andersen, P; Kragelund, BM; Olsen, AN; Larsen, FH; Chua, NH; Poulsen, FM; Skriver, K				Andersen, P; Kragelund, BM; Olsen, AN; Larsen, FH; Chua, NH; Poulsen, FM; Skriver, K			Structure and biochemical function of a prototypical Arabidopsis U-box domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; NMR STRUCTURE; REPEAT PROTEINS; DATABASE; BINDING; KINASE; PROGRAM; QUALITY; SYSTEM; FAMILY	U-box proteins, as well as other proteins involved in regulated protein degradation, are apparently over-represented in Arabidopsis compared with other model eukaryotes. The Arabidopsis protein AtPUB14 contains a typical U-box domain followed by an Armadillo repeat region, a domain organization that is frequently found in plant U-box proteins. In vitro ubiquitination assays demonstrated that AtPUB14 functions as an E3 ubiquitin ligase with specific E2 ubiquitin-conjugating enzymes. The structure of the AtPUB14 U-box domain was determined by NMR spectroscopy. It adopts the betabetaalphabeta fold of the Prp19p U-box and RING finger domains. In these proteins, conserved hydrophobic residues form a putative E2-binding cleft. By contrast, they contain no common polar E2 binding site motif. Two hydrophobic cores stabilize the AtPUB14 U-box fold, and hydrogen bonds and salt bridges interconnect the residues corresponding to zinc ion-coordinating residues in RING domains. Residues from a C-terminal alpha-helix interact with the core domain and contribute to stabilization. The Prp19p U-box lacks a corresponding C-terminal alpha-helix. Chemical shift analysis suggested that aromatic residues exposed at the N terminus and the C-terminal alpha-helix of the AtPUB14 U-box participate in dimerization. Thus, AtPUB14 may form a biologically relevant dimer. This is the first plant U-box structure to be determined, and it provides a model for studies of the many plant U-box proteins and their interactions. Structural insight into these interactions is important, because ubiquitin-dependent protein degradation is a prevalent regulatory mechanism in plants.	Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen K, Denmark; Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA	University of Copenhagen; Rockefeller University	Poulsen, FM (corresponding author), Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen K, Denmark.	fmp@apk.molbio.ku.dk; ks@apk.molbio.ku.dk	Larsen, Flemming/A-5255-2015; Kragelund, Birthe/M-3927-2014; Skriver, Karen/K-9860-2014; Poulsen, Flemming M/E-6848-2010	Larsen, Flemming/0000-0001-5180-6870; Kragelund, Birthe/0000-0002-7454-1761; Skriver, Karen/0000-0003-2225-4012; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amador V, 2001, CELL, V106, P343, DOI 10.1016/S0092-8674(01)00445-7; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Azevedo C, 2001, TRENDS PLANT SCI, V6, P354, DOI 10.1016/S1360-1385(01)01960-4; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Brunger A.T., 1992, X PLOR SOFTWARE MANU; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; Hare PD, 2003, CURR OPIN PLANT BIOL, V6, P453, DOI 10.1016/S1369-5266(03)00080-3; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mudgil Y, 2004, PLANT PHYSIOL, V134, P59, DOI 10.1104/pp.103.029553; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Stone SL, 2003, PLANT CELL, V15, P885, DOI 10.1105/tpc.009845; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VRIED G, 1990, J MOL GRAPHICS, V78, P713; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Yan JQ, 2003, PLANT PHYSIOL, V132, P861, DOI 10.1104/pp.103.020800; Yurchenko V, 2003, GENE DEV, V17, P581, DOI 10.1101/gad.1058103; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	49	69	79	4	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40053	40061		10.1074/jbc.M405057200	http://dx.doi.org/10.1074/jbc.M405057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15231834	hybrid			2022-12-25	WOS:000223791500103
J	Collins, RF; Frye, SA; Kitmitto, A; Ford, RC; Tonjum, T; Derrick, JP				Collins, RF; Frye, SA; Kitmitto, A; Ford, RC; Tonjum, T; Derrick, JP			Structure of the Neisseria meningitidis outer membrane PilQ secretin complex at 12 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; PROTEIN; BIOGENESIS; TRANSMEMBRANE; GONORRHOEAE; COMPONENTS; CHANNEL; IMAGES	The bacterial pathogen Neisseria meningitidis expresses long, thin, retractile fibers ( called type IV pili) from its cell surface and uses these adhesive structures to mediate primary attachment to epithelial cells during host colonization and invasion. PilQ is an outer membrane protein complex that is essential for the translocation of these pili across the outer membrane. Here, we present the structure of the PilQ complex determined by cryoelectron microscopy to 12 Angstrom resolution. The dominant feature of the structure is a large central cavity, formed by four arm features that spiral upwards from a squared ring base and meet to form a prominent cap region. The cavity, running through the center of the complex, is continuous and is effectively sealed at both the top and bottom. Analysis of the complex using self-orientation and by examination of two-dimensional crystals indicates a strong C4 rotational symmetry, with a much weaker C12 rotational symmetry, consistent with PilQ possessing true C4 symmetry with C12 quasisymmetry. We therefore suggest that the complex is a homododecamer, formed by association of 12 PilQ polypeptide chains into a tetramer of trimers. The structure of the PilQ complex, with its large and well defined central chamber, suggests that it may not function solely as a passive portal in the outer membrane, but could be actively involved in mediating pilus assembly or modification.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Oslo, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Inst Microbiol, N-0027 Oslo, Norway	University of Manchester; University of Oslo; University of Oslo	Derrick, JP (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Sackville St,POB 88, Manchester M60 1QD, Lancs, England.	Jeremy.Derrick@umist.ac.uk	Tønjum, Tone/J-4581-2014	Frye, Stephan/0000-0002-0786-8481; Tonjum, Tone/0000-0002-1709-6921; Derrick, Jeremy/0000-0002-4350-5354; Ford, Robert/0000-0002-0958-1505				Aas FE, 2002, MOL MICROBIOL, V46, P749, DOI 10.1046/j.1365-2958.2002.03193.x; Adrian M, 1998, MICRON, V29, P145, DOI 10.1016/S0968-4328(97)00068-1; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beis K, 2004, J BIOL CHEM, V279, P28227, DOI 10.1074/jbc.M402913200; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; Cohen-Krausz S, 2003, J MOL BIOL, V331, P1093, DOI 10.1016/S0022-2836(03)00810-6; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Drake SL, 1997, MOL MICROBIOL, V23, P657, DOI 10.1046/j.1365-2958.1997.2511618.x; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Golas MM, 2003, SCIENCE, V300, P980, DOI 10.1126/science.1084155; Hankamer BD, 2004, J BIOL CHEM, V279, P8862, DOI 10.1074/jbc.M307889200; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; Hwang JW, 2003, J BACTERIOL, V185, P6695, DOI 10.1128/JB.185.22.6695-6701.2003; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Maier B, 2002, P NATL ACAD SCI USA, V99, P16012, DOI 10.1073/pnas.242523299; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Park HSM, 2002, INFECT IMMUN, V70, P3891, DOI 10.1128/IAI.70.7.3891-3903.2002; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; Stewart PL, 1999, J STRUCT BIOL, V128, P58, DOI 10.1006/jsbi.1999.4176; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Tonjum T, 1998, MOL MICROBIOL, V29, P111, DOI 10.1046/j.1365-2958.1998.00910.x; Tonjum T, 1997, GENE, V192, P155, DOI 10.1016/S0378-1119(97)00018-8; Tsitrin Y, 2002, NAT STRUCT BIOL, V9, P729, DOI 10.1038/nsb839; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wang MC, 2002, J MOL BIOL, V323, P85, DOI 10.1016/S0022-2836(02)00890-2; Wolfgang M, 2000, EMBO J, V19, P6408, DOI 10.1093/emboj/19.23.6408; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	45	108	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39750	39756		10.1074/jbc.M405971200	http://dx.doi.org/10.1074/jbc.M405971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254043	hybrid			2022-12-25	WOS:000223791500068
J	He, X; de Montellano, PRO				He, X; de Montellano, PRO			Radical rebound mechanism in cytochrome P-450-catalyzed hydroxylation of the multifaceted radical clocks alpha- and beta-thujone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-H HYDROXYLATION; CYTOCHROME P450-CATALYZED HYDROXYLATION; 2-STATE REACTIVITY; CRYSTAL-STRUCTURE; MICROSOMAL CYTOCHROME-P-450; ALIPHATIC HYDROXYLATION; SPECIES-DIFFERENCES; LIVER-MICROSOMES; FATTY-ACIDS; IN-VITRO	alpha-Thujone (1alpha) and beta-thujone (1beta) were used to investigate the mechanism of hydrocarbon hydroxylation by cytochromes P-450(cam) (CYP101) and P-450(BM3) (CYP102). The thujones are hydroxylated by these enzymes at various positions, but oxidation at C-4 gives rise to both rearranged and unrearranged hydroxylation products. Rearranged products result from the formation of a radical intermediate that can undergo either inversion of stereochemistry or ring opening of the adjacent cyclopropane ring. Both of these rearrangements, as well as a C-4 desaturation reaction, are observed. The ring opening clock gives oxygen rebound rates that range from 0.2x10(10) to 2.8x10(10) s(-1) for the different substrate and enzyme combinations. The C-4 inversion reaction provides independent confirmation of a radical intermediate. The phenol product expected if a C-4 cationic rather than radical intermediate is formed is not detected. The results are consistent with a two-state process and provide support for a radical rebound but not a hydroperoxide insertion mechanism for cytochrome P-450 hydroxylation.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON JK, 1993, BIOCHEMISTRY-US, V32, P9209, DOI 10.1021/bi00086a028; Auclair K, 2002, J AM CHEM SOC, V124, P6020, DOI 10.1021/ja025608h; BARTON DHR, 1985, TETRAHEDRON, V41, P3901, DOI 10.1016/S0040-4020(01)97173-X; BOWRY VW, 1991, J AM CHEM SOC, V113, P5699, DOI 10.1021/ja00015a025; Chandrasena REP, 2004, J AM CHEM SOC, V126, P115, DOI 10.1021/ja038237t; Cryle MJ, 2004, CHEM COMMUN, P512, DOI 10.1039/b315911f; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; de Montellano PRO, 2002, NAT PROD REP, V19, P477, DOI 10.1039/b101297p; de Visser SP, 2004, J AM CHEM SOC, V126, P8362, DOI 10.1021/ja048528h; DEMONTELLANO PRO, 1987, J AM CHEM SOC, V109, P3415; DeVoss JJ, 1997, J AM CHEM SOC, V119, P5489, DOI 10.1021/ja970349v; FOSTER AB, 1974, CHEM-BIOL INTERACT, V9, P327, DOI 10.1016/0009-2797(74)90128-8; FROMMER U, 1970, H-S Z PHYSIOL CHEM, V351, P903, DOI 10.1515/bchm2.1970.351.2.903; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; GROVES JT, 1984, J AM CHEM SOC, V106, P2177, DOI 10.1021/ja00319a044; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Harris N, 2000, ANGEW CHEM INT EDIT, V39, P2003, DOI 10.1002/1521-3773(20000602)39:11<2003::AID-ANIE2003>3.0.CO;2-M; HJELMELAND LM, 1977, BIOCHEM BIOPH RES CO, V76, P541, DOI 10.1016/0006-291X(77)90758-6; Hold KM, 2000, P NATL ACAD SCI USA, V97, P3826, DOI 10.1073/pnas.070042397; Hold KM, 2001, CHEM RES TOXICOL, V14, P589, DOI 10.1021/tx000242c; Jin SX, 2003, J AM CHEM SOC, V125, P3406, DOI 10.1021/ja029272n; KORZEKWA KR, 1990, J AM CHEM SOC, V112, P7042, DOI 10.1021/ja00175a040; KORZEKWA KR, 1990, DRUG METAB DISPOS, V18, P974; Kumar D, 2004, J AM CHEM SOC, V126, P5072, DOI 10.1021/ja0318737; Kumar D, 2004, J AM CHEM SOC, V126, P1907, DOI 10.1021/ja039439s; Kumar D, 2003, J AM CHEM SOC, V125, P13024, DOI 10.1021/ja036906x; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; MCCLANAHAN RH, 1988, J AM CHEM SOC, V110, P1979, DOI 10.1021/ja00214a060; Newcomb M, 2000, ACCOUNTS CHEM RES, V33, P449, DOI 10.1021/ar960058b; Newcomb M, 2002, J AM CHEM SOC, V124, P6879, DOI 10.1021/ja017858o; Newcomb M, 2000, J AM CHEM SOC, V122, P2677, DOI 10.1021/ja994106+; Obach RS, 2001, DRUG METAB DISPOS, V29, P1599; Ogliaro F, 2002, J AM CHEM SOC, V124, P2806, DOI 10.1021/ja0171963; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RETTIE AE, 1988, J BIOL CHEM, V263, P13733; SCHENKMAN JB, 1982, INT ENCY PHARM THERA, P587; Schroder D, 2000, ACCOUNTS CHEM RES, V33, P139, DOI 10.1021/ar990028j; Shaik S, 1998, CHEM-EUR J, V4, P193, DOI 10.1002/(SICI)1521-3765(19980210)4:2<193::AID-CHEM193>3.0.CO;2-Q; Sirisoma NS, 2001, J AGR FOOD CHEM, V49, P1915, DOI 10.1021/jf001445+; Villorbina G, 2003, J ORG CHEM, V68, P2820, DOI 10.1021/jo0267100; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1986, J AM CHEM SOC, V108, P6024, DOI 10.1021/ja00279a059	45	35	36	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39479	39484		10.1074/jbc.M406838200	http://dx.doi.org/10.1074/jbc.M406838200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258138	hybrid			2022-12-25	WOS:000223791500037
J	Sun, Y; Mansour, M; Crack, JA; Gass, GL; MacRae, TH				Sun, Y; Mansour, M; Crack, JA; Gass, GL; MacRae, TH			Oligomerization, chaperone activity, and nuclear localization of p26, a small heat shock protein from Artemia franciscana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK/ALPHA-CRYSTALLIN PROTEIN; ALPHA-B-CRYSTALLIN; SUBUNIT EXCHANGE; MOLECULAR CHARACTERIZATION; STRESS RESISTANCE; ENCYSTED EMBRYOS; TERMINAL DOMAIN; A-CRYSTALLIN; BRINE SHRIMP; HSP27	Artemia franciscana embryos undergo encystment, developmental arrest and diapause, the last characterized by profound metabolic dormancy and extreme stress resistance. Encysted embryos contain an abundant small heat shock protein termed p26, a molecular chaperone that undoubtedly has an important role in development. To understand better the role of p26 in Artemia embryos, the structural and functional characteristics of full-length and truncated p26 expressed in Escherichia coli and COS-1 cells were determined. p26 chaperone activity declined with increasing truncation of the protein, and those deletions with the greatest adverse effect on protection of citrate synthase during thermal stress had the most influence on oligomerization. When produced in either prokaryotic or eukaryotic cells the p26 alpha-crystallin domain consisting of amino acid residues 61 - 152 existed predominantly as monomers, and p26 variants lacking the amino-terminal domain but with intact carboxyl-terminal extensions were mainly monomers and dimers. The amino terminus was, therefore, required for efficient dimer formation. Assembly of higher order oligomers was enhanced by the carboxyl-terminal extension, although removing the 10 carboxyl-terminal residues had relatively little effect on oligomerization and chaperoning. Full-length and carboxyl-terminal truncated p26 resided in the cytoplasm of transfected COS-1 cells; however, variants missing the complete amino-terminal domain and existing predominantly as monomers/dimers entered the nuclei. A mechanism whereby oligomer disassembly assisted entry of p26 into nuclei was suggested, this of importance because p26 translocates into Artemia embryo nuclei during development and stress. However, when examined in Artemia, the p26 oligomer size was unchanged under conditions that allowed movement into nuclei, suggesting a process more complex than just oligomer dissociation.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	MacRae, TH (corresponding author), Dalhousie Univ, Dept Biol, 1355 Oxford St, Halifax, NS B3H 4J1, Canada.	tmacrae@dal.ca						Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Basha E, 2004, J BIOL CHEM, V279, P7566, DOI 10.1074/jbc.M310684200; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; Borrelli MJ, 2002, CELL STRESS CHAPERON, V7, P281, DOI 10.1379/1466-1268(2002)007<0281:SPBAFH>2.0.CO;2; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bukach OV, 2004, EUR J BIOCHEM, V271, P291, DOI 10.1046/j.1432-1033.2003.03928.x; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Clegg JS, 1999, AM ZOOL, V39, P836; Clegg JS, 1996, PHYSIOL ZOOL, V69, P49, DOI 10.1086/physzool.69.1.30164200; CLEGG JS, 1995, EXP CELL RES, V219, P1, DOI 10.1006/excr.1995.1197; Clegg JS, 2000, CELL TISSUE RES, V301, P433, DOI 10.1007/s004410000249; Crack JA, 2002, EUR J BIOCHEM, V269, P933, DOI 10.1046/j.0014-2956.2001.02726.x; Day RM, 2003, CELL STRESS CHAPERON, V8, P183, DOI 10.1379/1466-1268(2003)008<0183:ASHCPF>2.0.CO;2; Denlinger DL, 2002, ANNU REV ENTOMOL, V47, P93, DOI 10.1146/annurev.ento.47.091201.145137; Duverger O, 2004, J BIOL CHEM, V279, P10252, DOI 10.1074/jbc.M309906200; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Fu XM, 2003, BIOCHEM BIOPH RES CO, V310, P412, DOI 10.1016/j.bbrc.2003.09.027; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Guruprasad K, 2003, INT J BIOL MACROMOL, V33, P107, DOI 10.1016/S0141-8130(03)00074-6; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Hasan A, 2004, PROTEIN SCI, V13, P332, DOI 10.1110/ps.03180004; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Jackson SA, 1996, DEV GROWTH DIFFER, V38, P153; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim MV, 2004, BIOCHEM BIOPH RES CO, V315, P796, DOI 10.1016/j.bbrc.2004.01.130; Kim R, 2003, P NATL ACAD SCI USA, V100, P8151, DOI 10.1073/pnas.1032940100; Laksanalamai P, 2004, EXTREMOPHILES, V8, P1, DOI 10.1007/s00792-003-0362-3; Laksanalamai P, 2003, EXTREMOPHILES, V7, P79, DOI 10.1007/s00792-002-0298-z; Lentze N, 2003, J MOL BIOL, V328, P927, DOI 10.1016/S0022-2836(03)00356-5; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liang P, 1997, J BIOL CHEM, V272, P19051, DOI 10.1074/jbc.272.30.19051; Liang P, 1997, EUR J BIOCHEM, V243, P225, DOI 10.1111/j.1432-1033.1997.0225a.x; Liang P, 1999, DEV BIOL, V207, P445, DOI 10.1006/dbio.1998.9138; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MacRae TH, 2003, SEMIN CELL DEV BIOL, V14, P251, DOI 10.1016/j.semcdb.2003.09.019; MacRae TH, 2001, EXPTL BIOL REV, P169; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Pasta SY, 2003, J BIOL CHEM, V278, P51159, DOI 10.1074/jbc.M307523200; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Siddique M, 2003, CELL STRESS CHAPERON, V8, P381, DOI 10.1379/1466-1268(2003)008<0381:THSPHR>2.0.CO;2; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Sun WN, 2002, BBA-GENE STRUCT EXPR, V1577, P1, DOI 10.1016/S0167-4781(02)00417-7; Takeuchi N, 2004, BIOL PHARM BULL, V27, P308, DOI 10.1248/bpb.27.308; Thampi P, 2003, BIOCHEMISTRY-US, V42, P11857, DOI 10.1021/bi030129w; Theriault JR, 2004, J BIOL CHEM, V279, P23463, DOI 10.1074/jbc.M402325200; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; van de Klundert FAJM, 1999, EUR J CELL BIOL, V78, P567, DOI 10.1016/S0171-9335(99)80022-3; van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Willsie JK, 2002, J CELL BIOCHEM, V84, P601, DOI 10.1002/jcb.10040; Willsie JK, 2001, J EXP BIOL, V204, P2339; Wintrode PL, 2003, BIOCHEMISTRY-US, V42, P10667, DOI 10.1021/bi034117m; Young LS, 1999, BIOCHEM J, V344, P31, DOI 10.1042/0264-6021:3440031	59	44	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39999	40006		10.1074/jbc.M406999200	http://dx.doi.org/10.1074/jbc.M406999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258152	hybrid			2022-12-25	WOS:000223791500097
J	Yue, GGL; Yip, TWN; Huang, Y; Ko, WH				Yue, GGL; Yip, TWN; Huang, Y; Ko, WH			Cellular mechanism for potentiation of Ca2+-mediated Cl- secretion by the flavonoid baicalein in intestinal epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RAT DISTAL COLON; SWEAT GLAND EPITHELIUM; CHLORIDE SECRETION; SCUTELLARIA-BAICALENSIS; ANION SECRETION; CYSTIC-FIBROSIS; T84 CELLS; ION-TRANSPORT; K+ CHANNELS	Flavonoids belong to a large group of plant polyphenols that are consumed daily in large amounts. Our previous findings have shown that baicalein, a major flavonoid derived from the medicinal herb Scutellariae radix, induces Cl- secretion across rat colonic mucosa. The current study examines the effect of baicalein on Cl- secretion in human colonic epithelial (T84) cells and its interaction with Ca2+- and cAMP-dependent secretagogues. We have employed a technique that allows concurrent monitoring of short-circuit current (I-SC) and [Ca2+](i) in polarized epithelium. Basolateral application of baicalein induced a concentration-dependent increase in I-SC. The increase in I-SC was because of Cl- secretion and was not accompanied by any discernible increase in [Ca2+](i). Baicalein acted synergistically with Ca2+- but not cAMP-dependent secretagogues. In the presence of baicalein, the carbachol and histamine induced increases in I-SC that were markedly potentiated while increases in [Ca2+](i) were not significantly enhanced. Baicalein treatment uncoupled Cl- secretion from inhibitory effects normally generated by muscarinic activation. Baicalein treatment also resulted in increased cAMP content and activated PKA activity. Nystatin permeabilization studies revealed that baicalein stimulated an apical Cl- current but did not activate any basolateral K+ current. These data suggest that baicalein potentiates Ca2+-mediated Cl- secretion through a signaling pathway involving cAMP and protein kinase A, most likely through the cystic fibrosis transmembrane conductance regulator in the apical membrane.	Chinese Univ Hong Kong, Dept Physiol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Ko, WH (corresponding author), Chinese Univ Hong Kong, Dept Physiol, Shatin, Hong Kong, Peoples R China.	whko@cuhk.edu.hk	Yue, Grace Gar-Lee/AAY-3945-2020; Ko, Hung/R-1802-2018; Huang, Yu/K-2866-2017	Yue, Grace Gar-Lee/0000-0002-1726-3566; Ko, Hung/0000-0002-2041-402X; Huang, Yu/0000-0002-1277-6784				Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Bochorakova H, 2003, PHYTOTHER RES, V17, P640, DOI 10.1002/ptr.1216; Cermak R, 2000, EXP PHYSIOL, V85, P255, DOI 10.1017/S0958067000019230; Cermak R, 2002, BRIT J PHARMACOL, V135, P1183, DOI 10.1038/sj.bjp.0704564; Cermak R, 2001, BIOCHEM PHARMACOL, V62, P1145, DOI 10.1016/S0006-2952(01)00758-4; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Chen ZY, 2000, J AM OIL CHEM SOC, V77, P73, DOI 10.1007/s11746-000-0011-y; Cuthbert AW, 1999, AM J PHYSIOL-CELL PH, V277, pC111, DOI 10.1152/ajpcell.1999.277.1.C111; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Di Carlo G, 1999, LIFE SCI, V65, P337, DOI 10.1016/S0024-3205(99)00120-4; Diener M, 1996, EUR J PHARMACOL, V299, P161, DOI 10.1016/0014-2999(95)00832-2; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; Greger R, 2000, ANNU REV PHYSIOL, V62, P467, DOI 10.1146/annurev.physiol.62.1.467; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Heinke B, 1999, ACTA PHYSIOL SCAND, V165, P403; HUANG HC, 1994, EUR J PHARM-MOLEC PH, V268, P73, DOI 10.1016/0922-4106(94)90121-X; Ikemoto S, 2000, UROLOGY, V55, P951, DOI 10.1016/S0090-4295(00)00467-2; Illek B, 1996, AM J PHYSIOL-CELL PH, V270, pC265, DOI 10.1152/ajpcell.1996.270.1.C265; Kahn MES, 2001, CLIN CANCER RES, V7, P343; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Ko WH, 1999, J MEMBRANE BIOL, V170, P205, DOI 10.1007/s002329900550; Ko WH, 2002, AM J PHYSIOL-GASTR L, V282, pG508, DOI 10.1152/ajpgi.00291.2001; Ko WH, 1996, J PHYSIOL-LONDON, V497, P19, DOI 10.1113/jphysiol.1996.sp021746; Ko WH, 1996, J PHYSIOL-LONDON, V493, P885, DOI 10.1113/jphysiol.1996.sp021431; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; MALL M, 1998, AM J PHYSIOL, V275, pC1274; McAlroy HL, 2000, BRIT J PHARMACOL, V131, P1651, DOI 10.1038/sj.bjp.0703743; NGUYEN TD, 1993, J NUTR, V123, P259; Roomans GM, 2001, EXPERT OPIN INV DRUG, V10, P1, DOI 10.1517/13543784.10.1.1; Rufo PA, 2004, AM J PHYSIOL-CELL PH, V286, pC998, DOI 10.1152/ajpcell.00357.2003; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Shen YC, 2003, EUR J PHARMACOL, V465, P171, DOI 10.1016/S0014-2999(03)01378-5; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; WARHURST G, 1991, AM J PHYSIOL, V261, pG220, DOI 10.1152/ajpgi.1991.261.2.G220; WASSERMAN SI, 1988, AM J PHYSIOL, V254, pC53, DOI 10.1152/ajpcell.1988.254.1.C53; Wilson SM, 1998, BRIT J PHARMACOL, V124, P832, DOI 10.1038/sj.bjp.0701888; Wong CHY, 2002, J BIOL CHEM, V277, P9016, DOI 10.1074/jbc.M111917200; WONG SME, 1989, AM J PHYSIOL, V257, pC976, DOI 10.1152/ajpcell.1989.257.5.C976; Wu JA, 2001, AM J CHINESE MED, V29, P69, DOI 10.1142/S0192415X01000083; Zhang DY, 2003, CANCER RES, V63, P4037	48	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39310	39316		10.1074/jbc.M406787200	http://dx.doi.org/10.1074/jbc.M406787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15234961	hybrid			2022-12-25	WOS:000223791500016
J	Boldt, HB; Kjaer-Sorensen, K; Overgaard, MT; Weyer, K; Poulsen, CB; Sottrup-Jensen, L; Conover, CA; Giudice, LC; Oxvig, C				Boldt, HB; Kjaer-Sorensen, K; Overgaard, MT; Weyer, K; Poulsen, CB; Sottrup-Jensen, L; Conover, CA; Giudice, LC; Oxvig, C			The Lin12-Notch repeats of pregnancy-associated plasma protein-A bind calcium and determine its proteolytic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; PHYSIOLOGICAL INHIBITOR; HUMAN NOTCH1; PAPP-A; GROWTH; EXPRESSION; MODULE; IGF; IDENTIFICATION; TRANSDUCTION	The Lin12-Notch repeat (LNR) module of about 35 residues is a hallmark of the Notch receptor family. Three copies, arranged in tandem, are invariably present in the extracellular portion of the Notch receptors. Although their function is unknown, genetic and biochemical data indicate that the LNR modules participate in the regulation of ligand-induced proteolytic cleavage of the Notch receptor, a prerequisite to intramembrane cleavage and Notch signaling. Outside the Notch receptor family, the LNR module is present only in the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) and its homologue PAPP-A2, which also contain three copies. Curiously, LNR modules 1 and 2 are present within the proteolytic domain of PAPP-A/A2, but LNR3 is separated from LNR2 by more than 1000 amino acids. The growth factor antagonists insulin-like growth factor-binding protein (IGFBP)-4 and -5 are both substrates of PAPP- A. We provide here evidence that the PAPP- A LNR modules function together to determine the proteolytic specificity of PAPP- A. Analysis of C-terminally truncated PAPP- A mutants followed by the analysis of LNR deletion mutants demonstrated that each of the three PAPP- A LNR modules is strictly required for proteolytic activity against IGFBP-4 but not for proteolytic activity against IGFBP-5. Individual substitution of conserved LNR residues predicted to participate in calcium coordination caused elimination (D341A, D356A, D389A, D1484A, D1499A, and D1502A) or a significant reduction (D359A and E392A) of IGFBP-4 proteolysis, whereas IGFBP-5 proteolysis was unaffected. The activity of the latter mutants against IGFBP-4 could be partially rescued by calcium, and the addition of the calcium-binding protein calbindin D9k to wild-type PAPP- A eliminated activity against IGFBP-4 but not against IGFBP-5, demonstrating that the PAPP- A LNR modules bind calcium ions. We propose a model in which LNR3 is spatially localized in proximity to LNR1 and -2, forming a single functional unit.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA; Stanford Univ, Dept Gynecol & Obstet, Stanford, CA 94305 USA	Aarhus University; Mayo Clinic; Stanford University	Oxvig, C (corresponding author), Univ Aarhus, Dept Mol Biol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk	Kjaer-Sorensen, Kasper/AAF-1457-2020; Overgaard, Michael Toft/E-1354-2011	Overgaard, Michael Toft/0000-0002-1423-2481; Oxvig, Claus/0000-0002-4715-9719; Weyer, Kathrin/0000-0002-8473-7987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031579] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31579-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1999, BIOCHEMISTRY-US, V38, P4736, DOI 10.1021/bi982713o; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHANSSON C, 1990, EUR J BIOCHEM, V187, P455, DOI 10.1111/j.1432-1033.1990.tb15325.x; Kimble J, 1998, TRENDS BIOCHEM SCI, V23, P353, DOI 10.1016/S0968-0004(98)01263-8; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0; Ortiz CO, 2003, J BONE MINER RES, V18, P1066, DOI 10.1359/jbmr.2003.18.6.1066; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, V1, P754; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin QP, 1997, CLIN CHEM, V43, P2323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STOCKER W, 1995, PROTEIN SCI, V4, P823; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x	47	45	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38525	38531		10.1074/jbc.M405222200	http://dx.doi.org/10.1074/jbc.M405222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15262980	hybrid			2022-12-25	WOS:000223684100058
J	Gao, MH; Tang, T; Guo, T; Sun, SQ; Feramisco, JR; Hammond, HK				Gao, MH; Tang, T; Guo, T; Sun, SQ; Feramisco, JR; Hammond, HK			Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCIBLE GENE; HEART-FAILURE; INDUCED APOPTOSIS; C-JUN; CONTRACTILE FUNCTION; TRANSGENIC MICE; ATF3; CARDIOMYOPATHY; STIMULATION; PROMOTER	Cardiac-directed expression of adenylyl cyclase type VI (AC(VI)) increases stimulated cAMP production, improves heart function, and increases survival in cardiomyopathy. In contrast, pharmacological agents that increase intracellular levels of cAMP have detrimental effects on cardiac function and survival. We wondered whether effects that are independent of cAMP might be responsible for these salutary outcomes associated with AC(VI) expression. We therefore conducted a series of experiments focused on how gene transcription is influenced by AC(VI) in cultured neonatal rat cardiac myocytes, with a particular focus on genes that might influence cardiac function. We found that overexpression of AC(VI) down-regulated mRNA and protein expression of phospholamban, an inhibitor of the sarcoplasmic reticulum Ca2+-ATPase. We determined that the cAMP-responsive-like element in the phospholamban (PLB) promoter was critical for down-regulation by AC(VI). Overexpression of AC(VI) did not alter the expression of CREB, CREM, ATF1, ATF2, or ATF4 proteins. In contrast, overexpression of AC(VI) increased expression of ATF3 protein, a suppressor of transcription. Following AC(VI) gene transfer, when cardiac myocytes were stimulated with isoproterenol or NKH477, a water-soluble forskolin analog that directly stimulates AC, expression of ATF3 protein was increased even more, which correlated with reduced expression of PLB. We then showed that AC(VI)-induced ATF3 protein binds to the cAMP-responsive-like element on the PLB promoter and that overexpression of ATF3 in cardiac myocytes inhibits PLB promoter activity. These findings indicate that AC(VI) has effects on gene transcription that are not directly dependent on cAMP generation.	Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Hammond, HK (corresponding author), Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, 111-A,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	khammond@ucsd.edu			NHLBI NIH HHS [1P01 HL66941] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brittsan AG, 2000, J MOL CELL CARDIOL, V32, P2131, DOI 10.1006/jmcc.2000.1270; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; Dash R, 2001, CIRCULATION, V103, P889, DOI 10.1161/01.CIR.103.6.889; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; Gao MH, 1996, CANCER RES, V56, P4229; Gao MH, 2002, CARDIOVASC RES, V56, P197, DOI 10.1016/S0008-6363(02)00539-4; Haghighi K, 1997, GENE, V203, P199, DOI 10.1016/S0378-1119(97)00514-3; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Hai T, 1999, GENE EXPRESSION, V7, P321; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; IKRAM H, 1990, LANCET, V336, P517, DOI 10.1016/0140-6736(90)92078-V; JOHNS DC, 1992, BIOCHEM BIOPH RES CO, V188, P927, DOI 10.1016/0006-291X(92)91144-F; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; KRELL MJ, 1986, AM HEART J, V112, P787, DOI 10.1016/0002-8703(86)90475-8; Lai NC, 2000, CIRCULATION, V102, P2396, DOI 10.1161/01.CIR.102.19.2396; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; McTiernan CF, 1999, J MOL CELL CARDIOL, V31, P679, DOI 10.1006/jmcc.1998.0904; McTiernan CF, 1999, J MOL CELL CARDIOL, V31, P2137, DOI 10.1006/jmcc.1999.1042; Minamisawa S, 2003, BIOCHEM BIOPH RES CO, V304, P1, DOI 10.1016/S0006-291X(03)00526-6; Muller FU, 1998, FASEB J, V12, P1191; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Pearson AG, 2003, MOL BRAIN RES, V120, P38, DOI 10.1016/j.molbrainres.2003.09.014; Roth DM, 2002, CIRCULATION, V105, P1989, DOI 10.1161/01.CIR.0000014968.54967.D3; Roth DM, 1999, CIRCULATION, V99, P3099, DOI 10.1161/01.CIR.99.24.3099; TOYOFUKU T, 1991, J BIOL CHEM, V266, P5375; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38797	38802		10.1074/jbc.M405701200	http://dx.doi.org/10.1074/jbc.M405701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231818	hybrid			2022-12-25	WOS:000223684100091
J	Singh, J; Khan, GA; Kinarsky, L; Cheng, H; Wilken, J; Choi, KH; Bedows, E; Sherman, S; Cheng, PW				Singh, J; Khan, GA; Kinarsky, L; Cheng, H; Wilken, J; Choi, KH; Bedows, E; Sherman, S; Cheng, PW			Identification of disulfide bonds among the nine core 2 N-acetylglucosaminyltransferase-M cysteines conserved in the mucin beta 6-N-acetylglucosaminyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC GONADOTROPIN; GLYCAN BRANCH FORMATION; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BETA SUBUNIT; ASPARTATE-AMINOTRANSFERASE; LINKED GLYCOSYLATION; BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; EXPRESSION; BIOSYNTHESIS	Bovine core 2 beta1,6-N-acetylglucosaminyltransferase-M (bC2GnT-M) catalyzes the formation of all mucin beta1,6-N-acetylglucosaminides, including core 2, core 4, and blood group I structures. These structures expand the complexity of mucin carbohydrate structure and thus the functional potential of mucins. The four known mucin beta1,6-N-acetylglucosaminyltransferases contain nine conserved cysteines. We determined the disulfide bond assignments of these cysteines in [S-35] cysteine-labeled bC2GnT-M isolated from the serum-free conditioned medium of Chinese hamster ovary cells stably transfected with a pSecTag plasmid. This plasmid contains bC2GnT-M cDNA devoid of the 5'-sequence coding the cytoplasmic tail and transmembrane domain. The C18 reversed phase high performance liquid chromatographic profile of the tryptic peptides of reduced-alkylated S-35-labeled C2GnT-M was established using microsequencing. Each cystine pair was identified by rechromatography of the C8 high performance liquid chromatographic radiolabeled tryptic peptides of alkylated bC2GnT-M on C18 column. Among the conserved cysteines in bC2GnT-M, the second (Cys(113)) was a free thiol, whereas the other eight cysteines formed four disulfide bridges, which included the first (Cys(73)) and sixth (Cys(230)), third (Cys(164)) and seventh (Cys(384)), fourth (Cys(185)) and fifth (Cys(212)), and eighth (Cys(393)) and ninth (Cys(425)) cysteine residues. This pattern of disulfide bond formation differs from that of mouse C2GnT-L, which may contribute to the difference in substrate specificity between these two enzymes. Molecular modeling using disulfide bond assignments and the fold recognition/threading method to search the Protein Data Bank found a match with aspartate aminotransferase structure. This structure is different from the two major protein folds proposed for glycosyltransferases.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Dept Obstet & Gynecol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Cheng, PW (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	pcheng@unmc.edu	Khan, Gausal A/B-9525-2009	Khan, Gausal A/0000-0002-0306-6641	NCI NIH HHS [CA09746, P30 CA36727] Funding Source: Medline; NCRR NIH HHS [RR15635, P20 RR16469] Funding Source: Medline; NHLBI NIH HHS [HL48282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469, P20RR015635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL048282, R01HL048282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; Beum PV, 2001, ADV EXP MED BIOL, V491, P279; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Brockhausen I., 1997, GLYCOPROTEINS HUMAN, P5; CARLSEN RB, 1973, J BIOL CHEM, V248, P6810; CHENG PW, 1996, HUM GENE THER, V7, P175; Choi KH, 2004, AM J RESP CELL MOL, V30, P710, DOI 10.1165/rcmb.2003-0202OC; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Franco OL, 2003, GLYCOBIOLOGY, V13, P707, DOI 10.1093/glycob/cwg098; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; HUTH JR, 1992, J BIOL CHEM, V267, P8870; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Li CM, 1998, AM J RESP CELL MOL, V18, P343, DOI 10.1165/ajrcmb.18.3.2593; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MALASHKEVICH VN, 1995, BIOCHEMISTRY-US, V34, P405, DOI 10.1021/bi00002a004; MONIAUX P, 2001, FRONT BIOSCI, V6, P1192; RAMPHAL R, 1991, INFECT IMMUN, V59, P700, DOI 10.1128/IAI.59.2.700-704.1991; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Tsuboi S, 2001, BIOESSAYS, V23, P46, DOI 10.1002/1521-1878(200101)23:1<46::AID-BIES1006>3.3.CO;2-V; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Vanderplasschen A, 2000, P NATL ACAD SCI USA, V97, P5756, DOI 10.1073/pnas.100058897; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yen TY, 2003, J BIOL CHEM, V278, P45864, DOI 10.1074/jbc.M303851200; ZHANG EL, 1994, BIOCHEMISTRY-US, V33, P6295, DOI 10.1021/bi00186a032	35	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38969	38977		10.1074/jbc.M401046200	http://dx.doi.org/10.1074/jbc.M401046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226299	hybrid			2022-12-25	WOS:000223684100111
J	Zanusso, G; Farinazzo, A; Prelli, F; Fiorini, M; Gelati, M; Frangione, B; Monaco, S				Zanusso, G; Farinazzo, A; Prelli, F; Fiorini, M; Gelati, M; Frangione, B; Monaco, S			Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CONFORMATION; FRAGMENT; ISOFORMS; CLASSIFICATION; BRAIN	In prion diseases, the cellular prion protein ( PrPC) is converted to an insoluble and protease-resistant abnormal isoform termed PrPSc. In different prion strains, PrPSc shows distinct sites of endogenous or exogenous proteolysis generating a core fragment named PrP27-30. Sporadic Creutzfeldt-Jakob disease (sCJD), the most frequent human prion disease, clinically presents with a variety of neurological signs. As yet, the clinical variability observed in sCJD has not been fully explained by molecular studies relating two major types of PrP27-30 with unglycosylated peptides of 21 ( type 1) and 19 kDa ( type 2) and the amino acid methionine or valine at position 129. Recently, smaller C-terminal fragments migrating at 12 and 13 kDa have been detected in different sCJD phenotypes, but their significance remains unclear. By using two-dimensional immunoblot with anti-PrP antibodies, we identified two novel groups of protease-resistant PrP fragments in sCJD brain tissues. All sCJD cases with type 1 PrP27-30, in addition to MM subjects with type 2 PrP27-30, were characterized by the presence of unglycosylated PrP fragments of 16 - 17 kDa. Conversely, brain homogenates from patients VV and MV with type 2 PrP27-30 contained fully glycosylated PrP fragments, which after deglycosylation migrated at 17.5-18 kDa. Interestingly, PrP species of 17.5-18 kDa matched deglycosylated forms of the C1 PrPC fragment and were associated with tissue PrP deposition as plaque-like aggregates or amyloid plaques. These data show the presence of multiple PrPSc conformations in sCJD and, in addition, shed new light on the correlation between sCJD phenotypes and disease-associated PrP molecules.	Univ Verona, Policlin GB Rossi, Dept Neurol & Visual Sci, Neurol Sect, I-37134 Verona, Italy; Univ Verona, Dept Agr & Ind Biotechnol, I-37134 Verona, Italy; NYU Med Ctr, Dept Pathol, New York, NY 10016 USA	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; New York University	Monaco, S (corresponding author), Univ Verona, Policlin GB Rossi, Dept Neurol & Visual Sci, Neurol Sect, Ple LA Scuro 10, I-37134 Verona, Italy.	salvatore.monaco@mail.univr.it	Monaco, Salvatore/K-4659-2018; Zanusso, Gianluigi/K-2823-2018; Gelati, Matteo/AAR-1692-2020	Monaco, Salvatore/0000-0003-3191-8597; Zanusso, Gianluigi/0000-0001-5199-6264; ferrari, sergio/0000-0003-3855-5135; Fiorini, Michele/0000-0002-5339-8716; Prelli, Frances/0000-0002-8744-4151	NIAMS NIH HHS [AR02584] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Collins S, 2002, ANN NEUROL, V52, P115, DOI 10.1002/ana.10224; Daniels M, 2001, EUR J BIOCHEM, V268, P6155, DOI 10.1046/j.0014-2956.2001.02567.x; DEARMOND SJ, 1999, NEUROPATHOLOGY PRION, P585; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Glatzel M, 2002, LANCET, V360, P139, DOI 10.1016/S0140-6736(02)09384-4; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; Satoh K, 2003, J GEN VIROL, V84, P2885, DOI 10.1099/vir.0.19236-0; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Zanusso G, 2003, NEW ENGL J MED, V348, P711, DOI 10.1056/NEJMoa022043; Zanusso G, 2002, ELECTROPHORESIS, V23, P347, DOI 10.1002/1522-2683(200202)23:2<347::AID-ELPS347>3.0.CO;2-1; Zanusso G, 2001, J BIOL CHEM, V276, P40377, DOI 10.1074/jbc.C100458200; Zou WQ, 2003, J BIOL CHEM, V278, P40429, DOI 10.1074/jbc.M308550200	28	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38936	38942		10.1074/jbc.M405468200	http://dx.doi.org/10.1074/jbc.M405468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247220	hybrid			2022-12-25	WOS:000223684100107
J	Zwartz, GJ; Chigaev, A; Dwyer, DC; Foutz, TD; Edwards, BS; Sklar, LA				Zwartz, GJ; Chigaev, A; Dwyer, DC; Foutz, TD; Edwards, BS; Sklar, LA			Real-time analysis of very late antigen-4 affinity modulation by shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; SIGNAL-TRANSDUCTION; INTEGRIN AVIDITY; LYMPHOCYTE RECIRCULATION; VASCULAR ENDOTHELIUM; EXTRACELLULAR-MATRIX; RECEPTOR SUBTYPES; TRAFFIC SIGNALS; GENE-EXPRESSION; OUTSIDE-IN	Shear promotes endothelial recruitment of leukocytes, cell activation, and transmigration. Mechanical stress on cells caused by shear can induce a rapid integrin conformational change and activation, followed by an increase in binding to the extracellular matrix. The molecular mechanism of increased avidity is unknown. We have shown previously that the affinity of the alpha(4)beta(1) integrin, very late antigen-4 (VLA-4), measured with an LDV-containing small molecule, varies with cellular avidity, measured from cell disaggregation rates. In this study, we measured in real time affinity changes of VLA-4 in response to shear. The resulting affinity was comparable with the state mediated by receptor signaling and corresponded in time with intracellular Ca2+ responses. Ca2+ ionophores and N,N'-[1,2-ethanediylbis( oxy-2,1-phenylene)] bis[N-[2-[(acetyloxy) methoxy]-2-oxoethyl]]-, bis[( acetyloxy) methyl] ester demonstrate that the affinity regulation of VLA-4 in the presence of shear was related to Ca2+ signaling. Pertussis toxin treatment implicates G(i) in an unknown pathway that connects shear, Ca2+ elevation, VLA-4 affinity, and cell avidity.	Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico	Sklar, LA (corresponding author), Univ New Mexico 1, Dept Pathol, MSC 08-4630, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Chigaev, Alexandre/A-3103-2010	Chigaev, Alexandre/0000-0002-7726-638X	NCRR NIH HHS [RR14175] Funding Source: Medline; NHLBI NIH HHS [HL56384] Funding Source: Medline; NIBIB NIH HHS [EB02022] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014175] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002022] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alon R, 2003, MICROCIRCULATION, V10, P297, DOI 10.1038/sj.mn.7800195; Alon R, 2003, BLOOD, V101, P4437, DOI 10.1182/blood-2002-11-3427; Ashida N, 2003, J BIOL CHEM, V278, P9327, DOI 10.1074/jbc.M212316200; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bodor ET, 2003, MOL PHARMACOL, V64, P1210, DOI 10.1124/mol.64.5.1210; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chan JR, 2003, J IMMUNOL METHODS, V273, P43, DOI 10.1016/S0022-1759(02)00417-9; Chen C, 1999, J IMMUNOL, V162, P1084; Chen JX, 2001, AM J PHYSIOL-CELL PH, V280, pC1475, DOI 10.1152/ajpcell.2001.280.6.C1475; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; CHIEN S, 1984, HDB PHYSL, P225; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2003, J BIOL CHEM, V278, P38174, DOI 10.1074/jbc.M210472200; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Cho JY, 2003, EXP CELL RES, V290, P155, DOI 10.1016/S0014-4827(03)00322-7; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Danen EHJ, 1998, CELL ADHES COMMUN, V6, P217, DOI 10.3109/15419069809004477; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; Garcia-Alvarez B, 2003, STRUCTURE, V11, P615, DOI 10.1016/S0969-2126(03)00090-X; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Goldfinger LE, 2003, J CELL BIOL, V162, P731, DOI 10.1083/jcb.200304031; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jen CYJ, 2000, J APPL PHYSIOL, V89, P1657, DOI 10.1152/jappl.2000.89.4.1657; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Labrador V, 2003, BIORHEOLOGY, V40, P47; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; Rowin ME, 1998, J CELL PHYSIOL, V175, P193, DOI 10.1002/(SICI)1097-4652(199805)175:2<193::AID-JCP9>3.0.CO;2-J; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; TURITTO VT, 1996, VASCULAR MED TXB VAS, P141; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Warnock RA, 2000, J EXP MED, V191, P77, DOI 10.1084/jem.191.1.77; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Weeks BS, 2001, J CELL PHYSIOL, V189, P179, DOI 10.1002/jcp.10015; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zwartz G, 2004, BIOPHYS J, V86, P1243, DOI 10.1016/S0006-3495(04)74198-3	77	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38277	38286		10.1074/jbc.M402944200	http://dx.doi.org/10.1074/jbc.M402944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226304	hybrid			2022-12-25	WOS:000223684100027
J	Galetto, R; Moumen, A; Giacomoni, V; Veron, M; Charneau, P; Negroni, M				Galetto, R; Moumen, A; Giacomoni, V; Veron, M; Charneau, P; Negroni, M			The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; REVERSE-TRANSCRIPTASE; STRAND TRANSFER; COPY-CHOICE; NUCLEOCAPSID PROTEIN; MECHANISM; FREQUENCY; DYNAMICS; PROMOTES	By frequently rearranging large regions of the genome, genetic recombination is a major determinant in the plasticity of the human immunodeficiency virus type I (HIV-1) population. In retroviruses, recombination mostly occurs by template switching during reverse transcription. The generation of retroviral vectors provides a means to study this process after a single cycle of infection of cells in culture. Using HIV-1-derived vectors, we present here the first characterization and estimate of the strength of a recombination hot spot in HIV-1 in vivo. In the hot spot region, located within the C2 portion of the gp120 envelope gene, the rate of recombination is up to ten times higher than in the surrounding regions. The hot region corresponds to a previously identified RNA hairpin structure. Although recombination breakpoints in vivo cluster in the top portion of the hairpin, the bias for template switching in this same region appears less marked in a cell-free system. By modulating the stability of this hairpin we were able to affect the local recombination rate both in vitro and in infected cells, indicating that the local folding of the genomic RNA is a major parameter in the recombination process. This characterization of reverse transcription products generated after a single cycle of infection provides insights in the understanding of the mechanism of recombination in vivo and suggests that specific regions of the genome might be prompted to yield different rates of evolution due to the presence of circumscribed recombination hot spots.	CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75700 Paris, France; Inst Pasteur, Grp Virol Mol & Vectorol, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Negroni, M (corresponding author), CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75700 Paris, France.	matteo@pasteur.fr	CHARNEAU, Pierre/M-1565-2017	CHARNEAU, Pierre/0000-0003-1184-5773; Negroni, Matteo/0000-0003-3005-8871				Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Onafuwa A, 2003, J VIROL, V77, P4577, DOI 10.1128/JVI.77.8.4577-4587.2003; Peeters M, 2000, AIDS, V14, pS129; Peeters M, 2003, AIDS, V17, P2547, DOI 10.1097/00002030-200312050-00002; Pfeiffer JK, 1999, J VIROL, V73, P8441, DOI 10.1128/JVI.73.10.8441-8447.1999; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; Raja A, 2003, J BIOL CHEM, V278, P10102, DOI 10.1074/jbc.M210201200; Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Telesnitsky A., 1997, P121; WEISS RA, 1973, VIROLOGY, V52, P535, DOI 10.1016/0042-6822(73)90349-8; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	35	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36625	36632		10.1074/jbc.M405476200	http://dx.doi.org/10.1074/jbc.M405476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218022	hybrid			2022-12-25	WOS:000223453600061
J	Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M				Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M			Paired-like homeodomain protein ESXR1 possesses a cleavable C-terminal region that inhibits cyclin degradation	ONCOGENE			English	Article						ESXR1; cyclin; paired-like homeodomain; processing; M-phase arrest	MITOSIS UNTIL; DNA-BINDING; KINASE; PHOSPHORYLATION; PROTEOLYSIS; CELLS; G1; PROGRESSION; ACTIVATION; ONSET	The eukaryotic cell cycle is regulated by sequential activation and inactivation of cyclin-cyclin-dependent kinase (Cdk) complexes. In this work, we screened human cDNAs that can rescue yeast Saccharomyces cerevisiae from lethality caused by ectopic expression of human cyclin E and isolated a cDNA encoding ESXR1, a paired-like homeodomain-containing protein with a unique C-terminal proline-rich repeat region. In adult tissues, ESXR1 is primarily expressed in the testis. We demonstrate that ESXR1 prevents degradation of ubiquitinated cyclins in human cells. Accordingly, elevation of ESXR1 level results in accumulation of cyclin A and cyclin B1 and thereby provokes M-phase arrest. In human cells, the 65-kDa full-length ESXR1 protein is capable of proteolytically processing into N-terminal 45-kDa and C-terminal 20-kDa fragments. The C-terminal fragment, containing a proline-rich repeat region, is localized to the cytoplasm and displays the ability to inhibit cyclin degradation. In contrast, the N-terminal fragment, containing a paired-like homeodomain, is localized exclusively in the nucleus, suggesting that it plays a role in transcription. Our results indicate that proteolytic processing of ESXR1 plays a role in concerted regulation of the cell cycle and transcription in human cells.	Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600815, Japan; Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Supramol Struct, Tokyo 1130032, Japan; Hokkaido Univ, Ctr Adv Sci & Technol, Lab Anim Cytogenet, Sapporo, Hokkaido 0600810, Japan; Kawasaki Med Sch, Dept Urol, Kurashiki, Okayama 7010192, Japan	Hokkaido University; Hokkaido University; Kitasato University; University of Tokyo; Hokkaido University; Kawasaki Medical School	Hatakeyama, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Maeda, Tatsuya/L-5540-2019; Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012	OHNISHI, Naomi/0000-0002-2382-3152				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Branford WW, 1997, MECH DEVELOP, V65, P87, DOI 10.1016/S0925-4773(97)00058-0; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAUMANN M, 1993, ONCOGENE, V8, P2275; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Sette C, 1999, J BIOL CHEM, V274, P33571, DOI 10.1074/jbc.274.47.33571; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Su TT, 2001, CURR BIOL, V11, pR467, DOI 10.1016/S0960-9822(01)00283-4; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000	32	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6590	6602		10.1038/sj.onc.1207884	http://dx.doi.org/10.1038/sj.onc.1207884			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235584				2022-12-25	WOS:000223530800006
J	Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K				Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K			Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells	ONCOGENE			English	Article						tumor suppressor; p53; mitochondria; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL TARGET; THERAPEUTIC AGENTS; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ACTIVATION	p53 can eliminate damaged cells through the induction of mitochondria-mediated apoptosis. Recent observations have provided strong evidence that a fraction of total p53 translocates to mitochondria specifically in response to a death stimulus. Unexpectedly, mutant p53, which is expressed at much higher levels than wild type in unstressed cells, is apparently always present at the mitochondria, independent of apoptotic signal. This prompted us to ask whether cell lines with intact p53-dependent apoptosis and cell cycle arrest pathways exist in which the mitochondrial localization of wild-type p53, like that of mutant, is independent of a death stimulus and instead, correlates with the total p53 levels. Here, we document that human HCT116 colorectal carcinoma cells treated with adriamycin or 5-fluorouracil (5FU) can accumulate total p53 to equally high levels, and mitochondrial p53 to proportionate levels, although only 5FU treatment provoked p53-dependent apoptosis. Along the same line, HCT116 derivatives with increased basal p53 levels, and glioblastoma cells with a doxycycline-inducible p53, also revealed proportionate mitochondrial p53 levels, and even unstressed HCT116 cells had some p53 located at the mitochondria. Finally, mitochondrial and total p53 showed distinct post-translational modi. cations. Thus, cell lines exist in which the mitochondrial p53 levels parallel total levels independent of apoptosis.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Anat & Cell Biol, Ctr Electron Microscopy, D-66421 Homburg, Germany	Saarland University; Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@med-rz.uni-saarland.de						Attardi LD, 2000, GENE DEV, V14, P704; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Robles AI, 2001, CANCER RES, V61, P6660; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	41	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6226	6236		10.1038/sj.onc.1207637	http://dx.doi.org/10.1038/sj.onc.1207637			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247902				2022-12-25	WOS:000223399000007
J	Simon, J; Wakimoto, H; Fujita, N; Lalande, M; Barnard, EA				Simon, J; Wakimoto, H; Fujita, N; Lalande, M; Barnard, EA			Analysis of the set of GABA(A) receptor genes in the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID-TYPE; GATED ION-CHANNEL; NICOTINIC ACETYLCHOLINE-RECEPTOR; SUBUNIT GENE; A RECEPTOR; MESSENGER-RNA; GLYCINE RECEPTOR; 2 FORMS; CHROMOSOMAL LOCALIZATION; FUNCTIONAL EXPRESSION	The genes of the ionotropic gamma-aminobutyric acid receptor (GABR) subunits have shown an unusual chromosomal clustering, but only now can this be fully specified by analyses of the human genome. We have characterized the genes encoding the 18 known human GABR subunits, plus one now located here, for their precise locations, sizes, and exon/intron structures. Clusters of 17 of the 19, distributed between five chromosomes, are specified in detail, and their possible significance is considered. By applying search algorithms designed to recognize sequences of all known GABR-type subunits in species from man down to nematodes, we found no new GABR subunit is detectable in the human genome. However, the sequence of the human orthologue of the rat GABR rho3 receptor subunit was uncovered by these algorithms, and its gene could be analyzed. Consistent with those search results, orthologues of the beta4 and gamma4 subunits from the chicken, not cloned from mammals, were not detectable in the human genome by specific searches for them. The relationships are consistent with the mammalian theta subunit being derived from the beta line and epsilon from the gamma line, with mammalian loss of beta4 and gamma4. In their structures the human GABR genes show a basic pattern of nine coding exons, with six different genomic mechanisms for the alternative splicing found in various subunits. Additional noncoding exons occur for certain subunits, which can be regulatory. A dicysteine loop and its exon show remarkable constancy between all GABR subunits and species, of deduced functional significance.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Ritsumeikan Univ, Dept Biosci & Bioinformat, Noji Higashi, Kutatsu 5258577, Japan; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Cambridge; Ritsumeikan University; University of Connecticut	Barnard, EA (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	eb247@cam.ac.uk						Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Bailey MES, 1999, MAMM GENOME, V10, P839, DOI 10.1007/s003359901101; Bailey MES, 1999, BBA-GENE STRUCT EXPR, V1447, P307, DOI 10.1016/S0167-4781(99)00167-0; Bamber BA, 2003, BRIT J PHARMACOL, V138, P883, DOI 10.1038/sj.bjp.0705119; Barnard EA, 1998, PHARMACOL REV, V50, P291; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; BARNARD EA, 2001, HANDB EXP PHARM, V150, P79; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; BELL MV, 1989, AM J HUM GENET, V45, P883; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; BORMANN J, 2001, HANDB EXP PHARM, V150, P271; BUCKLE VJ, 1989, NEURON, V3, P647, DOI 10.1016/0896-6273(89)90275-4; Cheng ATA, 1997, BIOCHEM BIOPH RES CO, V238, P683, DOI 10.1006/bbrc.1997.7360; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Davies PA, 2003, J BIOL CHEM, V278, P712, DOI 10.1074/jbc.M208814200; FOSTER IC, 2001, EUR J PHARMACOL, V419, P1; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; Fuchs K, 2002, J NEUROCHEM, V82, P1512, DOI 10.1046/j.1471-4159.2002.01098.x; Garret M, 1997, J NEUROCHEM, V68, P1382; Glatt K, 1997, GENOMICS, V41, P63, DOI 10.1006/geno.1997.4639; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; GREGER V, 1995, GENOMICS, V26, P258, DOI 10.1016/0888-7543(95)80209-5; HARVEY RJ, 1994, J NEUROCHEM, V62, P10; HARVEY RJ, 1993, FEBS LETT, V331, P211, DOI 10.1016/0014-5793(93)80339-V; Harvey RJ, 2000, EUR J NEUROSCI, V12, P994, DOI 10.1046/j.1460-9568.2000.00993.x; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; HERMAN GE, 1991, GENOMICS, V9, P670, DOI 10.1016/0888-7543(91)90360-Q; Hosie AM, 1997, TRENDS NEUROSCI, V20, P578, DOI 10.1016/S0166-2236(97)01127-2; Jin P, 2004, J BIOL CHEM, V279, P1408, DOI 10.1074/jbc.M308656200; Jones AK, 2003, GENOMICS, V82, P441, DOI 10.1016/S0888-7543(03)00153-8; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KIM HY, 2001, HANDB EXP PHARM, V150, P251; Kim YH, 1997, GENOMICS, V42, P378, DOI 10.1006/geno.1997.4770; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; Kostrzewa M, 1998, EUR J HUM GENET, V6, P266, DOI 10.1038/sj.ejhg.5200188; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Le Novere N, 2001, PHILOS T R SOC B, V356, P1121; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Leventhal AG, 2003, SCIENCE, V300, P812, DOI 10.1126/science.1082874; Levin ML, 1996, GENOME RES, V6, P465, DOI 10.1101/gr.6.6.465; Ludmerer SW, 2002, BIOCHEMISTRY-US, V41, P6548, DOI 10.1021/bi015920o; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; Martinez-Torres A, 1998, P NATL ACAD SCI USA, V95, P4019, DOI 10.1073/pnas.95.7.4019; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MCKINLEY DD, 1995, MOL BRAIN RES, V28, P175, DOI 10.1016/0169-328X(94)00228-7; MCLEAN PJ, 1995, GENOMICS, V26, P580, DOI 10.1016/0888-7543(95)80178-O; Mohler H, 2002, J PHARMACOL EXP THER, V300, P2, DOI 10.1124/jpet.300.1.2; Mu WT, 2002, BRAIN RES BULL, V58, P447, DOI 10.1016/S0361-9230(02)00816-X; NAYEEM N, 1994, J NEUROCHEM, V62, P815; Neelands TR, 1999, MOL PHARMACOL, V56, P598, DOI 10.1124/mol.56.3.598; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; Ogurusu T, 1996, BBA-GENE STRUCT EXPR, V1305, P15, DOI 10.1016/0167-4781(95)00205-7; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Poulsen CF, 2000, MOL BRAIN RES, V78, P201, DOI 10.1016/S0169-328X(00)00085-1; Russek SJ, 1999, GENE, V227, P213, DOI 10.1016/S0378-1119(98)00594-0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588, DOI 10.1523/JNEUROSCI.20-10-03588.2000; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Uusi-Oukari M, 2000, MOL CELL NEUROSCI, V16, P34, DOI 10.1006/mcne.2000.0856; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; WHITING PJ, 1990, P NATL ACAD SCI USA, V87, P330; Wilke K, 1997, GENOMICS, V45, P1, DOI 10.1006/geno.1997.4885; Windpassinger C, 2002, GENE, V292, P25, DOI 10.1016/S0378-1119(02)00649-2; Wu Q, 1999, MOL CELL BIOL, V19, P3225; Yates DM, 2003, INT J PARASITOL, V33, P1183, DOI 10.1016/S0020-7519(03)00172-3	75	203	207	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41422	41435		10.1074/jbc.M401354200	http://dx.doi.org/10.1074/jbc.M401354200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15258161	hybrid			2022-12-25	WOS:000224075500024
J	Erlemann, KR; Rokach, J; Powell, WS				Erlemann, KR; Rokach, J; Powell, WS			Oxidative stress stimulates the synthesis of the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid by inflammatory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; THIOREDOXIN REDUCTASE; RADICAL PRODUCTION; POTENT STIMULATOR; HUMAN MONOCYTES; GLUTATHIONE; METABOLISM; EXPRESSION; MECHANISM; HYDROPEROXIDES	5-Oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid) is a highly potent granulocyte chemoattractant that acts through a selective G-protein coupled receptor. It is formed by oxidation of the 5-lipoxygenase product 5-HETE (5S-hydroxy-6,8,11,14-eicosatetraenoic acid) by 5-hydroxyeicosanoid dehydrogenase (5-HEDH). Although leukocytes and platelets display high microsomal 5-HEDH activity, unstimulated intact cells do not convert 5-HETE to appreciable amounts of 5-oxo-ETE. To attempt to resolve this dilemma we explored the possibility that 5-oxo-ETE synthesis could be enhanced by oxidative stress. We found that hydrogen peroxide and t-butyl hydroperoxide strongly stimulate 5-oxo-ETE formation by U937 monocytic cells. This was dependent on the GSH redox cycle, as it was blocked by depletion of GSH or inhibition of glutathione reductase and mimicked by oxidation of GSH to GSSG by diamide. Glucose inhibited the response to H2O2 through its metabolism by the pentose phosphate pathway, as its effect was reversed by the glucose-6-phosphate dehydrogenase inhibitor dehydroepiandrosterone. 5-Oxo-ETE synthesis was also strongly stimulated by hydroperoxides in blood monocytes, lymphocytes, and platelets, but not neutrophils. Unlike monocytic cells, lymphocytes and platelets were resistant to the inhibitory effects of glucose. 5-Oxo-ETE synthesis following incubation of peripheral blood mononuclear cells with arachidonic acid and calcium ionophore was also strongly enhanced by t-butyl hydroperoxide. Oxidative stress could act by depleting NADPH, resulting in the formation NADP(+), the cofactor for 5-HEDH. This is opposed by the pentose phosphate pathway, which converts NADP(+) back to NADPH. Oxidative stress could be an important mechanism for stimulating 5-oxo-ETE production in inflammation, promoting further infiltration of granulocytes into inflammatory sites.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	William.Powell@McGill.ca	Powell, William/AAE-9000-2020	Rokach, Joshu/0000-0003-1814-7505; Powell, William/0000-0002-8507-4038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69835] Funding Source: Medline; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRINK M, 1994, LEUKEMIA, V8, P1579; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; DAVIS G, 1983, BIOCHIM BIOPHYS ACTA, V724, P456, DOI 10.1016/0005-2728(83)90106-8; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; FISCHER DG, 1981, CELL IMMUNOL, V58, P426, DOI 10.1016/0008-8749(81)90235-5; FRIEDMANN E, 1952, BIOCHIM BIOPHYS ACTA, V9, P65, DOI 10.1016/0006-3002(52)90121-2; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Furtmuller PG, 2000, FEBS LETT, V484, P139, DOI 10.1016/S0014-5793(00)02143-8; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hall LM, 1998, CHEM RES TOXICOL, V11, P1024, DOI 10.1021/tx9801155; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1975, LIPIDS, V10, P87, DOI 10.1007/BF02532161; Harrison D, 2003, AM J CARDIOL, V91, p7A; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; MARGOLIASH E, 1958, BIOCHEM J, V68, P468, DOI 10.1042/bj0680468; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nedeljkovic ZS, 2003, POSTGRAD MED J, V79, P195, DOI 10.1136/pmj.79.930.195; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; OBERMEIER H, 1995, BBA-MOL CELL RES, V1269, P25, DOI 10.1016/0167-4889(95)00095-A; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Pietarinen-Runtti P, 2000, AM J PHYSIOL-CELL PH, V278, pC118, DOI 10.1152/ajpcell.2000.278.1.C118; Powell WS, 1999, BLOOD, V93, P1086, DOI 10.1182/blood.V93.3.1086.403k09_1086_1096; POWELL WS, 1994, J BIOL CHEM, V269, P25373; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SMITH PJ, 1961, NATURE, V190, P84, DOI 10.1038/190084a0; Sozzani S, 1996, J IMMUNOL, V157, P4664; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; Troyano A, 2001, J BIOL CHEM, V276, P47107, DOI 10.1074/jbc.M104516200; TSUTSUI EA, 1962, J BIOL CHEM, V237, P3009; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; ZAMBONI R, 1983, TETRAHEDRON LETT, V24, P999, DOI 10.1016/S0040-4039(00)81586-5; Zarini S, 2003, J BIOL CHEM, V278, P11190, DOI 10.1074/jbc.M208496200; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847	51	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40376	40384		10.1074/jbc.M401294200	http://dx.doi.org/10.1074/jbc.M401294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15234979	hybrid			2022-12-25	WOS:000223916800021
J	Moustafa, I; Connaris, H; Taylor, M; Zaitsev, V; Wilson, JC; Kiefel, MJ; von Itzstein, M; Taylor, G				Moustafa, I; Connaris, H; Taylor, M; Zaitsev, V; Wilson, JC; Kiefel, MJ; von Itzstein, M; Taylor, G			Sialic acid recognition by Vibrio cholerae neuraminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; CRYSTAL-STRUCTURE; INFLUENZA-VIRUS; TRANS-SIALIDASE; BACTERIAL SIALIDASE; PERTUSSIS TOXIN; BINDING-SITE; RECEPTOR; SPECIFICITY; COMPLEX	Vibrio cholerae neuraminidase (VCNA) plays a significant role in the pathogenesis of cholera by removing sialic acid from higher order gangliosides to unmask GM1, the receptor for cholera toxin. We previously showed that the structure of VCNA is composed of a central beta-propeller catalytic domain flanked by two lectin-like domains; however the nature of the carbohydrates recognized by these lectin domains has remained unknown. We present here structures of the enzyme in complex with two substrates, alpha-2,3-sialyllactose and alpha-2,6-sialyllactose. Both substrate complexes reveal the alpha-anomer of N-acetylneuraminic acid (Neu5Ac) bound to the N-terminal lectin domain, thereby revealing the role of this domain. The large number of interactions suggest a relatively high binding affinity for sialic acid, which was confirmed by calorimetry, which gave a K-d similar to 30 muM. Saturation transfer difference NMR using a non-hydrolyzable substrate, Neu5,9Ac(2)-2-S(alpha-2,6)-GlcNAcbeta1Me, was also used to map the ligand interactions at the VCNA lectin binding site. It is well known that VCNA can hydrolyze both alpha-2,3- and alpha-2,6-linked sialic acid substrates. In this study using alpha-2,3-sialyllactose co-crystallized with VCNA it was revealed that the inhibitor 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (Neu5Ac2en) was bound at the catalytic site. This observation supports the notion that VCNA can produce its own inhibitor and has been further confirmed by H-1 NMR analysis. The discovery of the sialic acid binding site in the N-lectin-like domain suggests that this might help target VCNA to sialic acid-rich environments, thereby enhancing the catalytic efficiency of the enzyme.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Griffith Univ, Inst Glycom, Nathan, Qld 4111, Australia	University of St Andrews; Griffith University	Taylor, G (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	glt2@st-andrews.ac.uk	Taylor, Garry/G-3017-2014; Kiefel, Milton/A-6509-2015; von Itzstein, Mark/E-4823-2010; Wilson, Jennifer/H-5297-2013; Kiefel, Milton/O-4740-2019	Kiefel, Milton/0000-0003-1030-1440; Taylor, Garry/0000-0001-9486-566X				ADA GL, 1961, J GEN MICROBIOL, V24, P409, DOI 10.1099/00221287-24-3-409; Amaya MF, 2003, J MOL BIOL, V325, P773, DOI 10.1016/S0022-2836(02)01306-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1993, STRUCTURE, V1, P19, DOI 10.1016/0969-2126(93)90005-2; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; CHONG AKJ, 1992, EUR J BIOCHEM, V207, P335, DOI 10.1111/j.1432-1033.1992.tb17055.x; CORFIELD AP, 1983, BIOCHIM BIOPHYS ACTA, V744, P121, DOI 10.1016/0167-4838(83)90080-8; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; Dormitzer PR, 2002, J VIROL, V76, P10512, DOI 10.1128/JVI.76.20.10512-10517.2002; Dormitzer PR, 2002, EMBO J, V21, P885, DOI 10.1093/emboj/21.5.885; Emsley P, 2000, J BIOL CHEM, V275, P8889, DOI 10.1074/jbc.275.12.8889; GALEN JE, 1992, INFECT IMMUN, V60, P406, DOI 10.1128/IAI.60.2.406-415.1992; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; Haseley SR, 1999, ANAL BIOCHEM, V274, P203, DOI 10.1006/abio.1999.4277; Imberty A, 2000, J BIOL CHEM, V275, P17541, DOI 10.1074/jbc.M000560200; Jermyn WS, 2002, MICROBIOL-SGM, V148, P3681, DOI 10.1099/00221287-148-11-3681; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krell T, 2003, BIOTECHNOL APPL BIOC, V38, P241, DOI 10.1042/BA20030089; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LUBEN G, 1976, BEHRING I MITT, V59, P30; Luo Y, 1998, STRUCTURE, V6, P521, DOI 10.1016/S0969-2126(98)00053-7; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; MOHR E, 1960, Z NATURFORSCH PT B, V15, P575; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; SCHNEIDER DR, 1982, J INFECT DIS, V145, P474, DOI 10.1093/infdis/145.4.474; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Sedlacek HH, 1974, BEHRING I MITT, V55, P254; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; STEIN PE, 1994, NAT STRUCT BIOL, V1, P591, DOI 10.1038/nsb0994-591; TAYLOR NR, 1994, J MED CHEM, V37, P616, DOI 10.1021/jm00031a011; Thobhani S, 2003, J AM CHEM SOC, V125, P7154, DOI 10.1021/ja029759w; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VIMR ER, 1988, J BACTERIOL, V170, P1495, DOI 10.1128/jb.170.4.1495-1504.1988; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Yan JL, 2003, J MAGN RESON, V163, P270, DOI 10.1016/S1090-7807(03)00106-X; Zaitsev V, 2004, J VIROL, V78, P3733, DOI 10.1128/JVI.78.7.3733-3741.2004	46	118	123	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40819	40826		10.1074/jbc.M404965200	http://dx.doi.org/10.1074/jbc.M404965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15226294	hybrid			2022-12-25	WOS:000223916800076
J	Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM				Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM			ATM activity contributes to the tumor-suppressing functions of p14(ARF)	ONCOGENE			English	Article						ARF tumor suppressor; p53 and ATM	CELL-CYCLE ARREST; DNA-DAMAGE; P16(INK4A) GENES; TRANSCRIPTION FACTOR; P53 PROTEIN; MDM2; PATHWAY; CHECKPOINT; APOPTOSIS; P19(ARF)	P14/p19(ARF) (ARF) plays a major role in the activation of p53 by oncogenic signals. The biochemical basis of this has not been fully elucidated. We report here that forced expression of p14(ARF) enhances phosphorylation of p53 serine 15 (p53S15) in NIH3T3, IMR90 and MCF7 cells. Ectopic expression of the oncogenes c-myc, E2F1 and E1A, all of which activate p53 at least partially via ARF, lead to p53S15 phosphorylation in IMR90 cells. In addition, ectopic expression of p53 also results in p53S15 phosphorylation, suggesting that this is a common event in the ARF p53 tumor suppression system. Furthermore, p53-, p14(ARF)-, c-myc- and E2F1-, but not E1A-, induced p53S15 phosphorylation was substantially reduced in AT fibroblasts (GM05823). Downregulation of ATM in MCF7 cells using RNA interference (RNAi) technology significantly attenuated p14ARF- and p53- induced phosphorylation of p53S15. Ectopically expressed ARF in NIH3T3 cells induced ATM nuclear foci and activated ATM kinase. Functionally, ectopic expression of p14(ARF) and c-myc inhibited the proliferation of IMR90 but not ATM null GM05823 cells, and p14ARF- induced inhibition of MCF7 cell proliferation was significantly attenuated by downregulation of ATM by RNAi. Taken together, these data show a functional role for ATM in ARF-mediated tumor suppression.	St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; Peking Union Med Coll, Natl Lab Med Mol Biol, Dept Biochem, Beijing, Peoples R China; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; McMaster University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; McMaster University	Tang, DM (corresponding author), St Josephs Hosp, Father Sean OSullivan Res Inst, L305,50 Carlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Kapoor, Anil/AAQ-7184-2021; Zhu, Dahai/ABA-5315-2021; Tang, Damu/AAQ-1786-2021	Kapoor, Anil/0000-0001-9180-8029; Tang, Damu/0000-0002-3282-9521				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ichimura K, 2000, CANCER RES, V60, P417; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin SK, 2001, J CELL SCI, V114, P4139; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7355	7365		10.1038/sj.onc.1207957	http://dx.doi.org/10.1038/sj.onc.1207957			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15258567				2022-12-25	WOS:000224021400006
J	Gaertner, TR; Putkey, JA; Waxham, MN				Gaertner, TR; Putkey, JA; Waxham, MN			RC3/neurogranin and Ca2+/calmodulin-dependent protein kinase II produce opposing effects on the affinity of calmodulin for calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; STOPPED-FLOW FLUORESCENCE; CA2+ BINDING; DENDRITIC SPINES; AUTOPHOSPHORYLATION SITES; TRYPTIC FRAGMENTS; CAM-KINASE; IQ MOTIF; NEUROGRANIN; BRAIN	The interaction of calmodulin with its target proteins is known to affect the kinetics and affinity of Ca2+ binding to calmodulin. Based on thermodynamic principles, proteins that bind to Ca2+-calmodulin should increase the affinity of calmodulin for Ca2+, while proteins that bind to apo-calmodulin should decrease its affinity for Ca2+. We quantified the effects on Ca2+-calmodulin interaction of two neuronal calmodulin targets: RC3, which binds both Ca2+- and apo-calmodulin, and alphaCaM kinase II, which binds selectively to Ca2+-calmodulin. RC3 was found to decrease the affinity of calmodulin for Ca2+, whereas CaM kinase II increases the calmodulin affinity for Ca2+. Specifically, RC3 increases the rate of Ca2+ dissociation from the C-terminal sites of calmodulin up to 60-fold while having little effect on the rate of Ca2+ association. Conversely, CaM kinase II decreases the rates of dissociation of Ca2+ from both lobes of calmodulin and autophosphorylation of CaM kinase II at Thr(286) induces a further decrease in the rates of Ca2+ dissociation. RC3 dampens the effects of CaM kinase II on Ca2+ dissociation by increasing the rate of dissociation from the C-terminal lobe of calmodulin when in the presence of CaM kinase II. This effect is not seen with phosphorylated CaM kinase II. The results are interpreted according to a kinetic scheme in which there are competing pathways for dissociation of the Ca2+-calmodulin target complex. This work indicates that the Ca2+ binding properties of calmodulin are highly regulated and reveals a role for RC3 in accelerating the dissociation of Ca2+-calmodulin target complexes at the end of a Ca2+ signal.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Waxham, MN (corresponding author), 6431 Fannin St, Houston, TX 77030 USA.	m.n.waxham@uth.tmc.edu		Waxham, M. Neal/0000-0003-4801-1190	NINDS NIH HHS [NS26086] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS026086, R01NS026086] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; Bradshaw JM, 2002, J BIOL CHEM, V277, P20991, DOI 10.1074/jbc.M202154200; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Cui YF, 2003, ANAL BIOCHEM, V315, P175, DOI 10.1016/S0003-2697(03)00007-1; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Gaertner TR, 2004, J BIOL CHEM, V279, P12484, DOI 10.1074/jbc.M313597200; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; Gerendasy DD, 1997, MOL NEUROBIOL, V15, P131, DOI 10.1007/BF02740632; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; IKEDA A, 1991, J BIOL CHEM, V266, P11582; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; Krucker T, 2002, J NEUROSCI, V22, P5525; LINSE S, 1991, J BIOL CHEM, V266, P8050; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOU LL, 1989, J NEUROSCI, V9, P2020; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/0006-8993(96)00786-X; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Pak JH, 2000, P NATL ACAD SCI USA, V97, P11232, DOI 10.1073/pnas.210184697; Peersen OB, 1997, PROTEIN SCI, V6, P794; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Persechini A, 2000, J BIOL CHEM, V275, P4199, DOI 10.1074/jbc.275.6.4199; PETROZZINO JJ, 1995, NEURON, V14, P1223, DOI 10.1016/0896-6273(95)90269-4; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Putkey JA, 2003, J BIOL CHEM, V278, P49667, DOI 10.1074/jbc.C300372200; Ran XY, 2003, BIOCHEMISTRY-US, V42, P5143, DOI 10.1021/bi0271751; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Singla SI, 2001, J BIOL CHEM, V276, P29353, DOI 10.1074/jbc.M101744200; SOBUE K, 1981, FEBS LETT, V132, P137, DOI 10.1016/0014-5793(81)80447-4; TELEMAN A, 1986, BIOCHIM BIOPHYS ACTA, V873, P204, DOI 10.1016/0167-4838(86)90047-6; Torok K, 2001, BIOCHEMISTRY-US, V40, P14878, DOI 10.1021/bi010920+; van Dalen JJW, 2003, EUR J NEUROSCI, V18, P13, DOI 10.1046/j.1460-9568.2003.02720.x; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; Wu JF, 2002, J BIOL CHEM, V277, P19498, DOI 10.1074/jbc.M109082200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	49	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39374	39382		10.1074/jbc.M405352200	http://dx.doi.org/10.1074/jbc.M405352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262982	hybrid			2022-12-25	WOS:000223791500023
J	Millar, AH; Trend, AE; Heazlewood, JL				Millar, AH; Trend, AE; Heazlewood, JL			Changes in the mitochondrial proteome during the anoxia to air transition in rice focus around cytochrome-containing respiratory complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLIC FERMENTATION; PLANT-MITOCHONDRIA; SEEDLINGS; BIOGENESIS; EXPRESSION; TOLERANCE; NUCLEAR; OXIDASE; YEAST; WATER	The ability of rice seedlings to grow from dry seed under anoxia provides a rare opportunity in a multicellular eukaryote to study the stages of mitochondrial biogenesis triggered by oxygen availability. The function and proteome of rice mitochondria synthesized under 6 days of anoxia following 1 day of air adaptation have been compared with mitochondria isolated from 7-day aerobically grown rice seedlings. Rice coleoptiles grown under anoxia, and the mitochondria isolated from them respired very slowly compared with air-adapted and air-grown seedlings. Immunodetection of key mitochondrial protein markers, isoelectric focusing electrophoresis followed by SDS-PAGE to make soluble mitochondria proteome maps, and shotgun sequencing of mitochondrial proteins by liquid chromatography-tandem mass spectrometry all revealed similar patterns of the major function categories of mitochondrial proteins from both anoxic and air-adapted samples. Activity analysis showed respiratory oxidases markedly increased in activity during the air adaptation of seedlings. Blue-native electrophoresis followed by SDS-PAGE of mitochondrial membrane proteins clearly showed the very low abundance of assembled b/c(1) complex and cytochrome c oxidase complex in the mitochondrial membrane in anoxic samples and the dramatic increase in the abundance of these complexes on air adaptation. Total heme content, cytochrome absorbance spectra, and the electron carrier, cytochrome c, also increased markedly on air adaptation. These results likely reflect limited heme synthesis for cytochrome assembly in the absence of oxygen and represent a discrete and reversible blockage of full mitochondrial biogenesis in this anoxia-tolerant species.	Univ Western Australia, Fac Life & Phys Sci, Sch Biomed & Chem Sci, Plant Mol Biol Grp, Crawley, WA 6009, Australia	University of Western Australia	Millar, AH (corresponding author), Univ Western Australia, Fac Life & Phys Sci, Sch Biomed & Chem Sci, Plant Mol Biol Grp, Crawley, WA 6009, Australia.	hmillar@cyllene.uwa.edu.au	Millar, A. Harvey/A-5452-2008; Heazlewood, Joshua L/A-2554-2008	Millar, A. Harvey/0000-0001-9679-1473; Heazlewood, Joshua L/0000-0002-2080-3826				Appleby C. A., 1980, Methods for evaluating biological nitrogen fixation., P315; Boo YC, 1999, J PLANT PHYSIOL, V155, P255, DOI 10.1016/S0176-1617(99)80016-9; CHANCE B, 1955, J BIOL CHEM, V217, P395; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; COSTES C, 1978, PLANT SCI LETT, V11, P115, DOI 10.1016/0304-4211(78)90114-1; COUEE I, 1992, PLANT PHYSIOL, V98, P411, DOI 10.1104/pp.98.2.411; CRIDDLE RS, 1969, BIOCHEMISTRY-US, V8, P322, DOI 10.1021/bi00829a045; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; Dai H, 1998, EUR J CELL BIOL, V75, P198, DOI 10.1016/S0171-9335(98)80062-9; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; FOX TC, 1991, PLANTA, V184, P510, DOI 10.1007/BF00197900; Gibbs J, 2000, J EXP BOT, V51, P785, DOI 10.1093/jexbot/51.345.785; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Heazlewood JL, 2003, PLANT PHYSIOL, V132, P230, DOI 10.1104/pp.102.018986; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; Hodges DM, 1999, PLANTA, V207, P604, DOI 10.1007/s004250050524; Huang SB, 2003, J EXP BOT, V54, P2363, DOI 10.1093/jxb/erg252; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Lermontova I, 1997, P NATL ACAD SCI USA, V94, P8895, DOI 10.1073/pnas.94.16.8895; LIN CIP, 1982, EUR J BIOCHEM, V128, P309; Logan DC, 2001, PLANT PHYSIOL, V125, P662, DOI 10.1104/pp.125.2.662; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; MOROHASHI Y, 1981, PLANT PHYSIOL, V68, P318, DOI 10.1104/pp.68.2.318; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; SACHS MM, 1980, CELL, V20, P761, DOI 10.1016/0092-8674(80)90322-0; SALTZGABERMULLER J, 1978, J BIOL CHEM, V253, P305; Setter TL, 1997, ANN BOT-LONDON, V79, P67, DOI 10.1006/anbo.1996.0304; SETTER TL, 1994, ANN BOT-LONDON, V74, P265, DOI 10.1006/anbo.1994.1117; SHIBASAKA M, 1988, PLANT PHYSIOL, V86, P1008, DOI 10.1104/pp.86.4.1008; SHIBASAKA M, 1988, PLANT CELL PHYSIOL, V29, P629; SMITH AG, 1993, BIOCHEM J, V292, P503, DOI 10.1042/bj2920503; Subbaiah CC, 2003, ANN BOT-LONDON, V91, P119, DOI 10.1093/aob/mcf210; Surpin M, 1997, ESSAYS BIOCHEM, V32, P113; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Tsuji H, 2000, FEBS LETT, V471, P201, DOI 10.1016/S0014-5793(00)01411-3; Tsuji H, 2003, FEBS LETT, V546, P369, DOI 10.1016/S0014-5793(03)00631-8; TSUJI H, 1972, BOT MAG TOKYO, V85, P207, DOI 10.1007/BF02489213; UEDA K, 1971, PROTOPLASMA, V73, P203, DOI 10.1007/BF01275595; USHIMARU T, 1994, PLANT CELL PHYSIOL, V35, P211; USHIMARU T, 1992, PLANT CELL PHYSIOL, V33, P1065; VARTAPETIAN BB, 1975, PLANT SCI LETT, V4, P1, DOI 10.1016/0304-4211(75)90067-X; VARTAPETIAN BB, 1976, PROTOPLASMA, V88, P215, DOI 10.1007/BF01283247; WALLACE PG, 1964, NATURE, V201, P1191, DOI 10.1038/2011191a0; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	47	61	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39471	39478		10.1074/jbc.M406015200	http://dx.doi.org/10.1074/jbc.M406015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258153	hybrid			2022-12-25	WOS:000223791500036
J	Musch, MW; Koomoa, DLT; Goldstein, L				Musch, MW; Koomoa, DLT; Goldstein, L			Hypotonicity-induced exocytosis of the skate anion exchanger skAE1 - Role of lipid raft regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; OSMOLYTE CHANNEL; TAURINE EFFLUX; K+ CHANNELS; RED-CELL; BAND-3; TRANSPORT; EXPRESSION; RECEPTOR; PROTEIN	Upon hypotonic volume expansion, skate erythrocytes lose solutes via a pathway that requires participation of anion exchangers (AEs). Three skate AE isoforms (skAEs) are expressed, and at least skAE1 has been shown to mediate this effect when expressed in oocytes. Under isoosmotic conditions, only a small fraction of skAE1 is expressed on the external plasma membrane. Under these conditions, a portion of skAE1 may be found in non-ionic detergent-insoluble regions. However, the detergent-insoluble material is found intracellularly. Cellular volume expansion by hypoosmotic volume expansion but not volume expansion by isoosmotic medium by permeant solutes (ethylene glycol, diethyl urea, or ammonium chloride) stimulates the appearance of skAE1 in the external plasma membrane, and a significant portion of this is found in detergent-insoluble regions. Upon hypoosmotic volume expansion nearly half of the skAE1 is found as oligomers. SkAE1 in these detergent-insoluble fractions is highly tyrosine phosphorylated. These data suggest that volume expansion by hypoosmotic medium stimulates movement of skAE1 from an intracellular pool contained in detergent-insoluble lipid rafts to the plasma membrane. This skAE1 associates to form oligomers that could be involved in the solute efflux that occurs upon volume expansion.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Univ Chicago, Dept Med, Martin Boyer Labs, Inflammatory Bowel Dis Res Ctr, Chicago, IL 60637 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Brown University; University of Chicago; Mount Desert Island Biological Laboratory	Goldstein, L (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Box G B-311, Providence, RI 02912 USA.	Leon_Goldstein@Brown.edu			NIDDK NIH HHS [DK47722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047722, R01DK047722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Edidin M, 1997, CURR OPIN STRUC BIOL, V7, P528, DOI 10.1016/S0959-440X(97)80117-0; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; GarciaRomeu F, 1996, CELL MOL BIOL, V42, P985; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; Guizouarn H, 2003, J MEMBRANE BIOL, V193, P109, DOI 10.1007/s00232-002-2012-6; HAYNES JK, 1993, AM J PHYSIOL, V265, pR173, DOI 10.1152/ajpregu.1993.265.1.R173; HILDERSON HEL, 1984, ANAL BIOCHEM, V141, P116, DOI 10.1016/0003-2697(84)90433-0; JENSEN FB, 1995, J EXP BIOL, V198, P155; Koomoa DLT, 2004, J MEMBRANE BIOL, V198, P23, DOI 10.1007/s00232-004-0655-1; Koomoa DLT, 2002, J MEMBRANE BIOL, V185, P57, DOI 10.1007/s00232-001-0109-y; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lewis RA, 1996, J MEMBRANE BIOL, V149, P103, DOI 10.1007/s002329900011; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; Musch MW, 1996, J BIOL CHEM, V271, P21221, DOI 10.1074/jbc.271.35.21221; Musch MW, 2001, J EXP ZOOL, V289, P177, DOI 10.1002/1097-010X(20010215)289:3<177::AID-JEZ4>3.0.CO;2-1; MUSCH MW, 1994, J BIOL CHEM, V269, P19683; Musch MW, 1999, J BIOL CHEM, V274, P7923, DOI 10.1074/jbc.274.12.7923; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; PASSOW H, 1975, BIOMEMBRANES STRUCTU, V35, P197; Perlman DF, 1996, CELL MOL BIOL, V42, P975; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; Shao DM, 2003, FEBS LETT, V550, P101, DOI 10.1016/S0014-5793(03)00845-7; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Taouil K, 1999, PFLUG ARCH EUR J PHY, V439, P56, DOI 10.1007/s004240051128; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; vantHof W, 1997, J CELL BIOL, V139, P941; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Weskamp M, 2000, J MEMBRANE BIOL, V178, P11, DOI 10.1007/s002320010010; Wittels KA, 2000, AM J PHYSIOL-REG I, V279, pR69, DOI 10.1152/ajpregu.2000.279.1.R69; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200	43	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39447	39453		10.1074/jbc.M405363200	http://dx.doi.org/10.1074/jbc.M405363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258156	hybrid			2022-12-25	WOS:000223791500033
J	Shibata, M; Ishii, J; Koizumi, H; Shibata, N; Dohmae, N; Takio, K; Adachi, H; Tsujimoto, M; Arai, H				Shibata, M; Ishii, J; Koizumi, H; Shibata, N; Dohmae, N; Takio, K; Adachi, H; Tsujimoto, M; Arai, H			Type F scavenger receptor SREC-I interacts with advillin, a member of the gelsolin/villin family, and induces neurite-like outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN BINDING; EXPRESSION CLONING; CLASS-B; VILLIN; SITE	The scavenger receptor expressed by endothelial cells (SREC) was isolated from a human endothelial cell line and consists of two isoforms named SREC-I and -II. Both isoforms have no significant homology to other types of scavenger receptors. They contain 10 repeats of epidermal growth factor-like cysteine-rich motifs in the extracellular domains and have unusually long C-terminal cytoplasmic domains with Ser/Pro-rich regions. The extracellular domain of SREC-I binds modified low density lipoprotein and mediates a homophilic SREC-I/SREC-I or heterophilic SREC-I/SREC-II trans-interaction. However, the significance of large Ser/Pro-rich cytoplasmic domains of SRECs is not clear. Here, we found that when SREC-I was overexpressed in murine fibroblastic L cells, neurite-like outgrowth was induced, indicating that the receptor can lead to changes in cell morphology. The SREC-I-mediated morphological change required the cytoplasmic domain of the protein, and we identified advillin, a member of the gelsolin/villin family of actin regulatory proteins, as a protein binding to this domain. Reduction of advillin expression in L cells by RNAi led to the absence of the described SREC-I-induced morphological changes, indicating that advillin is a prerequisite for the change. Finally, we demonstrated that SREC-I and advillin were co-expressed and interacted with each other in dorsal root ganglion neurons during embryonic development and that overexpression of both SREC-I and advillin in cultured Neuro-2a cells induced long process formation. These results suggest that the interaction of SREC-I and advillin are involved in the development of dorsal root ganglion neurons by inducing the described morphological changes.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	harai@mol.f.u-tokyo.ac.jp	Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410; SHIBATA, NORIHITO/0000-0001-5792-8510				ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; GRONE HJ, 1986, AM J PATHOL, V124, P294; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Marks PW, 1998, J CELL SCI, V111, P2129; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Ravenall SJ, 2002, EUR J NEUROSCI, V15, P281, DOI 10.1046/j.0953-816x.2001.01862.x; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	27	33	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					40084	40090		10.1074/jbc.M403844200	http://dx.doi.org/10.1074/jbc.M403844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247299	hybrid			2022-12-25	WOS:000223791500106
J	Appelhoff, RJ; Tian, YM; Raval, RR; Turley, H; Harris, AL; Pugh, CW; Ratcliffe, PJ; Gleadle, JM				Appelhoff, RJ; Tian, YM; Raval, RR; Turley, H; Harris, AL; Pugh, CW; Ratcliffe, PJ; Gleadle, JM			Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; PROLINE HYDROXYLATION; MAMMALIAN-CELLS; HIF-ALPHA; HIF-1-ALPHA; EXPRESSION; GENE; VHL; FAMILY; FACTOR-1-ALPHA	Hypoxia-inducible factor (HIF) is a transcriptional regulator that plays a key role in many aspects of oxygen homeostasis. The heterodimeric HIF complex is regulated by proteolysis of its alpha-subunits, following oxygen-dependent hydroxylation of specific prolyl residues. Although three HIF prolyl hydroxylases, PHD1, PHD2, and PHD3, have been identified that have the potential to catalyze this reaction, the contribution of each isoform to the physiological regulation of HIF remains uncertain. Here we show using suppression by small interference RNA that each of the three PHD isoforms contributes in a non-redundant manner to the regulation of both HIF-1alpha and HIF-2alpha subunits and that the contribution of each PHD under particular culture conditions is strongly dependent on the abundance of the enzyme. Thus in different cell types, isoform-specific patterns of PHD induction by hypoxia and estrogen alter both the relative abundance of the PHDs and their relative contribution to the regulation of HIF. In addition, the PHDs manifest specificity for different prolyl hydroxylation sites within each HIF-alpha subunit, and a degree of selectively between HIF-1alpha and HIF-2alpha isoforms, indicating that differential PHD inhibition has the potential to selectively alter the characteristics of HIF activation.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Tumour Pathol Grp,Canc Res UK CRUK, Oxford OX3 9DU, England; John Radcliffe Hosp, Inst Mol Med, CRUK, Mol Oncol Grp, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford; University of Oxford	Gleadle, JM (corresponding author), Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	jgleadle@well.ox.ac.uk	Gleadle, Jonathan M/K-4188-2012; Harris, Adrian L/ABA-3343-2020	Gleadle, Jonathan M/0000-0002-5215-7208; Harris, Adrian L/0000-0003-1376-8409; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X				Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2002, ONCOGENE, V21, P6713, DOI 10.1038/sj.onc.1205867; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; PARELIKOVA O, 2004, J CELL BIOCHEM, V92, P491; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seth P, 2002, ONCOGENE, V21, P836, DOI 10.1038/sj.onc.1205113; Sowter HM, 2001, CANCER RES, V61, P6669; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wykoff CC, 2000, CANCER RES, V60, P7075; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	40	779	826	4	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38458	38465		10.1074/jbc.M406026200	http://dx.doi.org/10.1074/jbc.M406026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247232	hybrid			2022-12-25	WOS:000223684100049
J	Charych, EI; Yu, WD; Li, RW; Serwanski, DR; Miralles, CP; Li, XJ; Yang, BY; Pinal, N; Walikonis, R; De Blas, AL				Charych, EI; Yu, WD; Li, RW; Serwanski, DR; Miralles, CP; Li, XJ; Yang, BY; Pinal, N; Walikonis, R; De Blas, AL			A four PDZ domain-containing splice variant form of GRIP1 is localized in GABAergic and glutamatergic synapses in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; LONG-TERM DEPRESSION; AMINOBUTYRIC ACID(A) RECEPTOR; AMPA RECEPTOR; GABA(A) RECEPTORS; RAT-BRAIN; MONOCLONAL-ANTIBODIES; HIPPOCAMPAL-NEURONS; POSTSYNAPTIC DENSITY; BINDING PROTEIN	We have isolated, from a rat brain cDNA library, a clone corresponding to a 2779-bp cDNA encoding a novel splice form of the glutamate receptor interacting protein-1 (GRIP1). We call this 696-amino acid splice form GRIP1c 4-7 to differentiate it from longer splice forms of GRIP1a/b containing seven PDZ domains. The four PDZ domains of GRIP1c 4-7 are identical to PDZ domains 4 - 7 of GRIP1a/b. GRIP1c 4-7 also contains 35 amino acids at the N terminus and 12 amino acids at the C terminus that are different from GRIP1a/b. In transfected HEK293 cells, a majority of GRIP1c 4-7 was associated with the plasma membrane. GRIP1c 4-7 interacted with GluR2/3 subunits of the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor. In low density hippocampal cultures, GRIP1c 4-7 clusters colocalized with GABAergic ( where GABA is gamma-aminobutyric acid) and glutamatergic synapses, although a higher percentage of GRIP1c 4-7 clusters colocalized with gamma-aminobutyric acid, type A, receptor (GABA(A)R) clusters than with alpha-amino-3-hydroxy- 5-methyl-4-isoxazoleproprionic acid receptor clusters. Transfection of hippocampal neurons with hemagglutinin-tagged GRIP1c 4-7 showed that it could target to the postsynaptic complex of GABAergic synapses colocalizing with GABA(A)R clusters. GRIP1c 4-7-specific antibodies, which did not recognize previously described splice forms of GRIP1, recognized a 75-kDa protein that is enriched in a postsynaptic density fraction isolated from rat brain. EM immunocytochemistry experiments showed that in intact brain GRIP1c 4-7 concentrates at postsynaptic complexes of both type I glutamatergic and type II GABAergic synapses although it is also presynaptically localized. These results indicate that GRIP1c 4-7 plays a role not only in glutamatergic synapses but also in GABAergic synapses.	Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	University of Connecticut	De Blas, AL (corresponding author), 3107 Horsebarn Hill Rd,U-4156, Storrs, CT 06269 USA.	deblas@oracle.pnb.uconn.edu	Yu, Wendou/E-2871-2010	Yu, Wendou/0000-0002-9934-6954; Pinal, Noelia/0000-0002-4414-5135	NINDS NIH HHS [NS38752] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038752] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Betz H, 1998, NAT NEUROSCI, V1, P541, DOI 10.1038/2777; Bladt F, 2002, P NATL ACAD SCI USA, V99, P6816, DOI 10.1073/pnas.092130099; Brandon NJ, 2002, J NEUROSCI, V22, P6353; Brandon NJ, 2000, J BIOL CHEM, V275, P38856, DOI 10.1074/jbc.M004910200; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Brunig I, 2002, J NEUROSCI, V22, P4805, DOI 10.1523/JNEUROSCI.22-12-04805.2002; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Charych EI, 2004, J NEUROCHEM, V90, P173, DOI 10.1111/j.1471-4159.2004.02481.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christie SB, 2003, J COMP NEUROL, V456, P361, DOI 10.1002/cne.10535; Christie SB, 2002, PROG BRAIN RES, V136, P157; Christie SB, 2002, J NEUROSCI, V22, P684, DOI 10.1523/JNEUROSCI.22-03-00684.2002; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Craig AM, 1996, J NEUROSCI, V16, P3166; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; DEBLAS AL, 1984, BRAIN RES, V322, P277, DOI 10.1016/0006-8993(84)90118-5; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DEBLAS AL, 1988, J NEUROSCI, V8, P602; DeSouza S, 2002, J NEUROSCI, V22, P3493; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; EWERT M, 1992, BRAIN RES, V569, P57, DOI 10.1016/0006-8993(92)90368-J; Goslin K., 1998, CULTURING NERVE CELL, P339; Hering H, 2003, J NEUROSCI, V23, P3262; Kannenberg K, 1999, J BIOL CHEM, V274, P21257, DOI 10.1074/jbc.274.30.21257; KELLENBERGER E, 1991, COLLOIDAL GOLD PRINC, V3, P21; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Kittler JT, 2000, J NEUROSCI, V20, P7972; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Knuesel I, 1999, EUR J NEUROSCI, V11, P4457, DOI 10.1046/j.1460-9568.1999.00887.x; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Matsubara A, 1996, J NEUROSCI, V16, P4457; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Miralles CP, 1999, J COMP NEUROL, V413, P535; MORENO JI, 1994, J COMP NEUROL, V350, P260, DOI 10.1002/cne.903500209; Nusser Z, 1998, J NEUROSCI, V18, P1693; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Rao A, 2000, J NEUROSCI, V20, P8344, DOI 10.1523/JNEUROSCI.20-22-08344.2000; Riquelme R, 2002, J NEUROSCI, V22, P10720; Sato Y, 1967, J Electron Microsc (Tokyo), V16, P283; Schaerer MT, 2001, J BIOL CHEM, V276, P26597, DOI 10.1074/jbc.M102534200; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Srivastava S, 1999, ANN NY ACAD SCI, V868, P561, DOI 10.1111/j.1749-6632.1999.tb11329.x; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Takamiya K, 2004, NAT GENET, V36, P172, DOI 10.1038/ng1292; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; VITORICA J, 1988, J NEUROSCI, V8, P615; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang J, 2003, J NEUROSCI, V23, P826; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yamazaki M, 2001, NEUROSCI LETT, V304, P81, DOI 10.1016/S0304-3940(01)01766-9; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Yu GY, 2001, DEV BRAIN RES, V130, P217, DOI 10.1016/S0165-3806(01)00239-5	68	44	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38978	38990		10.1074/jbc.M405786200	http://dx.doi.org/10.1074/jbc.M405786200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226318	hybrid			2022-12-25	WOS:000223684100112
J	Cheng, JB; Russell, DW				Cheng, JB; Russell, DW			Mammalian wax biosynthesis - I. Identification of two fatty acyl-coenzyme A reductases with different substrate specificities and tissue distributions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN	The conversion of fatty acids to fatty alcohols is required for the synthesis of wax monoesters and ether lipids. The mammalian enzymes that synthesize fatty alcohols have not been identified. Here, an in silico approach was used to discern two putative reductase enzymes designated FAR1 and FAR2. Expression studies in intact cells showed that FAR1 and FAR2 cDNAs encoded isozymes that reduced fatty acids to fatty alcohols. Fatty acyl-CoA esters were the substrate of FAR1, and the enzyme required NADPH as a cofactor. FAR1 preferred saturated and unsaturated fatty acids of 16 or 18 carbons as substrates, whereas FAR2 preferred saturated fatty acids of 16 or 18 carbons. Confocal light microscopy indicated that FAR1 and FAR2 were localized in the peroxisome. The FAR1 mRNA was detected in many mouse tissues with the highest level found in the preputial gland, a modified sebaceous gland. The FAR2 mRNA was more restricted in distribution and most abundant in the eyelid, which contains wax-laden mei-bomian glands. Both FAR mRNAs were present in the brain, a tissue rich in ether lipids. The data suggest that fatty alcohol synthesis in mammals is accomplished by two fatty acyl-CoA reductase isozymes that are expressed at high levels in tissues known to synthesize wax monoesters and ether lipids.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.russell@utsouthwestern.edu		Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, P01 HL020948, P01 HL020948-32] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts MGM, 1997, PLANT J, V12, P615, DOI 10.1046/j.1365-313X.1997.00615.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BISHOP JE, 1981, J BIOL CHEM, V256, P9542; Cheng JB, 2004, J BIOL CHEM, V279, P37798, DOI 10.1074/jbc.M406226200; DOWNING DT, 1974, J INVEST DERMATOL, V62, P228, DOI 10.1111/1523-1747.ep12676793; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Jenks MA, 2002, ARABIDOPSIS BOOK; Kunst L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; Metz JG, 2000, PLANT PHYSIOL, V122, P635, DOI 10.1104/pp.122.3.635; MOORE C, 1982, ARCH BIOCHEM BIOPHYS, V214, P500, DOI 10.1016/0003-9861(82)90053-4; Moto K, 2003, P NATL ACAD SCI USA, V100, P9156, DOI 10.1073/pnas.1531993100; Munn NJ, 2003, J LIPID RES, V44, P182, DOI 10.1194/jlr.M200363-JLR200; Nagan N, 2001, PROG LIPID RES, V40, P199, DOI 10.1016/S0163-7827(01)00003-0; NIKKARI T, 1974, J INVEST DERMATOL, V62, P257, DOI 10.1111/1523-1747.ep12676800; Reiser S, 1997, J BACTERIOL, V179, P2969, DOI 10.1128/jb.179.9.2969-2975.1997; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Touchstone J. C., 1992, PRACTICE THIN LAYER; Wang AM, 2002, PLANT J, V30, P613, DOI 10.1046/j.1365-313X.2002.01313.x; WYKLE RL, 1979, J LIPID RES, V20, P890	19	174	224	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37789	37797		10.1074/jbc.M406225200	http://dx.doi.org/10.1074/jbc.M406225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220348	hybrid, Green Accepted			2022-12-25	WOS:000223554600071
J	Yildiz, A; Park, H; Safer, D; Yang, ZH; Chen, LQ; Selvin, PR; Sweeney, HL				Yildiz, A; Park, H; Safer, D; Yang, ZH; Chen, LQ; Selvin, PR; Sweeney, HL			Myosin VI steps via a hand-over-hand mechanism with its lever arm undergoing fluctuations when attached to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; MOTOR; GENE; DEAFNESS; BINDING	Myosin VI is a reverse direction myosin motor that, as a dimer, moves processively on actin with an average center-of-mass movement of similar to 30 nm for each step. We labeled myosin VI with a single fluorophore on either its motor domain or on the distal of two calmodulins (CaMs) located on its putative lever arm. Using a technique called FIONA ( fluorescence imaging with one nanometer accuracy), step size was observed with a standard deviation of < 1.5 nm, with 0.5-s temporal resolution, and observation times of minutes. Irrespective of probe position, the average step size of a labeled head was similar to 60 nm, strongly supporting a hand-over-hand model of motility and ruling out models in which the unique myosin VI insert comes apart. However, the CaM probe displayed large spatial fluctuations ( presence of ATP but not ADP or no nucleotide) around the mean position, whereas the motor domain probe did not. This supports a model of myosin VI motility in which the lever arm is either mechanically uncoupled from the motor domain or is undergoing reversible isomerization for part of its motile cycle on actin.	Univ Illinois, Dept Phys, Ctr Biophys & Computat Biol, Loomis Lab, Urbana, IL 61801 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Pennsylvania	Selvin, PR (corresponding author), Univ Illinois, Dept Phys, Ctr Biophys & Computat Biol, Loomis Lab, 1110 W Green St, Urbana, IL 61801 USA.	selvin@uiuc.edu; lsweeney@mail.med.upenn.edu	Park, Hyokeun/AAY-3073-2021; Sweeney, H Lee/F-1862-2010; Yildiz, Ahmet/E-6167-2015	Yildiz, Ahmet/0000-0003-4792-174X; Park, Hyo Keun/0000-0002-2655-4795				Al-Bassam J, 2003, J CELL BIOL, V163, P743, DOI 10.1083/jcb.200308020; Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	23	125	129	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37223	37226		10.1074/jbc.C400252200	http://dx.doi.org/10.1074/jbc.C400252200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15254036	hybrid			2022-12-25	WOS:000223554600004
J	Rajendra, R; Malegaonkar, D; Pungaliya, P; Marshall, H; Rasheed, Z; Brownell, J; Liu, LF; Lutzker, S; Saleem, A; Rubin, EH				Rajendra, R; Malegaonkar, D; Pungaliya, P; Marshall, H; Rasheed, Z; Brownell, J; Liu, LF; Lutzker, S; Saleem, A; Rubin, EH			Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I BINDING-PROTEIN; TOPOISOMERASE-I; RING FINGER; NEGATIVE REGULATOR; NUCLEAR-BODIES; C-CBL; DOMAIN; COMPLEX; LOCALIZATION; DEGRADATION	The human topoisomerase I- and p53-binding protein topors contains a highly conserved, N-terminal C3HC4-type RING domain that is homologous to the RING domains of known E3 ubiquitin ligases. We demonstrate that topors functions in vitro as a RING-dependent E3 ubiquitin ligase with the E2 enzymes UbcH5a, UbcH5c, and UbcH6 but not with UbcH7, CDC34, or UbcH2b. Additional studies indicate that a conserved tryptophan within the topors RING domain is required for ubiquitination activity. Furthermore, both in vitro and cellular studies implicate p53 as a ubiquitination substrate for topors. Similar to MDM2, overexpression of topors results in a proteasome-dependent decrease in p53 protein expression in a human osteosarcoma cell line. These results are similar to the recent finding that a Drosophila topors orthologue ubiquitinates the Hairy transcriptional repressor and suggest that topors functions as a ubiquitin ligase for multiple transcription factors.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Millennium Pharmaceut, Cambridge, MA 02139 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08901 USA.	liehrubin@umdnj.edu		Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA 39662] Funding Source: Medline; NIGMS NIH HHS [GM 59170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Dominguez C, 2004, STRUCTURE, V12, P633, DOI 10.1016/j.str.2004.03.004; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; SALEEM A, 1908, ONCOGENE, V23, P5293; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Secombe J, 2004, J BIOL CHEM, V279, P17126, DOI 10.1074/jbc.M310097200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Weger S, 2002, J GEN VIROL, V83, P511, DOI 10.1099/0022-1317-83-3-511; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	36	140	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36440	36444		10.1074/jbc.C400300200	http://dx.doi.org/10.1074/jbc.C400300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15247280	hybrid			2022-12-25	WOS:000223453600036
J	Vergnes, A; Gouffi-Belhabich, K; Blasco, F; Giordano, G; Magalon, A				Vergnes, A; Gouffi-Belhabich, K; Blasco, F; Giordano, G; Magalon, A			Involvement of the molybdenum cofactor Biosynthetic machinery in the maturation of the Escherichia coli nitrate reductase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; BACTERIAL 2-HYBRID SYSTEM; ELECTRON-TRANSFER; GENE-PRODUCTS; MOB LOCUS; CHAPERONE; DEHYDROGENASE; MOLYBDATE; PATHWAY; OPERON	The maturation of Escherichia coli nitrate reductase A requires the incorporation of the Mo-(bis-MGD) cofactor to the apoprotein. For this process, the NarJ chaperone is strictly required (Blasco, F., Dos Santos, J.P., Magalon, A., Frixon, C., Guigliarelli, B., Santini, C. L., and Giordano, G. (1998) Mol. Microbiol. 28, 435-447). We report the first description of protein interactions between molybdenum cofactor biosynthetic proteins (MogA, MoeA, MobA, and MobB) and the aponitrate reductase (NarG) using a bacterial two-hybrid approach. Two conditions have to be satisfied to allow the visualization of the interactions, (i) the presence of an active and mature molybdenum cofactor and (ii) the presence of the NarJ chaperone and of the NarG structural partner subunit, NarH. Formation of tungsten-substituted cofactor prevents the interaction between NarG and the four biosynthetic proteins. Our results suggested that the final stages of molybdenum cofactor biosynthesis occur on a complex made up by MogA, MoeA, MobA, and MobB, which is also in charge with the delivery of the mature cofactor onto the aponitrate reductase A in a NarJ-assisted process.	CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, F-13402 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS)	Magalon, A (corresponding author), CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille 09, France.	magalon@ibsm.cnrs-mrs.fr	Vergnes, Alexandra/AAM-2842-2020	Magalon, Axel/0000-0002-3375-738X				AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Buc J, 1999, MOL MICROBIOL, V32, P159, DOI 10.1046/j.1365-2958.1999.01340.x; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Hasona A, 2001, ARCH MICROBIOL, V175, P178, DOI 10.1007/s002030100252; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; Ilbert M, 2004, MICROBIOL-SGM, V150, P935, DOI 10.1099/mic.0.26909-0; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; IOBBINIVOL C, 1995, MICROBIOL-SGM, V141, P1663; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Karimova G, 2000, METHOD ENZYMOL, V328, P59, DOI 10.1016/S0076-6879(00)28390-0; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; MILLER JH, 1972, MOL CLONING LAB MANU; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Pau RN, 2002, MET IONS BIOL SYST, V39, P31; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Rothery RA, 2004, BIOCHEMISTRY-US, V43, P5324, DOI 10.1021/bi049938l; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089	37	41	45	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41398	41403		10.1074/jbc.M407087200	http://dx.doi.org/10.1074/jbc.M407087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247236	hybrid			2022-12-25	WOS:000224075500021
J	Lambert, AJ; Brand, MD				Lambert, AJ; Brand, MD			Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH : ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE PRODUCTION; ELECTRON-TRANSPORT CHAIN; HEART-MITOCHONDRIA; RESPIRATORY-CHAIN; RADICAL GENERATION; RAT; UBISEMIQUINONE; DISMUTASE; TOPOLOGY; ANION	Neither the route of electron transport nor the sites or mechanism of superoxide production in mitochondrial complex I has been established. We examined the rates of superoxide generation (measured as hydrogen peroxide production) by rat skeletal muscle mitochondria under a variety of conditions. The rate of superoxide production by complex I during NADH-linked forward electron transport was less than 10% of that during succinate-linked reverse electron transport even when complex I was fully reduced by pyruvate plus malate in the presence of the complex III inhibitor, stigmatellin. This asymmetry was not explained by differences in protonmotive force or its components. However, when inhibitors of the quinone-binding site of complex I were added in the presence of ATP to generate a pH gradient, there was a rapid rate of superoxide production by forward electron transport that was as great as the rate seen with reverse electron transport at the same pH gradient. These observations suggest that quinone-binding site inhibitors can make complex I adopt the highly radical-producing state that occurs during reverse electron transport. Despite complete inhibition of NADH: ubiquinone oxidoreductase activity in each case, different classes of quinone-binding site inhibitor (rotenone, piericidin, and high concentrations of myxothiazol) gave different rates of superoxide production during forward electron transport (the rate with myxothiazol was twice that with rotenone) suggesting that the site of rapid superoxide generation by complex I is in the region of the ubisemiquinone-binding sites and not upstream at the flavin or low potential FeS centers.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Brand, MD (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	martin.brand@mrc-dunn.cam.ac.uk	Zhu, Longjun/C-2938-2012; Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153				Brand M. D., 1995, BIOENERGETICS, V154, P62; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Han D, 2003, MOL PHARMACOL, V64, P1136, DOI 10.1124/mol.64.5.1136; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Yano T, 2000, BBA-BIOENERGETICS, V1459, P299, DOI 10.1016/S0005-2728(00)00164-X; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7	33	371	381	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39414	39420		10.1074/jbc.M406576200	http://dx.doi.org/10.1074/jbc.M406576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15262965	hybrid			2022-12-25	WOS:000223791500029
J	Galluhn, D; Langer, T				Galluhn, D; Langer, T			Reversible assembly of the ATP-binding cassette transporter Mdl1 with the F1F0-ATP synthase in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN DEGRADATION; OXIDATIVE STRESS; AAA PROTEASES; YEAST; IDENTIFICATION; DYSFUNCTION; F1-ATPASE; COMPLEXES; PATHWAY	The half-ABC transporter Mdl1 is localized in the inner membrane of mitochondria and mediates the export of peptides generated upon proteolysis of mitochondrial proteins. The physiological role of the peptides released from mitochondria is currently not understood. Here, we have analyzed the oligomeric state of Mdl1 in the inner membrane and demonstrate nucleotide-dependent binding to the F1F0-ATP synthase. Mdl1 forms homooligomeric, presumably dimeric complexes in the presence of ATP, but was found in association with the F1F0-ATP synthase at low ATP levels. Mdl1 binds membrane-embedded parts of the ATP synthase complex after the assembly of the F-1 and F-0 moieties. Although independent of Mdl1 activity, complex formation is impaired upon inhibition of the F1F0-ATP synthase with oligomycin or N,N'-dicyclohexylcarbodiimide. These results are consistent with an activation of Mdl1 upon dissociation from the ATP synthase and suggest a link of peptide export from mitochondria to the activity of the F1F0-ATP synthase and the cellular energy metabolism.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany	University of Cologne	Langer, T (corresponding author), Univ Cologne, Inst Genet, D-50674 Cologne, Germany.	Thomas.Langer@uni-koeln.de		Langer, Thomas/0000-0003-1250-1462				ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; Chloupkova M, 2003, J MOL BIOL, V331, P155, DOI 10.1016/S0022-2836(03)00666-1; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; LILL R, 2003, ABC PROTEINS BACTERI, P515; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Sharom FJ., 2003, ABC PROTEINS BACTERI, P107; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang F, 2000, FEBS LETT, V478, P89, DOI 10.1016/S0014-5793(00)01823-8; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	35	22	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38338	38345		10.1074/jbc.M405871200	http://dx.doi.org/10.1074/jbc.M405871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247210	hybrid			2022-12-25	WOS:000223684100034
J	Joosten, M; Blazquez-Domingo, M; Lindeboom, F; Boulme, F; Van Hoven-Beijen, A; Habermann, B; Lowenberg, R; Beug, H; Muller, EW; Delwel, R; Von Lindern, M				Joosten, M; Blazquez-Domingo, M; Lindeboom, F; Boulme, F; Van Hoven-Beijen, A; Habermann, B; Lowenberg, R; Beug, H; Muller, EW; Delwel, R; Von Lindern, M			Translational control of putative protooncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION INHIBITORY FACTOR; NUCLEOSIDE DIPHOSPHATE KINASE; INTERNAL RIBOSOME ENTRY; TOP MESSENGER-RNAS; GLUCOCORTICOID-RECEPTOR; METASTASIS SUPPRESSOR; ERYTHROID PROGENITORS; C-MYC; BINDING-PROTEIN; 5 UTR	The expansion and differentiation of hematopoietic progenitors is regulated by cytokine and growth factor signaling. To examine how signal transduction controls the gene expression program required for progenitor expansion, we screened ATLAS filters with polysome-associated mRNA derived from erythroid progenitors stimulated with erythropoietin and/or stem cell factor. The putative proto-oncogene nucleoside diphosphate kinase B (ndpk-B or nm23-M2) was identified as an erythropoietin and stem cell factor target gene. Factor-induced expression of nm23-M2 was regulated specifically at the level of polysome association by a phosphoinositide 3-kinase-dependent mechanism. Identification of the transcription initiation site revealed that nm23-M2 mRNA starts with a terminal oligopyrimidine sequence, which is known to render mRNA translation dependent on mitogenic factors. Recently, the nm23-M2 locus was identified as a common leukemia retrovirus integration site, suggesting that it plays a role in leukemia development. The expression of Nm23 from a retroviral vector in the absence of its 5'-untranslated region caused constitutive polysome association of nm23-M2. Polysome-association and protein expression of endogenous nm23-M2 declined during differentiation of erythroid progenitors, suggesting a role for Nm23-M2 in progenitor expansion. Taken together, nm23-m2 exemplifies that cytokine-dependent control of translation initiation is an important mechanism of gene expression regulation.	Erasmus MC, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Vienna Bioctr, Inst Med Biochem, A-1030 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Erasmus University Rotterdam; Erasmus MC; Vienna Biocenter (VBC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Von Lindern, M (corresponding author), Erasmus MC, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	m.vonlindern@erasmusmc.nl	Habermann, Bianca/N-4886-2016; von Lindern, Marieke/AAH-2350-2020	Habermann, Bianca/0000-0002-2457-7504; 				Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; Biberman Y, 1999, FEBS LETT, V456, P357, DOI 10.1016/S0014-5793(99)00983-7; Broudy VC, 1996, BLOOD, V88, P75; Calkhoven CF, 2002, TRENDS MOL MED, V8, P577, DOI 10.1016/S1471-4914(02)02424-3; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Hartsough MT, 2002, J BIOL CHEM, V277, P32389, DOI 10.1074/jbc.M203115200; Joosten M, 2002, ONCOGENE, V21, P7247, DOI 10.1038/sj.onc.1205813; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MANDAI M, 1994, CANCER RES, V54, P1825; MATHEWS D, 1996, RNASTRUCTURE VERSION; McKendrick L, 1999, INT J BIOCHEM CELL B, V31, P31, DOI 10.1016/S1357-2725(98)00129-0; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mikulits W, 1997, BIOCHEM BIOPH RES CO, V235, P212, DOI 10.1006/bbrc.1997.6647; Mullner E. W., 1997, MANUAL IMMUNOLOGICAL, V1, P457; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; Niitsu N, 2003, LEUKEMIA, V17, P987, DOI 10.1038/sj.leu.2402858; Niitsu N, 2003, LEUKEMIA, V17, P196, DOI 10.1038/sj.leu.2402699; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; OHTSUKI K, 1987, BIOCHIM BIOPHYS ACTA, V929, P231, DOI 10.1016/0167-4889(87)90248-5; Okabe-Kado J, 1998, LEUKEMIA LYMPHOMA, V32, P19, DOI 10.3109/10428199809059243; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; OKABEKADO J, 1995, BBA-MOL CELL RES, V1267, P101, DOI 10.1016/0167-4889(95)00037-S; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Proud CG, 1997, BIOCHEM J, V328, P329; QUANG CT, 1995, ONCOGENE, V11, P1229; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Salerno M, 2003, CLIN EXP METASTAS, V20, P3, DOI 10.1023/A:1022578000022; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Schmidt B, 1997, J UROLOGY, V158, P2000, DOI 10.1016/S0022-5347(01)64201-0; SEVERSON WE, 1995, EUR J BIOCHEM, V229, P426, DOI 10.1111/j.1432-1033.1995.tb20483.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Willems R, 1998, J BIOL CHEM, V273, P13663, DOI 10.1074/jbc.273.22.13663	55	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38169	38176		10.1074/jbc.M401283200	http://dx.doi.org/10.1074/jbc.M401283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247270	hybrid			2022-12-25	WOS:000223684100015
J	Pinte, S; Stankovic-Valentin, N; Deltour, S; Rood, BR; Guerardel, C; Leprince, D				Pinte, S; Stankovic-Valentin, N; Deltour, S; Rood, BR; Guerardel, C; Leprince, D			The tumor suppressor gene HIC1 (Hypermethylated in cancer 1) is a sequence-specific transcriptional repressor - Definition of its consensus binding sequence and analysis of its DNA binding and repressive properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BTB/POZ-DOMAIN; NEGATIVE AUTOREGULATION; CRYSTAL-STRUCTURE; DIEKER-SYNDROME; POZ DOMAIN; BTB DOMAIN; EXPRESSION; PLZF; GAGA; HYPERMETHYLATION	HIC1 (hypermethylated in cancer 1) is a tumor suppressor gene located at chromosome 17p13.3, a region frequently hypermethylated or deleted in human tumors and in a contiguous-gene syndrome, the Miller-Dieker syndrome. HIC1 is a transcriptional repressor containing five Kruppel-like C2H2 zinc fingers and an N-terminal dimerization and autonomous repression domain called BTB/POZ. Although some of the HIC1 transcriptional repression mechanisms have been recently deciphered, target genes are still to be discovered. In this study, we determined the consensus binding sequence for HIC1 and investigated its DNA binding properties. Using a selection and amplification of binding sites technique, we identified the sequence 5'-(C)/(G)NG(C)/(G)GGGCA(C)/ACC-3' as an optimal binding site. In silico and functional analyses fully validated this consensus and highlighted a GGCA core motif bound by zinc fingers 3 and 4. The BTB/POZ domain inhibits the binding of HIC1 to a single site but mediates cooperative binding to a probe containing five concatemerized binding sites, a property shared by other BTB/POZ proteins. Finally, full-length HIC1 proteins transiently expressed in RK13 cells and more importantly, endogenous HIC1 proteins from the DAOY medulloblastoma cell line, repress the transcription of a reporter gene through their direct binding to these sites, as confirmed by chromatin immunoprecipitation experiments. The definition of the HIC1-specific DNA binding sequence as well as the requirement for multiple sites for optimal binding of the full-length protein are mandatory prerequisites for the identification and analyses of bona fide HIC1 target genes.	Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, F-59017 Lille, France; Childrens Natl Med Ctr, Div Pediat Hematol Oncol, Washington, DC 20010 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Children's National Health System	Leprince, D (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59017 Lille, France.	dominique.leprince@ibl.fr		Leprince, Dominique/0000-0002-1999-0775				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bertrand S, 2004, BBA-GENE STRUCT EXPR, V1678, P57, DOI 10.1016/j.bbaexp.2004.01.009; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Cardoso C, 2003, AM J HUM GENET, V72, P918, DOI 10.1086/374320; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Corbi N, 1997, FEBS LETT, V417, P71, DOI 10.1016/S0014-5793(97)01257-X; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Eguchi K, 1997, CANCER RES, V57, P4913; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Grimm C, 1999, HUM MOL GENET, V8, P697, DOI 10.1093/hmg/8.4.697; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; Lehmann M, 2004, TRENDS GENET, V20, P15, DOI 10.1016/j.tig.2003.11.005; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LIU QR, 1994, DEV BIOL, V165, P165, DOI 10.1006/dbio.1994.1243; Lours C, 2003, NUCLEIC ACIDS RES, V31, P5389, DOI 10.1093/nar/gkg724; Mahmoudi T, 2002, EMBO J, V21, P1775, DOI 10.1093/emboj/21.7.1775; MAKOSWALES M, 1995, NAT MED, V1, P570; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pessler F, 2003, J BIOL CHEM, V278, P29327, DOI 10.1074/jbc.M302980200; REEMANN N, 1988, NATURE, V322, P90; Rood BR, 2002, CANCER RES, V62, P3794; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shimojima T, 2003, GENE DEV, V17, P1605, DOI 10.1101/gad.1086803; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801; Yingling J, 2003, AM J HUM GENET, V73, P475, DOI 10.1086/378096	52	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38313	38324		10.1074/jbc.M401610200	http://dx.doi.org/10.1074/jbc.M401610200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15231840	hybrid			2022-12-25	WOS:000223684100031
J	Prickett, TD; Brautigan, DL				Prickett, TD; Brautigan, DL			Overlapping binding sites in protein phosphatase 2A for association with regulatory A and alpha-4 (mTap42) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; CATALYTIC SUBUNIT; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PR65/A SUBUNIT; B-SUBUNIT; PHOSPHORYLATION; KINASE; FAMILY; PHOSPHOPROTEIN	Diverse functions of protein Ser/Thr phosphatases depend on the distribution of the catalytic subunits among multiple regulatory subunits. In cells protein phosphatase 2A catalytic subunit (PP2Ac) mostly binds to a scaffold subunit (A subunit or PR65); however, PP2Ac alternatively binds to alpha-4, a subunit related to yeast Tap42 protein, which also associates with phosphatases PP4 or PP6. We mapped alpha-4 binding to PP2Ac to the helical domain, residues 19-165. We mutated selected residues and transiently expressed epitope-tagged PP2Ac to assay for association with A and alpha-4 subunits by co-precipitation. The disabling H118N mutation at the active site or the presence of the active site inhibitor microcystin-LR did not interfere with binding of PP2Ac to either the A subunit or alpha-4, showing that these are allosteric regulators. Positively charged side chains Lys(41), Arg(49), and Lys(74) on the back surface of PP2Ac are unique to PP2Ac, compared with phosphatases PP4, PP6, and PP1. Substitution of one, two, or three of these residues with Ala produced a progressive loss of binding to the A subunit, with a corresponding increase in binding to alpha-4. Conversely, mutation of Glu42 in PP2Ac essentially eliminated PP2Ac binding to alpha-4, with an increase in binding to the A subunit. Reciprocal changes in binding because of mutations indicate competitive distribution of PP2Ac between these regulatory subunits and demonstrate that the mutated catalytic subunits retained a native conformation. Furthermore, neither the Lys(41)-Arg(49)-Lys(74) nor Glu(42) mutations affected the phosphatase-specific activity or binding to microcystin-agarose. Binding of PP2Ac to microcystin and to alpha-4 increased with temperature, consistent with an activation energy barrier for these interactions. Our results reveal that the A subunit and alpha-4 (mTap42) require charged residues in separate but overlapping surface regions to associate with the back side of PP2Ac and modulate phosphatase activity.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577,W Complex MSB 7196, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; CHEN J, 1994, J BIOL CHEM, V269, P7957; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 2003, METHOD ENZYMOL, V366, P243; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; INUI S, 1995, J IMMUNOL, V154, P2714; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; JOSHI B, 1990, J VIROL, V64, P5649, DOI 10.1128/JVI.64.11.5649-5651.1990; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Knapp J, 1998, GEN PHARMACOL, V31, P729, DOI 10.1016/S0306-3623(98)00053-6; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Price NE, 2000, BIOCHEMISTRY-US, V39, P11312, DOI 10.1021/bi0008478; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yokoyama N, 2001, FEBS LETT, V505, P460, DOI 10.1016/S0014-5793(01)02874-5; Yokoyama N, 2001, ONCOGENE, V20, P6057, DOI 10.1038/sj.onc.1204735; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	70	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38912	38920		10.1074/jbc.M401444200	http://dx.doi.org/10.1074/jbc.M401444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252037	hybrid			2022-12-25	WOS:000223684100105
J	Waggoner, DW; Johnson, LB; Mann, PC; Morris, V; Guastella, J; Bajjalieh, SM				Waggoner, DW; Johnson, LB; Mann, PC; Morris, V; Guastella, J; Bajjalieh, SM			MuLK, a eukaryotic multi-substrate lipid kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; LEUKEMIA HL-60 CELLS; DIACYLGLYCEROL KINASE; LYSOPHOSPHATIDIC ACID; ESCHERICHIA-COLI; SN-1,2-DIACYLGLYCEROL KINASE; CERAMIDE KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; JURKAT CELLS	We report the identification and characterization of a novel lipid kinase that phosphorylates multiple substrates. This enzyme, which we term MuLK for multisubstrate lipid kinase, does not belong to a previously described lipid kinase family. MuLK has orthologs in many organisms and is broadly expressed in human tissues. Although predicted to be a soluble protein, MuLK co-fractionates with membranes and localizes to an internal membrane compartment. Recombinant MuLK phosphorylates diacylglycerol, ceramide, and 1-acylglycerol but not sphingosine. Although its affinity for diacylglycerol and ceramide are similar, MuLK exhibits a higher V-max toward diacylglycerol in vitro, consistent with it acting primarily as a diacylglycerol kinase. MuLK activity was inhibited by sphingosine and enhanced by cardiolipin. It was stimulated by calcium when magnesium concentrations were low and inhibited by calcium when magnesium concentrations were high. The effects of charged lipids and cations on MuLK activity in vitro suggest that its activity in vivo is tightly regulated by cellular conditions.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bajjalieh, SM (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	bajjalie@u.washington.edu		Morris, Valerie/0000-0002-0355-7379	NIDA NIH HHS [R21 DA14954] Funding Source: Medline; NIGMS NIH HHS [T32 GM07750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014954] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abe T, 2003, BIOCHEM J, V375, P673, DOI 10.1042/BJ20031052; Bajjalieh S, 2000, METHOD ENZYMOL, V311, P207; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Brindley DN, 1996, BIOCHEM CELL BIOL, V74, P469, DOI 10.1139/o96-051; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Houssa B, 1997, J BIOL CHEM, V272, P10422; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Luquain C, 2003, TRENDS BIOCHEM SCI, V28, P377, DOI 10.1016/S0968-0004(03)00139-7; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; RAMER JK, 1990, J BIOL CHEM, V265, P16478; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Thirugnanam S, 2001, BIOCHEMISTRY-US, V40, P10607, DOI 10.1021/bi010609s; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WALSH JP, 1986, J BIOL CHEM, V261, P6239; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P217; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; Ye XQ, 2002, NEUROREPORT, V13, P2169, DOI 10.1097/00001756-200212030-00002; YOUNES A, 1992, J BIOL CHEM, V267, P842	39	47	49	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38228	38235		10.1074/jbc.M405932200	http://dx.doi.org/10.1074/jbc.M405932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252046	hybrid			2022-12-25	WOS:000223684100022
J	Marano, RJ; Brankov, M; Rakoczy, PE				Marano, RJ; Brankov, M; Rakoczy, PE			Discovery of a novel control element within the 5 '-untranslated region of the vascular endothelial growth factor - Regulation of expression using sense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CHOROIDAL NEOVASCULARIZATION; TRANSFERRIN RECEPTOR; DIABETIC-RETINOPATHY; UNTRANSLATED REGION; GENE-TRANSCRIPTION; PROTEIN-BINDING; DNA TRIPLEXES; FACTOR VEGF; IN-VIVO	The regulation of vascular endothelial growth factor ( VEGF), a potent stimulator of angiogenesis, is controlled primarily through the interactions of control elements located within the 5'- and 3'-untranslated regions, many of which are yet to be described. In this study we examined the 5'-untranslated region of human VEGF for control elements with the aim of regulating expression both in vitro and in vivo using oligonucleotide gene therapy. A potential control element was located, two sense oligonucleotides (S-1 and S-2) were designed based on its sequence, and a third oligonucleotide (S-3) was designed as a control and mapped to the 16 base pairs immediately upstream. Retinal cells cultured in the presence of S-1 and S-2 resulted in a 2-fold increase of VEGF protein and a 1.5-fold increase in mRNA 24 h post-transfection whereas S-3 had no significant effect ( p > 0.05) compared with controls. Subsequent reporter gene studies confirmed the necessity of this element for up-regulation by S-1. Further in vivo studies showed that S-1 and S-2 mediated an increase in VEGF protein in a rodent ocular model that resulted in angiogenesis. In addition to providing insight into the regulation of the vascular endothelial growth factor, the use of these oligonucleotides to stimulate vascular growth may prove useful for the treatment of ischemic tissues such as those found in the heart following infarct.	Univ Western Australia, Ctr Ophthalmol & Visual Sci, Nedlands, WA 6009, Australia; Univ Western Australia, Lions Eye Inst, Dept Mol Ophthalmol, Nedlands, WA 6009, Australia	University of Western Australia; Lions Eye Institute; University of Western Australia	Rakoczy, PE (corresponding author), Univ Western Australia, Ctr Ophthalmol & Visual Sci, 2 Verdun St, Nedlands, WA 6009, Australia.	robert@lei.org.au	Marano, Robert/A-3552-2015	Marano, Robert/0000-0001-9565-3167				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ALUNNIFABBRONI M, 1994, EUR J BIOCHEM, V226, P831, DOI 10.1111/j.1432-1033.1994.00831.x; Arnold R, 2000, GENE, V253, P209, DOI 10.1016/S0378-1119(00)00271-7; Axel DI, 2000, J VASC RES, V37, P221, DOI 10.1159/000025737; Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Ding I, 2003, ADV EXP MED BIOL, V530, P603; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197; Genuario RR, 1996, J BIOL CHEM, V271, P4388; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Iida K, 2002, LIFE SCI, V71, P1607, DOI 10.1016/S0024-3205(02)01842-8; Im SA, 2001, BRIT J CANCER, V84, P1252, DOI 10.1054/bjoc.2000.1734; Kawashima J, 2003, DIABETOLOGIA, V46, P231, DOI 10.1007/s00125-002-1022-3; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Moore J, 1999, J ANAT, V194, P89, DOI 10.1046/j.1469-7580.1999.19410089.x; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; Siemeister G, 1998, CANCER METAST REV, V17, P241, DOI 10.1023/A:1006027124696; Su H, 2002, P NATL ACAD SCI USA, V99, P9480, DOI 10.1073/pnas.132275299; TISCHER E, 1991, J BIOL CHEM, V266, P11947; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5	37	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37808	37814		10.1074/jbc.M400047200	http://dx.doi.org/10.1074/jbc.M400047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15213238	hybrid			2022-12-25	WOS:000223554600073
J	Robb, GB; Carson, AR; Tai, SC; Fish, JE; Singh, S; Yamada, T; Scherer, SW; Nakabayashi, K; Marsden, PA				Robb, GB; Carson, AR; Tai, SC; Fish, JE; Singh, S; Yamada, T; Scherer, SW; Nakabayashi, K; Marsden, PA			Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; POLYMERASE-II; IN-VIVO; ALLELIC VARIATION; DOWN-REGULATION; CELL-FUNCTION; DNA-SEQUENCE; MICE LACKING; HUMAN GENOME; INHIBITORS	Endothelial nitric-oxide synthase ( eNOS) mRNA levels are abnormal in diseases of the cardiovascular system, but changes in gene expression cannot be accounted for by transcription alone. We found evidence for the existence of an antisense mRNA (sONE) that is derived from a transcription unit ( NOS3AS) on the opposite DNA strand from which the human eNOS (NOS3) mRNA is transcribed at human chromosome 7q36. The genes are oriented in a tail-to-tail configuration, and the mRNAs encoding sONE and eNOS are complementary for 662 nucleotides. The mRNA for sONE could be detected in a variety of cell types, both in vivo and in vitro, but not vascular endothelial cells. In contrast, expression of eNOS is highly restricted to vascular endothelium. Most surprisingly, interrogation of transcriptional events across NOS3/NOS3AS genomic regions, using single- and double-stranded probes for nuclear run-off analyses and chromatin immunoprecipitation-based assessments of RNA polymerase II distribution, indicated that NOS3 and NOS3AS gene transcription did not correlate with steady-state mRNA levels. We found strong evidence supporting a role for NOS3AS in the post-transcriptional regulation of NOS3 expression. RNA interference-mediated inhibition of sONE expression in vascular smooth muscle cells increased eNOS expression. Overexpression of sONE in endothelial cells blunted eNOS expression. Finally, the histone deacetylase inhibitor trichostatin A is known to regulate the expression of eNOS via a post-transcriptional mechanism. We found that trichostatin A treatment of vascular endothelial cells increased expression of sONE mRNA levels prior to the observed decrease in eNOS mRNA expression. Taken together, these results indicate that an antisense mRNA ( sONE) participates in the post-transcriptional regulation of eNOS and provide a newer model for endothelial cell-specific gene expression.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Dept Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Rm 7358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Scherer, Stephen W./B-3785-2013; Yamada, Takahiro/A-4001-2011; Marsden, Philip A/B-1441-2012	Scherer, Stephen W./0000-0002-8326-1999; Robb, Gregory Brett/0000-0002-2382-2256; Fish, Jason/0000-0003-0640-7277				BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Freedman JE, 1999, CIRC RES, V84, P1416; Gnanapandithen K, 1996, BBA-GENE STRUCT EXPR, V1308, P103, DOI 10.1016/0167-4781(96)00098-X; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Hemberger M, 2003, DEV DYNAM, V227, P185, DOI 10.1002/dvdy.10291; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KASH SF, 1994, MOL CELL BIOL, V14, P6198, DOI 10.1128/MCB.14.9.6198; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Korneev S, 2002, MOL BIOL EVOL, V19, P1228, DOI 10.1093/oxfordjournals.molbev.a004183; Korneev SA, 1999, J NEUROSCI, V19, P7711; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lu JL, 1996, BIOCHEM BIOPH RES CO, V225, P1, DOI 10.1006/bbrc.1996.1121; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARTINEZ J, 2003, NUCL ACIDS RES S, V3, P333; Matzke M, 2003, SCIENCE, V301, P1060, DOI 10.1126/science.1089047; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Newton DC, 2003, J BIOL CHEM, V278, P636, DOI 10.1074/jbc.M209988200; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; PASTINEN T, 2003, PHYSL GENOMICS; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Shendure J, 2002, GENOME BIOL, V3; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Stewart RJ, 1996, J IMMUNOL, V156, P1221; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Takemoto M, 2002, CIRCULATION, V106, P57, DOI 10.1161/01.CIR.0000020682.73694.AB; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Whitney JA, 2000, AM J PHYSIOL-LUNG C, V278, pL131, DOI 10.1152/ajplung.2000.278.1.L131; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wu KK, 2002, ANN NY ACAD SCI, V962, P122, DOI 10.1111/j.1749-6632.2002.tb04062.x; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	67	110	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37982	37996		10.1074/jbc.M400271200	http://dx.doi.org/10.1074/jbc.M400271200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234981	hybrid			2022-12-25	WOS:000223554600092
J	Staruschenko, A; Patel, P; Tong, QS; Medina, JL; Stockand, JD				Staruschenko, A; Patel, P; Tong, QS; Medina, JL; Stockand, JD			Ras activates the epithelial Na+ channel through phosphoinositide 3-OH kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-TRANSPORT; SURFACE EXPRESSION; POTASSIUM CHANNEL; A6 EPITHELIA; CELL-SURFACE; ALDOSTERONE; ENAC; REABSORPTION; 3-KINASE; PATHWAY	Aldosterone induces expression and activation of the GTP-dependent signaling switch K-Ras. This small monomeric G protein is both necessary and sufficient for activation of the epithelial Na+ channel ( ENaC). The mechanism by which K-Ras enhances ENaC activity, however, is uncertain. We demonstrate here that K-Ras activates human ENaC reconstituted in Chinese hamster ovary cells in a GTP-dependent manner. K-Ras influences ENaC activity most likely by affecting open probability. Inhibition of phosphoinositide 3-OH kinase (PI3K) abolished K-Ras actions on ENaC. In contrast, inhibition of other K-Ras effector cascades, including the MAPK and Ral/Rac/Rho cascades, did not affect K-Ras actions on ENaC. Activation of ENaC by K-Ras, moreover, was sensitive to co-expression of dominant negative p85(PI3K). The G12: C40 effector-specific double mutant of Ras, which preferentially activates PI3K, enhanced ENaC activity in a manner sensitive to inhibition of PI3K. Other effector-specific mutants preferentially activating MAPK and RalGDS signaling had no effect. Constitutively active PI3K activated ENaC independent of K-Ras with the effects of PI3K and K-Ras on ENaC not being additive. We conclude that K-Ras activates ENaC via the PI3K cascade.	Univ Texas, Hlth Sci Ctr, Dept Physiol 7756, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol 7756, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Stockand, James/0000-0002-3817-4319; Staruschenko, Alexander/0000-0002-5190-8356	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Becchetti A, 2000, J BIOL CHEM, V275, P16550, DOI 10.1074/jbc.M000954200; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; FRUMAN D, 1998, ANNU REV BIOCHEM, V67, P507; Gamper N, 2003, J NEUROSCI, V23, P84; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Giovannardi S, 2002, J BIOL CHEM, V277, P12158, DOI 10.1074/jbc.M110466200; HAHNEL C, 1992, EUR J NEUROSCI, V4, P361, DOI 10.1111/j.1460-9568.1992.tb00883.x; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Hida H, 1998, J NEUROSCI, V18, P8712; Kristof AS, 2003, J BIOL CHEM, V278, P33637, DOI 10.1074/jbc.M301053200; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; OOTH RE, 2003, J BIOL CHEM, V278, P41367; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Spindler B, 1999, AM J PHYSIOL-CELL PH, V276, pC1154, DOI 10.1152/ajpcell.1999.276.5.C1154; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; YATANI A, 1991, J BIOL CHEM, V266, P22222	38	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37771	37778		10.1074/jbc.M402176200	http://dx.doi.org/10.1074/jbc.M402176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15215250	hybrid			2022-12-25	WOS:000223554600069
J	Varea, J; Monterroso, B; Saiz, JL; Lopez-Zumel, C; Garcia, JL; Laynez, J; Garcia, P; Menendez, M				Varea, J; Monterroso, B; Saiz, JL; Lopez-Zumel, C; Garcia, JL; Laynez, J; Garcia, P; Menendez, M			Structural and thermodynamic characterization of Pal, a phage natural chimeric lysin active against pneumococci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; STREPTOCOCCUS-PNEUMONIAE; CELL-WALL; LYTIC ENZYMES; BACTERIOPHAGE; LYSOZYME; CHOLINE; AMIDASE; DOMAINS	Pal amidase, encoded by pneumococcal bacteriophage Dp-1, represents one step beyond in the modular evolution of pneumococcal murein hydrolases. It exhibits the choline-binding module attaching pneumococcal lysins to the cell wall, but the catalytic module is different from those present in the amidases coded by the host or other pneumococcal phages. Pal is also an effective antimicrobial agent against Streptococcus pneumoniae that may constitute an alternative to antibiotic prophylaxis. The structural implications of Pal singular structure and their effect on the choline-amidase interactions have been examined by means of several techniques. Pal stability is maximum around pH 8.0 (T-m congruent to 50.2 degreesC; DeltaH(t) = 183 +/- 4 kcal mol(-1)), and its constituting modules fold as two tight interacting cooperative units whose denaturation merges into a single process in the free amidase but may proceed as two well resolved events in the choline-bound state. Choline titration curves reflect low energy ligand-protein interactions and are compatible with two sets of sites. Choline binding strongly stabilizes the cell wall binding module, and the conformational stabilization is transmitted to the catalytic region. Moreover, the high proportion of aggregates formed by the unbound amidase together with choline preferential interaction with Pal dimers suggest the existence of marginally stable regions that would become stabilized through choline-protein interactions without significantly modifying Pal secondary structure. This structural rearrangement may underlie in vitro "conversion" of Pal from the low to the full activity form triggered by choline. The Pal catalytic module secondary structure could denote folding conservation within pneumococcal lytic amidases, but the number of functional choline binding sites is reduced ( 2 - 3 sites per monomer) when compared with pneumococcal LytA amidase ( 4 - 5 sites per monomer) and displays different intermodular interactions.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Menendez, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	mmenendez@iqfr.csic.es	García, Pedro/L-2808-2017; Menendez, Margarita/M-1795-2014; Monterroso, Begoña/J-9748-2014; Garcia Lopez, Jose Luis/G-9139-2015	García, Pedro/0000-0001-6717-8717; Menendez, Margarita/0000-0002-3267-4443; Monterroso, Begoña/0000-0003-2538-084X; Garcia Lopez, Jose Luis/0000-0002-9238-2485				Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; BEAUREGARD DA, 1995, ANTIMICROB AGENTS CH, V39, P781, DOI 10.1128/AAC.39.3.781; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; Eyrich VA, 2001, BIOINFORMATICS, V17, P1242, DOI 10.1093/bioinformatics/17.12.1242; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; GARCIA P, 1984, J BACTERIOL, V159, P793; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hermoso JA, 2003, STRUCTURE, V11, P1239, DOI 10.1016/j.str.2003.09.005; Jado I, 2003, J ANTIMICROB CHEMOTH, V52, P967, DOI 10.1093/jac/dkg485; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kristinsson KG, 1997, MICROB DRUG RESIST, V3, P117, DOI 10.1089/mdr.1997.3.117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liepinsh E, 2003, J MOL BIOL, V327, P833, DOI 10.1016/S0022-2836(03)00185-2; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Loeffler JM, 2003, ANTIMICROB AGENTS CH, V47, P375, DOI 10.1128/AAC.47.1.375-377.2003; Lopez R, 2000, RES MICROBIOL, V151, P437, DOI 10.1016/S0923-2508(00)00172-8; LOPEZ R, 2004, IN PRESS PNEUMOCOCCU; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215; MCDONNELL M, 1975, VIROLOGY, V63, P577, DOI 10.1016/0042-6822(75)90329-3; Medrano FJ, 1996, J BIOL CHEM, V271, P29152, DOI 10.1074/jbc.271.46.29152; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Obregon V, 2003, MICROB DRUG RESIST, V9, P7, DOI 10.1089/107662903764736292; Pelton SI, 2000, VACCINE, V19, pS96, DOI 10.1016/S0264-410X(00)00286-3; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rost B, 2001, J STRUCT BIOL, V134, P204, DOI 10.1006/jsbi.2001.4336; Saiz JL, 2002, PROTEIN SCI, V11, P1788, DOI 10.1110/ps.4680102; SANCHEZPUELLES JM, 1992, EUR J BIOCHEM, V203, P153, DOI 10.1111/j.1432-1033.1992.tb19840.x; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANZ JM, 1993, J BIOL CHEM, V268, P6125; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; Sheehan MM, 1997, MOL MICROBIOL, V25, P717, DOI 10.1046/j.1365-2958.1997.5101880.x; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; van Holde K. E., 1986, PHYSICAL BIOCH, P110; Varea J, 2000, J BIOL CHEM, V275, P26842; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006	52	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43697	43707		10.1074/jbc.M407067200	http://dx.doi.org/10.1074/jbc.M407067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15247237	Green Published, hybrid			2022-12-25	WOS:000224383100044
J	Rohrer, B; Pinto, FR; Hulse, KE; Lohr, HR; Zhang, L; Almeida, JS				Rohrer, B; Pinto, FR; Hulse, KE; Lohr, HR; Zhang, L; Almeida, JS			Multidestructive pathways triggered in photoreceptor cell death of the RD mouse as determined through gene expression profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL DEGENERATION; OUTER SEGMENTS; MESSENGER-RNA; OLIGONUCLEOTIDE MICROARRAYS; MATRIX METALLOPROTEINASES; RETINITIS-PIGMENTOSA; OXIDATIVE STRESS; PROCTOR-LECTURE; RD/RD MOUSE; RPE CELLS	In the rd/rd mouse, photoreceptor degeneration is due to a mutation of the rod-specific enzyme cGMP phosphodiesterase, resulting in permanently opened cGMP-gated cation channels in the rod outer segment membrane that allow Na+ and Ca2+ ions to enter the cell, resulting in possibly toxic levels of Ca2+. To identify pathways involved in cell death of the rd/rd rods, we evaluated gene expression in the rd/rd and wild type (wt) mouse retina (U74A oligonucleotide arrays (Affymetrix)) over the known time course of photoreceptor degeneration. 181 genes passed the selection criteria ( low standard deviation and high correlation between replicates), falling into six clusters. For any given pair of genes, an expression profile correlation distance and a semantic distance ( one for each class of gene ontology terms) were established using newly designed software. Gene expression in rd/rd started to deviate from wt by postnatal day 10. The reduction in photoreceptor-specific genes followed the known time course of photoreceptor degeneration. Likewise the increase in transcription factors and apoptosis- and neuroinflammation-specific genes followed the kinetics of the rise in intracellular cGMP in the rod photoreceptors. In addition, genes coding for calcium-binding proteins and those implicated in tissue and vessel remodeling were increased. These results suggest that photoreceptor degeneration in the rd/rd mouse is a process starting with Ca2+ toxicity followed by secondary insults involving multidestructive pathways such as apoptosis and neuroinflammation, presumably boosting morphological changes. All of these components need to be addressed if rods are to be successfully protected.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biostat & Bioinformat & Epidemiol, Charleston, SC 29425 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Biomath Grp, P-2780 Oeiras, Portugal; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Universidade Nova de Lisboa; University of Texas System; UTMD Anderson Cancer Center	Rohrer, B (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.	rohrer@musc.edu	Almeida, Jonas/C-9093-2009; Pinto, Francisco/A-7443-2008	Almeida, Jonas/0000-0002-7883-7922; Pinto, Francisco/0000-0002-4217-0054; Hulse, Kathryn/0000-0003-0969-999X; Zhang, Li/0000-0003-0517-7860	NEI NIH HHS [EY-13520, EY-14793] Funding Source: Medline; NATIONAL EYE INSTITUTE [R24EY014793, R01EY013520] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agapova OA, 2003, BRAIN RES, V967, P132, DOI 10.1016/S0006-8993(02)04234-8; Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275; Calestani C, 2003, DEVELOPMENT, V130, P4587, DOI 10.1242/dev.00647; Cao W, 2001, EXP EYE RES, V72, P591, DOI 10.1006/exer.2001.0990; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; COLLEY NJ, 1986, EXP EYE RES, V42, P323, DOI 10.1016/0014-4835(86)90025-4; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; DANIEL WW, 1999, BIOSTATISTICS FDN AN, P600; Doonan F, 2003, J NEUROSCI, V23, P5723; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Everitt BS., 2001, APPL MULTIVARIATE DA, V2, P125, DOI [10.1002/9781118887486, DOI 10.1002/9781118887486]; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1995, INVEST OPHTH VIS SCI, V36, P263; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; Fox DA, 1999, ANN NY ACAD SCI, V893, P282, DOI 10.1111/j.1749-6632.1999.tb07837.x; Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Gobin SJP, 2001, J IMMUNOL, V167, P5175, DOI 10.4049/jimmunol.167.9.5175; Gold D, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-2; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; Hafezi F, 1998, INVEST OPHTH VIS SCI, V39, P2239; Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Jomary C, 1999, J NEUROCHEM, V72, P1923, DOI 10.1046/j.1471-4159.1999.0721923.x; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Katunuma N, 2001, ADV ENZYME REGUL, V41, P237, DOI 10.1016/S0065-2571(00)00018-2; Kendziorski CM, 2003, BIOSTATISTICS, V4, P465, DOI 10.1093/biostatistics/4.3.465; Kim DH, 2002, OPHTHALMIC RES, V34, P150, DOI 10.1159/000063659; Kim YS, 2003, BRAIN RES, V976, P53, DOI 10.1016/S0006-8993(03)02636-2; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; LOLLEY RN, 1994, INVEST OPHTH VIS SCI, V35, P4182; LORD P, 2003, PAC S BIOCOMPUT, V8, P601; Luhe A, 2003, TOXICOL SCI, V73, P315, DOI 10.1093/toxsci/kfg073; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; Nakanishi H, 2003, AGEING RES REV, V2, P367, DOI 10.1016/S1568-1637(03)00027-8; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nico B, 2001, J CELL SCI, V114, P1297; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Ogilvie JM, 2000, EXP NEUROL, V161, P676, DOI 10.1006/exnr.1999.7291; Paron I, 2004, BIOCHEM J, V378, P929, DOI 10.1042/BJ20031190; Pasinetti GM, 1999, SYNAPSE, V31, P278, DOI 10.1002/(SICI)1098-2396(19990315)31:4<278::AID-SYN5>3.0.CO;2-0; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; PINTO FR, 2004, IN PRESS BIOINFORMAT; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SANYAL S, 1981, EXP EYE RES, V33, P213, DOI 10.1016/S0014-4835(81)80070-X; Sharma AK, 2004, J BIOL CHEM, V279, P35564, DOI 10.1074/jbc.M401037200; Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9; Strettoi E, 2002, J NEUROSCI, V22, P5492; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Wu J, 2001, MOL VIS, V7, P101; Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836	65	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41903	41910		10.1074/jbc.M405085200	http://dx.doi.org/10.1074/jbc.M405085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15218024	hybrid			2022-12-25	WOS:000224075500081
J	Sneeden, JL; Loeb, LA				Sneeden, JL; Loeb, LA			Mutations in the R2 subunit of ribonucleotide reductase that confer resistance to hydroxyurea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; FETAL-HEMOGLOBIN; PROTEIN R2; IRON; MECHANISM; INHIBITORS; INDUCTION; HAMSTER; CLUSTER	Ribonucleotide reductase is an essential enzyme that catalyzes the reduction of ribonucleotides to deoxyribonucleotides for use in DNA synthesis. Ribonucleotide reductase from Escherichia coli consists of two subunits, R1 and R2. The R2 subunit contains an unusually stable radical at tyrosine 122 that participates in catalysis. Buried deep within a hydrophobic pocket, the radical is inaccessible to solvent although subject to inactivation by radical scavengers. One such scavenger, hydroxyurea, is a highly specific inhibitor of ribonucleotide reductase and therefore of DNA synthesis; thus it is an important anticancer and antiviral agent. The mechanism of radical access remains to be established; however, small molecules may be able to access Tyr-122 directly via channels from the surface of the protein. We used random oligonucleotide mutagenesis to create a library of 200,000 R2 mutants containing random substitutions at five contiguous residues (Ile-74, Ser-75, Asn-76, Leu-77, Lys-78) that partially comprise one side of a channel where Tyr-122 is visible from the protein surface. We subjected this library to increasing concentrations of hydroxyurea and identified mutants that enhance survival more than 1000-fold over wild-type R2 at high drug concentrations. Repetitive selections yielded S75T as the predominant R2 mutant in our library. Purified S75TR2 exhibits a radical half-life that is 50% greater than wild-type R2 in the presence of hydroxyurea. These data represent the first demonstration of R2 protein mutants in E. coli that are highly resistant to hydroxyurea; elucidation of their mechanism of resistance may provide valuable insight into the development of more effective inhibitors.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Biochem, K-056 HSB 1959 NE Pacific, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARA FM, 1995, CANCER RES, V55, P4503; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; Baliga BS, 2000, AM J HEMATOL, V65, P227, DOI 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; Burton TR, 2003, INT J ONCOL, V22, P21; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Fontecave M, 1998, CELL MOL LIFE SCI, V54, P684, DOI 10.1007/s000180050195; FUCHS JA, 1976, J BACTERIOL, V128, P810, DOI 10.1128/JB.128.3.810-814.1976; Gerez C, 1997, EUR J BIOCHEM, V249, P401, DOI 10.1111/j.1432-1033.1997.t01-2-00401.x; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Guzman EC, 2002, MOL MICROBIOL, V43, P487, DOI 10.1046/j.1365-2958.2002.02761.x; Ho JA, 2003, EXP HEMATOL, V31, P586, DOI 10.1016/S0301-472X(03)00086-9; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lye LF, 1997, MOL BIOCHEM PARASIT, V90, P353, DOI 10.1016/S0166-6851(97)00159-X; Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4; Mayhew CN, 1999, STEM CELLS, V17, P345, DOI 10.1002/stem.170345; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Parkin SE, 1998, BIOCHEMISTRY-US, V37, P1124, DOI 10.1021/bi9723717; REGNSTROM K, 1994, J BIOL CHEM, V269, P6355; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; Sambrook J, 2001, MOL CLONING LAB MANU; Sneeden Jessica L, 2003, Methods Mol Biol, V231, P65; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Suzuki M, 1996, MOL DIVERS, V2, P111, DOI 10.1007/BF01718708; TAGGER AY, 1988, INT J CANCER, V42, P760, DOI 10.1002/ijc.2910420522; Thelander L, 1978, Methods Enzymol, V51, P227; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695	35	28	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40723	40728		10.1074/jbc.M402699200	http://dx.doi.org/10.1074/jbc.M402699200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262976	hybrid			2022-12-25	WOS:000223916800064
J	Estevam, ML; Nascimento, OR; Baptista, MS; Di Mascio, P; Prado, FM; Faljoni-Alario, A; Zucchi, MD; Nantes, IL				Estevam, ML; Nascimento, OR; Baptista, MS; Di Mascio, P; Prado, FM; Faljoni-Alario, A; Zucchi, MD; Nantes, IL			Changes in the spin state and reactivity of cytochrome c induced by photochemically generated singlet oxygen and free radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-OXYGEN; HEME IRON; DNA-REPAIR; PHOTOSENSITIZED OXIDATION; MEDIATED DAMAGE; CELLULAR-DNA; 8-OXO-7,8-DIHYDROGUANINE; MUTAGENESIS; DIPEPTIDES; INTERFACES	This work compares the effect of photogenerated singlet oxygen (O-2((1)Delta(g))) ( type II mechanism) and free radicals ( type I mechanism) on cytochrome c structure and reactivity. Both reactive species were obtained by photoexcitation of methylene blue (MB+) in the monomer and dimer forms, respectively. The monomer form is predominant at low dye concentrations ( up to 8 muM) or in the presence of an excess of SDS micelles, while dimers are predominant at 0.7 mM SDS. Over a pH range in which cytochrome c is in the native form, O-2((1)Delta(g)) and free radicals induced a Soret band blue shift ( from 409 to 405 nm), predominantly. EPR measurements revealed that the blue shift of the Soret band was compatible with conversion of the heme iron from its native low spin state to a high spin state with axial symmetry ( g similar to 6.0). Soret band bleaching, due to direct attack on the heme group, was only detected under conditions that favored free radical production (MB+ dimer in SDS micelles) or in the presence of a less structured form of the protein ( above pH 9.3). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry of the heme group and the polypeptide chain of cytochrome c with Soret band at 405 nm (cytc405) revealed no alterations in the mass of the cytc405 heme group but oxidative modifications on methionine (Met(65) and Met(80)) and tyrosine (Tyr(74)) residues. Damage of cytc405 tyrosine residue impaired its reduction by diphenylacetaldehyde, but not by beta-mercaptoethanol, which was able to reduce cytc405, generating cytochrome c Fe(II) in the high spin state (spin 2).	Univ Mogi das Cruzes, CIIB, BR-08780911 Mogi Das Cruzes, SP, Brazil; Univ Sao Paulo, IFSC, BR-13560250 Sao Carlos, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade de Sao Paulo; Universidade de Sao Paulo	Nantes, IL (corresponding author), Univ Mogi das Cruzes, CIIB, Predio I,Sala 1S-15, BR-08780911 Mogi Das Cruzes, SP, Brazil.	ilnantes@umc.br	Baptista, Mauricio S/A-5140-2008; Nantes, Iseli Lourenço/B-9517-2012; Baptista, Mauricio S/AAO-5749-2021; Di Mascio, Paolo/D-1264-2014	Baptista, Mauricio S/0000-0001-7079-7666; Nantes, Iseli Lourenço/0000-0003-1434-3154; Baptista, Mauricio S/0000-0001-7079-7666; Di Mascio, Paolo/0000-0003-4125-8350				Agnez LF, 1996, CARCINOGENESIS, V17, P1183, DOI 10.1093/carcin/17.5.1183; Agnez-Lima LF, 2001, NUCLEIC ACIDS RES, V29, P2899, DOI 10.1093/nar/29.13.2899; Agnez-Lima LF, 2001, BIOL CHEM, V382, P1071, DOI 10.1515/BC.2001.134; BONNEAU R, 1975, PHOTOCHEM PHOTOBIOL, V21, P159, DOI 10.1111/j.1751-1097.1975.tb06646.x; Cavalcante AKD, 2002, DNA REPAIR, V1, P1051, DOI 10.1016/S1568-7864(02)00164-7; Criado S, 2001, J PHOTOCH PHOTOBIO B, V65, P74, DOI 10.1016/S1011-1344(01)00239-1; Davies MJ, 2003, BIOCHEM BIOPH RES CO, V305, P761, DOI 10.1016/S0006-291X(03)00817-9; Duarte V, 2000, J AM CHEM SOC, V122, P12622, DOI 10.1021/ja002218r; Eaton W A, 1981, Methods Enzymol, V76, P175; FOOTE CS, 1968, SCIENCE, V162, P963, DOI 10.1126/science.162.3857.963; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; GABRIELE D, 2004, PHOTOCHEM PHOTOBIOL, V163, P403; Goldberg ME, 1999, J BIOL CHEM, V274, P16052, DOI 10.1074/jbc.274.23.16052; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; JUNQUEIRA HC, 2002, PHYS CHEM CHEM PHYS, V230, P111; KLUCK RM, 1997, SCIENCE, V275, P7770; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lledias F, 1998, J BIOL CHEM, V273, P10630, DOI 10.1074/jbc.273.17.10630; Martinez GR, 2004, J AM CHEM SOC, V126, P3056, DOI 10.1021/ja039111z; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Martinez GR, 2003, MUTAT RES-REV MUTAT, V544, P115, DOI 10.1016/j.mrrev.2003.05.005; MICHAELI A, 1995, PHOTOCHEM PHOTOBIOL, V61, P255, DOI 10.1111/j.1751-1097.1995.tb03968.x; MICHAELI A, 1994, PHOTOCHEM PHOTOBIOL, V59, P284, DOI 10.1111/j.1751-1097.1994.tb05035.x; MICHAELI A, 1997, PHOTOCHEM PHOTOBIOL, V51, P299; Michan S, 2002, FREE RADICAL BIO MED, V33, P521, DOI 10.1016/S0891-5849(02)00909-7; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Pierlot C, 2000, METHOD ENZYMOL, V319, P3; Ravanat JL, 2004, ARCH BIOCHEM BIOPHYS, V423, P23, DOI 10.1016/j.abb.2003.10.018; Ravanat JL, 2004, BIOL CHEM, V385, P17, DOI 10.1515/BC.2004.003; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Ravanat JL, 2001, HELV CHIM ACTA, V84, P3702, DOI 10.1002/1522-2675(20011219)84:12<3702::AID-HLCA3702>3.0.CO;2-Y; Rinaldi TA, 2004, FREE RADICAL BIO MED, V36, P802, DOI 10.1016/j.freeradbiomed.2003.12.002; Severino D, 2003, PHOTOCHEM PHOTOBIOL, V77, P459, DOI 10.1562/0031-8655(2003)077<0459:IONCIO>2.0.CO;2; TUIETE EM, 1993, J PHOTOCHEM PHOTOBIO, V21, P103; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	39	60	61	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39214	39222		10.1074/jbc.M402093200	http://dx.doi.org/10.1074/jbc.M402093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247265	hybrid			2022-12-25	WOS:000223791500005
J	Kittur, FS; Manithody, C; Morrissey, JH; Rezaie, AR				Kittur, FS; Manithody, C; Morrissey, JH; Rezaie, AR			The cofactor function of the N-terminal domain of tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VIIA BINDING; BLOOD-COAGULATION; FACTOR-X; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; RESIDUES; PROTEIN; REGION; SITE; IDENTIFICATION	Tissue factor (TF) is an integral membrane protein cofactor for factor VIIa (fVIIa) that initiates the blood coagulation cascade during vascular injury. TF has two fibrinonectin type III-like domains, both of which make extensive interactions with both the light and heavy chains of fVIIa. In addition to interaction with fVIIa, the membrane proximal C-terminal domain of TF is also known to bind the natural substrates factors IX and X, thereby facilitating their assembly and recognition by fVIIa in the activation complex. Both fVIIa and TF are elongated proteins, and their complex appears to be positioned nearly perpendicular to the membrane surface. It is possible that, similar to fVIIa, the N- terminal domain of TF also contacts the natural substrates. To investigate this possibility, we substituted all 23 basic and acidic residues of the N- terminal domain of TF with Ala or Asn and expressed the mutants as soluble TF2-219 in a novel expression/purification vector system in the periplasmic space of bacteria. Following purification to homogeneity, the cofactor properties of mutants in promoting the amidolytic and proteolytic activity of fVIIa were analyzed in appropriate kinetic assays. The amidolytic activity assays indicated that several charged residues spatially clustered at the junction of the N- and C-terminal domains of TF are required for high affinity interaction with fVIIa. On the other hand, the proteolytic activity assays revealed that none of the residues under study may be an interactive site for either factor IX or factor X. However, it was discovered the Arg(74) mutant of TF was defective in enhancing both the amidolytic and proteolytic activity of fVIIa, suggesting that this residue may be required for the allosteric activation of the protease.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	Saint Louis University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Morrissey, James H./GLR-5645-2022; Kittur, Farooqahmed S/G-3832-2012; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569; Kittur, Farooqahmed/0000-0002-2272-3387	NHLBI NIH HHS [R01 HL47014, R01 HL68571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL047014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; FIORE MM, 1994, J BIOL CHEM, V269, P143; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Kelly CR, 1996, BIOCHEM J, V315, P145, DOI 10.1042/bj3150145; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; Lee GF, 1998, J BIOL CHEM, V273, P4149, DOI 10.1074/jbc.273.7.4149; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; Morrissey JH, 1997, THROMB HAEMOSTASIS, V78, P112; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PABORSKY LR, 1995, BIOCHEMISTRY-US, V34, P15328, DOI 10.1021/bi00046a042; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	23	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39745	39749		10.1074/jbc.M406628200	http://dx.doi.org/10.1074/jbc.M406628200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252050	hybrid			2022-12-25	WOS:000223791500067
J	Yamashita, M; Shinnakasu, R; Nigo, Y; Kimura, M; Hasegawa, A; Taniguchi, M; Nakayama, T				Yamashita, M; Shinnakasu, R; Nigo, Y; Kimura, M; Hasegawa, A; Taniguchi, M; Nakayama, T			Interleukin (IL)-4-independent maintenance of histone modification of the IL-4 gene loci in memory Th2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; RNA-POLYMERASE-II; T-CELLS; CUTTING EDGE; LYSINE METHYLATION; IN-VIVO; DIFFERENTIATION; EXPRESSION; GENERATION; SURVIVAL	Interleukin (IL)-4-induced STAT6 activation and the subsequent up-regulation of GATA3 are crucial for the induction of chromatin remodeling of the Th2 cytokine gene loci as Th2 cells undergo development. This study probes the role of these molecules in the maintenance of memory Th2 cells. IL-4 was not required to maintain the capability for Th2 cytokine production in in vivo generated antigen-specific memory Th2 cells. Histone H3K9/14 hyperacetylation and intergenic transcripts associated with the IL-4 gene locus were preserved in the absence of IL-4, but those associated with the IL-13 gene were partially IL-4-dependent. Histone H3-K4 methylation of the IL-13 and IL-4 gene loci was fully preserved in memory Th2 cells and accompanied by memory cell-specific accumulation of Pol II complex to highly restricted sites. Thus, memory Th2 cells maintain a unique Th2-specific remodeled chromatin in the IL-4 and IL-13 gene loci by active molecular events that are IL-4-independent.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 260, Japan; RIKEN Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan	Chiba University; RIKEN	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 260, Japan.	tnakayama@faculty.chiba-u.jp	Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahmadzadeh M, 2001, J IMMUNOL, V166, P926, DOI 10.4049/jimmunol.166.2.926; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dorfman JR, 2000, NAT IMMUNOL, V1, P329, DOI 10.1038/79783; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Grogan JL, 2002, CURR OPIN IMMUNOL, V14, P366, DOI 10.1016/S0952-7915(02)00340-0; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hengel RL, 2003, J IMMUNOL, V170, P28, DOI 10.4049/jimmunol.170.1.28; Huang H, 1997, J IMMUNOL, V159, P3731; HuLi J, 1997, P NATL ACAD SCI USA, V94, P3189, DOI 10.1073/pnas.94.7.3189; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lantz O, 2000, NAT IMMUNOL, V1, P54, DOI 10.1038/76917; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Li JC, 2003, J EXP MED, V198, P1807, DOI 10.1084/jem.20030725; Lohning M, 2002, ADV IMMUNOL, V80, P115, DOI 10.1016/S0065-2776(02)80014-1; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Rogers PR, 2000, J IMMUNOL, V164, P2338, DOI 10.4049/jimmunol.164.5.2338; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Seddon B, 2002, J IMMUNOL, V169, P2997, DOI 10.4049/jimmunol.169.6.2997; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Tan JT, 2002, J EXP MED, V195, P1523, DOI 10.1084/jem.20020066; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Yamashita M, 1998, INT IMMUNOL, V10, P577, DOI 10.1093/intimm/10.5.577; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yamashita M, 2000, J EXP MED, V191, P1869, DOI 10.1084/jem.191.11.1869; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	60	48	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39454	39464		10.1074/jbc.M405989200	http://dx.doi.org/10.1074/jbc.M405989200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258154	hybrid			2022-12-25	WOS:000223791500034
J	Chan, C; Burrows, LL; Deber, CM				Chan, C; Burrows, LL; Deber, CM			Helix induction in antimicrobial peptides by alginate in biofilms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ESCHERICHIA-COLI; MEMBRANE ENVIRONMENTS; BACTERIAL BIOFILMS; LACTOSE PERMEASE; CYSTIC-FIBROSIS; AMINO-ACIDS; PROTEIN; FLUORESCENCE; BINDING	Bacterial exopolysaccharides provide protection against phagocytosis, opsonization, and dehydration and act as a major structural component of the extracellular matrix in biofilms. They contribute to biofilm-related resistance by acting as a diffusion barrier to positively charged antimicrobial agents including cationic antimicrobial peptides (CAPs). We previously created novel CAPs consisting of a nonamphipathic hydrophobic core flanked by Lys residues and containing a Trp residue in the hydrophobic segment as a fluorescent probe. Peptides of this type above a specific hydrophobicity threshold insert spontaneously into membranes and have antimicrobial activity against Gram-positive and Gram-negative bacteria at micromolar concentrations. Here we show that alginate, a polymer of beta-D-mannuronate and alpha-L-guluronate secreted by the cystic fibrosis pathogen Pseudomonas aeruginosa, induces an alpha-helical conformation detected by circular dichroism spectroscopy and blue shifts in Trp fluorescence maxima in peptides above the hydrophobicity threshold, changes typically observed upon association of such peptides with nonpolar (membrane) environments. Parallel effects were observed in the archetypical CAPs magainin II amide and cecropin P1. Fluorescence resonance energy transfer studies indicated that alginate induces peptide-peptide association only in peptides above the hydrophobicity threshold, suggesting that the hydrophilic alginate polymer behaves as an "auxiliary membrane" for the bacteria, demonstrating a unique protective role for biofilm matrices against CAPs.	Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Div Infect Immun Injury & Repair, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	deber@sickkids.ca	Burrows, Lori/D-1142-2010	Burrows, Lori/0000-0003-0838-5040				ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; BYSTRICKY S, 1990, CARBOHYD POLYM, V13, P283, DOI 10.1016/0144-8617(90)90060-6; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P95, DOI 10.1016/0005-2736(91)90358-F; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; DIEFENBACH R, 1992, APPL MICROBIOL BIOT, V36, P530; Fundueanu G, 1999, BIOMATERIALS, V20, P1427, DOI 10.1016/S0142-9612(99)00050-2; Gacesa P, 1998, MICROBIOL-SGM, V144, P1133, DOI 10.1099/00221287-144-5-1133; Gesell J, 1997, J BIOMOL NMR, V9, P127, DOI 10.1023/A:1018698002314; Guan L, 2003, BIOCHEMISTRY-US, V42, P1377, DOI 10.1021/bi027152m; LAM J, 1980, INFECT IMMUN, V28, P546; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; Lu LP, 1998, BIOPOLYMERS, V47, P41, DOI 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X; MacDougall AJ, 2001, CARBOHYD RES, V335, P115, DOI 10.1016/S0008-6215(01)00221-X; MATYUS L, 1992, J PHOTOCH PHOTOBIO B, V12, P323, DOI 10.1016/1011-1344(92)85039-W; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; Mishima Y, 2003, J BIOL CHEM, V278, P6552, DOI 10.1074/jbc.M209932200; Neumann MG, 2003, CARBOHYD RES, V338, P1109, DOI 10.1016/S0008-6215(03)00051-X; NICHOLS WW, 1988, ANTIMICROB AGENTS CH, V32, P518, DOI 10.1128/AAC.32.4.518; Paradossi G, 1999, BIOPOLYMERS, V50, P201, DOI 10.1002/(SICI)1097-0282(199908)50:2<201::AID-BIP9>3.3.CO;2-P; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; SIPOS D, 1992, EUR J BIOCHEM, V209, P163, DOI 10.1111/j.1432-1033.1992.tb17273.x; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Vazquez-Ibar JL, 2003, P NATL ACAD SCI USA, V100, P12706, DOI 10.1073/pnas.1835645100; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Wang C, 2000, J BIOL CHEM, V275, P16155, DOI 10.1074/jbc.M000723200; Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	36	75	95	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38749	38754		10.1074/jbc.M406044200	http://dx.doi.org/10.1074/jbc.M406044200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247257	hybrid			2022-12-25	WOS:000223684100085
J	Coskun, U; Chaban, YL; Lingl, A; Muller, V; Keegstra, W; Boekema, EJ; Gruber, G				Coskun, U; Chaban, YL; Lingl, A; Muller, V; Keegstra, W; Boekema, EJ; Gruber, G			Structure and subunit arrangement of the A-type ATP synthase complex from the Archaeon Methanococcus jannaschii visualized by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; VACUOLAR ATPASE; ORGANIZATION; A(1)-ATPASE; EVOLUTION; FEATURES; STALKS; IMAGES; F-1; V-1	In Archaea, bacteria, and eukarya, ATP provides metabolic energy for energy-dependent processes. It is synthesized by enzymes known as A-type or F-type ATP synthase, which are the smallest rotatory engines in nature ( Yoshida, M., Muneyuki, E., and Hisabori, T. (2001) Nat. Rev. Mol. Cell. Biol. 2, 669 - 677; Imamura, H., Nakano, M., Noji, H., Muneyuki, E., Ohkuma, S., Yoshida, M., and Yokoyama, K. ( 2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2312 - 2315). Here, we report the first projected structure of an intact A(1)A(0) ATP synthase from Methanococcus jannaschii as determined by electron microscopy and single particle analysis at a resolution of 1.8 nm. The enzyme with an overall length of 25.9 nm is organized in an A(1) headpiece (9.4 x 11.5 nm) and a membrane domain, A(0) (6.4 x 10.6 nm), which are linked by a central stalk with a length of similar to 8 nm. A part of the central stalk is surrounded by a horizontal-situated rodlike structure ("collar"), which interacts with a peripheral stalk extending from the A(0) domain up to the top of the A(1) portion, and a second structure connecting the collar structure with A(1). Superposition of the three-dimensional reconstruction and the solution structure of the A(1) complex from Methanosarcina mazei Go1 have allowed the projections to be interpreted as the A(1) headpiece, a central and the peripheral stalk, and the integral A(0) domain. Finally, the structural organization of the A(1)A(0) complex is discussed in terms of the structural relationship to the related motors, F1F0 ATP synthase and V1V0 ATPases.	Univ Saarland, Fachrichtung Biophys 2 5, D-66421 Homburg, Germany; Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Saarland University; University of Groningen; Goethe University Frankfurt	Gruber, G (corresponding author), Univ Saarland, Fachrichtung Biophys 2 5, Univ Bau 76, D-66421 Homburg, Germany.	ggrueber@uniklinik-saarland.de	Mueller, Volker/ABE-4305-2021; Coskun, Ünal/F-4683-2011	Mueller, Volker/0000-0001-7955-5508; Coskun, Ünal/0000-0003-4375-3144				Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Coskun U, 2004, J BIOL CHEM, V279, P22759, DOI 10.1074/jbc.M313741200; Coskun U, 2002, J BIOL CHEM, V277, P17327, DOI 10.1074/jbc.M110407200; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; FRANK J, 1995, OPTIK, V98, P125; GRAAR TB, 2003, J BIOL CHEM, V37, P34751; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2001, BIOCHEMISTRY-US, V40, P1890, DOI 10.1021/bi002195t; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Gruber G, 2000, J BIOENERG BIOMEMBR, V32, P341, DOI 10.1023/A:1005519801891; Hardy AW, 2003, J BIOENERG BIOMEMBR, V35, P389, DOI 10.1023/A:1027363012727; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Lingl A, 2003, EXTREMOPHILES, V7, P249, DOI 10.1007/s00792-003-0318-7; Muller V, 2004, J BIOENERG BIOMEMBR, V36, P115, DOI 10.1023/B:JOBB.0000019603.68282.04; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Oostergetel GT, 1998, ULTRAMICROSCOPY, V74, P47, DOI 10.1016/S0304-3991(98)00022-9; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	37	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38644	38648		10.1074/jbc.M406196200	http://dx.doi.org/10.1074/jbc.M406196200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15220347	hybrid, Green Published			2022-12-25	WOS:000223684100072
J	Kunita, R; Otomo, A; Mizumura, H; Suzuki, K; Showguchi-Miyata, J; Yanagisawa, Y; Hadano, S; Ikeda, JE				Kunita, R; Otomo, A; Mizumura, H; Suzuki, K; Showguchi-Miyata, J; Yanagisawa, Y; Hadano, S; Ikeda, JE			Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; HEREDITARY SPASTIC PARALYSIS; ENDOCYTIC MEMBRANE-FUSION; INFANTILE-ONSET; RHO-GTPASES; BULBAR INVOLVEMENT; BINDING-PROTEIN; GENE; EFFECTOR; OLIGOMERIZATION	Mutations in the ALS2 gene have been known to account for a juvenile recessive form of amyotrophic lateral sclerosis ( ALS2), a rare juvenile recessive form of primary lateral sclerosis, and a form of hereditary spastic paraplegia (HSP), indicating that the ALS2 protein is essential for the maintenance of motor neurons. Recently, we have demonstrated that the ALS2 protein specifically binds to the small GTPase Rab5 and acts as a GEF ( guanine nucleotide exchange factor) for Rab5. We have also shown that its Rab5GEF-requisite domain resides within the C-terminal 640-amino acid region spanning membrane occupation and recognition nexus motifs and the vacuolar protein sorting 9 domain. Transiently expressed ALS2 localized onto early endosomal compartments and stimulated endosome fusions in neuronal and non-neuronal cells in an Rab5GEF activity-dependent manner. These results indicate that the C-terminal region of ALS2 plays a crucial role in endosomal dynamics by its Rab5GEF activity. Here we delineate a molecular feature of the ALS2-associated function through the C-terminal region-mediated homo-oligomerization. A yeast two-hybrid screen for interacting proteins with the ALS2 C-terminal portion identified ALS2 itself. ALS2 forms a homophilic oligomer through its distinct C-terminal regions. This homo-oligomerization is crucial for the Rab5GEF activity in vitro and the ALS2-mediated endosome enlargement in the cells. Taken together, these results indicate that oligomerization of the ALS2 protein is one of the fundamental features for its physiological function involving endosome dynamics in vivo.	Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Kanagawa 2591193, Japan; Tokai Univ, Sch Med, Japan Sci & Technol Agcy, Kanagawa 2591193, Japan; Univ Ottawa, Fac Med, Dept Paediat, Ottawa, ON K1H 8M5, Canada	Tokai University; Japan Science & Technology Agency (JST); Tokai University; University of Ottawa	Ikeda, JE (corresponding author), Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Kanagawa 2591193, Japan.	joh-e@nga.med.u-tokai.ac.jp	Otomo, Asako/AAA-6374-2019; Hadano, Shinji/ABA-5052-2021	Otomo, Asako/0000-0002-7849-4309; Hadano, Shinji/0000-0002-4997-3968				Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BENHAMIDA M, 1990, BRAIN, V113, P347; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Eisenhaure TM, 2003, J BIOL CHEM, V278, P30975, DOI 10.1074/jbc.M303277200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Garcia-Gonzalo FR, 2004, FEBS LETT, V559, P77, DOI 10.1016/S0014-5793(04)00030-4; Garcia-Gonzalo FR, 2003, FEBS LETT, V539, P78, DOI 10.1016/S0014-5793(03)00205-9; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kajiho H, 2003, J CELL SCI, V116, P4159, DOI 10.1242/jcs.00718; Kanekura K, 2004, J BIOL CHEM, V279, P19247, DOI 10.1074/jbc.M313236200; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Koh CG, 2001, J CELL SCI, V114, P4239; LermanSagie T, 1996, J CHILD NEUROL, V11, P54, DOI 10.1177/088307389601100114; Lesca G, 2003, NEUROLOGY, V60, P674, DOI 10.1212/01.WNL.0000048207.28790.25; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; ROSA JL, 1993, EMBO J, V15, P4242; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Yamanaka K, 2003, P NATL ACAD SCI USA, V100, P16041, DOI 10.1073/pnas.2635267100; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	42	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38626	38635		10.1074/jbc.M406120200	http://dx.doi.org/10.1074/jbc.M406120200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247254	hybrid			2022-12-25	WOS:000223684100070
J	Li, CM; Grosdidier, A; Crambert, G; Horisberger, JD; Michielin, O; Geering, K				Li, CM; Grosdidier, A; Crambert, G; Horisberger, JD; Michielin, O; Geering, K			Structural and functional interaction sites between Na,K-ATPase and FXYD proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; GAMMA-SUBUNIT; BETA-SUBUNIT; RENAL NA,K-ATPASE; ALPHA-SUBUNIT; TRANSPORT; ASSOCIATION; EXPRESSION; ISOZYMES; PUMP	Several members of the FXYD protein family are tissue-specific regulators of Na,K-ATPase that produce distinct effects on its apparent K+ and Na+ affinity. Little is known about the interaction sites between the Na, K-ATPase alpha subunit and FXYD proteins that mediate the efficient association and/or the functional effects of FXYD proteins. In this study, we have analyzed the role of the transmembrane segment TM9 of the Na,K-ATPase alpha subunit in the structural and functional interaction with FXYD2, FXYD4, and FXYD7. Mutational analysis combined with expression in Xenopus oocytes reveals that Phe(956), Glu(960), Leu(964), and Phe(967) in TM9 of the Na,K-ATPase alpha subunit represent one face interacting with the three FXYD proteins. Leu(964) and Phe(967) contribute to the efficient association of FXYD proteins with the Na,K-ATPase alpha subunit, whereas Phe(956) and Glu(960) are essential for the transmission of the functional effect of FXYD proteins on the apparent K+ affinity of Na,K-ATPase. The relative contribution of Phe(956) and Glu(960) to the K+ effect differs for different FXYD proteins, probably reflecting the intrinsic differences of FXYD proteins on the apparent K+ affinity of Na,K-ATPase. In contrast to the effect on the apparent K+ affinity, Phe(956) and Glu(960) are not involved in the effect of FXYD2 and FXYD4 on the apparent Na+ affinity of Na,K-ATPase. The mutational analysis is in good agreement with a docking model of the Na,K-ATPase/FXYD7 complex, which also predicts the importance of Phe(956), Glu(960), Leu(964), and Phe(967) in subunit interaction. In conclusion, by using mutational analysis and modeling, we show that TM9 of the Na,K-ATPase alpha subunit exposes one face of the helix that interacts with FXYD proteins and contributes to the stable interaction with FXYD proteins, as well as mediating the effect of FXYD proteins on the apparent K+ affinity of Na,K-ATPase.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; Swiss Institute of Bioinformatics	Geering, K (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009; Michielin, Olivier/ABE-7924-2020	Grosdidier, Aurelien/0000-0001-9873-3461; Crambert, Gilles/0000-0001-7065-9124				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; Crambert G, 2004, J BIOL CHEM, V279, P30888, DOI 10.1074/jbc.M313494200; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, STKES SCI GENOMICS; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 2000, BIOCHEMISTRY-US, V39, P12688, DOI 10.1021/bi0009791; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Horisberger JD, 2004, J BIOL CHEM, V279, P29542, DOI 10.1074/jbc.M400585200; Im W, 2003, BIOPHYS J, V85, P2900, DOI 10.1016/S0006-3495(03)74712-2; Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 2002, J MOL BIOL, V322, P583, DOI 10.1016/S0022-2836(02)00781-7; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497	39	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38895	38902		10.1074/jbc.M406697200	http://dx.doi.org/10.1074/jbc.M406697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234969	hybrid			2022-12-25	WOS:000223684100103
J	Reinhold, MI; Abe, M; Kapadia, RM; Liao, ZX; Naski, MC				Reinhold, MI; Abe, M; Kapadia, RM; Liao, ZX; Naski, MC			FGF18 represses noggin expression and is induced by calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; BONE MORPHOGENETIC PROTEIN-4; LIMB CHONDROGENESIS; FACTOR-BETA; ARTICULAR CHONDROCYTES; SIGNALING PATHWAYS; SPEMANN ORGANIZER; FACTOR RECEPTOR-3; BMP ANTAGONIST; DIFFERENTIATION	Fibroblast growth factors (FGFs) and bone morphogenetic proteins strongly regulate chondrogenesis and chondrocyte gene expression. The interactions of the signaling pathways initiated by these factors are central to the control of chondrocyte differentiation. Here we show that calcium-dependent signals induce expression of FGF18, an essential regulator of bone and cartilage differentiation. The induction of FGF18 expression required the calcium-dependent phosphatase, calcineurin. The activated forms of calcineurin or the calcineurin-dependent transcription factor, NFAT4 ( nuclear factor of activated T-cell 4), induced FGF18 expression. FGF18 or a constitutive active FGF receptor suppressed noggin gene induction and thereby increased chondrocyte gene expression and chondrogenesis by facilitating bone morphogenetic protein-dependent signals. These findings reinforce the interdependence of bone morphogenetic protein and FGF signaling and provide a rational explanation for abnormal bone development occurring in humans or mice with constitutively active FGF receptors.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Naski, MC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	naski@uthscsa.edu			NIAMS NIH HHS [AR050024, AR47070] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047070, R01AR050024] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chimal-Monroy J, 2003, DEV BIOL, V257, P292, DOI 10.1016/S0012-1606(03)00066-6; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Gong YQ, 1999, NAT GENET, V21, P302, DOI 10.1038/6821; Gooch JL, 2004, J BIOL CHEM, V279, P15561, DOI 10.1074/jbc.M308759200; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hajihosseini MK, 2002, MECH DEVELOP, V113, P79, DOI 10.1016/S0925-4773(01)00656-6; Ito H, 1999, BIOCHEM BIOPH RES CO, V260, P240, DOI 10.1006/bbrc.1999.0882; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Li Jun, 2003, J Orthop Sci, V8, P829, DOI 10.1007/s00776-003-0719-6; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; Nishida Y, 2000, ARTHRITIS RHEUM-US, V43, P206, DOI 10.1002/1529-0131(200001)43:1<206::AID-ANR25>3.0.CO;2-1; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Rosen V., 2002, PRINCIPLES BONE BIOL, P919; Sailor LZ, 1996, J ORTHOPAED RES, V14, P937, DOI 10.1002/jor.1100140614; Sanz-Ezquerro JJ, 2003, CURR BIOL, V13, P1830, DOI 10.1016/j.cub.2003.09.040; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHOFIELD JN, 1990, EXP CELL RES, V191, P144, DOI 10.1016/0014-4827(90)90048-F; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sharma K, 2003, AM J PHYSIOL-RENAL, V285, pF1258, DOI 10.1152/ajprenal.00145.2003; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Tomita M, 2002, J BIOL CHEM, V277, P42214, DOI 10.1074/jbc.C200504200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wang O, 2001, DEVELOPMENT, V128, P3867; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	62	63	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38209	38219		10.1074/jbc.M404855200	http://dx.doi.org/10.1074/jbc.M404855200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252029	hybrid			2022-12-25	WOS:000223684100020
J	Meller, N; Irani-Tehrani, M; Ratnikov, BI; Paschal, BM; Schwartz, MA				Meller, N; Irani-Tehrani, M; Ratnikov, BI; Paschal, BM; Schwartz, MA			The novel Cdc42 guanine nucleotide exchange factor, zizimin1, dimerizes via the Cdc42-binding CZH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; MYOBLAST CITY; PROTEIN; FAMILY; RAC; OLIGOMERIZATION; IDENTIFICATION; ACTIVATION; COMPLEX	Rho family small GTPases are critical regulators of multiple cellular processes and activities. Dbl homology domain-containing proteins are the classical guanine nucleotide exchange factors ( GEFs) responsible for activation of Rho proteins. Recently another group of mammalian Rho-GEFs was discovered that includes CDM (Ced-5, DOCK180, Myoblast city) proteins that activate Rac and zizimin1 that activates Cdc42 via a nonconventional GEF module that we named the CZH2 domain. We report here that zizimin1 dimerizes via the CZH2 domain and that dimers are the only form detected. Dimerization was mapped to a similar to200-amino acid region that overlaps but is distinct from the Cdc42-binding sequences. Rotary shadowing electron microscopy revealed zizimin1 to be a symmetric, V-shaped molecule. Experiments with DOCK180 and homology analysis suggest that dimerization may be a general feature of CZH proteins. Deletion and mutation analysis indicated existence of individual Cdc42-binding sites in the zizimin1 monomers. Kinetic measurements demonstrated increased binding affinity of Cdc42 to zizimin1 at higher Cdc42 concentration, suggesting positive cooperativity. These features are likely to be critical for Cdc42 activation.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Canc Inst, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; Scripps Research Institute	Schwartz, MA (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA.	maschwartz@virginia.edu		schwartz, martin/0000-0002-2071-1243				Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Qiu JL, 2002, PLANT CELL, V14, P101, DOI 10.1105/tpc.010346; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Valster AH, 2000, TRENDS CELL BIOL, V10, P141, DOI 10.1016/S0962-8924(00)01728-1; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001	27	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37470	37476		10.1074/jbc.M404535200	http://dx.doi.org/10.1074/jbc.M404535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247287	hybrid			2022-12-25	WOS:000223554600035
J	Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B				Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B			Histone deacetylase inhibitors specifically kill nonproliferating tumour cells	ONCOGENE			English	Article						histone deacetylase inhibitors; quiescent; apoptosis; chemotherapy; cell cycle	SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN LEUKEMIA-CELLS; SODIUM-BUTYRATE; P21(WAF1) EXPRESSION; APOPTOSIS; CHEMOTHERAPY; SAHA; CYTOTOXICITY; ACETYLATION; PROTECTION	Conventional chemotherapeutic drugs target proliferating cells, relying on often small differences in drug sensitivity of tumour cells compared to normal tissue to deliver a therapeutic benefit. Consequently, they have significant limiting toxicities and greatly reduced efficacy against nonproliferating compared to rapidly proliferating tumour cells. This lack of selectivity and inability to kill nonproliferating cells that exist in tumours with a low mitotic index are major failings of these drugs. A relatively new class of anticancer drugs, the histone deacetylase inhibitors (HDI), are selectively cytotoxic, killing tumour and immortalized cells but normal tissue appears resistant. Treatment of tumour cells with these drugs causes both G1 phase cell cycle arrest correlated with increase p21 expression, and cell death, but even the G1 arrested cells died although the onset of death was delayed. We have extended these observations using cells that were stably arrested by either serum starvation or expression of the cyclin-dependent kinase inhibitor p16(ink4a). We report that histone deacetylase inhibitors have similar cytotoxicity towards both proliferating and arrested tumour and immortalized cells, although the onset of apoptosis is delayed by 24 h in the arrested cells. Both proliferating and arrested normal cells are unaffected by HDI treatment. Thus, the histone deacetylase inhibitors are a class of anticancer drugs that have the desirable features of being tumour-selective cytotoxic drugs that are equally effective in killing proliferating and nonproliferating tumour cells and immortalized cells. These drugs have enormous potential for the treatment of not only rapidly proliferating tumours, but tumours with a low mitotic index.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	University of Queensland; Peter Maccallum Cancer Center	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Johnstone, Ricky w/H-3748-2014; saunders, nicholas/AAJ-6101-2020; Burgess, Andrew/C-7952-2009; McTaggart, Jill/G-4696-2010; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019	Johnstone, Ricky w/0000-0001-7053-9237; saunders, nicholas/0000-0002-2478-3420; Burgess, Andrew/0000-0003-4536-9226; McTaggart, Jill/0000-0002-9000-8529; Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; DREWINKO B, 1981, CANCER RES, V41, P2328; Fueyo J, 1998, INT J ONCOL, V12, P665; Gabrielli BG, 2002, CURR CANCER DRUG TAR, V2, P337, DOI 10.2174/1568009023333818; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Ju R, 2003, CANCER RES, V63, P2891; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; Parsons PG, 1997, BIOCHEM PHARMACOL, V53, P1719, DOI 10.1016/S0006-2952(97)00016-6; Peart MJ, 2003, CANCER RES, V63, P4460; Prabhu NS, 1999, INT J ONCOL, V15, P209; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Rahmani M, 2003, CANCER RES, V63, P8420; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2001, INT J ONCOL, V19, P181; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schmidt M, 2001, ONCOGENE, V20, P6164, DOI 10.1038/sj.onc.1204814; Stone S, 1996, CANCER RES, V56, P3199; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang XQ, 1996, CANCER RES, V56, P2510; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje	30	113	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6693	6701		10.1038/sj.onc.1207893	http://dx.doi.org/10.1038/sj.onc.1207893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15235588				2022-12-25	WOS:000223653600001
J	Tzavara, ET; Bymaster, FP; Davis, RJ; Wade, MR; Perry, KW; Wess, J; McKinzie, DL; Felder, C; Nomikos, GG				Tzavara, ET; Bymaster, FP; Davis, RJ; Wade, MR; Perry, KW; Wess, J; McKinzie, DL; Felder, C; Nomikos, GG			M-4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies	FASEB JOURNAL			English	Article						acetylcholine; microdialysis; dopamine; psychostimulants	VENTRAL TEGMENTAL AREA; STRIATAL DOPAMINE; SUBSTANTIA-NIGRA; ACETYLCHOLINE-RELEASE; GLUTAMATE RECEPTORS; NUCLEUS-ACCUMBENS; MESSENGER-RNAS; GABA RELEASE; STIMULATION; MODULATION	Dopaminergic dysfunction is an important pathogenetic factor for brain pathologies such as Parkinson's disease, ADHD, schizophrenia, and addiction as well as for metabolic disorders and anorexia. Dopaminergic neurons projecting from the midbrain to forebrain regions, such as the nucleus accumbens and the prefrontal cortex, regulate motor and cognitive functions and coordinate the patterned response of the organism to sensory, affective, and rewarding stimuli. In this study, we showed that dopaminergic neurotransmission is highly dependent on M-4 cholinergic muscarinic receptor function. Using in vivo microdialysis, we found elevated dopamine (DA) basal values and enhanced DA response to psychostimulants in the nucleus accumbens of M-4 knockout mice. We also demonstrated impaired homeostatic control of cholinergic activity that leads to increased basal acetylcholine efflux in the midbrain of these animals. Thus, loss of M-4 muscarinic receptor control of cholinergic function effectuates a state of dopaminergic hyperexcitability. This may be responsible for pathological conditions, in which appetitive motivation as well as affective and cognitive processing is impaired. We propose that M-4 receptor agonists could represent an innovative strategy for the treatment of pathologies associated with hyperdopaminergia.	Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA; NIDDKD, Bioorgan Chem Lab, Bethesda, MD 20892 USA	Eli Lilly; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nomikos, GG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, DC0510, Indianapolis, IN 46285 USA.	gnomikos@lilly.com		Felder, Christian/0000-0003-1134-8881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basile AS, 2002, P NATL ACAD SCI USA, V99, P11452, DOI 10.1073/pnas.162371899; BERNARD V, 1992, J NEUROSCI, V12, P3591; Bodick NC, 1997, ARCH NEUROL-CHICAGO, V54, P465, DOI 10.1001/archneur.1997.00550160091022; Bymaster FP, 2002, CNS NEUROL DISORD-DR, V1, P163, DOI 10.2174/1568007024606249; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chapman CA, 1997, NEUROSCIENCE, V76, P177; DAMSMA G, 1988, LIFE SCI, V43, P1161, DOI 10.1016/0024-3205(88)90475-4; DEBELLEROCHE J, 1978, BRAIN RES, V142, P53, DOI 10.1016/0006-8993(78)90176-2; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; Felder CC, 2001, LIFE SCI, V68, P2605, DOI 10.1016/S0024-3205(01)01059-1; Fink-Jensen A, 1998, NEUROREPORT, V9, P3481, DOI 10.1097/00001756-199810260-00027; Forster GL, 2000, EUR J NEUROSCI, V12, P3596, DOI 10.1046/j.1460-9568.2000.00250.x; Forster GL, 2003, EUR J NEUROSCI, V17, P751, DOI 10.1046/j.1460-9568.2003.02511.x; Forster GL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0001.2002; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Garzon M, 2000, J COMP NEUROL, V419, P32, DOI 10.1002/(SICI)1096-9861(20000327)419:1<32::AID-CNE2>3.0.CO;2-O; Gerber DJ, 2001, P NATL ACAD SCI USA, V98, P15312, DOI 10.1073/pnas.261583798; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Heidbreder CA, 1996, SYNAPSE, V24, P182, DOI 10.1002/(SICI)1098-2396(199610)24:2<182::AID-SYN10>3.0.CO;2-0; Iannazzo L, 2000, NEUROSCI LETT, V287, P129, DOI 10.1016/S0304-3940(00)01163-0; Ince E, 1997, SYNAPSE, V27, P357, DOI 10.1002/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B; Izurieta-Sanchez P, 2000, EUR J PHARMACOL, V399, P151, DOI 10.1016/S0014-2999(00)00353-8; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; Jones CK, 2000, J PHARMACOL EXP THER, V294, P1017; KAYADJANIAN H, 1994, NEUROSCIENCE, V63, P989, DOI 10.1016/0306-4522(94)90567-3; Kitai ST, 1999, CURR OPIN NEUROBIOL, V9, P690, DOI 10.1016/S0959-4388(99)00040-9; LEHMANN J, 1983, NEUROSCIENCE, V10, P1105, DOI 10.1016/0306-4522(83)90102-1; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; Lokwan SJA, 1999, NEUROSCIENCE, V92, P245, DOI 10.1016/S0306-4522(98)00748-9; Maviel T, 2003, NEUROSCIENCE, V120, P1049, DOI 10.1016/S0306-4522(03)00403-2; McGinty JF, 1999, ANN NY ACAD SCI, V877, P129, DOI 10.1111/j.1749-6632.1999.tb09265.x; OAKMAN SA, 1995, J NEUROSCI, V15, P5859; Perry KW, 1997, J NEURAL TRANSM, V104, P953, DOI 10.1007/BF01285563; RAITERI M, 1984, J PHARMACOL EXP THER, V228, P209; Rasmussen T, 2000, EUR J PHARMACOL, V402, P241, DOI 10.1016/S0014-2999(00)00442-8; Roth MT, 1996, NEUROREPORT, V7, P3069, DOI 10.1097/00001756-199611250-00055; Shannon HE, 2000, SCHIZOPHR RES, V42, P249, DOI 10.1016/S0920-9964(99)00138-3; Shippenberg TS, 1999, PSYCHOPHARMACOLOGY, V147, P33, DOI 10.1007/s002130051138; Smolders I, 1997, J NEUROCHEM, V68, P1942; Stanhope KJ, 2001, J PHARMACOL EXP THER, V299, P782; Sugaya K, 1997, MOL BRAIN RES, V50, P305, DOI 10.1016/S0169-328X(97)00199-X; Tandon R, 1999, BRIT J PSYCHIAT, V174, P7, DOI 10.1192/S0007125000293586; Tzavaral ET, 2003, MOL PSYCHIATR, V8, P673, DOI 10.1038/sj.mp.4001270; VILARO MT, 1994, MOL BRAIN RES, V21, P30, DOI 10.1016/0169-328X(94)90375-1; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Westerink BHC, 1996, J NEUROSCI, V16, P2605; XU M, 1989, BRAIN RES, V495, P232, DOI 10.1016/0006-8993(89)90217-5; Yan Z, 2001, NEUROSCIENCE, V103, P1017, DOI 10.1016/S0306-4522(01)00039-2; YEOMANS JS, 1995, NEUROPSYCHOPHARMACOL, V12, P3, DOI 10.1016/0893-133X(94)00054-4; Zhang WL, 2002, J NEUROSCI, V22, P6347	54	121	130	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1410	+		10.1096/fj.04-1575fje	http://dx.doi.org/10.1096/fj.04-1575fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231726				2022-12-25	WOS:000222979200020
J	Ertmer, A; Gilch, S; Yun, SW; Flechsig, E; Klebl, B; Stein-Gerlach, M; Klein, MA; Schatzl, HM				Ertmer, A; Gilch, S; Yun, SW; Flechsig, E; Klebl, B; Stein-Gerlach, M; Klein, MA; Schatzl, HM			The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; NEUROBLASTOMA-CELLS; C-ABL; PROTEIN ACCUMULATION; BRANCHED POLYAMINES; MOLECULAR-BIOLOGY; SCRAPIE ISOFORM; CULTURED-CELLS; CONGO RED; DISEASE	The conversion of the cellular prion protein (PrPc) into pathologic PrPSc and the accumulation of aggregated PrPSc are hallmarks of prion diseases. A variety of experimental approaches to interfere with prion conversion have been reported. Our interest was whether interference with intracellular signaling events has an impact on this conversion process. We screened similar to 50 prototype inhibitors of specific signaling pathways in prion-infected cells for their capacity to affect prion conversion. The tyrosine kinase inhibitor STI571 was highly effective against PrPSc propagation, with an IC50 of less than or equal to 1 muM. STI571 cleared prion-infected cells in a time- and dose-dependent manner from PrPSc without influencing biogenesis, localization, or biochemical features of PrPc. Interestingly, this compound did not interfere with the de novo formation of PrPSc but activated the lysosomal degradation of pre-existing PrPSc, lowering the half-life of PrPSc from greater than or equal to 24 h to < 9 h. Our data indicate that among the kinases known to be inhibited by STI571, c-Abl is likely responsible for the observed anti-prion effect. Taken together, we demonstrate that treatment with STI571 strongly activates the lysosomal degradation of PrPSc and that substances specifically interfering with cellular signaling pathways might represent a novel class of anti-prion compounds.	Tech Univ Munich, Inst Virol, Prion Res Grp, D-80802 Munich, Germany; Univ Wurzburg, Inst Virol & Immunobiol, D-97078 Wurzburg, Germany; Axxima Pharmaceut AG, D-81377 Munich, Germany	Technical University of Munich; University of Wurzburg	Schatzl, HM (corresponding author), Tech Univ Munich, Inst Virol, Prion Res Grp, Biedersteiner Str 29, D-80802 Munich, Germany.	schaetzl@lrz.tum.de	Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740				Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Buchdunger E, 1996, CANCER RES, V56, P100; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Caughey B, 1991, Curr Top Microbiol Immunol, V172, P93; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Clarke AR, 2001, PHILOS T ROY SOC B, V356, P185, DOI 10.1098/rstb.2000.0764; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Gilch S, 2003, TRENDS MOL MED, V9, P367, DOI 10.1016/S1471-4914(03)00144-8; Gilch S, 2003, J BIOL CHEM, V278, P18524, DOI 10.1074/jbc.M210723200; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; GOGA A, 1995, ONCOGENE, V11, P791; Head MW, 2000, TRENDS MICROBIOL, V8, P6, DOI 10.1016/S0966-842X(99)01656-X; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Liemann S, 1998, BIOCHEM BIOPH RES CO, V250, P187, DOI 10.1006/bbrc.1998.9169; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Nunziante M, 2003, CHEMBIOCHEM, V4, P1268, DOI 10.1002/cbic.200300704; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Petzer AL, 2002, BRIT J HAEMATOL, V117, P623, DOI 10.1046/j.1365-2141.2002.03523.x; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schatzl HM, 1997, J VIROL, V71, P8821; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Tilly G, 2003, BIOCHEM BIOPH RES CO, V305, P548, DOI 10.1016/S0006-291X(03)00805-2; TOBLER I, 1996, NATURE, V18, P939; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Weissmann C, 2001, PHILOS T R SOC B, V356, P177, DOI 10.1098/rstb.2000.0763; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yu JC, 2001, J PHARMACOL EXP THER, V298, P1172	61	105	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41918	41927		10.1074/jbc.M405652200	http://dx.doi.org/10.1074/jbc.M405652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15247213	hybrid			2022-12-25	WOS:000224075500083
J	Chakravarthi, S; Bulleid, NJ				Chakravarthi, S; Bulleid, NJ			Glutathione is required to regulate the formation of native disulfide bonds within proteins entering the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PLASMINOGEN-ACTIVATOR; CONSERVED CYSTEINES; LIVING CELLS; REDOX STATE; DITHIOTHREITOL; ISOMERASE; TRANSPORT; MEMBRANE; ERO1P	The formation of native disulfide bonds is an essential event in the folding and maturation of proteins entering the secretory pathway. For native disulfides to form efficiently an oxidative pathway is required for disulfide bond formation and a reductive pathway is required to ensure isomerization of non-native disulfide bonds. The oxidative pathway involves the oxidation of substrate proteins by PDI, which in turn is oxidized by endoplasmic reticulum oxidase (Ero1). Here we demonstrate that overexpression of Ero1 results in the acceleration of disulfide bond formation and correct protein folding. In contrast, lowering the levels of glutathione within the cell resulted in acceleration of disulfide bond formation but did not lead to correct protein folding. These results demonstrate that lowering the level of glutathione in the cell compromises the reductive pathway and prevents disulfide bond isomerization from occurring efficiently, highlighting the crucial role played by glutathione in native disulfide bond formation within the mammalian endoplasmic reticulum.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	neil.bulleid@man.ac.uk		Bulleid, Neil/0000-0002-9839-5279				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; LODISH HF, 1993, J BIOL CHEM, V268, P20598; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; WALLEN PB, 1984, HAEMOSTASIS, V4, P42	32	132	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39872	39879		10.1074/jbc.M406912200	http://dx.doi.org/10.1074/jbc.M406912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254031	hybrid			2022-12-25	WOS:000223791500083
J	Fortin, JF; Barat, C; Beausejour, Y; Barbeau, B; Tremblay, MJ				Fortin, JF; Barat, C; Beausejour, Y; Barbeau, B; Tremblay, MJ			Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4(+) T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappa B, and AP-1 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD28 RESPONSE ELEMENT; PHOSPHOTYROSYL PHOSPHATASE INHIBITORS; KINASE-C-THETA; HIV-1 NEF; TYPE-1 NEF; IMMUNE ACTIVATION; PROTEIN-KINASE; NUCLEAR FACTOR; INTERLEUKIN-2 PROMOTER; DISEASE PROGRESSION	A chronic state of immune hyperactivation is a feature of human immunodeficiency virus type-1 (HIV-1) infection. Studies on the molecular mechanisms by which HIV-1 can modulate the activation state of T cells indicate that both Nef and Tat can alter T cell activation. However, the vast majority of data has been obtained from experiments performed with vectors encoding a single virus protein. We demonstrate that infection of human CD4(+) T lymphocytes with fully infectious HIV-1 leads to a hyper-responsiveness of the interleukin-2 promoter. Hypersensitivity in HIV-1-infected T cells was observed upon stimulation with various agents that are engaging different signal transduction pathways. Experiments performed with recombinant heat stable antigen-encoding HIV-1 indicated that the virus-infected cells are the cells with an enhanced response. Both Nef and Tat are involved in this virus-mediated enhancing effect on interleukin-2 promoter activity. Interestingly, whereas Nef seems to be acting mainly through hyperactivation of nuclear factor of activated T cells (NFAT), Tat acts in an NFAT-independent manner. Mobility shift experiments demonstrated that the HIV-1-associated priming of human T cells for stimulation results in a greater induction of transcription factors recognized as essential players in T cell activation, i.e. NFAT, NF-kappaB, and AP-1. A hyper-responsive state was also established upon HIV-1 infection of a more natural cellular reservoir, i.e. primary CD4(+) T lymphocytes. Considering that the HIV-1 life cycle is tightly regulated by the T cell signaling machinery, the priming for activation of a major viral reservoir represents a means by which this retrovirus can create an ideal cellular microenvironment for its propagation and maintenance.	CHUL Res Ctr, Res Ctr Infect Dis, Lab Human Immunoretrovirol, Quebec City, PQ G1V 4G2, Canada; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Stanford University; Laval University	Tremblay, MJ (corresponding author), CHUL Res Ctr, Res Ctr Infect Dis, Lab Human Immunoretrovirol, RC709,2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	michel.j.tremblay@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Arendt CW, 2001, GENOME BIOL, V2; Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; AUKRUST P, 1995, INFECTION, V23, P9, DOI 10.1007/BF01710050; Aziz N, 1999, J INFECT DIS, V179, P843, DOI 10.1086/314673; BaierBitterlich G, 1996, J ACQ IMMUN DEF SYND, V13, P184, DOI 10.1097/00042560-199610010-00010; Barat C, 2003, J BIOL CHEM, V278, P6992, DOI 10.1074/jbc.M212433200; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; BASS HZ, 1992, CLIN IMMUNOL IMMUNOP, V64, P63, DOI 10.1016/0090-1229(92)90060-2; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chou CS, 1997, P NATL ACAD SCI USA, V94, P1361, DOI 10.1073/pnas.94.4.1361; Chow CW, 1999, MOL CELL BIOL, V19, P2300; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Djordjevic JT, 2004, AIDS RES HUM RETROV, V20, P547, DOI 10.1089/088922204323087804; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Gonzalez E, 2001, J IMMUNOL, V166, P4560, DOI 10.4049/jimmunol.166.7.4560; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hodge DR, 1998, J BIOL CHEM, V273, P15727, DOI 10.1074/jbc.273.25.15727; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; Khanna KV, 2000, J IMMUNOL, V164, P1408, DOI 10.4049/jimmunol.164.3.1408; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Kotov A, 1999, J VIROL, V73, P8824, DOI 10.1128/JVI.73.10.8824-8830.1999; LAI JH, 1995, MOL CELL BIOL, V15, P4260; Lederman MM, 2000, AIDS, V14, P951, DOI 10.1097/00002030-200005260-00006; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; MAHALINGAM M, 1993, CLIN EXP IMMUNOL, V93, P337, DOI 10.1111/j.1365-2249.1993.tb08182.x; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Manninen A, 2002, J EXP MED, V195, P1023, DOI 10.1084/jem.20012039; Manninen A, 2001, J VIROL, V75, P3034, DOI 10.1128/JVI.75.6.3034-3037.2001; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; McGuire KL, 1997, J IMMUNOL, V159, P1319; MUSTAFA F, 1993, J VIROL, V67, P6909, DOI 10.1128/JVI.67.11.6909-6915.1993; NISHANIAN P, 1991, AIDS, V5, P805, DOI 10.1097/00002030-199107000-00003; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Ouellet M, 2003, PROG NUCLEIC ACID RE, V73, P69, DOI 10.1016/S0079-6603(03)01003-1; Ouellet M, 2003, BIOCHEMISTRY-US, V42, P8260, DOI 10.1021/bi034013b; Ouellet M, 1999, J BIOL CHEM, V274, P35029, DOI 10.1074/jbc.274.49.35029; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZACK JA, 1995, ADV EXP MED BIOL, V374, P27; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZANGERLE R, 1994, J ACQ IMMUN DEF SYND, V7, P79; Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8	83	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39520	39531		10.1074/jbc.M407477200	http://dx.doi.org/10.1074/jbc.M407477200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258149	hybrid			2022-12-25	WOS:000223791500042
J	Kokkonen, N; Rivinoja, A; Kauppila, A; Suokas, M; Kellokumpu, I; Kellokumpu, S				Kokkonen, N; Rivinoja, A; Kauppila, A; Suokas, M; Kellokumpu, I; Kellokumpu, S			Defective acidification of intracellular organelles results in aberrant secretion of cathepsin D in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; LYSOSOMAL-ENZYMES; PROCATHEPSIN-D; LIGAND-BINDING; GOLGI-COMPLEX; PH REGULATION; TUMOR-CELLS; TRANSPORT; GLYCOSYLATION; FIBROBLASTS	Aberrant secretion of lysosomal hydrolases such as ( pro) cathepsin D (proCD) is a common phenotypic change in many human cancers. Here we explore the underlying molecular defect(s) and find that MCF-7 breast and CaCo-2 colorectal cancer cells that are unable to acidify their endosomal compartments secreted higher amounts of proCD than did acidification-competent cancer cell types. The latter secreted equivalent amounts of proCD only after dissipation of their organellar pH gradients with NH4Cl. Assessing the critical steps that resulted in proCD secretion revealed that the Golgi-associated sorting receptor for CD, i.e. the cation-independent mannose-6-phosphate receptor (MPR300), was aberrantly distributed in acidification-defective MCF-7 cells. It accumulated mainly in late endosomes and/or lysosomes as a complex with its ligand ( proCD or intermediate CD), as evidenced by its co-localization with both CD and LAMP-2, a late endosome/lysosome marker. Our immunoprecipitation analyses also showed that MCF-7 cells possessed 7-fold higher levels of receptor-enzyme complexes than did acidification-competent cells. NH4Cl induced similar receptor redistribution into LAMP-2-positive structures in acidification-competent cells but not in MCF-7 cells. The receptor also recovered its normal Golgi localization upon drug removal. Based on these observations, we conclude that defective acidification results in the aberrant secretion of proCD in certain cancer cells and interferes mainly with the normal disassembly of the receptor-enzyme complexes and efficient receptor reutilization in the Golgi.	Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Jyvaskyla Cent Hosp, FIN-40620 Jyvaskyla, Finland	Finland National Institute for Health & Welfare; University of Oulu; Central Finland Central Hospital	Kellokumpu, S (corresponding author), Univ Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	sakari.kellokumpu@oulu.fi		Kokkonen, Nina/0000-0003-0913-4892				Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Appenzeller-Herzog C, 2004, J BIOL CHEM, V279, P12943, DOI 10.1074/jbc.M313245200; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CAPONY F, 1989, CANCER RES, V49, P3904; CAPONY F, 1994, EXP CELL RES, V215, P154, DOI 10.1006/excr.1994.1327; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; Dellian M, 1996, BRIT J CANCER, V74, P1206, DOI 10.1038/bjc.1996.518; DeStafanis D, 1997, CELL TISSUE RES, V289, P109; Dittmer F, 1999, J CELL SCI, V112, P1591; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Helmlinger G, 2002, CLIN CANCER RES, V8, P1284; Hill R P, 2001, Novartis Found Symp, V240, P154; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; ISIDORO C, 1995, INT J CANCER, V60, P61, DOI 10.1002/ijc.2910600109; Isidoro C, 1997, INT J CANCER, V70, P561, DOI 10.1002/(SICI)1097-0215(19970304)70:5<561::AID-IJC12>3.0.CO;2-G; Kellokumpu S, 2002, FEBS LETT, V516, P217, DOI 10.1016/S0014-5793(02)02535-8; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; Machen TE, 2003, AM J PHYSIOL-CELL PH, V285, pC205, DOI 10.1152/ajpcell.00008.2003; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; Suokas M, 2000, J BIOL CHEM, V275, P17863, DOI 10.1074/jbc.M908025199; Thangaraju M, 1999, CANCER RES, V59, P1649; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WILSON DW, 1993, J BIOL CHEM, V268, P7465; Wittlin S, 1999, EUR J BIOCHEM, V265, P384, DOI 10.1046/j.1432-1327.1999.00747.x; Xiao H, 2003, P NATL ACAD SCI USA, V100, P5205, DOI 10.1073/pnas.0935978100; Yuan JL, 2000, CANCER RES, V60, P4372	49	70	72	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39982	39988		10.1074/jbc.M406698200	http://dx.doi.org/10.1074/jbc.M406698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15258139	hybrid			2022-12-25	WOS:000223791500095
J	Hamza, MS; Reyes, RA; Izumiya, Y; Wisdom, R; Kung, HJ; Luciw, PA				Hamza, MS; Reyes, RA; Izumiya, Y; Wisdom, R; Kung, HJ; Luciw, PA			ORF36 protein kinase of Kaposi's sarcoma herpesvirus activates the c-Jun N-terminal kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARICELLA-ZOSTER-VIRUS; ELONGATION-FACTOR 1-DELTA; HUMAN T-CELLS; SIMPLEX-VIRUS; HUMAN CYTOMEGALOVIRUS; TRANSCRIPTION FACTOR; CELLULAR-PROTEIN; SYNERGISTIC ACTIVATION; U(L)13 GENE; TYPE-1	alpha-, beta-, and gamma-Herpesviruses encode putative viral protein kinases. The herpes simplex virus UL13, varicella-zoster virus ORF47, and Epstein-Barr virus BGLF4 genes all show protein kinase domains in their protein sequences. Mutational analysis of these herpesviruses demonstrated that the viral kinase is important for optimal virus growth. Previous studies have shown that ORF36 of Kaposi's sarcoma herpesvirus (KSHV) has protein kinase activity and is autophosphorylated on serine. The gene for ORF36 is expressed during lytic growth of the virus and has been classified as a late gene. Inspection of the ORF36 sequence indicated potential motifs that could be involved in activation of cellular transcription factors. To analyze the function of ORF36, the cDNA for this viral gene was tagged with the FLAG epitope and inserted into an expression vector for mammalian cells. Transfection experiments in 293T and SLK cells demonstrated that expression of ORF36 resulted in phosphorylation of the c-Jun N-terminal kinase. Autophosphorylation of ORF36 is important for JNK activation because a mutation in the predicted catalytic domain of ORF36 blocked its ability to phosphorylate JNK. Western blot analysis, using phosphospecific antibodies, revealed that mitogen-activated kinases MKK4 and MKK7 were phosphorylated by ORF36 but not by the kinase-negative mutant. Binding experiments in transfected cells also demonstrated that both the wild type and kinase-negative mutant of ORF36 form a complex with JNK, MKK4, and MKK7. In addition, using a tetracycline-inducible Rta BCBL-1 cell line (TREx BCBL1-Rta), JNK was phosphorylated during lytic replication, and inhibition of JNK activation blocked late viral gene expression but not early viral gene expression. In summary, these studies demonstrate that KSHV ORF36 activates the JNK pathway; thus this cell signaling pathway may function in the KSHV life cycle by regulating viral and/or cellular transcription.	Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA; Univ Calif Davis, Div Hematol & Oncol, Davis, CA 95616 USA; Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Luciw, PA (corresponding author), Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA.	paluciw@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013; Hamza, Sabry/B-8184-2011	Izumiya, Yoshihiro/0000-0002-9184-2603	NCI NIH HHS [CA91574] Funding Source: Medline; NCRR NIH HHS [RR00169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091574] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Besser J, 2003, J VIROL, V77, P5964, DOI 10.1128/JVI.77.10.5964-5974.2003; Biggar RJ, 2003, J INFECT DIS, V187, P12, DOI 10.1086/345866; Brinkmann MM, 2003, J VIROL, V77, P9346, DOI 10.1128/JVI.77.17.9346-9358.2003; Bruening W, 1998, NUCLEIC ACIDS RES, V26, P486, DOI 10.1093/nar/26.2.486; Bruni R, 1999, J VIROL, V73, P3810, DOI 10.1128/JVI.73.5.3810-3817.1999; Bubman D, 2003, HEMATOL ONCOL CLIN N, V17, P717, DOI 10.1016/S0889-8588(03)00044-3; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Cotter MA, 2002, FRONT BIOSCI-LANDMRK, V7, pD358, DOI 10.2741/cotter; COULTER LJ, 1993, J GEN VIROL, V74, P387, DOI 10.1099/0022-1317-74-3-387; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEINEMAN TC, 1995, J VIROL, V69, P7367, DOI 10.1128/JVI.69.11.7367-7370.1995; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ikeda A, 2001, J BIOCHEM-TOKYO, V130, P773, DOI 10.1093/oxfordjournals.jbchem.a003048; Ito M, 1999, MOL CELL BIOL, V19, P7539; Izumiya Y, 2003, J VIROL, V77, P1441, DOI 10.1128/JVI.77.2.1441-1451.2003; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Kato K, 2001, J GEN VIROL, V82, P1457, DOI 10.1099/0022-1317-82-6-1457; Kawaguchi Y, 1999, J VIROL, V73, P4456, DOI 10.1128/JVI.73.5.4456-4460.1999; Kawaguchi Y, 2003, REV MED VIROL, V13, P331, DOI 10.1002/rmv.402; Kawaguchi Y, 2003, J VIROL, V77, P2359, DOI 10.1128/JVI.77.4.2359-2368.2003; Kawaguchi Y, 1998, J VIROL, V72, P1731, DOI 10.1128/JVI.72.3.1731-1736.1998; KIEFF E, 2001, FIELDS VIROLOGY, V2, P2576; Kim DB, 2002, J VIROL, V76, P6473, DOI 10.1128/JVI.76.13.6473-6479.2002; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lin SF, 1999, J VIROL, V73, P1909, DOI 10.1128/JVI.73.3.1909-1917.1999; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; Liu JL, 2000, VIRUS GENES, V21, P51, DOI 10.1023/A:1008132313289; McLean TI, 1999, J VIROL, V73, P8415, DOI 10.1128/JVI.73.10.8415-8426.1999; Moffat JF, 1998, P NATL ACAD SCI USA, V95, P11969, DOI 10.1073/pnas.95.20.11969; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Ng TI, 1996, VIROLOGY, V225, P347, DOI 10.1006/viro.1996.0609; NG TI, 1992, VIROLOGY, V191, P9, DOI 10.1016/0042-6822(92)90161-H; OVERTON HA, 1992, VIROLOGY, V190, P184, DOI 10.1016/0042-6822(92)91204-8; Park J, 2000, J GEN VIROL, V81, P1067, DOI 10.1099/0022-1317-81-4-1067; Prichard MN, 1999, J VIROL, V73, P5663, DOI 10.1128/JVI.73.7.5663-5670.1999; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; Rahaus M, 2003, VIRUS RES, V92, P9, DOI 10.1016/S0168-1702(02)00310-6; Roizman B, 2001, FIELDS VIROL, P2381; Sato H, 2003, J VIROL, V77, P11180, DOI 10.1128/JVI.77.20.11180-11185.2003; SMITH GA, 1991, ARCH VIROL, V119, P199, DOI 10.1007/BF01310670; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; STEVENSON D, 1994, J GEN VIROL, V75, P317, DOI 10.1099/0022-1317-75-2-317; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Talarico CL, 1999, ANTIMICROB AGENTS CH, V43, P1941, DOI 10.1128/AAC.43.8.1941; vanZeijl M, 1997, VIROLOGY, V231, P72, DOI 10.1006/viro.1997.8523; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wolf DG, 1998, ARCH VIROL, V143, P1223, DOI 10.1007/s007050050370; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097	57	59	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38325	38330		10.1074/jbc.M400964200	http://dx.doi.org/10.1074/jbc.M400964200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247271	hybrid			2022-12-25	WOS:000223684100032
J	Ling, TY; Chen, CL; Huang, YH; Liu, IH; Huang, SS; Huang, JS				Ling, TY; Chen, CL; Huang, YH; Liu, IH; Huang, SS; Huang, JS			Identification and characterization of the acidic pH binding sites for growth regulatory ligands of low density lipoprotein receptor-related protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA RECEPTOR; METHYL-D-ASPARTATE; ANNEXIN-VI; TGF-BETA; HIGH-AFFINITY; ALPHA(2)-MACROGLOBULIN RECEPTOR; SULFATE PROTEOGLYCANS; TUMOR PH; ALPHA-2-MACROGLOBULIN; CALCIUM	The type V TGF-alpha receptor (TbetaR-V) plays an important role in growth inhibition by IGFBP-3 and TGF-beta in responsive cells. Unexpectedly, TbetaR-V was recently found to be identical to the LRP-1/alpha(2)M receptor; this has disclosed previously unreported growth regulatory functions of LRP-1. Here we demonstrate that, in addition to expressing LRP-1, all cells examined exhibit low affinity but high density acidic pH binding sites for LRP-1 growth regulatory ligands (TGF-beta(1), IGFBP-3, and alpha(2)M*). These sites, like LRP-1, are sensitive to receptor-associated protein and calcium depletion but, unlike LRP-1, are also sensitive to chondroitin sulfate and heparin and capable of directly binding ligands, which do not bind to LRP-1. Annexin VI has been identified as a major membrane-associated protein capable of directly binding alpha(2)M* at acidic pH. This is evidenced by: 1) structural and Western blot analyses of the protein purified from bovine liver plasma membranes by alpha(2)M* affinity column chromatography at acidic pH, and 2) dot blot analysis of the interaction of annexin VI and I-125-alpha(2)M*. Cell surface annexin VI is involved in I-125-TGF-beta(1) and I-125-alpha(2)M* binding to the acidic pH binding sites and I-125-alpha(2)M* binding to LRP-1 at neutral pH as demonstrated by the sensitivity of cells to pretreatment with anti-annexin VI IgG. Cell surface annexin VI is also capable of mediating internalization and degradation of cell surface-bound I-125-TGF-beta(1) and I-125-alpha(2)M* at pH 6 and of forming ternary complexes with I-125-alpha(2)M* and LRP-1 at neutral pH as demonstrated by co-immunoprecipitation. Trifluoperazine and fluphenazine, which inhibit ligand binding to the acidic pH binding sites, block degradation after internalization of cell surface-bound I-125-TGF-beta(1) or I-125-alpha(2)M*. These results suggest that cell surface annexin VI may function as an acidic pH binding site or receptor and may also function as a co-receptor with LRP-1 at neutral pH.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Taipei Med Univ, Dept Biochem, Taipei 110, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Taipei Medical University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X	NCI NIH HHS [CA38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acker T, 2002, J MOL MED-JMM, V80, P562, DOI 10.1007/s00109-002-0355-1; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BASU SK, 1978, J BIOL CHEM, V253, P3852; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BURGESS CD, 1981, PHARMACOL THERAPEUT, V15, P553, DOI 10.1016/0163-7258(81)90057-7; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DIPAOLA M, 1984, J CELL PHYSIOL, V118, P193, DOI 10.1002/jcp.1041180212; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; FITZGERALD DJ, 1994, ANN NY ACAD SCI, V737, P138, DOI 10.1111/j.1749-6632.1994.tb44307.x; Forsten KE, 2001, J CELL PHYSIOL, V189, P356, DOI 10.1002/jcp.10033; Fukumura D, 2001, CANCER RES, V61, P6020; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HICKSON GB, 1990, PEDIATRICS, V86, P221; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; HUANG SS, 1988, J BIOL CHEM, V263, P1535; Ishitsuka R, 1998, J BIOL CHEM, V273, P9935, DOI 10.1074/jbc.273.16.9935; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; KANAMORI M, 1981, J PHARMACOL EXP THER, V217, P494; Kirilenko A, 2002, BIOPHYS J, V82, P2737, DOI 10.1016/S0006-3495(02)75614-2; Kourie JI, 2000, PROG BIOPHYS MOL BIO, V73, P91, DOI 10.1016/S0079-6107(00)00003-1; KURATOMI Y, 1986, EXP CELL RES, V162, P436, DOI 10.1016/0014-4827(86)90348-4; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LAHTI RA, 1993, EUR J PHARMACOL, V236, P483, DOI 10.1016/0014-2999(93)90488-4; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEAL SM, 1999, CHARACTERIZATION INT; Ling TY, 2003, FASEB J, V17, P1559, DOI 10.1096/fj.02-1063fje; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Liu QJ, 2001, J BIOL CHEM, V276, P46212, DOI 10.1074/jbc.M105177200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; MOORE PB, 1986, BIOCHEM J, V238, P49, DOI 10.1042/bj2380049; MORGAN EH, 1983, BIOCHIM BIOPHYS ACTA, V762, P498, DOI 10.1016/0167-4889(83)90052-6; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Ortega D, 1998, J CELL SCI, V111, P261; Pons M, 2000, EXP CELL RES, V257, P33, DOI 10.1006/excr.2000.4861; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Rathore D, 2000, P NATL ACAD SCI USA, V97, P8530, DOI 10.1073/pnas.140224597; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; Takagi H, 2002, J CELL SCI, V115, P3309; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WIKEHOOLEY JL, 1984, EUR J CANCER CLIN ON, V20, P619, DOI 10.1016/0277-5379(84)90006-3; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J	73	12	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38736	38748		10.1074/jbc.M310537200	http://dx.doi.org/10.1074/jbc.M310537200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15226301	hybrid			2022-12-25	WOS:000223684100084
J	Qahwash, I; He, WX; Tomasselli, A; Kletzien, RF; Yan, RQ				Qahwash, I; He, WX; Tomasselli, A; Kletzien, RF; Yan, RQ			Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; ASPARTYL PROTEASE; SECRETASE; CLEAVAGE; PEPTIDE; ENZYME; DOMAIN; FURIN; IDENTIFICATION	Membrane-bound BACE1 naturally cleaves its transmembrane substrate amyloid precursor protein (APP) at the two adjacent beta- and beta'-sites. Cleavage at these two sites generates the heterogeneous N-terminal end of APP C-terminal fragments that are further processed by gamma-secretase to release Abeta- (1 - 40/42) or Abeta- (11 - 40/42). The significance underlying Abeta- (11 - 40/42) in Alzheimer's disease pathogenesis has remained to be experimentally elucidated, but increased production of Abeta- (1 - 40/42) has been broadly demonstrated to contribute to amyloid depositions in senile plaques. In this study, we show that the cleavage of APP at the beta-site by BACE1 is readily disrupted through limited structural twists, whereas the beta'-site is relatively better positioned to gain access to the BACE1 catalytic cavity. Radical insertion or deletion of residues between beta- and beta'-site also favors cleavage of APP at the beta'-site. On the other hand, either lengthening or shortening the loop region of BACE1 has a minor impact on the selective cleavage of APP at these two adjacent sites, but significantly shortening the loop region impairs the ability of BACE1 to process APP at both sites. Thus, processing of APP by BACE1 is clearly dependent on a mutual structural compatibility in addition to the sequence feature. The knowledge gained from this study will potentially offer an opportunity for rational design of small molecule drugs to block the cleavage of APP specifically at the beta-site while not disturbing the functions of other cellular aspartyl proteases.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Pharmacia Corp, Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia Corp, Prot Sci, Kalamazoo, MI 49007 USA	Cleveland Clinic Foundation; Pfizer; Pfizer	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org		Yan, Riqiang/0000-0001-7195-7617				Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Crescenzi O, 2002, EUR J BIOCHEM, V269, P5642, DOI 10.1046/j.1432-1033.2002.03271.x; Demeester N, 2001, EUR J NEUROSCI, V13, P2015, DOI 10.1046/j.0953-816x.2001.01579.x; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; FOLZ RJ, 1994, HUM MOL GENET, V3, P2251, DOI 10.1093/hmg/3.12.2251; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P312; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; McGowan E, 1999, NEUROBIOL DIS, V6, P231, DOI 10.1006/nbdi.1999.0243; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Pinnix I, 2001, FASEB J, V15, P1810, DOI 10.1096/fj.00-0891fje; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vehmas AK, 2001, DNA CELL BIOL, V20, P713, DOI 10.1089/10445490152717578; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	38	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39010	39016		10.1074/jbc.M407101200	http://dx.doi.org/10.1074/jbc.M407101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234966	hybrid			2022-12-25	WOS:000223684100115
J	Reddy, ST; Chai, WG; Childs, RA; Page, JD; Feizi, T; Dahms, NM				Reddy, ST; Chai, WG; Childs, RA; Page, JD; Feizi, T; Dahms, NM			Identification of a low affinity mannose 6-phosphate-binding site in domain 5 of the cation-independent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; CARBOHYDRATE-RECOGNITION; OLIGOSACCHARIDE MICROARRAYS; EXTRACYTOPLASMIC REGION; LINKED OLIGOSACCHARIDES; LIGAND INTERACTIONS; ARGININE RESIDUES; LYSOSOMAL-ENZYMES; PICHIA-PASTORIS; BINDING-SITES	The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) and the 46-kDa cation-dependent MPR (CD-MPR) are type I integral membrane glycoproteins that play a critical role in the intracellular delivery of newly synthesized mannose 6-phosphate (Man-6-P)-containing acid hydrolases to the lysosome. The extracytoplasmic region of the CI-MPR contains 15 contiguous domains, and the two high affinity (similar to1 nM) Man-6-P-binding sites have been mapped to domains 1 - 3 and 9, with essential residues localized to domains 3 and 9. Domain 5 of the CI-MPR exhibits significant sequence homology to domains 3 and 9 as well as to the CD-MPR. A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket. To determine whether domain 5 harbors a carbohydrate-binding site, a construct that encodes domain 5 alone (Dom5His) was expressed in Pichia pastoris. Microarray analysis using 30 different oligosaccharides demonstrated that Dom5His bound specifically to a Man-6-P-containing oligosaccharide ( pentamannosyl 6-phosphate). Frontal affinity chromatography showed that the affinity of Dom5His for Man-6- P was similar to 300-fold lower (K-i = 5.3 mM) than that observed for domains 1 - 3 and 9. The interaction affinity for the lysosomal enzyme beta-glucuronidase was also much lower (K-d = 54 muM) as determined by surface plasmon resonance analysis. Taken together, these results demonstrate that the CI-MPR contains a third Man-6- P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1 - 3 and 9.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Imperial Coll, Fac Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Biacore Inc, Piscataway, NJ 08854 USA	Medical College of Wisconsin; Imperial College London	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ndahms@mcw.edu		Feizi, Ten/0000-0001-6495-0329	NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042667, R01DK042667, R29DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Grimme S, 2000, J BIOL CHEM, V275, P33697, DOI 10.1074/jbc.M003789200; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; Hirabayashi J, 2003, METHOD ENZYMOL, V362, P353; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KASAI K, 1986, J CHROMATOGR, V376, P33, DOI 10.1016/S0378-4347(00)80822-1; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; Matsuura F, 1998, GLYCOBIOLOGY, V8, P329, DOI 10.1093/glycob/8.4.329; Monsigny M, 2000, Carbohydr Lett, V4, P35; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; Olson LJ, 2004, J BIOL CHEM, V279, P34000, DOI 10.1074/jbc.M404588200; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Reddy ST, 2003, BIOCHEM BIOPH RES CO, V309, P643, DOI 10.1016/j.bbrc.2003.08.048; Reddy ST, 2002, PROTEIN EXPRES PURIF, V26, P290, DOI 10.1016/S1046-5928(02)00542-9; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; Sohar I, 1998, BIOCHEM J, V330, P903, DOI 10.1042/bj3300903; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	49	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38658	38667		10.1074/jbc.M407474200	http://dx.doi.org/10.1074/jbc.M407474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252023	hybrid			2022-12-25	WOS:000223684100074
J	Wietfeld, D; Heinrich, N; Furkert, J; Fechner, K; Beyermann, M; Bienert, M; Berger, H				Wietfeld, D; Heinrich, N; Furkert, J; Fechner, K; Beyermann, M; Bienert, M; Berger, H			Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RECEPTOR; HOMOLOGOUS DESENSITIZATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; HIGH-AFFINITY; CRF RECEPTOR; UROCORTIN; CLONING; EXPRESSION; PEPTIDE	The regulation of G protein activation by the rat corticotropin-releasing factor receptor type 1 (rCRFR1) in human embryonic kidney (HEK) 293 (HEK-rCRFR1) cell membranes was studied. Corresponding to a high and low affinity ligand binding site, sauvagine and other peptidic CRFR1 ligands evoked high and low potency responses of G protein activation, differing by 64-fold in their EC50 values as measured by stimulation of [S-35]GTPgammaS binding. Contrary to the low potency response, the high potency response was of lower GTPgammaS affinity, pertussis toxin (PTX)-insensitive, and homologously desensitized. Distinct desensitization was also observed in the adenylate cyclase activity, when its high potency stimulation was abolished and the activity became low potently inhibited by sauvagine. From these results and immunoprecipitation of [S-35]GTPgammaS-bound Galpha(s) and Galpha(i) subunits it is concluded that the high and low potency [S-35]GTPgammaS binding stimulation reflected coupling to G(s) and G(i) proteins, respectively, only G(s) coupling being homologously desensitized. Immunoprecipitation of [S-35]GTPgammaS-bound Galpha(q/11) revealed additional coupling to G(q/11), which also was homologously desensitized. Although Galpha(q/11) coupling was PTX-insensitive, half of the sauvagine-stimulated accumulation of inositol phosphates in the cells was PTX-sensitive, suggesting involvement of G(i) in addition to G(q/11) in the stimulation of inositol metabolism. It is concluded that CRFR1 signals through at least two different ways, one leading to G(s)- and G(q/11)-mediated signaling steps and desensitization and another leading to G(i)-mediated signals without being desensitized. Furthermore, the concentrations of the stimulating ligand and GTP and desensitization may be part of a regulatory mechanism determining the actual ratio of the coupling of CRFR1 to different G proteins.	Inst Mol Pharmacol, D-13125 Berlin, Germany		Berger, H (corresponding author), Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	berger@fmp-berlin.de						Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dautzenberg FM, 2002, BIOCHEM BIOPH RES CO, V298, P303, DOI 10.1016/S0006-291X(02)02463-4; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Dieterich KD, 1997, EXP CLIN ENDOCR DIAB, V105, P65, DOI 10.1055/s-0029-1211730; Grammatopoulos DK, 2001, J NEUROCHEM, V76, P509, DOI 10.1046/j.1471-4159.2001.00067.x; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076; Hauger RL, 1997, J NEUROCHEM, V68, P2308; Hauger RL, 2003, J PHARMACOL EXP THER, V306, P794, DOI 10.1124/jpet.103.050088; Hauger RL, 2000, BIOCHEM BIOPH RES CO, V268, P572, DOI 10.1006/bbrc.2000.2183; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Liaw CW, 1996, ENDOCRINOLOGY, V137, P72, DOI 10.1210/en.137.1.72; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Newman-Tancredi A, 2002, MOL PHARMACOL, V62, P590, DOI 10.1124/mol.62.3.590; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roseboom PH, 2001, MOL BRAIN RES, V92, P115, DOI 10.1016/S0169-328X(01)00162-0; Ruhmann A, 1999, PEPTIDES, V20, P1311, DOI 10.1016/S0196-9781(99)00136-9; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0	37	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38386	38394		10.1074/jbc.M405335200	http://dx.doi.org/10.1074/jbc.M405335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252011	hybrid			2022-12-25	WOS:000223684100040
J	Ding, H; Clark, RJ; Ding, BJ				Ding, H; Clark, RJ; Ding, BJ			IscA mediates iron delivery for assembly of iron-sulfur clusters in IscU under the limited accessible free iron conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTOGA-MARITIMA ISCU; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; 2FE-2S CLUSTER; HEAT-REPEATS; GENE-CLUSTER; PROTEIN; BIOSYNTHESIS; FRATAXIN	Increasing evidence suggests that IscS, a cysteine desulfurase, provides sulfur for assembly of transient iron-sulfur clusters in IscU. IscU appears to act as a scaffold and eventually transfers the assembled clusters to target proteins. However, the iron donor for the iron-sulfur cluster assembly largely remains elusive. Here we find that Escherichia coli IscU fails to assemble iron-sulfur clusters when the accessible "free" iron in solution is limited by an iron chelator sodium citrate. Remarkably, IscA, an iron-sulfur cluster assembly protein with an iron association constant of 3.0 x 10(19) M-1, is able to overcome the iron limitation due to sodium citrate and deliver iron for the IscS-mediated iron-sulfur cluster assembly in IscU. Substitution of the invariant cysteine residues Cys-99 or Cys-101 in IscA with serine completely abolishes the iron binding activity of the protein. The IscA mutants that fail to bind iron are unable to mediate iron delivery for the iron-sulfur cluster assembly in IscU under the limited accessible "free" iron conditions. The results suggest that IscA is capable of recruiting intracellular iron and providing iron for the iron-sulfur cluster assembly in IscU in cells in which the accessible "free" iron content is probably restricted.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, H (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	hding@lsu.edu	Ding, Baojin/J-5479-2015; Ding, Huangen/AAJ-8550-2020	Ding, Baojin/0000-0002-2149-2599; Ding, Huangen/0000-0002-4815-7336				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; AISEN P, 1978, J BIOL CHEM, V253, P1930; BENNETT DE, 1987, BIOCHIM BIOPHYS ACTA, V911, P71, DOI 10.1016/0167-4838(87)90272-X; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Li DS, 1999, FEBS LETT, V456, P13, DOI 10.1016/S0014-5793(99)00896-0; Mansy SS, 2004, J BIOL CHEM, V279, P10469, DOI 10.1074/jbc.M312051200; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Morimoto K, 2003, J BIOCHEM, V134, P211, DOI 10.1093/jb/mvg131; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2003, BIOCHEMISTRY-US, V42, P5784, DOI 10.1021/bi026939+; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	40	83	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37499	37504		10.1074/jbc.M404533200	http://dx.doi.org/10.1074/jbc.M404533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247288	Green Published, hybrid			2022-12-25	WOS:000223554600039
J	Kubota, K; Nakahara, K; Ohtsuka, T; Yoshida, S; Kawaguchi, J; Fujita, Y; Ozeki, Y; Hara, A; Yoshimura, C; Furukawa, H; Haruyama, H; Ichikawa, K; Yamashita, M; Matsuoka, T; Iijima, Y				Kubota, K; Nakahara, K; Ohtsuka, T; Yoshida, S; Kawaguchi, J; Fujita, Y; Ozeki, Y; Hara, A; Yoshimura, C; Furukawa, H; Haruyama, H; Ichikawa, K; Yamashita, M; Matsuoka, T; Iijima, Y			Identification of 2 '-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; PROTEIN-SYNTHESIS; RNASEL GENE; HIV-1 REPLICATION; PROSTATE-CANCER; SYNTHETASE; INHIBITION; RESISTANCE; CELLS; FAMILIES	The 2-5A system is one of the major pathways for antiviral and antitumor functions that can be induced by interferons (IFNs). The 2-5A system is modulated by 5'-triphosphorylated, 2',5'-phosphodiester-linked oligoadenylates ( 2-5A), which are synthesized by 2', 5'-oligoadenylate synthetases (2', 5'-OASs), inactivated by 5'-phosphatase and completely degraded by 2'-phosphodiesterase (2'-PDE). Generated 2 - 5A activates 2 - 5A-dependent endoribonuclease, RNase L, which induces RNA degradation in cells and finally apoptosis. Although 2', 5'-OASs and RNase L have been molecularly cloned and studied well, the identification of 2'-PDE has remained elusive. Here, we describe the first identification of 2'-PDE, the third key enzyme of the 2 - 5A system. We found a putative 2'-PDE band on SDS-PAGE by successive six-step chromatographies from ammonium sulfate precipitates of bovine liver and identified a partial amino acid sequence of the human 2'-PDE by mass spectrometry. Based on the full-length sequence of the human 2'-PDE obtained by in silico expressed sequence tag assembly, the gene was cloned by reverse transcription-PCR. The recombinant human 2'-PDE expressed in mammalian cells certainly cleaved the 2', 5'-phosphodiester bond of 2 - 5A trimer and 2 - 5A analogs. Because no sequences with high homology to this human 2'-PDE were found, the human 2'-PDE was considered to be a unique enzyme without isoform. Suppression of 2'-PDE by a small interfering RNA and a 2'-PDE inhibitor resulted in significant reduction of viral replication, whereas overexpression of 2'-PDE protected cells from IFN-induced antiproliferative activity. These observations identify 2'-PDE as a key regulator of the 2 - 5A system and as a potential novel target for antiviral and antitumor treatments.	Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Lead Discovery Res Labs, Shinagawa Ku, Tokyo 1408710, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Kubota, K (corresponding author), Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo 1408710, Japan.	kkubot@sankyo.co.jp		Matsuoka, Tatsuji/0000-0001-5982-4248				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BEIGELMAN L, 1995, NUCLEIC ACIDS RES, V23, P3989, DOI 10.1093/nar/23.19.3989; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Castelli J, 1998, BIOMED PHARMACOTHER, V52, P386, DOI 10.1016/S0753-3322(99)80006-7; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; DONG BH, 1994, J BIOL CHEM, V269, P14153; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Homan JW, 2002, J ACQ IMMUN DEF SYND, V30, P9, DOI 10.1097/00126334-200205010-00002; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Lee SH, 2002, GENOME RES, V12, P527, DOI 10.1101/gr.20102; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Liska AJ, 2003, PROTEOMICS, V3, P19, DOI 10.1002/pmic.200390004; MINKS MA, 1979, NUCLEIC ACIDS RES, V6, P767, DOI 10.1093/nar/6.2.767; OKUNO Y, 1990, J CLIN MICROBIOL, V28, P1308, DOI 10.1128/JCM.28.6.1308-1313.1990; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; RICE AP, 1984, J VIROL, V50, P220, DOI 10.1128/JVI.50.1.220-228.1984; Rivas C, 1998, VIROLOGY, V243, P406, DOI 10.1006/viro.1998.9072; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Sawai H, 1985, Prog Clin Biol Res, V202, P97; SCHMIDT A, 1978, FEBS LETT, V95, P257, DOI 10.1016/0014-5793(78)81006-0; SCHMIDT A, 1979, P NATL ACAD SCI USA, V76, P4788, DOI 10.1073/pnas.76.10.4788; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; Sokoloff MH, 1996, CANCER-AM CANCER SOC, V77, P1862; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tatsumi R, 2003, J INTERF CYTOK RES, V23, P667, DOI 10.1089/107999003322558809; Tatsumi R, 2000, BBA-GENE STRUCT EXPR, V1494, P263, DOI 10.1016/S0167-4781(00)00174-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang L, 2002, AM J HUM GENET, V71, P116, DOI 10.1086/341281; WILLIAMS BRG, 1978, EUR J BIOCHEM, V92, P455, DOI 10.1111/j.1432-1033.1978.tb12767.x; Yamamoto A, 1998, BBA-GENE STRUCT EXPR, V1395, P181, DOI 10.1016/S0167-4781(97)00148-6; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	48	60	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37832	37841		10.1074/jbc.M400089200	http://dx.doi.org/10.1074/jbc.M400089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231837	hybrid			2022-12-25	WOS:000223554600076
J	Buman, M; Djafarzadeh, S; Oberholzer, AE; Bigler, P; Altmann, M; Trachsel, H; Baumann, U				Buman, M; Djafarzadeh, S; Oberholzer, AE; Bigler, P; Altmann, M; Trachsel, H; Baumann, U			Crystal structure of yeast Ypr118w, a methylthioribose-1-phosphate isomerase related to regulatory eIF2B subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; INITIATION-FACTOR 2B; METHYLTHIOADENOSINE PHOSPHORYLASE; RIBOSE-5-PHOSPHATE ISOMERASE; ORNITHINE-DECARBOXYLASE; ATOMIC STRUCTURES; DELTA-SUBUNIT; FACTOR-II; PROTEIN; TRANSLATION	Ypr118w is a non-essential, low copy number gene product from Saccharomyces cerevisiae. It belongs to the PFAM family PF01008, which contains the alpha-, beta-, and delta-subunits of eukaryotic translation initiation factor eIF2B, as well as proteins of unknown function from all three kingdoms. Recently, one of those latter proteins from Bacillus subtilis has been characterized as a 5-methylthioribose-1-phosphate isomerase, an enzyme of the methionine salvage pathway. We report here the crystal structure of Ypr118w, which reveals a dimeric protein with two domains and a putative active site cleft. The C-terminal domain resembles ribose-5-phosphate isomerase from Escherichia coli with a similar location of the active site. In vivo, Ypr118w protein is required for yeast cells to grow on methylthioadenosine in the absence of methionine, showing that Ypr118w is involved in the methionine salvage pathway. The crystal structure of Ypr118w reveals for the first time the fold of a PF01008 member and allows a deeper discussion of an enzyme of the methionine salvage pathway, which has in the past attracted interest due to tumor suppression and as a target of aniprotozoal drugs.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch	Buman, Matthew/AAJ-4447-2020; Baumann, Ulrich/B-1220-2013	Buman, Matthew/0000-0002-5130-3162; 				Ashida H, 2003, SCIENCE, V302, P286, DOI 10.1126/science.1086997; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Avigad G, 1975, Methods Enzymol, V41, P27; Bussey H, 1997, NATURE, V387, P103, DOI 10.1038/387s103; Christopher SA, 2002, CANCER RES, V62, P6639; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; GROSS M, 1988, J BIOL CHEM, V263, P12486; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jacob U, 1997, STRUCTURE, V5, P415, DOI 10.1016/S0969-2126(97)00198-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P3726, DOI 10.1073/pnas.95.7.3726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nika J, 2000, J BIOL CHEM, V275, P26011, DOI 10.1074/jbc.M003718200; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PRICE NT, 1994, BBA-GENE STRUCT EXPR, V1217, P207, DOI 10.1016/0167-4781(94)90037-X; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Rangarajan ES, 2002, PROTEINS, V48, P737, DOI 10.1002/prot.10203; RISCOE MK, 1988, ANTIMICROB AGENTS CH, V32, P1904, DOI 10.1128/AAC.32.12.1904; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Subhi AL, 2003, J BIOL CHEM, V278, P49868, DOI 10.1074/jbc.M308451200; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Yang WM, 1996, MOL CELL BIOL, V16, P6603; Zhang RG, 2003, J MOL BIOL, V332, P1083, DOI 10.1016/j.jmb.2003.08.009; Zhang RG, 2003, STRUCTURE, V11, P31, DOI 10.1016/S0969-2126(02)00933-4	43	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37087	37094		10.1074/jbc.M404458200	http://dx.doi.org/10.1074/jbc.M404458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215245	hybrid			2022-12-25	WOS:000223453600112
J	Espada, J; Ballestar, E; Fraga, MF; Garea, AV; Juarranz, A; Stockert, JC; Robertson, KD; Fuks, FO; Esteller, M				Espada, J; Ballestar, E; Fraga, MF; Garea, AV; Juarranz, A; Stockert, JC; Robertson, KD; Fuks, FO; Esteller, M			Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; CPG ISLANDS; NUCLEAR ARCHITECTURE; LYSINE-9 METHYLATION; GENE; DEACETYLASE; REPEATS; DNMT1; HP1; HYPOMETHYLATION	DNA methyltransferase 1 (DNMT1) plays an essential role in murine development and is thought to be the enzyme primarily responsible for maintenance of the global methylation status of genomic DNA. However, loss of DNMT1 in human cancer cells affects only the methylation status of a limited number of pericentromeric sequences. Here we show that human cancer cells lacking DNMT1 display at least two important differences with respect to wild type cells: a profound disorganization of nuclear architecture, and an altered pattern of histone H3 modification that results in an increase in the acetylation and a decrease in the dimethylation and trimethylation of lysine 9. Additionally, this phenotype is associated with a loss of interaction of histone deacetylases (HDACs) and HP1 (heterochromatin protein 1) with histone H3 and pericentromeric repetitive sequences (satellite 2). Our data indicate that DNMT1 activity, via maintenance of the appropriate histone H3 modifications, contributes to the preservation of the correct organization of large heterochromatic regions.	Spanish Natl Canc Ctr CNIO, Epigenet Lab, Madrid 28029, Spain; Autonomous Univ Madrid, Fac Sci, Dept Biol, E-28049 Madrid, Spain; NCI, Epigenet Gene Regulat & Canc Sect, NIH, Bethesda, MD 20892 USA; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Espada, Jesús/AAA-3198-2019; Esteller, Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017; juarranz, angeles/L-2446-2013	Espada, Jesús/0000-0002-4202-4938; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; juarranz, angeles/0000-0002-6574-2887; Ballestar, Esteban/0000-0002-1400-2440; Robertson, Keith/0000-0002-7508-3328; Villar Garea, Ana/0000-0001-8960-1635				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; BALLESTAR E, 2003, NATURE ENCY HUMAN GE, V2, P114; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Brock GJR, 1997, HUM MOL GENET, V6, P451, DOI 10.1093/hmg/6.3.451; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Cross SH, 1997, GENOMICS, V40, P454, DOI 10.1006/geno.1996.4598; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434; Hernandez-Blazquez FJ, 2000, GUT, V47, P689, DOI 10.1136/gut.47.5.689; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; LYLE R, 1995, GENOMICS, V28, P389, DOI 10.1006/geno.1995.1166; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tariq M, 2003, P NATL ACAD SCI USA, V100, P8823, DOI 10.1073/pnas.1432939100; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; Trouche D, 2003, MOL CELL, V12, P281, DOI 10.1016/j.molcel.2003.08.015; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; VEILLEUX C, 1995, B CANCER, V82, P939; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; Woodcock DM, 1998, GENE, V206, P63, DOI 10.1016/S0378-1119(97)00566-0	52	147	159	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37175	37184		10.1074/jbc.M404842200	http://dx.doi.org/10.1074/jbc.M404842200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220328	Green Published, hybrid			2022-12-25	WOS:000223453600121
J	Stuchell, MD; Garrus, JE; Muller, B; Stray, KM; Ghaffarian, S; McKinnon, R; Krausslich, HG; Morham, SG; Sundquist, WI				Stuchell, MD; Garrus, JE; Muller, B; Stray, KM; Ghaffarian, S; McKinnon, R; Krausslich, HG; Morham, SG; Sundquist, WI			The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-PROTEIN INTERACTIONS; RECEPTOR DOWN-REGULATION; CELL-DERIVED EXOSOMES; TSG101 UEV DOMAIN; MAMMALIAN-CELLS; MULTIVESICULAR-BODY; PARTICLE RELEASE; COILED COILS; GAG PROTEIN	Efficient human immunodeficiency virus type 1 (HIV-1) budding requires an interaction between the PTAP late domain in the viral p6(Gag) protein and the cellular protein TSG101. In yeast, Vps23p/TSG101 binds both Vps28p and Vps37p to form the soluble ESCRT-I complex, which functions in sorting ubiquitylated protein cargoes into multivesicular bodies. Human cells also contain ESCRT-I, but the VPS37 component(s) have not been identified. Bioinformatics and yeast two-hybrid screening methods were therefore used to identify four novel human proteins (VPS37A-D) that share weak but significant sequence similarity with yeast Vps37p and to demonstrate that VPS37A and VPS37B bind TSG101. Detailed studies produced four lines of evidence that human VPS37B is a Vps37p ortholog. 1) TSG101 bound to several different sites on VPS37B, including a putative coiled-coil region and a PTAP motif. 2) TSG101 and VPS28 co-immunoprecipitated with VPS37B-FLAG, and the three proteins comigrated together in soluble complexes of the correct size for human ESCRT-I (similar to350 kDa). 3) Like TGS101, VPS37B became trapped on aberrant endosomal compartments in the presence of VPS4A proteins lacking ATPase activity. 4) Finally, VPS37B could recruit TSG101/ESCRT-I activity and thereby rescue the budding of both mutant Gag particles and HIV-1 viruses lacking native late domains. Further studies of ESCRT-I revealed that TSG101 mutations that inhibited PTAP or VPS28 binding blocked HIV-1 budding. Taken together, these experiments define new components of the human ESCRT-I complex and characterize several TSG101 protein/protein interactions required for HIV-1 budding and infectivity.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Klinikum Heidelberg, Abt Virol, D-69120 Heidelberg, Germany; Myriad Genet Inc, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Myriad Genetics, Inc	Sundquist, WI (corresponding author), Univ Utah, Sch Med, Dept Biochem, 20 N 1900 E, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu	Muller, Barbara/AAC-4483-2020	Muller, Barbara/0000-0001-5726-5585	NIAID NIH HHS [R01 AI51174] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051174] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BEGLEY D, 1995, MOL GEN GENET, V248, P69, DOI 10.1007/BF02456615; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Carter CA, 2002, TRENDS MICROBIOL, V10, P203, DOI 10.1016/S0966-842X(02)02350-8; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Denzer K, 2000, J CELL SCI, V113, P3365; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feng GH, 2000, CANCER RES, V60, P1736; FinkenEigen M, 1997, CURR GENET, V31, P469, DOI 10.1007/s002940050232; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gottwein E, 2003, J VIROL, V77, P9474, DOI 10.1128/JVI.77.17.9474-9485.2003; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martin-Serrano J, 2004, J VIROL, V78, P5554, DOI 10.1128/JVI.78.11.5554-5563.2004; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; MORITA E, 2004, IN PRESS ANN REV CEL; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Perez M, 2003, P NATL ACAD SCI USA, V100, P12978, DOI 10.1073/pnas.2133782100; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Strecker T, 2003, J VIROL, V77, P10700, DOI 10.1128/JVI.77.19.10700-10705.2003; Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xu ZH, 2003, BIOCHEM BIOPH RES CO, V311, P1057, DOI 10.1016/j.bbrc.2003.10.109; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	74	124	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36059	36071		10.1074/jbc.M405226200	http://dx.doi.org/10.1074/jbc.M405226200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15218037	hybrid			2022-12-25	WOS:000223303400108
J	Dougherty, CJ; Kubasiak, LA; Frazier, DP; Li, HF; Xiong, WC; Bishopric, NH; Webster, KA				Dougherty, CJ; Kubasiak, LA; Frazier, DP; Li, HF; Xiong, WC; Bishopric, NH; Webster, KA			Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation	FASEB JOURNAL			English	Article						cardiac myocyte; mitochondria; Pyk2; calcium; Rac-1; ROI; apoptosis	PROTEIN-KINASE; CARDIAC MYOCYTES; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; REGULATED KINASES; REDOX-REGULATION; TYROSINE KINASE; MAP KINASES; APOPTOSIS; DEATH	C-Jun N-terminal kinase (JNK) is part of the mitogen-activated protein kinase ( MAPK) family of signaling pathways that are induced in response to extracellular stimuli. JNK is primarily a stress-response pathway and can be activated by proinflammatory cytokines and growth factors coupled to membrane receptors or through non-receptor pathways by stimuli such as heat shock, UV irradiation, protein synthesis inhibitors, and conditions that elevate the levels of reactive oxygen intermediates (ROI). The molecular initiators of MAPKs by non-receptor stimuli have not been described. Ischemia followed by reperfusion or hypoxia with reoxygenation represents a condition of high oxidative stress where JNK activation is associated with elevated ROI. We show here that the activation of JNK by this condition is initiated in the mitochondria and requires coupled electron transport, ROI generation, and calcium flux. These signals cause the selective, sequential activation of the calcium-dependent, pro-line-rich kinase Pyk2 and the small GTP binding factors Rac-1 and Cdc42. Interruption of these interactions with inactivated dominant negative mutant proteins, blocking calcium flux, or inhibiting electron transport through mitochondrial complexes II, III, or IV prevents JNK activation and results in a proapoptotic phenotype that is characteristic of JNK inhibition in this model of ischemia-reperfusion. The signaling pathway is unique for the reoxygenation stimulus and provides a framework for other non-receptor-mediated pathways of MAPK activation.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Vasc Biol Inst, Miami, FL 33136 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Miami; University of Miami; University of Alabama System; University of Alabama Birmingham	Webster, KA (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,RMSB 6038, Miami, FL 33136 USA.	kwebster@chroma.med.miami.edu		Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R21HL069812, R29HL044578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69812, HL44578, HL07109] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bogoyevitch MA, 2000, J MOL CELL CARDIOL, V32, P1469, DOI 10.1006/jmcc.2000.1187; Caldefie-Chezet F, 2002, CLIN CHIM ACTA, V319, P9, DOI 10.1016/S0009-8981(02)00015-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Cook SA, 1999, J MOL CELL CARDIOL, V31, P1429, DOI 10.1006/jmcc.1999.0979; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CZAJA MJ, 2003, AM J PHYSIOL, V184, pG875; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; Delcamp TJ, 1998, AM J PHYSIOL-HEART C, V275, pH484, DOI 10.1152/ajpheart.1998.275.2.H484; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Floreani M, 2000, BIOCHEM PHARMACOL, V60, P601, DOI 10.1016/S0006-2952(00)00350-6; Gottlieb RA, 2003, ARCH BIOCHEM BIOPHYS, V420, P262, DOI 10.1016/j.abb.2003.07.004; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Inanami O, 1999, ANTIOXID REDOX SIGN, V1, P501, DOI 10.1089/ars.1999.1.4-501; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kam AYF, 2003, J NEUROCHEM, V84, P503, DOI 10.1046/j.1471-4159.2003.01535.x; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lukyanetz EA, 2003, ARCH BIOCHEM BIOPHYS, V410, P212, DOI 10.1016/S0003-9861(02)00682-3; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; Shao ZH, 2002, AM J PHYSIOL-HEART C, V282, pH999, DOI 10.1152/ajpheart.00163.2001; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V281, pH2113, DOI 10.1152/ajpheart.2001.281.5.H2113; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Slepak TI, 2001, J BIOL CHEM, V276, P7575, DOI 10.1074/jbc.M004625200; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; Tahara S, 2001, J AM COLL CARDIOL, V38, P1554, DOI 10.1016/S0735-1097(01)01558-3; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1; Webster KA, 1999, J CLIN INVEST, V104, P239; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1979, J BIOENERG BIOMEMBR, V10, P23; WEBSTER KA, 1993, J MOL CELL CARDIOL, V25, P747, DOI 10.1006/jmcc.1993.1087; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	66	83	97	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1060	1070		10.1096/fj.04-1505com	http://dx.doi.org/10.1096/fj.04-1505com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15226266				2022-12-25	WOS:000222979200033
J	Quaranta, MG; Mattioli, B; Giordani, L; Viora, M				Quaranta, MG; Mattioli, B; Giordani, L; Viora, M			HIV-1 Nef equips dendritic cells to reduce survival and function of CD8(+) T cells: a mechanism of immune evasion	FASEB JOURNAL			English	Article						Fas ligand; tumor necrosis factor; AIDS	VIRUS TYPE-1 NEF; FAS LIGAND; DOWN-REGULATION; UP-REGULATION; DC-SIGN; CLASS-I; SIGNALING PATHWAY; INFECTED-CELLS; APOPTOSIS; PROTEIN	The accessory HIV-1 Nef protein is a crucial determinant for viral replication and pathogenesis. During HIV infection, loss of immune control in the setting of a strong and broad HIV-specific T-lymphocyte response, leads to a lethal outcome through AIDS. Moreover, dysfunction of dendritic cells (DCs) may contribute to the immune suppression associated with AIDS progression. We recently demonstrated that exogenous Nef selectively activates immature DCs manipulating their phenotypical, morphological, and functional developmental program. Here, we tracked whether Nef, targeting DCs, could be involved in the dysregulation of CD8(+) T cell responses. We found that Nef inhibits the capacity of DCs to prime alloreactive CD8(+) T cell responses down-regulating their proliferation and functional competence. This coincides with the induction of CD8(+) T cell apoptosis. Nef oversees apoptotic killing of CD8(+) T cells up-regulating TNF-alpha and FasL production by DCs and interfering with the death receptor pathway in CD8(+) T cells and thus activating caspase 8. Our findings suggest that Nef may contribute to the immune evasion associated with HIV-1 infection, subverting DC biology. This may help explain the pleiotropic function that Nef plays during infection and makes this protein an attractive target for preventive and therapeutic intervention.	Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it		Quaranta, Maria Giovanna/0000-0002-1077-1488				Accapezzato D, 2003, ANN NY ACAD SCI, V987, P99, DOI 10.1111/j.1749-6632.2003.tb06037.x; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Andrieu M, 2001, AIDS RES HUM RETROV, V17, P1365, DOI 10.1089/08892220152596623; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Boirivant M, 1998, J CLIN IMMUNOL, V18, P39, DOI 10.1023/A:1023235803948; BROWN CC, 1994, J INFECT DIS, V169, P975, DOI 10.1093/infdis/169.5.975; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Conti L, 2000, J IMMUNOL, V165, P3293, DOI 10.4049/jimmunol.165.6.3293; Cramer LA, 2001, J ACQ IMMUN DEF SYND, V27, P417; Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; James CO, 2004, J VIROL, V78, P3099, DOI 10.1128/JVI.78.6.3099-3109.2004; Kaiser A, 2003, EUR J IMMUNOL, V33, P162, DOI 10.1002/immu.200390019; KALINKOVICH A, 1992, CLIN EXP IMMUNOL, V89, P351; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; LEWIS DE, 1994, J IMMUNOL, V153, P412; Lichtner M, 2004, AIDS RES HUM RETROV, V20, P175, DOI 10.1089/088922204773004897; Lieberman J, 2002, CURR OPIN IMMUNOL, V14, P478, DOI 10.1016/S0952-7915(02)00366-7; Lu GW, 2002, J IMMUNOL, V168, P1831, DOI 10.4049/jimmunol.168.4.1831; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Mosier DE, 2000, IMMUNOL RES, V21, P253, DOI 10.1385/IR:21:2-3:253; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; Raftery MJ, 2001, IMMUNITY, V15, P997, DOI 10.1016/S1074-7613(01)00239-4; Rasola A, 2001, J IMMUNOL, V166, P81, DOI 10.4049/jimmunol.166.1.81; Ross TM, 2001, LEUKEMIA, V15, P332, DOI 10.1038/sj.leu.2402028; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Suzuki S, 2000, MICROBIOL IMMUNOL, V44, P111, DOI 10.1111/j.1348-0421.2000.tb01254.x; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Teleshova N, 2003, J LEUKOCYTE BIOL, V74, P683, DOI 10.1189/jlb.0403178; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vidalain PO, 2001, IMMUNOBIOLOGY, V204, P629, DOI 10.1078/0171-2985-00102; VIORA M, 1995, CELL IMMUNOL, V163, P289, DOI 10.1006/cimm.1995.1128; VITOLO D, 1993, J IMMUNOL, V151, P1926; Vujanovic NL, 1996, J IMMUNOL, V157, P1117; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Yoon K, 2001, AIDS RES HUM RETROV, V17, P99, DOI 10.1089/08892220150217184	70	30	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1459	+		10.1096/fj.04-1633fje	http://dx.doi.org/10.1096/fj.04-1633fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240562				2022-12-25	WOS:000222979200018
J	Chen, HH; Luche, R; Wei, B; Tonks, NK				Chen, HH; Luche, R; Wei, B; Tonks, NK			Characterization of two distinct dual specificity phosphatases encoded in alternative open reading frames of a single gene located on human chromosome 10q22.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-REGULATED KINASE-2; MAP KINASE; TUMOR-SUPPRESSOR; ACTIVATION LOOP; VACCINIA VIRUS; IN-VIVO; PHOSPHORYLATION; PATHWAY; VHR	Dual specificity phosphatases (DSPs) are members of the protein-tyrosine phosphatase superfamily that dephosphorylate both phosphotyrosine and phosphoserine/threonine residues in vitro. Many DSPs have been found to play important roles in various aspects of cellular function and to be involved in human disease. We have identified a gene located on human chromosome 10q22.2, which utilizes alternative open reading frames (ORFs) to encode the following two distinct DSPs: the previously described (t) under bar estis and skeletal (m) under bar uscle-specific (d) under bar ual specificity (p) under bar hosphatase ( TMDP) and a novel DSP, (m) under bar uscle-restricted (d) under bar ual (s) under bar pecificity (p) under bar hosphatase (MDSP). Use of alternative ORFs encoding distinct proteins from a single gene is extremely rare in eukaryotes, and in all previously reported cases the two proteins produced from one gene are unrelated. To our knowledge this is the first example of a gene from which two distinct proteins of the same family are expressed using alternative ORFs. Here we provide evidence that both MDSP and TMDP proteins are expressed in vivo and are restricted to specific tissues, skeletal muscle and testis, respectively. Most interestingly, the protein expression profiles of both MDSP and TMDP during mouse postnatal development are strikingly similar. MDSP is expressed at very low levels in myotubes and early postnatal muscle. TMDP is not detectable in testis lysate in the first 3 weeks of life. The expression of both MDSP and TMDP proteins was markedly increased at approximately the 3rd week after birth and continued to increase gradually into adulthood, implying that the physiological functions of both DSPs are specific to the mature/late-developing organs. The conserved gene structure and the similarity in postnatal expression profile of these two proteins suggest biological significance of the unusual gene arrangement.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Prog Mol & Cell Biol, Stony Brook, NY 11794 USA; Ceptyr Inc, Bothell, WA 98021 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.edu		Wei, Bo/0000-0002-9688-5442	NATIONAL CANCER INSTITUTE [R37CA053840, P30CA045508, R01CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840, CA45508] Funding Source: Medline; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Bai L, 2004, CELL DEATH DIFFER, V11, P663, DOI 10.1038/sj.cdd.4401393; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; David A, 2002, J BIOL CHEM, V277, P18084, DOI 10.1074/jbc.M102285200; Delp MD, 1996, J APPL PHYSIOL, V80, P261, DOI 10.1152/jappl.1996.80.1.261; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Eckstein JW, 2000, INVEST NEW DRUG, V18, P149, DOI 10.1023/A:1006377913494; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; Gilley J, 2001, ONCOGENE, V20, P7447, DOI 10.1038/sj.onc.1204933; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Leder S, 2003, BIOCHEM J, V372, P881, DOI 10.1042/BJ20030182; LIU K, 1995, J VIROL, V69, P7823, DOI 10.1128/JVI.69.12.7823-7834.1995; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Martell KJ, 1998, MOL CELLS, V8, P2; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; MOSSMAN K, 1995, VIROLOGY, V206, P572, DOI 10.1016/S0042-6822(95)80074-3; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura K, 1999, BIOCHEM J, V344, P819, DOI 10.1042/0264-6021:3440819; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; QUELLE DE, 1995, CELL, V83, P993; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Theodosiou A, 2002, GENOME BIOL, V3; Todd JL, 2002, ONCOGENE, V21, P2573, DOI 10.1038/sj.onc.1205344; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Wiechmann S, 2003, BIOCHEM BIOPH RES CO, V302, P403, DOI 10.1016/S0006-291X(03)00148-7; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Yao Zhong, 2004, Current Genomics, V5, P385, DOI 10.2174/1389202043349309; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	55	26	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41404	41413		10.1074/jbc.M405286200	http://dx.doi.org/10.1074/jbc.M405286200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15252030	hybrid			2022-12-25	WOS:000224075500022
J	Szentpetery, Z; Kern, A; Liliom, K; Sarkadi, B; Varadi, A				Szentpetery, Z; Kern, A; Liliom, K; Sarkadi, B; Varadi, A			The role of the conserved glycines of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; HUMAN P-GLYCOPROTEIN; MYOSIN MOTOR DOMAIN; PHOTOAFFINITY ANALOG; CYSTIC-FIBROSIS; TRANSPORTER; NUCLEOTIDE; GLUTATHIONE; MRP1/ABCC1; MDR1	A key element of the structural model of ABC-ATPases is the interaction of the two ABC domains. They complement each other's active sites in a way that the ABC signature motif (LSGGQ) of one subunit interacts with the gamma-phosphate of the ATP, bound at the Walker motifs of the opposite subunit. In the present study, the conserved glycines in the fourth position of the LSGGQ motifs of human MRP1 were substituted for aspartic acids (G771D and G1433D), the mutants were expressed in Sf9 insect cells, and the nucleotide- as well as the transported substrate-protein interactions were studied. We found that these transport- and ATPase-incompetent mutants showed no nucleotide trapping under any of the conditions examined. However, when measuring the effect of nucleotide and transported substrates on the vanadate-induced cleavage reactions, we found that the effect of substrates on the cleavage reactions was significantly different in the mutant MRP1 proteins than in the wild type. Although the transported substrates (e.g. etoposide + oxidized glutathione) stimulated the formation of the posthydrolytic complex in the wild type, this reaction was inhibited in the signature mutants. Our study also revealed that a similar mutation in the ABC signature of either ABC unit resulted in the same effect. We suggest that the conserved glycine residues in both LSGGQ segments are part of the conformational network, which is responsible for the accelerated hydrolytic activity upon interaction of the protein with its transported substrates. This intramolecular communication between the substrate-binding site and the catalytic centers is assumed to be a general feature of the molecular mechanism of ABC transporters.	Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Membrane Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences	Varadi, A (corresponding author), Hungarian Acad Sci, Inst Enzymol, 29 Karolina Ut, H-1113 Budapest, Hungary.	varadi@enzim.hu	Sarkadi, Balazs/I-5024-2013; Liliom, Karoly/A-6563-2011; Varadi, Andras/A-2055-2012; Kern, Andras/F-2823-2014	Liliom, Karoly/0000-0002-7177-6872; 				Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FLENS MJ, 1994, CANCER RES, V54, P4557; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kern A, 2004, BIOCHEM J, V380, P549, DOI 10.1042/BJ20031607; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Ren XQ, 2004, MOL PHARMACOL, V65, P1536, DOI 10.1124/mol.65.6.1536; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; SARKADI B, 1992, J BIOL CHEM, V267, P1; Sharom FJ., 2003, ABC PROTEINS BACTERI, P107; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; Szentpetery Z, 2004, ANTICANCER RES, V24, P449; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579	32	29	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41670	41678		10.1074/jbc.M406484200	http://dx.doi.org/10.1074/jbc.M406484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15252017	hybrid			2022-12-25	WOS:000224075500054
J	Nozell, S; Ma, ZD; Wilson, C; Shah, R; Benveniste, EN				Nozell, S; Ma, ZD; Wilson, C; Shah, R; Benveniste, EN			Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; CREB-BINDING-PROTEIN; CBP-INDUCED STIMULATION; MATRIX METALLOPROTEINASES; IFN-GAMMA; CELL-DEATH; IL-4 GENE; TRANSCRIPTION; ACTIVATION; SUPPRESSION	Matrix metalloproteinases ( MMPs) are a family of structurally related proteins with the collective capability to degrade all components of the extracellular matrix. Although MMP-mediated degradation of the extracellular matrix occurs physiologically, numerous pathological conditions exhibit increased MMP levels and excessive matrix degradation. Previous work from our laboratory has shown that interferon-gamma inhibits MMP-9 expression in a manner dependent upon STAT-1alpha. Here we extend our previous observations and show that the class II major histocompatibility complex transactivator (CIITA), a transcriptional target of STAT-1alpha, is also capable of inhibiting MMP-9 expression. By using stable cell lines that inducibly express CIITA or various mutant forms of CIITA, we show that CIITA requires the ability to bind the CREB-binding protein (CBP) to effectively inhibit MMP-9 expression. Furthermore, we show that CIITA-mediated inhibition of the MMP-9 gene does not rely on the transcriptional capability of CIITA. These findings support a model wherein CIITA inhibits MMP-9 expression by binding to and sequestering CBP, which reduces the levels of CBP at the MMP-9 promoter, inhibits levels of acetylated histone 3 at the MMP-9 promoter, and subsequently inhibits MMP-9 expression.	Univ Alabama, Dept Cell Biol, Off Chair, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, Off Chair, 1530 3rd Ave S,MCLM 395, Birmingham, AL 35294 USA.	tika@uab.edu			NCI NIH HHS [CA-97247] Funding Source: Medline; NIAID NIH HHS [T32 AI-07493] Funding Source: Medline; NINDS NIH HHS [NS-36765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BODE J, 1980, EUR J BIOCHEM, V110, P143, DOI 10.1111/j.1432-1033.1980.tb04849.x; CHAHAL SS, 1980, NATURE, V287, P76, DOI 10.1038/287076a0; Chan HM, 2001, J CELL SCI, V114, P2363; Chin KC, 1997, J IMMUNOL, V159, P2789; Dong YS, 1999, J IMMUNOL, V162, P4731; Dong YS, 2001, J IMMUNOL, V167, P311, DOI 10.4049/jimmunol.167.1.311; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Goodman RH, 2000, GENE DEV, V14, P1553; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Itoh-Lindstrom Y, 1999, J IMMUNOL, V163, P2425; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lee YJ, 1996, J IMMUNOL, V157, P1559; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; LENGYEL E, 1995, CANCER RES, V55, P963; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Mori-Aoki A, 2000, BIOCHEM BIOPH RES CO, V278, P58, DOI 10.1006/bbrc.2000.3769; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rohn WM, 1996, CRIT REV IMMUNOL, V16, P311, DOI 10.1615/CritRevImmunol.v16.i3.40; SATO H, 1993, ONCOGENE, V8, P395; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Yee CSK, 2004, J IMMUNOL, V172, P5528, DOI 10.4049/jimmunol.172.9.5528; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	43	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38577	38589		10.1074/jbc.M403738200	http://dx.doi.org/10.1074/jbc.M403738200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247301	hybrid			2022-12-25	WOS:000223684100064
J	Roche, FM; Downer, R; Keane, F; Speziale, P; Park, PW; Foster, TJ				Roche, FM; Downer, R; Keane, F; Speziale, P; Park, PW; Foster, TJ			The N-terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; COLLAGEN ADHESIN; SEPTIC ARTHRITIS; FIBRINOGEN; ADHERENCE; SURFACE; EXPRESSION; MSCRAMM	The ability of Staphylococcus aureus to adhere to components of the extracellular matrix is an important mechanism for colonization of host tissues during infection. We have previously shown that S. aureus binds elastin, a major component of the extracellular matrix. The integral membrane protein, elastin-binding protein (EbpS), binds soluble elastin peptides and tropoelastin via its surface-exposed N-terminal domain. In this study, we demonstrate that some strains of S. aureus adhere strongly to immobilized human elastin and that this interaction is independent of EbpS but instead is mediated by the fibronectin-binding proteins, FnBPA and FnBPB. Our results show that EbpS mutant cells adhere to elastin-coated plates, whereas the cells negative for FnBPA and FnBPB do not adhere to the plates. Furthermore, only wild-type cells from the exponential phase of growth adhered when FnBPs were expressed maximally. We show that adherence to elastin promoted by FnBPA was not affected by soluble fibronectin, suggesting that the elastin binding domain is distinct from the fibronectin binding regions. Recombinant FnBPA(37-544) (rFnBPA(37-544)) protein corresponding to the A region of FnBPA and anti-FnBPA(37-544) antibodies inhibited FnBPA-mediated bacterial adherence to immobilized elastin. Finally, recombinant A domain proteins, rFnBPA(37-544) and rFnBPB(37-540), bound immobilized elastin dose-dependently and saturably. This interaction was inhibited by soluble elastin peptides, suggesting a specific receptor-ligand interaction.	Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Trinity College Dublin; University of Pavia; Baylor College of Medicine	Foster, TJ (corresponding author), Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	tfoster@tcd.ie		Park, Pyong Woo/0000-0002-7979-4979				Bisognano C, 1997, ANTIMICROB AGENTS CH, V41, P906, DOI 10.1128/AAC.41.5.906; COX BA, 1974, J BIOL CHEM, V249, P997; DEBELLE L, 1992, EUR BIOPHYS J BIOPHY, V21, P321, DOI 10.1007/BF00188344; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; Downer R, 2002, J BIOL CHEM, V277, P243, DOI 10.1074/jbc.M107621200; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Elasri MO, 2002, BONE, V30, P275, DOI 10.1016/S8756-3282(01)00632-9; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; GREENE C, 1995, MOL MICROBIOL, V17, P1143, DOI 10.1111/j.1365-2958.1995.mmi_17061143.x; Hartford O, 1999, MICROBIOL-SGM, V145, P2497, DOI 10.1099/00221287-145-9-2497; Hartleib J, 2000, BLOOD, V96, P2149; HEINZ SA, 1996, J INFECT DIS, V174, P83; Hinek A, 1999, ACTA NEUROPATHOL, V97, P399, DOI 10.1007/s004010051004; INDIK Z, 1989, AM J MED GENET, V34, P81, DOI 10.1002/ajmg.1320340115; ING MB, 1997, STAPHYLOOCCI HUMAN D; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; Josefsson E, 2001, J INFECT DIS, V184, P1572, DOI 10.1086/324430; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KREISWIRTH BN, 1983, NATURE, V305, P680; KUYPERS JM, 1989, INFECT IMMUN, V57, P2306, DOI 10.1128/IAI.57.8.2306-2312.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; Mongodin E, 2002, INFECT IMMUN, V70, P620; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; O'Brien LM, 2002, CELL MICROBIOL, V4, P759, DOI 10.1046/j.1462-5822.2002.00231.x; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OWEN P, 1985, ENTEROBACTERIAL SURF; OZ MC, 1989, J VASC SURG, V10, P439; PARK PW, 1991, J BIOL CHEM, V266, P23399; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Pohlmann-Dietze P, 2000, INFECT IMMUN, V68, P4865, DOI 10.1128/IAI.68.9.4865-4871.2000; Que YA, 2001, INFECT IMMUN, V69, P6296, DOI 10.1128/IAI.69.10.6296-6302.2001; ROSENBLOOM J, 1982, CONNECT TISSUE RES, V10, P73, DOI 10.3109/03008208209034408; SABATH LD, 1974, ANN NY ACAD SCI, V236, P435, DOI 10.1111/j.1749-6632.1974.tb41508.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SaraviaOtten P, 1997, J BACTERIOL, V179, P5259, DOI 10.1128/jb.179.17.5259-5263.1997; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Vaudaux PE, 1998, ANTIMICROB AGENTS CH, V42, P564, DOI 10.1128/AAC.42.3.564; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Wolz C, 2000, MOL MICROBIOL, V36, P230, DOI 10.1046/j.1365-2958.2000.01853.x	54	102	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38433	38440		10.1074/jbc.M402122200	http://dx.doi.org/10.1074/jbc.M402122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234962	Green Published, hybrid			2022-12-25	WOS:000223684100046
J	Adachi, N; So, SR; Koyama, H				Adachi, N; So, SR; Koyama, H			Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells - Implications for the repair of topoisomerase I-mediated DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; LIGASE-IV; V(D)J RECOMBINATION; COVALENT COMPLEXES; REPLICATION FORKS; DEFICIENT CELLS; HYPERSENSITIVITY; PATHWAYS	DNA topoisomerase I (Top1) generates transient DNA single-strand breaks via the formation of cleavage complexes in which the enzyme is linked to the 3'-phosphate of the cleavage strand. The anticancer drug camptothecin (CPT) poisons Top1 by trapping cleavage complexes, thereby inducing Top1-linked single-strand breaks. Such DNA lesions are converted into DNA double-strand breaks (DSBs) upon collision with replication forks, implying that DSB repair pathways could be involved in the processing/repair of Top1-mediated DNA damage. Here we report that Top1-mediated DNA damage is repaired primarily by homologous recombination, a major pathway of DSB repair. Unexpectedly, however, we found that nonhomologous end joining (NHEJ), another DSB repair pathway, has no positive role in the relevant repair; notably, DT40 cell mutants lacking either of the NHEJ factors ( namely, Ku70, DNA-dependent protein kinase catalytic subunit, and DNA ligase IV) were resistant to killing by CPT. In addition, we showed that the absence of NHEJ alleviates the requirement of homologous recombination in the repair of CPT-induced DNA damage. Our results indicate that NHEJ can be a cytotoxic pathway in the presence of CPT, shedding new light on the molecular mechanisms for the formation and repair of Top1-mediated DNA damage in vertebrates. Thus, our data have significant implications for cancer chemotherapy involving Top1 inhibitors.	Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Adachi, N (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	nadachi@yokohama-cu.ac.jp						Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Barrows LR, 1998, MUTAT RES-DNA REPAIR, V408, P103, DOI 10.1016/S0921-8777(98)00022-6; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hajji N, 2003, MUTAT RES-FUND MOL M, V530, P35, DOI 10.1016/S0027-5107(03)00135-0; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Hinz JM, 2003, CARCINOGENESIS, V24, P249, DOI 10.1093/carcin/24.2.249; HSIANG YH, 1989, CANCER RES, V49, P5077; Huang KC, 2001, J BIOL CHEM, V276, P44488, DOI 10.1074/jbc.M104383200; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KIJIMA T, 1994, ANTICANCER RES, V14, P799; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Morham SG, 1996, MOL CELL BIOL, V16, P6804; MULLER MT, 1988, MOL CELL BIOL, V8, P3661, DOI 10.1128/MCB.8.9.3661; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Sabourin M, 2003, NUCLEIC ACIDS RES, V31, P4373, DOI 10.1093/nar/gkg497; Sado K, 2001, J BIOL CHEM, V276, P9742, DOI 10.1074/jbc.M010530200; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SORENSON M, 1995, BRIT J CANCER, V73, P399; Subramanian D, 2000, METH MOL B, V95, P137; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TRUMBERG D, 2000, MOL CELL BIOL, V20, P3977; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	50	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37343	37348		10.1074/jbc.M313910200	http://dx.doi.org/10.1074/jbc.M313910200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15218034	hybrid			2022-12-25	WOS:000223554600020
J	Miller, WL; Wenzel, CQ; Daniels, C; Larocque, S; Brisson, JR; Lam, JS				Miller, WL; Wenzel, CQ; Daniels, C; Larocque, S; Brisson, JR; Lam, JS			Biochemical characterization of WbpA, a UDP-N-acetyl-D-glucosamine 6-dehydrogenase involved in O-antigen biosynthesis in Pseudomonas aeruginosa PAO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE DEHYDROGENASE; ESCHERICHIA-COLI; ACETYLENOLPYRUVYLGLUCOSAMINE REDUCTASE; SUBUNIT STRUCTURE; CRYSTAL-STRUCTURE; ACTIVE-SITE; LIPOPOLYSACCHARIDE; PROTEIN; MECHANISM; PATHOGENESIS	WbpA (PA3159) is an enzyme involved in the biosynthesis of unusual di-N-acetyl-D-mannosaminuronic acid-derived sugar nucleotides found in the O antigen of Pseudomonas aeruginosa PAO1 ( serotype O5). The wbpA gene that encodes this enzyme was cloned into pET-28a, overexpressed as a histidine-tagged fusion protein, and purified by nickel chelation chromatography. Capillary electrophoresis was used to examine substrate conversion by WbpA, and the data revealed that WbpA is a UDP-N-acetyl-D-glucosamine 6-dehydrogenase (EC 1.1.1.136), which uses NAD(+) as a coenzyme. The enzyme reaction product was purified by HPLC and analyzed using NMR spectroscopy. Our results showed unequivocally that the product of the WbpA reaction is UDP-N-acetyl-D-glucosaminuronic acid. WbpA requires either NH4+ or K+ for activity and the accompanying anions exert secondary effects on activity consistent with their ranking in the Hofmeister series. Kinetic analysis showed positive cooperativity with respect to UDP-N-acetyl-D-glucosamine binding with a K-0.5 of 94 muM, a k(cat) of 86 min(-1), and a Hill coefficient of 1.8. In addition, WbpA has a K-0.5 for NAD(+) of 220 muM, a k(cat) of 86 min(-1), and a Hill coefficient of 1.1. The oligomerization state of WbpA was analyzed by gel filtration, dynamic light scattering, and analytical ultracentrifugation, with all three techniques indicating that WbpA exists as a trimer in solution. However, tertiary structure predictions suggested a tetramer, which was supported by data from transmission electron microscopy. The electron micrograph of negatively stained WbpA samples revealed structures with 4-fold symmetry.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca						Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Burrows LL, 2000, FEMS MICROBIOL LETT, V189, P135, DOI 10.1111/j.1574-6968.2000.tb09219.x; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; Campbell RE, 1997, J BIOL CHEM, V272, P3416, DOI 10.1074/jbc.272.6.3416; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2001, MOL MICROBIOL, V41, P1295, DOI 10.1046/j.1365-2958.2001.02589.x; CRYZ SJ, 1984, INFECT IMMUN, V44, P508, DOI 10.1128/IAI.44.2.508-513.1984; DASGUPTA T, 1994, INFECT IMMUN, V62, P809, DOI 10.1128/IAI.62.3.809-817.1994; DHALLA AM, 1995, BIOCHEMISTRY-US, V34, P5390, DOI 10.1021/bi00016a010; ENGELS W, 1985, INFECT IMMUN, V49, P182, DOI 10.1128/IAI.49.1.182-189.1985; FAN DF, 1969, ARCH BIOCHEM BIOPHYS, V135, P45, DOI 10.1016/0003-9861(69)90514-1; FOE LG, 1980, ARCH BIOCHEM BIOPHYS, V199, P1, DOI 10.1016/0003-9861(80)90248-9; GAINEY PA, 1972, BIOCHEM J, V129, P821, DOI 10.1042/bj1290821; Ge X, 2004, EUR J BIOCHEM, V271, P14, DOI 10.1046/j.1432-1033.2003.03876.x; Ge X, 1998, J AM CHEM SOC, V120, P6613, DOI 10.1021/ja9805977; Goldberg JB, 1996, TRENDS MICROBIOL, V4, P490, DOI 10.1016/S0966-842X(97)82911-3; HALL DL, 1995, J BIOL CHEM, V270, P22697, DOI 10.1074/jbc.270.39.22697; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P331; KAWAMURA T, 1985, J BIOCHEM-TOKYO, V98, P105, DOI 10.1093/oxfordjournals.jbchem.a135248; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kiser KB, 1999, J BACTERIOL, V181, P4818, DOI 10.1128/JB.181.16.4818-4824.1999; Kneidinger B, 2003, BIOCHEM J, V371, P989, DOI 10.1042/BJ20030099; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; Lackner P, 2000, PROTEIN ENG, V13, P745, DOI 10.1093/protein/13.11.745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM JS, 1987, J BACTERIOL, V169, P3531, DOI 10.1128/jb.169.8.3531-3538.1987; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; Naught LE, 2002, BIOCHEMISTRY-US, V41, P9637, DOI 10.1021/bi025862m; Portoles M, 2001, INFECT IMMUN, V69, P917, DOI 10.1128/IAI.69.2.917-923.2001; Preston A, 1999, INFECT IMMUN, V67, P3763, DOI 10.1128/IAI.67.8.3763-3767.1999; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHILLER JG, 1976, BIOCHIM BIOPHYS ACTA, V453, P418, DOI 10.1016/0005-2795(76)90137-9; SCHILLER NL, 1983, DIAGN MICR INFEC DIS, V1, P145, DOI 10.1016/0732-8893(83)90044-5; Snook CF, 2003, BIOCHEMISTRY-US, V42, P4658, DOI 10.1021/bi027328k; Stein AJ, 2002, J BIOL CHEM, V277, P9484, DOI 10.1074/jbc.M109371200; Sylvester DR, 2001, BIOCHEM J, V355, P431, DOI 10.1042/0264-6021:3550431; Tang HB, 1996, INFECT IMMUN, V64, P37, DOI 10.1128/IAI.64.1.37-43.1996; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhao X, 2000, J BIOL CHEM, V275, P39802	47	33	36	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37551	37558		10.1074/jbc.M404749200	http://dx.doi.org/10.1074/jbc.M404749200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226302	hybrid			2022-12-25	WOS:000223554600046
J	Mizuno, K; Hayashi, T; Peyton, DH; Bachinger, HP				Mizuno, K; Hayashi, T; Peyton, DH; Bachinger, HP			Hydroxylation-induced stabilization of the collagen triple helix - Acetyl-(glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)(10)-NH2 forms a highly stable triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MODEL PEPTIDES; CONFORMATIONAL STABILITY; PROLYL 4-HYDROXYLASES; MOLECULAR-STRUCTURE; XAA POSITION; HYDROXYPROLINE; SEQUENCE; RESOLUTION; PROTEINS	The collagen triple helix is one of the most abundant protein motifs in animals. The structural motif of collagen is the triple helix formed by the repeated sequence of -Gly-Xaa-Yaa-. Previous reports showed that H-(Pro-4( R) Hyp-Gly)(10)-OH ( where '4( R) Hyp' is (2S, 4R)-4-hydroxyproline) forms a trimeric structure, whereas H-(4(R) Hyp-Pro-Gly)(10)-OH does not form a triple helix. Compared with H-(Pro-Pro-Gly)(10)-OH, the melting temperature of H-(Pro-4(R) Hyp-Gly)(10)-OH is higher, suggesting that 4( R) Hyp in the Yaa position has a stabilizing effect. The inability of triple helix formation of H-(4( R) Hyp-Pro- Gly)(10)-OH has been explained by a stereoelectronic effect, but the details are unknown. In this study, we synthesized a peptide that contains 4( R) Hyp in both the Xaa and the Yaa positions, that is, Ac-(Gly-4( R) Hyp-4(R) Hyp)(10)- NH2 and compared it to Ac-(Gly-Pro- 4(R) Hyp)(10)-NH2, and Ac-(Gly-4(R) Hyp-Pro)(10)-NH2. Ac-(Gly-4(R) Hyp-4(R) Hyp)(10)-NH2 showed a polyproline II-like circular dichroic spectrum in water. The thermal transition temperatures measured by circular dichroism and differential scanning calorimetry were slightly higher than the values measured for Ac-(Gly-Pro4( R) Hyp)(10)- NH2 under the same conditions. For Ac-(Gly-4( R) Hyp-4(R) Hyp)(10)-NH2, the calorimetric and the van't Hoff transition enthalpy DeltaH were significantly smaller than that of Ac-(Gly-Pro-4(R) Hyp)(10)- NH2. We postulate that the denatured states of the two peptides are significantly different, with Ac-(Gly-4(R) Hyp-4(R) Hyp)(10)-NH2 forming a more polyproline II-like structure instead of a random coil. Two-dimensional nuclear Overhauser effect spectroscopy suggests that the triple helical structure of Ac-(Gly-4(R) Hyp-4(R) Hyp)(10)-NH2 is more flexible than that of Ac-(Gly-Pro-4(R) Hyp)(10)-NH2. This is confirmed by the kinetics of amide H-1 exchange with solvent deuterium of Ac-(Gly-4(R)Hyp-4(R) Hyp)(10)-NH2, which is faster than that of Ac-(Gly-Pro-4(R) Hyp)(10)-NH2. The higher transition temperature of Ac-(Gly-4(R) Hyp4( R)Hyp)(10)-NH2, can be explained by the higher trans/cis ratio of the Gly-4(R) Hyp peptide bonds than that of the Gly-Pro bonds, and this ratio compensates for the weaker interchain hydrogen bonds.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Portland State Univ, Dept Chem, Portland, OR 97201 USA; Teikyo Hesei Univ, Fac Pharmaceut Sci, Ichihara 2900193, Japan	Oregon Health & Science University; Portland State University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Peyton, David/0000-0001-5828-055X				Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Bann JG, 2003, BIOCHEMISTRY-US, V42, P4042, DOI 10.1021/bi027050w; Barth D, 2003, CHEM-EUR J, V9, P3692, DOI 10.1002/chem.200304917; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Berisio R, 2001, BIOPOLYMERS, V56, P8, DOI 10.1002/1097-0282(2000)56:1<8::AID-BIP1037>3.0.CO;2-W; Boudko SP, 2004, J MOL BIOL, V335, P1289, DOI 10.1016/j.jmb.2003.11.054; BRAHMACHARI SK, 1979, MACROMOLECULES, V12, P23, DOI 10.1021/ma60067a006; Bretscher LE, 2001, J AM CHEM SOC, V123, P777, DOI 10.1021/ja005542v; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Buechter DD, 2003, J BIOL CHEM, V278, P645, DOI 10.1074/jbc.M209364200; Burjanadze TV, 1997, CONNECT TISSUE RES, V36, P347, DOI 10.3109/03008209709160233; Doi M, 2003, J AM CHEM SOC, V125, P9922, DOI 10.1021/ja035997v; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Engel J, 2000, MATRIX BIOL, V19, P235, DOI 10.1016/S0945-053X(00)00071-8; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010; GOLDSTEIN A, 1970, J BIOL CHEM, V245, P5478; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Hodges JA, 2003, J AM CHEM SOC, V125, P9262, DOI 10.1021/ja035881z; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; Hongo C, 2001, POLYM J, V33, P812; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; Improta R, 2001, J AM CHEM SOC, V123, P12568, DOI 10.1021/ja010599i; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; McMahon L, 2003, MOL BIOL CELL, V14, P1366, DOI 10.1091/mbc.E02-08-0479; Melacini G, 2000, J MOL BIOL, V300, P1041, DOI 10.1006/jmbi.2000.3919; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Mizuno K, 2003, J BIOL CHEM, V278, P32373, DOI 10.1074/jbc.M304741200; Mizuno K., 2003, CONNECT TISSUE, V35, P207; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Olsen D, 2003, ADV DRUG DELIVER REV, V55, P1547, DOI 10.1016/j.addr.2003.08.008; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; Persikov AV, 2003, J AM CHEM SOC, V125, P11500, DOI 10.1021/ja036673+; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Ruszczak Z, 2003, ADV DRUG DELIVER REV, V55, P1679, DOI 10.1016/j.addr.2003.08.007; Vitagliano L, 2001, PROTEIN SCI, V10, P2627, DOI 10.1110/ps.ps.26601a; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V	57	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38072	38078		10.1074/jbc.M402953200	http://dx.doi.org/10.1074/jbc.M402953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231845	hybrid			2022-12-25	WOS:000223554600102
J	Sumer, H; Saffery, R; Wong, N; Craig, JM; Choo, KHA				Sumer, H; Saffery, R; Wong, N; Craig, JM; Choo, KHA			Effects of scaffold/matrix alteration on centromeric function and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II; ATTACHMENT REGIONS; BINDING PROTEIN; NUCLEAR-MATRIX; ALPHA-SATELLITE; DNA-SEQUENCES; DISTAMYCIN-A; HISTONE; CHROMOSOME; HETEROCHROMATIN	We have previously described a 3.5-Mb domain of enhance scaffold/matrix attachment region (S/MAR) at a human neocentromere, and normal expression of underlying genes within this region. We also reported that partial inhibition of histone deacetylation using 33 nM trichostatin A (TSA) resulted in a shift in the position of the CENP-A-binding domain within the neocentromere, with no noticeable effects on mitotic segregation function. In this study, 33 nM TSA caused a reduction in the size of the enhanced S/MAR domain of one-half to 1.7 Mb. Treatment with a DNA-intercalating drug distamycin A (DST) at 75 mug/ml resulted in a size reduction of the enhanced S/MAR domain at the neocentromere of two-thirds to 1.2 Mb, and that of the CENP-A-binding domain of 40%, from 330 to 196 kb, with no significant shift in the position of the latter domain. Other DST effects include mitotic chromosomal missegregation, reduction in the levels of Topo IIalpha, CENP-A, CENP-C, and HP1alpha, and an increase in mitotic checkpoint protein BubR1. TSA or DST treatment similarly resulted in a significant reduction, by similar to 20 and 50%, respectively, in the size of the enhanced S/MAR domain at the alpha-satellite DNA of a native chromosome 10 centromere. Transcriptional competence within the neocentromere is overall not noticeably altered by either TSA or DST treatment, as is evident from the absence of any significant increase or decrease in the expression levels of 47 underlying genes tested. These results suggest that a substantial contraction of the S/MAR domain may not be deleterious to centromere function, that disruption of the S/MAR domain directly affects the binding properties of a host of scaffold/matrix and centromeric/pericentric proteins, and that the overall competence and regulation of transcription at the neocentromeric chromatin is similar to those found at the corresponding normal genomic sites.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Pediat, Melbourne, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Choo, KHA (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	andy.choo@mcri.edu.au	Wong, Nick Wong/AAF-8627-2021; Wong, Nick/B-3501-2012; Craig, Jeffrey M/B-3484-2012; Saffery, Richard/GLS-1976-2022	Wong, Nick Wong/0000-0003-4393-7541; Craig, Jeffrey M/0000-0003-3979-7849; Saffery, Richard/0000-0002-9510-4181; Sumer, Huseyin/0000-0001-9413-5579				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Amor DJ, 2002, AM J HUM GENET, V71, P695, DOI 10.1086/342730; BALCZON RD, 1987, J CELL BIOL, V105, P855, DOI 10.1083/jcb.105.2.855; Barry AE, 1999, HUM MOL GENET, V8, P217, DOI 10.1093/hmg/8.2.217; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bickmore WA, 1996, CELL, V84, P95, DOI 10.1016/S0092-8674(00)80996-4; Bode J, 1995, INT REV CYTOL, V162A, P389; Bonnefoy E, 1999, MOL CELL BIOL, V19, P2803; Chang CJ, 2003, J CELL SCI, V116, P4715, DOI 10.1242/jcs.00797; Choo KHA, 2000, TRENDS CELL BIOL, V10, P182, DOI 10.1016/S0962-8924(00)01739-6; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; Coelho PA, 2003, J CELL SCI, V116, P4763, DOI 10.1242/jcs.00799; Craig JM, 2003, EMBO J, V22, P2495, DOI 10.1093/emboj/cdg232; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DOLFINI SF, 1983, EXPERIENTIA, V39, P1402, DOI 10.1007/BF01990127; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; duSart D, 1997, NAT GENET, V16, P144; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V; He DC, 1998, CHROMOSOMA, V107, P189, DOI 10.1007/s004120050296; Hibino Y, 1997, CARCINOGENESIS, V18, P707, DOI 10.1093/carcin/18.4.707; Hudson DF, 2003, DEV CELL, V5, P323, DOI 10.1016/S1534-5807(03)00199-0; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; JABS EW, 1989, P NATL ACAD SCI USA, V86, P202, DOI 10.1073/pnas.86.1.202; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Johnson CA, 2001, J BIOL CHEM, V276, P4539, DOI 10.1074/jbc.C000824200; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Lo AWI, 2001, GENOME RES, V11, P448, DOI 10.1101/gr.GR-1676R; Lo AWI, 2001, EMBO J, V20, P2087, DOI 10.1093/emboj/20.8.2087; MEHTA R, 1990, INDIAN J EXP BIOL, V28, P106; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; Poirier MG, 2002, P NATL ACAD SCI USA, V99, P15393, DOI 10.1073/pnas.232442599; PRANTERA G, 1979, CYTOGENET CELL GENET, V23, P103, DOI 10.1159/000131310; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; ROMIG H, 1994, EUR J BIOCHEM, V221, P411, DOI 10.1111/j.1432-1033.1994.tb18753.x; Saffery R, 1999, MAMM GENOME, V10, P415, DOI 10.1007/s003359901014; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; Saffery R, 2003, MOL CELL, V12, P509, DOI 10.1016/S1097-2765(03)00279-X; Strissel PL, 1996, CHROMOSOMA, V105, P122, DOI 10.1007/s004120050167; Sumer H, 2003, GENOME RES, V13, P1737, DOI 10.1101/gr.1095903; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tolstonog GV, 2000, DNA CELL BIOL, V19, P647, DOI 10.1089/10445490050199054; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Zaffaroni N, 2002, EUR J CANCER, V38, P1792, DOI 10.1016/S0959-8049(02)00139-9	69	7	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37631	37639		10.1074/jbc.M401051200	http://dx.doi.org/10.1074/jbc.M401051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220334	Green Published, hybrid			2022-12-25	WOS:000223554600054
J	Swiatecka-Urban, A; Boyd, C; Coutermarsh, B; Karlson, KH; Barnaby, R; Aschenbrenner, L; Langford, GM; Hasson, T; Stanton, BA				Swiatecka-Urban, A; Boyd, C; Coutermarsh, B; Karlson, KH; Barnaby, R; Aschenbrenner, L; Langford, GM; Hasson, T; Stanton, BA			Myosin VI regulates endocytosis of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; DELTA-F508 HOMOZYGOUS TWINS; PDZ-INTERACTING DOMAIN; UNCONVENTIONAL MYOSINS; PLASMA-MEMBRANE; COATED PITS; ACTIN; CLATHRIN; CFTR; INTERNALIZATION	The cystic fibrosis transmembrane conductance regulator ( CFTR) is a cyclic AMP-regulated Cl- channel expressed in the apical plasma membrane in fluid-transporting epithelia. Although CFTR is rapidly endocytosed from the apical membrane of polarized epithelial cells and efficiently recycled back to the plasma membrane, little is known about the molecular mechanisms regulating CFTR endocytosis and endocytic recycling. Myosin VI, an actin-dependent, minus-end directed mechanoenzyme, has been implicated in clathrin-mediated endocytosis in epithelial cells. The goal of this study was to determine whether myosin VI regulates CFTR endocytosis. Endogenous, apical membrane CFTR in polarized human airway epithelial cells (Calu-3) formed a complex with myosin VI, the myosin VI adaptor protein Disabled 2 (Dab2), and clathrin. The tail domain of myosin VI, a dominant-negative recombinant fragment, displaced endogenous myosin VI from interacting with Dab2 and CFTR and increased the expression of CFTR in the plasma membrane by reducing CFTR endocytosis. However, the myosin VI tail fragment had no effect on the recycling of endocytosed CFTR or on fluid-phase endocytosis. CFTR endocytosis was decreased by cytochalasin D, an actin-filament depolymerizing agent. Taken together, these data indicate that myosin VI and Dab2 facilitate CFTR endocytosis by a mechanism that requires actin filaments.	Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; University of California System; University of California San Diego; Dartmouth College	Swiatecka-Urban, A (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA.	Agnieszka.Swiatecka-Urban@Dartmouth.edu	SWIATECKA-URBAN, AGNIESZKA/H-6494-2015; Swiatecka-Urban, Agnieszka/AAP-6041-2020	SWIATECKA-URBAN, AGNIESZKA/0000-0002-6575-0334; HASSON, TAMA/0000-0002-5405-662X; Langford, George/0000-0001-9737-2182	NCRR NIH HHS [P20-RR018787-01] Funding Source: Medline; NEI NIH HHS [R01-EY12695] Funding Source: Medline; NIDDK NIH HHS [R01-DK45881, R01-DK34533] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018787] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, R01DK034533] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Aschenbrenner L, 2004, MOL BIOL CELL, V15, P2253, DOI 10.1091/mbc.E04-01-0002; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Biemesderfer D, 2002, AM J PHYSIOL-RENAL, V282, pF785, DOI 10.1152/ajprenal.00287.2001; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Breckler J, 2000, EXP EYE RES, V70, P121, DOI 10.1006/exer.1999.0758; Bronsveld I, 2001, J CLIN INVEST, V108, P1705; Bronsveld I, 2000, GASTROENTEROLOGY, V119, P32, DOI 10.1053/gast.2000.8524; Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; da Costa SR, 2003, ADV DRUG DELIVER REV, V55, P1359, DOI 10.1016/j.addr.2003.07.011; Durrbach A, 1996, J CELL SCI, V109, P457; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hasson T, 2003, J CELL SCI, V116, P3453, DOI 10.1242/jcs.00669; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Loffing J, 2000, AM J PHYSIOL-CELL PH, V279, pC1016, DOI 10.1152/ajpcell.2000.279.4.C1016; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Poschet JF, 2002, J BIOL CHEM, V277, P13959, DOI 10.1074/jbc.M105441200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez OC, 2000, TRENDS CELL BIOL, V10, P307, DOI 10.1016/S0962-8924(00)01797-9; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Soldati T, 2003, TRAFFIC, V4, P358, DOI 10.1034/j.1600-0854.2003.t01-1-00095.x; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Warren RA, 1997, J BIOL CHEM, V272, P2116; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	68	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					38025	38031		10.1074/jbc.M403141200	http://dx.doi.org/10.1074/jbc.M403141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247260	hybrid			2022-12-25	WOS:000223554600096
J	Vachova, L; Devaux, F; Kucerova, H; Ricicova, M; Jacq, C; Palkova, Z				Vachova, L; Devaux, F; Kucerova, H; Ricicova, M; Jacq, C; Palkova, Z			Sok2p transcription factor is involved in adaptive program relevant for long term survival of Saccharomyces cerevisiae colonies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST COLONIES; POLYAMINE TRANSPORT; VACUOLAR MEMBRANE; AMMONIA PULSES; PROTEIN; REGULATOR; GROWTH; STAINS; ASSAY; GENE	Volatile ammonia functions as a long range alarm signal important for the transition of yeast colonies to their adaptive alkali developmental phase and for their consequent long term survival. Cells of aged Saccharomyces cerevisiae sok2 colonies deleted in the gene for Sok2p transcription factor are not able to release a sufficient amount of ammonia out of the cells, they are more fragile than cells of wild type colonies, and they exhibit a survival defect. Genome-wide analysis on gene expression differences between sok2 and WT colonies revealed that sok2 colonies are not able to switch on the genes of adaptive metabolisms effectively and display unbalanced expression and activity of various enzymes involved in cell protection against oxidative damage. Impaired amino acid metabolism and insufficient activation of genes for putative ammonium exporters Ato and of those for some other membrane transporters may be responsible for observed defects in ammonia production. Thus, Sok2p appears to be an important regulator of S. cerevisiae colony development. Gene expression differences caused by its absence in colonies differ from those described previously in liquid cultures, which suggests a pleiotropic effect of Sok2p under different conditions.	Charles Univ, Dept Genet & Microbiol, CR-12844 Prague 2, Czech Republic; Ecole Normale Super, CNRS 8541, Genet Mol Lab, F-75005 Paris, France; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague 4, Czech Republic	Charles University Prague; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Palkova, Z (corresponding author), Charles Univ, Dept Genet & Microbiol, CR-12844 Prague 2, Czech Republic.	zdenap@natur.cuni.cz	Vachova, Libuse/H-7620-2014; Palkova, Zdena/M-8692-2014; DEVAUX, Frédéric/N-2288-2019	Vachova, Libuse/0000-0002-8143-6054; Palkova, Zdena/0000-0002-0864-8042; DEVAUX, Frédéric/0000-0002-0039-9096				Albertsen M, 2003, J BIOL CHEM, V278, P12820, DOI 10.1074/jbc.M210715200; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; CLARE DA, 1984, ANAL BIOCHEM, V140, P532, DOI 10.1016/0003-2697(84)90204-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Golfier G, 2004, BIOINFORMATICS, V20, P1641, DOI 10.1093/bioinformatics/bth117; Guaragnella N, 2003, J BIOL CHEM, V278, P45882, DOI 10.1074/jbc.M309301200; HU ML, 1994, METHOD ENZYMOL, V233, P380; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Keller G, 2001, J BIOL CHEM, V276, P38697, DOI 10.1074/jbc.M107131200; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Palkova Z, 2000, J CELL SCI, V113, P1923; Palkova Z, 2002, MOL BIOL CELL, V13, P3901, DOI 10.1091/mbc.E01-12-0149; Palkova Z, 1997, NATURE, V390, P532, DOI 10.1038/37398; Palkova Z, 2003, INT REV CYTOL, V225, P229, DOI 10.1016/S0074-7696(05)25006-4; Pan XW, 2000, MOL CELL BIOL, V20, P8364, DOI 10.1128/MCB.20.22.8364-8372.2000; RABILLOUD T, 1992, ELECTROPHORESIS, V13, P429, DOI 10.1002/elps.1150130190; Ricicova M, 2003, FEMS YEAST RES, V4, P119, DOI 10.1016/S1567-1356(03)00145-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shenhar G, 2001, MOL CELL BIOL, V21, P1603, DOI 10.1128/MCB.21.5.1603-1612.2001; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; WARD MP, 1994, MOL CELL BIOL, V14, P5619, DOI 10.1128/MCB.14.9.5619; WARD MP, 1995, MOL CELL BIOL, V15, P6854; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zikanova B, 2002, BIOCHEM BIOPH RES CO, V294, P962, DOI 10.1016/S0006-291X(02)00589-2	26	35	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37973	37981		10.1074/jbc.M404594200	http://dx.doi.org/10.1074/jbc.M404594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15229222	hybrid			2022-12-25	WOS:000223554600091
J	Akiyama, S; Yonezawa, T; Kudo, TA; Li, MG; Wang, H; Ito, M; Yoshioka, K; Ninomiya-Tsuji, J; Matsumoto, K; Kanamaru, R; Tamura, S; Kobayashi, T				Akiyama, S; Yonezawa, T; Kudo, TA; Li, MG; Wang, H; Ito, M; Yoshioka, K; Ninomiya-Tsuji, J; Matsumoto, K; Kanamaru, R; Tamura, S; Kobayashi, T			Activation mechanism of c-Jun amino-terminal kinase in the course of neural differentiation of P19 embryonic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; RETINOIC ACID; KAPPA-B; EXPRESSION; MEMBER; JNK; PHOSPHORYLATION; PATHWAYS; SAPK/JNK	P19 embryonic carcinoma cells, a model system for studying early development and differentiation, can differentiate into neurons and primitive endoderm-like cells depending on the culture conditions. We have previously reported that the activation of c-Jun amino-terminal kinase (JNK) is required for the retinoic acid-induced neural differentiation of P19 cells. However, the signaling pathway(s) responsible for the activation of JNK has not been known. In this study, we demonstrated that activities of MAPK kinase 4 (MKK4) and TAK1, one of the upstream kinases of MKK4, were enhanced in the neurally differentiating cells. Inhibition of the neural differentiation by an overexpression of protein phosphatase 2Cepsilon, an inactivator of TAK1, suggested a critical role of the TAK1 signaling pathway during the differentiation. Confocal microscopic analysis indicated that TAK1, phospho-MKK4, and phospho-JNK were colocalized with tubulin in the neurites and localized also in the nuclei of the differentiating cells. In contrast, two TAK1-binding proteins, TAB1 and TAB2, which are involved in the activation of TAK1, were localized in the neurites and the nuclei of the differentiating cells, respectively. These results suggest that two distinct TAK1-MKK4-JNK signaling pathways are independently activated at the different intracellular locations and may participate in the regulation of the neural differentiation of P19 cells.	Tohoku Univ, Inst Dev Aging & Canc, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa 2288555, Japan; Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Tohoku University; Tohoku University; Kitasato University; Kanazawa University; University of North Carolina; North Carolina State University; Nagoya University	Tamura, S (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Biochem, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	tamura@idac.tohoku.ac.jp; takayasu@idac.tohoku.ac.jp		Ninomiya-Tsuji, Jun/0000-0002-5584-0176; Kudo, Tada-aki/0000-0003-1666-9588; YONEZAWA, Takayuki/0000-0001-8060-0839				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Coffey ET, 2000, J NEUROSCI, V20, P7602; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Kanungo J, 2000, J BIOL CHEM, V275, P24032, DOI 10.1074/jbc.M002747200; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kudo T, 2003, FEBS LETT, V539, P29, DOI 10.1016/S0014-5793(03)00179-0; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Robertson E.J., 1987, PRACTICAL APPROACH T, P19; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sasahara Y, 1996, J BIOL CHEM, V271, P25950, DOI 10.1074/jbc.271.42.25950; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang H, 2001, FEBS LETT, V503, P91, DOI 10.1016/S0014-5793(01)02699-0; Wang HY, 2002, J BIOL CHEM, V277, P3530, DOI 10.1074/jbc.M107031200; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	36	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36616	36620		10.1074/jbc.M406610200	http://dx.doi.org/10.1074/jbc.M406610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15218018	hybrid			2022-12-25	WOS:000223453600059
J	Boxrud, PD; Verhamme, IM; Bock, PE				Boxrud, PD; Verhamme, IM; Bock, PE			Resolution of conformational activation in the kinetic mechanism of plasminogen activation by streptokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE-CATALYZED ACTIVATION; PEPTIDE CHLOROMETHYL KETONES; ACTIVE-SITE; AFFINITY-CHROMATOGRAPHY; HUMAN <GLU1>PLASMINOGEN; FLUORESCENCE PROBES; EQUIMOLAR COMPLEXES; DOMAIN INTERACTIONS; SERINE PROTEINASES; BINDING REGION	Streptokinase (SK) activates plasminogen (Pg) by specific binding and nonproteolytic expression of the Pg catalytic site, initiating Pg proteolysis to form the fibrinolytic proteinase, plasmin (Pm). The SK-induced conformational activation mechanism was investigated in quantitative kinetic and equilibrium binding studies. Progress curves of Pg activation by SK monitored by chromogenic substrate hydrolysis were parabolic, with initial rates (upsilon(1)) that indicated no transient species and subsequent rate increases (upsilon(2)). The upsilon(1) dependence on SK concentration for [Glu]Pg and [Lys]Pg was hyperbolic with dissociation constants corresponding to those determined in fluorescence-based binding studies for the native Pg species, identifying upsilon(1) as rapid SK binding and conformational activation. Comparison of [Glu]Pg and [Lys]Pg activation showed an similar to12-fold higher affinity of SK for [Lys]Pg that was lysine-binding site dependent and no such dependence for [Glu]Pg. Stopped-flow kinetics of SK binding to fluorescently labeled Pg demonstrated at least two fast steps in the conformational activation pathway. Characterization of the specificity of the conformationally activated SK.[Lys]Pg* complex for tripeptide-p-nitroanilide substrates demonstrated 5-18- and 10-130-fold reduced specificity (k(cat)/K-m) compared with SK.Pm and Pm, respectively, with differences in K-m and k(cat) dependent on the P1 residue. The results support a kinetic mechanism in which SK binding and reversible conformational activation occur in a rapid equilibrium, multistep process.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu			NHLBI NIH HHS [HL 10082, HL 56181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181, F32HL010082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHIBBER BAK, 1986, J BIOL CHEM, V261, P5289; CHIBBER BAK, 1986, P NATL ACAD SCI USA, V83, P1237, DOI 10.1073/pnas.83.5.1237; CHIBBER BAK, 1985, BIOCHEMISTRY-US, V24, P3429, DOI 10.1021/bi00335a006; CHRISTENSEN U, 1978, BIOCHIM BIOPHYS ACTA, V526, P194, DOI 10.1016/0005-2744(78)90304-2; COLLEN D, 1991, BLOOD, V78, P3114; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HORREVOETS AJG, 1995, J BIOL CHEM, V270, P15770, DOI 10.1074/jbc.270.26.15770; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; KOSOW DP, 1975, BIOCHEMISTRY-US, V14, P4459, DOI 10.1021/bi00691a018; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1995, BIOCHEM BIOPH RES CO, V217, P1245, DOI 10.1006/bbrc.1995.2902; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.tb20441.x; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SJOHOLM I, 1973, EUR J BIOCHEM, V39, P471, DOI 10.1111/j.1432-1033.1973.tb03146.x; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; URANO T, 1987, J BIOL CHEM, V262, P15959; URANO T, 1987, P NATL ACAD SCI USA, V84, P4031, DOI 10.1073/pnas.84.12.4031; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WOHL RC, 1978, J BIOL CHEM, V253, P1402	58	38	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36633	36641		10.1074/jbc.M405264200	http://dx.doi.org/10.1074/jbc.M405264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215240	hybrid			2022-12-25	WOS:000223453600062
J	Choi, YA; Lim, HK; Kim, JR; Lee, CH; Kim, YJ; Kang, SS; Baek, SH				Choi, YA; Lim, HK; Kim, JR; Lee, CH; Kim, YJ; Kang, SS; Baek, SH			Group IB secretory phospholipase A(2) promotes matrix metalloproteinase-2-mediated cell migration via the phosphatidylinositol 3-kinase and Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; PROSTAGLANDIN SYNTHESIS; DERMAL FIBROBLASTS; MESANGIAL CELLS; EXPRESSION; BINDING; RAT; DEGRADATION; SURFACE; MMP-2	Secretory phospholipase A(2) (sPLA(2)), abundantly expressed in various cells including fibroblasts, is able to promote proliferation and migration. Degradation of collagenous extracellular matrix by matrix metalloproteinase (MMP) plays a role in the pathogenesis of various destructive disorders, such as rheumatoid arthritis, tumor invasion, and metastasis. Here we show that group IB PLA(2) increased pro-MMP-2 activation in NIH3T3 fibroblasts. MMP-2 activity was stimulated by group IB PLA(2) in a dose- and time-dependent manner. Consistent with MMP-2 activation, sPLA(2) decreased expression of type IV collagen. These effects are due to the reduction of tissue inhibitor of metalloproteinase-2 (TIMP-2) and the activation of the membrane type1-MMP (MT1-MMP). The decrease of TIMP-2 levels in conditioned media and the increase of MT1-MMP levels in plasma membrane were observed. In addition, treatment of cells with decanoyl Arg-Val-Lys-Arg-chloromethyl ketone, an inhibitor of pro-MT1-MMP, suppressed sPLA(2)-mediated MMP-2 activation, whereas treatment with bafilomycin A1, an inhibitor of H+-ATPase, sustained MMP-2 activation by sPLA(2). The involvement of phosphatidylinositol 3-kinase (PI3K) and Akt in the regulation of MMP-2 activity was further suggested by the findings that PI3K and Akt were phosphorylated by sPLA(2). Expression of p85alpha and Akt mutants, or pretreatment of cells with LY294002, a PI3K inhibitor, attenuated sPLA(2)-induced MMP-2 activation and migration. Taken together, these results suggest that sPLA(2) increases the pro-MMP-2 activation and migration of fibroblasts via the PI3K and Akt-dependent pathway. Because MMP-2 is an important factor directly involved in the control of cell migration and the turnover of extracellular matrix, our study may provide a mechanism for sPLA(2)-promoted fibroblasts migration.	Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Nam Gu 705717, Daegu, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Nam Gu 705717, Daegu, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Taegu 702701, South Korea	Yeungnam University; Yeungnam University; Kyungpook National University	Baek, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, 317-1 Daemyung 5 Dong, Nam Gu 705717, Daegu, South Korea.	sbaek@med.yu.ac.kr						Attiga FA, 2000, CANCER RES, V60, P4629; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Beck S, 2003, J BIOL CHEM, V278, P29799, DOI 10.1074/jbc.M211763200; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Fuentes L, 2002, CIRC RES, V91, P681, DOI 10.1161/01.RES.0000038341.34243.64; Gilles C, 2001, J CELL SCI, V114, P2967; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hess AR, 2003, CANCER RES, V63, P4757; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; Ihn H, 2000, J IMMUNOL, V165, P2149, DOI 10.4049/jimmunol.165.4.2149; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Leonardi A, 2003, INVEST OPHTH VIS SCI, V44, P183, DOI 10.1167/iovs.02-0420; MACKAY AR, 1990, CANCER RES, V50, P5997; Mandal AK, 2001, FASEB J, V15, P1834, DOI 10.1096/fj.00-0831fje; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McKaig BC, 2003, AM J PATHOL, V162, P1355, DOI 10.1016/S0002-9440(10)63931-4; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Minami T, 1997, INFLAMM RES, V46, P103, DOI 10.1007/s000110050119; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Rizzo MT, 2000, BLOOD, V96, P3809, DOI 10.1182/blood.V96.12.3809.h8003809_3809_3815; Saad S, 2002, CANCER RES, V62, P283; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; YANA I, 2003, MOL BIOL CELL, V7, P2387; Yuan CJ, 2000, CANCER RES, V60, P1084	48	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36579	36585		10.1074/jbc.M314235200	http://dx.doi.org/10.1074/jbc.M314235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15220345	hybrid			2022-12-25	WOS:000223453600054
J	Ben-Saadon, R; Fajerman, I; Ziv, T; Hellman, U; Schwartz, AL; Ciechanover, A				Ben-Saadon, R; Fajerman, I; Ziv, T; Hellman, U; Schwartz, AL; Ciechanover, A			The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system - Direct evidence for ubiquitination at the N-terminal residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-MEDIATED DEGRADATION; CONTACT-INHIBITION; CONJUGATION; EXPRESSION; TURNOVER; PATHWAY; BINDING; GROWTH; MYOD; P21	Conjugation of ubiquitin to an internal lysine is the initial step in the degradation of the majority of the substrates of the ubiquitin system. For several substrates, it has been shown that the first ubiquitin moiety is conjugated to the N-terminal residue. In all these substrates, however, the internal lysines also played a role in modulating their stability. To better understand the physiological significance of this novel mode of modification, it was important to identify proteins in which degradation is completely dependent on N-terminal ubiquitination. Also, although the experimental evidence for N-terminal ubiquitination is rather strong, nevertheless, it has remained indirect. Here we demonstrate that an important group of proteins that are targeted via N-terminal ubiquitination are the naturally occurring lysine-less proteins such as the human papillomavirus (HPV)-58 E7 oncoprotein and the cell cycle inhibitor and tumor suppressor p16(INK4a). For these proteins, the only residue that can be targeted is the N-terminal residue. Interestingly, p16(INK4a) is degraded in a cell density-dependent manner. Importantly, we provide for the first time direct evidence for N-terminal ubiquitination. Analysis of tryptic digest of the ubiquitin conjugate of HPV-58 E7 revealed a fusion peptide that is composed of the C-terminal domain of ubiquitin and the N-terminal domain of E7. With the abundance of native lysine-less proteins, among which are important viral and cell regulators, this novel mode of protein targeting has implications for both physiological and pathophysiological processes.	Technion Israel Inst Technol, Canc & Vasc Biol Res Ctr, Ruth & Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Biol, IL-31096 Haifa, Israel; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Ludwig Institute for Cancer Research; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Canc & Vasc Biol Res Ctr, Ruth & Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, Efron St,POB 9649, IL-31096 Haifa, Israel.	c_tzachy@netvision.net.il	Ciechanover, Aaron J/C-9166-2017	Ziv, Tamar/0000-0003-4299-7454; Sadeh, Ronen/0000-0003-1920-3898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067620] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM067620-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Doolman R, 2004, J BIOL CHEM, V279, P38184, DOI 10.1074/jbc.M405935200; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FERBER S, 1986, J BIOL CHEM, V261, P3128; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gump J, 2003, J BIOL CHEM, V278, P6619, DOI 10.1074/jbc.C200622200; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Meerson A, 2004, FEBS LETT, V559, P152, DOI 10.1016/S0014-5793(04)00027-4; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; Yanagisawa K, 1999, J BIOCHEM-TOKYO, V125, P36, DOI 10.1093/oxfordjournals.jbchem.a022265; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	28	90	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41414	41421		10.1074/jbc.M407201200	http://dx.doi.org/10.1074/jbc.M407201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15254040	hybrid			2022-12-25	WOS:000224075500023
J	Elenius, V; Gotte, M; Reizes, O; Elenius, K; Bernfield, M				Elenius, V; Gotte, M; Reizes, O; Elenius, K; Bernfield, M			Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; FACTOR STIMULATION; EXPRESSION; DEGRADATION; MOUSE; SKIN; KERATINOCYTES	Wound repair is a tightly regulated process stimulated by proteases, growth factors, and chemokines, which are modulated by heparan sulfate. To characterize further the role of the heparan sulfate proteoglycan syndecan-1 in wound repair, we generated mice overexpressing syndecan-1 (Snd/Snd) and studied dermal wound repair. Wound closure, reepithelialization, granulation tissue formation, and remodeling were delayed in Snd/Snd mice. Soluble syndecan-1 was increased, and shedding was prolonged in wounds from Snd/Snd mice. Excess syndecan-1 increased the elastolytic activity of wound fluids. Additionally, cells in the granulation tissue and keratinocytes at wound edges showed markedly reduced proliferation rates in Snd/Snd mice. Skin grafting experiments between Snd/Snd and control mice indicated that the slower growth rate was mainly due to a soluble factor in the Snd/Snd mouse skin. Syndecan-1 immunodepletion and further degradation experiments identified syndecan-1 ectodomain as a dominant negative inhibitor of cell proliferation. These studies indicate that shed syndecan-1 ectodomain may enhance proteolytic activity and inhibit cell proliferation during wound repair.	Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Turku, Cent Hosp, Dept Pediat, FIN-20520 Turku, Finland; Univ Turku, Med Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Munster Univ Hosp, Dept Obstet & Gynecol, D-48149 Munster, Germany; Procter & Gamble Pharmaceut Co, Hlth Care Res Ctr, Mason, OH 45040 USA; Univ Turku, Cent Hosp, Dept Oncol, FIN-20520 Turku, Finland	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Turku; University of Turku; University of Turku; University of Munster; Procter & Gamble; University of Turku	Elenius, V (corresponding author), Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.	varpu.elenius@utu.fi	Götte, Martin/G-2254-2018; Elenius, Klaus/AAI-7594-2021; Reizes, Ofer/ABA-4179-2021; Gotte, M/Z-5878-2019	Götte, Martin/0000-0003-2360-2496; Elenius, Klaus/0000-0001-5700-0827; Reizes, Ofer/0000-0003-0075-6871; Gotte, M/0000-0003-2360-2496	NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056398] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28735] Funding Source: Medline; NHLBI NIH HHS [HL-56398] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Baird A., 1991, PEPTIDE GROWTH FACTO, P369; Beare AHM, 2003, J INVEST DERMATOL, V120, P153, DOI 10.1046/j.1523-1747.2003.12019.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BILLINGHAM RE, 1951, J EXP BIOL, V28, P385; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CLARK RAF, 1996, MOL CELLULAR BIOL WO, P1; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GIBRAN NS, 1994, J SURG RES, V56, P226, DOI 10.1006/jsre.1994.1036; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Grinnell F, 1996, J INVEST DERMATOL, V106, P335, DOI 10.1111/1523-1747.ep12342990; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HEBDA PA, 1990, J INVEST DERMATOL, V95, P626, DOI 10.1111/1523-1747.ep12513528; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; MACIAG T, 1984, PROG HEMOST THROMB, V7, P167; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; RAO CN, 1995, J INVEST DERMATOL, V105, P572, DOI 10.1111/1523-1747.ep12323503; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SALO T, 1994, LAB INVEST, V70, P176; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639	52	91	94	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41928	41935		10.1074/jbc.M404506200	http://dx.doi.org/10.1074/jbc.M404506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15220342	hybrid			2022-12-25	WOS:000224075500084
J	Ostberg, T; Svensson, S; Selen, G; Uppenberg, J; Thor, M; Sundbom, M; Sydow-Backman, M; Gustavsson, AL; Jendeberg, L				Ostberg, T; Svensson, S; Selen, G; Uppenberg, J; Thor, M; Sundbom, M; Sydow-Backman, M; Gustavsson, AL; Jendeberg, L			A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							9-CIS RETINOIC ACID; PPAR-GAMMA LIGAND; FATTY-ACIDS; CRYSTAL-STRUCTURE; ADIPOCYTE DIFFERENTIATION; LIPID-METABOLISM; GENE-EXPRESSION; ALPHA; DOMAIN; EICOSANOIDS	The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the NR1 subfamily of nuclear receptors. The PPARs play key roles in the control of glucose and lipid homeostasis, and the synthetic isoform-specific PPAR agonists are used clinically to improve insulin sensitivity and to lower serum triglyceride levels. All of the previously reported PPAR agonists form the same characteristic interactions with the receptor, which have been postulated to be important for the induction of agonistic activity. Here we describe a new class of PPARalpha/gamma modulators, the 5-substituted 2-benzoylaminobenzoic acids (2-BABAs). As shown by x-ray crystallography, the representative compounds BVT.13, BVT.762, and BVT.763, utilize a novel binding epitope and lack the agonist-characteristic interactions. Despite this, some compounds within the 2-BABA family are potent agonists in a cell-based reporter gene assay. Furthermore, BVT.13 displays antidiabetic effects in ob/ob mice. We concluded that the 2-BABA binding mode can be used to design isoform-specific PPAR modulators with biological activity in vivo.	Biovitrum, Dept Med Chem, SE-11276 Stockholm, Sweden; Biovitrum, Dept Assay Dev & Screening, SE-11276 Stockholm, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Jendeberg, L (corresponding author), Biovitrum, Dept Med Chem, SE-11276 Stockholm, Sweden.	lena.jendeberg@biovitrum.com	Uppenberg, Jonas/F-5339-2011	Uppenberg, Jonas/0000-0002-6788-861X; Sundbom, Magnus/0000-0002-6243-2859; Gustavsson, Anna-Lena/0000-0003-4332-2336				Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaput E, 2000, BIOCHEM BIOPH RES CO, V271, P445, DOI 10.1006/bbrc.2000.2647; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kersten S, 2002, EUR J PHARMACOL, V440, P223, DOI 10.1016/S0014-2999(02)01431-0; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Thor M, 2002, BIOORG MED CHEM LETT, V12, P3565, DOI 10.1016/S0960-894X(02)00791-6; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	38	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					41124	41130		10.1074/jbc.M401552200	http://dx.doi.org/10.1074/jbc.M401552200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15258145	hybrid			2022-12-25	WOS:000223916800111
J	Aoki, K; Matsumoto, S; Hirayama, Y; Wada, T; Ozeki, Y; Niki, M; Domenech, P; Umemori, K; Yamamoto, S; Mineda, A; Matsumoto, M; Kobayashi, K				Aoki, K; Matsumoto, S; Hirayama, Y; Wada, T; Ozeki, Y; Niki, M; Domenech, P; Umemori, K; Yamamoto, S; Mineda, A; Matsumoto, M; Kobayashi, K			Extracellular mycobacterial DNA-binding protein 1 participates in mycobacterium-lung epithelial cell interaction through hyaluronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; NITRIC-OXIDE SYNTHASE; HISTONE-LIKE PROTEINS; SUPEROXIDE-DISMUTASE; BACTERIAL CHROMOSOME; MURINE MACROPHAGES; CHROMATIN PROTEIN; TUBERCULOSIS; HEMAGGLUTININ; IDENTIFICATION	Mycobacterium tuberculosis infects not only host macrophages but also nonprofessional phagocytes, such as alveolar epithelial cells. Glycosaminoglycans (GAGs) are considered as the component of mycobacterial adherence to epithelial cells. Here we show that extracellularly occurring mycobacterial DNA-binding protein 1 (MDP1) promotes mycobacterial infection to A549 human lung epithelial cells through hyaluronic acid ( HA). Both surface plasmon resonance analysis and enzyme-linked immunosorbent assay revealed that MDP1 bound to HA, heparin, and chondroitin sulfate. Utilizing synthetic peptides, we next defined heparin-binding site of 20 amino acids from 31 to 50 of MDP1, which is responsible for the specific DNA-binding site of MDP1. MDP1 bound to A549 cells, and exogenous DNA and HA interfered with the interaction. The binding was also abolished by treatment of A549 cells with hyaluronidase, suggesting that HA participates in the MDP1-A549 cell interaction. Adherence of bacillus Calmette-Guerin ( BCG) and M. tuberculosis to A549 cells was inhibited by addition of HA, DNA, and anti-MDP1 antibody, showing that MDP1 participates in the interaction between mycobacteria-alveolar epithelial cells. Simultaneous treatment of intratracheal BCG-infected mice with HA reduced the growth of BCG in vivo. Taken together, theses results suggest that HA participates in Mycobacterium-lung epithelium interaction and has potential for therapeutic and prophylactic interventions in mycobacterial infection.	Osaka City Univ, Grad Sch Med, Dept Host Def, Abeno Ku, Osaka 5458585, Japan; Osaka City Inst Publ Hlth & Environm Sci, Osaka 5458585, Japan; Osaka Int Coll Women, Osaka 5708555, Japan; NIAID, TB Res Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Natl Inst Infect Dis, Dept Bacterial & Blood Prod, Musashimurayama, Tokyo 2080011, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Oral Histol, Nagasaki 8528588, Japan; Otsuka Pharmaceut Co Ltd, Tokushima 7710192, Japan	Osaka Metropolitan University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institute of Infectious Diseases (NIID); Nagasaki University; Otsuka Pharmaceutical	Matsumoto, S (corresponding author), Osaka City Univ, Grad Sch Med, Dept Host Def, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	sohkichi@med.osaka-cu.ac.jp		Matsumoto, Sohkichi/0000-0002-6106-7538				Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; Bermudez LE, 1996, INFECT IMMUN, V64, P1400, DOI 10.1128/IAI.64.4.1400-1406.1996; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Bloom BR, 2002, NEW ENGL J MED, V346, P1434, DOI 10.1056/NEJM200205093461902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x; Brix K, 1998, J CLIN INVEST, V102, P283, DOI 10.1172/JCI1614; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Cichy J, 2003, J CELL BIOL, V161, P839, DOI 10.1083/jcb.200302098; Coutte L, 2003, J EXP MED, V197, P735, DOI 10.1084/jem.20021153; Delogu G, 1999, J BACTERIOL, V181, P7464, DOI 10.1128/JB.181.24.7464-7469.1999; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Furugen M, 2001, MICROB PATHOGENESIS, V30, P129, DOI 10.1006/mpat.2000.0416; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Harth G, 1999, J BIOL CHEM, V274, P4281, DOI 10.1074/jbc.274.7.4281; Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0; JANICKI BW, 1971, AM REV RESPIR DIS, V104, P602; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Lee BH, 1998, MOL GEN GENET, V260, P475, DOI 10.1007/s004380050919; Leemans JC, 2003, J CLIN INVEST, V111, P681, DOI 10.1172/JCI200316936; Matsumoto S, 1999, MICROBIOL IMMUNOL, V43, P1027, DOI 10.1111/j.1348-0421.1999.tb01232.x; Matsumoto S, 2000, FEMS MICROBIOL LETT, V182, P297, DOI 10.1016/S0378-1097(99)00606-0; MCDONOUGH KA, 1995, INFECT IMMUN, V63, P4802, DOI 10.1128/IAI.63.12.4802-4811.1995; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Naito M, 1998, SCAND J IMMUNOL, V48, P73; Naito M, 1998, J BIOL CHEM, V273, P2905, DOI 10.1074/jbc.273.5.2905; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083; Pethe K, 2000, J BIOL CHEM, V275, P14273, DOI 10.1074/jbc.275.19.14273; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SCHMID MB, 1988, TRENDS BIOCHEM SCI, V13, P131, DOI 10.1016/0968-0004(88)90069-2; Shimoji Y, 1999, P NATL ACAD SCI USA, V96, P9857, DOI 10.1073/pnas.96.17.9857; Shimono N, 2003, P NATL ACAD SCI USA, V100, P15918, DOI 10.1073/pnas.2433882100; Small PM, 2001, NEW ENGL J MED, V345, P189, DOI 10.1056/NEJM200107193450307; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Termeer C, 2003, TRENDS IMMUNOL, V24, P112, DOI 10.1016/S1471-4906(03)00029-2; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yang TB, 2002, CANCER RES, V62, P2583; YANG VC, 1987, APPL BIOCHEM BIOTECH, V16, P35, DOI 10.1007/BF02798354	48	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39798	39806		10.1074/jbc.M402677200	http://dx.doi.org/10.1074/jbc.M402677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15234978	hybrid			2022-12-25	WOS:000223791500074
J	Chen, J; Rusnak, M; Luedtke, RR; Sidhu, A				Chen, J; Rusnak, M; Luedtke, RR; Sidhu, A			D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEOTIDE-BINDING PROTEINS; FOCAL CEREBRAL-ISCHEMIA; MC NEUROBLASTOMA-CELLS; MAP KINASE; BETA-ARRESTIN; COUPLED RECEPTORS; OXIDATIVE STRESS; STRIATONIGRAL DEGENERATION; STRIATAL NEUROTOXICITY	Postsynaptic striatal neurodegeneration occurs through unknown mechanisms, but it is linked to high extracellular levels of synaptic dopamine. Dopamine-mediated cytotoxicity of striatal neurons occurs through two distinct pathways: autoxidation and the D1 dopamine receptor-linked signaling pathway. Here we investigated the mitogen-activated protein kinase ( MAPK) signaling pathways activated upon the acute stimulation of D1 dopamine receptors. In SK-N-MC neuroblastoma cells, endogenously expressing D1 dopamine receptors, dopamine caused activation of phosphorylated (p-) ERK1/2 and of the stress-signaling kinases, p-JNK and p-p38 MAPK, in a time- and dose-dependent manner. Selective stimulation of D1 receptors with the agonist SKF R-38393 caused p-ERK1/2, but not p-JNK or p-p38 MAPK activation, in a manner sensitive to the receptor-selective antagonist SCH 23390, protein kinase A inhibition (KT5720), and MEK1/2 inhibition (U0126 or PD98059). Activation of ERK by D1 dopamine receptors resulted in oxidative stress and cytotoxicity. In cells transfected with a catalytically defective mutant of MEK1, the upstream ERK-specific kinase, both dopamine- and SKF R-38393-mediated cytotoxicity was markedly attenuated, confirming the participation of the ERK signaling pathway. Cell fractionation studies showed that only a small amount of p- ERK1/2 was translocated to the nucleus, with the majority retained in the cytoplasm. From coimmunoprecipitation studies, p- ERK was found to form stable heterotrimeric complexes with the D1 dopamine receptor and beta-arrestin2. In cells transfected with the dominant negative mutant of beta-arrestin2, the formation of such complexes was substantially inhibited. These data provide novel mechanistic insights into the role of ERK in the cytotoxicity mediated upon activation of the D1 dopamine receptor.	Georgetown Univ, Dept Pediat, Lab Mol Neurochem, Washington, DC 20007 USA; Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Georgetown University; University of North Texas System; University of North Texas Health Science Center	Sidhu, A (corresponding author), Georgetown Univ, Dept Pediat, Lab Mol Neurochem, Res Bldg,Rm W222,3970 Reservoir Rd, Washington, DC 20007 USA.	sidhua@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034914] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-34914] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Andringa G, 1999, PSYCHOPHARMACOLOGY, V146, P328, DOI 10.1007/s002130051124; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chen J, 2003, J BIOL CHEM, V278, P28089, DOI 10.1074/jbc.M303094200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cools AR, 2002, NEUROPHARMACOLOGY, V42, P237, DOI 10.1016/S0028-3908(01)00169-1; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Drago J, 1998, J NEUROSCI, V18, P9845; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gerfen CR, 2002, J NEUROSCI, V22, P5042, DOI 10.1523/JNEUROSCI.22-12-05042.2002; Ghorayeb I, 2000, MOVEMENT DISORD, V15, P531, DOI 10.1002/1531-8257(200005)15:3<531::AID-MDS1017>3.0.CO;2-C; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hantraye P, 1998, NUCL MED BIOL, V25, P721, DOI 10.1016/S0969-8051(98)00054-7; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Imam SZ, 2001, ANN NY ACAD SCI, V939, P366; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; KIMURA K, 1995, J BIOL CHEM, V270, P14672, DOI 10.1074/jbc.270.24.14672; Kitazawa M, 2002, J PHARMACOL EXP THER, V302, P26, DOI 10.1124/jpet.302.1.26; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Liu JC, 2002, J BIOL CHEM, V277, P35819, DOI 10.1074/jbc.M202920200; Luedtke RR, 1999, J NEUROIMMUNOL, V101, P170, DOI 10.1016/S0165-5728(99)00142-3; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Sidhu A, 1998, J NEUROCHEM, V70, P2459; Sidhu A, 1999, NEUROSCIENCE, V91, P537, DOI 10.1016/S0306-4522(98)00555-7; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; SIDHU A, 1990, BIOCHEM BIOPH RES CO, V166, P574, DOI 10.1016/0006-291X(90)90847-G; Spencer JPE, 2002, J NEUROCHEM, V81, P122, DOI 10.1046/j.1471-4159.2002.00808.x; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Stefanova N, 2003, ACTA NEUROPATHOL, V106, P157, DOI 10.1007/s00401-003-0717-y; Stephans S, 1996, NEUROSCIENCE, V72, P593, DOI 10.1016/0306-4522(95)00587-0; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wersinger C, 2004, MOL CELL NEUROSCI, V25, P124, DOI 10.1016/j.mcn.2003.10.002; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Zhen XC, 2001, MOL PHARMACOL, V60, P857; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	73	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39317	39330		10.1074/jbc.M403891200	http://dx.doi.org/10.1074/jbc.M403891200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247297	hybrid			2022-12-25	WOS:000223791500017
J	Manchekar, M; Richardson, PE; Forte, TM; Datta, G; Segrest, JP; Dashti, N				Manchekar, M; Richardson, PE; Forte, TM; Datta, G; Segrest, JP; Dashti, N			Apolipoprotein b-containing lipoprotein particle assembly - Lipid capacity of the nascent lipoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; CARBOXYL-TERMINAL TRUNCATION; APO-B; ENDOPLASMIC-RETICULUM; AMPHIPATHIC HELIX; HEPG2 CELLS; RAT-LIVER; SECRETION; VITELLOGENIN	We previously proposed that the N-terminal 1000-residue betaalpha(1) domain of apolipoprotein B ( apoB) forms a bulk lipid pocket homologous to that of lamprey lipovitellin. In support of this "lipid pocket" hypothesis, we demonstrated that apoB: 1000 ( residues 1 - 1000) is secreted by a stable transformant of McA-RH7777 cells as a monodisperse particle with high density lipoprotein 3 (HDL3) density. In contrast, apoB: 931 ( residues 1 - 931), missing only 69 residues of the sequence homologous to lipovitellin, was secreted as a particle considerably more dense than HDL3. In the present study we have determined the stoichiometry of the lipid component of the apoB: 931 and apoB: 1000 particles. The secreted [H-3]glycerol- labeled apoB: 1000 particles, isolated by nondenaturing gradient gel electrophoresis, contained 50 phospholipid (PL) and 11 triacylglycerol ( TAG) molecules/ particle. In contrast, apoB: 931 particles contained only a few molecules of PL and were devoid of TAG. The unlabeled apoB: 1000 particles, isolated by immunoaffinity chromatography, contained 56 PL, 8 TAG, and 7 cholesteryl ester molecules/ particle. The surface to core lipid ratio of apoB: 1000-containing particles was similar to4: 1 and was not affected by oleate supplementation. Although very small amounts of microsomal triglyceride transfer protein (MTP) were associated with apoB: 1000 particles, it never approached a 1: 1 molar ratio of MTP to apoB. These results support a model in which (i) the first 1000 amino acid residues of apoB are competent to complete the lipid pocket without a structural requirement for MTP; (ii) a portion, or perhaps all, of the amino acid residues between 931 and 1000 of apoB-100 are critical for the formation of a stable, bulk lipid-containing nascent lipoprotein particle, and (iii) the lipid pocket created by the first 1000 residues of apoB-100 is PL-rich, suggesting a small bilayer type organization and has a maximum capacity on the order of 50 molecules of phospholipid.	Univ Alabama, Med Ctr, Dept Med, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; Univ Alabama, Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Georgia Inst Technol, Dept Biol, Atlanta, GA 30332 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University System of Georgia; Georgia Institute of Technology; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Dashti, N (corresponding author), Univ Alabama, Med Ctr, Dept Med, Atherosclerosis Res Unit, Birmingham, AL 35294 USA.	ndashti@uab.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574, P01HL034343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18574, P01 HL34343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Burch WL, 2000, J BIOL CHEM, V275, P16267, DOI 10.1074/jbc.M000446200; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Dashti N, 2002, J NUTR, V132, P2651, DOI 10.1093/jn/132.9.2651; DASHTI N, 1987, BIOCHEMISTRY-US, V26, P4837, DOI 10.1021/bi00389a035; DASHTI N, 1992, J BIOL CHEM, V267, P7160; EDELSTEIN C, 1979, J LIPID RES, V20, P143; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GERLACH E, 1963, BIOCHEM Z, V337, P477; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Ingram MF, 1997, J BIOL CHEM, V272, P10279; KANE JP, 1975, J CLIN INVEST, V56, P1622, DOI 10.1172/JCI108245; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DM, 1981, BIOCHIM BIOPHYS ACTA, V666, P133, DOI 10.1016/0005-2760(81)90099-0; Liang JS, 2001, J BIOL CHEM, V276, P28606, DOI 10.1074/jbc.M100294200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEREZ LE, 1991, COMP BIOCHEM PHYS B, V100, P821, DOI 10.1016/0305-0491(91)90297-Q; RICHARDSON PE, 2004, IN PRESS BIOPHYS J; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Segrest JP, 1999, J LIPID RES, V40, P1401; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; Shelness GS, 1996, J LIPID RES, V37, P408; STEYRER E, 1990, J BIOL CHEM, V265, P19575; SWIFT LL, 1995, J LIPID RES, V36, P395; Swift LL, 2001, J LIPID RES, V42, P218; WETTERAU JR, 1992, SCIENCE, V258, P999; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1991, J BIOL CHEM, V266, P3300	48	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39757	39766		10.1074/jbc.M406302200	http://dx.doi.org/10.1074/jbc.M406302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15254032	hybrid			2022-12-25	WOS:000223791500069
J	Pineda, AO; Chen, ZW; Caccia, S; Cantwell, AM; Savvides, SN; Waksman, G; Mathews, FS; Di Cera, E				Pineda, AO; Chen, ZW; Caccia, S; Cantwell, AM; Savvides, SN; Waksman, G; Mathews, FS; Di Cera, E			The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; POTENT ANTICOAGULANT; NA+ BINDING	The thrombin mutant W215A/E217A features a drastically impaired catalytic activity toward chromogenic and natural substrates but efficiently activates the anticoagulant protein C in the presence of thrombomodulin. As the remarkable anticoagulant properties of this mutant continue to be unraveled in preclinical studies, we solved the x-ray crystal structures of its free form and its complex with the active site inhibitor H-D-Phe-Pro-Arg- CH2Cl (PPACK). The PPACK-bound structure of W215A/E217A is identical to the structure of the PPACK-bound slow form of thrombin. On the other hand, the structure of the free form reveals a collapse of the 215 - 217 strand that crushes the primary specificity pocket. The collapse results from abrogation of the stacking interaction between Phe-227 and Trp-215 and the polar interactions of Glu-217 with Thr-172 and Lys-224. Other notable changes are a rotation of the carboxylate group of Asp-189, breakage of the H-bond between the catalytic residues Ser-195 and His-57, breakage of the ion pair between Asp-222 and Arg-187, and significant disorder in the 186- and 220-loops that define the Na+ site. These findings explain the impaired catalytic activity of W215A/E217A and demonstrate that the analysis of the molecular basis of substrate recognition by thrombin and other proteases requires crystallization of both the free and bound forms of the enzyme.	Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu	Caccia, Sonia/G-5938-2014; Savvides, Savvas/E-1938-2011	Caccia, Sonia/0000-0003-0829-5379; Savvides, Savvas/0000-0003-3420-5947	NHLBI NIH HHS [HL73813, HL49413, HL58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL058141, R01HL049413, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BODE W, 1992, PROTEIN SCI, V1, P426; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775	26	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39824	39828		10.1074/jbc.M407272200	http://dx.doi.org/10.1074/jbc.M407272200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252033	hybrid			2022-12-25	WOS:000223791500077
J	Rathore, N; Matta, H; Chaudhary, PM				Rathore, N; Matta, H; Chaudhary, PM			An evolutionary conserved pathway of nuclear factor-kappa B activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FADD-DEPENDENT APOPTOSIS; DEATH DOMAIN PROTEIN; IMMUNE-RESPONSES; FACTOR RELISH; DROSOPHILA; TRAIL; RECEPTORS; KINASE; TNF	The Drosophila nuclear factor-kappaB (NF-kappaB)-like transcription factor Relish is activated by an endoproteolytic cleavage step mediated by the Drosophila caspase Dredd. We have examined the contribution of the caspase cascade to NF-kappaB activation via TRAIL, a mammalian tumor necrosis factor family ligand that is a potent activator of caspases. Our results demonstrate that TRAIL activates NF-kappaB in two phases as follows: an early caspase independent phase and a late caspase dependent phase. The late phase of the TRAIL-induced NF-kappaB is critically dependent on caspase 8 and can be blocked by pharmacological and genetic inhibitors of caspase 8 activation, such as benzyloxycarbonyl-VAD-fluoromethyl ketone, benzyloxycarbonyl-IETD-fluoromethyl ketone, and small interfering RNA targeting caspase 8 and FADD. Whereas caspase 3 is required for TRAIL-induced apoptosis, it is not involved in TRAIL-induced NF-kappaB activation. The late phase of TRAIL-induced NF-kappaB activation involves caspase mediated cleavage of IkappaBalpha between Asp(31) and Ser(32) residues to generate an N-terminal truncated fragment that is degraded by the proteasome via the N-end rule pathway. Our results demonstrate that caspases play an evolutionarily conserved role as regulated entry points to the N-end rule pathway and in NF-kappaB activation in mammalian cells.	Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA; Dept Mol Biol, Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), 5117 Ctr Ave,Room 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047230] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/AR47230] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2000, Harvey Lect, V96, P93; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301	43	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39358	39365		10.1074/jbc.M406712200	http://dx.doi.org/10.1074/jbc.M406712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252032	hybrid			2022-12-25	WOS:000223791500021
J	Schmechel, A; Strauss, M; Schlicksupp, A; Pipkorn, R; Haass, C; Bayer, TA; Multhaup, G				Schmechel, A; Strauss, M; Schlicksupp, A; Pipkorn, R; Haass, C; Bayer, TA; Multhaup, G			Human BACE forms dimers and colocalizes with APP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; LIPID RAFTS; CONVERTING-ENZYME; ASPARTYL PROTEASE; DISEASE; CLEAVAGE; PEPTIDE; FAMILY; IDENTIFICATION	beta-Site APP-cleaving enzyme (BACE) is a membranebound aspartyl protease with no strict primary preference for cleavage. The molecular mechanisms that link the gamma-secretase multicomponent amyloid precursor protein (APP) processing complex to biochemical properties of BACE generating the N terminus of the amyloid beta-peptide have not, as yet, been identified. We found that in human brain tissue, BACE occurred as a dimer. The overall stability of the BACE homodimer was based on intermolecular interactions that were not affected by high salt, nonionic detergents or reducing conditions. BACE homodimers could only partially be separated even under strong denaturing conditions and revealed dramatic differences in the surface charge distribution compared with the monomer. In contrast, the soluble ectodomain of truncated BACE revealed a seemingly lower avidity to the prototypic aspartate protease inhibitor pepstatin and exclusively occurred in the monomeric form. Immunocytochemical studies colocalized APP and BACE in the plasma membrane of cells expressing endogenous levels of BACE and overexpressing APP. In cells that were cotransfected with APP and a putative active site D289A mutant of BACE, colocalization persisted. Remaining enzyme activity was found to be attributable to the mutant protease. Accordingly, inactivation of the carboxyl-terminal active site motif of BACE without an impairment of overall enzyme activity suggests that the enzyme may act as a dimer. Thus, homodimerization of BACE may help the enzyme to acquire specific mechanisms to associate with its substrates to exert catalytic activity.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; Deutsch Krebsforschungszentrum, German Canc Res Ctr, D-69120 Heidelberg, Germany; Univ Munich, Adolf Butenandt Inst, Dept Biochem, D-80336 Munich, Germany; Univ Saarland, Med Ctr, Div Neurobiol, Dept Psychiat, D-66421 Homburg, Germany	Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Saarland University	Multhaup, G (corresponding author), Free Univ Berlin, Inst Chem Biochem, Thielallee 63, D-14195 Berlin, Germany.	multhaup@chemie.fu-berlin.de						Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Coulson EJ, 2000, NEUROCHEM INT, V36, P175, DOI 10.1016/S0197-0186(99)00125-4; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; CULVENOR JG, 1995, EXP CELL RES, V220, P474, DOI 10.1006/excr.1995.1339; Davis DA, 2000, BIOCHEM J, V346, P305, DOI 10.1042/0264-6021:3460305; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JONES KS, 1992, J BIOL CHEM, V267, P16037; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARTENBECK J, 1981, EXP CELL RES, V133, P191, DOI 10.1016/0014-4827(81)90369-4; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; KUZMIC P, 1993, BIOCHEM BIOPH RES CO, V191, P998, DOI 10.1006/bbrc.1993.1316; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LI R, 2004, P NATL ACAD SCI US; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Regula JT, 2000, ELECTROPHORESIS, V21, P3765, DOI 10.1002/1522-2683(200011)21:17<3765::AID-ELPS3765>3.0.CO;2-6; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sidera C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-25; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3	55	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39710	39717		10.1074/jbc.M402785200	http://dx.doi.org/10.1074/jbc.M402785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247262	hybrid			2022-12-25	WOS:000223791500063
J	Bao, SZ; Miller, DJ; Ma, ZM; Wohltmann, M; Eng, G; Ramanadham, S; Moley, K; Turk, J				Bao, SZ; Miller, DJ; Ma, ZM; Wohltmann, M; Eng, G; Ramanadham, S; Moley, K; Turk, J			Male mice that do not express group VIA phospholipase A(2) produce spermatozoa with impaired motility and have greatly reduced fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID INCORPORATION; MEDIATES CREB PHOSPHORYLATION; TRANSFECTED INSULINOMA CELLS; PANCREATIC-ISLETS; SPERM-MOTILITY; LITHIATED ADDUCTS; OVEREXPRESS GROUP; CA2+; INHIBITION; MECHANISM	The Group VIA Phospholipase A(2) (iPLA(2)beta) is the first recognized cytosolic Ca2+-independent PLA2 and has been proposed to participate in arachidonic acid ( 20: 4) incorporation into glycerophosphocholine lipids, cell proliferation, exocytosis, apoptosis, and other processes. To study iPLA(2)beta functions, we disrupted its gene by homologous recombination to generate mice that do not express iPLA(2)beta. Heterozygous iPLA(2)beta(+/-) breeding pairs yield a Mendelian 1: 2: 1 ratio of iPLA(2)beta(+/-), iPLA(2)beta(+/-), and iPLA(2)beta(-/-) pups and a 1: 1 male: female gender distribution of iPLA(2)beta(+/-) pups. Several tissues of wild-type mice express iPLA(2)beta mRNA, immunoreactive protein, and activity, and testes express the highest levels. Testes or other tissues of iPLA(2)beta(+/-) mice express no iPLA(2)beta mRNA or protein, but iPLA(2)beta(+/-) testes are not deficient in 20: 4-containing glycerophosphocholine lipids, indicating that iPLA(2)beta does not play an obligatory role in formation of such lipids in that tissue. Spermatozoa from iPLA(2)beta(-/-) mice have reduced motility and impaired ability to fertilize mouse oocytes in vitro and in vivo, and inhibiting iPLA(2)beta with a bromoenol lactone suicide substrate reduces motility of wild-type spermatozoa in a time- and concentration-dependent manner. Mating iPLA(2)beta(-/-) male mice with iPLA(2)beta(+/-), iPLA(2)beta(+/-), or iPLA(2)beta(-/-) female mice yields only about 7% of the number of pups produced by mating pairs with an iPLA(2)beta(+/-) or iPLA(2)beta(-/-) male, but iPLA(2)beta(-/-) female mice have nearly normal fertility. These findings indicate that iPLA(2)beta plays an important functional role in spermatozoa, suggest a target for developing male contraceptive drugs, and complement reports that disruption of the Group IVA PLA(2) (cPLA(2)alpha) gene impairs female reproductive ability.	Washington Univ, Sch Med, Dept Med, Div Endocrinol,Mass Spectrometry Resource, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; CUNY Mt Sinai Sch Med, Div Expt Diabet, New York, NY 10029 USA	Washington University (WUSTL); Washington University (WUSTL); University of Illinois System; University of Illinois Urbana-Champaign; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Turk, J (corresponding author), Washington Univ, Sch Med, Dept Med, Div Endocrinol,Mass Spectrometry Resource, Box 8127,660 S Euclid, St Louis, MO 63110 USA.	jturk@wustl.edu		Bao, Shunzhong/0000-0002-3427-3678	NCRR NIH HHS [P41-RR00954, P41 RR000954] Funding Source: Medline; NHLBI NIH HHS [P01-HL57278, P01 HL057278] Funding Source: Medline; NICHD NIH HHS [R01 HD038311, R01 HD040390, R01-HD38311, HD40390] Funding Source: Medline; NIDDK NIH HHS [P60-DK20579, R01 DK069455, P30 DK056341, R37-DK34388, R37 DK034388, R01-DK063076, P60 DK020579, R01 DK063076, P30-DK56341] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040390] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038311] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388, P30DK056341, R01DK063076, P60DK020579, R01DK069455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Esposito G, 2004, P NATL ACAD SCI USA, V101, P2993, DOI 10.1073/pnas.0400050101; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Ho HC, 2003, BIOL REPROD, V68, P1590, DOI 10.1095/biolreprod.102.011320; Ho HC, 2001, BIOL REPROD, V65, P1606, DOI 10.1095/biolreprod65.5.1606; Hsu FF, 1999, J AM SOC MASS SPECTR, V10, P587, DOI 10.1016/S1044-0305(99)00035-5; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 2001, LIPIDS, V36, P689, DOI 10.1007/s11745-001-0774-9; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Marquez B, 2004, BIOL REPROD, V70, P1626, DOI 10.1095/biolreprod.103.026476; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; MILLER DJ, 1993, J CELL BIOL, V123, P1431, DOI 10.1083/jcb.123.6.1431; MOLEY KH, 1991, J REPROD FERTIL, V93, P325; MURPHY RC, 1990, METHOD ENZYMOL, V187, P90; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; SMANI T, 2000, NATURE CELL BIOL, V6, P113; SUAREZ SS, 1993, P NATL ACAD SCI USA, V90, P4660, DOI 10.1073/pnas.90.10.4660; Talbot P, 2003, BIOL REPROD, V68, P1, DOI 10.1095/biolreprod.102.007856; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Wu CG, 2001, J BIOL CHEM, V276, P26962, DOI 10.1074/jbc.M103107200; Yuan YY, 2003, BIOL REPROD, V68, P904, DOI 10.1095/biolreprod.102.005777	47	136	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38194	38200		10.1074/jbc.M406489200	http://dx.doi.org/10.1074/jbc.M406489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252026	Green Accepted, hybrid			2022-12-25	WOS:000223684100018
J	Chang, LK; Lee, YH; Cheng, TS; Hong, YR; Lu, PJ; Wang, JJ; Wang, WH; Kuo, CW; Li, SSL; Liu, ST				Chang, LK; Lee, YH; Cheng, TS; Hong, YR; Lu, PJ; Wang, JJ; Wang, WH; Kuo, CW; Li, SSL; Liu, ST			Post-translational modification of Rta of Epstein-Barr virus by SUMO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TRANSCRIPTIONAL REPRESSION; UBIQUITIN-CONJUGATING ENZYME; HUMAN CYTOMEGALOVIRUS; LYTIC CYCLE; COVALENT MODIFICATION; PROTEIN MODIFICATION; BRLF1 PROMOTER; ACTIVATION; PML; REQUIRES	Epstein-Barr virus (EBV) expresses an immediate-early protein, Rta, to activate the transcription of EBV lytic genes and the lytic cycle. This work identifies Ubc9 and PIAS1 as binding partners of Rta in a yeast two-hybrid screen. These bindings are verified by glutathione S-transferase pull-down assay, coimmunoprecipitation, and confocal microscopy. The interactions appear to cause Rta sumoylation, because not only can Rta be sumoylated in vitro but also sumoylated Rta can be detected in P3HR1 cells following lytic induction and in 293T cells after transfecting plasmids that express Rta and SUMO-1. Moreover, PIAS1 stimulates conjugation of SUMO-1 to Rta, thus acting as an E3 ligase. Furthermore, transfecting plasmids that express Ubc9, PIAS1, and SUMO-1 increases the capacity of Rta to transactivate the promoter that includes an Rta response element, indicating that the modification by SUMO-1 increases the transactivation activity of Rta. This study reveals that Rta is sumoylated at the Lys-19, Lys-213, and Lys-517 residues and that SUMO-1 conjugation at the Lys-19 residue is crucial for enhancing the transactivation activity of Rta. These results indicate that sumoylation of Rta may be important in EBV lytic activation.	Chang Gung Univ, Dept Microbiol & Immunol, Genet Mol Lab, Taoyuan 333, Taiwan; Kaohsiung Med Univ, Fac Biol Med & Environm Biol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Grad Inst Biochem, Kaohsiung 807, Taiwan; Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan; Natl Def Med Sch, Inst Biol & Anat, Taipei 114, Taiwan; Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan	Chang Gung University; Kaohsiung Medical University; Kaohsiung Medical University; National Defense Medical Center; National Sun Yat Sen University	Liu, ST (corresponding author), Chang Gung Univ, Dept Microbiol & Immunol, Genet Mol Lab, 259 Wen Hua 1st Rd, Taoyuan 333, Taiwan.	cgliu@mail.cgu.edu.tw	Hsiao, Wei-Hung/B-9931-2013	Wang, Wen-Hung/0000-0002-4494-1123; Hong, Yi-Ren/0000-0001-5470-6090				Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; Chang LK, 2000, NUCLEIC ACIDS RES, V28, P3918, DOI 10.1093/nar/28.20.3918; Chang PJ, 1998, J VIROL, V72, P5128, DOI 10.1128/JVI.72.6.5128-5136.1998; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin J, 2002, J VIROL, V76, P232, DOI 10.1128/JVI.76.1.232-242.2002; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Ragoczy T, 1998, J VIROL, V72, P7978, DOI 10.1128/JVI.72.10.7978-7984.1998; Ragoczy T, 2001, J VIROL, V75, P5240, DOI 10.1128/JVI.75.11.5240-5251.2001; Rangasamy D, 2000, J BIOL CHEM, V275, P30487, DOI 10.1074/jbc.M003898200; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Spengler ML, 2002, J VIROL, V76, P2990, DOI 10.1128/JVI.76.6.2990-2996.2002; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Su HL, 2002, GENE, V296, P65, DOI 10.1016/S0378-1119(02)00843-0; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Xu YX, 2001, J VIROL, V75, P10683, DOI 10.1128/JVI.75.22.10683-10695.2001; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Zacny VL, 1998, J VIROL, V72, P8043, DOI 10.1128/JVI.72.10.8043-8051.1998; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	62	77	79	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38803	38812		10.1074/jbc.M405470200	http://dx.doi.org/10.1074/jbc.M405470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15229220	hybrid, Green Published			2022-12-25	WOS:000223684100092
J	Nowak, N; Lotter, H; Tannich, E; Bruchhaus, I				Nowak, N; Lotter, H; Tannich, E; Bruchhaus, I			Resistance of Entamoeba histolytica to the cysteine proteinase inhibitor E64 is associated with secretion of pro-enzymes and reduced pathogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; LIVER-ABSCESS FORMATION; PROTEASE INHIBITORS; TRYPANOSOMA-CRUZI; PLASMODIUM-FALCIPARUM; IN-VITRO; METRONIDAZOLE RESISTANCE; SUPEROXIDE-DISMUTASE; FLUOROMETHYL KETONES; ANTISENSE INHIBITION	Cysteine proteinases (CPs) have been considered suitable targets for the development of antiparasitic drugs. To assess the importance of CPs for the growth and pathogenicity of the protozoan parasite Entamoeba histolytica we have cultured amoebae in the presence of various cysteine proteinase inhibitors (CPIs). It was found that broad range CPIs, which are membrane permeable and rapidly enter the cell, are highly toxic at micromolar concentrations, and all attempts to generate E. histolytica mutants resistant to these CPIs were unsuccessful. In contrast, the broad range CPI E64, which does not permeate membranes as well, was deleterious at much higher concentrations, and amoebae rapidly developed resistance to this inhibitor. Compared with sensitive wild-type cells, E64-resistant E. histolytica were substantially reduced in the expression of various CP genes and were able to secrete unprocessed enzyme into the culture medium. Moreover, E64 resistance was associated with a significant reduction in virulence, because these cells were greatly impaired in the ability to generate liver abscesses in experimentally infected gerbils.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Bruchhaus, I (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	bruchhaus@bni-hamburg.de						Ankri S, 1999, INFECT IMMUN, V67, P421, DOI 10.1128/IAI.67.1.421-422.1999; Ankri S, 1998, MOL MICROBIOL, V28, P777, DOI 10.1046/j.1365-2958.1998.00837.x; ASHALL F, 1990, BIOCHEM BIOPH RES CO, V170, P923, DOI 10.1016/0006-291X(90)92179-4; BAILLY E, 1992, J PROTOZOOL, V39, P593, DOI 10.1111/j.1550-7408.1992.tb04856.x; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; Bente M, 2003, PROTEOMICS, V3, P1811, DOI 10.1002/pmic.200300462; Blessmann J, 2003, J CLIN MICROBIOL, V41, P4745, DOI 10.1128/JCM.41.10.4745-4750.2003; Blessmann J, 2002, NEW ENGL J MED, V347, P1384, DOI 10.1056/NEJM200210243471722; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRACHA R, 1984, J EXP MED, V160, P353, DOI 10.1084/jem.160.2.353; Bruchhaus I, 2003, EUKARYOT CELL, V2, P501, DOI 10.1128/EC.2.3.501-509.2003; Bruchhaus I, 1996, MOL MICROBIOL, V22, P255, DOI 10.1046/j.1365-2958.1996.00111.x; Caffrey C. R., 2000, Current Drug Targets, V1, P155, DOI 10.2174/1389450003349290; Cazzulo Juan Jose, 2002, Current Topics in Medicinal Chemistry, V2, P1261, DOI 10.2174/1568026023392995; Cowman AF, 1995, AUST NZ J MED, V25, P837, DOI 10.1111/j.1445-5994.1995.tb02889.x; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Engel JC, 1998, J CELL SCI, V111, P597; Engel JC, 2000, J CELL SCI, V113, P1345; GATHIRAM V, 1987, S AFR MED J, V72, P669; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; Hellberg A, 2000, MOL BIOCHEM PARASIT, V105, P305, DOI 10.1016/S0166-6851(99)00194-2; Hellberg A, 2001, CELL MICROBIOL, V3, P13, DOI 10.1046/j.1462-5822.2001.00086.x; HOHENBERG H, 1994, J MICROSC-OXFORD, V175, P34, DOI 10.1111/j.1365-2818.1994.tb04785.x; Jacobs T, 1998, MOL MICROBIOL, V27, P269, DOI 10.1046/j.1365-2958.1998.00662.x; Leippe M, 1995, PARASITOLOGY, V111, P569, DOI 10.1017/S0031182000077040; LI E, 1995, INFECT IMMUN, V63, P4150, DOI 10.1128/IAI.63.10.4150-4153.1995; Lotter H, 1997, J EXP MED, V185, P1793, DOI 10.1084/jem.185.10.1793; LUACES AL, 1988, BIOCHEM J, V250, P903, DOI 10.1042/bj2500903; MBAWA ZR, 1992, EUR J BIOCHEM, V204, P371, DOI 10.1111/j.1432-1033.1992.tb16646.x; McKerrow JH, 1999, INT J PARASITOL, V29, P833, DOI 10.1016/S0020-7519(99)00044-2; MCKERROW JH, 1989, EXP PARASITOL, V68, P111, DOI 10.1016/0014-4894(89)90016-7; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Perez-Victoria JM, 2002, CURR DRUG TARGETS, V3, P311, DOI 10.2174/1389450023347588; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Samarawickrema NA, 1997, J ANTIMICROB CHEMOTH, V40, P833, DOI 10.1093/jac/40.6.833; SCHOLZE H, 1988, BIOMED BIOCHIM ACTA, V47, P115; Scory S, 1999, EXP PARASITOL, V91, P327, DOI 10.1006/expr.1998.4381; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; STANLEY SL, 1995, INFECT IMMUN, V63, P1587, DOI 10.1128/IAI.63.4.1587-1590.1995; Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386; Wassmann C, 1999, J BIOL CHEM, V274, P26051, DOI 10.1074/jbc.274.37.26051; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Willhoeft U, 1999, INFECT IMMUN, V67, P5925, DOI 10.1128/IAI.67.11.5925-5929.1999; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x	51	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38260	38266		10.1074/jbc.M405308200	http://dx.doi.org/10.1074/jbc.M405308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15215238	hybrid			2022-12-25	WOS:000223684100025
J	Dhanasekaran, A; Kotamraju, S; Kalivendi, SV; Matsunaga, T; Shang, T; Keszler, A; Joseph, J; Kalyanaraman, B				Dhanasekaran, A; Kotamraju, S; Kalivendi, SV; Matsunaga, T; Shang, T; Keszler, A; Joseph, J; Kalyanaraman, B			Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; REACTIVE OXYGEN; PERMEABILITY TRANSITION; MOLECULAR-MECHANISM; ALPHA-TOCOPHEROL; COMPLEX-I; PROTEASOME; ACTIVATION; RELEASE; DEATH	The mitochondria-targeted drugs mitoquinone (Mito-Q) and mitovitamin E (MitoVit-E) are a new class of antioxidants containing the triphenylphosphonium cation moiety that facilitates drug accumulation in mitochondria. In this study, Mito-Q ( ubiquinone attached to a triphenylphosphonium cation) and MitoVit-E ( vitamin E attached to a triphenylphosphonium cation) were used. The aim of this study was to test the hypothesis that mitochondria-targeted antioxidants inhibit peroxide-induced oxidative stress and apoptosis in bovine aortic endothelial cells ( BAEC) through enhanced scavenging of mitochondrial reactive oxygen species, thereby blocking reactive oxygen species-induced transferrin receptor (TfR)-mediated iron uptake into mitochondria. Glucose/glucose oxidase-induced oxidative stress in BAECs was monitored by oxidation of dichlorodihydrofluorescein that was catalyzed by both intracellular H2O2 and transferrin iron transported into cells. Pretreatment of BAECs with Mito-Q ( 1 muM) and MitoVit-E ( 1 muM) but not untargeted antioxidants ( e. g. vitamin E) significantly abrogated H2O2- and lipid peroxide-induced 2', 7'-dichlorofluorescein fluorescence and protein oxidation. Mitochondria-targeted antioxidants inhibit cytochrome c release, caspase-3 activation, and DNA fragmentation. Mito-Q and MitoVit-E inhibited H2O2- and lipid peroxide-induced inactivation of complex I and aconitase, TfR overexpression, and mitochondrial uptake of Fe-55, while restoring the mitochondrial membrane potential and proteasomal activity. We conclude that Mito-Q or MitoVit-E supplementation of endothelial cells mitigates peroxide-mediated oxidant stress and maintains proteasomal function, resulting in the overall inhibition of TfR-dependent iron uptake and apoptosis.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Dhanasekaran, Anuradha/AFH-8265-2022; Dhanasekaran, Anuradha/AAF-3160-2022	Dhanasekaran, Anuradha/0000-0002-0195-9681	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068769, T35HL007305] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P01HL68769-01, HL07305-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Atamna H, 2001, FASEB J, V15, P2196, DOI 10.1096/fj.01-0134com; AZZONE GF, 1984, CURR TOP BIOENERG, V13, P1; BALLA G, 1992, J BIOL CHEM, V267, P18148; Bartzokis G, 1999, ARCH NEUROL-CHICAGO, V56, P569, DOI 10.1001/archneur.56.5.569; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bernardi P, 1998, BBA-BIOENERGETICS, V1366, P1; BERRY MN, 1991, LAB TECHNIQUES BIOCH, V21, P386; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Burns RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P33, DOI 10.1006/abbi.1996.9861; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRANE FL, 1977, ANNU REV BIOCHEM, V46, P439, DOI 10.1146/annurev.bi.46.070177.002255; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Dick LR, 1997, J BIOL CHEM, V272, P182; Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80; ERNSTER L, 1992, BIOFACTORS, V3, P241; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu M, 1998, J NEUROL SCI, V158, P24, DOI 10.1016/S0022-510X(98)00095-1; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; KAGAN VE, 1994, METHOD ENZYMOL, V234, P343; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASARSKIS EJ, 1995, J NEUROL SCI, V130, P203, DOI 10.1016/0022-510X(95)00037-3; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kotamraju S, 2003, P NATL ACAD SCI USA, V100, P10653, DOI 10.1073/pnas.1933581100; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAND EJ, 1970, J BIOL CHEM, V245, P1890; Lass A, 1998, ARCH BIOCHEM BIOPHYS, V352, P229, DOI 10.1006/abbi.1997.0606; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Lin E, 2001, J BIOL CHEM, V276, P27685, DOI 10.1074/jbc.M100941200; MAGUIRE JJ, 1989, J BIOL CHEM, V264, P21462; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tampo Y, 2003, CIRC RES, V92, P56, DOI 10.1161/01.RES.0000048195.15637.AC; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; ZHAO K, 2004, IN PRESS J BIOL CHEM, V279; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	191	200	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37575	37587		10.1074/jbc.M404003200	http://dx.doi.org/10.1074/jbc.M404003200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15220329	hybrid			2022-12-25	WOS:000223554600049
J	Heine, GF; Hernandez, JM; Grotewold, E				Heine, GF; Hernandez, JM; Grotewold, E			Two cysteines in plant R2R3 MYB domains participate in REDOX-dependent DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; C-MYB; CONSERVED CYSTEINE; GENE FAMILY; IN-VITRO; MAIZE C1; V-MYB; RESIDUES; PROTEIN; RECOGNITION	Plant R2R3 MYB domain proteins comprise one of the largest known families of transcription factors. Discrete evolutionary steps have shaped the plant-specific R2R3 MYB family from the broadly distributed R1R2R3 MYB proteins. R1R2R3 MYB domains have a single Cys residue (Cys-130) that needs to be reduced for DNA binding and transcriptional activity. In contrast, most R2R3 MYB domains contain two cysteines, Cys-49 and Cys-53, with Cys-53 at the equivalent position as Cys-130 in R1R2R3 MYB. Using the maize P1 regulator of flavonoid biosynthesis as a typical R2R3 MYB-domain protein, we investigated here the in vitro REDOX requirement for DNA binding by P1. We show that the C53S mutation requires reducing conditions for DNA-binding, whereas C53A binds DNA under oxidizing and reducing conditions. Neither mutation impairs the in vivo regulatory activity of P1. The C49S and C49A mutants bind DNA in vitro irrespective of the REDOX conditions. A C49I mutant, which simulates the MYB domain of c-MYB, binds DNA only under reducing conditions, and its binding is significantly affected by the C53S replacement. It is interesting that under non-reducing conditions, Cys-49 and Cys-53 form a disulfide bond that prevents the R2R3 MYB domain from binding DNA. Together, our results suggest that the evolutionary origin of Cys-49 within the plants has provided R2R3 MYB domains with a regulatory feature not present in animal MYB domains, highlighting fundamental structural and functional differences between similar DNA-binding domains from plants and animals.	Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Grotewold, E (corresponding author), Ohio State Univ, Ctr Plant Biotechnol, 206 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	grotewold.1@osu.edu		Grotewold, Erich/0000-0002-4720-7290				Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Braun EL, 1999, PLANT PHYSIOL, V121, P21, DOI 10.1104/pp.121.1.21; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Cao X, 2002, BIOCHEM BIOPH RES CO, V297, P288, DOI 10.1016/S0006-291X(02)02196-4; Dias AP, 2003, PLANT PHYSIOL, V131, P610, DOI 10.1104/pp.012047; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; GRASSER FA, 1992, ONCOGENE, V7, P1005; Grotewold E, 2000, P NATL ACAD SCI USA, V97, P13579, DOI 10.1073/pnas.250379897; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; Grotewold E, 1998, PLANT CELL, V10, P721, DOI 10.1105/tpc.10.5.721; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gupta R, 2003, PLANT PHYSIOL, V132, P1149, DOI 10.1104/pp.103.020792; Jiang CH, 2004, GENE, V326, P13, DOI 10.1016/j.gene.2003.09.049; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Lipsick JS, 1996, ONCOGENE, V13, P223; Melcher K, 2000, ANAL BIOCHEM, V277, P109, DOI 10.1006/abio.1999.4383; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; Pinson B, 1998, NUCLEIC ACIDS RES, V26, P3977, DOI 10.1093/nar/26.17.3977; Rabinowicz PD, 1999, GENETICS, V153, P427; Riechmann JL, 2000, CURR OPIN PLANT BIOL, V3, P423, DOI 10.1016/S1369-5266(00)00107-2; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Sainz MB, 1997, PLANT CELL, V9, P611, DOI 10.1105/tpc.9.4.611; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tron AE, 2002, J BIOL CHEM, V277, P34800, DOI 10.1074/jbc.M203297200; Williams CE, 1997, J BIOL CHEM, V272, P563, DOI 10.1074/jbc.272.1.563; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j	34	76	83	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37878	37885		10.1074/jbc.M405166200	http://dx.doi.org/10.1074/jbc.M405166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15237103	hybrid			2022-12-25	WOS:000223554600081
J	Marraffini, LA; Ton-That, H; Zong, YN; Narayana, SVL; Schneewind, O				Marraffini, LA; Ton-That, H; Zong, YN; Narayana, SVL; Schneewind, O			Anchoring of surface proteins to the cell wall of Staphylococcus aureus - A conserved arginine residue is required for efficient catalysis of sortase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOLYTIC AGENT; ION-PAIR; TRANSPEPTIDASE; SUBSTRATE; PAPAIN; PURIFICATION; INTERNALIN; MODEL	Surface proteins of Staphylococcus aureus are anchored to the cell wall envelope by a mechanism requiring a C-terminal sorting signal with an LPXTG motif. Sortase A cleaves surface proteins between the threonine (T) and the glycine (G) residues of the LPXTG motif and catalyzes the formation of an amide bond between the carboxyl group of threonine at the C-terminal end of polypeptides and the amino group of pentaglycine cross-bridges of cell wall peptidoglycan. Previous work showed that Cys(184) and His(120) of sortase A are absolutely essential for catalysis; however an active site thiolate-imidazolium ion pair may not be formed. The three-dimensional crystal structure of sortase A revealed that Arg(197) is located in close proximity to both the active site Cys(184) and the scissile peptide bond between threonine and glycine. We show here that substitution of Arg(197) with alanine, lysine, or histidine severely reduced sortase A function both in vivo and in vitro, whereas Asn(98), which had earlier been implicated in hydrogen bonding to His(120), was found to be dispensable for catalysis. As the structural proximity of Arg(197) and Cys(184) is conserved in sortase enzymes and as ionization of the Cys(184) sulfhydryl group seems required for sortase activity, we propose that Arg(197) may function as a base, facilitating thiolate formation during sortase-mediated cleavage and transpeptidation reactions.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Alabama Birmingham, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA	University of Chicago; University of Chicago; University of Alabama System; University of Alabama Birmingham	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@delphi.bsd.uchicago.edu	Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Comfort D, 2004, INFECT IMMUN, V72, P2710, DOI 10.1128/IAI.72.5.2710-2722.2004; Connolly KM, 2003, J BIOL CHEM, V278, P34061, DOI 10.1074/jbc.M305245200; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Fersht A., 1985, ENZYME STRUCTURE MEC; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Huang XY, 2003, BIOCHEMISTRY-US, V42, P11307, DOI 10.1021/bi034391g; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; LIPMANN F, 1945, J BIOL CHEM, V161, P415; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Strominger J L, 1968, Harvey Lect, V64, P179; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156; Zhang RG, 2004, STRUCTURE, V12, P1147, DOI 10.1016/j.str.2004.06.001; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200; Zong YN, 2004, STRUCTURE, V12, P105, DOI 10.1016/j.str.2003.11.021	41	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37763	37770		10.1074/jbc.M405282200	http://dx.doi.org/10.1074/jbc.M405282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15247224	hybrid			2022-12-25	WOS:000223554600068
J	Samuilova, O; Krogerus, C; Poyry, T; Hyypia, T				Samuilova, O; Krogerus, C; Poyry, T; Hyypia, T			Specific interaction between human parechovirus nonstructural 2A protein and viral RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; HIGH-AFFINITY BINDING; 25K MOVEMENT PROTEIN; NUCLEOCAPSID PROTEIN; REPLICATION COMPLEX; NUCLEIC-ACID; POLY(A)-BINDING PROTEIN; FUNCTIONAL DISSECTION; CLEAVAGE SITE; MOSAIC-VIRUS	The functional properties of the nonstructural 2A protein are variable among different picornaviruses. The 2A protein of the human parechovirus 1 (HPEV1) has been shown to lack the proteolytic activity found in many other picornaviruses, but no particular function has been identified for HPEV1 2A. To obtain information about the role of HPEV1 2A in the viral life cycle, the protein was expressed in Escherichia coli. A polyclonal antibody was then raised against the protein and employed to investigate its subcellular localization in the infected cells by immunofluorescence microscopy. Typically, a diffuse cytoplasmic staining pattern, concentrated to the perinuclear area, was observed in the infected cells. However, at late stages of infection some infected cells also exhibited diffuse nuclear staining. Viral RNA, visualized by fluorescent in situ hybridization, partly colocalized with 2A in the perinuclear region. Three experimental approaches including Northwestern blot, UV crosslinking, and gel retardation demonstrated that 2A possesses RNA binding activity. Competition experiments with various single-stranded RNA molecules addressed the specificity of 2A binding. These studies revealed that the 2A protein bound RNA corresponding to the 3'-untranslated region (UTR) of the viral genome with highest affinity. At the N- and C-terminal ends of the protein, two regions, necessary for RNA binding, were identified by mutagenesis. In addition, we demonstrated that 2A has affinity to double-stranded RNA containing 3' UTR(+)-3' UTR(-). In conclusion, our experiments showed that HPEV1 2A binds to viral 3' UTR RNA, a feature that could be important for the function of the protein during HPEV1 replication.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Oulu, Dept Med Microbiol, Oulu 90014, Finland	University of Helsinki; University of Cambridge; University of Oulu	Samuilova, O (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, POB 21, FIN-00014 Helsinki, Finland.	olga.samuildva@helsinki.fi		Samuilova, Olga/0000-0002-1195-9116				Agol VI, 1999, VIRUS RES, V62, P129, DOI 10.1016/S0168-1702(99)00037-4; Allen P, 1996, VIROLOGY, V225, P306, DOI 10.1006/viro.1996.0605; Aminev AG, 2003, VIRUS RES, V95, P45, DOI 10.1016/S0168-1702(03)00162-X; ANSARDI DC, 1995, J VIROL, V69, P1359, DOI 10.1128/JVI.69.2.1359-1366.1995; Barco A, 2000, J VIROL, V74, P2383, DOI 10.1128/JVI.74.5.2383-2392.2000; Becker MM, 2003, J VIROL, V77, P5948, DOI 10.1128/JVI.77.10.5948-5963.2003; Belov GA, 2000, VIROLOGY, V275, P244, DOI 10.1006/viro.2000.0427; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; BIENZ K, 1994, ARCH VIROL, P147; Bolten R, 1998, J VIROL, V72, P8578, DOI 10.1128/JVI.72.11.8578-8585.1998; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; Daros JA, 1997, VIROLOGY, V237, P327, DOI 10.1006/viro.1997.8802; Dollenmaier G, 2003, J GEN VIROL, V84, P403, DOI 10.1099/VIR.0.18501-0; Donnelly MLL, 1997, J GEN VIROL, V78, P13, DOI 10.1099/0022-1317-78-1-13; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; Egger D, 1999, HISTOCHEM CELL BIOL, V111, P319, DOI 10.1007/s004180050363; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Foeger N, 2003, J BIOL CHEM, V278, P33200, DOI 10.1074/jbc.M304007200; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Hahn H, 2001, J VIROL, V75, P7215, DOI 10.1128/JVI.75.15.7215-7218.2001; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Hiscox JA, 2003, VIRUS RES, V95, P13, DOI 10.1016/S0168-1702(03)00160-6; Hughes PJ, 2000, J GEN VIROL, V81, P201, DOI 10.1099/0022-1317-81-1-201; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Kalinina NO, 1996, FEBS LETT, V397, P75, DOI 10.1016/S0014-5793(96)01138-6; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; Krogerus C, 2003, J VIROL, V77, P8512, DOI 10.1128/JVI.77.15.8512-8523.2003; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; Li QB, 1996, VIROLOGY, V216, P71, DOI 10.1006/viro.1996.0035; Li XY, 2001, J GEN VIROL, V82, P397, DOI 10.1099/0022-1317-82-2-397; Lopez C, 2000, VIROLOGY, V269, P462, DOI 10.1006/viro.2000.0235; Lymperopoulos K, 2003, J BIOL CHEM, V278, P31722, DOI 10.1074/jbc.M301072200; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Marcos JF, 1999, VIROLOGY, V255, P354, DOI 10.1006/viro.1998.9596; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Morozov SY, 1999, VIROLOGY, V260, P55, DOI 10.1006/viro.1999.9788; OBERSTE MS, 1988, NUCLEIC ACIDS RES, V16, P10338; Osborne JC, 2000, J VIROL, V74, P9946, DOI 10.1128/JVI.74.21.9946-9952.2000; OSMAN TAM, 1992, J GEN VIROL, V73, P223, DOI 10.1099/0022-1317-73-2-223; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PALMENBERG AC, 1992, VIROLOGY, V190, P754, DOI 10.1016/0042-6822(92)90913-A; Rajendran KS, 2003, J VIROL, V77, P9244, DOI 10.1128/JVI.77.17.9244-9258.2003; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultheiss T, 1995, BIOCHEM BIOPH RES CO, V217, P1120, DOI 10.1006/bbrc.1995.2885; Stanway G, 1999, J VIROL, V73, P5249, DOI 10.1128/JVI.73.7.5249-5254.1999; Stanway G, 2000, REV MED VIROL, V10, P57, DOI 10.1002/(SICI)1099-1654(200001/02)10:1&lt;57::AID-RMV266&gt;3.0.CO;2-H; Tijms MA, 2002, J GEN VIROL, V83, P795, DOI 10.1099/0022-1317-83-4-795; TILEY LS, 1994, J VIROL, V68, P5108, DOI 10.1128/JVI.68.8.5108-5116.1994; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; Tsai MS, 1999, J VIROL, V73, P3032, DOI 10.1128/JVI.73.4.3032-3039.1999; WEI N, 1991, J MOL BIOL, V222, P437, DOI 10.1016/0022-2836(91)90483-M; Weidman MK, 2003, VIRUS RES, V95, P75, DOI 10.1016/S0168-1702(03)00164-3; Yalamanchili P, 1997, J VIROL, V71, P6881, DOI 10.1128/JVI.71.9.6881-6886.1997; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003; YU SF, 1995, J VIROL, V69, P247, DOI 10.1128/JVI.69.1.247-252.1995; Yue ZY, 1996, J VIROL, V70, P3497, DOI 10.1128/JVI.70.6.3497-3501.1996; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	68	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37822	37831		10.1074/jbc.M314203200	http://dx.doi.org/10.1074/jbc.M314203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226313	hybrid			2022-12-25	WOS:000223554600075
J	Wu, BT; Su, YH; Tsai, MT; Wasserman, SM; Topper, JN; Yang, RB				Wu, BT; Su, YH; Tsai, MT; Wasserman, SM; Topper, JN; Yang, RB			A novel secreted, cell-surface glycoprotein containing multiple epidermal growth factor-like repeats and one CUB domain is highly expressed in primary osteoblasts and bones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED LIGAND; PDGF-BETA-RECEPTOR; ENDOTHELIAL-CELLS; GENE; CALCIUM; DISEASE; BINDS; ALPHA	We have previously identified a novel family of secreted, cell-surface proteins expressed in human vascular endothelium. To date, two family members have been described, sharing a characteristic domain structure including an amino-terminal signal peptide followed by multiple copies of epidermal growth factor (EGF)-like repeats, a spacer region, and one CUB domain at the carboxyl terminus. Thus, this family was termed SCUBE for signal peptide-CUB-EGF-like domain containing proteins. Here we described the identification and characterization of one additional member of the SCUBE family named SCUBE3 in humans, sharing an overall 60% protein identity and a similar domain structure with other family members. Real-time quantitative reverse transcriptase-PCR and Northern blot analyses revealed that this gene is highly expressed in primary osteoblasts and the long bones ( humerus and femur), followed by a low level of expression in human umbilical vein endothelial cells and in heart. When overexpressed in human embryonic kidney 293T cells, the recombinant hSCUBE3 protein is a secreted glycoprotein that can form oligomers tethered to the cell surface. Interestingly, the secreted hSCUBE3 protein can be further proteolytically processed by a serum-associated protease to release the EGF-like repeats from the CUB domain. The SCUBE3 gene is mapped to human chromosome 6p21.3, a region that has been linked with the locus for a rare form of metabolic bone disease, Paget's disease of bone 1. Together, this novel secreted, cell-surface osteoblast protein may act locally and/or distantly through a proteolytic mechanism, and may play an important role in bone cell biology.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Frazier Healthcare Ventures, Palo Alto, CA 94301 USA	Academia Sinica - Taiwan; Stanford University	Yang, RB (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	rbyang@ibms.sinica.edu.tw	Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; DAVIS C G, 1990, New Biologist, V2, P410; Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370; Grimmond S, 2001, MECH DEVELOP, V102, P209, DOI 10.1016/S0925-4773(00)00586-4; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Yang RB, 2002, J BIOL CHEM, V277, P46364, DOI 10.1074/jbc.M207410200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200	21	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37485	37490		10.1074/jbc.M405912200	http://dx.doi.org/10.1074/jbc.M405912200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234972	hybrid			2022-12-25	WOS:000223554600037
J	Opitz, B; Puschel, A; Schmeck, B; Hocke, AC; Rosseau, S; Hammerschmidt, S; Schumann, RR; Suttorp, N; Hippenstiel, S				Opitz, B; Puschel, A; Schmeck, B; Hocke, AC; Rosseau, S; Hammerschmidt, S; Schumann, RR; Suttorp, N; Hippenstiel, S			Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; NF-KAPPA-B; BACTERIAL PEPTIDOGLYCAN; HOST RECOGNITION; FAMILY-MEMBER; CUTTING EDGE; NOD2; LIPOPOLYSACCHARIDE; MENINGITIS; EXPRESSION	Streptococcus pneumoniae, the major cause of community-acquired pneumonia and bacterial meningitis, has been shown to transiently invade epithelial and endothelial cells. Innate immune receptors including Toll-like receptors recognize various pathogens, such as S. pneumoniae, by identifying conserved pathogen-associated molecular patterns. Recently, two members of a novel class of pattern recognition receptors, the cytosolic proteins nucleotide-binding oligomerization domain 1 (Nod1)/CARD4 and Nod2/CARD15, have been found to detect cell wall peptidoglycans. Here we tested the hypothesis that Nod proteins are involved in the intracellular recognition of pneumococci. Data indicate that pneumococci invade HEK293 cells. Genetic complementation studies in these cells demonstrate that NF-kappaB activation induced by S. pneumoniae depends on Nod2. Moreover, intracellular transfection of inactivated pneumococci yielded similar effects, confirming the Nod2 dependence of NF-kappaB activation by pneumococci in HEK293 cells. By dominant negative overexpression and small interfering RNA experiments, we show for the first time that interleukin-1 receptor-associated kinase participates in Nod2-dependent NF-kappaB activation. Additionally, dominant negative interleukin-1 receptor-associated kinase 2, tumor necrosis factor receptor-associated factor 6, NF-kappaB-inducing kinase, transforming growth factor-beta-activated kinase-binding protein 2, and transforming growth factor-beta-activated kinase 1 also inhibited Nod2-dependent NF-kappaB activation. We finally demonstrate that in C57BL/6 mouse lung tissue in vivo as well as in the bronchial epithelial cell line BEAS-2B, Nod1 and Nod2 mRNA expressions were up-regulated after pneumococcal infection. Data presented suggest that Nod proteins contribute to innate immune recognition of S. pneumoniae. Furthermore, Rip-2 and members of the Toll-like receptor- signaling cascade are involved in the Nod2-dependent activation of NF-kappaB induced by pneumococci.	Charite Univ Med Berlin, Dept Internal Med Infect Dis, D-13353 Berlin, Germany; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Charite Univ Med Berlin, Dept Microbiol & Hyg, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hippenstiel, S (corresponding author), Charite Univ Med Berlin, Dept Internal Med Infect Dis, 1 Augustenburger Pl, D-13353 Berlin, Germany.	stefan.hippenstiel@charite.de	Hammerschmidt, Sven/G-2598-2010; Rosseau, Simone/AAO-1201-2020	Hammerschmidt, Sven/0000-0002-6382-6681; Opitz, Bastian/0000-0003-1276-836X; Hippenstiel, Stefan/0000-0002-5146-1064; Suttorp, Norbert/0000-0002-3958-1151				BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hisamatsu T, 2003, J BIOL CHEM, V278, P32962, DOI 10.1074/jbc.M304355200; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koedel U, 2003, J IMMUNOL, V170, P438, DOI 10.4049/jimmunol.170.1.438; Krull M, 1999, J IMMUNOL, V162, P4834; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Ring A, 1998, J CLIN INVEST, V102, P347, DOI 10.1172/JCI2406; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; TIRABY JG, 1973, P NATL ACAD SCI USA, V70, P3541, DOI 10.1073/pnas.70.12.3541; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoshimura A, 1999, J IMMUNOL, V163, P1	30	257	274	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36426	36432		10.1074/jbc.M403861200	http://dx.doi.org/10.1074/jbc.M403861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215247	hybrid			2022-12-25	WOS:000223453600034
J	Yamaguchi, N; Xu, L; Evans, KE; Pasek, DA; Meissner, G				Yamaguchi, N; Xu, L; Evans, KE; Pasek, DA; Meissner, G			Different regions in skeletal and cardiac muscle ryanodine receptors are involved in transducing the functional effects of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; BINDING; APOCALMODULIN; MODULATION; EXPRESSION	Calmodulin (CaM) inhibits the skeletal muscle ryanodine receptor-1 (RyR1) and cardiac muscle RyR2 at micromolar Ca2+ but activates RyR1 and inhibits RyR2 at submicromolar Ca2+ by binding to a single, highly conserved CaM-binding site. To identify regions responsible for the differential regulation of RyR1 and RyR2 by CaM, we generated chimeras encompassing and flanking the CaM-binding domain. We found that the exchange of the N- and C-terminal flanking regions differentially affected RyR1 and RyR2. A RyR1/RyR2 chimera with an N- terminal flanking RyR2 substitution (RyR2 amino acid (aa) 3537-3579) was activated by CaM in single channel measurements at both submicromolar and micromolar Ca2+. A RyR2/RyR1 chimera with a C-terminal flanking the 86-amino acid RyR1 substitution (RyR1 aa 3640-3725) bound S-35-CaM but was not inhibited by CaM at submicromolar Ca2+. In this region, five non-conserved amino acid residues (RyR1 aa 3680 and 3682-3685 and RyR2 aa 3647 and 3649-3652) differentially affect RyR helical probability. Substitution of the five amino acid residues in RyR1 with those of RyR2 showed responses to CaM comparable with wild type RyR1. In contrast, substitution of the five amino acid residues in RyR2 with those of RyR1 showed loss of CaM inhibition, whereas substitution of the five RyR2 sequence residues in the RyR2 chimera containing the RyR1 calmodulin-binding domain and C-flanking sequence restored wild type RyR2 inhibition by CaM at submicromolar Ca2+. The results suggest that different regions are involved in CaM modulation of RyR1 and RyR2. They further suggest that five non-conserved amino acids in the C-terminal region flanking the CaM-binding domain have a key role in CaM inhibition of RyR2.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	meissner@med.unc.edu			NHLBI NIH HHS [HL 73051] Funding Source: Medline; NIAMS NIH HHS [AR 18687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; STULTZ CM, 1997, ADV MOL CEL A&B, V22, P447; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tang W, 2002, FRONT BIOSCI, V7, pD1583, DOI 10.2741/tang; Yamaguchi N, 2003, J BIOL CHEM, V278, P23480, DOI 10.1074/jbc.M301125200; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200; Zhu XS, 2004, CELL CALCIUM, V35, P165, DOI 10.1016/j.ceca.2003.09.002	24	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36433	36439		10.1074/jbc.M405834200	http://dx.doi.org/10.1074/jbc.M405834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15215235	Green Published, hybrid			2022-12-25	WOS:000223453600035
J	Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ				Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ			MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation	ONCOGENE			English	Article						mucin; involution; apoptosis; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; C-SRC; BREAST; APOPTOSIS; EXPRESSION; CLONING; TRANSCRIPTION; ASSOCIATION	MUC1 is a transmembrane mucin that was initially cloned from malignant mammary epithelial cells as a tumor antigen. More than 90% of human breast carcinomas overexpress MUC1. Numerous studies have demonstrated an interaction between MUC1 and other oncogenic proteins such as beta-catenin, erbB receptors and c-Src, but a functional role for MUC1 in transformation has not been identified. We previously reported the development of transgenic mice that overexpress human MUC1 in the mouse mammary gland (MMTV-MUC1). Analysis of these transgenic mice at an early age demonstrated the ability of MUC1 to potentiate EGF-dependent activation of MAP kinase signaling pathways in the lactating mammary gland. We now report that multiparous MMTV-MUC1 transgenic mice stochastically develop unifocal mammary gland carcinomas late in life. Molecular analysis of these tumors shows a tumor-specific coimmunoprecipitation between MUC1 and beta-catenin. Examination of the contralateral glands in MMTV-MUC1 transgenics demonstrates that the development of frank carcinomas is accompanied by a failure of multiparous glands to undergo postlactational involution. Furthermore, uniparous MMTV-MUC1 transgenic mice display decreased postlactational apoptosis, elevated whey acidic protein expression and aberrant pErk2 activation. These findings are the first to determine that MUC1 overexpression promotes in vivo transformation of the mammary gland.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA064389, F32CA081703] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA81703, F32 CA081703, R01CA64389, F32 CA081703-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURDON T, 1991, J BIOL CHEM, V266, P6909; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; Garrity MM, 2003, MODERN PATHOL, V16, P389, DOI 10.1097/01.MP.0000062657.30170.92; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Huang L, 2003, CANCER BIOL THER, V2, P702; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Marti A, 1999, J MAMMARY GLAND BIOL, V4, P145, DOI 10.1023/A:1018721107061; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; PANDEY P, 1995, CANCER RES, V55, P4000; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; Strange R, 2001, MICROSC RES TECHNIQ, V52, P171, DOI 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.3.CO;2-K; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	35	124	139	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5739	5747		10.1038/sj.onc.1207713	http://dx.doi.org/10.1038/sj.onc.1207713			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15221004				2022-12-25	WOS:000222629800003
J	Barnham, KJ; Haeffner, F; Ciccotosto, GD; Curtain, CC; Tew, D; Mavros, C; Beyreuther, K; Carrington, D; Masters, CL; Cherny, RA; Cappai, R; Bush, AI				Barnham, KJ; Haeffner, F; Ciccotosto, GD; Curtain, CC; Tew, D; Mavros, C; Beyreuther, K; Carrington, D; Masters, CL; Cherny, RA; Cappai, R; Bush, AI			Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid	FASEB JOURNAL			English	Article						reactive oxygen species; A beta; AD	HYDROGEN-ATOM TRANSFER; METAL-ION REDUCTION; IRON COMPLEXES; CROSS-LINKING; PEPTIDE; COPPER; NEUROTOXICITY; DITYROSINE; PEROXIDE; OXIDATION	Alzheimer's disease ( AD) is characterized by the presence of neurofibrillary tangles and amyloid plaques, which are abnormal protein deposits. The major constituent of the plaques is the neurotoxic beta-amyloid peptide (Abeta); the genetics of familial AD support a direct role for this peptide in AD. Abeta neurotoxicity is linked to hydrogen peroxide formation. A coordinates the redox active transition metals, copper and iron, to catalytically generate reactive oxygen species. The chemical mechanism underlying this process is not well defined. With the use of density functional theory calculations to delineate the chemical mechanisms that drive the catalytic production of H2O2 by Abeta/Cu, tyrosine10 (Y10) was identified as a pivotal residue for this reaction to proceed. The relative stability of tyrosyl radicals facilitates the electron transfers that are required to drive the reaction. Confirming the theoretical results, mutation of the tyrosine residue to alanine inhibited H2O2 production, Cu-induced radicalization, dityrosine cross-linking, and neurotoxicity.	Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Stockholm Univ, AlbaNova Univ Ctr, Dept Phys, SE-10691 Stockholm, Sweden; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Lab Oxidat Biol,Genet & Aging Res Unit, Charlestown, MA 02129 USA	University of Melbourne; Stockholm University; Monash University; Ruprecht Karls University Heidelberg; Harvard University; Harvard University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.	kbarnham@unimelb.edu.au; bush@helix.mgh.harvard.edu	Cappai, Roberto/B-3347-2010; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019	Cappai, Roberto/0000-0002-9505-8496; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Curtain, Cyril/0000-0001-6955-320X	NATIONAL INSTITUTE ON AGING [R01AG012686] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG12686] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramov AY, 2003, J NEUROSCI, V23, P5088; Atwood CS, 2004, BIOCHEMISTRY-US, V43, P560, DOI 10.1021/bi0358824; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Blomberg MRA, 1997, THEOR CHEM ACC, V97, P72, DOI 10.1007/s002140050239; Blomberg MRA, 1999, MOL PHYS, V96, P571, DOI 10.1080/00268979909482994; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frisch M. J., 1998, GAUSSIAN 98; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hensley K, 1998, J NEUROSCI, V18, P8126; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kato Y, 2000, BIOCHEM BIOPH RES CO, V275, P11, DOI 10.1006/bbrc.2000.3265; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; Mayer JM, 2002, J AM CHEM SOC, V124, P11142, DOI 10.1021/ja012732c; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rogers MS, 2003, CURR OPIN CHEM BIOL, V7, P189, DOI 10.1016/S1367-5931(03)00024-3; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Roth JP, 2001, SCIENCE, V294, P2524, DOI 10.1126/science.1066130; *SCHROD LLC, 2003, JAG 4 0 PROGR; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537; Whittaker JW, 2003, CHEM REV, V103, P2347, DOI 10.1021/cr020425z; Wirstam M, 2003, J AM CHEM SOC, V125, P3980, DOI 10.1021/ja017692r	42	231	235	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1427	+		10.1096/fj.04-1890fje	http://dx.doi.org/10.1096/fj.04-1890fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231727				2022-12-25	WOS:000222979200013
J	Graidist, P; Phongdara, A; Fujise, K				Graidist, P; Phongdara, A; Fujise, K			Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; TUMOR PROTEIN; RNA INTERFERENCE; INSULIN-RECEPTOR; DNA-DAMAGE; APOPTOSIS; BCL-2; SEQUENCE; BAX; HETERODIMERIZATION	Fortilin, a potent 172-amino acid antiapoptotic polypeptide (Li, F., Zhang, D., and Fujise, K. ( 2001) J. Biol. Chem. 276, 47542-47549), binds MCL1, a protein of the antiapoptotic Bcl-2 family. The fortilin-MCL1 interaction stabilizes and increases the half-life of fortilin but not necessarily of MCL1 (Zhang, D., Li, F., Weidner, D., Mnjoyan, Z. H., and Fujise, K. ( 2002) J. Biol. Chem. 277, 37430-37438). It is not known to what extent each protein depends on the other for its apoptotic activity. Here, we present evidence that fortilin and MCL1 are capable of functioning as antiapoptotic proteins independently of each other. Using a robust small interfering RNA (siRNA)-mediated gene silencing system developed in our laboratory, we analyzed the cytoprotective effects of fortilin and MCL1 together and apart in U2OS cell lines exposed to 5-fluorouracil (5-FU) in both monoclonal and polyclonal cell populations. When MCL1 was silenced by MCL1-targeted siRNA, fortilin was still able to protect cells from 5-FU-induced cytotoxicity in a dose-dependent manner. Conversely, when fortilin was silenced by fortilin-targeted siRNA, MCL1 was also able to protect cells from 5-FU-induced cytotoxicity in a dose-dependent manner. Together, these data clearly suggest that fortilin and MCL1 can exert their cytoprotective activities independently of each other. The silencing of fortilin and MCL1 did not qualitatively change the subcellular localization of MCL1 and fortilin, respectively. The biological significance of fortilin-MCL1 interaction may be that it increases cellular resistance to apoptosis by allowing MCL1, an independently antiapoptotic protein, to stabilize another independently antiapoptotic protein, fortilin.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Brown Fdn,Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Prince Songkla Univ, Dept Biochem, Fac Sci, Hat Yai 90112, Songkhla, Thailand	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Prince of Songkla University	Fujise, K (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Brown Fdn,Inst Mol Med Prevent Human Dis, 2121 W Holcombe,Suite 925B, Houston, TX 77030 USA.	Kenichi.Fujise@uth.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04015, HL68024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen E, 2000, EXP CELL RES, V259, P140, DOI 10.1006/excr.2000.4952; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stenmark H, 2001, GENOME BIOL, V2; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Thiele H, 1998, EUR J BIOCHEM, V257, P62, DOI 10.1046/j.1432-1327.1998.2570062.x; Thompson DL, 2003, MOL CELL BIOL, V23, P2277, DOI 10.1128/MCB.23.7.2277-2286.2003; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	33	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40868	40875		10.1074/jbc.M401454200	http://dx.doi.org/10.1074/jbc.M401454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262975	hybrid			2022-12-25	WOS:000223916800082
J	Allam, A; Niiro, H; Clark, EA; Marshall, AJ				Allam, A; Niiro, H; Clark, EA; Marshall, AJ			The adaptor protein Bam32 regulates Rac1 activation and actin remodeling through a phosphorylation-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; KINASE-3 SIGNALING PATHWAY; BRUTONS TYROSINE KINASE; SRC FAMILY KINASES; IMPAIRED B-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; DUAL ADAPTER; CYTOSKELETAL REORGANIZATION; PHOSPHOINOSITIDE 3-KINASE; GUANOSINE TRIPHOSPHATASES	The B cell adaptor molecule of 32 kDa (Bam32) is an adaptor that links the B cell antigen receptor (BCR) to ERK and JNK activation and ultimately to mitogenesis. After BCR cross-linking, Bam32 is recruited to the plasma membrane and accumulates within F-actin-rich membrane ruffles. Bam32 contains one Src homology 2 and one pleckstrin homology domain and is phosphorylated at a single site, tyrosine 139. To define the function of Bam32 in membrane-proximal signaling events, we established human B cell lines overexpressing wild-type or mutant Bam32 proteins. The basal level of F-actin increased in cells expressing wild-type or myristoylated Bam32 but decreased in cells expressing either an Src homology-2 or Tyr-139 Bam32 mutant. Overexpression of wild-type Bam32 also affected BCR-induced actin remodeling, which was visualized as increases in F-actin-rich membrane ruffles. In contrast, Bam32 mutants largely blocked the BCR-induced increase in cellular F-actin. The positive and negative effects of Bam32 variants on F-actin levels were closely mirrored by their effects on the activation of the GTPase Rac1, which is known to regulate actin remodeling in lymphocytes. Bam32-deficient DT40 B cells showed decreased Rac1 activation and a failure of Rac1 to co-localize with the BCR, whereas cells overexpressing Bam32 had increased constitutive Rac1 activation. These results suggest that Bam32 regulates the cytoskeleton through Rac1. Bam32 variants also affected downstream signaling to JNK in a manner similar to that of Rac1, suggesting that the effect of Bam32 on JNK activation may be at least partially mediated through Rac1. Our results demonstrate a novel phosphorylation-dependent function of Bam32 in regulating Rac1 activation and actin remodeling.	Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Manitoba; University of Washington; University of Washington Seattle	Marshall, AJ (corresponding author), Univ Manitoba, Dept Immunol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	marshall@ms.umanitoba.ca	Clark, Edward/K-3462-2012	Clark, Edward A/0000-0001-8061-5475; Marshall, Aaron/0000-0002-1175-5498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045088] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45088] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fournier E, 2003, CURR BIOL, V13, P1858, DOI 10.1016/j.cub.2003.09.034; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Han A, 2003, IMMUNITY, V19, P621, DOI 10.1016/S1074-7613(03)00275-9; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Krahn AK, 2004, J IMMUNOL, V172, P331, DOI 10.4049/jimmunol.172.1.331; KUROKAWA K, 2003, MOL BIOL CELL; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; Marshall AJ, 2002, MOL CELL BIOL, V22, P5479, DOI 10.1128/MCB.22.15.5479-5491.2002; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Niiro H, 2002, J EXP MED, V195, P143, DOI 10.1084/jem.20011524; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Okkenhaug K, 2002, SCIENCE, V297, P1031; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reif K, 2002, TRENDS CELL BIOL, V12, P368, DOI 10.1016/S0962-8924(02)02330-9; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Sanui T, 2003, BLOOD, V102, P2948, DOI 10.1182/blood-2003-01-0173; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Yu WP, 2001, CANCER RES, V61, P6569; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	58	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39775	39782		10.1074/jbc.M403367200	http://dx.doi.org/10.1074/jbc.M403367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15247305	hybrid			2022-12-25	WOS:000223791500071
J	Cheng, B; Feng, JY; Mulay, V; Gadgil, S; Tse-Dinh, YC				Cheng, B; Feng, JY; Mulay, V; Gadgil, S; Tse-Dinh, YC			Site-directed mutagenesis of residues involved in G strand DNA binding by Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BACTERIAL; MECHANISM; CLEAVAGE; COMPLEX; INVIVO; ROLES	Crystal structures of complexes between type IA DNA topoisomerases and single-stranded DNA suggest that the residues Ser-192, Arg-195, and Gln-197 in a conserved region of Escherichia coli topoisomerase I may be important for direct interactions with phosphates on the G strand of DNA, which is the substrate for DNA cleavage and religation (Changela A., DiGate, R. J., and Mondragon, A. ( 2001) Nature 411, 1077 - 1081; Perry, K., and Mondragon, A. ( 2003) Structure 11, 1349 - 1358). Site-directed mutagenesis experiments altering these residues to alanines and other amino acids were carried out to probe the relevance of these interactions in the catalytic activities of the enzyme. The results show that the side chains of Arg-195 and Gln-197 are required for DNA cleavage by the enzyme and are likely to be important for positioning of the G strand of DNA at the active site prior to DNA cleavage. Mutation of Ser-192 did not affect DNA binding and cleavage but nevertheless decreased the overall rate of relaxation of supercoiled DNA probably because of its participation in a later step of the reaction pathway.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Tse-Dinh, YC (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	yuk-ching_tse-dinh@nymc.edu			NIGMS NIH HHS [R01 GM054226] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054226] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; Caron PR, 1999, METH MOL B, V94, P279; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2002, TRENDS PHARMACOL SCI, V23, P199, DOI 10.1016/S0165-6147(02)01997-1; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; Cheng BK, 2004, J BIOL CHEM, V279, P8648, DOI 10.1074/jbc.M312095200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Li ZY, 2001, MOL CELL, V7, P301, DOI 10.1016/S1097-2765(01)00178-2; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Perry K, 2003, STRUCTURE, V11, P1349, DOI 10.1016/j.str.2003.09.013; Perry K, 2002, J BIOL CHEM, V277, P13237, DOI 10.1074/jbc.M112019200; RICHEY B, 1987, J BIOL CHEM, V262, P7157; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 2002, J BIOL CHEM, V277, P1203, DOI 10.1074/jbc.M109436200; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783; Zhu SP, 1999, COMPUTAT ENGN, V1, P1; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	29	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39207	39213		10.1074/jbc.M405891200	http://dx.doi.org/10.1074/jbc.M405891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15215234	hybrid			2022-12-25	WOS:000223791500004
J	Tian, LG; Sayer, JM; Jerina, DM; Shuman, S				Tian, LG; Sayer, JM; Jerina, DM; Shuman, S			Individual nucleotide bases, not base pairs, are critical for triggering site-specific DNA cleavage by vaccinia topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TOPOISOMERASE; CRYSTAL-STRUCTURE; TRANSESTERIFICATION; MECHANISM; BINDING; CATALYSIS; COVALENT	Vaccinia DNA topoisomerase forms a covalent DNA( 3'-phosphotyrosyl)-enzyme intermediate at a specific target site 5'-C(+5)C(+4)C(+3)T(+2)T(+1)pdown arrowN(-1) in duplex DNA. Here we study the effects of abasic lesions at individual positions of the scissile and nonscissile strands on the rate of single-turnover DNA transesterification and the cleavage-religation equilibrium. The rate of DNA incision was reduced by factors of 350, 250, 60, and 10 when abasic sites replaced the - 1N, + 1T, + 2T, and + 4C bases of the scissile strand, but abasic lesions at + 5C and + 3C had little or no effect. Abasic lesions in the nonscissile strand in lieu of + 4G, + 3G, + 2A, and + 1A reduced the rate of cleavage by factors of 130, 150, 10, and 5, whereas abasic lesions at + 5G and - 1N had no effect. The striking positional asymmetry of abasic interference on the scissile and nonscissile strands highlights the importance of individual bases, not base pairs, in promoting DNA cleavage. The rate of single-turnover DNA religation by the covalent topoisomerase-DNA complex was insensitive to abasic sites within the CCCTT sequence of the scissile strand, but an abasic lesion at the 5'-OH nucleoside ( - 1N) of the attacking DNA strand slowed the rate of religation by a factor of 600. Nonscissile strand abasic lesions at + 1A and - 1N slowed the rate of religation by factors of similar to 140 and 20, respectively, and strongly skewed the cleavage-religation equilibrium toward the covalent complex. Thus, abasic lesions immediately flanking the cleavage site act as topoisomerase poisons.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIAID NIH HHS [AI053471] Funding Source: Medline; NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P5449, DOI 10.1093/nar/gkg732; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; Kono H, 1999, PROTEINS, V35, P114, DOI 10.1002/(SICI)1097-0134(19990401)35:1<114::AID-PROT11>3.0.CO;2-T; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 1999, VIROLOGY, V264, P441, DOI 10.1006/viro.1999.0022; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kwon K, 2002, J BIOL CHEM, V277, P345, DOI 10.1074/jbc.M109449200; Nitiss JL, 2001, J BIOL CHEM, V276, P26708, DOI 10.1074/jbc.M102674200; Palaniyar N, 1996, VIROLOGY, V221, P351, DOI 10.1006/viro.1996.0385; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; Yakovleva L, 2004, J BIOL CHEM, V279, P23335, DOI 10.1074/jbc.M401203200; Yakovleva L, 2003, J BIOL CHEM, V278, P42170, DOI 10.1074/jbc.M308079200	37	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39718	39726		10.1074/jbc.M407376200	http://dx.doi.org/10.1074/jbc.M407376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15252055	hybrid			2022-12-25	WOS:000223791500064
J	Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ				Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ			AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity	ONCOGENE			English	Article						AKAP12; alternative promoter; DNA methylation; histone deacetylation; apoptosis	CPG ISLAND METHYLATION; C-KINASE SUBSTRATE; CANCER CELLS; SIGNALING COMPLEXES; LUNG CARCINOMAS; DNA METHYLATION; CYCLIN-D; GENE; PROTEIN; EXPRESSION	AKAP12/Gravin, one of the A-kinase anchoring proteins (AKAPs), functions as a kinase scaffold protein and as a dynamic regulator of the beta(2)-adrenergic receptor complex. However, the biological role of AKAP12 in cancer development is not well understood. The AKAP12 gene encodes two major isoforms of 305 and 287 kDa ( designated AKAP12A and AKAP12B, respectively, in this report). We found that these two isoforms are independently expressed and that they are probably under the control of two different promoters. Moreover, both isoforms were absent from the majority of human gastric cancer cells. The results from methylation-specific PCR (MSP) and bisulfite sequencing revealed that the 5' CpG islands of both AKAP12A and AKAP12B are frequently hypermethylated in gastric cancer cells. Treatment with DNA methyltransferase inhibitor and/or histone deacetylase inhibitor efficiently restored the expression of AKAP12 isoforms, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells. Hypermethylation of AKAP12A CpG island was also detected in 56% ( 10 of 18) of primary gastric tumors. The restoration of AKAP12A in AKAP12-nonexpressing cells reduced colony formation and induced apoptotic cell death. In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Canc Epigenet, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Clin Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/AAC-1146-2020; Kim, Tae-You/J-2750-2012; Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Lee, Dong soon/E-5079-2012	Lee, Jung Weon/0000-0003-2722-8200; Bang, Yung Jue/0000-0001-6000-4597; KIM, TAI YOUNG/0000-0001-8086-2476				Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Conway KE, 2000, CANCER RES, V60, P6236; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Diviani D, 2001, J CELL SCI, V114, P1431; Du Y, 2001, CANCER RES, V61, P8094; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Issa JPJ, 2001, CANCER RES, V61, P3573; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang GH, 2001, CANCER RES, V61, P2847; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Li B, 2001, CANCER RES, V61, P8014; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MILLIKIN D, 1991, CANCER RES, V51, P5449; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Park JH, 2003, CLIN CANCER RES, V9, P433; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Toyooka KO, 2001, CANCER RES, V61, P4556; Xia W, 2001, CANCER RES, V61, P5644; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	40	82	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7095	7103		10.1038/sj.onc.1207932	http://dx.doi.org/10.1038/sj.onc.1207932			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258566				2022-12-25	WOS:000223885100010
J	Du, LL; Moser, BA; Russell, P				Du, LL; Moser, BA; Russell, P			Homo-oligomerization is the essential function of the tandem BRCT domains in the checkpoint protein Crb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; REPRESSIBLE EXPRESSION VECTORS; TUMOR-SUPPRESSOR BRCA1; DOUBLE-STRAND BREAKS; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION CHECKPOINT; CRYSTAL-STRUCTURE; PHOSPHORYLATION; REPAIR	BRCT (BRCA1 C terminus) domains are frequently found as a tandem repeat in proteins involved in DNA damage responses, such as Saccharomyces cerevisiae Rad9, human 53BP1 and BRCA1. Tandem BRCT domains mediate protein-protein and protein-DNA interactions. However, the functional significance of these interactions is largely unknown. Here we report the oligomerization of Schizosaccharomyces pombe checkpoint protein Crb2 through its tandem BRCT domains. Truncated Crb2 without BRCT domains is defective in DNA damage checkpoint signaling. However, addition of either of two heterologous dimerization motifs largely restores the functions of truncated Crb2 without BRCT domains. Replacement of Crb2 BRCT domains with a dimerization motif also renders cells resistant to the dominant negative effect of overexpressing Crb2 BRCT domains. These results demonstrate that the crucial function of the tandem BRCT domains is to oligomerize Crb2.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu		Du, Li-Lin/0000-0002-1028-7397	NCI NIH HHS [CA77325] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077325] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfa C., 1993, EXPT FISSION YEAST L, P133; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Deng CX, 2000, BIOESSAYS, V22, P728; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Du LL, 2003, MOL CELL BIOL, V23, P6150, DOI 10.1128/MCB.23.17.6150-6158.2003; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Hohenstein P, 2003, HUM MOL GENET, V12, pR271, DOI 10.1093/hmg/ddg258; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; KEENEY JB, 1994, GENETICS, V136, P849; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Melcher K, 2000, ANAL BIOCHEM, V277, P109, DOI 10.1006/abio.1999.4383; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; Moreno MB, 2000, YEAST, V16, P861; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Williams RS, 2003, J BIOL CHEM, V278, P53007, DOI 10.1074/jbc.M310182200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38409	38414		10.1074/jbc.M403326200	http://dx.doi.org/10.1074/jbc.M403326200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15229228	hybrid			2022-12-25	WOS:000223684100043
J	Du, LN; Bayir, H; Lai, YC; Zhang, XP; Kochanek, PM; Watkins, SC; Graham, SH; Clark, RSB				Du, LN; Bayir, H; Lai, YC; Zhang, XP; Kochanek, PM; Watkins, SC; Graham, SH; Clark, RSB			Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SEXUAL-DIFFERENTIATION; NITRIC-OXIDE; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; OXIDATIVE STRESS; FACTOR AIF; NEURONS	Many central nervous system (CNS) diseases display sexual dimorphism. Exposure to circulating sex steroids is felt to be a chief contributor to this phenomenon; however, CNS diseases of childhood and the elderly also demonstrate gender predominance and/or a sexually dimorphic response to therapies. Here we show that XY and XX neurons cultured separately are differentially susceptible to various cytotoxic agents and treatments. XY neurons were more sensitive to nitrosative stress and excitotoxicity versus XX neurons. In contrast, XX neurons were more sensitive to etoposide- and staurosporine-induced apoptosis versus XY neurons. The responses to specific therapies were also sexually dimorphic. Moreover, gender proclivity in programmed cell death pathway was observed. After cytotoxic challenge, programmed cell death proceeded predominately via an apoptosis-inducing factor-dependent pathway in XY neurons versus a cytochrome c-dependent pathway in XX neurons. This gender-dependent susceptibility is related to the incapacity of XY neurons to maintain intracellular levels of reduced glutathione. In vivo studies further demonstrated an incapacity for male, but not female, 17-day-old rats to maintain reduced glutathione levels within cerebral cortex acutely after an 8-min asphyxial cardiac arrest. This gender difference in sensitivity to cytotoxic agents may be generalized to non-neuronal cells, as splenocytes from male and female 16-18-day-old rats show similar gender-dependent responses to nitrosative stress and staurosporine-induced apoptosis. These data support gender stratification in the evaluation of mechanisms and treatment of CNS disease, particularly those where glutathione may play a role in detoxification, such as Parkinson's disease, traumatic brain injury, and conditions producing cerebral ischemia, and may apply to non-CNS diseases as well.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Watkins, Simon/ABG-2590-2021; Kochanek, Patrick M/D-2371-2015	Watkins, Simon/0000-0003-4092-1552; Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506	NICHD NIH HHS [T32 HD40686] Funding Source: Medline; NINDS NIH HHS [R01 NS38620, P50 NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS030318, R01NS038620] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Canals S, 2001, J NEUROCHEM, V76, P56, DOI 10.1046/j.1471-4159.2001.00010.x; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; FIX AS, 1995, BRAIN RES, V696, P194, DOI 10.1016/0006-8993(95)00842-E; Gambassi G, 1999, NEUROLOGY, V53, P508, DOI 10.1212/WNL.53.3.508; Hariz GM, 2003, ACTA NEUROL SCAND, V108, P28, DOI 10.1034/j.1600-0404.2003.00092.x; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Hurvitz E A, 1999, Pediatr Rehabil, V3, P43; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishii E, 2001, MED PEDIATR ONCOL, V37, P10, DOI 10.1002/mpo.1156; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; MACLUSKY NJ, 1981, SCIENCE, V211, P1294, DOI 10.1126/science.6163211; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Nunez JL, 2001, J COMP NEUROL, V436, P32; Picazo O, 2003, BRAIN RES, V990, P20, DOI 10.1016/S0006-8993(03)03380-8; REISERT I, 1989, CELL TISSUE RES, V255, P411; Sacco RL, 2001, NEUROLOGY, V57, pS31, DOI 10.1212/WNL.57.suppl_2.S31; Singer CA, 1999, J NEUROSCI, V19, P2455; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Ueki A, 2001, INT J GERIATR PSYCH, V16, P810, DOI 10.1002/gps.419.abs; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; van Lieshout EMM, 1998, CARCINOGENESIS, V19, P1873, DOI 10.1093/carcin/19.10.1873; Vukmir RB, 2003, J WOMENS HEALTH, V12, P667, DOI 10.1089/154099903322404311; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Weil MD, 1998, JAMA-J AM MED ASSOC, V279, P1474, DOI 10.1001/jama.279.18.1474; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1995, J NEUROCHEM, V65, P1411; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	42	261	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38563	38570		10.1074/jbc.M405461200	http://dx.doi.org/10.1074/jbc.M405461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234982	hybrid			2022-12-25	WOS:000223684100062
J	Gai, DH; Li, DW; Finkielstein, CV; Ott, RD; Taneja, P; Fanning, E; Chen, XJS				Gai, DH; Li, DW; Finkielstein, CV; Ott, RD; Taneja, P; Fanning, E; Chen, XJS			Insights into the oligomeric states, conformational changes, and helicase activities of SV40 large tumor antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN; SIMIAN-VIRUS-40 DNA-REPLICATION; CELLULAR-TRANSFORMATION; BINDING DOMAINS; HOST-RANGE; ORIGIN; INITIATION	The large T (LT) antigen encoded by SV40 virus is a multi-domain, multi-functional protein that can not only transform cells but can also function as an efficient molecular machine to unwind duplex DNA for DNA replication. Here we report our findings on the oligomeric forms, domain interactions, and ATPase and helicase activities of various LT constructs. For the LT constructs that hexamerize, only two oligomeric forms, hexameric and monomeric, were detected in the absence of ATP/ADP. However, the presence of ATP/ADP stabilizes LT in the hexameric form. The LT constructs lacking the N- and C-terminal domains, but still retaining hexamerization ability, have ATPase as well as helicase activities at a level comparable to the full-length LT, suggesting the importance of hexamerization for these activities. The domain structures and the possible interactions between different LT fragments were probed with limited protease ( trypsin) digestion. Such protease digestion generated a distinct pattern in the presence and absence of ATP/ADP and Mg2+. The most C-terminal fragment ( residues 628 - 708, containing the host-range domain), which was thought to be completely unstructured, was somewhat trypsin-resistant despite the presence of multiple Arg and Lys, possibly due to a rather structured C terminus. Furthermore, the N- and C-terminal fragments cleaved by trypsin were associated with other parts of the molecule, suggesting the interdomain interactions for the fragments at both ends.	Univ Colorado, Hlth Sci Ctr, Sch Med, Denver, CO 80262 USA; Vanderbilt Univ, Nashville, TN 37235 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University	Chen, XJS (corresponding author), Univ So Calif, Los Angeles, CA 90089 USA.	Xiaojiac@usc.edu	Li, Dawei/I-8751-2016	Li, Dawei/0000-0003-4133-1263; finkielstein, carla/0000-0002-8417-4643				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; HOSS A, 1990, J VIROL, V64, P4799; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; Luo XL, 1996, NAT STRUCT BIOL, V3, P1034, DOI 10.1038/nsb1296-1034; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; PIPAS JM, 1985, J VIROL, V54, P569, DOI 10.1128/JVI.54.2.569-575.1985; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; Weisshart K, 2004, J BIOL CHEM, V279, P38943, DOI 10.1074/jbc.M406159200; Wu CX, 1998, J VIROL, V72, P10256, DOI 10.1128/JVI.72.12.10256-10259.1998; WUNKIM K, 1993, J VIROL, V67, P7608, DOI 10.1128/JVI.67.12.7608-7611.1993; WUNKIM K, 1990, J VIROL, V64, P2014, DOI 10.1128/JVI.64.5.2014-2020.1990	32	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38952	38959		10.1074/jbc.M406160200	http://dx.doi.org/10.1074/jbc.M406160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247252	hybrid			2022-12-25	WOS:000223684100109
J	Grant, M; Patel, RC; Kumar, U				Grant, M; Patel, RC; Kumar, U			The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DIMERIZATION; AGONIST; HORMONE; CELLS; OLIGOMERIZATION; HETERODIMERIZATION; EXPRESSION; ASSEMBLE; SURFACE	G-protein-coupled receptors (GPCRs) represent the largest and most diverse family of cell surface receptors. Several GPCRs have been documented to dimerize with resulting changes in pharmacology. We have previously reported by means of photobleaching fluorescence resonance energy transfer (pbFRET) microscopy and fluorescence correlation spectroscopic (FCS) analysis in live cells, that human somatostatin receptor (hSSTR) 5 could both homodimerize and heterodimerize with hSSTR1 in the presence of the agonist SST-14. In contrast, hSSTR1 remained monomeric when expressed alone regardless of agonist exposure in live cells. In an effort to elucidate the role of ligand and receptor subtypes in heterodimerization, we have employed both pbFRET microscopy and Western blot on cells stably coexpressing hSSTR1 and hSSTR5 treated with subtype-specific agonists. Here we provide evidence that activation of hSSTR5 but not hSSTR1 is necessary for heterodimeric assembly. This property was also reflected in signaling as shown by increases in adenylyl cyclase coupling efficiencies. Furthermore, receptor C-tail chimeras allowed for the identification of the C-tail as a determinant for dimerization. Finally, we demonstrate that heterodimerization is subtype-selective involving ligand-induced conformational changes in hSSTR5 but not hSSTR1 and could be attributed to molecular events occurring at the C-tail. Understanding the mechanisms by which GPCRs dimerize holds promise for improvements in drug design and efficacy.	McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs Diabet Res, Montreal, PQ H3A 1A1, Canada; Clarkson Univ, Dept Chem & Phys, Potsdam, NY 13699 USA	McGill University; Royal Victoria Hospital; Clarkson University	Kumar, U (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs Diabet Res, Room M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	ujendra.kumar@muhc.mcgill.ca		Grant, Michael/0000-0003-3758-5009				AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Hukovic N, 1999, J BIOL CHEM, V274, P24550, DOI 10.1074/jbc.274.35.24550; Jaquet P, 1999, J CLIN ENDOCR METAB, V84, P3268, DOI 10.1210/jc.84.9.3268; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; Latif R, 2002, J BIOL CHEM, V277, P45059, DOI 10.1074/jbc.M206693200; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Pagano A, 2001, J NEUROSCI, V21, P1189; Patel RC, 2002, METHODS, V27, P340, DOI 10.1016/S1046-2023(02)00092-0; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Shimon I, 1997, J CLIN INVEST, V100, P2386, DOI 10.1172/JCI119779; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6	40	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38636	38643		10.1074/jbc.M406276200	http://dx.doi.org/10.1074/jbc.M406276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247250	hybrid			2022-12-25	WOS:000223684100071
J	Siddals, KW; Marshman, E; Westwood, M; Gibson, JM				Siddals, KW; Marshman, E; Westwood, M; Gibson, JM			Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion - Synergy between protein prenylation and receptor glycosylation pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; SMOOTH-MUSCLE-CELLS; COENZYME-A REDUCTASE; ALTERNATIVE GLYCOSYLATION; DOLICHYL-PHOSPHATE; ALPHA-SUBUNIT; PROLIFERATION; INHIBITION; LOVASTATIN; APOPTOSIS	The vasculoprotective effects of hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins) correlate with cholesterol lowering. HMG-CoA reductase inhibitors also disrupt cellular processes by the depletion of isoprenoids and dolichol. Insulin and insulin-like growth factor (IGF) signaling appear particularly prone to such disruption as intracellular receptor processing requires dolichol for correct N-glycosylation, whereas downstream signaling through Ras requires the appropriate prenylation (farnesol). We determined how HMG-CoA reductase inhibition affected the mitogenic effects of IGF-I and metabolic actions of insulin in 3T3-L1 cells and examined the respective roles of receptor glycosylation and Ras prenylation. IGF-I- and insulin-induced proliferation was significantly reduced by all statins tested, although cerivastatin (10 nM) had the greatest effect (p<0.005). Although inhibitors of Ras prenylation induced similar results (10 mu M FTI-277 89%+/- 7.4%, p<0.01), the effect of HMG-CoA reductase inhibition could only be partially reversed by farnesyl pyrophosphate refeeding. Treatment with statins resulted in decreased membrane expression of receptors and accumulation of proreceptors, suggesting disruption of glycosylation-dependent cleavage. Glycosylation inhibitors inhibited IGF-I-induced proliferation (tunicamycin p<0.005, castanospermine p<0.01, deoxymannojirimycin p<0.01). High concentrations of statin were necessary to impair insulin-mediated glucose uptake (300 nM=33%+/- 12% p<0.05), and this process was not effected by farnesyl transferase inhibition. Gycosylation inhibitors mimicked the effect of statin treatment (tunicamycin p<0.001, castanospermine p<0.05, deoxymannojirimycin p<0.05), and there was insulin proreceptor accumulation. These data imply that HMG-CoA reductase inhibitors disrupt IGF-I signaling by combined effects on Ras prenylation and IGF receptor glycosylation, whereas insulin signaling is only affected by disrupted receptor glycosylation.	Univ Manchester, Manchester M13 9PT, Lancs, England; Hope Hosp, Salford M6 8HD, Lancs, England	University of Manchester	Gibson, JM (corresponding author), Hope Hosp, Salford M6 8HD, Lancs, England.	martin.gibson@man.ac.uk	Westwood, Melissa/G-5954-2015	Westwood, Melissa/0000-0001-9725-7010; gibson, martin/0000-0002-1331-1524				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021-9150(97)00319-5; Bouterfa HL, 2000, ANTICANCER RES, V20, P2761; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; Carlberg M, 1996, J BIOL CHEM, V271, P17453, DOI 10.1074/jbc.271.29.17453; CARLBERG M, 1993, ANTICANCER RES, V13, P167; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; Cuthbert JA, 1997, CANCER RES, V57, P3498; Dricu A, 1997, GLYCOBIOLOGY, V7, P625, DOI 10.1093/glycob/7.5.625; Furst J, 2002, CELL PHYSIOL BIOCHEM, V12, P19, DOI 10.1159/000047823; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Goalstone M, 1997, BIOCHEM BIOPH RES CO, V239, P42, DOI 10.1006/bbrc.1997.7413; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GOTTSCHALK S, 1989, BIOL CHEM H-S, V370, P75, DOI 10.1515/bchm3.1989.370.1.75; GRANT M, 1987, J CLIN ENDOCR METAB, V65, P370, DOI 10.1210/jcem-65-2-370; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; Heald AH, 2001, DIABETOLOGIA, V44, P333, DOI 10.1007/s001250051623; Hwang JB, 2000, BBA-MOL CELL RES, V1499, P74, DOI 10.1016/S0167-4889(00)00109-9; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Johnson MD, 2002, J NEURO-ONCOL, V56, P133, DOI 10.1023/A:1014588214966; LARSSON O, 1993, GLYCOBIOLOGY, V3, P475, DOI 10.1093/glycob/3.5.475; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LECONTE I, 1994, J BIOL CHEM, V269, P18062; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; MartinezGonzalez J, 1996, EUR J CLIN INVEST, V26, P1023, DOI 10.1046/j.1365-2362.1996.2550586.x; MASUNO H, 1991, BIOCHEM J, V277, P801, DOI 10.1042/bj2770801; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Morishita R, 2002, CURR DRUG TARGETS, V3, P379, DOI 10.2174/1389450023347434; Padayatty SJ, 1997, J CLIN ENDOCR METAB, V82, P1434, DOI 10.1210/jc.82.5.1434; Porter KE, 2002, J VASC SURG, V36, P150, DOI 10.1067/mva.2002.122029; REEDQUIST KA, 1995, BIOCHEM BIOPH RES CO, V211, P665, DOI 10.1006/bbrc.1995.1863; Renier G, 1996, ENDOCRINOLOGY, V137, P4611, DOI 10.1210/en.137.11.4611; Rubins JB, 1998, AM J RESP CRIT CARE, V157, P1616, DOI 10.1164/ajrccm.157.5.9709020; Sandhu MS, 2002, LANCET, V359, P1740, DOI 10.1016/S0140-6736(02)08655-5; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SCHROEPFER GJ, 1981, ANNU REV BIOCHEM, V50, P585, DOI 10.1146/annurev.bi.50.070181.003101; SHIMIZU M, 1986, BIOCHEM BIOPH RES CO, V137, P552, DOI 10.1016/0006-291X(86)91246-5; Siddals KW, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740289; Skaletz-Rorowski A, 2001, EUR J CELL BIOL, V80, P207, DOI 10.1078/0171-9335-00155; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Solomon CS, 2002, BIOCHEM BIOPH RES CO, V291, P458, DOI 10.1006/bbrc.2002.6471; SOMA MR, 1992, TOXICOL LETT, V64-5, P1, DOI 10.1016/0378-4274(92)90167-I; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Wang M, 1999, EXP CELL RES, V246, P38, DOI 10.1006/excr.1998.4280; Yoshimatsu K, 1997, Gan To Kagaku Ryoho, V24, P1495	53	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38353	38359		10.1074/jbc.M404838200	http://dx.doi.org/10.1074/jbc.M404838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247258	hybrid			2022-12-25	WOS:000223684100036
J	Suyama, E; Wadhwa, R; Kaur, K; Miyagishi, M; Kaul, SC; Kawasaki, H; Taira, K				Suyama, E; Wadhwa, R; Kaur, K; Miyagishi, M; Kaul, SC; Kawasaki, H; Taira, K			Identification of metastasis-related genes in a mouse model using a library of randomized ribozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMICS APPROACH; RNA; CLEAVAGE; CELLS	Libraries of randomized ribozymes have considerable potential as tools for the identification of functional genes critically involved in a biological phenotype of interest in vitro. We have used a ribozyme library in an in vivo mouse model to identify genes related to metastasis. We injected weakly metastatic melanoma cells that had been treated with the library intravenously into mice. We then isolated ribozymes that accelerated metastasis from pulmonary tumors that had developed from metastasizing cells. As candidates for metastasis-related genes that were targets of the isolated ribozymes, we identified five unknown and three known genes: stromal interaction molecule 1 (STIM1), polymerase gamma2 accessory subunit (Polg2), and cytochrome P450, family 2, subfamily d, polypeptide 22 (Cyp2d22). Repression of four of these by small interfering RNAs indeed resulted in the accelerated mobility of cells in in vitro scratch-wound assay. The further characterization of these candidate genes would provide clues to the complex mechanism(s) of metastasis.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Taira, K (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	taira@chembio.t.u-tokyo.ac.jp	Kaul, Sunil C/L-8671-2018; Miyagishi, Makoto/L-8174-2016; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Miyagishi, Makoto/0000-0001-7654-3616; Wadhwa, Renu/0000-0001-8248-5192				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; ETTENSON DS, 1995, ARTERIOSCL THROM VAS, V15, P515, DOI 10.1161/01.ATV.15.4.515; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GASTELAND RF, 1999, RNA WORLD; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HOLLAND JF, 2000, CANC MED; Kawasaki H, 2002, NAT BIOTECHNOL, V20, P376, DOI 10.1038/nbt0402-376; Kawasaki H, 2002, EMBO REP, V3, P443, DOI 10.1093/embo-reports/kvf098; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566; KRUPP G, 2000, RIBOZYME BIOCH BIOTE; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Li QX, 2000, NUCLEIC ACIDS RES, V28, P2605, DOI 10.1093/nar/28.13.2605; Magdalena J, 2003, J CELL SCI, V116, P743, DOI 10.1242/jcs.00288; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NELSON LD, 2003, TARGETS, V2, P191; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Sabbioni S, 1997, CANCER RES, V57, P4493; SUYAMA E, 2003, P NATL ACAD SCI USA, V63, P119; Tannock I, 1998, BASIC SCI ONCOLOGY; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WADHWA R, 2004, IN PRESS REV MUTAT R; Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230; Zhou DM, 1998, CHEM REV, V98, P991, DOI 10.1021/cr9604292	28	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38083	38086		10.1074/jbc.C400313200	http://dx.doi.org/10.1074/jbc.C400313200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247279	hybrid			2022-12-25	WOS:000223684100002
J	Macchioni, L; Corazzi, L; Nardicchi, V; Mannucci, R; Arcuri, C; Porcellati, S; Sposini, T; Donato, R; Goracci, G				Macchioni, L; Corazzi, L; Nardicchi, V; Mannucci, R; Arcuri, C; Porcellati, S; Sposini, T; Donato, R; Goracci, G			Rat brain cortex mitochondria release group II secretory phospholipase A(2) under reduced membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; HUMAN SYNOVIAL-FLUID; NEURODEGENERATIVE DISEASES; HUMAN-PLATELETS; CELL-DEATH; RECOMBINANT EXPRESSION; CEREBRAL-CORTEX; GERBIL BRAIN; ISCHEMIA	Activation of brain mitochondrial phospholipase(s) A(2) (PLA(2)) might contribute to cell damage and be involved in neurodegeneration. Despite the potential importance of the phenomenon, the number, identities, and properties of these enzymes are still unknown. Here, we demonstrate that isolated mitochondria from rat brain cortex, incubated in the absence of respiratory substrates, release a Ca2+-dependent PLA(2) having biochemical properties characteristic to secreted PLA(2) (sPLA(2)) and immunoreacting with the antibody raised against recombinant type IIA sPLA(2) (sPLA(2)-IIA). Under identical conditions, no release of fumarase in the extramitochondrial medium was observed. The release of sPLA2 from mitochondria decreases when mitochondria are incubated in the presence of respiratory substrates such as ADP, malate, and pyruvate, which causes an increase of transmembrane potential determined by cytofluorimetric analysis using DiOC(6)(3) as a probe. The treatment of mitochondria with the uncoupler carbonyl cyanide 3-chlorophenylhydrazone slightly enhances sPLA(2) release. The increase of sPLA(2) specific activity after removal of mitochondrial outer membrane indicates that the enzyme is associated with mitoplasts. The mitochondrial localization of the enzyme has been confirmed by electron microscopy in U-251 astrocytoma cells and by confocal laser microscopy in the same cells and in PC-12 cells, where the structurally similar isoform type V-sPLA(2) has mainly nuclear localization. In addition to sPLA(2), mitochondria contain another phospholipase A(2) that is Ca2+-independent and sensitive to bromoenol lactone, associated with the outer mitochondrial membrane. We hypothesize that, under reduced respiratory rate, brain mitochondria release sPLA(2)-IIA that might contribute to cell damage.	Univ Perugia, Dept Internal Med, Div Biochem, I-06125 Perugia, Italy; Univ Perugia, Lab Image Anal, I-06125 Perugia, Italy; Univ Perugia, Dept Expt Med & Biochem Sci, I-06125 Perugia, Italy	University of Perugia; University of Perugia; University of Perugia	Goracci, G (corresponding author), Univ Perugia, Dept Internal Med, Div Biochem, Via Giochetto, I-06125 Perugia, Italy.	goracci@unipg.it	mannucci, roberta/AAE-6662-2020; Donato, Rosario/I-3943-2019; NARDICCHI, VINCENZA/C-1138-2012	Macchioni, Lara/0000-0001-5293-4604; PORCELLATI, Serena/0000-0003-3410-5452; CORAZZI, Lanfranco/0000-0001-5184-6610; Arcuri, Cataldo/0000-0002-3114-8812				Aarsman AJ, 2000, BBA-MOL BASIS DIS, V1502, P257, DOI 10.1016/S0925-4439(00)00050-8; AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Arai K, 2001, EUR J NEUROSCI, V13, P2319, DOI 10.1046/j.0953-816x.2001.01623.x; Arita K, 2001, BIOCHEM PHARMACOL, V62, P821, DOI 10.1016/S0006-2952(01)00723-7; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1971, ACTA PHYSIOL LAT AM, V21, P101; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P452; Bonventre JV, 1996, J LIPID MEDIAT CELL, V14, P15, DOI 10.1016/0929-7855(96)00503-2; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; CAMICI O, 1995, J MEMBRANE BIOL, V148, P169; Camici O, 1997, MOL CELL BIOCHEM, V175, P71, DOI 10.1023/A:1006889328983; Capper EA, 2001, PROG LIPID RES, V40, P167, DOI 10.1016/S0163-7827(01)00002-9; CARLEMALM E, 1985, J MICROSC-OXFORD, V140, P55, DOI 10.1111/j.1365-2818.1985.tb02660.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; CHEN J, 1994, J BIOL CHEM, V269, P2365; Copic A, 1999, J BIOL CHEM, V274, P26315, DOI 10.1074/jbc.274.37.26315; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dorandeu F, 1998, J NEUROSCI RES, V51, P349, DOI 10.1002/(SICI)1097-4547(19980201)51:3<349::AID-JNR8>3.0.CO;2-G; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Goracci G, 1978, Adv Prostaglandin Thromboxane Res, V3, P55; Grassi S, 1998, J NEUROPHYSIOL, V79, P3266, DOI 10.1152/jn.1998.79.6.3266; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JESSE RL, 1979, BIOCHIM BIOPHYS ACTA, V575, P467, DOI 10.1016/0005-2760(79)90117-6; KALOUS M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P167, DOI 10.1016/S0005-2728(05)80332-9; Kishimoto K, 1999, NEUROSCIENCE, V92, P1061, DOI 10.1016/S0306-4522(99)00051-2; Kolko M, 1999, NEUROSCI LETT, V274, P167, DOI 10.1016/S0304-3940(99)00709-0; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kramer RM, 1996, J LIPID MEDIAT CELL, V14, P3, DOI 10.1016/0929-7855(96)01501-5; KRAMER RM, 1990, ADV PROSTAG THROMB L, V20, P79; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Li W, 1999, J INTERF CYTOK RES, V19, P121, DOI 10.1089/107999099314261; LINDAHL M, 1993, INFLAMMATION, V17, P573, DOI 10.1007/BF00914195; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MASSICOTTE G, 1990, NEUROSCI LETT, V118, P245, DOI 10.1016/0304-3940(90)90638-P; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; Molloy GY, 1998, NEUROSCI LETT, V258, P139, DOI 10.1016/S0304-3940(98)00838-6; Monni M, 2000, J MEMBRANE BIOL, V173, P97, DOI 10.1007/s002320001011; MUELLER HW, 1993, THROMB RES, V72, P519, DOI 10.1016/0049-3848(93)90112-2; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055; Nucciarelli F, 1999, FEBS LETT, V450, P39, DOI 10.1016/S0014-5793(99)00436-6; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; PERCY AK, 1983, ARCH BIOCHEM BIOPHYS, V223, P484, DOI 10.1016/0003-9861(83)90613-6; Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4; Piccotti L, 2002, J BIOL CHEM, V277, P12075, DOI 10.1074/jbc.M200029200; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RORDORF G, 1991, J NEUROSCI, V11, P1829; RUSTENBECK I, 1991, BIOCHIM BIOPHYS ACTA, V1069, P99, DOI 10.1016/0005-2736(91)90109-L; Rustenbeck I, 1996, BBA-LIPID LIPID MET, V1304, P129, DOI 10.1016/S0005-2760(96)00113-0; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Sharpe M, 1997, BIOCHEM CELL BIOL, V75, P71, DOI 10.1139/bcb-75-1-71; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P52, DOI 10.1006/abbi.2000.2195; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thomas G, 2000, J BIOL CHEM, V275, P10876, DOI 10.1074/jbc.275.15.10876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; van der Helm HA, 2000, BBA-MOL CELL BIOL L, V1484, P215, DOI 10.1016/S1388-1981(00)00021-4; VANSCHAIK RHN, 1993, INT J BIOCHEM, V25, P433, DOI 10.1016/0020-711X(93)90636-S; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; WOELK H, 1973, H-S Z PHYSIOL CHEM, V354, P90, DOI 10.1515/bchm2.1973.354.1.90; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053	89	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37860	37869		10.1074/jbc.M303855200	http://dx.doi.org/10.1074/jbc.M303855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15231825	hybrid			2022-12-25	WOS:000223554600079
J	Wu, J; Kuo, YP; George, AA; Xu, L; Hu, J; Lukas, RJ				Wu, J; Kuo, YP; George, AA; Xu, L; Hu, J; Lukas, RJ			beta-amyloid directly inhibits human alpha 4 beta 2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC CHOLINERGIC-RECEPTOR; ALZHEIMERS-DISEASE; HIGH-AFFINITY; MICE LACKING; PEPTIDE; BRAIN; HIPPOCAMPAL; SUBUNITS; NEURONS; PLASMA	Amyloid-beta (Abeta) accumulation and aggregation are thought to contribute to the pathogenesis of Alzheimer's disease ( AD). In AD, there is a selective decrease in the numbers of radioligand binding sites corresponding to the most abundant nicotinic acetylcholine receptor ( nAChR) subtype, which contains human alpha4 and beta2 subunits (halpha4beta2-nAChR). However, the relationships between these phenomena are uncertain, and effects of Abeta on halpha4beta2-nAChR function have not been investigated in detail. We first confirmed expression of halpha4 and hbeta2 subunits as messenger RNA in transfected, human SH-EP1 cells by reverse transcription-polymerase chain reaction and mRNA fluorescence in situ hybridization analyses. Immunoprecipitation Western analyses confirmed alpha4 and beta2 subunit protein expression and coassembly. Whole cell current recording demonstrated heterologous expression in SH-EP1-halpha4beta2 cells of functional halpha4beta2-nAChRs with characteristic responses to nicotinic agonists or antagonists. Nicotine-induced whole cell currents were suppressed by Abeta(1-42) in a dose-dependent manner. Functional inhibition was selective for Abeta(1-42) compared with the functionally inactive, control peptide Abeta(40-1). Abeta(1-42)-mediated inhibition of halpha4beta2-nAChR function was non-competitive, voltage-independent, and use-independent. Pre-loading of cells with guanyl-5'-yl thiophosphate failed to prevent Abeta(1-42)-induced inhibition, suggesting that down-regulation of halpha4beta2-nAChR function by Abeta(1-42) is not mediated by nAChR internalization. Sensitivity to Abeta(1-42) antagonism at 1 nM was evident for halpha4beta2-nAChRs, but not for heterologously expressed human alpha7-nAChRs, although both nAChR subtypes were functionally inhibited by 100 nM Abeta(1-42), with the magnitude of functional block being higher for 100 nM Abeta(1-42) acting on halpha7-nAChRs. These findings suggest that halpha4beta2-nAChRs are sensitive and perhaps pathophysiologically relevant targets for Abeta neurotoxicity in AD.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; St Josephs Hosp, Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Wu, J (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	jwu2@chw.edu	Wu, Jie/E-8906-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040417] Funding Source: NIH RePORTER; NINDS NIH HHS [NS040417] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER SPH, 2001, TRENDS PHARM SCI REC; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; BENCHERIF M, 1993, J NEUROCHEM, V61, P852, DOI 10.1111/j.1471-4159.1993.tb03596.x; Court J, 2001, BIOL PSYCHIAT, V49, P175, DOI 10.1016/S0006-3223(00)01116-1; Coyle J, 2001, BIOL PSYCHIAT, V49, P289, DOI 10.1016/S0006-3223(00)01101-X; Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200; Eaton JB, 2003, MOL PHARMACOL, V64, P1283, DOI 10.1124/mol.64.6.1283; Fenster CP, 1999, MOL PHARMACOL, V55, P432; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Fu W, 2003, J NEUROPHYSIOL, V90, P3130, DOI 10.1152/jn.00616.2003; GALDZICKI Z, 1994, BRAIN RES, V646, P332, DOI 10.1016/0006-8993(94)90101-5; Grassi F, 2003, J PHYSIOL-LONDON, V547, P147, DOI 10.1113/jphysiol.2002.035436; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kanfer JN, 1999, NEUROCHEM RES, V24, P1621, DOI 10.1023/A:1021172620295; Kar S, 1996, J NEUROSCI, V16, P1034; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; KUO YP, 2002, SOC NEUR ASTR, V28; Lindstrom J, 1996, Ion Channels, V4, P377; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; Lukas RJ, 1999, PHARMACOL REV, V51, P397; LUKAS RJ, 1998, NICOTINIC ACETYLCHOL, P145; LUKAS RJ, 2000, NICOTINIC ACETYLCHOL; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Maelicke A, 2001, BIOL PSYCHIAT, V49, P279, DOI 10.1016/S0006-3223(00)01109-4; Mark RJ, 1997, J NEUROSCI, V17, P1046; Martin-Ruiz CM, 1999, J NEUROCHEM, V73, P1635, DOI 10.1046/j.1471-4159.1999.0731635.x; Marubio LM, 2003, EUR J NEUROSCI, V17, P1329, DOI 10.1046/j.1460-9568.2003.02564.x; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; NORDBERG A, 1990, J NEURAL TRANSM-PARK, V2, P215, DOI 10.1007/BF02257652; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; Nordberg A, 1997, DEMENT GERIATR COGN, V8, P78, DOI 10.1159/000106611; NORDBERG A, 1995, ALZ DIS ASSOC DIS, V9, P21, DOI 10.1097/00002093-199505000-00006; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Pedersen WA, 1996, P NATL ACAD SCI USA, V93, P8068, DOI 10.1073/pnas.93.15.8068; Peng JH, 1999, BRAIN RES, V825, P172, DOI 10.1016/S0006-8993(99)01066-5; Pettit DL, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-01-j0003.2001; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; PRINCE DL, 1998, ANNU REV NEUROSCI, V21, P479; PUCHACZ E, 1994, FEBS LETT, V354, P155, DOI 10.1016/0014-5793(94)01108-7; Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Sparks DL, 1998, NEUROSCI LETT, V256, P151, DOI 10.1016/S0304-3940(98)00794-0; Tozaki H, 2002, BIOCHEM BIOPH RES CO, V294, P42, DOI 10.1016/S0006-291X(02)00429-1; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2000, J NEUROCHEM, V75, P1155, DOI 10.1046/j.1471-4159.2000.0751155.x; Warpman U, 1995, NEUROREPORT, V6, P2419, DOI 10.1097/00001756-199511270-00033; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; Wu J, 2002, J NEUROCHEM, V83, P87, DOI 10.1046/j.1471-4159.2002.01099.x; Wu J, 1996, BRIT J PHARMACOL, V119, P1013, DOI 10.1111/j.1476-5381.1996.tb15772.x; Zhao LK, 2003, J PHARMACOL EXP THER, V305, P1132, DOI 10.1124/jpet.103.048777	61	94	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37842	37851		10.1074/jbc.M400335200	http://dx.doi.org/10.1074/jbc.M400335200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15234980	hybrid			2022-12-25	WOS:000223554600077
J	Abdollahi, A; Domhan, S; Jenne, JW; Hallaj, M; Dell' Aqua, G; Mueckenthaler, M; Richter, A; Martin, H; Debus, J; Ansorge, W; Hynynen, K; Huber, PE				Abdollahi, A; Domhan, S; Jenne, JW; Hallaj, M; Dell' Aqua, G; Mueckenthaler, M; Richter, A; Martin, H; Debus, J; Ansorge, W; Hynynen, K; Huber, PE			Apoptosis signals in lymphoblasts induced by focused ultrasound	FASEB JOURNAL			English	Article						FUS; p53; bcl-2	BINDING PROTEIN TAXREB107; IN-VITRO; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNA; PLASMID DNA; CELL-LINES; P53; BREAST; TRANSFECTION	We investigated the effects of focused ultrasound (FUS) on specific molecular signaling and cellular response in three closely related human Tk6 lymphoblast cell lines that differed only in their p53 status. The applied ultrasound parameters fell between the physical dose range, which is safely used in medical diagnostics (peak pressure< 0.1 MPa) and that used for high-energy FUS thermal ablation therapy (peak pressure>10 MPa). Based on cDNA microarrays and protein analysis, we found that FUS at the intermediate peak pressure of 1.5 MPa induced a complex signaling cascade with upregulation of proapoptotic genes [e.g., p53, p21, Thy1 (CD 90)]. Simultaneously, FUS downregulated cellular survival components (e.g., bcl-2, SOD). The p53 status was important for the reaction of the cells to ultrasound. Apoptosis and G(1) arrest were induced primarily in p53+ cells, while p53- cells showed less apoptosis but exhibited G(2) arrest. Likewise, the proliferation of lymphoblasts was much more strongly inhibited in p53+ than in p53- cells. Microarray analysis further demonstrated an upregulation of genes involved in oxidative stress ( e. g., ferritin), suggesting that indirect sonochemical effects via reactive oxygen species play a causative role in the interaction of ultrasound with lymphoblasts. An important characteristic of FUS in therapeutic ultrasound applications is its ability to be administered to the human body in a targeted manner while sparing intermediate tissues. Therefore, our data indicate that this noninvasive, mechanical wave transmission, which is free of ionizing radiation, has the potential to specifically induce localized cell signals and apoptosis.	Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Radiat Oncol, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huber, PE (corresponding author), Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Radiat Oncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.huber@dkfz.de	Ansorge, Wilhelm/AAN-8780-2020					Ashush H, 2000, CANCER RES, V60, P1014; BARNARD GF, 1992, CANCER RES, V52, P3067; BARNETT SB, 1994, ULTRASOUND MED BIOL, V20, P205, DOI 10.1016/0301-5629(94)90060-4; BATAILLE R, 1984, BLOOD, V63, P468; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; CASPARY WJ, 1979, MOL PHARMACOL, V16, P256; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; Debus J, 1999, ULTRASOUND MED BIOL, V25, P301, DOI 10.1016/S0301-5629(98)00143-4; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; DUNN F, 1975, J ACOUST SOC AM, V58, P512, DOI 10.1121/1.380666; EDMONDS PD, 1983, ULTRASOUND MED BIOL, V9, P635, DOI 10.1016/0301-5629(83)90009-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRY WJ, 1955, SCIENCE, V122, P517, DOI 10.1126/science.122.3168.517; Fujita N, 1997, EXP CELL RES, V232, P400, DOI 10.1006/excr.1997.3505; HALDAR S, 1994, CANCER RES, V54, P2095; Hall EJ, 2000, RADIOBIOLOGY RADIOLO, P588; Halliwell B., 1999, FREE RADICAL BIO MED, P936; HENRY JL, 1993, CANCER RES, V53, P1403; Hileman Elizabeth A, 2001, Expert Opin Ther Targets, V5, P697, DOI 10.1517/14728222.5.6.697; Hill CR, 1995, BRIT J RADIOL, V68, P1296, DOI 10.1259/0007-1285-68-816-1296; Honda H, 2002, ULTRASOUND MED BIOL, V28, P673, DOI 10.1016/S0301-5629(02)00509-4; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huber PE, 2003, GENE THER, V10, P1600, DOI 10.1038/sj.gt.3302045; Huber PE, 2000, GENE THER, V7, P1516, DOI 10.1038/sj.gt.3301242; Huber PE, 2001, RADIAT RES, V156, P301, DOI 10.1667/0033-7587(2001)156[0301:TCIVAR]2.0.CO;2; Huber PE, 2001, CANCER RES, V61, P8441; Hynynen K, 2001, RADIOLOGY, V219, P176, DOI 10.1148/radiology.219.1.r01ap02176; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Killeen N, 1997, CURR BIOL, V7, pR774, DOI 10.1016/S0960-9822(06)00402-7; Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339; Lagneaux L, 2002, EXP HEMATOL, V30, P1293, DOI 10.1016/S0301-472X(02)00920-7; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Miller DL, 1996, ULTRASOUND MED BIOL, V22, P681, DOI 10.1016/0301-5629(95)02077-2; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; MOAN J, 1979, NATURE, V279, P450, DOI 10.1038/279450a0; MORITA T, 1993, AIDS RES HUM RETROV, V9, P115, DOI 10.1089/aid.1993.9.115; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; NACKEN W, 1995, BBA-GENE STRUCT EXPR, V1261, P432, DOI 10.1016/0167-4781(95)00046-J; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pani G, 2000, CANCER RES, V60, P4654; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Richter A, 2002, BIOTECHNIQUES, V33, P620, DOI 10.2144/02333rr05_11834a; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUSLICK KS, 1987, NATURE, V330, P553, DOI 10.1038/330553a0; Tabuchi Y, 2002, BIOCHEM BIOPH RES CO, V290, P498, DOI 10.1006/bbrc.2001.6203; Tata DB, 1997, BIOCHEM BIOPH RES CO, V234, P64, DOI 10.1006/bbrc.1997.6578; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Tyurina YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P413, DOI 10.1006/abbi.1997.0201; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vykhodtseva N, 2001, ULTRASOUND MED BIOL, V27, P111, DOI 10.1016/S0301-5629(00)00275-1; Xu WX, 2000, BIOCHEM BIOPH RES CO, V278, P318, DOI 10.1006/bbrc.2000.3792; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	62	55	65	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1413	+		10.1096/fj.04-1601fje	http://dx.doi.org/10.1096/fj.04-1601fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15231731				2022-12-25	WOS:000222979200019
J	Hegde, S; Pahne, J; Smola-Hess, S				Hegde, S; Pahne, J; Smola-Hess, S			Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappa B binding activity and CCR7 expression	FASEB JOURNAL			English	Article						antigen presenting cells; cytokines; chemotaxis; nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; BLOOD MONONUCLEAR-CELLS; CHEMOKINE RECEPTOR; IMMUNE-RESPONSE; UP-REGULATION; TNF-ALPHA; C-JUN; IL-6; LIPOPOLYSACCHARIDE	Interleukin-6 (IL-6) is produced during bacterial and viral infections and by various malignant tumors. Here, we describe novel immunosuppressive properties of IL-6 in dendritic cells ( DC). In the presence of GM-CSF, IL-4, and a maturation stimulus, IL-6 skewed monocyte differentiation into phenotypically mature but functionally impaired DC. In DC matured with the toll-like receptor (TLR) 4 stimulus lipopolysaccharide (LPS) or other pro-inflammatory stimuli, IL-6 inhibited CCR7 chemokine receptor up-regulation. As demonstrated for LPS-stimulated DC, IL-6 impaired chemotaxis to CCR7-activating chemokines required for recruiting DC to lymphoid tissues in vivo. Moreover, IL-6 inhibited production of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma inducible protein-10 (IP-10) in DC, and DC-driven allogeneic T cell proliferation in mixed lymphocyte reactions. CCR7 expression was blocked at the transcriptional level. IL-6 led to inhibition of nuclear factor-kappaB (NF-kappaB) binding activity, regulating CCR7 transcription. Neutralization experiments revealed that autocrine IL-10 partially contributed to CCR7 suppression in IL-6-treated DC. Thus IL-6, a cytokine once labeled as "proinflammatory," can mediate immunosuppressive functions, which may involve induction of the classical " anti-inflammatory" cytokine IL-10. Because IL-6 is expressed in response to various pro-inflammatory stimuli in vivo, this mechanism may contribute to down-regulating the immune response initiated by pathogens, in persistent infections or tumors.	Univ Cologne, Inst Virol, D-50935 Cologne, Germany	University of Cologne	Smola-Hess, S (corresponding author), Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany.	s.smola@uni-koeln.de	Hegde, Subramanya/B-4626-2008					ADERKA D, 1989, J IMMUNOL, V143, P3517; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Allavena P, 1997, ADV EXP MED BIOL, V417, P323; Ardeshna KM, 2002, BRIT J HAEMATOL, V119, P826, DOI 10.1046/j.1365-2141.2002.03869.x; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BLAY JY, 1992, CANCER RES, V52, P3317; BOT FJ, 1989, BLOOD, V73, P435; Brossart P, 2000, CANCER RES, V60, P4485; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; Buelens C, 1997, EUR J IMMUNOL, V27, P756, DOI 10.1002/eji.1830270326; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HESS S, 1995, J IMMUNOL, V155, P4588; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hess S, 2000, J IMMUNOL, V165, P1939, DOI 10.4049/jimmunol.165.4.1939; Hirano T, 1998, Int Rev Immunol, V16, P249; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; La Flamme AC, 2000, J IMMUNOL, V164, P2419, DOI 10.4049/jimmunol.164.5.2419; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mitani H, 2000, BRIT J HAEMATOL, V109, P288, DOI 10.1046/j.1365-2141.2000.02020.x; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neumann M, 2000, BLOOD, V95, P277; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Orsini E, 2003, CANCER RES, V63, P4497; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sato K, 1999, J IMMUNOL, V162, P3865; SCHINDLER R, 1990, BLOOD, V75, P40; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Takayama T, 2001, J IMMUNOL, V166, P7136, DOI 10.4049/jimmunol.166.12.7136; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	57	115	121	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1439	+		10.1096/fj.03-0969fje	http://dx.doi.org/10.1096/fj.03-0969fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247147				2022-12-25	WOS:000222979200009
J	Warnecke, C; Zaborowska, Z; Kurreck, J; Erdmann, VA; Frei, U; Wiesener, M; Eckardt, KU				Warnecke, C; Zaborowska, Z; Kurreck, J; Erdmann, VA; Frei, U; Wiesener, M; Eckardt, KU			Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells	FASEB JOURNAL			English	Article						hypoxia-responsive element; EPO; HLF	PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; HIF-ALPHA; EXPRESSION; HIF-1-ALPHA; HOMEOSTASIS; ENHANCER; O-2; VHL; FACTOR-1-ALPHA	Activation of the hypoxia-inducible factor alpha-subunits, HIF-1alpha and HIF-2alpha, seems to be subject to similar regulatory mechanisms, and transgene approaches suggested partial functional redundancy. Here, we used RNA interference to determine the contribution of HIF-1alpha vs. HIF-2alpha to the hypoxic gene induction. Surprisingly, most genes tested were responsive only to the HIF-1alpha siRNA, showing no effect by HIF-2alpha knock-down. The same was found for the activation of reporter genes driven by hypoxia-responsive elements (HREs) from the erythropoietin (EPO), vascular endothelial growth factor, or phosphoglycerate kinase gene. Interestingly, EPO was the only gene investigated that showed responsiveness only to HIF-2alpha knock-down, as observed in Hep3B and Kelly cells. In contrast to the EPO-HRE reporter, the complete EPO enhancer displayed dependency on HIF-2alpha regulation, indicating that additional cis-acting elements confer HIF-2alpha specificity within this region. In 786-0 cells lacking HIF-1alpha protein, the identified HIF-1alpha target genes were regulated by HIF-2alpha. Overexpression of the HIFalpha subunits in different cell lines also led to a loss of target gene specificity. In conclusion, we found a remarkably restricted target gene specificity of the HIFalpha subunits, which can be overcome in cells with perturbations in the pVHL/HIF system and under forced expression.	Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany; Charite, Virchow Clin, Dept Nephrol & Med Intens Care, Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Warnecke, C (corresponding author), Univ Erlangen Nurnberg, Med Klin 4, VMD Nephrol Forschungslab, Loschgestr 8 1-2, D-91054 Erlangen, Germany.	christina.warnecke@med4.imed.uni-erlangen.de	Kurreck, Jens/B-7785-2008	Kurreck, Jens/0000-0002-1469-0052				Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; KOURY ST, 1988, BLOOD, V71, P524; LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sowter HM, 2003, CANCER RES, V63, P6130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wykoff CC, 2000, CANCER RES, V60, P7075; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	44	320	338	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1462	+		10.1096/fj.04-1640fje	http://dx.doi.org/10.1096/fj.04-1640fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15240563				2022-12-25	WOS:000222979200017
J	Recio, E; Colinas, A; Rumbero, A; Aparicio, JF; Martin, JF				Recio, E; Colinas, A; Rumbero, A; Aparicio, JF; Martin, JF			PI factor, a novel type quorum-sensing inducer elicits pimaricin production in Streptomyces natalensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYENE MACROLIDE PIMARICIN; COELICOLOR A3(2); BUTYROLACTONE AUTOREGULATORS; ANTIBIOTIC BIOSYNTHESIS; SECONDARY METABOLISM; GAMMA-BUTYROLACTONE; GENOME SEQUENCE; NOCARDIA-SP; B-FACTOR; SYNTHASE	A chemically novel autoinducer ( PI factor) has been purified from cultures of the pimaricin producer Streptomyces natalensis ATCC27448. The chemical structure of the PI molecule was identified as 2,3-diamino-2,3-bis ( hydroxymethyl)-1,4-butanediol. Pimaricin biosynthesis in S. natalensis npi287, a mutant impaired in pimaricin production, was restored by supplementation with either A-factor from Streptomyces griseus IFO13350 or with PI factor. S. natalensis did not synthesize A-factor. The PI autoinducer was active at very low concentrations ( 50 - 350 nM). A threshold level of 50 nM was required to observe the induction effect. The dose-response curve was typical of a quorum-sensing type mechanism. The biosynthesis of PI factor was associated with cell growth of S. natalensis, both in defined and complex media. Supplementation of the wild-type S. natalensis with pure PI ( 300 nM) resulted in a stimulation of 33% of the production of pimaricin. These results indicate that the endogenous synthesis of PI factor is limiting for pimaricin biosynthesis in the wild-type strain. This water-soluble PI factor belongs to a novel class of autoinducers in Streptomyces species different from the classical butyrolactone autoinducers. Because restoration of pimaricin production in the npi287 mutant is conferred by both A-factor and PI factor, S. natalensis appears to be able to integrate different quorum signals from actinomycetes.	Univ Leon, Fac Ciencias Biol & Ambientales, Area Microbiol, E-24071 Leon, Spain; Inst Biotecnol Leon INBIOTEC, Leon 24006, Spain; Univ Autonoma Madrid, Fac Ciencias, Dept Quim Organ, E-28049 Madrid, Spain	Universidad de Leon; Autonomous University of Madrid	Martin, JF (corresponding author), Univ Leon, Fac Ciencias Biol & Ambientales, Area Microbiol, Campus Vegazana, E-24071 Leon, Spain.	degjmm@unileon.es	Aparicio, Jesús F./K-8686-2014	Aparicio, Jesús F./0000-0003-4242-4701				ALLISON C, 1991, SCI PROG, V75, P403; Anton N, 2004, J BACTERIOL, V186, P2567, DOI 10.1128/JB.186.9.2567-2575.2004; Aparicio JF, 2000, CHEM BIOL, V7, P895, DOI 10.1016/S1074-5521(00)00038-7; Aparicio JF, 2003, APPL MICROBIOL BIOT, V61, P179, DOI 10.1007/s00253-002-1183-5; Aparicio JF, 1999, J BIOL CHEM, V274, P10133, DOI 10.1074/jbc.274.15.10133; BAINTON NJ, 1992, GENE, V116, P87, DOI 10.1016/0378-1119(92)90633-Z; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; CHATER KF, 1997, BIOTECHNOLOGY, V7, P57; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; GIL JA, 1985, J GEN MICROBIOL, V131, P1279; GIL JA, 1997, BIOTECHNOLOGY ANTIBI, V19, P551; Holden MTG, 1999, MOL MICROBIOL, V33, P1254, DOI 10.1046/j.1365-2958.1999.01577.x; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HORINOUCHI S, 1985, J ANTIBIOT, V38, P636, DOI 10.7164/antibiotics.38.636; HORINOUCHI S, 1992, ANNU REV MICROBIOL, V46, P377, DOI 10.1146/annurev.micro.46.1.377; HORINOUCHI S, 1990, CRIT REV BIOTECHNOL, V10, P191, DOI 10.3109/07388559009038207; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; Kawabuchi M, 1997, FEMS MICROBIOL LETT, V157, P81, DOI 10.1111/j.1574-6968.1997.tb12756.x; KAWAGUCHI T, 1988, J ANTIBIOT, V41, P360, DOI 10.7164/antibiotics.41.360; KAWAGUCHI T, 1984, J ANTIBIOT, V37, P1587, DOI 10.7164/antibiotics.37.1587; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kinoshita H, 1999, J BACTERIOL, V181, P5075, DOI 10.1128/JB.181.16.5075-5080.1999; Kitani S, 2001, J BACTERIOL, V183, P4357, DOI 10.1128/JB.183.14.4357-4363.2001; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Koshla C., 1999, ANNU REV BIOCHEM, V68, P219; Martin J F, 1977, Annu Rev Microbiol, V31, P13, DOI 10.1146/annurev.mi.31.100177.000305; MARTIN JF, 1976, EUR J APPL MICROBIOL, V3, P135, DOI 10.1007/BF00928432; Martin JF, 2000, ENCY MICROBIOLOGY, V4, P213; Mendes MV, 2001, CHEM BIOL, V8, P635, DOI 10.1016/S1074-5521(01)00033-3; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Robson ND, 1997, TRENDS BIOTECHNOL, V15, P458, DOI 10.1016/S0167-7799(97)01102-5; SAKUDA S, 1991, TETRAHEDRON LETT, V32, P1817, DOI 10.1016/S0040-4039(00)74338-3; Sim KL, 1997, GLYCOCONJUGATE J, V14, P661, DOI 10.1023/A:1018505130422; Stratigopoulos G, 2002, MOL MICROBIOL, V45, P735, DOI 10.1046/j.1365-2958.2002.03044.x; Takano E, 2000, J BIOL CHEM, V275, P11010, DOI 10.1074/jbc.275.15.11010; VONDOHREN H, 1997, BIOTECHNOLOGY, V7, P1; YAMADA Y, 1999, COMPREHENSIVE NATURA, V8, P377; YAMADA Y, 1987, J ANTIBIOT, V40, P96504; [No title captured]	41	78	91	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41586	41593		10.1074/jbc.M402340200	http://dx.doi.org/10.1074/jbc.M402340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15231842	hybrid			2022-12-25	WOS:000224075500043
J	Seo, SY; Chen, YB; Ivanovska, I; Ranger, AM; Hong, SJ; Dawson, VL; Korsmeyer, SJ; Bellows, DS; Fannjiang, Y; Hardwick, JM				Seo, SY; Chen, YB; Ivanovska, I; Ranger, AM; Hong, SJ; Dawson, VL; Korsmeyer, SJ; Bellows, DS; Fannjiang, Y; Hardwick, JM			BAD is a pro-survival factor prior to activation of its pro-apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; CELL-DEATH; CYTOCHROME-C; BCL-2 FAMILY; MITOCHONDRIAL APOPTOSIS; ALPHAVIRUS INFECTION; CLEAVAGE; PROTEIN; CONVERSION; MICE	The mammalian BAD protein belongs to the BH3-only subgroup of the BCL-2 family. In contrast to its known pro-apoptotic function, we found that endogenous and overexpressed BAD(L) can inhibit cell death in neurons and other cell types. Several mechanisms regulate the conversion of BAD from an anti-death to a pro-death factor, including alternative splicing that produces the N-terminally truncated BAD(S). In addition, caspases convert BAD(L) into a pro-death fragment that resembles the short splice variant. The caspase site that is selectively cleaved during cell death following growth factor (interleukin-3) withdrawal is conserved between human and murine BAD. A second cleavage site that is required for murine BAD to promote death following Sindbis virus infection, gamma-irradiation, and staurosporine treatment is not conserved in human BAD, consistent with the inability of human BAD to promote death with these stimuli. However, loss of the BAD N terminus by any mechanism is not always sufficient to activate its pro-death activity, suggesting that the N terminus is a regulatory domain rather than an anti-death domain. These findings suggest that BAD is more than an inert death factor in healthy cells; it is also a pro-survival factor, prior to its role in promoting cell death.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Hardwick, JM (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, E5140 BSPH,615 N Wolfe St, Baltimore, MD 21205 USA.	hardwick@jhu.edu	Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037402, R01NS034175] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS037402, NS37402, NS34175, R01 NS034175] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; Bellows DS, 2002, J VIROL, V76, P2469, DOI 10.1128/JVI.76.5.2469-2479.2002; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Hardwick JM, 2000, METHOD ENZYMOL, V322, P492; HARDWICK JM, 2000, APOPTOSIS HLTH DIS, P195; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jonas EA, 2003, J NEUROSCI, V23, P8423; Kerr DA, 2002, J VIROL, V76, P10393, DOI 10.1128/JVI.76.20.10393-10400.2002; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim HT, 2002, J BIOL CHEM, V277, P32510, DOI 10.1074/jbc.M202852200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Levine B, 1996, P NATL ACAD SCI USA, V93, P4810, DOI 10.1073/pnas.93.10.4810; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Middleton G, 2001, DEVELOPMENT, V128, P4715; Munger J, 2001, P NATL ACAD SCI USA, V98, P10410, DOI 10.1073/pnas.181344498; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889	48	42	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					42240	42249		10.1074/jbc.M406775200	http://dx.doi.org/10.1074/jbc.M406775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15231831	Green Accepted, hybrid			2022-12-25	WOS:000224075500116
J	Boumann, HA; Chin, PTK; Heck, AJR; de Kruijff, B; de Kroon, AIPM				Boumann, HA; Chin, PTK; Heck, AJR; de Kruijff, B; de Kroon, AIPM			The yeast phospholipid N-methyltransferases catalyzing the synthesis of phosphatidylcholine preferentially convert Di-C16 : 1 Substrates both in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; TANDEM MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR MEMBRANES; INOSITOL SYNTHESIS; LIPID-COMPOSITION; TRANSFER PROTEIN; RAT HEPATOCYTES; PHOSPHATIDYLETHANOLAMINE; BIOSYNTHESIS	Phosphatidylcholine ( PC) is an important and abundant structural component of the membranes of eukaryotic cells. In the yeast Saccharomyces cerevisiae, the primary route for the biosynthesis of PC consists of three consecutive methylation steps of phosphatidylethanolamine (PE) catalyzed by the phospholipid N-methyltransferases Cho2p and Opi3p. To investigate how these biosynthetic enzymes contribute to the composition of the PC species profile, the precursor-product relationships between PE and newly synthesized PC were determined at the level of the molecular species by using electrospray ionization tandem mass spectrometry and stable isotope labeling. In vivo labeling of yeast cells for 10 min with [methyl-D-3] methionine revealed the preferential methylation of di-C16:1 PE over a range of PE species compositions. A similar preferential conversion of di-C16: 1 PE to PC was found in vitro upon incubating isolated microsomes with S-adenosyl[methyl-D-3] methionine. Yeast opi3 and cho2 deletion strains were used to distinguish between the substrate selectivities of Cho2p and Opi3p, respectively. Both biosynthetic enzymes were found to participate in the species-selective methylation with Cho2p contributing the most. The combined results indicate that the selective methylation of PE species by the methyltransferases plays an important role in shaping the steady-state profile of PC molecular species in yeast.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands; Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	Utrecht University; Utrecht University	Boumann, HA (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	h.a.boumann@chem.uu.nl	de Kroon, Anton I/O-4119-2016; Heck, Albert/D-7098-2011	Heck, Albert/0000-0002-2405-4404; de Kroon, Anton/0000-0003-1209-756X				Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumann HA, 2004, FEBS LETT, V569, P173, DOI 10.1016/j.febslet.2004.05.043; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUI Z, 1993, J BIOL CHEM, V268, P16655; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Kroon AIPM, 1999, MOL MEMBR BIOL, V16, P205; de Kroon AIPM, 2003, MOL BIOL CELL, V14, P2142, DOI 10.1091/mbc.e02-08-0460; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Egner A, 2002, P NATL ACAD SCI USA, V99, P3370, DOI 10.1073/pnas.052545099; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GAYNOR PM, 1990, BIOCHIM BIOPHYS ACTA, V1045, P156, DOI 10.1016/0005-2760(90)90145-N; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; Heikinheimo L, 1998, J BIOL CHEM, V273, P3327, DOI 10.1074/jbc.273.6.3327; Janssen MJFW, 2002, FEBS LETT, V513, P197, DOI 10.1016/S0014-5793(02)02298-6; Kanipes MI, 1997, BBA-LIPID LIPID MET, V1348, P134, DOI 10.1016/S0005-2760(97)00121-5; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Koivusalo M, 2001, J LIPID RES, V42, P663; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; SCHMID PC, 1995, ARCH BIOCHEM BIOPHYS, V319, P168, DOI 10.1006/abbi.1995.1279; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SUMMERS EF, 1988, GENETICS, V120, P909; TIJBURG LBM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P167, DOI 10.1016/0005-2760(91)90091-U; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; Tuller G, 1999, YEAST, V15, P1555, DOI 10.1002/(SICI)1097-0061(199910)15:14<1555::AID-YEA479>3.0.CO;2-Z; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	41	31	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40314	40319		10.1074/jbc.M406517200	http://dx.doi.org/10.1074/jbc.M406517200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15258140	hybrid, Green Published			2022-12-25	WOS:000223916800012
J	Staab, JF; Bahn, YS; Tai, CH; Cook, PF; Sundstrom, P				Staab, JF; Bahn, YS; Tai, CH; Cook, PF; Sundstrom, P			Expression of transglutaminase substrate activity on Candida albicans germ tubes through a coiled, disulfide-bonded N-terminal domain of Hwp1 requires C-terminal glycosylphosphatidylinositol modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PROTEINS; PLASMA-MEMBRANE; FILAMENTOUS GROWTH; ENVELOPE PROTEINS; CROSS-LINKING; YEAST; PROLINE; IDENTIFICATION; FAMILY; GENE	By serving as a microbial substrate for epithelial cell transglutaminase, Hwp1 (Hyphal wall protein 1) of Candida albicans participates in cross-links with proteins on the mammalian mucosa. Biophysical properties of the transglutaminase substrate domain were explored using a recombinant protein representative of the N-terminal domain of Hwp1 and were similar to other transglutaminase substrates, the small proline-rich proteins of cornified envelopes found in stratified squamous epithelia. Recombinant Hwp1 lacks alpha and beta structures by circular dichroism and likely exists as a disulfide-cross-linked coiled-coil. The transglutaminase substrate property prompted a unique approach for investigating the features of surface Hwp1 on germ tubes. A lysine analog, 5-(biotinamido)pentylamine, was crosslinked to germ tubes catalyzed by transglutaminase 2 prior to cell fractionation, immunoprecipitation, and detection with streptavidin conjugates. The majority of the transglutaminase-modifiable Hwp1 was covalently attached to the beta-glucan of hyphae by the C terminus of Hwp1 via a glycosylphosphatidylinositol remnant anchor. A putative precursor of cell wall forms of Hwp1 was identified in the cell extract and in the culture medium. Hwp1 was modified by relatively short N-linked glycans, and the molecular size of the protein was reduced by hypomannosylation when expressed in O-glycosylation mutant strains. Hwp1 combines features of mammalian transglutaminase substrate proteins with characteristics of fungal cell wall proteins to form an unconventional adhesin at the hyphal wall of C. albicans.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43201 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43201 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Oklahoma System; University of Oklahoma - Norman	Sundstrom, P (corresponding author), Dartmouth Coll, Sch Med, Dept Microbiol & Immunol, Vail Bldg,HB7550, Hanover, NH 03755 USA.	Paula.Sundstrom@Dartmouth.edu	Bahn, Yong-Sun/C-1211-2012	Bahn, Yong-Sun/0000-0001-9573-5752	NIDCR NIH HHS [DE 011375] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011375] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; Braun BR, 2000, GENETICS, V156, P31; Braun BR, 2000, GENETICS, V155, P57; Braun BR, 2001, EMBO J, V20, P4753, DOI 10.1093/emboj/20.17.4753; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DENOBEL JG, 1990, YEAST, V6, P491, DOI 10.1002/yea.320060606; ELORZA MV, 1988, J GEN MICROBIOL, V134, P2393; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Hamada K, 1999, J BACTERIOL, V181, P3886, DOI 10.1128/JB.181.13.3886-3889.1999; Hamada K, 1998, J BIOL CHEM, V273, P26946, DOI 10.1074/jbc.273.41.26946; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HARLOW E, 1988, ANTIBODIES LAB MANUA, P663; Kadosh D, 2001, MOL CELL BIOL, V21, P2496, DOI 10.1128/MCB.21.7.2496-2505.2001; Kapteyn JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/j.1365-2958.2000.01729.x; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Knodler LA, 2001, NAT REV MOL CELL BIO, V2, P578, DOI 10.1038/35085062; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CH, 2000, FEBS LETT, V477, P268, DOI 10.1016/S0014-5793(00)01806-8; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MANDELL GL, 2000, PRINCIPLES PRACTICES, V1, P1094; Mao YX, 2003, MOL MICROBIOL, V50, P1617, DOI 10.1046/j.1365-2958.2003.03794.x; MOLLOY C, 1989, MICROBIOS, V57, P73; MONK BC, 1993, J BACTERIOL, V175, P5566, DOI 10.1128/JB.175.17.5566-5574.1993; MONK BC, 1991, J BIOL CHEM, V266, P18097; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Sharkey LL, 1999, J BACTERIOL, V181, P5273, DOI 10.1128/JB.181.17.5273-5279.1999; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Staab JF, 2003, MICROBIOL-SGM, V149, P2977, DOI 10.1099/mic.0.26445-0; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Staab JF, 1996, J BIOL CHEM, V271, P6298, DOI 10.1074/jbc.271.11.6298; Steinert PM, 1999, CELL DEATH DIFFER, V6, P916, DOI 10.1038/sj.cdd.4400568; SULLIVAN PA, 1984, J GEN MICROBIOL, V130, P2213; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; Sundstrom P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002; Sundstrom P, 2002, J INFECT DIS, V185, P521, DOI 10.1086/338836; SUNDSTROM P, 1994, J INFECT DIS, V169, P452, DOI 10.1093/infdis/169.2.452; SUNDSTROM PM, 1985, INFECT IMMUN, V49, P609, DOI 10.1128/IAI.49.3.609-614.1985; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; [No title captured]	52	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40737	40747		10.1074/jbc.M406005200	http://dx.doi.org/10.1074/jbc.M406005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15262971	hybrid			2022-12-25	WOS:000223916800066
J	Bruinsma, P; Spelbrink, RG; Nothwehr, SF				Bruinsma, P; Spelbrink, RG; Nothwehr, SF			Retrograde transport of the mannosyltransferase Och1p to the early Golgi requires a component of the COG transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZING MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ALKALINE-PHOSPHATASE; SELECTIVE TRANSPORT; CARGO PROTEINS; OUTER CHAIN; YEAST; LOCALIZATION; RETENTION; ER	The yeast COG complex has been proposed to function as a vesicle-tethering complex on an early Golgi compartment, but its role is not fully understood. COG complex mutants exhibit a dramatic reduction in Golgi-specific glycosylation and other defects. Here we show that a strain carrying a COG3 temperature-sensitive allele, cog3-202, clearly exhibited the glycosylation defect while exhibiting nearly normal secretion kinetics. Two Golgi mannosyltransferases, Och1p and Mnn1p, were mislocalized in cog3-202 cells. In cog3-202 cells Och1-HA was found in lighter density membranes than in wild type cells. In sed5(ts) and sft1(ts) strains, Och1p rapidly accumulated in vesicle-like structures consistent with the delivery of Och1p back to the cis-Golgi on retrograde vesicles via a Sed5p/Sft1p-containing SNARE complex. In contrast to cog3-202 cells, the membranes in sed5ts cells that contained Och1p were denser than in wild type. Together these results indicate that Och1p does not accumulate in retrograde vesicles in the cog3-202 mutant and are consistent with the COG complex playing a role in sorting of Och1p into retrograde vesicles. In wild type cells Och1p has been shown previously to cycle between the cis-Golgi and minimally as far as the late Golgi. We find that Och1p does not cycle via endosomes during its normal itinerary suggesting that Och1p engages in intra-Golgi cycling only. However, Och1p does use a post-Golgi pathway for degradation because a portion of Och1p was degraded in the vacuole. Most surprisingly, Och1p can use either the carboxypeptidase Y or AP-3 pathways to reach the vacuole for degradation.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Nothwehr, SF (corresponding author), Univ Missouri, Div Biol Sci, 401 Tucker Hall, Columbia, MO 65211 USA.	nothwehrs@missouri.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053449, R29GM053449] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-53449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSEBEL FM, 2000, CURRENT PROTOCOLS MO; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; Ha SA, 2001, MOL BIOL CELL, V12, P3175, DOI 10.1091/mbc.12.10.3175; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Kim DW, 2001, TRAFFIC, V2, P820, DOI 10.1034/j.1600-0854.2001.21111.x; Loh E, 2004, J BIOL CHEM, V279, P24640, DOI 10.1074/jbc.M400662200; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Nothwehr SF, 1999, MOL BIOL CELL, V10, P875, DOI 10.1091/mbc.10.4.875; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SIKORSKI RS, 1989, GENETICS, V122, P19; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; Wilsbach Kathleen, 1993, Trends in Cell Biology, V3, P426, DOI 10.1016/0962-8924(93)90031-U; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Wuestehube LJ, 1996, GENETICS, V142, P393; Yang W, 1996, EUR J CELL BIOL, V71, P53	73	40	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39814	39823		10.1074/jbc.M405500200	http://dx.doi.org/10.1074/jbc.M405500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15229219	hybrid			2022-12-25	WOS:000223791500076
J	Caesar, R; Blomberg, A				Caesar, R; Blomberg, A			The stress-induced Tfs1p requires NatB-mediated acetylation to inhibit carboxypeptidase Y and to regulate the protein kinase A pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL ACETYLTRANSFERASES; SACCHAROMYCES-CEREVISIAE; METHIONINE AMINOPEPTIDASE; EUKARYOTIC PROTEINS; OSMOTIC-STRESS; BUDDING YEAST; DNA DAMAGE; GENES; TROPOMYOSIN; EXPRESSION	The Saccharomyces cerevisiae N-terminal acetyltransferase NatB consists of the subunits Nat3p and Mdm20p. We found by two-dimensional PAGE analysis that nat3Delta exhibited protein expression during growth in basal medium resembling protein expression in salt-adapted wild-type cells. The stress-induced carboxypeptidase Y (CPY) inhibitor and phosphatidylethanolamine-binding protein family member Tfs1p was identified as a novel NatB substrate. The N-terminal acetylation status of Tfs1p, Act1p, and Rnr4p in both wild type and nat3Delta was confirmed by tandem mass spectrometry. Furthermore it was found that unacetylated Tfs1p expressed in nat3Delta showed an similar to100-fold decrease in CPY inhibition compared with the acetylated form, indicating that the N-terminal acetyl group is essential for CPY inhibition by Tfs1p. Phosphatidylethanolamine-binding proteins in other organisms have been reported to be involved in the regulation of cell signaling. Here we report that a number of proteins, whose expression has been shown previously to be dependent on the activity in the protein kinase A (PKA) signaling pathway, was found to be regulated in line with low PKA activity in the nat3Delta strain. The involvement of Nat3p and Tfs1p in PKA signaling was supported by caffeine growth inhibition studies. First, growth inhibition by caffeine addition ( resulting in enhanced cAMP levels) was suppressed in tfs1Delta. Second, this suppression by tfs1Delta was abolished in the nat3Delta background, indicating that Tfs1p was not functional in the nat3Delta strain possibly because of a lack of N-terminal acetylation. We conclude that the NatB-dependent acetylation of Tfs1p appears to be essential for its inhibitory activity on CPY as well its role in regulating the PKA pathway.	Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol, S-41390 Gothenburg, Sweden	University of Gothenburg	Blomberg, A (corresponding author), Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol, Medicinaregatan 9C, S-41390 Gothenburg, Sweden.	anders.blomberg@gmm.gu.se	Caesar, Robert/AAX-3205-2020					Abe A, 2000, BIOCHEM BIOPH RES CO, V268, P14, DOI 10.1006/bbrc.1999.2069; Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; Blomberg A, 2002, METHOD ENZYMOL, V350, P559, DOI 10.1016/S0076-6879(02)50985-X; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; Chautard H, 2004, EUKARYOT CELL, V3, P459, DOI 10.1128/EC.3.2.459-470.2004; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kimura Y, 2000, J BIOL CHEM, V275, P4635, DOI 10.1074/jbc.275.7.4635; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Manning LR, 2001, BIOCHEMISTRY-US, V40, P1635, DOI 10.1021/bi002157+; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MCCLANAHAN T, 1986, MOL CELL BIOL, V6, P90, DOI 10.1128/MCB.6.1.90; Mima J, 2002, FEBS LETT, V532, P207, DOI 10.1016/S0014-5793(02)03676-1; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; Molin M, 2003, PROTEOMICS, V3, P752, DOI 10.1002/pmic.200300393; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2003, BIOCHEM BIOPH RES CO, V308, P1, DOI 10.1016/S0006-291X(03)01316-0; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; Sentandreu M, 1998, J BACTERIOL, V180, P282, DOI 10.1128/JB.180.2.282-289.1998; Serre L, 2001, J MOL BIOL, V310, P617, DOI 10.1006/jmbi.2001.4784; SHENG SJ, 1993, J BIOL CHEM, V268, P4752; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TONOUCHI A, 1994, J BIOCHEM-TOKYO, V115, P683, DOI 10.1093/oxfordjournals.jbchem.a124396; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Valadi H, 2004, CURR GENET, V45, P90, DOI 10.1007/s00294-003-0469-1; Warringer J, 2003, P NATL ACAD SCI USA, V100, P15724, DOI 10.1073/pnas.2435976100; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001	55	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38532	38543		10.1074/jbc.M402939200	http://dx.doi.org/10.1074/jbc.M402939200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15229224	hybrid			2022-12-25	WOS:000223684100059
J	Dai, S; Hirayama, T; Abbas, S; Abu-Amer, Y				Dai, S; Hirayama, T; Abbas, S; Abu-Amer, Y			The I kappa B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATION; EXPRESSION; COMPLEX; BETA; MACROPHAGES; REGULATOR; PROMOTER; PROTEINS; PATHWAY	Activation of NF-kappaB leads to expression of ample genes that regulate inflammatory and osteoclastogenic responses. The process is facilitated by induction of IkappaB kinase (IKK) complex that phosphorylates IkappaB and leads to its dissociation from the NF-kappaB complex, thus permitting activation of NF-kappaB. The IKK complex contains primarily IKKalpha,IKKbeta, and the regulatory kinase IKKgamma, also known as NEMO. NEMO regulates the IKK complex activity through its binding to carboxyl-terminal region of IKKalpha and IKKbeta, termed NEMO-binding domain (NBD). In this regard, a cell-permeable NBD peptide has been shown to block association of NEMO with the IKK complex and inhibit activation of NF-kappaB. Given the pivotal role of cytokine-induced NF-kappaB in osteoclastogenesis and inflammatory bone loss, we deduced that cell-permeable TAT-NBD peptide may hinder osteoclastogenesis and bone erosion in inflammatory arthritis. Using NBD peptides, we show that wild type, but not mutant, NBD blocks IKK activation and reduces cytokine-induced promoter and DNA binding activities of NF-kappaB and inhibits cytokine-induced osteoclast formation by osteoclast precursors. Consistent with the key role of NF-kappaB in osteoinflammatory responses in vivo, wild type TAT-NBD administered into mice prior to induction of inflammatory arthritis efficiently block in vivo osteoclastogenesis, inhibits focal bone erosion, and ameliorates inflammatory responses in the joints of arthritic mice. The mutant NBD peptide fails to exert these functions. These results provide strong evidence that IKKs are potent regulators of cytokine-induced osteoclastogenesis and inflammatory arthritis. More importantly, blockade of NEMO assembly with the IKK complex is a viable strategy to avert inflammatory osteolysis.	Washington Univ, Sch Med, Dept Orthopaed, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Hosp Plaza,11300 W Pavil,Campus Box 8233, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu			NIAMS NIH HHS [AR-47443] Funding Source: Medline; NIDCR NIH HHS [DE-13754] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abbas S, 2003, J BIOL CHEM, V278, P20077, DOI 10.1074/jbc.M208619200; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Abu-Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; ABUAMER Y, 2003, MOL BIOL ORTHOPEDICS, P229; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CLOHISY DR, 1989, J BIOL CHEM, V264, P5370; Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DROUET C, 1991, J IMMUNOL, V147, P1694; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Israel A, 2003, NATURE, V423, P596, DOI 10.1038/423596a; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MERCURIO F, 1997, SCIENCE, V278, P866; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tak PP, 2001, ARTHRITIS RHEUM, V44, P1897, DOI 10.1002/1529-0131(200108)44:8<1897::AID-ART328>3.0.CO;2-4; Tetsuka T, 1996, BIOCHEM BIOPH RES CO, V218, P808, DOI 10.1006/bbrc.1996.0144; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	33	162	175	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37219	37222		10.1074/jbc.C400258200	http://dx.doi.org/10.1074/jbc.C400258200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15252035	hybrid			2022-12-25	WOS:000223554600003
J	Wilson-Rawls, J; Rhee, JM; Rawls, A				Wilson-Rawls, J; Rhee, JM; Rawls, A			Paraxis is a basic helix-loop-helix protein that positively regulates transcription through binding to specific E-box elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL GRADIENT MORPHOGEN; NEURAL CREST DERIVATIVES; MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; DNA-BINDING; BHLH PROTEIN; MOUSE EMBRYOGENESIS; ACTIVATION DOMAINS; SOMITE FORMATION; IMMUNOGLOBULIN ENHANCER	Members of the Twist subfamily of basic helix-loop-helix transcription factors are important for the specification of mesodermal derivatives during vertebrate embryogenesis. This subfamily includes both transcriptional activators such as scleraxis, Hand2, and Dermo-1 and repressors such as Twist and Hand1. Paraxis is a member of this subfamily, and it has been shown to regulate morphogenetic events during somitogenesis, including the transition of cells from mesenchyme to epithelium and maintaining anterior/posterior polarity. Mice deficient in paraxis exhibit a caudal truncation of the axial skeleton and fusion of the vertebrae. Considering the developmental importance of paraxis, it is important for future studies to understand the molecular basis of its activity. Here we demonstrate that paraxis can function as a transcriptional activator when it forms a heterodimer with E12. Paraxis is able to bind to a set of E-boxes that overlaps with the closely related scleraxis. Paraxis expression precedes that of scleraxis in the region of the somite fated to form the axial skeleton and tendons and is able to direct transcription from an E-box found in the scleraxis promoter. Further, in the absence of paraxis, Pax-1 is no longer expressed in the somites and presomitic mesoderm. These results suggest that paraxis may regulate early events during chondrogenesis by positively directing transcription of sclerotome-specific genes.	Arizona State Univ, Arizona BioDesign Inst, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Arizona BioDesign Inst, Biol Grad Program, Tempe, AZ 85287 USA; Arizona State Univ, Arizona BioDesign Inst, Ctr Evolutionary Funct Genom, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Wilson-Rawls, J (corresponding author), Arizona State Univ, Arizona BioDesign Inst, Sch Life Sci, Box 4501,Life Sci C Bldg,Rm 550, Tempe, AZ 85287 USA.	nrawls@imap4.asu.edu		Wilson-Rawls, Jeanne/0000-0002-3704-6956				Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Barnes GL, 1997, DEV BIOL, V189, P95, DOI 10.1006/dbio.1997.8663; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; Bounpheng MA, 2000, EXP CELL RES, V257, P320, DOI 10.1006/excr.2000.4898; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Brown D, 1999, DEVELOPMENT, V126, P4317; Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Castanon I, 2001, DEVELOPMENT, V128, P3145; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dean J, 2002, J REPROD IMMUNOL, V53, P171, DOI 10.1016/S0165-0378(01)00100-0; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Firulli AB, 2003, GENE, V312, P27, DOI 10.1016/S0378-1119(03)00669-3; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Guillemot F, 1999, EXP CELL RES, V253, P357, DOI 10.1006/excr.1999.4717; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hofmann C, 1998, DEV DYNAM, V213, P199; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Johnson J, 2001, DEV BIOL, V229, P176, DOI 10.1006/dbio.2000.9969; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu Y, 1996, J ENDOCRINOL, V151, P491, DOI 10.1677/joe.0.1510491; Liu Y, 1997, J BIOL CHEM, V272, P29880, DOI 10.1074/jbc.272.47.29880; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Morrison SJ, 2001, CURR OPIN CELL BIOL, V13, P666, DOI 10.1016/S0955-0674(00)00269-6; Muller TS, 1996, DEV BIOL, V178, P403, DOI 10.1006/dbio.1996.0227; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Perez AV, 2003, MECH DEVELOP, V120, P1153, DOI 10.1016/j.mod.2003.08.003; PEYTON M, 1994, J BIOL CHEM, V269, P25936; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; SHAMMUMGALINGAM S, 1998, MECH DEVELOP, V78, P85; Sosic D, 1997, DEV BIOL, V185, P229, DOI 10.1006/dbio.1997.8561; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Staal FJT, 2001, STEM CELLS, V19, P165, DOI 10.1634/stemcells.19-3-165; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; WILSONRAWLS J, 1999, DEVELOPMENT, V53, P357; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	72	26	27	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37685	37692		10.1074/jbc.M401319200	http://dx.doi.org/10.1074/jbc.M401319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226298	hybrid			2022-12-25	WOS:000223554600060
J	Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW				Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW			MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol	ONCOGENE			English	Article						MCL1; BCL2; 12-O-tetradecanoylphorbol 13-acetate; extracellular signal regulated kinase; mitogen activated protein kinase; taxol; protein phosphorylation; protein phosphatase 1/2A	UBIQUITIN-DEPENDENT DEGRADATION; C-MYC PROTEOLYSIS; BCL-2 FAMILY; PROTEASOME PATHWAY; CYCLE PROGRESSION; GENE-PRODUCT; PROTEIN; KINASE; APOPTOSIS; SURVIVAL	BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events-mediated through separate signaling processes and involving different target sites-in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-independent sites.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Dartmouth College; Vanderbilt University	Craig, RW (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	ruth.w.craig@dartmouth.edu			NCI NIH HHS [R01-CA57359, R01 CA057359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Basu A, 1998, INT J ONCOL, V13, P659; Basu A, 2000, INT J ONCOL, V16, P497; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen MC, 2000, BIOCHEM BIOPH RES CO, V279, P725, DOI 10.1006/bbrc.2000.3977; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Haldar S, 1998, CANCER RES, V58, P1609; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Matsuoka K, 2002, EUR J BIOCHEM, V269, P3511, DOI 10.1046/j.1432-1033.2002.03033.x; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RIVIERE LR, 1996, CURRENT PROTOCOLS PR, V2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vrana JA, 2002, CANCER RES, V62, P892; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	62	244	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5301	5315		10.1038/sj.onc.1207692	http://dx.doi.org/10.1038/sj.onc.1207692			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15241487				2022-12-25	WOS:000222491600006
J	Matsusue, K; Peters, JM; Gonzalez, FJ				Matsusue, K; Peters, JM; Gonzalez, FJ			PPAR beta/delta potentiates PPAR gamma-stimulated adipocyte differentiation	FASEB JOURNAL			English	Article						peroxisome proliferator-activated receptor	ACTIVATED-RECEPTOR-DELTA; ADIPOSE DIFFERENTIATION; BROWN ADIPOCYTES; GENE-EXPRESSION; PERILIPIN-A; INSULIN; ADIPOGENESIS; MACROPHAGES; PROTEIN; TRANSCRIPTION	It is well established that peroxisome proliferator-activated receptor-gamma (PPARgamma) has a critical role in modulating adipocyte differentiation based on gain-of-function and loss-of-function experiments. However, recent gain-of-function experiments suggest that PPARbeta may also have a role in mediating adipocyte differentiation. Because ligands for PPARs can activate more than one receptor isoform, the specific role of PPARbeta in adipocyte differentiation was examined using PPARbeta-null adipocytes. Wild-type adipocytes accumulate lipids in response to differentiation signaling induced from standard differentiation medium, and this effect is significantly reduced in PPARbeta-null adipocytes. The addition of the PPARbeta ligand L165041 to the standard differentiation medium causes enhanced adipocyte differentiation and lipid accumulation, and this effect is diminished in adipocytes lacking expression of PPARbeta. Treatment of wild-type adipocytes with the PPARgamma ligand troglitazone causes accelerated adipocyte differentiation and lipid accumulation, and this effect is marginally reduced in PPARbeta-null adipocytes. Expression patterns of mRNA markers of early and late adipocyte differentiation are consistent with the morphological and biochemical differences observed. Results from these studies demonstrate that in the absence of PPARbeta expression, adipocyte differentiation is significantly impaired, providing loss-of-function evidence supporting a role for this receptor in adipocyte differentiation. These results also demonstrate that L165041-stimulated adipocyte differentiation and lipid accumulation is mediated by PPARbeta. In addition, as the ability of troglitazone to induce adipocyte differentiation is also impaired in PPARbeta null adipocytes, this suggests that both PPARbeta and PPARgamma isoforms are required to facilitate maximal lipid accumulation and differentiation during adipogenesis.	NCI, LAb Metab, Bethesda, MD 20892 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Gonzalez, FJ (corresponding author), NCI, LAb Metab, Bldg 37,Room 3106, Bethesda, MD 20892 USA.	fjgonz@helix.nih.gov	Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [R01CA097999, R01CA089607] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89607, CA97999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; SHIMIZU Y, 1994, J BIOCHEM-TOKYO, V115, P1069, DOI 10.1093/oxfordjournals.jbchem.a124459; TANG YL, 1994, J BIOL CHEM, V269, P6011; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	30	79	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2004	18	10					1477	+		10.1096/fj.04-1944fje	http://dx.doi.org/10.1096/fj.04-1944fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	842CB	15247146				2022-12-25	WOS:000222979200001
J	Gergs, U; Boknik, P; Buchwalow, I; Fabritz, L; Matus, M; Justus, I; Hanske, G; Schmitz, W; Neumann, J				Gergs, U; Boknik, P; Buchwalow, I; Fabritz, L; Matus, M; Justus, I; Hanske, G; Schmitz, W; Neumann, J			Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; TRANSGENIC MICE; DILATED CARDIOMYOPATHY; VENTRICULAR MYOCYTES; REGULATORY SUBUNITS; PHOSPHORYLATION; KINASE; PHOSPHOLAMBAN; HYPERTROPHY; RECEPTOR	Reversible protein phosphorylation is an essential regulatory mechanism in many cellular functions. In contrast to protein kinases, the role and regulation of protein phosphatases has remained ambiguous. To address this issue, we generated transgenic mice that overexpress the catalytic subunit alpha of protein phosphatase 2A (PP2A) (PP2Acalpha) in the heart driven by the alpha-myosin heavy chain promoter. Overexpression of the PP2Acalpha gene in the heart led to increased levels of the transgene both at RNA and protein levels. This was accompanied by a significant increase of PP2A enzyme activity in the myocardium. Morphological analysis revealed isles of necrosis and fibrosis. The phosphorylation state of phospholamban, troponin inhibitor, and eukaryotic elongation factor 2 was reduced significantly. The expression of junctional ( calsequestrin) and free SR proteins (SERCA and phospholamban) was not altered. Whereas no increase in morbidity or mortality was noted, transgenic mice developed cardiac hypertrophy and reduced contractility of the heart, as well as cardiac dilatation as shown by biplane echocardiography. Taken together, these findings are indicative of the fundamental role of PP2A in cardiac function and imply that disturbances in protein phosphatases expression and activity may cause or aggravate the course of cardiac diseases.	Univ Munster, Inst Pharmakol & Toxikol, Univ Klinikum, D-48129 Munster, Germany; Univ Munster, Med Klin & Poliklin C, Univ Klinikum, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, Univ Klinikum, D-48129 Munster, Germany	University of Munster; University of Munster; University of Munster	Neumann, J (corresponding author), Univ Klinikum Munster, Inst Pharmakol & Toxikol, Domagkstr 12, D-48149 Munster, Germany.	joachim.neumann@uni-muenster.de		Fabritz, Larissa/0000-0002-9241-1733; Gergs, Ulrich/0000-0001-6986-485X				Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bartel S, 1996, MOL CELL BIOCHEM, V157, P171; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; Boknik P, 2000, N-S ARCH PHARMACOL, V362, P222, DOI 10.1007/s002100000283; Bruchert N, 2004, N-S ARCH PHARMACOL, V369, pR91; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; duBell WH, 2004, J PHYSIOL-LONDON, V556, P79, DOI 10.1113/jphysiol.2003.059329; Dubell WH, 2002, AM J PHYSIOL-HEART C, V282, pH38, DOI 10.1152/ajpheart.00536.2001; duBell WH, 1996, J PHYSIOL-LONDON, V493, P793, DOI 10.1113/jphysiol.1996.sp021423; Everett AD, 2001, AM J PHYSIOL-HEART C, V281, pH161, DOI 10.1152/ajpheart.2001.281.1.H161; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kins S, 2001, J BIOL CHEM, V276, P38193; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Mishra S, 2002, J HEART LUNG TRANSPL, V21, P366, DOI 10.1016/S1053-2498(01)00390-4; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; Neumann J, 1999, J PHARMACOL EXP THER, V289, P188; Neumann J, 1998, J MOL CELL CARDIOL, V30, P1991, DOI 10.1006/jmcc.1998.0760; NEUMANN J, 1993, AM J PHYSIOL, V265, pH257, DOI 10.1152/ajpheart.1993.265.1.H257; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Weinbrenner C, 1998, CIRCULATION, V98, P899, DOI 10.1161/01.CIR.98.9.899; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200	41	104	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40827	40834		10.1074/jbc.M405770200	http://dx.doi.org/10.1074/jbc.M405770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15247211				2022-12-25	WOS:000223916800077
J	Pedreno, Y; Maicas, S; Arguelles, JC; Sentandreu, R; Valentin, E				Pedreno, Y; Maicas, S; Arguelles, JC; Sentandreu, R; Valentin, E			The ATC1 gene encodes a cell wall-linked acid trehalase required for growth on trehalose in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-TUBE FORMATION; MOLECULAR ANALYSIS; ESCHERICHIA-COLI; ATH1 GENE; YEAST; DISRUPTION; METABOLISM; TRANSFORMATION; MANNOPROTEINS; CONSTRUCTION	After screening a Candida albicans genome data base, the product of an open reading frame (IPF 19760/CA2574) with 41% identity to Saccharomyces cerevisiae vacuolar acid trehalase (Ath1p) was identified and named Atc1p. The deduced amino acid sequence shows that Atc1p contains an N-terminal hydrophobic signal peptide and 20 potential sites for N-glycosylation. C. albicans homozygous mutants that lack acid trehalase activity were constructed by gene disruption at the two ATC chromosomal alleles. Analysis of these null mutants shows that Atc1p is localized in the cell wall and is required for growth on trehalose as a carbon source. An Atc1p endowed with acid trehalase activity was obtained by an in vtro transcription-translation coupled system. These results strongly suggest that ATC1 is the structural gene encoding cell wall acid trehalase in C. albicans. Determinations of ATC1 mRNA expression as well as acid trehalase activity in the presence and absence of glucose point out that ATC1 gene is regulated by glucose repression.	Univ Valencia, Fac Farm, Dept Microbiol & Ecol, Fac Farm, Valencia 46100, Spain; Univ Murcia, Area Microbiol, Fac Biol, E-30071 Murcia, Spain; Univ Cardenal Herrera CEU, Fac Ciencias Expt & Salud, Valencia 46113, Spain	University of Valencia; University of Murcia; Universidad CEU Cardenal Herrera	Valentin, E (corresponding author), Univ Valencia, Fac Farm, Dept Microbiol & Ecol, Fac Farm, Avda Vicente Andres Estelles S-N, Valencia 46100, Spain.	Eulogio.Valentin@uv.es	Maicas, Sergi/J-6563-2019; Valentin, Eulogio/K-1436-2017; Maicas, Sergi/L-7462-2014	Valentin, Eulogio/0000-0002-7895-9460; Maicas, Sergi/0000-0003-4360-611X				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Alizadeh P, 1996, FEBS LETT, V391, P273, DOI 10.1016/0014-5793(96)00751-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alvarez-Peral FJ, 2000, RES MICROBIOL, V151, P837, DOI 10.1016/S0923-2508(00)01150-5; Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; Backen AC, 2000, YEAST, V16, P1121, DOI 10.1002/1097-0061(20000915)16:12&lt;1121::AID-YEA614&gt;3.0.CO;2-U; Bates PA, 1999, PROTEINS, P47; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; Burklen L, 1998, MOL GEN GENET, V260, P48, DOI 10.1007/s004380050869; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CASANOVA M, 1989, INFECT IMMUN, V57, P262, DOI 10.1128/IAI.57.1.262-271.1989; COLEMAN DC, 1993, CRIT REV MICROBIOL, V19, P61, DOI 10.3109/10408419309113523; de Pauw BE, 1999, CHEMOTHERAPY, V45, P1, DOI 10.1159/000048465; dEnfert C, 1997, MOL MICROBIOL, V24, P203, DOI 10.1046/j.1365-2958.1997.3131693.x; DESTRUELLE M, 1995, YEAST, V11, P1015, DOI 10.1002/yea.320111103; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Eck R, 1997, MICROBIOL-UK, V143, P3747, DOI 10.1099/00221287-143-12-3747; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Elbein A D, 1974, Adv Carbohydr Chem Biochem, V30, P227, DOI 10.1016/S0065-2318(08)60266-8; ELORZA MV, 1988, J GEN MICROBIOL, V134, P2393; FONZI WA, 1993, GENETICS, V134, P717; FOX JL, 1993, ASM NEWS, V59, P18; FUJIMURA HA, 1993, BIOTECHNIQUES, V14, P538; GALINSKI EA, 1990, ARCH MICROBIOL, V153, P607, DOI 10.1007/BF00245273; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HECKER LI, 1973, J BACTERIOL, V115, P592, DOI 10.1128/JB.115.2.592-599.1973; Ishihara R, 1997, GENE, V202, P69, DOI 10.1016/S0378-1119(97)00455-1; Jorge JA, 1997, FEMS MICROBIOL LETT, V154, P165, DOI 10.1016/S0378-1097(97)00332-7; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOPP M, 1993, J BIOL CHEM, V268, P4766; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Lucio AKB, 2000, FEMS MICROBIOL LETT, V182, P9, DOI 10.1016/S0378-1097(99)00557-1; Maneu V, 1996, FEMS MICROBIOL LETT, V145, P157, DOI 10.1016/S0378-1097(96)00386-2; MITTENBUHLER K, 1988, J BIOL CHEM, V263, P8537; Nwaka S, 1996, FEBS LETT, V386, P235, DOI 10.1016/0014-5793(96)00450-4; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; Odds F. C., 1994, ASM News (Washington), V60, P313; Odds FC, 1988, CANDIDA CANDIDOSIS R; PASTOR FIJ, 1984, BIOCHIM BIOPHYS ACTA, V802, P292; RAM SP, 1984, J GEN MICROBIOL, V130, P1227; Ramon AM, 1996, YEAST, V12, P1535, DOI 10.1002/(SICI)1097-0061(199612)12:15<1535::AID-YEA59>3.3.CO;2-4; Richards AB, 2002, FOOD CHEM TOXICOL, V40, P871, DOI 10.1016/S0278-6915(02)00011-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANMIGUEL PF, 1994, BBA-GEN SUBJECTS, V1200, P155, DOI 10.1016/0304-4165(94)90130-9; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SENTANDREU R, 1993, DIMORPHIC FUNGI BIOL, P111; SHERMAN F, 1991, P3; SPARGO BJ, 1991, P NATL ACAD SCI USA, V88, P737, DOI 10.1073/pnas.88.3.737; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; THEVELEIN JM, 1984, MICROBIOL REV, V48, P42, DOI 10.1128/MMBR.48.1.42-59.1984; THEVELEIN JM, 1996, MYCOTA, V3, P395; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTIN E, 1984, J GEN MICROBIOL, V130, P1419; Van Dijck P, 2002, INFECT IMMUN, V70, P1772, DOI 10.1128/IAI.70.4.1772-1782.2002; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; Zaragoza O, 1998, J BACTERIOL, V180, P3809, DOI 10.1128/JB.180.15.3809-3815.1998; Zaragoza O, 2002, MICROBIOL-SGM, V148, P1281, DOI 10.1099/00221287-148-5-1281	63	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40852	40860		10.1074/jbc.M400216200	http://dx.doi.org/10.1074/jbc.M400216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15252058	hybrid			2022-12-25	WOS:000223916800080
J	Shimba, S; Wada, T; Hara, S; Tezuka, M				Shimba, S; Wada, T; Hara, S; Tezuka, M			EPAS1 promotes adipose differentiation in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ACTIVATED RECEPTOR-GAMMA; ENDOTHELIAL PAS DOMAIN; BINDING-PROTEIN-ALPHA; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTION FACTOR; C/EBP-ALPHA; ADIPOCYTE DIFFERENTIATION; INSULIN SENSITIVITY	Adipose differentiation is regulated by several transcription factors, such as the CAAT/enhancer-binding protein family and peroxisome proliferator activator (PPAR) gamma2. Several recent studies have shown that the basic helix-loop-helix-PAS superfamily is also involved in the regulation of adipose differentiation. In this study, we investigated the roles played by EPAS1 (endothelial PAS domain protein 1) in adipogenesis. EPAS1, also referred to as hypoxia-inducible factor 2alpha, is a transcription factor known to play essential roles in catecholamine homeostasis, vascular remodeling, and the maintenance of reactive oxygen species, and so forth. During adipose differentiation in 3T3-L1 cells, the level of EPAS1 mRNA began to increase 6 days after the induction, and EPAS1 was highly expressed in differentiated cells. To examine whether EPAS1 is involved in adipogenesis, we first isolated stable clones from 3T3-L1 cells in which we could induce the expression of an EPAS1 C-terminal deletion mutant (designated EPAS1-(1-485)) with the insect hormone. The induction of EPAS1-(1-485) allowed the cells to accumulate only minimum amounts of intracellular lipid droplets. Consistent with the morphological observations, a minimum amount of aP2 and PPARgamma2 mRNA was induced in the EPAS1-(1-485) cells. We then examined whether or not EPAS1 was able to promote adipogenesis in NIH 3T3 cells, a relatively nonadipogenic cell line. Overexpression of EPAS1 in NIH 3T3 cells induced a significant amount of lipid accumulation compared with that of the control cells in the presence of the PPARgamma ligand. The results were also confirmed by measuring the expression of adipocyte-related genes. Adenovirus-mediated EPAS1-(1-485) expression resulted in the reduction of basal and insulin-dependent glucose transport in 3T3-L1 adipocytes. The mechanism involved the transcriptional regulation of GLUT1, GLUT4, and IRS3 expression by EPAS1. Taken together, these results suggest that EPAS1 plays several supporting roles in maintaining specific aspects of adipogenesis and adipocyte function including regulation of glucose uptake followed by lipid synthesis.	Nihon Univ, Dept Hlth Sci, Coll Pharm, Chiba 2748555, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth & Mol Toxicol, Minato Ku, Tokyo 1088641, Japan	Nihon University; Kitasato University	Tezuka, M (corresponding author), Nihon Univ, Dept Hlth Sci, Coll Pharm, 7-7-1 Narashinodai, Chiba 2748555, Japan.	tezukam@pha.nihon-u.ac.jp						Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Catron KM, 1998, CELL GROWTH DIFFER, V9, P949; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Elberg G, 2000, J BIOL CHEM, V275, P27815; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hansen AJ, 1998, MOL PHARMACOL, V53, P1027; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Holder JL, 2000, HUM MOL GENET, V9, P101; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; JOOST HG, 1982, MOL PHARMACOL, V22, P614; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Nugent C, 2001, J BIOL CHEM, V276, P9149, DOI 10.1074/jbc.M009817200; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SassoneCorsi P, 1997, NATURE, V389, P443, DOI 10.1038/38904; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shimba S, 2001, J CELL SCI, V114, P2809; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOZZO E, 1995, AM J PHYSIOL, V268, P956; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WEINER CM, 1996, BIOCHEM BIOPH RES CO, V225, P485; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	49	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40946	40953		10.1074/jbc.M400840200	http://dx.doi.org/10.1074/jbc.M400840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15258146	hybrid			2022-12-25	WOS:000223916800091
J	Kim, KT; Ongusaha, PP; Hong, YK; Kurdistani, SK; Nakamura, M; Lu, KP; Lee, SW				Kim, KT; Ongusaha, PP; Hong, YK; Kurdistani, SK; Nakamura, M; Lu, KP; Lee, SW			Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYC; GENE; DIFFERENTIATION; PROTEIN; P53; EXPRESSION; DRG-1; MICROTUBULES; TUBULIN; GROWTH	Mutations in the Drg1/RTP/Rit42 gene are commonly identified in hereditary neuropathies of the motor and sensory systems. This gene was also identified as a p53 target gene and a differentiation-related, putative metastatic suppressor gene in human colon and prostate cancer. In this study, we show that the Rit42 protein is a microtubule-associated protein that localizes to the centrosomes and participates in the spindle checkpoint in a p53-dependent manner. When ectopically expressed and exposed to spindle inhibitors, Rit42 inhibited polyploidy in several p53-deficient tumor cell lines and increased the population of cells in mitotic arrest. Blocking endogenous Rit42 expression by small interfering RNA in normal human mammary epithelial cells resulted in the disappearance of astral microtubules, and dividing spindle fiber formation was rarely detected. Moreover, these cells underwent microtubule inhibitor-induced reduplication, leading to a polyploidy state. Our findings imply that Rit42 plays a role in the regulation of microtubule dynamics and the maintenance of euploidy.	Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol & Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, SW (corresponding author), Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	sam.lee@cbrc2.mgh.harvard.edu		Kurdistani, Siavash/0000-0003-3295-3511	NCI NIH HHS [CA82211, CA80058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwala KL, 2000, BIOCHEM BIOPH RES CO, V272, P641, DOI 10.1006/bbrc.2000.2833; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bunz F, 2002, CANCER RES, V62, P1129; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gomez-Casero E, 2001, MOL CARCINOGEN, V32, P100, DOI 10.1002/mc.1069; Guang RJ, 2000, CANCER RES, V60, P749; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; Nimmrich I, 2000, CANCER LETT, V160, P37, DOI 10.1016/S0304-3835(00)00553-X; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364, DOI 10.1016/S0167-4889(99)00056-7; Rutherford MN, 2001, LEUKEMIA, V15, P362, DOI 10.1038/sj.leu.2402059; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; vanBelzen N, 1997, LAB INVEST, V77, P85; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhou DJ, 1998, CANCER RES, V58, P2182	29	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38597	38602		10.1074/jbc.M400781200	http://dx.doi.org/10.1074/jbc.M400781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247272	Green Published, hybrid			2022-12-25	WOS:000223684100066
J	Maresso, AW; Baldwin, MR; Barbieri, JT				Maresso, AW; Baldwin, MR; Barbieri, JT			Ezrin/radixin/moesin proteins are high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; EXOENZYME-S; IN-VIVO; RIBOSYLTRANSFERASE ACTIVITY; III CYTOTOXIN; ERM PROTEINS; MEMBRANE LOCALIZATION; EUKARYOTIC CELLS; HOST-CELLS	Pseudomonas aeruginosa ExoS is a bifunctional type III-secreted cytotoxin. The N terminus (amino acids 96-233) encodes a GTPase-activating protein activity, whereas the C terminus (amino acids 234-453) encodes a factor-activating ExoS-dependent ADP-ribosyltransferase activity. The GTPase-activating protein activity inactivates the Rho GTPases Rho, Rac, and Cdc42 in cultured cells and in vitro, whereas the ADP-ribosylation by ExoS is poly-substrate-specific and includes Ras as an early target for ADP-ribosylation. Infection of HeLa cells with P. aeruginosa producing a GTPase-activating protein-deficient form of ExoS rounded cells, indicating the ADP-ribosyltransferase domain alone is sufficient to elicit cytoskeletal changes. Examination of substrates modified by type III-delivered ExoS identified a 70-kDa protein as an early and predominant target for ADP-ribosylation. Matrix-assisted laser desorption ionization mass spectroscopy identified this protein as moesin, a member of the ezrin/radixin/moesin (ERM) family of proteins. ExoS ADP-ribosylated recombinant moesin at a linear velocity that was 5-fold faster and with a K-m that was 2 orders of magnitude lower than Ras. Moesin homologs ezrin and radixin were also ADP-ribosylated, indicating the ERMs collectively represent high affinity targets of ExoS. Type III delivered ExoS ADP-ribosylated moesin and ezrin (and/or radixin) in cultured HeLa cells. The ERM proteins contribute to cytoskeleton dynamics, and the ability of ExoS to ADP-ribosylate the ERM proteins links ADP-ribosylation with the cytoskeletal changes associated with ExoS intoxication.	Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu		Baldwin, Michael/0000-0002-7155-6271	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68912] Funding Source: Medline; NIAID NIH HHS [R21 AI146481, AI30162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams C, 1998, J INFECTION, V37, P151, DOI 10.1016/S0163-4453(98)80170-9; Armstrong S, 2004, BIOCHEMISTRY-US, V43, P183, DOI 10.1021/bi034772u; Barbieri JT, 2000, INT J MED MICROBIOL, V290, P381; Bretscher A, 1997, J CELL SCI, V110, P3011; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, J BIOL CHEM, V266, P6438; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Finck-Barbancon V, 2001, J BACTERIOL, V183, P4330, DOI 10.1128/JB.183.14.4330-4344.2001; Fraylick JE, 2002, BIOCHEMISTRY-US, V41, P9680, DOI 10.1021/bi025826n; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Ganesan AK, 1999, J BIOL CHEM, V274, P21823, DOI 10.1074/jbc.274.31.21823; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Krall R, 2004, J BIOL CHEM, V279, P2747, DOI 10.1074/jbc.M301963200; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; Liu SY, 1996, BIOCHEMISTRY-US, V35, P2754, DOI 10.1021/bi952340g; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Maresso AW, 2002, PROTEIN EXPRES PURIF, V26, P432, DOI 10.1016/S1046-5928(02)00544-2; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McGuffie EM, 1998, INFECT IMMUN, V66, P2607, DOI 10.1128/IAI.66.6.2607-2613.1998; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 2002, MOL MICROBIOL, V46, P1381, DOI 10.1046/j.1365-2958.2002.03256.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Riese MJ, 2001, BIOCHEMISTRY-US, V40, P3289, DOI 10.1021/bi002729q; Riese MJ, 2002, INFECT IMMUN, V70, P2230, DOI 10.1128/IAI.70.4.2230-2232.2002; Rocha CL, 2003, INFECT IMMUN, V71, P5296, DOI 10.1128/IAI.71.9.5296-5305.2003; Rucks EA, 2003, MICROBIOL-SGM, V149, P319, DOI 10.1099/mic.0.25985-0; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; Scheuring J, 1998, BIOCHEMISTRY-US, V37, P2748, DOI 10.1021/bi972594x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Tamura M, 2004, BIOCHEM BIOPH RES CO, V316, P323, DOI 10.1016/j.bbrc.2004.02.050; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; Vincent TS, 1999, MOL MICROBIOL, V32, P1054, DOI 10.1046/j.1365-2958.1999.01420.x; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yonemura S, 2002, J CELL SCI, V115, P2569; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l; Zhou DG, 2001, MICROBES INFECT, V3, P1293, DOI 10.1016/S1286-4579(01)01489-7	56	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38402	38408		10.1074/jbc.M405707200	http://dx.doi.org/10.1074/jbc.M405707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15252013	hybrid			2022-12-25	WOS:000223684100042
J	Mialet-Perez, J; Green, SA; Miller, WE; Liggett, SB				Mialet-Perez, J; Green, SA; Miller, WE; Liggett, SB			A primate-dominant third glycosylation site of the beta(2)-adrenergic receptor routes receptors to degradation during agonist regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PLASMA-MEMBRANE; DOWN-REGULATION; SEQUESTRATION; DESENSITIZATION; BINDING; PHOSPHORYLATION; ADRENOCEPTORS; POLYMORPHISM	beta(2)-adrenergic receptors (beta(2)AR) of all species are N-linked glycosylated at amino terminus residues similar to6 and similar to15. However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187. To determine whether this residue is glycosylated and to ascertain function, all possible single/multiple Asn --> Gln mutations were made in the human beta(2)AR at positions 6, 15, and 187 and were expressed in Chinese hamster fibroblast cells. Substitution of Asn-187 alone or with Asn-6 or Asn-15 decreased the apparent molecular mass of the receptor on SDS-PAGE in a manner consistent with Asn-187 glycosylation. All receptors bound the agonist isoproterenol and functionally coupled to adenylyl cyclase. However, receptors without 187 glycosylation failed to display long term agonist-promoted down-regulation. In contrast, loss of Asn-6/Asn-15 glycosylation did not alter down-regulation. Cell surface distribution and agonist-promoted internalization of receptors and recruitment of beta-arrestin 2 were unaffected by the loss of 187 glycosylation. Furthermore, acutely internalized wild-type and Gln-187 receptors were both localized by confocal microscopy to early endosomes. During prolonged agonist exposure, wild-type beta(2)AR co-localized with lysosomes, consistent with trafficking to a degradation compartment. However, Gln-187 beta(2)AR failed to co-localize with lysosomes despite agonist treatments up to 18 h. Phylogenetic analysis revealed that this third glycosylation site is found in humans and other higher order primates but not in lower order primates such as the monkey. Nor is this third site found in rodents, which are frequently utilized as animal models. These data thus reveal a previously unrecognized beta(2)AR regulatory motif that appeared late in primate evolution and serves to direct internalized receptors to lysosomal degradation during long term agonist exposure.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Cardiopulm Res Ctr, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Albert Sabin Way,ML 0564, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	MIALET-PEREZ, Jeanne/Y-7487-2018; liggett, stephen b/E-7453-2012	MIALET-PEREZ, Jeanne/0000-0002-1765-0283; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL45967, HL65899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, R01HL045967, R37HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Auman JT, 2001, AM J PHYSIOL-REG I, V281, pR1895, DOI 10.1152/ajpregu.2001.281.6.R1895; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Benya RV, 2000, MOL PHARMACOL, V58, P1490, DOI 10.1124/mol.58.6.1490; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; ELFELLAH MS, 1990, EUR J PHARMACOL, V182, P387, DOI 10.1016/0014-2999(90)90299-L; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; MOLENAAR P, 1990, J PHARMACOL EXP THER, V255, P393; Moore RH, 1999, J CELL SCI, V112, P329; NANOFF C, 1989, J CARDIOVASC PHARM, V13, P198, DOI 10.1097/00005344-198902000-00004; RANDS E, 1990, J BIOL CHEM, V265, P10759; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Xiang Y, 2003, P NATL ACAD SCI USA, V100, P10776, DOI 10.1073/pnas.1831718100	25	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38603	38607		10.1074/jbc.M403708200	http://dx.doi.org/10.1074/jbc.M403708200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247302	hybrid			2022-12-25	WOS:000223684100067
J	Tao, L; Harris, AL				Tao, L; Harris, AL			Biochemical requirements for inhibition of connexin26-containing channels by natural and synthetic taurine analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT PHOSPHOTYROSYL PHOSPHATASE; CRYSTAL-STRUCTURE; CONNEXIN CHANNELS; ESCHERICHIA-COLI; LIGAND-BINDING; PH REGULATION; ACTIVE-SITE; GAP; PROTEIN; DOMAIN	Previous work has shown that protonated taurine and aminosulfonate pH buffers, including HEPES, can directly and reversibly inhibit connexin channels that contain connexin26 (Cx26) (Bevans, C. G., and Harris, A. L. ( 1999) J. Biol. Chem. 274, 3711 - 3719). The structural requirements for this inhibition were explored by studies of the effects of structural analogs of taurine on the activity of Cx26-containing reconstituted hemichannels from native tissue. Several analogs inhibited the channels, with a range of relative affinities and efficacies. Each active compound contains a protonated amine separated from an ionized sulfonate or sulfinate moiety by several methylene groups. The inhibition is eliminated if the sulfonate/sulfinate moiety or the amine is not present. Compounds that contain a protonated amine but lack a sulfonate/sulfinate moiety do not inhibit but do competitively block the effect of the active compounds. Compounds that lack the protonated amine do not significantly inhibit or antagonize inhibition. The results suggest involvement of the protonated amine in binding and of the ionized sulfur-containing moiety in effecting the inhibition. The maximal effect of the inhibitory compounds is enhanced when a carboxyl group is linked to the alpha-carbon. Inhibition but not binding is stereospecific, with L-isomers being inhibitory and the corresponding D-isomers being inactive but able to antagonize inhibition by the L-isomers. Whereas not all connexins are sensitive to aminosulfonates, the well defined structural requirements described here argue strongly for a highly specific regulatory interaction with some connexins. The finding that cytoplasmic aminosulfonates inhibit connexin channels whereas other cytoplasmic compounds antagonize the inhibition suggests that gap junction channels are regulated by a complex interplay of cytoplasmic ligands.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Harris, AL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, MSB I-643,185 S Orange Ave, Newark, NJ 07103 USA.	aharris@umdnj.edu		Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044, GM61406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044, R01GM061406] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; Baldo GJ, 2001, J GEN PHYSIOL, V118, P447, DOI 10.1085/jgp.118.5.447; Bao XY, 2004, J BIOL CHEM, V279, P20058, DOI 10.1074/jbc.M311137200; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; Beyer EC, 2000, BRAZ J MED BIOL RES, V33, P391, DOI 10.1590/S0100-879X2000000400004; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bridges CC, 2001, AM J PHYSIOL-CELL PH, V281, pC1825, DOI 10.1152/ajpcell.2001.281.6.C1825; BRINK PR, 2000, GAP JUNCTIONS MOL BA, P43; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; COCKCROFT VB, 1990, MOL NEUROBIOL, V4, P129, DOI 10.1007/BF02780338; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Delmar M, 2000, CURR TOP MEMBR, V49, P223; DELMAR M, 1995, CARDIAC ELECTROPHYSI, P135; Duffy HS, 2001, CELL COMMUN ADHES, V8, P225, DOI 10.3109/15419060109080728; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; Ebihara L, 2003, NEWS PHYSIOL SCI, V18, P100, DOI 10.1152/nips.01431.2002; EBIHARA L, 1995, BIOPHYS J, V68, P1796, DOI 10.1016/S0006-3495(95)80356-5; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; Eckert R, 2002, PFLUG ARCH EUR J PHY, V443, P843, DOI 10.1007/s00424-001-0760-2; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; GANAPATHY V, 1995, CURR EYE RES, V14, P843, DOI 10.3109/02713689508995807; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; Han NLR, 2001, J NEUROCHEM, V79, P636, DOI 10.1046/j.1471-4159.2001.00601.x; Han XB, 1996, ADV EXP MED BIOL, V403, P173; Harris AL, 1998, GAP JUNCTIONS, P60; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Harris AL, 2001, METH MOL B, V154, P357; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; Hong EJ, 1996, ARCH PHARM RES, V19, P264, DOI 10.1007/BF02976238; HUXTABLE RJ, 1994, TAURINE HLTH DIS; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Kam Y, 1998, BBA-BIOMEMBRANES, V1372, P384, DOI 10.1016/S0005-2736(98)00075-3; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Knochel TR, 1996, J MOL BIOL, V262, P502, DOI 10.1006/jmbi.1996.0531; Liu Y, 2001, J MOL BIOL, V305, P481, DOI 10.1006/jmbi.2000.4326; Locke D, 2004, J BIOL CHEM, V279, P22883, DOI 10.1074/jbc.M401980200; Martin PEM, 2000, BIOCHEM J, V349, P281, DOI 10.1042/0264-6021:3490281; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Moore SA, 2001, J MOL BIOL, V312, P511, DOI 10.1006/jmbi.2001.4979; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; Ressot C, 1998, J NEUROSCI, V18, P4063; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Schofield PR, 1996, COLD SPRING HARB SYM, V61, P333; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Stevens MJ, 1999, AM J PHYSIOL-ENDOC M, V277, pE760, DOI 10.1152/ajpendo.1999.277.4.E760; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Tao L, 2002, MOL BIOL CELL, V13, p212A; TAO L, 2003, MOL BIOL CELL, V14, pA220; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; Trexler EB, 1999, J GEN PHYSIOL, V113, P721; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; Wang XG, 1997, BIOPHYS J, V73, P798, DOI 10.1016/S0006-3495(97)78112-8; WERNER R, 1991, P ROY SOC B-BIOL SCI, V243, P5, DOI 10.1098/rspb.1991.0002; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Xu X, 2002, J MEMBRANE BIOL, V186, P101, DOI 10.1007/s00232-001-0139-5; Yahuaca P, 2000, BRAZ J MED BIOL RES, V33, P399, DOI 10.1590/S0100-879X2000000400005; Zacharias N, 2002, TRENDS PHARMACOL SCI, V23, P281, DOI 10.1016/S0165-6147(02)02027-8; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	77	23	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38544	38554		10.1074/jbc.M405654200	http://dx.doi.org/10.1074/jbc.M405654200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15234974	hybrid			2022-12-25	WOS:000223684100060
J	Wells, L; Kreppel, LK; Comer, FI; Wadzinski, BE; Hart, GW				Wells, L; Kreppel, LK; Comer, FI; Wadzinski, BE; Hart, GW			O-GlcNAc transferase is in a functional complex with protein phosphatase 1 catalytic subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; CYTOSOLIC PROTEINS; INSULIN-RESISTANCE; POSTTRANSLATIONAL MODIFICATION; IN-VIVO; NUCLEAR; GLYCOSYLATION; CLONING; IDENTIFICATION; THREONINE	A hallmark of signal transduction is the dynamic and inducible post-translational modification of proteins. In addition to the well characterized phosphorylation of proteins, other modifications have been shown to be regulatory, including O-linked beta-N-acetylglucosamine (O-GlcNAc). O-GlcNAc modifies serine and threonine residues on a myriad of nuclear and cytosolic proteins, and for several proteins there appears to be a reciprocal relationship between phosphorylation and O-GlcNAc modification. Here we report further evidence of this yin-yang relationship by demonstrating that O-GlcNAc transferase, the enzyme that adds O-GlcNAc to proteins, exists in stable and active complexes with the serine/threonine phosphatases PP1beta and PP1gamma, enzymes that remove phosphate from proteins. The existence of this complex highlights the importance of understanding the dynamic relationship between O-GlcNAc and phosphate in modulating protein function in many cellular processes and disease states such as Alzheimer's disease and type II diabetes.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Johns Hopkins University; Vanderbilt University	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	gwhart@jhmi.edu	Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363; Hart, Gerald/0000-0001-7812-4351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R01GM062265, R56GM051366] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13563] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Alexander GE, 2002, AM J PSYCHIAT, V159, P738, DOI 10.1176/appi.ajp.159.5.738; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Avila J, 2000, FEBS LETT, V476, P89, DOI 10.1016/S0014-5793(00)01676-8; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Board M, 1997, BIOCHEM J, V328, P695, DOI 10.1042/bj3280695; Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Brady MJ, 2001, RECENT PROG HORM RES, V56, P157, DOI 10.1210/rp.56.1.157; COHEN P, 1990, ADV SEC MESS PHOSPH, V24, P230; Cohen PTW, 2002, J CELL SCI, V115, P241; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Filali M, 1999, J CELL BIOCHEM, V73, P153, DOI 10.1002/(SICI)1097-4644(19990501)73:2<153::AID-JCB2>3.3.CO;2-Z; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Gulledge BM, 2002, CURR MED CHEM, V9, P1991, DOI 10.2174/0929867023368845; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; HOYER S, 1985, ARCH GERONTOL GERIAT, V4, P193, DOI 10.1016/0167-4943(85)90001-9; Ibanez V, 1998, NEUROLOGY, V50, P1585, DOI 10.1212/WNL.50.6.1585; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lefebvre T, 2003, BBA-GEN SUBJECTS, V1619, P167, DOI 10.1016/S0304-4165(02)00477-4; MacCoss MJ, 2002, ANAL CHEM, V74, P5593, DOI 10.1021/ac025826t; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P429, DOI 10.1074/mcp.M300140-MCP200; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; Mufson EJ, 2002, NEUROCHEM RES, V27, P1035, DOI 10.1023/A:1020952704398; Parekh RB, 1997, CURR OPIN BIOTECH, V8, P718, DOI 10.1016/S0958-1669(97)80126-7; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, J NEUROCHEM, V68, P2119; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u	57	102	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38466	38470		10.1074/jbc.M406481200	http://dx.doi.org/10.1074/jbc.M406481200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15247246	hybrid			2022-12-25	WOS:000223684100050
J	Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K				Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K			Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1)	ONCOGENE			English	Article						WWP1; Smurfs; ubiquitin-proteasome pathway; Smad7; TGF-beta	UBIQUITIN LIGASE; SMAD7; RECEPTOR; TARGETS; SMURF1; INHIBITION; EXPRESSION; CANCER; DEGRADATION; ACTIVATION	Smad7 negatively regulates transforming growth factor (TGF)-beta superfamily signaling by binding to activated type I receptors, thereby preventing the phosphorylation of receptor-regulated Smads (R-Smads), as well as by recruiting HECT-type E3 ubiquitin ligases to degrade type I receptors through a ubiquitin-dependent mechanism. To elucidate the regulatory mechanisms of TGF-beta signaling, we searched for novel members of proteins that interact with Smad7 using a yeast two-hybrid system. One of the proteins identified was the WW domain-containing protein 1 (WWP1) that is structurally related to Smad ubiquitin regulatory factors (Smurfs), E3 ubiquitin ligases for Smads and TGF-beta superfamily receptors. Using a TGF-beta-responsive reporter in mammalian cells, we found that WWP1 inhibited transcriptional activities induced by TGF-beta. Similar to Smurfs, WWP1 associated with Smad7 and induced its nuclear export, and enhanced binding of Smad7 to TGF-beta type I receptor to cause ubiquitination and degradation of the receptor. Consistent with these results, WWP1 inhibited phosphorylation of Smad2 induced by TGF-beta. WWP1 thus negatively regulates TGF-beta signaling in cooperation with Smad7. However, unlike Smurfs, WWP1 failed to ubiquitinate R-Smads and SnoN. Importantly, WWP1 and Smurfs were expressed in distinct patterns in human tissues and carcinoma cell lines, suggesting unique pathophysiological roles of WWP1 and Smurfs.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Grad Sch Biosci Biotechnol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Inst Canc, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Tokyo Institute of Technology; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Miyazawa, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	keiji-miyazawa@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; 高, 雨莉/HGU-8187-2022					ARTEAGA CL, 1988, CANCER RES, V48, P3898; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Dan S, 2002, CANCER RES, V62, P1139; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fukuchi M, 2002, CANCER RES, V62, P7162; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	150	170	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6914	6923		10.1038/sj.onc.1207885	http://dx.doi.org/10.1038/sj.onc.1207885			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15221015	Bronze			2022-12-25	WOS:000223750700008
J	Quirling, M; Page, S; Jilg, N; Plenagl, K; Peus, D; Grubmuller, C; Weingartner, M; Fischer, C; Neumeier, D; Brand, K				Quirling, M; Page, S; Jilg, N; Plenagl, K; Peus, D; Grubmuller, C; Weingartner, M; Fischer, C; Neumeier, D; Brand, K			Detection of IKK beta-IKK gamma subcomplexes in monocytic cells and characterization of associated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; TUMOR-NECROSIS-FACTOR; MICE LACKING; COMPLEX ACTIVITY; KINASE-ACTIVITY; ALPHA SUBUNIT; ACTIVATION; PHOSPHORYLATION; EXPRESSION; NEMO	The IkappaB kinase (IKK) complex is one major step in the regulation of the NF-kappaB/Rel system that is involved in inflammatory and immune responses as well as in proliferation and apoptosis. At present it is not clear whether besides the "classical" IKKalpha-IKKbeta-IKKgamma configuration additional complexes exist in vivo that solely contain IKKbeta and IKKgamma ( without IKKalpha). In the current study we were able to demonstrate in monocytic cells that endogenous complexes, which only include IKKbeta as the kinase-active molecule do indeed exist in vivo and that these complexes contain IKKgamma as an additional component. Furthermore, we showed that these IKKbeta-IKKgamma complexes are involved in mainstream NF-kappaB activation cascades because they can be activated by tumor necrosis factor. In contrast, these subcomplexes appear not to participate in NIK-dependent pathways. As a next step we showed that exogenous IKKbeta-IKKgamma complexes can be formed in an intact cell by overexpression and that these artificial complexes fulfill the requirement for participation in regular signaling. Finally, in the absence of IKKalpha we found a retarded proteolysis of IkappaBalpha, but not of IkappaBepsilon, which is associated with a reduced IKK activity. Differential pathways represented by various IKK subcomplexes may open attractive possibilities in treatment of inflammation or cancer allowing specific therapeutic intervention.	Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, D-81675 Munich, Germany; Tech Univ Munich, Dept Dermatol & Allergol, D-80802 Munich, Germany	Technical University of Munich; Technical University of Munich	Brand, K (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, Ismaninger Str 22, D-81675 Munich, Germany.	brand@klinchem.med.tum.de	Jilg, Nikolaus/GON-5240-2022; Peus, Dominik/AAC-3840-2020	Page, Sharon/0000-0003-0228-3609				Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Israel A, 2003, NATURE, V423, P596, DOI 10.1038/423596a; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Weber M, 2003, J BIOL CHEM, V278, P23586, DOI 10.1074/jbc.M211646200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	47	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37452	37460		10.1074/jbc.M312119200	http://dx.doi.org/10.1074/jbc.M312119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15226300	hybrid			2022-12-25	WOS:000223554600033
J	Zhang, YH; Foster, JM; Kumar, S; Fougere, M; Carlow, CKS				Zhang, YH; Foster, JM; Kumar, S; Fougere, M; Carlow, CKS			Cofactor-independent phosphoglycerate mutase has an essential role in Caenorhabditis elegans and is conserved in parasitic nematodes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; C-ELEGANS; BACILLUS-STEAROTHERMOPHILUS; TRYPANOSOMA-BRUCEI; GENES; RNAI; PHOSPHATASE; MECHANISM; SEQUENCES	Phosphoglycerate mutases catalyze the interconversion of 2- and 3-phosphoglycerate in the glycolytic and gluconeogenic pathways. They exist in two unrelated forms that are either cofactor (2,3-diphosphoglycerate)-dependent or cofactor-independent. The two enzymes have no similarity in amino acid sequence, tertiary structure, or catalytic mechanism. Certain organisms including vertebrates have only the cofactor-dependent form, whereas other organisms can possess the independent form or both. Caenorhabditis elegans has been predicted to have only independent phosphoglycerate mutase. In this study, we have cloned and produced recombinant, independent phosphoglycerate mutases from C. elegans and the human-parasitic nematode Brugia malayi. They are 70% identical to each other and related to known bacterial, fungal, and protozoan enzymes. The nematode enzymes possess the catalytic serine, and other key amino acids proposed for catalysis and recombinant enzymes showed typical phosphoglycerate mutase activities in both the glycolytic and gluconeogenic directions. The gene is essential in C. elegans, because the reduction of its activity by RNA interference led to embryonic lethality, larval lethality, and abnormal body morphology. Promoter reporter analysis indicated widespread expression in larval and adult C. elegans with the highest levels apparent in the nerve ring, intestine, and body wall muscles. The enzyme was found in a diverse group of nematodes representing the major clades, indicating that it is conserved throughout this phylum. Our results demonstrate that nematodes, unlike vertebrates, utilize independent phosphoglycerate mutase in glycolytic and gluconeogenic pathways and that the enzyme is probably essential for all nematodes.	New England Biolabs Inc, Beverly, MA 01915 USA		Carlow, CKS (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	carlow@neb.com	Kumar, Sanjay/AAO-2593-2021	Zhang, Yinhua/0000-0003-0592-9153				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARRERAS J, 1982, COMP BIOCHEM PHYS B, V71, P591, DOI 10.1016/0305-0491(82)90467-9; CARRERAS J, 1980, BIOCHEM BIOPH RES CO, V96, P1267, DOI 10.1016/0006-291X(80)90088-1; Chander M, 1999, J STRUCT BIOL, V126, P156, DOI 10.1006/jsbi.1999.4112; Chander M, 1998, CAN J MICROBIOL, V44, P759, DOI 10.1139/cjm-44-8-759; Chevalier N, 2000, EUR J BIOCHEM, V267, P1464, DOI 10.1046/j.1432-1327.2000.01145.x; Collet JF, 2001, FEMS MICROBIOL LETT, V204, P39, DOI 10.1111/j.1574-6968.2001.tb10859.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fraser HI, 1999, FEBS LETT, V455, P344, DOI 10.1016/S0014-5793(99)00910-2; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GRANA X, 1995, COMP BIOCHEM PHYS B, V112, P287, DOI 10.1016/0305-0491(95)00076-3; Guerra DG, 2004, EUR J BIOCHEM, V271, P1798, DOI 10.1111/j.1432-1033.2004.04097.x; Jedrzejas MJ, 2000, J BIOL CHEM, V275, P23146, DOI 10.1074/jbc.M002544200; Jedrzejas MJ, 2000, EMBO J, V19, P1419, DOI 10.1093/emboj/19.7.1419; Jedrzejas MJ, 2000, PROG BIOPHYS MOL BIO, V73, P263, DOI 10.1016/S0079-6107(00)00007-9; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; LEYVAVAZQUEZ MA, 1994, J BACTERIOL, V176, P3903, DOI 10.1128/JB.176.13.3903-3910.1994; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORRIS VL, 1995, J BACTERIOL, V177, P1727, DOI 10.1128/jb.177.7.1727-1733.1995; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Rigden DJ, 2002, J MOL BIOL, V315, P1129, DOI 10.1006/jmbi.2001.5290; Rigden DJ, 2003, J MOL BIOL, V325, P411, DOI 10.1016/S0022-2836(02)01229-9; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Tabara H, 1999, DEVELOPMENT, V126, P1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Oost J, 2002, FEMS MICROBIOL LETT, V212, P111, DOI 10.1016/S0378-1097(02)00720-6; WHITE MF, 1992, EUR J BIOCHEM, V207, P709, DOI 10.1111/j.1432-1033.1992.tb17099.x; Wood WB, 1988, NEMATODE CAENORHABDI; Wylie T, 2004, NUCLEIC ACIDS RES, V32, pD423, DOI 10.1093/nar/gkh010	37	35	47	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37185	37190		10.1074/jbc.M405877200	http://dx.doi.org/10.1074/jbc.M405877200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15234973	hybrid			2022-12-25	WOS:000223453600122
J	Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM				Lee, AY; He, B; You, L; Dadfarmay, S; Xu, ZD; Mazieres, J; Mikami, I; McCormick, F; Jablons, DM			Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma	ONCOGENE			English	Article						SFRP; Wnt signaling; methylation; malignant pleural mesothelioma	DIFFERENTIAL EXPRESSION; BREAST-TUMORS; CANCER; INHIBITION; MECHANISMS; APOPTOSIS; PATTERNS; PATHWAY; BINDS; CELLS	Secreted frizzled-related proteins (sFRPs) comprise a family of five secreted glycoproteins that antagonize Wnt signaling. Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Thus, role of sFRP as a negative regulator of Wnt signaling may have important implications in tumorigenesis, and its downregulation has been correlated with human cancers. Recently, we reported Wnt signaling and dishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM). Here, we report significant transcriptional downregulation of the SFRP gene family in MM primary tissues and cell lines as well as several other cancer cell lines ( breast, lung, glioma, and cervical) compared to normal cells. One or more SFRPs were downregulated in approximately 85% ( 18 of 21) of primary MM tumor specimens compared to normal pleural tissue. Eight of the nine cancer cell lines we examined showed silencing of the SFRP family. Methylation-specific PCR (MSP) analysis showed that SFRP1, SFRP4, and SFRP5 gene promoters are frequently methylated in MM primary tissue (>80%). Furthermore, transfection of the SFRP gene construct into MM cell lines lacking SFRP expression resulted in apoptosis and growth suppression. Our results suggest that methylation silencing of SFRPs may be one of the important mechanisms of aberrant Wnt signaling activation in MM.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708-01A3, R01 CA093708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Butchart E G, 1999, Oncologist, V4, P488; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; Ijiri K, 2002, J RHEUMATOL, V29, P2266; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Ko JS, 2002, EXP CELL RES, V280, P280, DOI 10.1006/excr.2002.5649; Lee Y C, 2000, Curr Opin Pulm Med, V6, P267, DOI 10.1097/00063198-200007000-00003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Uematsu K, 2003, CANCER RES, V63, P4547; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	23	172	192	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6672	6676		10.1038/sj.onc.1207881	http://dx.doi.org/10.1038/sj.onc.1207881			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221014				2022-12-25	WOS:000223530800015
J	Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A				Robanus-Maandag, E; Giovannini, M; van der Valk, M; Niwa-Kawakita, M; Abramowski, V; Antonescu, C; Thomas, G; Berns, A			Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin	ONCOGENE			English	Article						MPNST; neural crest; P0 promoter; conditional knockout mice; compensatory signalling	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; P53-DEFICIENT MICE; MOUSE; SPECTRUM; PROTEIN; CD44; ORGANIZATION; MERLIN; CELLS	Previously, we have mimicked human neuro. bromatosis type 2 (NF2) in conditional Nf2 mutant (P0Cre; Nf2(flox2/flox2)) mice. Schwannomas, characteristic for NF2, were found at low frequency in older mice. Here, we report that these mice, upon additional hemizygosity for p53, rapidly develop multiple tumours showing features consistent with malignant peripheral nerve sheath tumours. Thus, p53 hemizygosity promotes tumorigenesis of mutant Nf2 peripheral nerve cells. In contrast, young P0Cre; Nf2(flox2/+); p53(+/-) cis mice mainly succumb to Nf2/p53-related osteogenic tumours. Therefore, Cre-mediated early biallelic loss of Nf2 function in neural crest-derived cells hemizygous for p53 results in resistance to osteogenic tumours and increased susceptibility to peripheral nerve sheath tumours.	Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; INSERM, Fdn Jean Dausset, CEPH, F-75010 Paris, France; Netherlands Canc Inst, Dept Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Netherlands Cancer Institute; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); Netherlands Cancer Institute; Memorial Sloan Kettering Cancer Center	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl		Kawakita, Michiko/0000-0002-9450-583X				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Mckusick V.A., 1994, MENDELIAN INHERITANC; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MESSING A, 1994, J NEUROSCI, V14, P3533; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; PURDIE CA, 1994, ONCOGENE, V9, P603; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	27	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6541	6547		10.1038/sj.onc.1207858	http://dx.doi.org/10.1038/sj.onc.1207858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221010				2022-12-25	WOS:000223530800001
J	Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R				Bursen, A; Moritz, S; Gaussmann, A; Moritz, S; Dingermann, T; Marschalek, R			Interaction of AF4 wild-type and AF4. MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?	ONCOGENE			English	Article						AF4; chromosomal MLL translocation t(4;11); SIAH1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOID PROGENITORS; PROTEASOME PATHWAY; AF4-RELATED GENE; UBIQUITIN LIGASE; NUCLEAR-PROTEIN; AF-4 GENE; CELL-LINE; HRX-ENL; EXPRESSION	The human AF4 (ALL-1 fused gene on chromosome 4) gene (4q11) is recurrently involved in reciprocal translocations to the MLL (mixed lineage leukemia) gene (11q23), correlated with high-risk acute lymphoblastic leukemia (ALL) in infants and early childhood. The t(4; 11) translocation is one of the most frequent MLL translocations known today. In general, MLL translocations are the result of an illegitimate recombination process leading to reciprocal fusions of unrelated translocation partner (TP) genes with the MLL gene. Owing to the constant presence of the derivative (11) product, it was hypothesised that only MLL. TP fusion genes are responsible for the leukemogenic process. This concept has been successfully tested for some known MLL fusions, while other MLL fusions failed. Here, we demonstrate growth-transforming potential of AF4 wild-type and the AF4. MLL fusion protein. The underlying oncogenic mechanism involves the two E3 ubiquitin ligases SIAH1 and SIAH2, the N-terminal portion of AF4 and the protection of the AF4. MLL fusion protein against proteosomal degradation.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44801 Bochum, Germany	Goethe University Frankfurt; Ruhr University Bochum	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHEN CS, 1993, BLOOD, V82, P1080; COHEN A, 1991, BLOOD, V78, P94; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; Frestedt JL, 1996, GENET ANAL-BIOMOL E, V12, P147, DOI 10.1016/1050-3862(95)00127-1; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Isaacs AM, 2003, J NEUROSCI, V23, P1631; Isnard P, 2000, BLOOD, V96, P705; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Strehl S, 2003, ONCOGENE, V22, P157, DOI 10.1038/sj.onc.1206042; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; von Bergh ARM, 2002, GENE CHROMOSOME CANC, V35, P92, DOI 10.1002/gcc.10091; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	61	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6237	6249		10.1038/sj.onc.1207837	http://dx.doi.org/10.1038/sj.onc.1207837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221006				2022-12-25	WOS:000223399000008
J	Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z				Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z			Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor	ONCOGENE			English	Article						HGF/c-Met; angiogenesis; squamous cell carcinoma; metastasis; Gro-1/KC; VEGF	PROINFLAMMATORY CYTOKINE EXPRESSION; PAPILLARY RENAL-CARCINOMAS; HOST ENVIRONMENT PROMOTES; FACTOR-KAPPA-B; TUMOR PROGRESSION; IN-VIVO; PROANGIOGENIC CYTOKINES; CANCER PATIENTS; CDNA ARRAYS; ONCOGENE	We previously performed gene expression pro. ling in a multistep squamous cell carcinoma (SCC) progression model, and identified growth-regulated oncogene-1 (Gro1/KC) as a factor that contributes to enhanced angiogenesis, tumorigenesis and metastasis. In the present study, we explored molecular pathways coactivated with Gro-1/KC, and identified a transcript that encodes c-Met, the receptor for hepatocyte growth factor/scatter factor (HGF). Northern, Western blot, and immunohistochemical analyses confirm that expression of c-Met mRNA and protein is increased with SCC progression. In vitro, HGF preferentially promoted scattering in the metastatic LY-1 and LY-2 lines, and enhanced angiogenesis factors Gro-1/KC and vascular endothelial growth factor (VEGF) production by all tumor cell lines. In vivo, tumor growth and lung metastasis were promoted by transfection and overexpression of HGF cDNA in metastatic LY-1 cells. Our data indicate that metastatic SCC cells that overexpress c-Met exhibit angiogenesis factor expression and enhanced scattering in response to HGF in vitro, and tumorigenesis and metastasis in response to HGF in the tumor microenvironment in vivo.	Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Chen, Z (corresponding author), Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, 10-5D55,MSC-1419, Bethesda, MD 20892 USA.	chenz@nided.nih.gov	Lee, Tin-Lap/A-7853-2009; Lee, Tin-Lap/W-6595-2019	Lee, Tin-Lap/0000-0002-6654-0988; Lee, Tin-Lap/0000-0002-6654-0988	NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, Z01DC000016] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; CHAN AML, 1988, ONCOGENE, V2, P593; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; CROWLBANCROFT C, 2001, CLIN CANCER RES, V7, P435; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 2001, CANCER RES, V61, P4797; Dong G, 2001, CANCER RES, V61, P5911; Duffey DC, 1999, CANCER RES, V59, P3468; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fukuura T, 1998, BRIT J CANCER, V78, P454, DOI 10.1038/bjc.1998.514; Gohji K, 2000, J CLIN ONCOL, V18, P2963, DOI 10.1200/JCO.2000.18.16.2963; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu YC, 2001, CLIN CANCER RES, V7, P3519; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Junbo Hu, 1999, In Vivo (Attiki), V13, P177; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; Naughton M, 2001, J UROLOGY, V165, P1325, DOI 10.1016/S0022-5347(01)69893-8; Porte H, 1998, CLIN CANCER RES, V4, P1375; Qian CN, 2002, CANCER RES, V62, P589; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takeo S, 2001, CANCER GENET CYTOGEN, V130, P127, DOI 10.1016/S0165-4608(01)00479-4; Takigawa N, 1997, LUNG CANCER-J IASLC, V17, P211, DOI 10.1016/S0169-5002(97)00651-X; Taniguchi T, 1997, BRIT J CANCER, V75, P673, DOI 10.1038/bjc.1997.120; Thomas GR, 1999, INT J CANCER, V82, P377, DOI 10.1002/(SICI)1097-0215(19990730)82:3<377::AID-IJC11>3.3.CO;2-0; Toi M, 1998, CLIN CANCER RES, V4, P659; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wojta J, 1999, LAB INVEST, V79, P427; Yu YL, 2002, CANCER RES, V62, P2951; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; YUSPA SH, 1980, CANCER RES, V40, P4694; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	50	44	48	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6199	6208		10.1038/sj.onc.1207851	http://dx.doi.org/10.1038/sj.onc.1207851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221009				2022-12-25	WOS:000223399000004
